NCT Number,Title,Acronym,Status,Study Results,Conditions,Interventions,Outcome Measures,Sponsor/Collaborators,Gender,Age,Phases,Enrollment,Funded Bys,Study Type,Study Designs,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents,URL
NCT03950180,Assessing The Impact Of Incorporating Charlson Comorbidity Scores On Patient Anxiety And Satisfaction,,Completed,No Results Available,Prostate Cancer,Other: Prostate Cancer Comorbidity Index (PCCI) score,Traditional Decisional Conflict Scale (DCS)|The Modified 18-item Memorial Anxiety Scale for Prostate Cancer,Benaroya Research Institute|Virginia Mason Hospital/Medical Center|Axio Research Corporation,Male,"18 Years and older   (Adult, Older Adult)",Not Applicable,277,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Other,IRB13054,12-Jul-13,27-Feb-15,27-Feb-15,15-May-19,null,15-May-19,,,https://ClinicalTrials.gov/show/NCT03950180
NCT03950661,Walking Green: The Effects of Walking in Forested and Urban Areas,NUWG,Completed,No Results Available,Mood|Stress|Anxiety|Depression|Obesity|Health Behavior|Physical Activity,Other: Walking,Psychological Effects - Mood|Psychological Effects - Anxiety|Psychological Effects - Attention|Psychological Effects - Depression|Physiological Effects - Blood Glucose|Physiological Effects - Salivary Cortisol|Physiological Effects - Blood|Physiological Effects - Heart Rate Variation,Northwestern University,All,18 Years to 35 Years   (Adult),Not Applicable,41,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,STU00201604,1-Jun-16,14-Aug-17,8-Dec-17,15-May-19,null,16-May-19,"Northwestern University, Evanston, Illinois, United States",,https://ClinicalTrials.gov/show/NCT03950661
NCT03930095,Efficacy of an Acceptance-based Group Behavioral Therapy for Generalized Anxiety Disorder.,ABBT-GAD,Completed,No Results Available,Generalized Anxiety Disorder,Behavioral: Acceptance-based Behavior Therapy|Behavioral: Non-directive Supportive Therapy,"Change in the Depression, Anxiety and Stress Scales|Change in the Hamilton Anxiety Scale|Change in the Penn State Worry Questionnaire (Meyer, 1990)|Change in the Clinical Global Impressions (CGI; Guy, 1976)|Change in the Depression sub scale of Depression, Anxiety and Stress Scales|Change in the abridged version of the quality of life inventory - World Health Organization Quality of Life ( WOQOL-BREF - Berlim, Pavanello, Caldieraro, & Fleck, 2005)|Change in the Sheehan Disability Scale (Sheehan, Harnett-Sheehan, & Raj, 1996)|Change in the Acceptance and Action Questionnaire score|Change in the Five Facets of Mindfulness Questionnaire score|Change in the Credibility and Expectancy Questionnaire score|Change in the Mental Health Continuum - Short Form - score",University of Sao Paulo General Hospital,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,92,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,51363615.4.0000.0068,6-Feb-16,6-Aug-16,6-Aug-16,29-Apr-19,null,29-Apr-19,"Department and Institute of Psychiatry - FMUSP, São Paulo, Sao Paulo, Brazil",,https://ClinicalTrials.gov/show/NCT03930095
NCT03925259,Dismantling the Efficacy of Self-As-Context During Acceptance and Commitment Therapy,,Completed,No Results Available,"Depression, Anxiety",Behavioral: Acceptance and Commitment Therapy,"Change in psychological flexibility abilities via the Acceptance and Action Questionnaire II (AAQ-II; Bond et al., 2011).|Change in decentering abilities via the Experiences Questionnaire (EQ; Fresco, Moore, van Dulmen, Segal, Teasdale, Ma, & Williams, 2007).",University of Sheffield,All,"16 Years and older   (Child, Adult, Older Adult)",Not Applicable,16,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,144363,1-Jan-12,1-Jan-13,1-Jun-14,24-Apr-19,null,24-Apr-19,"Clinical Psychology Unit, Department of Psychology, Uni of Sheffield, Sheffield, Yorkshire, United Kingdom",,https://ClinicalTrials.gov/show/NCT03925259
NCT03924921,The Effectiveness of a Relaxation Technique on the Quality of Life and Symptoms in People Living With HIV,,Completed,No Results Available,HIV,Other: autogenic training,PROQOL-HIV questionnaire|Pittsburgh Sleep Quality Index (PSQI)|Fatigue Severity Scale (FSS)|Brief Pain Inventory|State -Trait Anxiety Inventory (STAI)|PHQ-9,Université de Montréal|Fonds de la Recherche en Santé du Québec,All,"18 Years to 99 Years   (Adult, Older Adult)",Not Applicable,62,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care",2016-5940:PRG,Apr-15,Jun-18,Dec-18,23-Apr-19,null,23-Apr-19,"CHUM, Montréal, Quebec, Canada|CUSM, Montréal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT03924921
NCT03921255,Cognitive Bias Modification for Thought-Action Fusion,TAF,Recruiting,No Results Available,Obsessive-Compulsive Disorder,Other: Cognitive Bias Modification,"Change in Thought-Action Fusion Scale (TAFS) across Pre-training, Post-training, and 1-Month follow-up|Change in Primary Obsession Evaluation of TAF Scale (POETS) across Pre-training, Post-training, and 1-Month follow-up|Change in Revised Obsessional Intrusions Inventory - Distress (ROII-Distress) across Pre-training, Post-training, and 1-Month follow-up","University of Wisconsin, Milwaukee",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,66,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",TAF Extended,10-Apr-16,31-Aug-19,31-Aug-19,19-Apr-19,null,19-Apr-19,"UWM Anxiety Disorders Laboratory, Milwaukee, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT03921255
NCT03917875,Computer-Delivered PFI for Anxiety Sensitivity/Alcohol Intervention for Hazardous Drinkers With Elevated Anxiety Sensitivity,,Recruiting,No Results Available,Alcohol Drinking|Anxiety|Coping Behavior,Behavioral: Personalized feedback intervention,Motivation for change|Drinks per occasion|Anxiety Sensitivity|Drinking to cope,University of Houston,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,130,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,STUDY00001045,1-Sep-16,Sep-19,Sep-19,17-Apr-19,null,17-Apr-19,"University of Houston, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT03917875
NCT03882541,Could Music be an Alternative to Sedation in Patients Treated Total Knee Arthroplasty With Regional Anesthesia?,,Completed,No Results Available,Anxiety|Surgery|Drug Toxicity|Anesthesia|Pain,Other: Music therapy|Drug: Sedation with midazolam,Anxiety State-Trait Anxiety Inventory (STAI)|Pain Vale Numerical Scale (VNS),Consorci Sanitari de l'Anoia,All,"50 Years to 85 Years   (Adult, Older Adult)",Not Applicable,85,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Other,PRCSA0077,8-Jan-17,30-Jan-18,30-Jan-18,20-Mar-19,null,20-Mar-19,,,https://ClinicalTrials.gov/show/NCT03882541
NCT03874442,"The Effectiveness of a Preoperative, Interactive Game ""SERES Pain in Children"".",,Completed,No Results Available,Ambulatory Surgery in Children,Other: CliniPup serious game,Preoperative anxiety|Postoperative pain|User experience and satisfaction|parental anxiety,Universitaire Ziekenhuizen Leuven,All,6 Years to 10 Years   (Child),Not Applicable,20,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,S58541,22-Feb-16,26-Apr-16,26-Apr-16,14-Mar-19,null,14-Mar-19,,,https://ClinicalTrials.gov/show/NCT03874442
NCT03874611,Electrophysiology of Brain Activity During Electrode Implantation in Patients Treated With Deep Brain Stimulation,LFP-DBS,Recruiting,No Results Available,Parkinson Disease|Obsessive-Compulsive Disorder|Epilepsy|Depression,Other: electrophysiological data from DBS,Number of functional markers derived from electrophysiological signals recorded during cognitive tests.|cognitive and sensorimotor tasks|functional atlas of basal ganglia|number of electrophysiological responses,"University Hospital, Grenoble",All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,125,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,38RC11.242,13-Apr-11,31-Mar-21,31-Mar-21,14-Mar-19,null,14-Mar-19,"CHU Grenoble-Alpes, Grenoble, France",,https://ClinicalTrials.gov/show/NCT03874611
NCT03865459,The Effect of Watching Relaxing Video During Cystoscopy,,Completed,No Results Available,Pain|Anxiety|Urological Nursing|Lower Urinary Tract Symptoms,Other: Video group,change on pain intensity as measured by Visual Analog Scale|score change on anxiety level as measured by State-Trait Anxiety Inventory,Saglik Bilimleri Universitesi Gulhane Tip Fakultesi,Female,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,46418926,1-Dec-17,22-Mar-18,1-Jun-18,6-Mar-19,null,12-Mar-19,"University of Health Sciences, Istanbul, Turkey",,https://ClinicalTrials.gov/show/NCT03865459
NCT03861013,Reward Under Stress: Effects of a Multidimensional Stress Prevention Program in University Students,,Completed,No Results Available,"Stress, Psychological",Behavioral: Multidimensional stress prevention program (GeDStress),Change in depression scores|Change in anxiety trait and state scores|Change in sense of coherence scores|Change in burnout scores|Change in social anxiety scores|Change in quality of life scores|Change in difficulties in emotion regulation scores|Change in perceived stress scores|Change in general self-efficacy scores|Change in mindfulness skills scores|Change in symptoms of mental health scores|Change in self-compassion scores|Change in perceived social support scores|Change in reward responsiveness scores|Change in self-esteem scores|Change in reactions after traumatic events scores|Childhood trauma|Posttraumatic stress|Change in cannabis abuse scores|Change in coping scores|Change in life orientation scores|Change in smartphone addiction scores|Change in internet addiction scores|Changes in clients progress through the course of the therapy scores|Change in ambulatory assessment scores|Change in the answer to the reward task scores|Change in cortisol levels in daily life|Change in cortisol levels in laboratory task,Chantal Martin Soelch|University of Fribourg|University of Bern,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,64,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,Reward_Stress|Project 6239,14-Mar-15,4-Jun-17,4-Jun-17,4-Mar-19,null,4-Mar-19,"University of Fribourg, Fribourg, Switzerland",,https://ClinicalTrials.gov/show/NCT03861013
NCT03850613,Alleviating Caregivers' Stress Through an E-painting Mobile Application,,Recruiting,No Results Available,Caregivers|Anxiety,Behavioral: E-painting mobile app,Caregivers' level of stress|Self-rated health status|Depressive symptoms|Instrumental and emotional social support,The Hong Kong Polytechnic University,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,30,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,G-YBWL,1-Oct-17,31-Mar-19,30-Apr-19,22-Feb-19,null,22-Feb-19,"The Hong Kong Polytechnic University, Hong Kong, Hong Kong",,https://ClinicalTrials.gov/show/NCT03850613
NCT03839147,The Effect of Education and Counseling on Reducing Pain and Anxiety in Women Undergoing Hysterosalpingography,,Completed,No Results Available,Women's Health,Behavioral: Education and counseling,Spielberger State Anxiety Scale|Visual Analog Scale for pain intensity,Saglik Bilimleri Universitesi Gulhane Tip Fakultesi,Female,18 Years to 45 Years   (Adult),Not Applicable,105,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",50687469,1-May-16,1-Jan-17,1-Jan-17,15-Feb-19,null,16-Apr-19,,,https://ClinicalTrials.gov/show/NCT03839147
NCT03829839,Effects of Oxytocin and Lorazepam on Fear-related Intra-amygdalar Activity,,Completed,No Results Available,"Oxytocin, Lorazepam, Anti-Anxiety Agents, Physiological Effects of Drugs",Drug: Oxytocin|Drug: Lorazepam 1 mg|Drug: Placebo nasalspray|Drug: Placebo Oral Tablet,Neural responses to emotional faces in the amygdala subregions,"University Hospital, Bonn",Male,18 Years to 40 Years   (Adult),Phase 1,120,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",LOXY,3-Mar-16,16-Aug-17,16-Aug-17,4-Feb-19,null,17-Apr-19,"Department of Psychiatry, University of Bonn, Bonn, Germany",,https://ClinicalTrials.gov/show/NCT03829839
NCT03825978,Efficacy of Counseling for Prenatal Screening and Diagnostic Tests on Pregnant Women: Randomised Controlled Study,,Completed,No Results Available,"Decision Making|Chromosome Abnormality|Anxiety|Knowledge, Attitudes, Practice",Behavioral: Prenatal Genetic Counseling,Anxiety|Decisional Conflict|SURE Scale|Knowledge Form About Prenatal Genetic Screening and Diagnostic Tests|Attitudes Towards The Tests Scale|Decision Satisfaction Form|Decisional Conflict Scale,Saglik Bilimleri Universitesi Gulhane Tip Fakultesi,Female,19 Years to 46 Years   (Adult),Not Applicable,260,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care,Ilknur Yesilcinar,10-Jun-17,5-Mar-18,5-Mar-18,1-Feb-19,null,1-Feb-19,"Health Science University, Ankara, Turkey|University Of Health Sciences, Ankara, Turkey",,https://ClinicalTrials.gov/show/NCT03825978
NCT03827408,"Nebulized Midazolam, Dexmedetomidine, and Their Combination in Sedation of Preschoolers Undergoing Dental Treatment",,Recruiting,No Results Available,Dental Anxiety,Drug: Midazolam group (MDZ)|Drug: Dexmedetomidine group (DEX)|Drug: Combination of Midazolam and Dexmedetomidine (MDZ/DEX),Facemask acceptance during drug delivery|Effect of sedation on children's future behavior|The 'ease of treatment completion' sing separate five-point scales.|Post-operative effects of the sedation|Analgo-sedative effect of each drug|Analgo-sedative effect of each drug.|Amnesic effect of sedative agents.|Hemodynamic response of sedative agents.,Nourhan M.Aly|Alexandria University|University of Alexandria,All,4 Years to 6 Years   (Child),Phase 2,72,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other",IORG0008839,27-Nov-17,Apr-19,Dec-19,1-Feb-19,null,1-Feb-19,"Faculty of Dentistry, Alexandria University, Alexandria, Egypt",,https://ClinicalTrials.gov/show/NCT03827408
NCT03822598,Promoting Asylum-seeking and Refugee Children's Coping With Trauma,,Completed,No Results Available,Mental Health Disorder|Post-Traumatic Stress Disorder in Adolescence|Depression|Social Anxiety,"Behavioral: Teaching Recovery Techniques, TRT","Children's Revised Impact of Event Scale (CRIES-13)|Screen for Child Anxiety Related Disorders (SCARED). 9 items tapping symptoms of generalized anxiety disorder, and 7 items tapping symptoms of social anxiety|Cantril Ladder|Montgomery-Aasberg Depression Scale, MADRS","Norwegian Institute of Public Health|University of Tromso|University of Bergen|Norwegian Directorate of Children, Youth, and Family Affairs|Norwegian Directorate of Immigration|Norwegian Directorate of Integration and Diversity",All,"8 Years to 20 Years   (Child, Adult)",Not Applicable,170,Other,Interventional,"Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment",16/54571,20-Jun-17,31-May-18,30-Jun-18,30-Jan-19,null,30-Jan-19,"Bergen Municipality, Bergen, Norway|Nordre Land municipality, Dokka, Norway|Drammen Municipality, Drammen, Norway|Engerdal Municipality, Drevsjø, Norway|Fredrikstad municipality, Fredrikstad, Norway|Gjøvik municipality, Gjøvik, Norway|Ringerike Municipality, Hønefoss, Norway|Grue municipality, Kirkenær, Norway|Levanger municipality, Leira, Norway|Lyngdal municipality, Lyngdal, Norway|Lyngdal municipality, Lyng, Norway|Bærum municipality, Rud, Norway|Salten municipality, Sjøvegan, Norway|Stavanger municipality, Stavanger, Norway|Trondheim municipality, Trondheim, Norway|Vadsø municipality, Vadsø, Norway","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/98/NCT03822598/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03822598
NCT03818490,Aromatherapy for Anxiety Among Children With Autism Spectrum Disorder,,Completed,No Results Available,Anxiety|Autism Spectrum Disorder,Other: Bergamot Aromatherapy,Change from baseline State Trait Anxiety Inventory for Children|Change from baseline in Blood Pressure|Change from baseline in Heart Rate,Franklin Institute of Wellness,All,6 Years to 11 Years   (Child),Not Applicable,28,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,17-1200,24-Jun-16,9-Mar-18,30-Mar-18,28-Jan-19,null,28-Jan-19,"Franklin Institute of Wellness, Franklin, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT03818490
NCT03818789,Acceptance and Mindfulness for Exercise in Anxiety,,Recruiting,No Results Available,Anxiety,Behavioral: Mindfulness and acceptance training|Behavioral: Study skills video,"Amount of time run in minutes|Amount of time in minutes of vigorous and moderate exercise in following week|Anxiety symptoms: Generalized Anxiety Disorder - 7 Scale, Beck Anxiety Inventory|Depression symptoms: Beck Depression Inventory|Mindfulness during exercise: State Mindfulness Scale for Physical Activity",University of Texas at Austin,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,120,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,2016-11-0091,23-Feb-17,Aug-19,Sep-19,28-Jan-19,null,28-Jan-19,"College of Liberal Arts, Austin, Texas, United States",,https://ClinicalTrials.gov/show/NCT03818789
NCT03819166,Behavioral Support Techniques on Anxiety and Physical Reaction From Dental Treatment,,Recruiting,No Results Available,Dental Anxiety|Dental Diseases|Dental Trauma,Device: with deep touch pressure application|Device: without deep touch pressure application,Heart Rate Variability (HRV)|Electrodermal Activity (EDA)|Dental Anxiety Scale (DAS)|Numeric State Anxiety Scale (NSAS),National Taiwan University Hospital,All,"10 Years to 75 Years   (Child, Adult, Older Adult)",Not Applicable,200,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care,201012061RC,11-Mar-11,18-Jul-13,31-Dec-19,28-Jan-19,null,28-Jan-19,"National Taiwan University Hospital, Taipei, Taiwan",,https://ClinicalTrials.gov/show/NCT03819166
NCT03810391,Using Preoperative Anxiety Score to Determine the Total Dose of Butorphanol for Sedation,,Completed,No Results Available,Preoperative Anxiety Score|Total Dose of Butorphanol,Drug: Butorphanol|Other: physiological saline,"preoperative anxiety score (Amsterdam preoperative anxiety and information scale, APAIS)|Ramsay sedation score (Ramsay sedation scale, RSS)|the time when Ramsay sedation score reached 4 points|vital signs|The incidence of nausea/ vomiting, dizzy, bradycardia and hypotension|post-operative visual analgesia scale scores (VAS)|Vital signs",Shengjing Hospital,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,126,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Effect of butorphanol,1-Dec-17,20-Dec-18,31-Dec-18,18-Jan-19,null,18-Jan-19,"shengjing hospital of China medical university, Shenyang, Liao Ning, China",,https://ClinicalTrials.gov/show/NCT03810391
NCT03810599,Patient-reported Outcomes in the Bergen Early Cardiac Rehabilitation Study,BECARES,Recruiting,No Results Available,Coronary Artery Disease,Other: Early cardiac rehabilitation,"Time to composite of total mortality, and hospitalization for heart failure and atherothrombotic disease (including non-fatal MI, unstable angina and stroke).|Change in Self-reported health|Change in self-reported global health|Change in post traumatic growth|Nicotine dependence|Change in anxiety and depression|Change in physical and mental dimensions of health|Change in health status following myocardial infarction",Haukeland University Hospital,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,870,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,2014/333,9-Sep-13,Feb-19,Feb-29,18-Jan-19,null,18-Jan-19,"Haukeland University Hospital, Bergen, Norway",,https://ClinicalTrials.gov/show/NCT03810599
NCT03798548,Brief CBT for Patients Undergoing TAVR,,Completed,No Results Available,"Depression, Anxiety",Behavioral: Brief Bedside CBT,Change from Baseline Score on Beck Depression Inventory II (BDI-II)|Change from Baseline Score on State Trait Anxiety Inventory Form YI (STAI-YI)|Change from Baseline Score on Minnesota Living With Heart Failure Questionnaire (MLHFQ)|Change from Baseline Score on 12-Item Short Form Health Survey (SF12v2),Stanford University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,146,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention",32178,15-Jan-15,31-Mar-17,15-May-17,10-Jan-19,null,10-Jan-19,,,https://ClinicalTrials.gov/show/NCT03798548
NCT03790696,Novel Anxiety Treatment,,Recruiting,No Results Available,Cognitive Training|Anxiety Disorders,Device: Cognitive Training Program,Change in symptoms of anxiety based on Screen for Anxiety and Related Disorders (SCARED)|Change in symptoms of anxiety based on Pediatric Anxiety Rating Scale (PARS).,Washington University School of Medicine|National Institutes of Health (NIH),All,8 Years to 12 Years   (Child),Not Applicable,60,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",201702012,2-Feb-17,30-Jun-19,30-Jun-19,1-Jan-19,null,1-Jan-19,"Washinton University School of Medicine, Saint Louis, Missouri, United States",,https://ClinicalTrials.gov/show/NCT03790696
NCT03786328,An Outreach Collaborative Model for Early Identification and Treatment of Mental Disorder in Danish Workplaces,,Completed,No Results Available,"Depression, Anxiety",Behavioral: Standard Psychiatric Treatment|Behavioral: Preventive Psychological Treatment,Change in Severity of Psychopathological symptoms,Helle Østermark Sørensen|Spar Nord Foundation|Aalborg University Hospital,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,73,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Screening,2013-18,1-Apr-08,31-Aug-13,31-Aug-13,25-Dec-18,null,25-Dec-18,,,https://ClinicalTrials.gov/show/NCT03786328
NCT03764644,Web-based Attention Bias Modification Treatment for Childhood Anxiety Disorders,ATTENTIO,Terminated,No Results Available,"Anxiety Disorder|Anxiety Disorder of Childhood|Separation Anxiety Disorder of Childhood, Early Onset|Specific Phobia|Social Anxiety Disorder|Generalized Anxiety Disorder",Behavioral: Combined ABMT and CBT|Behavioral: Combined Sham ABMT and CBT,Anxiety disorder status|Number of anxiety disorders|Anxiety symptoms|Depression symptoms,Erasmus Medical Center,All,8 Years to 16 Years   (Child),Not Applicable,55,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",S13-11,Oct-13,Feb-17,Jul-17,5-Dec-18,null,5-Dec-18,"Erasmus MC - Sophia Children's Hospital, Rotterdam, Zuid-Holland, Netherlands",,https://ClinicalTrials.gov/show/NCT03764644
NCT03758599,Exercise in Anxiety and Posttraumatic Stress Disorders,,Recruiting,No Results Available,Anxiety,Procedure: Climbing|Procedure: Nordic Walking|Procedure: Social Contact,"Change from Baseline (t1) Symptoms of Anxiety at four weeks (t2), three months after intervention (t3) and six months after intervention (t4)|Change from Baseline (t1) Symptoms of Posttraumatic Stress Disorder at four weeks (t2), three months after intervention (t3) and six months after intervention (t4)|Change from Baseline (t1) Depression at four weeks (t2), three months after intervention (t3) and six months after intervention (t4)|Change from Baseline (t1) Worry Symptoms at four weeks (t2), three months after intervention (t3) and six months after intervention (t4)|Change from Baseline (t1) Quality of Life (WHO) at four weeks (t2), three months after intervention (t3) and six months after intervention (t4)|Change from Baseline (t1) Self Efficacy at four weeks (t2), three months after intervention (t3) and six months after intervention (t4)|Affective Responses_a|Affective Responses_b|Affective Responses_c|Affective Responses_d|Change from Baseline (t1) Analyses of neurotransmitter metabolites at four weeks (t2), three months after intervention (t3) and six months after intervention (t4)|Change from Baseline (t1) Analyses of immune-activation markers at four weeks (t2), three months after intervention (t3) and six months after intervention (t4)",Universitaet Innsbruck|Medical University Innsbruck,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,30,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,256912,1-Oct-17,Oct-19,Apr-20,29-Nov-18,null,29-Nov-18,"University of Innsbruck, Innsbruck, Tyrol, Austria",,https://ClinicalTrials.gov/show/NCT03758599
NCT03754647,Effect of Vitamin C Upon SSRI-treated OCD Patients,,Recruiting,No Results Available,OCD,Dietary Supplement: Vitamin C,To examine the effect of vitamin C upon Selective Serotonin Reuptake Inhibitors (SSRIs) - treated Obsessive Compulsive Disorder patients.,"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh",All,18 Years to 50 Years   (Adult),Not Applicable,90,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BSMMU/2018/3110,14-Dec-17,10-Feb-19,10-Feb-19,27-Nov-18,null,28-Nov-18,"BSMMU, Dhaka, Bangladesh",,https://ClinicalTrials.gov/show/NCT03754647
NCT03755284,The Effect of Sacral Massage on Labor,,Completed,No Results Available,Labor Pain,Other: Sacral Massage,The state-trait anxiety inventory (STAI FORM TX-I) evaluated|The Visual Analogue Scale (VAS) evaluated,"Semra Çevik, phD|University of Gaziantep",Female,19 Years to 40 Years   (Adult),Not Applicable,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Sacral Massage,25-Jan-16,25-Oct-16,25-Oct-16,27-Nov-18,null,7-Dec-18,"Gaziantep University, Gaziantep, Şahinbey, Turkey","""Statistical Analysis Plan: statistical analysis"", https://ClinicalTrials.gov/ProvidedDocs/84/NCT03755284/SAP_000.pdf|""Informed Consent Form: Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/84/NCT03755284/ICF_001.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/84/NCT03755284/Prot_002.pdf",https://ClinicalTrials.gov/show/NCT03755284
NCT03748394,Interventions to Facilitate Working While Depressed and Anxious,,Recruiting,No Results Available,Work Capacity,Behavioral: Work-directed rehabilitation|Behavioral: Physical activity,Work ability|Depression severity|Anxiety symptoms|Mental wellbeing,Göteborg University,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,VGFOUREG-588531,1-Feb-17,Dec-18,Dec-18,20-Nov-18,null,20-Nov-18,"Närhälsan Gibraltar Rehabmottagning, Gothenburg, Sweden",,https://ClinicalTrials.gov/show/NCT03748394
NCT03722771,Influence of Lavender Oil on Vital Signs in Oral Surgery Patients,,Completed,No Results Available,Dental Anxiety|Sedative; Anxiety Disorder,Behavioral: Inhalation|Other: Anxiety Questionnaires 1|Other: Anxiety Questionnaires 2|Diagnostic Test: Vital Signs 1|Diagnostic Test: Vital Signs 2|Diagnostic Test: Vital Signs 3|Diagnostic Test: Vital Signs 4,Vital Sign Measurements - 1 - changes in blood pressure|Vital Sign Measurements - 2 - changes in respiratory rate|Vital Sign Measurements - 3 - changes in heart rate|Vital Sign Measurements - 4 - changes in saturation level|Anxiety Test 1 - MDAS tests|Anxiety Test 2 - STAI-S tests,Nazife Begüm KARAN|Recep Tayyip Erdogan University Training and Research Hospital,All,18 Years to 37 Years   (Adult),Not Applicable,126,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care",106,1-Sep-17,2-Nov-18,2-Nov-18,29-Oct-18,null,6-Nov-18,"Nazife Begüm KARAN, Ri̇ze, Merkez, Turkey",,https://ClinicalTrials.gov/show/NCT03722771
NCT03712319,Efficacy of a Mobile Application vs MBSR in Healthcare Students,,"Active, not recruiting",No Results Available,Students,Behavioral: REM Volver a casa|Behavioral: Mindfulness-Based Stress Reduction program,State-trait anxiety|State-Trait Anger|Mindfulness|Self-compassion|Empathy|Depression|Expectancy of improvement|Autonomous motivation|State-Trait Anxiety,Instituto de Investigación Hospital Universitario La Paz|Universidad Autonoma de Madrid,All,"Child, Adult, Older Adult",Not Applicable,125,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care,DHAERMP,13-Sep-16,1-Jul-19,1-Jul-19,19-Oct-18,null,19-Oct-18,"Hospital Universitario La Paz [La Paz University Hospital], Madrid, Spain",,https://ClinicalTrials.gov/show/NCT03712319
NCT03711513,"Facing Fears by Focussing on Behaviour, Body, or Mind?",,Recruiting,No Results Available,Social Anxiety,Behavioral: Cognitive behavioral therapy,Change in fear of performance/public speaking symptoms|Change in level of anxiety|Change in social phobia diagnosis|Change in speech behavior|Change in self-efficacy,University of Groningen|ZonMw: The Netherlands Organisation for Health Research and Development,All,12 Years to 15 Years   (Child),Not Applicable,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,NL60377.042.16,6-Nov-17,31-Jan-19,31-Jan-19,18-Oct-18,null,18-Oct-18,"RSG De Borgen Lindenborg, Leek, Groningen, Netherlands|Greijdanus College, Zwolle, Overijssel, Netherlands|Gomarus College, Groningen, Netherlands|CSG Augustinus, Groningen, Netherlands",,https://ClinicalTrials.gov/show/NCT03711513
NCT03709615,Therapeutic Processes in iCBT for SAD,,Recruiting,No Results Available,Social Anxiety Disorder|Social Phobia,Behavioral: Internet delivered CBT for social anxiety disorder,Social anxiety severity|Diagnosis of SAD based on clinical interview|Social anxiety severity - additional measure,University of Haifa|Hebrew University of Jerusalem|Linkoeping University,All,18 Years to 60 Years   (Adult),Not Applicable,100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,UHaifaCBT,20-Dec-17,20-Dec-19,20-May-20,17-Oct-18,null,19-Oct-18,"University of Haifa, Haifa, Israel",,https://ClinicalTrials.gov/show/NCT03709615
NCT03702803,Efficacy and Safety Study of a IMSS Developed Phytopharmaceutical for the Treatment of Anxiety.,Alpra,Recruiting,No Results Available,Generalized Anxiety Disorder,Dietary Supplement: Galphimia glauca standardized extract|Drug: alprazolam 1mg,Therapeutic efficacy: improvement of the clinical condition higher than 90%. It will be measured by means of the Hamilton Rating Scale for Anxiety.|Therapeutic Tolerability: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Clinical Global Impression of Improvement Scale (CGI-I). A 7 points scale that is used to evaluate how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention.,"Coordinación de Investigación en Salud, Mexico",All,"18 Years and older   (Adult, Older Adult)",Phase 2,122,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Galphimia glauca phytopharm,16-Mar-16,Mar-19,Apr-19,11-Oct-18,null,12-Oct-18,"Regional General Hospital Number 1 at Cuernavaca, Morelos. Mexican Insitute of Social Security, Cuernavaca, Morelos, Mexico",,https://ClinicalTrials.gov/show/NCT03702803
NCT03692793,Pulmonary Rehabilitation in Functional Outcomes and Its Relationship With Morbidity and Mortality in Patients With COPD,,Recruiting,No Results Available,"Pulmonary Disease, Chronic Obstructive",Other: Pulmonary rehabilitation,Physical activity in daily life|Morbidity|Mortality|Dyspnea|Health status - COPD Assessment Test (CAT)|Health status - Saint George Respiratory questionnaire (SGRQ)|Anxiety and depression symptoms - Hospital Anxiety and Depression Scale (HADS)|Functional status - Glittre-ADL Test (TGlittre)|Functional status - Six-Minute Walk Test (6MWT)|Functional status - London Chest Activity of Daily Living (LCADL)|Postural balance - force platform NeuroCom (COP)|Postural balance - force platform NeuroCom (COG)|Postural balance -Timed Up and Go (TUG) Test|Postural balance - Berg Balance Scale (BBS)|Postural balance - Activities-specific Balance Confidence (ABC)|Postural balance - Falls Efficacy Scale - International - Brasil (FES-I-Brasil)|Peripheral muscle oxygenation during exercise and activities of daily living (oxyhemoglobin)|Peripheral muscle oxygenation during exercise and activities of daily living (deoxyhemoglobin)|Peripheral muscle oxygenation during exercise and activities of daily living (total hemoglobin)|Peripheral muscle oxygenation during exercise and activities of daily living|Motivation - Amotivation|Motivation - External regulation|Motivation - Identified regulation|Motivation - Introjected regulation|Motivation - Intrinsic regulation|Motivation - Self determination|General Self-efficacy|Disease-specific self-efficacy|Pulmonary Rehabilitation self-efficacy|Basic Psychological Needs,University of the State of Santa Catarina,All,"40 Years and older   (Adult, Older Adult)",Not Applicable,100,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NuReabPRP,1-Apr-13,31-Aug-20,31-Aug-21,2-Oct-18,null,2-Oct-18,"Núcleo de Assistência, Ensino e Pesquisa em Reabilitação Pulmonar, Florianópolis, SC, Brazil",,https://ClinicalTrials.gov/show/NCT03692793
NCT03688360,Facing Fears In-session or Out-session?,,Recruiting,No Results Available,Specific Phobia,Behavioral: Cognitive Behavioral Therapy,"Change in specific phobia severity (Interference, number of symptoms and general impression of the psychologist)|Change in level of anxiety (Subjective level of fear, Fearful cognitions, Bodily tension, Avoidance and Coping)|Change in approach behaviour towards phobic stimulus (Time and distance)|Change in self-efficacy (Academic, Social and Emotional)",University of Groningen|ZonMw: The Netherlands Organisation for Health Research and Development,All,8 Years to 12 Years   (Child),Not Applicable,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,NL59889.042.16,4-Oct-17,4-Oct-19,4-Oct-19,28-Sep-18,null,19-Oct-18,"Accare Universitair Centrum voor Kinder en Jeugdpsychiatrie, Groningen, Netherlands",,https://ClinicalTrials.gov/show/NCT03688360
NCT03688373,Facing Fears in Big or Smalls Steps?,,Recruiting,No Results Available,Specific Phobia,Behavioral: Cognitive Behavioral Therapy,"Change in specific phobia severity (Interference, number of symptoms and general impression of the psychologist)|Change in level of anxiety (Subjective level of fear, Fearful cognitions, Bodily tension, Avoidance and Coping)|Change in approach behaviour (Time and Distance)|Change in self-efficacy (Academic, Social and Emotional)",University of Groningen|ZonMw: The Netherlands Organisation for Health Research and Development,All,12 Years to 17 Years   (Child),Not Applicable,50,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,NL59986.042.16,4-Oct-17,4-Oct-19,4-Oct-19,28-Sep-18,null,19-Oct-18,"Accare Drachten, Drachten, Friesland, Netherlands|Accare Leeuwarden, Leeuwarden, Friesland, Netherlands|Accare Universitair Centrum voor Kinder en Jeugdpsychiatrie, Groningen, Netherlands",,https://ClinicalTrials.gov/show/NCT03688373
NCT03683303,"The Effects of Educational Program Using APP on Pre-Discharge Knowledge, Skills and Anxiety of Wound Care",,Completed,No Results Available,Wound,Behavioral: mobile applications (APP)|Behavioral: oral education,wound care knowledge|wound care skills|wound care anxiety|Heart rate variability (HRV)|Blood pressure(BP)|Heart rate (HR)|High frequency power (HF)|Low frequency power (LF)|The ratio of LF/HF,Kaohsiung Medical University Chung-Ho Memorial Hospital,All,"20 Years and older   (Adult, Older Adult)",Not Applicable,70,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Health Services Research,KMUHIRB-E(II)-20160030,Mar-16,Dec-16,Dec-16,25-Sep-18,null,26-Sep-18,,,https://ClinicalTrials.gov/show/NCT03683303
NCT03678415,Package of Community-based Mental Healthcare Services in Preventing Perinatal Mental Disorders,,Recruiting,No Results Available,Mental Disorder,Behavioral: Community-Based Primary Mental Health Care (CBPMHC) package,"Number of study participants with depression, anxiety and stress in perinatal period|Number of live births among the study participant's fetus|Number of still births among the study participant's fetus|Number of low birth weight babies among the study participant's fetus","International Centre for Diarrhoeal Disease Research, Bangladesh",Female,"Child, Adult, Older Adult",Not Applicable,1210,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,PR-17042,1-Apr-17,30-Jun-19,31-Dec-19,19-Sep-18,null,28-Feb-19,"ICDDR,B, Dhaka, Bangladesh",,https://ClinicalTrials.gov/show/NCT03678415
NCT03671057,"Effectiveness Study ""HospiAvontuur"":",,Recruiting,No Results Available,Children|Preoperative Anxiety|Surgery,Device: HospiAvontuur|Drug: Midazolam,mYPAS-SF (pre-operative)|VAK 4-12 (Vragenlijst Angst Kinderen) for anxiety (pre-operative)|ICC (pre-operative)|PAEDS (Pediatric Anxiety Emergency delirium Scale) (post-operative)|OPS (Objective Pain Score) (Post-operative)|Faces Pain Scale - Revised (FPS-R) (post-operative),PXL University College|Jessa Hospital,All,4 Years to 7 Years   (Child),Not Applicable,164,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",PXL_hospi game,1-Oct-17,30-May-19,30-Jul-19,14-Sep-18,null,20-Nov-18,"Jessa, Hasselt, Belgium",,https://ClinicalTrials.gov/show/NCT03671057
NCT03667729,The Effects of Progressive Muscle Relaxation Therapy in Patients With Schizophrenia,,Completed,No Results Available,Affective Disorders|Psychotic Disorder,Behavioral: progressive muscle relaxation,Quality of life simplified Chinese versions of the WHOQOL-BREF questionnaire were used|Anxiety Scale|Positive and Negative Syndrome Scale (PANSS),Taipei Medical University,All,"20 Years to 65 Years   (Adult, Older Adult)",Not Applicable,75,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care,C20140205,30-Jun-14,29-Jun-15,29-Jun-15,12-Sep-18,null,12-Sep-18,,,https://ClinicalTrials.gov/show/NCT03667729
NCT03664310,Transdiagnostic Sleep and Anxiety Treatment,,"Active, not recruiting",No Results Available,Anxiety Disorders,Other: FSET Anxiety and Sleep Treatment|Other: Control,Safety Aid Scale|Sleep Related Behavior Questionnaire|Penn State Worry Questionnaire|Dimensional Obsessive Compulsive Scale|Insomnia Severity Index,Florida State University,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,61,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,2018.23848,1-Aug-17,1-Aug-18,31-Dec-19,10-Sep-18,null,10-Sep-18,"Anxiety and Behavioral Health Clinic, Tallahassee, Florida, United States",,https://ClinicalTrials.gov/show/NCT03664310
NCT03662607,Impact of Virtual Reality on Pre-procedural anxieTy Prior to Heart cathEterIzAtion - VR-THEIA,VR-THEIA,Recruiting,No Results Available,Preprocedure Anxiety,Behavioral: Virtual reality experience,Change in Anxiety Measured by the STAI|Sense of Preparedness evaluated by site survey,Spectrum Health Hospitals,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,172,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2017-074,18-Apr-17,31-Dec-19,31-Dec-20,7-Sep-18,null,7-Sep-18,"Spectrum Health, Grand Rapids, Michigan, United States",,https://ClinicalTrials.gov/show/NCT03662607
NCT03659409,Stroke Of Mindfulness: Investigating Physiological and Psychological Well-being,SOM,Completed,No Results Available,Stroke|Stress|Anxiety|Depression,Behavioral: Mindfulness-Based Intervention|Behavioral: Waitlist - Mindfulness-Based Intervention,Cohen Perceived Stress Scale|Centre for Epidemiologic Studies Depression Scale (CES-D)|Stroke Specific Quality of Life Scale (SS-QOL)|Stroke Impact Scale (SIS)|Short-Form-36 (SF-36)|Zarit Burden Interview|Five Facet Mindfulness Questionnaire|Big Five Personality Inventory,Singapore General Hospital,All,"21 Years to 80 Years   (Adult, Older Adult)",Not Applicable,50,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2016/2361,12-May-16,31-Dec-18,31-Dec-18,6-Sep-18,null,1-May-19,"Singapore General Hospital, Singapore, Singapore",,https://ClinicalTrials.gov/show/NCT03659409
NCT03659630,MyCompass in a Swedish Context - an Automated Self-help Intervention Targeting Mental Health Problems,,Completed,No Results Available,"Mild Depression|Anxiety State|Sleep Disturbance|Stress, Psychological",Behavioral: MyCompass|Behavioral: Comparison group,PHQ-9|GAD-7,Karolinska Institutet,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,837,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,2015/1268-31/2 + 2016/88,Dec-15,Jan-17,Jan-17,6-Sep-18,null,6-Sep-18,,,https://ClinicalTrials.gov/show/NCT03659630
NCT03660319,The Effect of EMT on Anxiety Levels and Perception of Waiting Time in the Radiation Oncology Waiting Room,,Completed,No Results Available,Cancer,Other: Environmental Music Therapy,Wong-Baker Faces Scale|Short-Form STAI|Perceived Waiting Time,Icahn School of Medicine at Mount Sinai,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,160,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GCO 16-1190,20-Nov-12,26-Mar-19,26-Mar-19,6-Sep-18,null,18-Apr-19,"Mount Sinai Downtown Union Square, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT03660319
NCT03654599,Effects of Digital Stories Intervention on Psychosocial Well-being,,Recruiting,No Results Available,Bone Marrow Transplant|Information Disclosure|Hematopoietic Stem Cell Transplantation|Psychosocial Health|Depression|Anxiety|Stress|Narrative,Behavioral: Baseline Surveys|Behavioral: Digital Stories Intervention|Behavioral: Information Control Intervention,Changes from Baseline Profile of Mood States (POMS) short version (Emotional Well-being or /Reduction of Emotional Distress) at 4 weeks and 3 months|Changes from Baseline social well-being (using the general Functional Assessment of Cancer Therapy (FACT-G) social well-being scale) at 4 weeks and 3 months,Arizona State University|Mayo Clinic|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,220,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care",GR11968|R15CA213035,1-Sep-17,Dec-19,31-Aug-20,31-Aug-18,null,5-Sep-18,"Mayo Clinic, Phoenix, Arizona, United States",,https://ClinicalTrials.gov/show/NCT03654599
NCT03650465,Comparing Different CBT Approaches in GAD,CBTforGAD,Completed,No Results Available,Generalized Anxiety Disorder,Behavioral: Cognitive-behavioral therapy (CBT),Generalized anxiety symptoms|Worry|Automatic thoughts frequency|Automatic thoughts believability,"Babes-Bolyai University|Albert Ellis Institute, New York",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,75,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BabesBolyaiU,16-May-09,30-Sep-18,30-Sep-18,28-Aug-18,null,15-Jan-19,"Babes-Bolyai University, Department of Clinical Psychology and Psychotherapy, Cluj Napoca, Non-US/Non-Canadian, Romania",,https://ClinicalTrials.gov/show/NCT03650465
NCT03645811,The Comparison of Three Different Techniques on OSCE,,Completed,No Results Available,Anxiety|Educational Problems,Behavioral: Breathing Technique|Behavioral: Music Therapy|Behavioral: EFT,The Situational-Continuous Anxiety Inventory,Istanbul Saglik Bilimleri University,All,18 Years to 24 Years   (Adult),Not Applicable,120,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care,10840098-604.01.01-E.11892,1-Jan-17,31-May-17,14-May-18,24-Aug-18,null,24-Aug-18,"Medipol Universtiy, Istanbul, Turkey",,https://ClinicalTrials.gov/show/NCT03645811
NCT03642015,The Effect of Music on Anxiety in Patients Prior to Gastrointestinal Procedures,,Completed,No Results Available,Music|Anxiety,Behavioral: Music listening,Change from Baseline Anxiety after intervention immediately|Change from Baseline Blood pressure after intervention immediately|Change from Baseline Heart Rate after intervention immediately|Change from Baseline Respiratory Rate after intervention immediately,"National Defense Medical Center, Taiwan",All,"20 Years and older   (Adult, Older Adult)",Not Applicable,200,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care,TSGH-C97-151,1-Jul-08,1-Sep-08,30-Jun-09,22-Aug-18,null,22-Aug-18,,,https://ClinicalTrials.gov/show/NCT03642015
NCT03639831,"ACUTE AND CHRONIC EFFECTS OF A BOTANICAL EXTRACT ON ANXIETY, PERCEIVED STRESS, MOOD AND CORTISOL IN HEALTHY ADULTS",,Completed,No Results Available,Mood Disorders,"Dietary Supplement: Proprietary, standardized botanical extract|Dietary Supplement: Placebo (maltodextrin)",Mood state|POMS-2 subscores|Anxiety state State-Trait Anxiety Inventory|Anxiety state according to the Hospital Anxiety and Depression Scale|Percentage of responders|Psychological stress|Worry feeling|Coping response to stress|Depressive-like state|Quality of life score|Cognitive performances|Diurnal cortisol secretion|Diurnal cortisol metabolism|Biological response to an acute stressor|Psychological response to an acute stressor assessed through the STAI|Psychological response to an acute stressor assessed on a Visual Analogical Scale|Hemodynamic response to an acute stressor|Galvanic Skin Response to the acute stressor,Activ'inside|Northumbria University,All,18 Years to 60 Years   (Adult),Not Applicable,65,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other",PTC198-2017,6-Nov-17,15-Nov-18,31-Mar-19,21-Aug-18,null,10-Apr-19,"Brain, Performance and Nutrition Research Centre, Northumbria University, Newcastle upon Tyne, United Kingdom",,https://ClinicalTrials.gov/show/NCT03639831
NCT03636880,Heart Failure Insomnia Treatment Study,H-FITS,Recruiting,No Results Available,Heart Failure|Cardiac Failure|Congestive Heart Failure|Insomnia|Sleep Disorder|Sleep Initiation and Maintenance Disorders|Disorders of Initiating and Maintaining Sleep|Anxiety|Depression,Behavioral: Brief treatment for Insomnia|Behavioral: Sleep Monitoring,Insomnia severity|Sleep quality assessed by the PSQI|Sleep efficiency|Executive function|Memory|Attention and psychomotor performance|Decision making assessed by the IGT|Decision making assessed by the MCQ|Decision making assessed by the GDT|Anxiety|Depression|HF-related quality of life|HF self-care|Functional Status,Ohio State University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,200,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,2016H0451,24-Feb-17,May-19,Dec-19,17-Aug-18,null,17-Aug-18,"The Ohio State University Wexner Medical Center, Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT03636880
NCT03630783,Combined CBM For Social Anxiety in Turkey,,Completed,No Results Available,"Phobia, Social",Behavioral: Combined Cognitive Bias Modification,Social anxiety|Depression|Anxiety|Automatic Thoughts Questionnaire|Dysfunctional Attitudes|Attentional bias|Interpretational bias,Istanbul Sabahattin Zaim University|Hacettepe University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,84,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Prevention",IstanbulSZU,Mar-15,Apr-16,Jun-16,15-Aug-18,null,20-Aug-18,"Volkan Koç, Küçükçekmece, İstanbul, Turkey",,https://ClinicalTrials.gov/show/NCT03630783
NCT03630965,CPR Audiovisual Tool to Impact ICU Patients' Surrogate Anxiety Level.,,Recruiting,No Results Available,Critical Illness,Other: CPR Video,"Measure the impact of CPR video on the Surrogate's level of anxiety during the decision-making process on code status, in the ICU compared to the control group of surrogates (No intervention group).|Measure the impact of CPR video on patients' surrogate's knowledge about CPR, when compared to the No intervention group.|Analyze the surrogates' comfort when watching the video.|Describe if the CPR video's impact on surrogates' anxiety level, is affected by the patient's severity of illness as per the SOFA score.",Medical College of Wisconsin,All,"18 Years to 100 Years   (Adult, Older Adult)",Not Applicable,30,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,PULM-AV-CPR|PRO00029203,8-May-17,31-Dec-19,30-May-20,15-Aug-18,null,16-Aug-18,"Medical College of Wisconsin/Froedtert Hospital, Milwaukee, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT03630965
NCT03625297,Shelter Cat Adoption in Families of Children With Autism (Feline Friends),,Recruiting,No Results Available,Social Skills|Anxiety,Other: shelter cat,"Change in Social Skills of child with autism over time from baseline to 6, to 12 and to 18 weeks|Change in Anxiety of child with autism over time from baseline to 6, to 12 and to 18 weeks|change in parent Human-animal Bonding over time from 2-3 days, to 6, to 12 and 18 weeks|change in child Human-animal Bonding over time from 2-3 days, to 6, to 12 and 18 weeks",University of Missouri-Columbia|Winn Feline Foundation|Human Animal Bond Research Institute (HABRI),All,6 Years to 17 Years   (Child),Not Applicable,64,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other,2008460,23-Jun-17,1-Jun-20,1-Dec-20,10-Aug-18,null,10-Aug-18,"University of Missouri, Columbia, Missouri, United States",,https://ClinicalTrials.gov/show/NCT03625297
NCT03625843,Mindfulness Exercises to Reduce Anxiety and Pain During Urodynamic Testing,,Completed,No Results Available,"Stress Incontinence, Female|Overactive Bladder|Lower Urinary Tract Symptoms",Behavioral: Mindfulness exercises,Anxiety during urodynamics as measured the STAI-6.|Positive and negative emotions as measured by the urodynamic questionnaire|Pain as measured by the VAS,San Antonio Uniformed Services Health Education Consortium,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,27,U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,c.2016.202d,29-Sep-16,30-Dec-17,30-Apr-18,10-Aug-18,null,10-Aug-18,,"""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT03625843/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03625843
NCT03623815,A Functional Magnetic Resonance Imaging Investigation of Transcranial Direct Current Stimulation,,Completed,No Results Available,Anxiety State,Other: transcranial direct current stimulation,The change in neural activity during an attentional control task after sham versus real tDCS|The change in accuracy in an attentional control task after sham versus real tDCS|The change in reaction time in an attentional control task after sham versus real tDCS|The change in self report anxiety after sham versus real tDCS|The change in sadness/happiness after sham versus real tDCS|The change in hostility/friendliness after sham versus real tDCS|The change in calmness/tenseness after sham versus real tDCS,University of Oxford|Medical Research Council,Female,18 Years to 45 Years   (Adult),Not Applicable,18,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other,MS-IDREC-C2-2015-003,5-Feb-15,8-Sep-15,6-Oct-15,9-Aug-18,null,9-Aug-18,,,https://ClinicalTrials.gov/show/NCT03623815
NCT03621722,AroMatherapy for Blood and Marrow Transplant PatIENTs (AMBIENT),AMBIENT,"Active, not recruiting",No Results Available,Anxiety|Nausea|Vomiting,Other: Elequil Aromatabs,Using the Halpin 0-to-5 Nausea and Vomiting Scales to document the degree of severity of patients' self-reported blood and marrow transplant conditioning regimen induced nausea and vomiting|Using the Patient Self-Report of Anxiety Assessment Tool to document the degree of severity of patients' self-reported anxiety|Number of PRN antiemetics for prolonged standardized antiemetic regimen|Duration of PRN antiemetics for prolonged standardized antiemetic regimen|Number of PRN anxiolytics for prolonged standardized anxiolytic regimen|Duration of PRN anxiolytics for prolonged standardized anxiolytic regimen|Using the Patient Self-Report of Anxiety Assessment Tool to document the severity of anxiety prior to and following application of the patch|Using the Halpin 0-to-5 Nausea and Vomiting Scales to document the severity of nausea/vomiting prior to and following application of the patch,Hackensack Meridian Health,All,"22 Years and older   (Adult, Older Adult)",Not Applicable,30,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PRO2017-0162,27-Feb-17,2-Oct-19,31-Dec-19,8-Aug-18,null,2-Oct-18,"Hackensack University Medical Center, Hackensack, New Jersey, United States",,https://ClinicalTrials.gov/show/NCT03621722
NCT03618121,Innovations in Biofeedback and Its Use in Mental Health,,Withdrawn,No Results Available,"Anxiety|Biofeedback, Psychology",Device: Biofeedback plus gaming (Nevermind)|Device: Biofeedback only (The Pip)|Behavioral: Relaxation training|Behavioral: Gaming only,Anxiety Disorders Interview Schedule - 5 (ADIS-5)|Beck Anxiety Inventory|COPE|Perceived Stress Scale|Functional outcome (sleep),East Tennessee State University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",0516.15f,15-Jul-17,15-Jul-19,15-Jul-19,7-Aug-18,null,8-Aug-18,,,https://ClinicalTrials.gov/show/NCT03618121
NCT03619135,Effectiveness of External Vibration for Pain Relief During Intravenous Access in Adult Patients,,Completed,Has Results,Pain Management|Anxiety,Device: Buzzy|Other: Placebo,Change in Pain|Change in Anxiety,Kyle Stein|University of Iowa,All,18 Years to 40 Years   (Adult),Not Applicable,100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,201601806,17-Oct-16,24-Aug-17,24-Aug-17,7-Aug-18,5-Feb-19,5-Feb-19,"University of Iowa College of Dentistry, Iowa City, Iowa, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/35/NCT03619135/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03619135
NCT03612102,Evaluating Intensive Group Behavioral Treatment for Children With Selective Mutism,,Completed,No Results Available,Selective Mutism,Behavioral: Intensive Group Behavioral Treatment (IGBT),Clinical Global Impressions Scales - Improvement (CGI-I)|Anxiety Disorders Interview Schedule for Children (ADIS)|Selective Mutism Questionnaire (SMQ)|Children's Global Assessment Scale (CGAS)|Child Behavior Checklist (CBCL)|School Speech Questionnaire (SSQ)|Impairment Rating Scale (IRS),Florida International University|National Institute of Mental Health (NIMH)|American Psychological Association (APA) Division 53,All,5 Years to 9 Years   (Child),Not Applicable,29,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,800008139,11-Feb-17,14-Dec-17,14-Dec-17,2-Aug-18,null,15-Aug-18,"Florida International University, Miami, Florida, United States",,https://ClinicalTrials.gov/show/NCT03612102
NCT03610373,Testing Psychosocial Treatment Planning Methods for Youth Anxiety and Depression,,"Active, not recruiting",No Results Available,Anxiety Disorders|Depressive Disorder,Behavioral: Modular Approach to Therapy for Children (MATCH),Anxiety Disorders Interview Schedule for DSM-IV - Child/Parent|Satisfaction with Decision Scale,Boston University Charles River Campus|National Institute of Mental Health (NIMH),All,7 Years to 15 Years   (Child),Not Applicable,45,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research,3462|K23MH101238,4-Oct-16,27-Nov-19,27-Nov-19,1-Aug-18,null,25-Oct-18,"Boston University, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT03610373
NCT03601377,Attention Bias Modification Treatment in Social Anxiety,ABMT,Completed,No Results Available,Social Anxiety,Behavioral: Training away from threat|Behavioral: Training towards threat|Behavioral: Placebo,Social Anxiety levels|Social Anxiety changes|Attentional Biases|Attentional Biases changes|Physical social anxiety levels|Physical social anxiety changes|Social Anxiety levels (clinical interview)|Physical social anxiety levels 1|Physical social anxiety levels 2|Social anxiety changes|Physical social anxiety changes 1|Physical social anxiety changes 2,University of Cyprus|Youth Board of Cyprus|Tel Aviv University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,140,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ABMT University of Cyprus,3-Oct-16,31-Jul-18,30-Sep-18,26-Jul-18,null,30-Oct-18,"Department of Psychology, University of Cyprus, Nicosia, Cyprus",,https://ClinicalTrials.gov/show/NCT03601377
NCT03586921,Primary Care Group Therapy for Depression/Anxiety for Women in Petropolis,,Completed,No Results Available,Depression|Anxiety Disorders,Behavioral: Psychosocial Group Intervention|Other: Enhanced Usual Care,"Depression (Beck Depression Inventory)|Anxiety (Beck Anxiety Inventory)|Quality of Life (World Health Organization Quality of Life Assessment, Brief Version)",Rio de Janeiro State University,Female,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,340,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DEP-ANX_PETROPOLIS,19-May-06,25-Sep-07,15-Jan-08,16-Jul-18,null,16-Jul-18,,"""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/21/NCT03586921/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03586921
NCT03581097,Educational Video and Peri-operative Anxiety,,Completed,No Results Available,Ambulatory Surgical Procedures|Anxiety Disorders,Other: Video Group,VAS-A score anxiety level|Degree of satisfaction|Vital Parameters 1: arterial Blood Pressure|Vital Parameters 2: Respiratory Rate|Vital Parameters 3: Heart Rate|First subgroups analyze: anxious patients|Second subgroups analyze: higher anxiety score|Third subgroup analyze: first experience with surgery.,"University Hospital, Geneva",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,150,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,CERU-1801,1-Feb-13,30-May-13,10-Jun-18,10-Jul-18,null,11-Jul-18,"Andrea Saporito MD, Bellinzona, Switzerland",,https://ClinicalTrials.gov/show/NCT03581097
NCT03572543,Enhancement of Therapeutic Learning in OCD Using tDCS,,"Active, not recruiting",No Results Available,Obsessive-Compulsive Disorder,Device: tDCS,Subjective Units of Distress,Yale University|National Institute of Mental Health (NIMH),All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,24,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Basic Science",1412015006_a|1K23MH111977,14-Feb-17,31-Jul-19,1-Dec-19,28-Jun-18,null,24-Jan-19,"Connecticut Mental Health Center, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT03572543
NCT03566212,Efficacy of Camouflaged Syringe vs Conventional Syringe,ECC,Completed,No Results Available,Dental Anxiety|Behavior,Device: Conventional Syringe|Device: Camouflage Syringe,Anxiety levels by using the Chotta Bheem and Chutki scale|Behavior rating by using Frankel Behaviour rating scale,Sneha D. Suwarnkar|Saraswati-Dhanwantari Dental College & Hospital,All,3 Years to 12 Years   (Child),Not Applicable,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SaraswatiDhanwantari,13-Aug-17,27-Aug-17,30-Aug-17,25-Jun-18,null,5-Oct-18,"Dr Sneha D Suwarnkar, Parbhani, Maharashtra, India",,https://ClinicalTrials.gov/show/NCT03566212
NCT03554512,TelePremie: Telehomecare for Step-down Care Post-NICU Discharge,,"Active, not recruiting",No Results Available,Anxiety|Self Efficacy,Other: Telehealth virtual appointment,The State-Trait Anxiety Inventory|The Maternal Confidence Questionnaire,Horizon Health Network|Canada Health Infoway,All,"Child, Adult, Older Adult",Not Applicable,37,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,CHSTHCHHN02,1-Jul-17,Jul-18,Jul-18,13-Jun-18,null,13-Jun-18,"Saint John Regional Hospital, Saint John, New Brunswick, Canada",,https://ClinicalTrials.gov/show/NCT03554512
NCT03550144,Improving Mental Health and Well-Being Via Awe Walks,,Completed,No Results Available,Awe|Compassion|Anxiety,Behavioral: Awe Walk|Behavioral: Control Walk,Daily awe experience questionnaire|Daily compassion experience questionnaire|Daily negative emotional experience questionnaire|Generalized Anxiety Disorder- 7 Item Scale|Satisfaction With Life Scale,"University of California, San Francisco|University of California, Berkeley",All,"40 Years to 90 Years   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention,16-20001,5-Dec-16,10-Dec-17,26-May-18,8-Jun-18,null,12-Oct-18,"UCSF Memory and Aging Center, San Francisco, California, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/44/NCT03550144/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/44/NCT03550144/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03550144
NCT03548402,Acceptance and Commitment Therapy for Nonsuicidal Self-injury,,Completed,No Results Available,Nonsuicidal Self-Injury|Anxiety,Behavioral: Acceptance and Commitment Therapy (ACT),Urges to Self-Injure|Experiential Avoidance,Southern Methodist University,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,10,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2012-029-MEUA,19-Mar-12,19-Mar-15,May-15,7-Jun-18,null,7-Jun-18,"Stress, Anxiety, and Chronic Disease Research Program, Southern Methodist University, Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT03548402
NCT03547180,Mechanisms of Treatment Change in Panic Disorder and Agoraphobia,,Completed,No Results Available,Panic Disorder With Agoraphobia,Behavioral: Cognitive Therapy|Behavioral: Capnometry-Assisted Respiratory Training|Behavioral: In-vivo exposure,Change in panic symptom severity assessed by the Panic Disorder Severity Scale/CGI|Cortisol Assessments collecting 8 saliva samples per day|Heart rate measures using lifeshirt|CO2 level measures using capnometer|respiratory rate measures using lifeshirt|Anxiety Sensitivity Index measuring fear of panic symptoms|Beck Depression Inventory measuring mood symptoms|Body Sensations Questionnaire measuring fear of panic symptoms|The Mobility Inventory for Agoraphobia questionnaire to assess agoraphobic avoidance|Agoraphobia Cognition Questionnaire to assess cognitive misappraisal|Anxiety Control Questionnaire to assess perceived control|self-report (questionnaires),Southern Methodist University|Boston University|University of Michigan,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,41,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,MEUA-2005,Jan-04,Jan-08,Mar-08,6-Jun-18,null,6-Jun-18,"Southern Methodist University, Department of Psychology, Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT03547180
NCT03545022,Acupuncture on Anxiety and Inflammatory Events Following Surgery of Mandibular Third Molars,,Completed,No Results Available,"Tooth Extraction|Molar, Third|Pain, Postoperative|Trismus|Edema|Anxiety",Procedure: Acupuncture,Presence and intensity of postoperative pain at 24 hours following the surgery|Presence and intensity of postoperative pain at 48 hours following the surgery.|Presence and intensity of postoperative pain at 72 hours following the surgery.|Change from baseline facial swelling (edema) at 24 hours following the surgery.|Change from baseline facial swelling (edema) at 48 hours following the surgery.|Change from baseline facial swelling (edema) at 72 hours following the surgery.|Change from baseline facial swelling (edema) at 7 days following the surgery.|Change from baseline mouth opening at 24 hours following the surgery.|Change from baseline mouth opening at 48 hours following the surgery.|Change from baseline mouth opening at 72 hours following the surgery.|Change from baseline mouth opening at 7 days following the surgery.|Change of anxiety state scores using STAI questionnaire at the moment before the preoperative acupuncture and after the acupuncture.|Change of anxiety state scores using a Visual Analogue Scale (VAS) questionnaire at the moment before the preoperative acupuncture and after the acupuncture.|Duration of surgery|Number of painkillers tablets,Federal University of the Valleys of Jequitinhonha and Mucuri,All,"17 Years to 30 Years   (Child, Adult)",Not Applicable,18,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",1.688.806,Aug-16,Mar-17,Mar-17,4-Jun-18,null,4-Jun-18,,,https://ClinicalTrials.gov/show/NCT03545022
NCT03544450,Effectiveness of Non-medical Health Worker (NMHW) Led Counseling on Common Mental Disorders in Rural Mid-western Nepal,,Completed,No Results Available,Mental Disorders|Psychological Distress|Depression|Anxiety|Coping,Behavioral: Psychosocial counselling|Other: Enhanced Usual Care,The proportion of participants who have a response to treatment when assessed by change in the symptoms of depressive symptoms measured by Beck Depression Inventory|Change in the symptoms of anxiety assessed by Beck Anxiety Inventory|Change in the functional capacity assessed by World Health Organisation Disability Assessment Schedule - II|Change in the symptoms of depression assessed by Beck Depression Inventory,"Centre for Victims of Torture, Nepal|Physicians for Social Responsibility, Finland",All,"16 Years and older   (Child, Adult, Older Adult)",Not Applicable,287,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,CounselingCvict,May-16,Aug-17,Dec-17,1-Jun-18,null,11-Jun-18,,,https://ClinicalTrials.gov/show/NCT03544450
NCT03538860,Validation of an Automated Online Language Interpreting Tool - Phase Two.,,Recruiting,No Results Available,Mood Disorder|Anxiety Disorder|Substance Use Disorder|Chronic Medical Condition,Behavioral: Active comparator: Human interpreter|Behavioral: Intervention: Asynchronous Telepsychiatry,Diagnostic accuracy|Diagnostic Inter-rater reliability|Satisfaction ratings|Interview and language interpretation quality|Interview and language interpretation accuracy,"University of California, Davis|Agency for Healthcare Research and Quality (AHRQ)",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100,Other|U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,1131922|R01HS024949,14-Nov-17,31-Jul-21,31-Jul-21,28-May-18,null,1-May-19,"UC Davis Medical Center, Sacramento, California, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/60/NCT03538860/ICF_001.pdf|""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/60/NCT03538860/Prot_SAP_002.pdf",https://ClinicalTrials.gov/show/NCT03538860
NCT03538873,"""Prevention and Treatment of Depression in the Elderly: A Population-Based Study""",,"Active, not recruiting",No Results Available,Subsyndromic Symptoms of Depression|Subsyndromic Symptoms of Anxiety,Behavioral: Physical activity,"Cumulative incidence of major depressive disorder, or anxiety disorders|CES-D|SF36",University of Sao Paulo General Hospital|Fundação de Amparo à Pesquisa do Estado de São Paulo,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,70,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,LLD10446,Aug-14,Feb-19,Feb-19,28-May-18,null,28-May-18,"Institute of Psychiatry, USaoPauloGH, Sao Paulo, Brazil",,https://ClinicalTrials.gov/show/NCT03538873
NCT03539263,Effects of Probiotics on Mood,,Completed,No Results Available,"Depression, Anxiety",Dietary Supplement: Bifihappy|Other: Placebo,Change in the psychological profile|Evaluation of mood - State Trait Anxiety Inventory (STAI) standardized questionnarie.|Evaluation of mood - Beck Depression Inventory (BDI-2) standardized questionnarie.|Evaluation of mood - Profile od Mood State (POMS) standardized questionnarie.|Evaluation of the quality of sleep.|Evaluation of personality - Temperament and Character Inventory (TCI) standardized questionnarie.|Evaluation of personality - Cope Orientation to Problem Experienced-New Italian Version (COPE-NIV) standardized questionnarie.|Evaluation of personality - Behavioral Inhibition System and Behavioral Activation System Scale (BIS/BAS) standardized questionnarie.|Evaluation of personality - Life Orientation Test-revisited (LOT-R) standardized questionnarie.,Probiotical S.p.A.|Universita di Verona,All,18 Years to 35 Years   (Adult),Not Applicable,39,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",766CESC,20-Dec-16,15-Jun-17,15-Jun-17,28-May-18,null,28-May-18,"University of Verona, Verona, Italy",,https://ClinicalTrials.gov/show/NCT03539263
NCT03535805,"Transdiagnostic, Cognitive and Behavioral Intervention for in School-aged Children With Emotional and Behavioral Disturbances",MindMyMind RCT,Enrolling by invitation,No Results Available,Anxiety|Anxiety Disorders|Depressive Symptoms|Depressive Disorders|Problem Behavior|Oppositional Defiant Disorder|Conduct Disorder|Other Behavioral and Emotional Disorders With Onset Usually Occurring in Childhood and Adolescence,Behavioral: Mind My Mind (MMM)|Behavioral: Treatment as Usual (TAU),"The child's impact of mental health problems reported by the parent on the Strengths and Difficulties Questionnaire (SDQ)|Child' anxiety reported by the parent on 'Spence Children's Anxiety Scale (SCAS)|Child's depressive symptoms reported by the parent on the Mood and Feelings Questionnaire (MFQ)|Weiss Functional impairment rating Scale (WFIRS)|The self-reported physical and psychological well-being (two subscales from the KIDSCREEN).|The child's behavioural problems, reported by the parent on the Eyberg Child Behaviour Inventory (ECBI)|Total emotional and behavioural difficulties, reported by parents (SDQ)|School attendance|Top-problem scores, parent-reported|The self-reported impact of mental health problems (SDQ, only children of age ≥ 11 years)|The teacher-reported impact of mental health problems (SDQ)|Self-reported anxiety reported (SCAS, only children of age ≥ 8 years)|Self-reported depressive symptoms (MFQ, only children of age ≥ 8 years)|Self-reported Top-problem scores|The parent-reported Health-Related Quality of Life (HRQOL) of their child (KIDSCREEN)|Self-reported emotional and behavioural difficulties (SDQ, only children of age ≥ 11 years)|Teacher-reported emotional and behavioural difficulties (SDQ)|Parental Stress Scale (PSS)|The parent-reported Experience of Service Questionnaire (ESQ)|The self-reported Experience of Service Questionnaire (ESQ)|The parent- and child-reported Child Health Utility 9D (CHU9D)|Parents' absence from work|Treatment and support received by the child and the family|The primary measures of potential harms|The secondary measures of potential harm|Costs|Incremental cost-effectiveness ratio (ICER)","Mental Health Services in the Capital Region, Denmark|TrygFonden, Denmark|The Danish Mental Health Foundation|Defactum, Central Denmark Region",All,6 Years to 16 Years   (Child),Not Applicable,412,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,The Mind My Mind Trial,7-Sep-17,30-Apr-19,30-Apr-19,24-May-18,null,28-May-18,"Mental Health Services in the Capital Region, Denmark, Copenhagen, Denmark",,https://ClinicalTrials.gov/show/NCT03535805
NCT03533036,Virtual Reality Experience in First Trimester D&C,,"Active, not recruiting",No Results Available,First Trimester Abortion|Virtual Reality,Device: applied VR headset,Number of participants able to use VR device throughout the entire duration of first trimester surgical abortion.|Number of participants with decreased procedure related anxiety as assessed by the Modified Amsterdam Preoperative Anxiety and Information Scale (APAIS) survey,"University of California, Los Angeles|Society of Family Planning",Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,30,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,IRB#17-001122,13-Dec-17,29-Nov-18,13-Dec-18,22-May-18,null,22-May-18,"University of California Los Angeles Obstetrics and Gynecology Clinic, Los Angeles, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/36/NCT03533036/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03533036
NCT03530943,Pet Partners for Promotion of Academic Life Skills,Pet PALS,Recruiting,No Results Available,Stress Prevention|Cortisol|Anxiety Disorders and Symptoms|Depression Disorders and Symptoms|Executive Functioning|Motivation and Learning|Momentary Emotion|Study Strategies|Perceived Stress|Animal Behavior|Animal Stress|Dyadic Interaction|Alpha-amylase,Behavioral: Animal Assisted Activities|Behavioral: Academic Stress Management tools,Change in Salivary Cortisol (Diurnal)|Change in Salivary Cortisol (Basal)|Change in Salivary Cortisol (Momentary Reactivity)|Change in Momentary Emotion (Experience Sampling Method Questionnaire)|Change in Learning and Study Strategies (Learning and Study Strategies Inventory)|Change in Depression (Beck Depression Inventory)|Change in Anxiety (Beck Anxiety Inventory)|Change in Perceived Stress (Perceived Stress Scale - 10)|Change in Executive Functioning (Behavior Rating Inventory of Executive Functioning - Adult Version)|Salivary Alpha-Amylase (Diurnal)|Salivary Alpha-Amylase (Basal)|Salivary Alpha-Amylase (Momentary Reactivity)|Attitudes Towards Learning|Self-perceived worry (Penn State Worry Questionnaire),Washington State University,All,18 Years to 30 Years   (Adult),Not Applicable,300,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention,126634-001,Aug-16,Dec-18,Dec-18,21-May-18,null,21-May-18,"Washington State University, Pullman, Washington, United States",,https://ClinicalTrials.gov/show/NCT03530943
NCT03515486,Cerebellar Stroke and Mood Disorders,CERMOOD,Recruiting,No Results Available,Stroke,Other: Post stroke mood disorders evaluation,Center of Epidemiological Studies-Depression scale (CES-D)|Beck Anxiety Inventory (BAI)|Apathy Inventory (AI)|Experience Sampling Method (ESM) evaluations|Actimetry|Trait-Meta-Mood-Scale (TMMS)|Interpersonal Reactivity Index (IRI)|Facial emotion recognition tests|Brain Magnetic Resonance Imaging,"University Hospital, Bordeaux",All,"18 Years to 90 Years   (Adult, Older Adult)",Not Applicable,70,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,CHUBX 2015/36,16-Jan-17,16-Dec-18,16-Dec-18,3-May-18,null,3-May-18,"CHU de Bordeaux, Bordeaux, France",,https://ClinicalTrials.gov/show/NCT03515486
NCT03515564,Alternative Therapies for High Stress and Trauma-Exposed Refugees,,Enrolling by invitation,No Results Available,PTSD|Depression|Anxiety|Stress|Trauma,"Behavioral: Dance/Movement Therapy, Art Therapy, Mindful Yoga, or HIIT|Behavioral: Standard Care",PTSD symptoms (children)|PTSD symptoms (adults)|Depressive symptoms (adults)|Depressive Symptoms (Children)|Anxiety Symptoms (Children)|Somatic Symptoms (adults and children)|Inflammatory State|Cortisol,Wayne State University,All,"7 Years to 45 Years   (Child, Adult)",Not Applicable,300,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1706000635,26-Jul-17,Jul-19,May-22,3-May-18,null,3-May-18,"Wayne State U Department of Psychiatry, Detroit, Michigan, United States",,https://ClinicalTrials.gov/show/NCT03515564
NCT03512587,Personalized Quantum Sonotherapy in Regional Anesthesia,,Completed,No Results Available,"Pain, Postoperative|Anxiety",Procedure: Personalized quantum sonotherapy|Procedure: Placebo,Pain|Anxiety,CES University,All,18 Years to 60 Years   (Adult),Not Applicable,80,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,645,1-Feb-17,31-Mar-17,31-Mar-17,1-May-18,null,1-May-18,"Instituto Colombiano del Dolor, Medellin, Antioquia, Colombia",,https://ClinicalTrials.gov/show/NCT03512587
NCT03511534,Open/Aftercare Treatment for Participants Diagnosed With Obsessive Compulsive Disorder,,Recruiting,No Results Available,OCD,Behavioral: Psychotherapy|Other: Pharmacotherapy,Improvement in the severity of OCD symptoms as measured by the Yale-Brown Obsessive Compulsive Scale (YBOCS),Stanford University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,200,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,41165,23-Jun-17,Jun-25,Jun-26,30-Apr-18,null,3-May-19,"Stanford University, Stanford, California, United States",,https://ClinicalTrials.gov/show/NCT03511534
NCT03509714,Oxaloacetate Supplementation for Emotional PMS,OAA4PMS,Completed,No Results Available,Premenstrual Syndrome (PMS),Dietary Supplement: Jubilance (100 mg Oxaloacetate/150 mg Ascorbic Acid)|Dietary Supplement: rice flour (Placebo),Depression associated with Emotional PMS|Anxiety associated with Emotional PMS|Perceived Stress with Emotional PMS|Aggression with Emotional PMS|Adverse Event Reporting|Suicidal Ideation with Emotional PMS,Terra Biological LLC,Female,18 Years to 50 Years   (Adult),Not Applicable,48,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",EmotionalPMS1|TV-OX-108,17-Oct-16,1-Sep-17,1-Sep-17,26-Apr-18,null,26-Apr-18,,,https://ClinicalTrials.gov/show/NCT03509714
NCT03505866,Community Home-based Care Intervention and Its Health Outcome in HIV-positive People,HIV,Completed,No Results Available,Human Immunodeficiency Virus|Depression|Stress|Anxiety|Quality of Life,Behavioral: Community home-based care intervention,Depression|Anti-retroviral therapy non-adherence|Anxiety|stress,Integrated Development Foundation Nepal|Tokyo University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,720,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,1523,1-Mar-15,31-Aug-15,31-Aug-15,23-Apr-18,null,24-Apr-18,,,https://ClinicalTrials.gov/show/NCT03505866
NCT03498599,Neuroimaging of Pavlovian Fear Conditioning Processes in Patients With Pathological Anxiety,,Recruiting,No Results Available,Post Traumatic Stress Disorder|Anxiety Disorders|Panic Disorder|Social Phobia|Phobia,Behavioral: Novelty facilitated extinction|Behavioral: Standard Extinction,"Changes in functional magnetic resonance imaging (fMRI)-BOLD (blood-oxygen-level dependent) signal in sensory, prefrontal, and limbic regions during a study on the neurobiology of Pavlovian fear conditioning in humans|Skin conductance responses evoked during a Pavlovian fear conditioning task in humans as an index of physiological arousal.",University of Texas at Austin,All,18 Years to 50 Years   (Adult),Not Applicable,40,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science,UTfearconditioning,1-Aug-17,Jun-20,Jun-20,13-Apr-18,null,13-Apr-18,"The University of Texas at Austin, Austin, Texas, United States",,https://ClinicalTrials.gov/show/NCT03498599
NCT03489811,The Effect of Aroma on Anxiety Among Children With Autism.,,Recruiting,No Results Available,Anxiety|Autism Spectrum Disorder,Other: Test Essential Oil Blend|Other: Active Essential Oil Blend|Other: Control Blend,39-Question Spence Children's Anxiety Scale (SCAS),Franklin Institute of Wellness,All,6 Years to 11 Years   (Child),Not Applicable,100,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention",17-2100,24-Jul-17,31-Aug-18,21-Sep-18,6-Apr-18,null,9-Apr-18,"Franklin Institute of Wellness, Franklin, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT03489811
NCT03488459,"Influence of Preoperative Support on Anxiety, Pain and Satisfaction With Postoperative Analgesia",,Completed,No Results Available,"Pain, Postoperative|Surgery, Thoracic",Behavioral: Routine preoperative information from a nurse|Behavioral: Additional information support from a psychologist,Change in anxiety intensity scores|Pain intensity scores at rest|Pain intensity scores during deep breathing|Pain intensity scores during coughing|Patient satisfaction,"National Institute for Tuberculosis and Lung Diseases, Poland",All,"9 Years to 18 Years   (Child, Adult)",Not Applicable,112,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Supportive Care",10.5,1-Mar-12,30-Dec-14,30-Dec-14,5-Apr-18,null,5-Apr-18,"Institute for Tuberculosis and Lung Diseases, Pediatric Division, Rabka-Zdrój, Małopolska, Poland",,https://ClinicalTrials.gov/show/NCT03488459
NCT03486860,A Multi-Method Early Intervention Program for Inhibited and Anxious Preschoolers,,Completed,No Results Available,Behavioral Inhibition|Anxiety,Behavioral: Parent Psychoeducation|Behavioral: Turtle Program,Change in child anxiety disorder symptoms,University of Maryland,All,42 Months to 60 Months   (Child),Not Applicable,51,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,R34MH083832,1-Feb-10,30-Nov-12,30-Nov-12,3-Apr-18,null,3-Apr-18,"University of Maryland, College Park, Maryland, United States",,https://ClinicalTrials.gov/show/NCT03486860
NCT03481673,COPE for Children With Asthma: Intervention for Children With Asthma,,Completed,No Results Available,Childhood Asthma|Childhood Anxiety Disorder|Childhood Depression,Behavioral: COPE for Asthma,Measure change in perception of asthma self-management over three time points|Measure change in anxiety symptoms over three time points|Measure change in depressive symptoms over three time points|Measure change in confidence in managing stress over three time points|Measure change in symptom interpretation over three time points|Measure change in barriers to controller medications over three time points|Measure change in quality of life over three time points|Measure change in asthma control over three time points|Measure comprehension over each lesson,Ohio State University|American Nurses Foundation|Sigma Theta Tau International Honor Society of Nursing|National Association of Pediatric Nurse Practitioners|Sigma Theta Tau Epsilon Branch,All,8 Years to 12 Years   (Child),Not Applicable,33,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,2017B0094,15-Jul-17,21-May-18,21-May-18,29-Mar-18,null,21-Aug-18,"Columbus City Schools, Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT03481673
NCT03476902,"Feasibility, Acceptability, and Preliminary Efficacy of a Mobile App (nOCD) for OCD",nOCD,Recruiting,No Results Available,Obsessive Compulsive Disorder (OCD),Behavioral: Therapist assisted mobile intervention,Feasibility and acceptability of using a therapist assisted mobile app using the System Usability Scale (SUS).|Effect of therapist assisted mobile app on OCD symptoms as assessed by the Yale-Brown Obsessive Compulsive Scale (Y-BOCS).,New York State Psychiatric Institute,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,30,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,7572,27-Oct-17,27-Oct-19,27-Dec-19,26-Mar-18,null,13-Mar-19,"New York State Psychiatric Institute, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT03476902
NCT03475810,The Effect of Virtual Reality Glasses on Anxiety During Surgery Under Spinal Anesthesia,VR,Completed,No Results Available,VIRTUAL REALITY,Device: Virtual Reality|Drug: Midazolam,State Anxiety Test|Total tolerance time of Virtual Reality glasses|incidence of vomiting|incidence of nausea|incidence of dizziness|incidence of headache|Postoperative Visual Analog Scale Score|change in mean arterial pressure|change in heart rate|change in respiratory rate,Derince Training and Research Hospital,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DerinceTRH-02,7-Nov-17,1-Jul-18,1-Jul-18,23-Mar-18,null,11-Jul-18,"Derince Research and Training Hospital, Kocaeli, Turkey",,https://ClinicalTrials.gov/show/NCT03475810
NCT03469453,Internet-delivered CBT for Adolescents With GAD,BIPWorry,Completed,No Results Available,Generalized Anxiety Disorder,Behavioral: Internet-Delivered Cognitive Behavioral Therapy,"Brief Penn State Worry Questionnaire for Children|Penn State Worry Questionnaire for Children|Brief Intolerance of Uncertainty Scale|Brief Cognitive Avoidance Questionnaire|Negative Problem Orientation Questionnaire, abbreviated|Revised Children's Anxiety and Depression Scale|Education, Work and Social Adjustment Scale|Clinical Global Impression - Improvement|Anxiety Disorder Interview Schedule for the Diagnostic and Statistical Manual -IV|Clinician Severity Rating|Children's Global Assessment Scale","Karolinska Institutet|Stockholm County Council, Sweden",All,13 Years to 17 Years   (Child),Not Applicable,13,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EPN DNR 2017/1879-31/5,28-Nov-17,28-Aug-18,28-Aug-18,19-Mar-18,null,6-May-19,"Karolinska Institutet, Stockholm, Sweden",,https://ClinicalTrials.gov/show/NCT03469453
NCT03468517,Preoperative Anxiety and BATHE Method,,Completed,No Results Available,Anxiety State,Other: Bathe method:,2 item State Trait Anxiety Intentory (STAI) Score Measure|Patient satisfaction score,Izmir Ataturk Training and Research Hospital,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,463,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention",KÇÜ-IATRH,1-Jan-16,28-Feb-16,30-Mar-16,16-Mar-18,null,21-Mar-18,"Katip Çelebi University İzmir Atatürk Training and Reseach Hospital, İzmir, Turkey","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/17/NCT03468517/Prot_000.pdf",https://ClinicalTrials.gov/show/NCT03468517
NCT03459677,Back2School - CBT Intervention for School Absenteeism,B2S,"Active, not recruiting",No Results Available,Anxiety Symptoms|Depressive Symptoms|Behavioral Problem|School Absenteeism,Behavioral: Back2School|Other: Treatment As Usual,Change in School Attendance - Registry data|Change in School Attendance - Self-reported data|The Strength and Difficulties Questionnaire (SDQ)|The Spence Children's Anxiety Scale (SCAS)|The Mood and Feelings Questionnaire (MFQ)|The Child Health Utility 9D Index (CHU-9D)|The Self-efficacy Questionnaire for School Situations (SEQ-SS)|Self-Efficacy Questionnaire for Responding to School Attendance Problems (SEQ-RSAP)|The Family Assessment Device (FAD),"University of Aarhus|Aarhus County, Denmark|Innovation Fund Denmark|The Danish Mental Health Foundation|TRYG Foundation",All,"7 Years to 18 Years   (Child, Adult)",Not Applicable,160,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Sponsor,25-Aug-17,Sep-19,Dec-20,9-Mar-18,null,13-May-19,"Aarhus University, Department of Psychology and Behavioural Sciences, Århus, Denmark",,https://ClinicalTrials.gov/show/NCT03459677
NCT03461016,Smartphone-Based Exposure Treatment for Dental Anxiety,,Enrolling by invitation,No Results Available,Phobic Disorders|Dental Anxiety|Treatment Outcome,Behavioral: Exposure Therapy,Change in Dental Fear Survey (scale 20-item)|Change in Subjective Units of Distress (scale 1-item)|Acceptability (scale 8-item),West Virginia University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,40,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1506718933,1-Apr-16,22-Aug-18,22-Aug-18,9-Mar-18,null,9-Mar-18,"West Virginia University, Morgantown, West Virginia, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/16/NCT03461016/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/16/NCT03461016/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03461016
NCT03461055,Lavender During Intrauterine Insemination,,Completed,No Results Available,"Infertility, Female|Anxiety",Other: Lavender|Other: Water,Anxiety|Pain,Mayo Clinic,Female,18 Years to 45 Years   (Adult),Not Applicable,62,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,17-001147,24-May-17,29-Mar-18,16-Apr-18,9-Mar-18,null,26-Jun-18,"Mayo Clinic, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT03461055
NCT03458702,The Effects of Emotional Exposure on State Anxiety,,Completed,No Results Available,Generalized Anxiety Disorder,Behavioral: YogaFit,Change in state anxiety from baseline and then after 30 min of quiet rest|Change in state anxiety after 30 min of quiet rest and then after 30 min of viewing emotionally disturbing pictures from the International Affective Picture System (IAPS)|Change in state anxiety after 30 min of yoga and then after 30 min of viewing emotionally disturbing pictures from the International Affective Picture System (IAPS)|Change in heart rate (HR) from baseline and then after 30 min of quiet rest|Change in HR after 30 min of quiet rest and then after 30 min of viewing emotionally disturbing pictures from IAPS|Change in HR after 30 min of yoga and then after viewing 30 min of emotionally disturbing pictures from IAPS|Change in time domain measures of Heart Rate Variability (HRV) the Root Mean Square of Successive R R Intervals (RMSSD) from baseline and then after 30 min of quiet rest|Change in RMSSD after 30 min of quiet rest and then after 30 min of viewing emotionally disturbing pictures from the International Affective Picture System (IAPS)|Change in RMSSD after 30 min of yoga and then after 30 min of viewing emotionally disturbing pictures from the International Affective Picture System (IAPS)|Change in the low-frequency measure of HRV in n.u. (LFNU) from baseline and then after 30 min of quiet rest|Change in LFNU after 30 min of quiet rest and then after 30 min of viewing emotionally disturbing pictures from the International Affective Picture System (IAPS)|Change in LFNU after 30 min of yoga and then after 30 min of viewing emotionally disturbing pictures from the International Affective Picture System (IAPS),Texas Tech University,Female,18 Years to 25 Years   (Adult),Not Applicable,56,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,504055,12-Sep-13,15-Mar-14,May-14,8-Mar-18,null,21-Mar-18,"Texas Tech University, Lubbock, Texas, United States",,https://ClinicalTrials.gov/show/NCT03458702
NCT03452670,Contemplative Well-being Apps for the Workplace,,Recruiting,No Results Available,Social Behavior|Depression|Inflammation,Behavioral: Active Group|Other: Waitlist Group,Change in Incivility in Nursing Education Revised Survey score|Change in School-Burnout Inventory score|Change in Depression score on the Depression Anxiety and Stress Scale (DASS)|Change in Anxiety score on the Depression Anxiety and Stress Scale (DASS)|Change in Empathic Accuracy (EA) Task|Change in gray matter density in the brain stem|Change in white matter density in the brain stem|Change in Gene (mRNA) expression in peripheral blood mononuclear cells (PBMCs),Emory University,All,"21 Years and older   (Adult, Older Adult)",Not Applicable,52,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention",IRB00088349,6-Jun-16,Jul-19,Jul-19,2-Mar-18,null,16-Jan-19,"Emory University, Wesley Woods Health Center, Atlanta, Georgia, United States",,https://ClinicalTrials.gov/show/NCT03452670
NCT03448809,Randomized Feasibility Trial of Mind My Mind,MindMyMind,Completed,No Results Available,Anxiety|Anxiety Disorders|Depressive Symptoms|Depressive Disorder|Problem Behavior|Oppositional Defiant Disorder|Conduct Disorder|Behavior Disorders,Behavioral: Mind My Mind|Behavioral: TAU (Treatment as Usual),"The flow of participants through the visitation.|The family and social background characteristics.|The Strengths and Difficulties Questionnaire (SDQ).|The retention of children in the MMM arm.|The proportion of children in the MMM arm who were referred to more specialized services during the study period.|The satisfaction with MMM sessions among children and parents in the MMM arm.|The dosing and sequencing of the MMM modules.|The authorized Danish version of the Achenbach System of Empirically Based Assessment (ASEBA), Child Behaviour Checklist (CBCL).|The authorized Danish version of the Achenbach System of Empirically Based Assessment (ASEBA), the Youth Self-Report (YSR).|Spence Children's Anxiety Scale (SCAS)|The Mood and Feelings Questionnaire (MFQ)|The KIDSCREEN|Eyberg Child Behaviour Inventory (ECBI)|Weiss Functional impairment rating Scale (WFIRS)|Parental Stress Scale (PSS)|The Experience of Service Questionnaire (ESQ)|Top-3-problems|The Brief Problem Monitor (BPM)","Mental Health Services in the Capital Region, Denmark|TrygFonden, Denmark|The Danish Mental Health Foundation",All,6 Years to 16 Years   (Child),Not Applicable,150,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MMMpilotrct,8-Dec-15,2-Apr-17,2-Apr-17,28-Feb-18,null,28-Feb-18,,,https://ClinicalTrials.gov/show/NCT03448809
NCT03440255,Transcutaneous Vagus Nerve Stimulation in Private Healthcare Center,,Completed,No Results Available,Generalized Anxiety Disorder|Chronic Pain|Irritable Bowel Syndrome,Device: Transcutaneous Vagus Nerve Stimulation,Change from baseline generalized anxiety disorder severity|Change from baseline pain severity and pain interference|Change from baseline irritable bowels syndrome severity,Kinesis Health Associates,All,"20 Years to 65 Years   (Adult, Older Adult)",Not Applicable,11,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TaVNS_PHC,1-Jul-17,31-Jul-17,15-Sep-17,21-Feb-18,null,22-Feb-18,"Kinesis Health Associates, Dartmouth, Nova Scotia, Canada",,https://ClinicalTrials.gov/show/NCT03440255
NCT03437317,Emotional Perceptual Training as a Treatment for Social Anxiety: Behavioral and Neural Evidence.,PTL,Completed,No Results Available,Anxiety Disorders and Symptoms|Social Anxiety Disorder,Behavioral: Perceptual Retraining|Behavioral: Gender Discrimination,Behavioral Evidence for Categorical Perception Changes|Neural Evidence for Categorical Perception Changes|Social Anxiety Symptoms - Social Phobia Scale|Social Anxiety Symptoms - Liebowitz Social Anxiety Scale,Florida State University|Medical College of Wisconsin,All,18 Years to 35 Years   (Adult),Not Applicable,154,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,PTL-2017.21521,1-Nov-14,15-Dec-16,15-Dec-16,19-Feb-18,null,19-Feb-18,,,https://ClinicalTrials.gov/show/NCT03437317
NCT03434054,The Effect of Losartan on Emotional Processing in Healthy Volunteers,,Completed,No Results Available,Healthy Volunteers,Drug: Losartan|Other: Placebo,BOLD signal change,University of Oxford,All,18 Years to 50 Years   (Adult),Not Applicable,30,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",MSD-IDREC-C3-2015-832,1-Jun-16,30-Jun-17,30-Jun-17,15-Feb-18,null,19-Feb-18,,,https://ClinicalTrials.gov/show/NCT03434054
NCT03430765,Preventing Persistent Pain and Reducing Depressive and Anxious Symptoms Following Mastectomy and Lumpectomy,,Completed,No Results Available,Persistent Postsurgical Pain|Breast Cancer Female|Ductal Carcinoma in Situ,Behavioral: Acceptance and Commitment Therapy,Numeric Rating Scale|The Brief Pain Inventory (BPI: pain severity)|The Brief Pain Inventory (BPI: pain interference)|Generalized Anxiety Disorder 7-item scale|Patient Health Questionnaire -8 item|SF-12 Health Survey|Pain catastrophizing Scale|Chronic Pain Acceptance Questionnaire,Katherine Hadlandsmyth|Holden Comprehensive Cancer Center|University of Iowa,Female,"18 Years to 100 Years   (Adult, Older Adult)",Not Applicable,62,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,201502709,21-Jun-15,19-Nov-17,22-Nov-17,13-Feb-18,null,11-Feb-19,"University of Iowa Hospital and Clinics, Iowa City, Iowa, United States",,https://ClinicalTrials.gov/show/NCT03430765
NCT03427515,Probiotics and Examination-related Stress in Healthy Medical Students,,Completed,No Results Available,Healthy|Stress-related Problem|Anxiety,Dietary Supplement: Lactobacillus rhamnosus GG (ATCC 53103)|Dietary Supplement: Saccharomyces boulardii (CNCM I-1079)|Dietary Supplement: Placebo,Performance under examination-related stress|State anxiety under examination-related stress|Cortisol|Pulse rate|Metanephrine,Medical Universtity of Lodz,All,18 Years to 30 Years   (Adult),Not Applicable,92,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",502-03/5-108-03/502-54-157,20-Apr-16,20-Jun-16,20-Jun-16,9-Feb-18,null,9-Feb-18,,,https://ClinicalTrials.gov/show/NCT03427515
NCT03428282,Pain and Anxiety Control During Traditional Mandibular Anesthesia in Children Using Distracting Tools,,Completed,No Results Available,Inferior Alveolar Nerve Block,Procedure: VR Box|Procedure: Tablet Device|Drug: Anesthesia,Pain levels|Anxiety levels|Change in physiological pulse rate,Damascus University,All,6 Years to 10 Years   (Child),Not Applicable,102,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,UDDS-Pedo-03-2017,15-May-17,10-Feb-18,15-Jul-18,9-Feb-18,null,30-Jul-18,"Department of Peadodontics, University of Damascus Dental School, Damascus, Syrian Arab Republic",,https://ClinicalTrials.gov/show/NCT03428282
NCT03428542,Yoga and Psychological and Physiological Health,,Completed,No Results Available,Stress|Anxiety|Depression|Sleep|Physiological Stress,Behavioral: Yin yoga|Behavioral: YOMI,Perceived Stress Scale|The Hospital Anxiety and Depression Scale|The COPE Inventory|The Insomnia Severity Index|Diet|General Health Questionnaire|The Harmony in Life Scale|The Kentucky Inventory of Mindfulness Skills -Short Version|The Brief Experiential Avoidance Questionnaire|The Self-Compassion Scale|Fasting blood sampling|Fasting and 120-minute glucose tolerance test (mmol/L)|Office and 24-hour blood pressure measurement (mmHg)|Pulse-wave velocity|Heart rate variability|Gut microbiota,Region Skane|Lund University,All,"40 Years to 65 Years   (Adult, Older Adult)",Not Applicable,105,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,2015610,11-Jan-16,23-Apr-16,23-Apr-16,9-Feb-18,null,14-Feb-18,"KFE, Skåne University Hospital in Malmö, Malmö, Sweden","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/42/NCT03428542/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03428542
NCT03424967,Statistical Learning as a Predictor of Attention Bias Modification Outcome,,Completed,No Results Available,Social Anxiety Disorder,Behavioral: ABM,The Liebowitz Social Anxiety Scale (LSAS) - Diagnostic Interview scores|The Social Phobia Inventory scores,Tel Aviv University,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,30,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TAU-SL,2-Aug-16,12-Jun-17,12-Jun-17,7-Feb-18,null,7-Feb-18,"Tel Aviv University, Tel Aviv, Israel",,https://ClinicalTrials.gov/show/NCT03424967
NCT03420911,Determination of the Effects of Change in Anxiety Level on Pain Perception in Patients Who Present to Emergency Department,,Completed,No Results Available,"Pain, Acute|Anxiety",Drug: dexketoprofen trometamol|Drug: Midazolam,the change in pain levels|the change in anxiety levels|the need for rescue treatment|the rate of the request for the same treatment|the comparison of the pain and anxiety change on the visual analogue scale,Derince Training and Research Hospital,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,180,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2013/147,Jun-13,Dec-13,Dec-13,2-Feb-18,null,2-Feb-18,,,https://ClinicalTrials.gov/show/NCT03420911
NCT03416504,Methods for Managing Intrusive Thoughts,,Completed,No Results Available,Obsessive-Compulsive Disorder,Behavioral: Gradual Exposure (EXP-G)|Behavioral: Variable Exposure (EXP-V),Change from baseline in Yale-Brown Obsessive Compulsive Scale (Y-BOCS) score at 3-month follow-up (week 14)|Change from baseline in Yale-Brown Obsessive Compulsive Scale (Y-BOCS) score at post-treatment (week 2)|Changes from baseline in Dimensional Obsessive-Compulsive Scale-Unacceptable Thoughts (DOCS-UT) at 3-month follow-up (week 14)|Changes from baseline in Dimensional Obsessive-Compulsive Scale-Unacceptable Thoughts (DOCS-UT) at post-treatment (week 2)|Changes from baseline in Behavioral Approach Test (BAT) Mean Subjective Units of Distress (SUDS) at 3-month follow-up (week 14)|Changes from baseline in Behavioral Approach Test (BAT) Mean Subjective Units of Distress (SUDS) at post-treatment (week 2)|Changes from baseline in Behavioral Approach Test (BAT) Number of Steps Completed at 3-month follow-up (week 14)|Changes from baseline in Behavioral Approach Test (BAT) Number of Steps Completed at post-treatment (week 2),"University of North Carolina, Chapel Hill|Association for Behavioral and Cognitive Therapies (ABCT)|American Psychological Association (APA)",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,40,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,14-3310|5101599|5103050,22-Sep-15,4-Oct-16,4-Oct-16,31-Jan-18,null,31-Jan-18,"University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT03416504
NCT03413631,A Prenatal Mentalization-focused 4D Ultrasound and a Pregnancy Diary Intervention for Substance-abusing Women,,Completed,No Results Available,"Substance-Related Disorders|Pregnancy, High Risk|Prenatal Care|Maternal-Fetal Relations|Parenting|Depression|Anxiety|Perinatal Outcome|Fetal Exposure During Pregnancy",Behavioral: Prenatal mentalization intervention|Other: Prenatal obstetric treatment as usual,Prenatal depressive symptoms post-intervention at 35 gestational weeks|Prenatal parental mentalization post-intervention at 35 gestational weeks|Maternal-fetal attachment post-intervention at 35 gestational weeks|Prenatal maternal substance abuse (health behaviour)|Prenatal anxiety symptoms post-intervention at 35 gestational weeks,"Turku University Hospital|Foundation for Paediatric Research, Finland|Academy of Finland|Hospital District of Southwestern Finland|University of Turku",Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,126,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,13924,18-Oct-11,31-Dec-15,31-Dec-15,29-Jan-18,null,29-Jan-18,"Department of Obstetrics and Gynecology and Department of Child Psychiatry, Turku University Hospital; Department of Obstetrics and Gynecology and Department of Child Psychiatry, University of Turku, Turku, Finland, Turku, Finland",,https://ClinicalTrials.gov/show/NCT03413631
NCT03408002,PREPARE - PREoPerative Anxiety REduction,PREPARE,Enrolling by invitation,No Results Available,Anxiety Disorder|Surgery,Behavioral: Psychological intervention,"Change of Perceived self-efficacy, comparing the score on analogue scale (range 1-10) before (baseline) and after the psychological intervention in the experimental group.|Post-operative pain measured by the Brief Pain Inventory|Number of perioperative complications|Number of days of hospitalization|VAS-P Visual Analogue Scale of Pain.",Azienda Ospedaliera Universitaria Integrata Verona|University of Pisa|Universita di Verona,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,400,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention,Prog. 1288CESC,14-Jun-17,1-Jul-18,1-Jul-18,23-Jan-18,null,25-Jan-18,"Azienda Ospedaliera Universitaria Integrata, Verona, Italy",,https://ClinicalTrials.gov/show/NCT03408002
NCT03393078,Repetitive Transcranial Magnetic Stimulation (rTMS) Treatment for Obsessive Compulsive Disease,,Recruiting,No Results Available,Obsessive-Compulsive Disorder|Transcranial Magnetic Stimulation|Functional Magnetic Resonance Imaging|Event-Related Potentials,Device: transcranial magnetic stimulation with real coil|Device: transcranial magnetic stimulation with sham coil,Symptom improvement assessed by the Yale-Brown Obsessive Compulsive Scale|Symptom improvement assessed by the Padua Inventory-Washington State University Revision|Stop-Signal Task|Task Switch|Wisconsin CardSorting Test|Hanoi Tower,Anhui Medical University,All,18 Years to 50 Years   (Adult),Not Applicable,60,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AnhuiMU,1-Aug-17,1-Apr-19,1-Apr-19,8-Jan-18,null,19-Mar-19,"Anhui Medical University, Hefei, Anhui, China",,https://ClinicalTrials.gov/show/NCT03393078
NCT03393637,Mentors Offering Maternal Support (M-O-M-S™): A Prenatal Program for Decreasing Maternal Anxiety and Depression,M-O-M-S,Recruiting,No Results Available,"Anxiety Fear|Prenatal Depression|Infant, Low Birth Weight|Preterm Birth|Maternal",Behavioral: Mentors Offering Maternal Support (M-O-M-S),Lederman Self-Evaluation Questionnaire|Rosenberg Self-Esteem Scale|Family Adaptability and Cohesion Evaluation Scales|Edinburgh Postnatal Depression Scale|Social Support Index|Family Index Coherence|Brief Resilience Scale|Postpartum Self-Evaluation Questionnaire|Infant birthweight|Gestational age at birth,"University of the Incarnate Word|Joint Program Committee - 5|59th Medical Wing Science and Technology|United States Naval Medical Center, San Diego|Madigan Army Medical Center|711th Human Performance Wing",Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,1080,Other|U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,FWH20170069H,1-Dec-17,30-Jun-20,15-Sep-20,8-Jan-18,null,16-May-19,"Naval Medical Center San Diego, San Diego, California, United States|Joint Base San Antonio, San Antonio, Texas, United States|Madigan Army Medical Center, Tacoma, Washington, United States",,https://ClinicalTrials.gov/show/NCT03393637
NCT03393702,Pain Control in Children and Adolescent After Thoracic Surgery: The Effect of Gabapentin,,Recruiting,No Results Available,"Pain, Postoperative|Surgery, Thoracic",Drug: Gabapentin|Drug: Placebo,"Pain intensity scores at rest (FLACC for patients <7 y.o., NRS for patients >7 y.o.)|Pain intensity scores during deep breathing (FLACC for patients <7 y.o., NRS for patients >7 y.o.)|Pain intensity scores during coughing (FLACC for patients <7 y.o., NRS for patients >7 y.o.)|Total ropivacaine/fentanyl consumption.|Total morphine consumption.|Anxiety intensity scores.|Side Effect Occurrence|The number of doses of metamizol as a ""rescue drug""|Patient satisfaction.","National Institute for Tuberculosis and Lung Diseases, Poland",All,"5 Years to 18 Years   (Child, Adult)",Phase 4,80,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",10.11,9-May-17,30-Dec-19,30-Dec-20,8-Jan-18,null,23-Apr-19,"Institute for Tuberculosis and Lung Diseases, Pediatric Division, Rabka-Zdrój, Małopolska, Poland",,https://ClinicalTrials.gov/show/NCT03393702
NCT03392129,Ai Chi Method for Children With Asthma,,Recruiting,No Results Available,Asthma|Child|Respiratory Disease|Hydrotherapy|Respiratory Tract Diseases|Respiratory Hypersensitivity|Respiration Disorders,Other: Ai Chi|Other: Asthma education,Change in pulmonary function (spirometry).|Change in asthma control.|Change in Quality of life|Change in Anxiety symptoms.|Change in Disturbed Sleep.,Universidade Federal do Rio Grande do Norte,All,7 Years to 12 Years   (Child),Not Applicable,42,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,67253617.4.0000.5537,20-Dec-17,20-Jun-19,20-Jul-19,5-Jan-18,null,19-Feb-19,"Universidade Federal do Rio Grande do Norte (UFRN), Natal, Rio Grande Do Norte, Brazil",,https://ClinicalTrials.gov/show/NCT03392129
NCT03388489,Mind-Body Walking Exercise for Chronic Obstructive Pulmonary Disease,,Completed,No Results Available,Chronic Obstructive Pulmonary Disease|Exercise|Anxiety|Depression|Dyspnea|Quality of Life|Heart Rate Variability,Behavioral: Mind-Body Walking,Change of modified Borg scale for dyspnea level|Heart rate variability (HRV)|Hospital anxiety and depression scale (HADS) for anxiety and depression|The Chinese version multidimensional assessment of interoceptive awareness (MAIA-C) for interoceptive awareness|Six-minute walk distance for exercise capacity|modified Medical Research Council (mMRC) for perception of dyspnea in daily life|COPD assessment test (CAT) for quality of life,National Taiwan University Hospital,All,"40 Years and older   (Adult, Older Adult)",Not Applicable,84,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Supportive Care,201312004RIND,18-Aug-14,13-Aug-15,13-Aug-15,3-Jan-18,null,3-Jan-18,,,https://ClinicalTrials.gov/show/NCT03388489
NCT03388736,Anxiolytic Effect of Lavender Oil on Orthognathic Surgery Patients,,Recruiting,No Results Available,Anxiety|Osteotomy,Behavioral: Supplementary Medicine,Reduction of preoperative anxiety,Ankara University,All,18 Years to 45 Years   (Adult),Not Applicable,90,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care,15/10,1-Nov-17,1-May-19,1-May-19,3-Jan-18,null,28-Jan-19,"Ankara University Faculty of Dentistry, Ankara, Turkey",,https://ClinicalTrials.gov/show/NCT03388736
NCT03388957,Oral Propranolol for Reducing Pediatric Dental Patients Anxiety,,Recruiting,No Results Available,Extrusion of Tooth,Drug: Propranolol|Drug: Midazolam,Change in Anxiety-1 levels|Change in Anxiety-2 levels|Change in Behavior|Change in Sedation status|Change in pulse rate|Change in Oxygen Saturation|Change in Blood Pressure,Damascus University,All,6 Years to 9 Years   (Child),Not Applicable,80,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",UDDS-Pedo-02-2017,30-Sep-17,Oct-18,Feb-19,3-Jan-18,null,3-Jan-18,"Department of Peadodontics, University of Damascus Dental School, Damascus, Syrian Arab Republic",,https://ClinicalTrials.gov/show/NCT03388957
NCT03385317,Mindfulness to Mitigate the Effect of Anxiety-depression-fear in Chronic Obstructive Pulmonary Disease (COPD),,Withdrawn,No Results Available,Chronic Obstructive Pulmonary Disease,Behavioral: Mindfulness,Change in Quality of Life as measured by the Chronic Respiratory Questionnaire,Mayo Clinic,All,"40 Years and older   (Adult, Older Adult)",Not Applicable,0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,15-007994,Apr-16,31-Oct-17,31-Oct-17,28-Dec-17,null,28-Dec-17,"Mayo Clinic, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT03385317
NCT03382067,Influence of Chocolate With Plant Additives on Episodic Memory in Healthy Subjects Experiencing Test Anxiety,MaRS-Basel,Completed,No Results Available,Test Anxiety,Dietary Supplement: High Epicatechin/ Melissa|Other: Low Epicatechin/ Oat bran,Pictorial memory task|Verbal memory task|Saliva cortisol level|Working memory|Visual Analogue Scale VAS test anxiety|Visual Analogue Scale VAS confidence|Visual Analogue Scale VAS interference|Visual Analogue Scale VAS solicitude|Visual Analogue Scale VAS excitement,"Prof. Dominique de Quervain, MD|University of Basel",All,18 Years to 30 Years   (Adult),Not Applicable,128,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",MaRS-Basel,4-Dec-17,31-Aug-18,31-Aug-18,22-Dec-17,null,5-Sep-18,"University of Basel, Division of Cognitive Neuroscience, Basel, Switzerland",,https://ClinicalTrials.gov/show/NCT03382067
NCT03382093,Personalized Feedback for Smokers With Elevated Anxiety Sensitivity,,Recruiting,No Results Available,"Anxiety Disorders|Anxiety|Tobacco Dependence|Smoking, Cigarette|Smoking, Tobacco",Behavioral: Personalized Feedback Intervention|Behavioral: Smoking Information Control,Evaluate PFI|Smoking Motivational Processes|Smoking Behavior|Affective Processes|Mechanisms,University of Houston|National Institute on Drug Abuse (NIDA),All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,130,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,CR00000267|5F31DA043390-02,23-Aug-17,Jun-19,Jun-19,22-Dec-17,null,18-Apr-19,"Anxiety and Health Research Laboratory and Substance Use Treatment Clinic, University of Houston, Houston, Texas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/93/NCT03382093/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03382093
NCT03380091,"Metformin, Vitamin D, and Depression in Polycystic Ovary Syndrome (PCOS) Trial",MINDD,Recruiting,No Results Available,PCOS|Depression|Vitamin D Deficiency|Insulin Resistance,Drug: Metformin|Drug: Vitamin D,Depression|Insulin resistance,"University of California, San Francisco",Female,18 Years to 45 Years   (Adult),Phase 4,25,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,17-22550,12-Dec-17,Apr-21,Apr-21,20-Dec-17,null,5-Mar-19,"UCSF Center for Reproductive Health, San Francisco, California, United States",,https://ClinicalTrials.gov/show/NCT03380091
NCT03376633,"The Impact of a School-Based, Trauma-Informed CBT Intervention for Young Women",,Enrolling by invitation,No Results Available,"Anxiety|Anxiety Disorders|Behavioral Symptoms|Depression|Mental Disorders|Stress Disorders, Post-Traumatic|Stress Disorders, Traumatic|Trauma and Stressor Related Disorders|Wounds and Injuries",Behavioral: Working on Womanhood (WOW),"Change in depression assessment score|Change in post-traumatic stress disorder (PTSD) assessment score|Change in anxiety assessment score|Change in high school graduation|Change in absences|Change in index of CPS schooling outcomes|Change in student misconduct|Change in course failures|Change in overall arrests|Change in violent crime arrests|Change in other arrests (property, drug, and other)",University of Chicago|Northwestern University|Youth Guidance|Chicago Public Schools|U.S. Department of Justice|Paul M. Angell Family Foundation|Polk Bros. Foundation|The Reva & David Logan Foundation|DePaul University|Laura and John Arnold Foundation|MacArthur Foundation,Female,"Child, Adult, Older Adult",Not Applicable,5106,Other|U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IRB17-0585,1-Oct-17,31-Dec-21,31-Aug-23,18-Dec-17,null,17-Apr-19,"University of Chicago, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT03376633
NCT03373734,Enjoy Your Bump : Online Cognitive Behavioural Therapy in Pregnancy,,Recruiting,No Results Available,Perinatal Mental Health|Antenatal Depression|Antenatal Anxiety,Device: Enjoy Your Bump,Evaluation of recruitment and retention.|Evaluation of feedback questionnaire data.|Estimation of effect size for changes in depression.|Estimate of Effect Size for changes in depression (2)|Estimate of effect size for changes in depression (3)|Estimation of effect size for changes in anxiety.|Estimation of effect size for changes in social function.|Estimation of effect size for changes in attachment.|Depression score (1)|Depression score (2)|Depression score (3)|Anxiety score|Pregnancy Experience|Measure mother-baby relationship (Antenatal)|Measure mother-baby relationship (Postnatal)|Time taken to complete intervention (1)|Time taken to complete intervention (2).|Delivery and support of intervention,University of Edinburgh|Edinburgh & Lothians Health Foundation|Tommy's Edinburgh Maternal & Fetal Health Centre|National Health Service (NHS) Lothian|Five Areas Ltd,Female,18 Years to 55 Years   (Adult),Not Applicable,30,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,AC17015,31-May-17,1-Mar-19,1-Mar-19,14-Dec-17,null,14-Dec-17,"NHS Lothian / University of Edinburgh, Edinburgh, Scotland, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/34/NCT03373734/Prot_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/34/NCT03373734/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT03373734
NCT03371836,Use of Clobazam for Epilepsy and Anxiety,,Recruiting,No Results Available,Epilepsy|Anxiety,Drug: Clobazam,Clinical Global Impression-Improvement (CGI-I) from Baseline,"Hugo W. Moser Research Institute at Kennedy Krieger, Inc.",All,6 Years to 17 Years   (Child),Phase 4,30,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,onfi90037,1-Oct-17,31-Dec-19,31-Dec-19,13-Dec-17,null,15-Feb-19,"Kennedy Krieger Institute, Baltimore, Maryland, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/36/NCT03371836/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03371836
NCT03369418,Effectiveness of CES on Emotional and Cellular Wellbeing,,Completed,No Results Available,Anxiety|Depression,Device: Alpha-Stim Active|Device: Alpha-Stim Inactive,HADS questionnaire|Cellular health,"University of California, Los Angeles",Male,18 Years to 40 Years   (Adult),Not Applicable,44,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",15-001639,Mar-16,20-Oct-18,20-Oct-18,12-Dec-17,null,15-May-19,"University of California, Los Angeles (UCLA), Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT03369418
NCT03369873,Effectiveness of Nursing Orientation for the Reduction of Anxiety and Stress,,Completed,No Results Available,Coronary Syndrome,Other: Guidance Manual,Change from score of anxiety and stress,Federal University of São Paulo|Conselho Nacional de Desenvolvimento Científico e Tecnológico,All,"18 Years to 79 Years   (Adult, Older Adult)",Not Applicable,122,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other,UNIFESP30,1-Apr-16,1-Dec-16,1-Dec-16,12-Dec-17,null,13-Dec-17,,,https://ClinicalTrials.gov/show/NCT03369873
NCT03368950,Online Mindfulness for Stroke Sufferers,,"Active, not recruiting",No Results Available,Stroke,Other: Online Mindfulness Course,Change to Stress Scale Score|Change to Anxiety Measure Score|Change to Depression Measure Score|Change to Mindfulness Measure Score|Change to Worry and Rumination Measure Score|Change to Health Status Measure|Change to Stroke Specific Quality of Life Measure,University of Surrey|First Community Health and Care|Surrey and Borders Partnership NHS Foundation Trust,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,30,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SPON/2017/03/FHMS,1-Jun-17,1-Jun-18,1-Sep-18,11-Dec-17,null,14-Feb-18,"First Community Health and Care (FCHC), Surrey, United Kingdom",,https://ClinicalTrials.gov/show/NCT03368950
NCT03363737,Transtheoretical Model of Behavior Change and Anxiety,,Completed,No Results Available,Psychological|Physical Activity,Behavioral: Transtheoretical Model,Changes in Anxiety,"University of Mississippi, Oxford",All,18 Years to 35 Years   (Adult),Not Applicable,39,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,17-018,18-Oct-16,24-Aug-17,24-Aug-17,6-Dec-17,null,7-Dec-17,,,https://ClinicalTrials.gov/show/NCT03363737
NCT03358056,Effects of Mindfulness Based Cognitive Therapy on Emotional Processing,MESI,Recruiting,No Results Available,Unipolar Depression|Anxiety Disorders|Adjustment Disorders|Emotional Instability,Behavioral: Mindfulness-Based Cognitive Therapy,Facial Emotion Recognition Task|Quick Depression Inventory,Parc de Salut Mar,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,30,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2017/7185/I,1-Sep-17,1-Apr-18,1-Apr-18,30-Nov-17,null,30-Nov-17,"Parc de Salut Mar, Barcelona, Spain",,https://ClinicalTrials.gov/show/NCT03358056
NCT03356691,The Evaluation Complementary Spirit Therapy,,Recruiting,No Results Available,Anxiety|Depression|Pain|Well-being|Stress,"Other: Complementary Spiritist Therapy|Other: Prayer|Other: Spiritist ""passe""|Other: laying on of hands with intent to heal|Other: Fluid therapy.|Other: No-fluid therapy.",Change in Anxiety sympton.|change in Depression.|Change in Depression sympton.|Change in Tension muscle.|Change in wellness subjective.|Change in wellness.|Change in hematological and immunological responses.|Change in pain.|Change in blood pressure|Change in respiratory rate|Change in cardiac rate|Change in oxygen saturation|Change in Heart rate variability|Change in Burnout.|Change in Quality of life|Change in Stress score.|Change in Stress.|Change in perceived anxiety.|Change in Anxiety.,Universidade Federal do Triangulo Mineiro,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,160,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other",UFTM,10-Sep-15,9-Apr-18,30-Dec-25,29-Nov-17,null,17-Apr-18,"Élida Mara Carneiro, Uberaba, Minas Gerais, Brazil",,https://ClinicalTrials.gov/show/NCT03356691
NCT03352752,Virtual Reality Technology to Alleviate the Acute Pain of Scar Treatment With Fractional Laser Under Local Anesthesia,,Recruiting,No Results Available,Scar|Acute Pain,Device: HTC Vive|Other: Without HTC Vive,Pain scores|Anxiety score|Heart rate|Respiratory rate|Blood pressure|Surgical satisfaction|Operating time,Kai-Yang Lv|Changhai Hospital,All,18 Years to 60 Years   (Adult),Not Applicable,218,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,kylv,2-Aug-17,11-Aug-20,21-Dec-20,24-Nov-17,null,28-Nov-17,"HTC Vive, Shanghai, China",,https://ClinicalTrials.gov/show/NCT03352752
NCT03348618,A Study to Evaluate the Benefit of Octagam 5%® in Subjects With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS),PANS,"Active, not recruiting",No Results Available,Pediatric Acute-Onset Neuropsychiatric Syndrome|Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections,Biological: IVIG,"Change in Anxiety Disorders Interview Schedule for DSM-IV, Child, Parent Versions (ADIS)|Change in Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS)|Change in Yale Global Tic Severity Scale (YGTSS)|Change in Clinical Global Impressions (CGI)|Change in biomarkers levels",IMMUNOe Research Centers|Octapharma,All,4 Years to 16 Years   (Child),Phase 4,21,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IIS201701-PANS,24-Nov-17,Nov-19,Mar-20,21-Nov-17,null,5-Mar-19,"IMMUNOe Research Centers, Centennial, Colorado, United States|Midwest Pediatrics, Papillion, Nebraska, United States|Allergy, Asthma & Immunology Relief Research Institute, Charlotte, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT03348618
NCT03348800,Evaluation of Pain Perception and Heart Rate in Children Who Received Dental Anesthesia,RCT,Completed,No Results Available,Dental Anxiety,Procedure: Dental anesthesia,Pain felt during dental anesthesia|Heart Rate during dental anesthesia,Catholic University of the Sacred Heart,All,5 Years to 12 Years   (Child),Not Applicable,76,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",RP-01,22-Nov-17,22-Nov-17,21-May-18,21-Nov-17,null,30-Jan-19,"Catholic University of Sacred Heart, Roma, Italy",,https://ClinicalTrials.gov/show/NCT03348800
NCT03348865,Fertility Life Counselling Aid- FeLiCiA,FeLiCiA,Recruiting,No Results Available,Infertility/Sterility|Psychological Distress|Psychological Stress|Anxiety Disorders|Depressive Disorder,Behavioral: Fertility Life Counselling Aid (FeLiCiA),"Measurement for absence of psychological morbidities post intervention|Explore patient perspective on benefits of intervention using qualitative methods, post intervention.|Measurement for sustained absence of psychological morbidities, 6months post intervention",Andrew Weeks MD MRCOG|University of Liverpool|University of Ibadan,All,21 Years to 45 Years   (Adult),Not Applicable,42,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care,2121,20-Nov-17,27-Mar-18,30-Jun-18,21-Nov-17,null,6-Mar-18,"University College Hospital, Ibadan, Ibadan, Oyo, Nigeria",,https://ClinicalTrials.gov/show/NCT03348865
NCT03349047,Anxiety About Casual Exposure to Food Allergens,TOUCH,Completed,No Results Available,Food Allergy,Behavioral: Behavioral intervention group|Behavioral: Education,Child worry about casual exposure|Parent worry about casual exposure|Food Allergy Quality of Life-Parental Burden (FAQL-PB) Questionnaire|The Screen for Child Anxiety Related Disorders (SCARED)|SCARED - parent version,Icahn School of Medicine at Mount Sinai,All,108 Months to 210 Months   (Child),Not Applicable,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GCO 17-1957,15-Nov-17,13-Jun-18,13-Jun-18,21-Nov-17,null,21-Feb-19,"Icahn School of Medicine at Mount Sinai, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT03349047
NCT03348423,Evaluation of DEX-IN During Outpatient Procedures,,Recruiting,No Results Available,Pain,Drug: DEX-IN|Drug: Fentanyl|Drug: Placebo,Evaluation of Pain Intensity,"Recro Pharma, Inc.",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,45,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",REC-17-023,15-Nov-17,Apr-18,Apr-18,20-Nov-17,null,20-Nov-17,"Research Center, Pasadena, California, United States",,https://ClinicalTrials.gov/show/NCT03348423
NCT03343106,Combining Acceptance and Commitment Therapy With Exposure and Response Prevention to Enhance Treatment Engagement,,Completed,No Results Available,Obsessive-Compulsive Disorder,Behavioral: ACT plus ERP|Behavioral: ERP alone,Change from Baseline Yale-Brown Obsessive Compulsive Scale (Y-BOCS) at 8 weeks|Change from Posttreatment Yale-Brown Obsessive Compulsive Scale (Y-BOCS) at 6 months|Change from Baseline Beck Depression Inventory II (BDI-II) at 8 weeks|Change from Posttreatment Beck Depression Inventory II (BDI-II) at 6 months|Change from Baseline Acceptance and Action Questionnaire - II (AAQ-II) at 8 weeks|Change from Posttreatment Acceptance and Action Questionnaire - II (AAQ-II) at 6 months|Session-level Change in Acceptance and Action Questionnaire - II (AAQ-II) at each session|Change from Baseline Distress Tolerance Scale (DTS) at 8 weeks|Change from Posttreatment Distress Tolerance Scale (DTS) at 6 months|Change from Baseline Interpretation of Intrusions Inventory (III) at 8 weeks|Change from Posttreatment Interpretation of Intrusions Inventory (III) at 6 months|Session-level Change in Interpretation of Intrusions Inventory (III) at each session|Change from Baseline Believability of Anxious Feelings and Thoughts Questionnaire (BAFT) at 8 weeks|Change from Posttreatment Believability of Anxious Feelings and Thoughts Questionnaire (BAFT) at 6 months|Change from Baseline Obsessive Beliefs Questionnaire (OBQ) at 8 weeks|Change from Posttreatment Obsessive Beliefs Questionnaire (OBQ) at 6 months|Session-level Change in Patient EX/RP Adherence Scale - Therapist Rated at each session beginning with session 4|Treatment Credibility and Expectancy Questionnaire|Change from Baseline Dimensional Obsessive Compulsive Scale (DOCS) at 8 weeks|Change from Posttreatment Dimensional Obsessive Compulsive Scale (DOCS) at 6 months|Session-level Change in Dimensional Obsessive Compulsive Scale at each session,"Utah State University|University of North Carolina, Chapel Hill|International OCD Foundation",All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,58,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",2965,12-Jul-11,9-Jan-17,9-Jan-17,17-Nov-17,null,17-Nov-17,"University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Utah State University, Logan, Utah, United States",,https://ClinicalTrials.gov/show/NCT03343106
NCT03343457,Return To Work for People on Long Term Sick Leave,Vitalis,Completed,No Results Available,Anxiety|Chronic Pain,Behavioral: Cognitive therapy,Return to work (RTW),"Uppsala University|Stockholm County Council, Sweden",All,20 Years to 64 Years   (Adult),Not Applicable,400,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,VITALIS 2010,1-Jan-10,31-Dec-12,31-Dec-12,17-Nov-17,null,17-Nov-17,,,https://ClinicalTrials.gov/show/NCT03343457
NCT03344497,Animated Video Consultation for Reducing Pre-Operative Anxiety in Outpatient Dermatologic Surgery,,Recruiting,No Results Available,Dermatology/Skin - Other,Other: VC Group,Pre-operative anxiety levels assessed via questionnaire,University of Arizona,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,1702192435,1-Jun-17,1-Feb-18,1-Feb-18,17-Nov-17,null,22-Nov-17,"University of Arizona, Banner-University Medical Center, Tucson, Arizona, United States",,https://ClinicalTrials.gov/show/NCT03344497
NCT03345368,Effect of rTMS in Combination With a Low-carbohydrate Diet in Patients With Obesity,,Completed,No Results Available,Obesity|Anxiety,Device: rTMS|Device: sham rTMS|Other: Diet,"Obesity, changes in the body mass index",Hospital General Ajusco Medio,All,18 Years to 40 Years   (Adult),Not Applicable,49,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,211-010-01-17,26-Sep-17,21-Feb-19,21-Feb-19,17-Nov-17,null,30-Apr-19,"Hospital General Ajusco Medio, Mexico, Tlalpan, Mexico",,https://ClinicalTrials.gov/show/NCT03345368
NCT03336112,Internet-delivered CBT for Patients With NCCP,IKSIT,Recruiting,No Results Available,Non-cardiac Chest Pain|Cardiac Anxiety,Behavioral: Internet-delivered cognitive behavioral therapy (I-CBT)|Other: Information program,Cardiac anxiety|Fear of body sensations|Depressive symptoms|Quality of life|Chest pain frequency|Healthcare use|Societal costs,"Linkoeping University|Ostergotland County Council, Sweden",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,140,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,I-CBT for NCCP,1-Nov-17,31-Dec-20,31-Dec-20,8-Nov-17,null,26-Feb-19,"Linköping University, Linköping, Sweden",,https://ClinicalTrials.gov/show/NCT03336112
NCT03336827,Improving Emotion Regulation at the End of Breast Cancer Treatment,,Recruiting,No Results Available,Breast Cancer|Emotional Disturbances|Emotional Dysfunction|Anxiety Depression|Fear of Cancer,Behavioral: Cognitive-Behavioral Group Therapy and Hypnosis,"Change in Patients' Subjective Emotion Regulation through six 10-cm visual analog scales assessing anxiety, sadness, fear of cancer recurrence, physical fatigue, psychological fatigue, and energy state-levels|Change in Patients' Objective Emotion Regulation through an ambulatory digital Holter recording heart rate (beats per minute)|Change in Patients' Emotion Regulation in their Everyday Life through an ecological momentary assessment|Change in Patients' Anxiety State through the Hospital Anxiety Depression Scale (HADS) - anxiety subscale and the Penn State Worry Questionnaire (PSWQ)|Change in Patients' Depression State through the Hospital Anxiety Depression Scale (HADS)|Change in Patients' Fear of Cancer Recurrence State through the Fear of Cancer Recurrence Inventory (FCRI)|Change in an adapted Emotion Symptom Assessment Scale (ESAS)|Change in the Hospital Anxiety and Depression Scale (HADS) Questionnaire|Change in the Fear of Cancer Recurrence Inventory (FCRI) Questionnaire|Change in the White Bear Suppression Inventory (WBSI)|Change in the Mental Adjustment to Cancer Scale (MAC)|Change in Penn State Worry Questionnaire (PSWQ)|Change in the Five Facet of Mindfulness Questionnaire (FFMQ)|Change in the Metacognitions About Health Anxiety Questionnaire (MCQ-30)|Change in the Insomnia Severity Index (ISI)|Change in the Impact of Cancer Scale (IOCv2)|Change in the Cognitive Emotion Regulation Questionnaire (CERQ)|Change in the Multidimensional Fatigue Inventory (MFI-20)|Change in a Life Event Questionnaire|Change in Ecological Momentary Assessment through the use of a pedometer and a measure of cardio frequency (Garmin vívoactive® HR)|Change in Attentional Bias through a dot probe task",Université Libre de Bruxelles|Jules Bordet Institute|Centre de Psycho-Oncologie (CPO),Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,116,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,Emotion Regulation,1-Jan-17,1-Dec-19,1-Jun-20,8-Nov-17,null,8-Nov-17,"Institut Jules Bordet, Brussels, Belgium",,https://ClinicalTrials.gov/show/NCT03336827
NCT03333707,"Impact of a Mobile Application (Pacifica) on Stress, Anxiety, and Depression",,Completed,No Results Available,Anxiety|Stress|Depression,Behavioral: Pacifica App,"Change in Depression|Change in Anxiety|Change in Depression, Anxiety, Stress|Change in Self-Efficacy",Pacifica Labs Inc.,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,500,Industry,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Pacifica Study 1,2-Nov-17,10-May-18,10-May-18,7-Nov-17,null,17-May-18,"Pacifica Labs, Inc., San Francisco, California, United States",,https://ClinicalTrials.gov/show/NCT03333707
NCT03333798,Psychosocial Intervention With Community Worker Support for Survivors of Intimate Partner Violence,IPCCOS,Not yet recruiting,No Results Available,Intimate Partner Violence|Depression|Anxiety|Post-traumatic Stress Disorder|Activities of Daily Living|Self Esteem,Behavioral: Cognitive-Behavioral Intervention|Behavioral: Standard psychosocial care,Score Difference in Symptoms of Anxiety|Score Difference in Symptoms of Depression|Score Difference in Symptoms of Post-Traumatic Stress Disorders|Score Difference in Disability|Score Difference in Self-Esteem.|Score Difference in Emotional Dependence Scales.,"Universidad del Valle, Colombia|Universidad Unidad Central del Valle (UCEVA)|Red de Salud de Ladera E.S.E|Hospital Rubén Cruz Vélez E.S.E|Heartland Alliance",Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,200,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Code No.110674456022,Nov-17,Jun-18,Jan-19,7-Nov-17,null,7-Nov-17,,,https://ClinicalTrials.gov/show/NCT03333798
NCT03334929,Virtual Reality Distraction for Anxiety Reduction During Trigger Points Procedures in Pain Medicine Clinic,,Completed,No Results Available,Pain Management,Device: Virtual Reality headset,Change in anxiety level|Change in pain score,"University of California, Davis",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,47,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Other",1088873,8-Sep-17,31-Aug-18,24-Sep-18,7-Nov-17,null,24-Oct-18,"University of California, Davis, Sacramento, California, United States",,https://ClinicalTrials.gov/show/NCT03334929
NCT03330938,Decreasing Depression and Anxiety and Their Effect on QoL of ESRD Patients (End-Stage Renal Disease),ESRD,Recruiting,No Results Available,End-Stage Renal Disease,Behavioral: CBI and Resilience|Behavioral: Cognitive-behavioral Intervention,"Quality of Life Perception (change is being assessed from baseline depression, at 8 weeks and after 5 weeks).",Hospital Civil de Guadalajara|University of Guadalajara,All,18 Years to 60 Years   (Adult),Not Applicable,50,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,p3wkkbgz,1-Dec-17,23-Oct-18,30-Dec-18,6-Nov-17,null,24-Jul-18,"Cristina Jazmín Gonzalez Flores, Guadalajara, Jalisco, Mexico",,https://ClinicalTrials.gov/show/NCT03330938
NCT03332381,Attention Training Technique and Mindful Self-Compassion,,Completed,No Results Available,"Anxiety|Depression|Stress, Psychological",Behavioral: Attention training technique|Behavioral: Mindful self-compassion,Change in symptoms of depression as assessed with the Patient Health Questionnaire-9|Change in symptoms of anxiety as assessed with the Generalized Anxiety Disorder-7 scale|Changes in self-compassion as assessed by the Self-Compassion Scale Short Form|Changes in the attention flexibility subscale of the Detached Mindfulness Questionnaire|Changes in mindfulness as assessed with The Five Facet Mindfulness Questionnaire,Norwegian University of Science and Technology,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,81,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2015/470-1,1-May-15,1-May-17,1-Sep-17,6-Nov-17,null,6-Nov-17,"Psykologisk Institutt, Dragvoll, Trondheim, Norway",,https://ClinicalTrials.gov/show/NCT03332381
NCT03333239,"Short-term, Long-term and Cost-effectiveness of Treating Depression and Anxiety Disorders in Children and Adolescents",,Not yet recruiting,No Results Available,"Depression, Anxiety",Behavioral: psychodynamic psychotherapy|Behavioral: cognitive behavioral psychotherapy|Behavioral: psychodynamic family intervention,Change from baseline children´s psychiatric symptomatology at 12 months|Change from baseline children´s psychiatric symptomatology at 24 months|Change from baseline children´s psychiatric symptomatology at 36 months|Change from baseline children´s psychiatric symptomatology at 48 months|Change from baseline children´s psychiatric symptomatology at 60 months|Change from baseline children´s depressive symptomatology at 12 months|Change from baseline children´s depressive symptomatology at 24 months|Change from baseline children´s depressive symptomatology at 36 months|Change from baseline children´s depressive symptomatology at 48 months|Change from baseline children´s depressive symptomatology at 60 months|Change from baseline children´s anxiety at 12 months|Change from baseline children´s anxiety at 24 months|Change from baseline children´s anxiety at 36 months|Change from baseline children´s anxiety at 48 months|Change from baseline children´s anxiety at 60 months|Change from baseline parent reported children´s psychiatric symptoms at 12 months|Change from baseline parent reported children´s psychiatric symptoms at 24 months|Change from baseline parent reported children´s psychiatric symptoms at 36 months|Change from baseline parent reported children´s psychiatric symptoms at 48 months|Change from baseline parent reported children´s psychiatric symptoms at 60 months|Change from baseline children´s self reported psychiatric symptoms at 12 months|Change from baseline children´s self reported psychiatric symptoms at 24 months|Change from baseline children´s self reported psychiatric symptoms at 36 months|Change from baseline children´s self reported psychiatric symptoms at 48 months|Change from baseline children´s self reported psychiatric symptoms at 60 months|Change from baseline children´s structural functioning at 12 months|Change from baseline children´s structural functioning at 24 months|Change from baseline children´s structural functioning at 36 months|Change from baseline children´s structural functioning at 48 months|Change from baseline children´s structural functioning at 60 months|Change from baseline children´s health related quality of life at 12 months|Change from baseline children´s health related quality of life at 24 months|Change from baseline children´s health related quality of life at 36 months|Change from baseline children´s health related quality of life at 48 months|Change from baseline children´s health related quality of life at 60 months|Change from baseline children´s global impairment at 12 months|Change from baseline children´s global impairment at 24 months|Change from baseline children´s global impairment at 36 months|Change from baseline children´s global impairment at 48 months|Change from baseline children´s global impairment at 60 months|Change from baseline relational functioning at 12 months|Change from baseline relational functioning at 24 months|Change from baseline relational functioning at 36 months|Change from baseline relational functioning at 48 months|Change from baseline relational functioning at 60 months|Change from baseline children´s global functioning at 12 months|Change from baseline children´s global functioning at 24 months|Change from baseline children´s global functioning at 36 months|Change from baseline children´s global functioning at 48 months|Change from baseline children´s global functioning at 60 months|Change from baseline health economic data at 12 months|Change from baseline health economic data at 24 months|Change from baseline health economic data at 36 months|Change from baseline health economic data at 48 months|Change from baseline health economic data at 60 months,Universitätsklinikum Hamburg-Eppendorf|University of Bremen,All,8 Years to 16 Years   (Child),Not Applicable,420,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,vakjp_2,22-Dec-17,Aug-23,Aug-23,6-Nov-17,null,21-Dec-17,,,https://ClinicalTrials.gov/show/NCT03333239
NCT03328208,Nonpharmacologic Reduction of Periprocedural Distress and Drug Use,,Completed,No Results Available,Dental Anxiety|Pain|Drug Use|Opioid Use,Other: Comfort Talk® app|Other: White Noise app,Study design feasibility|Enrollment ability|Follow-up feasibility,"Hypnalgesics, LLC|Tufts University",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,72,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other",R43AT009517,22-Nov-17,30-Oct-18,31-Dec-18,1-Nov-17,null,1-Mar-19,"Tufts University School of Dental Medicine, Boston, Massachusetts, United States|Hypnalgesics, LLC, Brookline, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT03328208
NCT03328520,"WILD 5 Wellness, A 30-Day Intervention",,Completed,No Results Available,Anxiety|Depression|Cognitive Functioning|Wellness,Behavioral: WILD 5 Wellness Intervention,Change in Patient Health Questionnaire-9 (PHQ-9)|Change in Generalized Anxiety Disorder-7 (GAD-7)|Change in the HERO Wellness Scale|Change in World Health Organization-5 (WHO-5)|Change in Cognitive and Physical Functioning Questionnaire (CPFQ)|The Post-Program Participant Questionnaire,Beloit College,All,"17 Years and older   (Child, Adult, Older Adult)",Not Applicable,33,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,374,24-Oct-17,29-Nov-17,29-Nov-17,1-Nov-17,null,26-Apr-18,"Beloit College, Beloit, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT03328520
NCT03329287,Simplified Cognitive Behavioral Therapy for Generalized Anxiety Disorder and Depression,,Recruiting,No Results Available,Generalized Anxiety Disorder|Major Depressive Disorder,Behavioral: SCBT|Drug: SSRIs and/or SNRIs|Behavioral: Psychological Placebo,changes of The Hamilton Depression Scale (HAMD-17)|changes of The Hamilton Anxiety Scale (HAMA-14)|changes of The Patient Health Questionnaire (PHQ-9)|changes of The GAD-7|changes of The Mos 36-item Short Form Health Survey (SF-36)|changes of Treatment Emergent Symptom Scale (TESS)|changes of Clinical Global Impression (CGI),Shanghai Mental Health Center|Changhai Hospital|Shanghai 10th People's Hospital|Tongji Hospital|Fudan University|Second Hospital of Shanxi Medical University,All,18 Years to 60 Years   (Adult),Not Applicable,180,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",15411950201,1-Jul-17,30-Mar-18,30-Jun-18,1-Nov-17,null,1-Nov-17,"Shanghai Mental Health Center, Shanghai, Shanghai, China",,https://ClinicalTrials.gov/show/NCT03329287
NCT03327714,"Mindfulness as a Method of Improving the Well-being, Quality of Life and Health of Primary School Pupils",,Recruiting,No Results Available,Anxiety|Depression,Behavioral: Mindfulness and compassion,"Effect of mindfulness on change in anxiety and depression in children, grade 3-9, as measured by the Beck Depression Inventory for Youth and the Beck Anxiety Inventory for Youth.|Effect of mindfulness on changes in daily life as measured by questions about school and leisure time (adapted from the Scania Public Health Survey).|Effect of regular mindfulness practice on school performance (data collected from school registers)|Effect of mindfulness on change in class room environment (evaluated by questionnaires, weekly schedule, and interviews with teachers).|Effect of risk factors on mental health: longitudinal follow-up study.|Effect of mindfulness on risk factors: longitudinal follow-up study.|Effect of mindfulness on changes in quality of life as measured by questions adapted from the Scania Public Health Survey and Living Conditions Surveys (ULF/SILC)|Effect of mindfulness on changes in health as measured by questions about school and leisure time (adapted from the Scania Public Health Survey).|Long-term effect of mindfulness practice on anxiety, depression, daily life, quality of life and health as measured by the BDI Youth, the Scania Public Health Survey and Living Conditions Surveys (ULF/SILC) and registries: longitudinal follow-up study",Lund University|Region Skane,All,6 Years to 16 Years   (Child),Not Applicable,1750,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2016/299,12-Oct-16,30-Jan-20,30-Jun-39,31-Oct-17,null,15-Jan-19,"Center for Primary Health Care Research, Malmö, Sweden",,https://ClinicalTrials.gov/show/NCT03327714
NCT03324828,Presurgery Anxiolysis in Children Treated With Hydroxyzine Versus Non-pharmacological Intervention (Distractoria Technique Clown),SONRISA,Not yet recruiting,No Results Available,Anxiety,Drug: Hydroxyzine|Other: Clowns intervention,m-YPAS|Cortisol level (blood)|Cortisol level (salive)|Anesthesia induction,"Hospital San Carlos, Madrid",All,2 Years to 16 Years   (Child),Phase 4,188,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SONRISA,1-Nov-17,1-Nov-19,30-Nov-19,30-Oct-17,null,30-Oct-17,,,https://ClinicalTrials.gov/show/NCT03324828
NCT03324906,Effects of Transcranial Direct Current Stimulation (tDCS) on Individuals With Prader-Willi Syndrome,,Enrolling by invitation,No Results Available,Prader-Willi Syndrome|Obesity|Depressive Disorder|Obsessive-Compulsive Disorder,Device: tDCS,Hyperphagia changes|Improve depressive symptoms,Federal University of São Paulo,All,"11 Years and older   (Child, Adult, Older Adult)",Not Applicable,40,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,58280016.1.0000.5505,8-May-17,29-Sep-17,Nov-19,30-Oct-17,null,6-Nov-17,"Caroline Azevedo, São Paulo, Brazil",,https://ClinicalTrials.gov/show/NCT03324906
NCT03325335,Assessing the Effectiveness of Midazolam Premedication,,Completed,No Results Available,Midazolam Premedication|Anxiety Preoperative|Premedication,Drug: Midazolam premedication|Drug: Remifentanil infusion|Drug: Propofol infusion,"Change in degree of anxiety|Change in sedation level|Change in noninvasive blood pressure (hemodynamic parameters 1)|Change in SPI value (Analgesic profile 1)|Numeric rating scale (Analgesic profile 2)|Analgesic requirement (Analgesic profile 3)|Change in heart rate (hemodynamic parameters 2)|Procedure time of intubation|Correlation analysis between the SPI values and other parameters (heart rate, blood pressure, and entropy values)",Pusan National University Hospital,Female,"20 Years to 65 Years   (Adult, Older Adult)",Not Applicable,128,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1607-003-057,19-Jul-16,14-Aug-17,15-Aug-17,30-Oct-17,null,31-Oct-17,"Pusan national university hospital, Busan, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT03325335
NCT03323697,Chinese Herb for the Treatment of Depression and Anxiety Disorders,,Recruiting,No Results Available,"Depression, Anxiety",Other: SZ-05|Drug: Escitalopram Pill,Anxiety symptoms|Depressive symptoms|Wellbeing,Mazra Mental Health Center|The Academic College of Tel-Aviv Yaffo,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,60,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",MZR-0018-016,28-Aug-17,1-Sep-18,30-Dec-18,27-Oct-17,null,27-Oct-17,"Mazor MHC, Akko, Israel",,https://ClinicalTrials.gov/show/NCT03323697
NCT03324048,A Single Mindfulness Meditation Session in Preoperative Anxiety : Effects on the Autonomous Nervous System,,Completed,No Results Available,Anxiety|Relaxation,Other: relaxation session,high frequency|anxiety|low frequency|the ratio of high frequencies to low frequencies|PetCO2,Centre Hospitalier Universitaire de Saint Etienne,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,33,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,1708097|ID-RCB,14-Nov-17,17-Sep-18,17-Sep-18,27-Oct-17,null,17-May-19,"CHU de SAINT-ETIENNE, Saint-etienne, France",,https://ClinicalTrials.gov/show/NCT03324048
NCT03324347,Dog-Assisted Therapy in Dentistry,,Recruiting,No Results Available,Dental Anxiety|Pediatric Dentistry|Animal Assisted Therapy,Procedure: Therapydog,Examination achieved; Yes or No|Child satisfaction|Measurement of anxiety through the CFSS-DS scale (Dental subscale of Children's Fear Survey Schedule)|Salivary cortisol level|Heart rate variability|Skin conductance (Electrodermal activity),University of Tromso,All,6 Years to 12 Years   (Child),Not Applicable,16,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,2017/1078 (REK),31-Oct-17,Jun-19,Jul-20,27-Oct-17,null,31-Oct-18,"Department of Clinical Dentistry, UiT The Arctic University of Norway, Tromsø, Norway",,https://ClinicalTrials.gov/show/NCT03324347
NCT03322228,Music Therapy Intervention to Reduce Caregiver Distress at the End of Life,,Recruiting,No Results Available,Quality of Life|Stress|Anxiety|Depression,Other: Music Therapy,Pearlin role overload measure (ROM)|Linear Analogue Self-Assessment (LASA)|Patient Health Questionnaire for Depression and Anxiety (PHQ-4)|Music Therapy Program Survey,Mayo Clinic,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,20,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,17-005811,5-Oct-17,31-Aug-19,31-Aug-19,26-Oct-17,null,6-Nov-18,"Mayo Clinic, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT03322228
NCT03318367,Virtual Reality Education Module in Reducing Anxiety and Increasing Knowledge in Patients With Prostate Cancer Undergoing Radiation Therapy,,Terminated,No Results Available,Prostate,Other: Educational Intervention,Standard deviation for difference in questionnaire response from pre-education to post-education,Sidney Kimmel Cancer Center at Thomas Jefferson University|Thomas Jefferson University,Male,"Child, Adult, Older Adult",Not Applicable,23,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,14D.354,6-Aug-14,3-Jun-16,11-Aug-16,23-Oct-17,null,27-Oct-17,,,https://ClinicalTrials.gov/show/NCT03318367
NCT03315208,"Study of a Transdiagnostic, Emotion-focused Group Intervention for Young Adults With Substance Use Disorders",ARMS UP,Recruiting,No Results Available,Substance Use Disorders|Depression|Anxiety|Emotional Disorder|Suicidal Ideation|Suicidal and Self-injurious Behavior,Behavioral: Unified Protocol (UP)|Other: Treatment as Usual (TAU),Acceptability of adding UP group intervention to TAU|Feasibility of adding UP group intervention to TAU|Anxiety symptoms|Depressive symptoms Scale (ODSIS)|Suicidal ideation|Nonsuicidal self-injury|Commitment to sobriety|Substance craving|Substance use,Massachusetts General Hospital,All,18 Years to 26 Years   (Adult),Not Applicable,50,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2017P001274,22-Nov-17,31-Oct-19,31-Oct-19,20-Oct-17,null,7-Dec-18,"Massachusetts General Hospital Addiction Recovery Management Service, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT03315208
NCT03316846,Internet-delivered Cognitive Behavioral Therapy for Patients With Chronic Pain and Psychiatric Distress,TIPPS,"Active, not recruiting",No Results Available,"Chronic Pain|Depressive Symptoms|Anxiety|Stress, Psychological",Behavioral: Internet-Delivered Cognitive Behavioral Therapy,Change from baseline in depressive symptoms|Change from baseline in anxiety sensitivity|Change from baseline in symptoms of depression and anxiety|Change from baseline in psychosocial consequences of pain|Change from baseline in pain disability|Change from baseline in quality of life|Fear of pain due to movement|Change from baseline in insomnia symptoms|Change from baseline in PTSD symptoms|Change from baseline in stress|Change from baseline in GAD-symptoms|Change from baseline in pain catastrophizing|Change from baseline in coping strategies|Change from baseline in pain acceptance|Change from baseline in self efficacy|Treatment credibility rating,Uppsala University|Uppsala University Hospital,All,"16 Years to 70 Years   (Child, Adult, Older Adult)",Not Applicable,200,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,140371,13-Sep-16,Aug-18,Aug-18,20-Oct-17,null,6-Dec-17,"Department of Psychology, Uppsala University, Uppsala, Uppland, Sweden",,https://ClinicalTrials.gov/show/NCT03316846
NCT03313193,Acupressure for Children in Treatment for a Childhood Cancer,ACT-CC,Recruiting,No Results Available,Treatment-Related Cancer,Other: Acupressure for Children in Treatment for a Childhood Cancer,"Decrease in nausea/vomiting severity|Decreased nausea (PeNAT)|Decreased vomiting (Vol, 2016)|Use of fewer rescue anti-emetics (from Electronic Medical Records)|Complete control of nausea/vomiting|Decreased pain interference assessed using the PROMIS Pediatric Pain Interference Scale|Decreased Pain intensity|Decreased pain assessed (ages 5-7)|Decreased fatigue symptoms|Decreased depression symptoms|Decreased anxiety|Increased Well-being|Fewer overall symptoms assessed using the Symptom Screening in Pediatrics (SSPedi) tool (Tomlinson, 2014)|Decreased depression symptoms using the PROMIS depression (adult) measure.|Decreased anxiety assessed using PROMIS anxiety (adult)|Fewer PTSD symptoms, (PCL-5) (adult)|Increased Caregiver Self-Efficacy (parent)","University of California, San Francisco|Patient-Centered Outcomes Research Institute|Pierre's Birthday Fund",All,"5 Years to 24 Years   (Child, Adult)",Not Applicable,200,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,170820,26-Sep-17,30-Oct-19,30-Oct-19,18-Oct-17,null,17-Apr-19,"UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States",,https://ClinicalTrials.gov/show/NCT03313193
NCT03311529,Effectiveness and Underlying Mechanisms of Applied Relaxation as Indicated Preventive Intervention,EASY,Recruiting,No Results Available,Anxiety Disorders|Depressive Disorder|Stress Disorder,Behavioral: Applied Relaxation,primary outcome intervention efficacy|primary outcome prevention efficacy|secondary outcomes intervention efficacy|secondary outcomes prevention efficacy,Technische Universität Dresden,All,18 Years to 54 Years   (Adult),Not Applicable,210,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,AS 497/1-1,1-Sep-16,31-Dec-18,31-Dec-18,17-Oct-17,null,17-Oct-17,"Technische Universität Dresden, Dresden, Germany",,https://ClinicalTrials.gov/show/NCT03311529
NCT03310112,Mindfulness Training in U.S. Army Cohorts,,Completed,No Results Available,Psychological Stress|Anxiety|Post Traumatic Stress Disorder|Depression|Cognitive Change,Behavioral: 4-week MBAT|Behavioral: 2-week MBAT,Change in Sustained Attention to Response Task (SART)|Change in Working Memory Task with Affective Distraction (WMDA)|Change in Patient Health Questionnaire depression scale (PHQ)|Change in Generalized Anxiety Disorder assessment (GAD-7)|Change in PTSD Checklist_Military (PCLM)|Change in the Pittsburgh Sleep Quality Index (PSQI)|Change in Alcohol Use Disorders Identification Test—Consumption (AUDIT-C)|Change in Brief Resilience Scale (BRS)|Change in Perceived Stress Scale (PSS)|Change in Positive and Negative Affect Scale (PANAS)|Change in Adult Decision-Making Competence scale (Sunk Costs questionnaire)|Change in Cognitive Failures Questionnaire (CFQ)|Change in Five-Facet Mindfulness Questionnaire (5FMQ)|Change in Emotion Regulation Questionnaire (ERQ)|Change in Combat Experiences Scale (CES)|Change in Rumination and Response Scale (RRS)|Change in Self-Compassion Questionnaire (SCQ)|Change in Mind Wandering Questionnaire (MWQ)|Practice logs|Motivation,University of Miami,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,120,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,20170243,9-Oct-17,27-Mar-18,27-Mar-18,16-Oct-17,null,18-Sep-18,"University of Miami, Coral Gables, Florida, United States",,https://ClinicalTrials.gov/show/NCT03310112
NCT03310489,A Randomized Controlled Study of Digitalized Cognitive-behavioral Intervention for Childhood Anxiety,,Recruiting,No Results Available,Anxiety,Behavioral: Digitalized cognitive-behavioral intervention for anxiety|Behavioral: Psychoeducation about anxiety,"Change from Baseline to 6 months follow up; the Screen for Child Anxiety Related Disorders - child and parent reports|Change from Baseline to 6 months follow up; the Child Anxiety Impact Scale - child and parent reports|Change from Baseline to 6 months follow up (in the Intervention group); the Development and Well-Being Assessment - child and parent reports|Change from Baseline to 6 months follow up; the Revised Children Quality of Life - Questionnaire - child and parent reports|Change from Baseline to 6 months follow up; the Child Depression inventory - child report|Change from Baseline to 6 months follow up; the Strengths and Difficulties Questionnaire, extended version - parent report|Change from Baseline to 6 months follow up of the relations with peers and school (not a standardized scale)|Change from Baseline to 6 months follow up; the Brief resilience scale - parent report (parental resilience)|Change from Baseline to 6 months follow up; the Depression Anxiety and Stress Scale Short Form - parent report (parental depression, anxiety and stress)|Change from Baseline to 6 months follow up; the Customised Client Receipt Inventory Questionnaire - parent report",University of Turku,All,"Child, Adult, Older Adult",Not Applicable,360,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ANXIETY-2017,24-Oct-17,Aug-20,Aug-20,16-Oct-17,null,11-Apr-19,"Child Psychiatric Research Center, University of Turku, Turku, Finland",,https://ClinicalTrials.gov/show/NCT03310489
NCT03308240,Magic Therapy to Relieve Pediatric Patient Anxiety and Improve the Hospitalization Experience,,Recruiting,No Results Available,Anxiety,Behavioral: Magic Therapy,To assess the therapeutic benefits of magic therapeutic intervention and impact on patient anxiety age 5-13 years.|To assess the therapeutic benefits of magic therapeutic intervention and impact on pediatric patient anxiety age 5-16 years.|To assess the therapeutic benefits of magic therapeutic intervention and impact on patient (age 5-16) and caregiver anxiety.|To determine medical professional opinions regarding magic therapeutic services as offered at Stony Brook Children's Hospital.,Stony Brook University,All,5 Years to 16 Years   (Child),Not Applicable,260,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1037793-2,26-Jul-17,26-Jul-18,26-Jul-18,12-Oct-17,null,12-Oct-17,"Stony Brook University, Stony Brook, New York, United States",,https://ClinicalTrials.gov/show/NCT03308240
NCT03304392,Therapist-guided Internet-delivered Cognitive Behavioural Therapy,,Recruiting,No Results Available,Anxiety|Depression,Behavioral: Personalized ICBT|Behavioral: Standard ICBT,Change in depression|Change in anxiety|Change in psychological distress|Change in disability|Change in panic symptoms|Change in social anxiety symptoms|Change in social phobia symptoms|Change in post-traumatic symptoms|Change in quality of life symptoms|Change in treatment costs|Therapeutic alliance|Treatment credibility|Treatment satisfaction|Engagement,University of Regina|Canadian Institutes of Health Research (CIHR),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,440,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,375860,11-Oct-17,Sep-19,Sep-19,9-Oct-17,null,19-Apr-19,"Online Therapy Unit, University of Regina, Regina, Saskatchewan, Canada",,https://ClinicalTrials.gov/show/NCT03304392
NCT03304600,tDCS for Treatment Resistant Obsessive Compulsive Disorder,tDCS-TOC,Recruiting,No Results Available,Obsessive-Compulsive Disorder,Device: Active stimulation|Device: Sham stimulation,"Yale Brown Obsessive Compulsive Scale (YBOCS) score|Yale Brown Obsessive Compulsive Scale (YBOCS)|Yale Brown Obsessive Compulsive Scale (YBOCS),|Clinical Global Impression (CGI)|Brown Assessment of Beliefs Scale (BABS)|Brief Anxiety Scale (BAS)|Montgomery and Asberg Depression Rating Scale (MADRS)|Hospital Anxiety and Depression scale (HAD)|Sheehan Disability Scale, (SDS)","Centre Hospitalier Henri Laborit|Ministry of Health, France",All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,100,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",2016-A01983-48,3-Nov-17,Nov-19,Mar-20,9-Oct-17,null,2-Apr-19,"CHU de Nantes, Nantes, France|Centre Hospitalier Henri Laborit, Poitiers, France|C.H. Guillaume Regnier, Rennes, France",,https://ClinicalTrials.gov/show/NCT03304600
NCT03305328,Assessing the Clinical Utility of tACS,,Completed,No Results Available,Anxiety Disorders and Symptoms|Sensory Disorders|Hypervigilance|Post Traumatic Stress Disorder,Device: Transcranial Alternating Current Stimulation,"Immediate and lasting changes in alpha oscillatory power and directed, long-range cortico-cortical connectivity.|Immediate and lasting reductions in anxious arousal|Immediate and lasting changes in affective perception of sensory stimuli",Florida State University,All,18 Years to 60 Years   (Adult),Not Applicable,38,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,2017.207,29-Jul-16,31-Mar-17,31-Mar-17,9-Oct-17,null,9-Oct-17,,,https://ClinicalTrials.gov/show/NCT03305328
NCT03301922,Work-focused Metacognitive Therapy for Patients on Sick Leave Due to Common Mental Disorders,,Recruiting,No Results Available,Anxiety|Depression,Behavioral: Work-focused Metacognitive therapy|Other: Waiting list,Changes in degree of sick leave|Changes in depressive symptoms|Changes in anxiety symptoms|Changes in metacognitions|Changes in subjective health complaints|Changes in bullying and victimisation at work|Changes in self-efficacy|Changes in resilience|Changes in quality of life|MINI - diagnostic interview,Norwegian University of Science and Technology|Diakonhjemmet Hospital,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,240,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2015/1794,31-Oct-17,Apr-23,Apr-23,4-Oct-17,null,9-Nov-18,"Poliklinikken Raskere Tilbake, Diakonhjemmet Sykehus, Oslo, Norway",,https://ClinicalTrials.gov/show/NCT03301922
NCT03299166,BHV-4157 in Adult Subjects With Obsessive Compulsive Disorder,,Recruiting,No Results Available,Obsessive-Compulsive Disorder,Drug: BHV-4157|Drug: Placebo,"Change in the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) total score|Safety and tolerability assessed using the frequency of subjects with serious adverse events, adverse events leading to discontinuation, and adverse events judged to be related to study medication.|Improvement in functional disability assessed using the Sheehan Disability Scale (SDS) total score.|Assessment of the improvement on the clinical global impression of severity scale (CGI-S).|Change in the Y-BOCS obsessions sub-scale score.","Biohaven Pharmaceuticals, Inc.",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2|Phase 3,226,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BHV4157-202,19-Dec-17,18-Nov-19,18-Nov-20,2-Oct-17,null,8-Apr-19,"Metropolitan Neuro Behavioral Institute, Chandler, Arizona, United States|Preferred Research Partners, Inc., Little Rock, Arkansas, United States|Collaborative Neuroscience Network, LLC, Garden Grove, California, United States|University of California San Diego, La Jolla, California, United States|Synergy Research San Diego, Lemon Grove, California, United States|CalNeuro Research Group, Los Angeles, California, United States|Pacific Research Partners, LLC, Oakland, California, United States|NRC Research Institute, Orange, California, United States|Desert Valley Research, Rancho Mirage, California, United States|Artemis Institute for Clinical Research, San Diego, California, United States|Artemis Institute for Clinical Research, San Marcos, California, United States|Stanford University, Department of Psychiatry and Behavioral Sciences, Stanford, California, United States|Pacific Clinical Research Medical Group, Upland, California, United States|Mountain View Clinical Research, Inc., Denver, Colorado, United States|Institute of Living / Hartford Hospital, Hartford, Connecticut, United States|Yale University, New Haven, Connecticut, United States|Comprehensive Psychiatric Care, Norwich, Connecticut, United States|Gulfcoast Clinical Research Center, Fort Myers, Florida, United States|University of Florida Department of Psychiatry, Gainesville, Florida, United States|Galiz Research, Hialeah, Florida, United States|Clinical Neuroscience Solutions, Inc, Jacksonville, Florida, United States|SIH Research, Inc, Kissimmee, Florida, United States|Harmony Clinical Research, North Miami Beach, Florida, United States|Medical Research Group of Central Florida, Orange City, Florida, United States|Clinical Neuroscience Solutions, Inc, Orlando, Florida, United States|iResearch Atlanta, LLC, Decatur, Georgia, United States|iResearch Savannah, Savannah, Georgia, United States|Chicago Research Center, Chicago, Illinois, United States|University of Chicago Department of Psychiatry & Behavioral Neuroscience, Chicago, Illinois, United States|AMR-Baber Research, Inc, Naperville, Illinois, United States|Phoenix Medical Research, Inc., Prairie Village, Kansas, United States|Heartland Research Associates, LLC, Wichita, Kansas, United States|Pharmasite Research, Inc., Pikesville, Maryland, United States|McLean Hospital, Belmont, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Boston Clinical Trials, Boston, Massachusetts, United States|Michigan Clinical Research PC, Ann Arbor, Michigan, United States|Precise Research Centers, Flowood, Mississippi, United States|ActivMed Practices and Research, Inc., Portsmouth, New Hampshire, United States|Center for Emotional Fitness, Cherry Hill, New Jersey, United States|Integrative Clinical Trials LLC, Brooklyn, New York, United States|Bio Behavioral Institute, Great Neck, New York, United States|New York State Psychiatric Institute, New York, New York, United States|Finger Lakes Clinical Research, Rochester, New York, United States|Richmond Behavioral Associates, Staten Island, New York, United States|New Hope Clinical Research, Charlotte, North Carolina, United States|New Horizons Clinical Research, Cincinnati, Ohio, United States|Midwest Clinical Research Center, Dayton, Ohio, United States|Summit Research Network (Oregon) Inc., Portland, Oregon, United States|Suburban Research Associates, Media, Pennsylvania, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Clinical Neuroscience Solutions, Inc., Memphis, Tennessee, United States|FutureSearch Trials of Dallas, LP, Dallas, Texas, United States|InSite Clinical Research, DeSoto, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Wasatch Clinical Research, LLC, Salt Lake City, Utah, United States|Psychiatric Alliance of the Blue Ridge, Inc., Charlottesville, Virginia, United States|Northwest Clinical Research Center, Bellevue, Washington, United States",,https://ClinicalTrials.gov/show/NCT03299166
NCT03297619,Self-help Books for Social Anxiety,,Completed,No Results Available,Social Anxiety,Behavioral: Mindfulness and Acceptance Workbook for Social Anxiety and Shyness|Behavioral: The Shyness and Social Anxiety Workbook,"Liebowitz Social Anxiety Scale - Self Report (Fresco et al., 2001)|General Health Questionnaire-12 (Banks et al., 1980; Goldberg, 1978)|Patient-Reported Outcomes Measurement Information System (PROMIS) Satisfaction with Social Roles And Activities Short Form 8 v2.0 (Hahn et al., 2014)|Valuing Questionnaire - Progress subscale (Smout, Davies, Burns, & Christie, 2014)",Utah State University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,109,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,8694,16-Sep-17,2-Jan-19,2-Jan-19,29-Sep-17,null,17-Apr-19,"Utah State University, Logan, Utah, United States",,https://ClinicalTrials.gov/show/NCT03297619
NCT03296007,Evaluating the Psychophysiological Effects of a Smartphone-Based Mindfulness Task,,Recruiting,No Results Available,"Chronic Pain|Depression, Anxiety",Behavioral: Mindfulness Meditation,Heart Rate Variability,York University,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,180,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,#e2017 - 303,10-Nov-17,31-Jul-19,31-Jul-19,28-Sep-17,null,13-Mar-19,"York University, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT03296007
NCT03290625,Intranasal Sedation With Dexmedetomidine and Ketamine in Pediatric Dentistry (NASO II),,Recruiting,No Results Available,Caries of Infancy|Dental Anxiety,Drug: Dexmedetomidine Hydrochloride|Drug: Ketamine Hydrochloride,"Children's behavior according to observational scale|Acceptance of intranasal administration according to observation|Memory of the procedure through questionnaire|Salivary cortisol according to ELISA|Salivary melatonin according to ELISA|Pain according to the FLACC scale|Accompanying person perception through VAS|Pediatric dentist perception through VAS|Child's perception through qualitative interview|Adverse events|Child's dental anxiety and sedation efficacy, according to the Venham's picture test|Child's dental behavior in the reception and sedation efficacy, according to the Sharath Scale|Parents' anxiety and sedation efficacy, according to the STAI|Parents' dental anxiety and sedation efficacy, according to the Corah Scale|Parents' overall stress and sedation efficacy, according to the Lipp Inventory|Procedural dental sedation impact according to the B-ECOHIS|Economic analysis",Universidade Federal de Goias|Fundação de Amparo à Pesquisa do Estado de Goiás (FAPEG),All,20 Months to 83 Months   (Child),Phase 4,182,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",PV0939-2017,9-Nov-17,Dec-19,Dec-21,25-Sep-17,null,19-Apr-19,"Dental School, Goiania, Goias, Brazil",,https://ClinicalTrials.gov/show/NCT03290625
NCT03286881,Brief Evidence-based Psychological Treatments for Common Mental Disorders,PsycBrief,Recruiting,No Results Available,Anxiety Disorders|Depression|Somatoform Disorders|Common Mental Disorders,Other: Brief psychotherapy|Other: Extensive psychotherapy|Other: Combined intervention|Other: Minimum psychological intervention|Other: Usual treatment,Generalised Anxiety Disorder Assessment (GAD-7)|The State-Trait Anxiety Inventory (STAI)|The Patient Health Questionnaire (PHQ-9)|Beck Depression Inventory-Second Edition (BDI-II)|The Patient Health Questionnaire (PHQ-15)|The Patient Health Questionnaire (PHQ-PD)|Brief Symptom Inventory 18 (BSI-18),"Universidad de Córdoba|Ministerio de Economía y Competitividad, Spain",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,165,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Investigator)|Primary Purpose: Treatment",PSI2014-56368-R,15-Jan-17,15-Jan-18,15-Jan-19,19-Sep-17,null,19-Sep-17,"Universidad de Córdoba, Cordoba, Córdoba, Spain",,https://ClinicalTrials.gov/show/NCT03286881
NCT03285685,Effect of Noninvasive Neuromodulation on Chronic Pain,,Recruiting,No Results Available,Temporomandibular Dysfunction (TMD),Device: active tDCS|Device: sham tDCS,Change from baseline in Visual Analogic Scale|Patient Global Impression of Change Scale (PGICS)|State-Trait Anxiety Inventory,Federal University of Paraíba,All,18 Years to 60 Years   (Adult),Phase 2,10,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",NeuroDTM,2-Oct-17,26-Jan-18,16-Feb-18,18-Sep-17,null,18-Sep-17,"Tatyanne Falcão, João Pessoa, Paraíba, Brazil",,https://ClinicalTrials.gov/show/NCT03285685
NCT03284671,tDCS Stimulation to Treat Patients With Severe and Resistant Obsessive Compulsive Disorder-Pilot Study,tDCS-TOC,Completed,No Results Available,Obsessive-compulsive Disorders and Symptoms,Other: bifocal stimulation with tDCS,The primary outcome measure is used to show that bifocal tDCS with anodal stimulation on OFC and cathodic stimulation on the SMA is an effective treatment|Evaluate the persistence of therapeutic response at 45 days|Evaluate the persistence of therapeutic response at 105 days|Evaluate the therapeutic effect of tDCS on the depressive and anxious symptoms associated with Obsessive compulsive disorder at 14 days|Evaluate the therapeutic effect of tDCS on the depressive and anxious symptoms associated with Obsessive compulsive disorder at 45 days|Evaluate the therapeutic effect of tDCS on the depressive and anxious symptoms associated with Obsessive compulsive disorder at 105 days|Evaluate the effect of tDCS on the quality of life at day 14|Evaluate the effect of tDCS on the quality of life at day 45|Evaluate the effect of tDCS on global functioning at day 14|Evaluate the effect of tDCS on global functioning at day 45|Evaluate the effect of tDCS on social adjustment at day 14|Evaluate the effect of tDCS on social adjustement at day 45,Centre Hospitalier Henri Laborit,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,20,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,tDCS-TOC pilote,19-Feb-16,19-Feb-16,12-May-17,15-Sep-17,null,15-Sep-17,"Centre Hospitalier Henri Laborit, Poitiers, France",,https://ClinicalTrials.gov/show/NCT03284671
NCT03283930,ABMT Augmentation of CBT,,Recruiting,No Results Available,"Anxiety Disorders|Children, Only",Behavioral: Active Attention Bias Modification Training|Behavioral: Placebo Attention Bias Modification Training,The Pediatric Anxiety Rating Scale (PARS)|Clinical Global Impression Scale (CGI),National Institutes of Health Clinical Center (CC),All,8 Years to 17 Years   (Child),Not Applicable,120,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",0192A,1-Feb-17,Jan-21,Jan-21,14-Sep-17,null,13-Mar-19,"NIH Clinical Center, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT03283930
NCT03281018,Preoperative Hypnosis in Gynecology,HYPPOGYN,Recruiting,No Results Available,Pelvic Gynecological Cancer,Behavioral: Caregiver Accompaniment Time (CAT) + preoperative hypnosis session,evolution of anxiety|pain|nausea and vomiting|concomitant medication|medical history|length of hospital stay|hypnosis intervention feasibility (composite outcome),"University Hospital, Bordeaux",Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,30,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,CHUBX 2016/18,10-Nov-17,30-Jun-19,30-Jun-19,13-Sep-17,null,16-Apr-19,"CHU Bordeaux, Bordeau, France",,https://ClinicalTrials.gov/show/NCT03281018
NCT03279471,Specifying and Treating Anxiety in Autism Research,STAAR,Recruiting,No Results Available,Autism Spectrum Disorder|Anxiety,Drug: Sertraline|Behavioral: CBT/BIACA|Drug: Placebo,Change in Pediatric Anxiety Rating Scale,"University of California, Davis",All,8 Years to 12 Years   (Child),Phase 2,132,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",1097281,1-Oct-17,15-Feb-22,14-Sep-22,12-Sep-17,null,16-Oct-18,"UC Davis MIND Institute, Sacramento, California, United States",,https://ClinicalTrials.gov/show/NCT03279471
NCT03277339,Psycho-biological Substrates of Therapeutic Benefit of Thermal Cure on Generalized Anxiety Disorders,Insula-TOP,Recruiting,No Results Available,Generalized Anxious Disorders,Drug: Paroxetine|Other: Thermal cure,"Decrease Insula activity during a resting state task|Changes of HAM-A score between day 1 and day 24.|Sensibility non conscientious to emotional interference in lexical task and in color identification task|Modulation of electrodermal response during presentation of predictive stimuli on aversive images and its links to the subjective view of emotional state|Modulation of electrodermal response during presentation of predictive stimuli on aversive images and insula activation|Lost of significant correlation (Day 24) between HAM-A score, introspective acuity and insula hyperactivation|Evolution (Day 1 and Day 24) of the correlation between HAM-A global score and 1- the measure of heartbeat 2- emotional reactivity during aversive images task.|Difference (Day 1 and Day 24) of correlations between the symptoms severity and the activation of insula cortex during 1-aversive images task, 2-heartbeat measure task.|Evaluation of efficacy of the thermal cure Day 56 using HAM-A score","Centre Hospitalier Henri Laborit|Association Francaise pour la Recherche Thermale|Les thermes de Saujon|Poitiers University Hospital|Centre National de la Recherche Scientifique (CeRCA, umr 7295), France",All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 4,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,InsulaTOP,19-Jan-17,Aug-19,Oct-19,11-Sep-17,null,2-Apr-19,"Centre Hospitalier Henri Laborit, Poitiers, France|Les thermes de Saujon, Saujon, France",,https://ClinicalTrials.gov/show/NCT03277339
NCT03274440,Effects of Marijuana on Symptoms of OCD,ECOS,Recruiting,No Results Available,Obsessive-Compulsive Disorder,Drug: Marijuana|Other: Placebo,Yale-Brown Obsessive-Compulsive Challenge Scale,New York State Psychiatric Institute,All,21 Years to 55 Years   (Adult),Phase 1|Phase 2,20,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",# 7405,1-Oct-17,Apr-19,Apr-19,7-Sep-17,null,13-Mar-19,"New York State Psychiatric Institute, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT03274440
NCT03275337,Cerebellar Neuromodulation to Enhance Fear Extinction and Predict Response to Exposure Therapy,,Recruiting,No Results Available,Anxiety Disorders|Social Phobia,Device: Transcranial Direct Current Stimulation,Activation of ventromedial prefrontal cortex after cerebellar stimulation|Change in resting state connectivity between vmPFC and cerebellar stimulation target|Baseline cerebellar-cerebral connectivity prediction of exposure therapy outcomes,"Laureate Institute for Brain Research, Inc.",All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,96,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science,2017_001_01,1-Aug-17,31-Jul-22,31-Jul-22,7-Sep-17,null,1-Mar-19,"Laureate Institute for Brain Research, Tulsa, Oklahoma, United States",,https://ClinicalTrials.gov/show/NCT03275337
NCT03273699,Mindfulness Meditation Utilizing an EEG Biofeedback Device for the Treatment for Obsessive Compulsive Disorder,,Completed,No Results Available,Obsessive-Compulsive Disorder,Device: Mindfulness,Yale-Brown Obsessive Compulsive Scale (YBOCS)|Obsessive Compulsive Inventory|Obsessive Beliefs Questionnaire|Five Factor Mindfulness Questionnaire|Thought Control Questionnaire|Acceptance and Action Questionnaire|Mind Wandering Scale|Metacognitions Questionnaire,Sunnybrook Health Sciences Centre,All,18 Years to 60 Years   (Adult),Not Applicable,71,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,196-2016,10-Apr-17,31-Jan-19,31-Jan-19,6-Sep-17,null,10-Apr-19,"Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT03273699/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT03273699/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT03273699
NCT03271476,EMDR Psychotherapy to Treat Anxious-depressive Symptoms in Breast Cancer Patient,PSYCANCER,Completed,No Results Available,Breast Cancer|Eye Movement Desensitization and Processing|Psychoterapy,Behavioral: EMDR psychotherapy,"patients involvement|adequacy of the intervention with the field|EMDR psychotherapy efficacy during the study, we will survey our population several times with differents questionnaires",Centre Hospitalier Régional Metz-Thionville|University of Lorraine,Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,15,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,2017-01-CHRMT,1-Sep-17,25-Jul-18,25-Jul-18,5-Sep-17,null,31-Jan-19,"CHR Metz-Thionville, Metz, France",,https://ClinicalTrials.gov/show/NCT03271476
NCT03272516,Mindfulness Based Cognitive Therapy (MBCT) for Primary Care Patients,,"Active, not recruiting",No Results Available,"Depression, Anxiety",Behavioral: Mindfulness based cognitive therapy (MBCT)|Other: Treatment as usual (TAU),Symptoms of depression measured with the PHQ-9 questionnaire|Symptoms of anxiety measured with the GAD-7 questionnaire|Subjective well-being measured with the SWEMWBS questionnaire|Change in use of antidepressants|Change in use of anxiolytics,University of Iceland|University of Aarhus,All,"18 Years to 67 Years   (Adult, Older Adult)",Not Applicable,120,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Health Services Research,UI-2017-MBCT.,12-Sep-17,10-Oct-19,10-Oct-20,5-Sep-17,null,21-Feb-19,"Heilsugæslan Grafarvogi, Reykjavík, Grafarvogur, Iceland|Heilsugæslan Miðbæ, Reykjavík, Iceland",,https://ClinicalTrials.gov/show/NCT03272516
NCT03272555,WILD 5 Wellness: A 30-Day Intervention,,Terminated,No Results Available,Wellness|Anxiety|Depression|Cognitive and Executive Dysfunction,Other: WILD 5 Wellness Interventions,Change in Patient Health Questionnaire-9 (PHQ-9)|Change in Generalized Anxiety Disorder-7 (GAD-7)|Change in The HERO Wellness Scale|Change in World Health Organization-5 (WHO-5)|Change in Cognitive and Physical Functioning Questionnaire (CPFQ)|The Post-Program Participant Questionnaire,Beloit College,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,14,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,365,5-Sep-17,10-Oct-17,13-Oct-17,5-Sep-17,null,26-Apr-18,"Beloit College, Beloit, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT03272555
NCT03269929,Comparison Between Efficacy of Music Therapy and Intravenous Midazolam 0.02 mg/kgBW in Reducing Preoperative Anxiety,,Completed,No Results Available,Cancer,Other: Music therapy|Drug: Midazolam,APAIS score|Blood pressure|Pulse rate|Mean Arterial Pressure,Indonesia University,Female,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care",IndonesiaUAnes018,1-Jan-17,31-Mar-17,1-Jul-17,1-Sep-17,null,1-Sep-17,"Cipto Mangunkusumo Central National Hospital, Central Jakarta, DKI Jakarta, Indonesia",,https://ClinicalTrials.gov/show/NCT03269929
NCT03264365,The Effectiveness of a Post-ICU Recovery Program on Relatives,RAPIT-II,Completed,No Results Available,Intensive Care Unit Syndrome|Relatives,Behavioral: Intervention,Mental Component Score|Physical Component Score|Anxiety|Depression|Post-traumatic stress Disorders|Sense of coherence,"Holbaek Sygehus|Nordsjaellands Hospital|Herlev Hospital|Horsens Hospital|Nykøbing Falster County Hospital|Naestved Hospital|Rigshospitalet, Denmark|Aabenraa Hospital|Sonderborg Hospital|Sydvestjysk Hospital|Svendborg Hospital",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,181,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care,01863 HIH-2012-011|NCT-01721239,15-Dec-12,31-Dec-15,6-Mar-18,29-Aug-17,null,7-Mar-18,"Holbæk Hospital, Holbæk, Sjælland, Denmark",,https://ClinicalTrials.gov/show/NCT03264365
NCT03265015,Theta Burst Stimulation for Compulsive Behavior Non-invasive Brain Stimulation Study,,Recruiting,No Results Available,Compulsive Behavior|Obsessive-Compulsive Disorder,Behavioral: Habit Override Practice|Other: Transcranial Magnetic Stimulation,functional Magnetic Resonance Imaging (fMRI)|Quantity of compulsive behaviors in response to laboratory triggers|Duration of compulsive behaviors in response to laboratory triggers|Intensity of urges to perform compulsive behaviors in response to laboratory triggers|Number of habitual responses made following cue devaluation|Goal-directed cognition|Yale-Brown Obsessive Compulsive Scale (Y-BOCS)|Mood and Anxiety Symptoms Questionnaire|Obsessive Compulsive Inventory-Revised (OCI-R),University of Pittsburgh,All,18 Years to 55 Years   (Adult),Not Applicable,70,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",R21MH112770,15-Sep-17,Jan-20,Mar-20,29-Aug-17,null,4-Feb-19,"Western Psychiatric Institute and Clinic, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT03265015
NCT03265600,Integrating Mindfulness Into the Patient-Centered Medical Home (Phase 2),MINDFUL-PC-2,"Active, not recruiting",No Results Available,Depression|Anxiety|Stress Related Disorder|Adjustment Disorders,Behavioral: Mindfulness Training for Primary Care|Behavioral: 60-minute Introduction to Mindfulness,Action Plan Initiation Survey (APIS-5)|Change in Perceived Stress Scale|Change in Patient Reported Outcomes Measurement Information System - Anxiety Short Form (PROMIS-ASF)|Change in Patient Reported Outcomes Measurement Information System - Depression Short Form (PROMIS-DSF)|Five Facet Mindfulness Questionnaire (FFMQ)|Self-Compassion Scale-Short Form (SCS-SF)|Change in Self-Efficacy for Managing Chronic Disease (SECD-6)|Perceived Control Questionnaire (PCQ)|Patient Activation Measure (PAM)|Difficulty in Emotion Regulation Scale (DERS)|Multidimensional Assessment of Interoceptive Awareness (MAIA),Cambridge Health Alliance|The Arthur Vining Davis Foundations|The Arnold P. Gold Foundation|National Institutes of Health (NIH)|Brown University|National Center for Complementary and Integrative Health (NCCIH),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,136,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CHA-IRB-1002/08/14_2|UH2AT009145,1-Feb-17,15-Sep-18,30-Jul-20,29-Aug-17,null,4-Feb-19,"Cambridge Health Alliance, Somerville, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT03265600
NCT03266120,Health Benefits of Gardening,,Completed,No Results Available,Anxiety|Depression|Healthy|Mood Disturbance|Stress|Quality of Life|Physical Activity|Social Interaction,Other: Art|Other: Gardening,Biometric Changes in Heart Rate|Biometric Changes in Blood Pressure|Biometric Changes in Overall Health Status|Biometric Changes in Depressive Symptomatology|Biometric Changes in State Anxiety|Biometric Changes in Mood States|Biometric Changes in Perceived Stress|Biometric Changes in Satisfaction in Social Activities,University of Florida,Female,26 Years to 49 Years   (Adult),Not Applicable,36,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,IRB201701647,3-Aug-17,9-Nov-17,15-Jan-18,29-Aug-17,null,5-Jun-18,"Fifield and Merhof Halls, Gainesville, Florida, United States|Wilmot Gardens Conference Center and Greenhouse, Gainesville, Florida, United States",,https://ClinicalTrials.gov/show/NCT03266120
NCT03263546,Internet-delivered CBT for Paediatric OCD,,Recruiting,No Results Available,Obsessive-Compulsive Disorder,Behavioral: Internet-delivered cognitive behavioral therapy (ICBT)|Behavioral: Cognitive behavioral therapy (CBT),"Children's Yale Brown Obsessive-Compulsive Scale (CY-BOCS)|Clinical global impression severity (CGI-S)|Clinical global impression improvement (CGI-I)|Children's global assessment scale (C-GAS)|Obsessive-compulsive inventory - child version (OCI-CV)|The Child Health Utility 9D (CHU9D)|Insomnia Severity Index (ISI)|Children's Obsessional Compulsive Inventory Revised - parent version (ChOCI-R)|Family accommodation scale for obsessive-compulsive disorder - self-rated version (FAS-SR)|Trimbos/iMTA questionnaire for Costs associated with Psychiatric Illness (TiC-P)|Mood and Feeling Questionnaire (MFQ)|Education, work and social adjustment scale (EWSAS)","Karolinska Institutet|Stockholm County Council, Sweden|Vastra Gotaland Region",All,7 Years to 17 Years   (Child),Not Applicable,152,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,REPN 2017/1070-31/1,6-Oct-17,30-Jun-20,31-Dec-25,28-Aug-17,null,6-May-19,"BUP Specialmottagning, Göteborg, Sweden|Child and Adolescent Psychiatry (CAP) research center, Stockholm, Sweden",,https://ClinicalTrials.gov/show/NCT03263546
NCT03262376,Minerals and Botanicals for Acute Stress,,Completed,No Results Available,Stress|Anxiety,Dietary Supplement: Minerals + Vitamins|Dietary Supplement: Botanical A|Dietary Supplement: Botanical B|Other: Placebo,"Oscillatory brain activity during the rested state and attentional processing (EEG; Biosemi Active2, 64-channel, DC amplifier, 24-bit resolution system)|Subjective stress (Stress & Arousal Checklist; Mackay et al., 1978)|Subjective mood (Profile of Mood States [MCNair et al., 1971] & Bond Visual analogue scales, 1974)|Subjective anxiety (Spielberger State Trait Anxiety Inventory, 1983)|Cognitive performance (Digit attention switching & threat vs neutral dot probe task)|Blood pressure|Heart rate|Salivary cortisol|Event related potentials (EEG; Biosemi Active2, 64-channel, DC amplifier, 24-bit resolution system)",University of Leeds,All,18 Years to 50 Years   (Adult),Not Applicable,100,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",IIT15073,4-Dec-17,12-Dec-18,12-Dec-18,25-Aug-17,null,7-Jan-19,"Human Appetite Research Unit, University of Leeds, Leeds, West Yorkshire, United Kingdom",,https://ClinicalTrials.gov/show/NCT03262376
NCT03260335,A Biofeedback Intervention for the Prevention of Challenging Behaviour,,Withdrawn,No Results Available,Acquired Brain Injury,Behavioral: Anxiety management strategy,Number of incidents of challenging behaviour|Implementation of anxiety management strategy,University of Glasgow|Brain Injury Rehabilitation Trust,All,"16 Years and older   (Child, Adult, Older Adult)",Not Applicable,0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,17/SS/0119,Nov-17,Jun-18,Jun-18,24-Aug-17,null,29-Mar-18,,,https://ClinicalTrials.gov/show/NCT03260335
NCT03260985,Precision Psychiatry Continuity Clinic Project,PPC,Enrolling by invitation,No Results Available,Depressive Disorders|Depressive Symptoms|Anxiety Disorders and Symptoms|Psychological Distress|Mood Disorders,Other: Feedback Report,"Patient Health Questionnaire (PHQ-9)|Generalized Anxiety Disorder Questionnaire (GAD-7)|Sheehan Disability Scale (SDS) of Social/Occupational Functioning|Frequency, Intensity, and Burden of Side Effects Ratings (FIBSER)",Stanford University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,75,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,41868,25-Jul-17,Dec-19,Dec-19,24-Aug-17,null,20-Mar-19,"Stanford Center for Cognitive and Neurobiological Imaging (CNI), Stanford, California, United States",,https://ClinicalTrials.gov/show/NCT03260985
NCT03255122,Technology and Early Anxiety Treatment,,Recruiting,No Results Available,Anxiety Disorders,Behavioral: I-CALM|Behavioral: Delayed I-CALM,Clinical Global Impressions Scales - Severity and Improvement (CGI-S/I)|Children's Global Assessment Scale|Child Anxiety Impact Scale|Family Burden Assessment Scale|Family Accommodation Checklist and Interference Scale|Family Accommodation Scale- Anxiety|Working Alliance Inventory|Client Satisfaction Questionnaire|Child Behavior Checklist|Anxiety Disorders Interview Schedule for Children (ADIS-C/P)|Spence Children's Anxiety Scale,Florida International University|Andrew Kukes Foundation for Social Anxiety,All,3 Years to 8 Years   (Child),Not Applicable,40,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,IRB-16-0182,3-Nov-16,7-May-19,1-Aug-19,21-Aug-17,null,29-Aug-18,"Florida International University, Miami, Florida, United States",,https://ClinicalTrials.gov/show/NCT03255122
NCT03251235,Neural Effects of Cognitive-behaviour Therapy in Panic Disorder,,Completed,No Results Available,Panic Disorder,Behavioral: Cognitive Behaviour Therapy,Emotional processing|Clinical symptom severity - Global anxiety and depression (self-report)|Clinical symptom severity - Fear of physical sensations (self-report)|Clinical symptom severity - Agoraphobic fear (self-report)|Clinical symptom severity - Clinical severity and improvement (clinician-report),University of Oxford,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,28,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Basic Science,09/H0604/55,1-Jan-11,4-Sep-13,1-Feb-16,16-Aug-17,null,16-Aug-17,,,https://ClinicalTrials.gov/show/NCT03251235
NCT03249116,Assessing Mechanisms of Anxiety Reduction in Animal-assisted Interventions,,Recruiting,No Results Available,Social Anxiety Disorder|Social Anxiety|Social Anxiety Disorder of Childhood,Other: animal-assisted intervention|Other: active control,Self-reported affective experience|Autonomic physiological reactivity|Cognitive performance - number of errors|Cognitive performance - lowest number reached,Tufts University,All,13 Years to 17 Years   (Child),Not Applicable,75,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,1R03HD091892-01,1-Oct-17,Oct-19,30-Oct-19,15-Aug-17,null,22-Nov-18,"Cummings School of Veterinary Medicine at Tufts University, North Grafton, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT03249116
NCT03250026,Cooperation for Primary Care Patients on Sick Leave for CMD: Care Manager and Workplace Intervention - CO-WORK-CARE,CO-WORK-CARE,Recruiting,No Results Available,Depressive Disorder|Anxiety Disorders,Behavioral: Workplace convergence dialogue|Behavioral: Care Manager,Net and gross sick-leave days|Depressive symptoms|Anxiety symptoms|Quality of life|Work ability|Exhaustion,Göteborg University|Vastra Gotaland Region,All,"18 Years to 67 Years   (Adult, Older Adult)",Not Applicable,300,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,459-17,5-Dec-17,30-Jun-21,30-Jun-21,15-Aug-17,null,29-Apr-19,"Department of Primary Health Care, Sahlgrenska Academy, Göteborg, Region Västra Götaland, Sweden",,https://ClinicalTrials.gov/show/NCT03250026
NCT03247959,Effectiveness of Active and Passive Distraction Techniques on Reducing Fear and Anxiety and Improving Oral Health Knowledge of Children Undergoing Extraction in the Dental Operatory- A Randomized Controlled Trial,,Recruiting,No Results Available,Fear Anxiety,Behavioral: Video game distraction and video distraction,Reduction in fear during the treatment|Reduction in anxiety during the treatment|Improvement in Oral health knowledge,Indira Gandhi Institute of Dental Science,All,6 Years to 12 Years   (Child),Not Applicable,114,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,IGIDSIRB2016NDP27PGSKPPD,3-Apr-17,Dec-17,Jul-18,14-Aug-17,null,14-Aug-17,"Swarna, Puducherry, Pondicherry, India",,https://ClinicalTrials.gov/show/NCT03247959
NCT03247075,Internet-delivered CBT vs Internet-delivered Support and Counseling for Youth With Social Anxiety Disorder - An RCT,SOFT RCT,"Active, not recruiting",No Results Available,Social Anxiety Disorder,Behavioral: Cognitive Behavior Therapy|Behavioral: Support and Counseling,"Clinician Severity Rating (CSR)|Anxiety Disorder Interview Schedule for DSM-IV, child and parent versions (ADIS C/P) - Social anxiety disorder|Anxiety Disorder Interview Schedule for DSM-IV, child and parent versions (ADIS C/P) - Comorbid disorders|Clinical Global Impression - Improvement (CGI-I)|Children's Global Assessment Scale (CGAS)|Liebowitz social anxiety scale for children and adolescents (LSAS-CA) - Child version|Liebowitz social anxiety scale for children and adolescents (LSAS-CA) - Parent version|Revised Children´s Anxiety and Depression Scale - (RCADS) - Parent version|Revised Children´s Anxiety and Depression Scale - (RCADS) Depression sub scale - Child version|Anticipatory social behaviors scale (ASBQ)|Post-event processing questionnaire revised (PEPQ-R)|Focus of attention questionnaire (FAQ)|The Subtle Avoidance Frequency Examination (SAFE)|The Child Health Utility 9D (CHU 9D) - Child version|Client Satisfaction Questionnaire (CSQ-) - Child version|Client Satisfaction Questionnaire (CSQ-) - Parent version|Treatment credibility and expectancy - Child version|Treatment credibility and expectancy - Parent version|Education, Work and Social Adjustment Scale (EWSAS) - Parent version|Hospital Anxiety and Depression Scale (HADS)|Alcohol Disorder Identification Test (AUDIT)|Drug Use Disorders Identification Test (DUDIT)|Family Accommodation Scale-Anxiety (FASA)|Trimbos/iMTA questionnaire for Costs associated with Psychiatric Illness (TiC-P) - Child version|The Negative Effects Questionnaire (NEQ)|Internet intervention Patient Adherence Scale (iiPAS)|School absenteeism",Karolinska Institutet,All,10 Years to 17 Years   (Child),Not Applicable,103,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,DNR 2017/1027-31/2,19-Sep-17,30-Apr-19,30-Sep-19,11-Aug-17,null,20-Feb-19,"BUP KFE, Stockholm, Stockholms County, Sweden",,https://ClinicalTrials.gov/show/NCT03247075
NCT03247270,Physical Fitness and Brain - Interventional Study,PHYSBI,Recruiting,No Results Available,Anxiety Disorders,Behavioral: Intervention I|Behavioral: Intervention II,Anxiety symptom burden|Cognitive ability|Sick leave|Biomarkers in serum,Göteborg University,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,192,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",Dnr300-16,21-Aug-17,15-Dec-20,15-Jun-21,11-Aug-17,null,19-Feb-19,"Department of Public Health and Community Medicine, Gothenburg, Sweden",,https://ClinicalTrials.gov/show/NCT03247270
NCT03241277,Nonsurgical Periodontal Treatment in Patients With Social Phobia,NSPTSP,Not yet recruiting,No Results Available,Social Phobia|Periodontal Diseases,Procedure: Non surgical periodontal treatment,Probing depth|Clinical attachment level,University of Sao Paulo General Hospital|Fundação de Amparo à Pesquisa do Estado de São Paulo,All,"35 Years to 65 Years   (Adult, Older Adult)",Not Applicable,45,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,33267314.9.0000.0068|821.780,5-Oct-17,5-May-19,5-Oct-19,7-Aug-17,null,7-Aug-17,"Department and Institute of Psychiatry - FMUSP, São Paulo, Sao Paulo, Brazil",,https://ClinicalTrials.gov/show/NCT03241277
NCT03239743,Effects of Virtual Reality on Pre-Operative Anxiety and Induction of Anesthesia in Children and Adolescents,,Recruiting,No Results Available,Tonsillectomy,Device: Virtual Reality|Drug: Midazolam,Pre-Operative Anxiety measured by mYPAS anxiety scores|Induction Compliance of Anesthesia measured by the induction compliance checklist|Post-Operative Emergence Delirium measured by the PAED scale|Post-Operative Pain|Post-Operative Opioid Use,Valley Anesthesiology Consultants|KindVR|Phoenix Children's Hospital,All,5 Years to 11 Years   (Child),Not Applicable,80,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,17-025,20-Jul-17,May-19,May-19,4-Aug-17,null,19-Oct-18,"Phoenix Children's Hospital, Phoenix, Arizona, United States",,https://ClinicalTrials.gov/show/NCT03239743
NCT03240003,A Novel Computer-Based Therapy for Social Anxiety,,Recruiting,No Results Available,Social Anxiety Disorder,Behavioral: GC-MRT|Behavioral: modified GC-MRT|Behavioral: Non-GC-MRT,Liebowitz Social Anxiety Scale|Social Phobia Inventory (SPIN)|Quality of Life Enjoyment & Satisfaction Questionnaire|Revised Social Anhedonia Scale|Snaith Hamilton Pleasure Scale|Hamilton Rating Scale for Depression - 17 item version|Clinical Global Impression-Change Scale,New York State Psychiatric Institute,All,18 Years to 60 Years   (Adult),Not Applicable,60,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",7527 (SAD),25-Aug-17,1-Aug-20,1-Aug-20,4-Aug-17,null,10-Sep-18,"New York State Psychiatric Institute, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT03240003
NCT03238872,Trial of Prompt Mental Health Care,,"Active, not recruiting",No Results Available,Anxiety|Mild to Moderate Depression,Behavioral: Cognitive Behavioural Therapy|Other: Treatment as usual,"Recovery rate|Changes in mean levels of depression and anxiety|Recovery rate / Changes in mean levels of depression and anxiety at 12-month follow-up|Recovery rate / Changes in mean levels of depression and anxiety at 24-month and 36-month follow-up, experimental group only.|Work participation|Functional status|Health-related quality of life|Mental Well-being",Norwegian Institute of Public Health|The Research Council of Norway|University of Bergen|Göteborg University|Sussex Partnership NHS Foundation Trust,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,774,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,260659,9-Nov-15,1-Mar-18,30-Sep-20,3-Aug-17,null,4-Apr-18,"Rask Psykisk Helsehjelp Kristiansand, Kristiansand, Norway|Rask Psykisk Helsehjelp Sandnes, Sandnes, Norway",,https://ClinicalTrials.gov/show/NCT03238872
NCT03238976,Nature Sounds as a Pain and Anxiety Reducing Strategy in Patients Undergoing Breast Core Biopsy,,Recruiting,No Results Available,Breast Cancer,Other: Nature sounds,Measure of psychologic stress of patients and staff|Measure of physiologic stress of patients and staff,University of Chicago,Female,"21 Years and older   (Adult, Older Adult)",Not Applicable,200,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,IRB17-0355,11-Sep-17,Dec-20,Dec-20,3-Aug-17,null,17-Apr-18,"University of Chicago, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT03238976
NCT03239210,Effects of Ondansetron in Obsessive-compulsive and Tic Disorders,,Recruiting,No Results Available,Obsessive-Compulsive Disorder|Tic Disorders|Tourette Syndrome,Drug: Ondansetron|Drug: Placebo,Change in Sensory phenomena severity from baseline to 4 weeks|Percent BOLD signal change|Patient-Related Inventory of Side effects,New York University School of Medicine|National Institutes of Health (NIH),All,18 Years to 60 Years   (Adult),Phase 4,60,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",17-01608,16-Jun-17,Apr-20,Apr-20,3-Aug-17,null,1-Aug-18,"New York University School of Medicine, New York, New York, United States|The Nathan S. Kline Institute for Psychiatric Research, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT03239210
NCT03234439,Digital Tools for Coping With Chronic Pain,,Completed,No Results Available,Chronic Pain|Depression|Anxiety|Opioid Use,Behavioral: myStrength,Change in baseline thoughts and feelings about chronic pain as measured by Global Pain Scale at 6 months|Change in baseline PHQ9 at 6 months|Change in baseline Current Opioid Misuse Measure at 6 months|Change in baseline confidence to live with chronic pain as measured by Pain Self-Efficacy Scale at 6 months|Change in baseline and GAD7 at 6 months,"MyStrength, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Not Applicable,144,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Supportive Care,6/13/2017,8-Dec-17,30-Sep-18,31-Dec-18,31-Jul-17,null,4-Jan-19,"Craigslist, Los Angeles, California, United States|Craigslist, San Francisco, California, United States|Craigslist, Denver, Colorado, United States|Craigslist, Washington, District of Columbia, United States|Craigslist, Miami, Florida, United States|Craigslist, Atlanta, Georgia, United States|Craigslist, Boston, Massachusetts, United States|Craigslist, Minneapolis, Minnesota, United States|Craigslist, New York, New York, United States|Craigslist, Philadelphia, Pennsylvania, United States|Craigslist, Houston, Texas, United States|Craigslist, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT03234439
NCT03232502,Pharmacogenetics in Primary Care Psychotropics,,Not yet recruiting,No Results Available,Depression|Obsessive-Compulsive Disorder|Generalized Anxiety Disorder,Diagnostic Test: Pharmacogenetic testing,Patient oriented outcome1- Clinical Improvement|Patient oriented outcome2- Adverse effects|Patient oriented outcome3- Time to Improvement|Patient oriented outcome5- Visits,University of Arizona,All,"18 Years and older   (Adult, Older Adult)",Phase 3,130,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Pending1,15-Aug-17,15-Jan-18,31-Dec-18,28-Jul-17,null,28-Jul-17,,,https://ClinicalTrials.gov/show/NCT03232502
NCT03233100,FMT Treating Constipation Patients With Depression and/or Anxiety Symptoms - Clinical Efficacy and Potential Mechanisms,,Recruiting,No Results Available,Constipation - Functional|Depressive Symptoms|Anxiety Symptoms|Gut-Brain Disorders,Other: FMT,CSBMs per week|HAMA|HAMD|Wexner|PAC-SYM|Bristol Bristol PAC-SYM|PAC-QOL,"Jianfeng Gong|Jinling Hospital, China",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,40,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,STC-D-A-2017-FMT,30-Jul-17,31-Dec-18,31-Dec-18,28-Jul-17,null,28-Jul-17,"Department of Generay Surgery, Jinling hosptal, Medical School of Nanjing University, Nanjing, Jiangsu, China",,https://ClinicalTrials.gov/show/NCT03233100
NCT03233113,The Effects of Safety Seeking Behaviors During Exposure Therapy for Adults With Spider Phobia,,Completed,No Results Available,Specific Phobia,Behavioral: Exposure therapy,Change from baseline Fear of Spiders Questionnaire Score at 1-month follow-up|Change from baseline Spider Behavioral Approach Task Score at 1-month follow-up|Change from baseline FSQ Score at 0-48 hours post-treatment|Change from baseline Spider BAT Score at 0-48 hours post-treatment|Treatment Acceptability and Adherence Scale Score at Baseline|TAAS Score at 0-48 hours post-treatment|TAAS Score at 1-month follow-up|Change from baseline BAT Peak Distress Score at 0-48 hours post-treatment|Change from baseline BAT Peak Distress Score at 1-month follow-up|Change from baseline In-Vivo Distress Tolerance Score at 0-48 hours post-treatment|Change from baseline In-Vivo Distress Tolerance Score at 1-month follow-up,"University of North Carolina, Chapel Hill|Society for a Science of Clinical Psychology|Association for Behavioral and Cognitive Therapies",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,16-0700,20-Sep-16,13-Sep-17,13-Sep-17,28-Jul-17,null,16-Jan-18,"University of North Carolina, Chapel Hill, Chapel Hill, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT03233113
NCT03233542,The Association Between Physical Sensations and Thinking Styles,,Recruiting,No Results Available,Panic Disorder,Behavioral: Cognitive Behaviour Therapy,Priming Task|Single Target Association Test|Scrambled Sentences Test|Interpretation Bias Questionnaire|Anxiety Sensitivity Index (ASI)|Depression Anxiety Stress Scale (DASS)|Agoraphobic Cognitions Questionnaire (ACQ)|Body Sensations Questionnaire (BSQ)|Panic Disorder Severity Scale (PDSS)|Mobility Inventory (MI)|Subjective ratings DSM panic symptoms|Responses Hyperventilation Task|Heart rate variability|Muscle activity|Respiration|Galvanic skin response|Cortisol|Alpha amylase,Ruhr University of Bochum|German Research Foundation|University of Oxford|University of Salzburg,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,114,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,145|WO2018/2-1|MA1116/13-1,18-Sep-17,Dec-19,Dec-19,28-Jul-17,null,29-Jan-19,"Psychotherapy Centre, Department of Clinical Psychology and Psychotherapy, Ruhr-Universität Bochum, Bochum, North Rhine Westphalia, Germany",,https://ClinicalTrials.gov/show/NCT03233542
NCT03228628,Nitrous Oxide for Lumbar Puncture,NO for LP,Not yet recruiting,No Results Available,Pain|Anxiety,Drug: Fixed 50:50 mixture of nitrous oxide and oxygen|Other: Placebo,Proportion of patients with significant pain|Proportion of patients with significant anxiety|Analgesic efficacy measured with pain as a continuous variable|Anxiolytic efficacy measured with anxiety as a continuous variable|Pain during the procedure evaluated one hour after the end of the lumbar puncture|Anxiety during the procedure evaluated one hour after the end of the lumbar puncture|Side effects|Impact of age on side effects|Induced cost,"University Hospital, Clermont-Ferrand|University Hospital, Bordeaux|Hospices Civils de Lyon|Inserm U1107, NeuroDol|Université d'Auvergne",All,"18 Years and older   (Adult, Older Adult)",Phase 4,162,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",CHU-342|2017-002750-37,1-Oct-17,6-Jun-18,1-Sep-19,25-Jul-17,null,25-Jul-17,"CHU de Clermont-Ferrand, Clermont-Ferrand, Auvergne, France",,https://ClinicalTrials.gov/show/NCT03228628
NCT03229720,Evaluation of Audio-Visual Distraction Technique on Child's Anxiety,,Not yet recruiting,No Results Available,"Anxiety, Dental|Fear, Dental",Device: Nibiru 3D Virtual Reality Headset,Facial Image Scale|Oxygen Saturation (using Pulse oximetry),Cairo University,All,5 Years to 8 Years   (Child),Not Applicable,42,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care,Protocol CairoU,1-Sep-17,1-Jul-18,1-Sep-18,25-Jul-17,null,25-Jul-17,,,https://ClinicalTrials.gov/show/NCT03229720
NCT03226834,Efficiency of Favourite Versus Predetermined Musical Sequence on Gynecology Pre-operative Anxiety,MUANX,Recruiting,No Results Available,Surgery|Anxiety State,Device: MUSIC CARE|Other: PERSONAL PLAY-LIST,Situation anxiety measurement|Blood pressure|Post-operative pain|Care stay duration|Post-operative complications|Heart rate,Centre Hospitalier Universitaire de la Réunion,Female,18 Years to 55 Years   (Adult),Not Applicable,170,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Investigator)|Primary Purpose: Prevention",2016/CHU/04,31-Jul-17,Aug-18,Dec-18,24-Jul-17,null,19-Dec-17,"Chu Reunion Island, Saint-Pierre, Reunion Island, Réunion",,https://ClinicalTrials.gov/show/NCT03226834
NCT03227562,Is Initial Response to Low Dose Risperidone Predictive for Outcome in Anxiety?,,Recruiting,No Results Available,Anxiety State,Drug: RisperiDONE 0.5 MG,Anxiety|Type of anxiety,Marion Trousselard|Institut de Recherche Biomedicale des Armees,All,18 Years to 50 Years   (Adult),Phase 3,120,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2016-000341-31,1-Sep-17,1-Dec-17,1-Jan-20,24-Jul-17,null,27-Feb-19,"Marion Trousselard, Brétigny-sur-Orge, Not In US/Canada, France",,https://ClinicalTrials.gov/show/NCT03227562
NCT03227614,Friends/Family in the Abortion Procedure Room (FAIR),FAIR,Enrolling by invitation,No Results Available,Anxiety|Pain|Abortion,Behavioral: Support Person Intervention,Anxiety|Perceived Pain,Planned Parenthood of Southwest and Central Florida,All,"Child, Adult, Older Adult",Not Applicable,410,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,Pro00019968,18-Jul-17,30-Dec-17,30-Dec-17,24-Jul-17,null,24-Jul-17,"Planned Parentehood of Southwest and Central Florida (PPSWCF), Tampa, Florida, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/14/NCT03227614/Prot_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/14/NCT03227614/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT03227614
NCT03227744,A Pilot Study of Prostate Cancer-specific Anxiety in Active Surveillance,,Terminated,No Results Available,Prostate Cancer,Behavioral: Group therapy|Other: Surveys,Assessment of MAX-PC Scores|Assessment of FACT-P Scores|Assessment of anxiety scores as a function of time,New York University School of Medicine,Male,"40 Years and older   (Adult, Older Adult)",Not Applicable,26,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,17314,19-Apr-17,28-Dec-18,28-Dec-18,24-Jul-17,null,6-Feb-19,"NYU Winthrop Hospital, Mineola, New York, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/44/NCT03227744/Prot_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/44/NCT03227744/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT03227744
NCT03224468,Effect of Medical Marijuana on Neurocognition and Escalation of Use,MMNE,Recruiting,No Results Available,Pain|Insomnia|Depression|Anxiety,Drug: Medical Marijuana,Cannabis Use Disorders|Changes in Symptoms of Depression and Anxiety|Changes in Pain|Changes in Sleep|General Medical/Psychiatric Health|Cognitive Testing|Brain-based Measures,Massachusetts General Hospital,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,200,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2015P001600,1-Jul-17,31-Mar-22,31-Mar-22,21-Jul-17,null,13-Mar-19,"Massachusetts General Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT03224468
NCT03224845,"Courageous Parents, Courageous Children",COACH,Not yet recruiting,No Results Available,Anxiety Disorder,Behavioral: Cognitive behavioural skills training,Kiddie Schedule for Affective Disorders and Schizophrenia (K-SADS)|Teaching Task Battery|Structured Clinical Interview for DSM-5 diagnoses (SCID-5)|Laboratory Temperament Assessment Battery|Global Assessment of Functioning|Screen for Child Anxiety Related Disorders|Spence Children's Anxiety Scale,Barbara Pavlova|Nova Scotia Health Authority,All,"Child, Adult, Older Adult",Not Applicable,88,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,1022588,Sep-17,Sep-20,Sep-20,21-Jul-17,null,25-Jul-17,,,https://ClinicalTrials.gov/show/NCT03224845
NCT03225885,Counseling for Prematurity Using a Multimedia Education Tool,,Completed,No Results Available,"Premature Birth|Counseling|Decision Making|Prenatal Care|Infant, Premature|Resuscitation",Other: Multimedia Information|Other: Printed Handout,Overall knowledge of prematurity|Gestational age sub-group knowledge scores|Sub-domain knowledge scores|Anxiety,"Medical College of Wisconsin|Marquette University|Children's Research Institute|AMAG Pharmaceuticals, Inc.",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,76,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,PRO00028712,1-Dec-17,25-Jan-19,25-Jan-19,21-Jul-17,null,27-Feb-19,"Froedtert Hospital, Milwaukee, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT03225885
NCT03226028,"Perioperative Music Listening on Anxiety, Analgesia Use and Patient Satisfaction",,"Active, not recruiting",No Results Available,Music|Pain|Anxiety|Patient Satisfaction|Analgesia,Procedure: Music listening,Change in Pain score|Change in Analgesia usage|Change in Patient's satisfaction with the use of music listening|Change in Hospital Anxiety and Depression Scale (HADS) score|Change in EQ-5D-3L score,KK Women's and Children's Hospital,Female,"21 Years to 70 Years   (Adult, Older Adult)",Not Applicable,100,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MT2017,4-May-17,31-Aug-20,31-Dec-20,21-Jul-17,null,15-Feb-19,"KK Women's and Children's Hospital, Singapore, Singapore",,https://ClinicalTrials.gov/show/NCT03226028
NCT03222063,Effectiveness of Play Interventions on Anxiety Among Hospitalized Children,,Completed,No Results Available,Anxiety,Other: Play interventions,Structured anxiety rating scale,Maharishi Markendeswar University,All,6 Years to 12 Years   (Child),Not Applicable,60,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,785,Nov-16,Jan-17,Jun-17,19-Jul-17,null,19-Jul-17,,,https://ClinicalTrials.gov/show/NCT03222063
NCT03220061,Effectiveness of Music Therapy on Blood Pressure and Anxiety Among Patients Undergoing Haemodialysis,,Completed,No Results Available,Kidney Diseases,Behavioral: music therapy,beck anxiety inventory,Maharishi Markendeswar University,Female,"17 Years to 75 Years   (Child, Adult, Older Adult)",Not Applicable,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,200197,12-Dec-16,12-Dec-16,12-Dec-16,18-Jul-17,null,18-Jul-17,"Maharishi Markandeshwar University, Ambala, Haryana, India",,https://ClinicalTrials.gov/show/NCT03220061
NCT03217682,Impact of Massage Therapy and Music Therapy on the Quality of Life of Hospice Patients,,Recruiting,No Results Available,Pain|Anxiety|Depression|Quality of Life,Other: Music Therapy|Other: Massage Therapy,Change in Edmonton Symptom Assessment System - Revised|Change in Edmonton Symptom Assessment System - Revised (Other symptoms)|Change in Linear Analogue Self Assessment (LASA)|Change in Patient Health Questionnaire for Depression and Anxiety (PHQ-4)|Change in Pearlin role overload measure (ROM),Mayo Clinic,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,120,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,17-002950,4-Dec-17,Dec-19,Dec-19,14-Jul-17,null,15-Jan-19,"Mayo Clinic, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT03217682
NCT03218462,Effect of Sensory Adapted Dental Environment on Dental Anxiety of Children With Intellectual and Developmental Disabilities,,Completed,No Results Available,Developmental Disability|Intellectual Disability|Dental Anxiety,Behavioral: Sensory Adapted Dental Environment (SADE),Behavior during initial dental exam|Behavior during recall exam|Physiologic outcomes (oxygen saturation) during initial exam|Physiologic outcomes (oxygen saturation) during recall exam|Physiologic outcomes (hearts rate) during initial exam|Patient cooperation during initial exam|Patient cooperation during recall exam,Virginia Commonwealth University,All,"6 Years to 21 Years   (Child, Adult)",Not Applicable,22,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,HM20009272,10-Jul-17,30-Mar-18,30-Mar-18,14-Jul-17,null,18-Apr-18,"Virginia Commonwealth University, Richmond, Virginia, United States",,https://ClinicalTrials.gov/show/NCT03218462
NCT03216382,The Impact of the Attention Training Technique on Attention Control and High Worry,,Recruiting,No Results Available,Excessive Worry,Behavioral: Attention Training Technique|Behavioral: Control Condition,Breathing focus task|Daily Worry Questions|Penn State Worry Questionnaire-Past Week|Self-Attention Rating Scale|Attention Network Task (ANT)|Metacognition Questionnaire 30 (MCQ-30) Cognitive Self Consciousness subscale|Metacognitions Questionnaire 30 (MCQ-30) Negative beliefs about the uncontrollability of thoughts and danger subscale|Attention Control Scale|Dot Probe|Southampton Mindfulness Questionnaire,"Ryerson University|Ministry of Research, Innovation and Science, Ontario",All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,80,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,2017-186,15-Aug-17,May-19,May-19,13-Jul-17,null,11-Apr-18,"Ryerson University, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT03216382
NCT03216655,Individual vs Cohort Long Distance Advising for Mental Care for Congenital Cataract Guardians,,Recruiting,No Results Available,Cataract,Other: phone call|Other: wechat group,similar effect|efficient effect|invalid effect,Sun Yat-sen University,All,"Child, Adult, Older Adult",Not Applicable,80,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Health Services Research",CCPMOH2017-China-1,1-Apr-17,Jul-17,Jul-17,13-Jul-17,null,13-Jul-17,"Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, Guangdong, China",,https://ClinicalTrials.gov/show/NCT03216655
NCT03217123,"Deep-brain Stimulation in Obsessive-compulsive Disorder: Randomized, Double-blinded Clinical Trial",10/131,Completed,No Results Available,Obsessive-Compulsive Disorder,Device: Deep Brain stimulation,Yale-Brown Obsessive-Compulsive Scale|Emotion,"Hospital San Carlos, Madrid",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,7,Other,Interventional,"Intervention Model: Sequential Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",10/131,1-Jan-11,31-Dec-14,30-Jun-15,13-Jul-17,null,18-Jul-17,,,https://ClinicalTrials.gov/show/NCT03217123
NCT03212703,Mindfulness for Parents of OCD-affected Children,MBST,Recruiting,No Results Available,Obsessive-Compulsive Disorder,Behavioral: Mindfulness-Based Skills Training (MBST)|Other: Waitlist control (WLC),Change in parental stress levels compared to waiting list control (WLC).|Change in ability to tolerate OCD-related distress compared to waiting list control (WLC).|Change in ability to resist family accommodation of the child's OCD symptoms compared to waiting list control (WLC).|Change in family functioning compared to the waiting list control (WLC).|Change in OCD severity compared to waiting list control (WLC).|Change in OCD-associated coercive and disruptive symptoms compared to waiting list control (WLC).,University of British Columbia|Michael Smith Foundation for Health Research,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,45,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,H14-02099,Jul-15,Sep-19,Oct-19,11-Jul-17,null,11-Oct-18,"BC Children's Hospital Research Institute, Vancouver, British Columbia, Canada",,https://ClinicalTrials.gov/show/NCT03212703
NCT03213782,Effect of Nature Based Sounds' Intervention on Agitation and Anxiety of Patients Admitted in Intensive Care Units.,,Completed,No Results Available,"Agitated; State, Acute Reaction to Stress|Anxiety",Other: Nature based sounds,Agitation assessed with the Agitation Behavior Assessment Scale,Maharishi Markendeswar University,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,200014,1-Aug-15,7-Jan-17,7-Jan-17,11-Jul-17,null,11-Jul-17,,,https://ClinicalTrials.gov/show/NCT03213782
NCT03211221,rTMS Over the Supplementary Motor Area for Treatment-resistant Obsessive-compulsive Disorder.,rTMSOCD,Recruiting,No Results Available,Obsessive-Compulsive Disorder,Device: rTMS (repetitive transcranial magnetic stimulation),rTMS effects on OC symptoms,CNS Onlus|University of Florence,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,30,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Pallanti,1-Mar-17,1-Mar-19,1-Dec-19,7-Jul-17,null,7-Jul-17,"Stefano Pallanti, Florence, I, Italy",,https://ClinicalTrials.gov/show/NCT03211221
NCT03208816,Community-Led Action Research in Oncology: Improving Symptom Management,CLARO,Completed,No Results Available,Chemotherapy-induced Neutropenia|Chemotherapy-induced Nausea and Vomiting|Anxiety|Depression|Fatigue|Neoplasms,Behavioral: symptom management program for chemotherapy patients,Recruitment feasibility|Intervention feasibility|Fidelity to treatment|Acceptability of intervention|Healthcare utilization,Dartmouth-Hitchcock Medical Center,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,25,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,CPHS30340,24-Jul-17,31-Dec-17,31-Dec-17,6-Jul-17,null,27-Mar-18,"Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|La Liga Contra el Cancer, San Pedro Sula, Honduras",,https://ClinicalTrials.gov/show/NCT03208816
NCT03210155,Efficacy of CES in New Mothers During the Post Partum Period,,Suspended,No Results Available,Anxiety|Depression|Insomnia|Sleep Quality,Device: Alpha-Stim AID CES (Active Comparator)|Device: Alpha-Stim AID CES (Sham Comparator),To measure the effect of CES on anxiety in new mothers during the postpartum period.|To measure the effect of CES on depression in new mothers during the postpartum period.|To measure the effect of CES on sleep quality in new mothers during the postpartum period.|To measure the effect of CES on insomnia in new mothers during the postpartum period.,"Christina Murphey, RN, PhD|Murphey, Christina, RN, PhD",Female,18 Years to 45 Years   (Adult),Not Applicable,50,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",HSRP #36-17,24-Jul-17,31-Dec-19,1-Jan-20,6-Jul-17,null,18-Mar-19,"Primay care; OB-GYN Clinic, Austin, Texas, United States|Primary care; OB-GYN Clinic, Corpus Christi, Texas, United States",,https://ClinicalTrials.gov/show/NCT03210155
NCT03208348,Pilot Study of Virtual Reality for Providing Exposure Therapy to Children,,Completed,No Results Available,Generalized Anxiety Disorder,Other: Pilot Virtual Reality,Qualitative response to the system as assessed by observation while using the system and interview following use.|Anxiety as assessed by the Subjective Units of Distress Scale,Minnesota HealthSolutions|Mayo Clinic,All,7 Years to 12 Years   (Child),Not Applicable,20,Industry|Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,Virtual Reality,1-Sep-17,31-Jan-18,31-Jan-18,5-Jul-17,null,24-Apr-18,"Mayo Clinic, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT03208348
NCT03208400,Virtual Reality Exposure in Spider Phobia,,Recruiting,No Results Available,Specific Phobia|Cognitive-behavioral Therapy|Virtual Reality,Behavioral: virtual reality exposure,Spider Phobia Questionnaire (SPQ)|Behavioral Avoidance Text (BAT)|Clinical Global Impressions (CGI),Julius-Maximilians University|University Hospital Muenster,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,200,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Spider_VR,1-Sep-17,31-Aug-19,28-Feb-20,5-Jul-17,null,8-Aug-18,"Center of Mental Health, Dept. of Psychiatry, Psychosomatics, and Psychiatry, University Hospital of Wuerzburg, Wuerzburg, Bavaria, Germany|Dept. of Psychiatry, University Hospital Münster, Münster, North Rhine-Westphalia, Germany",,https://ClinicalTrials.gov/show/NCT03208400
NCT03205332,Training Mental Habits Study,,Recruiting,No Results Available,Generalized Anxiety|Worry,Behavioral: Concreteness Training,Change in worry as measured by the Penn State Worry Questionnaire - Past Week|Change in depressive symptoms as measured by the Centre for Epidemiological Studies Depression Scale|Change in negative problem orientation as measured by the Negative Problem Orientation Questionnaire|Change in quality of problem-solving as measured by The Means-Ends Problem-Solving task|Change in problem solving style as measured by the Social Problem Solving Inventory Revised|Change in attentional control as measured by the Attentional Control Scale|Change in residual working memory capacity as measured by the Random Interval Generation Task|- Change in interpretation bias as measured by the Ambiguous/ Unambiguous Situations Diary Extended|Change in cognitive avoidance as measured by the Cognitive Avoidance Questionnaire|Change in worry as measured by experience sampling completed during the 7 days between baseline and post test|Change in affect as measured by experience sampling completed during the 7 days between baseline and post test|Change in concreteness as measured by experience sampling completed during the 7 days between baseline and post test.|Change in GAD-Q-IV severity,Ryerson University|Canadian Institutes of Health Research (CIHR),All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,110,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2015-146-1,12-Jun-15,31-Mar-19,31-Mar-19,2-Jul-17,null,28-Aug-18,"Psychology Research and Training Centre, Ryerson University, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT03205332
NCT03205397,Impact of a Child-Parent Preoperative Accompanying Procedure on the Anxiety of Children Aged 5 to 12 With Scheduled Surgery,I-PPOP,Completed,No Results Available,Anxiety,Other: Experimental Group|Other: usual care,Level of anxiety,"University Hospital, Limoges",All,5 Years to 12 Years   (Child),Not Applicable,50,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,I15004,17-Aug-17,30-Sep-18,31-Oct-18,2-Jul-17,null,1-Nov-18,"CHU de Limoges, Limoges, France",,https://ClinicalTrials.gov/show/NCT03205397
NCT03205839,Acceptance-based Self-help for Individuals With Visible Difference and Social Anxiety,,Completed,No Results Available,Visible Difference|Acceptance and Commitment Therapy|ACT|Skin Condition|Hair Condition|Craniofacial|Burns,Behavioral: Acceptance-based self-help intervention,Comprehensive assessment of Acceptance and Commitment Therapy processes|Brief Fear of Negative Evaluation Scale II (BFNE-II)|Work and Social Adjustment Scale (WSAS),University of Sheffield,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,284,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,151066,27-Jul-17,18-Nov-17,1-Jun-18,2-Jul-17,null,19-Jun-18,"University of Sheffield, Sheffield, United Kingdom",,https://ClinicalTrials.gov/show/NCT03205839
NCT03206437,Effect of Mindfulness Meditation on Physiological Response to Unpredictable Stimuli,,"Active, not recruiting",No Results Available,Anxiety Disorders|Generalized Anxiety Disorder|Social Anxiety Disorder|Panic Disorder|Post Traumatic Stress Disorder|Agoraphobia|Simple Phobia,Behavioral: Mindfulness-Based Stress Reduction|Behavioral: Waitlist,"Fear and anxiety potentiated startle|Center for Epidemiologic Studies Depression Scale (CES-D),|The State-Trait Anxiety Inventory (STAI)|Delay Discounting",Georgetown University,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,45,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2017-0698,20-Jun-17,25-Jul-20,25-Jul-21,2-Jul-17,null,21-Aug-18,"Georgetown University Medical Center, Washington, District of Columbia, United States",,https://ClinicalTrials.gov/show/NCT03206437
NCT03203395,Screening for Depression and Anxiety in Patients With Heart Disease,,Enrolling by invitation,No Results Available,Depression|Depressive Symptoms|Depressive Disorder|Anxiety|Anxiety Disorders|Panic Attacks|Heart Diseases|Collaboration,Behavioral: Screening and counselling,"Detection of symptoms of depression, anxiety and/or recent panic attack in heart patients.|Detection of patients with or at risk for depression and/or anxiety disorders.|Implementation of counselling for treatment and prevention of depression and anxiety disorders in heart patients.",Diakonhjemmet Hospital|Extrastiftelsen|LHL – The Norwegian Heart and Lung Patient Organization,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,200,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening,2016/16558 (PVO)|2016/16558,1-Jan-17,1-Oct-17,1-Jan-18,29-Jun-17,null,29-Jun-17,,,https://ClinicalTrials.gov/show/NCT03203395
NCT03201640,VR for Preoperative Anxiety in Children,,Recruiting,No Results Available,Anxiety,Behavioral: slideshow|Behavioral: virtual,Anxiety in children|Change in child anxiety|Induction compliance|Anesthetic requirements|Post-hospitalization negative behaviours,The Hospital for Sick Children,All,"6 Years to 18 Years   (Child, Adult)",Not Applicable,240,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Other,1000056779,18-Sep-17,31-Aug-19,31-Dec-19,28-Jun-17,null,16-Apr-19,"The Hospital for Sick Children, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT03201640
NCT03199625,Different Neural Circuit Mechanisms Between Cognitive Therapy and Behavior Therapy for Patients With Panic Disorder: a Dynamic Research,,Recruiting,No Results Available,Panic Disorder,Behavioral: Cognitive therapy|Behavioral: Behavior therapy|Drug: SSRI antidepressants,Hamilton Anxiety Scale behavior therapy for patients with panic disorder: a dynamic research|Magnetic Resonance Imaging,Nanjing Medical University,All,20 Years to 50 Years   (Adult),Phase 2,96,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",81571344,Jan-16,Dec-18,Dec-19,27-Jun-17,null,27-Jun-17,"Nanjing Brain Hospital, Nanjing, Jiangsu, China",,https://ClinicalTrials.gov/show/NCT03199625
NCT03194191,Pregnancy With Insomnia: a Trial of Acupuncture,GAS,Unknown status,No Results Available,Insomnia,Device: Acupuncture needles,Insomnia severity index (ISI)|Pittsburgh Sleep Quality Index (PSQI)|Hospital Anxiety and Depression Scale (HADS)|Cumulated dose of each psychotropic medicine|Cumulated dose of alcohol|Cumulated dose of tobacco|Cumulated dose of cannabis|Cumulated dose of other recreational substances or medicine|Difference in the frequency of restless leg syndrome|Perinatal outcome - Gestational age at birth|Perinatal outcome - birth weight|Perinatal outcome - birth height|Perinatal outcome - sex|Perinatal outcome - perinatal mortality|Perinatal outcome - five minutes Apgar score|Perinatal outcome - cesarean section rate,Assistance Publique - Hôpitaux de Paris,Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,P150951,Sep-17,Jan-19,May-19,21-Jun-17,null,28-Jun-17,,,https://ClinicalTrials.gov/show/NCT03194191
NCT03190707,A Good Start to Life - an Early Cross-sectorial Intervention,,Enrolling by invitation,No Results Available,Anxiety|Attachment Disorder|Maternal Sensitivity|Depression|Personality Disorders,Behavioral: Intervention,Maternal sensitivity|Prenatal Parental Reflective Functioning Questionnaire|Parental Reflective Functioning Questionnaire|The Parenting Stress Index|Edinburgh Postnatal Depression Scale|Maternal Antenatal Attachment Scale|Warwick Edinburg Mental Well-being Scale|Ages and Stages Questionnaire - Social Emotional|Experiences in Close Relationship - revised version|Family and Social Support Scale|Attitude towards breast-feeding|Breast-feeding status|APGAR-score|Birth weight|Length at birth|Head circumference at birth|Questions regarding the intervention,Intersectoral Research Unit for Health Services|University of Copenhagen,Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,100,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention",CSU-2017-001,16-Jun-17,30-Jun-19,30-Jun-19,19-Jun-17,null,29-Jan-18,"Intersectoral Research Unit for Health Services, Copenhagen, Denmark",,https://ClinicalTrials.gov/show/NCT03190707
NCT03190512,Periodontal Treatment and Psychology,,Completed,No Results Available,Gum Disease,Other: Psychological measurements,Depression level|Body image level|Anxiety level|Self-esteem level|Probing pocket depth|Clinical attachment level|Gingival index|Plaque index|Bleeding on probing,Ozge Gokturk|Tokat Gaziosmanpasa University,All,18 Years to 60 Years   (Adult),Not Applicable,184,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",14-KAEK-218,4-May-15,31-Mar-16,1-Sep-16,16-Jun-17,null,16-Jun-17,"Gaziosmanpasa University, Tokat, Turkey",,https://ClinicalTrials.gov/show/NCT03190512
NCT03188575,Effectiveness & Cost-effectiveness of Internet-delivered Interventions for Depression and Anxiety Disorders in IAPT,D-IAPT,"Active, not recruiting",No Results Available,Depression|Anxiety Disorders|Depressive Disorder|Generalized Anxiety Disorder|Social Anxiety Disorder|Phobic Disorders|Panic Disorder|Health Anxiety,Behavioral: SilverCloud Internet-delivered Cognitive Behavioural Therapy|Other: Waiting List,Change in Depression symptoms|Change in Anxiety symptoms|Work and Social Adjustment|Social Anxiety|Health Anxiety|Panic|Generalised Anxiety Symptoms|Quality of life|Quality of life for users of mental health services|Client service usage|Emotion Regulation|Rumination|Therapeutic Expectancy|CBT Skills Usage|Therapist Behaviours|Therapeutic Alliance for patients|Therapeutic Alliance for clinicians|M.I.N.I. International Neuropsychiatric Interview|Patient Experience/Satisfaction,Silver Cloud Health|Berkshire Healthcare NHS Foundation Trust,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,384,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,D-IAPT,15-Jun-17,25-Jul-19,30-Aug-19,15-Jun-17,null,10-Sep-18,"Berkshire NHS Foundation Trust, Berkshire, United Kingdom",,https://ClinicalTrials.gov/show/NCT03188575
NCT03184909,"Tulsi Consumption and Its Effects on Cognition, Stress and Anxiety",,Completed,No Results Available,Cognitive Change,Drug: Ocimum Sanctum|Drug: Placebo,To assess a change in facilitative cognitive function from baseline in 6 weeks by comparing the results on cognitive tests measured by Cambridge Neuropsychological Test Automated Battery (Cantab®) between active and placebo group|To measure change in cortisol level from saliva in 6 weeks|To measure change in Generalized Anxiety Disorder 7-Item Scale in 6 weeks,Composite Interceptive Med Science,All,18 Years to 50 Years   (Adult),Not Applicable,30,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care",OI-006-2017,14-Dec-17,30-Mar-18,31-Mar-18,14-Jun-17,null,17-Sep-18,"Narayana Hrudayalaya Limited, Mazumdar Shaw multispecialty Hospital, Bangalore, Karnataka, India",,https://ClinicalTrials.gov/show/NCT03184909
NCT03185247,Implementation of Transdx Group for POTS,,"Active, not recruiting",No Results Available,Dysautonomia|Anxiety|Depression,Behavioral: Transdiagnostic Group-Based Treatment,Change in Composite Autonomic Symptom Score (self-report)|Change in Functional Disability Inventory (caregiver and self-report)|Change in Children's Depression Inventory (caregiver and self-report)|Change in Screen for Childhood Anxiety Related Emotional Disorders (caregiver and self-report)|Change in Transdiagnostic Youth/Parent Questionnaire|Change in Pain Coping Questionnaire (caregiver and self-report)|Satisfaction Questionnaire (caregiver and self-report),"University of Colorado, Denver",All,"13 Years to 18 Years   (Child, Adult)",Not Applicable,16,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,17-0470,26-May-17,1-Mar-19,Jun-19,14-Jun-17,null,26-Apr-19,"Children's Hospital Colorado, Aurora, Colorado, United States",,https://ClinicalTrials.gov/show/NCT03185247
NCT03186872,Improving Quality of Care With a Digital Behavioral Program in IBD Patient Centered Medical Home,,Recruiting,No Results Available,Anxiety|Irritable Bowel Disease,Behavioral: Digital behavioral program app,GAD7 Score (Anxiety)|PHQ-8 (Depression),"University of Pittsburgh|Mount Sinai Hospital, New York",All,21 Years to 55 Years   (Adult),Not Applicable,150,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,PRO17020464,15-May-17,31-Oct-19,31-Oct-19,14-Jun-17,null,13-Dec-18,"University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT03186872
NCT03187249,Intervention Strategy in Chronic Obstructive Pulmonary Disease With Anxiety and Depression,,Recruiting,No Results Available,COPD|Anxiety|Depression,Behavioral: Cognitive Behavioral Therapy|Behavioral: Pulmonary Rehabilitation Therapy|Behavioral: Combined Therapy,Hospital Anxiety and Depression Scale|moderate and severe COPD exacerbations|modified British medical research council score|COPD assessment test score,"Chinese Academy of Medical Sciences, Fuwai Hospital",All,"up to 80 Years   (Child, Adult, Older Adult)",Not Applicable,500,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2016YFC1304404B,15-Jun-17,31-Dec-20,31-Dec-20,14-Jun-17,null,14-Jun-17,"Peking Union Medical College Hospital, Beijing, Beijing, China",,https://ClinicalTrials.gov/show/NCT03187249
NCT03184454,Combined Cortical/Subcortical Recording and Stimulation as a Circuit-Oriented Treatment for Obsessive-Compulsive Disorder,,Recruiting,No Results Available,Obsessive Compulsive Disorder,Device: Medtronic PC+S Deep Brain Stimulation,Yale-Brown Obsessive-Compulsive Scale (YBOCS)|Montgomery-Asberg Depression Rating Scale (MADRS)|Clinical Global Impressions (CGI) Severity and Change scale|Patient Global Impressions (PGI) scale,Massachusetts General Hospital,All,21 Years to 64 Years   (Adult),Phase 2,5,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2015P000456,Oct-16,Oct-21,Oct-21,12-Jun-17,null,7-Mar-19,"Massachusetts General Hospital, Charlestown, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT03184454
NCT03182101,Quality Assessment in Exposure Therapy,,Recruiting,No Results Available,Obsessive-Compulsive Disorder in Children,Behavioral: Exposure Therapy,Clinical Global Impression Scales,Bradley Hospital,All,"5 Years to 25 Years   (Child, Adult)",Not Applicable,300,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1039342,13-Sep-17,Sep-20,Apr-21,9-Jun-17,null,18-May-18,"Emma Pendleton Bradley Hospital, Riverside, Rhode Island, United States",,https://ClinicalTrials.gov/show/NCT03182101
NCT03180632,Effect of A Single Dose of Lorazepam on Salivary Cortisol Response in Children Undergoing Digestive Endoscopy:,Endo-Lora,Completed,No Results Available,Anxiety,Drug: Lorazepam|Other: Placebo,Change of sCortisol from baseline to one hour after drug administration|Procedural pain|Duration of endoscopic procedure|Children Satisfaction|Physician Satisfaction|Nurse Satisfaction|Medication needed For sedation|Change in sCortisol levels between pre-op and post-op,St. Justine's Hospital,All,"9 Years to 18 Years   (Child, Adult)",Phase 2,98,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",JP2017,28-Jun-17,1-Jun-18,1-Jun-18,8-Jun-17,null,5-Sep-18,"CHU Sainte-Justine, Montréal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT03180632
NCT03179839,The Study of Mindfulness Based Cognitive Therapy and Obsessive-Compulsive Disorder,,Recruiting,No Results Available,Obsessive-Compulsive Disorder,"Behavioral: Mindfulness-based Cognitive Therapy|Behavioral: Psycho-education Program|Drug: sertraline, fluvoxamine",Yale-Brown Obsessive-Compulsive Scale|Hamilton Anxiety Scale|Hamilton Depression Scale-24,Shanghai Mental Health Center,All,18 Years to 54 Years   (Adult),Not Applicable,120,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,MBCT2017,20-Jan-17,1-Dec-18,20-Feb-19,7-Jun-17,null,2-Jul-17,"Clinical psychiatrist, Shanghai, Shanghai, China",,https://ClinicalTrials.gov/show/NCT03179839
NCT03174808,Mindfulness Interventions and Cutaneous T Cell Lymphoma (CTCL),,"Active, not recruiting",No Results Available,Anxiety|Quality of Life,Behavioral: Mindfulness-Based Stress Reduction (MBSR),Feasibility|Adherence|Stress|Quality of Life,Yale University|Wallace Research Foundation,All,"21 Years and older   (Adult, Older Adult)",Not Applicable,15,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,2000020161,20-Aug-17,31-Oct-17,30-Dec-18,5-Jun-17,null,10-May-18,"Yale Cancer Center/Smilow, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT03174808
NCT03175068,Transdiagnostic Brain-Behavior Profiling to Enhance Cognitive Behavioral Therapy Response,,Recruiting,No Results Available,Major Depressive Disorder|Social Anxiety Disorder,Behavioral: CBT|Behavioral: ST,BOLD Effects Measured with Functional Magnetic Resonance Imaging (fMRI),University of Illinois at Chicago|National Institute of Mental Health (NIMH),All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,240,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Basic Science,2017-0258|1R01MH112705-01A1,5-Jul-17,30-Jun-22,30-Jun-22,5-Jun-17,null,26-Oct-17,"University of Illinois at Chicago, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT03175068
NCT03176004,Attention Training to Modify Error-related Negativity and Risk for Anxiety in Adolescence,,Recruiting,No Results Available,Anxiety,Other: Attention Bias Modification,Change in Anxiety Symptoms,Florida State University|San Diego State University,All,11 Years to 14 Years   (Child),Not Applicable,600,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",MH106477,Oct-16,Sep-19,Jun-21,5-Jun-17,null,20-Jun-18,"San Diego State University, San Diego, California, United States|Florida State University, Tallahassee, Florida, United States",,https://ClinicalTrials.gov/show/NCT03176004
NCT03176446,Pain and Anxiety Evaluation in Children Using Different Techniques of Local Anesthesia for Dental Treatment,,Not yet recruiting,No Results Available,Pediatric Dentistry|Local Anesthesia|Pain Management,Procedure: Local anesthesia with traditional technique|Procedure: Local anesthesia with computerized technique|Procedure: Local anesthesia with DentalVibe technique|Procedure: Local anesthesia with Computerized more DentalVibe technique|Drug: Topic anesthesia|Drug: Local anesthetic,Pain|Pain Behavior|SCARED Questionnaire|Corah Questionnaire|VPT modified|Blood pressure|Respiratory rate|Heart rate|Oxygen saturation|Salivary cortisol,Universidade Estadual de Ponta Grossa,All,5 Years to 12 Years   (Child),Phase 2,240,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Investigator)|Primary Purpose: Device Feasibility,64773417.3.0000.5689,1-Jun-17,20-Dec-18,1-Mar-19,5-Jun-17,null,5-Jun-17,,,https://ClinicalTrials.gov/show/NCT03176446
NCT03172182,Perioperative Effects of Operating Room Virtual Tour,,Completed,No Results Available,Preoperative Care|Anxiety|Emergence Delirium|Postoperative Complications,Behavioral: a 360-degree VR video tour,Emergence delirium|Preoperative anxiety|Postoperative behavioral change,Seoul National University Bundang Hospital,All,4 Years to 10 Years   (Child),Not Applicable,86,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention",B-1705-396-302,1-Aug-17,27-Sep-17,11-Oct-17,1-Jun-17,null,26-Mar-18,"Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/82/NCT03172182/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03172182
NCT03172728,Psycho-education Intervention for Postpartum OCD and it's Influence on Symptom Severity and Treatment Self Referral Rates,,Not yet recruiting,No Results Available,Obsessive-Compulsive Disorder,Behavioral: psycho-education pamphlet,Obsessive Compulsive Inventory-Revised questionnaire,Tel-Aviv Sourasky Medical Center,Female,18 Years to 45 Years   (Adult),Not Applicable,100,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",TASMC-16-GA-0658-CTIL,Jun-17,Jun-19,Jun-20,1-Jun-17,null,1-Jun-17,,,https://ClinicalTrials.gov/show/NCT03172728
NCT03171363,Gaze Contingent Feedback for Anxiety Disorders in Children,,Completed,No Results Available,Anxiety Disorders,Behavioral: Gaze-contingent feedback,Change from baseline in anxiety symptoms - the Pediatric Anxiety Rating (PARS)|Change from baseline in anxiety related emotional disorders symptoms - Child/Parent (the SCARED 41-item),Tel Aviv University,All,6 Years to 10 Years   (Child),Not Applicable,12,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TAUANX,1-Apr-17,1-Apr-18,1-Apr-18,31-May-17,null,18-Sep-18,"Tel Aviv University, Tel Aviv, Israel",,https://ClinicalTrials.gov/show/NCT03171363
NCT03171753,Preoperative Anxiety and Music Therapy,,Completed,No Results Available,Anxiety State,Diagnostic Test: questionnaire|Diagnostic Test: laboratory test|Diagnostic Test: cardiac monitoring|Diagnostic Test: skin resistance|Device: Music listening|Device: No sound,cardiac monitoring|questionnaire|laboratory test,University of Foggia,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care,5/CE/2016,15-Feb-16,30-Jun-17,30-Jun-17,31-May-17,null,18-Sep-17,"Ospedali Riuniti, Foggia, FG, Italy",,https://ClinicalTrials.gov/show/NCT03171753
NCT03169374,Virtual Reality for Anxiety Management in Mechanically Vented Patients,,Enrolling by invitation,No Results Available,Situational Anxiety,Device: Virtual Reality Technology,Incidence of safety events|Change in anxiety level during virtual reality treatment,University of Minnesota - Clinical and Translational Science Institute,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,50,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,STUDY00000220,9-Nov-17,Aug-19,Aug-19,30-May-17,null,17-Apr-19,"Fairview Southdale Hospital, Edina, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT03169374
NCT03165500,Comparative Evaluation of Three Anxiety Control Protocols in Third Molar Extraction,,Completed,No Results Available,Anxiety Disease,Drug: Diazepam|Drug: Midazolam|Drug: Nitrous Oxide + Oxygen Gas|Procedure: Third molar extraction,Assessment of blood pressure change|Assessment of heart rate change|Assessment of oxygen saturation change,Universidade Estadual Paulista Júlio de Mesquita Filho,All,18 Years to 30 Years   (Adult),Early Phase 1,3,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Universidade Estadual Paulista,23-Dec-15,20-Dec-16,4-May-17,24-May-17,null,24-May-17,,,https://ClinicalTrials.gov/show/NCT03165500
NCT03163940,Laughter Yoga Intervention for People With Major Depressive Disorder,,Completed,No Results Available,Major Depressive Disorder|Mood Disorder|Depression,Behavioral: Laughter Yoga,"Change in Depression, Anxiety and Stress Scale (DASS-21) scores from baseline|Change in Short form 12 item Health Survey (SF12v2) scores from baseline","The Hong Kong Polytechnic University|Community Psychiatric Service, Castle Peak Hospital, Tuen Mun, Hong Kong.",All,18 Years to 60 Years   (Adult),Not Applicable,50,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,G-UAB6,1-Jun-17,1-Aug-18,1-Aug-18,23-May-17,null,22-Feb-19,"The Castle Peak Hospital, Hong Kong, Hong Kong",,https://ClinicalTrials.gov/show/NCT03163940
NCT03159793,Evaluation of Different Modelling Techniques on Child Anxiety (RCT),,Recruiting,No Results Available,Anxiety,Behavioral: Live Modelling Technique|Behavioral: Filmed Modelling technique,Dental Anxiety [using Facial Image Scale]|Oxygen Saturation [using Pulse oximetry]|Heart Rate [using Pulse oximetry]|Patient Cooperation [usind Frankl rating scale],Cairo University,All,5 Years to 6 Years   (Child),Not Applicable,51,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,Protocol Paper,15-Dec-17,Mar-19,Sep-19,19-May-17,null,25-Jan-18,"Cairo university, Cairo, Egypt",,https://ClinicalTrials.gov/show/NCT03159793
NCT03160586,Stuttering and Anxiety,,Unknown status,No Results Available,"Stuttering, Childhood|Anxiety Disorders",Diagnostic Test: Stuttering severity instrument-3|Diagnostic Test: Child Behavior Checklist for age 4-18,Stuttering severity index|Child Behavior Checklist for age 4-18,Assiut University,All,6 Years to 16 Years   (Child),Not Applicable,100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,SSI,17-May-17,1-Apr-18,1-Apr-19,19-May-17,null,19-May-17,"Assiut University, Assiut, Egypt",,https://ClinicalTrials.gov/show/NCT03160586
NCT03158194,Cognitive Behavior Therapy for Anxiety-related Asthma in Adults.,,Completed,No Results Available,Asthma,Behavioral: CBT for anxiety-related asthma,Penn State Worry Questionnaire|Anxiety Sensitivity Index-3|Short Health Anxiety Inventory (SHAI)|Asthma Quality of Life Questionnaire|Asthma control test|Catastrophizing about asthma Scale|Perceived Stress Scale|Patient Health Questionnaire,Karolinska Institutet,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,6,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MANTRA 01,16-Aug-17,7-Mar-18,7-Mar-18,18-May-17,null,8-Mar-18,"Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden",,https://ClinicalTrials.gov/show/NCT03158194
NCT03156335,Trial of MR-guided Focused Ultrasound (MRgFUS) Bilateral Capsulotomy for the Treatment of Refractory Obsessive-compulsive Disorder (OCD),,Recruiting,No Results Available,Obsessive-Compulsive Disorder,Device: Focused Ultrasound,Incidence of Treatment-Emergent Adverse Events [Safety]|Clinically meaningful reduction in symptoms [Efficacy],Sunnybrook Health Sciences Centre,All,"20 Years to 80 Years   (Adult, Older Adult)",Not Applicable,10,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility,002-2017,20-Apr-17,Apr-19,Apr-19,17-May-17,null,3-Aug-18,"Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT03156335
NCT03156556,Improving Access to the Treatment of Anxiety and Depression Among Youth Linguistic Minorities,,"Active, not recruiting",No Results Available,Generalized Anxiety Disorder|Major Depressive Disorder|Social Anxiety Disorder|Panic Disorder|Agoraphobia,Behavioral: Mood Mechanic Course,Changes in depression as assessed with the Patient Health Questionnaire-9 items|Changes in anxiety as assessed with the Generalized Anxiety Disorder Scale 7-Item Scale|Changes in anxiety as assessed with the Panic and Agoraphobia Scale (PAS)|Changes in anxiety as assessed with the Social Phobia Inventory (SPIN)|Changes in resilience as assessed with the Connor-Davidson Resilience Scale|Changes in life satisfaction as assessed with the Life Satisfaction Questionnaire|Treatment acceptability,"Universite de Moncton|Royal Bank of Canada|MindCare Inc.|Macquarie University, Australia|University of Regina",All,18 Years to 25 Years   (Adult),Not Applicable,28,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1617070,15-May-17,31-Oct-18,31-Oct-18,17-May-17,null,15-Oct-18,"Université de Moncton, Moncton, New Brunswick, Canada",,https://ClinicalTrials.gov/show/NCT03156556
NCT03153579,LSD Treatment in Persons Suffering From Anxiety Symptoms in Severe Somatic Diseases or in Psychiatric Anxiety Disorders,LSD-assist,Recruiting,No Results Available,Patients|Anxiety Disorders,Drug: LSD|Drug: Placebo,Reduction in anxiety assessed by questionnaires|Reduction in Depression assessed by questionnaires|Reduction of psychopathological symptoms assessed by questionnaires|Sustained Response assessed by questionnaires,"University Hospital, Basel, Switzerland",All,"25 Years and older   (Adult, Older Adult)",Phase 2,40,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",BASEC 2016-00992,31-May-17,1-May-21,1-May-21,15-May-17,null,14-Mar-19,"University Hospital Basel, Basel, BS, Switzerland|Private Practice P.Gasser, Solothurn, SO, Switzerland",,https://ClinicalTrials.gov/show/NCT03153579
NCT03153904,Connecticut Child STEPs,,Completed,No Results Available,Anxiety|Depression|Trauma|Behavior Problems,"Behavioral: Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, and Conduct Problems|Other: Monitoring and Feedback System",Brief Problem Monitor (BPM)|Top Problems Assessment (TPA)|Therapist Satisfaction Inventory (TSI)|Youth Services Survey for Families (YSS-F)|Youth Self-Report and Child Behavior Checklist|Evidence-Based Practice Attitudes Scale (EBPAS)|Early Adolescent Temperament Questionnaire Revised (EATQ-R)|Child Satisfaction Survey (CSC)|Therapeutic Alliance Scale for Children (TASC),Harvard University,All,7 Years to 15 Years   (Child),Not Applicable,210,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",13-1904,Oct-13,Jun-18,Jun-18,15-May-17,null,9-Aug-18,"Harvard University, Cambridge, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT03153904
NCT03147924,Examining the Effects of an Improvisation Group,,Completed,No Results Available,Anxiety|Depression|Self Concept Alteration|Social Support,Other: Improvisation Group,Change in Generalized Anxiety Disorder 7 (GAD-7)|Change in Social Phobia Inventory (SPIN)|Change in Subjective Units of Distress Scale (SUDS)|Change in Patient Health Questionnaire (PHQ-9)|Change in Kessler Psychological Distress Scale (K-10)|Change in Rosenberg Self-Esteem Scale (RSES)|Change in Multidimensional Scale of Perceived Social Support (MSPSS),St. Joseph's Healthcare Hamilton,All,"17 Years to 25 Years   (Child, Adult)",Not Applicable,5,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,2927,6-Mar-17,31-Aug-17,31-Aug-17,10-May-17,null,30-Apr-18,"Youth Wellness Centre, Hamilton, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT03147924
NCT03144739,Collaborative Care for Children's Mental Health Problems,,Recruiting,No Results Available,Depression|Anxiety|Attention Deficit Hyperactivity Disorder|Oppositional Defiant Disorder|Parent-Child Relations|Substance Use,Other: Training in management of children's mental health problems|Other: Current collaborative care protocol,Change in child mental health-related symptoms|Change in child mental health-related functioning|Change in maternal mental health-related symptoms,Johns Hopkins University|National Institute of Mental Health (NIMH),All,5 Years to 15 Years   (Child),Not Applicable,1440,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research,IRB00111549|R34MH106645-01A1,1-Aug-17,Aug-19,Aug-19,9-May-17,null,28-Dec-18,"Tehran University of Medical Sciences, Tehran, Iran, Islamic Republic of",,https://ClinicalTrials.gov/show/NCT03144739
NCT03143634,The Modular Protocol for Mental Health (MPMH),MPMH,Enrolling by invitation,No Results Available,Major Depressive Disorder|Generalized Anxiety Disorder|Posttraumatic Stress Disorder|Social Anxiety Disorder|Panic Disorder|Agoraphobia|Obsessive-Compulsive Disorder|Illness Anxiety Disorder,Behavioral: The Modular Protocol for Mental Health|Behavioral: Treatment-as-usual,"Change in Depression symptoms|Change in Anxiety symptoms|Change in Level of disability and functional impairment|Change in symptoms of social phobia, agoraphobia and specific phobia|Change in symptoms of social anxiety|Change in symptoms of generalised anxiety|Change in symptoms of obsessive-compulsive disorder|Change in symptoms of post-traumatic stress disorder|Change in symptoms of agoraphobia|Change in symptoms of specific phobias|Change in symptoms of panic disorder|Change in symptoms of illness anxiety|Change in level of disability and functional impairment|Change in expectancy about treatment outcome, as well as the credibility of the treatment|Change in ability to contextualize negative events within a wider frame of reference|Change in disengagement from and acceptance of troublesome mental content, rumination|Intensity with which participants experience 36 different emotions on a typical day|Change in personality functioning on four subscales: Identity, Self-Direction, Empathy, and Intimacy|Change in use of NHS services, other mental health services or activities, help at home, and time off work/lost income|Change in quality of life assessment of health and wellbeing, daily functioning, and general life satisfaction across multiple domains",Medical Research Council Cognition and Brain Sciences Unit|Cambridge and Peterborough NHS Foundation Trust,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,50,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,MP:MH RfPB PB-PG-0214-33072,18-Jul-17,31-Mar-19,31-Mar-19,8-May-17,null,15-Aug-18,"MRC Cognition and Brain Sciences Unit, Cambridge, United Kingdom",,https://ClinicalTrials.gov/show/NCT03143634
NCT03142490,Acupuncture as a Complementary Therapy for in Vitro Fertilization Patients: a Randomized Controlled Trial,,Unknown status,No Results Available,Acupuncture|Quality of Life|Infertility|Stress|Anxiety,Other: Acupuncture|Other: Questionnaires,Quality of life|Quality of life 2|Stress|Pregnancy rate|Quality of life 3,Federal University of Minas Gerais,Female,18 Years to 50 Years   (Adult),Not Applicable,100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,60852116.2.0000.5149,1-Dec-16,30-Jun-18,31-Dec-18,5-May-17,null,5-May-17,"Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil",,https://ClinicalTrials.gov/show/NCT03142490
NCT03140124,Enhancing Therapy Process With Movement Strategies,,Terminated,No Results Available,Anxiety Disorders|Mood Disorders,Behavioral: Exercise|Behavioral: Worry Stone,Session Rating Scale - Patient version (Questions 1 and 2)|Session Rating Scale - Therapist version (Questions 1 and 2)|Positive and Negative Affect Schedule - Patient|Positive and Negative Affect Schedule - Therapist|Affect Grid - Patient|Affect Grid - Therapist|Credibility-Expectations Questionnaire - Patient|Credibility-Expectations Questionnaire - Therapist|Session Rating Scales (Questions 3-7) - Patient|Session Rating Scales (Questions 3-7) - Therapist|Qualitative Feedback - Therapist,Boston University Charles River Campus,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,1,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,3889,3-Nov-15,6-Mar-17,6-Mar-17,4-May-17,null,4-May-17,"Boston University, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT03140124
NCT03140293,Pain Perception During Chorionic Villus Sampling,,Completed,No Results Available,Chorionic Villi Sampling,Drug: Lidocaine injection|Drug: Gebauer Ethyl Chloride Spray,Visual Analog Scale (VAS) Pain perception scores VAS ()|Verbal Rating Scale (VRS),Angela Bianco|Icahn School of Medicine at Mount Sinai,Female,"18 Years to 65 Years   (Adult, Older Adult)",Early Phase 1,120,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GCO 14-1425,Sep-16,23-May-17,23-May-17,4-May-17,null,25-Oct-17,"Icahn School of Medicine at Mount Sinai, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT03140293
NCT03140839,Treating Negative Mental Images and Memories in Social Anxiety,,Completed,No Results Available,Social Anxiety,Behavioral: Imaginal Rescripting|Behavioral: Imaginal Exposure|Other: Supportive Counselling,Change in self-reported social anxiety symptoms|Change in clinician-rated social anxiety symptoms|Change in memory narratives and appraisals|Change in behavioral indices of social anxiety|Change in quality of life,University of Waterloo|Hebrew University of Jerusalem|University of Toronto|Baycrest,All,"Child, Adult, Older Adult",Not Applicable,33,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,ORE # 22071,10-May-17,23-Aug-18,23-Aug-18,4-May-17,null,16-Jan-19,"University of Waterloo Department of Psychology and Centre for Mental Health Research, Waterloo, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT03140839
NCT03138278,"Impact on Family or Care-givers of Very Old ICU-survivors, Trajectories and 6 Months' Outcome in the Very Old.",VIP2,Unknown status,No Results Available,"Functionally-Impaired Elderly|Caregivers|PTSD|Depression, Anxiety|Intensive Care Unit Syndrome",Other: Telephone support on demand,Burden scale for Family Caregiver|Post traumatic stress (PTSD) in caregivers|Anxiety and Depression in caregivers|6 months survival in the elderly ICU survivors|Trajectories in the elderly ICU survivors,University of Bergen|European Society of Intensive Care Medicine,All,80 Years and older   (Older Adult),Not Applicable,1000,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,ESICM VIP2,Dec-17,Dec-18,May-19,3-May-17,null,3-May-17,,,https://ClinicalTrials.gov/show/NCT03138278
NCT03139266,Project UPLIFT to Reduce Anxiety and Depression in CF Patients,,Recruiting,No Results Available,Cystic Fibrosis|Anxiety|Depression,Behavioral: UPLIFT|Behavioral: Treatment as usual,Reduce symptoms of anxiety among UPLIFT Tx Group participants.|Reduce symptoms of depression among UPLIFT Tx Group participants.|Increase quality of life among UPLIFT Tx Group participants.|Increase satisfaction with life among UPLIFT Tx Group participants.|Improve medication adherence among UPLIFT Tx Group participants.|Improve knowledge and skills regarding self-management of anxiety and depression among UPLIFT Tx Group participants.|Increase self-efficacy among UPLIFT Tx Group participants.,"Virginia Commonwealth University|University of Michigan|Boston Children’s Hospital|University at Buffalo|Emory University|Children's Hospital Medical Center, Cincinnati",All,"13 Years and older   (Child, Adult, Older Adult)",Not Applicable,70,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,HM20002923,7-Apr-15,1-May-20,1-May-20,3-May-17,null,20-May-19,"Virginia Commonwealth University, Richmond, Virginia, United States",,https://ClinicalTrials.gov/show/NCT03139266
NCT03134651,Preoperative Anxiety at Oocyte Retrieval,,Completed,No Results Available,"Infertility, Female|Anesthesia Awareness|Anxiety State",Device: Monitoring brain function|Drug: propofol,Changes in perioperative Monitoring brain function were measured|pregnancy rate,Trakya University,Female,25 Years to 43 Years   (Adult),Not Applicable,131,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",TUTF-GOKAEK 2014/115,24-Jul-14,24-Jul-16,24-Sep-16,1-May-17,null,1-May-17,,,https://ClinicalTrials.gov/show/NCT03134651
NCT03134950,Improving Care for Youth With FAP: A Stepped Care CBT Delivery Approach,,"Active, not recruiting",No Results Available,Functional Abdominal Pain Syndrome|Anxiety,Behavioral: ADAPT,"Functional Disability Inventory - Child Version (FDI-C)|Screen for Child Anxiety Related Disorders - Child Report (SCARED-C)|Pain Intensity via a Visual Analog Scale (VAS)|Anxiety Disorder Interview Schedule - Child Version (ADIS)|Child Depression Inventory 2 Self Report (CDI-2)|Pain Catastrophizing Scale for Children, Child Version (PCS-C)|Functional Gastrointestinal Disorders (FGIDs) Questionnaire|Children's Somatization Inventory (CSI-24)|Depression Anxiety Stress Scales (DASS21)|Children's Global Assessment Scale (C-GAS)|Affective Reactivity Index (ARI)","Children's Hospital Medical Center, Cincinnati|American Pain Society",All,9 Years to 14 Years   (Child),Not Applicable,139,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2015-1388,20-Jul-15,8-Feb-18,Jun-19,1-May-17,null,24-Jul-18,"Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT03134950
NCT03132597,"Impact of Teaching ""Meditation Techniques"" on the Mental Health and Quality of Life of Medical Students",,Completed,No Results Available,Stress|Anxiety|Depression|Quality of Life,Behavioral: Mindfulness training,"Assess emotional states of depression, anxiety and stress.|Assess general facet of ""quality of life"" and ""health""|Evaluation of empathy, spirituality openness and wellness",Federal University of Juiz de Fora,All,"Child, Adult, Older Adult",Not Applicable,360,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,61240016.3.0000.5133,1-May-17,31-Jul-18,31-Dec-18,28-Apr-17,null,18-Feb-19,"Federal University of Juiz de Fora, Juiz de Fora, Minas Gerais, Brazil",,https://ClinicalTrials.gov/show/NCT03132597
NCT03130842,Premedication With Alprazolam and Midazolam for Upper Gastrointestinal Endoscopy,,Completed,No Results Available,Diagnostic Esophagogastroduodenoscopy,Drug: Sublingual alprazolam|Drug: Oral midazolam,Discomfort assessed by patients on a 11-point numeric rating scales about 5 minutes after the procedure when patients are fully awake|Change in anxiety|Satisfaction is assessed by patients on a 11-point numeric rating scales about 5 minutes after the procedure when patients are fully awake.|Tolerance is assessed by patients from no compliance (0) to excellent compliance (4) about 5 minutes after the procedure when patients are fully awake.|Duration of the procedure|Hypotension|Bradycardia|Desaturation,Isfahan University of Medical Sciences,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2|Phase 3,136,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,395569,17-Sep-16,15-Feb-17,15-Feb-17,27-Apr-17,null,27-Apr-17,"Department of Gastroenterology, Alzahra Hospital, Isfahan, Iran, Islamic Republic of",,https://ClinicalTrials.gov/show/NCT03130842
NCT03131258,The Effects of Pre-operative Anxiety on Anesthetic Recovery and Post-operative Pain in Donor Nephrectomy,,Completed,No Results Available,"Kidney Transplantation|Anxiety|Pain, Acute|Anesthesia Recovery Period",Procedure: Donor Nephrectomy,Postoperative Pain Intensity,Ege University,All,18 Years to 60 Years   (Adult),Not Applicable,48,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,14-5.1/5,Jun-14,Jun-15,Jan-16,27-Apr-17,null,27-Apr-17,,,https://ClinicalTrials.gov/show/NCT03131258
NCT03132298,Effects of a Single-session Implicit Theories of Personality Intervention on Early Adolescent Psychopathology,,Completed,Has Results,Anxiety Symptoms|Depressive Symptoms,Other: Implicit Theories of Personality Program|Other: Control Program,Change in Children's Depression Inventory (CDI) From Baseline to 9-month Follow-up|Change in Children's Depression Inventory - Parent (CDI-P) From Baseline to 9-month Follow-up|Change in Screen for Child Anxiety Related Disorders - Child (SCARED-C) From Baseline to 9-month Follow-up|Change in Screen for Child Anxiety Related Disorders - Parent (SCARED-P) From Baseline to 9-month Follow-up|Primary Control Scale for Children (PCSC)|Secondary Control Scale for Children (SCSC)|Electrodermal Activity (EDA) Recovery Slope|Heart Rate Variability (HRV) Recovery Slope,Harvard University|National Institute of Mental Health (NIMH)|American Psychological Foundation,All,12 Years to 15 Years   (Child),Not Applicable,96,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",IRB15-0855|1F31MH108280-01|5F31MH108280-02,17-Aug-15,30-Oct-16,30-Oct-16,27-Apr-17,23-Jan-19,7-Feb-19,"Harvard University, Cambridge, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT03132298
NCT03129165,ProSALUTE: Community Program for Cardiovascular Health,ProSALUTE,Unknown status,No Results Available,Primary Prevention,Other: Screening and prevention of CVD,Primary adherence at baseline screening|Influence of education level on primary adherence|Influence of working category on primary adherence|Influence of immigrant or native status on primary adherence|Awareness of own cardiovascular risk factors|Accuracy of the perception of own cardiovascular risk|Prevalence of positive screening for anxiety|Prevalence of positive screening for depression|Extent of adherence to the Mediterranean Diet (MD)|Prevalence of physically active subjects|Human resources utilization|Persistence in the program at 6th months|Changes in adherence to MD at 6 months|Changes in PA at 6 months|Changes in declared cigarette consumption|Changes in objective measures of cigarette smoke exposure|Change in positive screening for anxiety|Change in positive screening for depression|Global change in traditional risk factors at 6th months|Global change in estimated risk at 6th months|Persistence in the program at 12th months|Global change in traditional risk factors at 12th months|Global change in estimated risk at 12th months,Centro Cardiologico Monzino,All,"40 Years to 65 Years   (Adult, Older Adult)",Not Applicable,600,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,R212/15 - CCM 226,11-May-15,11-May-18,11-May-18,26-Apr-17,null,26-Apr-17,"Centro Cardiologico Monzino, Milan, Italy",,https://ClinicalTrials.gov/show/NCT03129165
NCT03129204,Sensation Awareness Focused Training for Spouses,SAF-T,Completed,No Results Available,Post Intensive Care Syndrome|Anxiety|Depression|Posttraumatic Stress Disorder|Sleep Deprivation,Behavioral: SAF-T,Change from Baseline Symptoms of Anxiety following ICU discharge and at 1 and 3 months post hospital discharge|Change from Baseline Symptoms of Depression following ICU discharge and at 1 and 3 months post hospital discharge|Change from Baseline Symptoms of Post Traumatic Stress Disorder following ICU discharge and at 1 and 3 months post hospital discharge|Sleep|Change from Baseline Symptoms of Stress following ICU discharge and at 1 and 3 months post hospital discharge,University of South Florida,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,10,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,Pro00026246,3-Sep-17,26-Feb-18,26-Feb-18,26-Apr-17,null,1-Nov-18,"Tampa General Hospital, Tampa, Florida, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/04/NCT03129204/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03129204
NCT03129282,Pathway Study WS3 - Home Based Metacognitive Therapy for Cardiac Rehabilitation Patients,,Recruiting,No Results Available,Depression|Anxiety|Cardiac Rehabilitation|Psychological Distress,Other: Home-based Metacognitive Therapy (Home-MCT),Acceptability|Change in the Hospital Anxiety and Depression Scale (HADS)|Metacognitions Questionnaire 30 (MCQ-30)|Cognitive Attentional Syndrome Scale (CAS-1)|Impact of Events Scale - Revised (IES-R)|Health Related Quality of Life (EQ-5D)|Economic Patient Questionnaire (EPQ)|Credibility questionnaire (regarding the Home-MCT intervention)|Adherence questionnaire (regarding the Home-MCT intervention)|Qualitative interviews with intervention patients to identify enablers and barriers to recruitment and engagement with the intervention (Home-MCT),University of Manchester|Greater Manchester Mental Health NHS Foundation Trust|University of Liverpool,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,108,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment",186990 (RP-PG-1211-20011),4-Apr-17,Apr-19,Apr-21,26-Apr-17,null,17-Apr-19,"Bolton NHS Foundation Trust, Bolton, United Kingdom|Aintree Liverpool NHS Foundation Trust, Liverpool, United Kingdom",,https://ClinicalTrials.gov/show/NCT03129282
NCT03127982,Unified Protocol for Emotional Problems in Victims of the Armed Conflict in Colombia,,Recruiting,No Results Available,Emotional Disorder,Behavioral: Unified Protocol,"Changes in symptoms of depression, and anxiety, as assessed by the Patient Health Questionnaire.|Quality of Life.|Anxiety measure.|Depression measure.|Current level of functioning.|Change in symptoms of post-traumatic stress as measured by the Post-Traumatic Stress Disorder (PTSD)","University of Los Andes, Columbia",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Treatment,COLCIENCIAS 644-2014,1-Jan-15,30-Dec-18,1-May-19,25-Apr-17,null,12-Jun-18,"Laboratorio de Psicología Clínica Uniandes - Universidad de Los Andes, Bogotá, DC, Colombia",,https://ClinicalTrials.gov/show/NCT03127982
NCT03128437,"Anxiety, Mood, and Health Behaviors in Young Adults",,"Active, not recruiting",No Results Available,Anxiety Sensitivity,Behavioral: Aerobic Exercise,Anxiety sensitivity|Physical activity|Heart rate variability|Alcohol use|Binge eating|Sleep|Exercise Stage of Change,Virginia Commonwealth University,All,18 Years to 35 Years   (Adult),Not Applicable,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,HM20009285,9-May-17,31-Dec-19,31-Dec-19,25-Apr-17,null,20-Feb-19,"Virginia Commonwealth University, School of Medicine, Richmond, Virginia, United States",,https://ClinicalTrials.gov/show/NCT03128437
NCT03125330,The Impact of Professional Coaching on Early Career Academic Emergency Physicians,,Recruiting,No Results Available,"Development, Human|Well-Being|Professional Burnout|Goals|Leadership|Professional Role|Physician's Role|Stress|Anxiety",Behavioral: Professional coaching,"Goal Setting and Attainment|Psychological Well-Being Scale|Empowerment at Work Scale|Abbreviated Two-Item Maslach Burnout Inventory|Depression, Anxiety, and Stress Scale (DASS 21)|Leadership Self-Efficacy Scale|Self-Insight Scale|Solution-Focused Thinking Scale|Tolerance for Ambiguity Scale|Perspective Taking Scale|Qualitative Summary of Coaching Program|Subject-Object Interview",Mayo Clinic,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,90,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,16-010192,1-Jun-17,Sep-20,Apr-21,24-Apr-17,null,12-Mar-19,"Mayo Clinic in Rochester, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT03125330
NCT03123991,Applying the Spanish Version of the UP-A as a Universal School-based Anxiety and Depression Prevention Program,,Completed,No Results Available,Anxiety|Depression,"Behavioral: UP-A adapted as a preventive intervention|Behavioral: Same than experimental group (EG), after EG finishes","Change in Revised Child Anxiety and Depression Scale—30 (RCADS-30) at pre, post intervention and at 3 months follow-up.|Change in Depression Questionnaire for Children [Cuestionario de Depresión para Niños] (CDN) (Sandín, Chorot, & Valiente, 2016) at pre, post intervention and at 3 months follow-up.|Change in Anxiety Scale for Children [Escala de Ansiedad para Niños] (EAN) (Sandín et al., 2016) at pre, post intervention and at 3 months follow-up.|Strenghts and Difficulties Questionnaire (SDQ) (Goodman, 1997).|Children Positive and Negative Affect Schedule [Escalas PANAS para niños] (PANASN) (Sandín, 2003).|Childhood Anxiety Sensitivity Index (CASI) (Silverman, Fleisig, Rabian, & Peterson, 1991).|Emotional Avoidance Strategy Inventory for Adolescents (EASI-A) (Kennedy & Ehrenreich-May, 2016).|Depression and Anxiety Interference Scale for children [Escala de Interferencia de Depresión y Ansiedad en Niños] (EIDAN) (García-Escalera, Sandín, Chorot, & Valiente, 2017).|Rosenberg Self-Esteem Scale (RSES) (Rosenberg, 1965)|Satisfacion With Life Scale for Children (SWLS-C) (Sandín, Chorot, & Valiente, 2015).|Kidscreen-10 (KIDSCREEN Group, 2006)|Schoool Adjustment Brief Scale [Escala Breve de Ajuste escolar] (EBAE-10) (Moral, Sánchez-Sosa, & Villarreal, 2010).|General Indiscipline Scale [Escala de Indisciplina General] (IG)|Socio-Demographic Information Questionnaire|End of Program Questionnaire","Universidad Nacional de Educación a Distancia|Spanish Ministry of Education, Culture and Sport|Ministerio de Economía y Competitividad, Spain",All,"11 Years to 18 Years   (Child, Adult)",Not Applicable,157,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention,13/03315,10-Oct-16,Jul-17,Jul-17,21-Apr-17,null,29-Nov-17,,,https://ClinicalTrials.gov/show/NCT03123991
NCT03122158,Escitalopram in the Treatment of Adolescents With Major Depressive Disorder or Anxiety Disorders,,Unknown status,No Results Available,Major Depressive Disorder|Anxiety Disorders,Drug: Escitalopram,Clinical Global Impression Scale (CGI)|The Hamilton Rating Scale for Depression|The Hamilton Anxiety Rating Scale,Erzurum Regional Training & Research Hospital,All,"12 Years to 18 Years   (Child, Adult)",Phase 4,60,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ErzurumRTRH,8-Apr-17,15-Sep-18,15-Dec-18,20-Apr-17,null,20-Apr-17,"ErzurumRTRH, Erzurum, Palandöken, Turkey",,https://ClinicalTrials.gov/show/NCT03122158
NCT03120208,Prevalence of Psychological Disorders After Immediate Postpartum Hemorrhage,PSYCHE,Recruiting,No Results Available,Postpartum Hemorrhage|Postpartum Women|Postpartum Depression|Postpartum Stress|Postpartum Anxiety,"Behavioral: • The Edinburgh postnatal depression scale (EPDS), validated in French, with a discrimination threshold ≥ 11.|Behavioral: The GAD-7 with a discrimination threshold ≥10.|Behavioral: • Spielberger's State-Trait anxiety inventory, Form Y (validated in French), with a STAI (form Y-A) discrimination threshold ≥ 46|Behavioral: The IES-R, validated in French, with a discrimination threshold ≥ 30.|Behavioral: EPDS, MINI, STAI-A and B, IES-R and QEVA (experience)","prevalence of depression|prevalence of depression among women with PPH between 500-1000 mL compared with those with severe PPH (≥ 1000 mL)|The prevalence of depression among women with a PPH requiring a so-called second-order medical intervention (transfusion, vascular embolization, etc.) compared with women who had a PPH without such a second-order intervention|severity of depression among women with PPH between 500-1000 mL compared with those with severe PPH (≥ 1000 mL)|severity of depression among women with a PPH requiring a so-called second-order medical intervention (transfusion, vascular embolization, etc.) compared with women who had a PPH without such a second-order intervention|prevalence of anxiety and post-traumatic stress among women after an immediate PPH|prevalence of anxiety and post-traumatic stress among women with PPH between 500-1000 mL compared with those with severe PPH (≥ 1000 mL)|prevalence of anxiety and post-traumatic stress among women with a PPH requiring a so-called second-order medical intervention (transfusion, vascular embolization, etc.) compared with women who had a PPH without such a second-order intervention|severity of anxiety and post-traumatic stress among women with PPH between 500-1000 mL compared with those with severe PPH (≥ 1000 mL)|severity of anxiety and post-traumatic stress among women with a PPH requiring a so-called second-order medical intervention (transfusion, vascular embolization, etc.) compared with women who had a PPH without such a second-order intervention|prevalence of depression, post-traumatic stress, and anxiety, the experience of delivery, in partners of women with an immediate postpartum hemorrhage (< 24 hours)","University Hospital, Clermont-Ferrand",Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,1968,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,CHU-314|2016-A00092-49,27-Apr-17,Aug-19,Feb-20,19-Apr-17,null,31-Dec-18,"CHU Clermont-Ferrand, Clermont-Ferrand, France",,https://ClinicalTrials.gov/show/NCT03120208
NCT03118752,Pragmatic Collaborative Care for Cardiac Inpatients With Depression or Anxiety,,Recruiting,No Results Available,Acute Coronary Syndrome|Heart Failure|Depression|Generalized Anxiety Disorder|Panic Disorder,Behavioral: Collaborative Care,Change in physical function|Change in generic health-related quality of life|Change in disease-specific health-related quality of life|Change in mental health (depression)|Change in mental health (anxiety)|Change in optimism|Change in patient satisfaction|Change in physical activity adherence|Change in dietary adherence (saturated fat)|Change in dietary adherence (sodium intake)|Change in smoking|Change in cardiac medication adherence|Major adverse cardiac events|Healthcare costs|Cost-effectiveness,"Massachusetts General Hospital|National Heart, Lung, and Blood Institute (NHLBI)",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,260,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,2016P002870|1R01HL133149-01A1,16-Oct-17,30-Sep-22,30-Sep-22,18-Apr-17,null,4-Apr-18,"Massachusetts General Hospital, Boston, Massachusetts, United States|Salem Hospital, Salem, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT03118752
NCT03113903,Validation of the French Version of the Pain Sensitivity Questionnaire,PSQ-F,Completed,No Results Available,Scheduled Surgery|Healthy Volunteers,Behavioral: Psychophysical exploration,"The psychometric properties of the French version of the PSQ|The natural smell sensitivity assessed independently by a home-made questionnaire|The natural noise sensitivity assessed independently by a home-made questionnaire|The natural light sensitivity, assessed independently by a home-made questionnaire","University Hospital, Clermont-Ferrand|Inserm U1107 « Neuro-Dol », Clermont-Ferrand, France|Centre Jean Perrin|Klinikum der Universität München, Deutschland",All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,232,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Other,CHU-311|2016-A02079-42,30-Apr-17,23-Jan-18,23-Jan-18,14-Apr-17,null,3-Dec-18,"CHU Clermont-Ferrand, Clermont-Ferrand, France",,https://ClinicalTrials.gov/show/NCT03113903
NCT03112265,Using Neuroimaging to Understand Children's Mental Health and Treatment Outcomes,,Recruiting,No Results Available,Anxiety|Depression|Trauma|Behavior Problems,"Behavioral: Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, and Conduct Problems|Other: Monitoring and Feedback System|Behavioral: Treatment as usual",Change from Baseline Emotion Regulation Task at End of Treatment|Change from Baseline Emotional Go/No-Go Task at End of Treatment|Change from Baseline Attentional Bias Task at End of Treatment|Change from Baseline Granularity Task at End of Treatment|Change from Baseline Behavior Rating Inventory of Executive Function (BRIEF) at End of Treatment|Change from Baseline Early Adolescent Temperament Questionnaire Revised (EATQ-R) at End of Treatment,Harvard University,All,7 Years to 13 Years   (Child),Not Applicable,84,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",313704,Jan-15,Jul-20,Jul-20,13-Apr-17,null,9-Aug-18,"Harvard University, Cambridge, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT03112265
NCT03112304,Child STEPS for Youth Mental Health in Maine Sustainability,,Completed,No Results Available,Anxiety|Depression|Trauma|Behavior Problems,Behavioral: MATCH-ADTC|Other: TRAC,Brief Problem Checklist (BPC)|Top Problems Assessment (TPA)|Youth Self-Report and Child Behavior Checklist|Therapeutic Alliance Scale for Children (TASC)|Client Satisfaction Questionnaire- 8 (CSQ-8 )|Youth Satisfaction Questionnaire-8 (YSQ-8)|Therapist Satisfaction Inventory (TSI)|Evidence-Based Practice Attitudes Scale (EBPAS),Harvard University,All,6 Years to 15 Years   (Child),Not Applicable,153,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,H030711,Sep-11,Jul-14,Aug-15,13-Apr-17,null,13-Apr-17,"Harvard University, Cambridge, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT03112304
NCT03109795,Anxiety-mediated Impairments in Large Elastic Artery Function and the Autonomic Nervous System,ATLAS,"Active, not recruiting",No Results Available,Anxiety|Hypertension,Drug: Clonidine Pill|Drug: Hydrochlorothiazide,Aortic stiffness,Seth Holwerda|University of Iowa,All,"18 Years to 79 Years   (Adult, Older Adult)",Phase 4,30,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",201701762,10-Apr-17,30-Jun-23,31-Dec-23,12-Apr-17,null,19-Feb-19,"University of Iowa, Iowa City, Iowa, United States",,https://ClinicalTrials.gov/show/NCT03109795
NCT03103217,Exploring the Effectiveness of a Brief CBT Intervention for Anxious Pregnant Women,,Unknown status,No Results Available,Anxiety,Behavioral: brief CBT for anxious pregnant women,Change from Baseline to post intervention and at follow-up -Hospital depression and anxiety scale|Change from Baseline to post intervention - Pregnancy Related Anxiety Questionnaire - Short|Change from Baseline to post intervention and at follow-up - The Warick Edinburgh Mental Well-being scale|Childbirth experience questionnaire,University of Edinburgh|NHS Grampian,Female,"16 Years and older   (Child, Adult, Older Adult)",Not Applicable,29,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AC 16012,Jul-16,Jan-17,Apr-17,6-Apr-17,null,6-Apr-17,"Victoria Ross, Aberdeen, Scotland, United Kingdom",,https://ClinicalTrials.gov/show/NCT03103217
NCT03103269,Challenge! Adolescent Obesity Prevention,Challenge,Completed,No Results Available,Overweight|Obesity,Behavioral: Challenge! Small Group Intervention|Other: Challenge! Environmental Intervention,Change of Body Mass Index Percentile for Age and Sex for adolescent females|Change of Dietary Quality for adolescent females,University of Maryland|Robert Wood Johnson Foundation|Johns Hopkins Bloomberg School of Public Health|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),All,"10 Years and older   (Child, Adult, Older Adult)",Not Applicable,789,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,HP-00040540|R01HD054727,Sep-09,Jan-14,Jan-14,6-Apr-17,null,6-Apr-17,"Baltimore City Public Schools, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT03103269
NCT03101332,Virtual Reality for Panic Disorder With Agoraphobia,,Unknown status,No Results Available,Panic; Agoraphobia,Behavioral: Virtual Reality cognitive behavior therapy,Mobility Inventory|Panic disorder severity scale|Patient Health Questionnaire|World Health Organisation Disability Assessment Schedule|The World Health Organisation Quality of Life,Karolinska Institutet,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,25,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,VR for panic with agoraphobia,1-May-17,1-Jun-18,1-Jun-18,5-Apr-17,null,21-Apr-17,"Gustavsberg primary care center, Gustavsberg, Stockholm, Sweden|Karolinska Institutet, Stockholm, Sweden",,https://ClinicalTrials.gov/show/NCT03101332
NCT03101553,Computerized Treatment for Social Anxiety,,Completed,No Results Available,Social Anxiety Disorder,Behavioral: Interpretation Bias Modification|Behavioral: Progressive Muscle Relaxation,"Social Phobia Inventory (SPIN; Davidson, 1995)|Beck Depression Inventory (BDI-II; Beck, Steer, & Brown, 1996)|Beck Anxiety Inventory (BAI; Steer & Beck, 1997)|Interpretations Questionnaire-modified (IQ-modified; Buhlmann et al., 2002)",Florida State University,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,65,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,2016.20077,10-Feb-17,1-Nov-17,1-Nov-17,5-Apr-17,null,4-Apr-18,"Florida State University, Department of Psychology, Tallahassee, Florida, United States",,https://ClinicalTrials.gov/show/NCT03101553
NCT03102008,Unified Protocol for Adolescents (UP-A) Change Processes,,Completed,No Results Available,Anxiety Disorders|Depression|Obsessive-Compulsive Disorder|Adolescent - Emotional Problem|Emotional Disorder,Behavioral: Unified Protocol for Emotional Disorders in Adolescents (UP-A),"Change in DSM-5 Anxiety and Depressive Disorder Diagnoses and Severity in Accordance with Anxiety Disorders Interview Schedule for the DSM-5, Child and Parent Versions (ADIS-5-C/P)|Session to Session Change in a measure of emotion regulation in youth, Emotion Regulation Questionnaire-Child and Adolescent Form (ERQ-CA)|Session to Session Change in a measure of distress tolerance in youth, Distress Tolerance Scale (DTS)|Session to Session Change in a measure of avoidance behaviors in youth associated with emotional disorders, Emotional Avoidance Strategy Inventory for Adolescents (EASI-A)|Session to Session Change in a measure of anxiety and depressive symptoms in youth (self-report), Revised Children's Anxiety and Depression Scale-Short Form (RCADS-Short Form)|Session to Session Change in a measure of anxiety and depressive symptoms in youth reported by parents, Revised Children's Anxiety and Depression Scale-Parent Report-Short Form (RCADS-P-Short Form)|Session to Session Change in a measure of severity of presenting problems in youth, Top Problems|Session to Session Change in Score on a measure of youth distress tolerance, The Behavioral Indicator of Resiliency to Distress (BIRD)",University of Miami,All,13 Years to 17 Years   (Child),Not Applicable,9,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,20161193,12-Jan-17,14-Dec-17,14-Dec-17,5-Apr-17,null,27-Nov-18,"University of Miami, Coral Gables, Florida, United States",,https://ClinicalTrials.gov/show/NCT03102008
NCT03099772,CBT for GAD: Impact of Cognitive Processing on Treatment Outcome,,Completed,No Results Available,Generalized Anxiety Disorder,Behavioral: CBT-IU,Change from Baseline in symptoms of GAD and comorbid conditions at 4 months|Change from Baseline in symptoms of GAD at 4 months|Change from Baseline in worry at 4 months|Change from Baseline in symptoms of depression at 4 months|Change from Baseline in symptoms of anxiety at 4 months,"Concordia University, Montreal|Hopital du Sacre-Coeur de Montreal",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,80,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,UH2005-093,Apr-07,Mar-12,Mar-12,4-Apr-17,null,4-Apr-17,,,https://ClinicalTrials.gov/show/NCT03099772
NCT03100279,Process and Outcomes in CBT for Anxious and Depressed Youth,,Recruiting,No Results Available,Anxiety Disorders|Depression,Behavioral: Coping Cat/CAT Project|Behavioral: Primary and Secondary Coping Enhancement Therapy,Change in Clinical Global Impression - Severity (CGI-S) Scale: interviewer|Change in Anxiety Disorders Interview Schedule (ADIS-IV) - Principal Diagnosis|Change in Children's Depression Rating Scale-Revised (CDRS-R): Total depression score|Change in Strengths and Difficulties Questionnaire total impairment - parent report|Change in Strengths and Difficulties Questionnaire total impairment - child report|Change in State-Trait Anxiety Inventory for Children (STAIC) - Trait Scale: parent|Change in State-Trait Anxiety Inventory for Children (STAIC) - Trait Scale: child|Change in Revised Children's Anxiety and Depression Scale (RCADS) - Parent|Change in Revised Children's Anxiety and Depression Scale (RCADS) - depression subscale|Change in Multidimensional Anxiety Scale for Children - Child|Change in Multidimensional Anxiety Scale for Children - Parent|Change in Multidimensional Anxiety Scale for Children - Brief form|Change in Center for Epidemiologic Studies-Depression Scale (CES-D) - Child|Change in Center for Epidemiologic Studies-Depression Scale (CES-D) - Parent|Change in Adolescent Alcohol and Drug Involvement Scale (AADIS): incidents of substance abuse|Change in Olweus Bully/Victim Questionnaire - Parent and Child report (OBVQ-P/C): frequency of victimization events|Change in Multidimensional Bullying Impact Scale (MBIS) - total impairment score|Change in Child Behavior Checklist (CBCL) - total internalizing score|Change in Child Behavior Checklist (CBCL) - total externalizing score|Change in Responses to Stress Questionnaire (RSQ)—Youth|Change in Responses to Stress Questionnaire (RSQ)— Parent|Change in Behavioral Activation for Depression Scale - Adolescent (BADS-A); youth|Change in Behavioral Activation for Depression Scale - Adolescent (BADS-A); parent forms|Change in Child Automatic Thoughts Scale: child report|Change in Affect and Arousal Scale: child report|Change in Difficulties in Emotion Regulation Scale: child report|Change in Real-time Emotion Action and Cognition Tracker (REACT) system: child|Change in Rearing Behaviors Questionnaire: child|Change in Rearing Behaviors Questionnaire: parent|Change in Family Environment Scale - parent and child|Change in Me and My Mother (MMM): child report|Change in Me and My Father (MMF): child report|Change in Depression Anxiety Stress Scales-21 (DASS-21) - parent|Change in Parent-Child Interaction Questionnaire (PCIQ) - parent report|Change in Parental Acceptance and Action Questionnaire (PAAQ) - parent report|Change in Stroop Color-Word Association Test error score: child|Change in Emotional Stroop error score: child|Change in Therapeutic Alliance Scale for Children/Adolescents - therapist report|Change in Therapeutic Alliance Scale for Children/Adolescents - child|Change in Child Involvement Rating Scale-Therapist report|Change in Service Assessment for Children and Adolescents (SACA) - Service Use Scale: parent report,Rutgers University,All,7 Years to 17 Years   (Child),Not Applicable,400,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,05-504Rc11,1-Jul-05,31-Aug-22,31-Aug-22,4-Apr-17,null,4-Apr-17,"Rutgers University (Youth Anxiety and Depression Clinic), Piscataway, New Jersey, United States",,https://ClinicalTrials.gov/show/NCT03100279
NCT03100773,Impact of Atraumatic Restorative Treatment and Oral Health Promotion on Psychological and Salivary Aspects of Children,,Completed,No Results Available,Dental Caries,Other: Oral health educational strategy|Procedure: Atraumatic Restorative Treatment,Change in dental anxiety assessed by measuring the cognitive and behavioral aspects.|Change in dental anxiety assessed by measuring the salivary biomarkers.|Change in dental anxiety assessed by measuring the physiological aspect.|Change in salivary physicochemical properties.|Change in salivary microbiological properties.|Change in oral hygiene.|Change in oral health-related quality of life.,"University of Campinas, Brazil|Fundação de Amparo à Pesquisa do Estado de São Paulo",All,6 Years to 8 Years   (Child),Not Applicable,78,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CJK-2014-ART,Jan-15,Nov-15,Nov-15,4-Apr-17,null,4-Apr-17,,,https://ClinicalTrials.gov/show/NCT03100773
NCT03100981,Online Mindfulness for Women Treated for Breast Cancer and Men Treated for Prostate Cancer,,Completed,No Results Available,Anxiety Depression|Breast Cancer Female|Prostate Cancer,Behavioral: Internet-delivered Mindfulness-Based Cognitive Therapy|Behavioral: Waitlist control,Symptoms of Depression|Symptoms of Anxiety|Symptoms of Stress|Cost-Effectiveness,"University of Aarhus|Aarhus University Hospital|Karolinska Institutet|Stockholm County Council, Sweden",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,150,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Krop & Sind|R87-A5432|7-12.0736|R113-A7015-14-S34,24-Feb-16,27-Nov-17,27-Jun-18,4-Apr-17,null,8-Jan-19,"Department of Psychology, Aarhus University, Aarhus, Central Region Denmark, Denmark",,https://ClinicalTrials.gov/show/NCT03100981
NCT03098134,The Efficacy of a VR Enhanced Video Exposure Therapy for Dental Phobia,VR-DENT,Unknown status,No Results Available,Dental Phobia,Behavioral: Behavior Therapy|Other: Health Education,Change in Subjective Dental Anxiety|Change in Dysfunctional Dental Cognitions|Change in Psychophysiological defensive reactivity,"Ruhr University of Bochum|Ruhr University of Bochum (Dr. Andre Wannemüller)|Zahnklinik Bochum, Augusta Hospital (Prof. Dr. Peter Jöhren)|Ruhr University of Bochum (Prof. Dr. Jürgen Margraf)",All,"18 Years and older   (Adult, Older Adult)",Phase 2,100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,VR-DENT-1,Apr-17,31-Dec-17,1-May-18,31-Mar-17,null,31-Mar-17,,,https://ClinicalTrials.gov/show/NCT03098134
NCT03096925,Non-cardiac Chest Pain: Effect of Cognitive Therapy Administered as Guided Self-help,,"Active, not recruiting",No Results Available,Chest Pain,Behavioral: Guided self-help,Change in Cardiac Anxiety Questionnaire (CAQ)|Change in Body Sensations Questionnaire (BSQ)|Change in Brief Illness Perception Questionnaire (BIPQ)|Change in Patient Health Questionnaire (PHQ-9)|Change in General perceived Self-Efficacy Scale|Change in EQ-5D-5L|Health care costs,Sorlandet Hospital HF,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,160,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,815443|2016031,3-Apr-17,15-Jul-19,15-Dec-19,30-Mar-17,null,31-Dec-18,"Sorlandet Sykehus HF, Kristiansand, Vest Agder, Norway",,https://ClinicalTrials.gov/show/NCT03096925
NCT03092609,Neuroplasticity in an Extended Amygdala Network as a Target Mechanism for Attention Bias Modification Outcome,,Recruiting,No Results Available,Anxiety,Behavioral: Attention Bias Modification|Behavioral: Attention Control,Attentional Bias|State and Trait Anxiety,Northern Michigan University|National Institute of Mental Health (NIMH),All,18 Years to 37 Years   (Adult),Not Applicable,100,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",HS13-555,15-Dec-17,14-Sep-20,14-Sep-20,28-Mar-17,null,29-Mar-18,"Northern Michigan University, Marquette, Michigan, United States",,https://ClinicalTrials.gov/show/NCT03092609
NCT03093376,Neurally Targeted Interventions to Reduce Early Childhood Anxiety,,Recruiting,No Results Available,Anxiety Disorders,Behavioral: Effortful Control Camp|Behavioral: Waitlist,Change from Baseline Error Related Negativity (ERN) at Post-Intervention|Change from Baseline Fear Potentiated Startle (FPS) at Post-Intervention|Change in Anxiety Symptoms,University of Michigan|Michigan State University|One Mind Institute,All,48 Months to 83 Months   (Child),Not Applicable,40,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HUM00117593,30-Mar-17,Dec-19,Dec-19,28-Mar-17,null,20-Jul-18,"University of Michigan, Ann Arbor, Michigan, United States",,https://ClinicalTrials.gov/show/NCT03093376
NCT03093571,Auricular Stimulation vs. Relaxation for Pre-exam Anxiety,AAvsPMR,Completed,No Results Available,Anxiety,Device: Auricular stimulation|Behavioral: Relaxation,Intensity of anxiety|Salivary alpha-amylase|heart rate|blood pressure,University Medicine Greifswald,All,19 Years to 35 Years   (Adult),Not Applicable,47,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",BB 041/15,Apr-15,Jul-15,Jul-15,28-Mar-17,null,29-Mar-17,,,https://ClinicalTrials.gov/show/NCT03093571
NCT03093584,Auricular Stimulation vs. Expressive Writing for Exam Anxiety,AA_EW_Anxi,Completed,No Results Available,Anxiety,Device: Auricular acupuncture|Behavioral: Expressive writing,Intensity of anxiety|salivary alpha-amylase|heart rate|blood pressure,University Medicine Greifswald,All,19 Years to 35 Years   (Adult),Not Applicable,37,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",BB 037/14,Apr-14,Jul-14,Jul-14,28-Mar-17,null,29-Mar-17,,,https://ClinicalTrials.gov/show/NCT03093584
NCT03090750,Effects of Aromatherapy on Anxiety in Invasive Radiologic Procedure,,Completed,No Results Available,Anxiety|Anxiety Preoperative,Drug: Lavender Oil|Drug: Bergamot Oil|Other: Water,Anxiety level of patients,Atrium Health,All,"18 Years and older   (Adult, Older Adult)",Phase 1,31,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,04-14-09B,16-Jul-15,19-Dec-16,Mar-17,27-Mar-17,null,5-Mar-18,,,https://ClinicalTrials.gov/show/NCT03090750
NCT03090867,Participation of Relative or Surrogate in the Patient's Care in Reanimation,PARTICIPATE,Recruiting,No Results Available,Critical Care|Anxiety Depression,"Other: Relatives or surrogates are encouraged to perform care|Other: Conventional ,care",Change from baseline HAD scale at ICU's discharge|Evolution of the relative or surrogate anxiety/depression|Evaluation of the satisfaction's relatives or surrogates regarding their participation in the ICU patient care by a questionnaire|Evaluation of the satisfaction of the ICU staff by a questionnaire|Quantify which care have been realized by the relatives or surrogates|HAD scale of the patient,Assistance Publique - Hôpitaux de Paris|ICAN Nutrition Education and Research,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,140,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,P150301,16-Nov-17,Dec-18,Jan-19,27-Mar-17,null,4-Jun-18,"Hôpital Pitié Salpêtrière, Paris, France",,https://ClinicalTrials.gov/show/NCT03090867
NCT03091335,Music-listening During Deep Brain Stimulation to Relieve Anxiety,,Completed,No Results Available,Movement Disorders|Deep Brain Stimulation,Other: Music-listening,Cortisol Response|Blood Pressure|Medication Requirements|Post-operative Recall Questionnaire,"Darlene A. Lobel, MD|The Cleveland Clinic",All,"18 Years to 100 Years   (Adult, Older Adult)",Not Applicable,10,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,16-467,1-Jul-16,30-Nov-17,30-Nov-17,27-Mar-17,null,14-Dec-17,"Cleveland Clinic, Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT03091335
NCT03089736,Pain Related to Head and Neck Cancer (HNC); Implementation and Evaluation of Self-care Measure Due to the Same Illness,HNC,Completed,No Results Available,Pain|Head and Neck Cancer,Behavioral: Education|Behavioral: Self Care|Other: Treatment as usual (TAU),Change in Pain intensity|Change in Pain Interference|Change in Perceived health index|Change in Perceived health scale|Change in depression|Change in anxiety|Change in catastrophizing,Linkoeping University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,62,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"HNC, pain-coaching during RT",1-Jan-15,31-Dec-16,19-Mar-17,24-Mar-17,null,30-Mar-17,,,https://ClinicalTrials.gov/show/NCT03089736
NCT03086980,Automatic Self Transcending Meditation (ASTM) Versus Usual Care in Patients With Glaucoma,,Recruiting,No Results Available,Glaucoma|Depression|Anxiety|Quality of Life,Other: Automatic Self Transcending Meditation|Other: Treatment as Usual,Change in Health-related quality of life (HRQoL)|Visual Function Score|Depression|Anxiety,Lawson Health Research Institute,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,142,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care,108387,1-Aug-17,1-Jul-19,1-Dec-19,22-Mar-17,null,24-Aug-17,"St. Joseph's Hospital, Ivey Eye Institute, London, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT03086980
NCT03085654,Multiple Dose Effect of Oxytocin on Males With High or Low Trait Anxiety,,Completed,No Results Available,Healthy,Drug: Oxytocin nasal spray|Drug: Placebo nasal spray,Changes between acute and chronic administration of oxytocin on amygdala activity as assessed by fMRI|Changes between acute and chronic administration of oxytocin on amygdala connectivity as assessed by fMRI|Interaction of acute and chronic treatment effects with trait anxiety on neural activity|Interaction of acute and chronic treatment effects with trait anxiety on neural connectivity|Effects of oxytocin on arousal ratings of emotional stimuli (acute and changes with chronic treatment)|Effects of oxytocin on valence ratings of emotional stimuli (acute and changes with chronic treatment)|Interaction of treatment effects on valence ratings with trait anxiety (acute and changes with chronic treatment)|Interaction of treatment effects on arousal ratings with trait anxiety (acute and changes with chronic treatment),University of Electronic Science and Technology of China,Male,18 Years to 30 Years   (Adult),Early Phase 1,147,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",UESTC-neuSCAN_10,3-Mar-17,31-Mar-18,30-Apr-18,21-Mar-17,null,29-Oct-18,"school of life science and technology, University of Electronic Science and Technology of China, Chengdu, Sichuan, China",,https://ClinicalTrials.gov/show/NCT03085654
NCT03079336,Implementation of Psychological Treatment in Generalized Anxiety,IMPLEMENT2_0,Recruiting,No Results Available,Generalized Anxiety Disorder,Behavioral: Implementation - SOTA|Behavioral: Implementation - Prolonged focus on changes|Behavioral: Mastery your Anxiety and Worry (MAW),"Change from baseline to 6 months treatment completion of a latent 5-facet, self-report outcome-factor",University of Zurich,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,80,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,PP00P1_163702,Jan-17,Jan-20,Jul-20,14-Mar-17,null,9-May-18,"Department of Psychology, University of Zürich, Zurich, Switzerland",,https://ClinicalTrials.gov/show/NCT03079336
NCT03077919,Effectiveness and Acceptability of Stellate Ganglion Block for Posttraumatic Stress Disorder Symptoms - Effectiveness,,Completed,No Results Available,PostTraumatic Stress Disorder,Drug: Ropivacaine|Drug: Sham treatment,Clinician Administered PTSD Score (CAPS-5)|PTSD Checklist (PCL-5)|PTSD Checklist Civilian (PCL-C)|Mini-International Neuropsychiatric Interview (M.I.N.I.-Plus) Suicidality Items|Alcohol Use Disorders Identification Test (AUDIT/AUDIT-C)|Alcohol Use Disorders Identification Test (AUDIT/AUDIT-C) Improvement|Kessler Psychiatric Distress Scale (K6)|The Patient Health Questionnaire (PHQ-9)|Generalized Anxiety Disorder 7-item survey (GAD-7)|12-item Short Form Survey (SF-12)|Short Pain Scale|Current Medications,RTI International|Womack Army Medical Center|Tripler Army Medical Center|Landstuhl Regional Medical Center,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,127,Other|U.S. Fed,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SGB-201,25-May-16,9-Jun-18,9-Jun-18,13-Mar-17,null,2-Aug-18,"Tripler Army Medical Center (TAMC), Honolulu, Hawaii, United States|Womack Army Medical Center (WAMC), Fort Bragg, North Carolina, United States|Landstuhl Regional Medical Center (LRMC), Landstuhl, Germany",,https://ClinicalTrials.gov/show/NCT03077919
NCT03078270,A Study of the Efficacy of Botox in the Treatment of Social Anxiety Disorder,,Terminated,Has Results,Anxiety Disorder Social|Anxiety,Drug: botulinum toxin A|Other: Placebo,Efficacy of of Botulinum Toxin A Reducing Symptoms of Social Anxiety Disorder,Daniel Lieberman|George Washington University,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,4,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",41641,1-Feb-17,12-Sep-17,12-Sep-17,13-Mar-17,23-Jan-19,23-Jan-19,"GW University Medical Faculty Associated, Washington, District of Columbia, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/70/NCT03078270/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03078270
NCT03078608,POEM (Practice Of Embracing Each Moment) STUDY,POEM,Completed,No Results Available,Distress|Cancer|Chemotherapy Effect,Behavioral: Mindfulness meditation program (administered via mobile app)|Behavioral: Progressive muscle relaxation (via mobile app),Change in anxiety and depression|Change in distress|Change in fatigue|Change in Pain|Change in sleep quality|Change in mindfulness|Change in Post Traumatic Growth,"Kaiser Permanente|American Cancer Society, Inc.",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,129,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,CN-17-2851,24-Oct-17,8-Nov-18,8-Nov-18,13-Mar-17,null,5-Dec-18,"Kaiser Permanente Northern California, Oakland, California, United States",,https://ClinicalTrials.gov/show/NCT03078608
NCT03078790,Implementing a Paced Deep Breathing Module to Decrease Preoperative Anxiety in Gynecological Surgery Patients,,Completed,No Results Available,Anxiety,Device: iPad,change from baseline anxiety score,Mayo Clinic,Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,38,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,16-005071,13-Mar-17,19-Jul-17,19-Jul-17,13-Mar-17,null,16-Apr-19,"Mayo Clinic, Rochester, Minnesota, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/90/NCT03078790/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03078790
NCT03074669,Online Acceptance and Commitment Therapy for Reducing Anxiety,,Unknown status,No Results Available,Anxiety Disorder/Anxiety State,Behavioral: ACT program,Changes in Anxiety Sensitivity Index (ASI)|Penn State Worry Questionnaire (PSWQ)|Social Phobia Inventory (SPIN)|Yale-Brown Obsessive Compulsive Scale (YBOCS)|Panic Disorder Severity Scale - Self Report (PDSS-SR)|Post-Traumatic Stress Disorder Checklist for the Diagnostic and Statistical Manual-5 (PCL-5)|Beck Depression Inventory-II (BDI-II)|Overall Anxiety Severity and Impairment Scale (OASIS)|Overall Depression Severity and Impairment Scale (ODSIS)|Acceptance and Action Questionnaire 2 (AAQ2)|Mindful Attention Awareness Scale (MAAS)|Believability of Anxious Feelings and Thoughts Questionnaire (BAFT)|Brief Multidimensional Experiential Avoidance Questionnaire (BMEAQ)|Quality of Life Inventory (QOLI)|Work and Social Adjustment Scale (WSAS),West University of Timisoara,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,80,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,WUTimisoara ACT-online,15-Mar-17,15-May-17,30-Jan-18,9-Mar-17,null,11-May-17,"West University of Timisoara, Timișoara, Timiș, Romania",,https://ClinicalTrials.gov/show/NCT03074669
NCT03075059,Child Life Intervention to Decrease Anxiety in Patients and Caregivers for Outpatient Surgical Intervention,,Recruiting,No Results Available,Surgery,Behavioral: Child Life,Patient and Parent/Guardian State and Trait Anxiety|Patient and Parent/Guardian PRAP scores,Ann & Robert H Lurie Children's Hospital of Chicago,All,6 Years to 17 Years   (Child),Not Applicable,44,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care,2016-161,Feb-16,Jun-18,Jun-18,9-Mar-17,null,8-Feb-18,"Ann & Robert H. Lurie Children's Hospital, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT03075059
NCT03073746,Google Health Search Trial,GHST,Completed,No Results Available,Diagnoses Disease,Other: Health Search|Other: Standard Search,Accuracy of patient's pre-visit differential diagnosis after Google searching on a tablet or mobile phone.|Accuracy of differential diagnosis of Health Search vs. Standard Search,Johns Hopkins University|Google Inc.,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,300,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Other,IRB00088552,7-Sep-16,9-Aug-17,15-Aug-17,8-Mar-17,null,15-Apr-19,"Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States|Johns Hopkins Hospital, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT03073746
NCT03072264,Randomized Clinical Trial of a Mindfulness Based Intervention in Generalized Anxiety Disorder,,Completed,No Results Available,Generalized Anxiety Disorder,Behavioral: Body in Mind Training (BMT)|Drug: Fluoxetine|Behavioral: Quality of Life Group,Mean Change From Baseline in Penn State Worry Questionnaire (PSWQ) Score|Mean Change From Baseline in Hamilton Anxiety Scale (HAM-A) Score|Mean Change From Baseline in Heart Rate variability (HRV)|Mean Change From Baseline in Error-Related Negativity (ERN)|Mean Change From Baseline in Quality of Life (WHOQOL) Scores,Hospital de Clinicas de Porto Alegre,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,200,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,160301,Oct-16,Dec-18,Dec-18,7-Mar-17,null,27-Feb-19,"Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil",,https://ClinicalTrials.gov/show/NCT03072264
NCT03068676,Internet-delivered Treatments for Depression and Anxiety in Primary Care (SUMMA),,Terminated,No Results Available,Depressive Disorder|Anxiety Disorders|Depression,Behavioral: Space from Depression|Behavioral: Space from Anxiety,Patient health Questionnaire|Generalized Anxiety Disorder|Socio-demographic Questionnaire|Work and Social Adjustment|Satisfaction with Treatment|Attitudes towards Psychological Online Interventions,Silver Cloud Health|Summa Health System,All,"18 Years to 100 Years   (Adult, Older Adult)",Not Applicable,12,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SUMMA-PC,8-Feb-17,8-Feb-18,9-Feb-18,3-Mar-17,null,10-Sep-18,"Summa Health, Akron, Ohio, United States",,https://ClinicalTrials.gov/show/NCT03068676
NCT03069677,Music vs Midazolam During Preop Nerve Block Placement,,Completed,No Results Available,Anxiety|Peripheral Nerve Block,Other: music|Drug: Midazolam,Spielberger State-Trait Anxiety Inventory 6|patient satisfaction scores of the experience during procedure|provider satisfaction scores of the experience during procedure|evaluation of difficulties in communication from provider to patient and patient to provider|block times|adverse effects,University of Pennsylvania,All,"18 Years and older   (Adult, Older Adult)",Phase 3,160,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,826754,12-Apr-17,11-May-18,11-May-18,3-Mar-17,null,6-Mar-19,"University of Pennsylvania, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT03069677
NCT03070587,A Pilot Study of Loving-Kindness Meditation for Social Anxiety Disorder,,Recruiting,No Results Available,Social Anxiety Disorder|Compassion,Behavioral: Positive Affect Training for SAD,Change from Baseline in the Liebowitz Social Anxiety Scale (LSAS)|Change from Baseline in Self-Compassion Scale (SCS)|Change from Baseline in Positive and Negative Affect Scale (PANAS)|Change from Baseline in compassion subscale of Differential Positive Emotions Scale,Komazawa University,All,"20 Years to 70 Years   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,1,Dec-16,Mar-19,Sep-22,3-Mar-17,null,12-Jan-18,"Kwansei Gakuin University, Nishinomiya, Hyogo, Japan",,https://ClinicalTrials.gov/show/NCT03070587
NCT03068286,iCBT for Long-term Conditions in IAPT,,Terminated,No Results Available,Diabetes|Chronic Pain|COPD|CHD - Coronary Heart Disease|Depression|Anxiety,Behavioral: Space in Diabetes|Behavioral: Space in COPD|Behavioral: Space in Chronic Pain,Depression (as measured by the Patient Health Questionnaire)|Anxiety (as measured by the 7 item Generalised Anxiety Disorder inventory)|Diabetes Distress (As measured by the Diabetes Distress Scale)|Pain Acceptance (As measured by the Pain Acceptance Questionnaire - revised)|Clinical COPD Symptoms (As measured by the Clinical COPD Questionnaire)|Quality of Life (As measured by the EuroQOL 5D5L)|Work and Social Adjustment (as measured by the Work and Social Adjustment Scale)|Patient Experience (As measured by the Patient Experience Questionnaire),Derek Richards|Silver Cloud Health,All,"25 Years to 80 Years   (Adult, Older Adult)",Not Applicable,20,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IAPTLTC,1-Jan-17,1-Jul-18,1-Jul-18,1-Mar-17,null,11-Sep-18,"Barnet, Enfield, and harringey Mental Health Trust, Enfield, United Kingdom",,https://ClinicalTrials.gov/show/NCT03068286
NCT03068429,Fear Conditioned Response in Healthy Subjects and in OCD Patients Pre and Post Treatment With Sertraline.,FEARCON,Recruiting,No Results Available,Obsessive-Compulsive Disorder,Drug: Sertraline Hydrochloride,"Main behavioral measure (extinction retention index)|Main functional neuroimaging measure|Main treatment outcome measure|Main behavioral measure baseline comparison (extinction retention index OCD patients versus healthy subjects)|Main functional neuroimaging measure (activation maps for contrast CS+E versus CS-during recall phase,OCD patients versus healthy subjects)|Secondary behavioral measure (learning- conditioning index, OCD patients pre and post treatment)|Secondary behavioral measure (learning- conditioning index, OCD patients versus healthy subjects)|Secondary Behavioral Measure (context discrimination index based on skin conductance, OCD patients pre and post treatment)|Secondary Behavioral Measure (context discrimination index based on skin conductance, OCD patients versus healthy subjects)|Secondary functional neuroimaging measure (functional activation maps for contrast CS+/CS- during conditioning phase, OCD patients pre and post treatment)|Secondary functional neuroimaging measure (functional activation maps for contrast CS+/CS- during conditioning phase, OCD patients versus healthy subjects)|Secondary functional neuroimaging measure (functional activation maps for contrast CS+E/CS- during recall phase of baseline measurement, OCD patients versus healthy subjects)|Secondary functional neuroimaging measure (functional activation maps for contrast CS+E/CS- during recall phase comparing change between post and pre treatment)",University of Sao Paulo,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,48,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,0182/11,1-Dec-16,20-Feb-19,30-Jun-19,1-Mar-17,null,27-Oct-17,"Institute of Psychiatry, Hospital das Clínicas, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil",,https://ClinicalTrials.gov/show/NCT03068429
NCT03066570,Graded Exposure in Patients With Painful Diabetic Neuropathy,PDN&GEXP,Recruiting,No Results Available,"Painful Diabetic Neuropathy|Diabetic Neuropathies, Painful|Neuralgia, Diabetic",Behavioral: Graded Exposure,"Quality of Life as measured with Norfolk Quality of Life Questionnaire, Diabetic Neuropathy Version (Norfolk-QOL-DN)",Maastricht University Medical Center,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,6,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NL 57919.068.16,1-Jun-17,1-Mar-19,1-Jun-19,28-Feb-17,null,5-Sep-18,"Maastricht University Medical Center, Maastricht, Limburg, Netherlands",,https://ClinicalTrials.gov/show/NCT03066570
NCT03064477,The Unified Protocol for the Treatment of Emotional Disorders in Spanish Public Mental Health System,,Recruiting,No Results Available,Emotional Disorder|Anxiety Disorders|Depressive Disorder,Behavioral: Unified Protocol|Behavioral: Cognitive Behavioral Therapy (TAU),Change in the severity of depressive symptoms|Change in the severity of anxiety symptoms|Change in quality of life|Change in the general tendency to worry|Change in obsessions and compulsions|Change in the severity of panic symptoms|Change in agoraphobia severity|Change in the severity of post-traumatic symptoms|Change in social anxiety symptoms|Change in the severity of hypochondriacal attitudes,Universitat Jaume I|Universidad de Zaragoza,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,200,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,UJIUP,14-Sep-14,30-Jun-19,31-Dec-19,27-Feb-17,null,21-Jun-18,"Hospital General Universitario de Elda, Elda, Spain|Clínica de Navarra, Pamplona, Spain|Hospital Comarcal de Vinaròs, Vinaroz, Spain",,https://ClinicalTrials.gov/show/NCT03064477
NCT03063931,Pain and Magnesium,,Unknown status,No Results Available,Neuropathic Pain Induced by Mastectomy,Drug: Magnesium: Magnésium UPSA Action Continue®|Drug: Placebo: Lactose,Measure of average pain intensity by a numerical rating scale|Pain assessment by the Neuropathic pain questionnaire|Evaluation of analgesic consumption|Cognitive assessment by Trail Making Test A and B|Quality of life assessment by EORTC QLQ-C30|Quality of life assessment by Pittsburg Sleep Quality Index (PSQI)|Anxiety and Depression assessment by DASS scale|Plasma and erythrocyte assays of magnesium|Creatinine dosage|Urine assays of magnesium,"University Hospital, Clermont-Ferrand",Female,"18 Years and older   (Adult, Older Adult)",Phase 2,100,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",CHU-306|2016-A01749-42,Mar-17,Mar-19,Apr-19,24-Feb-17,null,27-Feb-17,"CHU Clermont-Ferrand, Clermont-Ferrand, France",,https://ClinicalTrials.gov/show/NCT03063931
NCT03064061,Impact of Virtual Reality Before Oocytes Retrieval on Anxiety and Pregnancy Rate,,Recruiting,No Results Available,Anxiety|in Vitro Fertilization|Virtual Reality,Device: Virtual reality,impact of the virtual reality on the pregnancy rate (Ultrasound)|impact of the virtual reality on anxiety (numeric scale)|impact of the virtual reality on satisfaction|impact of the virtual reality on pregnancy test|state-trait Anxiety Inventory,Cliniques universitaires Saint-Luc- Université Catholique de Louvain,Female,18 Years to 42 Years   (Adult),Not Applicable,600,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Supportive Care",2016/20JUL/346,17-Feb-17,Mar-19,30-Jun-19,24-Feb-17,null,22-Mar-18,"Cliniques universitaires Saint-luc, Brussels, Belgium",,https://ClinicalTrials.gov/show/NCT03064061
NCT03060291,Prevention of Substance Use in At-Risk Students: A Family-Centered Web Program,,"Active, not recruiting",No Results Available,Substance Use|Conduct Disorders in Adolescence|Depression|Anxiety,"Behavioral: FCU-Online, web/ mobile only|Behavioral: FCU-Online, web/ mobile + coach",Change from Baseline in Youth Behavioral Control across 12 months (parent report)|Change from Baseline in Youth Behavioral Control across 12 months (youth report)|Change from Baseline in Youth Substance Use across 12 months (parent report)|Change from Baseline in Youth Substance Use across 12 months (youth report)|Change from Baseline in Youth Problem Behavior across 12 months (parent report)|Change from Baseline in Youth Problem Behavior across 12 months (youth report)|Change from Baseline in Family Conflict across 12 months (parent report)|Change from Baseline in Family Conflict across 12 months (youth report)|Change from Baseline in Positive Family Relationships across 12 months (parent report)|Change from Baseline in Positive Family Relationships across 12 months (youth report)|Change From Baseline in Positive Behavior Support across 12 months (parent report)|Change from Baseline in Limit Setting across 12 months (parent report)|Change from Baseline in Monitoring across 12 months (parent report)|Change from Baseline in School Involvement across 12 months (parent report)|Change from Baseline in Parenting Self-Efficacy across 12 months (parent report),University of Oregon|National Institute on Drug Abuse (NIDA),All,"Child, Adult, Older Adult",Not Applicable,347,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,R01DA037628,21-Feb-17,30-Sep-19,30-Sep-19,23-Feb-17,null,15-Oct-18,"University of Oregon, Portland, Oregon, United States",,https://ClinicalTrials.gov/show/NCT03060291
NCT03061448,Internet-based Exposure Therapy for Panic Disorder,,Completed,No Results Available,Panic Disorder With Agoraphobia,Behavioral: Internet-based cognitive-behavior therapy,Panic Disorder Severity Scale - Self rated (PDSS-SR)|Credibility/Expectancy Questionnaire (CEQ)|Client Satisfaction Questionnaire (CSQ)|Adverse events scale|Patient Health Questionnaire (PHQ-9)|Anxiety Sensitivity Index (ASI)|Agoraphobic Cognitions Questionnaire (ACQ)|Body Sensations Questionnaire (BSQ)|Brunnsviken Quality of Life Questionnaire (BBQ)|WHO Disability Assessment Schedule 2.0 (WHODAS 2.0)|Generalised Anxiety Disorder Assessment (GAD-7)|The Cardiac Anxiety Questionnaire (CAQ)|HA-NI-SSD Symptom Preoccupation Scale - testversion (SPSt),Karolinska Institutet,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,61,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2016/2422-31,1-Feb-17,1-Jun-17,1-Jun-17,23-Feb-17,null,22-Aug-17,"Karolinska Institutet, Stockholm, Sweden",,https://ClinicalTrials.gov/show/NCT03061448
NCT03061864,The Periviable Birth Plan,,Recruiting,No Results Available,"Pregnancy, High Risk|Parturition Complication as Antepartum Condition|Anxiety|PTSD|PreTerm Birth",Behavioral: Periviable Birth Plan,Change in Anxiety Scores|Change in PTSD Scores,Albany Medical College,Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,54,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,4622,Aug-16,Aug-19,Aug-19,23-Feb-17,null,23-Feb-17,"Albany Medical Center, Albany, New York, United States",,https://ClinicalTrials.gov/show/NCT03061864
NCT03062202,Internet-delivered Cognitive Behaviour Therapy at Step 3 of IAPT,ICBT@STEP3,Completed,No Results Available,Depression|Anxiety,Behavioral: SilverCloud,Changes in depression symptoms (as measured by the 9 item Patient Health Questionnaire)|Changes in anxiety symptoms (as measured by the 7 item Generalised Anxiety Disorder inventory)|Work and Social Adjustment|Social Phobia|Obsessive Compulsive Tendencies|Heath Anxiety|Avoidance Behaviours|Responses to Traumatic Events|Patient Experience|Therapeutic Alliance for patients|Usability and Acceptability of the iCBT platforms for clinicians.|Therapeutic Alliance for clinicians|Qualitative Investigation into Therapeutic Alliance for Clinicians,"Derek Richards|Silver Cloud Health|University of Dublin, Trinity College",All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,126,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ICBT@STEP3,12-Dec-16,25-Sep-17,25-Sep-17,23-Feb-17,null,10-May-18,"Sussex Community NHS Trust, Brighton, United Kingdom",,https://ClinicalTrials.gov/show/NCT03062202
NCT03054077,REducing Anxiety in CHildren Undergoing Procedures,REACH-UP!,Completed,Has Results,Ambulatory Surgery,Other: iPad with downloaded games,Change in Anxiety Scores With the Addition of the iPad Intervention-Comparing Group 1 to Group 2,Virginia Commonwealth University,All,4 Years to 12 Years   (Child),Not Applicable,24,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Supportive Care,HM200008056,10-Mar-17,19-May-17,19-May-17,15-Feb-17,10-Oct-17,10-Oct-17,"Virginia Commonwealth University Health System, Richmond, Virginia, United States","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/77/NCT03054077/Prot_SAP_ICF_000.pdf",https://ClinicalTrials.gov/show/NCT03054077
NCT03052660,Impact of Preoperative Midazolam on Outcome of Elderly Patients,I-PROMOTE,Recruiting,No Results Available,Preanesthetic Medication,Drug: Midazolam|Drug: Placebo oral capsule,"Global patient satisfaction on the first postoperative day|Cognitive testing|Delirium testing|Preoperative anxiety|Quality of Life|Activities of daily living|Perception of pain, well-being, and sleeping|Number of participants with adverse events and serious adverse events|Patient cooperation|Anaesthesia related data|Surgery related data|Rescue benzodiazepine application|Patients vital data|Mortality|Major adverse events|Hospital length of stay|Intensive care unit length of stay",RWTH Aachen University,All,65 Years to 80 Years   (Older Adult),Phase 4,614,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",16-115,12-Oct-17,Apr-19,May-19,14-Feb-17,null,12-Feb-19,"Department of Anesthesiology, University Hospital Aachen, Aachen, NRW, Germany|Klinik für Anästhesiologie und Operative Intensivmedizin, Universitätsklinikum Bonn, Bonn, NRW, Germany|Klinik für Anästhesiologie, Universitätsklinikum Düsseldorf, Dusseldorf, NRW, Germany|Marien-Hospital Herne, Herne, Germany|Universitätsklinikum Magdeburg A.ö.R., Magdeburg, Germany|Department of Anaesthesiology, University Hospital Klinikum rechts der Isar Munich, Munich, Germany|LMU München, München, Germany|Kreiskliniken Reutlingen, Klinikum am steinenberg, Reutlingen, Germany|Klinik für Anästhesiologie und Intensivmedizin, Universitätsklinikum Tübingen, Tubingen, Germany",,https://ClinicalTrials.gov/show/NCT03052660
NCT03051074,Examining the Effects of Reduced Environmental Stimulation on Anxiety,,Recruiting,No Results Available,Generalized Anxiety Disorder|Agoraphobia|Panic Disorder|PostTraumatic Stress Disorder|Social Anxiety Disorder|Major Depressive Disorder,Behavioral: Floating|Behavioral: Comparison,"Spielberger State Anxiety Inventory (STAI-S) change score|Blood pressure changes during the float experience|Heart rate variability changes during the float experience|EEG changes during the float experience|Brain activation and connectivity changes from pre- to post-float as measured with functional magnetic resonance imaging (fMRI)|Bioassay changes in magnesium, sulfate, cortisol, and inflammatory markers|Subjective changes in emotion and mood","Laureate Institute for Brain Research, Inc.",All,18 Years to 55 Years   (Adult),Not Applicable,100,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,2015-002 Float-Anxiety,Dec-16,Dec-19,Dec-19,13-Feb-17,null,5-Mar-19,"Laureate Institute for Brain Research, Tulsa, Oklahoma, United States",,https://ClinicalTrials.gov/show/NCT03051074
NCT03047915,Music in the Emergency Department (ED),,"Active, not recruiting",No Results Available,Anxiety,Other: Music,Mean Change in STAI Score|Mean Change in Heart Rate (HR)|Mean Change in Blood Pressure (BP),Columbia University,All,65 Years and older   (Older Adult),Not Applicable,143,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,AAAQ3016,Jun-16,Oct-17,Dec-19,9-Feb-17,null,9-Apr-19,"Columbia University Medical Center, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT03047915
NCT03044678,School Based Prevention for Childhood Anxiety,,Completed,No Results Available,Anxiety Disorders,Behavioral: REACH for Success|Behavioral: Self-Study,Change in child anxiety symptoms (clinical)|Change in child anxiety levels (typical)|Changes in child negative cognition|Changes in emotion understanding and expression|Changes in self efficacy|Changes in child social skills|Changes in somatic arousal,Arizona State University,All,8 Years to 11 Years   (Child),Not Applicable,109,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Prevention",MH086687,1-Jan-10,1-Jan-15,1-Jan-15,7-Feb-17,null,7-Feb-17,,,https://ClinicalTrials.gov/show/NCT03044678
NCT03043430,Intranasal Ketamine for Anxiolysis in Pediatric Emergency Department Patients,,Unknown status,No Results Available,Anxiety|Pediatric ALL|Procedural Anxiety,Drug: Ketamine 100 MG/ML|Drug: Midazolam 5 MG/ML,Change in mYPAS|Change in sedation scale|Change in pain rating (Wong-Baker Pain Faces Rating Scale)|Change in anxiety score (Visual analogue scale),Brooke Army Medical Center,All,2 Years to 12 Years   (Child),Phase 4,80,U.S. Fed,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",C.2016.021,May-16,Jun-17,Jul-17,6-Feb-17,null,6-Feb-17,"San Antonio Military Medical Center, Fort Sam Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT03043430
NCT03043833,Internet-Delivered Cognitive Behavior Therapy for Anxiety and Depression Amongst French Canadians,,Completed,No Results Available,Major Depression|Anxiety Disorders,Behavioral: The Wellbeing Course,Changes in depression as assessed by the Patient Health Questionnaire-9 (PHQ-9)|Changes in anxiety as assessed by the Generalized Anxiety Disorder-7 (GAD-7)|Changes in life satisfaction as assessed by the Satisfaction with Life Scale (SWLS)|Changes in health as assessed by the Short-Form Health Survey|Changes in personality as assessed by the Self-administered Standardised Assessment of Personality - Abbreviated Scale|Changes in anxiety as assessed by the Penn State Worry Questionnaire (PSWQ)|Changes in social anxiety as assessed by the Social Phobia Inventory (SPIN)|Changes in panic and agoraphobia as assessed by the Panic and Agoraphobia Scale (PAS),"Universite de Moncton|Macquarie University, Australia",All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,64,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,File 1516-077,18-Jan-17,30-Jan-18,30-Mar-18,6-Feb-17,null,1-May-18,"Université de Moncton - Adult Clinical Psychology Laboratory, Moncton, New Brunswick, Canada",,https://ClinicalTrials.gov/show/NCT03043833
NCT03037905,Effect of the Built Operating Room Environment on Patient Outcome,,Completed,Has Results,Anxiety,Device: SignatureSuite OR Integration System by STERIS Corporation,Change (Difference) in Anxiety|Difference Between Pre-operative Systolic Blood Pressure and a Mean of 3 Post-operative Systolic Blood Pressures|Difference Between Pre-operative Heart Rate and a Mean of 3 Post-operative Heart Rates,The Cleveland Clinic|STERIS Corporation,All,"18 Years to 90 Years   (Adult, Older Adult)",Not Applicable,100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CCF15-009,Jan-15,May-16,May-16,31-Jan-17,22-Nov-17,19-Dec-17,"Cleveland Clinic Marymount Hospital, Garfield Heights, Ohio, United States",,https://ClinicalTrials.gov/show/NCT03037905
NCT03036293,"Clinical Trial of Tenoten® in the Treatment of Anxiety in Patients With Somatoform, Stress-related and Other Neurotic Disorders",,Completed,No Results Available,Anxiety,Drug: Tenoten|Drug: Placebo,"Change from baseline in the mean HAM-A score at 12 weeks of treatment in patients from: 1. Group 1 (Tenoten®, 4 tablets a day); 2. Group 3 (Tenoten®, 8 tablets a day).|Change from baseline in the mean HAM-A score at 4 weeks of treatment in patients from: 1.1. Group 1 (Tenoten®, 4 tablets a day); 1.2. Group 3 (Tenoten®, 8 tablets a day).|The mean HAM-A score at 8 weeks of treatment versus baseline in patients from: 2.1. Group 1 (Tenoten®, 4 tablets a day); 2.2. Group 3 (Tenoten®, 8 tablets a day).|Percentage of patients achieving at least a 50% improvement in the HAM-A score from baseline in: 3.1. Group 1 (Tenoten®, 4 tablets a day) 3.1.1. at 4 weeks; 3.1.2. at 8 weeks; 3.1.3. at 12 weeks; 3.2. Group 3 (Tenoten®, 8 tablets a day) 3.2.1. at|Percentage of patients with no anxiety (HAM-A score <14) in: 4.1. Group 1 (Tenoten®, 4 tablets a day) 4.1.1. at 4 weeks; 4.1.2. at 8 weeks; 4.1.3. at 12 weeks;|Change from baseline in the total EQ-5D-3L score at 12 weeks of treatment in patients from: 5.1. Group 1 (Tenoten®, 4 tablets a day); 5.2. Group 3 (Tenoten®, 8 tablets a day).|Total CGI scores in patients from: 6.1. Group 1 (Tenoten®, 4 tablets a day); 6.2. Group 3 (Tenoten®, 8 tablets a day).",Materia Medica Holding,All,18 Years to 45 Years   (Adult),Phase 4,390,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MMH-TN-001,8-Feb-17,22-Sep-18,22-Sep-18,30-Jan-17,null,20-May-19,"Kazakh National Medical University named after S.D. Asfendiyarov, Almaty, Kazakhstan|South - Kazakhstan State Pharmaceutical Academy, Shymkent, Kazakhstan|Municipal Autonomous Healthcare Institution Order of the Red Banner of Labor City Clinical Hospital No. 1, Chelyabinsk, Russian Federation|Federal State Budgetary Educational Institution of Higher Education ""Kazan Medical University"" of the Ministry of Healthcare of the Russian Federation, Kazan', Russian Federation|The State Autonomic Health Care institution ""Interregional clinical and diagnostical center"", Kazan', Russian Federation|LLC ""City Center for Neurology and Pain Management"", Kazan', Russian Federation|Limited Liability Company ""Family policlinic no. 4"", Korolev, Russian Federation|State Budget Health Care institution of Moscow the City ""Scientific and practical psychoneurological center n.a. Z.P. Solovyov"" of the Administration of Health Care of Moscow City, Moscow, Russian Federation|The State Budget Health Care institution of Moscow the City ""City clinical hospital No. 12 of the Administration of Health Care of Moscow City"", Moscow, Russian Federation|Pirogov Russian National Research Medical University, Moscow, Russian Federation|The State Budget Educational institution of High Professional Training I.M. Sechenov First Moscow State Medical University of Ministry of Health Care of the Russian Federation, Hospital of nervous diseases A.Y. Kozhevnikov, Moscow, Russian Federation|State budgetary institution of public health services of the Nizhniy Novgorod region ""Nizhegorod Regional Clinical Hospital named after NA Semashko"", Nizhny Novgorod, Russian Federation|LLC ""City Neurological Center"" Sibneyromed "", Novosibirsk, Russian Federation|Pavlov First Saint Petersburg State Medical University, Saint Petersburg, Russian Federation|State-Funded Healthcare Institution of the Samara Region ""Samara City N.I. Pirogov Clinical Hospital №1"", Samara, Russian Federation|Saratov State Medical University named after V. I. Razumovsky, Saratov, Russian Federation|The State Budget Educational institution of High Professional Training Smolensk State Medical University of Ministry of Health Care of the Russian Federation, Smolensk regional clinical hospital, Smolensk, Russian Federation|The state budgetary health care institution of the Vladimir region ""Regional Clinical Hospital"", Vladimir, Russian Federation|Volgograd State Medical University, Volgograd, Russian Federation|The State Health Care Institution Yaroslavl region ""Clinical Hospital №8, Yaroslavl', Russian Federation|State Institution of Health of the Yaroslavl Region Clinical Hospital No. 8, Yaroslavl, Russian Federation",,https://ClinicalTrials.gov/show/NCT03036293
NCT03036371,Pilot Study of the Impact of Exercise on Hippocampal Function,,Completed,No Results Available,Anxiety,Behavioral: High Intensity Interval Exercise,"Change in Percent Correct Score for the Treasure Hunt Task (THT)|Change in Percent Correct Score for the Mnemonic Similarity Test (MST)|Change in Depression, Anxiety, and Stress Scale (DASS)|Change in Intolerance of Uncertainty Scale (IUS)|Change in Baecke Physical Activity Questionnaire",New York State Psychiatric Institute|Columbia University,All,18 Years to 40 Years   (Adult),Not Applicable,14,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,7418,28-Mar-17,13-Sep-18,13-Sep-18,30-Jan-17,null,27-Mar-19,"New York State Psychiatric Institute, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT03036371
NCT03036397,"Effects of SRX246, a Vasopressin Receptor (V1a) Antagonist, on an Experimental Model of Fear and Anxiety in Humans",,Recruiting,No Results Available,Anxiety Disorder|Fear,Drug: SRX246|Drug: Placebo,Fear and anxiety potentiated startle|Skin conductance|Subjective Anxious Mood|Latency of emotion recognition|Accuracy of emotion recognition,National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC),All,21 Years to 50 Years   (Adult),Phase 1,47,NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",170046|17-M-0046,3-Mar-17,31-Dec-30,31-Dec-30,30-Jan-17,null,11-Apr-19,"National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT03036397
NCT03033628,"Pain Perception of Dental Local Anesthesia Using ""DentalVibe Comfort System"" in a Group of Egyptian Children",,Unknown status,No Results Available,Dental Anxiety,Device: injection using DentalVibe comfort system|Device: traditional dental injection,pain during injection,Cairo University,All,6 Years to 7 Years   (Child),Not Applicable,21,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other,CEBC-CU-2017-01-06,1-Apr-17,1-Jun-17,1-Jan-18,27-Jan-17,null,15-Feb-17,,,https://ClinicalTrials.gov/show/NCT03033628
NCT03034720,Collaborative Care Model for the Treatment of Persistent Symptoms After Concussion Among Youth,,Recruiting,No Results Available,"Concussion, Brain|TBI|Depression|Anxiety",Behavioral: Collaborative Care,Post-concussive symptoms measured with the HBI|Health related quality of life as measured with the PedsQL|Depressive symptoms measured by the PHQ-9|Anxiety symptoms measured by the GAD-7|Anxiety symptoms measured by the RCADS|School performance as measured by GPA|Return to full activities at school as measured by the CLASS,Seattle Children's Hospital,All,"11 Years to 18 Years   (Child, Adult)",Not Applicable,200,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,STUDY00000437,9-Mar-17,Feb-21,Feb-21,27-Jan-17,null,16-May-19,"Seattle Childrens Hospital, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT03034720
NCT03035019,Reducing Stress in Primary Care Patients,,Completed,No Results Available,Stress,Behavioral: Lantern,GAD7 scores (anxiety) completion.|Patient satisfaction/acceptability post program|Quality of life (SF-12)|medical utilization,University of Pittsburgh,All,"20 Years to 65 Years   (Adult, Older Adult)",Not Applicable,593,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,16040173,1-Jul-16,1-Jun-18,1-Jun-18,27-Jan-17,null,6-Dec-18,"University of Medical Center, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT03035019
NCT03031990,Stress and Fertility: How to Lower Stress When Trying to Conceive,,Unknown status,No Results Available,"Anxiety|Infertility, Female",Behavioral: In-person yoga for fertility group|Behavioral: Online yoga for fertility group|Behavioral: In person discussion only group,Stress levels pre and post intervention between groups using STAI|Stress levels pre and post intervention between groups using FPI|Difference between mean pre and post STAI test scores between in person and online yoga for fertility programs|Difference between mean pre and post FPI test scores between in person and online yoga for fertility programs|Influence of ethnicity on baseline stress levels and reduction in stress using the STAI|Influence of ethnicity on baseline stress levels and reduction in stress using FPI|Influence of age on baseline stress levels and reduction in stress using STAI|Influence of age on baseline stress levels and reduction in stress using FPI|Influence of number of previous IVF failures on baseline stress levels and reductions in stress using STAI|Influence of number of previous IVF failures on baseline stress levels and reductions in stress using FPI|Influence of yoga participation on number of days required for ovarian stimulation|Influence of yoga participation on number of oocytes obtained|Influence of yoga participation on number of mature (M2) oocytes|Influence of yoga participation on fertilization rate|Influence of yoga participation on number of high quality embryos (as evidenced by embryologists embryo grading criteria)|Influence of yoga participation on rates of positive pregnancy test|Influence of yoga participation on clinical pregnancy rate|Influence of yoga participation on ongoing pregnancy/live birth rate,"Fertility Centers of Illinois|Pulling Down the Moon, Holistic Health|Rush University Medical Center",Female,24 Years to 42 Years   (Adult),Not Applicable,300,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,15121505,Jan-17,Mar-17,Apr-17,26-Jan-17,null,20-Feb-17,"Fertility Centers of Illinois, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT03031990
NCT03032952,The Efficacy of a Mobile Application for Treating Depression and Anxiety Symptoms,,Completed,No Results Available,"Stress, Psychological|Depression|Anxiety","Other: ""Feel Stress Free"" mobile application",Hospital Anxiety and Depression Scale (HADS)|1 Patient Health Questionnaire (PHQ-9),"University College, London|University of Roehampton",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,168,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,8227/001,Feb-16,Oct-16,Oct-16,26-Jan-17,null,26-Jan-17,,,https://ClinicalTrials.gov/show/NCT03032952
NCT03030482,Evaluation of Touch Massage on Anxiety in Critically Ill Patients,REaLAX,Recruiting,No Results Available,Anxiety,Procedure: touch massage,"Measure the anxiolytic value of touch massage to critically ill patient, awake, communicating|Measure the correlation between the Spielberger STAI Y-A (short form) anxiety scale and the Anxiety Visual Anxiety Scale (EVA-A).|Measure the analgesic effect of touch massage to critically ill patient awake, communicating",Versailles Hospital,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,70,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,P14/10_REaLAX,20-Apr-17,30-Dec-19,30-Dec-19,25-Jan-17,null,9-Aug-18,"Versailles Hospital, Le Chesnay, Yvelines, France",,https://ClinicalTrials.gov/show/NCT03030482
NCT03031002,Extinction Generalization in Exposure Therapy,,Completed,No Results Available,Specific Phobia,Behavioral: Exposure treatment for spider fear,Change in the Behavioral Approach Test (BAT) from pre- to posttreatment|Change in Subjective Fear / Disgust during the Behavioral Approach Tests (BATs) using the Subjective Units of Distress Scale (SUDS)|Change in Heart Rate during the Behavioral Approach Tests (BATs) from pre- to posttreatment|Change in the Fear of Spiders Questionnaire (FSQ)|Change in the Spider Phobia Questionnaire (SPQ)|Change in the Spider Beliefs Questionnaire (SBQ),Ruhr University of Bochum,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,77,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ZL 59/2-2,Feb-15,Jul-16,Jul-16,25-Jan-17,null,25-Jan-17,,,https://ClinicalTrials.gov/show/NCT03031002
NCT03028792,Attention Training for Underserved Youth With Anxiety,,Recruiting,No Results Available,Anxiety,Behavioral: Attention Modification Program|Behavioral: Attention Control Condition,"Change in Clinical Global Impression-Severity (CGI-S) and Improvement, (CGI-I) Scales, Pre- to Post-Treatment|Change in Attention Network Task Pre- to Post-Treatment|Change in Visual search task Pre to Post-Treatment|Change in Pediatric Anxiety Rating Scale Pre to Post-treatment|Change in Screen for Child Anxiety Related Emotional Disorders (SCARED) Pre- to Post-Treatment","University of California, Los Angeles",All,8 Years to 17 Years   (Child),Not Applicable,52,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",IRB#15-000334,1-Sep-17,1-Sep-19,30-Oct-19,23-Jan-17,null,8-May-18,"Clinicas de Salud del Pueblo healthcare system, El Centro, California, United States",,https://ClinicalTrials.gov/show/NCT03028792
NCT03023267,"The Contribution of Parent-infant Interaction While Singing During Kangaroo Care, on Preterm-infants' Autonomic Stability and Parental Anxiety Reduction",,Recruiting,No Results Available,PreTerm Birth|Stress Reaction,Behavioral: Music therapy and Kangaroo care|Behavioral: Kangaroo Care alone,parasympathetic tone,Meir Medical Center,All,up to 18 Weeks   (Child),Not Applicable,50,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care",0283-15-MMC,28-Aug-17,22-Mar-19,Oct-19,18-Jan-17,null,17-Aug-18,"Neonatal Intensive Care Unit, Kfar-Saba, Israel",,https://ClinicalTrials.gov/show/NCT03023267
NCT03023501,Effect of Gabapentin on Postoperative Morphine Consumption After Sleeve Gastrectomy,,Completed,No Results Available,Postoperative Complications,Drug: Gabapentin|Drug: Placebo Oral Capsule,Post operative Morphine requirement|Post operative pain|Preoperative anxiety,King Saud University,All,18 Years to 50 Years   (Adult),Phase 2,50,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",E-13-902,Mar-14,Jan-17,Jan-17,18-Jan-17,null,18-Jan-17,,,https://ClinicalTrials.gov/show/NCT03023501
NCT03024151,The Effects of T4 Versus T4/T3 on Psychological Distress After Total Thyroidectomy in Thyroid Cancer Patients,,Completed,No Results Available,Thyroid Cancer|Distress|Depression|Anxiety|Fatigue,Drug: Comthyroid|Drug: Synthroid,Psychological distress (depression or anxiety) assessed with HADS|Fatigue assessed with MDASI-F|Depression assessed with BDI|Anxiety assessed with BAI|Fatigue assessed with BFI|Response rate using BDI|Response rate using BAI|Response rate using BFI|Remisssion rate using BDI|Remission rate using BAI|Remission rate using BFI,Inje University|Dongnam Institute of Radiological & Medical Sciences,All,"20 Years to 70 Years   (Adult, Older Adult)",Not Applicable,150,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2016-05-010-001,Dec-16,Nov-17,Nov-17,18-Jan-17,null,22-Feb-19,"Dong sik Bae, Busan, Korea, Republic of|Dongsik Bae, Busan, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT03024151
NCT03019497,Cognitive-behavioral Therapy for Treatment of Post-traumatic Stress Disorder and Related Problems,CBT-PTSD-RP,Not yet recruiting,No Results Available,PTSD,Behavioral: Specific Modules|Behavioral: Cognitive behavioral therapy,"Change from Baseline in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5; Weathers et al., 2013)|The Structured Clinical Interview (SCID-I; First, Spitzer, Gibbon & Williams, 1995)|The Beck II Depression Inventory (BDI-II; Beck, Steer & Brown, 1996)|The Beck Anxiety Inventory (BAI; Beck, Epstein, Brown & Steer, 1988)|The WHOQOL - Bref (WHOQOL Group, 1998)|The Inventory of Social Support in Anxious Situations (ISSAS; St-Jean-Trudel et al., 2005)|The Pittsburgh Sleep Quality Index (PSQI)|The Life Events Questionnaire (LEQ; Norbeck, 1984)|The Brief Pain Inventory (BPI; Cleeland, 1989)|The Health Cost Interview|The Social Provisions Scale (SPS; Cutrona & Russel, 1987)|The Posttraumatic Stress Disorder Checklist Scale-version DSM-5 (PCL-5; Weathers, Litz et al., 2013)",Université de Montréal|Centre de Recherche de l'Institut Universitaire en santé Mentale de Montréal,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,134,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,365935,Jan-17,Jun-21,Dec-21,12-Jan-17,null,13-Jan-17,"Stephane Guay, Montreal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT03019497
NCT03017508,Acute Anxiolytic Effects of Riluzole on Subjects With Social Anxiety Disorder,,Recruiting,No Results Available,Social Anxiety Disorder|Performance Anxiety,Drug: BHV-0223|Drug: Placebo,VAS-anxiety after the impromptu speech task,"Yale University|Biohaven Pharmaceuticals, Inc.",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2|Phase 3,20,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",1605017768,Jan-17,Dec-18,Oct-19,11-Jan-17,null,13-Jan-17,"Connecticut Mental Health Center, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT03017508
NCT03018145,Effect of Transportation Method on Preoperative Anxiety in Children,,Completed,No Results Available,Anxiety|Child Behavior,Device: Wagon|Device: Standard stretcher car,Preoperative anxiety score using the Modified Yale Preoperative Anxiety Scale,Chonnam National University Hospital,All,2 Years to 7 Years   (Child),Not Applicable,80,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CNUH-2016-185,12-Jan-17,25-Mar-17,20-Apr-17,11-Jan-17,null,2-Jan-18,"Chonnam National University Hospital, Gwangju, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT03018145
NCT03015285,CBT for Anxiety Sensitivity vs. Disorder-specific CBT: An RCT,,Not yet recruiting,No Results Available,"Generalized Anxiety|Stress Disorder, Posttraumatic|Social Anxiety|Major Depression|Panic Disorder",Behavioral: Cognitive Behavioural Therapy,"Change in anxiety sensitivity: the Anxiety Sensitivity Index - 3 (ASI-3)|Change in primary diagnosis (e.g., anxiety disorder or depression) symptoms|Change in comorbid diagnosis (e.g., anxiety disorders or depression) symptoms|Diagnostic status as measured by the Structured Clinical Interview for DSM-5 (SCID-5)|General distress as measured by the Depression Anxiety Stress Scale (DASS-21)|General distress as measured by the Clinical Outcomes in Routine Evaluation measure (CORE-10)|Functional disability as measured by the Sheehan Disability Scale (SDS)|Drinking Motives as measured by the Modified Drinking Motives Questionnaire - Revised (MDMQ-R)|Hazardous alcohol use as measured by the Alcohol Use Disorders Identification Test (AUDIT)|Alcohol-related problems as measured by the Short Inventory of Problems (SIP-2R)|Treatment alliance as measured by the Working Alliance Inventory - Short-form (WAI-SR)|Treatment satisfaction as measured by several short researcher-generated questions",Sherry Stewart|University of New Brunswick|Canadian Institutes of Health Research (CIHR)|Dalhousie University|Nova Scotia Health Authority,All,"19 Years and older   (Adult, Older Adult)",Not Applicable,136,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,1021903,Jan-17,Aug-19,Aug-19,10-Jan-17,null,10-Jan-17,,,https://ClinicalTrials.gov/show/NCT03015285
NCT03015662,"Clinical Outcomes After Dry Needling on Cervical Muscles, and Quality of Life, in Patients With Fibromyalgia Syndrome.",,Completed,No Results Available,Fibromyalgia,Other: Dry Needling Therapy|Other: Myofascial Release Therapy,Active and Latent Myofascial Trigger Points (Number of trigger Points)|Quality of Life (SF-36 quality of life questionnaire)|Impact of Fibromyalgia Symptoms (Fibromyalgia Impact Questionnaire)|Quality of Sleep (Pittsburgh Quality of Sleep Questionnaire Index)|Pain (Visual Analog Scale)|Anxiety levels (State-Trait Anxiety Inventory )|State of depression (Beck Depression Inventory)|Impact of fatigue (Fatigue Impact Scale ),Universidad de Almeria,All,18 Years to 60 Years   (Adult),Not Applicable,64,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,UAL-428,Jan-16,Feb-17,Aug-17,10-Jan-17,null,19-Oct-17,"University of Almeria, Almeria, Spain",,https://ClinicalTrials.gov/show/NCT03015662
NCT03016052,Visual Mismatch Negativity in Attention Bias Modifcation Treatment for Anxiety,,Completed,No Results Available,Social Anxiety Disorder|Generalized Anxiety Disorder,Behavioral: ABMT,Change from baseline - the Liebowitz Social Anxiety Scale - Diagnostic Interview scores|Change from baseline - The Generalized Anxiety Disorder Severity Scale|Change from baseline - the Social Phobia Inventory scores|Change from baseline - the Penn State Worry Questionnaire|Change from baseline - the GAD-7,Tel Aviv University,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,80,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TAUvMMN,May-16,Sep-17,Oct-17,10-Jan-17,null,17-Nov-17,"Tel Aviv University, Tel Aviv, Israel",,https://ClinicalTrials.gov/show/NCT03016052
NCT03016572,Promote Access to Stop Suicide: Comparison of Follow up Services for Youth at Risk for Suicide,PASS,Recruiting,No Results Available,"Suicide|Depressive Disorder, Major|Anxiety Disorders|Suicidal Ideation|Suicidal Impulses",Behavioral: Standard of Care|Behavioral: Crisis Intervention|Behavioral: Wraparound Services,Frequency of repeat suicide attempts in adolescents.|Frequency of readmissions after a suicide attempt in adolescents.|Relation between service type and frequency of repeat suicide attempts in adolescents.|Relation between service type and frequency of readmissions after a suicide attempt in adolescents.,The Cleveland Clinic|Case Western Reserve University,All,"10 Years to 18 Years   (Child, Adult)",Not Applicable,135,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Care Provider, Investigator)|Primary Purpose: Treatment",16-886,4-May-17,Dec-20,Dec-20,10-Jan-17,null,29-Jun-18,"Cleveland Clinic Fairview Hospital, Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT03016572
NCT03014050,Bio Electro Stimulation Therapy for Parkinson's Disease,BEST,"Active, not recruiting",No Results Available,Parkinson Disease,Device: e-Tapper TT-R1,Physical activity|Visuospatial Cognition|Mood|Sleep quality|Resting tremor|Gait|Perceived pain|Quality of life and subjective health status|Physical activity - Other|Functional Fitness|Cognition - Language|Cognition - Cognitive Control|Cognition - learning and memory,Boston University,All,"50 Years to 75 Years   (Adult, Older Adult)",Not Applicable,66,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,H-34609|BEST-PD2017,22-Sep-17,1-Jun-19,1-Jun-19,9-Jan-17,null,9-May-19,"Boston University School of Medicine, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT03014050
NCT03014466,Screen-Based Distraction Tool for Preoperative Preparation,,Completed,No Results Available,Anxiety,Behavioral: Use of Video Projector|Behavioral: Use of Video Tablet,Anxiety at Induction of Anesthesia|Induction Compliance,Stanford University,All,4 Years to 10 Years   (Child),Not Applicable,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,IRB-37577,Jan-17,Jan-18,Jan-18,9-Jan-17,null,1-Oct-18,,,https://ClinicalTrials.gov/show/NCT03014466
NCT03012035,The Role of Treatment Expectation in Exposure Training With Spider Fearful Participants,,Completed,No Results Available,Phobic Disorders,Other: positive treatment expectations|Other: neutral treatment expectations,Change in subjective anxiety assessed by questionnaire,"University Hospital, Basel, Switzerland",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,70,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other,SPFE 2017,18-May-17,12-Mar-18,12-Mar-18,6-Jan-17,null,21-Mar-18,"Department of Clinical Psychology and Psychotherapy University of Basel, Basel, Switzerland",,https://ClinicalTrials.gov/show/NCT03012035
NCT03013777,A Trial of Cognitive Behavioral Therapy in Familial Dysautonomia,,Completed,No Results Available,Dysthymia|Anxiety Disorders|Familial Dysautonomia|Paroxysmal Hypertension|Autosomal Recessive Disease,Behavioral: 8-week CBT Program,Patient Health Questionnaire (PHQ-9) depression scale|Rosenberg Self-Esteem Scale|State-Trait Anxiety Inventory (STAI),New York University School of Medicine,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,15,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,16-01823,6-Dec-16,20-Jul-18,20-Jul-18,6-Jan-17,null,29-Jan-19,"New York University School of Medicine, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT03013777
NCT03011658,Serum Cortisol Levels in Patients With Anxiety and Depression With Symptomatic Oral Lichen Planus,,Completed,No Results Available,Oral Lichen Planus Related Stress,Procedure: venepuncture,Serum- cortisol levels from venous blood.|Hospital Anxiety and Depression scale,Panineeya Mahavidyalaya Institute of Dental Sciences & Research Centre,All,"18 Years to 90 Years   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Diagnostic,PMVIDS&RC/IEC/OMR/DN/0004-15,Jan-16,Nov-17,Dec-17,5-Jan-17,null,19-Dec-17,"Panineeya Institute of Dental Sciences, Hyderabad, Telangana, India",,https://ClinicalTrials.gov/show/NCT03011658
NCT03007095,Preterm Birth and Social Cognition,TERM-COG,Recruiting,No Results Available,Preterm Children,Behavioral: Evaluation of the children's social cognitive development,Social cognition / Theory of mind|working memory|shifting|Trait Anxiety Inventory|Beck Depression Inventory|Social Support Questionnaire|Trauma|Parental Stress Index,CHU de Reims,All,6 Years to 10 Years   (Child),Not Applicable,130,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,PO16068,20-Jul-17,20-Feb-20,Jun-20,2-Jan-17,null,25-Feb-19,"Chu Reims, Reims, France",,https://ClinicalTrials.gov/show/NCT03007095
NCT03007602,Effects of Upper Extremity Aerobic Exercise Training in Hematopoietic Stem Cell Transplantation Recipients,,Completed,No Results Available,Hematopoietic Stem Cell Transplantation|Aerobic Exercise,Other: Upper Extremity Aerobic Exercise,functional exercise capacity evaluation|pulmonary functions test|muscle strength|cough strength|physical activity level|fatigue severity|anxiety and depression perception|dyspnea perception|quality of life level|maximal exercise capacity evaluation,Gazi University,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,30,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care,Gazi-231,Apr-16,Aug-18,Sep-18,2-Jan-17,null,9-Oct-18,"Gazi University Faculty of Health Sciences Department of Physical Therapy and Rehabilitation, Ankara, Turkey",,https://ClinicalTrials.gov/show/NCT03007602
NCT03006757,Measurement of the Biting Force of Rabid Heat Cured Acrylic Resin Versus Modified Conventional Acrylic,,Unknown status,No Results Available,Dental Anxiety,Other: titanium dioxide denture base,measurement of the biting force of rabid heat cured acrylic resin versus modified conventional acrylic with titanium dioxide nanoparticles in maxillary single denture using i load star sensor,emad gamal ismail|Cairo University,All,30 Years to 60 Years   (Adult),Not Applicable,2,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Investigator)|Primary Purpose: Health Services Research,900,May-16,Aug-16,Dec-17,30-Dec-16,null,30-Dec-16,"Mahmoud Adly, Giza, Egypt",,https://ClinicalTrials.gov/show/NCT03006757
NCT03005795,Music and Colposcopy in Women With Cervical Dysplasia.,,Completed,No Results Available,Uterine Cervical Dysplasia,Device: Headphones|Other: No Headphones,Change in anxiety scores|Anxiety score after colposcopy|Change in heart rate|Pain during examination|Pain after examination|general unpleasantness during examination|Anxiety during examination|Overall Satisfaction,Zydolab - Institute of Cytology and Immune Cytochemistry,Female,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,205,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,COLPO-3,1-Feb-17,2-May-18,7-May-18,29-Dec-16,null,8-May-18,"Zydolab - Institute of Cytology and Immune Cytochemistry, Dortmund, NRW, Germany|Department of Obstetrics and Gynecology of the Ruhr University Bochum, Herne, NRW, Germany",,https://ClinicalTrials.gov/show/NCT03005795
NCT03003429,Correlation Study Between Heart Rate Variability and Anxiety in Anorexia Nervosa,VARIASTRESS,Recruiting,No Results Available,Anorexia Nervosa,Other: Heart rate monitor,Statistical correlation between autonomic dysfunction (measured by HRV) and anxiety (measured by questionnaire)|Statistical correlation between autonomic dysfunction (measured by HRV) and measures of Beck Depression inventory|Statistical correlation between autonomic dysfunction (measured by HRV) and measures of International physical activity questionnaire,Hospices Civils de Lyon,Female,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,40,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,69HCL16_0376|2016-A01659-42,1-Mar-17,1-Nov-19,1-Nov-19,28-Dec-16,null,26-Jul-18,"Hospices Civils de Lyon, Bron, France",,https://ClinicalTrials.gov/show/NCT03003429
NCT03004027,Enhancing Psychological Self-help With Implementation Intentions,,Completed,No Results Available,Social Anxiety,Other: Self help leaflet,"Change in Brief Fear of Negative Evaluation-II at four weeks (Carleton, Collimore, & Asmundson, 2007)|Change in Generalised Anxiety Disorder 7 at four weeks",University of Sheffield,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,326,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,147400,Jan-17,May-17,May-17,28-Dec-16,null,26-Oct-17,"University of Sheffield, Sheffield, South Yorkshire, United Kingdom",,https://ClinicalTrials.gov/show/NCT03004027
NCT03002753,Dealing With Intrusive Thoughts in OCD - a Comparison of Detached Mindfulness and Cognitive Restructuring,,Completed,Has Results,Obsessive-Compulsive Disorder,Behavioral: detached mindfulness|Behavioral: cognitive restructuring,Y-BOCS Change Score (Pre to Post Assessment),Christoph-Dornier-Stiftung für Klinische Psychologie|Westfälische Wilhelms-Universität Münster,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,43,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",CDS-MS-JR-2016,Dec-16,12-Jul-18,12-Jul-18,26-Dec-16,16-Apr-19,16-Apr-19,"Christoph-Dornier-Stiftung für Klinische Psychologie, Muenster, NRW, Germany","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/53/NCT03002753/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/53/NCT03002753/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03002753
NCT03002896,Mobilized Psychoeducation and Skills Based Intervention (Pep-Pal) for Caregivers of Patients With Advanced Illness,,Completed,No Results Available,Distress|Anxiety|Depression,Behavioral: Pep-Pal|Other: Treatment as Usual,Evaluation of Exit Interviews|Pep-Pal Self-Report sessions at 12 Weeks|Evaluation of Self-Report Caregiver reported outcomes at Baseline|Evaluation of Self-report caregiver reported outcomes at 12 weeks,"University of Colorado, Denver|Icahn School of Medicine at Mount Sinai",All,"18 Years to 85 Years   (Adult, Older Adult)",Not Applicable,69,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Supportive Care,16-0990,Dec-16,17-Nov-17,13-Jul-18,26-Dec-16,null,23-Jul-18,"University of Colorado, Denver, Aurora, Colorado, United States",,https://ClinicalTrials.gov/show/NCT03002896
NCT03003091,Needs-Based Patient Education Versus Traditional Patient Education in Reducing Pre-operative Anxiety in Day Surgery,,Completed,No Results Available,Educational Problems|Surgery,Other: Needs-based patient education|Other: Traditional patient education,Patient anxiety before patient education (STAI)|Patient anxiety before patient education (VAS)|Patient anxiety after patient education (STAI)|Patient anxiety after patient education (VAS)|Patient anxiety after operation (STAI)|Patient anxiety after operation (VAS)|Patient Satisfaction before patient education|Patient Satisfaction after patient education|Patient Satisfaction after surgery|Education time,Chulabhorn Hospital,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,470,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant),Chulabhorn,Apr-16,Sep-16,Dec-16,26-Dec-16,null,10-Jan-17,,,https://ClinicalTrials.gov/show/NCT03003091
NCT03002311,Improving Medical Care With Electronic Interventions Based on Automated Text and Phone Messages,,Enrolling by invitation,No Results Available,General Medicine|Maternal Health|Pediatric Health|Neurology|Psychiatry|Emergency Medicine|Internal Medicine|Nephrology|Wellness|Mobile Health|Surgery|Mental Health|Chronic Obstructive Pulmonary Disease|Diabetes Mellitus|CHF|Depression|Breast Feeding|PostPartum Depression|Perinatal Mood and Anxiety Disorder,Other: Epharmix|Other: Standard of care|Other: Placebo,Adherence|Patient engagement|Time to COPD specific hospitalization(s)|Change in HbA1c from baseline|Follow-up appointment adherence|Breastfeeding duration,"Washington University School of Medicine|Epharmix, Inc.",All,"5 Years and older   (Child, Adult, Older Adult)",Phase 1|Phase 2,5000,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,201504079,Jan-16,Dec-20,null,23-Dec-16,null,25-Sep-17,"St. Louis Children's Hospital, Saint Louis, Missouri, United States|Washington University School of Medicine - Barnes Jewish Hospital, Saint Louis, Missouri, United States",,https://ClinicalTrials.gov/show/NCT03002311
NCT03001154,Virtual Reality Exposure Therapy for Speech Anxiety Using Commercial Hardware and Software,VRETORIK,Completed,No Results Available,Social Phobia|Anxiety|Behavior Therapy,Behavioral: Face-to-face Virtual Reality Exposure Therapy|Behavioral: Internet-administered Virtual Reality Exposure Therapy|Other: Waiting-list,Public Speaking Anxiety Scale|Liebowitz Social Anxiety Scale Self-Report|Brief Fear of Negative Evaluation Scale|Patient Health Questionnaire 9-item|Generalized Anxiety Disorder 7-item|Brunnsviken Brief Quality of life scale,Stockholm University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,50,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,VRetorik,1-Jan-17,May-17,Jun-18,22-Dec-16,null,7-Mar-19,"Department of Psychology, Stockholm, Sweden",,https://ClinicalTrials.gov/show/NCT03001154
NCT02998502,"The Use of a FDA Cleared, Drug-free, Breathing System for Anxiety and Panic Disorders in Children and Teens",,Recruiting,No Results Available,Anxiety|Panic Disorder,Device: Freespira Breathing System,"Primary outcome is a score of Screen for Child Anxiety Related Disorders (SCARED) scale, the anxiety measuring scale.|SCARED anxiety scale score|End-tidal carbon dioxide (CO2)|Respiratory rate level|Panic Disorder Severity Scale for Adolescents (PDSS-A)|Clinician's Global Impression scale.|Child Yale Brown Obsessive-Compulsive Scale score|Decrease in severity of panic attacks as documented in panic dairy (only for participants with panic attacks)","Johns Hopkins University|Palo Alto Health Sciences, Inc.",All,9 Years to 17 Years   (Child),Not Applicable,60,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IRB00097094,Sep-16,Sep-19,Sep-19,20-Dec-16,null,19-Mar-19,"Johns Hopkins University, Baltimore, Maryland, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/02/NCT02998502/ICF_000.pdf",https://ClinicalTrials.gov/show/NCT02998502
NCT02998801,Alleviating Pre-operative Anxiety With Innovative 3D Immersive Virtual Reality,VR-Anxiety,Completed,No Results Available,Virtual Reality|Anxiety|Preoperative Anxiety,Other: IPAD|Other: VR Goggles,Change in anxiety levels as measured using VAS score from baseline to the day of surgery inside the OR.|Change in heart rate between patients randomized to IPAD or VR Goggles from baseline to the day of surgery inside the OR.|Change in blood pressure between patients randomized to IPAD or VR Goggles from baseline to the day of surgery inside the OR.,Sunnybrook Health Sciences Centre,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,484-2015,Nov-16,20-Mar-17,20-Mar-17,20-Dec-16,null,6-Apr-17,"Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT02998801
NCT02992405,FOCUS:Families OverComing Under Stress,,Completed,No Results Available,Cancer|Depression|PostTraumatic Stress Disorder|Anxiety,Behavioral: FOCUS Resilience Enhancement Program|Behavioral: Waitlist (No Study Treatment),Feasibility of program as defined by dropout rate|Change in score of depression as measured by the Patient Health Questionnaire 9 (PHQ-9).|Change in score of anxiety as measured by the General Anxiety Disorder 7 (GAD-7).|Change in score of post traumatic stress as measured by the PTSD Checklist - Civilian (PCL-C).|Change in score of stress in Human Functioning as measured by the Sense of Coherency (SOC).|Change in score of quality of life as measured by the Functional Assessment of Cancer Therapy - General Version (FACT-G).|Change in score of caregiver's quality of life as measured by the Caregiver Quality of Life Index - Cancer (CQOLC).|Change in score of family functioning as measured by the McMasters Family Assessment Device (FAD).|Change in score of couples relational functioning as measured by the Revised Dyadic Adjustment Scale (RDAS).|Change in parents' score of child functioning as measured by the Strengths and Difficulties Questionnaire (SDQ).|Change in patient satisfaction score as measured by the FOCUS Impact Rating Scale (FIRS).,Cedars-Sinai Medical Center,All,"5 Years and older   (Child, Adult, Older Adult)",Not Applicable,32,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,IIT2016-02-SALTZMAN-FOCUS,5-Dec-16,18-May-18,18-May-18,14-Dec-16,null,7-Feb-19,"Cedars-Sinai Medical Center, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT02992405
NCT02989493,Testing Doxazosin to Treat Stress Mechanisms in Alcoholism,,Recruiting,No Results Available,Alcoholism,Drug: Doxazosin|Other: Placebo,Startle potentiation during stress reactivity task|No heavy drinking days|Total number of alcoholic drinks|Total number of drinking days|Self-reported anxiety during stress reactivity task,"University of Wisconsin, Madison|National Institute on Alcohol Abuse and Alcoholism (NIAAA)",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,136,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Dox|R01AA024388,12-Apr-17,Dec-20,Dec-20,12-Dec-16,null,14-Mar-19,"University of Wisconsin, Madison, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT02989493
NCT02987582,A Feasibility Study of an Emotion-Focused Mindfulness Group,,Unknown status,No Results Available,Depression|Anxiety,Behavioral: Emotion-focused mindfulness group,"Self-Compassion Scale (SCS) to assess change between baseline, midpoint, group completion and 2 months post group.|Positive and Negative Affect Scale (PANAS) to assess change between baseline, midpoint, group completion and 2 months post group.|Patient Health Questionnaire - Somatic Anxiety Depression Scale (PHQ-SADS) to assess change between baseline, midpoint, group completion and 2 months post group.|Internalized Shame Scale to assess change between baseline, midpoint, group completion and 2 months post group.|World Health Organization Disability Assessment Schedule (WHODAS) to assess change between baseline, midpoint, group completion and 2 months post group.","University of Toronto Practice Based Research Network|Mount Sinai Hospital, Canada",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,35,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EFM 1,Sep-16,Jul-17,Jul-18,9-Dec-16,null,16-Dec-16,"Mount Sinai Hospital, Canada, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT02987582
NCT02986152,Cancer Distress Coach Mobile App Trial,,Recruiting,No Results Available,Posttraumatic Stress Disorder|Cancer,Behavioral: Cancer Distress Coach Mobile App,Change in PTSD symptoms as measured by the PTSD Checklist (PCL-5)|Change in distress level as measured by the Distress Thermometer|Change in stress management self-efficacy as measured by the Self-efficacy questionnaire,Duke University|Duke Institute for Health Innovation,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,1000,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,Pro00075411,1-Jun-17,28-Nov-19,28-Nov-19,8-Dec-16,null,10-Dec-18,"Duke University Medical Center, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT02986152
NCT02982213,Presence of a Companion During Performance of Neuraxial Labor Analgesia,Companion,Completed,No Results Available,"Anxiety|Pain|Health Knowledge, Attitudes, Practice",Other: Companion Present,Does the presence of a companion when it is the desire of the participant have a positive effect on maternal satisfaction during the placement of epidural catheter for labor analgesia?|Does having a companion present when it is the desire of the subject have a positive effect on the perception of pain during the placement of epidural catheter for labor analgesia on pain?|Does the desire of subject to have the companion present affect the anxiety of the subject measured using the STAI questionnaire during the placement of neuraxial labor analgesia?|. Does the presence of a companion affect the perceived difficulty of the procedure by the provider placing the labor epidural catheter using a Likert scale?|Does the subjects level of health literacy measured by the latest vital sign questionnaire affect the level of anxiety during the placement of neuraxial labor analgesia?|Does the score on the Pain Catastrophizing Scale correlate with the the subjects level of anxiety during the placement of neuraxial labor analgesia?|Does the relationship of the subject to the companion have an effect on the level of anxiety of the subject during the placement of neuraxial labor analgesia?|Does the ethnicity of the subject affect the level of anxiety?|Does the initiation of labor (induction vs spontaneous) effect on the level of anxiety of the subject during the placement of neuraxial labor analgesia?,Northwestern University,Female,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,150,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,STU00203896,1-Dec-16,1-Apr-17,1-Apr-17,5-Dec-16,null,19-May-17,"Prentice Women's Hospital, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT02982213
NCT02982239,Recovery Enhancement and Sleep Training,REST,Completed,No Results Available,Sleep|Performance|Mental Health|Stress|Anxiety,Behavioral: Sleep Diary|Device: Fitbit|Device: Blue-Blocking Glasses|Device: LED light|Other: Information Sessions|Behavioral: Text messages,"Pittsburgh Sleep quality index ( PSQI)|Sleep Disorders Questionnaire (SDQ)|Insomnia Severity Index (ISI)|Multivariable Apnea Prediction (MAP) Index|Morningness-Eveningness Questionnaire (MEQ)|Sleep items from the National Health and Nutrition Examination Survey (NHANES)|Centers for Disease Control and Prevention Health-Related Quality of Life Scale (HRQOL)|Multifactorial Scale of Perceived Social Support (MSPSS)|Positive and Negative Affect Scales (PANAS)|Centers for Epidemiological Studies Depression Scale (CESD)|Perceived Stress Scale (PSS)|Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST)|Time and Travel Demands|Academic Stress",University of Arizona|National Collegiate Athletic Association - NCAA,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,190,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,1605615210,Jun-16,4-Jan-17,5-Jan-17,5-Dec-16,null,3-May-17,,,https://ClinicalTrials.gov/show/NCT02982239
NCT02977845,"Effect of Qigong on the Symptom Clusters of Dyspnea, Fatigue, and Anxiety.",,Completed,No Results Available,"Lung Cancer, Nonsmall Cell|Lung Cancer Non-Small Cell Stage 0|Lung Cancer, Nonsmall Cell, Stage I|Lung Cancer Non-Small Cell Stage II|Lung Cancer, Limited Stage Small Cell",Behavioral: Qigong,"A cluster symptom of dyspnea, fatigue, and anxiety in lung cancer patients.|Cough|Quality of Life",Nam Dinh University of Nursing|The Hong Kong Polytechnic University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,162,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care,NamDUN,1-Jan-17,Dec-17,22-Jun-18,30-Nov-16,null,28-Jun-18,"The Hong Kong Polytechnic University, Hong Kong, Hong Kong",,https://ClinicalTrials.gov/show/NCT02977845
NCT02977923,Decreasing REcurrent Pain and Anxiety in Medical Procedures With a Pediatric Population: a Pilot Study,DREAM-P,Completed,No Results Available,Pain|Anxiety|Burns|Child|Injuries,Device: VR distraction via Oculus Rift|Other: Standard pharmacological treatment,Acceptability|Mean Pain Score|Pain Experience|Expected Anxiety|Experienced Anxiety|Comfort Level|Pain Memory|Anxiety Memory|Range Of Motion,St. Justine's Hospital|Quebec Nursing Intervention Research Network,All,"7 Years to 18 Years   (Child, Adult)",Not Applicable,20,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1383,10-Jul-17,1-Aug-18,1-Aug-18,30-Nov-16,null,21-Sep-18,"CHU Ste. Justine, Montreal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT02977923
NCT02977962,Treatment of Anxiety in Late Adolescents With Autism,TALAA,Recruiting,No Results Available,Autism Spectrum Disorder,Behavioral: Cognitive-Behavior Therapy|Other: Treatment as Usual,Change from Baseline in anxiety severity on the Hamilton Anxiety Scale after 16 weeks of treatment.|Change from Baseline in anxiety severity on the Clinical Global Impressions Scale after 16 weeks of treatment.,University of South Florida|Johns Hopkins All Children's Hospital,All,"16 Years to 21 Years   (Child, Adult)",Not Applicable,44,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,USF-ACH 001,Jan-17,Dec-20,Aug-21,30-Nov-16,null,20-Mar-19,"Rothman Center for Neuropsychiatry, University of South Florida, Saint Petersburg, Florida, United States",,https://ClinicalTrials.gov/show/NCT02977962
NCT02973919,EMDR in Spider Phobia: Work Mechanisms and Treatment Outcome,,Completed,No Results Available,Spider Phobia,Behavioral: Eye Movement Desensitization and Reprocessing Therapy|Behavioral: Virtual Reality Exposure Therapy,Change in Behavioral Assessment Test (BAT) in vivo|Skin Conductance Reactivity (SCR)|Electrocardiogram (ECG)|manipulation check electrode below the right eye (M. orbicularis oculi)|Change in Subjective Fear Ratings,University of Regensburg,Female,18 Years to 55 Years   (Adult),Not Applicable,53,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,URegensburg,Jul-15,Dec-15,Sep-16,28-Nov-16,null,28-Nov-16,,,https://ClinicalTrials.gov/show/NCT02973919
NCT02973932,iCBT for Children and Adolescents With Obsessive-compulsive Disorder,,Unknown status,No Results Available,Psychotherapy Intervention Evaluation,Behavioral: Cognitive-bahavioral psychotherapy,The Schedule for Affective Disorders and Schizophrenia for School-Age Children Present and Lifetime Version (K-SADS-PL)|The Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS)|Children's Global Assessment Scale (CGAS)|Child Behavior Checklist (CBCL)|Questionnaire for Measuring Health-Related Quality of Life in Children and Adolescents (KINDL)|Impairment by OCD symptoms|Extend of avoidance behavior|Daily mood|How the day was|How strong OCD is|How Every week throughout the therapy processgood e progress was with specific treatment goals|Anxiety ratings during exposures|Heart rate variability|Skin conductance level|Body temperature|Body movements,University Hospital Tuebingen,All,7 Years to 17 Years   (Child),Not Applicable,20,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,F.1331477,Nov-16,Nov-17,null,28-Nov-16,null,28-Nov-16,,,https://ClinicalTrials.gov/show/NCT02973932
NCT02972853,Mindful Self-Regulation fMRI Pilot Study,MindfulPCMRI,"Active, not recruiting",No Results Available,Psychiatric Problem|Depression|Anxiety|Neuroimaging|Self-Control,Behavioral: Mindfulness Training for Primary Care (MTPC),Change in Brain activation in regions of interest|Correlations between brain activation changes and self-regulation measures|Correlations between brain activation changes and chronic disease self-management action plan initiation.,Cambridge Health Alliance|Martinos Center for Biomedical Imaging|National Center for Complementary and Integrative Health (NCCIH)|Brown University,All,21 Years to 60 Years   (Adult),Not Applicable,26,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,CHA-IRB-1002/08/14|1UH2AT009145-01,Sep-16,Dec-20,Jul-21,25-Nov-16,null,27-Jul-18,"CHA Center for Mindfulness and Compassion, Somerville, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT02972853
NCT02972203,MINDFUL-PC: Integrating Mindfulness Into the Patient-Centered Medical Home,MINDFUL-PC,Completed,No Results Available,Depression|Anxiety|Stress Related Disorder|Adjustment Disorder,Behavioral: Mindfulness Training for Primary Care|Behavioral: Mindfulness Intro. +resources +waitlist,Change in Perceived Stress Scale|Change in Patient Reported Outcomes Measurement Information System - Anxiety Short Form (PROMIS-ASF)|Change in Patient Reported Outcomes Measurement Information System - Depression Short Form (PROMIS-DSF)|Change in Self-Efficacy for Managing Chronic Disease (SECD-6)|Action Plan Initiation Survey (APIS-5)|Five Facet Mindfulness Questionnaire (FFMQ)|Self-Compassion Scale-Short Form (SCS-SF)|Difficulty in Emotion Regulation Scale (DERS)|Multidimensional Assessment of Interoceptive Awareness (MAIA)|Perceived Control Questionnaire (PCQ)|Patient Activation Measure (PAM),Cambridge Health Alliance|The Arthur Vining Davis Foundations|The Arnold P. Gold Foundation,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,87,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IRB number: CHA-IRB-1002/08/14,Oct-15,30-Aug-18,30-Aug-18,23-Nov-16,null,12-Dec-18,"Cambridge Health Alliance Center for Mindfulness and Compassion, Somerville, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT02972203
NCT02970734,Evaluating an Internet-based Program for Anxious Adolescents,,Completed,No Results Available,Anxiety,Behavioral: Breathe|Behavioral: Resource Webpage,Change in adolescent anxiety using the total Multidimensional Anxiety Scale for Children (MASC 2) score|Change in adolescent anxiety using the total MASC 2 score|Change in quality of life using the Youth Quality of Life Instrument - Short Form (YQOL-SF)|User experience|Intervention adherence|health care utilization,University of Alberta,All,"13 Years to 19 Years   (Child, Adult)",Not Applicable,563,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,Pro00066393,1-Dec-16,30-Aug-18,22-Nov-18,22-Nov-16,null,2-May-19,"The Breathe Team, Edmonton, Alberta, Canada",,https://ClinicalTrials.gov/show/NCT02970734
NCT02970825,"Move and Feel Good : Effects of Intensive Physical Training on Brain Plasticity, Cognition and Psychological Well-being.",Move&FG,Recruiting,No Results Available,Learning Disorders|Depression|Anxiety,Other: Exercise|Other: Relaxation,"Change from baseline psychological well-being as assessed using depression, self-esteem and anxiety questionnaires|Change from baseline psychological well-being as assessed using depression questionnaires for children|Change from baseline psychological well-being as assessed using depression questionnaires for adolescents and adults|Change from baseline psychological well-being as assessed using depression and anxiety questionnaires|Change from baseline psychological well-being as assessed using depression questionnaire for young people and adults|Change from baseline psychological well-being as assessed using self-esteem questionnaires|Change from baseline physical condition : size|Change from baseline physical condition : weight|Change from baseline physical condition as assessed in bioelectrical impedance analysis|Change from baseline physical condition : body muscle ratio|Change from baseline physical condition : body fat ratio|Change from baseline physical condition as assessed using field running tests|Change from baseline cognitive function as assessed using computerized neuropsychological testing of cognitive control|Change from baseline cognitive function as assessed using computerized neuropsychological testing of inhibitory control",Université Catholique de Louvain,All,"9 Years to 30 Years   (Child, Adult)",Not Applicable,100,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Etude 2016/17FEV/060,Sep-16,Nov-18,Dec-19,22-Nov-16,null,14-May-18,"Université catholique de Louvain, Brussels, Belgium",,https://ClinicalTrials.gov/show/NCT02970825
NCT02970877,Stool Transplantation for Treatment of Insulin Resistance in Morbidly Obese Patients,,Recruiting,No Results Available,"Obesity, Morbid|Insulin Resistance",Biological: Fecal filtrate from 150 g stool from healthy lean donors|Biological: Fecal filtrate from 150 g of the recipient's own stool,Change in Insulin Resistance compared to baseline|Weight|Body mass index|Percentage weight change compared to baseline|Appetite score|Quality of Life Questionnaire|Depression score|Anxiety score,"Johane Allard|Canadian Institutes of Health Research (CIHR)|MOUNT SINAI HOSPITAL|University of Toronto|University Health Network, Toronto",All,"18 Years and older   (Adult, Older Adult)",Phase 2,48,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",16-5475,1-Mar-17,Sep-20,Sep-21,22-Nov-16,null,30-Oct-18,"University Health Network, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT02970877
NCT02971137,Pain and Smoking Study,PASS,Recruiting,No Results Available,Smoking|Pain|Smoking Cessation,Behavioral: Smoking Cessation plus CBI|Behavioral: Smoking Cessation Standard,Cigarette Smoking Abstinence Rates|Cigarette Smoking 7-day Point Prevalence Abstinence Rates|Change in Pain Intensity|Change in Pain Interference,VA Office of Research and Development,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,370,U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IIR 15-092,22-Dec-17,2-Apr-20,2-Nov-20,22-Nov-16,null,11-Apr-19,"VA Connecticut Healthcare System West Haven Campus, West Haven, CT, West Haven, Connecticut, United States|VA Central Western Massachusetts Healthcare System, Leeds, MA, Leeds, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT02971137
NCT02968238,Tranquil Moments II-CBT vs. Yoga for Worry,,"Active, not recruiting",No Results Available,Anxiety,Behavioral: Cognitive-behavioral therapy|Behavioral: Yoga,"Penn State Worry Questionnaire-Abbreviated|PROMIS Anxiety|Insomnia Sleep Index|PROMIS 29|PROMIS Depression|PROMIS Physical Function with Mobility Aid|GAD-7|Cornell Medical Services Index|Client Satisfaction Questionnaire|Working Alliance Inventory, Client and Therapist|Adherence to the intervention as assessed by the number of sessions attended|Attrition from the intervention as assessed by the number of participants who do not complete study assessments at Week 11 and Week 37|FES-I|Falls",Wake Forest University Health Sciences|Patient-Centered Outcomes Research Institute,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,500,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Care Provider)|Primary Purpose: Treatment,IRB00041530|CER-1511-33007,1-May-17,May-19,Nov-19,18-Nov-16,null,4-Apr-19,"Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT02968238
NCT02966340,Repurposing alpha1 Noradrenergic Antagonists for Alcoholism Treatment,,Completed,No Results Available,Alcoholism,Drug: Prazosin|Drug: Placebo,Startle potentiation during stress reactivity task.|Self-reported anxiety during stress reactivity task.,"University of Wisconsin, Madison|National Institute on Alcohol Abuse and Alcoholism (NIAAA)",All,18 Years to 50 Years   (Adult),Phase 1|Phase 2,64,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Screening",2014-0966|F31AA022845-01|Kaye2,1-Nov-16,12-Mar-18,12-Mar-18,17-Nov-16,null,15-Feb-19,"University of Wisconsin, Madison, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT02966340
NCT02964520,EEG Alpha/Theta Neurofeedback to Reduce Trait Anxiety,,Completed,No Results Available,Anxiety,Behavioral: Neurofeedback training|Behavioral: Sham comparator: Sham neurofeedback training,Change from baseline in the State-Trait Anxiety Inventory (STAI) Scale|Theta/alpha (T/A) ratios in EEG recorded at Pz scalp location|19-channel Mini-QEEG|Change from baseline in Generalized Anxiety Disorder 7-item Scale (GAD-7)|Change from baseline in Beck Anxiety Inventory (BAI) Scale|Change from baseline in Activation Deactivation Adjective Checklist (AD ACL)|Rotter Locus of Control Scale,University of Hartford,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,28,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,PRO15070009,Jul-15,Jan-17,Jan-17,16-Nov-16,null,5-Jan-17,"University of Hartford, West Hartford, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT02964520
NCT02958228,The Effect of Computerized Cognitive Training on Mood and Thinking Style Amongst Patients in Inpatient Settings,,Completed,No Results Available,Depression|Anxiety|Anhedonia,Behavioral: Positive Mental Imagery Training (PMIT)|Behavioral: Cognitive Control Training (CCT)|Other: Treatment as Usual,21-item positive subscale from the extended Positive and Negative Affect Schedules|Dimensional Anhedonia Rating Scale|Quick Inventory of Depressive Symptomatology - Self Report|GAD-7|Positive Mental Health Scale|Prospective Imagery Test|Scrambled Sentences Test (SST)|Implicit Associations Test (IAT),Ruhr University of Bochum,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,57,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,325,Nov-16,Dec-17,Mar-18,8-Nov-16,null,29-Mar-18,"Nexus-Klinik, Baden-Baden, Germany|St. Marien Hospital Eickel, Herne, Germany",,https://ClinicalTrials.gov/show/NCT02958228
NCT02955108,The Effect of Distractive Auditory Stimuli (Music) on Dyspnea and Anxiety During Exercise in Adults With Chronic Respiratory Diseases,,Enrolling by invitation,No Results Available,Chronic Obstructive Pulmonary Disease,Procedure: Distractive Auditory Stimuli|Procedure: No Distractive Auditory Stimuli,Dyspnea Intensity (DI),New York University School of Medicine,All,"40 Years and older   (Adult, Older Adult)",Not Applicable,50,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care",16-01676,27-Oct-17,31-Mar-20,31-Mar-20,4-Nov-16,null,10-May-19,"New York University School of Medicine, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT02955108
NCT02955563,CSDM: A Trial to Improve Communication and Shared Decision Making Using a Web-Based Tool,CSDM Pilot,Recruiting,No Results Available,Intervention Compliance|Usability|Acceptability,Other: CSDM Web-Based Tool Intervention,Intervention compliance|Participants' ratings of usability of the tool|Participants' ratings of acceptability of the tool|Participants' ratings of perceived usefulness of the tool|Feasibility of enrolling family members in a critical care setting|Feasibility of retaining family members in a critical care setting in a trial,University of Pittsburgh,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other,PRO16050247,1-May-17,May-19,Aug-19,4-Nov-16,null,28-Sep-18,"University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT02955563
NCT02955654,Acceptance and Commitment Therapy in SSRI-Resistant Obsessive Compulsive Disorder,,Unknown status,No Results Available,Obsessive-Compulsive Disorder,Behavioral: Acceptance and commitment therapy|Drug: Aripiprazole|Behavioral: Stress management training,Yale Brown Obsessive Compulsive Scale|Beck Depression Inventory-II|Acceptance and Action Questionnaire|Treatment Evaluation Inventory-Short Form|Basic life sign|BMI|Abnormal Involuntary Movement Scale,Shanghai Mental Health Center,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,135,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",SMHC-OCD-002,1-Sep-17,Dec-18,Dec-18,4-Nov-16,null,1-May-17,,,https://ClinicalTrials.gov/show/NCT02955654
NCT02955719,CAMH - McMaster Collaborative Care Initiative For Mental Health Risk Factors In Dementia,CCI,"Active, not recruiting",No Results Available,Depression|Anxiety|Mild Cognitive Impairment,Drug: Sertraline|Drug: Venlafaxine|Other: CBT/Psychological Therapy|Other: Psychiatric Consultation|Other: Lifestyle Intervention Resources,"Change in anxiety/depression/quality of life (QOL) scores among participants in the ICP and comparison groups|Acceptability and perceived utility of the ICP|Feasibility of the ICP|Adjustments made for the adoption of the ICP in primary care teams|Barriers to implementation of the ICP and the key elements to initiate, sustain and spread the ICP|Changes in the primary care providers' knowledge of, and ability to recognize and manage, depression, anxiety, and MCI in older adults.|Time-to-treatment initiation among those in the ICP arm versus those in the comparison arm.|Specific Aim 3a: To assess the impact of the ICP on the rates of diagnoses/detection among older patients with anxiety, depression, or MCI compared to before ICP implementation.|Specific Aim 3b: To assess the impact of ICP on rates of diagnoses/detection among patients of the same age cohort as our target ICP population, but not in our study sample.",Centre for Addiction and Mental Health|McMaster University,All,"60 Years to 65 Years   (Adult, Older Adult)",Not Applicable,144,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,019/2016,30-Mar-16,Jul-21,Jul-21,4-Nov-16,null,28-Feb-19,"Centre for Addiction and Mental Health, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT02955719
NCT02955784,Sinasprite: A Pilot Feasibility Study for Patients With Anxiety or Stress,,Unknown status,No Results Available,Stress|Depression|Anxiety,Device: Sinasprite Mobile App,Patient satisfaction. These data will be collected via questionnaire at the end of the study only|Measure of perceived stress (PSS)|Quality of life (LiSAT-9)|Symptom reports: measure of depression symptoms (PHQ-9 score)|Symptom reports: measure of anxiety symptoms (GAD-7 score)|Measure of coping self-efficacy (CSE) questionnaire|App daily usage (minutes/day)|App frequency usage (days/week)|App duration of usage (total weeks),Madigan Army Medical Center,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,50,U.S. Fed,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,215019,22-Jan-15,Dec-17,Mar-18,4-Nov-16,null,8-May-17,"Madigan Army Medical Center, Tacoma, Washington, United States",,https://ClinicalTrials.gov/show/NCT02955784
NCT02953691,"Exploring the Impact of Perioperative Galacto-Oligosaccharides (GOS) on Stress, Anxiety and Cognition",,Withdrawn,No Results Available,Anxiety|Pain|Surgery,Drug: Galacto-Oligosaccharide|Drug: Maltodextrin (Placebo),Change in Waking Salivary Cortisol|Changes in pain perception|Changes in cognition|Changes in perceived stress|Suicidal ideation and behavior,"Jeff Taekman, M.D.|Duke University",All,"21 Years to 70 Years   (Adult, Older Adult)",Phase 2,0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",Pro00075000,9-Jun-17,1-Jan-18,1-Jan-18,3-Nov-16,null,31-Jan-18,"Duke University Medical Center, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT02953691
NCT02953717,Cognitive Outcome After SRS or WBRT in Patients With Multiple Brain Metastases (CAR-Study B),,Recruiting,No Results Available,Neoplasm Metastasis,Radiation: Gamma Knife radiosurgery|Radiation: Whole Brain Radiation Therapy,Cognitive decline at 3 months|Verbal memory|Cognitive flexibility|Word Fluency|Working memory|Processing speed|Motor dexterity|Health Related Quality Of Life (HRQOL)|Fatigue|Depression and anxiety|Median Overall Survival|Local tumor control|Distant tumor control,Elisabeth-TweeSteden Ziekenhuis|University of Tilburg|ZonMw: The Netherlands Organisation for Health Research and Development,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,46,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,842003006|NTR5463,Feb-16,Mar-19,Mar-19,3-Nov-16,null,2-Mar-18,"Gamma Knife Center Tilburg, Elisabeth-TweeSteden Hospital, Tilburg, Noord-Brabant, Netherlands",,https://ClinicalTrials.gov/show/NCT02953717
NCT02954250,Mindfulness Based Cognitive Therapy for Depression and Cognitive Inhibition in Suicide,,Unknown status,No Results Available,"Depression, Anxiety",Behavioral: Mindfulness Based Cognitive Therapy,Fulfillment of initial recruitment goals (first 20 patients)|Decreases in HAM-D Scale|Improvement in the Stroop task performances,Lady Davis Institute,All,"18 Years to 100 Years   (Adult, Older Adult)",Early Phase 1,30,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,IUSMD-16-17,Sep-16,Jul-17,Jul-18,3-Nov-16,null,3-Nov-16,"Douglas Mental Health University Institute, Montreal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT02954250
NCT02954731,"Trans-diagnostic Group CBT vs. Standard Group CBT for Depression, Social Anxiety and Agoraphobia/Panic Disorder",TRACT-RCT,"Active, not recruiting",No Results Available,"Depression, Unipolar|Anxiety Disorder Social|Panic Disorder",Behavioral: UP-CBT|Behavioral: Standard-CBT,WHO Well-Being Index (WHO-5)|Hopkins Symptom Check List (SCL-25)|Work and Social Adjustment Scale (WSAS)|Hamilton Depression Rating Scale (HDRS)|Hamilton Anxiety Rating Scale (HARS),"Psychiatric Research Unit, Region Zealand, Denmark|Aarhus University Hospital|Mental Health Centre Copenhagen|University of Copenhagen",All,18 Years to 64 Years   (Adult),Not Applicable,292,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SA005,Dec-16,11-Apr-19,Dec-19,3-Nov-16,null,15-Apr-19,"Psychotherapeutic Unit, Mental Health Centre Copenhagen, Copenhagen, Capital Region, Denmark|Outpatient Clinic for Anxiety and Personality Disorders, Risskov, Central Region, Denmark|Outpatient Clinic for Mania and Depression, Risskov, Central Region, Denmark|Psychiatric Outpatient Clinic, Slagelse, Region Zealand, Denmark","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/31/NCT02954731/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/31/NCT02954731/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02954731
NCT02953444,The Feasibility and Efficacy of an Extremely Brief Mindfulness Practice,,Terminated,No Results Available,Depression|Anxiety|Mental Disorders,Other: Thirty-Second Mindfulness Practice|Other: Three-Minute Mindfulness Practice,"Change in trait mindfulness as measured by the Five Facet Mindfulness Questionnaire (Baer et al. 2006)|Change in perceived stress as measured by the Perceived Stress Scale (Cohen, Kamarck, & Mermelstein, 1983)|Change in anxiety symptoms as measured by the GAD-7, Generalized Anxiety Disorder Scale (Spitzer, Kroenke, Williams, & Löwe, 2006)|Change in mood as measured by the Positive and Negative Affect Schedule (Watson, Clark, & Tellegen, 1988)|Change in quality of life as measured by the Medical Outcomes Study 36-Item Short-Form Health Survey (Ware & Sherbourne, 1992)|Change in depression symptoms as measured by the PHQ-8, Patient Health Questionnaire - depression module (Spitzer, Kroenke, & Williams, 1999)|Group difference in intervention's acceptability as measured by qualitative questions|Group difference in adherence as measured by frequency of daily brief mindfulness practice use|Group difference in continued brief mindfulness practice use as measured by follow-up question|Change in daily mood measured on a visual analogue scale|Change in daily stress level measured on a visual analogue scale|Change in empathy as measured by the Interpersonal Reactivity Index (Davis, 1980) and four questions adapted from Hawk, Fischer and Van Kleef, (2011)|Change in perspective taking as measured by questions adapted from Hawk, Fischer and Van Kleef, (2011)",Duke University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,42,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Pro00072981,Nov-16,9-Sep-18,9-Sep-18,2-Nov-16,null,12-Dec-18,"Duke Office of Clinical Research REDCap Online Data Collection Software, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT02953444
NCT02950415,Does Virtual Parental Presence Reduce Preoperative Anxiety in Children,,Recruiting,No Results Available,Anxiety,Behavioral: virtual|Behavioral: coaching|Behavioral: physical|Behavioral: no coaching,Anxiety in children|Change in child anxiety|Induction compliance|Child temperament|Parental anxiety|Change in parental anxiety|Parental satisfaction|Anesthesiologist satisfaction with task load|Anesthesiologist satisfaction with technology usability|Induction nurse satisfaction with task load|Induction nurse satisfaction with technology usability|Anesthetic requirements|Post-hospitalization negative behaviours,The Hospital for Sick Children,All,18 Months to 12 Years   (Child),Not Applicable,320,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Investigator)|Primary Purpose: Other,1000053821,16-May-17,31-Aug-19,31-Dec-19,1-Nov-16,null,16-Apr-19,"The Hospital for Sick Children, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT02950415
NCT02950636,Effect of Yoga on Mood and Quality of Life in Patients With Refractory Epilepsy,,Completed,No Results Available,Depression|Anxiety,Other: Yoga,Change in Neurological Disorders Depression Inventory for Epilepsy (NDDI-E)|Change in Generalized Anxiety Disorder 7-item (GAD-7) scale|Change in Quality of Life in Epilepsy-Patient-Weighted (QOLIE-31-p)|Frequency of seizures,University of Kansas Medical Center|National Institutes of Health (NIH),All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,3,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,STUDY00140045|UL1TR000001,Dec-16,Jun-17,4-Oct-17,1-Nov-16,null,30-Apr-18,"University of Kansas Medical Center, Kansas City, Kansas, United States",,https://ClinicalTrials.gov/show/NCT02950636
NCT02950961,Collaborative Care for Women Veterans,CCWV,"Active, not recruiting",No Results Available,"Anxiety|Depression|Stress Disorders, Post Traumatic",Behavioral: Collaborative Care for Women Veterans,Change in Referrals|Adoption of care models|Acceptability of care model|Feasibility of care model|Satisfaction with care model|Patient-Reported Outcomes Measurement Information System (PROMIS)|Overall Anxiety Severity and Impairment Scale (OASIS)|Patient Health Questionnaire for Depression and Anxiety (PHQ-4)|WHO Disability Assessment Schedule (WHODAS) Out Of Role Days items|Global rating of satisfaction/quality of care|Altarum Consumer Engagement|Health literacy (Chew et al. 2004),VA Office of Research and Development,Female,"18 Years and older   (Adult, Older Adult)",Phase 1,240,U.S. Fed,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,QUX 16-008,30-Jun-17,31-Mar-20,30-Sep-20,1-Nov-16,null,9-Jan-19,"VA San Diego Healthcare System, San Diego, CA, San Diego, California, United States|VA Greater Los Angeles Healthcare System, West Los Angeles, CA, West Los Angeles, California, United States|VA Portland Health Care System, Portland, OR, Portland, Oregon, United States",,https://ClinicalTrials.gov/show/NCT02950961
NCT02949401,Stress Inoculation Through Virtual Reality in the Pediatric Electrophysiology Laboratory,,Completed,No Results Available,"Stress, Psychological|Stress, Physiological|Anxiety|Pain Perception",Behavioral: Use of Virtual Reality App,Change in anxiety levels from baseline in patients as measured by the State Trait Anxiety Inventory (STAI).|Change in anxiety levels from baseline in patients as measured by Visual Analog Scale of Anxiety|Change in parent observation of child behavior from baseline as measured by Child Behavior Checklist (CBCL)|Change in anxiety levels from baseline in parents as measured by parental STAI|Change in salivary cortisol levels from baseline in patients|Heart rate in patients|blood pressure in patients,Stanford University,All,"10 Years to 20 Years   (Child, Adult)",Not Applicable,40,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,37603,Jan-17,16-Apr-18,16-Apr-18,31-Oct-16,null,20-Mar-19,"Stanford University / Lucile Packard Children's Hospital, Stanford, California, United States",,https://ClinicalTrials.gov/show/NCT02949401
NCT02944994,Effectiveness of a Unified Transdiagnostic Treatment in Routine Care,,Recruiting,No Results Available,Anxiety|Traumatic Stress Disorders|Depression,Other: Unified protocol|Other: Routine Care,Barriers and facilitators that impact implementation of the intervention measured by the Consolidated Framework for Implementation Research (CFIR)|Change in clinician administered Anxiety Disorders Interview Scheduled will be used to generate clinical diagnoses for mental health disorders|Change in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) will be used to asses the presence or absence of a clinical diagnosis of PTSD,Boston University|National Institute of Mental Health (NIMH),All,"18 Years to 100 Years   (Adult, Older Adult)",Not Applicable,80,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research,H-33257|K23MH103396,Dec-14,Oct-19,Oct-19,26-Oct-16,null,1-Oct-18,"VA Boston Healthcare System, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT02944994
NCT02945111,Watching Live VIA/VILI Examinations on a Digital Screen May Reduce Patients' Anxiety,,Completed,No Results Available,Cervical Cancer|Anxiety,Behavioral: Real-time view|Behavioral: No visual support,Anxiety level,"Prof. Patrick Petignat|University Hospital, Geneva",Female,30 Years to 49 Years   (Adult),Not Applicable,122,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),PB_2016-01745,Sep-16,Oct-16,Oct-16,26-Oct-16,null,26-Oct-16,"Dschang District Hospital, Dschang, Yaoundé, Cameroon",,https://ClinicalTrials.gov/show/NCT02945111
NCT02943408,Development of a Patient Centered Mental Health Intervention for Recent Veterans,PCC MH,Recruiting,No Results Available,"Stress Disorders, Post-Traumatic|Depression|Anxiety|Substance-Related Disorders",Behavioral: person-centered mental health intervention|Behavioral: health and wellness,patient-centered communication|change in self-assessment of functioning|change in depression and anxiety symptoms|change in PTSD symptoms|change in alcohol use symptoms|change in substance use symptoms,VA Office of Research and Development,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,88,U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,D2159-W|1IK2RX002159-01A2,31-Jul-17,1-Jan-22,1-Jun-22,24-Oct-16,null,5-Dec-18,"Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD, Baltimore, Maryland, United States|Rehabilitation R&D Service, Baltimore, MD, Baltimore, Maryland, United States|Perry Point VA Medical Center VA Maryland Health Care System, Perry Point, MD, Perry Point, Maryland, United States",,https://ClinicalTrials.gov/show/NCT02943408
NCT02938845,Does Minimally Invasive Surgery Reduce Anxiety?,,Completed,No Results Available,Anxiety,Behavioral: Spielberger's State-Trait Anxiety Inventory(STAI )|Procedure: total laparoscopic hysterectomy(TLH)|Procedure: total abdominal hysterectomy(TAH),STAI-S's Inventory|STAI-T's Inventory,Zeynep Kamil Maternity and Pediatric Research and Training Hospital,Female,"35 Years to 70 Years   (Adult, Older Adult)",Not Applicable,74,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,25,Jan-13,Dec-16,Dec-16,19-Oct-16,null,8-Dec-16,"Zeynep Kamil Woman and Child Diseases Education and Research Hospital, Istanbul, Turkey",,https://ClinicalTrials.gov/show/NCT02938845
NCT02933684,D-Cycloserine and Virtual Reality Exposure Therapy,,Withdrawn,No Results Available,Social Anxiety Disorder,Drug: Seromycin|Behavioral: Virtual Reality Exposure Therapy|Drug: Placebo,"Change in scores on the Liebowitz Social Anxiety Scale-self report version (LSAS-SR)|Change in behavioral avoidance|Change in scores on the Clinical Global Improvement Scale, Patient Report|Change in scores on the Social Phobia Scale|Change in scores on the Social Interaction Anxiety Scale|Change in scores on the Patient Health Questionnaire|Change in scores on the Sheehan Disability Scale|Change in scores on the Quality of Life Inventory",Georgia State University|Emory University,All,"18 Years and older   (Adult, Older Adult)",Phase 2,0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",ULTR000454,1-Jan-15,31-Dec-16,31-Dec-16,14-Oct-16,null,13-Apr-18,"Georgia State University, Atlanta, Georgia, United States",,https://ClinicalTrials.gov/show/NCT02933684
NCT02932358,"Effectiveness and Safety of a Flexible Family Visitation Model for Delirium Prevention in Adult Intensive Care Units: a Cluster-randomized, Crossover Trial (The ICU Visits Study)",,Completed,No Results Available,Delirium,Other: Flexible Family Visitation Model (FFVM)|Other: Restrictive Family Visitation Model (RFVM),Incidence of Delirium among ICU patients|Daily hazard of delirium among ICU patients|Antipsychotic use among ICU patients|Need of mechanical restraints among ICU patients|Coma-free days at day 7 among ICU patients|Unplanned loss of invasive devices among ICU patients|Mechanical ventilation-free days at day 7 among ICU patients|Any ICU-acquired infection among ICU patients|ICU-acquired pneumonia among ICU patients|ICU-acquired bloodstream infection among ICU patients|ICU-acquired urinary tract infection among ICU patients|ICU length of stay among ICU patients|All-cause hospital mortality among ICU patients|Symptoms of anxiety among family members|Symptoms of depression among family members|Satisfaction among among family members|Prevalence of Burnout Syndrome among ICU professionals|Satisfaction with the current ICU visiting policy among ICU professionals|Any adverse event related to ICU visitation,"Hospital Moinhos de Vento|Ministry of Health, Brazil",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,1650,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,ICU Visits,28-Apr-17,22-Jun-18,22-Jun-18,13-Oct-16,null,22-Nov-18,"Hospital de Urgência e Emergência de Rio Branco, Rio Branco, AC, Brazil|Fundação Hospital Adriano Jorge, Manaus, AM, Brazil|Hospital Geral Clériston Andrade, Feira De Santana, BA, Brazil|Hospital INCARDIO, Feira De Santana, BA, Brazil|Hospital de Urgências de Goiânia, Goiânia, Goias, Brazil|Hospital das Clínicas da Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil|Santa Casa de Misericórdia de São João Del Rei, São João Del Rei, MG, Brazil|Hospital Regional do Baixo Amazonas, Santarém, PA, Brazil|Hospital Universitário Alcides Carneiro, Campina Grande, PB, Brazil|Hospital Universitário Lauro Wanderley, João Pessoa, PB, Brazil|Hospital Universitário de Petrolina, Petrolina, PE, Brazil|Hospital Agamenom Magalhães, Recife, PE, Brazil|Hospital Universitário da Universidade Federal do Piauí, Teresina, PI, Brazil|Hospital do Caâncer de Cascavel (UOPECCAN), Cascavel, PR, Brazil|Hospital Universitário do Oeste do Paraná (UNIOESTE), Cascavel, PR, Brazil|Hospital Geral de Nova Iguaçú, Nova Iguaçú, RJ, Brazil|Hospital Deoclécio Marques de Lucena, Parnamirim, RN, Brazil|Hospital Tacchini, Bento Gonçalves, RS, Brazil|Hospital São Camilo de Esteio, Esteio, RS, Brazil|Hospital da Cidade de Passo Fundo, Passo Fundo, RS, Brazil|Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil|Hospital Dom Vicente Scherer, Porto Alegre, RS, Brazil|Hospital Mãe de Deus, Porto Alegre, RS, Brazil|Hospital Nossa Senhora da Conceiçaão, Porto Alegre, RS, Brazil|Hospital Santa Rita, Porto Alegre, RS, Brazil|Pavilhão Pereira Filho, Porto Alegre, RS, Brazil|Hospital Ana Nery, Santa Cruz Do Sul, RS, Brazil|Hospital Santa Cruz, Santa Cruz Do Sul, RS, Brazil|Hospital Dona Helena, Joinville, SC, Brazil|Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto, Ribeirão Preto, SP, Brazil|Hospital do Coração (HCor), São Paulo, SP, Brazil|Hospital Alberto Urquiza Wanderley (UNIMED João Pessoa), João, Brazil|Hospital Montenegro, Montenegro, Brazil",,https://ClinicalTrials.gov/show/NCT02932358
NCT02930473,Evaluation of a Psychotherapeutic Intervention Model in Nursing,,Completed,No Results Available,Anxiety,Behavioral: NIC Psychotherapeutic Intervention(s) for Anxiety|Drug: Psychopharmaceuticals (any drugs prescribed by the psychiatrist),"Change in the Level of Anxiety (NOC outcomes ""Anxiety Level"" and ""Anxiety Self-Control"" - Portuguese version)",Francisco Miguel Correia Sampaio|Universidade do Porto,All,18 Years to 64 Years   (Adult),Not Applicable,133,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",ICBAS 1988,Nov-16,Apr-17,May-17,12-Oct-16,null,16-May-17,,,https://ClinicalTrials.gov/show/NCT02930473
NCT02926352,Effects of Low-Level Laser Stimulation With and Without Fear Extinction Training,,Recruiting,No Results Available,Phobias|Claustrophobia|Social Phobia,Behavioral: Extinction Training|Device: Low-Level Laser Therapy|Device: Sham Low-Level Laser Therapy,Behavioral Approach Test- Generalization Context|Behavioral Approach Test - Treatment Context|Beck Depression Inventory-II (BDI-II)|Beck Anxiety Inventory (BAI)|Claustrophobia Questionnaire (CLQ)|Claustrophobia Concerns Questionnaire (CCQ)|Obsessive Compulsive Inventory-Revised (OCI-R)|Washing Threat Questionnaire (WTQ)|Liebowitz Social Anxiety Scale Self Report Version (LSAS-SR)|Speech Anxiety Thoughts Inventory (SATI)|Anxiety sensitivity Index (ASI-3)|Body Sensations Questionnaire (BSQ),University of Texas at Austin,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,120,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,2013-12-0068,Aug-15,May-18,May-18,6-Oct-16,null,30-Jan-18,"Laboratory for the Study of Anxiety Disorders, Austin, Texas, United States",,https://ClinicalTrials.gov/show/NCT02926352
NCT02926365,BIP in Jämtland Härjedalen: Increased Access to CBT Within Regular Health Care in Northern Sweden,BIPBJÖRN,"Active, not recruiting",No Results Available,Anxiety Disorder|Obsessive-Compulsive Disorder,Behavioral: ICBT,CGI-S|CGI-I|CGAS|CY-BOCS|RCADS|EWSAS|Patient satisfaction|Adverse events,Karolinska Institutet,All,8 Years to 17 Years   (Child),Not Applicable,160,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EPN DNR 2016/1355-31/5,1-Oct-16,Apr-19,Dec-21,6-Oct-16,null,21-Jan-19,"BUP Jämtland Härjedalen, Östersund, Region Jämtland Härjedalen, Sweden",,https://ClinicalTrials.gov/show/NCT02926365
NCT02922166,Effects of SRX246 on an Experimental Model of Fear and Anxiety in Humans,,Unknown status,No Results Available,Fear|Anxiety,Drug: SRX246|Drug: Placebo,Change in startle reflex between SRX246 and Placebo|Change in emotional expression recognition between SRX246 and Placebo|Change in State Anxiety Scale between SRX246 and Placebo,Azevan Pharmaceuticals|National Institute of Mental Health (NIMH),All,21 Years to 50 Years   (Adult),Phase 1,47,Industry|NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AVN012|T-M-1970,3-Feb-17,Dec-17,Dec-18,4-Oct-16,null,9-Feb-17,"National Institute of Mental Health, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT02922166
NCT02920164,Auricular Acupuncture for Exam Anxiety in Medical Students,AAAnx,Completed,No Results Available,Anxiety,Device: Auricular acupuncture|Device: Placebo acupuncture,Intensity of anxiety|heart rate|blood pressure,University Medicine Greifswald,All,19 Years to 35 Years   (Adult),Phase 2,44,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",BB 49/12,Apr-12,Jul-12,Jul-12,30-Sep-16,null,30-Sep-16,"University Medicine of Greifswald, Greifswald, Germany",,https://ClinicalTrials.gov/show/NCT02920164
NCT02920814,Time Intensive CBT for a Specific Phobia of Vomiting,,Completed,No Results Available,Specific Phobia of Vomiting|Emetophobia,Other: Cognitive Behavioural Therapy,Specific Phobia of Vomiting Inventory (SPOVI)|Emetophobia Questionnaire|Patient Health Questionnaire (PHQ-9)|Generalised Anxiety Disorder (GAD7)|Work and Social Adjustment Scale|IAPT Employment Status Questions,King's College London|South London and Maudsley NHS Foundation Trust,All,"18 Years and older   (Adult, Older Adult)",Phase 1,8,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,16/LO/0095,Apr-16,30-Aug-18,30-Aug-18,30-Sep-16,null,5-Dec-18,"Centre for Anxiety Disorders and Trauma, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT02920814
NCT02919241,Diagnostic Interview and One-session Cognitive Therapy in Treatment of Dental Fear,,Recruiting,No Results Available,Dental Fear,Behavioral: Diagnostic interview|Behavioral: Combined interview and treatment.,Change in dental fear|Compliance to care,University of Eastern Finland,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,30,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,UKuopio 001/2016,Aug-16,30-Jun-19,Dec-21,29-Sep-16,null,12-Oct-18,"University of Eastern Finland, Kuopio, Finland",,https://ClinicalTrials.gov/show/NCT02919241
NCT02915874,Does Treating Anxiety Symptoms With ACT Improve Vascular Inflammation and Function?,ACT on Anxiety,Completed,No Results Available,Anxiety,Behavioral: Acceptance and Commitment Therapy,Beck Anxiety Inventory|State-Trait Anxiety Inventory|Flow-mediated dilation of the brachial artery|Pulse Wave Velocity|Forearm blood flow|Muscle sympathetic nerve activity,University of Iowa,All,"25 Years to 65 Years   (Adult, Older Adult)",Not Applicable,117,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,201409782,Oct-14,Dec-17,Dec-17,27-Sep-16,null,18-May-18,"University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States",,https://ClinicalTrials.gov/show/NCT02915874
NCT02916550,Breathing Intervention for Cardiac Anxiety,,Recruiting,No Results Available,Atrial Fibrillation|Implantable Cardioverter Defibrillator,Behavioral: Breathing exercise,Cardiac anxiety|Disability|Wellbeing|ICD anxiety|Arrhythmia burden,"Laureate Institute for Brain Research, Inc.|University of Arizona",All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,50,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Laureateinstitute,Sep-16,Sep-19,Sep-19,27-Sep-16,null,23-Oct-17,"Laureate Institute for Brain Research, Tulsa, Oklahoma, United States",,https://ClinicalTrials.gov/show/NCT02916550
NCT02911324,Cannabinoid Medication for Adults With OCD,,Completed,No Results Available,Obsessive-Compulsive Disorder,Drug: Nabilone|Behavioral: Exposure and Response Prevention Therapy,Change in Yale-Brown Obsessive Compulsive Scale|Feasibility of Recruitment,New York State Psychiatric Institute,All,18 Years to 60 Years   (Adult),Phase 1|Phase 2,16,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,7239,Sep-16,Jan-19,Jan-19,22-Sep-16,null,21-Jan-19,"New York State Psychiatric Institute, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT02911324
NCT02911441,Evaluating CBT Delivered by Community Health Workers on Maternal Mental Health and Infant Cognitive Development in Insecure Environments,,Unknown status,No Results Available,Maternal Anxiety|Maternal Depression|Infant Cognitive Development,Behavioral: Cognitive Behavioral Therapy,Symptoms of anxiety and depression as measured by Hopkins Symptoms Checklist|Infant Cognitive Development as measured by Mullen Scales of Early Learning,Heartland Alliance,Female,"Child, Adult, Older Adult",Not Applicable,262,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0721-03,Dec-15,Oct-16,Oct-16,22-Sep-16,null,22-Sep-16,"Heartland Alliance International, Bukavu, South Kivu, Congo, The Democratic Republic of the",,https://ClinicalTrials.gov/show/NCT02911441
NCT02909660,What Are You Looking for? Psychometric and Experimental Analyses of Reassurance Seeking in Obsessive-compulsive Disorder,,Terminated,No Results Available,Obsessive-Compulsive Disorder,Other: Cognitive-behavioural therapy,"Self-reported reassurance seeking behaviour|Self-reported support-seeking behaviour|Self-reported anxiety|One-week follow-up: Treatment Acceptability and Adherence Scale (TAAS; Milosevic, Levy, Alcolado, & Radomsky, 2015)|One-week follow-up: Endorsement and Discomfort Scales (EDS; Tarrier, Liversidge, & Gregg, 2006)|Three-week follow-up: Treatment Acceptability and Adherence Scale (TAAS; Milosevic, Levy, Alcolado, & Radomsky, 2015)|Three-week follow-up: Endorsement and Discomfort Scales (EDS; Tarrier, Liversidge, & Gregg, 2006)|Change in self-reported reassurance-seeking|Change in anxiety","Concordia University, Montreal",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,7,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,30006114,Sep-16,Oct-17,Nov-17,21-Sep-16,null,12-Dec-17,"Concordia University, Montreal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT02909660
NCT02907138,Medical Yoga for Patients With Stress-related Symptoms,,Recruiting,No Results Available,Stress-related Illness/Anxiety,Other: Medical Yoga|Other: Treatment as Usual (physical therapy),"Perceived Stress Scale (PSS)|Hospital Anxiety and Depression Scale (HADS)|Health-related quality of Life; EQ5D|Thorax excursion: Measured in centimeters with tape measure, chest size at the level of processus xiphoideus, the difference between the maximum inhalation and exhalation is registered|Health-related quality of Life; EQ-VAS",Maria Larsson|Vastra Gotaland Region,All,"18 Years to 100 Years   (Adult, Older Adult)",Not Applicable,40,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,VGFOUGSB-602221,Sep-16,Dec-19,Dec-19,20-Sep-16,null,1-May-18,"Narhalsan Gibraltar rehabmottagning, Gothenburg, Sweden",,https://ClinicalTrials.gov/show/NCT02907138
NCT02907476,The Treatment of Depression With Yoga and Walking,,Recruiting,No Results Available,Depression|Major Depressive Disorder|PTSD|Anxiety,Behavioral: Iyengar Yoga|Behavioral: Walking,Brain gamma amino-butyric acid (GABA) levels (change will be measured)|Beck Depression Index Inventory (BDI-II)|Spielberger State-Trait Anxiety Inventory (STAI)|Exercise-Induced feeling Inventory (EIFI)|Pittsburgh Sleep Quality Index (PSQI)|Positivity Self Test (PST)|Columbia Suicide Safety Rating (C-SSR)|PTSD Check List - Civilian (PCL-C)|Patient Health Questionnaire 9 (PHQ-9),Boston University|Partners HealthCare|National Center for Complementary and Integrative Health (NCCIH),All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,900,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,H-34681|5R01AT007483-05,4-Jan-17,30-Jul-19,30-Jul-19,20-Sep-16,null,6-Jun-18,"Solomon Carter Fuller Building, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT02907476
NCT02908321,CBT for Anxiety Disorder in Children With Co-morbid ASD,,Recruiting,No Results Available,Randomized Treatment Study,Behavioral: CBT,"Anxiety Disorders Interview Schedule for DSM-IV: Parent & Child interview schedule (ADIS/CP).|Spence Children's Anxiety Scale (SCAS),|Children's Anxiety Life Inference Scale (CALIS)|Children's Automatic Thoughts Scale (CATS).",University of Aarhus,All,7 Years to 14 Years   (Child),Not Applicable,50,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2016-2018,Aug-16,Dec-19,Dec-19,20-Sep-16,null,24-Apr-19,"Centre for Child and Adolescent Psychiatry, Risskov, Region Of Midtjylland, Denmark",,https://ClinicalTrials.gov/show/NCT02908321
NCT02904356,Repetitive Transcranial Magnetic Stimulation (rTMS) for Obsessive-Compulsive Disorder (OCD),,Terminated,No Results Available,Obsessive-Compulsive Disorder,Device: Repetitive transcranial magnetic stimulation,Change in functional magnetic resonance imaging (fMRI) BOLD response,Columbia University,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,3,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,AAAQ8771,Oct-16,Oct-18,Oct-18,19-Sep-16,null,28-Mar-19,"Columbia University Medical Center, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT02904356
NCT02905279,Spider Phobia Opposite Action Treatment Study,,Unknown status,No Results Available,Specific Phobia,Behavioral: Biofeedback Relaxation Training|Behavioral: Exposure Therapy|Behavioral: Exposure with Threat-Relevant Opposite Actions|Behavioral: Exposure with Threat-Irrelevant Opposite Actions,Change in Performance on a Behavioral Approach Test in a Generalization Context (Pre-treatment to 2-week Follow-Up)|Change in Performance on a Behavioral Approach Test in a Generalization Context (Pre-treatment to Post-treatment)|Change in Performance on a Behavioral Approach Test in the Treatment Context (Pre-treatment to 2-week Follow-Up)|Change in Performance on a Behavioral Approach Test in the Treatment Context (Pre-treatment to Post-treatment)|Change in Fear of Spiders Questionnaire (Pre-treatment to 2-week Follow-Up)|Change in Armfield and Mattiske Disgust Questionnaire (Pre-treatment to 2-week Follow-Up)|Change in Spider Belief Questionnaire from pre-treatment to follow-up (Pre-treatment to 2-Week Follow-Up),University of Texas at Austin,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,120,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2015-07-0020,Jun-16,Dec-17,Dec-17,19-Sep-16,null,19-Sep-16,"Laboratory for the Study of Anxiety Disorders, University of Texas at Austin, Austin, Texas, United States",,https://ClinicalTrials.gov/show/NCT02905279
NCT02906033,"The Effect of A New Perioperative Practice Model on Patient, Nursing And Organisational Outcomes",,"Active, not recruiting",No Results Available,"Arthroplasties, Hip Replacement|Arthroplasties, Knee Replacement",Other: New perioperative practice model,Change from baseline Health Related Quality of Life at three months after the surgical procedure|Change from baseline Surgery-related anxiety at three months after the surgical procedure|Quality of perioperative care as experienced by surgical patients,Hospital District of Helsinki and Uusimaa|University of Turku|Karlstad University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,490,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Health Services Research,TYH2014211|U1111-1185-9612,Sep-16,Dec-18,Dec-18,19-Sep-16,null,21-Dec-17,"Peijas Hospital / Helsinki University Hospital, Vantaa, Finland",,https://ClinicalTrials.gov/show/NCT02906033
NCT02902952,Physical Exercise to Reduce Anxiety in Underserved Children With ASD,PETRA,Recruiting,No Results Available,Physical Exercise Condition|Control Condition,Behavioral: Physical Exercise|Behavioral: Control Intervention,Anxiety rating|Salivary Cortisol,"University of California, Irvine|Massachusetts General Hospital|University of Missouri-Columbia",All,6 Years to 12 Years   (Child),Not Applicable,220,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HS 2016-2859,Oct-16,Dec-20,Dec-21,16-Sep-16,null,16-Apr-19,"2500 Red Hill Avenue, Santa Ana, California, United States|Thompson Center for Autism, Columbia, Missouri, United States",,https://ClinicalTrials.gov/show/NCT02902952
NCT02903030,Probiotics for Quality of Life in Autism Spectrum Disorders,,Completed,No Results Available,Autism Spectrum Disorders|Anxiety,Drug: Maltose (placebo)|Drug: Visbiome Extra Strength,"Change in Gastrointestinal (GI) Module of the Pediatric Quality of Life Inventory (PedsQL) (Varni et al., 2001; (Varni, Burwinkle, & Seid, 2006; Varni et al, 2014)|Change in Target Symptom Rating (Arnold et al, 2003)|Change in Parent Anxiety Checklist--ASD (Scahill, Lecavalier, Bears, & Aman, 2015)|Change in The Aberrant Behavior Checklist (ABC) (Aman et al., 1985a, 1985b)|Change in Social Responsiveness Scale (SRS) (Costantino et al., 2003)|Change in Children's Sleep Habits Questionnaire (CSHQ) (Owens, Spirito, & Mcguinn, 2000)|Change in The Parenting Stress Index Short Form (PSI) (Abidin,1995)",Ohio State University|Autism Treatment Network|Autism Speaks,All,3 Years to 12 Years   (Child),Early Phase 1,12,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",2016H0174,Aug-16,1-Dec-17,1-Dec-17,16-Sep-16,null,14-Dec-17,"Ohio State University Wexner Medical Center, Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02903030
NCT02901080,Clinical and Cost Effectiveness of Alpha-Stim AID CES,,Unknown status,No Results Available,Anxiety,Device: Alpha Stim AID cranial electrotherapy stimulation|Behavioral: Pregnancy test|Other: Anxiety questionnaire|Other: Quality of life questionnaire|Other: Work and social questionnaire|Other: Sleep questionnaire|Other: Depression questionnaire|Other: Quality of life and financial questionnaire,Clinical effectiveness in generalised anxiety disorder|Cost effectiveness in generalised anxiety disorder|Clinical effectiveness in depression|Clinical effectiveness in insomnia,"Electromedical Products International, Inc.",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,120,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,206555,Sep-16,Sep-17,Sep-17,15-Sep-16,null,15-Sep-16,"Leicestershire and Rutland Improving Access to Psychological Therapies (IAPT) Service, Nottingham, Nottinghamshire, United Kingdom",,https://ClinicalTrials.gov/show/NCT02901080
NCT02902159,RCT of the Effectiveness of Big White Wall Compared to Other Online Support,REBOOT,Recruiting,No Results Available,Depression|Anxiety,Other: BWW Online Peer Support|Other: NHS Moodzone Online Information,Warwick-Edinburgh Mental Well-being Scale - 14 Item|Generalised Anxiety Disorder 7 Item Scale (GAD-7)|Personal Health Questionnaire 9 Item (PHQ-9) 11|SF-12 v2 Health Survey 12|Work and Social Adjustment Scale 8 Item - Social Function 13|8-item social support measure14|12-item Brugha Inventory of Life Events15|8-item Standardised Assessment of Personality-Abbreviated Scale (SAPAS,University of Nottingham,All,"16 Years and older   (Child, Adult, Older Adult)",Not Applicable,2200,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Health Services Research,CLAHRC-EM 16053,Sep-16,Jun-18,Dec-18,15-Sep-16,null,15-Feb-18,"Nottinghamshire Healthcare NHS foundation Trust., Nottingham, Nottinghamshire, United Kingdom|Nottingham University Hospitals Nhs Trust, Nottingham, Nottinghamshire, United Kingdom",,https://ClinicalTrials.gov/show/NCT02902159
NCT02902458,Psychological Intervention modifiEs Outcome of Patients With implAntable Cardioverter dEfibrillator: The PEACE Study,PEACE,Completed,No Results Available,Implantable Defibrillator User,Other: Individual interview with a qualified psychologist,Mini International Neuropsychiatric Interview score|Quality of life|State-Trait Anxiety Inventory|Minnesota Living with Heart Failure questionnaire,Centre Hospitalier Universitaire de Besancon,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,18,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,P/2014/217,Sep-14,Aug-16,Aug-16,15-Sep-16,null,15-Sep-16,"CHU Besancon, Besancon, France",,https://ClinicalTrials.gov/show/NCT02902458
NCT02899806,Impact of a Video Explaining Epidural Analgesia in Obstetrics,VIDEOCLIP,"Active, not recruiting",No Results Available,Difficulty Processing Information,Other: Written Information|Other: Video Information,Satisfaction evaluated by numerical scale from 0 to 10|Comprehension was evaluated by by multiple choice questions with a final score of 10|Anxiety was evaluated by numerical scale from 0 to 10,Centre Hospitalier Intercommunal Creteil,Female,18 Years to 60 Years   (Adult),Not Applicable,301,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,VIDEOCLIP,Sep-15,Oct-15,Oct-17,14-Sep-16,null,1-Aug-17,"Centre Hospitalier Intercommunal, Creteil, France",,https://ClinicalTrials.gov/show/NCT02899806
NCT02895906,Safety and Efficacy Study of NFC-1 in Subjects Aged 12-17 Years With 22q11.2DS & Associated Neuropsychiatric Conditions,,Completed,No Results Available,22q11.2 Deletion Syndrome,Drug: NFC-1,"Time to symptom relapse|Response to treatment based on Clinical Global Impression - Improvement scale|Safety and tolerability as determined by AEs, laboratory results, C-SSRS, and K-SADS",Aevi Genomic Medicine,All,12 Years to 17 Years   (Child),Phase 1,2,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MDGN-NFC1-22Q-101,28-Nov-16,13-Apr-17,20-Apr-17,12-Sep-16,null,27-Apr-17,"Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT02895906
NCT02892825,Music Listening for Cataract Surgery,MUSICATOP,Recruiting,No Results Available,Cataract Surgery,Other: Music|Other: No Music,Hypertensive event|Anxiety score before surgery|Anxiety score after surgery|Duration of surgery|Intraoperative surgical complications,Assistance Publique - Hôpitaux de Paris,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,400,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care,K150903|2016-A00728-43,2-Feb-17,Jul-18,Jul-18,8-Sep-16,null,19-Mar-18,"Cochin Hospital, Paris, France",,https://ClinicalTrials.gov/show/NCT02892825
NCT02889172,Intervention for Reducing Psychiatric Symptoms and Metabolic Variables in Patients With Diabetes Mellitus (DM),DM,Unknown status,No Results Available,"Diabetes Mellitus, Type 2",Behavioral: Problem Solving Therapy,Beck Depression Inventory|Beck Anxiety Inventory|Simplified Medication Adherence Questionnaire,Instituto Nacional de Psiquiatría Dr. Ramón de la Fuente|Universidad Nacional Autonoma de Mexico,All,"35 Years to 70 Years   (Adult, Older Adult)",Not Applicable,70,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,SC-14-2411,Feb-15,Jan-17,Dec-17,5-Sep-16,null,7-Sep-16,"Instituto Nacional de Psiquiatría Dr. Ramón de la Fuente, Mexico city, Mexico",,https://ClinicalTrials.gov/show/NCT02889172
NCT02888028,Quality of Life and Device Acceptance in Patients With ICD Undergoing Remote ICD FU,,Completed,No Results Available,Anxiety|Depression,Procedure: ICD remote monitoring|Other: Control group,"Influence of ICD remote monitoring on Quality of Life, measured by the EQ5D questionnaire|Influence of ICD remote monitoring on levels of anxiety and depression, measured by the HADS questionnaire (Hospital Anxiety and Depression scale)|Influence of ICD remote monitoring on device acceptance, measured by the Florida Patient acceptance scale (FPAS)",Klinikum der Universitaet Muenchen|Klinikum Bielefeld,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,182,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GE IDE MucM001-11,May-11,Apr-14,Jun-14,2-Sep-16,null,21-Jun-18,"Bielefeld University, School of public health, Bielefeld, Germany|Munich University Clinic, Campus Grosshadern, Munich, Germany",,https://ClinicalTrials.gov/show/NCT02888028
NCT02886351,High-Concentration Nitrous Oxide for Dental Procedural Sedation in Children,,Unknown status,No Results Available,Anxiety,Drug: Nitrous Oxide,Achieving cooperation in Pediatric dentistry numerical scale,Bnai Zion Medical Center,All,3 Years to 15 Years   (Child),Not Applicable,30,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BnaiZionMC-16-MS-002,Jan-17,Jan-18,Jun-18,1-Sep-16,null,1-Sep-16,,,https://ClinicalTrials.gov/show/NCT02886351
NCT02886780,"""Concentrated Exposure Treatment"" (cET) for for Obsessive Compulsive Disorder",,"Active, not recruiting",No Results Available,Obsessive Compulsive Disorder (OCD),Behavioral: Concentrated exposure treatment (cET)|Behavioral: Self-help,Changes in Y-BOCS from pre cET-treatment to post treatment/ waiting list/ self-help|Changes i OCD diagnostic status (DSM-5) as measured by SCID|Well-being|Work and social adjustment|Generalized anxiety|Depression|Insomnia|Client satisfaction,Haukeland University Hospital|Sorlandet Hospital HF,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,48,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2016/794 (REK vest),Sep-16,Aug-19,Jun-20,1-Sep-16,null,5-Mar-19,,,https://ClinicalTrials.gov/show/NCT02886780
NCT02887027,"Exercise, Mood and Stress Study",,Completed,No Results Available,Anxiety|Post-Traumatic Stress Disorder|Depression,Behavioral: Exercise4Mood Intervention,Credibility-Expectations Questionnaire (CEQ)|Client Satisfaction Questionnaire (CSQ-8)|7-Day Physical Activity Recall (PAR)|Physical Activity measured in METS (assessed via Actigraphy)|Anxiety Sensitivity Index (ASI)|Center for Epidemiological Studies-Depression (CES-D)|PTSD Checklist for DSM 5 (PCL) - for individuals with PTSD diagnosis only|Depression Anxiety Stress Scale 21 (DASS 21),Boston University Charles River Campus|Clara Mayo Fellowship,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,4,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,4017,Feb-16,May-17,May-17,1-Sep-16,null,14-Jul-17,,,https://ClinicalTrials.gov/show/NCT02887027
NCT02884674,Repetitive Transcranial Magnetic Stimulation in Obsessive Compulsive Disorder,MAGTOC,Recruiting,No Results Available,Obsessive-Compulsive Disorder,Device: Active Repetitive Transcranial Magnetic Stimulation|Device: Placebo Repetitive Transcranial Magnetic Stimulation,"Change from baseline of the score at the Yale - Brown Obsessive and Compulsive Scale|Score of Montgomery and Asberg Depression Rating Scale, as a Measure of effects on Mood (depression)|Score of Young Mania Rating Scale, as a Measure of effects on Mood (hyperthymia)|Score of Multidimensional Assessment of Thymic States Scale as a Measure of effects on Emotional Reactivity|Number of patients with Side effects as a measure of Safety and Tolerability|Inferior Frontal Region Activity (percentage of the BOLD signal change (parameter estimates beta)|Fractional Anisotropy (FA), mean and radial diffusivity (MD, RD), tracti integrity of the inhibition network,|Yale - Brown Obsessive and Compulsion Scale score after the TMS treatment as an evaluation of the persistence of the clinical benefit|Cortical Excitability|Evaluation of Impulsivity using specific scales|Evaluation of the Clinical global State|type of side effects (pain, paresthesia, other) as a measure of Safety and Tolerability","University Hospital, Grenoble",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,56,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",38RC14.156|2014-A00668-39,May-15,Nov-17,May-20,31-Aug-16,null,15-May-18,"CHU de Grenoble - Pavillon Dominique Villars, Grenoble, Rhone Alpes, France",,https://ClinicalTrials.gov/show/NCT02884674
NCT02885285,"The Impact of Three Distinct Exercise Types on Fatigue, Anxiety, and Depression in Parkinson's Disease",PD&Exercise,Terminated,No Results Available,Parkinson's Disease,Behavioral: Spinning Class|Behavioral: Yoga Class|Behavioral: Dance Class|Other: No Exercise Class,"Change from baseline, if any, in subjects' Fatigue Severity Scale|Change from baseline, if any, in subjects' Zung self-report Anxiety Scale|Change from baseline, if any, in subjects' Beck Depression Inventory II scale",Dartmouth-Hitchcock Medical Center|Parkinson's Disease Foundation,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,2,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AWD00010460,Aug-16,24-Feb-17,24-Feb-17,31-Aug-16,null,26-Jul-17,"Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States",,https://ClinicalTrials.gov/show/NCT02885285
NCT02880202,Impact of Massage Therapy on the Quality of Life of Hospice Patients,,Completed,No Results Available,Pain|Anxiety|Depression|Quality of Life,Other: Massage Therapy,Change in Edmonton Symptom Assessment System - Revised|Change in Edmonton Symptom Assessment System - Revised (Other symptoms)|Change in Linear Analogue Self Assessment (LASA)|Change in Patient Health Questionnaire for Depression and Anxiety (PHQ-4)|Change in Pearlin role overload measure (ROM),Mayo Clinic,All,"Child, Adult, Older Adult",Not Applicable,53,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,15-007515,Aug-16,Nov-18,Dec-18,26-Aug-16,null,25-Dec-18,"Mayo Clinic, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT02880202
NCT02878928,Clinical Study Evaluating Effects of Pharmacogenetic-guided vs Standard-of-Care Treatment on Depression and/or Anxiety,,Completed,No Results Available,Depression|Anxiety,Genetic: IDgenetix Neuropsychiatric Test Panel,"The reduction of adverse drug events (ADE) subsequent to pharmacogenetics-guided treatment as compared to standard of care for treatment of depression and/or anxiety symptoms.|Change in the Hamilton Rating Scale for Depression (HAMD-17) score from baseline.|Change in the Hamilton Rating Scale for Anxiety (HAM-A) score from baseline.|Percentage of depression subjects who respond (≥50% decrease in HAM-D17 from baseline or remit, HAM-D17 total score ≤7).|Percentage of anxiety subjects who respond (≥50% decrease in HAM-A from baseline or remit, HAM-A total score ≤7)|Time to response/remission of depressive symptoms.|Time to response/remission of anxiety symptoms.|Medication change: Number of subjects who changed their antidepressant and anxiety medication regimens from baseline.|The impact of pharmacogenetic-guided treatment.care costs as measured by HMWDQ",AltheaDx|Innovis LLC,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,579,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Diagnostic",CLP-0009,May-16,Dec-16,Dec-16,25-Aug-16,null,19-Dec-16,"Adnab Research, Rolling Hills, California, United States|Artemis Clinical Research, San Diego, California, United States|Adnab Research, Torrance, California, United States|Collaborative Neuroscience Network, Torrance, California, United States|Innovative Clinical Research, Lauderhill, Florida, United States|Innova Clinical Trials, Miami, Florida, United States|APG Research, Orlando, Florida, United States|iResearch Atlanta, Decatur, Georgia, United States|Meridian Clinical Research, Savannah, Georgia, United States|Medpharmics, Metairie, Louisiana, United States|Meridian Clinical Research, Norfolk, Nebraska, United States|United Medical Associates, Binghamton, New York, United States|Richmond Behavioral Associates, Staten Island, New York, United States|Carolina Partners in Mental HealthCare, Raleigh, North Carolina, United States|Detweiler Family Medicine, Lansdale, Pennsylvania, United States|Relaro Medical Trials, Dallas, Texas, United States|Tidewater Clinical Research, Virginia Beach, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02878928
NCT02877875,Student Outcomes of Integrative Mental Health Services,,Recruiting,No Results Available,Anxiety|Depression|Trauma|Behavior Problems,"Behavioral: Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, and Conduct Problems|Other: Monitoring and Feedback System|Behavioral: Treatment as usual","Change from Baseline Behavior and Emotions Survey (BES) at End of Treatment, at 6-month Follow-Up, and Weekly and Monthly Progress Monitoring|Change from Baseline Top Problems Assessment (TPA) at End of Treatment, at 6-month Follow-Up, and Weekly and Monthly Progress Monitoring|Change from Baseline National Survey of American Families (NSAF) Parent School Engagement Scale at End of Treatment, at 6-month Follow-Up, and Weekly Progress Monitoring|Academic outcomes, assessed via school grades and standardized test performance|Youth Self-Report (YSR)|Child Behavior Checklist (CBCL)|Teacher Report Form (TRF)|UCLA Post-traumatic Stress Disorder Reaction Index|Services Assessment for Children and Adolescents (SACA)|Therapeutic Alliance Scale (TASC)|Caregiver Satisfaction Questionnaire|Youth Satisfaction Questionnaire|Therapist Satisfaction Inventory (TSI)|Emotion Regulation Checklist (ERC)|Brief Symptom Inventory (BSI)|The Children's Emotion Management Scale (CEMS)|The Children's Response Style Questionnaire (CRSQ)|Perceived Control Scale for Children (PCSC)|Secondary Control Scale for Children (SCSC)|Implicit Theories of Personality Measure|Reduced Aggression and Victimization Scales (RAVS)|Implicit Theories of Thoughts, Emotions, and Behaviors Scale (ITEB-Q)|Children's Alexithymia Scale (CAS)|Evidence-Based Practice Attitudes Scale (EBPAS)|Academic Competence Evaluation Scales|The School Engagement Measure-MacArthur Network",Harvard University,All,7 Years to 13 Years   (Child),Not Applicable,168,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",R305A140253,Jan-15,Jul-20,Jul-20,24-Aug-16,null,9-Aug-18,"Harvard University, Cambridge, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT02877875
NCT02875912,Prospective Evaluation of Family Care Rituals in the ICU,FCR,Completed,No Results Available,"Stress Disorders, Post-Traumatic|Depression|Anxiety",Behavioral: Family Care Rituals,Symptoms of Post-Traumatic Stress Disorder in family members of intensive care patients|Symptoms of depression in family members of intensive care patients|Symptoms of anxiety in family members of intensive care patients|Family satisfaction with ICU care|Congruency of goals of care|Validation of the End of Life Scoring System (ENDING-S)|ICU length of stay|Use of palliative/spiritual care during ICU stay|Location of discharge from ICU,Brown University|James M. Cox Foundation,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,452,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,763434-9,Sep-15,12-Mar-17,12-Jun-17,23-Aug-16,null,13-Jul-17,"Rush University Medical Center, Chicago, Illinois, United States|Brown University, Providence, Rhode Island, United States|Azienda Ospedaliero-Universitaria Careggi, Florence, Italy",,https://ClinicalTrials.gov/show/NCT02875912
NCT02874417,Computerized Psychoeducation for Anxiety Sensitivity,,Completed,No Results Available,Anxiety Sensitivity,Behavioral: CAST psychoeducation|Behavioral: PHET,Anxiety Sensitivity Index-3,Florida State University,Male,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,54,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention,Norr01,Sep-13,Nov-14,Nov-14,22-Aug-16,null,22-Aug-16,,,https://ClinicalTrials.gov/show/NCT02874417
NCT02873455,Effects of Video Information on Preoperative Anxiety in Patients With Colorectal Cancer,,Unknown status,No Results Available,Colorectal Cancer|Video Information,"Other: Short video clip including the circumstance of operation theater, and surgeon's interview",Change of APAIS ((Amsterdam preoperative anxiety and information scale) from baseline APAIS to watching video.|Change of HADS (Hospital Anxiety and Depression Scale) from baseline HADS to watching video.|Postoperative hospital stay,Seoul National University Hospital,All,"20 Years to 75 Years   (Adult, Older Adult)",Not Applicable,32,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,B-1608-359-302,Aug-16,May-17,Dec-17,19-Aug-16,null,26-Apr-17,,,https://ClinicalTrials.gov/show/NCT02873455
NCT02872051,Integrated Mental Health Care and Vocational Rehabilitation to Individuals on Sick Leave Due to Anxiety and Depression,IBBIS,"Active, not recruiting",No Results Available,Generalized Anxiety|Social Phobia|Panic Disorder|Depression,Behavioral: IBBIS mental health care and standard vocational rehabilitation|Other: Integrated mental health care and vocational rehabilitation,Time to return to work|Work|Recurrent Sickness Absence|Degree of depressive symptoms|Degree of anxiety symptoms|Degree of psychological stress symptoms|Work and social functioning,"Mental Health Centre Copenhagen|The Danish Agency for Labour Market and Recruitment|Copenhagen Municipality, Denmark|Gentofte Municipality, Denmark|Municipality of Lyngby-Taarbæk, Denmark|Gladsaxe Municipality, Denmark",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,603,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Other",IBBIS Anxiety Depression,Apr-16,Jun-19,Dec-20,18-Aug-16,null,13-Mar-19,"Mental Health Services of the Capital Region of Denmark, Copenhagen, Capital Region Of Denmark, Denmark",,https://ClinicalTrials.gov/show/NCT02872051
NCT02867449,Metacognitive Therapy for Obsessive-Compulsive Disorder,,Recruiting,No Results Available,Obsessive-Compulsive Disorder (OCD),Behavioral: Metacognitive Therapy|Behavioral: Exposure and Response Prevention,"Change in Symptom Severity (Yale Brown Obsessive-Compulsive Scale; Y-BOCS)|Change in Symptom Severity (Padua Inventory; PI)|Change in general psychopathology (Symptom Checklist-90-Revised, SCL-90-R)|Change in Metacognitions (Metacognitions Questionnaire, short version, MCQ-30)|Change in Obsessive Beliefs (Obsessive Beliefs Questionnaire, OBQ)|Change in Behavioral Avoidance (Behavioral Avoidance Test, BAT)|Change in Depression (Beck Depression Inventory, BDI-II)|Change in Anxiety (Beck Anxiety Inventory, BAI)|Change in Symptom Severity (Clinical Global Impressions; CGI)|Change in psychosocial functioning (Global Assessment of Functioning Scale, GAF)|Change in quality of life (The World Health Organization Quality of Life, WHOQOL_BREF)|Difference in efficiency (length of treatment)|Difference in medical costs (based on the length of treatment)|Difference in negative effects of psychotherapy (Inventory for the Assessment of Negative Effects of Psychotherapy, INEP)|Difference in satisfaction with the treatment",University of Leipzig|Philipps University Marburg Medical Center|German Research Foundation,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,70,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",MCT_OCD,Jun-16,Nov-18,Apr-19,16-Aug-16,null,26-Jun-18,"Leipzig University, Leipzig, Germany|Philipps University Marburg, Marburg, Germany",,https://ClinicalTrials.gov/show/NCT02867449
NCT02867644,Conversational Hypnosis in Women Undergoing Imaging for Breast Cancer,HYCOREMA,Recruiting,No Results Available,Breast Cancer,Other: standard care|Other: standard care + conversational hypnosis,Compare anxiety of patients undergoing for a preoperative breast marking under ultrasound according two different procedures (standard care versus standard care with conversational hypnosis)|Compare the pain felt by patients during a preoperative breast marking under ultrasound according two different procedures (standard care versus standard care with conversational hypnosis)|Compare the manipulator's satisfaction during a preoperative breast marking under ultrasound according two different procedures (standard care versus standard care with conversational hypnosis)|Evaluate the receptivity of women to conversational hypnosis|Assess the impact of conversational hypnosis on completion of the examination,Institut de Cancérologie de Lorraine,Female,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,334,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care,2016-A00232-49,17-Nov-16,Nov-19,Nov-19,16-Aug-16,null,24-Jan-19,"CH Bastia, Bastia, France|Chu Bordeaux-Pellegrin, Bordeaux, France|CHRU de Brest, Brest, France|Centre Léon Bérard, Lyon, France|APHM La Timone, Marseille, France|Centre Paul Strauss, Strasbourg, France|Institut de Cancerologie de Lorraine, Vandoeuvre Les Nancy, France",,https://ClinicalTrials.gov/show/NCT02867644
NCT02868983,Integrating Behavioral Health and Primary Care for Comorbid Behavioral and Medical Problems,IBHPC,Enrolling by invitation,No Results Available,Arthritis|Asthma|Chronic Obstructive Lung Disease|Diabetes|Heart Failure|Hypertension|Anxiety|Chronic Pain|Depression|Fibromyalgia|Insomnia|Irritable Bowel Syndrome|Problem Drinking|Substance Use Disorder,Other: Integration,PROMIS-29 v2|CAHPS 12-Month PCMH Adult Questionnaire 2.0|Consultation and Relational Empathy measure|Patient Activation Measure-13|Modified Self-reported Medication-taking Scale|Patient Report of Utilization|Restricted Activity Days|Duke Activity Status Index|Hgb A1C|30-day use|Global Appraisal of Individual Needs - Short Screener|Systolic blood pressure|Asthma Symptom Utility Index,"University of Vermont|Arizona State University|State University of New York at Buffalo|Case Western Reserve University|DARTNet|National Committee for Quality Assurance|University of Massachusetts, Worcester",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,3000,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research,WLPS-1409-24372,Apr-16,Apr-21,Apr-21,16-Aug-16,null,17-Apr-19,"University of Vermont, Burlington, Vermont, United States",,https://ClinicalTrials.gov/show/NCT02868983
NCT02869035,Treatment Outcome in Major Depressive Disorder,,Recruiting,No Results Available,Major Depressive Disorder,Drug: Escitalopram|Drug: Duloxetine,Binary treatment outcome in terms of remission from depression.|Baseline cerebral 5-HT4R binding as imaged by 11C-SB207145 PET.|Changes from baseline in cerebral 5-HT4R binding as imaged by 11C-SB207145 PET|Baseline hippocampus volume|Changes from baseline in hippocampus volume.|Baseline fMRI BOLD response to an emotional faces paradigm|Changes from baseline in fMRI BOLD response to an emotional faces paradigm|Baseline fMRI BOLD response to reward paradigm.|Changes from baseline in fMRI BOLD response to reward paradigm|Baseline rsfMRI based spontaneous co-fluctuations in low frequency BOLD signal (functional connectivity)|Changes from baseline in rsfMRI spontaneous co-fluctuations in low frequency BOLD signal (functional connectivity)|Sexual function in depression|Changes in sexual function|Baseline EEG including event related potentials (ERP)|Changes in EEG including event related potentials (ERP)|Cortisol awakening response|Changes in cortisol awakening response (HPA-axis dynamics)|Systemic inflammation peripheral blood hsCRP and immunoactive cytokines|Changes in systemic inflammation peripheral blood hsCRP and immunoactive cytokines|Systemic oxidative stress in terms of 8-oxodG and 8-oxoGuo in urine|Changes in systemic oxidative stress in terms of 8-oxodG and 8-oxoGuo in urine|Early life Stress|Performance on Verbal Affective Memory Tasks (VAMT-26).|Performance on Moral Judgement Task|Performance on Letter-Number Sequence Task.|Changes from baseline in HAMD-6 score|HAMD-6 score after 8 and 12 weeks of antidepressant treatment|Regional 5-HT4R binding|Sexual side-effects from antidepressant treatment|Baseline latent variable construct of self-reported mental state|Baseline self reported family history of mood disorders|Changes from baseline in self-reported mental state questionnaire-based latent variable construct|Total daily cortisol output|Changes in total daily cortisol output|Parental bonding quality|5-HTTLPR genotype status|Epigenetic FK506-binding protein 51 (FKBP5) status at baseline|Changes in epigenetic FKBP5 status from baseline|Epigenetic 5-HTTLPR status at baseline|Changes in epigenetic 5-HTTLPR status from baseline|Epigenetic spindle and kinetochore associated complex subunit 2 (SKA2) status at baseline|Changes in epigenetic SKA2 status from baseline|Performance on Face and Eyes Emotion Recognition Task|Performance on Intensity Morphing Task|Performance on Social Information Preference Task|Performance on Simple Reaction Time.,"Rigshospitalet, Denmark|Center for Integrated Molecular Brain Imaging, Copenhagen, Denmak|Psychiatric Centre Copenhagen|Central Visitation, Region Hovedstaden",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,100,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,NP1,Aug-16,Jul-19,Jul-19,16-Aug-16,null,2-Jun-17,"Neurobiology Research Unit, Rigshospitalet, Copenhagen, Denmark",,https://ClinicalTrials.gov/show/NCT02869035
NCT02861066,Abbreviating Mindfulness-Based Therapy for Depressive and Anxious Symptoms,,Completed,No Results Available,Anxiety|Depression|Mood,Behavioral: Mindfulness-based Intervention,Change from Baseline Depressive Symptoms at 6 Weeks|Change from Baseline Anxiety Symptoms at 6 Weeks|Change from Baseline Mental Wellbeing at 6 Weeks,Sunnybrook Health Sciences Centre,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,54,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,387-2105,Aug-16,Mar-17,Mar-17,10-Aug-16,null,20-Sep-18,,,https://ClinicalTrials.gov/show/NCT02861066
NCT02862236,The Acute Effect of Hypericum Perforatum on Short-Term Memory in Healthy Adults,,Completed,No Results Available,Subclinical Anxious Adults|Nootropic Potential of Hypericum and Alprazolam|Healthy Adults,Drug: Hypericum perforatum extract,Go/no-go task|Digit span task|Symmetry span task|Operation span task|Groton's Maze task|DASS-21|PANAS|STAI,"Prof. Eldad Yechiam|Beer Yaakov – Ness Ziona Mental Health Center|Technion, Israel Institute of Technology",All,18 Years to 40 Years   (Adult),Phase 4,104,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",Oct-16,21-Feb-17,2-Feb-18,2-Feb-18,10-Aug-16,null,14-Sep-18,"Technion, Israel Institute of Technology, Haifa, Israel",,https://ClinicalTrials.gov/show/NCT02862236
NCT02860910,Cognitive Behavioral Group Therapy for the Management of Menopause Symptoms in Mood Disorders,Conklin MWW,Completed,No Results Available,Bipolar Disorder|Major Depressive Disorder|Menopause,Behavioral: Cognitive Behavioral Group Therapy,Number of participants who begin cognitive group behavioral therapy|Change in Hot Flush Frequency and Problem Rating Scale (HFFPRS) total score|Change in Hot Flash Daily Interference Scale (HFRDIS) total score|Change in Menopause Representation Questionnaire (MRQ) total score,"Danette Conklin, PhD|University Hospitals Cleveland Medical Center",Female,"40 Years to 65 Years   (Adult, Older Adult)",Not Applicable,59,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,4/16/2011,Jul-16,Oct-18,Oct-18,9-Aug-16,null,9-Nov-18,"University Hospitals Cleveland Medical Center - Mood Disorders Program, Cleveland, Ohio, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/10/NCT02860910/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02860910
NCT02857647,The Effects of an Information Video on Anxiety and Bariatric Surgery Knowledge Among Bariatric Surgery Candidates,,Unknown status,No Results Available,Bariatric Surgery Candidates,Behavioral: An information video,Anxiety|Bariatric surgery and nutrition knowledge|Weight loss expectation,Assuta Medical Center,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,200,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,0041-16,Aug-16,Dec-17,Dec-17,5-Aug-16,null,5-Aug-16,,,https://ClinicalTrials.gov/show/NCT02857647
NCT02852174,The Veteran Caregiver Reducing Stress Time (VetCareReST) Study,VetCareReST,Completed,No Results Available,"Stress, Depression, Anxiety and Worry",Behavioral: Mindfulness meditation training,Stress|Depressed mood,Sandraluz Lara-Cinisomo|University of Illinois at Urbana-Champaign,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,30,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,16648,May-16,Nov-17,Nov-17,2-Aug-16,null,1-May-18,"University of Illinois at Urbana-Champaign, Champaign, Illinois, United States",,https://ClinicalTrials.gov/show/NCT02852174
NCT02852577,Long Term Treatment of Panic Disorder With Clonazepam or Paroxetine,LTTPANIC,Completed,No Results Available,Panic Disorder|Agoraphobia,Drug: Clonazepam|Drug: Paroxetine,Clinical Global Impression Severity scores at 8 weeks|Clinical Global Impression Severity scores at 36 months|Clinical Global Impression Severity scores at 4 years|Clinical Global Impression Severity scores at 9 years|Change from baseline of Clinical Global Impression Severity (CGI-S) scale scores at 8 weeks|Change from baseline of Clinical Global Impression Severity (CGI-S) scale scores at 36 months,Universidade Federal do Rio de Janeiro|Conselho Nacional de Desenvolvimento Científico e Tecnológico,All,18 Years to 60 Years   (Adult),Phase 4,120,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0003.0.249.000-09,Jan-00,Aug-12,Aug-12,2-Aug-16,null,2-Aug-16,"Instituto de Psiquiatria da Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil",,https://ClinicalTrials.gov/show/NCT02852577
NCT02850393,Inhibitory Control of the Mind : Neural Bases and Impact for Obsessive-compulsive Disorders,SUPTOC,Not yet recruiting,No Results Available,Obsessive Compulsive Disorder|Healthy,Other: Functional magnetic resonance imaging|Behavioral: behavioral measures|Other: physiological measurements,Blood Oxigen Level Dependent (BOLD) response as measured with fMRI,"University Hospital, Caen|Institut National de la Santé Et de la Recherche Médicale, France|Centre National de la Recherche Scientifique, France|Université de Caen Normandie",All,18 Years to 55 Years   (Adult),Not Applicable,48,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,2015-A01609-40|160028B-31,Jul-16,Mar-19,Dec-19,1-Aug-16,null,1-Aug-16,"GIP Cyceron, Caen, Calvados, France",,https://ClinicalTrials.gov/show/NCT02850393
NCT02850523,Cognitive Behavioural Group Therapy for Perinatal Anxiety,CBT-PA,Completed,No Results Available,Perinatal Anxiety,Other: Cognitive Behavioural Therapy for Perinatal Anxiety,State-Trait Inventory of Cognitive and Somatic Anxiety (STICSA)|Edinburgh Postnatal Depression Scale (EPDS)|Penn State Worry Questionnaire (PSWQ)|Intolerance of Uncertainty Scale (IUS-12)|Multidimensional Perfectionism Scale (MPS)|Multidimensional Parenting Perfectionism Scale (MPPQ)|Parenting Sense of Competence Scale (PSOC)|Social Provisions Scale (SPS)|Abbreviated Dyadic Adjustment Scale (ADAS)|Perceived Stress Scale (PSS)|Emotion Regulation Questionnaire (ERQ)|WHO Disability Assessment Scale 2.0 (WHODAS)|Hamilton Anxiety Scale (HAM-A)|Montgomery-Asberg Depression Scale (MADRS)|Difficulties in Emotion Regulation Scale (DERS-II)|Worry Behaviors Inventory (WBI)|The Female Sexual Function Index (FSFI)|The Sexual Quality of Life - Female (SQoL-F)|Client Satisfaction Questionnaire (CSQ)|Postpartum Bonding Questionnaire (PBQ),St. Joseph's Healthcare Hamilton,Female,18 Years to 45 Years   (Adult),Not Applicable,86,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,TCRA-SG2,Sep-16,Jan-19,Jan-19,1-Aug-16,null,20-Mar-19,"Women's Health Concerns, St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT02850523
NCT02846740,Cranial Electric Stimulation to Modify Suicide Risk Factors in Psychiatric Inpatients.,,Terminated,No Results Available,Suicide|Depression|Anxiety|Insomnia|Agitation,"Device: Alpha-Stim®.|Behavioral: Montgomery-Åsberg Depression Rating Scale, Hamilton Anxiety Rating Scale, The Pittsburgh Sleep Quality Index and agitated behavior Scale",Change in the modifiable suicide risk factors (MSRF's)|Assess adverse effects and safety|Assess length of stay,University of Maryland,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,30,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",HP-00065640,1-Mar-17,22-Jan-18,22-Jan-18,27-Jul-16,null,25-Jan-18,"University of Maryland School of Medicine, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT02846740
NCT02844049,European Study of Quality of Life in Resistant OCD Patients Treated by STN DBS,EQOLOC,Recruiting,No Results Available,Obsessive-Compulsive Disorder,Device: Deep Brain Stimulation,Assessment of the impact of DBS+BMT versus BMT alone on a measure of Quality of life in resistant OCD patients at 1-year follow-up|Psychiatric assessment n°1|Psychiatric assessment n°2|Psychiatric assessment n°3|Psychiatric assessment n°4|Psychiatric assessment n°5|Psychiatric assessment n°6|Psychiatric assessment n°7|Assessment of the impact of DBS+BMT versus BMT alone on a measure of Functioning score n°1|Assessment of the impact of DBS+BMT versus BMT alone on a measure of Functioning score n°2|side effects|Psychiatric markers n°1|Psychiatric markers n°2|Neurological markers n°3|Neuropsychological markers n°4|Neuropsychological markers n°5|Neuropsychological markers n°6|Neuropsychological markers|Per-op electrophysiological mapping of the STN activity n°1|Per-op electrophysiological mapping of the STN activity n°2|Per-op electrophysiological mapping of the STN activity n°3|Per-op electrophysiological mapping of the STN activity n°4|Assessment of the suicidal risk under DBS+BMT vs BMT in resistant OCD,"University Hospital, Grenoble",All,"18 Years to 69 Years   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,38RC15.344,Sep-16,Dec-21,Dec-23,26-Jul-16,null,24-Apr-19,"CHU Henri Mondor, Creteil, France|University Hospital of Grenoble Michallon, Grenoble, France|APHP La Pitié Salpêtrière, Paris, France|Universitätsklinikum Freiburg (i.Br.), Freiburg, Germany|Universitätsklinikum Köln (AöR), Koln, Germany|Hadassah Medical Center The Hebrew University, Jerusalem, Israel|DISS - Università degli Studi di Milano, Milano, Italy|Karolinska University Hospital, Stockholm, Sweden|Hôpitaux Universitaires de Genève, Geneve, Switzerland",,https://ClinicalTrials.gov/show/NCT02844049
NCT02843308,Enhancing Treatment of Hoarding Disorder With Personalized In-Home Sorting and Decluttering Practice,BITS,Recruiting,No Results Available,Hoarding Disorder|Hoarding|Clutter,Behavioral: Facilitated group therapy with behavioral practice; 18 weeks,Saving Inventory-Revised (SI-R)|Clutter Image Rating Scale,Stanford University|National Institute of Mental Health (NIMH),All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,60,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment",36788|K23MH092434,Sep-16,Sep-19,Sep-21,25-Jul-16,null,4-Feb-19,"Stanford University, Stanford, California, United States",,https://ClinicalTrials.gov/show/NCT02843308
NCT02839785,Analgesia and Physiotherapy in Children With Cerebral Palsy (ANTALKINECP),ANTALKINECP,Terminated,No Results Available,Cerebral Palsy,Drug: Ibuprofen|Drug: Placebo,Reduction of at least 20% of the average VAS between the run-in phase and the treatment phase (placebo and ibuprofen)|Pain|Anxiety|Quality of life|Incidence of adverse events,"University Hospital, Brest",All,6 Years to 17 Years   (Child),Phase 3,3,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ANTALKINECP RB15.213,29-Mar-17,19-Sep-18,19-Sep-18,21-Jul-16,null,27-Sep-18,"Hôpital Morvan - CHRU Brest, Brest, France|Hopitaux de Saint-Maurice, Saint-Maurice, France|Ch Lannion-Trestel, Trevou-Treguignec, France",,https://ClinicalTrials.gov/show/NCT02839785
NCT02840071,ACT for Distress in Head and Neck Cancer Patients,,Unknown status,No Results Available,Anxiety|Depression,Other: Psychological therapy,Change in psychological flexibility assessed using the Acceptance and Action Questionnaire (AAQ-II)|Change in psychological flexibility assessed using the Problem Questionnaire (PQ)|Depression assessed by PHQ-9 questionnaire|Anxiety assessed by GAD-7 questionnaire,University of Nottingham,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,3,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,16067,Oct-16,Mar-17,Mar-17,21-Jul-16,null,21-Jul-16,"City Hospital, Nottingham, Notitnghamshire, United Kingdom|King's Mill Hospital, Mansfield, Nottinghamshire, United Kingdom",,https://ClinicalTrials.gov/show/NCT02840071
NCT02840942,Robots to Reduce Pain During IV Placement,,Unknown status,No Results Available,Pain|Anxiety,Behavioral: Coping Robot|Behavioral: Non-coping Robot,Change in Pain Scale Score from baseline to post-intervention|IV placement attempts|Patient/Child satisfaction with robot interaction|CAMPIS score|mYPAS score|Change in Anxiety Scale Score from baseline to post-intervention|heart rate,Children's Hospital Los Angeles|University of Southern California,All,4 Years to 12 Years   (Child),Not Applicable,100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,CHLA-14-00231,Sep-16,Jul-17,Aug-18,21-Jul-16,null,15-Aug-16,"Children's Hospital Los Angeles, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT02840942
NCT02838290,Occupational Distress in Doctors: The Effect of an Induction Programme,,Completed,No Results Available,"Burnout, Professional|Anxiety|Grief|Adaptation, Psychological|Eating Behavior|Alcohol Drinking|Drug Use",Other: Induction|Other: Control group,The Anxiety Disorder Scale|The Grief Inventory|The Coping Mechanisms Scale|The Psychiatric Morbidity Scale|The Physical Symptoms Scale|The Insomnia Scale|The Binge Eating Scale|The Burnout Inventory|Alcohol use|Drug use|The Effort-Reward Scale|The Work Engagement Scale|The Work-Family Conflict Scale,"Birkbeck, University of London",All,"Child, Adult, Older Adult",Not Applicable,232,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Other,01N/A,Jul-16,Nov-16,Nov-16,20-Jul-16,null,31-Jan-17,,,https://ClinicalTrials.gov/show/NCT02838290
NCT02837016,Biofeedback-aided Intervention for Self-regulation,,"Active, not recruiting",No Results Available,Anxiety,Device: Wearable biofeedback|Behavioral: Relaxation Treatment,State/Trait Anxiety Scale|Difficulties in Emotion Regulation Scale|Heart Rate|Heart Rate Reactivity|Respiratory Sinus Arrithmiya|Perceived Stress Scale,Texas A&M University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,40,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,IRB2015-0786D,Jul-16,Jul-19,Jul-19,19-Jul-16,null,26-Apr-18,"Texas A&M Univeristy, College Station, Texas, United States",,https://ClinicalTrials.gov/show/NCT02837016
NCT02835352,Essential Oils on Anxiety of Patients Suffering From Cancer,RHECAP,Terminated,No Results Available,Neoplasm Metastasis,Other: Essential oils massages|Other: Oil massages,Anxiolytic consumption,Center Eugene Marquis,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,29,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2014-AH-DOUL-SC,21-Jun-16,1-May-17,1-May-17,18-Jul-16,null,24-Jan-18,"Centre Eugène Marquis, Rennes, France",,https://ClinicalTrials.gov/show/NCT02835352
NCT02833519,Exercise and Wellbeing: The Effect of Group Exercise on Mental Wellbeing Among Pregnant Women,EWE,"Active, not recruiting",No Results Available,Depression,Behavioral: group exercise,"World Health Organisation Five Well-being Index (WHO-5).|Edinburgh Postnatal Depression Scale (EPDS)|The 12-item General Health Questionnaire (GHQ-12)|Spielbergers State Anxiety Inventory (STAI)|Pittsburgh Sleep Quality Index (PSQI)|Percentage of participants with sick leave|Antenatal contacts|Hospitalization, length of stay|Percentage of participants with respectively spontaneous onset of labor or inducted labor|Use of epidural anaesthesia|Duration of labor|Mode of delivery. Percentage of participants with respectively spontaneous delivery, vacuum extraction or cesarean section|Birth weight in kilograms|Birth length in centimeters|Consultations by telephone","Rigshospitalet, Denmark",Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,300,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,"Rigshospitalet, Denmark",Aug-16,Apr-19,30-Apr-19,14-Jul-16,null,5-Mar-19,"Hanne Kristine Hegaard, Department of Obstetrics, The Juliane Marie Centre for Women, Children and Reproduction, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark",,https://ClinicalTrials.gov/show/NCT02833519
NCT02831153,Evaluation of Emotional Status and Coronary Flow Characteristics by TIMI Frame Count Method,STRAIN-TIMI,Unknown status,No Results Available,Coronary Artery Disease|Coronary Artery Ectasia|Slow-Flow Phenomenon|Endothelial Dysfunction|Anxiety|Depression,Procedure: coronary angiography,TIMI frame count method analysis,Ertan YETKIN|Abant Izzet Baysal University|Saglik Bilimleri Universitesi Gulhane Tip Fakultesi|Ankara Numune Training and Research Hospital|Private Yenisehir Hospital|Private Gozde Hospital|Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital|Vascular and Molecular Cardiology Society,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,2000,Other,Interventional,"Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic",Vasmol001,Jul-16,Jul-17,Jul-17,13-Jul-16,null,13-Jul-16,"Gulhane Military Medical Academy, Ankara, Kecioren, Turkey|Ankara Numune Training and Research Hospital, Ankara, Turkey|Ankara Research and Training Hospital, Ankara, Turkey|Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, Turkey|Private Gözde Hospital, Malatya, Turkey|Private Yenisehir Hospital, Mersin, Turkey",,https://ClinicalTrials.gov/show/NCT02831153
NCT02832050,PLAY Therapy Intervention: Re-Modelling Patient Experience (The PLAYTIME Study),PLAYTIME,Recruiting,No Results Available,Pain|Anxiety|Rheumatology,Behavioral: Play therapy|Behavioral: Standard of care,Procedure-related anxiety visual analogue scale (VAS) score - completed by child|Observer procedure-related anxiety VAS score - completed by parent|Procedure-related coping VAS score - completed by child|Procedure-related pain VAS score - completed by child|Patient experience VAS score - completed by child and parent separately,Alder Hey Children's NHS Foundation Trust,All,5 Years to 17 Years   (Child),Not Applicable,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,197779,May-16,Oct-19,Jan-20,13-Jul-16,null,10-Jan-19,"Alder Hey Children's Hospital, Liverpool, Merseyside, United Kingdom",,https://ClinicalTrials.gov/show/NCT02832050
NCT02827799,Cognitive Behavioral Therapy for Insomnia in Stable Heart Failure,CBTI-HF,Completed,No Results Available,Heart Failure|Insomnia|Cardiomyopathy,Behavioral: Cognitive Behavioral Therapy for Insomnia (CBT-I)|Behavioral: Heart Failure Self-Management Education,Insomnia severity|Depressive symptoms|Sleepiness|Anxiety|Fatigue|Sleep efficiency|Functional Performance|Thoughts and beliefs about sleep|Cortisol|Melatonin|Epinephrine|Norepinephrine|Nocturnal symptoms,Yale University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,51,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label),R21NR011387,Aug-09,Jul-12,Jul-12,11-Jul-16,null,21-Jul-16,"Yale University School of Nursing, West Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT02827799
NCT02828072,Sudarshan Kriya Yoga and Cardiac Autonomic Control in Patients With Anxiety-Depression Disorders,,Completed,No Results Available,Anxiety|Depression,Other: SKY therapy|Drug: usual drug therapy,Changes in autonomic control,University of Milan,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,50,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,SKY-1,Mar-11,Sep-11,Mar-12,11-Jul-16,null,11-Jul-16,,,https://ClinicalTrials.gov/show/NCT02828072
NCT02826096,A Brief Version of Biofeedback Therapy for Panic Disorder,,Unknown status,No Results Available,"Panic Disorder|Feedback, Psychological",Behavioral: Biofeedback therapy,Panic Disorder Severity Scale(PDSS),National Taiwan University Hospital,All,"20 Years to 70 Years   (Adult, Older Adult)",Not Applicable,100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,201511031RIND,Jun-16,Dec-18,Dec-18,7-Jul-16,null,11-Jul-16,"National Taiwan University Hospital, Dou-Liou, Yun-Lin, Taiwan",,https://ClinicalTrials.gov/show/NCT02826096
NCT02822443,Improve: Integrating Emotion Focused Components Into Psychological Therapy,Improve,"Active, not recruiting",No Results Available,Unipolar Depression|Anxiety Disorder|Adjustment Disorder,Behavioral: Psychological therapy (PT) as TAU with integrated emotion focused components (TAU - EFT)|Behavioral: Psychological therapy (PT) as TAU with focus on self-regulation (TAU - SR),"Change from baseline in symptom impairment measured by the Brief Symptom Inventory (BSI; Franke, 2000)|Change from baseline in depressive symptoms measured by the Beck Depression Inventory (BDI-II; Hautzinger et al., 2006)|Change from baseline in anxiety symptoms measured by the Beck Anxiety Inventory (BAI; Ehlers & Margraf, 2007)|Severity of panic disorder and agoraphobia with the Panic and Agoraphobia Scale (PAS; Bandelow, 1997)|Severity of social phobia measured by the Social Phobia Scale SPS; Stangier et al., 1999)|Severity of social interaction anxiety measured by the Social Interaction Anxiety Scale (SIAS; Stangier et al., 1999)|Severity of anxiety symptoms measured by the Questionnaire for General Anxiety Disorder (GAD-7; Spitzer et al., 2006)|Psychological well-being measured with the WHO Well-Being Index (WHO-5; Henkel et al., 2004)|Health-related quality of life measured with the Short Form Healthy Survey (SF-12; Gandek et al., 1998)|Motivational schemata measured by the Questionnaire for Analysis of Motivational Schemata (FAMOS; grosse Holtforth & Grawe, 2000)|Motivational incongruence measured by the Incongruence Questionnaire (K-INK; grosse Holtforth et al., 2003)|Interpersonal problems measured by the Inventory of Interpersonal Problems (IIP-32; Thomas et al., 2011)|Personality structure measured by the Operationalized Psychodynamic Diagnosis Structure Questionnaire (OPD-SFK; Ehrenthal et al., 2012)|Personality traits measured by the Inventory of Personality Organization (IPO-16; Zimmermann et al., 2013)|Ambivalence over emotional expressiveness measured by the Ambivalence over the Expression of Emotion Scale (AVEX; Trachsel et al., 2010)|Emotional competency measured by the Questionnaire for the self-assessment of emotional competencies (SEK-27; Berking & Znoj, 2008)|Generalized expectancies for negative mood regulation measured by the Negative Mood Regulation Scale (NMR-SF; Pfeiffer et al., 2013)|Psychological flexibility measured by the Acceptance and Action Questionnaire (Fragebogen zu Akzeptanz und Handeln; FAH-II; Gloster et al., 2013)|General self-efficacy measured by the General Self-Efficacy Scale (SWE; Schwarzer & Jerusalem, 1999)|Therapy evaluation and outcome expectancies measured by the Patient Questionnaire on Therapy Expectation and Evaluation (PATHEV; Schulte, 2005)|Social desirability measured by the Balanced Inventory of Desirable Responding (BIDR-K; Winkler et al., 2006)|Client satisfaction measured by the Brief Global Measure of Client Satisfaction (ZUF-8; Schmidt & Wittmann, 2002)|External assessment of interpersonal personality measured by the Impact Message Inventory (IMI-R; Caspar et al. 2002)|External assessment of resources measured by the Bernese Inventory of Resources (REF-F and REF-T; Tröske, 2000)|External assessment of positive interpersonal qualities measured by the Inventory of Interpersonal Strengths (IIS; Hatcher & Rogers, 2012)|Goal attainment measured by the Goal Attainment Scaling (GAS; Kirusek, 1994)|Regular quality monitoring with the Bern Post Session Report, Patient and Therapist Version (BPSR-P/T; Flückiger et al. 2010)|Symptom impairment measured by the Symptom Checklist (SCL-9; Bogerts et al., 2001)|Implicit motives measured by the Picture-Story-Exercise - Online Version (PSE-O: Bernecker & Jobst, 2013)",University of Bern,All,"18 Years and older   (Adult, Older Adult)",Phase 2,130,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,SNF100019_159425 /1,Apr-15,Jul-18,Aug-19,4-Jul-16,null,15-Jan-19,"University of Bern, Bern, Switzerland",,https://ClinicalTrials.gov/show/NCT02822443
NCT02818751,Neurofunctional Predictors of Escitalopram Treatment Response in Adolescents With Anxiety,FiESTAA,Recruiting,No Results Available,Anxiety,Drug: Escitalopram|Other: Placebo,Early escitalopram-related functional brain activity changes during emotional processing|Change in functional activity in the ventrolateral prefrontal cortex (from baseline to week 2) and improvement in Pediatric Anxiety Rating Scale score (at week 8/early termination)|Change in functional connectivity between the ventrolateral prefrontal cortex and the amygdala (from baseline to week 2) and improvement in Pediatric Anxiety Rating Scale score (at week 8/early termination)|Change in glutamate concentrations in the anterior cingulate cortex predict improvement in Pediatric Anxiety Rating Scale score from baseline to week 8/early termination.|Change in γ-aminobutyric acid concentrations in the anterior cingulate (from baseline to week 2) predicts improvement in Pediatric Anxiety Rating Scale score from baseline to week 8 (or early termination),University of Cincinnati|National Institute of Mental Health (NIMH),All,12 Years to 17 Years   (Child),Not Applicable,84,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",Strawn FiESTAA|K23MH106037,May-15,May-19,May-20,30-Jun-16,null,27-Mar-18,"University of Cincinnati, Department of Psychiatry & Behavioral Neuroscience, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02818751
NCT02818777,A Study of Tolerability and Efficacy of Cannabidiol on Tremor in Parkinson's Disease,,Completed,Has Results,Parkinson's Disease,Drug: cannabidiol,Severity of Participants Reporting Study-related Adverse Events at Each Dose Level|Number of Participants Had Changes in Orthostatic Blood Pressure|Number of Participants Had Changes in Physical Exam|Number of Participants Had Changes in EKG|Number of Participants Had Changes in Laboratory Values|Proportion of Subjects That Drop Out of the Study Due to Study Drug Intolerance|Change in Movement Disorder Society-Unified Parkinsons Disease Rating Scale Total Score|Change in Montreal Cognitive Assessment (MoCA)|Change in Anxiety Short Form|Change in Neuropsychiatric Inventory (NPI)|Change in Depression Short Form|Change in Scales for Outcomes in Parkinson's Disease (SCOPA)-Sleep-night Time Sleep|Change From Baseline of REM Sleep Behavior Disorder Screening Questionnaire (RBDSQ)|Change in Emotional and Behavioral Dyscontrol Short Form|Change in Pain Severity Form|Change in Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale (QUIP-RS)|Change in Fatigue Severity Scale|Change in International Restless Legs Syndrome Study Group Rating Scale for Restless|Change in Unified Dyskinesia Rating Scale (UDysRS)|Change in MDS-UPDRS Tremor Score (Total of Items 3.17 and 3.18) in the ON State,"University of Colorado, Denver|Colorado Department of Public Health and Environment|GW Research Ltd",All,"40 Years to 80 Years   (Adult, Older Adult)",Phase 2,13,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,15-0929,Oct-16,Nov-17,Nov-17,30-Jun-16,19-Feb-19,19-Feb-19,"University of Colorado School of Medicine, Aurora, Colorado, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/77/NCT02818777/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02818777
NCT02819141,Self-management of Sedative Therapy by Ventilated Patients,,Recruiting,No Results Available,Critical Illness|Anxiety|Respiratory Failure,Drug: Dexmedetomidine,Changes in anxiety using the 100mm vertical visual analog scale|Changes in duration of days receiving mechanical ventilation after study enrollment|Changes in delirium using the CAM-ICU tool|Comparison of level of arousal and alertness using the Richmond Agitation-Sedation Scale|Comparison of sedative exposure (sedation frequency + sedation intensity) using electronic health record data of intravenous sedative medications.,"Mayo Clinic|University of Minnesota, MN|National Heart, Lung, and Blood Institute (NHLBI)",All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,228,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,16-000417|R01HL030881,Nov-16,Nov-21,Apr-22,30-Jun-16,null,9-Apr-19,"School of Medicine, University of Minnesota, Minneapolis, Minnesota, United States|Mayo Clinic in Rochester, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT02819141
NCT02819986,Effectiveness of Using the Progressive Goal Attainment Program in Anxiety and Mood Disorders,PGAP,Recruiting,No Results Available,Anxiety|Mood Disorder,Behavioral: Progressive Goal Attainment Program,Impact of PGAP on disability (participant perception)|Impact of PGAP on symptom change|Impact of PGAP on level of interference from mood and anxiety symptoms|Impact of PGAP on fear avoidance beliefs|PGAP retention rates|Satisfaction with the PGAP|Impact of PGAP on disability (clinician report)|Impact of PGAP on role functioning,St. Joseph's Healthcare Hamilton,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,44,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1784,16-Nov-16,Oct-18,Oct-18,30-Jun-16,null,20-Apr-18,"St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT02819986
NCT02816996,Patient Comfort During Dermatologic Procedures,,Completed,No Results Available,Pain|Anxiety,Procedure: Hand-holding|Procedure: Stress Ball,Anxiety|Pain,Northwestern University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,135,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,STU00203158,24-Jan-17,26-Apr-17,26-Apr-17,29-Jun-16,null,13-Jul-17,"Northwestern Memorial Hospital, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT02816996
NCT02817438,Research on Anxiety and Depression: Computer-Assisted Therapy,RADCAT,Completed,No Results Available,Mood Disorders|Anxiety Disorders,Behavioral: Good Days Ahead,Depression and Anxiety Composite Score|Quality of Life,Stanford University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,136,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IRB-36790,Jun-16,Mar-18,Mar-18,29-Jun-16,null,20-Mar-19,"Stanford University, Stanford, California, United States",,https://ClinicalTrials.gov/show/NCT02817438
NCT02818088,Cognitive Training in Obsessive Compulsive Disorder,CTOCD,Recruiting,No Results Available,Obsessive-Compulsive Disorder,Behavioral: n-Back (Cognitive Training),Yale-Brown Obsessive Compulsive Scale (YBOCS)|Cambridge neuropsychological test automated battery (CANTAB),University of Stellenbosch|University of Cape Town,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,40,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,S14/05/113,Feb-16,Dec-19,Dec-20,29-Jun-16,null,12-Oct-18,"Stellenbosch University, Cape Town, Western Cape, South Africa",,https://ClinicalTrials.gov/show/NCT02818088
NCT02818101,Hypnosis Efficacy for the Prevention of Anxiety During a Coronary Angiography,HypCor,Unknown status,No Results Available,Coronary Angiography,Behavioral: Hypnosis session,State Anxiety|Comfort for the operator of the angiography|Pain|Heart rate|Blood pressure|Major complications|dose of sedative drugs,Centre Hospitalier Régional Metz-Thionville,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,170,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Supportive Care,2016-02-CHRMT,Mar-16,Jun-17,May-18,29-Jun-16,null,29-Dec-17,"Chr Metz Thionville, Metz, France",,https://ClinicalTrials.gov/show/NCT02818101
NCT02818296,Computerized Cognitive Bias Intervention for Intolerance of Uncertainty,,Completed,No Results Available,Intolerance of Uncertainty; Anxiety,Behavioral: Active IU CBM-I|Behavioral: Control CBM-I,Change in Intolerance of Uncertainty Scale-Short Form,Florida State University,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,79,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention,Oglesby01,Aug-14,May-16,May-16,29-Jun-16,null,29-Jun-16,"Anxiety and Behavioral Health Clinic, Tallahassee, Florida, United States",,https://ClinicalTrials.gov/show/NCT02818296
NCT02816502,Hippocampal Plasticity of Young Adults With Childhood Adversity,,"Active, not recruiting",No Results Available,Depression|Anxiety,Behavioral: Stress Management Skill Building Program A|Behavioral: Stress Management Skill Building Program B,Changes in hippocampal subfield gray matter density measured with high resolution structural MRI at 3T|Changes in stress level measured by the Perceived Stress Scale (PSS)|Changes in severity of depression symptom measured by Beck Depression Inventory (BDI)|Changes in severity of anxiety symptom measured by State-Trait Anxiety Inventory (STAI),Mclean Hospital|Massachusetts General Hospital,All,21 Years to 35 Years   (Adult),Not Applicable,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,2016P000335,15-Jun-17,Mar-21,Dec-21,28-Jun-16,null,6-Mar-19,"McLean Hospital, Belmont, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT02816502
NCT02816684,Pegasys VR: Integrating Virtual Humans in the Treatment of Child Social Anxiety,,Completed,No Results Available,Anxiety Disorders,Behavioral: Pegasys-VR|Behavioral: Social Effectiveness Therapy for Children,Social Phobia and Anxiety Inventory for Children|Diagnosis of Social Anxiety Disorder|Child Behavior Checklist|Child Global Assessment of Functioning|Clinical Global Improvement Scale|Behavioral Assessment,"University of Central Florida|Virtually Better, Inc.",All,7 Years to 12 Years   (Child),Phase 2,43,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",5R42MH094019-05,Jun-16,Aug-18,Aug-18,28-Jun-16,null,19-Oct-18,"UCF RESTORES, University of Central Florida, Orlando, Florida, United States",,https://ClinicalTrials.gov/show/NCT02816684
NCT02813447,Safety of Anti-Depressant for Chronic Obstructive Pulmonary Disease (SAD-COPD),SAD-COPD,Recruiting,No Results Available,COPD|Anxiety|Depression|Stress|Interstitial Lung Disease,Drug: Sertraline|Drug: Placebo,"Change in 6MW distance|Change in dyspnea scores, as measured by UCSD Medical Center Pulmonary Rehabilitation Program Shortness of Breath Questionnaire (UCSD-SOB)|Change in quality of life, as measured by Ferrans & Powers Quality of Life Index - Pulmonary version (QOL)|Change in perceived stress, as measured by General Health Questionnaire-12 (GHQ-12)|Change in anxiety, as measured by Hamilton Anxiety and Depression Scale (HADS)|Change in anxiety, as measured by Anxiety Inventory for Respiratory Disease (AIR)|Change in depression, as measured by Hamilton Anxiety and Depression Scale (HADS)|Tolerability",Duke University,All,"40 Years and older   (Adult, Older Adult)",Not Applicable,30,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Pro00071349,Aug-16,Aug-20,Dec-20,27-Jun-16,null,27-Feb-19,"Duke Pulmonary Rehabilitation, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT02813447
NCT02811458,Clinical Trial of Transdiagnostic Cognitive-Behavior Therapy for Anxiety Disorders,T-CBT,"Active, not recruiting",No Results Available,Panic Disorder|Agoraphobia|Social Anxiety Disorder|Generalized Anxiety Disorder,Behavioral: Transdiagnostic Cognitive-Behavioral Therapy,Change in Beck Anxiety Inventory (BAI)|Change in Clinical Severity Rating from the Anxiety Disorders Interview Schedule for DSM-5 - Adult Version (ADIS-5)|Change in Panic Disorder Severity Scale (Self-Report)|Change in Mobility Inventory for Agoraphobia|Change in Penn State Worry Questionnaire|Change in Social Phobia Inventory|Change in Patient Health Questionnaire (PHQ-9)|Change in EuroQol (EQ-5D-5L)|Change in Administrative databases records|Change in Anxiety Disorder Diagnostic Questionnaire - weekly version (ADDQ-W),Université de Sherbrooke|Canadian Institutes of Health Research (CIHR)|Estrie University Integrated Health and Social Services Center - University Hospital of Sherbrooke|CISSS de Laval|Integrated University Health and Social Services Center of the Capitale-Nationale,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,211,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CIHR-340410|CIHR-334091,12-Sep-16,15-Jun-18,Jun-19,23-Jun-16,null,11-Oct-18,"Centre intégré de santé et de services sociaux de Laval, Laval, Quebec, Canada|Centre intégré universitaire de santé et de services sociaux de l'Estrie, Sherbrooke, Quebec, Canada|Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT02811458
NCT02808702,Brain Correlates of Self-Focused Processing,,Recruiting,No Results Available,Social Phobia|Body Dysmorphic Disorder,Behavioral: Cognitive-behavioral therapy,Change from baseline clinical symptoms at 12 weeks|Neural activation in the default mode network|Resting state functional connectivity within the default mode network|Structural connectivity within the default mode network|Response latencies during Self vs. Other conditions,Massachusetts General Hospital,All,22 Years to 45 Years   (Adult),Not Applicable,60,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1K23MH109593-01,1-May-17,Jun-21,Jun-21,22-Jun-16,null,6-Mar-19,"Richard B. Simches Research Center, Boston, Massachusetts, United States|Athinoula A. Martinos Center for Biomedical Imaging, Charlestown, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT02808702
NCT02810171,Dimensional Brain Behavior Predictors of CBT Outcomes in Pediatric Anxiety,Anxiety-CBT,Recruiting,No Results Available,Anxiety Disorders|Social Anxiety Disorder|Social Phobia|Generalized Anxiety Disorder|Separation Anxiety Disorder|Specific Phobia|Phobia|Agoraphobia|Panic Disorder|Panic Attack|Anxiety,Behavioral: Cognitive Behavioral Therapy|Behavioral: Relaxation Therapy,Brain function/structure as assessed by Magnetic Resonance Imaging scans|Pediatric Anxiety Rating Scale,University of Michigan|University of Illinois at Chicago|National Institute of Mental Health (NIMH),All,7 Years to 17 Years   (Child),Not Applicable,280,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment",HUM00118950|R01MH107419,Dec-16,Jun-21,Jun-21,22-Jun-16,null,31-Jan-19,"University of Michigan, Ann Arbor, Michigan, United States",,https://ClinicalTrials.gov/show/NCT02810171
NCT02807480,Approach-Avoidance Conflict-a Multi-level Predictor for Therapy Response,,Recruiting,No Results Available,Generalized Anxiety Disorder,Behavioral: Exposure-based therapy|Behavioral: Behavioral Activation therapy|Behavioral: Computer-based behavioral assessment|Behavioral: Surveys and Interviews|Device: Magnetic resonance imaging (MRI)|Device: Electroencephalography (EEG),For Aim1: Baseline generalized anxiety disorder symptoms as measured by the Generalized Anxiety Disorder - 7 item scale (GAD-7).|For Aims 2 and 3: Change in generalized anxiety disorder symptoms as measured by the Generalized Anxiety Disorder - 7 item scale (GAD-7).|Change in anxiety symptoms as measured by the Patient Reported Outcomes Measurement Information System (PROMIS) Anxiety Scale.|Change in depressive symptoms as measured by the Patient Reported Outcomes Measurement Information System (PROMIS) Depression Scale.|Change in level of disability as measured by the Sheehan Disability Scale|Change in depressive symptoms as measured by the Beck Depression Inventory - II.|Change in worry symptoms as measured by the Penn State Worry Questionnaire.,"Laureate Institute for Brain Research, Inc.|National Institute of Mental Health (NIMH)",All,18 Years to 55 Years   (Adult),Not Applicable,100,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,2015-006-02|1K23MH108707-01A1,Jun-16,Apr-21,Apr-21,21-Jun-16,null,15-Feb-19,"Laureate Institute for Brain Research, Tulsa, Oklahoma, United States",,https://ClinicalTrials.gov/show/NCT02807480
NCT02806271,Short-Term Efficacy and Mechanisms of Change of a Worry Postponement Intervention for Generalized Anxiety Disorder,,Completed,No Results Available,Generalized Anxiety Disorder,Behavioral: Worry Postponement|Behavioral: Worry Monitoring,"Change in worry as measures by the Penn State Worry Questionnaire - Past Week|Change in mindfulness the Cognitive and Affective Mindfulness Scale-Revised|Change in mindfulness as measured by the Southampton Mindfulness Questionnaire|Change in problem solving as measured by Social Problem Solving Inventory - Revised|Change in cognitive avoidance as measured by the Cognitive Avoidance Questionnaire|Change in attentional control as measured by the Random Interval Generation Task|Change in attentional control as measured by the N-back task|Change in worry frequency as measured by daily worry diaries|Change in meta cognitive beliefs about worry as measured by the Metacognitions Questionnaire-30|Change in attentional control over worry as measured by the Breathing Focus Task|Change in symptoms of depression as measured by the Depression, Anxiety, and Stress Scales - 21|Change in symptoms of anxiety as measured by the Depression, Anxiety, and Stress Scales - 21|Change in symptoms of insomnia as measured by the Insomnia Severity Index|Change in health complaints as measured by the Subjective Health Complaints Questionnaire|Change in rumination as measured by the Ruminative Response Scales",Ryerson University|Canadian Institutes of Health Research (CIHR),All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,83,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,2016 - 143,Jun-16,Jul-18,Jul-18,20-Jun-16,null,19-Jul-18,"Ryerson University, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT02806271
NCT02803749,Buspirone in Parkinson's Disease,,Completed,No Results Available,Parkinson Disease|Anxiety,Drug: Buspirone|Drug: Placebo,"The proportion of participants who fail to complete the 12-week study on study drug.|Mean change in Hamilton Anxiety Rating Scale (HAM-A) from baseline to 12 weeks|Proportion of responders (>50% reduction from baseline or reduction to ≤7 on HAM-A) at 12 weeks|Proportion ""much improved"" or ""very much improved"" on Patient Global Impressions-Improvement (PGI-I) at 12 weeks|Mean change in Hospital Anxiety and Depression Scale (HADS) from baseline to 12 weeks|Mean change in Unified Dyskinesia Rating Scale (UDysRS) from baseline to 12 weeks|Correlation of change in Parkinson Anxiety Scale score with change in Clinical Global Impressions-Improvement scale score.|Proportion ""much improved"" or ""very much improved"" on Clinical Global Impressions-Improvement (CGI-I) at 12 weeks|Correlation of change in Parkinson Anxiety Scale score with change in Patient Global Impressions-Improvement scale score.",University of Rochester|Michael J. Fox Foundation for Parkinson's Research,All,"18 Years and older   (Adult, Older Adult)",Phase 2,21,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",61141,Oct-16,Jan-19,25-Jan-19,17-Jun-16,null,20-May-19,"University of Rochester Medical Center, Rochester, New York, United States",,https://ClinicalTrials.gov/show/NCT02803749
NCT02801877,IntelliCare Study: Artificial Intelligence in a Mobile (AIM) Intervention for Depression,AIM,Completed,No Results Available,Depression|Anxiety,Behavioral: IntelliCare|Behavioral: Hub App with the Recommender System|Behavioral: Coaching,Adherence to the mobile application intervention|Depression/Anxiety severity|Participant satisfaction,Northwestern University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,301,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,R01MH100482-01-RCTIC|R01MH100482-01,Jul-16,Jan-18,Jan-18,16-Jun-16,null,8-Oct-18,"Northwestern University, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT02801877
NCT02802839,Virtual Reality for the Reduction of Pain During Venipuncture in Children With CF,VRAP,Unknown status,No Results Available,Cystic Fibrosis,Device: Virtual Reality,Pain|Anxiety|Distress,University of Florence,All,"6 Years to 18 Years   (Child, Adult)",Not Applicable,50,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),vers 1 del 15.02.16,Jun-16,Jun-17,Jun-17,16-Jun-16,null,16-Jun-16,"Meyer Children Hospital, Florence, Italy",,https://ClinicalTrials.gov/show/NCT02802839
NCT02800096,Online Interventions for Gamblers With and Without Co-occurring Mental Health Concerns,,Completed,No Results Available,Gambling|Depression|Anxiety,Behavioral: Gambling Internet intervention|Behavioral: MoodGYM,The NORC DSM-IV Screen for Gambling Problems (NODS) past 3 month version indicating DSM-IV gambling severity.|Number of days gambled per month,Centre for Addiction and Mental Health,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,284,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Health Services Research",004/2015,Jun-16,11-Aug-17,11-Aug-17,15-Jun-16,null,25-Oct-17,"Centre for Addiction and Mental Health, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT02800096
NCT02800733,Effects of Saffron on Mild to Moderate Generalized Anxiety Disorder (GAD),,Unknown status,No Results Available,Patients With Mild to Moderate GAD,Dietary Supplement: Saffron|Dietary Supplement: placebo,Hamilton anxiety score,National Nutrition and Food Technology Institute,All,18 Years to 55 Years   (Adult),Phase 2|Phase 3,40,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",450/3654,Jun-16,Aug-16,Sep-16,15-Jun-16,null,15-Jun-16,,,https://ClinicalTrials.gov/show/NCT02800733
NCT02796612,Empathy and Standard Diagnostic Procedures in an Outpatient Breast Clinic Might Not be Enough,,Completed,No Results Available,Anxiety,Other: no intervention|Behavioral: delivery of a take-home brochure|Behavioral: patient care by a psychologically trained physician,Reduction of level of anxiety compared between arm 'no intervention' and arm 'intervention' as measured via questionnaires|level of anxiety in the intervention group during and after biopsy measured via questionnaires|correlation of the level of anxiety and the histological diagnosis of breast cancer measured via questionnaires|perception of pain during and after biopsy measured via pain score|influence of waiting time between biopsy and histological diagnosis on the level of anxiety measured via questionnaires|correlation of patient's perception of pain and anxiety and physician's impression of patient's perception measured by questionnaires|patient's satisfaction with additional information concerning biopsy measured by Visual Analog Scale,"University Hospital, Basel, Switzerland",Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,250,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,EK261/12,Apr-14,5-Oct-18,5-Oct-18,13-Jun-16,null,12-Nov-18,"University Hospital of Basel, Basel, Basel-Stadt, Switzerland|Claraspital, Basel, Basel-Stadt, Switzerland|GZO Wetzikon, Wetzikon, Zürich, Switzerland",,https://ClinicalTrials.gov/show/NCT02796612
NCT02797379,The Development of a Psychoeducational Tool to Manage Anxiety in People With Autism Spectrum Disorders,MANAGE,Unknown status,No Results Available,Autism Spectrum Disorders|Anxiety,Other: Psychoeducation,"Knowledge about anxiety in ASD|Anxiety symptoms|Acceptability, usefulness and appropriateness of the guide",King's College London|South London and Maudsley NHS Foundation Trust|Guy's and St Thomas' NHS Foundation Trust,All,"8 Years to 25 Years   (Child, Adult)",Not Applicable,35,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,200774,Sep-16,Aug-17,Sep-17,13-Jun-16,null,14-Jul-17,"South London and the Maudsley, London, United Kingdom|Guy's and St Thomas' NHS trust, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT02797379
NCT02797691,Developing and Testing of Culturally Adapted Cognitive Behavior Therapy (CaCBT) for Pashto Speaking Pakistanis and Afghans,,Completed,No Results Available,"Depression, Anxiety",Other: CaCBT|Other: Medication/ Psychotherapy,Change in score of Hospital Anxiety and Depression Scale (HADS) from baseline to end of therapy|Change in score of Bradford Somatic Inventory (BSI) from baseline to end of therapy|Change in score of Brief Disability Questionnaire/ WHO DAS from baseline to end of therapy,Peshawar Medical College,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,40,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,CBT Pashtu 1,Jan-16,Jul-16,Jul-16,13-Jun-16,null,16-Aug-16,"PRIME Foundation/ Lady Reading Hospital, Peshawar, Khyber Pakhtunkhwa, Pakistan",,https://ClinicalTrials.gov/show/NCT02797691
NCT02797808,Effects of Sertraline on Brain Connectivity in Adolescents With OCD,,Completed,No Results Available,OCD,Drug: Sertraline|Other: No Intervention,Change in brain connectivity,University of Minnesota - Clinical and Translational Science Institute|National Institute of Mental Health (NIMH),All,8 Years to 17 Years   (Child),Phase 1|Phase 2,41,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,1105M99532|5R21MH101395-02,Aug-13,31-Jan-17,31-Jan-17,13-Jun-16,null,6-Oct-17,"University of Minnesota, Minneapolis, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT02797808
NCT02794103,Virtual Reality Distraction for Procedural Pain Management and Anxiety in Children With Burn Injuries : A Pilot Study,,Completed,No Results Available,Burn|Child|Pain|Anxiety,Device: Virtual Reality Distraction,Acceptability|Pain intensity|Anxiety Level|Comfort Level|Analgesic requirement|Sedation level|Baseline anxiety level,"St. Justine's Hospital|Société des Arts Technologiques (SAT), Montreal, Canada|Quebec Nursing Intervention Research Network, Canada|CHU Ste-Justine`s Direction of Nursing, Montreal, Canada|Users Committee of CHU Ste-Justine, Montreal, Canada|Quebec Firefighters Foundation for Burns",All,2 Months to 10 Years   (Child),Not Applicable,18,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,3943,Jun-16,31-Jan-17,31-Jan-17,8-Jun-16,null,25-Apr-17,"CHU Ste. Justine, Montreal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT02794103
NCT02792127,Online Program for Social Anxiety,,Completed,No Results Available,Social Anxiety,Behavioral: Online Program for Social Anxiety,Social Anxiety,University of British Columbia,All,"Child, Adult, Older Adult",Not Applicable,101,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,H16-00319,Jul-16,Dec-17,Dec-17,7-Jun-16,null,29-Dec-17,,,https://ClinicalTrials.gov/show/NCT02792127
NCT02792153,Estradiol and Fear Extinction in Anorexia Nervosa (AN),,Withdrawn,No Results Available,Anorexia Nervosa,Drug: Estradiol,Electrodermal skin conductance activity (EDA) during a test meal|Heart rate variability during a test meal|Subjective ratings of anxiety|Salivary cortisol concentration during a test meal,Johns Hopkins University,Female,18 Years to 50 Years   (Adult),Phase 1,0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IRB00030009,Dec-16,22-Aug-18,22-Aug-18,7-Jun-16,null,24-Aug-18,"Johns Hopkins Hospital, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT02792153
NCT02790710,Brief Intervention for OCD Fears,,Suspended,No Results Available,Obsessive-compulsive Disorder,Drug: Propanolol|Drug: Placebo,Yale Brown Obsessive-Compulsive Scale|Behavioral Avoidance Task,New York State Psychiatric Institute,All,18 Years to 60 Years   (Adult),Phase 4,20,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Other",7293 (OCD),Jun-16,Jun-19,Jun-19,6-Jun-16,null,30-Nov-18,"New York State Psychiatric Institute, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT02790710
NCT02790736,Brief Intervention to Reduce Fear of Public Speaking,,"Active, not recruiting",Has Results,Social Anxiety Disorder,Drug: propranolol|Drug: Placebo,Personal Report of Confidence as a Speaker|Behavioral Avoidance Task,New York State Psychiatric Institute,All,18 Years to 60 Years   (Adult),Phase 4,6,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Other",7293 (SAD),Jun-16,May-17,Sep-20,6-Jun-16,5-Sep-18,3-Apr-19,"New York State Psychiatric Institute, 1051 Riverside Drive, New York, New York, United States","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/36/NCT02790736/Prot_SAP_ICF_000.pdf",https://ClinicalTrials.gov/show/NCT02790736
NCT02789800,Patient-Centred Innovations for Persons With Multimorbidity - Quebec,PACEinMM-QC,"Active, not recruiting",No Results Available,Hypertension|Depression|Anxiety|Musculoskeletal Pain|Arthritis|Rheumatoid Arthritis|Osteoporosis|Chronic Obstructive Pulmonary Disease (COPD)|Asthma|Chronic Bronchitis|Cardiovascular Disease|Heart Failure|Stroke|Transient Ischemic Attacks|Ulcer|Gastroesophageal Reflux|Irritable Bowel|Crohn's Disease|Ulcerative Colitis|Diverticulosis|Chronic Hepatitis|Diabetes|Thyroid Disorder|Cancer|Kidney Disease|Urinary Tract Problem|Dementia|Alzheimer's Disease|Hyperlipidemia|HIV,Behavioral: DIMAC02,Evaluation of Intervention Effectiveness - Change in Self-Management outcomes|Evaluation of Intervention Effectiveness - Change in Chronic Diseases|Evaluation of Intervention Effectiveness - Change in Health Status|Evaluation of Intervention Effectiveness - Change in Quality of Life|Evaluation of Intervention Effectiveness - Change in Psychological Well-being|Evaluation of Intervention Effectiveness - Change in Lifestyle/Health Behaviours|Evaluation of Intervention Effectiveness - Equity|Demographics|Evaluation of Intervention Effectiveness - Change in Transitions of Care|Evaluation of Intervention Effectiveness - Change in Self-Efficacy|Evaluation of Intervention Effectiveness - Change in Patient-Centredness,"Université de Sherbrooke|Canadian Institutes of Health Research (CIHR)|Western University, Canada|Agence de la Sante et des Services Sociaux du Saguenay-Lac-Saint-Jean",All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,1956,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,2013-010,22-Apr-16,8-Mar-19,1-Mar-20,3-Jun-16,null,15-Dec-17,"Université de Sherbrooke, Chicoutimi, Quebec, Canada|CIUSSS du Sageunay-Lac-Saint-Jean, Chicoutimi, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT02789800
NCT02790398,Up-regulating Positive Affect in Emotional Disorders,,Completed,No Results Available,Anxiety|Depression,Behavioral: Transdiagnostic treatment protocol|Behavioral: Transdiagnostic treatment protocol + PA regulation component,"Change in the Positive and Negative Affect Scale (PANAS) at pre-, post-intervention (up to 4 months) and at 3-month follow-up.|Change in the Beck Depression Inventory II (BDI-II) at pre-, post-intervention (up to 4 months) and at 3-month follow-up.|Change in the Overall Anxiety Severity and Impairment Scale (OASIS) at pre-, post-intervention (up to 4 months) and at 3-month follow-up.|Change in the Quality of Life Inventory (QLI) at pre-, post-intervention (up to 4 months) and at 3-month follow-up.",Universitat Jaume I,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,24,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,UJaumeI_Transd_PS,Jan-14,Mar-16,Mar-16,3-Jun-16,null,30-Nov-16,"University Jaume I, Castellón, Spain",,https://ClinicalTrials.gov/show/NCT02790398
NCT02784301,Evaluation of a Biofeedback Tool to Minimize Procedural Pain and Anxiety in Children,,Unknown status,No Results Available,Pain|Anxiety,Device: Belly breathing with biofeedback app|Behavioral: Belly breathing without biofeedback app|Behavioral: Belly breathing + visual distraction,Self-reported experienced pain|Change in self-reported preprocedural anxiety|Change in self-reported expected pain|Belly breathing compliance|Belly breathing engagement|Self-reported experienced anxiety,British Columbia Children's Hospital,All,5 Years to 17 Years   (Child),Not Applicable,300,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,BBAppP2,May-16,Dec-16,Dec-16,27-May-16,null,27-May-16,"British Columbia Children's Hospital, Vancouver, British Columbia, Canada",,https://ClinicalTrials.gov/show/NCT02784301
NCT02785406,"Role of the Orexin Receptor System in Stress, Sleep and Cocaine Use",,Completed,No Results Available,Cocaine Use Disorder|Anxiety,Drug: suvorexant|Drug: Placebo (for suvorexant),"Cue Reactivity as Assessed by the Attention Bias (AB) Task|Total Sleep as Assessed by the Misfit Shine Device|Stress as Assessed by the DASS21 Self-report Questionnaire|Anxiety as Assessed by the DASS21 Self-report Questionnaire|Cue Reactivity as Assessed by the Cocaine Craving Questionnaire (CCQ)|Sleep Quality as by the Pittsburg Sleep Quality Index (PSQI)|Stress/Anxiety as Assessed by Blood Pressure During the Cold Pressor Test (CPT)|Stress/Anxiety as Assessed by Cortisol Level During the Cold Pressor Test (CPT)|Stress as Assessed by a Visual Analog Scale (VAS) for Stress|Medication Compliance as Assessed by the Medical Event Monitoring System (MEMS, Aprex Corporation) Bottles|Medication Compliance as Assessed by Pill Counts|Medication Compliance as Assessed by Analysis of Riboflavin Markers in Urine Samples|Medication Compliance as Assessed by Text Reminders and Replies","The University of Texas Health Science Center, Houston|Peter F. McManus Charitable Trust",All,19 Years to 55 Years   (Adult),Phase 2,20,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",HSC-MS-16-0120,May-16,15-Nov-18,15-Nov-18,27-May-16,null,20-Nov-18,"The University of Texas Health Science Center at Houston, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT02785406
NCT02777905,Mindfulness-Based Cognitive Therapy for Depression and Anxiety,,Unknown status,No Results Available,Symptoms of Depression|Symptoms of Anxiety,Behavioral: Mindfulness Based Cognitive Therapy,Significant decrease in the PHQ-9 (depression) score between baseline and 8-week follow-up|Decrease in the GAD-7 score (anxiety) between baseline and 8-week follow-up,Lady Davis Institute,All,"60 Years and older   (Adult, Older Adult)",Phase 4,100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,2016-008,Sep-16,Jun-17,Dec-17,19-May-16,null,3-Nov-16,"CLSC Benny Farm, Montreal, Quebec, Canada|CLSC Benny Farm, Montreal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT02777905
NCT02778334,"Links Between Depression, Anxiety, Coping and Quality of Life After a Stroke",COPING,Completed,No Results Available,Cerebral Stroke,Other: survey,Assessment the change of WHOQOL BREF (Life QUALITY) change|Assessment the change of MINI (Mini International Neuropsychiatric Inventory) score|Assessment the change of MADRS (Montgoméry and Asberg Depression Rating Scale) score|Assessment the change of HAM-A (Hamilton Anxiety Rating Scale) score|Assessment the change of BDI-II (Beck Depression Inventory 2e ed) score|Assessment the change of HADS (Hospital Anxiety Depression Scale) score|Assessment the change of Brief-COPE score|Assessment the change of ESM score,Groupe Hospitalier Paris Saint Joseph|University of Paris 5 - Rene Descartes|Laboratoire Psychopathologie et Processus de Santé,Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,75,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,COPING,13-Apr-15,11-Nov-17,4-Apr-19,19-May-16,null,25-Apr-19,"Groupe Hopitalier Paris Saint Joseph Service de neurologie, Paris, Ile-de-France, France",,https://ClinicalTrials.gov/show/NCT02778334
NCT02776293,Prenatal Listening to Songs Composed for Pregnancy and Symptoms of Anxiety and Depression: a Pilot Study,,Completed,No Results Available,Prenatal Anxiety|Depression,Behavioral: Relaxation|Behavioral: Music,State-Trait Anxiety Inventory|Edinburgh Postnatal Depression Scale,"Goldsmiths, University of London",Female,"Child, Adult, Older Adult",Not Applicable,223,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,LV-001,Jan-14,Jul-15,Jul-15,18-May-16,null,4-May-17,,,https://ClinicalTrials.gov/show/NCT02776293
NCT02773706,Detecting and Evaluating Childhood and Anxiety and Depression Effectively in Subspecialties,DECADES,Not yet recruiting,No Results Available,Anxiety|Depression,Other: Automated Psychology Services|Other: Notification of Subspecialist,Quality of life (baseline)|Quality of life (followup)|Utilization of endoscopy|Utilization of radiologic testing|Utilization of laboratory testing|Utilization of emergency department visits|Utilization of outpatient gastroenterology,Indiana University|Agency for Healthcare Research and Quality (AHRQ),All,"10 Years to 18 Years   (Child, Adult)",Not Applicable,100,Other|U.S. Fed,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DECADES,18-Dec-17,Oct-18,Oct-18,16-May-16,null,8-Dec-17,,,https://ClinicalTrials.gov/show/NCT02773706
NCT02774018,Life Satisfaction and Psychopathology in Institutionalized Elderly People,,Completed,No Results Available,Anxiety Depression (Mild or Not Persistent),Behavioral: Mindfulness-Based Stress Reduction (MBSR) program,Change in depression levels assessed with the GDS|Change in anxiety levels assessed with the DASS-21|Change in experiential avoidance levels assessed with the AAQ-II|Change in subjective pain levels assessed with the Faces Scale|Change in life satisfaction levels assessed with the SWLS,Irmandade da Misericórdia de Albergaria-a-Velha,All,65 Years to 95 Years   (Older Adult),Not Applicable,12,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,01_PSI_MINDFULNESS,Jun-15,Oct-15,Oct-15,16-May-16,null,16-May-16,,,https://ClinicalTrials.gov/show/NCT02774018
NCT02765906,Comparing Different Methods of Patient Education on Preeclampsia,,Completed,No Results Available,Preeclampsia|Anxiety|Hypertension|Pregnancy|Eclampsia|HELLP,Other: Graphic card|Other: Video,Percentage of correct responses on preeclampsia knowledge survey score at follow-up assessment|Change in anxiety level after educational intervention as measured by the STAI 6,Geisinger Clinic,Female,"Child, Adult, Older Adult",Not Applicable,150,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,2016-0116,May-16,30-Jul-17,30-Jul-17,9-May-16,null,2-Aug-18,"Geisinger Medical Center: Maternal Fetal Medicine and Prenatal Clinics, Danville, Pennsylvania, United States|Geisinger Maternal Fetal Medicine, Forty Fort, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT02765906
NCT02766101,Manville Moves: an Exercise Intervention for Behavioral Regulation Among Children With Behavioral Health Challenges,MM,Completed,No Results Available,Autistic Disorder|Attention Deficit and Disruptive Behavior Disorders|Anxiety Disorders|Mood Disorders|Conduct Disorder|Oppositional Defiant Disorder,Behavioral: Aerobic Exergaming PE Curriculum|Behavioral: Standard PE,Change in Minutes and Number of Disciplinary Time Out of Class Events (classroom functioning)|Change in Conners Abbreviated Teacher Rating Scale score (behavioral dysregulation: impulsivity/emotional lability),Harvard School of Public Health|Judge Baker Children's Center,All,"7 Years to 18 Years   (Child, Adult)",Not Applicable,103,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IRB14-2312,Oct-14,Apr-15,Apr-15,9-May-16,null,9-May-16,"Judge Baker Children's Center, Manville School, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT02766101
NCT02764138,Preventing Internalizing in Preadolescents Exposed to Chronic Stress,,Recruiting,No Results Available,Chronic Stress|Anxiety|Depression,Behavioral: Building a Strong Identity and Coping Skills,HPA Reactivity Profile|Internalizing symptoms|Coping Skills Acquisition,Penn State University,All,11 Years to 12 Years   (Child),Not Applicable,150,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,R33MH107631,Apr-16,Mar-21,Mar-21,6-May-16,null,17-May-19,"Hamilton Health Center, Harrisburg, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT02764138
NCT02764294,Effectiveness of the Distraction Methods During Cystoscopy,,Completed,No Results Available,Pain|Anxiety|Satisfaction,Other: Music Group|Other: Stress Ball Group|Other: DVD Group,Pain Measure|Anxiety Measure|Satisfaction Measure,Saglik Bilimleri Universitesi Gulhane Tip Fakultesi,Male,"18 Years and older   (Adult, Older Adult)",Not Applicable,120,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,50687469-1491-263-16/1648-736,Mar-16,Mar-17,Mar-17,6-May-16,null,7-Mar-19,,,https://ClinicalTrials.gov/show/NCT02764294
NCT02758990,Interventional Testing of Gene-environment Interactions Via the Verifomics Mobile Application,,Terminated,No Results Available,"Obesity|Rhinitis|Rhinitis, Allergic|Respiratory Sounds|Dyspnea|Headache|Migraine Disorders|Arthritis|Arthralgia|Anxiety|Sleep Initiation and Maintenance Disorders|Sleep Deprivation",Dietary Supplement: Vitamin A|Dietary Supplement: Vitamin B6|Dietary Supplement: Vitamin C|Dietary Supplement: Nicotinamide|Dietary Supplement: Vitamin D3|Dietary Supplement: Vitamin E|Other: Broccoli|Other: Spinach|Dietary Supplement: Caffeine|Other: Coffee|Device: Axon Eyewear|Other: Chocolate,"Frequency of correct predictions|Genotype-independent effects of substances of interest|Change in body mass index|Change in headache severity|Change in headache frequency|Change in rhinitis severity|Change in rhinitis frequency|Change in insomnia frequency|Change in insomnia severity|Change in joint pain severity|Change in joint pain frequency|""Question of the day"" questionnaire",Verifomics LLC,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,16,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1,Mar-16,23-Nov-16,23-Nov-16,3-May-16,null,2-Oct-17,"Verifomics, LLC, Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT02758990
NCT02755909,The Effect of Pre-anesthetic Education on Cardiac Surgery Patients' Anxiety Level,,Completed,No Results Available,Cardiac Surgery Patients,Behavioral: Pre-anesthetic Education,Subjects' Anxiety Level before Education|Subjects' Anxiety Level after Education,Indonesia University,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,36,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,IndonesiaUAnes002,Dec-15,Mar-16,Mar-16,29-Apr-16,null,3-May-16,,,https://ClinicalTrials.gov/show/NCT02755909
NCT02756507,Transdiagnostic REBT Prevention Program for Adolescents,,Completed,No Results Available,Social Anxiety|Major Depression Mild|Panic Disorder|Specific Phobia|Generalized Anxiety Disorder,Behavioral: video-based transdiagnostic REBT|Behavioral: Wait list,"The Multidimensional Anxiety Scale for Children (MASC; March, Parker, Sullivan, Stallings, & Conners, 1997)|Beck Depression Inventory for Youth subscale from the Beck Youth Inventories—Second edition for children and adolescents (Beck, 2005)|The Children's Automatic Thoughts Scale - Negative/Positive (CATS-N/P) (Hogendoorn et al., 2010)|The Strengths and Difficulties Questionnaire (SDQ) (Goodman, 1997)|The Questionnaire for Measuring Health-Related Quality of Life in Children and Adolescents, The Revised Version - adolescent version (Kiddo-KINDL) (Ravens-Sieberer et al., 2001)|The Credibility/ Expectancy Questionnaire (Devilly & Borkovec, 2000)|The Client Satisfaction Scale (Vigerland et al., 2016)",Babes-Bolyai University,All,12 Years to 17 Years   (Child),Not Applicable,381,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention",PN-II-PT-PCCA-2011-3.1-1500,Jun-16,Jun-18,Jun-18,29-Apr-16,null,24-Sep-18,"Babes-Bolyai University, Cluj-Napoca, Romania",,https://ClinicalTrials.gov/show/NCT02756507
NCT02756598,"Stress, Anxiety and Type A Personality and Analgesics",SATA-1,Completed,No Results Available,Postoperative; Dysfunction Following Cardiac Surgery,Drug: Sufentanil I|Drug: Sufentanil II|Drug: Propofol I|Drug: Propofol II,"Association between preoperative personality/stress/anxiety and time (minutes) to reach anaesthetic depth goal by bi-spectral index (BIS)|Potential of sufentanil regime on fast-track measured by ventilation time and association with eligible discharge from intensive care unit.|Sufentanil regime and association to haemodynamic parameters (blood pressures, heart rate, cardiac output, oxygenation)|Association between preoperative personality/stress/anxiety tests and postoperative care using postoperative quality score|Association between preoperative personality/stress/anxiety and total amounts of sufentanil and propofol",Aarhus University Hospital,null,"16 Years to 90 Years   (Child, Adult, Older Adult)",Phase 4,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care,SATA-1,Jan-15,1-Jan-18,30-Jun-18,29-Apr-16,null,11-Jul-18,,,https://ClinicalTrials.gov/show/NCT02756598
NCT02752945,"Feasibility Trial of a One-day CBT Workshop (""DISCOVER"") for 15-18 Year Olds With Anxiety and/or Depression in Clinics",,Completed,No Results Available,Anxiety|Depression,Other: One-day CBT workshop|Other: Usual care,Mood and Feelings Questionnaire (MFQ)|Revised Child Anxiety and Depression Scale (RCADS)|Warwick-Edinburgh Mental Well-being Scale (WEMWBS),King's College London|South London and Maudsley NHS Foundation Trust,All,"15 Years to 18 Years   (Child, Adult)",Not Applicable,28,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other,192806|16/LO/0231|R&D2016/021,Apr-16,Dec-16,Dec-16,27-Apr-16,null,4-May-17,"South London and Maudsley NHS Foundation Trust, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT02752945
NCT02752295,Intensive Stress Coping Intervention Week - A Secondary Prevention For Real World Affective Disorder Patients,ISCIW,Completed,No Results Available,Affective Disorders|Psychological Stress|Inflammation|Oxidative Stress|Anxiety Disorders|Mood Disorders|Emotions,Behavioral: stress-coping week|Behavioral: additional two days follow-up weekend,Change of saliva cortisol|Change of myeloperoxidase|Change of interleukin-6|Change of homocystein|Change of psychometric stress-index (Questionnaire),Medical University of Vienna|Sanatorium Hera Vienna,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,43,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,ISCIW trial,May-15,Jul-16,Jul-16,26-Apr-16,null,16-Sep-16,,,https://ClinicalTrials.gov/show/NCT02752295
NCT02746679,"Impact of Mindfulness Based Stress Reduction on Anxiety, Depression and QOL in Women With Intrauterine Adhesion.",IMBSRADQWIUA,Completed,Has Results,Asherman Syndrome,Other: Mindfulness Based Stress Reduction,The Zung Self-Rating Anxiety Scale Scores Before and After the Intervention|Endometrial Thickness Were Measured by Ultrasound in the Middle of Menstruation in All Patients.|Menstruation Was Evaluated With Visual Analogue Scale (VAS) in Which the Menstruation Was Assessed by the Patients Themselves With 0 as Amenorrhea and 100 as Normal Menstruation|Numbers of Participants With Reformation of Intrauterine Adhesions Were Counted by the Follow-up Hysteroscopy Was Performed in the Third Month After the Surgery|The Zung Self-Rating Depression Scale Scores Before and After the Intervention|The Scores of Physical Function Before and After the Intervention(One Dimensions of the 36-item Short-form Health Survey)|The Scores of Role-physical Before and After the Intervention(One Dimensions of the 36-item Short-form Health Survey)|The Scores of Role-emotional Before and After the Intervention(One Dimensions of the 36-item Short-form Health Survey)|The Scores of Vitality Before and After the Intervention(One Dimensions of the 36-item Short-form Health Survey)|The Scores of Mental Health Before and After the Intervention(One Dimensions of the 36-item Short-form Health Survey)|The Scores of Social Functioning Before and After the Intervention(One Dimensions of the 36-item Short-form Health Survey)|The Scores of Bodily Pain Before and After the Intervention(One Dimensions of the 36-item Short-form Health Survey)|The Scores of General Health Before and After the Intervention(One Dimensions of the 36-item Short-form Health Survey),"Yuqing Chen|First Affiliated Hospital, Sun Yat-Sen University",Female,20 Years to 46 Years   (Adult),Not Applicable,226,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",MBSR-5,Jan-15,Nov-15,Jan-16,21-Apr-16,26-Aug-16,26-Aug-16,,,https://ClinicalTrials.gov/show/NCT02746679
NCT02747160,Anxiety With Cancer in the Elderly (ACE): A Cognitive-behavioral Intervention,,"Active, not recruiting",No Results Available,Anxiety|Depression|Quality of Life,Behavioral: Managing Anxiety from Cancer (MAC),Intervention feasibility|Intervention acceptability|Patient/caregiver adherence|Change in anxiety from baseline to post-intervention|Change in distress from baseline to post-intervention|Emotional health-related quality of life|Change in depression from baseline to post-intervention,Weill Medical College of Cornell University,All,65 Years and older   (Older Adult),Not Applicable,30,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,1510016676,Jun-16,Dec-16,Apr-19,21-Apr-16,null,1-Aug-18,"Weill Medical College of Cornell University, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT02747160
NCT02742389,Urodynamic Testing: Can we Improve Patient Experience?,,Completed,No Results Available,"Urinary Incontinence|Urinary Bladder, Overactive|Lower Urinary Tract Symptoms",Other: Preprocedure Telephone Call,Overall pre-procedure anxiety as measured on a visual analog scale.,Boston Urogynecology Associates|Harvard University,Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,130,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,004-2016,Apr-16,Jun-17,Jun-17,19-Apr-16,null,19-Jan-18,"Mount Auburn Hospital, Cambridge, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT02742389
NCT02742532,Oxytocin Suppresses Substance Use Disorders Associated With Chronic Stress,,Enrolling by invitation,No Results Available,"Alcohol Use Disorder|Stress Disorders, Post-Traumatic|Anxiety Disorders|Substance Use Disorders",Drug: Oxytocin|Drug: Placebo,Craving to use alcohol (Visual Analog Scale)|Stress rating (Visual Analog Scale),"University of California, San Francisco|United States Naval Medical Center, San Diego|United States Department of Defense|Congressionally Directed Medical Research Programs|Eisenhower Army Medical Center",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,80,Other|U.S. Fed,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science",NMCSD Oxytocin,20-Apr-17,Jul-19,Dec-19,19-Apr-16,null,5-Dec-18,"Naval Medical Center San Diego, San Diego, California, United States",,https://ClinicalTrials.gov/show/NCT02742532
NCT02742597,Patient-Centred Innovations for Persons With Multimorbidity - Ontario,PACEinMM-ON,"Active, not recruiting",No Results Available,Hypertension|Depression|Anxiety|Musculoskeletal Pain|Arthritis|Rheumatoid Arthritis|Osteoporosis|Chronic Obstructive Pulmonary Disease (COPD)|Asthma|Chronic Bronchitis|Cardiovascular Disease|Heart Failure|Stroke|Transient Ischemic Attacks|Ulcer|Gastroesophageal Reflux|Irritable Bowel|Crohn's Disease|Ulcerative Colitis|Diverticulosis|Chronic Hepatitis|Diabetes|Thyroid Disorder|Cancer|Kidney Disease|Urinary Tract Problem|Dementia|Alzheimer's Disease|Hyperlipidemia|HIV|Multimorbidity,Behavioral: TIP / IMPACT Plus Care Coordination,Evaluation of Intervention Effectiveness - Change in Self-Management outcomes|Evaluation of Intervention Effectiveness - Change in Transitions of Care|Evaluation of Intervention Effectiveness - Change in Self-Efficacy|Evaluation of Intervention Effectiveness - Change in Patient-Centredness|Evaluation of Intervention Effectiveness - Change in Chronic Diseases|Evaluation of Intervention Effectiveness - Change in Health Status|Evaluation of Intervention Effectiveness - Change in Quality of Life|Evaluation of Intervention Effectiveness - Change in Psychological Well-being|Evaluation of Intervention Effectiveness - Change in Lifestyle/Health Behaviours|Evaluation of Intervention Effectiveness - Change in Equity|Evaluation of Intervention Effectiveness - Change in Demographics,"Lawson Health Research Institute|Western University, Canada|Université de Sherbrooke|Canadian Institutes of Health Research (CIHR)|Sunnybrook Health Sciences Centre|St. Michael's Hospital, Toronto|University Health Network, Toronto|Toronto East General Hospital|Providence Healthcare|Mount Sinai Hospital, Canada|Toronto Central Community Care Access Centre|Women's College Hospital",All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,1980,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,104191,12-Jan-16,7-Apr-19,1-Mar-20,19-Apr-16,null,18-Dec-17,"Western University, London, Ontario, Canada|Mount Sinai Hospital, Toronto, Ontario, Canada|Providence Healthcare, Toronto, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|Toronto Central Community Care Access Centre, Toronto, Ontario, Canada|Toronto East General Hospital, Toronto, Ontario, Canada|University Hospital Network, Toronto, Ontario, Canada|Women's College Hospital, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT02742597
NCT02743715,Transcranial Direct Current Stimulation (tDCS) for Treatment-Resistant Obsessive-Compulsive Disorder (FRONT),FRONT,Completed,No Results Available,Obsessive-Compulsive Disorder,Device: Active tDCS (transcranial direct current stimulation)|Device: Sham tDCS,"change in baseline Yale-Brown Obsessive Compulsive Scale score|Beck Depression Inventory symptoms,|Beck Anxiety Inventory|Hamilton Depression Scale|Hamilton Anxiety Scale|Global Clinical Impression Scale - improvement",University of Sao Paulo|Fundação de Amparo à Pesquisa do Estado de São Paulo,All,"14 Years to 65 Years   (Child, Adult, Older Adult)",Not Applicable,44,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",FRONT2016,Apr-15,Aug-18,Aug-18,19-Apr-16,null,12-Oct-18,"USP, São Paulo, Brazil",,https://ClinicalTrials.gov/show/NCT02743715
NCT02739607,Internet-delivered Transdiagnostic Intervention for Anxiety and Depression,iTAD,Unknown status,No Results Available,Depression|Dysthymic Disorder|Panic Disorder|Social Phobia|Specific Phobia|Obsessive-Compulsive Disorder|Generalized Anxiety Disorder,Behavioral: Transdiagnostic program,Penn State Worry Questionnaire (PSWQ)|Social Phobia Inventory (SPIN)|Yale-Brown Obsessive Compulsive Scale (YBOCS)|Panic Disorder Severity Scale - Self Report (PDSS-SR)|Post-Traumatic Stress Disorder Checklist for the Diagnostic and Statistical Manual-5 (PCL-5)|Beck Depression Inventory-II (BDI-II)|Emotion Regulation Questionnaire (ERQ)|Anxiety Sensitivity Index (ASI)|Beck Anxiety Inventory (BAI)|Almost Perfect Scale-Revised (APS-R),West University of Timisoara,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,WUTimisoara-iTAD,Apr-16,Sep-16,Mar-17,15-Apr-16,null,6-May-16,"West University of Timisoara, Timișoara, Timiș, Romania",,https://ClinicalTrials.gov/show/NCT02739607
NCT02740309,Integrated Behavioral Health Innovations in Childhood Chronic Illness Care Delivery Systems,,Withdrawn,No Results Available,Inflammatory Bowel Disease,Behavioral: Integrated Brief Behavior Therapy (IBBT) Intervention|Behavioral: Treatment as usual,Change in Anxiety and/or Depression Symptoms|Treatment Engagement at Baseline|Screen for Childhood Anxiety Related Emotional Disorders (SCARED)|Children's Global Assessment Scale (CGAS)|Columbia Suicide Severity Rating Scale (C-SSRS)|IBD disease activity - Pediatric Ulcerative Colitis Activity Index (PUCAI)|IBD-related quality of life-SIBDQ|Medical Adherence Measure|Health Care Utilization|Pediatric Crohn's Disease Activity Index (PCDAI)|Health Care Cost,New York University School of Medicine,All,"12 Years to 21 Years   (Child, Adult)",Not Applicable,0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Treatment,15-01065,Apr-16,Mar-18,Mar-18,15-Apr-16,null,5-Dec-18,"Sala Institute for Child and Family Centered Care, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT02740309
NCT02740465,Anxiety and COPD Evaluation,ACE,Completed,No Results Available,Chronic Obstructive Pulmonary Disease,Behavioral: Anxiety Inventory for Respiratory Disease (AIR)|Behavioral: Hospital Anxiety and Depression Scale (HADS),Montreal Cognitive Assessment (MoCA)|COPD Assessment Test (CAT)|Modified Medical Research Council dyspnea scale (MMRC)|Pittsburgh Sleep Quality Index (PSQI)|Patient-Reported Outcomes Measurement Information System Questionnaires: Emotional Distress—Anxiety Function -(PROMIS-29)|Patient-Reported Outcomes Measurement Information System Questionnaires: Physical Function - Short Form 20a (PROMIS-20a)|EuroQol EQ-5D- 5L|Patient Health Questionnaire for Depression (PHQ9)|Patient Health Questionnaire for Anxiety (GAD7)|Hospital Anxiety and Depression Scale (HADS)|Mini International Neuropsychiatric Interview (MINI)|6 Minute Walk Distance|Pulmonary function Spirometry pre and post bronchodilator,New York University School of Medicine,All,"40 Years and older   (Adult, Older Adult)",Not Applicable,200,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,15-00336,Jan-16,1-Mar-19,1-Mar-19,15-Apr-16,null,22-Mar-19,"New York University School of Medicine, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT02740465
NCT02739061,The Study of the Pathogenesis and Cognitive Behavioral Group Therapy in Obsessive-Compulsive Disorder,,Unknown status,No Results Available,Obsessive-Compulsive Disorder,"Behavioral: cognitive behavioral group therapy|Drug: sertraline, fluvoxamine|Other: cognitive behavioral group therapy and drug therapy",Y-BOCS (The Yale-Brown Obsessive Compulsive Scale),Shanghai Mental Health Center,All,18 Years to 54 Years   (Adult),Not Applicable,240,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,HYZhang,Apr-16,Jul-17,Jul-17,14-Apr-16,null,5-May-17,"Clinical psychiatrist, Shanghai, Shanghai, China",,https://ClinicalTrials.gov/show/NCT02739061
NCT02736045,Ameliorating Work Burnout and Medical Residents,,Unknown status,No Results Available,"Burnout, Professional|Depression|Stress|Anxiety|Distress",Device: emWave,"Change in Work Burnout Symptoms ( measured by Maslach Burnout Inventory) (Of note, changes in Work Burnout Symptoms & Findings by Medical Residents will be attempted to be observed)|Change in Depression ( measured by Epidemiologic Studies Depression Scale) (Of note, changes in Depressive Symptoms by Medical Residents will be attempted to be observed)",Larkin Community Hospital,All,25 Years to 50 Years   (Adult),Phase 1|Phase 2,150,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,LCH-1-032015,Jul-15,Dec-16,Feb-17,13-Apr-16,null,13-Apr-16,"Larkin Community Hospital, South Miami, Florida, United States",,https://ClinicalTrials.gov/show/NCT02736045
NCT02736136,An Early Intervention to Increase Maternal Self-efficacy After Preterm Birth,JOIN,Recruiting,No Results Available,Posttraumatic Stress Disorder|Stress|Anxiety|Depression,Behavioral: joint observation and video feedback,Perceived Maternal Parenting Self-Efficacy tool|Posttraumatic Diagnostic Scale|Parental Stressor Scale: Neonatal Intensive Care Unit|Parental Stress Index - Short form|Hospital Anxiety and Depression Scale|Edinburgh Postnatal Depression Scale|Mother-to-Infant Bonding Scale|Infant Behaviour Questionnaire - Revised very short form|Emotional Availability Scale|Perceived Maternal Parental Self-Efficacy tool|CARE-Index,Centre Hospitalier Universitaire Vaudois,Female,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,80,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,496/15,Apr-16,Dec-19,Dec-19,13-Apr-16,null,19-Jul-18,"Neonatology Service, University Hospital Lausanne, Lausanne, Vaud, Switzerland",,https://ClinicalTrials.gov/show/NCT02736136
NCT02734251,"Effect of Relora Supplement on Anxiety, Cognitive Performance & Mood Tested After Induced Stress",,Completed,No Results Available,Mood (Psychological Function),Dietary Supplement: Relora|Dietary Supplement: Placebo,Mean STAI-Part 1 post-dose score (collected as part of the test battery at the t = 90 and 180 min timepoints) at the end (day 7) of each of the two treatment conditions.|Total area under the curve (AUC) for salivary cortisol from 90 to 150 min and 180 to 240 min at the end (day 7) of each of the two treatment conditions|Bond-Lader post-dose VAS scores (collected as part of the test battery at the t = 90 and 180 min timepoints) at the end (day 7) of each of the two treatment conditions.|Cognitive function post-dose test scores (collected as part of the test battery at the t = 90 and 180 min timepoints) at the end (day 7) of each of the two treatment conditions.,"InterHealth Nutraceuticals, Inc.|MB Clinical Research, LLC",All,21 Years to 59 Years   (Adult),Not Applicable,36,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care",MC-1514,Feb-16,May-16,null,12-Apr-16,null,24-May-16,"MB Clinical Research, Boca Raton, Florida, United States",,https://ClinicalTrials.gov/show/NCT02734251
NCT02735434,Internet-delivered Acceptance and Commitment Therapy for Patients With Health Anxiety,,Unknown status,No Results Available,Hypochondriasis,Behavioral: Internet-based ACT|Other: Internet-based discussion forum,"Whiteley-7 index|Demographic questions measured with questions from the Danish study for Functional Disorders (DanFund)|Diagnosed somatic illnesses measured with questions from the Danish study for Functional Disorders (DanFund)|Quality of life measured with the World Health Organisation Well-being Index-Five (WHO-5)|Quality of life measured with the visual analogue scale (VAS question) from Youth profile, National Institute of Public Health|Stress measured with questions from the survey Youth stress, Danish Health Authority|Health anxiety symptoms measured with the Short Health Anxiety Inventory (SHAI)|Anxiety, depression, obsessive-compulsive and physical symptoms measured with subscales from the Symptom Checklist (SCL-92)|Somatisation measured with the Bodily Distress Syndrome Checklist (BDS Checklist)|General health status and functioning measured with the Short Form 12 Health Survey (SF-12)",University of Aarhus|Aarhus University Hospital|Karolinska Institutet,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,150,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,9032016,Apr-16,Apr-17,Jul-18,12-Apr-16,null,3-May-17,,,https://ClinicalTrials.gov/show/NCT02735434
NCT02732964,"Impact of Music on Satisfaction, Anxiety, and Hemodynamics During Spinal Anesthesia for Cesarean Delivery",,Completed,No Results Available,Anxiety|Hypotension,Other: Pandora Music|Other: Mozart Music,"maternal anxiety level, VAS|Change in maternal blood pressure after spinal anesthesia induction , compared to baseline blood pressure|maternal anxiety level, STAI|Overall patient satisfaction, questionnaire|Overall patient satisfaction, pain control|Vasopressor requirement, phenylephrine|Vasopressor requirement, ephedrine",Brigham and Women's Hospital,Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,150,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2015P002043,Nov-15,Sep-16,Oct-17,11-Apr-16,null,30-Oct-17,"Brigham and Women's Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT02732964
NCT02732561,The Efficacy of Cranial Electrostimulating Therapy for Depression and Anxiety Among Homeless Adults,,Completed,Has Results,Depression|Anxiety,Device: Alpha Stim device|Device: Sham device,Depressive Symptoms|Anxiety,Wake Forest University Health Sciences,All,18 Years to 64 Years   (Adult),Not Applicable,10,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,IRB00036461,Mar-16,Jun-16,Jun-16,8-Apr-16,1-May-17,16-Oct-18,"Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT02732561
NCT02725619,CBT for Anxiety in Children With Autism,,Recruiting,No Results Available,Autism Spectrum Disorder|Anxiety,Behavioral: CBT|Behavioral: PST,Pediatric Anxiety Rating Scale (PARS)|Clinical Global Impression - Improvement (CGI-I) scale|blood oxygenation level dependent signal (BOLD) during down-regulation versus passive viewing of affective images.|blood oxygenation level dependent signal (BOLD) during emotional face perception task,Yale University,All,8 Years to 14 Years   (Child),Not Applicable,150,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,1211011144B,Apr-16,Jun-20,Nov-20,1-Apr-16,null,9-Jan-18,"Yale Child Study Center, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT02725619
NCT02723903,Hierarchical Treatment Based on Somatization Symptom Checklist,,Unknown status,No Results Available,Syndrome X,Drug: Deanxit|Drug: Prozac|Procedure: coronary artery disease treatment,The efficacy of somatization symptom score|scale chest discomfort|The efficacy of Patient Health Questionnaire|The efficacy of Generalized Anxiety Disorder 7-items,RenJi Hospital,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1|Phase 2,200,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,81470391,Dec-15,Dec-16,Dec-17,31-Mar-16,null,31-Mar-16,"Renji Hospital, Shanghai, China",,https://ClinicalTrials.gov/show/NCT02723903
NCT02725281,Pain and Anxiety During Extracorporeal Shock Wave Lithotripsy,,Completed,No Results Available,Urinary Tract Stones|Pain|Anxiety,Other: Stress ball|Other: Music,A change on pain severity in VAS (Visual Analogue Scale) pain scale reported by the patients at the end of lithotripsy procedure compared with the baseline|A change on anxiety level in STAI-SA (State-Trait Anxiety Inventory-State Anxiety) at the end of procedure compared with the baseline,Saglik Bilimleri Universitesi Gulhane Tip Fakultesi,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,120,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),50687469-1491-85-14/1648.4-464,Apr-14,Sep-14,Sep-14,31-Mar-16,null,31-Mar-16,,,https://ClinicalTrials.gov/show/NCT02725281
NCT02723188,Modulation of Fear Extinction Processes Using Transcranial Electrical Stimulation,,Completed,Has Results,Stress Related Disorder|Anxiety,"Device: Sham stimulation (1.5 milliampere,30 seconds)|Device: DC stimulation (1.5 milliampere, 20 minutes)|Device: AC stimulation (1.5 milliampere,1.5 Hertz frequency)",Galvanic Skin Response (GSR)|Self-reported Fear Rankings,Tel Aviv University,All,18 Years to 50 Years   (Adult),Not Applicable,45,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",TASMC-13-TH-334,Sep-14,Apr-15,Apr-15,30-Mar-16,14-Jun-17,14-Jun-17,,,https://ClinicalTrials.gov/show/NCT02723188
NCT02712749,Use of Binaural Beat Premedication in Elderly Submitted to Major Orthopedic Surgery,,Completed,No Results Available,Anxiety|Postoperative Pain|Morphine Consumption,Device: Sound with Binaural Beats|Device: Sound without Binaural Beats,Reduction on postoperative morphine consumption|Reduction in the level of preoperative anxiety assessed by State Anxiety inventory (STAI-1),L'Azienda USL Nord Ovest,All,65 Years to 90 Years   (Older Adult),Not Applicable,40,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",IDE,1-Sep-16,15-Mar-19,28-Mar-19,18-Mar-16,null,1-Apr-19,"Santa Maria Maddalena Hospital, Volterra, Pisa, Italy",,https://ClinicalTrials.gov/show/NCT02712749
NCT02713360,Screening and Intervention Reducing Anxiety in Patients With Implanted Cardioverter Defibrillator (ICD),,"Active, not recruiting",No Results Available,ICD|Cognitive Therapy|Anxiety,Behavioral: Cognitive Therapy,Primary outcome is anxiety measured by HADS.|Anxiety measured by HADS.|Becks Anxiety Inventory (BAI)|Hamilton Anxiety Scale (HAM-A)|HeartQoL,"Rigshospitalet, Denmark|University Hospital, Gentofte, Copenhagen",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,88,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening,Screen-ICD,May-16,May-18,Dec-18,18-Mar-16,null,29-Aug-18,"Rigshospitalet, Copenhagen, Denmark|Herlev and Gentofte Hospital, Hellerup, Denmark",,https://ClinicalTrials.gov/show/NCT02713360
NCT02713425,Pediatric Anxiety Intervention With an Entertaining Video Game: Feasibility Study,,Completed,No Results Available,Anxiety,Device: Entertaining Video Game,Mean change from Baseline in Subjective Units of Distress Scale (SUDS) at end of session|Percent of children to describe the game as engaging and easy to use,Mayo Clinic,All,7 Years to 17 Years   (Child),Not Applicable,40,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,14-000162,1-Oct-16,15-Jun-17,15-Jul-17,18-Mar-16,null,25-Feb-19,"Mayo Clinic, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT02713425
NCT02713516,Virtual Reality System to Increase Access to Exposure Therapy for Anxiety and OCD,,Completed,No Results Available,Anxiety|Obsessive Compulsive Disorder,Other: Virtual Reality,Mean change from baseline in Subjective Units of Distress Scale (SUDS) at end of session|Percent of children to describe the virtual reality system as engaging and easy to use based on qualitative interviews,Mayo Clinic,All,7 Years to 12 Years   (Child),Not Applicable,40,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,15-008235,1-Aug-17,1-May-18,31-May-18,18-Mar-16,null,12-Nov-18,"Mayo Clinic in Rochester, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT02713516
NCT02711800,The Probiotic Study: Using Bacteria to Calm Your Mind,,Completed,Has Results,Anxiety|Abdominal Pain,Drug: Lactobacillus rhamnosus,Change in Child Abdominal Pain Rating|Change in Child Abdominal Pain Frequency|Change in Child Anxiety Symptoms|Percentage of Adherence to Treatment|Change in Relative Quantities of Taxa Among Groups Relative to Probiotic Administration|Change in Alpha Diversity|Change in Beta Diversity (PCoA)|Change in Trait-associated Co-functional Modules of Organisms|Change in Salivary Cortisol (ug/dL)|Change in Heart Rate,Nancy Zucker|Duke University,All,9 Years to 13 Years   (Child),Phase 2,9,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Pro00063870,8-Nov-16,18-Sep-17,18-Sep-17,17-Mar-16,3-Jan-19,3-Jan-19,"Duke Center for Developmental Epedimiology, Durham, North Carolina, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/00/NCT02711800/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02711800
NCT02709369,HIRREM Developmental Study,,Completed,No Results Available,Sleep Initiation and Maintenance Disorders|Anxiety|Post-Traumatic Stress Disorder|Hot Flashes|Headache|Traumatic Brain Injury|Post Concussion Symptoms,Device: HIRREM,Heart rate variability|Baroreflex Sensitivity|Center for Epidemiologic Studies Depression Scale (CES-D)|EQ-5D|Generalized Anxiety Disorder-7 (GAD-7)|Insomnia Severity Index (ISI)|PCL|Rivermead Post-Concussion Symptoms Questionnaire (RPQ)|Drop stick reaction time,Wake Forest University Health Sciences,All,"11 Years and older   (Child, Adult, Older Adult)",Not Applicable,300,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IRB00017651,23-Aug-11,25-Oct-18,25-Oct-18,16-Mar-16,null,3-Dec-18,"Department of Neurology, Wake Forest School of Medicine, Winston-Salem, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT02709369
NCT02708472,Safety and Efficacy of Synchronized Transcranial Magnetic Stimulation for the Treatment of Generalized Anxiety Disorder,,Withdrawn,No Results Available,Generalized Anxiety Disorder (GAD),Device: synchronized Transcranial Magnetic Stimulation (sTMS),Mean change in score on the Hamilton Anxiety Rating Scale (HAM-A)|Clinical response on the Hamilton Anxiety Rating Scale|Clinical response on the Generalized Anxiety Disorder 7-item scale (GAD-7)|Clinical response on the Hamilton Depression Rating Scale (HAM-D17)|Clinical response on the Quick Inventory of Depressive Symptomatology Self Report (QIDS-SR16),"University of Texas Southwestern Medical Center|NeoSync, Inc.",All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,0,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,STU 112015-078,1-Apr-16,1-Apr-17,22-Jan-18,15-Mar-16,null,14-Aug-18,,,https://ClinicalTrials.gov/show/NCT02708472
NCT02708940,Participatory Messaging in the UCLA Psychiatry Partial Hospitalization and Intensive Outpatient Programs,,Unknown status,No Results Available,Depression|Anxiety|Psychosis,Other: Participatory technology development|Other: Usual Care,Change in homework completion rate|length of stay|time to discharge|Number of patient visits to health care organizations outside of clinic|Types of health care services patients utilize outside of clinic|change in depression symptoms|Change in Patient Treatment Self-Efficacy|Difference in Patient Satisfaction with Program between Intervention vs Control groups|Messaging Application Usability|Patient Involvement in Message Development,"University of California, Los Angeles",All,"Child, Adult, Older Adult",Not Applicable,150,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IRB#14-001879,Feb-16,Sep-16,Dec-16,15-Mar-16,null,15-Mar-16,"UCLA Partial Hospitalization and Intensive Outpatient Programs, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT02708940
NCT02707705,Preoperative Auricular Acupuncture in Elective Cesarean Section.,CESAUR,Completed,No Results Available,"Anxiety Reduction, Elective Cesarean Section",Device: Apply an auricular acupuncture protocol by stimulating specific points of the ear with needles inserted on adhesive tape (Pyonex®).|Device: Apply a device having no real effect|Procedure: Disinfection,"Comparison of anxiety variation between group A (Auricular acupuncture, needle patch) and group P (needle-free patch) via visual analog scale.|Potential placebo effect of auricular acupuncture by measuring Anxiety variation between the 3 groups.|To evaluate anxiolytic effect of auricular acupuncture on anxiety measured by Amsterdam Preoperative Anxiety and Information Scale (APAIS).|To evaluate the effect of auricular acupuncture on parasympathetic tone measured by Analgesia Nociception Index (ANI).|Study of the correlation between ANI and anxiety VAS.|To evaluate the effect of auricular acupuncture on perioperative pain.|Report of potential adverse events of auricular acupuncture.|Correlation between APAIS and anxiety VAS.",Hospices Civils de Lyon,Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,91,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care,69HCL15_0352,Feb-16,Feb-18,Feb-18,14-Mar-16,null,6-Apr-18,"Hôpital de la Croix Rousse, Lyon, France",,https://ClinicalTrials.gov/show/NCT02707705
NCT02705261,Coaching for Confidence: Evaluating an Internet-based Program to Help Parents Help Children With Difficulty With Anxiety,,"Active, not recruiting",No Results Available,Anxiety Disorders,Behavioral: cognitive-behavior therapy,Spence Children's Anxiety Scale - Parent-rated|Clinical Global Improvement Scale - parent confidence|Clinical Global Improvement Scale - child anxiety,University of Manitoba,All,4 Years to 12 Years   (Child),Not Applicable,92,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,246529,Mar-16,30-Sep-18,31-Dec-18,10-Mar-16,null,24-Jul-18,"University of Manitoba, College of Medicine, Winnipeg, Manitoba, Canada",,https://ClinicalTrials.gov/show/NCT02705261
NCT02704117,Neurocircuitry of Obsessive-Compulsive Disorder: Modulation by Transcranial Magnetic Stimulation,,Recruiting,No Results Available,Obsessive-Compulsive Disorder,Device: Transcranial Magentic Stimulation,Change in activation of pre-supplementary motor area/dorsal anterior cingulate cortex (pSMA/dACC) on functional magnetic resonance imaging (fMRI) during the Multi-Source Interference task (MSIT)|Change in Yale-Brown Obsessive Compulsive Scale (Y-BOCS),Butler Hospital|University of Rochester|Harvard University|University of Pittsburgh|University of Puerto Rico,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,30,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,P50MH106435,Jun-15,May-20,May-20,9-Mar-16,null,4-Mar-19,"Butler Hospital, Providence, Rhode Island, United States",,https://ClinicalTrials.gov/show/NCT02704117
NCT02701361,Mobile Mindfulness to Improve Psychological Distress After Critical Illness,,Completed,Has Results,Psychological Distress|Depression|Anxiety|Post-traumatic Stress Disorder|Informal Caregivers|Family Members,Behavioral: mobile mindfulness|Behavioral: standard mindfulness|Behavioral: education,Percent of Eligible Participants Who Provided Consent|Percent of Eligible Participants Who Provide Informed Consent and Were Randomized|Client Satisfaction Questionnaire (CSQ) Score|System Usability Scale (SUS)|Percent of Randomized Participants Who Drop Out of Study|Percent of Participants Who Have Neither Dropped Out Nor Died Who Complete Telephone Interviews|Percent of Participants in the Self-directed MBT Group Who Complete Weekly Surveys|Percentage of Self-directed MBT Sessions Attended by Eligible Participants|Visual Analog Satisfaction Scale|Number of Participant Clicks on Study Website|Change in Psychological Distress Symptoms as Measured by the Patient Health Questionnaire (PHQ) Scale|Change in Distress Associated With Physical Symptoms|Change in Mindfulness Skills|Change in Psychological Distress Symptoms as Measured by the GAD-7|Change in Psychological Distress Symptoms as Measured by the PTSS|Change in the Avoidance Domain of the Brief COPE Scale,Duke University|University of Washington|University of Pennsylvania|National Center for Complementary and Integrative Health (NCCIH),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,90,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,Pro00064250|R34AT008819,Mar-16,1-May-17,5-Jul-17,8-Mar-16,10-Jan-18,7-Feb-18,"Duke University, Durham, North Carolina, United States|University of Washington, Seattle, Washington, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/61/NCT02701361/ICF_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/61/NCT02701361/Prot_001.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/61/NCT02701361/SAP_003.pdf",https://ClinicalTrials.gov/show/NCT02701361
NCT02698904,Relaxation Training for People With Chronic Obstructive Pulmonary Disease (COPD),,Completed,No Results Available,Chronic Obstructive Pulmonary Disease (COPD),Behavioral: Guided Relaxation Technique|Other: Documentary Movie,"Differences in patients' state of dyspnea, before and after the treatment, as assessed by the Borg Scale (BORG)|Changes in Heart Rate Variability (HRV), before, during and after the treatment|Changes in oxygen saturation (SpO2), before, during and after the treatment|Changes in airway resistance (kPa/l/s) before and after the treatment|Changes in subjective feelings of anxiety, before and after the treatment, as measured by the State Trait Anxiety Inventory (STAI-Y1)|Changes in the intensity of subjective feelings, before and after the treatment, as assessed by a Visual Analogue Scale (VAS)|Changes in the intensity of positive and negative affects, before and after the treatment, as assessed by the Positive and Negative Affective Schedule (PANAS)|Presence and intensity of the possible subjective experience of engaging just-manageable challenges by tackling a series of goals, continuously processing feedback about progress, and adjusting action based on this feedback, after the treatment|Differences in Forced Vital Capacity (FVC), before and after the treatment|Differences in Forced Expiratory Volume in The First Second (FEV1), before and after the treatment",Fondazione Don Carlo Gnocchi Onlus|Catholic University of the Sacred Heart,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,39,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,FDG_COPDRELAX_01,Jan-16,Mar-16,Jul-16,4-Mar-16,null,31-Jul-17,"Paolo Banfi, Milan, Italy",,https://ClinicalTrials.gov/show/NCT02698904
NCT02699814,"H3: Healthy Minds, Healthy Children, Healthy Chicago Project Evaluation",H3,"Active, not recruiting",No Results Available,Developmental Delay|Mental Health Disorder,Behavioral: H3 Services,H3 intervention care processes|Mental health functioning|Child development|Child functioning|Response to trauma and resilience|Care process delivered,"University of California, Los Angeles|University of Illinois at Chicago",All,up to 16 Years   (Child),Not Applicable,277,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,IRB#15-000757,Mar-16,Aug-18,Apr-19,4-Mar-16,null,14-Sep-18,"Miles Square Health Center, Englewood, Chicago, Illinois, United States|Erie Family Health Center, West Town, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT02699814
NCT02697175,Video Colposcopy in Women With Dysplasia,,Completed,No Results Available,Uterine Cervical Dysplasia,Device: Live Video-Colposcopy|Other: No Live Video-Colposcopy,Anxiety score after colposcopy|Change in anxiety scores|Pain during examination|Pain after examination|general unpleasantness during examination|Anxiety during examination|Satisfaction concerning the medical consultation|Overall Satisfaction,Zydolab - Institute of Cytology and Immune Cytochemistry,Female,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,275,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,COLPO-2,Aug-16,Mar-17,Mar-17,3-Mar-16,null,27-Mar-17,"Zydolab - Institute of Cytology and Immune Cytochemistry, Dortmund, NRW, Germany|Department of Obstetrics and Gynecology of the Ruhr University Bochum, Herne, NRW, Germany",,https://ClinicalTrials.gov/show/NCT02697175
NCT02697435,Making Better Lives: Patient-Focused Care for Low Back Pain (LBP),,Completed,No Results Available,Chronic Low Back Pain|Hip Ostearthritis|Myofascial Pain Syndrome|Fibromyalgia|Depression|Maladaptive Coping|Lumbar Spinal Stenosis|Insomnia|Sacroiliac Joint Pain|Lateral Hip and Thigh Pain|Anxiety|Dementia|Recent Leg Length Discrepancy,Other: Patient-Centered Care|Other: Imaging-Directed Care,Participants' level of low back pain-associated disability as assessed by Roland Morris Disability Questionnaire (RMDQ)|Participants' level of low back pain as assessed by O-10 Numeric Rating Scale for Pain,VA Office of Research and Development,All,"60 Years to 89 Years   (Adult, Older Adult)",Not Applicable,50,U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,F2021-P|PRO 1653,1-Apr-16,31-May-18,31-Aug-18,3-Mar-16,null,13-Sep-18,"VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA, Pittsburgh, Pennsylvania, United States|Hunter Holmes McGuire VA Medical Center, Richmond, VA, Richmond, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02697435
NCT02692300,EEG Guidance of Anesthesia (ENGAGES-CANADA),ENGAGES,Recruiting,No Results Available,Post-operative Delirium,Procedure: EEG-Guided Group,Incidence of post-operative delirium|Incidence of mortality at 30 days and at 1 year|Length of ICU stay|Length of Hospital stay,University of Manitoba|Université de Montréal|Queen's University|University of Washington|University of Toronto,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,1200,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",HS18290,Feb-16,Dec-20,Dec-21,26-Feb-16,null,3-May-19,"Montreal Heart Institute, Université de Montréal, Montréal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT02692300
NCT02692768,The Effect of Music Therapy Intervention on Pain and Anxiety in Adult Patients Undergoing Total Shoulder Arthroplasty,,Enrolling by invitation,No Results Available,Arthritis,Other: Live Music Therapy|Other: Recorded Music Therapy|Other: Control,Change from baseline in pain scores on the visual analog scale at 6 months|Change from baseline in anxiety scores on the PROMIS Emotional Distress-Anxiety-Short Form at 6 months,April Armstrong|Milton S. Hershey Medical Center,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,105,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,STUDY00004093,Mar-16,31-Dec-20,31-Dec-21,26-Feb-16,null,6-May-19,"Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT02692768
NCT02693561,"Effects of Deep Breathing,Self-Help Book in Cigarette Consumption,Anxiety,Depression and Motivation to Stop Smoking",,Unknown status,No Results Available,Smoking Cessation,Behavioral: Deep Breathing Exercises|Behavioral: Self-Help Book,"Motivation measured with the Portuguese version of the ""URICA"" (Scale University of Rhode Island Change Assessment)|Nicotine addiction measured whit the Portuguese version of the Fagerstrom test|Depression measured with the portuguese version of the ""BDI"" ( The Beck Depression Inventory).|Anxiety measured with the Portuguese version of the ""BAI"" ( The Beck Anxiety Inventory)",Anhembi Morumbi University,All,18 Years to 30 Years   (Adult),Not Applicable,85,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AnhembiMU,Jan-15,Feb-16,Aug-16,26-Feb-16,null,29-Feb-16,"Anhembi Morumbi University, São Paulo, Brazil",,https://ClinicalTrials.gov/show/NCT02693561
NCT02690194,A Prospective Study Investigating the Use of Relaxation Prior to Medical Procedures.,,Completed,Has Results,Pain|Anxiety,Device: Placebo Group|Device: Buddhify Therapy,Pre-therapy/Pre-procedure Stress Level Measured by Blood Pressure|Pre-therapy/Pre-procedure Stress Level Measured by Pulse|Pre-therapy/Pre-procedure Stress Level Measured by Respiratory Rate|Pre-therapy/Pre-procedure Anxiety Level|Post-therapy/Pre-procedure Change in Stress Level Measured by Pulse|Post-therapy/Pre-procedure Change in Stress Level Measured by Respiration Rate|Post-therapy/Pre-procedure Change in Anxiety Level|Post-therapy/Pre-procedure Change in Stress Level Measured by Blood Pressure|Perceived Pain Level of the Procedure as Assessed by the Wong-Baker FACES Pain Rating Scale|Drink in Last Hour|Eat in Last Hour|Exercise in Last Hour|Injection Experiences|Number of Injections,Boston Children’s Hospital,All,"14 Years and older   (Child, Adult, Older Adult)",Not Applicable,54,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,IRB-P00016464,Aug-15,10-Jan-17,10-Jan-17,24-Feb-16,21-Dec-18,21-Dec-18,"Boston Childrens Hospital - Sports Medicine, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT02690194
NCT02690324,The Development of Skin Adhesive Patches for the Monitoring and Prediction of Mental Disorders,,Unknown status,No Results Available,"Major Depressive Disorder, Anxiety Disorder",Behavioral: cognitive stress (serial 7),Electrodermal activity(EDA)|Heart rate variability|Brain-derived neurotrophic factor(BDNF) genotyping: Val66Met|Cytokines|Leptin|Adiponectin|Epinephrine|Norepinephrine|C reactive protein|BDNF|MINI plus|MINI Suicidality Module|Hamilton Depression Rating Scale-17(HAMD-17)|Hamilton Anxiety Rating Scale(HAMA)|Anxiety Sensitivity Index(ASI)|APPQ(Albany Panic and Phobia Questionnaire)|PSWQ(Penn state worry questionnaire)|SRI(Stress response Inventory)|Perceived Stress Scale(PSS)|Barratt Impulsivity Scale|Panic disorder severity scale(PDSS),Samsung Medical Center,All,"20 Years and older   (Adult, Older Adult)",Not Applicable,80,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,2015-07-151,Nov-15,Feb-18,null,24-Feb-16,null,24-Feb-16,"Samsung Medical Center, Seoul, Irwon-dong, Gangnam-gu, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02690324
NCT02690441,Physical Exercise Augmented CBT for GAD,PEXACOG,Recruiting,No Results Available,Generalized Anxiety Disorder,Behavioral: Cognitive Behavioural Therapy|Behavioral: Physical Exercise|Behavioral: Placebo control,"Changes in The Penn State Worry Questionnaire|Change in clinical diagnosis after treatment assessed by independent, blinded rater with Anxiety Disorders Interview Schedule (ADIS-IV)|Geriatric Anxiety Inventory|Generalized Anxiety Disorder 7-item scale (GAD-7)|Beck Anxiety Inventory|Beck Depression Inventory - II|Bergen Insomnia Scale|Quality of Life Inventory|International Physical Activity Questionnaire (IPAQ)|5-item Treatment Credibility and Expectancy Scale (CES)","Solli Distriktspsykiatriske Senter|University of Bergen|Norwegian University of Science and Technology|University of Oslo|University of California, Berkeley|William Paterson University of New Jersey|Ohio State University",All,"60 Years to 75 Years   (Adult, Older Adult)",Phase 2,70,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,971427272T1,Mar-16,Dec-20,Dec-21,24-Feb-16,null,6-Sep-18,"Solli DPS, Bergen, Nesttun, Norway",,https://ClinicalTrials.gov/show/NCT02690441
NCT02690597,Validation and Pertinence of Anxiety Analogic Visual Scale in Pain Management,ANXYDOL,Completed,No Results Available,Anxiety|Pain,Other: Anxiety visual analog scale,Evaluation of pertinence of anxiety analogic visual scale in systematic use as assessed by anxiety levels obtained with State Trait of anxiety Y-A form score|Evaluation of validity of anxiety analogic visual scale in systematic use as assessed by anxiety levels obtained with State Trait of anxiety Y-A form score|Evaluation of pertinence of anxiety analogic visual scale in systematic use as assessed by anxiety levels obtained with anxiety analogic visual scale score|Evaluation of validity of anxiety analogic visual scale in systematic use as assessed by anxiety levels obtained with anxiety analogic visual scale score|Evaluation of pain consultation impact on anxiety part of pain as assessed by anxiety levels obtained with State Trait of anxiety Y-A form score|Evaluation of pain consultation impact on anxiety part of pain as assessed by anxiety levels obtained with anxiety analogic visual scale score|Evaluation of clinical utility of anxiety analogic visual scale in nursing care as assessed by anxiety levels obtained with State Trait of anxiety Y-A form score|Evaluation of clinical utility of anxiety analogic visual scale in nursing care as assessed by anxiety levels anxiety analogic visual scale score,"University Hospital, Toulouse",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,55,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,12 560 07|2013-A00451-44,Feb-15,Dec-16,Dec-16,24-Feb-16,null,3-Dec-18,"CHU Rangueil, Toulouse, France",,https://ClinicalTrials.gov/show/NCT02690597
NCT02685787,Early Counseling and Support for Alzheimer's Disease Caregivers,D_CareGiver,Unknown status,No Results Available,Alzheimer's Disease,Behavioral: Psychosocial Intervention|Behavioral: Educational Intervention on AD,Care-giver burden measured with Zarit Burden Inventory (ZBI)|Care-giver burden measured with ZBI|Caregiver depression measured using the Hospital Anxiety and Depression Scale (HADS)|Behavioural and psychological symptoms of dementia (BPSD) using the Neuropsychiatric Inventory (NPI)|BPSD using the Revised Memory and Behaviour Checklist (RMBC)|Patient quality-of-life measure with Logdson's Quality of Life AD|Care-giver quality-of-life measure with Euro-Quality of Life,Azienda Sanitaria Locale N.1 dell'Umbria|Azienda Ospedaliera di Perugia|Azienda Ospedaliera di Terni|Azienda Unità Sanitaria Locale Umbria n. 2,All,"18 Years to 100 Years   (Adult, Older Adult)",Not Applicable,230,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,GR-2009-1607340,Apr-12,Jan-17,Dec-17,19-Feb-16,null,19-Feb-16,"USL Umbria 1, Perugia, Italy",,https://ClinicalTrials.gov/show/NCT02685787
NCT02686333,Meditation for Depression and Anxiety Symptoms in Dialysis Patients,,"Active, not recruiting",No Results Available,Depression|Anxiety,Other: Meditation,Proportion of participants screened as eligible who enroll|Proportion of participants who enrolled who completed the 8 week-trial|Tolerability of Meditation Intervention on a 10-point Likert scale|Change in Patient Health Questionnaire (PHQ-9)|Change in General Anxiety Disorder-7 (GAD-7),"Lady Davis Institute|University Health Network, Toronto|Sunnybrook Health Sciences Centre",All,"18 Years and older   (Adult, Older Adult)",Phase 3,50,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,15-160,Mar-16,1-Feb-17,Jun-19,19-Feb-16,null,12-Jun-17,"Jewish General Hospital, Montreal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT02686333
NCT02685280,Rechargeable Neurostimulators in Deep Brain Stimulation for Psychiatric Disorders,,Completed,No Results Available,Obsessive-compulsive Disorder|Depression,Device: Medtronic Restore Advanced 37713,Change in Y-BOCS (for OCD)|Change in HAM-D (for MD)|Change in HAM-D (for OCD)|Change in BDI|Change in GAF|Change in Stimulation Amplitude|Change in Stimulation Frequency|Change in Pulse Width|Change in Contact Configuration|Change in frequency of outpatient clinic contacts at the Psychiatry department|Change in fraction of hospitalized days at the Psychiatry department|Change in frequency of outpatient clinic contacts at the Neurosurgery department|Change in fraction of hospitalized days at the Neurosurgery department|Change in frequency of DBS-related surgical procedures|Adverse events,Universitaire Ziekenhuizen Leuven|Medtronic,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,12,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,S50760|B32220072682,Oct-07,Dec-14,Dec-14,18-Feb-16,null,18-Feb-16,,,https://ClinicalTrials.gov/show/NCT02685280
NCT02685488,Investigating Transcranial Ultrasound as a Potential Intervention for Depression,,Completed,Has Results,Depression|Anxiety Disorders,Device: Transcranial Ultrasound Power|Device: Transcranial Ultrasound Sham,Depressive Symptoms Assessed With the Beck Depression Inventory-II|Rumination Symptoms Assessed With the Ruminative Responses Scale|Worry Symptoms Assessed With the Penn State Worry Questionnaire|Anxiety Symptoms Assessed With the Overall Anxiety Severity and Impairment Scale,University of Arizona,All,18 Years to 35 Years   (Adult),Not Applicable,26,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",RSRCH--‐703FY'15,Oct-15,Apr-16,May-16,18-Feb-16,8-Jan-18,8-Jan-18,,,https://ClinicalTrials.gov/show/NCT02685488
NCT02682888,Trait Anxiety and Defensive Networks,,Recruiting,No Results Available,Healthy,Behavioral: trait anxiety scale|Drug: Oxytocin|Drug: Placebo,the resting state functional connectivity changes in the defensive network,University of Electronic Science and Technology of China,All,18 Years to 35 Years   (Adult),Not Applicable,130,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",UESTC-neuSCAN_20,8-Dec-15,8-Mar-19,28-Mar-19,17-Feb-16,null,31-Oct-18,"school of life science and technology, University of Electronic Science and Technology of China, Chengdu, Sichuan, China",,https://ClinicalTrials.gov/show/NCT02682888
NCT02678624,Project Collabri for Treatment of Anxiety,,"Active, not recruiting",No Results Available,Generalized Anxiety|Social Phobia|Panic Disorder,Other: Treatment according to the Collabri model,Degree of anxiety measured by the Beck Anxiety Inventory (BAI)|Degree of depression measured by the Beck Depression Inventory (BDI)|Psychological stress measured with the Symptom Checklist (SCL-92)|Functional impairment measured with the Global Assessment of Functioning (GAF-F split version),Mental Health Centre Copenhagen,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,406,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,H-3-2013-203-A,Nov-14,Jul-17,Jul-19,10-Feb-16,null,17-Apr-19,"Mental Health Centre Copenhagen, Copenhagen, Denmark",,https://ClinicalTrials.gov/show/NCT02678624
NCT02671266,Oxytocin Administration in BDD and OCD,,Completed,Has Results,Body Dysmorphic Disorder|Obsessive-compulsive Disorder,Drug: Oxytocin|Drug: Placebo,Emotion Recognition Questionnaire|Interpretation Questionnaire|Engagement Towards and Disengagement From Threat Cues in a Spatial Cueing Task|Amount of Initial Monetary Transfer During Trust Game,Massachusetts General Hospital,All,"18 Years and older   (Adult, Older Adult)",Phase 2,41,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other",2014P001777,Dec-14,Oct-17,Oct-17,2-Feb-16,22-Nov-18,22-Nov-18,"Massachusetts General Hospital/Harvard Medical School, Boston, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/66/NCT02671266/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02671266
NCT02671578,Bispectral Index and Clinical Parameters Evaluation in Dental Procedures,BIS-01,Completed,No Results Available,Anxiety|Pain,Drug: Nitrous Oxide,BIS value|Pain|Anxiety|Blood Pressure|Heart rate|Respiratory Frequency (RF)|Trieger test,"Francisco Groppo|Faculty Sao Leopoldo Mandic Campinas|pontifical catholic university - Rio de Janeiro|University of Campinas, Brazil",All,18 Years to 60 Years   (Adult),Phase 4,100,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BIS-01FOP,Nov-06,Nov-07,Nov-08,2-Feb-16,null,2-Feb-16,,,https://ClinicalTrials.gov/show/NCT02671578
NCT02667522,Shaping Neural Activity Through Parenting,SNAP,Recruiting,No Results Available,Depression|Anxiety,Behavioral: Parent Child Interaction Therapy (PCIT),Event-Related Potentials (ERP)|Parenting quality|Child anxiety symptoms|Child depressive symptoms|Child anxiety|Child depression,Stony Brook University,All,6 Years to 7 Years   (Child),Not Applicable,160,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention,R21MH108766-01A1,Apr-16,Jan-19,Jan-19,29-Jan-16,null,18-Apr-18,"Stony Brook University, Stony Brook, New York, United States",,https://ClinicalTrials.gov/show/NCT02667522
NCT02667782,Feasibility Study on the Use of Mindfulness-based Intervention for Family Carers of People With Dementia,,Completed,No Results Available,"Anxiety|Depression|Dependency Burden|Stress, Psychological",Behavioral: Mindfulness-Based Stress Reduction (MBSR)|Behavioral: Mindfulness-Based Cognitive Therapy (MBCT),Change of Perceived Stress Scale (PSS)|Change of Hospital Anxiety and Depression Scale (HADS)|Center for Epidemiologic Studies Depression Scale (CESD)|Zarit Burden Inventory (ZBI),The Hong Kong Polytechnic University|Griffith University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,53,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",1-ZVG9,18-Feb-16,30-Sep-17,30-Sep-17,29-Jan-16,null,22-Feb-18,"School of Nursing, The Hong Kong Polytechnic University, Hong Kong, Hong Kong|Community care centres, Kowloon, Hong Kong",,https://ClinicalTrials.gov/show/NCT02667782
NCT02666339,Mélisses Garden: Effect on Anxious State in Adult Patients Hospitalized in Psychiatry,JDM,Recruiting,No Results Available,Psychiatric Decompensation,Other: Usual care|Behavioral: Hortitherapy,Effect of the mediation by care-garden on anxious state in adult patients hospitalized in psychiatry,Centre Hospitalier Universitaire de Saint Etienne,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,190,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,1508192|2016-A00057-44,30-Sep-16,31-Dec-20,28-Feb-21,28-Jan-16,null,19-Apr-19,"Chu Saint-Etienne, St Etienne, France",,https://ClinicalTrials.gov/show/NCT02666339
NCT02667015,Development of an Anxiety Sensitivity-Based Intervention for Substance Use and Anxiety Comorbidity,SUD/Anx,Completed,No Results Available,Other (or Unknown) Substance Use Disorders,Behavioral: Psychotherapy (Anxiety Sensitivity Intervention),"Change in total score on Anxiety Sensitivity Index (ASI; Peterson & Plehn, 1999), from baseline (pre-treatment) to ASI score at 3-months post-treatment.|Change in Percent Days Abstinent over the past 30 days on the Timeline Follow-Back (TLFB; Sobell & Sobell, 1996), from Pre-treatment to 3-months post-treatment.|Change in total score on Depression, Anxiety, and Stress Scales (DASS; Brown, Chorpita, Korotitsch, & Barlow, 1997).",Hartford Hospital,All,"18 Years and older   (Adult, Older Adult)",Phase 2,41,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,126253,May-12,May-15,May-15,28-Jan-16,null,28-Mar-16,"Institute of Living/Hartford Hospital, Hartford, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT02667015
NCT02665403,Play Interventions to Reduce Anxiety and Negative Emotions in Hospitalized Children,,Completed,No Results Available,Anxiety,Other: Play intervention|Other: control,Anxiety levels change from baseline at 2 days after admission between intervention and control group for children aged 3 - 7|Anxiety levels change from baseline at 2 days after admission between intervention and control group for children aged 8 - 12|baseline anxiety levels for children aged 3 - 7|baseline anxiety levels for children aged 8 -12|overall emotion behaviors for the 2-day period of hospitalization (CEMS),The University of Hong Kong,All,3 Years to 12 Years   (Child),Not Applicable,304,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,KW/FR-12-020,Nov-12,Oct-13,Oct-13,27-Jan-16,null,27-Jan-16,,,https://ClinicalTrials.gov/show/NCT02665403
NCT02662803,"Clinical, Neurophysiological and Neuroendocrine Effects of Aerobe Exercise in Generalized Anxiety Disorder (GAD)",GAD_exercise,Completed,No Results Available,Generalized Anxiety Disorder (GAD),Other: high-intensive aerobe exercise|Other: low-intensive aerobe exercise,"Change in Penn State Worry Questionnaire (PSWQ, german version)|Change in Screening für somatoforme Störungen (SOMS)|Change in Penn State Worry Questionnaire-past week (PSWQ-PW, german version)|Change in Screening für somatoforme Störungen - 7 Tage (SOMS-7T)|Change in Hamilton Anxiety Rating Scale (HAM-A, german version)|Change in Anxiety Control Questionnaire (ACQ, german version)|Change in saliva cortisol|Change in saliva alpha amylase|Change in mismatch negativity|Change in loudness dependence auditory evoked potentials","Charite University, Berlin, Germany",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,29,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",EA1/217/15,Jan-15,Jan-19,Jan-19,26-Jan-16,null,5-Feb-19,"Department of Psychiatry and Psychotherapy, Charité - Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany",,https://ClinicalTrials.gov/show/NCT02662803
NCT02663167,Internet-based Cognitive-behavior Therapy for Children With Obsessive-compulsive Disorder,,Completed,No Results Available,Obsessive-Compulsive Disorder,Behavioral: Internet-delivered Cognitive Behavioral Therapy,"Children´s Yale Brown Compulsive Scale (CY-BOCS)|Children's Global Assessment Scale (C-GAS)|Clinical Global Impression - Severity (CGI-S)|Clinical Global Impression - Improvement (CGI-I)|Obsessive-Compulsive Inventory - Child Version (OCI-CV)|Children's Obsessional Compulsive Inventory Revised - Parent version (ChOCI-R-P)|Family Accommodation Scale - Self Rated (FAS-SR)|Euroqol - Youth (EQ-5D-Y)|Autism Spectrum Quotient (AQ-10)|Education, Work and Social Adjustment Scale - child and parent version (EWSAS)|Child Depression Inventory - Short version (CDI-S)|Mood and Feeling Questionnaire - parent version (MFQ)|Qualitative data on treatment credibility|Qualitative data on treatment satisfaction|Safety Monitoring Uniform Report Form (SMURF)|Internet Intervention Patient Adherence Scale (iiPAS)|Patient Exposure/Response prevention Adherence Scale (PEAS)",Karolinska Institutet,All,7 Years to 11 Years   (Child),Not Applicable,11,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,REPN 2015/470-31,Jan-16,Oct-16,Oct-16,26-Jan-16,null,28-Nov-16,"BUP CPF, Stockholm, Sweden",,https://ClinicalTrials.gov/show/NCT02663167
NCT02661828,Tapering Off Antidepressants,,Terminated,Has Results,Major Depressive Disorder|Anxiety Disorder|Obsessive Compulsive Disorder|Post-Traumatic Stress Disorder,Other: Two-Week Antidepressant Taper Regimen|Other: One-Week Antidepressant Taper Regimen,Discontinuation Emergent Signs and Symptoms Scale (DESS) Scores|Physician Withdrawal Checklist (PWC-20) Scores|Number of Participants Who Meet Criteria for Antidepressant Discontinuation Syndrome,Emory University,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,2,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IRB00084849,Jan-16,17-Mar-17,17-Mar-17,25-Jan-16,25-Sep-18,25-Sep-18,"Emory University, Atlanta, Georgia, United States|The Emory Clinic, Atlanta, Georgia, United States|12 Executive Park Drive, 3rd floor, Atlanta, Georgia, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/28/NCT02661828/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02661828
NCT02661906,A Pilot Study on Effect of SKY on Psychosocial Parameters of Type 2 Diabetic Patients After a 6 Days,,Completed,No Results Available,"Diabetes Mellitus, Non-Insulin-Dependent",Other: SKY,Improvement in quality of life|Improvement in HbA1c|Improvement in BMI|Improvement in lipid profile,Dasman Diabetes Institute,All,"30 Years to 65 Years   (Adult, Older Adult)",Not Applicable,24,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,RA 2014-028,Aug-16,Dec-17,Feb-18,25-Jan-16,null,12-Feb-19,"Dasman Diabetes Institute, Kuwait, Kuwait",,https://ClinicalTrials.gov/show/NCT02661906
NCT02660099,Internet Delivered CBT for OCD in Adolescents With ASD - A Clinical Case Series,,Completed,No Results Available,Obsessive Compulsive Disorder|Autism Spectrum Disorder,Behavioral: Internet-delivered Cognitive Behavior Therapy,"Obsessional Compulsive Inventory - Child version, OCI-CV|Children's Yale Brown Obsessive Compulsive Scale|Mini International Neuropsychiatric Interview for Children and Adolescents, MINI-KID|Clinical Global Impression - Severity, CGI-S|Clinical Global Impression - Improvement, CGI-I|Children's Global Assessment Scale, CGAS|Children´s Depression Inventory - Short version|Strength and difficulties, SDQ|Family Accommodation Scale, Parent-Report, FAS-PR|Patient ICBT Adherence Rating, PIAR|Education, Work and Social Adjustment Scale - child and parent version, EWSAS",Karolinska Institutet,All,12 Years to 17 Years   (Child),Not Applicable,4,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BiP-ASD/OCD,Jul-15,Apr-16,Jun-16,21-Jan-16,null,7-Sep-16,"Karolinska Institutet, Stockholm, Sweden|Karolinska insititute, Stockholm, Sweden",,https://ClinicalTrials.gov/show/NCT02660099
NCT02660307,A Stress Reduction Program for Companies,,Completed,No Results Available,Stress,Other: PROGRESS group,changes in subjective symptoms of stress|changes in subjective depression symptoms|changes in anxiety symptoms|changes in speed of perception and visual and motor response|changes in Mindful Awareness and attention|changes in psychiatric symptoms,Centro de estudos em Atenção Plena|SESI (Serviço Social da Indústria),All,18 Years to 60 Years   (Adult),Not Applicable,41,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PROGRESS,Feb-14,Jun-14,Sep-14,21-Jan-16,null,16-May-18,,,https://ClinicalTrials.gov/show/NCT02660307
NCT02660385,Insomnia Self-Management in Heart Failure,HSS,Recruiting,No Results Available,"Cardiac Failure|Heart Failure|Congestive Heart Failure|Heart Failure, Congestive|Sleep Initiation and Maintenance Disorders|Chronic Insomnia|Disorders of Initiating and Maintaining Sleep|Fatigue|Pain|Depressive Symptoms|Sleep Disorders|Anxiety",Behavioral: Cognitive Behavioral Therapy for Insomnia|Behavioral: Self-Management Education for Heart Failure,Insomnia Severity|Fatigue|Sleep Efficiency|Sleep duration|Anxiety|Depressive symptoms|Sleepiness|Dyspnea|Psychomotor vigilance|Functional performance|Functional capacity|Cost effectiveness|Event-free survival,Yale University|Milton S. Hershey Medical Center|National Institute of Nursing Research (NINR),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,200,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0904005041a|R01NR016191,Oct-15,Jun-19,Jun-20,21-Jan-16,null,10-Jan-19,"Yale University School of Nursing, West Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT02660385
NCT02659345,"Evaluating the Effectiveness of Art Therapy on Mood, Anxiety, and Pain Levels in Cancer Patients",,Completed,No Results Available,Cancer,Behavioral: Emotions Thermometer|Behavioral: Art Therapy,"The effect of art therapy on the cancer patient's mood|The effect of art therapy on the cancer patient's anxiety|The effect of art therapy on the cancer patient's pain|exploratory assessment of the association between sum of pain, anxiety, and mood visual analog scale (VAS) scores and ethnic group of patients|exploratory assessment of the association between sum of pain, anxiety, and mood visual analog scale (VAS) scores and race of patients|exploratory assessment of the association between sum of pain, anxiety, and mood visual analog scale (VAS) scores and age of patients|exploratory assessment of the association between sum of pain, anxiety, and mood visual analog scale (VAS) scores and sex of patients|exploratory assessment of the association between sum of pain, anxiety, and mood visual analog scale (VAS) scores and caregiver support of patients|exploratory assessment of the association between sum of pain, anxiety, and mood visual analog scale (VAS) scores and cancer diagnosis of patients|exploratory assessment of the association between sum of pain, anxiety, and mood visual analog scale (VAS) scores and reason for visit of patients|exploratory assessment of the association between sum of pain, anxiety, and mood visual analog scale (VAS) scores and marital status of patients|exploratory assessment of the association between sum of pain, anxiety, and mood visual analog scale (VAS) scores and primary concern expressed by patients during art therapy session",Case Comprehensive Cancer Center,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,50,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,CASE5Z15,May-15,25-Jan-16,25-Jan-17,20-Jan-16,null,26-Jan-17,"Maroone Cancer Center - Cleveland Clinic Florida, Weston, Florida, United States",,https://ClinicalTrials.gov/show/NCT02659345
NCT02659436,Imagery-based CBT for Social Anxiety Disorder: Piloting a Treatment Augmentation Protocol,,Completed,No Results Available,Social Anxiety Disorder,Other: Verbal-linguistic CBT|Other: Imagery-based CBT,Social Phobia Inventory|Vividness of Visual Imagery Questionnaire|Homework Adherence Scale|Treatment Satisfaction Scale|Brief Fear of Negative Evaluation Scale|Illness Intrusiveness Rating Scale,St. Joseph's Healthcare Hamilton,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,9,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,986,Jan-16,Dec-16,Dec-16,20-Jan-16,null,29-Dec-16,,,https://ClinicalTrials.gov/show/NCT02659436
NCT02656641,Using the PHQ-9 and GAD-7 as Feedback Instruments in Brief Psychotherapy,,Completed,No Results Available,"Depressive Symptoms|Anxiety States, Neurotic",Behavioral: Continuous Client Feedback|Behavioral: Continuous Self Feedback,Change in depressive symptoms as assessed by Patient Health Questionnaire-9|Change in anxiety symptoms as assessed by Generalized Anxiety Disorder 7-Item Scale|World Health Organization - Quality of Life BREF Scale|Schwartz Outcome Scale,Christiana Care Health Services|Immaculata University,All,18 Years to 64 Years   (Adult),Not Applicable,81,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,35156,Nov-15,31-Aug-16,31-Aug-16,15-Jan-16,null,19-Jul-17,"Christiana Care Health System - Adult Bridge Program, Wilmington, Delaware, United States",,https://ClinicalTrials.gov/show/NCT02656641
NCT02656784,"The Efficacy of TBCT Compared to ERP in the Treatment of OCD Patients, by the Assessment of Magnetic Resonance.",,Completed,No Results Available,OBSESSIVE COMPULSIVE DISORDER (OCD),Behavioral: Cognitive Therapy|Behavioral: Behavioral Therapy,"The severity of OCD (Morphological and physiological changes in the brain)|Quality of Life|Cognitive Distortions|Severity of OCD|The Assessment of Depression|The Assessment of Anxiety|The Assessment of Magnetic Resonance (MRI)|The Assessment of The Obssessive Beliefs|The level of Anxiety (Obssessive, Compulsive and Evitation Symptoms)",Universidade Estadual do PiauÍ|Federal University of Bahia,All,18 Years to 60 Years   (Adult),Not Applicable,96,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,UESPI,Feb-15,Dec-16,3-May-17,15-Jan-16,null,22-Jun-17,"Piauí State University - UESPI, Teresina, Piauí, Brazil",,https://ClinicalTrials.gov/show/NCT02656784
NCT02656966,Auricular Acupuncture for Treatment of Preoperative Anxiety,AcuAnx,Completed,No Results Available,Anxiety,Device: Auricular acupuncture,Situational anxiety_1|Situational anxiety_2|Situational anxiety_3|Heart rate|Blood pressure,University Medicine Greifswald,Female,19 Years to 55 Years   (Adult),Phase 2,42,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BB 158/15,Dec-15,May-16,May-16,15-Jan-16,null,28-Jun-16,"University Medicine of Greifswald, Greifswald, Germany",,https://ClinicalTrials.gov/show/NCT02656966
NCT02655926,Deep Brain Stimulation for Severe Obsessive Compulsive Disorder,,Completed,No Results Available,Obsessive-Compulsive Disorder,Procedure: Deep Brain Stimulation,Improvement of OCD symptoms on YBOCS scale greater than or equal to 35%,"University College, London",All,"20 Years and older   (Adult, Older Adult)",Not Applicable,6,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",12/0226|MR/J012009/1|12/LO/1087|105869|18430630,Sep-12,Nov-16,Nov-16,14-Jan-16,null,3-Mar-17,"UCL Institute of Neurology, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT02655926
NCT02656342,Translational Approach to the Understanding and Treatment of Obsessive-Compulsive Disorder (OCD). Can D-Cycloserine Enhance and Stabilize the Treatment-response in Relapsed and Non-responding OCD-patients?,,"Active, not recruiting",No Results Available,Obsessive-Compulsive Disorder,Drug: D-Cycloserine|Drug: Placebo,"Changes in Y-BOCS|Changes in diagnostic status|Changes in Y-BOCS evaluated by Jacobson and Truax, Reliable Change Index (RCI)",Haukeland University Hospital|The Research Council of Norway|Helse Vest,All,"18 Years and older   (Adult, Older Adult)",Phase 4,160,Other,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2013-002574-49,Nov-15,Dec-19,Dec-23,14-Jan-16,null,5-Mar-19,"Haukeland University Hospital, Bergen, Norway|Innlandet Hospital, Brumunddal, Norway|Forde Hospital, Forde, Norway|Sørlandet Hospital, Kristiansand, Norway|Nord Trøndelag Hospital, Levanger, Norway|Akershus University Hospital, Lorenskog, Norway|More and Romsdal Hospital, Molde, Norway|Østfold Hospital, Moss, Norway|Oslo University Hospital, Oslo, Norway|Vestre Viken, Sandvika, Norway|Stavanger University Hospital, Stavanger, Norway|Sykehuset i Vestfold, Tonsberg, Norway|Tromso University Hospital, Tromso, Norway|St. Olavs Hospital, Trondheim, Norway",,https://ClinicalTrials.gov/show/NCT02656342
NCT02651402,A Hybrid Effectiveness-Implementation Trial of Group CBT in Urban Schools,,Recruiting,No Results Available,Anxiety Disorders,Behavioral: FRIENDS for Life|Behavioral: Adapted FRIENDS|Behavioral: Train-the-Trainer|Behavioral: Train-the-Trainer Plus,Change in Manifest Anxiety Scale for Children (MASC) from Baseline to Post Intervention completed by parents and children|Cost Effectiveness,Children's Hospital of Philadelphia|University of Pennsylvania|National Institute of Mental Health (NIMH),All,"8 Years to 99 Years   (Child, Adult, Older Adult)",Not Applicable,534,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,15-012311|1R01MH108555-01,Feb-16,Nov-20,Nov-20,11-Jan-16,null,8-Jan-19,"Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/02/NCT02651402/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02651402
NCT02648737,Cognitive Behavioural Therapy for Anxiety Disorders in PD,,Recruiting,No Results Available,Parkinson's Disease|Generalized Anxiety Disorder|Social Phobia,Behavioral: Cognitive Behavioural Therapy (CBT)|Other: Clinical monitoring,Change in anxiety score as measured with the Hamilton Anxiety Rating Scale (HARS).|Changes in cerebral connectivity between limbic and frontal cortices as measured with resting state blood-oxygen-level dependent functional magnetic resonance imaging (BOLD fMRI) and diffusion tensor imaging (DTI)|Long term clinical effectiveness of the CBT module measured by the change in HARS score,Maastricht University Medical Center|Michael J. Fox Foundation for Parkinson's Research,All,"35 Years to 80 Years   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,11169,Oct-16,Dec-19,Dec-19,7-Jan-16,null,21-Mar-18,"Neurology and Movement Disorders Unit, Lille University Hospital, Lille Cedex, France|Maastricht University Medical Centre, Maastricht, Netherlands",,https://ClinicalTrials.gov/show/NCT02648737
NCT02648945,Effects of Low and High Intensity Exercise in Improving Working Memory Among Students With Anxiety Symptoms,,Unknown status,No Results Available,Aerobic Exercise,Other: Exercise,Change in Verbal Memory Task,Manisha Parai|Universiti Tunku Abdul Rahman,All,18 Years to 25 Years   (Adult),Not Applicable,30,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,U/SERC/86/2015,Nov-15,Feb-16,null,7-Jan-16,null,9-Feb-16,"Universiti Tunku Abdul Rahman, Kajang, Selangor, Malaysia",,https://ClinicalTrials.gov/show/NCT02648945
NCT02646865,Self-Compassion Enhanced CBT vs. Standard CBT for Social Anxiety (SCE-CBT),SCE-CBT,Completed,No Results Available,Social Anxiety Disorder,Behavioral: Self-Compassion Enhanced Cognitive-Behavioral Therapy|Behavioral: Cognitive-Behavioral Therapy,"Changes in social anxiety symptoms using (Liebowitz Social Anxiety Scale; Leibowitz, 1987)|Changes in social anxiety symptoms using SPIN (Social Phobia Inventory; Connor et al., 2000)|Changes in social anxiety symptoms using SIAS (Social Interaction Anxiety Scale; Mattick & Clarke, 1998)|Changes in shame-proneness using TOSCA-3 (Test of Self-Conscious Affect-3; Tangney, Dearing, Wagner, & Gramzow, 2000)|Changes in social anxiety disorder clinical status|Changes in self-compassion using SCS (Self-Compassion Scale; Neff, 2003)|Changes in self-compassion using SCSs (Self-Compassion Scale Short Form; Raes et al., 2011)|Changes in depressive symptoms using BDI-II (Beck Depression Inventory-II; Beck, 1996)|Changes in positive and negative affect using PANAS (Positive and Negative Affect Schedule; Watson & Clark, 1999)|Changes in positive and negative emotions using PDA (Profile of Affective Distress; Opriș & Macavei, 2005)|Changes in irrational and rational thinking using ABS-II (Attitudes and Beliefs Scale- 2; DiGiuseppe, Leaf, Exner, & Robin, 1988)|Changes in emotion regulation using ERQ (Emotion Regulation Questionnaire; Gross & John, 2003)|Changes in emotion regulation using DERS (Difficulties in Emotion Regulation Scale; Gratz & Roemer, 2004)|Changes in rational and irrational beliefs using GABS (General Attitudes and Beliefs Scale; Bernard, 1998)|Changes in social phobia related thoughts using BFNE (Brief Fear of Negative Evaluation Scale; Leary, 1983)|Changes in shame with PFQ-2 (Personal Feelings Questionnaire-2; Harder & Zalma, 1990)",Babes-Bolyai University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",UBB-CLINPSY-2016-1,Jan-16,Jul-17,Jan-18,6-Jan-16,null,18-Jul-18,"Babes-Bolyai University, Cluj-Napoca, Cluj, Romania",,https://ClinicalTrials.gov/show/NCT02646865
NCT02647216,Mindfulness for Breast Cancer,,Recruiting,No Results Available,Anxiety|Depression|Breast Cancer,Behavioral: Mindfulness Based Cognitive Therapy|Behavioral: Treatment as Usual,Change in Anxiety Level using the State-Trait Anxiety Inventory (STAI)-Form Y|Change in level of Depression using the Beck Depression Inventory-II (BDI-II)|Change in Quality of Life using the Patient Reported Outcomes Measurement Information System (PROMISE)|Change in fatigues score using a Functional Assessment of Cancer Therapy Breast and Fatigue subscales (FACIT-B and F):|Change in Physical Health Symptoms|Change in Sleep Quality using the Pittsburgh Sleep Quality Index (PSQI):|Change in Illness Perceptions using the Brief Illness Perception Questionnaire (B-IPQ)|Change in Rumination using the Ruminative Responses Scale (RSS):,New York University School of Medicine,Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",14-01138,Dec-15,Mar-19,Mar-19,6-Jan-16,null,2-Aug-18,"New York University School of Medicine, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT02647216
NCT02642536,Improving Obesity Self-Care Among Mentally Ill Veterans,MH MOVE!,Completed,Has Results,Anxiety|Depression|PTSD|Obesity,Behavioral: MH MOVE|Behavioral: Enhanced Usual Care,MOVE! Attendance|Number of Days Engaged in Vigorous Activity|Self Efficacy for Practicing Good Dietary Habits|Assessing Depression Symptom Severity|Assessing Anxiety Symptom Severity|Assessing PTSD Symptom Severity,VA Office of Research and Development,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,44,U.S. Fed,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",D7886-W,1-Jan-11,31-Dec-16,31-Dec-16,30-Dec-15,7-Aug-17,22-Feb-18,"Michael E. DeBakey VA Medical Center, Houston, TX, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT02642536
NCT02637297,Hypnotherapy in Treating Chronic Pain in Cancer Survivors,,Completed,No Results Available,Anxiety|Cancer Survivor|Chronic Pain|Depression|Sleep Disorder,Procedure: Hypnotherapy|Other: Questionnaire Administration,"Acceptability of hypnotherapy determined by structured phone interviews with participants|Change in beliefs on how well the treatment might work, as measured by the Credibility/Expectancy Questionnaire|Change in imaginative involvement as measured by the Tellegen Absorption Scale|Change in pain and anxiety, as measured using the patient diary|Change in pain and anxiety, as measured using the Pre- Post-Intervention Questionnaire|Change in pain-associated anxiety, measured using the Pain Catastrophizing Scale|Change in Patient Reported Outcomes Measurement Information System-29 scores (measures function, anxiety, depression, fatigue, sleep, and pain interference and intensity)|Feasibility of delivering hypnotherapy in terms of recruitment, attrition, adherence, and logistical issues|Patient demographics, as measured by the Demographic Questionnaire",Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)|National Institute of Nursing Research (NINR)|American Nurses Foundation,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,39,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Supportive Care,9445|NCI-2015-01868|P30CA015704|T32NR013456,8-Jan-16,9-Feb-17,3-Aug-17,22-Dec-15,null,21-Aug-17,"Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT02637297
NCT02637895,Vortioxetine for Posttraumatic Stress Disorder,,Recruiting,No Results Available,Post-Traumatic Stress Disorder,Drug: Placebo|Drug: Vortioxetine,An improved PTSD scale score|A 50% improved overall response rate on a PTSD scaled score.|Reduction in depressive symptoms in PTSD|50% improvement in CGI-Score,University of Miami|Takeda|Emory University,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,80,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",20150534,Dec-16,May-19,Jul-19,22-Dec-15,null,19-Nov-18,"University of Miami, Miami, Florida, United States|Emory University, Atlanta, Georgia, United States",,https://ClinicalTrials.gov/show/NCT02637895
NCT02634255,The Onset Time of Rocuronium in Emergency and Elective Surgery,,Unknown status,No Results Available,Inguinal Hernia|Acute Appendicitis,Drug: Rocuronium elective surgery|Drug: Rocuronium emergency surgery|Drug: Propofol|Drug: Fentanyl|Other: Ringer Lactate|Device: Acceleromyography device,Train of Four Ratio (TOF 0.1)|anxiety score,Diskapi Yildirim Beyazit Education and Research Hospital,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,50,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,Rocuronium onset,Dec-15,May-16,Jul-16,18-Dec-15,null,18-Dec-15,,,https://ClinicalTrials.gov/show/NCT02634255
NCT02634697,Impact of the Relaxation Response Resiliency Program on Patients With Atrial Fibrillation,,Recruiting,No Results Available,Atrial Fibrillation|Stress|Quality of Life|Anxiety|Depression|Hostility,Behavioral: Relaxation Response Resiliency Program,AF Symptoms Severity and Burden questionnaire|Measure of Current Status (MOCS-A)|Visual Analog Stress Scale|Buss-Perry Hostility Scale|Cognitive and Affective Mindfulness Scale (CAMS)|Cigna Healthy Eating Scale|FACIT-Spirituality|Generalized Anxiety Disorder 7-item (GAD-7)|The Gratitude Questionnaire (GQ-6)|Interpersonal Reactivity Index (IRI)|Life Orientation Test (LOT) Optimism Scale|Medical Outcomes Study (MOS) Social Support Survey|Positive and Negative Affect Schedule (PANAS)|Patient Health Questionnaire (PHQ)|Lifestyle Questionnaire|Pittsburgh Sleep Quality Index (PSQI)|Perceived Stress Scale (PSS-10)|Penn State Worry Questionnaire (PSWQ)|RR Adherence Questionnaire|General Self-Efficacy Scale|Fatigue and Distress Analogue Scale|Smoking Questionnaire|Medication Use Questionnaire,Massachusetts General Hospital|Benson-Henry Institute for Mind Body Medicine,All,"18 Years to 90 Years   (Adult, Older Adult)",Not Applicable,30,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,2015P000552,Apr-15,Feb-20,Feb-20,18-Dec-15,null,16-Aug-18,"Massachusetts General Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT02634697
NCT02635178,Brief Anxiety Sensitivity Treatment for Obsessive Compulsive Symptoms,,Completed,No Results Available,Obsessive-compulsive Disorders and Symptoms,Other: Cognitive Anxiety Sensitivity Treatment|Other: Physical Health Education Training,Anxiety Sensitivity Index-3 (ASI-3)|Dimensional Obsessive Compulsive Scale (DOCS),Florida State University,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,Raines02,Aug-14,May-15,May-15,18-Dec-15,null,18-Dec-15,,,https://ClinicalTrials.gov/show/NCT02635178
NCT02633267,1/2 A Multi-site Systems Intervention for Unemployed Persons With Social Anxiety,,Recruiting,No Results Available,Social Anxiety,Behavioral: Vocational Services as usual plus Cognitive Behavioral Therapy (CBT)|Behavioral: Usual Vocational Services,Liebowitz Social Anxiety Scale|Patient Health Questionnaire|Hours worked per week,"University of Michigan|University of California, Los Angeles|National Institutes of Health (NIH)|National Institute of Mental Health (NIMH)",All,18 Years to 60 Years   (Adult),Not Applicable,300,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,1R01MH102263-01A1,Jan-16,Jan-19,May-19,17-Dec-15,null,20-Apr-18,"University of Michigan, Ann Arbor, Michigan, United States",,https://ClinicalTrials.gov/show/NCT02633267
NCT02631291,Promoting Widowed Elders Lifestyle After Loss,,Recruiting,No Results Available,Mood Disorders|Depression|Anxiety|Grief|Bereavement|Health Behavior,Behavioral: Behavioral self-monitoring|Behavioral: Behavioral self-monitoring + Motivational interviewing,Depressive symptoms (Hamilton Rating Scale of Depression [HRSD])|Anxiety symptoms (7-item Generalized Anxiety Disorder Scale [GAD-7])|Grief symptoms (Inventory of Complicated Grief [ICG]),University of Pittsburgh,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,PRO14110233,Nov-15,31-Jan-20,31-Jan-20,16-Dec-15,null,6-Mar-19,"Sarah Stahl, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT02631291
NCT02631694,Disruption of Memory Reconsolidating as a Treatment for Panic Disorder,,Not yet recruiting,No Results Available,Panic Disorder,Drug: Propranolol|Drug: Placebo|Other: Carbon dioxide|Other: Compressed air,"Change in the number of participants diagnosed with panic disorder assessed by the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, fourth addition (DSM-IV) Axis I Disorders|Change in score on the Panic Disorder Severity Scale (PDSS-SR)|Carbon dioxide challenge using a visual analogue scale ranging from 0-100 mm|Change in score on the Panic Appraisal Inventory (PAI)|Change in score on the Mobility Inventory (MI)|Change in score on the Body Sensations Questionnaire (BSQ)|Change in score on the Agoraphobic Cognitions Questionnaire (ACQ)|Change in the number of participants diagnosed with panic disorder assessed by the Structured Clinical Interview for DSM-IV Axis I Disorders",VU University of Amsterdam,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,60,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",MKAEWC1,Apr-16,Sep-18,Sep-19,16-Dec-15,null,16-Dec-15,,,https://ClinicalTrials.gov/show/NCT02631694
NCT02631785,"Fear Conditioning, Extinction and Its Recall in Anxious Youth",FCPA,Not yet recruiting,No Results Available,Pediatric Anxiety Disorders,Other: Cognitive Behavioral Therapy,fMRI Bold signal|Autonomous measures- skin conductance response (SCR)|Self report of anxiety|Autonomous measures-Fear-Potentiated Startle|Anxiety symptom- SCARED|Anxiety symptoms- ADIS|Anxiety symptoms- CGI,"University of Haifa|HaEmek Medical Center, Israel|Weizmann Institute of Science",All,8 Years to 17 Years   (Child),Not Applicable,60,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),97-15|1377/14|618534,Feb-16,Feb-18,Feb-20,16-Dec-15,null,16-Dec-15,"University of Haifa, Haifa, Israel|Weizmann Institue of Science, Rehovot, Israel",,https://ClinicalTrials.gov/show/NCT02631785
NCT02630342,The Use of a Mock MRI Scanner for Reducing the Use of Anesthesia in Children Undergoing Clinical MRI Scans,,Unknown status,No Results Available,Magnetic Resonance Imaging,Behavioral: Mock MRI scanner|Behavioral: Preparation materials|Behavioral: Child Life Specialist preparation|Behavioral: Review Preparation Materials,Success of Diagnostic Scan|Neuro-oncology Age of completion of MRI without GA|Quality of scan Quality of MRI for diagnostic purposes|Time taken to complete diagnostic MRI|Number of scan sequences that require repeating|Childs feelings of stress|Salivary stress hormone levels (cortisol & alpha amylase)|Compliance with training,University of Calgary|Alberta Children's Hospital,All,3 Years to 7 Years   (Child),Not Applicable,160,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),REB-15-368,Jan-16,Nov-18,Nov-18,15-Dec-15,null,30-Sep-16,"Alberta Children's Hospital, Calgary, Alberta, Canada",,https://ClinicalTrials.gov/show/NCT02630342
NCT02624596,Understanding How Ketamine Brings About Rapid Improvement in OCD,MKET,Recruiting,No Results Available,Obsessive-Compulsive Disorder,Drug: Ketamine|Drug: Midazolam,"improvement in the severity of OCD symptoms as measured by the Yale-Brown Obsessive Compulsive Scale (YBOCS)|Regional gamma-aminobutyric acid, glutamate/glutamine levels derived from 3T Magnetic Resonance Spectroscopy",Stanford University|University of Connecticut,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,120,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",IRB-34622,Jun-16,Jun-20,Jun-21,8-Dec-15,null,8-May-19,"Stanford University, Stanford, California, United States",,https://ClinicalTrials.gov/show/NCT02624596
NCT02622958,Feasibility Study of PH94B Nasal Spray for Acute Treatment of Social Anxiety Disorder (SAD),,Completed,No Results Available,Social Anxiety Disorder,Drug: PH94B|Other: Placebo,Subjective units of distress|Clinical Global Impression of Improvement rating & Liebowitz Social Anxiety Scale,"Pherin Pharmaceuticals, Inc.",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,23,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",PH94B CL028,Mar-14,Oct-14,Mar-15,7-Dec-15,null,7-Dec-15,"The Medical Research Network, LLC, New York City, New York, United States",,https://ClinicalTrials.gov/show/NCT02622958
NCT02622087,The Impact of Sex Hormones on One-session Treatment for Spider Phobia in Women,,Completed,No Results Available,"Phobia, Specific",Behavioral: One-Session-Treatment,Change from baseline in level of approach on the Behavioural Approach Test (BAT)|Change from baseline in severity of spider phobia on the Spider Phobia Questionnaire,The University of New South Wales,Female,18 Years to 35 Years   (Adult),Not Applicable,90,Other,Interventional,"Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",MQ13002,Nov-15,15-Jun-17,15-Jun-17,4-Dec-15,null,21-Sep-17,"University of New South Wales, Sydney, New South Wales, Australia",,https://ClinicalTrials.gov/show/NCT02622087
NCT02621775,Effectiveness of Two Stress Management Programs in Adaptation Disorder With Anxiety (ADA),Seren@ctif,Recruiting,No Results Available,Adjustment Disorders|Psychological Stress,Behavioral: Computer-based stress management program|Behavioral: Stress management in face-to-face|Other: Waiting list,"Score of State-Trait Anxiety Inventory (STAI-S),|Hospital Anxiety and Depression scale (HAD),|The Penn-State Worry Questionnaire (PSWQ),|The Perceived Stress Scale (PSS)|Visual Analogue Scale for stress (VAS-stress)|The Beck depression inventory (BDI-21)","University Hospital, Lille|Ministry of Health, France",All,18 Years to 60 Years   (Adult),Not Applicable,120,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,2014_36|2015-A00098-41|PHRCI_2014,14-Sep-15,Mar-20,Mar-20,3-Dec-15,null,20-Apr-18,"Centre Pinel, Amiens, France|Centre Esquirol CHU de Caen, Caen, France|CHRU , Hôpital FONTAN, Lille, France",,https://ClinicalTrials.gov/show/NCT02621775
NCT02619981,The Effect of Parental Presence on Dental Fear,,Completed,No Results Available,Dental Fear,Procedure: Restorative procedure|Drug: Maxillary infiltration anesthesia with 2%Lidocaine,Child behavior - Subjective|Child Behavior - Objective,Riyadh Colleges of Dentistry and Pharmacy,All,5 Years to 7 Years   (Child),Phase 4,150,Other,Interventional,"Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Diagnostic",IRP/2012/48,Nov-12,Nov-14,Feb-15,2-Dec-15,null,2-Dec-15,"Riyadh Colleges of Dentistry and Pharmacy, Riyadh, Saudi Arabia",,https://ClinicalTrials.gov/show/NCT02619981
NCT02618772,Intranasal Midazolam for Treatment of Anxiety in Children Undergoing Suturing in the Pediatric Emergency Department,,Completed,Has Results,Anxiety|Lacerations,Drug: Midazolam|Drug: Saline,Intention to Treat (ITT): Modified Yale Preoperative Anxiety Score (mYPAS)|Per-Protocol: Modified Yale Preoperative Anxiety Score (mYPAS)|Intention to Treat (ITT): State Trait Anxiety Inventory (STAI)|Per-Protocol: State Trait Anxiety Inventory (STAI)|Intention to Treat (ITT): Dartmouth Operative Conditions Scale|Per-Protocol: Dartmouth Operative Conditions Scale|Intention to Treat (ITT): Faces Pain Scale-Revised/ FLACC Scale|Per-Protocol: Faces Pain Scale-Revised/ FLACC Scale,McGill University Health Center,All,2 Years to 12 Years   (Child),Phase 4,79,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",PED-08-053,Jan-10,Mar-15,Nov-15,1-Dec-15,7-Oct-16,7-Oct-16,,,https://ClinicalTrials.gov/show/NCT02618772
NCT02615119,Neural Basis of Meal Related Interoceptive Dysfunction in Anorexia Nervosa,,Recruiting,No Results Available,Anorexia Nervosa|Major Depressive Disorder|Generalized Anxiety Disorder|Panic Disorder|Brain Injury,Drug: Isoproterenol|Drug: Normal saline,Change in cardiorespiratory sensation intensity|Change in anxiety level|Generalized anxiety disorder severity (Generalized Anxiety Disorder 7 scale)|Panic disorder severity (Panic Disorder Severity scale)|Major depressive disorder severity (Patient Health Questionnaire-9 scale)|Eating disorder severity (Eating Disorder Examination scale),"Laureate Institute for Brain Research, Inc.|National Institute of Mental Health (NIMH)",All,18 Years to 55 Years   (Adult),Not Applicable,310,Other|NIH,Interventional,"Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",2017-002,Oct-15,Oct-20,Dec-27,26-Nov-15,null,7-Aug-18,"Laureate Institute for Brain Research, Tulsa, Oklahoma, United States",,https://ClinicalTrials.gov/show/NCT02615119
NCT02615483,Lumbar Spinal Fusion - Web-based Platform Targeting Anxiety and Depression,,Unknown status,No Results Available,Lumbar Spine Fusion|Anxiety|Depression,Other: Web-based platform,Anxiety and Depression|Functional outcome|Self-perceived health status|Back and leg pain,Central Jutland Regional Hospital,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,114,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,654902,Nov-15,May-17,Mar-19,26-Nov-15,null,28-Mar-17,"Centre og Elective Surgery, Regional Hospital Silkeborg, Silkeborg, Denmark",,https://ClinicalTrials.gov/show/NCT02615483
NCT02616341,Development of a Behavioral Team Intervention for Obsessive Compulsive Disorder,,Completed,No Results Available,Obsessive Compulsive Disorder,Behavioral: Team ERP (T-ERP) Intervention|Behavioral: Treatment as Usual (TAU),Changes in OCD symptom severity as measured by the Yale-Brown Obsessive Compulsive Scale (Y-BOCS),Butler Hospital|National Institute of Mental Health (NIMH),All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,51,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,1005-008,Nov-12,Feb-16,Feb-16,26-Nov-15,null,10-Aug-17,,,https://ClinicalTrials.gov/show/NCT02616341
NCT02616419,External Cold and Vibration Stimulation (Buzzy®) for Procedural Pain Management in Children Undergoing Needle-Related Procedures,,Recruiting,No Results Available,Child|Pain Due to Certain Specified Procedures,Device: Buzzy® device|Drug: Maxilene® (Lidocaine liposomal 4%),Mean per-procedural pain scores|Mean level of per-procedural distress|Satisfaction regarding the use of the Buzzy® device|Memory of pain (mean post-procedural pain scores 24 hours after the procedure)|Proportion of participants with success of the needle-related procedure at the first attempt,St. Justine's Hospital,All,4 Years to 17 Years   (Child),Not Applicable,380,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Supportive Care,2017-1405,15-May-17,Aug-18,Aug-18,26-Nov-15,null,26-Apr-18,"CHU Ste-Justine, Montreal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT02616419
NCT02614443,"Effectiveness and Acceptability of Internet-delivered Treatment for Depression, Anxiety and Stress",EAITDAS,Completed,No Results Available,Depression|Anxiety|Stress,Other: Space from Depression|Other: Space from Anxiety|Other: Space from Stress,Change in Stress sub-scale of Depression Anxiety and Stress Scale-21 (DASS-21)|Change in Patient Health Questionnaire-9 (PHQ-9)|Change in Generalized Anxiety Disorder-7 (GAD-7),Silver Cloud Health,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,120,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EAITDAS,Oct-15,Sep-17,Sep-17,25-Nov-15,null,11-Sep-18,"University of Minnesota, Minneapolis, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT02614443
NCT02611544,Investigation of Three Approaches to Address Fear of Recurrence Among Breast Cancer Survivors,,Completed,No Results Available,"Breast Neoplasms|Breast Cancer|Breast Carcinoma|Malignant Neoplasm of Breast|Cancer of Breast|Mammary Neoplasm, Human|Human Mammary Carcinoma|Malignant Tumor of Breast|Mammary Cancer|Mammary Carcinoma|Anxiety|Fear|Neoplasm Remission, Spontaneous|Spontaneous Neoplasm Regression|Regression, Spontaneous Neoplasm|Remission, Spontaneous Neoplasm|Spontaneous Neoplasm Remission",Behavioral: Acceptance and Commitment Therapy|Behavioral: Survivorship Education|Behavioral: Enhanced Usual Care,"Change from baseline in fear of recurrence (FCR) at Post-Intervention, 1-month, and 6-month follow-up as assessed by Fear of Cancer Recurrence Inventory (FCRI).|Change from baseline in fear of recurrence (FCR) at Post-Intervention, 1-month, and 6-month follow-up as assessed by Concerns about Recurrence Scale (CARS).|Change from baseline in cancer-related avoidant coping at Post-Intervention, 1-month, and 6-month follow-up as assessed by Acceptance & Action Questionnaire-Cancer|Change from baseline in anxiety at Post-Intervention, 1-month, and 6-month follow-up as assessed Generalized Anxiety Disorder Scale (GAD-7).|Change from baseline in depression at Post-Intervention, 1-month, and 6-month follow-up as assessed by as measured by Patient Health Questionnaire Depression Scale (PHQ-8).|Change from baseline in post-traumatic stress symptoms at Post-Intervention, 1-month, and 6-month follow-up as assessed by Impact of Events Scale-Revised (IES-R).|Change from baseline in vitality at Post-Intervention, 1-month, and 6-month follow-up as assessed by Short Form(SF)-36 Vitality Scale.|Change from baseline in Breast Cancer Self-Efficacy at Post-Intervention, 1-month, and 6-month follow-up as assessed by Breast Cancer Self-Efficacy Scale|Change from baseline in quality of life at Post-Intervention, 1-month, and 6-month follow-up as assessed by 10-item PROMIS Global Health Scale|Change from baseline in spiritual well-being at Post-Intervention, 1-month, and 6-month follow-up as assessed by Functional Assessment of Chronic Illness Therapy-Spiritual Well-being (FACIT-Sp) scale|Change from baseline in mindfulness at Post-Intervention, 1-month, and 6-month follow-up as assessed by Five Facet Mindfulness Questionnaire-Short Form|Change from baseline in telomere length at Post-Intervention, 1-month, and 6-month follow-up as assessed by quantitative telomere length.|Intervention ratings for satisfaction and helpfulness at Post-Intervention as assessed by a 5-item investigator-created measure.",Indiana University|Indiana University Health,Female,"18 Years to 99 Years   (Adult, Older Adult)",Not Applicable,91,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,IUSCC-0563,Dec-15,1-Dec-16,1-Dec-16,20-Nov-15,null,21-Aug-17,"Indiana University, Indianapolis, Indiana, United States",,https://ClinicalTrials.gov/show/NCT02611544
NCT02605668,Providing Tools for Effective Care and Treatment of Anxiety Disorders,PROTECT-AD,Unknown status,No Results Available,Panic Disorder|Agoraphobia|Specific Phobias|Social Anxiety Disorder,Behavioral: Intensified psychological intervention|Behavioral: Standard intervention,change in somatic and psychic anxiety symptoms|change in severity of the anxiety disorder|change in categorial diagnosis according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV/5)|change in screened anxiety symptoms|change in depressive symptoms|change in anxiety sensitivity|change in panic and agoraphobic symptoms|change in agoraphobic avoidance|change in symptoms of Generalized Anxiety Disorder|change in social anxiety|change in Specific Phobia symptoms|change in disability|change in quality of life|change in psychopathological symptoms|change in agoraphobic cognitions|fear of body sensations,"Technische Universität Dresden|Ruhr University of Bochum|University Medicine Greifswald|Charite University, Berlin, Germany|University of Wuerzburg|Philipps University Marburg Medical Center|Wuerzburg University Hospital|Westfälische Wilhelms-Universität Münster",All,"15 Years to 70 Years   (Child, Adult, Older Adult)",Not Applicable,620,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,01EE1402A|DRKS00008743,Jan-16,Feb-18,Jan-19,16-Nov-15,null,3-Aug-16,"Technische Universität Dresden, Institute of Clinical Psychology and Psychotherapy, Dresden, Sachsen, Germany",,https://ClinicalTrials.gov/show/NCT02605668
NCT02604706,"Auricular Acupuncture in Substance Abuse: Effects on Anxiety, Sleep, Drug Use.",,Completed,No Results Available,Substance Abuse|Anxiety|Sleep,Device: NADA Acupuncture|Device: LP acupuncture|Behavioral: Relaxation,Change in self rated anxiety measured with Beck Anxiety Inventory (BAI).|Change in self rated sleep quality measured with Insomnia Severity Index (ISI).|Change in self rated drug use using The self-report Drug Use Disorders Identification Test (DUDIT).|Change in self rated alcohol use using The self report Alcholol Disorders Identification Test (ADUIT).,Örebro Läns Landsting,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,280,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,11,Oct-10,Jun-14,Jun-14,13-Nov-15,null,16-Nov-15,"Psychiatric Research Centre, Örebro, Sweden",,https://ClinicalTrials.gov/show/NCT02604706
NCT02602886,Exposure and Response Prevention Therapy for Obsessive-compulsive Disorder,,Unknown status,No Results Available,Obsessive-Compulsive Disorder,Behavioral: Exposure and Response Prevention Therapy,"Change in Yale-Brown Obsessive Compulsive Scale (Y-BOCS) Score|Change in Florida Obsessive-Compulsive Inventory (FOCI) Score|Change in Obsessive-Compulsive Inventory-Revised (OCI-R) Score|Change in Hamilton Anxiety Scale, Hamilton Depression Scale-17 Score|Change in Obsessional beliefs questionnaire (OBQ-44) Score|Change in Patient EX/RP Adherence Scale (PEAS) Score|Disability: Change in Sheehan Disability Scale|Disability: Change in WHO disability assessment 2.0|Treatment Ambivalence Questionnaire (TAQ)",Ruijin Hospital|Shanghai Hongkou Mental Health Center|West China Hospital|Suzhou Guangji Hospital|First Affiliated Hospital of Xinjiang Medical University|The SHSMU-ION Research Center for Brain Disorders,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,48,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,OCD#020,Nov-16,Dec-17,Dec-17,11-Nov-15,null,29-Nov-16,"Shanghai Ruijin Hospital, Shanghai, Shanghai, China|West China Hospital, Chengdu, Sichuan, China|Shanghai Hongkou Mental Health Center, Shanghai Shi, China|Suzhou Guangji Hospital, Suzhou, China|The First Hospital affiliated to XinJiang Medical University, Wulumuqi, China",,https://ClinicalTrials.gov/show/NCT02602886
NCT02601677,Deep Brain Stimulation of NAc/ALIC to Prevent Treatment-Refractory Obsessive Compulsive Disorder,,Unknown status,No Results Available,Obsessive Compulsive Disorder,Procedure: Deep brain stimulation|Drug: Fluoxetine,Yale-Brown Obsessive Compulsive Scale (Y-BOCS)|Clinical Global Impression (CGI)|Global assessment of functioning (GAF)|The Hamilton Anxiety Scale (HAM-A)|The Hamilton Rating Scale for Depression (HAM-D)|Sheehan Disability Scale (SDS)|Event related potentials(ERPs)|local field potential(LFP)|Change in two static positron emission tomography(PET) images study,Tang-Du Hospital,All,18 Years to 60 Years   (Adult),Not Applicable,10,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,OCD-DBS,Nov-15,Nov-18,Nov-18,10-Nov-15,null,10-Nov-15,,,https://ClinicalTrials.gov/show/NCT02601677
NCT02600091,Mindfulness-based Cognitive Therapy to Improve Emotional Wellbeing and Glycaemic Control in Diabetes,MILESTONE,Completed,No Results Available,Anxiety|Depression|Diabetes,Behavioral: Mindfulness-Based Cognitive Therapy,Recruitment/Retention Rates|Acceptability,University of Aberdeen|NHS Grampian|University of Glasgow|NHS Greater Glasgow and Clyde,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,29,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RG12976-10,30-Oct-15,Dec-17,Dec-17,9-Nov-15,null,9-May-18,"University of Aberdeen, Aberdeen, United Kingdom",,https://ClinicalTrials.gov/show/NCT02600091
NCT02600299,Effectiveness of a Psycho-educational Group (PEG) Intervention on Supportive Care and Survivorship Issues in Early-stage Breast Cancer Survivors Who Have Received Systemic Treatment,,Completed,No Results Available,Breast Cancer|Cancer|Anxiety|Cognitive Dysfunction,Behavioral: Psychoeducation group|Behavioral: Usual Care,"Severity of anxiety, as measured using Beck Anxiety Inventory|Quality of life|Severity of cognitive dysfunction, as measured using FACT-Cog|Severity of symptom burden, as measured using Rotterdam Symptom Checklist","National University, Singapore",Female,"21 Years to 99 Years   (Adult, Older Adult)",Phase 2,80,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research,201504-00102,Jul-15,Jan-16,Mar-16,9-Nov-15,null,22-Sep-16,"National Cancer Centre Singapore, Singapore, Singapore",,https://ClinicalTrials.gov/show/NCT02600299
NCT02600637,Wellness Programs for Brain-Injured Individuals,WPBI,Completed,No Results Available,Depression|Anxiety|Stroke,Behavioral: MBSR|Behavioral: Brain Health class,Depression scores on Beck Depression Inventory Questionnaire|Anxiety scores on Beck Anxiety Inventory Questionnaire|CogState Computerized Battery Overall Cognitive Score,VA Office of Research and Development,All,"20 Years to 80 Years   (Adult, Older Adult)",Not Applicable,37,U.S. Fed,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",D1893-P,1-Nov-15,10-Apr-18,30-Jun-18,9-Nov-15,null,17-Jul-18,"VA Northern California Health Care System, Mather, CA, Sacramento, California, United States",,https://ClinicalTrials.gov/show/NCT02600637
NCT02599610,Effects of Digital Vaginal Examination During Labor on Pain and Anxiety Levels,,Unknown status,No Results Available,Pregnancy|Obstetric Labor,Other: Digital vaginal examination|Device: Transperineal ultrasound examination,Anxiety levels|Labor pain,Ankara University,Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,40,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor),6,Oct-15,Mar-16,Mar-16,6-Nov-15,null,17-Feb-16,"Ankara University Faculty of Medicine, Department of Obstetrics and Gynecology, Ankara, Turkey",,https://ClinicalTrials.gov/show/NCT02599610
NCT02593682,The Role of Orexin in Human Panic Disorder,,"Active, not recruiting",No Results Available,Panic Disorder,Drug: suvorexant|Drug: placebo,Change in orexin levels (blood) +1 minute|Change in orexin levels (blood) +5 minutes|Change in orexin levels (blood) +15 minutes|Change in orexin levels (blood) +60 minutes,"University of California, San Francisco",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,12,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",2015078,May-16,Jul-19,Dec-19,2-Nov-15,null,13-Dec-18,"UCSF Fresno Medical Education Program, Fresno, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/82/NCT02593682/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02593682
NCT02593734,Integrating Psychotropic Medication Into the Care of People With Mental Disorders in a Prayer Camp in Ghana,JFR,Completed,No Results Available,"Schizophrenia|Mood Disorders,|Anxiety Disorder",Drug: olanzapine|Drug: risperidone|Drug: amitryptaline|Drug: fluoxetine,"Brief Psychiatric Rating Scale (BPRS)|Clinical Global Impressions(CGI)|Global Assessment of functioning(GAF)|De-chaining,",University of Ghana Medical School,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 4,139,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,JFR,Jul-13,Jul-15,Jul-15,2-Nov-15,null,2-Nov-15,"Mount Horeb Prayer Centre, Mamfe, Ghana",,https://ClinicalTrials.gov/show/NCT02593734
NCT02591797,Effectiveness of Hand/Eyes/Mouth Behavior Management Technique During Local Anesthesia in Preschool Children,,Completed,No Results Available,Dental Anxiety|Pain|Infant Behavior|Heart Rate and Rhythm Disorders,Procedure: inferior alveolar and lingual nerve block procedure,Preschool children´s anxiety levels-Facial Image Scale (FIS)|Preschool children´s pain levels-Wong Baker Faces Pain Scale,Cardenal Herrera University,All,36 Months to 71 Months   (Child),Not Applicable,52,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,AMLUCHBR,Oct-15,Jun-17,Jul-17,30-Oct-15,null,19-Jul-17,"Facultad de Odontología. Universidad Cardenal Herrera CEU, Valencia, Spain",,https://ClinicalTrials.gov/show/NCT02591797
NCT02592044,Effect of Aromatherapy on Venopuncture Pain and Anxiety,,Completed,No Results Available,Pain,Procedure: peripheral venous cannulation|Procedure: Aromatherapy with lavender essential oil|Procedure: Placebo,Pain Level|Anxiety Level|Patient Satisfaction,Tokat Gaziosmanpasa University,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,106,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,Venpuncture pain,Nov-15,Mar-16,Mar-16,30-Oct-15,null,21-Mar-16,"Gaziosmanpasa University Medical School, Tokat, Turkey",,https://ClinicalTrials.gov/show/NCT02592044
NCT02592564,Brain Plasticity and Cellular Aging After Internet-delivered CBT for Social Anxiety Disorder,UMEII,"Active, not recruiting",No Results Available,Anxiety Disorders|Social Anxiety Disorder,Behavioral: Internet-delivered cognitive behavior therapy,"Clinically Global Impression-Improvement scale (CGI-I; Change from baseline)|Liebowitz Social Anxiety Scale, Self-report version (LSAS-SR; Change from baseline)|Clinically Global Impression-Severity scale (CGI-S)|Social Phobia Screening Questionnaire (SPSQ)|Beck Anxiety Inventory (BAI)|Social Interaction Anxiety Scale (SIAS)|Social Phobia Scale (SPS)|Montgomery Åsberg Depression Rating Scale, Self-report version (MADRS-S)|Subjective unit of discomfort on fear and distress (SUD)|Social Probability/Cost Questionnaire|Quality of Life (QOLI)|Social Network Index (SNI)|Brown Attention-Deficit Disorder Scales (Brown ADD)|Difficulties in Emotion Regulation Scale (DERS)|Treatment Credibility Scale (TCS)|Revised NEO Personality Inventory (NEO-PI-R)|Insomnia Severity Index (ISI)|Karolinska Sleep Questionnaire (KSQ)|State-Trait Anxiety Inventory (STAI-T)|State-Trait Anxiety Inventory (STAI-S)|MINI International Neuropsychiatric Interview",Linkoeping University|Umeå University|Uppsala University|Stockholm University|Karolinska Institutet,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,50,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,UMESTUDIEN-II,Oct-15,Apr-17,May-21,30-Oct-15,null,1-Sep-17,"Umeå university, Umeå, Sweden",,https://ClinicalTrials.gov/show/NCT02592564
NCT02590445,Novel Deep Brain Stimulation in Ventral Capsule and Stratum for Refractory Obsessive-Compulsive Disorder,,Unknown status,No Results Available,Obsessive-Compulsive Disorder,Device: deep brain stimulation system,"Change in Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) Score|Change in Obsessive-Compulsive Inventory - Revised (OCI-R) Score|Adverse Events|Change in Hamilton Anxiety Scale, Hamilton Depression Scale-17 Score|Functional magnetic resonance imaging (fMRI) images|Quality of life: Global assessment of function|Disability: WHO disability assessment 2.0|Neurobehavior Task (Decision making task, such as Model task, IGT)|Neurobehavior Task (Working memory task, such as N-back)|Disability: Sheehan Disability Scale|Change in Obsessional beliefs questionnaire (OBQ-44) Score|Change in Adult Temperament Questionnaire (ATQ-77) Score|Change in Temperament and Character Inventory Revised (TRI-R) Score|Cerebral glucose metabolism measured by PET-CT images",Ruijin Hospital,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2|Phase 3,8,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",OCD pilot,Oct-15,Oct-17,Apr-18,29-Oct-15,null,6-Dec-16,"Shanghai Ruijin Hospital, Shanghai, Shanghai, China",,https://ClinicalTrials.gov/show/NCT02590445
NCT02590770,Gaze Contingent Feedback in Social Anxiety Disorder,,Completed,No Results Available,"Phobia, Social",Behavioral: attention modification|Other: Placebo,Change from baseline - the Liebowitz Social Anxiety Scale - Diagnostic Interview scores|Change from baseline - the Social Phobia Inventory scores,Tel Aviv University,All,18 Years to 60 Years   (Adult),Not Applicable,40,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",TAUSAD,Oct-15,Jul-16,Jul-16,29-Oct-15,null,28-Jul-16,"Tel-Aviv University, Tel-Aviv, Israel",,https://ClinicalTrials.gov/show/NCT02590770
NCT02588079,Internet-Based Cognitive Behavioral Therapy for Children With Dental Anxiety,,Recruiting,No Results Available,Dental Anxiety,Behavioral: Internet-based cognitive behavioral therapy,"Picture guided behavioral approach test, child version|Picture guided behavioral approach test, parent version|Self-Efficacy Questionnaire for Phobic Situations ( dentistry adapted version )|Children's Fear Survey Schedule - Dental Subscale (child version)|Children's Fear Survey Schedule - Dental Subscale (parent version)|Kiddie Sads (phobic disorders supplement)",Karolinska Institutet,All,8 Years to 15 Years   (Child),Not Applicable,50,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,KIPED20151008,Oct-15,Jun-20,Jun-20,27-Oct-15,null,14-Sep-18,"Department of Dental Medicine, Stockholm, Huddinge, Sweden",,https://ClinicalTrials.gov/show/NCT02588079
NCT02584764,Internet Supported Group Cognitive Behavior Therapy (CBT) for Hoarding Disorder (HD),,Completed,No Results Available,Hoarding Disorder,Behavioral: Cognitive behavior therapy|Behavioral: Internet support,Saving Inventory - Revised (SI-R)|Hoarding Rating Scale - Self Report (HRS-SR)|Saving Cognitions Inventory (SCI)|Clutter Image Rating (CIR)|Global Assessment of Functioning (GAF)|Clinical global impression (CGI)|EuroQol- 5 Dimension (EQ-5D)|Trimbos and Institute of Medical Technology Assessment Cost Questionnaire for Psychiatry (TIC-P),Karolinska Institutet,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,20,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Hoarding Pilot,Oct-15,Jun-17,Jun-17,23-Oct-15,null,18-Aug-17,"Psykiatri Nordväst, Stockholms Läns Sjukvårdsområde (SLSO), Stockholms Läns Landsting, Stockholm, Sweden",,https://ClinicalTrials.gov/show/NCT02584764
NCT02582528,Cognitive Remediation in Youth at Risk of Serious Mental Illness,,Terminated,No Results Available,Depression|Psychosis|Anxiety|Mental Illness,Behavioral: Cognitive remediation treatment|Behavioral: Motivational Interviewing,Cognitive function assessment pre- and post-CRT in youth at risk of SMI using WebNeuro computerized cognitive battery|Social functioning assessment pre- and post-CRT in youth at risk of SMI using Global Functioning: Social (GFS) scale.|Social functioning assessment pre- and post-CRT in youth at risk of SMI using Global Functioning: Role (GFR) scale.|Functional capacity assessment pre- and post-CRT in youth at risk of SMI using Social Skills Performance Assessment (SSPA).,University of Calgary,All,"14 Years to 25 Years   (Child, Adult)",Not Applicable,12,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,UCalgary-MAT,Feb-16,Mar-17,Mar-17,21-Oct-15,null,4-Apr-17,"University of Calgary, Calgary, Alberta, Canada",,https://ClinicalTrials.gov/show/NCT02582528
NCT02579915,Developing a Low-Intensity Primary Care Intervention for Anxiety Disorders (AIM-PC),,Completed,No Results Available,Anxiety Disorders,Behavioral: FaceAnxiety|Behavioral: Symptom Tracking,Hamilton Anxiety Rating Scale|7-item Generalized Anxiety Disorder Scale|Patient Health Questionnaire-9,Brown University|Mclean Hospital|Memorial Hospital of Rhode Island|National Institute of Mental Health (NIMH),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,40,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,1308000908-Phase 2|1R34MH097820-01A1,Sep-15,31-Dec-18,31-Dec-18,20-Oct-15,null,12-Apr-19,"Family Care Center at Memorial Hospital of Rhode Island, Pawtucket, Rhode Island, United States",,https://ClinicalTrials.gov/show/NCT02579915
NCT02579928,Ketamine Infusion for Adolescent Depression and Anxiety,,"Active, not recruiting",No Results Available,Major Depressive Disorder|Anxiety Disorder,Drug: Ketamine|Drug: Midazolam,Improvement in depressive symptoms|Improvement in anxiety|Ketamine metabolites and D-serine|Risk of suicidality|Effect on school refusal behavior,Yale University|American Academy of Child Adolescent Psychiatry.,All,13 Years to 17 Years   (Child),Phase 4,20,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",1506016041,Oct-15,28-Sep-18,Jun-19,20-Oct-15,null,15-Nov-18,"Hospital Research Unit at the Yale New Haven Hospital, New Haven, Connecticut, United States|Yale Child Study Center, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT02579928
NCT02580656,An Open Trial of Metacognitive Therapy for Anxiety and Depression in Cancer,,Completed,No Results Available,Anxiety|Depression|Cancer,Behavioral: Metacognitive Therapy,Hospital Anxiety and Depression Scale (HADS-Total),University of Liverpool|Medical Research Council,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,28,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,UoL001166,Jan-16,Jul-17,Jul-17,20-Oct-15,null,3-Oct-17,"Royal Liverpool and Broadgreen NHS Trust, Liverpool, Merseyside, United Kingdom",,https://ClinicalTrials.gov/show/NCT02580656
NCT02578758,Efficacy of a Transdiagnostic Internet-based Protocol in Community Sample,,"Active, not recruiting",No Results Available,Emotional Disorders|Anxiety|Depression,Behavioral: Transdiagnostic internet-based protocol|Behavioral: Transdiagnostic internet-based protocol + positive affect component|Other: Waiting List Control Group,"Change in the Beck Depression Inventory II (BDI-II) (Beck, Steer, & Brown, 1996) at pre, post intervention and at 3 and 12 months follow-ups.|Change in the Beck Anxiety Inventory (BAI) (Beck, & Steer, 1990) at pre, post intervention and at 3 and 12 months follow-ups.|Change in the Obsessive-Compulsive Inventory (OCI-R) (Foa et al., 2002) at pre, post intervention and at 3 and 12 months follow-ups.|Change in the Self-Reported Panic Disorder Severity Scale (PDSS-SR) (Houck, Spiegel, Shear, & Rucci, 2002) at pre, post intervention and at 3 and 12 months follow-ups.|Change in the Pen State Worry Questionnaire (PSWQ) (Meyer, Miller, Metzger, & Borkovec, 1990) at pre, post intervention and at 3 and 12 months follow-ups.|Change in the Social Interaction Anxiety Inventory (SIAS) (Mattick y Clarke, 1998) at pre, post intervention and at 3 and 12 months follow-ups.|The Positive and Negative Affect Schedule (PANAS) (Watson, Clark y Tellengen, 1988; Sandín et al., 1999) at pre, post intervention and at 3 and 12 months follow-ups.","Universitat Jaume I|Ministerio de Economía y Competitividad, Spain",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,252,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,UJAUMEI014,Sep-14,Nov-19,Jan-20,19-Oct-15,null,9-May-19,"Universitat Jaume I, Castelló de la Plana, Castelló, Spain",,https://ClinicalTrials.gov/show/NCT02578758
NCT02577250,Ketamine Infusions for PTSD and Treatment-Resistant Depression,,Completed,No Results Available,"Depressive Disorder, Treatment-Resistant|Stress Disorders, Post-Traumatic",Drug: Ketamine,Montgomery-Asberg Depression Rating Scale (MADRS)|Clinical-Administered PTSD Scale (CAPS)|PTSD Checklist,Minneapolis Veterans Affairs Medical Center,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1,20,U.S. Fed,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,4555-B,May-15,Jun-16,Jul-16,16-Oct-15,null,14-May-19,"Minneapolis Va Health Care System, Minneapolis MN, Minneapolis, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT02577250
NCT02578160,Efficacy of Tell-Show-Do Behavior-Management Technique During Local Anesthesia in Preschool Children,,Unknown status,No Results Available,Dental Anxiety|Pain|Infant Behavior|Heart Rate and Rhythm Disorders,Procedure: inferior alveolar and lingual nerve block procedure,Preschool children's anxiety levels changes before and after anesthesia procedure - Facial Image Scale (FIS)|Preschool children's pain levels - Wong-Baker FACES Pain Scale|Preschool children's behavior - Frankl Behavioral Rating Scale|Heart rates|Parent's anxiety levels - Corah's dental anxiety scale (DAS) - parent questionnaire|family socioeconomic indicators - questionnaire related to socioeconomic conditions,Evelyn Alvarez Vidigal|University of Sao Paulo,All,36 Months to 71 Months   (Child),Not Applicable,52,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,EBEMATECH,Nov-15,Oct-16,Nov-16,16-Oct-15,null,25-Oct-16,"Faculdade de Odontologia da Universidade de Sao Paulo, Sao Paulo, Brazil",,https://ClinicalTrials.gov/show/NCT02578160
NCT02576171,Group Therapy Supported Internet-based CBT for Adolescents With Social Anxiety Disorder - A Feasibility Trial,SoFT,Completed,No Results Available,Social Anxiety Disorder,Behavioral: Group-therapy + ICBT,"Clinical Global Impression - Severity|Presence of DSM-5 Social Anxiety Disorder|Clinical Global Impression - Improvement|Social Phobia and Anxiety Inventory (SPAI) - Child version|Social Phobia and Anxiety Inventory (SPAI) - Parent version|Revised Children´s Anxiety and Depression Scale (RCADS) - Child version|Revised Children´s Anxiety and Depression Scale (RCADS) - Parent version|Children's Global Assessment Scale (CGAS)|Social Phobia Weekly Summary Scale (SPWSS)|Patient ICBT Adherence Scale (PIAS)|KIDSCREEN-10 - Child version|KIDSCREEN-10 - Parent version|Education, Work and Social Adjustment Scale - child version|Education, Work and Social Adjustment Scale - parent version|Trimbos/iMTA questionnaire for Costs associated with Psychiatric Illness - Child version (TiC-P)|Client Satisfaction Scale (CSS)|Measurement of anxiety levels during exposure (app)|Unintended treatment effects|Technology acceptance scale (TAS) - child version|Technology acceptance scale (TAS) - parent version|Hospital Anxiety and Depression Scale (HADS)|Social Responsiveness Scale - Parent version|DNA through saliva sampling|Attention bias when presented with social stimuli (eye-tracking)|Qualitative interviews of experience from treatment",Karolinska Institutet,All,13 Years to 17 Years   (Child),Not Applicable,30,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SoFT Pilot,15-Oct-15,31-Jan-17,31-Jan-17,15-Oct-15,null,22-Jun-17,"BUP CPF, Stockholm, Sweden",,https://ClinicalTrials.gov/show/NCT02576171
NCT02574273,Pilot Trial of a Social Skills Group Treatment (Secret Agent Society Program),,Completed,No Results Available,Anxiety|Attention Deficit Hyperactivity Disorder (ADHD)|Autistic Spectrum Disorder (ASD),Behavioral: Secret Agent Society (SAS) Program|Other: Waitlist Group / Treatment As Usual,Anxiety Disorders Interview Schedule for DSM-IV—Child Version (ADIS),Weill Medical College of Cornell University,All,8 Years to 12 Years   (Child),Not Applicable,106,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1503015990,Oct-15,Dec-18,Dec-18,12-Oct-15,null,6-Feb-19,"Weill Cornell Medical College, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT02574273
NCT02572973,Acoustic Neuromodulation (ANM) for Youth With Anxiety Disorders,ANM,Terminated,No Results Available,Separation Anxiety Disorder|Generalized Anxiety Disorder|Social Phobia,Other: Acoustic Neuromodulation (ANM),Anxiety Disorders Interview Schedule (ADIS)|Electroencephalogram (EEG),Weill Medical College of Cornell University|The Hartwell Foundation,All,7 Years to 17 Years   (Child),Not Applicable,6,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",1403014928,Jul-14,Apr-16,Apr-16,9-Oct-15,null,14-Jan-19,"Weill Cornell Medical College, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT02572973
NCT02573246,Neuromodulation Enhanced Cognitive Restructuring: A Proof of Concept Study,,Recruiting,No Results Available,Anxiety|Depression|Personality Disorders|Trauma and Stress-related Disorders|Somatic Disorders|Obsessive Compulsive Disorders|Eating Disorders|Difficulties With Cognitive Emotion Regulation,Behavioral: Cognitive Restructuring|Device: rTMS|Device: Sham rTMS,"Time to return to heart rate baseline during the regulation period during training|Time to return to heart rate baseline during the regulation period at follow up|Acceptability, as measured by qualitative exit interview|Feasibility, as measured by qualitative exit interview|Change in general psychological distress, as measured by the Outcome Questionaire -45|Change in general emotional distress, as measured by daily mobile phone ratings 8 times/day of subjective units of distress)|Change in emotion dysregulation and functional impairment as measured by Emotion Regulation Questionnaire (ERQ) and Difficulties with Emotion Regulation Scale (DERS)",Duke University|Brain & Behavior Research Foundation,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,105,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",Pro00066383,Mar-16,Jul-19,Jul-19,9-Oct-15,null,28-May-18,"Duke University Medical Center-Civitan Bldg, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT02573246
NCT02571790,Virtual Reality and Relaxation for the Treatment of Generalized Anxiety Disorders: a Comparative Study With Standard Relaxation,Relax-TAG,Unknown status,No Results Available,Generalized Anxiety Disorders,Behavioral: Relaxation optimized virtual reality|Behavioral: Classical relaxation (without Virtual Reality),scores on psychometric scales in connection with the Generalized Anxiety Disorders (TAG)|Short self-completion questionnaire on the Generalized Anxiety Disorders (TAG),Assistance Publique Hopitaux De Marseille,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,58,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,2015-23,Oct-15,Oct-17,Oct-17,8-Oct-15,null,8-Oct-15,"Assistance Publique Hôpitaux de Marseille, Marseille, France",,https://ClinicalTrials.gov/show/NCT02571790
NCT02570763,Combining Non-Invasive Brain Stimulation With Cognitive Behavioral Intervention in Substance Use Disorder,,Withdrawn,No Results Available,Active tDCS|Sham tDCS,Device: Active tDCS stimulation|Device: Sham tDCS stimulation,Therapy Content Memory Assessment,University of Minnesota - Clinical and Translational Science Institute,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,1508M77345,Nov-15,Jul-16,Jul-16,7-Oct-15,null,6-Nov-17,,,https://ClinicalTrials.gov/show/NCT02570763
NCT02568813,Epilepsy and Mood Regulation Disorder in Children,EPILETRE,Recruiting,No Results Available,Epilepsy,Behavioral: Multiscore Depression Inventory for Children scale,Number of children with new- or recent-onset epilepsy with a pathological score in a least one of the 3 scales|Correlate pathological scores obtained with the type of epilepsy|Correlate pathological scores with the progression of epilepsy disease,Hospices Civils de Lyon,All,6 Years to 15 Years   (Child),Not Applicable,300,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,2013-834,30-Mar-15,30-Sep-19,30-Sep-19,6-Oct-15,null,9-Aug-17,"Hôpital Femme Mère Enfant, Bron, Rhône, France",,https://ClinicalTrials.gov/show/NCT02568813
NCT02568878,Creatine for Depressed Male and Female Methamphetamine Users,,Unknown status,No Results Available,Depression|Anxiety|Methamphetamine Dependence,Drug: Creatine monohydrate,Hamilton Depression Rating Scale (HAMD) Scores|Hamilton Anxiety Rating Scale (HAMA) Scores|Self-reported methamphetamine use|Incidence of treatment-emergent adverse events|Percent of positive urine drug screens for methamphetamine,Montana State University,All,18 Years to 59 Years   (Adult),Phase 3,29,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1,Nov-15,Oct-16,May-17,6-Oct-15,null,11-Dec-15,"Montana State University College of Nursing (Missoula campus), Missoula, Montana, United States",,https://ClinicalTrials.gov/show/NCT02568878
NCT02567266,Community Study of Outcome Monitoring for Emotional Disorders in Teens,COMET,Recruiting,No Results Available,Depression|Anxiety,Behavioral: Unified Protocol for Adolescents (UP-A)|Behavioral: Youth Outcomes Questionnaire|Behavioral: Treatment as Usual,Change over time in Clinical Global Impression-Improvement (CGI-I)|Change over time in Clinical Global Impression-Severity (CGI-S)|Change over time in Children's Global Assessment Scale (CGAS),University of Miami|University of Connecticut|National Institute of Mental Health (NIMH),All,"12 Years to 18 Years   (Child, Adult)",Not Applicable,222,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",20150187|R01MH106536|R01MH064089,Jan-16,Jul-20,Jul-20,2-Oct-15,null,3-May-19,"University of Connecticut Health Center, West Hartford, Connecticut, United States|University of Miami, Coral Gables, Florida, United States",,https://ClinicalTrials.gov/show/NCT02567266
NCT02565316,Efficacy of Nepeta Menthoides Extract on Anxiety of Patients With Depression: a Double-blind Randomized Controlled Clinical Trial,,Completed,No Results Available,Depression|Anxiety,Drug: Nepeta menthoides Boiss & Bohse freeze dried extract|Drug: Sertraline,Persian version of Beck Anxiety Inventory (BAI)|side effects of intervention drugs,Shiraz University of Medical Sciences,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2|Phase 3,70,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",9470-7440,Nov-14,Mar-15,Mar-15,1-Oct-15,null,1-Oct-15,,,https://ClinicalTrials.gov/show/NCT02565316
NCT02563483,Yoga for Family Caregivers of Alzheimers Disease Patient,,Completed,No Results Available,Stress|Anxiety|Compassion,Behavioral: yoga and compassion meditation program,change in cortisol|change in stress|change in depression|change in anxiety|change in quality of life|change in vitality|change in attention|change in self-compassion,Federal University of São Paulo,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,46,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,yoga caregivers,Sep-07,Feb-08,Nov-09,30-Sep-15,null,30-Sep-15,,,https://ClinicalTrials.gov/show/NCT02563483
NCT02563587,Efficacy of Spontaneous Laughter in the Postoperative Treatment of Children,,Unknown status,No Results Available,Pain,Other: Laughter therapy|Other: Accompaniment without causing the laughter of children.|Drug: Conventional treatment,Postoperative pain level|Postoperative anxiety level|Postoperative urinary cortisol level|Postoperative heart rate|Postoperative respiratory rates|Postoperative systolic blood pressure|Postoperative diastolic blood pressure|Postoperative oxygen saturation|Length of hospital stay,Hospital General Naval de Alta Especialidad - Escuela Medico Naval,All,6 Years to 14 Years   (Child),Not Applicable,210,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,HGNAE-02|pecm830703,Sep-15,Jan-16,Jan-18,30-Sep-15,null,30-Sep-15,"Hospital General Naval de Alta Especialidad, México, Distrito Federal, Distrito Federal, Mexico",,https://ClinicalTrials.gov/show/NCT02563587
NCT02563743,Stress and Mental Ill-health in the Workplace: Evaluation of an Intervention for the Prevention of Sick Leave,,"Active, not recruiting",No Results Available,Common Mental Disorders and/or Stress Related Symptoms,Behavioral: Problem-solving based intervention|Behavioral: Treatment as usual,"Change from Baseline in total registered sickness absenteeism during the 12 month follow-up period.|Change from baseline in self-reported sickness absenteeism during the 12 months follow-up period|The prevalence of no sick leave, part-time sick leave and full-time sick leave during the 12 months follow-up period following baseline|Among those sick listed at baseline: Time to full Return to Work (RTW) during a follow-up period of 12 months|Among those sick listed at baseline: Time to Return to Work (RTW) during a follow-up period of 12 months|Work performance impairment due to health problems|Work performance impairment due to problems in working environment|Cost-effectiveness of the intervention compared to treatment as usual.|Work satisfaction|Work ability index (WAI)|Sickness presenteeism|The Institute of Stress Medicine's instrument for self-rating of stress-related Exhaustion Disorder (s-ED)|Maslach Burnout Inventory - General Survey, Exhaustion-scale|Hospital Anxiety and Depression Scale|Self-perceived health|European Quality of Life - 5 Dimensions questionnaire (EQ-5D)|Self-reported stress|Karolinska Sleep Questionnaire, Insomnia sub-scale|Demand-control-support model. Prognostic variable.|Other work related variables such as ongoing conflicts with the superior, perceived loss of control over work tasks and conflicts between the employee´s values and how the work actually is done. Prognostic variables.|Physical activity. Prognostic variable.|Change in work conditions. Prognostic variable.|Change in the organization. Prognostic variable.|Participants' satisfaction and experiences with the intervention or treatment as usual will be assessed at 6 months after completed intervention by eleven items (response format from 0-10 or yes/no/do not know). Process evaluation data.|OHS staff's adherence to the intervention (process evaluation data)|Implementation of the intervention and entire research project at the OHS units (process evaluation data)|Three years follow-up: Change from Baseline in registered sickness absenteeism during a 3-year follow-up period",Karolinska Institutet,All,18 Years to 63 Years   (Adult),Not Applicable,100,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",4-2544/2014|2014-0742,Sep-15,Jun-18,Jun-20,30-Sep-15,null,13-Aug-18,"Karolinska Institutet, Stockholm, Sweden",,https://ClinicalTrials.gov/show/NCT02563743
NCT02564302,Effects of Mindfulness on Atrial Fibrillation,,Recruiting,No Results Available,Atrial Fibrillation,Device: MUSE Headband,Quality of Life,Newmarket Electrophysiology Research Group Inc,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NERG-03,Aug-15,Dec-18,May-19,30-Sep-15,null,29-Mar-18,"Southlake Regional Health Centre, Newmarket, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT02564302
NCT02562248,Improving Anxiety Detection in Pediatrics Using Health Information Technology,,Completed,No Results Available,"Anxiety|Attention Deficit Hyperactivity Disorder|Disorder, Pediatric",Other: Automated screening for pediatric anxiety|Other: Usual Care,Caregiver perception about screening process and satisfaction with index visit|Physician satisfaction,Indiana University|Agency for Healthcare Research and Quality (AHRQ),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,3267,Other|U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Screening,1508683196|1508624213,1-Sep-15,31-Aug-17,31-Jul-18,29-Sep-15,null,22-Apr-19,,,https://ClinicalTrials.gov/show/NCT02562248
NCT02561572,"The Effect of Acupuncture on Pre-operative Anxiety Levels in Neurosurgical Patients: a Randomised, Controlled Trail",,Completed,Has Results,Anxiety,Other: Acupuncture,State-Trait Anxiety Inventory Score|Amsterdam Preoperative Anxiety and Information Scale Scores|Incidence of Postoperative Nausea and Vomiting (PONV) in the Postanaesthetic Care Unit (PACU)|Incidence of Postoperative Nausea and Vomiting (PONV)|Pain Score in the Postanaesthetic Care Unit (PACU)|Pain Score,Sheffield Teaching Hospitals NHS Foundation Trust|University of Sheffield,All,"16 Years and older   (Child, Adult, Older Adult)",Not Applicable,128,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,STH19048,Oct-15,Apr-16,Apr-16,28-Sep-15,31-Jan-17,13-Mar-17,"Sheffield Teaching Hospital NHS Foundation Trust, Sheffield, South Yorkshire, United Kingdom",,https://ClinicalTrials.gov/show/NCT02561572
NCT02561949,Adapting Mental Health Interventions for War-Affected Youth Through Employment Programs,,Completed,No Results Available,"Anxiety Disorder/Anxiety State|Depressive Disorder/Psychology|Social Problems/Psychology|Violence, Non-accidental",Behavioral: YRI|Other: Income generating activity program,"Change in % of youth with improved health outcomes|YRI Fidelity Protocol|Change in knowledge, attitudes, and behaviors of youth around employment and access to employment services.",Boston College|Caritas Freetown|World Bank|The City College of New York,All,"15 Years to 24 Years   (Child, Adult)",Not Applicable,80,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research,0603-04,Sep-15,Aug-17,Oct-17,28-Sep-15,null,31-May-18,"CARITAS, Freetown, Sierra Leone",,https://ClinicalTrials.gov/show/NCT02561949
NCT02558075,Mood Lifters: A Self Help Program,,"Active, not recruiting",No Results Available,Depression|Anxiety|Bipolar Disorder,Behavioral: MoodLifters Sessions,Satisfaction with Life Scale|Patient Health Questionnaire|Generalized Anxiety Disorder scale|Emotion visual analog scale,University of Michigan,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,50,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,HUM00097120,1-May-17,Jul-19,Dec-19,23-Sep-15,null,25-Jan-19,"University of Michigan, Ann Arbor, Michigan, United States",,https://ClinicalTrials.gov/show/NCT02558075
NCT02554838,How to Act on the Mobility Restriction Linked to Senior's Phobia of Falling,PACTE,"Active, not recruiting",No Results Available,Specific Phobia|Fear of Falling,Other: Physical activity|Other: Home assessment and modification|Behavioral: Cognitive behavioral therapy,"Change from baseline in Life-space mobility assessed by the LSC (a composite score of the Life-Space Assessment which reflects the distance, frequency and level of independence of movement during the 4 weeks preceding the assessment) at 5 months.|Change from baseline in Life-space frequency (a composite score of the Life-Space Assessment which reflects the distance and frequency of movement during the 4 weeks preceding the assessment) at 2, 5 and 8 months.|Change from baseline in Assisted life-space (a score of the Life-Space Assessment which indicating the highest level of life-space attained using the help of assistive devices if needed but not the help of another person) at 2, 5 and 8 months.|Change from baseline in Life-space mobility assessed by the LSC (a composite score of the Life-Space Assessment which reflects the distance, frequency and level of independence of movement during the 4 weeks preceding the assessment) at 2, 5, 8 months.|Number of falls and injurious falls|Fear of falling|Use of anxiolytics drugs in phobic situations related to the phobia of falling|Self- perceived health",Assistance Publique - Hôpitaux de Paris,All,70 Years and older   (Older Adult),Not Applicable,48,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,K140702|2015-A00400-49,Nov-15,May-19,Sep-19,18-Sep-15,null,24-Oct-18,"Hôpital Bretonneau, Paris, France",,https://ClinicalTrials.gov/show/NCT02554838
NCT02554929,Treatment of Social Anxiety Disorder and Selective Mutism,SAD & SM TRMT,"Active, not recruiting",No Results Available,Social Anxiety Disorder|Selective Mutism,Behavioral: Taming Sneaky Fears|Behavioral: Parent Psycho-education and Child Socialization,Change in Clinical Severity Ratings (CSR) of SAD & SM on the Anxiety Disorders Interview Schedule - Parent Version (ADIS-P)|Change in Children's Global Assessment Scale (CGAS) which ranges from 1 (needs constant supervision to 100 (superior functioning)|Change in Children's Global Assessment Scale (CGAS)|Selective Mutism Questionnaire (SMQ)|Preschool Anxiety Scale (PAS),The Hospital for Sick Children,All,4 Years to 7 Years   (Child),Not Applicable,88,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,1000050447,Sep-15,Dec-17,Dec-17,18-Sep-15,null,18-Jul-17,"Hospital for Sick Children, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT02554929
NCT02552797,The Development and Piloting of 'Power Up': A Tool for Young People With Internalising/Emotional Disorders to Make Shared Decisions in Child and Adolescent Mental Health Services (CAMHS),Power Up,Unknown status,No Results Available,Internalising Disorders|Anxiety|Depression,Behavioral: Shared Decision Making tool,Shared Decision Making Questionnaire (CollaboRATE),"University College, London",All,"11 Years and older   (Child, Adult, Older Adult)",Not Applicable,105,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,15/0340,Sep-15,Jul-17,Jul-17,17-Sep-15,null,17-Sep-15,,,https://ClinicalTrials.gov/show/NCT02552797
NCT02553161,Mechanism of Antidepressant-Related Dysfunctional Arousal in High-Risk Youth,,Recruiting,No Results Available,Depression|Anxiety|Bipolar Disorder,Drug: Escitalopram|Behavioral: Cognitive behavioral Psychotherapy,Baseline-endpoint change in prefrontal-amygdala functional connectivity by Scan.|Week 4- endpoint change in mood by and arousal ratings,University of Cincinnati|National Institute of Mental Health (NIMH),All,12 Years to 17 Years   (Child),Not Applicable,210,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",DelBello/Singh AIM|R01MH105469,Dec-15,Dec-19,Dec-20,17-Sep-15,null,2-May-18,"Stanford University, Stanford, California, United States|University of Cincinnati, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02553161
NCT02550925,Acceptance and Commitment Therapy (ACT) for Anxious Cancer Survivors,,"Active, not recruiting",No Results Available,Cancer,Behavioral: Acceptance and Commitment Therapy (ACT) Group|Behavioral: Usual Care,Anxiety symptoms|Depressive symptoms|Medical resource use|Fear of cancer recurrence|Sense of life meaning|Fatigue / Vitality|Anxiety disorder severity,"University of Colorado, Boulder|American Cancer Society, Inc.|Rocky Mountain Cancer Centers|University of California, Los Angeles",All,"21 Years to 95 Years   (Adult, Older Adult)",Not Applicable,100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,RSG-15-020-01,Sep-15,Jul-19,Aug-19,16-Sep-15,null,1-May-19,"University of Colorado Boulder, Boulder, Colorado, United States",,https://ClinicalTrials.gov/show/NCT02550925
NCT02552108,A Single-Component CBT for GAD,,"Active, not recruiting",No Results Available,Generalized Anxiety Disorder,Behavioral: Behavioural experiments for intolerance of uncertainty (BE-IU),Clinician's Severity Rating (CSR) of Anxiety Disorders Interview Schedule (ADIS)|Penn State Worry Questionnaire (PSWQ)|Worry and Anxiety Questionnaire (WAQ)|Beck Anxiety Inventory (BAI)|Beck Depression Inventory-II (BDI-II),"Universite du Quebec en Outaouais|Canadian Institutes of Health Research (CIHR)|Concordia University, Montreal|University College, London",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,UQuebecOutaouais,Oct-15,Mar-20,Mar-20,16-Sep-15,null,19-Apr-19,"Université du Québec en Outaouais, Gatineau, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT02552108
NCT02549547,Jump Step - A Participatory Approach to Physical Activity & Mental Wellness,JumpStep,Unknown status,No Results Available,"Major Depressive Disorder|Bipolar, Depression",Behavioral: Group Medical Visits,'Jump Step Intervention Questionnaire'|Physical Activity|Patient Activation|Anxiety|Social Support|Depression,University of British Columbia|Vancouver Foundation|Mood Disorders Association of BC|YMCA,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,80,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ID: H15-01932,Aug-15,Jan-16,Jun-17,15-Sep-15,null,15-Sep-15,"Centre for Hip Health & Mobility, Department of Family Practice, Vancouver, British Columbia, Canada|Mood Disorders Association of BC, Vancouver, British Columbia, Canada|Robert Lee YMCA, Vancouver, British Columbia, Canada",,https://ClinicalTrials.gov/show/NCT02549547
NCT02550379,Emotion Recognition Training for Young People,,Completed,No Results Available,Anxiety|Depression,Behavioral: Intervention|Other: Placebo,Change from baseline in social anxiety at post-intervention|Change from baseline in social anxiety at 2-week follow-up|Change from baseline in emotion sensitivity measurement at post-intervention and 2-week follow-up|Change from baseline in fear of negative evaluation at post-intervention and 2-week follow-up|Change from baseline in anxiety related disorders at post-intervention and 2-week follow-up|Change from baseline in depression symptoms at post-intervention and 2-week follow-up,University College Dublin|University of Bristol,All,"15 Years to 18 Years   (Child, Adult)",Not Applicable,115,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",HS-15-41-Fitzgerald,Sep-15,Mar-16,Mar-16,15-Sep-15,null,9-Nov-16,,,https://ClinicalTrials.gov/show/NCT02550379
NCT02547584,Impact of Anxiety on Cardiac Substrate Modification in Women With Atrial Fibrillation Undergoing Catheter Ablation,AWARE,Recruiting,No Results Available,Atrial Fibrillation,Procedure: Catheter ablation,Correlation between baseline anxiety score and prevalence of left atrial scar and non-pulmonary vein triggers|Correlation of baseline anxiety score with scar severity|Correlation of baseline TWBC and CRP level with the anxiety score|Change in CAQ score|Recurrence status|Change in HAD score|Change in State-anxiety,Texas Cardiac Arrhythmia Research Foundation,Female,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,152,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,TCAI_AWARE,Sep-15,Jul-18,Jul-19,11-Sep-15,null,19-Oct-17,"Texas Cardiac Arrhythmia Institute, St. david's Medical Center, Austin, Texas, United States",,https://ClinicalTrials.gov/show/NCT02547584
NCT02545634,Effects of a Probiotic Supplement on Symptoms of Attention Deficit Hyperactivity Disorder and Anxiety in Children,,Unknown status,No Results Available,Attention Deficit Hyperactivity Disorder|Anxiety,Dietary Supplement: L. helveticus R0052 and B. longum R0175|Other: Placebo,Change in ADHD-specific items of the Child Disruptive Behavior Disorders Scale|Change in Salivary cortisol|Change in total score on the Screen for Child Anxiety Related Emotional Disorders|Change in Word Pairs Memory Test|Change in Visual Memory Test|Change in total omission and commission errors on the Continuous Performance Task,Acadia University|Lallemand Health Solutions,All,6 Years to 14 Years   (Child),Phase 4,100,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",APB-C1,Jun-15,May-16,Jun-16,10-Sep-15,null,10-Sep-15,"Acadia University, Wolfville, Nova Scotia, Canada",,https://ClinicalTrials.gov/show/NCT02545634
NCT02546180,Improving Patient Understanding of the Surgical Hospital Experience: Use of YouTube Video Playlist,,Completed,No Results Available,Anxiety,Other: Viewing YouTube videos|Other: Standard preoperative education,Change in Generalized Anxiety Disorder (GAD) Score,Mayo Clinic,All,"Child, Adult, Older Adult",Not Applicable,65,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,IRB # 14-000084,Feb-14,May-14,May-14,10-Sep-15,null,10-Sep-15,,,https://ClinicalTrials.gov/show/NCT02546180
NCT02544295,Based-virtual Reality Diagnosis for Neuropsychiatric Diseases and Sleep/Wake Disorders,PHENOVIRTPSY,Unknown status,No Results Available,Aging|Addiction|Attention Deficit Disorder With Hyperactivity|Sleep Disorders|Anxiety|Depression|Attention Deficit,Behavioral: Clinical interview|Behavioral: Virtual reality task,Presence or absence of the disease|Sleepiness scale|BDI-II questionnaire|IDS-R questionnaire|Acceptability scale|ASRS|Physiological parameters: Polysomnography (total sleep time (min))|Physiological parameters: Polysomnography (sleep structure (stage %))|Physiological parameters: Polysomnography (Apnea/Hypopnea index and Periodic movements index (events/hr)),University of Bordeaux,All,"7 Years to 75 Years   (Child, Adult, Older Adult)",Not Applicable,590,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening,UBXS 2011-02|2011-A01418-33,Jan-12,Jan-19,Jan-19,9-Sep-15,null,9-Sep-15,"University Hospital of Bordeaux, Bordeaux, France",,https://ClinicalTrials.gov/show/NCT02544295
NCT02544607,Ketamine for Depression: An MRI Study,,Completed,Has Results,Depression|Anxious Depression|Major Depressive Disorder,Drug: Ketamine|Other: Magnetic Resonance Imaging (MRI),Change in Hamilton Depression Rating Scale (HDRS) From Baseline/Minute 0 to 4 Hours Post-infusion.|Percent Change in Tissue Fractional Anisotropy Quantification (Left Inferior Longitudinal Fasciculus)|Percent Change in Tissue Fractional Anisotropy Quantification (Right Inferior Longitudinal Fasciculus)|Percent Change in Tissue Fractional Anisotropy Quantification (Left Superior Longitudinal Fasciculus)|Percent Change in Tissue Fractional Anisotropy Quantification (Right Uncinate Fasciculus),Massachusetts General Hospital|Brain & Behavior Research Foundation|National Institutes of Health (NIH),All,18 Years to 64 Years   (Adult),Phase 4,25,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,2015P001912|24032,Mar-16,29-Dec-17,29-Dec-17,9-Sep-15,9-Mar-17,16-Apr-19,"Massachusetts General Hospital, Boston, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/07/NCT02544607/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02544607
NCT02542475,Low Field Magnetic Stimulation: Open Label Study.,,"Active, not recruiting",No Results Available,Mood Disorders|Anxiety,Device: Low Field Magnetic Stimulation,Changes in daily mood after LFMS treatment using the Beck Depression Inventory (BDI)|Change in mood after 5 days of LFMS treatment using the Hamilton Depression Rating Scale (HDRS),Mclean Hospital,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,40,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2015P001011,Sep-15,Aug-19,Aug-20,7-Sep-15,null,13-Apr-16,"McLean Hospital, Belmont, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT02542475
NCT02541812,"The Use of Magnetic Brain Stimulation to Treat Obsessive Compulsive Disorder, a Pilot Study",,Completed,No Results Available,Obsessive-Compulsive Disorder,Device: Transcranial Magnetic Stimulation,Change in obsessive and compulsive symptom severity (Yale-Brown Obsessive Compulsive Scale)|Change in performance on neurocognitive tests,University of Manitoba,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,20,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,B2009:077,Jul-11,Jun-15,Jun-15,4-Sep-15,null,4-Sep-15,,,https://ClinicalTrials.gov/show/NCT02541812
NCT02541968,Internet-based vs Face-to-face Cognitive Behavioural Therapy for Obsessive-compulsive Disorder,,Recruiting,No Results Available,Obsessive-compulsive Disorder,Behavioral: Cognitive-behavioral therapy (face-to-face)|Behavioral: Internet-based Cognitive-behavioral therapy|Behavioral: Internet-based Cognitive-behavioral therapy without therapist support,Yale-Brown Obsessive-Compulsive Scale (Y-BOCS)|Clinical Global Impression - Severity (CGI-S)|Global Assessment of Functioning (GAF)|Structured Clinical Interview for DSM-5 (SCID-5) obsessive-compulsive and related disorders Structured Clinical Interview for DSM-5 (SCID-5) obsessive-compulsive and related disorders|Yale-Brown Obsessive-Compulsive Scale - self-rated (Y-BOCS)|Obsessive-Compulsive Inventory - Revised (OCI-R)|Sheehan Disability Scale (SDS)|Montgomery-Åsberg Depression Rating Scale - self-rated (MADRS-S)|Euroqol (EQ-5D)|Clinical Global Impression - Improvement (CGI-I)|Insomnia Severity Index (ISI)|Treatment credibility scale|Satisfaction with treatment scale|TiC-P|Safety Monitoring Uniform Report Form (SMURF)|Patient EX/RP Adherence Scale (PEAS)|Working Alliance Inventory - short revised,Karolinska Institutet,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,120,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,OCD F2F vs ICBT,Aug-15,Dec-18,Mar-19,4-Sep-15,null,9-Aug-18,"Mottagningen för Tvångssyndrom, Huddinge, Sweden",,https://ClinicalTrials.gov/show/NCT02541968
NCT02539524,Effects of Yoga on Clinical Impact and Psychosocial Aspects of COPD,,Completed,No Results Available,Chronic Pulmonary Obstructive Disease,Other: Yoga bhastrika pranayama breathing exercise|Other: Pulmonary Rehabilitation,Changes in COPD Clinical Impact|Changes in Anxiety and Depression Scale|Changes in Quality of Life Questionnaire,University of Sao Paulo,All,"50 Years to 90 Years   (Adult, Older Adult)",Not Applicable,18,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,102838/2014,Jan-15,Nov-15,Dec-15,3-Sep-15,null,14-Sep-16,"Pulmonary and Rehabilitation Ambulatory of the Clinical Hospital of the University of São Paulo, São Paulo, Brazil",,https://ClinicalTrials.gov/show/NCT02539524
NCT02538549,Pilot RCT to Test Effectiveness of the ACE4 (Activity Challenge- 4 Areas) for Depression and Anxiety,,Unknown status,No Results Available,Anxiety Disorder; Mixed With Depression (Mild),Behavioral: ACE4,The Hospital Anxiety and Depression Scale (HAD)|The Clinical Outcome in Routine Evaluation (CORE)|Brief Disability Questionnaire (BDQ),Queen's University,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,120,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Health Services Research,6015291,Aug-15,Aug-16,Aug-16,2-Sep-15,null,2-Sep-15,"Addiction & Mental Health Services - Kingston Frontenac Lennox & Addington, Kingston, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT02538549
NCT02536924,RCT of RESOLVE: A Waiting Room Intervention for Crisis Clients,RESOLVE,Unknown status,No Results Available,Depression Anxiety Disorder,Behavioral: Waiting Room Intervention|Behavioral: Treatment as usual.,Hospital Anxiety and Depression Scale (HADS)|The Clinical Outcome in Routine Evaluation (CORE)|World Health Organization Disability Assessment Schedule 2.0 (WHODAS),Queen's University,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,140,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Health Services Research,6015290,Aug-15,Aug-16,Aug-16,1-Sep-15,null,1-Sep-15,"Addiction & Mental Health Services- Kingston Frontenac Lennox and Addington, Kingston, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT02536924
NCT02537093,﻿﻿Pilot Study of Asynchronous and Synchronous Telepsychiatry for Skilled Nursing Facilities,,Completed,No Results Available,Dementia|Depression|Mood Disorder|Anxiety Disorder|Substance Use Disorder,Behavioral: Psychiatric Consultation,Clinical Global Impression|Brief Interview for Mental Status (BIMS),"University of California, Davis",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,40,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,741223,Aug-15,May-17,May-17,1-Sep-15,null,11-Jul-17,"Norwood Pines Care Center, Sacramento, California, United States|Cottonwood Post-Acute Rehabilitation Center, Woodland, California, United States",,https://ClinicalTrials.gov/show/NCT02537093
NCT02537184,Impact of Two Recall Intervals on Dental Caries Incidence and Other Outcomes of Preschool Children,,Unknown status,No Results Available,Dental Caries|Quality of Life|Anxiety,Procedure: Oral Clinical conditions,Dental caries incidence|Level of anxiety|Oral health related quality of life|Time|Costs,University of Sao Paulo,All,3 Years to 5 Years   (Child),Not Applicable,224,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention,2014/17758-6,Sep-14,Aug-16,Aug-16,1-Sep-15,null,3-Sep-15,"Dental School of University of São Paulo, São Paulo, Brazil",,https://ClinicalTrials.gov/show/NCT02537184
NCT02535858,Virtual Environment With Biofeedback to Promote Awareness of Relapse Risk Among Chemically Dependent Individuals,,Completed,No Results Available,Anxiety,Device: Heart and respiratory rate and VE|Device: Heart and respiratory rate and video,Percentage of the variation in respiratory and heart rate.,University of Mogi das Cruzes,Male,20 Years to 50 Years   (Adult),Not Applicable,80,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,0094.0.237.000-07,Nov-07,Dec-07,May-08,31-Aug-15,null,31-Aug-15,"University of Mogi das Cruzes, Mogi das Cruzes, São Paulo, Brazil",,https://ClinicalTrials.gov/show/NCT02535858
NCT02534948,Feasibility Study of Mindfulness and Acceptance Based Group Therapy for Social Anxiety,MABT,Unknown status,No Results Available,Social Anxiety,Behavioral: Mindfulness and acceptance group therapy,Mini Social Phobia inventory,Bahria University,Female,18 Years to 28 Years   (Adult),Phase 1,32,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,MABT001,Oct-15,Aug-16,Sep-16,28-Aug-15,null,26-Jul-16,"Institute of Professional Psychology, Bahria University, Karachi, Sindh, Pakistan",,https://ClinicalTrials.gov/show/NCT02534948
NCT02535403,Internet-based Cognitive Behavioral Therapy (CBT) for Adolescents With Anxiety Disorders,,Completed,No Results Available,Anxiety Disorders,Behavioral: ICBT,"Change in The Anxiety Disorder Interview Schedule for DSM-IV, Parent and Child Versions (ADIS-IV c/p)|Change in Spence Child Anxiety Scale (SCAS-C/P)|Change in Children's Anxiety Life Inference Scale (CALIS)|Change in Self-Efficacy Questionnaire for Children (SEQ-c)|Change in the Short version of the Mood and Feelings Questionnaire (S-MFQ-c/p)|Change in WHO Quality of Life (5 items)|Change in Strength and Difficulties Questionnaire for Youth (SDQ)|Change in Working Alliance Inventory - Short form (WAI-S)|Experience of Service Questionnaire (ESQ)|Adherence to the program I|Adherence to the program II|Adherence to the program III|Adherence to the program IV|Parent support",University of Aarhus,All,13 Years to 17 Years   (Child),Not Applicable,70,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Chilled Out DK,Aug-15,Jul-16,Jul-16,28-Aug-15,null,27-Jan-17,"Aarhus University, Aarhus, Denmark",,https://ClinicalTrials.gov/show/NCT02535403
NCT02535429,"Massage Therapy for HIV-positive People : Effects on Anxiety, Depression, Hyperventilation and Quality of Life",,Completed,No Results Available,HIV-positive Diagnosis,Other: massage,Anxiety measured by Hospital anxiety and depression scale|Depression measured by Hospital anxiety and depression scale|Hyperventilation measured by NIJMEGEN questionnaire|quality of life measured by World Health Organization Quality of Life Questionnaire,Cliniques universitaires Saint-Luc- Université Catholique de Louvain,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,28,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care,HIV massage,Jul-15,Dec-15,Jul-16,28-Aug-15,null,12-Aug-16,"Clinique universitaire Saint-Luc, Brussels, Belgium",,https://ClinicalTrials.gov/show/NCT02535429
NCT02533310,Virtual Reality Immersive Method for Spider (Phobia) Exposure Therapy (VIMSE),VIMSE,"Active, not recruiting",No Results Available,"Phobia, Specific",Other: OST treatment with in-vivo spiders|Other: VR-OST treatment with virtual spiders,Behavioral Approach Test (BAT)|Spider Phobia Questionnaire 31 (SPQ-31)|Fear of Spiders Questionnaire 18 (FSQ-18)|Generalized Anxiety Disorder Assessment 7 (GAD-7)|Patient Health Questionnaire 9 (PHQ-9)|Brunnsviken Brief Quality of Life Scale (BBQ)|Diagnostic criteria for specific phobia according to interview (DSM-5),Stockholm University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,VIMSE,1-Aug-15,Dec-18,Jun-19,26-Aug-15,null,7-Mar-19,"Department of Psychology, Stockholm, Sweden",,https://ClinicalTrials.gov/show/NCT02533310
NCT02528331,Cognitive Behavioral Strategies and Transcranial Magnetic Stimulation in Obsessive-Compulsive Disorder: Open Label Study,CBT-TMS,Terminated,Has Results,Obsessive Compulsive Disorder (OCD),Device: Transcranial magnetic stimulation|Behavioral: Cognitive behavioral therapy,"Remission Rate, as Measured by Y-BOCS|Complete Response, as Measured by Y-BOCS|Partial Response Rate, as Measured by Y-BOCS|Percentage of Adverse Events",Duke University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,2,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label),Pro00047168,Mar-16,Jul-16,Aug-16,19-Aug-15,9-Feb-17,9-Feb-17,"Duke University Medical Center, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT02528331
NCT02519725,Impact of an ICU Diary on the Well-being of Patients and Families. A Prospective Multicenter Mixed Study,ICU-diary,Completed,No Results Available,Stress Disorders Post Traumatic,Other: ICU diary,Post traumatic stress disorder symptoms in patients|Post traumatic stress disorder symptoms in families|Anxiety and depression related symptoms in patients|Anxiety and depression related symptoms in families|Recollection of the memories of the ICU stay by the patient,Groupe Hospitalier Paris Saint Joseph|Fondation de France,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,715,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,ICU DIARY,11-Jun-15,2-Feb-17,9-Aug-17,11-Aug-15,null,12-Mar-18,"Medical and surgical Intensive Care unit, Paris, France",,https://ClinicalTrials.gov/show/NCT02519725
NCT02520271,Ostrobothnia Depression Study (ODS). A Naturalistic Follow-up Study on Depression and Related Substance Use Disorders,ODS,Completed,No Results Available,Major Depression|Dual Diagnosis|Anxiety Disorders|Substance Related Disorders,Behavioral: Behavioral Activation|Behavioral: Motivational Interview,"Change in severity of depressive symptoms from baseline at 6 weeks, 6 months, 12 months, and 24 months|Change in quality of life from baseline at 6 weeks, 6 months, 12 months, and 24 months|Change in number of weekly consumed alcohol drinks from baseline at 6 weeks, 6 months, 12 months, and 24 months|Change in severity of alcohol use from baseline at 6 weeks, 6 months, 12 months, and 24 months",Seinajoki Central Hospital|Tampere University,All,"17 Years to 65 Years   (Child, Adult, Older Adult)",Not Applicable,242,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,EVO1114,Oct-09,Oct-13,Jun-14,11-Aug-15,null,13-Aug-15,"Seinäjoki Hospital District, Seinäjoki, South Ostrobothnia, Finland",,https://ClinicalTrials.gov/show/NCT02520271
NCT02518308,Mindfulness Intervention in Reducing Anxiety in Patients Who Have Been Treated for Gynecologic Cancer,,"Active, not recruiting",No Results Available,Anxiety|Cancer Survivor|Cognitive Impairment|Depression|Distress|Fatigue|Malignant Female Reproductive System Neoplasm|Pain|Sexual Dysfunction,Behavioral: Mindfulness-Based Stress Reduction,Change in anxiety|Change in depression|Change in fatigue|Change in sleep disturbance|Change in sexual function|Change in existential/spiritual distress|Change in cognitive function|Change in cortisol levels|Change in levels of pro-inflammatory cytokines|Change in immune cell phenotypes|Change in NK cell function,"University of Wisconsin, Madison",Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,38,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Supportive Care,UW15000,2-Oct-15,4-May-19,4-May-19,7-Aug-15,null,7-Jan-19,"University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT02518308
NCT02516332,Exercise and Pharmacotherapy for Anxiety in Cardiac Patients,,Recruiting,No Results Available,Anxiety|Cardiovascular Disease,Drug: Lexapro|Drug: Placebo|Behavioral: Supervised Aerboic Exercise,"Change in Hospital Anxiety and Depression Scale, Total Score|Change in Heart Rate Variability, SDNN (msec)|Change in Baroreflex Sensitivity, ms/mm Hg|Change in Vascular Endothelial Function, % dilation|Change in Inflammation (C-Reactive Protein, ug/ml)|Change in Urinary Catecholamines (epinephrine and norepinephrine, pg/ml)|Change in Lipids (total cholesterol, LDL, and HDL; mg/dL)",Duke University,All,"40 Years and older   (Adult, Older Adult)",Not Applicable,150,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Pro00064329,Dec-15,Jul-20,Jul-20,5-Aug-15,null,28-Mar-19,"Duke University Medical Center, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT02516332
NCT02511392,Repetitive Transcranial Magnetic Stimulation in the Treatment of Obsessive Compulsive Disorders,rTMS-OCD,Completed,No Results Available,Obsessive Compulsive Disorders,Procedure: rTMS-1Hz|Procedure: rTMS-10 Hz|Procedure: Sham rTMS,changes of Y-BOCS|Changes in HAM-A score|Changes in CGI-S score,Assiut University,All,20 Years to 50 Years   (Adult),Not Applicable,45,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",rTMS-OCD,Jan-14,Jul-15,Jul-15,30-Jul-15,null,30-Jul-15,,,https://ClinicalTrials.gov/show/NCT02511392
NCT02510391,Modular Treatment for Preschool Anxiety,,Recruiting,No Results Available,Anxiety,Behavioral: PIPA,Anxiety Improvement as assessed by Clinical Global Impression- Improvement (CGI-I)|Key Child Problems as assessed by Top Problems Assessment (TPA)|Child Diagnostic Presence as measured by the Schedule for Affective Disorders and Schizophrenia for School-Age Children (K-SADS)|Anxiety Severity as measured by the Clinical Global Impression- Severity (CGI-S),Adam Lewin|Johns Hopkins All Children's Hospital|University of South Florida,All,3 Years to 7 Years   (Child),Not Applicable,60,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ACH-Preschool 2015,Oct-15,Sep-19,Dec-19,29-Jul-15,null,3-May-18,"Rothman Center for Pediatric Neuropsychiatry, Saint Petersburg, Florida, United States",,https://ClinicalTrials.gov/show/NCT02510391
NCT02511210,Regional Anesthesia / Peripheral Nerve Block and General Anesthesia on Preoperative Anxiety,,Unknown status,No Results Available,Anxiety Disorders,Behavioral: regional anesthesia|Behavioral: general anesthesia,State-Trait Anxiety Inventory scores in patients undergoing regional anesthesia|State-Trait Anxiety Inventory scores in operating rooms|Amsterdam Preoperative Anxiety and Information Scale scores in operating rooms|Amsterdam Preoperative Anxiety and Information Scale scores in patients undergoing regional anesthesia,Cukurova University|Erzincan University,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,500,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,erzincan university,Jun-15,Dec-15,Dec-15,29-Jul-15,null,29-Dec-15,"Mengucek Gazi Training and Research Hospital, Erzincan, Merkez, Turkey",,https://ClinicalTrials.gov/show/NCT02511210
NCT02506673,Audiovisual Aid Pilot Study,,Completed,No Results Available,"Stress, Psychological","Device: Zeiss, Cinema ProMED (audiovisual equipment)|Drug: Midazolam|Device: Skin Conductance Monitor",Skin conductance response|Heart rate|Blood pressure|Respiratory rate|Number of requests for additional sedation|Pain numerical rating scale (NRS) levels|Narcotic consumption|State-Trait Anxiety Inventory Questionnaire (STAI)|Heidelberg Peri-anaesthetic Questionnaire|CSQ-8 Questionnaire|Provider Feedback|Requests for sedation/termination of audiovisual aids|Incidence of complications,"Hospital for Special Surgery, New York",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,26,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2014-394,14-Jan-16,May-17,Jul-17,23-Jul-15,null,12-Mar-18,"Hospital for Special Surgery (HSS), New York, New York, United States",,https://ClinicalTrials.gov/show/NCT02506673
NCT02504515,"Effect of Homeopathy, Acupuncture or Anthroposophic Medicine in Women's Quality of Life",,Unknown status,No Results Available,Anxiety|Depression|Premenstrual Tension|Hot Flashes|Muscular Diseases,Other: World Health Organization Quality of Life Bref Questionnaire,Quality of life,Federal University of Minas Gerais|Conselho Nacional de Desenvolvimento Científico e Tecnológico,Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,906,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,22858113.9.0000.5149,Apr-15,Dec-17,Dec-17,22-Jul-15,null,3-May-17,"Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil",,https://ClinicalTrials.gov/show/NCT02504515
NCT02505984,Preventing Postpartum Depression With Intranasal Oxytocin,IN-OXT,Recruiting,No Results Available,"Depression, Postpartum|Anxiety",Drug: Oxytocin|Drug: Placebo,Treatment effect on mother-infant bonding|Change in depression symptoms|Change in anxiety symptoms|Child development,Massachusetts General Hospital|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Female,18 Years to 50 Years   (Adult),Phase 2,90,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",2015P001100|224421|225686|1R21HD090396-01A1,Oct-15,Jun-19,Dec-19,22-Jul-15,null,6-Mar-19,"Massachusetts General Hosptial, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT02505984
NCT02500888,Evaluation of Capsulotomy by Linear Accelerator Radiosurgery in Severe and Refractory Obsessive-compulsive Disorder,,Recruiting,No Results Available,OCD|Quality of Life,Radiation: Radiosurgery,Change in OCD symptoms|Change in quality of life.|Change in brain-derived neurotrophic factor (BDNF) blood dosing|Change in psychological tests|Side effects and complications|Change in familial accommodation|Change in anxiety symptoms.|Change in depressive symptoms.|Change in near-infrared spectroscopy (NIRS) brain blood flow|Change in Global Functioning,Hospital de Clinicas de Porto Alegre,All,18 Years to 55 Years   (Adult),Not Applicable,10,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,14-0341,30-Jun-15,30-Jun-19,30-Jun-19,17-Jul-15,null,13-Mar-18,"Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil",,https://ClinicalTrials.gov/show/NCT02500888
NCT02499250,Effect of Daily Remote Ischemic Conditioning on the Life Quality of Refractory Angina Pectoris Patients,D-RIC-RAP,Unknown status,No Results Available,Refractory Angina Pectoris,Device: remote ischemic conditioning (TDFT-12-A2)|Drug: Optimal medical treatment,Frequencies of angina pectoris onset|Canadian Cardiovascular Society Angina Class|Flow mediated vasodilation in percentage increase|Flow mediated vasodilation in absolute increase|Self-Rating Anxiety Scale|Self-Rating Depression Scale|Inflammatory cytokines expression|Grip strength|Skin and muscle abnormalities|Circulating CD34+ progenitor cells,"Navy General Hospital, Beijing",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,30,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,HZKY-PJ-2014-1-A,Jan-15,Jun-16,Jan-17,16-Jul-15,null,16-Jul-15,"Heart Center, Navy General Hospital of PLA, Beijing, Beijing, China",,https://ClinicalTrials.gov/show/NCT02499250
NCT02498392,"An Efficacy, Safety and Tolerability Study of JNJ-42165279 in Participants With Major Depressive Disorder With Anxious Distress",,Completed,No Results Available,Depressive Disorder|Anxiety,Drug: JNJ-42165279|Other: Placebo,Change from Baseline to Endpoint on the Hamilton Depression Rating Scale (HDRS17) Total Score|Change from Baseline to Endpoint on the Hamilton Anxiety Rating scale (HAM-A6) Score|Change from Baseline to Endpoint on the SIGH-A (Structured Interview Guide of the Hamilton Anxiety Scale 14-item HAM-A) Total Score|Change from Baseline to Endpoint on the Hamilton Anxiety Rating scale (HAM-D6) Score|Change from Baseline to Endpoint in the Hamilton Depression Rating Scale (HDRS17) Anxiety/Somatization Factor Total Score|Number of Participants with a Hamilton Depression Rating Scale (HDRS17) Anxiety/Somatization Factor Score Greater than or equal to 7 at Week 6|Maximum Plasma Concentration (Cmax) of JNJ-42165279|Time to Reach the Maximum Plasma Concentration (Tmax) of JNJ-42165279|Area Under the Plasma Concentration-time Curve From Time Zero to Dosing Interval [AUC(0-t)],"Janssen Research & Development, LLC",All,18 Years to 64 Years   (Adult),Phase 2,161,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",CR107733|2015-002007-29|42165279MDD2001,7-Oct-15,4-Feb-19,4-Feb-19,15-Jul-15,null,5-Mar-19,"Costa Mesa, California, United States|Oceanside, California, United States|Miami, Florida, United States|Natick, Massachusetts, United States|Cedarhurst, New York, United States|Raleigh, North Carolina, United States|Allentown, Pennsylvania, United States|Salt Lake City, Utah, United States|Chisinau, Moldova, Republic of|Ekaterinburg, Russian Federation|Orenburg, Russian Federation|Saratov, Russian Federation|St-Petersburg, Russian Federation|Tomsk, Russian Federation|Alicante, Spain|Barcelona, Spain|Bilbao, Spain|Sant Boi De Llobregat, Spain|Zamora, Spain|Glevakha, Ukraine|Kharkiv, Ukraine|Kherson, Ukraine|Kyiv, Ukraine|Lviv, Ukraine|Smila, Ukraine|Uzhgorod, Ukraine|Barnsley, United Kingdom|Blackpool, United Kingdom|Liverpool, United Kingdom|Manchester, United Kingdom|South Staffordshire, United Kingdom|Stourton, United Kingdom",,https://ClinicalTrials.gov/show/NCT02498392
NCT02499055,A Randomised Feasibility Trial With Internet Based Self-help Therapy,IBT,Unknown status,No Results Available,Anxiety,Behavioral: FearFighter,Fractions of participants that are eligible and can be randomised|Fraction of participants randomised to the experimental group that will comply with the experimental intervention|Proportion of participants who fulfil the diagnostic criteria for an anxiety disorder at the end of the intervention measured with 'Mini International Neuropsychiatric Interview' (M.I.N.I.)|Symptoms: Beck Anxiety Inventory (BAI)|Symptoms: Symptom check list-90R (SCL-90R)|Functionality: Sheehan Disability Scale (SDS)|Quality of life: WHO Well-Being Index|Serious adverse events (SAE),"Mental Health Services in the Capital Region, Denmark|Copenhagen Trial Unit, Center for Clinical Intervention Research|TrygFonden, Denmark|Student Counselling Service, Denmark",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,64,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,FearFighter-RHP2015,Aug-15,Dec-16,Dec-17,15-Jul-15,null,12-Oct-16,"Psychotherapy Center Stolpegård, Mental Health Services in the Capital Region of Denmark, Gentofte, Capital Region, Denmark",,https://ClinicalTrials.gov/show/NCT02499055
NCT02496533,Patient Anxiety During Radiological Examination,,Completed,Has Results,Anxiety,Procedure: Hand Massage,Change in Anxiety as Measured by Visual Analog Scale|Change in Blood Pressure in mmHg|Change in Respiration Rate in Breaths Per Minute|Change in Pulse Rate,Midwestern Regional Medical Center,All,"18 Years and older   (Adult, Older Adult)",Phase 2,217,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention,MRMC14-14,Feb-14,Jan-15,Jan-15,14-Jul-15,29-Nov-16,30-Jan-17,,,https://ClinicalTrials.gov/show/NCT02496533
NCT02497755,Connection to Care: Pilot Study of a Mobile Health Tool for Patients With Depression and Anxiety,,Completed,Has Results,Anxiety|Depression,Behavioral: App for smartphone|Device: smartphone,App Acceptability as Measured by Number of Patient App Users Who Rate App Easy to Use and Time Spent Reasonable|App Acceptability as Measured by Number of Care Manager Dashboard Users Who Rate Dashboard Easy to Use and Time Spent Reasonable|App Usefulness as Measured by Number of Patient App Users Who Rate App as Useful|App Usefulness as Measured by Number of Care Manager Dashboard Users Who Rate Dashboard as Useful|Technology Acceptability as Measured by the Obtrusiveness Scale for Pervasive Technology (Modified)|Patient Satisfaction as Measured by the Ginger.io Product Feedback Survey.|Patient Use of the App as Measured by Percentage of App Surveys Completed.|Care Team Communication as Measured by the Consumer Assessment of Healthcare Providers and Systems (CAHPS) - Communication Scale|Care Process Measures as Measured by the Number and Type of Contacts With Care Manager.,University of Washington,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,18,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,47871,Jul-15,Oct-15,Oct-15,14-Jul-15,2-Dec-17,2-Dec-17,"University of Washington Neighborhood Clinic, Ravenna, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT02497755
NCT02493010,Arousal Training for Social Anxiety Disorder,,Completed,No Results Available,Social Anxiety,Device: Arousal-based biofeedback system,"Change in Liebowitz Social Anxiety Scale scores from Week 0 to Week 5|Satisfaction and Immersion Questionnaire|Safety Measure: After each intervention session (once a week), participants will be queried on whether they have experienced any physical or psychological adverse events during the study|Change in Fear of Negative Evaluation-Brief (FNE-B) scores|Change in Self-Statements during Public Speaking (SSPS) scores|Change in Public Speaking Anxiety Scale scores from Week 0 to Week 5","Duke-NUS Graduate Medical School|Agency for Science, Technology and Research|Singapore General Hospital",All,21 Years to 35 Years   (Adult),Not Applicable,50,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,B-14-098,Feb-16,Jul-17,Jul-17,9-Jul-15,null,19-Dec-17,"Duke-NUS Graduate Medical School, Singapore, Singapore",,https://ClinicalTrials.gov/show/NCT02493010
NCT02491307,Ginger.io Behavioral Health Study,,Terminated,No Results Available,Anxiety|Depression|Bipolar I Disorder|Bipolar II Disorder,Other: Ginger.io Smartphone Application,Emergecny room and hospitalization Data|Service Utilization|Patient activation/self-management|Patient perceived physical health status|Patient perceived mental health status|Patient satisfaction/connectedness|Behavioral Health provider satisfaction|Behavioral health provider effectiveness score|Progress towards treatment goals,"Community Health Center, Inc.|Ginger.io|Robert Wood Johnson Foundation",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,10,Industry|Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,1059,Jul-15,Oct-15,Oct-15,8-Jul-15,null,25-Apr-17,"Community Health Center, Inc.-Meriden, Meriden, Connecticut, United States|Community Health Center, Inc.- Middletown, Middletown, Connecticut, United States|Community Health Center, Inc.-New Britain, New Britain, Connecticut, United States|Community Health Center, Inc.-New London, New London, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT02491307
NCT02490995,Inform and Reduce Pre-surgical Anxiety of the Child and His Parents: Interest of an Explanatory Movie.,,Unknown status,No Results Available,Anxiety Linked to the Surgery and / or Anesthesia,Other: Movie,The Yale Preoperative Anxiety Scale (m-YPAS)|Induction Compliance Checklist (ICC)|The agitation in recovery room,"University Hospital, Montpellier",All,up to 12 Years   (Child),Not Applicable,150,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Supportive Care,9392|2014-A00416-41,Nov-14,Dec-16,Dec-16,7-Jul-15,null,7-Jul-15,"Montpellier university hospital, Montpellier, France",,https://ClinicalTrials.gov/show/NCT02490995
NCT02489812,Music Distraction Strategy in Children Dental Care,,Completed,No Results Available,Children Behavior,Behavioral: Music,Number of participants|Composite measure of Cardiac and respiratory frequencies using a pulse oximeter,Federal University of Minas Gerais,All,4 Years to 6 Years   (Child),Phase 4,34,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,UFMG,Mar-14,Oct-14,Apr-15,3-Jul-15,null,7-Jul-15,,,https://ClinicalTrials.gov/show/NCT02489812
NCT02490189,Mindfulness-based Intervention Versus CBT for Social Anxiety Disorder,,Completed,No Results Available,Social Anxiety Disorder,Behavioral: Mindfulness-based Intervention|Behavioral: Cognitive Behavior Group Therapy,Liebowitz Social Anxiety Scale|Social Phobia Inventory|Clinical Global Impression Improvement Ratings|Beck Depression Inventory|Social Adjustment Scale-Self Report Revised|Rosenberg Self-Esteem Scale|Satisfaction with Life Questionnaire,Hopital Montfort|Ontario Mental Health Foundation|University of Ottawa,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,97,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,DK-27-02-15,25-Jul-15,15-Dec-17,21-Feb-18,3-Jul-15,null,21-Feb-18,"Hopital Montfort, Ottawa, Ontario, Canada|Montfort Hospital, Ottawa, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT02490189
NCT02490280,Examining Cortisol and Alpha Amylase in a Healthy Sample of Youth and Adults,,Completed,No Results Available,Anxiety,Behavioral: Trier Social Stress Test,"Anxiety Disorders Interview Schedule for Diagnostic and Statistical Manual for Psychological Disorders-IV, Child and Parent Versions (C/P-ADIS), and Adult Versions (Client-ADIS)",Johns Hopkins University|National Institute of Mental Health (NIMH),All,"11 Years to 34 Years   (Child, Adult)",Not Applicable,50,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label),NA00083366|1K24MH096760-01A1,Apr-13,Apr-15,Apr-15,3-Jul-15,null,3-Jul-15,"Johns Hopkins School of Medicine, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT02490280
NCT02482805,Hormones and Social Anxiety Disorder Treatment,,Completed,Has Results,Social Anxiety Disorder,Behavioral: Cognitive Behavioral Therapy,LSAS-performance Subscale|Subjective Units of Distress Scale (SUDs)|Salivary Testosterone Levels,University of Texas at Austin,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,73,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,SAD - Hormones,Jul-15,Dec-16,Apr-17,26-Jun-15,16-Oct-17,24-Nov-17,"University of Texas at Austin, Austin, Texas, United States",,https://ClinicalTrials.gov/show/NCT02482805
NCT02483338,FASS (Facial Action Summary Score) Scale to Differentiate the Pain of Postoperative Anxiety in Children Under 7 Years,FASS,Unknown status,No Results Available,Postoperative Pain,Behavioral: Assessment of pain,FASS (Facial Action Summary Score),"University Hospital, Montpellier",All,up to 7 Years   (Child),Not Applicable,150,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,8824|2011-A00533-38,Jul-11,Dec-15,Dec-15,26-Jun-15,null,9-Jul-15,"University hospital Lapeyronie, Montpellier, France",,https://ClinicalTrials.gov/show/NCT02483338
NCT02480257,"UCSF TARA Study: Training for Awareness, Resilience and Action",,Completed,No Results Available,Depression|Anxiety,Behavioral: TARA,"Reynolds Adolescent Depression Scale (RADS-2)|Multidimensional Anxiety Scale for Children (MASC)|Children's Depression Rating Scale, Revised (CDRS-R)|Insomnia Severity Index (ISI)|Affective Reactivity Index (ARI)|The Avoidance and Fusion Questionnaire for Youth (AFQ-Y8)|Child and Adolescent Mindfulness Measure (CAMM)|Dot-Probe Attention Task","University of California, San Francisco|Edgewood Center for Children and Families",All,"14 Years to 18 Years   (Child, Adult)",Not Applicable,26,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,13-12380,Jan-14,Dec-15,Dec-15,24-Jun-15,null,14-Jun-17,"UCSF Osher Center for Integrative Medicine, San Francisco, California, United States",,https://ClinicalTrials.gov/show/NCT02480257
NCT02478593,Impact of Patient Education on Benzodiazepine Use in the Elderly,,Unknown status,No Results Available,Anxiety|Insomnia,Behavioral: Educational booklet,Benzodiazepine or non-benzodiazepine hypnotic medication use|Patient attempt to discontinuing benzodiazepine|Patient knowledge regarding benzodiazepines|Belief about Medicines Questionnaire (BMQ),University of Vermont,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,500,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Health Services Research",485,Jun-15,Jan-17,Jan-17,23-Jun-15,null,12-May-16,,,https://ClinicalTrials.gov/show/NCT02478593
NCT02476370,Effects of Preoperative Relaxation and Intensified Surgery Education in Patients Undergoing Herniotomy,MBM_Hernio,Unknown status,No Results Available,"Hernia, Inguinal|Anxiety|Postoperative Pain",Behavioral: relaxation program|Behavioral: surgery education,preoperative anxiety (State Anxiety (STAI-S)|postoperative pain intensity (numeric rating scale)|preoperative anxiety Trait Anxiety (STAI-T)|preoperative anxiety Amsterdam Preoperative Anxiety and Information Scale (APAIS)|preoperative anxiety Anaesthesia- and Surgery-dependent Preoperative Anxiety (ASPA)|postoperative disability|postoperative fatigue Fatigue measured by 0-10 Numeric Rating Scale|postoperative nausea Nausea measured by 0-10 Numeric Rating Scale|postoperative complications|Satisfaction with care|Satisfaction with interventions,Universität Duisburg-Essen,Male,"18 Years and older   (Adult, Older Adult)",Not Applicable,108,Other,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention",14-6060-BO MBM_Hernio,Jun-15,Jun-17,Jun-17,19-Jun-15,null,25-May-17,"Abteilung für Allgemein-, Viszeral-, Gefäßchirurgie und Koloproktologie, Johanniter-Krankenhaus Rheinhausen, Duisburg, Germany",,https://ClinicalTrials.gov/show/NCT02476370
NCT02472483,"Effectiveness of TCC Followed by MBCT and Predictive Factors (Genetic, Clinical and Cognitive) Response",TCC-MBCT,Recruiting,No Results Available,Bipolar Disorder|Anxious Disorder|Alcohol Dependence,Behavioral: Cognitive and Behavior Therapy (CBT)|Behavioral: Mindfulness Based Cognitive Therapy (MBCT),Number of relapses (for bipolar disorders)|Number of hospitalizations (for bipolar disorders)|Number of days in an episode (for bipolar disorders)|Anxious symptomatology|Maniac symptomatology|Depressive symptomatology|Genetic polymorphisms,Centre Hospitalier St Anne,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,672,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,D470,13-Sep-12,Apr-19,Sep-19,16-Jun-15,null,20-Oct-17,"Centre Hospitalier Sainte Anne, Paris, France",,https://ClinicalTrials.gov/show/NCT02472483
NCT02473523,"Yoga to Alleviate Fatigue, Anxiety and Pain in Adolescents During Treatment for Lymphoma or Leukemia",,Terminated,Has Results,"Leukemia|Hodgkin Lymphoma|Lymphoma, Non-Hodgkin's",Other: PedsQL Cancer Module|Other: PedsQL Multidimensional Fatigue Scale|Device: Biodex System 3 Dynamometer|Device: Jamar Hydraulic Hand Dynamometer|Other: Sit and Reach Test|Other: Test of Motor Proficiency|Other: Verbal Numeric Pain Scale|Other: :Yoga Therapy,Rate of Patients Who Are Willing to Participate|Rate of Patients Who Complete the Study,St. Jude Children's Research Hospital,All,13 Years to 17 Years   (Child),Not Applicable,2,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,YOGAOT|NCI-2015-00975,Jun-15,Dec-16,Dec-16,16-Jun-15,8-Mar-17,8-Mar-17,"St. Jude Children's Research Hospital, Memphis, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT02473523
NCT02470130,Relaxation Before Debriefing and Memorization in High Fidelity Simulation in Healthcare,RELAXSIMHF,Completed,No Results Available,Anxiety,Behavioral: relaxation,memorization of the active scenario|anxiety|debriefing|observing|memorization of the passive scenario,Claude Bernard University,All,"Child, Adult, Older Adult",Not Applicable,150,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,CLESS 2014,Oct-14,Mar-16,Mar-16,12-Jun-15,null,7-Jul-16,"CLESS, Lyon, Rhône-Alpes, France",,https://ClinicalTrials.gov/show/NCT02470130
NCT02469545,Effect of Lactobacillus Plantarum 299v Supplementation on Major Depression Treatment,,Completed,No Results Available,Depression|Anxiety Disorder,Drug: Lactobacillus Plantarum 299v|Drug: Crystalline cellulose powder|Drug: Escitalopram|Drug: Sertraline,Evaluation of psychometric parameters - Change in Hamilton Depression Rating Scale from baseline at 3 weeks and 8 weeks of the study.|Evaluation of psychometric parameters - Change in Perceived Stress Scale (PSS-10) from baseline at 3 weeks and 8 weeks of the study.|Evaluation of psychometric parameters - Change in Symptom Checklist 90 Scale (SCL-90) from baseline at 3 weeks and 8 weeks of the study.|Cognitive functions evaluation - California Verbal Learning Test (CVLT)|Cognitive functions evaluation - Ruff Figural Fluency Test (RFFT)|Cognitive functions evaluation - Stroop Test (A and B)|Cognitive functions evaluation - Connecting Points Test (A and B)|Cognitive functions evaluation - Attention and Perceptivity Test|Biochemical analysis - morning cortisol level|Biochemical analysis - cytokines measurements profile|Biochemical analysis - kynurenic pathway metabolites measurements profile,Medical University of Bialystok,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,60,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",133-47818,Jun-14,Mar-16,Mar-16,11-Jun-15,null,7-Sep-18,"Department of Psychiatry, Medical University of Bialystok, Bialystok, Poland",,https://ClinicalTrials.gov/show/NCT02469545
NCT02467374,Fear Extinction and Mechanisms of Change in Obsessive Compulsive Disorder,,Recruiting,No Results Available,Obsessive Compulsive Disorder,Behavioral: Behavior Therapy,Obsessive compulsive symptoms as measured by Yale-Brown Obsessive Compulsive Scale (Y-BOCS),Massachusetts General Hospital,All,18 Years to 60 Years   (Adult),Not Applicable,40,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,2014P002325,Dec-14,Sep-19,Sep-19,10-Jun-15,null,15-Feb-19,"Massachusetts General Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT02467374
NCT02467517,Ketamine and Neuropathic Pain,KETAPAIN,Unknown status,No Results Available,Neuropathic Pain,Drug: Ketamine|Drug: Magnesium Sulfate|Drug: placebo : sodium chloride,Numerical rating scale (NRS)|Intensity of the average|Intensity of maximum daily pain|Impact on quality of life|Impact on mood|Impact on sleep,"University Hospital, Clermont-Ferrand",All,"18 Years and older   (Adult, Older Adult)",Phase 2,22,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",CHU-0235,Nov-15,Mar-18,Apr-18,10-Jun-15,null,29-Jul-16,"CHU de Clermont-Ferrand, Clermont-Ferrand, France",,https://ClinicalTrials.gov/show/NCT02467517
NCT02468050,Study of Exercise to Manage Distress During Breast Screening,,Completed,No Results Available,Breast Cancer|Anxiety|Depression,Behavioral: Moderate intensity exercise training|Behavioral: Self Management of exercise,Symptoms of anxiety will be assessed using patient reported anxiety inventory|Symptoms of subclinical depression will be assessed using a patient reported inventory|Exercise behaviour will be assessed using a patient reported inventory|Body composition: Dual X-Ray Absorptiometry scan (GE Lunar iDXA)|Self Efficacy: patient reported inventory assessing efficacy for self management of exercise|Optimism: patient reported inventory assessing dispositional optimism|Symptoms of dispositional anxiety will be assessed using patient reported anxiety inventory,"University of Western Ontario, Canada",Female,"18 Years to 69 Years   (Adult, Older Adult)",Phase 2,7,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,17796,Feb-12,Feb-14,Feb-14,10-Jun-15,null,10-Jun-15,"Exercise and Health Psychology Laboratory, Western University, London, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT02468050
NCT02465892,Pillars4Life Trial,Pillars4Life,Completed,No Results Available,Breast Cancer|Lung Cancer|Esophageal Cancer|Colon Cancer|Pancreatic Cancer|Liver Cancer|Renal Cancer|Bladder Cancer|Prostate Cancer|Ovarian Cancer|Cervical Cancer|Uterine Cancer,Behavioral: Pillars4Life,Chronic pain|Stress|Anxiety,Duke University|Pfizer,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,284,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Supportive Care,Pro00061381,May-15,Oct-16,Oct-16,9-Jun-15,null,2-Jul-17,"Duke University Medical Center, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT02465892
NCT02467218,HBOT in Fibromyalgia,,Completed,No Results Available,Fibromyalgia|Chronic Pain,Other: Hyperbaric Oxygen Treatment,Number of participants finishing the study protocol|Number of participants experiencing intervention related adverse events,"University Health Network, Toronto",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,16,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,14-7888-A,Nov-15,Aug-17,Dec-18,9-Jun-15,null,17-May-19,"University Health Network, Toronto, Ontario, Canada|Mount Sinai Hospital, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT02467218
NCT02464293,A Pilot Evaluation of Mindfulness-based Cognitive Therapy for People With Huntington's Disease,,"Active, not recruiting",No Results Available,Huntington Disease,Other: Mindfulness-based cognitive therapy,depression post intervention|depression at 3 months|depression at 1 year|depression mid-course|anxiety mid-course|anxiety post intervention|anxiety at 3 months|anxiety at 1 year|stress mid course|stress post intervention|stress at 3 months|stress at 1 year|mindfulness mid-course|mindfulness post intervention|mindfulness at 3 months|mindfulness at 1 year|sleep post intervention|sleep at 3 months|sleep at 1 year|quality of life post intervention|quality of life at 3 months|quality of life at 1 year|positive affect post intervention|positive affect at 3 months|positive affect at 1 year|coping post intervention|coping at 3 months|coping at 1 year|relationship satisfaction at 3 months|relationship satisfaction at 1 year|carer burden at 3 months|carer burden at 1 year,Lancaster University|Manchester University NHS Foundation Trust,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,16,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EHDN Seed Fund Project 561|15/NW/0238,Jun-15,Dec-17,May-18,8-Jun-15,null,2-Jun-17,"Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom",,https://ClinicalTrials.gov/show/NCT02464293
NCT02462642,Effect of Bacopa Monniera Extract on Cognition and Anxiety and Exploration of PK Properties,Yaaddasht,Completed,No Results Available,Cognition|Anxiety|Pharmacokinetics,Dietary Supplement: Brahmi|Other: Placebo,"Change in Delayed recall from Baseline at day 0 to post intervention at day 84|Total learning, change between baseline at day 0 to post intervention at day 84|Pro-active interference, change between baseline at day 0 to post intervention at day 84|Retro-active interference, change between baseline at day 0 to post intervention at day 84|Inspection Time, change between baseline at day 0 to post intervention at day 84|Reaction time, correct responses, change between baseline at day 0 to post intervention at day 84|Reaction time, errors, change between baseline at day 0 to post intervention at day 84|Interference, change between baseline at day 0 to post intervention at day 84|State, change between baseline at day 0 to post intervention at day 84|Trait, change between baseline at day 0 to post intervention at day 84|Absorption constant|Tmax|T1/2|Metabolites",Unilever R&D|St. John's Research Institute,All,35 Years to 60 Years   (Adult),Not Applicable,84,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care",08068B,Mar-10,Jul-10,Jul-10,4-Jun-15,null,4-Jun-15,"St Johns Research Institute, Bangalore, Karnataka, India",,https://ClinicalTrials.gov/show/NCT02462642
NCT02463136,Fmri-based Neurofeedback With Anxious Adolescents Study,NF-AA,Unknown status,No Results Available,Anxiety,Behavioral: questionnaires|Device: Functional magnetic resonance imaging w neurofeedback,"Proof of concept for using NF in anxious adolescents|Improved emotion regulation skills (questionnaires, behavioural tasks)|Successful reduction in anxious mood (questionnaire)|Demographics (Demographic questionnaire)|Thought control abilities (questionnaire)|IQ levels (Wechsler Abbreviated Intelligence Scale)|Emotion regulation skills (Cognitive Emotion Regulation Questionnaire)|Mood and feelings (Moods and feelings questionnaire)|Debriefing interview questionnaire",University of Oxford|King's College London|Cardiff University,Female,14 Years to 17 Years   (Child),Phase 1,50,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,MSD-IDREC-C2-2013-014,Nov-15,Oct-17,Oct-17,4-Jun-15,null,10-Nov-16,"University of Oxford, Oxford, Oxfordshire, United Kingdom",,https://ClinicalTrials.gov/show/NCT02463136
NCT02463903,Coping Effectiveness Training in Patients With Chronic Heart Failure,,Completed,No Results Available,Heart Failure,Behavioral: Coping Effectiveness Training (CET),Emotional well-being (Composite measure of positive and negative affect)|Depression and anxiety (Composite measure)|Health-related quality of life (Composite measure),Karolinska Institutet|Swedish Red Cross University College,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,103,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,20140001,Mar-11,Dec-14,Dec-14,4-Jun-15,null,8-Jun-15,,,https://ClinicalTrials.gov/show/NCT02463903
NCT02459509,A Comparison of Two Doses of Intranasal Dexmedetomidine for Premedication in Children,,Unknown status,No Results Available,"Anxiety, Separation",Drug: Dexmedetomidine,Satisfactory sedation|Time to satisfactory sedation|Blood pressure|Heart rate|Oxygen saturations,The University of Hong Kong,All,6 Months to 5 Years   (Child),Phase 4,140,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",UW 15-105,Jun-15,May-16,May-16,2-Jun-15,null,18-Apr-16,"Queen Mary Hospital, Hong Kong, Hong Kong",,https://ClinicalTrials.gov/show/NCT02459509
NCT02459847,Mind-Body Training for Hand Rehabilitation,,Completed,No Results Available,Arm Injuries|Hand Injuries,Behavioral: Mindfulness Training|Behavioral: Sonographic Biofeedback|Other: Standard Care,"Change in Salivary Cortisol throughout duration of intervention|Change in State Anxiety Inventory throughout duration of intervention|Change in Visual Analogue Pain Scale throughout duration of intervention|Change from Baseline in Mindfulness Attention Awareness Scale at 2 weeks|Change from Baseline in Disabilities of the Arm, Shoulder, and Hand (DASH) Outcome Measure at 2 weeks|Change from Baseline in Five Facet Mindfulness Questionnaire - Short Form at 2 weeks|Change from Baseline in Trait Anxiety Inventory at 2 weeks",University of Southern California,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,21,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HS-14-00320|Founders Grant,Aug-14,May-15,May-15,2-Jun-15,null,10-Mar-17,"USC Keck Hospital Hand Clinic, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT02459847
NCT02460536,Attention Bias Modification Treatment (ABMT) for Anxiety Disorders in Youth,,Completed,No Results Available,Anxiety Disorders,Behavioral: Attention Bias Modification treatment (ABMT)|Behavioral: Exposure only +ABMT|Behavioral: Attention training only +ABMT|Behavioral: Placebo group,Change from baseline in anxiety symptoms - the Pediatric Anxiety Rating (PARS)|Change from baseline in anxiety related emotional disorders symptoms - Child/Parent Version (SCARED-C/P),Tel Aviv University,All,"10 Years to 18 Years   (Child, Adult)",Not Applicable,100,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2009341,May-15,May-18,May-18,2-Jun-15,null,18-Sep-18,"Tel-Aviv University, Tel-Aviv, Israel",,https://ClinicalTrials.gov/show/NCT02460536
NCT02453880,Web-based CBT for Symptoms of Mild-to-Moderate Anxiety and Depression in Youth With Chronic Illness,,Completed,No Results Available,Depression|Anxiety|Inflammatory Bowel Disease|Systemic Lupus Erythematosus|Juvenile Idiopathic Arthritis,Behavioral: Web-based Cognitive Behavioral Therapy,Program completion rates|Change in pre-and post-intervention score on measure of depression (PHQ-9)|Change in pre-and post-intervention score on measure of anxiety (GAD-7)|Change in pre-and post-intervention score on measure of quality of life (Peds-QL)|Change in pre-and post-intervention score on measure of patient activation (PAM),Stanford University,All,"15 Years to 25 Years   (Child, Adult)",Not Applicable,14,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,29456,Jan-14,May-15,Aug-15,27-May-15,null,26-Apr-16,,,https://ClinicalTrials.gov/show/NCT02453880
NCT02455128,Therapeutic Listening in Patients With Colorectal Cancer,,Completed,No Results Available,Anxiety|Fear,Other: Therapeutic listening,State-Trait Anxiety Inventory (STAI)|Blood pressure|Heart rate|Respiratory rate|Salivary cortisol|Salivary amylase|Surgical Fear Questionnaire (SFQ),University of Sao Paulo,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,50,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,ACM 2015,Aug-14,Sep-15,Aug-17,27-May-15,null,15-Aug-17,,,https://ClinicalTrials.gov/show/NCT02455128
NCT02453347,Cranial Electrotherapy Stimulation (CES) Therapy,CES,Completed,Has Results,TBI|Anxiety|PTSD|Depression,Device: CES Therapy,PCL-5 (Post Traumatic Stress Disorder Checklist for the Diagnostic and Statistical Manual of Mental Disorders) for Use in Treating PTSD Symptoms|State-Trait Anxiety Inventory (STAI)|Beck Depression Inventory (BDI)|TFI (Tinnitus Functional Index)|MPAI (Mayo Portland Adaptability Inventory)|WAIS (Wechsler Adult Intelligence Scale) Symbol Search|WAIS Coding - Wechsler Adult Intelligence Scale|Dizziness- NSI (Neurobehavioral Symptom Inventory)|Headache - HIT6 (Headache Impact Test)|Sleep - Pittsburgh Sleep Quality Index (PSQI),The University of Texas Health Science Center at San Antonio,Male,"18 Years and older   (Adult, Older Adult)",Not Applicable,6,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,15-352H (UTHSCSA IRB),Oct-15,May-16,May-16,25-May-15,28-Feb-18,28-Feb-18,"Audie L. Murphy VA Hospital, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT02453347
NCT02451878,Improving Wellbeing and Social Anxiety Symptoms (Shyness),SocWell,Completed,No Results Available,Shyness|Wellbeing,Behavioral: E-Couch,change in social anxiety symptoms (self-report using SPIN-17 measure)|mental wellbeing (self-report WEMWBS measure)|depression (self-report CES-D measure)|quality of life (using SF36 measure)|use of health services (self-reported use of health services)|time off work or study (self-reported time off work or study)|social anxiety symptoms (fear of negative evaluation) (self-report using BFNE-S measure)|social anxiety symptoms (SOPHS)|social anxiety symptoms (self-report using SPIN-17 measure) at secondary time points,University of Oxford|Australian National University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,2105,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,MQ14PE_25|Human Ethics Protocol 2015/229,May-15,30-Jun-18,30-Jun-18,22-May-15,null,13-Jul-18,"National Institute for Mental Health Research, Australian National University, Canberra, Australian Capital Territory, Australia|Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, Oxfordshire, United Kingdom",,https://ClinicalTrials.gov/show/NCT02451878
NCT02452203,Examining the Effects of Reduced Environmental Stimulation on the Brain,,Recruiting,No Results Available,Anxiety,Behavioral: Floating,Brain activation changes in limbic and paralimbic neural circuitry from pre- to post-float as measured with functional magnetic resonance imaging (fMRI),"Laureate Institute for Brain Research, Inc.",All,18 Years to 55 Years   (Adult),Not Applicable,40,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,float-fMRI-1,May-15,Dec-19,Dec-19,22-May-15,null,5-Mar-19,"Laureate Institute for Brain Research, Tulsa, Oklahoma, United States",,https://ClinicalTrials.gov/show/NCT02452203
NCT02450695,rTMS in Treatment Refractory Obsessive-Compulsive Disorder,,Recruiting,No Results Available,Obsessive-Compulsive Disorder,Device: rTMS,Yale Brown Obsessive Compulsive Scale|Barratt Impulsiveness Scale|Hamilton Anxiety rating Scale|Hamilton Depression Rating Scale|Clinical Global Impression Scale,McMaster University|St. Joseph's Healthcare Hamilton|Hamilton Health Sciences Corporation,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,25,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",190,Jul-16,Dec-18,null,21-May-15,null,11-Apr-18,"MacAnxiety Research Center, Hamilton, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT02450695
NCT02451293,"The Effect of MElatonin on Depression, Anxiety, CIrcadian and Sleep Disturbances in Patients After Acute Myocardial Syndrome",MEDACIS,Completed,No Results Available,Depression|Acute Coronary Syndrome,Drug: Melatonin (N-acetyl-5-methoxytryptamine)|Drug: Placebo,Major Depression Inventory (MDI)|Actigraphy - Sleep outcomes - Time in bed|Actigraphy - Sleep outcomes - total sleep time|Actigraphy - Sleep outcomes - sleep effetiveness|Actigraphy - Sleep outcomes - wake after sleep onset|Actigraphy - Sleep outcomes - sleep latency|Actigraphy - Sleep outcomes - number of awakenings|Actigraphy - Sleep outcomes - time awake|Actigraphy - Sleep outcomes - time asleep|Actigraphy - Sleep outcomes - number of naps|Actigraphy - circadian outcomes - Mesor|Actigraphy - circadian outcomes - Acrophase|Actigraphy - circadian outcomes - Amplitude|Actigraphy - circadian outcomes - F-statistics|Actigraphy - circadian outcomes - Inter-daily stability|Actigraphy - circadian outcomes - Inter-daily variability|Anxiety measured by Hospital anxiety and depression scale (HADS-A)|Depression measured by Hospital anxiety and depression scale (HADS-D)|Subjective sleep quality measured by Pittsburgh sleep quality index (PSQI)|Sleep diary|UKU side effect rating scale|VAS Data on Anxiety|VAS Data on Fatigue|VAS Data on Pain|VAS Data on Sleep Quality|VAS Data on General Well-being|Endothelial function (EndoPAT),"Zealand University Hospital|Psychiatric Research Unit, Region Zealand, Denmark|University of Copenhagen|Pharma Nord",All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,252,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MTM-03|2015-002116-32,18-Jan-16,18-Aug-17,20-Jul-18,21-May-15,null,15-Jan-19,"Roskilde and Køge Hospital, Department of Surgery., Køge, Danmark, Denmark|Department of internal Medicin, Holbaek Sygehus, Holbæk, Zealand, Denmark|Department of Cardiology, Roskilde Sygehus, Roskilde, Zealand, Denmark|Department of internal medicin, M5, Køge, Zeland, Denmark|Department of Cardiology, Hvidovre Hospital,, Hvidovre, Denmark|Department of Cardiology, Slagelse Sygehus, Slagelse, Denmark",,https://ClinicalTrials.gov/show/NCT02451293
NCT02449759,"An ACT Manual-based, Guided Self-help Intervention Pilot",ACT,Completed,No Results Available,Anxiety|Depression,Behavioral: ACT Intervention Group,"Change is being assessed using the Quality of Life BREF (WHOQOLBREF; Skevington et al., 2004) questionnaire|Change is being assessed using the Acceptance and Action Questionnaire II (AAQII; Bond, Hayes & Baer et. al, 2011).",University of Edinburgh,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,52,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,166325,Apr-15,May-17,May-17,20-May-15,null,6-Nov-17,"Adult Psychology Department, Falkirk, Stirlingshire, United Kingdom",,https://ClinicalTrials.gov/show/NCT02449759
NCT02447744,Neural Changes Associated With a Mindfulness-based Intervention for Young Adults With Childhood Maltreatment,,Completed,No Results Available,Depression|Anxiety|PTSD,Behavioral: Mindfulness based stress reduction,Changes of Hippocampal Volumes (High resolution MRI)|Changes of Levels of Depression (Beck Depression Inventory)|Changes of Levels of Anxiety (Anxiety Sensitivity Index and State-Trait Anxiety scale)|Changes of Levels of Perceived Stress (measure levels of perceived stress),Massachusetts General Hospital|Mclean Hospital,All,18 Years to 35 Years   (Adult),Not Applicable,49,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2014P000295,1-Aug-14,21-Jul-16,21-Jul-16,19-May-15,null,5-Apr-18,"Massachusetts General Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT02447744
NCT02448186,"Intervention Development for Social Stress, Mental Health, and HIV Risk MSM",ESTEEM,Completed,No Results Available,HIV Infections|Depression|Anxiety,Behavioral: ESTEEM,"reductions in the number of condomless anal sex acts in the past 90 days with HIV-positive or HIV-status-unknown male partners|reduction in depression severity as measured with the Center for Epidemiological Studies Depression Scale|reduction in anxiety severity as measured with the Overall Anxiety Severity & Impairment Scale|reduction in minority stressors as measured with the Sexual Orientation Concealment Scale|reductions in psychological risk factors measured with the Ruminative Responses Scale|reductions in number of days in which heavy alcohol and potentially harmful recreational substances were use|among individuals with body image disturbance, improvements in body attitudes as measured with the Male Body Attitude Scale|among individuals with sexual compulsivity, reduction in sexual compulsivity severity as measured with the Sexual Compulsivity Scale|reduction in alcohol use problems as assessed with the Alcohol Use Disorders Identification Test|in participants with generalized anxiety disorder, reduction in Penn State Worry Questionnaire|reduction in depression severity as measured with the Overall Depression Severity & Impairment Scale|reduction in anxiety severity as measured with the State Trait Anxiety Inventory (State subscale)|reduction in minority stressors as measured with the Internalized Homophobia Scale|reduction in minority stressors as measured with the Rejection Sensitivity Scale|reductions in psychological risk factors measured with the Rathus Assertiveness Schedule|reductions in psychological risk factors measured with the Difficulties of Emotion Regulation Scale|reductions in psychological risk factors measured with the Multidimensional Scale of Perceived Social Support|in participants with obsessive-compulsive disorder, reductions in the Yale-Brown OC Scale|in participants with panic disorder, reduction in the Panic Disorder Severity Scale",Yale University|Hunter College of City University of New York,Male,18 Years to 35 Years   (Adult),Not Applicable,63,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,1306012230,Jul-12,Dec-14,Dec-14,19-May-15,null,19-May-15,,,https://ClinicalTrials.gov/show/NCT02448186
NCT02445378,Aromatherapy and Essential Oils in Improving Insomnia and Other Symptoms in Patients With Newly Diagnosed Acute Leukemia Undergoing Chemotherapy,,Completed,No Results Available,Acute Leukemia|Anorexia|Anxiety|Depression|Dyspnea|Insomnia|Nausea|Pain,Procedure: Aromatherapy and Essential Oils|Other: Placebo|Other: Questionnaire Administration,"Improvement of Insomnia graded by Pittsburgh Sleep Quality Index (PSQI)|Improvement of common symptoms including pain, nausea, lack of appetite, shortness of breath, depression, anxiety, and wellbeing graded by Edmonton Symptom Assessment Scale - revised (ESASr)|Rate of positive experience with aromatherapy",Ohio State University Comprehensive Cancer Center,All,"Child, Adult, Older Adult",Not Applicable,48,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care",OSU-14182|NCI-2015-00549,28-Dec-14,Sep-16,5-Nov-16,15-May-15,null,5-Apr-19,"Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02445378
NCT02445937,PARTNER II: Improving Patient and Family Centered Care in Advanced Critical Illness,,Recruiting,No Results Available,Anxiety|Depression,Behavioral: PARTNER II,Quality of Communication (QOC) scale|Hospital Anxiety and Depression Scale|Patient-Centeredness of Care Scale|Intensive Care Unit Length of Stay|Impact of Events Scale|Decision Regret Scale,University of Pittsburgh,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,690,Other,Interventional,Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care,PRO14090204,1-Jun-15,Jun-19,Sep-19,15-May-15,null,8-Apr-19,"UPMC Hamot, Erie, Pennsylvania, United States|UPMC Presby/Shady, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT02445937
NCT02443051,Treatment of Social Anxiety in Youth,,Completed,No Results Available,Social Anxiety Disorder,Behavioral: Attention Bias Modification,Clinician Severity Rating,Virginia Polytechnic Institute and State University,All,11 Years to 16 Years   (Child),Not Applicable,58,Other,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",13-180THO,May-13,May-16,Dec-16,13-May-15,null,16-May-17,"Child Study Center, Blacksburg, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02443051
NCT02441569,Common Engagement Strategies (Common Factors) for Childhood Anxiety,,Completed,No Results Available,Anxiety,Behavioral: Common factors engagement training for provider|Behavioral: Standard pediatric advice for childhood anxiety,The Screen for Child Anxiety Related Emotional Disorders (SCARED),Johns Hopkins Bloomberg School of Public Health|Georgetown University,All,6 Years to 12 Years   (Child),Not Applicable,32,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,P20MH086048,Sep-14,Jan-16,Jan-16,12-May-15,null,9-May-17,"Georgetown University Pediatric Clinic, Washington, D.C., District of Columbia, United States",,https://ClinicalTrials.gov/show/NCT02441569
NCT02437773,Neurocircuit Mechanisms of OCD Across the Lifespan,,Recruiting,No Results Available,Obsessive-Compulsive Disorder,Behavioral: Cognitive Behavioral Therapy - Adolescents|Behavioral: Stress Management Therapy - Adolescents|Behavioral: Optional CBT - Adolescents|Behavioral: Cognitive Behavioral Therapy - Adults|Behavioral: Stress Management Therapy - Adults|Behavioral: Optional CBT - Adults|Other: fMRI only - Healthy Control Adults|Other: fMRI only - Healthy Control Adolescents,Brain activity as assessed by Magnetic Resonance Imaging (fMRI) scans|OCD symptom severity measured by the Yale Brown Obsessive Compulsive Scale for adults or the Child Yale Brown Obsessive Compulsive Scale for adolescents.,University of Michigan,All,"13 Years to 45 Years   (Child, Adult)",Not Applicable,220,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment",HUM00091368,Sep-14,Jul-19,Jul-19,8-May-15,null,15-Jan-19,"University of Michigan, Ann Arbor, Michigan, United States",,https://ClinicalTrials.gov/show/NCT02437773
NCT02437968,Disseminating Evidence-based Practice to the Schools: CBT for Child Anxiety,Cats&Dogs,Completed,No Results Available,Anxiety Disorders,Behavioral: Camp Cope-A-Lot (Computer-assisted CBT program),Change in the number of children identified as anxious.|Change in the number of children treated for anxiety.,Temple University,All,"Child, Adult, Older Adult",Not Applicable,76,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MH086438,Dec-10,Jun-16,Jun-16,8-May-15,null,9-Nov-16,,,https://ClinicalTrials.gov/show/NCT02437968
NCT02437214,Music to Decrease Pain and Anxiety During Head CTs Performed at the PEds ED,,Completed,No Results Available,Anxiety Disorder of Childhood or Adolescence,Other: Use of music for anxiety in children,Visual analogue scale of anxiety|Modified Ramsey Sedation Scale,Steven Weiss|University of New Mexico,null,1 Month to 36 Months   (Child),Not Applicable,62,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,07-030,May-08,Jul-10,Jul-10,7-May-15,null,4-Feb-16,,,https://ClinicalTrials.gov/show/NCT02437214
NCT02433886,Efficacy and Adverse Events of Bilateral Single-shot VC/VS Gamma Capsulotomy for OCD: a Pilot Study,,Recruiting,No Results Available,Obsessive-compulsive Disorder,Procedure: Gamma Ventral Capsulotomy,Yale-Brown Obsessive Compulsive Scale (Y-BOCS),University of Sao Paulo General Hospital|Hospital do Coracao|Brown University,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,5,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GammaOCD_IPq_HCor,Dec-14,Dec-18,Dec-20,5-May-15,null,5-May-15,"OCD Clinics (PROTOC), Department of Psychiatry, University of Sao Paulo General Hospital, Sao Paulo, SP, Brazil",,https://ClinicalTrials.gov/show/NCT02433886
NCT02434406,Website-Based Self-Help for Women With Anxiety After Childbirth,,Completed,No Results Available,Anxiety Disorders,Behavioral: internet-What Am I Worried About,"Engagement as measured by the number of log-ins into the web-based intervention|Engagement as measured by the duration of log-ins into the web-based intervention|Engagement as measured by the total duration of time spent on the web-based intervention|Engagement as measured by the time spent on individual pages of the web-based intervention|Engagement as measured by the number of intervention coach calls|Usability as measured by participant's report of usefulness (""I found this module useful."") of each intervention module on a 7-point Likert scale (1 = strongly disagree to 7 = strongly agree).|Usability as measured by participant's report of clarity (""This module was clear and understandable."") of each intervention module on a 7-point Likert scale (1 = strongly disagree to 7 = strongly agree).|Usability as measured by participant's report of usability on the System Usability Scale (SUS)|Usability as measured by participant's report of usability on a series of items designed to measure ease-of-use and unobtrusiveness on 7-point Likert scale (1 = strongly disagree to 7 = strongly agree)|Usability as measured by participant's report of any technical problems experienced with the intervention website|Usability as measured by participant's report of interest in future usage of the intervention|Usefulness as measured by participant's report of a series of items designed to measure perceived usefulness on a 7-point Likert scale (1 = strongly disagree to 7 = strongly agree).|Satisfaction as measured by participant's report of a series of items designed to measure perceived satisfaction on a 7-point Likert scale (1 = strongly disagree to 7 = strongly agree).|Satisfaction as measured by participant's report on the Client Satisfaction Questionnaire (CSQ-8)|Credibility as measured by participant's report on the first 4 items of Credibility/ Expectancy Questionnaire (CEQ)|Women's perspectives and experiences as measured by semi-structured interviews|Engagement as measured by the duration of intervention coach calls|Usability as measured by participant's report of hypothetical recommendation of the intervention to others.|Anxiety level as measured by participant's report on the Generalized Anxiety Disorder Scale (GAD-7)|Depression, anxiety and stress symptomatology as measured by participant's report on the Depression, Anxiety, and Stress Scale (DASS 21)|Study feasibility as measured by recruitment rate|Study feasibility as measured by eligibility rate|Study feasibility as measured by consent rate|Study feasibility as measured by retention rate|Study feasibility as measured by pre-intervention data collection rate|Study feasibility as measured by pre-intervention data collection completeness|Study feasibility as measured by post-intervention data collection rate|Study feasibility as measured by post-intervention data collection completeness|Study feasibility as measured by 4 week post intervention follow-up data collection rate|Study feasibility as measured by 4 week post intervention follow-up data collection completeness","City, University of London|Monash University",Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,89,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PhD/14-15/16,26-Mar-17,30-Aug-17,30-Aug-17,5-May-15,null,31-Jan-18,"City, University of London, London, Greater London, United Kingdom|City University of London, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT02434406
NCT02432703,A Safety and Efficacy Study of JNJ-42165279 in Participants With Social Anxiety Disorder,,Completed,No Results Available,Phobic Disorders,Drug: JNJ-42165279|Drug: Placebo,Change From Baseline in the Liebowitz Social Anxiety Scale (LSAS) Total Score at Week 12|Change From Baseline in Liebowitz Social Anxiety Scale (LSAS) Fear/Anxiety and Avoidance Subscales at Week 12|Number of Participants who are Responders and Remitters on Liebowitz Social Anxiety Scale (LSAS) Total Score at Week 12|Percentage of Participants who are Responders and Remitters on Liebowitz Social Anxiety Scale (LSAS) Total Score at Week 12|Change from Baseline in Structured Interview Guide for the Hamilton Anxiety Rating Scale (SIGH-A) Total Score at Week 12|Change from Baseline in Hamilton Anxiety Rating scale (HAM-A6) Score at Week 12|Change from Baseline in Hamilton Depression Rating Scale (HDRS17) Total Score at Week 12|Change From Baseline in HDRS17 Anxiety/Somatization Factor Total Score at Week 12|Change From Baseline in 6-Item Hamilton Depression Scale (HAM-D6) Score at Week 12|Clinical Global Impression - Improvement (CGI-I) Score From Baseline at Week 12|Number of Participants who are Responders on SIGH-A Total Score at Week 12|Percentage of Participants who are Responders on SIGH-A Total Score at Week 12,"Janssen Research & Development, LLC",All,18 Years to 64 Years   (Adult),Phase 2,150,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",CR106641|42165279SAX2001|2014-004258-32,15-Jun-15,9-Aug-18,9-Aug-18,4-May-15,null,22-Oct-18,"La Jolla, California, United States|Hartford, Connecticut, United States|Orlando, Florida, United States|Chicago, Illinois, United States|Boston, Massachusetts, United States|Natick, Massachusetts, United States|New York, New York, United States|Rochester, New York, United States|Staten Island, New York, United States|Allentown, Pennsylvania, United States|Reading, Pennsylvania, United States|Dallas, Texas, United States|Salt Lake City, Utah, United States|Adelaide, Australia|Frankston, Australia|Melbourne, Australia|Perth, Australia|Edmonton, Alberta, Canada|Hamilton, Ontario, Canada|Mississauga, Ontario, Canada|Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT02432703
NCT02431728,The Effect of Melatonin Upon Post-Acute Withdrawal Among Males in a Residential Treatment Program,M-PAWS,Completed,No Results Available,Substance Withdrawal Syndrome,Dietary Supplement: Melatonin|Dietary Supplement: Matched Placebo,"The effect of melatonin or placebo on the change in anxiety as measured by the Generalized Anxiety Disorder (GAD-7) scale|The effect of melatonin or placebo on the change in depressive symptoms as measured by the Personal Health Questionnaire Depression Scale (PHQ-8)|The effect of melatonin or placebo on the change in sleep symptoms as measured by the Pittsburgh Sleep Symptom Questionnaire - Insomnia (PSSQ-1)|The effect of melatonin or placebo on the change in stress as measured by the Perceived Stress Scale (PSS-14)|Patient health histories (social, medical, medication, preventive, and mental health)|The number of reported adverse effects",Duquesne University,Male,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,70,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",DuquesneU,May-15,Jan-16,Jan-16,1-May-15,null,8-Aug-16,"Salvation Army Harbor Light Center, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT02431728
NCT02431845,Pharmaco(Epi)Genetic Study of Obsessive-Compulsive Disorder,,Recruiting,No Results Available,Obsessive-Compulsive Disorder,Drug: SSRIs,Change from baseline in the Yale-Brown Obsessive-Compulsive Scale|Change from the baseline Montgomery-Asberg Depression Rating Scale|Occurrence of any side effects during the SSRIs treatment,Severance Hospital,All,19 Years to 60 Years   (Adult),Not Applicable,200,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,4-2010-0577,Jan-13,Dec-23,Dec-23,1-May-15,null,7-Sep-18,"Yonsei Univ. Health System Severance Hospital, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02431845
NCT02429778,Relaxation Treatment for Anxiety in Adults Aged 60 or Older,BREATHE,Completed,No Results Available,Anxiety Disorders,Behavioral: Diaphragmatic Breathing|Behavioral: Progressive Muscle Relaxation,Change in Anxiety Symptoms|Change in Activity Engagement|change in depressive symptoms|Change in Somatic Symptoms,Palo Alto Veterans Institute for Research|VA Palo Alto Health Care System|Brain & Behavior Research Foundation,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,40,Other|U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GOU0001APR|22277,May-15,Jun-17,Jun-17,29-Apr-15,null,18-Apr-18,"VA Palo Alto Health Care System, Palo Alto, California, United States",,https://ClinicalTrials.gov/show/NCT02429778
NCT02430051,Sensory Adapted Dental Environments to Enhance Oral Care for Children,SADE-2,Recruiting,No Results Available,Autism,Behavioral: Sensory Adapted Dental Environment,Electrodermal Activity (EDA)|Children's Dental Behavior Rating Scale (CDBRS)|Anxiety and Cooperation Scale|Duration|Number of hands used to restrain child|Faces Pain Scale - Revised|Dental Sensory Sensitivity Scale|Frankl Scale,University of Southern California|Children's Hospital Los Angeles,All,6 Years to 12 Years   (Child),Not Applicable,220,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DE024978-01,May-15,Jun-19,Apr-20,29-Apr-15,null,9-Aug-18,"Children's Hospital Los Angeles, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT02430051
NCT02427568,MDMA-assisted Psychotherapy for Anxiety Associated With a Life-threatening Illness,,Completed,No Results Available,Anxiety,Drug: MDMA|Drug: Placebo,"Change in State Trait Anxiety Inventory (STAI) Trait Score - Primary Endpoint|Change in STAi score Trait score - 6 month follow up|Change in STAI score Trait (12 month follow up)|Change in State Trait Anxiety Inventory (STAI) State score - Primary endpoint|Change in State Trait Anxiety Inventory (STAI) State score - 6 month follow up|Change in State Trait Anxiety Inventory (STAI) State score - 12 month follow up|Change in Beck Depression Inventory II score - 3rd Integration session|Change in Beck Depression Inventory II score - Primary Endpoint|Change in Beck Depression Inventory II score - 6 month follow up|Change in Beck Depression Inventory II score - 12 month follow up|Change in Global Assessment of Functioning (GAF) score - Primary Endpoint|Change in Global Assessment of Functioning (GAF) score - 6 month follow up|Change in Global Assessment of Functioning (GAF) score - 12 month follow up|Columbia Suicide Severity Rating Scale (CSSRS) Baseline|Average Pre-treatment CSSRS|Average CSSRS - Experimental sessions|Average Post-treatment CSSRS|6 month Follow up CSSRS|12 month Follow up CSSRS|Change in MADRS score - Primary endpoint|Change in MADRS score - Six-month follow up|Change in MADRS score - 12-month follow up|Pittsburgh Sleep Quality Inventory (PSQI) - Primary Endpoint|Pittsburgh Sleep Quality Inventory (PSQI) - 6 month follow up|Pittsburgh Sleep Quality Inventory (PSQI) - 12 month follow up|Change in Posttraumatic Growth Inventory (PTGI) - Primary Endpoint|Change in Posttraumatic Growth Inventory (PTGI) - 6 month follow up|Change in Posttraumatic Growth Inventory (PTGI) - 12 month follow up|Posttraumatic Growth Inventory, Caregiver form - Primary Endpoint|Posttraumatic Growth Inventory, Caregiver form - 6 month follow up|Posttraumatic Growth Inventory, Caregiver form - 12 month follow up|Functional Assessment of Chronic Illness Therapy Scale (FACIT-Sp) - Primary Endpoint|Functional Assessment of Chronic Illness Therapy Scale (FACIT-Sp) - 6 month follow up|Functional Assessment of Chronic Illness Therapy Scale (FACIT-Sp) - 12 month follow up|Change in Death Attitude Profile (DAP) - Primary Endpoint|Change in Death Attitude Profile (DAP) - 6 Month Follow up|Change in Death Attitude Profile (DAP) - 12 Month Follow up|Change in Five-Factor Mindfulness Questionnaire (FFMQ) - Primary Endpoint|Change in Five-Factor Mindfulness Questionnaire (FFMQ) - 6 Month follow up|Change in Five-Factor Mindfulness Questionnaire (FFMQ) - 12 Month follow up|Change in Self-Compassion Scale (SCS) - Primary Endpoint|Change in Self-Compassion Scale (SCS) - 6 Month follow up|Change in Self-Compassion Scale (SCS) - 12 Month follow up|Long Term Follow Up Questionnaire - 6 Month follow up|Long Term Follow Up Questionnaire - 12 Month follow up|Observer Rating Form scores - Baseline|Observer Rating Form scores - Primary Endpoint|Observer Rating Form scores - 6 Month follow up|Observer Rating Form scores - 12 Month follow up|Brief Pain Inventory - Short Version (BPI-S) - Baseline|Average Brief Pain Inventory - Short Version (BPI-S) Score after drug|Brief Pain Inventory - Short Version (BPI-S) Score - Primary Endpoint|Average pre-drug Systolic Blood Pressure (SBP)|Average peak Systolic Blood Pressure (SBP)|Average end of Session Systolic Blood Pressure (SBP)|Average pre-drug diastolic blood pressure (DBP)|Average peak diastolic blood pressure (DBP)|Average end of session diastolic blood pressure (DBP)|Average pre-drug heart rate (HR)|Average peak heart rate (HR)|Average end of session heart rate (HR)|Average pre-drug body temperature|Average peak body temperature|Average end of session body temperature|Average pre-drug Subjective Units of Distress (SUD)|Average peak Subjective Units of Distress (SUD)|Average end of session Subjective Units of Distress (SUD)",Multidisciplinary Association for Psychedelic Studies,All,"18 Years and older   (Adult, Older Adult)",Phase 2,18,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MDA-1,Apr-15,May-18,Jul-18,28-Apr-15,null,13-Jul-18,"Offices of Philip Wolfson MD, San Anselmo, California, United States",,https://ClinicalTrials.gov/show/NCT02427568
NCT02427737,Comfort Talk and Economic Outcomes in MRI,ComfortTalk®,Completed,No Results Available,Claustrophobia|Complication of Diagnostic Procedure,Behavioral: Comfort Talk® Training,Non-completion rate|Sedation Rate|Patient Satisfaction|No show rate,"Hypnalgesics, LLC|Ohio State University|Duke University",All,"Child, Adult, Older Adult",Not Applicable,12,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,2CTOSUD2015,Apr-15,31-Jul-17,31-Jul-17,28-Apr-15,null,11-Sep-17,"Hypnalgesics, LLC, Brookline, Massachusetts, United States|Duke University Medical Center, Durham, North Carolina, United States|Ohio State University Medical Center, Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02427737
NCT02421861,Critical Care Anxiety and Long-Term Outcomes Management,CALM,Terminated,No Results Available,Anxiety,Behavioral: Anxiety Management in the ICU|Other: Usual Care (UC),Anxiety (Visual Analog Scale for Anxiety (VAS-A)|Engagement in rehabilitation therapies (As measured by a 2-item engagement questionnaire)|Length of ICU and Hospital Stay|Long-Term Anxiety and Depressive Symptoms (as measured by the Hospital Anxiety and Depression Scale (HADS)|Long-Term Posttraumatic Stress Symptoms (as measured by the PCL-5)|Health-Related Quality of Life (as measured by the EQ-5D-5L and SF-36),University of Washington,All,"18 Years and older   (Adult, Older Adult)",Phase 2,10,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,48493-G,Apr-15,Feb-16,null,21-Apr-15,null,1-Nov-16,,,https://ClinicalTrials.gov/show/NCT02421861
NCT02422290,Ketamine Treatment for Pediatric-Refractory Obsessive-Compulsive Disorder (OCD),,Completed,No Results Available,Obsessive-Compulsive Disorder,Drug: Ketamine,"Yale-Brown Obsessive Compulsive Scale, Child version (CYBOCS)|Clinical Global Impressions Scale (CGI-S)|OCD Visual Analogue Scale (OCD-VAS)|Yale-Brown Obsessive Compulsive Challenge Scale (YBOCCS)",New York State Psychiatric Institute|New York Presbyterian Hospital,All,"14 Years to 22 Years   (Child, Adult)",Phase 1|Phase 2,5,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,#7023,Mar-15,1-Jan-18,1-Jan-18,21-Apr-15,null,20-Aug-18,"New York State Psychiatric Institute/Columbia University, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT02422290
NCT02421315,Overlapping Neural Circuits in Pediatric OCD,,Recruiting,No Results Available,Obsessive Compulsive Disorder,Behavioral: Exposure & Response Prevention (EX/RP) and when indicated medication treatment,Change from baseline in brain activation (fMRI) after therapy|Change from baseline in fractional anisotropy (Diffusion tensor imaging) after therapy|Probabilistic Go/No-go reinforcement learning task|Continuous Performance Task|Stroop Word-Color Interference,New York State Psychiatric Institute|National Institute of Mental Health (NIMH),All,5 Years to 17 Years   (Child),Not Applicable,80,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,7006|R21MH101441,Oct-14,May-18,May-18,20-Apr-15,null,14-Feb-18,"NY State Psychiatric Institute, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT02421315
NCT02420431,Treating Depression and Anxiety in the Cardiac Rehabilitation Pathway,PATHWAY,"Active, not recruiting",No Results Available,Depression|Anxiety|Cardiac Rehabilitation,Behavioral: Metacognitive Therapy|Behavioral: Cardiac Rehabilitation (treatment as usual),Change in Hospital Anxiety and Depression Scale (HADS)|Impact of Events Scale -revised|Metacognitions Questionnaire 30|Cognitive Attentional Syndrome scale (CAS-1)|Health Related Quality of Life (EQ-5D)|Economic Patient Questionnaire|Hospital Anxiety and Depression Scale,"University of Manchester|National Institute for Health Research, United Kingdom|Manchester Mental Health & Social Care Trust|University of Liverpool",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,332,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,156862 (RP-PG-1211-20011),Jul-15,May-19,Aug-19,17-Apr-15,null,17-Apr-19,"Macclesfield District General Hospital, Macclesfield, Cheshire, United Kingdom|Central Manchester University Hospitals NHS Foundation Trust, Manchester, Lancashire, United Kingdom|University Hospital of South Manchester NHS Foundation Trust, Manchester, Lancashire, United Kingdom|Pennine Acute Hospitals NHS Trust, Manchester, United Kingdom|Stepping Hill Hospital, Manchester, United Kingdom",,https://ClinicalTrials.gov/show/NCT02420431
NCT02418026,Improving Cesarean Section Experience Through Hypnotherapy,,Completed,Has Results,Cesarean Section|Pain|Anxiety,Other: hypnosis,Wellbeing Measured Using a Comfort Scale|Score at Numeric Pain Rating Scale|Mean Blood Pressure|Mean Pulse|Non-steroidal Anti-inflammatory Drug Intake,Groupe Hospitalier de la Rochelle Ré Aunis,Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,79,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label),2014/P01/034,Feb-13,Oct-13,Oct-13,16-Apr-15,1-Mar-17,1-Mar-17,,,https://ClinicalTrials.gov/show/NCT02418026
NCT02417025,Innovative Delivery of Evidence Based Psychotherapy to Women With Military Sexual Trauma,,Recruiting,No Results Available,"PTSD|Stress Disorders, Post - Traumatic|Anxiety Disorders|Mental Disorders|Stress Disorders, Traumatic",Behavioral: PE,"Number of Participants Receiving Prolonged Exposure Treatment via Telemedicine with significantly decreased PTSD symptoms Compared to Number of Participants Receiving Prolonged Exposure Treatment with Standard In-Person Delivery|Veteran (VR) Short Form (SF) -12 Health Survey (VR-12)|Index of Functional Impairment (IFI)|Treatment Credibility Questionnaire|Charleston Psychiatric Outpatient Satisfaction Scale (CPOSS)|Mini International Neuropsychiatric Interview (M.I.N.I.)|Alcohol Use Disorder Identification Test (AUDIT)|Drug Abuse Screening Test (DAST-10)|Pittsburgh Sleep Quality Index (PSQI)|Sexual Assault Related Mental Contamination Scale (SARA)|Beck Depression Inventory - II (BDI-II)|PTSD Checklist, 5th Version (PCL-5)|Clinical Administrated PTSD Scale (CAPS)",Medical University of South Carolina|Charleston Research Institute,Female,"21 Years and older   (Adult, Older Adult)",Not Applicable,175,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,Pro00034989,Aug-14,Aug-19,Aug-19,15-Apr-15,null,18-Jul-18,"Ralph H. Johnson VAMC, Charleston, South Carolina, United States",,https://ClinicalTrials.gov/show/NCT02417025
NCT02415309,Premedication With Melatonin in Lumbar Medial Branch Block Procedure,,Unknown status,No Results Available,Anxiety,Dietary Supplement: 2 mg Melatonin|Dietary Supplement: 10mg Melatonin|Other: Placebo,Change in anxiety level scores as assessed by the data collection sheet given to patients at all three time points (listed below),"United States Naval Medical Center, San Diego",All,18 Years to 50 Years   (Adult),Phase 3,120,U.S. Fed,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care",NMCSD.2015.0048,Jul-16,Sep-17,Sep-17,14-Apr-15,null,22-Aug-16,"Pain Medicine Center, San Diego, California, United States",,https://ClinicalTrials.gov/show/NCT02415309
NCT02413840,"Evaluation, Psychological Intervention and Follow-up Study of Anxiety and Depression in Stable COPD Patients",,Unknown status,No Results Available,COPD|Anxiety|Depression,Behavioral: Baduanjin qigong,"stage of anxiety and depression ((Hospital Anxiety and Depression Scale)|the number of acute exacerbations|lung function (pulmonary function test(20 minutes after inhaled 400ug albuterol),the forced expiratory volume in 1 second(FEV1)will be detected)",Huimin Gong|Capital Medical University,All,"40 Years to 75 Years   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CMU900314,Dec-14,May-15,null,10-Apr-15,null,10-Apr-15,"Beijing institute of respiratory diseases, Beijing, China",,https://ClinicalTrials.gov/show/NCT02413840
NCT02410967,Attention Bias Modification Training in Youth With Subthreshold Impairing Anxiety,,Completed,Has Results,Anxiety,Behavioral: Attention Bias Modification|Behavioral: Placebo Attention Task,Pediatric Anxiety Rating Scale at Posttreatment|Pediatric Anxiety Rating Scale at Follow-up|Screen for Child Anxiety Related Emotional Disorders - Parent Version at Posttreatment|Screen for Child Anxiety Related Emotional Disorders - Parent Version at Follow-up|Screen for Child Anxiety Related Emotional Disorders - Child Version at Posttreatment|Screen for Child Anxiety Related Emotional Disorders - Child Version at Follow-up,Florida International University,All,8 Years to 16 Years   (Child),Not Applicable,53,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",UH2MH101470,Jul-14,30-Mar-18,30-Mar-18,8-Apr-15,19-Jun-18,19-Jun-18,"Florida International University Center for Children and Families, Miami, Florida, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/67/NCT02410967/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02410967
NCT02411123,Clinical Study to Evaluate Patient Outcomes Following Pharmacogenetic Testing of Subjects Exhibiting Neuropsychiatric Disorders,,Completed,No Results Available,Depression|Anxiety,Genetic: IDgenetix Neuropsychiatric Test Panel,Comparison of change in neuropsychiatric state between the two treatment arms measured by Neuropsychiatric Questionnaire (NPQ)|Comparison of change in responsiveness between the two treatment arms measured by Symbol Digit Coding (SDC) test|Comparison of hospital utilization between the two treatment arms as measured by hospital admission and re-admission rates|Comparison of adverse drug events between the two treatment arms over a 4-month period,AltheaDx|Carolina Partners in Mental Healthcare,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,220,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Diagnostic,CLP0002,Mar-15,Oct-15,Dec-15,8-Apr-15,null,29-Dec-15,"Carolina Partners in Mental HealthCare, Raleigh, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT02411123
NCT02411721,The Effects of Dog Intervention on Anxiety Levels in Children Undergoing an MRI Examination,yes,Unknown status,No Results Available,Anxiety,Behavioral: Animal Assisted Intervention,Anxiety level|Anxiety profile assessment|Evaluate children experience|Quality of the MRI scan|Pulse measurements,Rambam Health Care Campus,All,7 Years to 15 Years   (Child),Not Applicable,52,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0530-14-RMB CTIL,May-15,May-16,May-16,8-Apr-15,null,8-Apr-15,,,https://ClinicalTrials.gov/show/NCT02411721
NCT02409810,Patient-Controlled Anxiolysis With Dexmedetomidine (PCA-DEX) for Burn-care Dressing Changes,,Recruiting,No Results Available,Anxiety|Burns,Drug: Dexmedetomidine,"Safety (proportion of patients successfully completing the pilot trial without adverse effects)|Feasibility (defined by the following criteria: a) number and proportion of patients who consent to enrollment, b) proportion of eligible subjects c) number of days on protocol that patients successfully use the PCS device, d) ability of burn nurses)|Patient Acceptability (willingness to use PCS-DEX prior to and during burn dressing changes)",Ohio State University,All,"18 Years to 89 Years   (Adult, Older Adult)",Phase 1|Phase 2,20,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,2015H0019,Mar-15,Apr-16,Apr-20,7-Apr-15,null,7-Apr-15,"The Ohio State University Hospital, Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02409810
NCT02409966,"Effect of Periodontitis Treatment on Quality of Life and Experiences of Fear, Anxiety and Pain",,Completed,No Results Available,Periodontitis,Procedure: Quadrant-wise scaling|Procedure: Full-mouth 24-hour scaling,Oral health related quality of life|Pain|Fear and anxiety,University of Taubate,All,35 Years to 60 Years   (Adult),Not Applicable,90,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",552264/2011-3|521-10|CAAE 07172212.3.0000.514,Feb-11,Dec-13,Dec-14,7-Apr-15,null,7-Apr-15,,,https://ClinicalTrials.gov/show/NCT02409966
NCT02410265,"Online, Guided Interventions to Reduce Generalized Anxiety Disorder Among Indian University Students",,Completed,No Results Available,Anxiety Disorders,Behavioral: Lantern: Guided self-help program|Behavioral: Mental Health Online: Self-help program,"Change in GAD symptoms measured by the 4th edition of the Generalized Anxiety Disorder Questionnaire (GAD-Q-IV)|Sustained change in GAD symptoms measured by the 4th edition of the Generalized Anxiety Disorder Questionnaire (GAD-Q-IV)|Change in panic disorder symptoms measured by The Panic Disorder Self-Report (PDSR)|Change in social phobia symptoms measured by the Social Phobia Diagnostic Questionnaire (SPDQ)|Change in post-traumatic stress disorder symptoms measured by the Post Traumatic Stress Disorder Checklist for DSM-5 (PCL5)|Change in obsessive compulsive disorder (OCD) symptoms measured by the LEVEL 2—Repetitive Thoughts and Behaviors—Adult (adapted from the Florida Obsessive-Compulsive Inventory [FOCI] Severity Scale [Part B])|Change in specific phobia symptoms measured by questions of distress severity for specific fears|Change in depression symptoms measured by the Depression Anxiety Stress Scales (DASS)|Change in worry symptoms measured by the Penn State Worry Questionnaire (PSWQ)|Change in insomnia symptoms measured by the Insomnia Severity Index (ISI)|Change in subject self-efficacy measured by the General Self-efficacy Scale|Change in emotional distress from anxiety measured by the Patient Reported Outcomes Measurement Information System (PROMIS) Emotional Distress from Anxiety measure|Change in self-report difficulties with emotions, concentration, and relationships measured by the Strengths and Difficulties Questionnaire (SDQ)|Change in relationship satisfaction measured by the PROMIS Satisfaction with Social Roles and Activities measure|Factors associated with poor program engagement and/or discontinuation measured by analysis of self-report assessments of motivation, belief in program efficacy, satisfaction, etc. as well as analysis of demographics, comorbid mental illness, etc.|Change in non-specific distress measured by the Kessler Distress Measure (K10)","Stanford University|Birla Institute of Technology and Science, Hyderabad Campus|Vignana Jyothi Institute of Management|VNR Vignana Jyothi Institute of Engineering and Technology|National Institute of Mental Health and Neuro Sciences, India",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,193,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,31629,Jan-15,Dec-16,Dec-16,7-Apr-15,null,27-Jun-17,,,https://ClinicalTrials.gov/show/NCT02410265
NCT02408198,The Street Smart Group: A Feasibility Trial of a Group Intervention Targeting Anxiety Processes in Paranoia,,Completed,No Results Available,Paranoia|Schizophrenia-spectrum Diagnosis,Behavioral: Anxiety intervention,Green Paranoid Thoughts Scale,King's College London,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,18,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,R&D 2013/066,Feb-15,Jan-16,May-16,3-Apr-15,null,20-Mar-17,"Institute of Psychiatry, Psychology & Neuroscience (IoPPN), King's College London, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT02408198
NCT02407288,tDCS as an add-on Treatment in SSRI-resistant OCD,TDCSTOC,Unknown status,No Results Available,Obsessive-Compulsive Disorder,Device: transcranial dirrect current stimulation|Device: Sham tDCS,score improvement on the Yale Brown Obsessive and Compulsive Scale after one month|Number of responders on the YBOCS|score improvement on the Yale Brown Obsessive and Compulsive Scale after 3 months,Hôpital le Vinatier,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,46,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CSR G01,12-Mar-15,Jun-18,Jun-18,2-Apr-15,null,8-May-17,"Centre Hospitalier Le Vinatier, Bron, France",,https://ClinicalTrials.gov/show/NCT02407288
NCT02403557,Internet-delivered Cognitive Behaviour Therapy for Older Adults With Anxiety,,Completed,No Results Available,Anxiety|Depression,Behavioral: Waitlist|Behavioral: Tailored Internet-delivered CBT,Beck Anxiety Inventory (BAI)|Patient Health Questionnaire (PHQ)|The Generalized Anxiety Disorder 7-item Scale (GAD-7)|Quality of Life Inventory (QOLI)|Montgomery Åsberg Depression Rating Scale - Self Rated (MADRS-S)|Clinical Outcome in Routine Evaluation - Outcome Measure (CORE-OM)|Cognitive Failures Questionnaire (CFQ)|Wisconsin Card Sorting Test-64 (WCST-64),Linkoeping University,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,66,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GA-Forte-Older-Adults-Anx,Feb-12,Dec-15,Dec-15,31-Mar-15,null,2-Mar-16,,,https://ClinicalTrials.gov/show/NCT02403557
NCT02404116,Metacognitive Therapy for Health Anxiety,,Completed,No Results Available,Hypochondriasis,Other: Metacognitive Therapy|Other: Wait List,Change in health anxiety levels over 12weeks of treatment measured by the Whiteley Index 7 (WI7)|Change in health anxiety levels over 12weeks of treatment measured by the Bodily Perception Questionnaire (BP).|Change in anxiety levels over 12weeks of treatment measured by the Beck Anxiety Inventory|Change in general metacognition levels over 12weeks of treatment measured by the The Metacognitions Questionaire-30 (MCQ-30)|Change in depression levels over 12weeks of treatment measured by the Beck Depression inventory|Change in health anxious metacognition levels over 12weeks of treatment measured by the The Meta-Cognitions about Health Questionnaire (MCHQ)|Change in dysfunctional beliefs over 12weeks of treatment measured by the Health cognition Questionnaire,University of Manchester,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,21,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,: z83hdhmg,Mar-15,Jan-17,Jan-17,31-Mar-15,null,7-Feb-17,"University of Central Lancashire, Preston, Lancashire, United Kingdom|University of Manchester, Manchester, United Kingdom",,https://ClinicalTrials.gov/show/NCT02404116
NCT02402322,Internet-based Self-help Treatment for Panic Disorder: Two Ways of Complementary Psychological Support,,Completed,Has Results,Panic Disorder,Behavioral: Scheduled support|Behavioral: Non-scheduled support,Change From Baseline Score in the Panic Disorder Severity Scale at 8 Weeks and 6 Months.|Change From Baseline Score in the Anxiety Sensitivity Index-3 at 8 Weeks and 6 Months.|Change From Baseline Score in the Beck Anxiety Inventory at 8 Weeks and 6 Months.|Change From Baseline Score in the Beck Depression Inventory at 8 Weeks and 6 Months.|Change From Baseline Score in the Sheehan Disability Inventory (Work Subscale) at 8 Weeks and 6 Months.|Change From Baseline Score in the Sheehan Disability Inventory (Social Life Subscale) at 8 Weeks and 6 Months.|Change From Baseline Score in the Sheehan Disability Inventory (Family Subscale) at 8 Weeks and 6 Months.|Change From Baseline Score in the Sheehan Disability Inventory (Stress Subscale) at 8 Weeks and 6 Months.|Change From Baseline Score in the Sheehan Disability Inventory (Social Support Subscale) at 8 Weeks and 6 Months.,Universitat Autonoma de Barcelona,All,18 Years to 60 Years   (Adult),Not Applicable,77,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",PTCCAP,Aug-13,Nov-14,Nov-14,30-Mar-15,7-Dec-15,7-Dec-15,,,https://ClinicalTrials.gov/show/NCT02402322
NCT02402582,Effect of Family-Centered Empowerment Model,,Completed,No Results Available,Acute Myocardial Infarction: Rehabilitation Phase,Other: Family-centered empowerment model|Other: Control,Patient quality of life as measured by the SF-36|Patient Stress|Anxiety,Baqiyatallah Medical Sciences University|Tarbiat Modarres University,All,"45 Years to 85 Years   (Adult, Older Adult)",Not Applicable,70,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care",BMSU,Jun-12,Jan-15,Jan-15,30-Mar-15,null,3-Jul-18,,,https://ClinicalTrials.gov/show/NCT02402582
NCT02402647,Cognitive Rehab and Exposure Treatment for Hoarding,CREST,Recruiting,No Results Available,Hoarding Disorder,Behavioral: CREST|Behavioral: ET,Saving Inventory Revised|UCSD Performance-Based Skills Assessment (UPSA)|UCSD SORT Test|Specific Levels of Functioning test (SLOF),VA Office of Research and Development,All,"18 Years to 85 Years   (Adult, Older Adult)",Not Applicable,136,U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,CLNA-005-14S,1-Oct-15,1-Oct-20,1-Oct-20,30-Mar-15,null,18-Dec-18,"VA San Diego Healthcare System, San Diego, CA, San Diego, California, United States",,https://ClinicalTrials.gov/show/NCT02402647
NCT02400918,Self-help for Treating Social Anxiety Disorder: An Evaluation of a Mindfulness and Acceptance-based Approach,,Completed,No Results Available,Anxiety|Shyness,"Other: The Mindfulness and Acceptance-based Workbook for Social Anxiety and Shyness (Fleming & Kocovski, 2013)","Change from Baseline to 4 and 8 weeks later in The Liebowitz Social Anxiety Scale (Liebowitz, 1987)|Change from Baseline to 4 and 8 weeks later in the Freiberg Mindfulness Inventory (Buchheld, Grossman, & Walach, 2001)|Change from Baseline to 4 and 8 weeks later in the Social Anxiety - Acceptance and Action Questionnaire (MacKenzie & Kocovski, 2010)|Change from Baseline to 4 and 8 weeks later in the Beck Depression Inventory (Beck, Steer, & Brown, 1996)|Treatment credibility will be assessed using the scale by Devilly and Borkovec (2000) one week following the start of treatment (consistent with Nordgreen et al., 2012).",Wilfrid Laurier University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,170,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,WilfridLU,Mar-15,Sep-16,Sep-16,27-Mar-15,null,25-Nov-16,"Wilfrid Laurier University, Waterloo, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT02400918
NCT02401282,Attention and Social Behavior in Children,BRAINS,Completed,No Results Available,Anxiety,Behavioral: Attention Bias Modification|Behavioral: Dot-probe task,Anxiety Symptoms|Attention bias levels|Electrophysiological and neural correlates of attention bias,Penn State University|National Institute of Mental Health (NIMH),All,9 Years to 12 Years   (Child),Not Applicable,251,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Basic Science",5R01MH094633-04,Dec-11,17-Dec-16,17-Dec-16,27-Mar-15,null,16-Jan-18,"Penn State University Child Study Center, University Park, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT02401282
NCT02398916,Music Listening to Reduce Pain and Anxiety During LEEP,,Completed,No Results Available,Cervical Intraepithelial Neoplasia,Behavioral: Music listening,"Procedure-related pain, as measured by Visual Analog Scale|Procedure-related anxiety, as measured by Visual Analog Scale|Procedure-related satisfaction, as measured by Visual Analog Scale",Chiang Mai University,Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,150,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,OBG-2557-02665,Feb-15,Aug-16,Aug-16,26-Mar-15,null,30-Aug-16,"Department of OB-GYN, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand",,https://ClinicalTrials.gov/show/NCT02398916
NCT02398045,Developing Computerised CBT for Adults With OCD,CCBT,Unknown status,No Results Available,Obsessive-compulsive Disorder,Other: Computerised CBT for OCD,Change in Y-BOCS-OCD|Psychiatric Diagnostic Screening Questionnaire|DSM-IV OCD SCID|Patient Health Questionnaire|Generalised anxiety disorder assessment|Work and social adjustment scale|Expectation for treatment success and credibility|demographic variables|Obsessive-compulsive inventory,"Institute of Psychiatry, London|South London and Maudsley NHS Foundation Trust",All,"18 Years to 65 Years   (Adult, Older Adult)",Early Phase 1,12,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CCBT-1111|658-PAHTLZB,Oct-15,Oct-17,Dec-17,25-Mar-15,null,30-Aug-16,"Centre for Anxiety Disorders and Trauma, London, United Kingdom|South London and Maudsley NHS Trust, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT02398045
NCT02398318,China Refractory Obsessive-Compulsive Disorder Deep Brain Stimulation Study,CRODS,Withdrawn,No Results Available,Obsessive Compulsive Disorder,Device: Bilateral Nucleus Accumbens DBS (Suzhou Sceneray)|Device: Sham Bilateral Nucleus Accumbens DBS,"Change in Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) Score|Change in Obsessive-Compulsive Inventory - Revised (OCI-R) Score|Change in Hamilton Anxiety Scale, Hamilton Depression Scale-17, Beck Anxiety Scale, Beck Depression Scale-1 Score|Change in Temperament and Character Inventory revised version (TCI-R) Score|Iowa Gambling Task (change in task performance scores)|Change in functional magnetic resonance imaging (fMRI) images|Change in positron emission tomography (PET) brain glucose metabolism images|Quality of life: Global assessment of function|Disability: WHO disability assessment 2.0|Model Task (change in task performance scores)","Ruijin Hospital|Suzhou Sceneray Medical Co. , Ltd|National Natural Science Foundation of China|Icahn School of Medicine at Mount Sinai",All,18 Years to 60 Years   (Adult),Phase 2|Phase 3,0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",RCT-YY2015-CRODS,Apr-15,Oct-16,Apr-18,25-Mar-15,null,6-Dec-16,"Guangzhou psychiatric hospital, Guangzhou, Guangdong, China|Shanghai Mental Health Center, Shanghai, Shanghai, China|West China Hospital, Chengdu, Sichuan, China",,https://ClinicalTrials.gov/show/NCT02398318
NCT02396472,Mental Health Pathways in Internet Support Groups,,Recruiting,No Results Available,Depression|Stress|Anxiety,Behavioral: Order by time and topic|Behavioral: Order by information relevance|Behavioral: Order by social relationship|Behavioral: Order by help giving|Behavioral: Order by self-disclosure,"Read message (Does the user read the message they were exposed to?)|Interaction satisfaction (Self-report measure of satisfaction 3-item survey)|Reply to message (How long does it take the users to reply to a message they were exposed to, if they reply at all.)","Carnegie Mellon University|University of Pittsburgh|National Institute of Mental Health (NIMH)|American Cancer Society, Inc.",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,6500,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Supportive Care",CarnegieMU,Jun-16,Apr-19,Apr-19,24-Mar-15,null,6-Mar-18,"Carnegie Mellon University, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT02396472
NCT02396576,Using Telehealth to Deliver Mental Health Services in Primary Care Settings for Children in Underserved Areas,,Completed,No Results Available,"Developmental, Behavioral and Mental Health|Adhd|Depression|Anxiety|Developmental Delay|Autism|Behavioral Problems",Behavioral: Telehealth Intervention,Access to specialty services- Referral time|Access to specialty services- Travel|Access to specialty services- Missed school/work|Access to specialty services- Out of pocket cost|Access to specialty services- Visits|Quality of care measures|Child Behavior measures|Provider coordination- Communication|Provider coordination- Comfort level,"University of California, Los Angeles|Patient-Centered Outcomes Research Institute",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,359,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,IH-12-11-4168,7-Apr-15,15-Jun-17,15-Jun-17,24-Mar-15,null,10-Aug-17,"Northeast Valley Health Corporation- Canoga Park, Canoga Park, California, United States|Northeast Valley Health Corporation- Pacoima, Pacoima, California, United States|Northeast Valley Health Corporation- San Fernando, San Fernando, California, United States|Northeast Valley Health Corporation- Santa Clarita, Santa Clarita, California, United States|Northeast Valley Health Corporation- Valencia, Valencia, California, United States|Northeast Valley Health Corporation- Van Nuys, Van Nuys, California, United States",,https://ClinicalTrials.gov/show/NCT02396576
NCT02396797,Effect Evaluation of a Workplace Intervention Targeting Subjective Health Complaints,atWork,Completed,No Results Available,Mental Disorders|Back Pain|Anxiety|Depression,Behavioral: The new atWork intervention|Behavioral: The original atWork intervention,"Sick leave, unit level|Coping Expectancies; Theoretically Originated Measure of the Cognitive Activation Theory of Stress, TOMCATS|Health; self-rated health, Subjective Health Complaints Inventory, SHC, Hopkins Symptom Checklist, HSCL-10|Job Satisfaction; Global Job Satisfaction, GJO, Demand-Control-Support-Questionnaire, short Swedish version|Social Support; Non directive and Directive Support Survey, NDSS-16.",NORCE Norwegian Research Centre AS|The Hospital of Vestfold,All,"18 Years to 67 Years   (Adult, Older Adult)",Not Applicable,1011,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,9747,Jan-15,May-18,May-18,24-Mar-15,null,15-May-18,"Torill Helene Tveito, Bergen, Norway",,https://ClinicalTrials.gov/show/NCT02396797
NCT02395510,"A 10-Week, Open-Label, Flexible Dose Adaptive Study Evaluating the Efficacy of Vortioxetine in Subjects With Panic Disorder",,Completed,No Results Available,Panic Disorder,Drug: Vortioxetine,Mean Change from Baseline in the Panic Disorder Severity Scale (PDSS) score|Improvement on the Quality of Life Scale (QLOS) from Baseline|Information from the Monitoring of Side Effects Scale (MOSES),Siyan Clinical Corporation,All,18 Years to 60 Years   (Adult),Phase 4,27,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,VOR-ITT-0024,May-15,Jun-16,Jun-16,23-Mar-15,null,25-Jul-16,"Siyan Clinical Corporation, Santa Rosa, California, United States",,https://ClinicalTrials.gov/show/NCT02395510
NCT02394704,Intervention for Intrusive Negative Thinking,,Recruiting,No Results Available,Intrusive Negative Thinking,Other: Sensory attention training,Sustained attention composite (computer based tasks and physiological measures)|Depressive severity (patient self-report)|Rumination (patient self-report),"University of Pittsburgh|University of California, Los Angeles",All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,95,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,PRO13040640,Nov-15,Feb-21,Mar-21,20-Mar-15,null,13-Mar-19,"Oxford Building, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT02394704
NCT02395094,Study to Examine the Effects of Child Life Interventions on Children's Anxiety Levels at Induction of Anesthesia,ChildLife,Completed,No Results Available,"Preoperative, Anxiety",Behavioral: Child Life,Preoperative anxiety using m-YPAS-SF scoring tool|Preoperative anxiety using PACBIS scoring tool,University of British Columbia,All,3 Years to 10 Years   (Child),Not Applicable,72,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care,H15-00342,Apr-15,Jun-16,Jun-16,20-Mar-15,null,27-Oct-17,"British Columbia Children's Hospital Department of Anesthesia, Vancouver, British Columbia, Canada",,https://ClinicalTrials.gov/show/NCT02395094
NCT02391363,"Calmer Life: Treating Worry Among Older Adults In Underserved, Low-income, Minority Communities",,"Active, not recruiting",No Results Available,Anxiety,Behavioral: Cognitive behavior treatment|Behavioral: Information and referral,Penn State Worry Questionnaire - A (PSWQ-A) Change at 6 months|GAD-7 Change at 6 months|Geriatric Anxiety Inventory - SF (GAI-SF) Change at 6 months|PHQ-9 Change at 6 months|Insomnia Severity Index (ISI) Change at 6 months|LL-FDI Change at 6 months|12-item Medical Outcomes Study Short Form (SF-12) Change at 6 months,Baylor College of Medicine|Patient-Centered Outcomes Research Institute,All,"50 Years and older   (Adult, Older Adult)",Not Applicable,147,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,AD-1310-06824,Nov-14,Feb-18,Feb-18,18-Mar-15,null,23-Jan-18,"VA HSR&D Center for Innovations in Quality, Effectiveness & Safety (IQuESt), Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT02391363
NCT02390271,How Reducing Anxiety in Schizophrenia,,Completed,No Results Available,Schizophrenia,Other: emotion focused therapy training,psychometric outcome: Spielberger State Anxiety Inventory (S-STAI)|psychometric outcome: Freiburg Mindfulness Inventory (FMI),Institut de Recherche Biomedicale des Armees,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,10,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,m trousselard,Jun-10,Sep-10,Jun-11,17-Mar-15,null,17-Mar-15,,,https://ClinicalTrials.gov/show/NCT02390271
NCT02387320,Evaluation of a Self-Care Toolkit in Surgical Breast Cancer Patients,,Unknown status,No Results Available,Anxiety|Pain|Nausea|Fatigue|Sleep Disturbance,Other: Self-Care Toolkit,Change from preoperative in VAS General Anxiety at post-operative|Change from pre-operative DVPRS at post-operative|Change from preoperative VAS Nausea at post- operative|Change from baseline (PROMIS-57) Fatigue to pre-operative and follow-up 2 weeks post-operative|Change from baseline (PROMIS-57) Sleep Disturbance to pre-operative and follow-up 2 weeks post-operative,Samueli Institute for Information Biology|San Antonio Military Medical Center|United States Department of Defense,Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,100,Other|U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),396717,Jul-14,Feb-17,Feb-17,13-Mar-15,null,12-May-16,"Carl R. Darnall Army Medical Center, Fort Hood, Texas, United States|San Antonio Military Medical Center, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT02387320
NCT02386319,Anxiolytic and Analgesic Effects of Melatonin,,"Active, not recruiting",No Results Available,Anxiety|Pain,Drug: Melatonin|Drug: Placebo,Integrated pain score during movement|Anxiety|Integrated pain score (0-24 hours) at rest|Pre- and postoperative anxiety|Intraoperative requirement of remifentanil|Intraoperative requirement of propofol|Use of rescue-opioids in the PACU|Use of rescue-opioids in the ward|Perioperative sleep quality|General well-being and fatigue|Plasma concentrations of melatonin,Herlev Hospital,Female,"Child, Adult, Older Adult",Phase 3,84,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",Melatonin1234,Aug-16,Aug-20,Aug-20,11-Mar-15,null,21-Jan-19,,,https://ClinicalTrials.gov/show/NCT02386319
NCT02386410,Selective Prevention of Anxiety Disorders in Children: A Parent Training Intervention for Anxious Parents,,Completed,No Results Available,Anxiety Disorders,Behavioral: Group parent training for anxious parents|Behavioral: Internet delivered parent training for anxious parents,Anxiety Disorders Interview Schedule - Child and Parent Version|The Spence Children's Anxiety Scale|Children Depression Inventory|The Rearing Behavior Questionnaire|Strengths and Difficulties Questionnaire|State-Trait Anxiety Inventory|Montgomery-Åsberg Depression Rating Scale|Quality of Life Inventory,Karolinska Institutet,All,"Child, Adult, Older Adult",Not Applicable,40,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,AGJA-02,Aug-15,Dec-16,Jan-17,11-Mar-15,null,13-Nov-17,"Karolinska Institutet, Solna, Sweden",,https://ClinicalTrials.gov/show/NCT02386410
NCT02384590,Cognitive Behavioral Therapy and Real-time Self-management Intervention for SCD Via Mobile Applications,CaRISMA,Completed,No Results Available,Sickle Cell Disease|Depression|Anxiety,Behavioral: Computerized cognitive behavioral therapy,Patient acceptability as measured by CCBT sessions completed,University of Pittsburgh,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,30,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,PRO14120495,Mar-15,Jan-17,17-Jan-17,10-Mar-15,null,25-Jan-17,"University of Pittsburgh, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT02384590
NCT02383862,PROMIS Measures in Primary Care Practice,,Completed,Has Results,Sleep|Pain|Anxiety|Depression|Fatigue,Other: Feedback Group,"Change From Baseline in PROMIS Composite T-Score at 3-Month Follow-up|Change From Baseline in PROMIS Sleep T-score at 3-Month Follow up|Change From Baseline in PROMIS Pain T-score at 3-Month Follow up|Change From Baseline in PROMIS Anxiety T-score at 3-Month Follow up|Change From Baseline in PROMIS Depression T-score at 3-Month Follow up|Change From Baseline in PROMIS Fatigue T-score at 3-Month Follow up|Treatment Satisfaction at 3-Month Follow-up|Sleep at 3-month Follow up, as Measured by the Pittsburgh Insomnia Rating Scale (PIRS-2)|Pain at 3 Month Follow up, as Measured by PEG|Anxiety at 3 Month Follow up, as Measured by the Generalized Anxiety Disorder Scale (GAD-2)|Depression at 3-month Follow up, as Measured by the Patient Health Questionnaire (PHQ-2)|Fatigue at 3-month Follow up, as Measured by the SF-36 Vitality Scale|Percentage of Participants With Laboratory Tests Ordered for SPADE Symptoms at Baseline Clinic Visit|Percentage of Participants With Radiologic (RAD) Tests Ordered for SPADE Symptoms at Baseline Clinic Visit|Percentage of Participants With Tests Ordered (Other Than Radiologic and Laboratory Tests) for SPADE Symptoms at Baseline Clinic Visit|Percentage of Participants With Medications Ordered for SPADE Symptoms at Baseline Clinic Visit",Indiana University|Patient-Centered Outcomes Research Institute,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,300,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Screening,1410447721,Mar-15,Aug-16,Oct-16,9-Mar-15,16-Jun-17,16-Jun-17,"Indiana University, Indianapolis, Indiana, United States",,https://ClinicalTrials.gov/show/NCT02383862
NCT02382003,Web-based Interpretation Training For Anxiety,,Completed,No Results Available,Anxiety,Behavioral: Positive Cognitive Bias Modification - Interpretation|Behavioral: 50/50 Cognitive Bias Modification - Interpretation|Behavioral: Anxious Imagery Prime|Behavioral: Neutral Imagery Prime,"Change in Recognition Ratings|Change in Overall Anxiety Severity and Impairment Scale|Multi-Session User Experience Questionnaire|Change in Brief Bodily Sensations Interpretations Questionnaire|Impact of Anxious Imagery Prime (change over time is exploratory but should show anxious/neutral prime differences; e.g., in subjective distress)|Change in Depression, Anxiety, Stress Scales-Short Form: Anxiety Subscale|Change in Quality of Life Scale",University of Virginia,All,"18 Years and older   (Adult, Older Adult)",Phase 2,233,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",2013-0331-00,Apr-16,Jan-19,Mar-19,6-Mar-15,null,17-Apr-19,"MindTrails web site: https://mindtrails.virginia.edu/ (thru Univ. of Virginia), Charlottesville, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02382003
NCT02382224,Worry Exposure for Generalized Anxiety Disorder,,Withdrawn,No Results Available,Generalized Anxiety Disorder,Behavioral: Worry Exposure for GAD|Behavioral: 12-week Waitlist,Change in Penn State Worry Questionnaire (PSWQ).|Beck Anxiety Inventory (BAI).,University of Texas at Austin,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2015-02-0025,Sep-15,Jul-18,Sep-18,6-Mar-15,null,24-Jul-18,"University of Texas at Austin, Austin, Texas, United States",,https://ClinicalTrials.gov/show/NCT02382224
NCT02379949,Virtual Reality Exposure Therapy for the Treatment of Social Phobia,FOPSII,Completed,No Results Available,Social Anxiety Disorder,Behavioral: Virtual Reality Exposure Therapy|Behavioral: Exposure Group Therapy,Personal Report of Confidence as a Speaker|Fear of Negative Evaluation—Brief Form|Behavioral Avoidance Test|Clinician Global Impressions of Improvement,"Georgia State University|Virtually Better, Inc.",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,97,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,R42MH060506-02,Aug-04,Aug-07,Aug-07,5-Mar-15,null,5-Mar-15,"Georgia State University, Atlanta, Georgia, United States",,https://ClinicalTrials.gov/show/NCT02379949
NCT02377986,Augmenting Buried in Treasures Workshop (BIT) With In-home Decluttering Practice for Individuals With Hoarding Disorder,,Completed,No Results Available,Hoarding Disorder,Behavioral: BIT+in-home decluterring|Behavioral: In-Home Decluttering,Savings Inventory Revised|Clutter Image Rating Scale,New York State Psychiatric Institute,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,8,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,7073,Feb-15,Aug-15,Aug-15,4-Mar-15,null,10-Feb-16,,,https://ClinicalTrials.gov/show/NCT02377986
NCT02378012,iPad Use in Reducing Anxiety and Depression in Patients Undergoing Bone Marrow Transplant,BUCKiPAD,Terminated,No Results Available,Anxiety|Depression|Malignant Neoplasm,Other: Computer-Assisted Intervention|Other: Questionnaire Administration,Change in Hospital Anxiety and Depression Scale (HADS)-Anxiety score|Change in HADS depression score|Change in Profile of Mood States Short Form (POMS-SF) scores,Ohio State University Comprehensive Cancer Center,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,124,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,OSU-12207|NCI-2014-00935,Mar-14,Sep-14,Sep-14,4-Mar-15,null,2-Oct-17,"Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02378012
NCT02378896,Personalized Computerized Inhibitory Control Training for OCD,,Completed,No Results Available,Obsessive-Compulsive Disorder,Behavioral: Personalized Computer Program|Behavioral: Cognitive Behavioral Therapy,Obsessive-compulsive symptoms measured after 3 weeks of treatment,New York State Psychiatric Institute,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,11,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,#7059,Feb-15,Dec-17,Jan-18,4-Mar-15,null,29-Jan-18,"New York State Psychiactic Institute, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT02378896
NCT02376634,Hypnotherapy in Major Surgical Procedures,,Withdrawn,No Results Available,Scoliosis|Pectus Excavatum,Behavioral: Hypnosis,Pre-operative anxiety|Post-operative pain,Nationwide Children's Hospital,All,"10 Years to 21 Years   (Child, Adult)",Not Applicable,0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,IRB14-00837,Jun-16,Jul-16,Jul-16,3-Mar-15,null,9-Sep-16,"Nationwide Children's Hospital, Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02376634
NCT02376959,"Effect of Spiritist ""Passe"" Energy Therapy in Reducing Anxiety in Volunteers",,Unknown status,No Results Available,Anxiety Disorders,"Behavioral: Spiritist ""passe""",Change in Anxiety questionnaire from baselaine at 8 weeks|Change in Beck Depression Inventory from baselaine at 8 weeks|Change in WHOQOL-BREF quality of life questionnaire from baselaine at 8 weeks|Change in DUREL questionnaire for assessment of spirituality from baselaine at 8 weeks,Associação Médico Espírita de Botucatu,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,31078414.5.0000.5411,Sep-14,Nov-15,Dec-15,3-Mar-15,null,3-Mar-15,"Botucatu Medical School, Botucatu, Sao Paulo, Brazil",,https://ClinicalTrials.gov/show/NCT02376959
NCT02377375,Deep Brain Stimulation (DBS) for Obsessive Compulsive Disorder (OCD): Improving Targeting Precision,,Recruiting,No Results Available,Obsessive-Compulsive Disorder,Procedure: Micro-assisted technique|Procedure: Standard technique,Millimeter difference in position between planned and actual target,Universitaire Ziekenhuizen Leuven,All,"20 Years to 65 Years   (Adult, Older Adult)",Not Applicable,10,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",S57471,Jan-15,Dec-19,null,3-Mar-15,null,27-Jan-16,"UZ Leuven, Leuven, Vlaams-Brabant, Belgium",,https://ClinicalTrials.gov/show/NCT02377375
NCT02374567,Pharmacovigilance in Gerontopsychiatric Patients,GAP,Terminated,No Results Available,Dementia|Depression|Schizophrenia|Psychosomatic Disorders|Anxiety Disorders,Drug: Phenobarbital|Drug: Phenytoin|Drug: Carbamazepine|Drug: Oxcarbazepine|Drug: Valproic Acid|Drug: Lamotrigine|Drug: Topiramate|Drug: Gabapentin|Drug: Levetiracetam|Drug: Pregabalin|Drug: Lacosamide|Drug: Clonazepam|Drug: Biperiden|Drug: Levomepromazine|Drug: Fluphenazine|Drug: Perphenazine|Drug: Perazine|Drug: Thioridazine|Drug: Haloperidol|Drug: Melperone|Drug: Pipamperone|Drug: Bromperidol|Drug: Benperidol|Drug: Sertindole|Drug: Ziprasidone|Drug: Flupentixol|Drug: Chlorprothixene|Drug: Zuclopenthixol|Drug: Fluspirilene|Drug: Pimozide|Drug: Clozapine|Drug: Olanzapine|Drug: Quetiapine|Drug: Sulpiride|Drug: Tiapride|Drug: Amisulpride|Drug: Prothipendyl|Drug: Risperidone|Drug: Aripiprazole|Drug: Paliperidone|Drug: Diazepam|Drug: Oxazepam|Drug: Lorazepam|Drug: Bromazepam|Drug: Clobazam|Drug: Alprazolam|Drug: Hydroxyzine|Drug: Buspirone|Drug: Chloral Hydrate|Drug: Flurazepam|Drug: Nitrazepam|Drug: Triazolam|Drug: Lormetazepam|Drug: Temazepam|Drug: Midazolam|Drug: Brotizolam|Drug: Zopiclone|Drug: Zolpidem|Drug: Zaleplon|Drug: Melatonin|Drug: Clomethiazole|Drug: Diphenhydramine|Drug: Promethazine|Drug: Imipramine|Drug: Clomipramine|Drug: Opipramol|Drug: Trimipramine|Drug: Amitriptyline|Drug: Nortriptyline|Drug: Doxepin|Drug: Maprotiline|Drug: Amitriptyline oxide|Drug: Fluoxetine|Drug: Citalopram|Drug: Paroxetine|Drug: Sertraline|Drug: Fluvoxamine|Drug: Escitalopram|Drug: Tranylcypromine|Drug: Moclobemide|Drug: Mianserin|Drug: Trazodone|Drug: Mirtazapine|Drug: Bupropion|Drug: Venlafaxine|Drug: Reboxetine|Drug: Duloxetine|Drug: Agomelatine|Drug: Pyritinol|Drug: Piracetam|Drug: Donepezil|Drug: Rivastigmine|Drug: Galantamine|Drug: Memantine|Drug: Nicergoline|Drug: Acamprosate|Drug: Lithium,Assessment of frequency and severity of adverse events|Assessment of cognitive functioning|Quality of life|Adverse drug reactions|Serum level of substances|Electrocardiogram|Medication intake,Hannover Medical School,All,65 Years and older   (Older Adult),Phase 3,407,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GAP-2014,Jan-15,28-Jun-17,28-Jun-17,2-Mar-15,null,28-Feb-18,"Bezirkskrankenhaus Augsburg, Augsburg, Germany|Krankenhaus Hedwigshöhe, Berlin, Germany|Hannover Medical School, Hannover, Germany|Asklepios Fachklinikum Lübben, Lübben, Germany|Asklepios Fachklinikum Teupitz, Teupitz, Germany",,https://ClinicalTrials.gov/show/NCT02374567
NCT02375152,Safety and Effectiveness of Capsulotomy in Refractory OCD,,Unknown status,No Results Available,Obsessive-Compulsive Disorder,Procedure: Anterior Capsulotomy,"Change in Y-BOCS Score|Change in Clinical Global Impressions Scale Score|Change in Hamilton Anxiety Scale, Hamilton Depression Scale-17 Score|Change in Temperament and Character Inventory revised version (TCI-R) Score|Change in functional magnetic resonance imaging (fMRI) images|Change in Psychophysical tasks（ Iowa Gambling Task , Model Task, Working memory task ）|WHO disability assessment 2.0 (self, 12 terms)",Ruijin Hospital|National Natural Science Foundation of China,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2|Phase 3,30,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2014-14,Apr-15,Dec-18,Dec-18,2-Mar-15,null,28-Apr-15,"Shanghai Ruijin Hospital, Shanghai, Shanghai, China",,https://ClinicalTrials.gov/show/NCT02375152
NCT02371954,Exercise to Prevent Depression and Anxiety in Older Hispanics,,Completed,No Results Available,Anxiety|Depression,Behavioral: Happy Older Latinos are Active|Other: Fotonovela,"Prevention of major depression, generalized anxiety, and social anxiety as measured the Mini International Neuropsychiatric Interview|Physical functioning as measured by the World Health Organization Disability Assessment Schedule 2.0 (WHO-DAS 2)|Social functioningas measured by the World Health Organization Disability Assessment Schedule 2.0 (WHO-DAS 2)|Self-efficacy as measured by the General Self-Efficacy Scale|Sleep quality as measured by the Pittsburgh Sleep Quality Index|Change in depression symptom severity as measured by the Quick Inventory of Depressive Symptomatology - Self Report (QIDS-SR).|Change in anxiety symptom severity as measured by the Beck Anxiety Inventory (BAI)",University of Miami,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,20140607,Sep-13,Aug-18,Aug-18,26-Feb-15,null,7-Sep-18,"Jackson Memorial Mental Health Hospital, Miami, Florida, United States",,https://ClinicalTrials.gov/show/NCT02371954
NCT02372019,Augmentation Study of A Computerized Treatment for Social Anxiety Disorder,,Unknown status,No Results Available,Social Anxiety Disorder,Behavioral: CBM With Active Fear Reactivation|Behavioral: CBM With Inert Fear Reactivation|Behavioral: Inert CBM With Inert Fear Reactivation,Change From Baseline in Liebowitz Social Anxiety Scale (LSAS) at 24 Hours|Change From Baseline in Liebowitz Social Anxiety Scale (LSAS) at 1 Week|Change From Baseline in Liebowitz Social Anxiety Scale (LSAS) at 2 Weeks|Change From Baseline in Brief Fear of Negative Evaluation Scale (BFNE) at 24 Hours|Change From Baseline in Brief Fear of Negative Evaluation Scale (BFNE) at 1 Week|Change From Baseline in Brief Fear of Negative Evaluation Scale (BFNE) at 2 Weeks|Change From Baseline in Appraisal of Social Concerns Scale (ASC) at 24 Hours|Change From Baseline in Appraisal of Social Concerns Scale (ASC) at 1 Week|Change From Baseline in Appraisal of Social Concerns Scale (ASC) at 2 Weeks|Word Sentence Association Paradigm (WSAP)|Ambiguous Social Scenarios Interpretation Questionnaire (ASSIQ)|Brief State-Trait Anxiety Inventory- State (BSTAI)|Perception of Speech Performance Measure (PSP)|Self-Beliefs Related To Social Anxiety Scale (SBSA)|Interpretation of Positive Events Scale (IPES)|Beck Depression Inventory-II (BDI-II)|Dot Probe Task|Anxiety and Related Disorders Interview Schedule for DSM-5 (ADIS),University of Texas at Austin,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,122,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",2014-11-0009,Feb-15,Dec-16,Dec-16,26-Feb-15,null,2-Sep-15,"Laboratory for the Study of Anxiety Disorders, University of Texas at Austin, Austin, Texas, United States",,https://ClinicalTrials.gov/show/NCT02372019
NCT02372110,Disentangling Anxiety Sensitivity and Anxiety-induced Physiological Stress Response,,Completed,No Results Available,Anxiety,"Drug: HPA, ANS stimulation|Drug: Placebo",Heart Rate,University of Texas at Austin,All,"18 Years and older   (Adult, Older Adult)",Phase 4,120,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",2015010023,Mar-15,Nov-15,Nov-15,26-Feb-15,null,2-Dec-15,"University of Texas at Austin, Austin, Texas, United States",,https://ClinicalTrials.gov/show/NCT02372110
NCT02367430,Critical Time Intervention for Individuals With Hoarding Disorder,CTI-HD,Completed,No Results Available,Hoarding Disorder,Behavioral: Critical Time Intervention With Buried in Treasures included|Behavioral: Buried in Treasures Workshop,Savings Inventory-Revised|Clutter Image Rating Scale,New York State Psychiatric Institute,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,28,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,6681,Jan-13,Jul-15,Jul-15,20-Feb-15,null,1-Sep-15,,,https://ClinicalTrials.gov/show/NCT02367430
NCT02367508,Mindfully Optimizing Delivery of End-of-Life Care,MODEL Care,Completed,No Results Available,Cancer|Coping Skills,Behavioral: MODEL Care,Feasibility: Recruitment Rates at Baseline|Feasibility: Enrollment Rates at Baseline|Feasibility: Attendance at Post-Intervention (6 weeks)|Feasibility: Retention Rates at Post-Intervention (6 weeks)|Acceptability: Intervention Satisfaction at Post-Intervention (6 weeks)|Feasibility: Retention Rates at 1-Month Follow-up (10 weeks)|Change from Baseline in Avoidant Coping at Post-Intervention (6 weeks)|Change from Baseline in Avoidant Coping at 1-Month Follow-up (10 weeks)|Change from Baseline in Quality of Life at Post-Intervention (6 weeks)|Change from Baseline in Quality of Life at 1-Month Follow-up (10 weeks)|Change from Baseline in Depression at Post-Intervention (6 weeks)|Change from Baseline in Depression at 1-Month Follow-up (10 weeks)|Change from Baseline in Anxiety at Post-Intervention (6 weeks)|Change from Baseline in Anxiety at 1-Month Follow-up (10 weeks)|Change from Baseline in Readiness for Advance Care Planning at Post-Intervention (6 weeks)|Change from Baseline in Readiness for Advance Care Planning at 1-Month Follow-up (10 weeks),Indiana University|Walther Cancer Institute|Charles Warren Fairbanks Center for Medical Ethics,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,31,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,1312088151,Feb-14,Apr-14,May-15,20-Feb-15,null,28-Jul-16,,,https://ClinicalTrials.gov/show/NCT02367508
NCT02365870,Anxiety in Parkinson's: Use of Quantitative Methods to Guide Rational Treatment,ANXPD,Recruiting,No Results Available,Anxiety Disorders|Parkinson Disease,Drug: rotigotine transdermal patch|Drug: placebo,Hamilton Anxiety Rating Scale|17-item Hamilton Depression Rating Scale,Johns Hopkins University|National Institute on Aging (NIA),All,"21 Years to 89 Years   (Adult, Older Adult)",Phase 4,60,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",NA_00092051|1K23AG044441-01A1,Aug-16,Oct-19,Dec-19,19-Feb-15,null,8-Jan-19,"Johns Hopkins University School of Medicine, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT02365870
NCT02366390,Dialogue Aimed at Reducing Anxiety in Patients With Severe COPD,DIACOL,Completed,No Results Available,Chronic Obstructive Pulmonary Disease|Anxiety,Behavioral: Psychoeducative intervention,Change in HADS-A score from baseline to three months follow-up|Change in CRQ score from baseline to three months follow-up|Change in SGRQ score from baseline to three months follow-up|Change in HADS-D score from baseline to three months follow-up|Number of admissions|Length of Stay (LOS),Nordsjaellands Hospital,All,"Child, Adult, Older Adult",Phase 4,66,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,DIACOL,Feb-15,Apr-16,Apr-16,19-Feb-15,null,23-Jun-16,"Nordsjællands Hospital, Department of Pulmonary & Infectious Diseases, Hillerød, Capital Region of Denmark, Denmark",,https://ClinicalTrials.gov/show/NCT02366390
NCT02366520,Handheld Mirror to Improve Child's Behavior During Dental Treatment,,Recruiting,No Results Available,Behavior,Device: handheld mirror,Number of instances of child's disruptive behavior defined by the Anxious and Disruptive Behavior Code|Child's cooperative behavior level assessed by Frankle's Cooperative Behavior Scale,Case Western Reserve University,All,3 Years to 17 Years   (Child),Not Applicable,60,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research,3/14/1937,May-15,Apr-18,Jun-19,19-Feb-15,null,29-Mar-17,"University Hospitals, Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02366520
NCT02363634,Clinical Trial to Evaluate Magtein in Older Adults,,Completed,No Results Available,Mood|Anxiety,Dietary Supplement: magnesium threonate,To determine the acute effects and the effects of 12-weeks supplementation with Magtein™ as compared to placebo on magnesium status as measured by the sponsor's protocol for determining body magnesium status.|To determine the effects of Magtein on Mood states ( as measured by the Hamilton Anxiety Rating Scale (HAM-A))|To determine the effects of Magtein on Mood states ( As measured by the Positive and Negative Affect Schedule (PANAS)|To determine the effects of Magtein on sleep quality (as measured by the Pittsburgh Sleep Quality Index (PSQI)|4. To determine the effects of Magtein on cognitive function (as measured by the Erikson Flanker Task)|4. To determine the effects of Magtein on cognitive function (as measured by computerized cognitive tests including Short-Term Memory Test (STM))|To determine relative safety of Magtein with 12 weeks use,Miami Research Associates,All,"45 Years to 70 Years   (Adult, Older Adult)",Not Applicable,50,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",AIDP-Mg-2012,Aug-12,Sep-13,Nov-13,16-Feb-15,null,16-Feb-15,"Miami Research Associates, Miami, Florida, United States",,https://ClinicalTrials.gov/show/NCT02363634
NCT02363205,Internet-Delivered Cognitive Behaviour Therapy for Adolescent Depression,,"Active, not recruiting",No Results Available,Depression|Anxiety,Behavioral: Tailored Internet-administrated CBT-Treatment,"Beck Depression Inventory|Beck Anxiety Inventory (BAI)|Social Interaction Anxiety Scale (SIAS)|The General Self-Efficacy Scale (GSE)|Subscale Life activites, WHO Disability Assessment Schedule 2.0 (WHODAS 2.0)|Knowledge of CBT strategies (developed by the research group)|Patient Health Questionnaire (PHQ)|The Mood and Feelings Questionnaire (MFQ)",Linkoeping University,All,"15 Years to 19 Years   (Child, Adult)",Not Applicable,150,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2014/427-31,Feb-15,Dec-17,Dec-17,13-Feb-15,null,7-Sep-17,"Linköping University, Linköping, Östergotland, Sweden",,https://ClinicalTrials.gov/show/NCT02363205
NCT02361190,Effects of Fast Acting Testosterone Nasal Spray on Anxiety,,Completed,No Results Available,Anxiety,Drug: Testosterone|Drug: Placebo,Magnitude of behavioral approach,University of Texas at Austin,Male,"18 Years and older   (Adult, Older Adult)",Not Applicable,96,Other,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",2014-07-0062,Feb-15,Apr-16,May-16,11-Feb-15,null,13-Jun-16,"University of Texas at Austin Department of Psychology, Austin, Texas, United States",,https://ClinicalTrials.gov/show/NCT02361190
NCT02360033,Systemic Therapy and Cognitive Behavioral Therapy for Social Anxiety Disorders,,Unknown status,No Results Available,Social Anxiety Disorder,Behavioral: Systemic Therapy for Social Anxiety Disorder|Behavioral: Cognitive Behavioral Therapy for Social Anxiety Disorder,"Change of Liebowitz Social Anxiety Scale (LSAS-SR)|Change of Social Interaction Anxiety Scale (SIAS)|Change of Social Phobia Scale (SPS)|Change of Adjustment to Symptomatology Scale (ASS)|Change of Evaluation of Social Systems (EVOS)|Change of Experience in Social Systems (EXIS)|Change of Beck Depression Inventory-II (BDI-II)|Change of Brief Symptom Checklist (BSCL)|Change of Inventory of Interpersonal Problems (IIP-32)|Change of Dyadic Adjustment Scale (DAS-12)|Change of University of Rhode Island Change Assessment (URICA-S, short version)|Change of Burden Assessment Scale (BAS)|Change of Scale for the Multiperspective Assessment of General Change Mechanisms in Psychotherapy (SACiP),",Heidelberg University,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,32,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SOPHO-PT-2014,Jan-15,Jan-16,Aug-16,10-Feb-15,null,10-Feb-15,"Institute of Medical Psychology, University Hospital Heidelberg, Heidelberg, Baden-Württemberg, Germany",,https://ClinicalTrials.gov/show/NCT02360033
NCT02357680,Diaries for Critically Ill Patients Written by Relatives,,Completed,No Results Available,"Stress Disorders, Post-Traumatic|Anxiety|Depression",Other: Diary,PTSS-14 (Post Traumatic Stress Symptoms)|HADS (Hospital Anxiety and Depression Scale)|SF-36,Hospitalsenheden Vest|University of Aarhus,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,189,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care,45129,15-Mar-15,31-Oct-17,31-Oct-17,6-Feb-15,null,20-Nov-17,"Regionshospitalet Herning, Herning, Region Midtjylland, Denmark|Regionshospitalet Holstebro, Holstebro, Region Midtjylland, Denmark",,https://ClinicalTrials.gov/show/NCT02357680
NCT02355002,Transcranial Magnetic Stimulation (TMS) in Obsessive Compulsive Disorder (OCD): Mechanisms and Biomarkers,TMSOCD,Recruiting,No Results Available,Obsessive Compulsive Disorder,Device: Transcranial Magnetic Stimulation,Obsessive compulsive symptoms as measured by Yale-Brown Obsessive Compulsive Scale (Y-BOCS)|Obsessive compulsive beliefs as measured by Obsessive-Compulsive Beliefs Questionnaire (OBQ)|Total number of obsessive symptoms is reduced as measured by Obsessive-Compulsive Inventory Questionnaire (OCI),Massachusetts General Hospital,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,58,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2014P002560,May-15,Jan-20,Jan-20,4-Feb-15,null,15-Feb-19,"Massachusetts General Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT02355002
NCT02352870,Intervention for Improving Psychological Distress in Dialysis,iDiD,Completed,No Results Available,"Kidney Failure, Chronic|Depression|Anxiety",Behavioral: Computerised Cognitive Behavioural Therapy|Behavioral: Telephone support,"Consent to psychological screen rate using self-report measures of depression (PHQ-9) and anxiety (GAD-7)|Recruitment , randomisation, and retention rates|Adherence to the online intervention + telephone support calls (therapist supported arm only)|PHQ-9 (A self-report 9 item measure of depression)|GAD-7 (A self-report 7 item measure of anxiety)|EQ-5D (A self-report measure of quality of life)|Brief Illness Perceptions Questionnaire|Client Service Receipt Inventory (A self-report measure of health service utilisation)|Satisfaction with treatment (A 2 item measure generated for the purposes of present study)","King's College London|National Health Service, United Kingdom|University of Southampton",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,25,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other,PAHTMZA WPAH 68913|14.LO.1934,Feb-15,Jun-16,Jun-16,2-Feb-15,null,10-Oct-17,"Guy's and St Thomas NHS Trust, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT02352870
NCT02350257,Internet-Based CBT for Children With Anxiety Disorders: Implementation in Clinical Settings,,Completed,No Results Available,Anxiety Disorders,Behavioral: Internet-based CBT,"Clinician Severity Rating (CSR)|Presence of DSM Anxiety disorder|Children´s Globas Assessment Scale (CGAS)|Clinical Global Impression - Improvement (CGI-I)|Revised Children´s Anxiety and Depression Scale - Child version (RCADS-C)|Revised Children´s Anxiety and Depression Scale - Parent version (RCADS-P)|KIDSCREEN-10 Child version|KIDSCREEN-10 Parent version|Education, Work and Social Adjustment Scale - Child version (EWSAS-C)|Education, Work and Social Adjustment Scale - Parent version (EWSAS-P)|Hospital Anxiety and Depression Scale - Parents (HADS)|Technology Acceptance Scale - Child (TAS-C)|Technology Acceptance Scale - Parent (TAS-P)|Trimbos/iMTA questionnaire for Costs associated with Psychiatric Illness (TIC-P)|Measurement of compliance to exposure assignments and anxiety levels, through mobile app|Unintended treatment effects|Specific Phobia Questionnaire - Child version (SPQ-C)|Specific Phobia Questionnaire - Parent version (SPQ-P)",Karolinska Institutet,All,8 Years to 12 Years   (Child),Not Applicable,131,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,BIPSY RCT,Mar-15,Apr-18,Apr-18,29-Jan-15,null,6-Sep-18,"BUP CPF, Stockholm, Sweden",,https://ClinicalTrials.gov/show/NCT02350257
NCT02350504,Impact of Childrens Preparation Before MRI on Anxiety and Need for Anesthesia: a Prospective Randomized Clinical Trial,,Completed,No Results Available,Proportion of Anesthesia|Anxiety Level,Behavioral: Full interactive instruction,Proportion of children which will be anesthetized,Soroka University Medical Center,All,5 Years to 16 Years   (Child),Not Applicable,131,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,SOR033614CTIL,Dec-13,Mar-15,Mar-15,29-Jan-15,null,19-Jun-15,"Soroka University Medical Center, Beer-Sheva, Israel",,https://ClinicalTrials.gov/show/NCT02350504
NCT02349412,Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers,,"Active, not recruiting",Has Results,Liver Cancer|Anxiety Disorder|Depression|Small Cell Lung Cancer|Extrahepatic Bile Duct Cancer|Malignant Mesothelioma|Pancreatic Cancer|Esophageal Cancer|Gastric Cancer|Non-small Cell Lung Cancer,Other: Early palliative care,"Change in Quality of Life (QOL) From Baseline to Week 12 Per the Functional Assessment of Cancer Therapy-General (FACT-G)|Change in Quality of Life (QOL) From Baseline to Week 24 Per the Functional Assessment of Cancer Therapy-General (FACT-G)|Change in Quality of Life (QOL) From Baseline to Week 12 Per the Hospital Anxiety and Depression Scale (HADS) - Depression|Change in Quality of Life (QOL) From Baseline to Week 12 Per the Hospital Anxiety and Depression Scale (HADS) - Anxiety|Prognostic Understanding at Week-12 as Measured by ""Have You and Your Oncologist Discussed Any Particular Wishes About the Care You Would Want to Receive if You Were Dying?"" Question on the Prognosis and Treatment Perceptions Questionnaire|Change in QOL on the SF-36 Over Time|Rate of Referral, Enrollment and Length of Stay on Hospice|Location of Death|Number of Hospital and Intensive Care Unit (ICU) Admissions and Days|Chemotherapy and Radiation Administration|Overall Survival|Concordance Between Patient and Family Caregiver Report of Prognosis/Curability",Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 3,405,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,A221303|U10CA037447|UG1CA189823|NCI-2014-01943,Apr-15,3-Jul-17,null,28-Jan-15,28-Feb-19,28-Feb-19,"UC San Diego Moores Cancer Center, La Jolla, California, United States|Queen's Medical Center, Honolulu, Hawaii, United States|University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States|NorthShore University HealthSystem-Evanston Hospital, Evanston, Illinois, United States|NorthShore University HealthSystem-Glenbrook Hospital, Glenview, Illinois, United States|NorthShore University HealthSystem-Highland Park Hospital, Highland Park, Illinois, United States|University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Mercy Health Saint Mary's, Grand Rapids, Michigan, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Park Nicollet Clinic - Saint Louis Park, Saint Louis Park, Minnesota, United States|Regions Hospital, Saint Paul, Minnesota, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|North Shore-LIJ Health System/Center for Advanced Medicine, New Hyde Park, New York, United States|Columbia University/Herbert Irving Cancer Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Altru Cancer Center, Grand Forks, North Dakota, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States|Gundersen Lutheran Medical Center, La Crosse, Wisconsin, United States|Marshfield Clinic, Marshfield, Wisconsin, United States|Froedtert and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/12/NCT02349412/Prot_SAP_ICF_000.pdf",https://ClinicalTrials.gov/show/NCT02349412
NCT02347033,Trial of Sertraline Versus Cognitive Behaviour Therapy for Generalised Anxiety,ToSCA,Terminated,No Results Available,Generalised Anxiety Disorder,Drug: Sertraline|Behavioral: Cognitive Behavioural Therapy,GAD-7|HAM-A|Patient Health Questionnaire (PHQ-9)|Work and Social Activity Scale (WASAS)|Euroquol-5 item-3 level (EQ-5D-3L)|Employment and Social Care Questionnaire (ESC)|(CSQ) Client Satisfaction Questionnaire|Patient preference rating scale,"University College, London|NHS Health Technology Assessment Programme|National Institute for Health Research, United Kingdom",All,"18 Years and older   (Adult, Older Adult)",Phase 4,5,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,14/0249,Aug-14,Feb-16,Feb-16,27-Jan-15,null,11-Jul-16,"Camden & Islington (with Kingston), London, United Kingdom",,https://ClinicalTrials.gov/show/NCT02347033
NCT02347748,Comfort Talk for Pediatric Cardiac Catheterization,,"Active, not recruiting",No Results Available,"Anxiety|Pain|Adaptation, Psychological|Stress, Psychological",Behavioral: Reading pre-procedure script|Behavioral: Reading pre-extubation script|Behavioral: Reading 2 scripts,Pre-anesthesia Anxiety|Postoperative Behavior|Satisfaction with care|Procedure Time|Recovery room time|Drug usage during procedure|Drug usage during recovery|Antiemetics|Anesthesia induction behavior|Nausea|Rebleeds|Pain|Self-reported anxiety,The Hospital for Sick Children,All,"7 Years to 18 Years   (Child, Adult)",Not Applicable,160,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Supportive Care",1000046792,Jan-15,Jun-18,Jan-19,27-Jan-15,null,5-Sep-18,"Hospital for Sick Children, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT02347748
NCT02344745,Lavender Aromatherapy for Anxiety During Urodynamics,,Completed,Has Results,Anxiety|Pain,Other: Lavandula angustifolia essential oil (Aura Cacia)|Other: Distilled water,Anxiety Measured by VAS|Wong Baker Pain Scale,University of Southern California,Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,80,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Treatment,HS-14-00444,Oct-14,Aug-15,Aug-15,26-Jan-15,16-Dec-16,16-Dec-16,"Los Angeles Count + USC Medical Center, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT02344745
NCT02345122,CAMH PARTNERs Integrated Care Study,PARTNERs,Enrolling by invitation,No Results Available,Depression|Anxiety|Alcohol Drinking,Behavioral: Intervention: Mental Health Technician|Other: Enhanced Usual Care,"Severity of depressive symptoms, as measured with PHQ-9 during phone interviews at 4, 8, and 12 months|Initiation or change in antidepressant medication documented in the health record at the 4-, 8-, and 12-month follow up|Severity of anxiety symptoms during the past 2 weeks and number of drinks during the past week|Time to initiation of first specific treatment for depression by the primary care provider",Centre for Addiction and Mental Health|CAMH Foundation|Capital Solution Design LLC,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,504,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",054/2014,Nov-14,Apr-19,Apr-19,26-Jan-15,null,2-Apr-19,"Centre for Addiction and Mental Health, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT02345122
NCT02345668,Effectiveness of a Transdiagnostic Internet-based Treatment for Emotional Disorders,,Recruiting,No Results Available,Anxiety|Depression,Behavioral: Emotion Regulation Protocol|Drug: Treatment as Usual (Pharmacological Treatment)|Behavioral: Treatment as Usual (Psychological Treatment),"Change in the Beck Depression Inventory II (BDI-II) (Beck, Steer, & Brown, 1996) at pre, post intervention and at 3 and 12 months follow-ups.|Change in the Beck Anxiety Inventory (BAI) (Beck, & Steer, 1990) at pre, post intervention and at 3 and 12 months follow-ups.|Change in the Obsessive-Compulsive Inventory (OCI-R) (Foa et al., 2002) at pre, post intervention and at 3 and 12 months follow-ups.|Change in the Self-Reported Panic Disorder Severity Scale (PDSS-SR) (Houck, Spiegel, Shear, & Rucci, 2002) at pre, post intervention and at 3 and 12 months follow-ups.|Change in the Pen State Worry Questionnaire (PSWQ) (Meyer, Miller, Metzger, & Borkovec, 1990) at pre, post intervention and at 3 and 12 months follow-ups.|Change in the Social Interaction Anxiety Inventory (SIAS) (Mattick y Clarke, 1998) at pre, post intervention and at 3 and 12 months follow-ups.",Universitat Jaume I|Consorcio Hospitalario Provincial de Castellón,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,200,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,UJaumeI09,Apr-15,Jul-19,Jul-19,26-Jan-15,null,9-May-19,"University Jaume I, Castellón, Spain",,https://ClinicalTrials.gov/show/NCT02345668
NCT02343965,"The Impact of the Practice of Touch-massage on the Anxiety of Patients With Hematological Disorders Hospitalized in a Protective Environment, a Randomized, Controlled Study",TANDHEMS,Completed,No Results Available,Hematologic Diseases,Other: Touch-massage,"Impact of touch-massage practice on patients' anxiety state, as measured by the anxiety-state questionnaire (Spielberger, CD et al, 1983) to assess the predisposition to anxiety.|Evolution of Self Esteem, as measured by the self-esteem questionnaire|Evolution of anxiety, measured by the the anxiety-state questionnaire (Spielberger, CD et al, 1983)|Evolution of anxiety",Nantes University Hospital,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,62,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,RC14_0202,Jan-15,Dec-15,Dec-15,22-Jan-15,null,21-Jan-16,,,https://ClinicalTrials.gov/show/NCT02343965
NCT02340351,Auricular Acupuncture vs. Progressive Muscle Relaxation in Patients With Anxiety Disorders or Major Depressive Disorder.,,Completed,No Results Available,"Anxiety Disorders|Depressive Disorder, Major",Device: Auricular acupuncture|Procedure: Progressive muscle relaxation,"Mean VAS scores of anxiety, tension, anger/aggression and mood before and after treatment within each treatment group at week 1.|Mean VAS scores of anxiety, tension, anger/aggression and mood before and after treatment within each treatment group at week 2.|Mean VAS scores of anxiety, tension, anger/aggression and mood before and after treatment within each treatment group at week 3.|Mean VAS scores of anxiety, tension, anger/aggression and mood before and after treatment within each treatment group at week 4.",Universitätsklinikum Hamburg-Eppendorf,All,"Child, Adult, Older Adult",Not Applicable,136,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,UKE-Psych-Aku-08-14,Jul-07,Mar-09,Aug-13,16-Jan-15,null,16-Jan-15,,,https://ClinicalTrials.gov/show/NCT02340351
NCT02340637,Coping Kids: Early Intervention for Anxiety and Depression,TIM,Completed,No Results Available,Anxiety|Depression,Behavioral: Coping Kids|Behavioral: TAU,MASC-C (Multidimensional Anxiety Scale for Children)|MFQ (Mood and Feelings Questionnaire-short version),Regionsenter for barn og unges psykiske helse|The Research Council of Norway|Regional kunnskapssenter for barn og unge - Midt|Regional kunnskapssenter for barn og unge - Nord,All,8 Years to 13 Years   (Child),Not Applicable,700,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,228846/H10,Jan-14,Jul-17,Jul-17,16-Jan-15,null,26-Sep-18,"Regionsenter for barn og unges psykiske helse, Oslo, Norway|Regional kunnskapssenter for barn og unge - Nord, Tromsø, Norway|Regional kunnskapssenter for barn og unge - Midt, Trondheim, Norway",,https://ClinicalTrials.gov/show/NCT02340637
NCT02339363,Effects of Sitting Meditation and Hatha Yoga in Adolescents,,Completed,No Results Available,Anxiety|Psychological Stress,Behavioral: Sitting Meditation|Behavioral: Hatha yoga,Working Memory Capacity: Automated Operational Span Task (AOSPAN)|Stress: Perceived Stress Scale (PSS-10)|Anxiety: Screen for Child Anxiety and Related Emotional Disorders (SCARED)|Mindfulness: Child Acceptance and Mindfulness Measure (CAMM),Alliant International University,All,12 Years to 17 Years   (Child),Phase 1|Phase 2,198,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Quach-1-2013,Mar-13,Jun-13,Jul-13,15-Jan-15,null,15-Jan-15,,,https://ClinicalTrials.gov/show/NCT02339363
NCT02338453,Attention Bias Modification Treatment (ABMT) and Cognitive-Behavioral Group Therapy (CBGT) in Social Anxiety Disorder,ABMT+CBGT,Completed,No Results Available,Social Anxiety Disorder,Behavioral: Active Attention Bias Modification Treatment|Behavioral: Placebo Attention Bias Modification Treatment,"Change from baseline - the Liebowitz Social Anxiety Scale - Diagnostic Interview (LSAS; Liebowitz, 1987) scores|Change from baseline - the Social Phobia Inventory (SPIN; Connor et al., 2000) scores",Yair Bar-Haim|Geha Mental Health Center|Tel Aviv University,All,18 Years to 60 Years   (Adult),Not Applicable,50,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",TauGeha-001-15,Mar-15,Mar-17,Mar-17,14-Jan-15,null,22-Aug-17,"Geha Mental Health Center, Petah-Tikva, Israel|Tel-Aviv University, Tel-Aviv, Israel",,https://ClinicalTrials.gov/show/NCT02338453
NCT02336880,Internet-delivered CBT for NCCP-patients - a Pilot Trial,,Completed,No Results Available,Chest Pain|Anxiety|Fear,Behavioral: Internet-delivered cognitive behavioural therapy,Cardiac anxiety (Data collection)|Fear of body sensations (Data collection)|Depressive symptoms (Data collection)|Healthcare utilization and costs (Data collection),"Linkoeping University|Ostergotland County Council, Sweden|Medical Research Council of Southeast Sweden",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,15,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,I-CBT in NCCP,Jan-15,Mar-15,Jun-16,13-Jan-15,null,22-Aug-16,"Linkoeping University, Linkoeping, Sweden",,https://ClinicalTrials.gov/show/NCT02336880
NCT02336308,"A Randomized, Double-Blind Study of Placebo vs. Ketamine For Use During Dressing Changes in Critically Ill Burn Patients",,Withdrawn,No Results Available,Thermal Hyperalgesia|Anxiety|Pain,"Drug: Ketamine|Drug: Placebo, Normal Saline","Opioid and benzodiazepine requirements before, during, and after dressing changes between placebo and ketamine|Pain levels before, during, and after dressing changes between placebo and ketamine.|Pain-related anxiety surrounding dressing changes between placebo and ketamine.|The occurrence of hypo- or hypertension, tachycardia, neurologic agitation / disassociation, over-sedation, and the need for open-label ketamine between placebo and ketamine.|Evaluate the magnitude of change in serum concentrations of IL-1β and IL-6 levels during dressing changes between placebo and ketamine.|The incidence of ASD between placebo and ketamine after dressing changes.|The incidence of depression between placebo and ketamine after dressing changes.|The incidence of PTSD between placebo and ketamine after dressing changes.","University of Colorado, Denver",All,"18 Years to 89 Years   (Adult, Older Adult)",Phase 4,0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",14-1671,Jan-15,Jan-15,Jan-15,12-Jan-15,null,26-Nov-15,"University of Colorado, Aurora, Colorado, United States",,https://ClinicalTrials.gov/show/NCT02336308
NCT02334332,Educational Brochure in Preparing Patients With Gastric Cancer and Their Caregivers for Recovery After Surgery,,Withdrawn,No Results Available,Anxiety|Gastric Carcinoma|Stress,Other: Educational Intervention|Procedure: Standard Follow-Up Care|Procedure: Quality-of-Life Assessment,"Patient/informal caregiver satisfaction with timing, content, and delivery of the intervention|Change in mean survey scores",City of Hope Medical Center|National Cancer Institute (NCI),All,"21 Years and older   (Adult, Older Adult)",Not Applicable,0,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,14286|NCI-2014-02563,Jan-15,Sep-15,Sep-15,8-Jan-15,null,25-Sep-15,"City of Hope Medical Center, Duarte, California, United States",,https://ClinicalTrials.gov/show/NCT02334332
NCT02334644,Probiotic Treatment in Adult Obsessive-Compulsive Disorder,,Recruiting,No Results Available,Obsessive-Compulsive Disorder,Dietary Supplement: Probiotic Formula (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175)|Dietary Supplement: Placebo,Yale Brown Obsessive-Compulsive Scale [YBOCS]|Clinical Global Impression - Improvement ≤ 2 [CGI-I]|Mean change from baseline on the following scales: Quality of Life and Employment Satisfaction Questionnaire|Sheehan Disability Scale|Montgomery-Asberg Depression Rating Scale (MADRS)|Obsessive-Compulsive Inventory - Revised|Depression Anxiety Stress Scale|Dutch Dimensional Obsessive-Compulsive Scale,McMaster University|Hamilton Health Sciences Corporation|Lallemand Health Solutions,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,64,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",15-049,Apr-15,Apr-19,Aug-19,8-Jan-15,null,11-Apr-18,"MacAnxiety Research Centre, Hamilton, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT02334644
NCT02330627,Positive Valence System Enhancement Treatment for Anxiety and Depression: Clinical Efficacy and Neural Changes,,Completed,No Results Available,Anxiety Disorders and Symptoms|Depression,Behavioral: Positive Valence System Treatment,"Change from baseline in positive affect (Positive and Negative Affect Schedule; Modified Differential Emotions Scale; composite)|Change from baseline in blood oxygen level dependent (BOLD) response in the striatum and medial prefrontal cortex, as measured with functional magnetic resonance imaging (fMRI) during reward trials on the Monetary Incentive Delay (MID) task|Change from baseline in negative affect (Positive and Negative Affect Schedule; Modified Differential Emotions Scale; composite)|Change from baseline in blood oxygen level dependent (BOLD) response in the striatum and insula, as measured with functional magnetic resonance imaging (fMRI) during loss trials on the Monetary Incentive Delay (MID) task","University of California, San Diego|National Institutes of Health (NIH)",All,18 Years to 55 Years   (Adult),Not Applicable,29,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,5UL1TR000100,Apr-14,Jul-15,Mar-16,5-Jan-15,null,31-Oct-16,"UCSD Psychiatry Clinical Research, La Jolla, California, United States",,https://ClinicalTrials.gov/show/NCT02330627
NCT02328690,The Sound Mind Warrior Study,,Completed,No Results Available,Anxiety|Stress,Other: Binaural Beat Technology,C-Reactive Protein|State-Trait Anxiety (STAI)|Morning Blood Pressure/Evening Blood Pressure Decline|Cardiovascular Reactivity|Post Intervention Questionnaire,Fort Belvoir Community Hospital|Walter Reed National Military Medical Center|TriService Nursing Research Program,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,74,U.S. Fed|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",361395,Jun-12,Jul-15,Jul-15,31-Dec-14,null,30-May-17,"Walter Reed National Military Medical Center, Bethesda, Maryland, United States|Fort Belvoir Community Hospital, Fort Belvoir, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02328690
NCT02329548,Qualitative Sweat Distribution During Tilt Table Procedure,,Completed,No Results Available,Postural Tachycardia Syndrome|Syncope|Anxiety,Other: Alizarin Red,Orthostatic versus emotional sweat distribution assessed by serial photography|Sweat distribution among patients with POTS assessed by serial photography,Nationwide Children's Hospital,All,"12 Years to 25 Years   (Child, Adult)",Not Applicable,95,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,IRB14-00528,Dec-14,Dec-16,Dec-16,31-Dec-14,null,31-Jan-17,"Nationwide Children's Hospital, neurology outpatient clinic, Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02329548
NCT02329587,Transcranial Direct Current Stimulation Augmented Exposure and Response Prevention for Obsessive-Compulsive Disorder,,Completed,Has Results,Obsessive-Compulsive Disorder,Other: ERP plus tDCS|Other: ERP plus sham tDCS,Yale-Brown Obsessive Compulsive Scale (Y-BOCS): Total Score|Client Satisfaction Questionnaire-8: Total Score|Rates of Session Completion|Yale-Brown Obsessive-Compulsive Scale: Total Score|Rates of Retention in Intervention,Butler Hospital|National Institute of Mental Health (NIMH),All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,13,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",1405-003|1R21MH104728-01,Jan-15,Feb-17,null,31-Dec-14,15-May-18,15-May-18,"Butler Hospital, Providence, Rhode Island, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/87/NCT02329587/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02329587
NCT02327377,Web-based Management of Pediatric Functional Abdominal Pain,,Completed,No Results Available,"Gastrointestinal Disorders, Functional",Behavioral: Online Cognitive Behavior Therapy|Behavioral: Online Education,Change from baseline somatic symptoms|Change from baseline abdominal pain|Change from baseline activity limitations,Vanderbilt University Medical Center|Seattle Children's Hospital,All,11 Years to 17 Years   (Child),Not Applicable,344,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,140559,Apr-14,16-Jan-19,28-Jan-19,30-Dec-14,null,28-Mar-19,"Vanderbilt Children's Hospital, Nashville, Tennessee, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/77/NCT02327377/ICF_000.pdf",https://ClinicalTrials.gov/show/NCT02327377
NCT02326363,Mindfulness-Based Recovery in Veterans,MBR-Veterans,Completed,No Results Available,Substance Abuse|Depression|Anxiety Disorder,Behavioral: Mindfulness Based Relapse Prevention (MBRP)|Behavioral: Twelve-Step Facilitation Intervention (TSF),"Timeline Follow-Back (TLFB)|Urine Drug Screen|Alcohol Breathalyzer Test|EtG|Mindfulness Acceptance and Awareness Scale (MAAS)|Beck Depression Inventory 2|Beck Anxiety Inventory|Addiction Severity Index, Lite|Days Engaging in Structured/Productive Work Activities (PWAC)|Treatment Engagement: Treatment Attendance Calendar (TAC)|Quality of Life Scale (QOLS)",VA Office of Research and Development,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,214,U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,D1292-R|I01RX001292,16-Mar-15,29-Oct-18,29-Oct-18,29-Dec-14,null,13-Dec-18,"Tuscaloosa VA Medical Center, Tuscaloosa, AL, Tuscaloosa, Alabama, United States|Ralph H. Johnson VA Medical Center, Charleston, SC, Charleston, South Carolina, United States",,https://ClinicalTrials.gov/show/NCT02326363
NCT02326545,MindLight: A Video Game Intervention to Reduce Children's Anxiety,,Unknown status,No Results Available,Anxiety,Behavioral: MindLight|Behavioral: Online CBT,Change in Spence Children's Anxiety Scale following intervention,Queen's University|Ontario Mental Health Foundation,All,8 Years to 16 Years   (Child),Phase 2,200,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MindLight,Dec-14,Jun-16,Jun-16,29-Dec-14,null,1-Apr-16,"Queen's University, Kingston, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT02326545
NCT02325128,Augmentation of Exposure Therapy for High Levels of Social Anxiety Using Post-exposure Naps,SANAP,Completed,No Results Available,Social Anxiety Disorder|Sleep Laboratory,Behavioral: Sleep-enhancement of extinction memory,Leibowitz Social Anxiety Scale|Fear-potentiated startle|Fear of Negative Evaluation Scale|Social Phobia and Anxiety Inventory|Clinical Global Impressions Scale|Pre- to-post TSST change in Spielberger State-Trait Anxiety Inventory-State portion score|Subjective Units of Distress Ratings|Pre- to-post TSST change in salivary cortisol|Fear potentiation of loud-tone evoked heart-rate acceleration (HRA) and skin conductance response (SCR)|Increase in baseline heart rate from baseline to performance phases of TSST|Increase in mean corrugator supercilii EMG from baseline to performance phases of TSST,Massachusetts General Hospital|Boston University,All,18 Years to 40 Years   (Adult),Not Applicable,35,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Care Provider)|Primary Purpose: Treatment,2014P001501/MGH,Jan-15,Aug-16,Aug-16,24-Dec-14,null,21-Nov-18,"Massachusetts General Hospital, One Bowdoin Square, Boston, Massachusetts, United States|Massachusetts General Hospital-East, Building 149, Charlestown, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT02325128
NCT02322905,Cancer Caregiver Burden: Targeting Emotion Regulation in a Trial,ERT-ICs,Completed,No Results Available,Anxiety Depression,Behavioral: Emotion Regulation Therapy,"Change in The Caregiver Reaction Assessment and EORTC-QLQ-30|Change in Hospital Anxiety and Depression Scale (HADS)|Change in Penn State Worry Questionnaire|Change in Rumination Response Scale - Brooding subscale only|Change in Difficulty in Emotion Regulation Scale|Change in Emotion Regulation Questionnaire|Change in Five Facet Mindfulness Questionnaire|Change in Experiences Questionnaire|Change in The Pittsburgh Sleep Quality Index|Change in quality of life - WHO-5|Change in Pro-inflammatory markers: CRP, TNFalpha, IL-1, IL-6|Emotional closeness|Emotional attention coping (EAC)",University of Aarhus,All,"18 Years to 69 Years   (Adult, Older Adult)",Not Applicable,80,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ERT15-17,Aug-15,25-Jun-18,31-Dec-18,23-Dec-14,null,6-Mar-19,"Unit for Psychooncology and Health Psychology, Aarhus C, Denmark",,https://ClinicalTrials.gov/show/NCT02322905
NCT02321891,A Pilot Study to Determine a Candidate Protocol for Transcranial Electrical Stimulation in the Treatment of Anxiety,,Unknown status,No Results Available,Anxiety,"Device: NeuroConn DC Stimulator Plus, tDCS",Beck Anxiety Inventory,University of Eastern Finland,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,14,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,OptES-Anx-pilot,Dec-14,Oct-15,Dec-15,22-Dec-14,null,22-Dec-14,"University of Eastern Finland, Kuopio, Finland",,https://ClinicalTrials.gov/show/NCT02321891
NCT02320370,Transcranial Electrical Stimulation in the Treatment of Acute Anxiety Induced by Stressful Life Events: A Pilot Study,OptesStressP,Unknown status,No Results Available,Anxiety,Device: NeuroConn DC Stimulator Plus tDCS,Impact of Event Scale (Change in scores of event-related anxiety),University of Eastern Finland,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,14,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,OptES-Stress-pilot,Jan-15,Dec-15,Mar-16,19-Dec-14,null,19-Dec-14,,,https://ClinicalTrials.gov/show/NCT02320370
NCT02320916,A Randomized Controlled Trial on the Effect of Needle Gauge on the Pain and Anxiety Experienced During Arterial Puncture,,Completed,No Results Available,Blood Gas Analysis|Pain,Procedure: 23Gauge|Procedure: 25Gauge,Pain experienced by the patient during arterial puncture|Anxiety before and after puncture arterial puncture|Most painful moment of the arterial puncture|Duration of arterial puncture,"University Hospital, Rouen",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,200,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention",2010/191/SC,Apr-13,May-13,May-13,19-Dec-14,null,17-Aug-16,"CHU de Rouen, Rouen, France",,https://ClinicalTrials.gov/show/NCT02320916
NCT02319681,"Reminiscence, Anxiety and Early Alzheimer's Disease",,Withdrawn,No Results Available,Alzheimer's Disease,Behavioral: Simple Reminiscence (SR)|Behavioral: Attention Control (AC),Acceptability of SR and AC|Number of times AC was used|Number of times SR was used|Change in Beck Depression Inventory-II (BDI-II) scale|Change in State-Trait Anxiety Inventory (STAI) scale|Change in Katz Instrumental Activities of Daily Living (IADL) scale|Change in Well-Being Picture Scale (WBPS) scale|Change in Short Psychological Well-Being Scale (SPWBS) scale|Change in Revised Memory and Behavior Problems Checklist (RMBPC) scale|Caregiver's mastery of SR intervention technique|Change in levels of cortisol,Emory University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,IRB00075912,Jan-15,Dec-16,Jun-17,18-Dec-14,null,26-Jun-15,"Emory Alzheimer's Disease Research Center, Atlanta, Georgia, United States",,https://ClinicalTrials.gov/show/NCT02319681
NCT02317432,Building Community Capacity for Disability Prevention for Minority Elders (Positive Minds - Strong Bodies),,"Active, not recruiting",No Results Available,Depression|Anxiety|Physical Disability,Behavioral: Comparison of a combined CBT + exercise intervention and enhanced usual care,"Percentage of participants attending more than 50% of CBT sessions.|Change in depressive symptoms from baseline, at multiple follow-up periods.|Change in functional limitations from baseline, at multiple follow-up periods.|Change in self-reported disability from baseline, at multiple follow-up periods.|Change in number of disability days from baseline, at multiple follow-up periods.|Change in anxiety symptoms from baseline, at multiple follow-up periods",Massachusetts General Hospital|New York University|Vanderbilt University,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,307,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,1R01AG046149-01A1,Jul-15,28-Feb-19,Apr-19,16-Dec-14,null,16-Aug-18,"King David Foundation, Aventura, Florida, United States|Greater Boston Chinese Golden Age Center, Boston, Massachusetts, United States|MGH Chelsea, Chelsea, Massachusetts, United States|Kit Clark Senior Services, Dorchester, Massachusetts, United States|MGH Revere, Revere, Massachusetts, United States|Central Harlem Senior Citizens' Center, New York, New York, United States|Hamilton Madison City Hall Senior Center, New York, New York, United States|University of Puerto Rico, San Juan, Puerto Rico",,https://ClinicalTrials.gov/show/NCT02317432
NCT02317523,Alzheimer's Caregiver Coping: Mental and Physical Health,,Recruiting,No Results Available,Alzheimer Disease|Alzheimer Dementia|Alzheimer's Disease|Dementia,Behavioral: Behavioral Activation|Behavioral: Information and Support,Endothelium-dependent Flow Mediated Dilation (FMD)|Center for Epidemiologic Studies - Depression (CES-D) scale|Interleukin-6|Baroreflex Sensitivity (BRS)|Arterial Compliance (AC)|Carotid Intima Media Thickness (IMT)|D-dimer|C-reactive Protein (CRP)|Tumor Necrosis Factor (TNF)- alpha|Plasminogen Activator Inhibitor (PAI)-1|von Willebrand Factor (vWF),"University of California, San Diego|National Institute on Aging (NIA)",All,"55 Years and older   (Adult, Older Adult)",Not Applicable,200,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,BMausbach|RF1AG015301,Sep-14,Aug-19,Aug-19,16-Dec-14,null,1-Nov-18,"University of California San Diego, La Jolla, California, United States",,https://ClinicalTrials.gov/show/NCT02317523
NCT02314195,Music Therapy in Obsessive Compulsive Disorder,,Completed,No Results Available,Obsessive-Compulsive Disorder|Anxiety|Depression,Drug: Selective serotonin re-uptake inhibitor|Behavioral: Cognitive Behavioral Therapy|Other: Music therapy,Obsession (Maudsley Obsessive-Compulsive Inventory)|Obsession subtype (Maudsley Obsessive-Compulsive Inventory sub-types)|Anxiety symptoms (Beck Anxiety Inventory)|Depressive symptoms (Beck Depression Inventory - Short Form),"Islamic Azad University, Marvdasht",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,30,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2172719,Apr-14,Jun-14,Aug-14,11-Dec-14,null,11-Dec-14,"Shariati Hospital, Esfahan, Iran, Islamic Republic of",,https://ClinicalTrials.gov/show/NCT02314195
NCT02315378,Anxiety Reduction Treatment for Acute Trauma,,Terminated,No Results Available,Anxiety,Behavioral: TAU|Behavioral: ARTAT,Acute Stress Disorder (ASD) Interview|Clinician Administered PTSD Scale (CAPS)|Structured Clinical Interview for DSM-IV|Event Severity Rating Scale (ESR)|Mini-Mental status Exam (MMSE)|Beck Anxiety Inventory (BA1)|Peritraumatic Dissociative Experiences Questionnaire (PDEQ)|Peritraumatic Distress Inventory (PDI)|Life Stressor Checklist - Revised (LSC-R)|Posttraumatic Stress Disorder Checklist - Specific Stressor Version (PCL-S),New York University School of Medicine,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,36,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,10-01334|W81XWH-08-1-0412,Jun-08,Oct-10,Aug-13,11-Dec-14,null,17-Aug-16,,,https://ClinicalTrials.gov/show/NCT02315378
NCT02314065,Cognitive Behavioral Therapy for Health Anxiety: Internet Treatment Versus Face-to-Face Therapy,HA-NonInf,"Active, not recruiting",No Results Available,Severe Health Anxiety|Somatic Symptom Disorder|Illness Anxiety Disorder,"Behavioral: CBT, exposure and response prevention (Face-to-face)|Behavioral: CBT, exposure and response prevention (Internet-based)","Health Anxiety Inventory (HAI)|Illness Attitude Scale (IAS)|Whiteley Index (WI)|Montgomery-Åsberg Depression Rating Scale - Self report (MADRS-S)|Beck Anxiety Inventory (BAI)|Anxiety Sensitivity Index (ASI)|Sheehan Disability Scale (SDS)|Trimbos and institute of medical technology assessment cost questionnaire (TIC-P)|Euroqol-5D (EQ-5D)|Insomnia Severity Index (ISI)|Self-rated health 5 (SRH-5)|Quality of Life Inventory (QOLI)|Alcohol Use Disorders Identification Test (AUDIT)|Client Satisfaction Questionnaire (CSQ-8)|Sickness Questionnaire (SQ)|Perceived Vulnerability for Disease (PVD)|Disgust Scale-Rev (DS-R)|WHO Disability Assessment Schedule (WHODAS) 2.0, 12-item version",Karolinska Institutet,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,204,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HA-NonInf,Dec-14,Jun-19,Jun-19,10-Dec-14,null,21-Feb-18,"Gustavsberg primary care clinic, Gustavsberg, Stockholm, Sweden","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/65/NCT02314065/SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02314065
NCT02312739,Nitrous Oxide for Pain Management During In-office Transcervical Sterilization,NEST,Completed,Has Results,Contraception|Inhalation of Nitrous Oxide,Procedure: In-office Transcervical Sterilization (Essure®)|Drug: Standard Oral pain medications|Drug: Intramuscular Ketorolac|Drug: Placebo pills|Other: Oxygen|Other: Nitrous Oxide,Change From Baseline in Pain Scale Measurement During and After the Procedure|Pain Scale Measurement - Maximum Pain Experienced|Change From Baseline in Patient Anxiety Scale After the Procedure|Patient Satisfaction (5-point Likert Scale)|Provider Ease of Insertion (0-100mm VAS),University of New Mexico|Society of Family Planning|Bayer,Female,"21 Years and older   (Adult, Older Adult)",Not Applicable,72,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",UNMHSC13-594,Feb-14,Mar-15,Mar-15,9-Dec-14,6-Jul-16,6-Jul-16,"UNM Center for Reproductive Health, Albuquerque, New Mexico, United States",,https://ClinicalTrials.gov/show/NCT02312739
NCT02310568,POC Study in Partially Responsive Generalized Anxiety Disorder,,Terminated,Has Results,Generalized Anxiety Disorder,Drug: PF-06372865.,"Hamilton Anxiety Rating Scale (HAM-A) Total Scores at Baseline: Stage 1 and 2|Change From Baseline in Hamilton Anxiety Rating Scale (HAM-A) Total Scores at Week 4: Stage 1|Hamilton Anxiety Rating Scale (HAM-A) Total Scores at Week 4 During Stage 1 and at Week 8 During Stage 2|Change From Baseline in Hamilton Anxiety Rating Scale (HAM-A) Total Scores at Week 5, Week 6, Week 7 and Week 8: Stage 2|Sheehan Disability Scale (SDS) Total Score and Social, Work, Family Subscale Scores at Baseline: Stage 1 and Stage 2|Change From Baseline in Sheehan Disability Scale (SDS) Total Score and Social, Work, Family Subscale Scores: Stage 1 and Stage 2|Change From Baseline in Hamilton Anxiety Rating Scale (HAM-A) Total Scores at Week 1, Week 2 and Week 3: Stage 1|Percentage of Responders of Total Hamilton Anxiety Rating Scale (HAM-A): Stage 1 and Stage 2|Change From Baseline in Clinical Global Impression - Improvement (CGI-I) Scale Score at Week 1, 2, 3, 4 in Stage 1 and Week 5, 6, 7, 8 in Stage 2|Change From Baseline in Clinical Global Impression -Severity (CGI-S) Scale Score at Week 1, 2, 3, 4 in Stage 1 and Week 5, 6, 7, 8 in Stage 2|Plasma Concentration Versus Time Summary of PF-06372865: Stage 1|Plasma Concentration Versus Time Summary of PF-06372865: Stage 2|Change From Baseline in the Hamilton Anxiety Rating Scale (HAM-A): Psychic Subscale Score at Week 1, 2, 3, 4, 5, 6, 7, 8|Change From Baseline in the Hamilton Anxiety Rating Scale (HAM-A): Somatic Subscale Score at Week 1, 2, 3, 4, 5, 6, 7, 8|Percentage of Participants With Remission of Total Hamilton Anxiety Rating Scale (HAM-A) Scores",Pfizer,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,90,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",B7431007,Nov-14,Oct-15,Oct-15,8-Dec-14,15-Nov-16,9-Jan-17,"Comprehensive Clinical Development, Inc., Cerritos, California, United States|Pharmacology Research Institute, Encino, California, United States|Sun Valley Research Center, Imperial, California, United States|Excell Research, Inc., Oceanside, California, United States|NRC Research Institute, Orange, California, United States|California Neuorpsychopharmacology Clinical Research Institute, LLC (CNRI-San Diego, LLC), San Diego, California, United States|Artemis Institute for Clinical Research, San Diego, California, United States|Pacific Clinical Research Medical Group, Upland, California, United States|Hartford Hospital, Hartford, Connecticut, United States|Institute of Living, Hartford, Connecticut, United States|Avail Clinical Research, LLC, DeLand, Florida, United States|Gulfcoast Clinical Center, Fort Meyers, Florida, United States|Sarkis Clinical Trials, Gainesville, Florida, United States|Berma Research Group, Hialeah, Florida, United States|Clinical Neuroscience Solutions, Inc., Jacksonville, Florida, United States|Sarkis Clinical Trials, Lake City, Florida, United States|Medical Research Group of Central Florida, Orange City, Florida, United States|Clinical Neuroscience Solutions, Inc., Orlando, Florida, United States|Stedman Clinical Trials, Tampa, Florida, United States|Institute for Advanced Medical Research, Alpharetta, Georgia, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|Northwest Behavioral Research Center, Roswell, Georgia, United States|Great Lakes Clinical Trials, Chicago, Illinois, United States|Phoenix Medica Research, Inc, Prairie Village, Kansas, United States|Pharmasite Research Inc, Baltimore, Maryland, United States|Beacon Clinical Research, LLC, Brockton, Massachusetts, United States|ActivMed Practices & Research, Inc, Methuen, Massachusetts, United States|BCCR Trials, Natick, Massachusetts, United States|Premier Psychiatric Research Institute. LLC., Lincoln, Nebraska, United States|Center for Emotional Fitness, Cherry Hill, New Jersey, United States|Bio Behavioral Health, Toms River, New Jersey, United States|SPRI Clinical Trials LLC, Brooklyn, New York, United States|Neurobehavioral Research, Inc., Cedarhurst, New York, United States|Comprehensive Clinical Development, Inc., Jamaica, New York, United States|Bioscience Research LLC, Mount Kisco, New York, United States|Fieve Clinical Research, Inc, New York, New York, United States|Patient Priority Clinical Sites, LLC, Cincinnati, Ohio, United States|CTI Clinical Research Center, Cincinnati, Ohio, United States|Cutting Edge Research Group, Oklahoma City, Oklahoma, United States|Summit Research Network (Oregon) Inc., Portland, Oregon, United States|Suburban Research Associates, Media, Pennsylvania, United States|Clinical Neuroscience Solutions, Inc., Memphis, Tennessee, United States|Futuresearch Trials of Dallas, Dallas, Texas, United States|InSite Clinical Research, LLC, DeSoto, Texas, United States|Family Psychiatry of The Woodlands, The Woodlands, Texas, United States|Northwest Clinical Research Center, Bellevue, Washington, United States|Summit Research Network (Seattle) LLC, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT02310568
NCT02310932,Improving Mental Health Through Integration With Primary Care in Rural Karnataka,,"Active, not recruiting",No Results Available,Chronic Disease|Depression|Anxiety,Behavioral: Healthy Living Intervention,incidence of dually diagnosed participants|anxiety or depression|blood glucose control|blood pressure|cholesterol|medication adherence,"University of California, San Francisco|National Institute of Mental Health (NIMH)",All,"30 Years and older   (Adult, Older Adult)",Not Applicable,2507,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,R01MH100311,Feb-15,Apr-19,Apr-19,8-Dec-14,null,5-Mar-19,"St. John & Research Institute/St John & Medical College & Hospital, Bangalore, Karnataka, India",,https://ClinicalTrials.gov/show/NCT02310932
NCT02310152,Explanatory Clinical Trial of a Novel Parent Intervention for Childhood Anxiety (SPACE),SPACE,"Active, not recruiting",No Results Available,"Anxiety Disorders|Anxiety, Separation|Phobic Disorders",Behavioral: Parent-Based Treatment of Child and Adolescent Anxiety Disorders|Behavioral: CBT,Clinical Global Impression Scale Improvement and Severity|Pediatric Anxiety Rating Scale|Screen for Childhood Anxiety Related Disorders,Yale University,All,7 Years to 14 Years   (Child),Not Applicable,124,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,1311013020,Nov-14,Nov-18,Nov-19,5-Dec-14,null,23-Oct-18,"Yale University Child Study Center, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT02310152
NCT02307097,RCT of Bibliotherapy for Social Anxiety Disorder as a Prelude to CBT in IAPT,RCT of CBB/CBT,Completed,No Results Available,Bibliotherapy|Social Anxiety Disorder|Cognitive Behavioral Therapy,Procedure: Cognitive-Behavioural Bibliotherapy|Procedure: Cognitive-Behavioural Therapy|Other: WAIT,"IAPT Standard Minimum Data Set (MDS)|The Social Phobia Inventory (SPIN; Connor, 2000)|The Social Participation & Satisfaction Questionnaire (SPSQ; Alden & Taylor, 2011)|Liebowitz Social Anxiety Scale (LSAS-SR; Baker, Heinrich, Kim, & Hofmann, 2002; Liebowitz, 1987)|Self-Focused Attention Scale (SFA; Bögels, Alberts, & de Jong, 1996)|Social Behaviour Questionnaire (SBQ; Clark et al., 2006)|Social Phobia Cognitions Questionnaire (SPC; Clark et al., 2006)|Anticipatory Processing Questionnaire (APQ; Vassilopoulos, 2004) and Post-Event Processing Questionnaire-Revised (PEPQ-R; McEvoy & Kingsep, 2006)",Solent NHS Trust|University of Oxford|Talking Change (Solent NHS Trust)|Constable & Robinson,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,114,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TC-OxCADAT-2014,1-Jan-16,1-Oct-17,1-Oct-17,4-Dec-14,null,10-Oct-17,"Talking Change (Solent NHS Trust), Portsmouth, Hampshire, United Kingdom",,https://ClinicalTrials.gov/show/NCT02307097
NCT02308462,Implementation and Evaluation of a Family-based Intervention Program for Children of Mentally Ill Parents,CHIMPs,"Active, not recruiting",No Results Available,Schizophrenia and Disorders With Psychotic Features|Mood Disorders|Neurotic Disorders|Personality Disorders|Substance-Related Disorders,Behavioral: CHIMPS intervention,"children's psychiatric symptomatology (Kiddie-SADS interview)|children's psychiatric symptomatology (Child behaviour checklist)|children's psychiatric symptomatology (assessed by Youth Self Report)|children's psychiatric symptomatology (assessed by the SGKJ)|children's health related quality of life (Kidscreen)|parents' health related quality of life (EQ-5D)|Symptomatology of the parents (Brief Symptom Inventory)|Symptomatology of the parents (only Intervention group) (SKID; a structured clinical interview for DSM-IV)|parents' coping with the disorder (Freiburger Fragebogen zur Krankheitsbewältigung)|family relations (children and parents) (Allgemeiner Familienfragebogen)|Social Support (Oslo Social Support Questionnaire)|Objectives of the treatment (children and parents)|achievement of the objectives of the treatment (children and parents)|Evaluation of the Treatment (children and parents) (Fragebogen zur Beurteilung der Behandlung)|health economic assessment of treatment costs (children) (German version of the ""Children and adolescent mental health Services receipt inventory)|health economic assessment of treatment costs (parents) (German version of the Client Socioeconomic and Services Receipt Inventory)|Symptomatology of the parents","Silke Wiegand-Grefe, Prof. Dr.|Universitätsklinikum Hamburg-Eppendorf|University of Ulm|Universitätsklinikum Leipzig|LWL-Klinikum Gütersloh|Vitos Klinik Rheinhöhe|Charite University, Berlin, Germany|Cantonal Hospital Winterthur, Switzerland",All,"3 Years to 19 Years   (Child, Adult)",Not Applicable,400,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,O1GY1337|U1111-1162-2635|DRKS00006806,Nov-14,Jun-19,Jun-19,4-Dec-14,null,20-Mar-19,"Charité Campus Virchow Klinikum, Klinik für Psychiatrie, Psychosomatik und Psychotherapie des Kindes- und Jugendalters, Berlin, Germany|Vitos psychiatrische Ambulanz Eltville, Eltville, Germany|Bezirkskrankenhaus Günzburg, Klinik für Psychiatrie, Psychotherapie und Psychosomatik, Günzburg, Germany|LWL-Klinikum Gütersloh, Klinik für Allgemeine Psychiatrie und Psychotherapie, Gütersloh, Germany|Asklepios Klinikum Harburg, Hamburg-Harburg, Germany|Schön Klinik Hamburg Eilbek, Abteilung für Psychiatrie und Psychotherapie, Hamburg, Germany|University Medical Center Hamburg-Eppendorf, Clinic and Polyclinic for psychiatry and psychotherapy, Hamburg, Germany|Vitos psychiatrische Ambulanzen Idstein, Idstein, Germany|Universitätsklinikum Leipzig, Klinik für Psychiatrie, Psychotherapie und Psychosomatik des Kindes- und Jugendalters, Leipzig, Germany|Universitätsklinkum Leipzig, Klinik und Poliklinik für Psychiatrie und Psychotherapie, Leipzig, Germany|LWL-Klinik Paderborn, Allgemeine Psychiatrie und Psychotherapie, Paderborn, Germany|Klinik für Psychiatrie und Psychotherapie des Sächsischen Krankenhauses Altscherbitz, Schkeuditz, Germany|Vitos psychiatrische Tageskliniken Wiesbaden, Wiesbaden, Germany|Centre of Social Pediatrics, Dept. of Pediatrics and Adolescent Medicine, Winterthur, Switzerland",,https://ClinicalTrials.gov/show/NCT02308462
NCT02308826,Multi-Component Early Intervention for Socially Inhibited Preschool Children,,"Active, not recruiting",No Results Available,Behavioral Inhibition|Anxiety,Behavioral: Turtle Program|Behavioral: Cool Little Kids,Change in child anxiety disorder symptoms,University of Maryland,All,45 Months to 64 Months   (Child),Not Applicable,169,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,R01MH103253-01A1,Dec-14,Oct-19,Oct-19,4-Dec-14,null,4-May-18,"Maryland ADHD Program, College Park, Maryland, United States",,https://ClinicalTrials.gov/show/NCT02308826
NCT02305797,EDG004 Treatment of Adult Patients With Generalized Anxiety Disorder (GAD),,Completed,Has Results,Generalized Anxiety Disorder (GAD),Drug: Extended-release lorazepam|Drug: Placebo,Change From Baseline in Hamilton Anxiety Rating Scale (HAM-A) Total Score at Visit 7 (Day 42)|Change From Baseline in the Clinical Global Impression-Severity (CGI-S) Score at Visit 7 (Day 42),"Edgemont Pharmaceuticals, LLC",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,495,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",EDG004-003,Jan-15,May-16,May-16,3-Dec-14,26-Sep-18,26-Sep-18,"Multiple Investigational Sites, Multiple Locations, California, United States",,https://ClinicalTrials.gov/show/NCT02305797
NCT02306174,Cognitive Rehabilitation and Exposure-based Class for Compulsive Hoarding,,"Active, not recruiting",No Results Available,Hoarding Disorder,Behavioral: Cognitive Rehabilitation and Exposure-based Class for Compulsive Hoarding,Hoarding Rating Scale Interview|Clinician's Global Impression Improvement and Severity ratings,University of Miami,All,"18 Years to 85 Years   (Adult, Older Adult)",Not Applicable,200,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20140644,Sep-14,Feb-21,Aug-21,3-Dec-14,null,4-Mar-19,,,https://ClinicalTrials.gov/show/NCT02306174
NCT02306356,Internet-delivered Treatment for Children With Anxiety Disorders in a Rural Area; an Open Trial in a Clinical Setting,,Completed,No Results Available,Specific Phobia|Separation Anxiety|Generalized Anxiety Disorder,Behavioral: Internet-delivered Cognitive Behavior Therapy,Change in Clinical Global Impressions - severity (CGI-S)|Children´s Global Assessment Scale (CGAS|Spence Child Anxiety Scale C/P (SCAS-C/P)|Penn State Worry Questionnaire (PSWQ)|Separation Anxiety Index (SAI)|Fear Survey Schedule for Children - Revised (FSSC-R)|Child Sheehan Disability Scale (CSDS)|Child Depression Inventory (CDI)|Hospital Anxiety Depression Scale (HAD)|Client Satisfaction Scale (CSS)|Trimbos and Institute of Technology Cost Questionnaire for Psychiatry (TIC-P),Karolinska Institutet|BUP Östersund,All,8 Years to 12 Years   (Child),Not Applicable,20,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2014/1225-31/4,Sep-14,Oct-15,Oct-15,3-Dec-14,null,20-Jan-16,"Child and Adolescent Mental Health Services Östersund, Östersund, Jämtland, Sweden",,https://ClinicalTrials.gov/show/NCT02306356
NCT02307019,Intervention on Caregivers Caring for Patients Poststroke With Upper Limb Apraxia,CPA,Completed,No Results Available,Performance Anxiety|Emotional Stress,Other: Program on specific prevention of health|Other: Program on general prevention of health,"Change from Baseline in Stroke Impact Scale (SIS-16) at 8 weeks|Change from Baseline in Stroke Impact Scale (SIS-16) at 16 weeks|Change from Baseline in Barthel index at 8 weeks|Change from Baseline in Barthel index at 16 weeks|Change from Baseline in Disabilities of the Arm, Shoulder and Hand (Quick-DASH) at 8 weeks|Change from Baseline in Disabilities of the Arm, Shoulder and Hand (Quick-DASH) at 16 weeks|Change from Baseline in General health questionnaire (GHQ-28) at 8 weeks|Change from Baseline in General health questionnaire (GHQ-28) at 16 weeks|Change from Baseline in Zarit questionnaire at 8 weeks|Change from Baseline in Zarit questionnaire at 16 weeks|Change from Baseline in family APGAR at 8 weeks|Change from Baseline in family APGAR at 16 weeks|Change from Baseline in Duke-UNC-11 questionnaire of functional social support at 8 weeks|Change from Baseline in Duke-UNC-11 questionnaire of functional social support at 16 weeks",Universidad de Granada,All,"18 Years to 90 Years   (Adult, Older Adult)",Not Applicable,50,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Investigator)|Primary Purpose: Treatment",Caregiver patients apraxia,Jul-14,Sep-18,Sep-18,3-Dec-14,null,5-Oct-18,"University of Granada, Granada, Andalucía, Spain",,https://ClinicalTrials.gov/show/NCT02307019
NCT02304796,Unified Cognitive-Behavioral Therapy (CBT) vs. Combined CBT and Dance/Movement Therapy (DMT) for Anxiety Disorders,,Unknown status,No Results Available,Anxiety Disorders,Behavioral: Unified Cognitive-Behavioral Therapy|Behavioral: Combined Cognitive-Behavioral and Dance/Movement Therapy,"Change in Hamilton Anxiety Rating Scale|Change in Depression, Anxiety, Stress Scales-21|Change in Valued Living Questionnaire|Change in Mini International Neuropsychiatric Interview",Shalvata Mental Health Center,All,"20 Years to 65 Years   (Adult, Older Adult)",Not Applicable,24,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,0015-14-SHA,Jan-15,Sep-16,Sep-16,2-Dec-14,null,14-Apr-16,"Shalvata Mental Health Center, Hod Hasharon, Israel",,https://ClinicalTrials.gov/show/NCT02304796
NCT02305537,Building an Outcomes Assessment Infrastructure to Assess Anxiety Treatment,,Recruiting,No Results Available,Social Anxiety Disorder|Specific Phobia|Separation Anxiety Disorder|Panic Disorder|Agoraphobia|Obsessive-Compulsive Disorder,Behavioral: McLean Anxiety Mastery Program,Change in Score in Spence Children's Anxiety Scale (SCAS; Spence 1997).|Change in Score in Center for Epidemiolgic Studies Depression Scale (CES-D; Radloff 1977).,Mclean Hospital,All,"9 Years to 18 Years   (Child, Adult)",Not Applicable,45,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,2014P000353,Oct-14,Oct-24,Oct-30,2-Dec-14,null,21-Mar-18,"McLean Hospital, Cambridge, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT02305537
NCT02303691,Attention Bias Modification for Transdiagnostic Anxiety,,Completed,No Results Available,Anxiety|Anxiety Disorders,Behavioral: Attention Bias Modification|Behavioral: Neutral Training,CAPS--Hypervigilance item|Mood and Anxiety Symptoms Questionnaire|Mini International Neuropsychiatric Interview (MINI)|Attentional bias towards threat (Performance-based assessment of attentional bias towards threat based on reaction times and eye tracking)|Penn State Worry Questionnaire|Liebowitz Social Anxiety Scale|World Health Organization Disability Assessment Scale (WHODAS)|Speilberger State-Trait Anxiety Inventory|Beck Anxiety Inventory,University of Pittsburgh|National Institute of Mental Health (NIMH),All,18 Years to 55 Years   (Adult),Not Applicable,70,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",5K23MH100259,Apr-13,Jan-17,Jan-18,1-Dec-14,null,8-Mar-18,"University of Pittsburgh Department of Psychiatry, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT02303691
NCT02298478,Efficacy of an Internet-based Treatment for Flying Phobia: NO-FEAR Airlines,,Completed,No Results Available,Flying Phobia,Behavioral: NO-FEAR Airlines,"The Fear of Flying Questionnaire-II (FFQ-II; Bornas, Tortella-Feliu, García de la Banda, Fullana, & Llabrés, 1999).|The Fear of Flying scale (FFS; Haug et al. (1987)|Fear and Avoidance Scales (adapted from Marks & Mathews, 1979)|The Fear of flying scale (FFS; Haug et al., 1987)",Universitat Jaume I,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,69,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,UJaumeI05,1-Sep-15,Sep-17,Oct-17,24-Nov-14,null,13-Mar-18,"University Jaume I, Castellon, Spain",,https://ClinicalTrials.gov/show/NCT02298478
NCT02299583,Controlled Trial of Early Intervention With Children and Adolescents Exposed to Nonrelational Traumatic Events,,Unknown status,No Results Available,Posttraumatic Stress Disorder|Depression|Anxiety,Other: Preventive intervention trauma-informed early intervention,Severity of posttraumatic stress symptoms (Children's Revised Impact of Event Scale.)|Change from baseline in severity of posttraumatic stress symptoms at 6 months (Children's Revised Impact of Event Scale.)|Severity of anxiety symptoms (Revised Child Anxiety and Depression Scale.)|Change from baseline in severity of anxiety symptoms at 6 months (Revised Child Anxiety and Depression Scale.)|Severity of depressive symptoms (Revised Child Anxiety and Depression Scale.)|Change from baseline in severity of depressive symptoms at 6 months (Revised Child Anxiety and Depression Scale.)|Social functioning of the family (Crisis Support Scale and the WHO-Five Well-being Index.)|Change from baseline in social functioning of the family at 6 months (Crisis Support Scale and the WHO-Five Well-being Index.)|Cognitive coping skills of the children and their parents ( Post-traumatic Cognitions Inventory.)|Change from baseline in cognitive coping skills of the children and their parents at 6 months ( Post-traumatic Cognitions Inventory.),"Carolina Magdalene Maier|The Egmont Foundation|Ramboll Group|Rigshospitalet, Denmark",All,"8 Years to 18 Years   (Child, Adult)",Not Applicable,684,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,f-22834-02,Oct-14,Sep-16,Dec-16,24-Nov-14,null,24-Nov-14,"Hospitals of the Capitol Region of Denmark, Copenhagen, Denmark",,https://ClinicalTrials.gov/show/NCT02299583
NCT02298036,Helping Urgent Care Users Cope With Distress About Physical Complaints,,Completed,No Results Available,Frequent Utilisers of Urgent Medical Care Who Have High Health Anxiety,Behavioral: (Remote) Cognitive Behaviour Therapy,"Health Anxiety Inventory: 14-Item Self Rated Short Form (Salkovskis 2002)|Generalised Anxiety Disorder: 7 Item (Spitzer et al 2006)|9 item Patient Health Questionnaire for depression (PHQ-9; Kroenke et al, 2001).|8 item Work and Social Adjustment Scale for social function (WSAS; Mundt et al, 2002).|5 item quality of life on the EQ5D-5L (EuroQol Group, 1990)|36 item Short Form Health Survey (SF-36; Ware et al, 2000).|Change in number of contacts with unscheduled or emergency care established through a totally adapted and stylised Client Service Receipt Inventory (CSRI; Beecham and Knapp 2001).",University of Nottingham,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,156,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,CLAHRC-EM 14056,Jan-14,Dec-17,Dec-17,21-Nov-14,null,17-Jan-18,"Leicestershire Partnership Nhs Trust, Leicester, Leicestershire, United Kingdom|United Lincolnshire Hospitals NHS Trust, Lincoln, Lincolnshire, United Kingdom|Nottinghamshire Healthcare Nhs Trust, Nottingham, Nottinghamshire, United Kingdom|Nottingham University Hospitals Nhs Trust, Nottingham, Nottinghamshire, United Kingdom",,https://ClinicalTrials.gov/show/NCT02298036
NCT02294305,Vortioxetine Versus Placebo in Major Depressive Disorder Comorbid With Social Anxiety Disorder,,Unknown status,No Results Available,Social Anxiety Disorder|Major Depressive Disorder,Drug: Vortioxetine|Drug: Placebo,Clinical Global Impression of Improvement (CGI-I) Responder Rate|Change in total Montgomery Asberg Depression Rating Scale (MADRS) score|Change in total Liebowitz Social Anxiety Scale (LSAS) score,The Medical Research Network,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 4,40,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",TAK-S001560,Dec-14,Nov-16,Nov-16,19-Nov-14,null,24-Aug-16,"The Medical Research Network, LLC, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT02294305
NCT02294409,Manualized Group Cognitive-behavioral Therapy for Social Anxiety in First Episode Psychosis,,Recruiting,No Results Available,Social Phobia|Psychosis,Behavioral: Manualized group Cognitive-behavioral therapy (CBT) for social anxiety in first episode psychosis|Behavioral: Group Computer assisted cognitive remediation therapy,Social anxiety symptoms as measured by the Social Interaction Anxiety Scale (SIAS)|Social anxiety symptoms as measured by the Social Phobia Inventory (SPIN)|Social anxiety symptoms as measured by the the Brief Social Phobia Scale (BSPS)|Psychosis Symptoms Remission as measured by the Scale for Assessment of Positive Symptoms (SAPS) and Negative Symptoms (SANS)|Functional outcome as measured by the Recovery Assessment Scale (RAS)|Functional outcome as measured by the Social and Occupational Functioning Scale (SOFAS).,McGill University|Canadian Institutes of Health Research (CIHR),All,18 Years to 35 Years   (Adult),Not Applicable,120,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,CBT_SA-FEP RCT,Oct-14,Dec-19,Dec-20,19-Nov-14,null,15-Mar-19,"Douglas Mental Health University Institute, Verdun, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT02294409
NCT02290678,Pushing Limits - Adventure: Pilot Study,,Unknown status,No Results Available,Anxiety|Depression,Behavioral: Adventure-based Programming,"Feasibility, as measured by Number of Participants who complete the Adventure-based Programming retreat and team building exercises and Qualitative engagement feedback|BDI-II Score|BAI Score",St. Joseph's Healthcare Hamilton,All,"16 Years and older   (Child, Adult, Older Adult)",Not Applicable,25,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Adventure_PILOT,Feb-15,Dec-15,Dec-15,14-Nov-14,null,20-Feb-15,"St Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT02290678
NCT02288416,Video-Based Intervention in Reducing Anxiety in Patients Undergoing Lung Cancer Screening,,Completed,No Results Available,Anxiety|No Evidence of Disease|Lung Carcinoma,Other: educational intervention|Other: questionnaire administration|Other: quality-of-life assessment|Other: Best Practice,"Percent of patients who complete the intervention|Patient satisfaction with the timing, content, and delivery of the video-based intervention assessed by survey|Patient screen-related anxiety as assessed by the mean score of the State Trait Anxiety Inventory (STAI)|Health-related quality of life as assessed by the mean survey score of the Short Form-12 (SF-12) questionnaire|Consequences of screening, assessed by the mean survey score of the Consequences of Screening in Lung Cancer (COS-LC) questionnaire",City of Hope Medical Center|National Cancer Institute (NCI),All,"55 Years and older   (Adult, Older Adult)",Not Applicable,20,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,14169|NCI-2014-02220,8-Dec-14,6-Sep-18,6-Sep-18,11-Nov-14,null,10-Sep-18,"City of Hope Medical Center, Duarte, California, United States",,https://ClinicalTrials.gov/show/NCT02288416
NCT02286674,Use of Handheld Audiovisual Devices to Treat Pediatric Preoperative Anxiety,,Unknown status,No Results Available,Pediatric Preoperative Anxiety,Other: Tablet (Audio/Visual Device),Yale Preoperative Anxiety Score|Yale Preoperative Aniety Score,McLaren Health Care,All,2 Years to 12 Years   (Child),Phase 3,200,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,201400076,Nov-14,Nov-16,Jan-17,10-Nov-14,null,28-Sep-16,"McLaren Greater Lansing Hospital, Lansing, Michigan, United States",,https://ClinicalTrials.gov/show/NCT02286674
NCT02285699,The Gut Microbiota in Obsessive-Compulsive Disorder,,Recruiting,No Results Available,Obsessive-Compulsive Disorder,Drug: SSRIs,Yale Brown Obsessive Compulsive Scale|Clinical Global Impression - Improvement|Obsessive-Compulsive Inventory - Revised (OCI-R)|Dutch Dimensional Obsessive Compulsive Scale (DDOCS)|Depression Anxiety Stress Scale (DASS-21)|Anti-Cancer Council of Victoria Food Frequency Questionnaire,McMaster University|Hamilton Health Sciences Corporation,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,25,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,14-722,Nov-14,Dec-19,Mar-20,7-Nov-14,null,11-Apr-18,"MacAnxiety Research Centre, Hamilton, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT02285699
NCT02286466,Mobile App of CBT for Anxiety and Cancer,,Completed,Has Results,Cancer|Anxiety,Behavioral: Health Education Program|Behavioral: CBT Mobile Application,Change in Anxiety Symptoms From Baseline to Post-assessment|Change in Quality of Life From Baseline to Post-assessment|Change in Mood Symptoms From Baseline to Post-assessment|Change in Depression Symptoms From Baseline to Post-assessment,Massachusetts General Hospital,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,145,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care,12-533,18-Feb-15,25-Oct-16,25-Oct-16,7-Nov-14,28-Aug-18,28-Aug-18,"Massachusetts General Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT02286466
NCT02283281,Anesthetic Premedication With a Cannabis Extract (Cannapremed),Cannapremed,Unknown status,No Results Available,"Pain, Postoperative|Postoperative Nausea and Vomiting|Anxiety",Drug: Tetrahydrocannabinol|Drug: Acetaminophen|Drug: Midazolam|Drug: Dummy oromucosal spray,Postoperative pain - VAS|Postoperative pain - PCA|Postoperative nausea and vomiting (PONV) score|Anxiety - VAS|Cannabinoid blood levels,Hadassah Medical Organization|GW Pharmaceuticals Ltd.,All,18 Years to 60 Years   (Adult),Phase 2|Phase 3,200,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Cannapremed-HMO-CTIL,May-15,Dec-16,Feb-17,5-Nov-14,null,24-Mar-16,"Hasassah - Hebrew University Ein Kerem Medical Center, Jerusalem, Israel",,https://ClinicalTrials.gov/show/NCT02283281
NCT02284204,Sevoflurane Associated With Oral Midazolam and Ketamine for Dental Sedation,,Completed,No Results Available,Dental Anxiety,"Drug: Midazolam, Ketamine and Sevoflurane|Drug: Midazolam and Ketamine",adverse events|Behavioral Control,Universidade Federal de Goias,All,4 Years to 6 Years   (Child),Phase 2,27,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care",MKSevadversos,Jan-12,Aug-14,Nov-14,5-Nov-14,null,11-Jan-17,"Faculty of Dentistry, Goiania, Goias, Brazil",,https://ClinicalTrials.gov/show/NCT02284204
NCT02279251,School Based Low-intensity Cognitive Behavioral Intervention for Anxious Youth,LIST,"Active, not recruiting",No Results Available,Anxiety,Behavioral: VÅG|Behavioral: CHILLED,"Spence Children's Anxiety Scale|Children Anxiety Life Interference Scale|Short Mood and Feeling Questionnaire|Questionnaire for Measuring Health-Related Quality of Life in Children and Adolescents (KINDL-R)|Clinical Global Impression Scale, severity/improvement (CGI-S/I)",NORCE Norwegian Research Centre AS|The Research Council of Norway|Modum Bad|Sorlandet Hospital HF,All,12 Years to 16 Years   (Child),Not Applicable,311,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,229020,Oct-13,Jul-18,Dec-23,31-Oct-14,null,12-Nov-18,"Municipality of Modum, Oslo, East Norway, Norway|Municipality of Fjell, Sund and Askoy, Fjell, Norway|Soerlandet Hospital HF, Kristiansand, Norway",,https://ClinicalTrials.gov/show/NCT02279251
NCT02279290,Using CBT to Probe Psychobiobehavioral Resilience to Post-trauma Psychopathology,,Completed,No Results Available,Anxiety|Depression,Behavioral: Healthy Mind Intervention (HMI)|Behavioral: Healthy Body Intervention (HBI),"Psychological resilience outcomes include emotion regulation (DERS), hardiness (CD-RISC), optimism (LOT-R), perceived control (SMS), social support (MSPSS), and task-oriented coping (CISS-SFT).|Biological resilience outcomes include neuropeptide Y [NPY], dehydroepiandrosterone [DHEA], allopregnanolone [ALLO] taken from a blood draw.|Extinction learning will be analyzed using the fear potentiated startle data from a fear conditioning paradigm.",Rush University Medical Center,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,50,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,K23MH103394,13-Jul-15,14-Nov-18,26-Apr-19,31-Oct-14,null,6-May-19,"Rush University Medical Center, Chicago, Illinois, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/90/NCT02279290/ICF_000.pdf",https://ClinicalTrials.gov/show/NCT02279290
NCT02272959,Attention Bias Modification Treatment (ABMT) for Anxiety Disorders in Youth Who do Not Respond to CBT,,Recruiting,No Results Available,Anxiety Disorders,Behavioral: Attention bias modification treatment (ABMT)|Behavioral: Attention Control Condition,The Pediatric Anxiety Rating Scale (PARS)|Anxiety Related Emotional Disorders - Child/Parent Version (SCARED-C/P),Yair Bar-Haim|United States - Israel Binational Science Foundation|Schneider Children's Hospital|Sheba Medical Center|Tel Aviv University,All,"10 Years to 18 Years   (Child, Adult)",Not Applicable,100,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",loe140498ctil,Jan-15,Jul-19,Jul-19,23-Oct-14,null,18-Sep-18,"Tel-Aviv University, Tel-Aviv, Israel",,https://ClinicalTrials.gov/show/NCT02272959
NCT02273154,Randomized，Controlled and Open-label Study of Buspirone add-on Treatment in Patients With Major Depression Disorder,,Unknown status,No Results Available,Major Depression Disorder,Drug: Buspirone|Drug: Paroxetine,Rate of onset of effect|clinical response rate|remission rate|Changes of HAMD scores at week 4 and week 8 compared with baseline|Changes of HAMA scores at week 4 and week 8 compared with baseline,Si Tianmei|Peking University,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,240,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BUS-IV-01,Aug-14,Dec-15,Dec-15,23-Oct-14,null,23-Oct-14,"Institute of mental health, Peking University, Beijing, Beijing, China|Henan mental health center, Xinxiang, Henan, China|Wuhan mental health center, Wuhan, Hubei, China|Nanjing Brain Hospital, Nanjing, Jiangsu, China|Dalian No.7 People's Hospital, Dalian, Liaoning, China|Shanxi Dayi Hospital, Taiyuan, Shanxi, China",,https://ClinicalTrials.gov/show/NCT02273154
NCT02269527,"Effects of an Live Music on the Perception of Noise in the SICU: A Patient, Caregiver, and Medical Staff Environmental Study",,Recruiting,No Results Available,Pain|Anxiety|Stress,Other: Live music,"Self-report stress level from SICU staff|2. Pre and Post-intervention score on the perception of SICU noises from SICU and Hospital Anxiety and Depression Scale for SICU patients|Pre and Post-intervention score on the perception of SICU noises from SICU patients, caregivers",Beth Israel Medical Center,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,318,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,8810,Jun-10,Jun-18,Jun-18,21-Oct-14,null,13-Sep-17,"Beth Israel Medical Center, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT02269527
NCT02270073,The Process Outcome Mindfulness Effects in Trainees (PrOMET)-Study,PrOMET,Completed,No Results Available,Major Depression|Anxiety Disorder,Behavioral: Cognitive behavior therapy of trainee therapists,Working Alliance Inventory - Short Revised (WAI-SR)|Brief Symptom Inventory (BSI)|Beck Depression Inventory (BDI)|Inventory of Interpersonal Problems (IIP)|Kentucky Inventory of Mindfulness Skills (KIMS)|Global Assessment of Functioning (GAF)|Development of Psychotherapists Common Core Questionnaire (DPCCQ) short version|Scale for the Multiperspective Assessment of General Change Mechanisms in Psychotherapy (SACiP)|Beck Anxiety Inventory (BAI),Heidelberg University|University of Trier|University of Zurich|University of Applied Sciences Esslingen,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,150,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MA6526/2-1(DFG),Oct-14,Jan-18,Jul-18,21-Oct-14,null,26-Oct-18,"Center for Psychological Psychotherapy - University of Heidelberg, Heidelberg, Baden Wuerttemberg, Germany",,https://ClinicalTrials.gov/show/NCT02270073
NCT02270671,Attention Bias Modification Training for Young People,,Completed,Has Results,Anxiety|Depression,Behavioral: ABMT|Other: Placebo,Threat Bias Measurement at 4-week Post-intervention and 12-week Follow-up|Social Phobia and Anxiety at 4-week Post-intervention and 12-week Follow-up|Fear of Negative Evaluation at 4-week Post-Intervention and 12-week Follow-Up|Anxiety Related Disorders at 4-week Post-intervention and 12-week Follow-up|Depression Symptoms at 4-week Post-intervention and 12-week Follow-up,University College Dublin|Tel Aviv University,All,"15 Years to 18 Years   (Child, Adult)",Not Applicable,130,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,HS-14-49-Fitzgerald,Oct-14,May-15,May-15,21-Oct-14,20-Nov-18,20-Nov-18,,,https://ClinicalTrials.gov/show/NCT02270671
NCT02268357,The Effects of Propranolol on Fear of Tooth or Molar Extraction,,Unknown status,No Results Available,Dental Anxiety,Drug: Propranolol,Change from baseline at 1 month follow-up in Short version of the Dental Anxiety Inventory (S-DAI)|Change from baseline at 1 month follow-up in Self-reported vividness and emotional charge of the crucial fear-related memory|Change from baseline at 1 month follow-up in State anxiety during treatment|Change from baseline at 1 month follow-up in Physiological parameters (heart rate and blood pressure) during recall of the crucial fear-related memory,Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA),All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,34,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NL42210.018.13,Oct-14,Aug-18,Aug-18,20-Oct-14,null,11-Aug-16,"Dept. of Oral and Maxillofacial Surgery, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands",,https://ClinicalTrials.gov/show/NCT02268357
NCT02266446,Developing a Low-Intensity Primary Care Intervention for Anxiety Disorders,AIM-PC,Completed,No Results Available,Anxiety Disorders,Behavioral: Attention & Interpretation Modification,Client Satisfaction Questionnaire|Generalized Anxiety Disorder 7-Item Scale|Patient Health Questionnaire-9,Brown University|National Institute of Mental Health (NIMH)|Memorial Hospital of Rhode Island|Mclean Hospital,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,14,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1308000908|1R34MH097820-01A1,Jun-14,Aug-15,Dec-15,17-Oct-14,null,23-Jan-18,"Family Care Center of Memorial Hospital of Rhode Island, Pawtucket, Rhode Island, United States",,https://ClinicalTrials.gov/show/NCT02266446
NCT02266680,Breathing Focused Yoga in Social Anxiety Disorder,,Completed,No Results Available,Social Anxiety Disorder,Behavioral: Yoga Treatment Group,Change in Liebowitz Social Anxiety Scale (LSAS) Total Score|Change in Clinical Global Impression Scale|Change in Hamilton Depression Rating Scale (HAM-D) Total Score|Change in Quality of Life Enjoyment and Satisfaction Scale (QLESQ) Total Score|Change in Quick Inventory of Depressive Symptomatology (QIDS) Total Score,Centre for Addiction and Mental Health,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,150/2011,Jan-12,Jan-17,30-Jan-17,17-Oct-14,null,19-Jul-17,"Centre for Addition and Mental Health, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT02266680
NCT02266693,Transdiagnostic iCBT for Depression and Anxiety,,Completed,No Results Available,Major Depressive Disorder|Social Anxiety Disorder|Panic Disorder|Generalized Anxiety Disorder,Behavioral: iCBT,Change in Hamilton Depression Rating Scale (HAM-D) Total Score|Change in Hamilton Anxiety Rating Scale (HAM-A) Total Score|Change in Quick Inventory of Depressive Symptomatology Self-Report (QIDS-SR) Total Score|Change in Liebowitz Social Anxiety Scale (LSAS) Total Score|Change in Panic Disorder Severity Scale Total Score|Change in Penn State Worry Questionnaire Total Score|Change in Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) Total Score|Change in Sheehan Disability Scale (SDS) Total Score|Change in Clinical Global Impression (CGI),Centre for Addiction and Mental Health,All,18 Years to 29 Years   (Adult),Not Applicable,77,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,057/2012,Aug-14,Aug-18,Aug-18,17-Oct-14,null,15-Feb-19,"Centre for Addiction and Mental Health, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT02266693
NCT02267629,Open Label Trial of Rapastinel (Formerly GLYX-13) in Individuals With Obsessive-Compulsive Disorder,,Completed,Has Results,Obsessive-Compulsive Disorder (OCD),Drug: Rapastinel (formerly GLYX-13),Scores Change in Yale-Brown Obsessive Compulsive Challenge Scale (YBOCCS) Scores From Baseline to 230 Minutes Postinfusion.|Number of Patients Who Met and Exceeded Response Criteria of Yale-Brown Obsessive-Compulsive Scale.,New York State Psychiatric Institute,All,18 Years to 55 Years   (Adult),Phase 2,7,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,#6986,Oct-14,Feb-16,Feb-16,17-Oct-14,10-May-17,18-Jul-17,"New York State Psychiatric Insitute, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT02267629
NCT02265588,Healthy Approach to Physical and Psychological Problems in Youngsters With IBD (HAPPY-IBD).,HAPPY-IBD,Unknown status,No Results Available,Inflammatory Bowel Disease (IBD)|Ulcerative Colitis|Crohn's Disease|Anxiety|Depression,Behavioral: Cognitive behavioral therapy,Reduction in symptoms of depression (change from baseline)|Reduction in symptoms of anxiety (change from baseline)|Quality of Life|Social Skills|Social competence|Disease specific quality of life|Disease Activity|Clinical relapse (number of flares)|Maintaining remission|Medication Usage (change from baseline)|Necessity of surgical intervention|Adherence to therapy (change from baseline)|Health care utilization (change from baseline)|Inflammatory markers,Erasmus Medical Center|Reinier de Graaf Groep|Albert Schweitzer Hospital|Maasstad Hospital|Haga Hospital|Amphia Hospital|Leiden University Medical Center,All,"10 Years to 20 Years   (Child, Adult)",Not Applicable,70,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,NL49147.078.14,Sep-14,1-Oct-16,Sep-17,16-Oct-14,null,6-Mar-17,"Erasmus Medical Center, Rotterdam, Nederland, Netherlands",,https://ClinicalTrials.gov/show/NCT02265588
NCT02265822,Melatonin Premedication in Children Undergoing Surgery,,Completed,No Results Available,Premedication|Anaesthesia,Drug: melatonin in children premedication|Drug: midazolam in children premedication,efficacy of melatonin as premedicant in children undergoing elective surgery|effect of melatonin premedication in postoperative analgesia in children undergoing elective surgery,"Azienda Ospedaliera Universitaria Policlinico ""G. Martino""|Eloisa Gitto|Lucia Marseglia|Gabriella D’Angelo|Sara Manti|Simona Montalto|Pietro Impellizzeri",All,5 Years to 14 Years   (Child),Phase 4,92,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",797/2012,Sep-12,Oct-13,Oct-13,16-Oct-14,null,16-Oct-14,,,https://ClinicalTrials.gov/show/NCT02265822
NCT02265211,Mindfulness and Acceptance-Based Treatments for Social Anxiety: Defusion App,,Completed,No Results Available,Anxiety|Shyness,Behavioral: Self-Help App,Change from Baseline in Social Anxiety Interaction Scale at 7 days|Change from Baseline in Social Phobia Scale at 7 days|Change from Baseline in Cognitive Fusion Questionnaire at 7 days|Change from Baseline in Believability of Anxious Feelings and Thoughts Questionnaire at 7 days|Change from Baseline in Experiences Questionnaire at 7 days|Change from Baseline in Brief Social Anxiety - Acceptance and Action Questionnaire at 7 days|Readiness Ruler|Credibility/Expectancy Questionnaire,Wilfrid Laurier University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,15,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,4207,Oct-14,Apr-15,Jun-15,15-Oct-14,null,16-Jun-15,"Wilfrid Laurier University, Waterloo, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT02265211
NCT02263768,"Impact of Two Recall Intervals on Dental Caries Incidence, Anxiety and Quality of Life of Preschool Children",,Completed,No Results Available,Dental Caries|Quality of Life|Anxiety,Procedure: Oral clinical conditions,Dental caries incidence - Change|Level of anxiety - Change|Oral health related quality of life - Change|Time|Costs,University of Sao Paulo,All,3 Years to 5 Years   (Child),Not Applicable,224,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention,7709191,Mar-15,Mar-18,Mar-18,13-Oct-14,null,18-Apr-19,"Dental School of University of São Paulo, São Paulo, Brazil",,https://ClinicalTrials.gov/show/NCT02263768
NCT02261558,Effects of Clinical Music Improvisation on Resiliency in Adults Undergoing Infusion Therapy,,Recruiting,No Results Available,Anxiety,Other: Clinical Improvisation Instrumental Music Therapy|Other: Clinical Vocal Improvisation,Resiliency Scale|Hospital Anxiety and Depression Scale (HADS)|Music Psychotherapy Data Tool|Visual Analogue Scale (VAS)|Body Pain Scale - Color Analysis Scale (CAS),Beth Israel Medical Center,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care",09-090,Jun-11,May-18,May-18,10-Oct-14,null,13-Sep-17,"Beth Israel Medical Center, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT02261558
NCT02259036,Using Smartphones to Enhance the Treatment of Childhood Anxiety,Smart-CAT,Completed,No Results Available,Anxiety,Other: Ecological Momentary Treatment Enhancement,PARS Treatment response|Absence of diagnosis on K-SADS,University of Pittsburgh|National Institute of Mental Health (NIMH),All,9 Years to 14 Years   (Child),Not Applicable,40,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MH102666|1R34MH102666-01A1,Aug-14,31-May-17,31-May-17,8-Oct-14,null,16-Nov-18,"University of Pittsburgh, Dept. of Psychology, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT02259036
NCT02257996,Effectiveness of Online Systematic Brief Psychodynamic Psychotherapy for Neurotic Disorders: Randomized Controlled Trial,,Unknown status,No Results Available,Neurotic Disorders,Behavioral: Online Systematic Brief Psychodynamic Psychotherapy,Change in Systematic Adaptive Diagnosis Scale (SADS),University of Sao Paulo,All,"22 Years to 65 Years   (Adult, Older Adult)",Not Applicable,32,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,SBPP-1,Aug-15,May-17,Oct-17,7-Oct-14,null,15-Jan-15,"Clinical Psychology Department from Institute of Psychology at University of Sao Paulo, Sao Paulo, Brazil",,https://ClinicalTrials.gov/show/NCT02257996
NCT02256566,Cognitive Training for Mood and Anxiety Disorders,,Completed,No Results Available,Major Depressive Disorder|Depression|Bipolar Disorder|Post-traumatic Stress Disorder|Generalized Anxiety Disorder|Social Phobia,Behavioral: emotional memory training exercise|Behavioral: memory training exercise,Proportion of completers to measure feasibility|Change in Depression Symptom Severity|Change in Anxiety Symptom Severity|Change in Negative Affective Bias|Change in Neurocognition,Icahn School of Medicine at Mount Sinai,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,28,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",GCO 14-0994,Sep-14,20-Apr-16,20-Apr-16,3-Oct-14,null,21-Jul-17,"Icahn School of Medicine at Mount Sinai, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT02256566
NCT02253472,The Safety and Efficacy of Long-term Treatment of PINS Stimulator System for Patients With Obsessive-Compulsive Disorder,,Unknown status,No Results Available,Obsessive-Compulsive Disorder,Device: Deep Brain Stimulation,Yale-Brown obsessive-compulsive psychiatrists rating scale(Y-BOCS)|Hamilton anxiety scale (HAMD),"Beijing Pins Medical Co., Ltd|Beijing Tiantan Hospital",All,"18 Years to 65 Years   (Adult, Older Adult)",Early Phase 1,30,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",PINS-008,Dec-16,Dec-18,Dec-18,1-Oct-14,null,14-Oct-16,,,https://ClinicalTrials.gov/show/NCT02253472
NCT02252068,Study of Treatment for Opioid Dependence and Anxiety Disorders,,Recruiting,No Results Available,Anxiety Disorders|Opiate Addiction,Behavioral: I-CBT|Behavioral: IDC,Urine-confirmed self-reported weeks of opioid use|Anxiety symptom severity|Quality of life|Non-opioid substance use|Functional impairment,Mclean Hospital,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,K23DA035297,Jan-15,Mar-20,Mar-20,29-Sep-14,null,6-Feb-19,"McLean Hospital, Belmont, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT02252068
NCT02248675,Adjunctive Brief Behavioral Treatment of Insomnia (BBTI) for Sleep Intervention (SI),,Completed,Has Results,Insomnia|Depression|Posttraumatic Stress Disorder|Suicidal Ideation,Behavioral: CBT-I|Other: TAU,Columbia Suicide Severity Rating Scale (C-SSRS)|Perceived Treatment Beliefs (PTS)|Patient Health Questionnaire-9 (PHQ-9)|Insomnia Severity Index (ISI),VA Office of Research and Development,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,54,U.S. Fed,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Health Services Research",PPO 13-373|I21HX001473,Feb-15,Jan-16,Jan-16,25-Sep-14,28-Apr-17,28-Apr-17,"Syracuse VA Medical Center, Syracuse, NY, Syracuse, New York, United States",,https://ClinicalTrials.gov/show/NCT02248675
NCT02246062,Impact of Preanesthetic Information and Behavioral Intervention Using Smartphone on Anxiety of Children,,Completed,Has Results,Anxiety State|Parent-Child Relations,Behavioral: info|Behavioral: smartphone,Impact of Preanesthetic Information and Behavioral Intervention Using Smartphone Application on Anxiety of Children Measure by m-YPAS.,Faculdade de Ciências Médicas da Santa Casa de São Paulo,All,4 Years to 8 Years   (Child),Not Applicable,84,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),288.712,Jun-13,Sep-14,Sep-14,22-Sep-14,7-Jan-16,7-Jan-16,"Irmandade Santa Casa de Misericórdia de São Paulo, São Paulo, Brazil",,https://ClinicalTrials.gov/show/NCT02246062
NCT02244970,Mindfulness RCT for Early Psychosis,MBIp,Unknown status,No Results Available,Psychosis,Other: Mindfulness|Other: Psychoeducation,Depressive mood|Anxiety|Quality of Life|Life Functioning|Mindfulness,The University of Hong Kong,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,MIND2014,Sep-14,Sep-15,Sep-15,19-Sep-14,null,19-Sep-14,"The University of Hong Kong, Hong Kong, China",,https://ClinicalTrials.gov/show/NCT02244970
NCT02243826,Impact of 50% Nitrous Oxide Inhalation on Pain and Anxiety Induced by Lumbar Puncture: a Double-blind Randomized Controlled Trial,,Unknown status,No Results Available,Lumbar Puncture,Drug: 50:50 mixture of nitrous oxide/oxygen,Maximal pain level during the procedure|Maximal anxiety level during the procedure|Anxiety evaluated by 2 questionnaires: the Hospital Anxiety and Depression (HAD) State Trait Anxiety Inventory (STAI)|Proportion of patients presenting side effects|Total duration of the lumbar puncture|Proportion of patients that would accept another lumbar puncture in the same conditions,"University Hospital, Clermont-Ferrand",All,18 Years to 60 Years   (Adult),Phase 4,66,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",CHU-206|2014-001452-28,Jul-14,Oct-15,Oct-15,18-Sep-14,null,21-Sep-15,"CHU de Clermont-Ferrand, Clermont-Ferrand, France",,https://ClinicalTrials.gov/show/NCT02243826
NCT02244099,Controlled Substance Treatment Agreements in an Internal Medicine Residents' Clinic,,Completed,No Results Available,"Anxiety|Chronic Pain|Opioid Use, Unspecified",Other: Controlled Substance,Percentage of Patients Adhering to Controlled Substance Agreement|Discrepancy on urine drug screen|Morphine Equivalent Review|Healthcare Utilization,Ohio State University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,96,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,2014H0102,Sep-14,Jan-15,Mar-15,18-Sep-14,null,24-Sep-15,"The Ohio State University, Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02244099
NCT02242955,Impact of a One-month Long Detoxification Diazepam Treatment on Early Alcohol Relapse,DIAMA,Completed,No Results Available,Alcoholism,Drug: Diazepam,Rate of relapse in alcohol drinking|Occurrence of adverse events|Rate of relapse in heavy drinking|Ratio of drinking days/heavy drinking days|Level of self-reported anxiety|Level of clinician-assessed anxiety|Level of alcohol craving|Average weekly alcohol consumption,"University Hospital, Lille",All,18 Years to 60 Years   (Adult),Not Applicable,26,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2011_44|2012-003336-23,Jul-14,Jul-16,Jul-16,17-Sep-14,null,15-Sep-16,"Department of Addiction Medicine, Lille, France|Outpatient Addiction Center ""CSAPA - Le Pari"", Lille, France",,https://ClinicalTrials.gov/show/NCT02242955
NCT02238652,Improving Quality of Life in Nursing Home Residents: A Cluster Randomized Clinical Trial of Efficacy,KOSMOS,Completed,No Results Available,Quality of Life,Behavioral: Communication|Behavioral: Systematic Pain Assessment and Treatment|Behavioral: Medication Review|Behavioral: Occupational therapy|Behavioral: Safety,Neuropsychiatric symptoms|Quality of life|Activities of daily living|Mood or depression|Pain|Medication review|Drug-related problems|Admission to hospital and mortality|Cost-effectiveness|Cost of medication|Measure of activity|Nursing home activity|Relatives satisfaction with conducted KOSMOS elements,University of Bergen|The Research Council of Norway|Rebekka Ege Hegemanns legat|Helse Stavanger HF|University of Oslo|King's College London|Karolinska Institutet,All,65 Years and older   (Older Adult),Not Applicable,560,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Supportive Care,222113,Aug-14,Nov-15,Nov-15,12-Sep-14,null,15-Apr-16,"Solvik, Baerum, Akershus, Norway|Donski Bo og behandlingssenter, Baerum, Akershus, Norway|Mariehaven Bo og behandlingssenter, Baerum, Akershus, Norway|Berger Bo og Behandlingssenter, Baerum, Akershus, Norway|Kolaashjemmet Bo og Behandlingssenter, Baerum, Akershus, Norway|Gullhaug Bo og behandlingssenter, Baerum, Akershus, Norway|Osteraas Bo og behandlingssenter, Baerum, Akershus, Norway|Solbakken Bo og Behandlingssenter, Baerum, Akershus, Norway|Lønnås Bo og Rehabsenter, Baerum, Akershus, Norway|Nordraaksvei bo og behandlingssenter, Baerum, Akershus, Norway|Stabaekktunet Bo og behandlingssenter, Baerum, Akershus, Norway|Stabekk Bo og Behandlingssenter, Baerum, Akershus, Norway|Ask bo og omsorgssenter, Askøy, Norway|Arna helseheim, Bergen, Norway|Frieda Fasmers minne, Bergen, Norway|Gullstøltunet Sykehjem, Bergen, Norway|Hospitalet Betanien, Bergen, Norway|Lyngbøtunet Bo og servicesenter, Bergen, Norway|Slettebakken menighets eldresenter, Bergen, Norway|University of Bergen, Bergen, Norway|Strandebarmheimen, Kvam, Norway|Toloheimen, Kvam, Norway|Øysteseheimen, Kvam, Norway|Borgen sykehjem, Sarpsborg, Norway|Eplehagen bofellesskap, Sarpsborg, Norway|Haugvoll sykehjem, Sarpsborg, Norway|Helsehuset, Sarpsborg, Norway|Kurland, Sarpsborg, Norway|Tingvoll sykehjem, Sarpsborg, Norway|Valaskjold omsorgssenter, Sarpsborg, Norway|Sundheimen, Sund, Norway|Tednebakkane omsorgssenter, Øygarden, Norway",,https://ClinicalTrials.gov/show/NCT02238652
NCT02236767,Transcranial Magnetic Stimulation Treatment of Hoarding Disorder,,Completed,Has Results,Hoarding,Device: Neurostar Transcranial Magnetic Stimulation Therapy System,The Saving Inventory-Revised (SI-R) Total Score,Hartford Hospital|Neuronetics,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,1,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DIEF003523.4,Jul-14,Dec-14,Dec-14,11-Sep-14,6-Oct-16,6-Oct-16,"Hartford Hospital, Hartford, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT02236767
NCT02237300,Virtual Reality Based Cue-exposure Treatment for Bulimia Nervosa,,Completed,No Results Available,Bulimia Nervosa|Binge-Eating Disorder|Binge Eating,Behavioral: VR based cue-exposure therapy|Behavioral: Additional Cognitive-behavioral treatment,"Change from baseline in eating disorders symptomatology on the BN, DT and BD subscales of EDI-3 (Eating Disorders Inventory-3), at the end of the treatment and at six month follow-up|Change from baseline in the frequency of binging and purging episodes using self-reports at the end of the treatment and at six month follow-up|Change from baseline in food craving on the FCQ-T/S (Food Craving Questionnaire-Trait/State) at the end of the treatment and at six months follow-up|Change from baseline in anxiety on the State-Trait Anxiety Inventory at the end of the treatment and at six month follow-up",University of Barcelona|Hospital Universitari de Bellvitge|Consorci Sanitari de l'Anoia|Centro ABB|Hospital Universitari Joan XXIII de Tarragona.|Istituto Auxologico Italiano,All,18 Years to 60 Years   (Adult),Not Applicable,60,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",PSI2011-28801,Feb-15,Sep-15,Mar-16,11-Sep-14,null,9-Feb-17,"Università Cattolica del Sacro Cuore, Milan, Italy|Universitat de Barcelona, Barcelona, Spain",,https://ClinicalTrials.gov/show/NCT02237300
NCT02236455,Effects of Complementary Therapies Delivered Via Mobile Technologies,,Completed,No Results Available,Acute Pain|Anxiety|Self Efficacy,Behavioral: Audio Relaxation Technique|Behavioral: Medical Music Intervention|Behavioral: Nature Therapy without Music|Behavioral: Nature Therapy with Music,Change from baseline state anxiety via the State Trait Anxiety Scale (STAI)|Change in baseline pain level using the Numeric Rating Scale (NRS),University of San Francisco|Fulbright,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,105,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,S5862,Mar-12,Dec-12,Dec-12,10-Sep-14,null,10-Sep-14,"Landspítala, Reykjavik, Iceland",,https://ClinicalTrials.gov/show/NCT02236455
NCT02234011,A Trial of Intranasal Ketamine for the Treatment of Obsessive-Compulsive Disorder,,Terminated,Has Results,Obsessive-Compulsive Disorder,Drug: Ketamine|Drug: Placebo,Observing if Ketamine May Cause a Decrease in OCD Symptoms,Mclean Hospital,All,18 Years to 55 Years   (Adult),Phase 2,1,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",2014P001140,Sep-14,Jan-16,Jan-16,9-Sep-14,12-May-17,12-May-17,"McLean Hospital, Belmont, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT02234011
NCT02232438,Psychotherapy for Depressed or Anxious Adolescents With Cancer,,Withdrawn,No Results Available,Depression|Anxiety|Cancer,Behavioral: Behavioral activation therapy,Change in Multidimensional Anxiety Scale for Children (MASC 2),New York State Psychiatric Institute,All,"12 Years to 21 Years   (Child, Adult)",Not Applicable,0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,6797,Jan-15,Dec-17,Dec-17,5-Sep-14,null,7-Oct-15,"New York State Psychiatric Institute, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT02232438
NCT02229903,An Evaluation of the Safety and Efficacy of the dTMS Treatment for OCD,,Completed,No Results Available,Obsessive Compulsive Disorder,Device: Active DTMS Treatment|Device: Sham Treatment,"Yale Brown Obsessive Compulsive Scale (YBOCS) score|Yale Brown Obsessive Compulsive Scale (YBOCS), Sheehan Disability Scale (SDS), Clinical Global Impression - Severity Scale (CGI-S), Clinical Global Impression - Improvement Scale (CGI-I)",Brainsway,All,"22 Years to 68 Years   (Adult, Older Adult)",Phase 3,100,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CTP-OCD-01,Sep-14,Jun-17,Jun-17,3-Sep-14,null,25-Jan-18,"University of California (UCLA), Los Angeles, California, United States|University of California, San Diego, California, United States|University of Florida College of Medicine, Gainesville, Florida, United States|Advanced Mental Health Care Inc. - Juno Beach, Juno Beach, Florida, United States|Advanced Mental Health Care Inc. - Royal Palm Beach, Royal Palm Beach, Florida, United States|University of Chicago, Chicago, Illinois, United States|Neuropharmacology Services, New York, New York, United States|Mount Sinai Hospital, New York, New York, United States|TMS Hope Center of Long Island, New York, New York, United States|Lindner Center of HOPE, University of Cincinnati College of Medicine, Mason, Ohio, United States|Center for Addiction and Mental Health (CAMH), Toronto, Ontario, Canada|Tel Hashomer Hospital, Tel Hashomer, Israel",,https://ClinicalTrials.gov/show/NCT02229903
NCT02229305,Maine Implementation Study - Phase III,,Completed,No Results Available,Anxiety|Trauma|Depression|Problem Behavior,Behavioral: Usual Care Treatment|Behavioral: Modular Approach to Therapy for Children,"Brief Problem Checklist (BPC, parent and child forms)|Top Problems Assessment|UCLA PTSD Index|Youth Self Report (YSR)|Child Behavior Checklist|Therapeutic Alliance Scale for Children|Service Assessment for Children and Adolescents: Treatment and Auxiliary Service Use Scales|Brief Impairment Scale|Services for Children and Adolescents - Parent Interview (SCAPI)",Harvard University|MacArthur Foundation|Casey Family Programs|Annie E. Casey Foundation,All,6 Years to 15 Years   (Child),Not Applicable,235,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",STEPs Phase III,Dec-08,Oct-12,Oct-12,1-Sep-14,null,1-Sep-14,"Judge Baker Children's Center, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT02229305
NCT02226770,Heart-focused Anxiety in Patients With Heart Failure and ICD,Anxiety-CHF,Unknown status,No Results Available,Heart Failure Patients Before and After ICD Implantation,Device: Implantable Cardioverter Defibrillator (ICD),Extent of heart-focused anxiety before and change after ICD implantation|Extent of general anxiety and depression before and change after ICD implantation|Quality of life before and change after ICD implantation|Number of patients affected by PTSD before and after ICD implantation|Impact of type D personality on heart-focused anxiety|Impact of type D personality on general anxiety and depression|Impact of type D personality on quality of life.|Impact of type D personality on PTSD.|Impact of type D personality on numbers of shocks.|Impact of type D Personality on rehospitalization and morbidity.|Influence of heart-focused anxiety on rehospitalization and morbidity|Influence of general anxiety and depression in rehospitalization and morbidity|Influence of quality of life on rehospitalization and morbidity|Effect of ICD-shocks on heart-focused anxiety and effect of heart-focused anxiety on frequency of shocks|Effect of ICD-shocks on general anxiety and depression and effect of general anxiety and depression on frequency of shocks|Effect of ICD-shocks on quality of life and effect of quality of life on frequency of shocks,"University Hospital, Saarland|Friede Springer Herz Stiftung",All,"Child, Adult, Older Adult",Not Applicable,100,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening,252/12,Jul-10,Oct-14,Oct-16,27-Aug-14,null,27-Aug-14,"Saarland University Hospital, Homburg, Saarland, Germany",,https://ClinicalTrials.gov/show/NCT02226770
NCT02225808,Neural Mechanisms of CBT for Anxiety in Autism,,Unknown status,No Results Available,Autism|Autism Spectrum Disorder|Anxiety,Behavioral: CBT for anxiety in autism,functional magnetic resonance imaging (fMRI)|Multidimensional anxiety scale for children (MASC)|Pediatric Anxiety Rating Scale (PARS),Yale University,All,8 Years to 14 Years   (Child),Not Applicable,10,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1211011144,Aug-14,Jan-17,Jan-17,26-Aug-14,null,2-Sep-16,"Yale School of Medicine, Child Study Center, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT02225808
NCT02225847,Effect of Gardening on Brain Activity,,Completed,No Results Available,Stress|Depression|Anxiety|Quality of Life,Other: Gardening|Procedure: Functional Magnetic Resonance Imaging (fMRI)|Behavioral: psychometric assessments,Change in Spatial Patterns of Brain Network Activation|Change in Overall Health Status|Change in Depressive Symptomatology|Change in State Anxiety|Change in Mood States|Change in Perceived Stress,University of Florida|National Foliage Foundation,Female,26 Years to 49 Years   (Adult),Not Applicable,24,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,IRB201400425,Sep-14,May-15,May-15,26-Aug-14,null,2-Jul-18,"Fifield Hall, Gainesville, Florida, United States|McKnight Brain Institute, Gainesville, Florida, United States|Wilmot Greenhouse, Gainesville, Florida, United States",,https://ClinicalTrials.gov/show/NCT02225847
NCT02223845,Randomised Controlled Trial of the Effect of Music on Women Undergoing Assisted Reproductive Technology Treatments.,,Completed,No Results Available,Anxiety,Other: Music,Anxiety level|Background anxiety|Quality of life scores|Ongoing pregnancy rate,University of Southampton,Female,18 Years to 40 Years   (Adult),Not Applicable,42,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,RHMO&G0201,Feb-13,Jan-14,Jan-14,22-Aug-14,null,22-Aug-14,"Complete Fertility, Southampton, Hampshire, United Kingdom",,https://ClinicalTrials.gov/show/NCT02223845
NCT02223936,Follow up of Neurologic Development of Children Who Presented at the First Trimester of Pregnancy an Isolated Nuchal Anomaly With Normal Karyotype,EDEN,Completed,No Results Available,Neurological Development After Exposition to an Antenatal Nuchal Translucency,Other: group exposed|Other: Control,"Incidence of developmental quotient below 70 compared to a group control|comparison of the mean and distribution of developmental quotient between the two arms|composite outcome measure : comparison of weight, height and head circumference between the two arms|The status deceased / living and the date and cause of death if applicable|study differences in score post-traumatic stress, anxiety and depression between parents of the two arms",Hospices Civils de Lyon,All,up to 26 Months   (Child),Not Applicable,500,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening,2007-491,Feb-09,Feb-11,Mar-14,22-Aug-14,null,22-Aug-14,,,https://ClinicalTrials.gov/show/NCT02223936
NCT02221518,Control and Reward Circuits in Obsessive Compulsive Disorder,,Completed,No Results Available,Obsessive-Compulsive Disorder,Behavioral: Exposure & Response Prevention (EX/RP),Change from baseline in brain activation (fMRI) and fractional anisotropy (Diffusion tensor imaging) after therapy|Change in reaction times and correct responses on Stop signal reaction time task,New York State Psychiatric Institute,All,18 Years to 55 Years   (Adult),Not Applicable,80,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,#7000/R01MH104648-01,Oct-14,Jun-18,Aug-18,20-Aug-14,null,13-Mar-19,"NY State Psychiatric Institute, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT02221518
NCT02219880,Kava for the Treatment of Generalised Anxiety Disorder: A Double-Blind Randomised Placebo-Controlled Trial,KGAD,Completed,No Results Available,Generalized Anxiety Disorder,Dietary Supplement: Kava (240mg of kavalactones per day)|Dietary Supplement: Placebo,Hamilton Anxiety Rating Scale (HAMA) - change in score|Gamma-aminobutyric acid (GABA) transporter polymorphisms moderating response to study intervention,University of Melbourne|Swinburne University of Technology|The University of Queensland,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 4,178,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",137/14,13-Oct-15,31-May-18,31-May-18,19-Aug-14,null,15-Oct-18,"Royal Brisbane & Women's Hospital, Brisbane, Queensland, Australia|Centre for Human Psychopharmacology - Swinburne University, Melbourne, Victoria, Australia",,https://ClinicalTrials.gov/show/NCT02219880
NCT02218736,Fast-Fail Trials in Mood and Anxiety Spectrum Disorders; Kappa Opioid Receptor Phase 2a,FASTMAS_Kor2,Completed,Has Results,ANXIETY DISORDERS (or Anxiety and Phobic Neuroses),Drug: CERC-501|Drug: placebo,Change in Ventral Striatal Activation Occurring in Anticipation of Reward During the Monetary Incentive Delay Task Measured by fMRI|Clinical Anhedonia Measured by the Snaith-Hamilton Pleasure Scale (SHAPS; Total Score)|Change in Behavioral Measure of Anhedonia Using the Probabilistic Reward Task,Duke University|Yale University|Baylor College of Medicine|Indiana University|Icahn School of Medicine at Mount Sinai|Case Western Reserve University,All,"21 Years to 65 Years   (Adult, Older Adult)",Phase 2,163,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Health Services Research",Pro00052485|HHSN271201200006I,Jun-15,1-Nov-17,1-Dec-17,18-Aug-14,8-Jan-19,8-Jan-19,"Yale University, New Haven, Connecticut, United States|Andrew Goddard, MD, Indianapolis, Indiana, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|CaseWestern Reserve University, Cleveland, Ohio, United States|Baylor College of Medicine, Houston, Texas, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/36/NCT02218736/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/36/NCT02218736/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02218736
NCT02218775,FASTMAS (Fast-Fail Trials in Mood and Anxiety Spectrum Disorders) Kappa Opioid Receptor Phase 1 Study,KOR1,Withdrawn,No Results Available,Anxiety Disorders,Drug: LY2456302,Primary: Kappa opioid receptor occupancy determined with LY2879788 PET imaging; Mu opioid receptor occupancy determined with [11C]-Carfentanil PET imaging|Peak PET Mu Occupancy|Reward Circuit Engagement Outcome|Clinical Anhedonia Outcome Utilizing the Snaith-Hamilton Pleasure Scale (SHAPS)|Anhedonia Outcome Utilizing the Snaith-Hamilton Pleasure Scale (SHAPS)|Behavioral Anhedonia Outcome as measured by the Probabilistic Reward Task (PRT),Andrew Krystal|Yale University|Duke University,All,"21 Years to 65 Years   (Adult, Older Adult)",Phase 1,0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,Pro00052483|HHSN271201200006I,Oct-14,Apr-15,Apr-15,18-Aug-14,null,28-May-15,"Yale University, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT02218775
NCT02219243,Interpretive Biases in Children With Social Anxiety,,Terminated,No Results Available,Social Anxiety|Social Anxiety Disorder,Behavioral: Online Interpretation Training Condition 1|Behavioral: Online Interpretation Training Condition 2,Change on the Liebowitz Social Anxiety Scale for Children and Adolescents|Change on the Multidimensional Anxiety Scale for Children-2nd edition Parent and Self Report,"University of Wisconsin, Milwaukee",All,8 Years to 12 Years   (Child),Not Applicable,5,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,UWM14.141,Aug-14,Aug-16,Aug-16,18-Aug-14,null,25-Oct-16,"UWM Anxiety Disorders Laboratory, Milwaukee, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT02219243
NCT02216981,Examining the Feasibility and Acceptability of Good Quality Intensive CBT for OCD and Good Quality Weekly CBT for OCD,,Unknown status,No Results Available,Obsessive Compulsive Disorder (OCD),Behavioral: Cognitive Behavioural Therapy (CBT),Yale- Brown Obsessive Compulsive Scale (Y-BOCS) & Obsessive Compulsive Inventory,University of Bath|South London and Maudsley NHS Foundation Trust|Avon and Wiltshire Mental Health Partnership NHS Trust,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,40,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,MILSALK1,Aug-14,Dec-17,null,15-Aug-14,null,26-Oct-16,"Centre for Anxiety Disorders and Trauma (CADAT), London, Denmark Hill, United Kingdom|Centre for Specialist Psychological Treatments of Anxiety and Related Problems (CSPTARP), Bath, United Kingdom",,https://ClinicalTrials.gov/show/NCT02216981
NCT02217436,iPad as a Distraction Tool During Facial Laceration Repair,,Completed,No Results Available,Anxiety|Laceration Repair|Children,Device: iPad|Other: Standard Care,Observational Score Behavioral Distress Revised (OSBD-R) scores from videotapes made during facial laceration repair|Parent and provider satisfaction surveys,"University of California, San Diego",All,2 Years to 12 Years   (Child),Not Applicable,77,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,iPadWilliams,Apr-14,Jul-15,Jul-15,15-Aug-14,null,11-Jul-16,"Rady Children's Hospital San Diego, San Diego, California, United States",,https://ClinicalTrials.gov/show/NCT02217436
NCT02217995,Mindfulness-Based Cognitive Therapy in a Clinical Sample of OCD Patients,,Completed,No Results Available,Obsessive-Compulsive Disorder,Behavioral: Mindfulness-Based Cognitive Therapy (MBCT),Change in Symptom Severity from Baseline in OCD Measures|Change in Level of Impairment from Baseline|Change in Mood from Baseline|Change in Mindfulness from Baseline|Retention of Gains at Follow-up,Sunnybrook Health Sciences Centre,All,"Child, Adult, Older Adult",Not Applicable,32,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,138-2014,Sep-14,Aug-17,28-Sep-17,15-Aug-14,null,6-Sep-18,"The Frederick W. Thompson Anxiety Disorders Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT02217995
NCT02213900,"Preventing Post-Operative Delirium in Patients Undergoing a Pneumonectomy, Esophagectomy or Thoracotomy",PE-POD,Completed,Has Results,Delirium|Cognitive Impairment|Post-traumatic Stress Disorder|Depression|Anxiety,Drug: Haloperidol|Drug: Placebo,Efficacy of Low-dose Haloperidol in Reducing Delirium Incidence|Efficacy of Low-dose Haloperidol in Reducing Days With Delirium|Efficacy of Low-dose Haloperidol in Reducing ICU and Hospital Length of Stay|Efficacy of Low-dose Haloperidol in Reducing Cognitive Impairment at Post-operative Follow-up,Indiana University,All,"18 Years and older   (Adult, Older Adult)",Phase 4,135,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",VFR-398-Khan,Sep-13,Dec-15,Dec-15,12-Aug-14,13-Apr-17,13-Apr-17,"University Hospital, Indianapolis, Indiana, United States",,https://ClinicalTrials.gov/show/NCT02213900
NCT02214732,Mindfulness Based Cognitive Therapy for Psychological Distress in Pregnancy,,Completed,No Results Available,Depression|Anxiety|Stress,Behavioral: Mindfulness Based Cognitive Therapy,Change in Edinburgh Postpartum Depression Scale scores from baseline to 3 months follow-up postpartum|Change in Pregnancy Related Anxiety Measure scores from baseline to post-treatment|Change in Perceived Stress Scale (PSS-10) scores from baseline to 3 months|Change in Pittsburgh Sleep Quality Index (PSQI) scores from baseline to 3 months|Change in objective measures of sleep using Wrist Actigraphy from baseline to 3 months|Change in salivary cortisol profile from baseline to 3 months|Change in measures of blood pressure (BP) from baseline to 3 months|Changes in measures of heart rate variability from baseline to 3 months,"University of Calgary|Alberta Centre for Child, Family & Community Research|Alberta Family Wellness Initiative",Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,61,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,REB13-0860,Aug-14,Apr-17,Sep-17,12-Aug-14,null,14-Sep-18,"Riley Park Maternity Clinic, Calgary, Alberta, Canada|University Of Calgary, Calgary, Alberta, Canada",,https://ClinicalTrials.gov/show/NCT02214732
NCT02213016,Effectiveness of Repetitive Transcranial Magnetic Stimulation in Depressed Patients,,Unknown status,No Results Available,Major Depression,Device: Transcranial Magnetic Stimulation|Device: Sham Transcranial Magnetic Stimulation,Total scores on the Hamilton depression scale depression|Performance on the Wisconsin card sorting test,Universidad Nacional Autonoma de Mexico,All,18 Years to 35 Years   (Adult),Phase 4,80,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",141-2011,Sep-13,Sep-16,Feb-17,11-Aug-14,null,11-Aug-14,"Department of Psychiatry and Mental Health, Faculty of Medicine, UNAM, Mexico, Mexico City, Mexico",,https://ClinicalTrials.gov/show/NCT02213016
NCT02213302,Premedication by Midazolam for Emergency Surgery,,Completed,No Results Available,Anxiety,Drug: placebo administration|Drug: midazolam intravenous administration,visual analog scale of anxiety|salivary cortisol level|Global anxiety|Patient's satisfaction|Intraoperative consumption of hypnotics and opioids|Comfort induction|Intubation score|Adverse midazolam effects|Output score of recovery room (Aldrete score),"University Hospital, Lille",All,"18 Years to 79 Years   (Adult, Older Adult)",Phase 4,59,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2014-000873-38|PROM 2012_30,Jul-14,Jan-16,Jan-16,11-Aug-14,null,11-Feb-16,"Emergency, University Hopital, Lille, France",,https://ClinicalTrials.gov/show/NCT02213302
NCT02212236,Psychological Intervention for Distress During HSCT,,Completed,No Results Available,Psychological Distress|Haematopoietic Stem Cell Transplantation|Bone Marrow Transplantation,Other: Psychological preparation,Depression Anxiety Stress Scales (DASS-21)|Brief Resilience Scale (BRS)|Brief Coping with Problems Experienced scale (COPE)|Brief Illness Perceptions Questionnaire (IPQ),University of Nottingham|Nottingham University Hospitals NHS Trust|Sheffield Teaching Hospitals NHS Foundation Trust,All,"18 Years and older   (Adult, Older Adult)",Phase 2,45,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention",14069,Sep-14,Oct-15,Oct-15,8-Aug-14,null,28-Oct-15,"Nottingham City Hospital, Nottingham, Nottinghamshire, United Kingdom|Royal Hallamshire Hospital, Sheffield, South Yorkshire, United Kingdom",,https://ClinicalTrials.gov/show/NCT02212236
NCT02208726,The Effect of Picricum Acidum and Phosphoricum Acidum Homaccord on Perceived Levels of Anxiety in University Students,,Completed,No Results Available,Anxiety,Other: Sucrose pillules|Other: Homeopathic homaccord,State-Trait-Anxiety-Inventory|Anxiety Symptom Score Card,University of Johannesburg,All,18 Years to 45 Years   (Adult),Phase 2,30,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",KaronWillson200731900|AEC44-01-2013,Sep-13,Nov-13,Aug-14,5-Aug-14,null,17-May-16,"University of Johannesburg, Johannesburg, Gauteng, South Africa",,https://ClinicalTrials.gov/show/NCT02208726
NCT02209233,Effects of Massage on Post-operative Pain in Urologic Patients,,Withdrawn,No Results Available,Postoperative Pain|Anxiety,Other: Massage Therapy,"Change from baseline in pain on the visual analogue scale score and survey|Change from baseline in anxiety on the State Trait Anxiety Inventory (STAI)|Change from baseline in patient satisfaction on the Patient Satisfaction Questionnaire 18 (PSQ18)|Length of hospital stay by chart review|Narcotic use (dosage, frequency, etc.) by chart review",Loma Linda University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,5140181,Feb-15,Feb-15,null,5-Aug-14,null,9-Feb-15,"Loma Linda University Heart and Surgical Hospital, Loma Linda, California, United States",,https://ClinicalTrials.gov/show/NCT02209233
NCT02206776,Randomized Controlled Trial of Intranasal Ketamine vs. Intranasal Midazolam in Individuals With OCD,,Terminated,Has Results,Obsessive-Compulsive Disorder,Drug: Intranasal Ketamine|Drug: Intranasal Midazolam,Number of Patients Who Met and Exceeded Response Criteria of Yale-Brown Obsessive-Compulsive Scale.,New York State Psychiatric Institute,All,18 Years to 55 Years   (Adult),Phase 2,2,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",#6952,Sep-14,May-15,May-15,1-Aug-14,23-Feb-17,3-May-17,"New York State Psychiatric Institute, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT02206776
NCT02206945,Neurofeedback for Obsessive-Compulsive Disorder (OCD),,Recruiting,No Results Available,Obsessive-Compulsive Disorder,Behavioral: neurofeedback|Behavioral: control feedback,"A modified version of the Yale-Brown Obsessive-Compulsive Symptom scale (Y-BOCS) will be used, that queries subjects regarding symptoms|Control over target brain area|Control over the target brain area.",Yale University|National Institute of Mental Health (NIMH),All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,54,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",0206017435-2|R01MH100068,Jul-15,May-19,Jul-19,1-Aug-14,null,6-Feb-18,"Yale University School of Medicine, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT02206945
NCT02205177,Youth Mayo Clinic Anxiety Coach Pilot Study,,Completed,No Results Available,Anxiety,Device: Mayo Clinic Anxiety Coach,Mean change from Baseline in Pediatric Anxiety Rating Scale (PARS) at Treatment Completion|Qualitative interview assessing subject safety and treatment adherence,Stephen Whiteside|National Institute of Mental Health (NIMH)|Mayo Clinic,All,7 Years to 17 Years   (Child),Not Applicable,10,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other,13-000288 - PILOT|R34MH100468,15-Jan-16,Mar-17,Mar-17,31-Jul-14,null,25-Feb-19,"Mayo Clinic in Rochester, Rochester, Minnesota, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/77/NCT02205177/Prot_000.pdf",https://ClinicalTrials.gov/show/NCT02205177
NCT02203552,Minocycline Hydrochloride in Reducing Chemotherapy Induced Depression and Anxiety in Patients With Stage I-III Breast Cancer,,Recruiting,No Results Available,Anxiety Disorder|Depression|Recurrent Breast Cancer|Stage IA Breast Cancer|Stage IB Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer,Drug: minocycline hydrochloride|Other: placebo|Other: laboratory biomarker analysis|Other: Questionnaire administration,Changes in Center for Epidemiological Studies Depression Scale (CES-D) scores|Changes in the State Trait Anxiety Index (STAI) scores|Changes in Hamilton Anxiety Rating Scale scores|Changes in Hamilton Rating Scale for Depression scores|Changes in inflammatory blood markers|Changes in the PET/MRI measures,Ohio State University Comprehensive Cancer Center,Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,36,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care",OSU-13165|NCI-2014-00851,23-Jun-15,31-Aug-19,31-Aug-19,30-Jul-14,null,21-Aug-18,"Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02203552
NCT02202915,CBT for Pediatric OCD: Community Training Pilot,,"Active, not recruiting",No Results Available,Obsessive Compulsive Disorder,Behavioral: Behavioral Checklist,Observed therapist behaviors,Rhode Island Hospital,All,5 Years to 17 Years   (Child),Not Applicable,46,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,4R33MH096828-03,Sep-14,Mar-18,May-18,29-Jul-14,null,12-Apr-18,"Bradley Hospital, East Providence, Rhode Island, United States",,https://ClinicalTrials.gov/show/NCT02202915
NCT02200003,Attention Bias Modification for Anxiety: A Randomized Control Trial With Biomarkers,ABMT,Completed,No Results Available,Anxiety,Behavioral: attention bias modification for anxiety,Change in anxiety severity - immediate post intervention|Change in threat bias|Change in anxiety severity - four-month follow-up|Change in neural responses to threat|Change in behavioral stress reactivity|Change in physiological measures of stress reactivity,Hunter College of City University of New York,All,18 Years to 40 Years   (Adult),Phase 2,100,Other,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",1 SC MH 109349-01,Feb-15,Jun-18,Jul-18,25-Jul-14,null,1-Aug-18,"Hunter College of the City University of New York, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT02200003
NCT02199587,The Effect of Medical Clown on the Pain and Anxiety Perception During LRH Analog Treatment or GH Provocation Test,,Completed,No Results Available,Precocious Puberty|Growth Hormone Tests,Behavioral: Presence of medical clown during endocrine test,"change from base line of the anxiety of the child and his parent by State-Trait (STAI) Inventory questionnaires for the parent and STAIC questionnaires for the kids.|Changes in hormones: cortisol , Growth hormone, prolactin and adrenalin during growth hormone tests in the presence of a clown.",Meir Medical Center,All,"4 Years to 18 Years   (Child, Adult)",Not Applicable,58,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,MeirMc069-14CTIL,17-Dec-14,16-Jul-18,1-Aug-18,24-Jul-14,null,15-Oct-18,"Meir Medical Center endocrine unit, Kfar Saba, Israel",,https://ClinicalTrials.gov/show/NCT02199587
NCT02196506,Study of the Safety and Efficacy of Fixed-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder With and Without Anxious Distress,,Completed,Has Results,"Depressive Disorder|Depression|Depressive Disorder, Major|Mood Disorders|Mental Disorders",Drug: Placebo + ADT|Drug: Brexpiprazole +ADT,"Change in the Montgomery-Asberg Depression|Change in the Sheehan Disability Scale (SDS) From Baseline to End of Treatment|Change From End of Phase A to End of Phase B in MADRS Total Score for the Subpopulation With <25% Improvement From Baseline of Phase A to End of Phase A in MADRS Total Score|Change From End of Phase A to End of Phase B in MADRS Total Score for the Subpopulations With Anxious Distress as Specified in Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V).","Otsuka Pharmaceutical Development & Commercialization, Inc.|H. Lundbeck A/S",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,837,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",331-13-214,Jul-14,Apr-16,May-16,22-Jul-14,21-Aug-18,21-Aug-18,"Birmingham, Alabama, United States|Beverly Hills, California, United States|Denver, Colorado, United States|Hialeah, Florida, United States|Orlando, Florida, United States|Alpharetta, Georgia, United States|Smyrna, Georgia, United States|Baltimore, Maryland, United States|Boston, Massachusetts, United States|Rochester Hills, Michigan, United States|Cherry Hill, New Jersey, United States|Jamaica, New York, United States|New York, New York, United States|Staten Island, New York, United States|Raleigh, North Carolina, United States|Cincinnati, Ohio, United States|Edmond, Oklahoma, United States|Portland, Oregon, United States|Salem, Oregon, United States|Philadelphia, Pennsylvania, United States|Lincoln, Rhode Island, United States|Columbia, South Carolina, United States|Memphis, Tennessee, United States|Wichita Falls, Texas, United States|Murray, Utah, United States|Woodstock, Vermont, United States|Charlottesville, Virginia, United States|Richmond, Virginia, United States|Seattle, Washington, United States|Spokane, Washington, United States|Achim, Germany|Berlin, Germany|Dusseldorf, Germany|Frankfurt, Germany|Freiburg, Germany|Oranienburg, Germany|Stralsund, Germany|Wurzburg, Germany|Budapest, Hungary|Gyor, Hungary|Gdansk, Poland|Lubin, Poland|Sosnowiec, Poland|Warszawa, Poland|Bratislava, Slovakia|Kosice-Barca, Slovakia|Liptovsky Mikulas, Slovakia",,https://ClinicalTrials.gov/show/NCT02196506
NCT02196090,Application of Vagal Stimulation in Exposure and Response Prevention for Obsessive Compulsive Disorder,,Unknown status,No Results Available,Obsessive Compulsive Disorder,Behavioral: Exposure and Response Prevention|Device: Cold face gel mask,Visual analogue scales at baseline|Visual analogue scales at exposure|Visual analogue scales 5 minutes post exposure|Visual analogue scales 10 minutes post exposure|Visual analogue scales 15 minutes post exposure|Heart rate variability measures,King's College London,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,10,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SLAM-RD-001,Jul-14,Feb-16,Feb-16,21-Jul-14,null,29-Feb-16,"Anxiety Disorders Residential Unit, Bethlem Royal Hospital, Beckenham, Kent, United Kingdom",,https://ClinicalTrials.gov/show/NCT02196090
NCT02194036,Learning Oriented Physiotherapy - a New Approach,LOF,Completed,No Results Available,Agitation|Anxiety|Dizziness|Pain|Numbness|Depression|Fatigue|Sleep Disturbances,Behavioral: Learning Oriented Physiotherapy|Behavioral: Widely Recognized Psychiatric Treatment,Changes in Health Related Quality of Life (HRoQL)|Changes in Levels of Anxiety and Depression,Central Norway Regional Health Authority|Health North Trøndelag|Health Møre and Romsdal|South Coast Hospital Hf Dps Aust-Agder Units Arendal,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,81,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,2014/393 (REK),Aug-14,1-Sep-17,1-Sep-17,18-Jul-14,null,30-Jan-18,"Regional Psychiatric Centre Aust-Agder, Arendal, Aust-Agder, Norway|Psychiatric Clinic, Molde, Møre And Romsdal, Norway|Psychiatric Clinic, Levanger, North Trøndelag, Norway",,https://ClinicalTrials.gov/show/NCT02194036
NCT02194075,Methylphenidate Hydrochloride Controlled-Release Tablets Augmentation Strategy for Patients With Obsessive Compulsive Disorder,,Completed,No Results Available,Obsessive Compulsive Disorder,Drug: Fluvoxamine+Methylphenidate hydrochloride|Drug: Fluvoxamine+sugar pill,Yale-Brown Obsessive Compulsive Scale (Y-BOCS),Guangdong General Hospital,All,18 Years to 40 Years   (Adult),Phase 4,60,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",B2013006,Oct-13,Oct-15,Oct-15,18-Jul-14,null,23-Oct-15,"Guangdong General Hospital, Guangdong academy of medical science, Guangzhou, Guangdong, China",,https://ClinicalTrials.gov/show/NCT02194075
NCT02194413,Effects of Healing Touch on Patients Undergoing Hematopoietic Stem Cell Transplant,,Completed,No Results Available,Anxiety Disorder|Fatigue|Hematopoietic/Lymphoid Cancer|Pain,Procedure: therapeutic touch|Other: quality-of-life assessment|Other: questionnaire administration,"Length of hospital stay, Days to engraftment defined as absolute neutrophil count (ANC: segs + bands) greater|Changes in QoL (POMS-SF, FACT-BMT, CES-D)|Number of hospital readmissions",University of Iowa|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,60,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,201111724|P30CA086862,Mar-12,Jan-16,18-Jan-17,18-Jul-14,null,1-Feb-17,"University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States",,https://ClinicalTrials.gov/show/NCT02194413
NCT02192710,Reduction of Preoperative Anxiety in Children: Electronic Tab vs Midazolam,IPAD,Completed,No Results Available,Paediatric Outpatient Surgery,Procedure: electronic tab|Drug: Midazolam oral intake,"Patient's level of anxiety|Parents' level of anxiety|Satisfaction of patients, parents and medical team",Hospices Civils de Lyon,All,4 Years to 10 Years   (Child),Phase 3,118,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2013.794,May-13,Apr-14,Apr-14,17-Jul-14,null,17-Jul-14,"Service d'anesthésie, Hôpital Femme Mère Enfant, Hospices Civils de Lyon, Bron, France",,https://ClinicalTrials.gov/show/NCT02192710
NCT02191345,The Effectiveness of Guided Imagery for a Nonprofit's Employees,,Completed,No Results Available,Focus of Study|Stress,Behavioral: Guided Imagery,"State Anxiety as Measured by the State Anxiety Short Form|Compassion Fatigue, Compassion Satisfaction, and Burnout, as measured by the ProQol|Perceived Stress as measured by the Perceived Stress Scale",FrontLine Service|National Institutes of Health (NIH),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,69,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,MD002265|IRB-2014-743,Jul-14,Nov-14,Nov-14,16-Jul-14,null,23-Feb-17,"FrontLine Service, Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02191345
NCT02191553,Differential Effect of Four Mindfulness Exercises,,Completed,No Results Available,Well-being|Depression|Anxiety,Behavioral: Control group relaxation techniques|Behavioral: Loving-kindness meditation|Behavioral: Body scan|Behavioral: Sitting practice,Different facets of Mindfulness|Brain function|Positive and negative affectivity|anxiety and depression|Insomnia|Self-compassion,Hospital Miguel Servet,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,80,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",PI13/0129,Sep-14,Sep-15,Apr-17,16-Jul-14,null,25-Feb-19,"Arrabal Health Center, Zaragoza, Spain",,https://ClinicalTrials.gov/show/NCT02191553
NCT02191631,Internet-delivered CBT for Adolescents With OCD: A Randomized Controlled Study,BiPOCD,Completed,No Results Available,Obsessive-Compulsive Disorder,Behavioral: Internet-delivered Cognitive Behavior Therapy,"Children's Yale Brown Obsessive Compulsive Scale, CY-BOCS|Clinical Global Impression - Severity, CGI-S|Clinical Global Impression - Improvement, CGI-I|Parent Adherence EX/RP Scale, PEAS|Children's Obsessional Compulsive Inventory Revised, (CHOCI-R, Shafran et al., 2003)|Education, Work and Social Adjustment Scale - child and parent version (EWSAS)|Spence Child Anxiety Scale - Child and Parent version (SCAS-C/P, Spence, 1998|Child Depression Inventory - Short version (CDI-S, Kovacs, 1985)|Family Accommodation Scale, Parent-Report (FAS-PR, Flessner et al., 2009)|Technology acceptance scale|Trimbos/iMTA questionnaire for Costs associated with Psychiatric Illness - Child version (TiC-P)|EQ-5D - quality of life",Karolinska Institutet,All,12 Years to 17 Years   (Child),Not Applicable,67,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,BiPOCD RCT,Aug-14,Mar-16,Dec-16,16-Jul-14,null,22-Dec-16,"Karolinska Institutet, Stockholm, Sweden",,https://ClinicalTrials.gov/show/NCT02191631
NCT02189213,Treatment of Pediatric Anxiety Disorders by Predicting Treatment Response Through Biocellular Markers and Sleep,,"Active, not recruiting",No Results Available,Generalized Anxiety Disorder|Separation Anxiety Disorder|Social Phobia,Drug: Sertraline|Drug: Fluoxetine|Drug: Escitalopram,Clinical Global Impression-Improvement (CGI-I) Score,New York State Psychiatric Institute|Columbia University,All,"8 Years to 25 Years   (Child, Adult)",Not Applicable,60,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,6884,Jul-14,Sep-19,Oct-19,14-Jul-14,null,16-Nov-18,"NYSPI, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT02189213
NCT02185976,Effect of Cartoons on Preoperative Anxiety in Paediatric Patients.,,Unknown status,No Results Available,Anxiety,Other: cartoon,anxiety score|family anxiety scores,Balikesir University,All,3 Years to 9 Years   (Child),Not Applicable,60,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor),2013/051,Jan-14,Aug-16,Dec-16,10-Jul-14,null,10-Feb-16,"Balikesir University Faculty of Medicine, Balikesir, Turkey",,https://ClinicalTrials.gov/show/NCT02185976
NCT02186366,Efficacy Study of Abdominal Massage Therapy to Treat Generalized Anxiety Disorder of Deficiency of Both Heart and Spleen Type,,Unknown status,No Results Available,Anxiety Disorders,Other: Abdominal Massage Therapy|Drug: Buspirone,reductive rate of Hamilton Depression Scale（ HAMD reductive rate）|Scores of Hamilton Depression Scale(HAMD)|Scores of self-rating anxiety scale( SAS)|Scores of Quality of life assessment scale|Scores of Clinical Global Impression,Sun Qing|First Teaching Hospital of Tianjin University of Traditional Chinese Medicine,All,30 Years to 50 Years   (Adult),Not Applicable,140,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,TECF 20120210,Sep-14,Oct-15,null,10-Jul-14,null,3-Sep-14,"The First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, Tianjin, China",,https://ClinicalTrials.gov/show/NCT02186366
NCT02186392,The Impact of Ergonomic Circadian Light on Hospitalized Stroke Patients in a Rehabilitation Unit,,Completed,No Results Available,Stroke|Sleep Apnea Syndromes|Depression|Anxiety,Device: Circadian Light luminaries,well-being|Depression|Anxiety|Circadian rhythm specific blood marker|Sleep and sleep-wake cycle|Cognitive function|Autonomic function,"Glostrup University Hospital, Copenhagen",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,90,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,H-4-2013-114,May-14,Jun-15,15-Aug-16,10-Jul-14,null,22-Dec-17,"Department of clinical stroke reseach, Department of Neurology, Glostrup Hospital., Glostrup, Denmark",,https://ClinicalTrials.gov/show/NCT02186392
NCT02184481,Working Memory Training for Dysphoric Students,,Completed,No Results Available,Depression,Behavioral: Working memory training|Behavioral: Placebo training,Beck Depression Inventory Second Edition (BDI-II) score change between pre and post measurement|State-Trait Anxiety Inventory (STAI) scores change from pre to post training measurement,Erasmus Medical Center,All,"17 Years and older   (Child, Adult, Older Adult)",Not Applicable,94,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",Franken 5,Sep-13,Jun-14,null,9-Jul-14,null,9-Jul-14,"Erasmus University Rotterdam, Rotterdam, Zuid Holland, Netherlands",,https://ClinicalTrials.gov/show/NCT02184481
NCT02185612,The EARN-Health Trial of Financial Savings and Health,EARN-Health,"Active, not recruiting",No Results Available,Depression|Anxiety|Alcohol Abuse|Tobacco Abuse,Behavioral: Savings program,Self-rated health scales|Depression and anxiety symptoms: yes/no questions|Alcohol abuse screening questions|Tobacco abuse screening questions|Locus of control Likert scales|Optimism Likert scales|Spending behaviors,Stanford University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,700,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention,30641,Oct-16,Jul-18,Jul-18,9-Jul-14,null,8-Aug-17,"Stanford University, Stanford, California, United States",,https://ClinicalTrials.gov/show/NCT02185612
NCT02181751,A 1-year Program to Treat Children Who Have Been Victims of Child Sexual Abuse,,Unknown status,No Results Available,Sexual Abuse of Child (If Focus of Attention is on Victim),Other: Trauma Focused Cognitive Behavioural Therapy Group,Post Traumatic Stress Disorder Symptom Severity|Quality of Life|Depression and Anxiety|Level of Attachment,Little Warriors,All,8 Years to 12 Years   (Child),Not Applicable,100,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,LW2014,Oct-14,Apr-16,Apr-16,4-Jul-14,null,8-Jul-14,"Be Brave Ranch, Ardrossan, Alberta, Canada",,https://ClinicalTrials.gov/show/NCT02181751
NCT02177903,Study to Determine the Effects of Pre-warming on OR Patient Temperatures and Surgical Outcomes,,Completed,No Results Available,Hypothermia,Device: Bair Paws Patient Adjustable Warming System,Duration of hypothermia,3M,All,"19 Years to 85 Years   (Adult, Older Adult)",Not Applicable,220,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,EM-05-013093,Sep-14,Dec-15,Dec-15,30-Jun-14,null,1-Sep-16,"Royal Columbian Hospital, Vancouver, British Columbia, Canada",,https://ClinicalTrials.gov/show/NCT02177903
NCT02177955,Comparative Study of Hemodynamic Changes Caused by Diazepam and Midazolam During Third Molar Surgery,,Completed,No Results Available,Anxiety,Drug: 7.5 mg Midazolam|Drug: 10 mg diazepam,Changes from baseline in systolic blood pressure until the end of surgery|Changes from baseline in diastolic blood pressure until the end of surgery|Changes from baseline in mean blood pressure until the end of surgery|Changes from baseline in heart rate until the end of surgery|Changes from baseline in rate pressure product until the end of surgery|Changes from baseline in oxygen saturation until the end of surgery|Change from baseline in pressure rate quotient until the end of surgery,Jimmy Barbalho|University of Pernambuco,All,18 Years to 40 Years   (Adult),Phase 4,120,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",001.0.097.000-08,Jan-11,Jul-12,Sep-12,30-Jun-14,null,30-Jun-14,"School of Dentistry of Pernambuco, Recife, Pernambuco, Brazil",,https://ClinicalTrials.gov/show/NCT02177955
NCT02176226,IntelliCare: Artificial Intelligence in a Mobile Intervention for Depression and Anxiety (AIM),,Completed,Has Results,Major Depressive Disorder|Anxiety Disorders,Behavioral: IntelliCare,Patient Health Questionnaire - 9 (PHQ-9) - Depression Severity Module|GAD-7 (Generalized Anxiety Disorder Scale-7)|Mean Number of Treatment App Use Sessions by Study Week,Northwestern University,All,"19 Years and older   (Adult, Older Adult)",Not Applicable,105,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,R01MH100482-01FTIC,Mar-15,Jun-16,Jun-16,27-Jun-14,29-Oct-18,29-Oct-18,"Northwestern University, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT02176226
NCT02169960,Comprehensive Program for Youth Mental Health,EMPATHY,Completed,No Results Available,Depression|Suicide|Anxiety,"Behavioral: Smart, Positive, Active, Realistic X-factor thoughts (SPARX)|Behavioral: Breaking Free|Behavioral: This Way Up|Behavioral: Resiliency Training","Decrease from baseline in rates of depression and suicide|Decreased use of alcohol, tobacco and other drugs|Decreased school drop-out rates|Decreased rates of interactions with the justice system",University of Alberta|Red Deer Public School District|Addiction & Mental Health Strategic Clinical Network,All,"11 Years to 18 Years   (Child, Adult)",Not Applicable,5514,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,AMH-SCN-02,Feb-14,Jun-15,Jun-15,23-Jun-14,null,10-Dec-15,"Red Deer Public Schools, Red Deer, Alberta, Canada",,https://ClinicalTrials.gov/show/NCT02169960
NCT02170259,Manual Therapy for Tension Headache With Psychological Disorders,,Completed,No Results Available,Tension-type Headache,Other: The suboccipital technique|Other: The articulatory technique|Other: Combined treatment,Change from baseline in Frequency of TTH at week 4 and at week 8|Change from baseline in Intensity of TTH at week 4 and at week 8|Anxiety|Depression,University of Valencia,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,84,Other,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",UVtensiontype,Jan-12,Dec-12,Jan-16,23-Jun-14,null,9-May-16,"Gemma v. Espí López, Valencia, Spain",,https://ClinicalTrials.gov/show/NCT02170259
NCT02168439,Intranasal Dexmedetomidine vs Intranasal Midazolam as Anxiolysis Prior to Pediatric Laceration Repair,,Completed,Has Results,Laceration|Anxiety,Drug: Dexmedetomidine|Drug: Midazolam,mYPAS Score as Completed by Researchers to Assess Anxiety|mYPAS Scores at Other Time Points|VAS for Anxiety as Completed by Caregiver and Observer,University of Pittsburgh,All,1 Year to 5 Years   (Child),Phase 4,40,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care",PRO13120431|UL1TR000005,Jun-14,Apr-15,Jun-16,20-Jun-14,10-Mar-17,10-Mar-17,"Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT02168439
NCT02168556,Interventions to Decrease Anxiety in Patients Undergoing Urodynamic Testing,,Completed,No Results Available,Incontinence,Behavioral: Music|Behavioral: Video|Other: Standard of care,Anxiety|Discomfort,The Cleveland Clinic,Female,"18 Years to 90 Years   (Adult, Older Adult)",Not Applicable,98,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,12-1351,Jun-13,May-14,May-14,20-Jun-14,null,23-Jun-14,"Fairview Hospital, Cleveland, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02168556
NCT02166164,Characterization of Secondary Hyperalgesia in Healthy Volunteers,,Completed,No Results Available,Experimental Pain in Healthy Males,Other: Brief thermal sensitization|Other: Long thermal stimulation|Other: Heat-pain-detection threshold,"Change in area of secondary hyperalgesia following brief thermal sensitization|Score of Pain Catastrophizing Scale|Score of Hospital Anxiety and Depression Scale|Score of Subscales of Pain Catastrophizing Scale and Hospital Anxiety and Depression Scale|Heat-pain-detection threshold registered by degrees celsius|Pain following Long Thermal Stimulation, evaluated by maximum on the visual analog scale|Pain following Long Thermal Stimulation, evaluated by Area under the curve of the visual analog scale.","Rigshospitalet, Denmark|Copenhagen Trial Unit, Center for Clinical Intervention Research|University of Copenhagen",Male,18 Years to 35 Years   (Adult),Not Applicable,50,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,SM1-MSH-2014,Jun-14,Jan-15,Jan-15,18-Jun-14,null,27-Jan-15,"Department of anaesthesia and surgery, 4231, Rigshospitalet, Copenhagen, Denmark",,https://ClinicalTrials.gov/show/NCT02166164
NCT02164227,Effective Use of Respiratory Patterns in the First Period of Labor in Control of Maternal Anxiety,,Unknown status,No Results Available,Anxiety,Other: Respiratory pattern,Anxiety,Universidade Federal de Pernambuco,Female,"12 Years to 40 Years   (Child, Adult)",Not Applicable,30,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research,025972/2013,Mar-14,Jul-14,Apr-15,16-Jun-14,null,16-Jun-14,"Maternidade Professor Bandeira Filho, Recife, Pernambuco, Brazil",,https://ClinicalTrials.gov/show/NCT02164227
NCT02163369,The Use of Aromatherapy for Symptom Management,,Unknown status,No Results Available,"Nausea, Vomiting and Anxiety Associated With Medical Oncology Patients",Drug: Peppermint and Lavender Essential Oils,Post Intervention Patient Interview Form,Central DuPage Hospital,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,40,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,14-031-1,Jul-14,Jun-15,null,13-Jun-14,null,4-Feb-15,"Central DuPage Hospital, Winfield, Illinois, United States",,https://ClinicalTrials.gov/show/NCT02163369
NCT02162030,A Component Analysis of Acceptance and Commitment Therapy,,Completed,No Results Available,Long-term Physical Health Conditions|Mild to Moderate Anxiety and/or Depression,Behavioral: Acceptance and Commitment Therapy,Change from baseline psychological flexibility at end of 8-session psychological intervention (approximately 8 weeks) and at post-therapy eight week follow-up (using the Acceptance and Action Questionnaire II)|Change from baseline self-report 'quality of life' at end of 8-session psychological intervention (approximately 8 weeks) and at post-therapy eight week follow-up (using the Work and Social Adjustment Scale),University of Sheffield,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,17,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,139593,Oct-14,Jun-17,Jun-17,12-Jun-14,null,9-Feb-18,"Primary Care Health and Medical Psychology Services, Sheffield, South Yorkshire, United Kingdom",,https://ClinicalTrials.gov/show/NCT02162030
NCT02160691,Examining the Efficacy of the Anxiety Meter for Recognition and Management of Anxiety Signs in Autism Spectrum Disorder,,Recruiting,No Results Available,Autism Spectrum Disorder,Device: Anxiety Meter,Proportion of responders|Change in heart rate|Change in self-reported anxiety level,Holland Bloorview Kids Rehabilitation Hospital,All,"8 Years to 18 Years   (Child, Adult)",Not Applicable,30,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ANXMT_RCT1,Oct-15,Aug-20,Aug-20,11-Jun-14,null,16-Jan-19,"Holland Bloorview Kids Rehabilitation Hospital, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT02160691
NCT02161211,Dismantling the Components and Dosing of CBT for Co-Occurring Disorders,CBT,Recruiting,No Results Available,CBT Decoupling|CBT Anxiety Reduction|CBT Combined,Behavioral: De-coupling|Behavioral: Anxiety Reduction|Behavioral: Combined,Relapse Status,University of Minnesota - Clinical and Translational Science Institute,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,300,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,1404S49427,Jul-14,1-Jun-19,1-Jun-19,11-Jun-14,null,14-May-19,"Lodging Plus Program, Fairview Hospital, Minneapolis, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT02161211
NCT02160028,Pain and Placebo Analgesia. Does Extended Information About Dental Procedures Reduce Pain Induced by Dental Treatment?,,Completed,No Results Available,Anxiety|Odontophobia,Other: anesthetics and extended information before dental treatment|Other: anesthetics and standard information before dental treatment,Reduction of pain|Reduction of stress,"Norwegian University of Science and Technology|University of Bergen|Tannhelsetjenestens Kompetansesenter Vest, TK Vest|Tannlegesenteret Madlagården, TSMG",All,"Child, Adult, Older Adult",Not Applicable,52,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Prevention",2014/2615/SGK,Aug-14,Jan-15,Jan-15,10-Jun-14,null,14-Feb-17,"Tannlegesenteret Madlagården, TSMG, Hafrsfjord, Norway",,https://ClinicalTrials.gov/show/NCT02160028
NCT02160431,Neuropsychological Profiles of Pediatric Obsessive Compulsive Disorder (OCD),,Terminated,No Results Available,Obsessive Compulsive Disorder (OCD),Behavioral: CBT for pediatric OCD,Children's Yale Brown Obsessive Compulsive Scale measures change in severity of OCD symptoms from baseline to post-treatment and assesses maintenance of treatment effects at one year and two year follow-up assessments.|Anxiety Disorders Interview Schedule-Diagnostic and Statistical Manual-IV measures change in severity of OCD symptoms from baseline to post-treatment and assesses maintenance of treatment effects at one year and two year follow-up assessments.|Clinical Global Impression Severity and Improvement Scales measures change in severity of OCD and co-morbid disorders from baseline to post-treatment and assesses maintenance of treatment effects at one year and two year follow-up assessments.|Global Assessment Scale for Children measures change in overall functioning from baseline to post-treatment and assesses maintenance of treatment effects at one year and two year follow-up assessments.|Child Obsessive-Compulsive Inventory measures change in severity of OCD symptoms from baseline to post-treatment and assesses maintenance of treatment effects at one year and two year follow-up assessments.|Behavior Rating Inventory of Executive Function measures change in executive functioning from baseline to post-treatment and assesses maintenance of treatment effects at one year and two year follow-up assessments.|Multidimensional Anxiety Scale for Children measures change in severity of anxiety symptoms from baseline to post-treatment and assesses maintenance of treatment effects at one year and two year follow-up assessments.|Child Behavior Checklist measures change in severity internalizing and externalizing symptoms from baseline to post-treatment and assesses maintenance of treatment effects at one year and two year follow-up assessments.|Screen for Child Anxiety and Related Emotional Disorders measures change in severity of anxiety and other disorders from baseline to post-treatment and assesses maintenance of treatment effects at one year and two year follow-up assessments.|Brief Symptom Interview measures change in severity of parental psychopathology from baseline to post-treatment and assesses maintenance of treatment effects at one year and two year follow-up assessments.|Family Accommodation Scale measures change in parental accommodation from baseline to post-treatment and assesses maintenance of treatment effects at one year and two year follow-up assessments.|Test of Everyday Attention-Children's Version measures change in attention from baseline to post-treatment and assesses maintenance of treatment effects at one year and two year follow-up assessments.|Wisconsin Card Sorting Test Revised and Expanded measures change in executive functioning from baseline to post-treatment and assesses maintenance of treatment effects at one year and two year follow-up assessments.|Delis-Kaplan Executive Function System measures change in executive functioning from baseline to post-treatment and assesses maintenance of treatment effects at one year and two year follow-up assessments.|Children's Color Trails Test measures change in cognitive flexibility from baseline to post-treatment and assesses maintenance of treatment effects at one year and two year follow-up assessments.|The Conners' Continuous Performance Test II Version 5measures change in continuous attention from baseline to post-treatment and assesses maintenance of treatment effects at one year and two year follow-up assessments.,University of Texas at Austin,All,8 Years to 16 Years   (Child),Not Applicable,3,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2013-004-0024,Jul-14,Jul-14,Jul-14,10-Jun-14,null,12-May-16,"Texas Child Study Center, Austin, Texas, United States",,https://ClinicalTrials.gov/show/NCT02160431
NCT02160444,Investigating the Effects of Parent Component to Cognitive Behavior Therapy (CBT) for Youth With Anxiety Disorders,,Unknown status,No Results Available,Anxiety Disorders,Behavioral: CBT plus Parent as CBT Coach Training,"Pediatric Anxiety Rating Scale measures change in severity of anxiety from baseline to post-treatment and assesses maintenance of treatment effects at one year and two year follow-up assessments.|Multidimensional Anxiety Scale for Children measures change in severity of anxiety from baseline to post-treatment and assesses maintenance of treatment effects at one year and two year follow-up assessments.|Screen for Child Anxiety Related Emotional Disorders measures change in severity of anxiety and related co-morbid disorders from baseline to post-treatment and assesses maintenance of treatment effects at one year and two year follow-up assessments.|Clinical Global Severity and Improvement Scales measure change in severity of anxiety and co-morbid disorders from baseline to post-treatment and assesses maintenance of treatment effects at one year and two year follow-up assessments.|Children's Global Assessment Scale measures change in severity of anxiety and co-morbid disorders from baseline to post-treatment and assesses maintenance of treatment effects at one year and two year follow-up assessments.|Anxiety Disorders Schedule for DSM-IV: Child Version and Parent Version|Family Assessment Measure III, Dyadic Relationship Scale measures change in perceived family environment from baseline to post-treatment and assesses maintenance of treatment effects at one year and two year follow-up assessments.|Child Behavior Checklist measures change in severity of internalizing and externalizing symptoms from the parent's perspective from baseline to post-treatment and assesses maintenance of treatment effects at one year and two year follow-up assessments.|Family Burden Assessment measures change in severity of the burden the child's anxiety disorder creates for the family from baseline to post-treatment and assesses maintenance of treatment effects at one year and two year follow-up assessments.|Brief Symptom Inventory measures change in severity of parental psychopathology from baseline to post-treatment and assesses maintenance of treatment effects at one year and two year follow-up assessments.|State Trait Anxiety Inventory measures change in severity of anxiety for parents from baseline to post-treatment and assesses maintenance of treatment effects at one year and two year follow-up assessments.|Mood and Feelings Questionnaire measures change in severity of depressive symptoms from baseline to post-treatment and assesses maintenance of treatment effects at one year and two year follow-up assessments.|Goal Attainment Scale measures goal attainment from baseline to post-treatment and assess maintenance of goal attainment at one year and two year follow-up assessments.|Coping Questionnaire measures change in coping skills from baseline to post-treatment and assesses maintenance of treatment effects at one year and two year follow-up assessments.|Negative Affective Self-Statement Questionnaire measures change in negative cognitions from baseline to post-treatment and assesses maintenance of treatment effects at one year and two year follow-up assessments.|Harm to Self and Others Interview measures change in suicidal ideation, homicidal ideation and self-harming behaviors from baseline to post-treatment and assesses maintenance of treatment effects at one year and two year follow-up assessments.",University of Texas at Austin,All,7 Years to 17 Years   (Child),Not Applicable,35,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2012-05-0009,Jun-12,Feb-19,Feb-19,10-Jun-14,null,12-May-16,"Texas Child Study Center, Austin, Texas, United States",,https://ClinicalTrials.gov/show/NCT02160444
NCT02160470,Enhancing Exposure Therapy for Snake and Spider Phobias,Snake/Spider,Unknown status,No Results Available,Specific Phobia,Behavioral: Exposure Therapy with Retrieval|Behavioral: Exposure Therapy with Compound Extinction|Behavioral: Exposure Therapy with Retrieval and Compound Extinction|Behavioral: Therapist-guided Exposure Therapy,"Change in peak subjective fear (0 - 100), behavioral approach (0 - 4), and heart rate reactivity to a live snake/spider not used during treatment (generalization context) from pre-treatment to follow-up|Change in peak subjective fear (0 - 100), behavioral approach (0 - 4), and heart rate reactivity to a live snake/spider not used during treatment (generalization context) from pre-treatment to post-treatment.|Change in peak subjective fear (0 - 100), behavioral approach (1 - 8), and heart rate reactivity to a live snake/spider used during treatment (treatment context) from pre-treatment to follow-up|Change in peak subjective fear (0 - 100), behavioral approach (1 - 8), and heart rate reactivity to a live snake/spider used during treatment (treatment context) from pre-treatment to post-treatment|Change in Fear of Snakes/Spiders Questionnaire from pre-treatment to follow-up|Change in Snake/Spider Belief Questionnaire from pre-treatment to follow-up|Change in Agoraphobic Cognitions Questionnaire for Snake/Spider Phobia from pre-treatment to follow-up|Change in Self-Efficacy Questionnaire for Spider/Snake Phobia from pre-treatment to follow-up|Change in Armfield and Mattiske Disgust Questionnaire from pre-treatment to follow-up|Change in Lab for the Study of Anxiety Disorders Specific Phobia Diagnostic Questionnaire from pre-treatment to follow-up",University of Texas at Austin|National Institute of Mental Health (NIMH),All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,120,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2011-10-0012|1F31MH100760-01,Aug-12,Dec-16,Dec-16,10-Jun-14,null,25-Jul-16,"University of Texas at Austin, Austin, Texas, United States",,https://ClinicalTrials.gov/show/NCT02160470
NCT02156128,"Subjective Memory Complaints, Objective Memory Performance and Cognitive Training",,Completed,No Results Available,"Fatigue Syndrome, Chronic|Chronic Pain|Anxiety Disorders|Depressive Disorder|Sleep Disorders",Behavioral: Cogmed working memory training|Behavioral: Control group,Working memory capacity|Subjective memory complaints (SMC)|Transfer to inhibition,Norwegian University of Science and Technology,All,18 Years to 59 Years   (Adult),Not Applicable,54,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,100878,Oct-13,Mar-15,Apr-15,5-Jun-14,null,25-Jan-17,"NKSS Nasjonal kompetansetjeneste for sammensatte symptomlidelser, Trondheim, Norway",,https://ClinicalTrials.gov/show/NCT02156128
NCT02156531,Cognitive Bias Modification for Youth Anxiety,TeenCBM,"Active, not recruiting",No Results Available,Anxiety,"Behavioral: Self-Administered, Active Cognitive Bias Modification (CBM)|Behavioral: Self-Administered, minimally effective attention-control version of the CBM program",Clinical effectiveness|Cost Effectiveness,Kaiser Permanente|National Institute of Mental Health (NIMH),All,12 Years to 17 Years   (Child),Not Applicable,488,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",1R01MH101118-01A1,Sep-14,May-19,Sep-19,5-Jun-14,null,26-Mar-19,"Kaiser Permanente Center for Health Research, Portland, Oregon, United States",,https://ClinicalTrials.gov/show/NCT02156531
NCT02156973,Using Media to Reduce Anxiety for Cardiac Computed Tomography,,Completed,No Results Available,Anxiety,Other: Video information,Self-reported level of anxiety in patients attending for CT coronary angiography.|The impact of a patient information film on the pre-scan heart rate.|Patient experience of scan|The impact of a patient information film on the amount of use of intravenous beta blockers.|The impact of a patient information film on the diagnostic image quality.,University Hospital Plymouth NHS Trust,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,130,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care,14/P/059|14/WA/0176,Jun-14,Jul-14,Jul-14,5-Jun-14,null,30-Oct-15,"Plymouth Hospitals NHS Trust, Plymouth, Devon, United Kingdom",,https://ClinicalTrials.gov/show/NCT02156973
NCT02155010,Dexmedetomidine in Spinal Anesthesia,,Completed,Has Results,Blood Pressure|Anxiety,Drug: Dexmedetomidine|Drug: Dexmedetomidine with heavy bupivacaine,Incidence of Hypotension|Patient's Anxiety,Inje University,All,20 Years to 60 Years   (Adult),Not Applicable,74,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)",2014-003,Mar-14,Jul-15,Jul-15,4-Jun-14,26-Sep-16,26-Sep-16,"Inje University, Haeundae paik hospital, Busan, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02155010
NCT02153567,SSRI Study for Functional Dyspepsia (SS),,Completed,No Results Available,Dyspepsia|Anxiety|Depression,Drug: Escitalopram|Other: Placebo,"To evaluate the change of serotonin and ghrelin level in blood plasma before and after treatment|To measure expression of serotonin and ghrelin blood plasma using global symptom assessment, symptom scores and the fullness rating of the Fullness Rating Scale (FRS) during satiety test|To measure the rate of adequate relief using global symptom assessment, symptom scores and the fullness rating of the Fullness Rating Scale (FRS) during satiety test",Chinese University of Hong Kong,All,18 Years to 60 Years   (Adult),Phase 3,71,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SS,6-Dec-13,31-Dec-18,9-Jan-19,3-Jun-14,null,31-Jan-19,"Prince of Wales Hospital, Hong Kong, Hong Kong",,https://ClinicalTrials.gov/show/NCT02153567
NCT02153944,Cognitive vs. Emotional Psychopharmacological Manipulations of Fear vs. Anxiety,,Completed,No Results Available,Anxiety Disorder,Drug: Propanolol|Drug: Methylphenidate,Will the reduction of induced-anxiety with propranolol improve cognitive performance.|Will the facilitation of cognitive performance with methylphenidate reduce induced-anxiety.,National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC),All,18 Years to 50 Years   (Adult),Phase 3,138,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other",140114|14-M-0114,31-May-14,26-Sep-18,26-Sep-18,3-Jun-14,null,1-Oct-18,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT02153944
NCT02151162,Happy Nurse Project: Lifestyle Interventions to Maintain Healthy Mental State in Hospital Nurses,HNP,Completed,No Results Available,Depressive Disorder|Anxiety Disorders,Behavioral: Mindfulness-based stress management program|Dietary Supplement: Omega-3 fatty acids pills|Behavioral: Psychoeducation leaflet|Dietary Supplement: Placebo pills,Blindly-rated depression and anxiety severity: Hospital Anxiety and Depression Scale (HADS)|Major depressive episode: Primary Care Evaluation of Mental Disorders (PRIME-MD)|Depression severity: Personal Health Questionnaire-9 (PHQ-9)|Anxiety severity: Generalized Anxiety Disorder Assessment (GAD-7)|Insomnia severity: Insomnia Severity Index (ISI)|Somatic symptoms: The Bradford Somatic Inventory (BSI)|Presenteeism: World Health Organization Heath and Work Performance Questionnaire (HPQ)|Burnout: Maslach Burnout Inventory (MBI)|Quality of Life: EuroQol (EQ-5D),"National Center of Neurology and Psychiatry, Japan",Female,20 Years to 59 Years   (Adult),Not Applicable,80,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,IRG-NP-NCNP-25-8,11-Jun-14,2-Mar-16,6-Sep-16,30-May-14,null,22-Aug-18,"National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan|Kyoto University, Kyoto, Japan",,https://ClinicalTrials.gov/show/NCT02151162
NCT02150265,Effectiveness of Cognitive Behavioral Short-term Treatment for Adolescents With Emotional Symptom Problems in Community Clinics in Norway,SMART,Unknown status,No Results Available,Generalized Anxiety Disorder|Social Phobia|Agoraphobia|Depression|Panic Disorder,Behavioral: SMART manual cognitive behavioral therapy,Status of primary emotional disorder based on theDevelopment and Well-Being Assessment (DAWBA) interview schedule with parents and youths|Depression symptom status as measured by the self-rating instrument Beck Depression Inventory (BDI-II)|Anxiety symptom score on the Multi-Dimensional Anxiety Scale for Children (MASC)|Life functioning as measured by the rating scale C-GAS rated by clinicians|General outcome measured by Clinical Outcomes in Routine Evaluations Outcome Measure (CORE-OM)|SDQ Strengths and Difficulties Questionnaire,University of Tromso|The Royal Norwegian Ministry of Health|Regionsenter for barn og unges psykiske helse,All,"14 Years to 18 Years   (Child, Adult)",Not Applicable,173,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,2011/1937|8563/PFP1112-13,Jan-13,30-Jun-17,31-Jan-18,29-May-14,null,30-May-17,"University Hospital of North Norway, Tromsø, Norway",,https://ClinicalTrials.gov/show/NCT02150265
NCT02150395,Impact of Music Therapy on Anxiety in Patients With Cancer Undergoing Simulation for Radiation Therapy,,Completed,No Results Available,Anxiety and Distress,Other: music therapy,Reduction in state anxiety|reduced distress,Beth Israel Medical Center,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,82,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,IRB 199-13,Jul-11,Feb-14,Feb-14,29-May-14,null,29-May-14,"Beth Israel Medical Center, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT02150395
NCT02147912,Evaluation of Depression In Chronic Obstructive Pulmonary Disease,EDIC,Unknown status,No Results Available,Depression in Patients With Chronic Obstructive Pulmonary Disease,Other: Aerobic Exercise,variation of HDRS total score|daily functioning assessment,"University Hospital, Catania",All,"40 Years to 80 Years   (Adult, Older Adult)",Not Applicable,154,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,UHCatania,Nov-14,May-15,Nov-15,28-May-14,null,28-May-14,,,https://ClinicalTrials.gov/show/NCT02147912
NCT02144688,COMO: Cognition Study With HIV+ Patients (CTNPT 015),COMO,Terminated,No Results Available,HIV - Human Immunodeficiency Virus|Cognitive Symptoms,Drug: Change in antiretrovirals,Changes in neurocognitive functioning over 6 months,Marie-Josée Brouillette|Fonds de la Recherche en Santé du Québec|CIHR Canadian HIV Trials Network|McGill University Health Center,All,"18 Years and older   (Adult, Older Adult)",Early Phase 1,19,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CTNPT 015,Jun-11,Mar-16,Mar-16,22-May-14,null,16-Mar-16,"Montreal Chest Institute - Chronic Viral Illness Service - McGill University Health Centre (MUHC), Montreal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT02144688
NCT02145429,Preventing Depression in Late Life: A Model for Low and Middle Income Countries,,Completed,Has Results,Depression|Anxiety Disorder,Behavioral: Problem Solving therapy and Brief Behavioral Treatment of Insomnia,Percent of Participants Who Develop Major Depression and Anxiety Disorders|General Health Questionnaire (GHQ) Scores|World Health Organization Disability Assessment Schedule (WHODAS-II) Scores,University of Pittsburgh|National Institutes of Health (NIH)|Goa Medical College|Sangath,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,181,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,1R34MH096997-01A1,Sep-13,7-Nov-18,7-Nov-18,22-May-14,24-Jan-19,24-Jan-19,"Goa Medical College, Bambolim, Goa, India","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/29/NCT02145429/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02145429
NCT02142231,AcuTA: Acupuncture in Test Anxiety,AcuTA,Completed,No Results Available,Test Anxiety|Experimental Setting (Trier Social Stress Test TSST),Device: Acupuncture|Device: Laser Acupuncture,Cortisol in saliva|Test Anxiety on a Visual Analogue Scale|Primary Appraisal Secondary Appraisal|Multidimensional Mood State Questionnaire|State Trait Anxiety Questionnaire|alpha amylase in saliva,Goethe University|Ludwig-Maximilians - University of Munich,Male,"18 Years and older   (Adult, Older Adult)",Not Applicable,25,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Prevention",AcuTA,Apr-14,Jun-14,Jun-14,20-May-14,null,7-Jan-15,"Medical School, University of Regensburg, Germany, Bavaria, Germany",,https://ClinicalTrials.gov/show/NCT02142231
NCT02137941,Stress Management Programs in Fire-fighters,,Completed,No Results Available,Stress|Anxiety,Behavioral: techniques to optimize potential (TOP)|Behavioral: heart coherence (HC),Change from Baseline in Perceived stress at the end of the stress managements programs|the profile of mood states (POMS)|the Freiburg Mindfulness Inventory-14|the Spielberger State-Trait-Anxiety Inventory (S-STAI)|heart rate variability|salivary cortisol|salivary immunoglobulin A|urinary catecholamines,French Defence Health Service,Male,18 Years to 40 Years   (Adult),Not Applicable,180,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening,n° EudraCT 2010-A00212-37,Sep-10,Sep-13,Sep-13,14-May-14,null,14-May-14,"Paris Fire Brigade, Paris, France",,https://ClinicalTrials.gov/show/NCT02137941
NCT02138513,(Cost-)Effectiveness of Mindfulness-Based Cognitive Therapy (MBCT) in Cancer Patients,BeMind,Completed,No Results Available,Distress|Anxiety|Depression,Behavioral: Mindfulness Based Cognitive Therapy,Change from baseline in anxiety and depressive symptoms|Change from baseline in fear of cancer recurrence|DSM-IV Axis I mood or anxiety disorders|Change from baseline in positive mental health|Change from baseline in healthcare consumption|Change from baseline in health-related quality of life|Change from baseline in mindfulness skills|Change from baseline in rumination|Change from baseline in personality assessment|Change in mindfulness skills during intervention|Group cohesion during intervention|Working alliance during intervention|Change in mood during intervention|Change from baseline in anxiety and depressive symptoms - follow up,Radboud University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,245,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,2012.WO14.C153|NL46338.091.13,Apr-14,20-Jul-16,1-May-17,14-May-14,null,19-Sep-17,"Radboud University Medical Centre for Mindfulness, Radboud University Nijmegen Medical Centre, Nijmegen, Gelderland, Netherlands|Helen Dowling Institute, Bilthoven, Utrecht, Netherlands",,https://ClinicalTrials.gov/show/NCT02138513
NCT02136953,"Physical Exercise in OCD: Treatment Efficacy, Additive Benefits to CBT, and Cognitive Correlates of Change",,"Active, not recruiting",No Results Available,Obsessive-Compulsive Disorder|Cognition Disorders,Behavioral: Exercise|Behavioral: Cognitive Behavioural Therapy (CBT),"Change from baseline in OCD symptom severity, as measured by the Yale-Brown Obsessive Compulsive Scale (YBOCS)|Change from baseline in cognitive domains sensitive to OCD, as measured by a targeted neuropsychological battery",Sunnybrook Health Sciences Centre|Canadian Institutes of Health Research (CIHR)|Centre for Addiction and Mental Health|McMaster University|Ryerson University,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,480,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,MOP133452,May-14,Jul-19,Jul-19,13-May-14,null,6-Sep-18,"St. Joseph's Healthcare Hamilton at McMaster University, Hamilton, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|Centre for Addiction and Mental Health, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT02136953
NCT02136212,Positive Emotional Processing: Exploring Novel Treatment Targets in Social Phobia,,Completed,No Results Available,Social Anxiety Disorder,Behavioral: Approach-positive AAT|Behavioral: Control AAT,Change from baseline in positive affect (Positive and Negative Affect Schedule)|Change from baseline in social connectedness (Social Connectedness Scale - Revised)|Change from baseline in social relationship functioning (Interpersonal Outcomes Scale)|Change from baseline in social anxiety symptoms (Liebowitz Social Anxiety Scale),"University of California, San Diego|National Institute of Mental Health (NIMH)",All,18 Years to 55 Years   (Adult),Not Applicable,57,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",5R00MH090243|R00MH090243,Apr-13,Jul-16,Sep-16,12-May-14,null,1-Sep-17,"University of California, San Diego; Psychiatry Clinical Research, San Diego, California, United States",,https://ClinicalTrials.gov/show/NCT02136212
NCT02134730,School-based Universal Prevention for Anxiety and Depression in Sweden: A Cluster-randomized Trial,,Completed,No Results Available,Anxiety Disorders,Behavioral: FRIENDS for life,Change in SCAS (Spence Children's Anxiety Scale)|The Mini International Neuropsychiatric Interview for Children and Adolescents (MINI-KID)|Change in Children's Depression Inventory (CDI)|Change in Strengths and Difficulties Questionnaire (SDQ),Uppsala University,All,8 Years to 12 Years   (Child),Not Applicable,695,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,AGJA-01,Sep-13,Jan-15,null,9-May-14,null,30-Jan-15,"Department of Psychology, Uppsala University, Uppsala, Sweden",,https://ClinicalTrials.gov/show/NCT02134730
NCT02133365,"Atrial Fibrillation, Cardiac Symptoms, and Anxiety",,Suspended,No Results Available,Atrial Fibrillation|Anxiety,Behavioral: Mindfulness and Interoceptive Exposure,Cardiac symptoms as measured by the Cardiac Symptom Questionnaire (CSQ).|Cardiac anxiety as measured by the Cardiac Anxiety Questionnaire (CAQ-R)|Anxiety sensitivity as measured by the Anxiety Sensitivity Index-3 (ASI-3)|Health related quality of life as measured by the Atrial Fibrillation Effect on Quality of Life (AFEQT)|Atrial fibrillation severity,Brigham and Women's Hospital,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,130,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2014P000363,Sep-14,Mar-17,Jan-20,8-May-14,null,15-Jan-19,"Brigham and Women's Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT02133365
NCT02131883,Outcome of Cognitive Behavioral Therapy for Patients With Severe Health Anxiety Treated in Group Only. A RCT.,CHAG,"Active, not recruiting",No Results Available,Severe Health Anxiety|Hypochondriasis|Illness Anxiety Disorder|Somatic Symptom Disorder|Personality Disorders,Behavioral: Group-Cognitive Behavioral Therapy|Other: Wait-List with treatment as usual,Change in degree of health anxiety on the questionnaire Whiteley Index 7 (WI-7) from baseline to 6 month after 12 weeks group-CBT intervention|Cure from severe health anxiety|Change in degree of health anxiety on the questionnaire Health Anxiety Inventory-14/18 (HAI) from baseline to 6 months after 12 weeks group-CBT intervention|Personality Inventory for DSM-5 Total Score (PID-5)|Social level of Functioning (SF-36)|Symptome Check List-90-Revised (SCL-90-R) subscales|WHO-5 Well-being Index|EQ-5D (EuroQol)|CAGE|Illness Perception Questionnaire (IPQ)|Client Satisfaction Questionnaire (CSQ)|Global Assessment of Functioning (F-GAF)|Resource Use from Register data for health and social care (cost/effectiveness),"Psychiatric Research Unit, Region Zealand, Denmark|The Clinic for Liaison Psychiatry in Koege, Department of Special Functions, Psychiatry Region Zealand|The Regional Fund for Health Sciences in Region Zealand",All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,84,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,SJ-374,Feb-14,Jan-19,Jan-19,6-May-14,null,20-Jun-18,"The Clinic of Liaison Psychiatry, Koege, Denmark",,https://ClinicalTrials.gov/show/NCT02131883
NCT02129569,Psychoeducational and Behavioral Strategies in Reducing Distress and Anxiety in Patients With Multiple Myeloma and Their Family Caregivers,,Completed,No Results Available,Multiple Myeloma,Other: Psychoeducational intervention|Behavioral: behavioral intervention|Other: counseling intervention|Other: educational intervention|Other: telephone-based intervention|Other: questionnaire administration|Other: quality-of-life assessment,"Change in emotional distress in patients measured as anxiety using the Patient-Reported Outcomes Measurement Information System (PROMIS)|Change in activation for self-management in patients using the Patient Activation Measure (PAM)|Change in activation for self-management in caregivers using the PAM|Change in fatigue in patients using the PROMIS|Change in fatigue in caregivers using the PROMIS|Change in depression in patients using the PROMIS|Change in depression in caregivers using the PROMIS|Change in HRQOL in patients using the PROMIS short form, Global Health|Change in HRQOL in caregivers using the PROMIS short form, Global Health|Feasibility of the intervention, assessed via attrition rates|Acceptability of the intervention, assessed via consent rates|Satisfaction with the intervention assessed using an exit interview survey|Integrity of the intervention, assessed through fidelity monitoring",Case Comprehensive Cancer Center|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,30,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,CASE5A13|NCI-2014-00836|CASE 5A13|P30CA043703,11-Nov-13,11-Apr-15,17-Aug-16,2-May-14,null,20-Mar-17,"Case Comprehensive Cancer Center, Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02129569
NCT02128568,Sub-Trial of the Youth Readiness Intervention (YRI): Treatment of Control Group and Addition of Stress Biomarkers,,Withdrawn,No Results Available,"Anxiety Disorder|Depressive Disorder|Social Problems|Stress, Psychological|Violence, Non-accidental",Behavioral: Youth Readiness Intervention,"Collection of epigenetic biomarker samples|Change in scores on the Oxford Measure of Psychosocial Adjustment & World Health Organization Disability Assessment Schedule, 2.0 (WHODAS 2.0)|Change in scores on the Youth Assessment Battery",Harvard School of Public Health|Caritas Freetown|McGill University|Yale University|The City College of New York,All,"15 Years to 24 Years   (Child, Adult)",Not Applicable,0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,RPCGA-YRI-21003-Bio,Mar-14,Sep-17,Sep-17,1-May-14,null,26-Apr-19,"CARITAS Freetown, Freetown, Sierra Leone",,https://ClinicalTrials.gov/show/NCT02128568
NCT02126787,"Short-term, Intensive Psychodynamic Group Therapy Versus Cognitive-behavioral Group Therapy in the Day Treatment",,Unknown status,No Results Available,Anxiety Disorders|Depressive Disorders|Personality Disorders,Behavioral: Intensive Group Analytic Psychotherapy|Behavioral: Intensive transdiagnostic cognitive-behavioral group therapy,State-Trait Anxiety Inventory|Hamilton Anxiety Rating Scale|Clinical Global Impression - Severity scale|Clinical Global Impression - Improvement scale|Mini-International Neuropsychiatric Interview 5|Becks Depression Inventory II|Structured Clinical Interview for DSM-IV Personality Disorders Questionnaire|Symptoms Checklist|Self-Esteem Scale|Defense Style Questionnaire|Personality Beliefs Questionnaire|Inventory of Interpersonal Problems|Dysfunctional Working Models Scale|Experiences in Close Relationships|Bell Object Relations and Reality Testing Inventory|Meta-cognitions Questionnaire|Five Facet Mindfulness Questionnaire|Satisfaction With Life Scale|Credibility/Expectancy Questionnaire,Medical University of Warsaw|Wola Hospital|University of Warsaw,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,123,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,NN402464340,Sep-14,Apr-16,Apr-16,30-Apr-14,null,30-Apr-14,"Hospital of Wola, Warsaw, Poland",,https://ClinicalTrials.gov/show/NCT02126787
NCT02122796,"A Pilot Trial to Assess the Impact of Acupuncture on Post-mastectomy Pain, Nausea, Anxiety and Ability to Cope",,Completed,Has Results,Breast Cancer,Other: Acupuncture,Number of Patients Eligible Compared to the Number Approached and Enrolled|Change in Pain Post Intervention|Change in Anxiety Post Intervention|Change in Nausea Post Intervention|Change in Ability to Cope Post Intervention,Allina Health System,Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,30,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,S121301,Jun-14,Dec-14,Jan-16,25-Apr-14,2-Apr-18,2-Apr-18,"Abbott Northwestern Hospital, Minneapolis, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT02122796
NCT02122393,"A Randomised Trial of Sertraline, Cognitive Behaviour Therapy & Combined Therapy for Postnatal Depression",,Completed,No Results Available,Depression|Anxiety,Drug: Sertraline|Behavioral: Cognitive Behavioural Therapy,Beck Depression Inventory|Beck Anxiety Inventory|Parenting Stress Index,University of Melbourne|Pfizer,Female,18 Years to 40 Years   (Adult),Phase 3,45,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,H2001/01263,Apr-02,Apr-05,Apr-05,24-Apr-14,null,29-Apr-14,"Austin Health, Melbourne, Victoria, Australia",,https://ClinicalTrials.gov/show/NCT02122393
NCT02119923,Tackling Depression and Anxiety: A Working Memory Intervention,,Completed,No Results Available,Major Depression|Anxiety Disorder,Behavioral: Working memory training|Behavioral: Placebo training,Beck Depression Inventory Second Edition (BDI-II) score change between pre and post training and at follow-up measurement (2 months after post measurement)|State-Trait Anxiety Inventory (STAI) scores change from pre to post training and to follow up measurement (2 months after post measurement),Erasmus Medical Center,All,"16 Years to 68 Years   (Child, Adult, Older Adult)",Not Applicable,240,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",1,Apr-11,Oct-11,Oct-11,22-Apr-14,null,22-Apr-14,"Erasmus University Rotterdam, Rotterdam, Zuid Holland, Netherlands",,https://ClinicalTrials.gov/show/NCT02119923
NCT02119936,Feasibility of Heart Rate Variability Biofeedback With In-patient Pregnant Women,,Terminated,Has Results,Maternal Stress|Maternal Anxiety|Maternal Health Services,Behavioral: Heart Rate Variability Biofeedback Tool,Feasibility of Using HRVB Among Hospitalized Pregnant Women|Change in State-Trait Anxiety Inventory From Baseline to In-patient Follow up (5-7 Days).|Association Between HRVB and High-Frequency Heart Rate Variability (HF-HRV)|Correlation of HRVB Feedback With Varying Levels of Clinical Depression and Anxiety|Change in Linear Analog Self-Assessment (LASA) From Baseline to In-patient Follow up (5-7 Days).|Change in Warwick Edinburgh Mental Well Being Scale From Baseline to In-patient Follow up (5-7 Days).,"University of North Carolina, Chapel Hill|North Carolina Translational and Clinical Sciences Institute",Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,10,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,13-2051,May-14,May-16,Oct-16,22-Apr-14,19-Mar-18,19-Mar-18,"UNC-Chapel Hill, Chapel Hill, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT02119936
NCT02119949,Working Memory Training for Substance Dependent Individuals,,Completed,No Results Available,Substance Dependency|Addiction|Anxiety|Depression,Behavioral: Working memory training|Behavioral: Placebo training,Craving: Desires for Alcohol Questionnaire and Desires for Drug Questionnaire score change and Obsessive Compulsive Drug Use Scale and Obsessive Compulsive Drinking Scale score change between pre and post training and follow up (two months after post)|Change in Digit Span score on pre and post training and follow up after two months|Change in Reading Span partial-scredit uni score on pre and post training and follow up after two months,Erasmus Medical Center,All,"16 Years to 67 Years   (Child, Adult, Older Adult)",Not Applicable,180,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",2,May-12,Jun-14,Jun-14,22-Apr-14,null,21-Aug-14,"Bouman Clinic, Rotterdam, Zuid Holland, Netherlands",,https://ClinicalTrials.gov/show/NCT02119949
NCT02119975,A Working Memory Training to Decrease Rumination in Depressed and Anxious Individuals,,Completed,No Results Available,Major Depression|Anxiety Disorder,Behavioral: Working memory training|Behavioral: Placebo training,Change in Ruminative Response Scale (RRS) score from pre to post training and after two months (follow up 2)|Change in Beck Depression Inventory Second Edition (BDI-II) score from pre to post training and after two months (follow up 2)|Change in State-Trait Anxiety Inventory (STAI) score from pre to post training and after two months (follow up 2),Erasmus Medical Center,All,"18 Years to 67 Years   (Adult, Older Adult)",Not Applicable,98,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",4,Aug-11,Dec-11,null,22-Apr-14,null,22-Apr-14,"Erasmus University Rotterdam, Rotterdam, Zuid Holland, Netherlands",,https://ClinicalTrials.gov/show/NCT02119975
NCT02114918,Attention Training for Childhood Obsessive Compulsive Disorder,AMP-OCD,Completed,No Results Available,Obsessive Compulsive Disorder,Behavioral: Attention Modification Program|Behavioral: Attention Control Condition,Clinical Global Impression-Severity (CGI-S) and Improvement (CGI-I) Scales Change From Pre-Treatment to Post-Treatment|Children's Yale-Brown Obsessive Compulsive Scale Change From Pre-Treatment to Post-Treatment|Attention Bias Assessment Change from Pre-Treatment to Post-Treatment,"University of California, Los Angeles|National Institute of Mental Health (NIMH)",All,8 Years to 17 Years   (Child),Not Applicable,47,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",IRB#11-000195|1R34MH095885-01A1,Apr-13,Jan-16,May-16,15-Apr-14,null,16-Jan-17,"UCLA Semel Institute for Neuroscience and Human Behavior, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT02114918
NCT02105259,Internet-delivered Psychodynamic Therapy for Social Anxiety Disorder (SOFIA),SOFIA,Completed,No Results Available,Social Anxiety Disorder,Behavioral: Psychodynamic Internet Treatment|Other: Waiting list,Liebowitz Social Anxiety Scale|Patient Health Questionnaire Depression 9 item|Patient Health Questionnaire Anxiety 7 item,Linkoeping University|Karolinska Institutet|Stockholm University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,72,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GA-ANX2014-APT,Mar-14,May-14,May-14,7-Apr-14,null,2-Sep-15,"Department of Behavioural Sciences and Learning, Linköping University, Linköping, Sweden",,https://ClinicalTrials.gov/show/NCT02105259
NCT02105740,"Hypnosis in Pain Management, Anxiety and Depression in Oncological Patients",HPMADOP,Completed,Has Results,Pain|Depression Anxiety Disorder,Behavioral: Hypnosis|Behavioral: Control,Change of Pain Score in the Visual Analogue Scale|Change of Anxiety and Depression in the Hospital Anxiety and Depression Scale (HADS),Gil Montenegro|University of Brasilia,All,"40 Years to 70 Years   (Adult, Older Adult)",Not Applicable,24,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care,UNB19739513900000030,Jul-15,May-16,May-16,7-Apr-14,30-Mar-17,30-Mar-17,"UNB- Universidade de Brasilia, Brasilia, Distrito Federal, Brazil",,https://ClinicalTrials.gov/show/NCT02105740
NCT02103621,Assisting Obsessive Compulsive Disorder (OCD) Patients With Discontinuing Long-term Serotonin Reuptake Inhibitors (SRIs),,Completed,No Results Available,Obsessive Compulsive Disorder,Behavioral: Unified Protocol (UP)|Behavioral: Taper and Monitoring (TAP-M),Yale-Brown Obsessive Compulsive Scale (Y-BOCS),Butler Hospital|National Institute of Mental Health (NIMH),All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,14,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,1402-002|1R21MH100444-01A1,May-14,Sep-17,Jan-18,4-Apr-14,null,14-Jun-18,"Butler Hospital, Providence, Rhode Island, United States",,https://ClinicalTrials.gov/show/NCT02103621
NCT02099825,Medication Enhanced Rapid Therapy,MERiT,"Active, not recruiting",No Results Available,Anxiety Disorders,Drug: d-cycloserine and mifepristone,Will measure medication tolerability and safety per participant report (i.e. few or no side effects severe enough to stop treatment)|Improvements in Anxiety as measured by several Self Report Assessments|Level of Anxiety as measured by several Self Report Assessments,Washington University School of Medicine,Male,18 Years to 55 Years   (Adult),Phase 1,90,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,201306084,Jan-14,Aug-18,Aug-18,31-Mar-14,null,11-Oct-17,"Washington University School of Medicine, Saint Louis, Missouri, United States",,https://ClinicalTrials.gov/show/NCT02099825
NCT02100163,Virtual Reality Pain Control Orthopedic Trauma,VROT,Completed,No Results Available,Trauma/Injury Problem,Behavioral: Virtual Reality Hypnosis|Behavioral: Audio Hypnosis|Other: Standard treatment,Graphic Rating Scale (GRS) pain and anxiety Questionnaire|Tellegen Absorption Scale,National Institute of General Medical Sciences (NIGMS),All,"16 Years and older   (Child, Adult, Older Adult)",Not Applicable,211,NIH,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Care Provider)|Primary Purpose: Treatment,43654-J/001500,Mar-14,24-Jun-18,24-Jun-18,31-Mar-14,null,13-Mar-19,"Harborview Medical Center, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT02100163
NCT02098148,Trial of Low-Dose Xenon For The Treatment Of Obsessive-Compulsive Disorder,,Withdrawn,No Results Available,Obsessive-Compulsive Disorder,Drug: Xenon|Drug: Placebo,Decrease in OCD Symptoms|Decrease in Depressive Symptoms,Mclean Hospital,All,18 Years to 55 Years   (Adult),Phase 2,0,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",2013P001349,Nov-13,Jan-14,Jan-14,27-Mar-14,null,27-Mar-14,"McLean Hospital, Belmont, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT02098148
NCT02096484,A Feasibility Study of Group Metacognitive Therapy Versus Mindfulness Meditation Therapy,MCT,Completed,No Results Available,Generalized Anxiety Disorder,Behavioral: Group Metacognitive Therapy|Behavioral: Mindfulness Meditation Therapy,Hospital Anxiety and Depression Scale (HADS)|CAS-I|GAD-7|PHQ-9,University of Manchester,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,40,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,UM145073,Aug-14,Dec-15,Jun-16,26-Mar-14,null,17-Oct-16,"The Rawnsley Building, Manchester Royal Infirmary, Oxford Road, Manchester, Lancashire, United Kingdom",,https://ClinicalTrials.gov/show/NCT02096484
NCT02096783,Scripted Sexual Health Informational Intervention in Improving Sexual Function in Patients With Gynecologic Cancer,,Completed,No Results Available,Anxiety Disorder|Cervical Cancer|Endometrial Cancer|Female Reproductive Cancer|Gestational Trophoblastic Tumor|Ovarian Epithelial Cancer|Ovarian Germ Cell Tumor|Sexual Dysfunction|Uterine Sarcoma|Vaginal Cancer|Vulvar Cancer,Other: informational intervention|Other: counseling intervention|Other: questionnaire administration,Feasibility of patient recruitment|Resumption of sexual activity after cancer surgery|Retention|Satisfaction with sex life independent of specific sexual function measured by Patient Reported Outcomes Measurement Information System (PROMIS) Global Satisfaction with Sex Life questionnaire|PROMIS Sexual Function Profile|Recall of intervention|Patient-reported anxiety measured by PROMIS Anxiety 4a short form|Rate of referral acceptance,"University of Wisconsin, Madison|National Cancer Institute (NCI)",Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,15,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care,UW13080|NCI-2014-00471|P30CA014520,Sep-14,Jun-15,Jun-16,26-Mar-14,null,3-Nov-16,"University of Wisconsin, Madison, Madison, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT02096783
NCT02096900,A Comparison of Midazolam and Zolpidem as Oral Premedication in Children,PedsPreMed,Completed,Has Results,Parental/Caregiver Anxiety|Child's Anxiety,Drug: zolpidem|Drug: Midazolam,Patient Anxiety at the Time of Separation|Mask Acceptance Score|Presence of Emergence Delirium During Recovery|Parental/Caregiver Anxiety Assessed Using the Validated State-Trait Anxiety Inventory for Adults (STAI),Loma Linda University,All,2 Years to 9 Years   (Child),Phase 3,86,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",5140032,21-Jul-14,6-May-16,6-May-16,26-Mar-14,11-Aug-17,14-Mar-19,"Loma Linda University, Loma Linda, California, United States",,https://ClinicalTrials.gov/show/NCT02096900
NCT02095340,Effects of Maternal Interpretation Biases on Child Anxiety and Related Responses,,Completed,No Results Available,Anxiety Disorders,Other: Positive Interpretation Bias Training|Other: Neutral Interpretation Bias Training,Number of threatening interpretations made.,University of Houston,All,8 Years to 12 Years   (Child),Not Applicable,210,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Basic Science",2014-0035,May-14,30-Apr-18,30-Apr-18,24-Mar-14,null,10-Oct-18,"University of Houston, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT02095340
NCT02095457,Routine Outcome Monitoring in Mental Health Outpatient,ROM-Shalvata,Unknown status,No Results Available,Affective Disorders|Anxiety Disorders|Psychotic Disorders|Personality Disorders,Behavioral: Frequent monitoring and feedback,Overall clinical well-being as measured by the CORE-OM rating scale|Hospitalization rates,Shalvata Mental Health Center,All,"6 Years and older   (Child, Adult, Older Adult)",Not Applicable,900,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,NIHP-R-161-2013|R-161-2013,Jul-14,Jul-17,null,24-Mar-14,null,24-Mar-14,"Shalvata Mental Health Center Outpatient clinics, Hod Hasharon, Israel",,https://ClinicalTrials.gov/show/NCT02095457
NCT02089984,Web Based Therapist Training on Cognitive Behavior Therapy for Anxiety Disorders,,Completed,No Results Available,Anxiety Disorders|Obsessive Compulsive Disorder|PTSD,Behavioral: Internet Based CBT Training,System Usability Scale|CBT Concepts|Yale Adherence and Competence Scale (YACS)|User Satisfaction Questionnaire,Center for Psychological Consultation|National Institute of Mental Health (NIMH),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,70,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label),R44MH086951,Sep-11,Jun-15,Dec-15,18-Mar-14,null,3-Feb-16,"Center for Telepsychology, Madison, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT02089984
NCT02090595,Mindfulness Based Cognitive Therapy for Youth With Anxiety at Risk for Bipolar Disorder,Mindfulness,Completed,No Results Available,Anxiety|Bipolar Disorder,Behavioral: MBCT-C|Behavioral: Waitlist Control,The Pediatric Anxiety Rating Scale|Change in other Anxiety|Mood|Behavioral|Quality of Life,University of Cincinnati,All,10 Years to 17 Years   (Child),Not Applicable,35,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2013-3124,Jul-13,Jul-15,Jul-15,18-Mar-14,null,18-May-16,"University of Cincinnati, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02090595
NCT02088593,Simulated Dawn Med Students,,Completed,No Results Available,Depression|Anxiety|Fatigue|Sleepiness|Sleep Disruption,Device: Simulated Dawn Light Box|Behavioral: Sleep Hygiene instructions,Sleep quality,Medical University of South Carolina|University at Buffalo,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,46,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention,Dawn,Jul-07,Jan-10,Jan-10,17-Mar-14,null,2-Aug-18,"University at Buffalo, Buffalo, New York, United States",,https://ClinicalTrials.gov/show/NCT02088593
NCT02088619,Positive Therapy for Autonomic Function & Mood in ICD Patients,PAM-ICD,Completed,No Results Available,Ventricular Arrhythmia|Implantable Cardioverter Defibrillator,Behavioral: Quality of Life Therapy (QOLT)|Behavioral: Heart Healthy Education (HHE),Frequency of arrhythmias between baseline and 3-months|Frequency of arrhythmias between 3-months and 9-months|Frequency of ICD therapies between baseline and 3-months|Change in High Frequency heart rate variability (HF-HRV) between baseline and 3-months|Frequency of ICD therapies between 3-months and 9-months|Change in High Frequency heart rate variability (HF-HRV) between 3- and 9-months,"Medical University of South Carolina|National Heart, Lung, and Blood Institute (NHLBI)",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,29,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,Pro00028869|1R34HL107733-01A1,Jul-14,Jan-17,Jan-17,17-Mar-14,null,2-Oct-17,"Medical University of South Carolina, Dept of Psychiatry, Division of Bio-Behavioral Medicine, Charleston, South Carolina, United States",,https://ClinicalTrials.gov/show/NCT02088619
NCT02085512,Prevention of PTSD III: Neurocognitive Training of Emotional Regulation,,Completed,No Results Available,Post Traumatic Stress Disorder|Major Depression|Anxiety Disorders,"Procedure: Neurocognitive retraining Web Based Intervention|Other: Control, web-based tasks",Amelioration of neurocognitive impairments that are associated with post-traumatic stress disorder|Post-traumatic Stress Disorder (PTSD) symptoms,New York University School of Medicine|Stanford University|Shaare Zedek Medical Center,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,180,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,14-00879,17-Mar-17,31-Dec-17,31-Dec-17,13-Mar-14,null,31-Aug-18,"Shaare Zedek Medical Center, Jerusalem, Israel","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/12/NCT02085512/Prot_000.pdf",https://ClinicalTrials.gov/show/NCT02085512
NCT02084979,A Controlled Trial of Patient Centered Telepsychiatry Interventions,,"Active, not recruiting",No Results Available,Mood Disorder|Anxiety Disorder|Substance Use Disorder,Behavioral: telepsychiatry evaluation,Global Assessment of Functioning (GAF)|The Clinical Global Impression (CGI)|The Alcohol Use Disorders Identification Test (AUDIT)|The Patient Telemedicine Satisfaction Questionnaire|PHQ-9|The Generalized Anxiety Disorder 7 item (GAD-7)|Provider Telepsychiatry Satisfaction Questionnaire|PCL|SF12|Manual for WHO Disability Assessment Schedule - WHODAS 2.0,"University of California, Davis",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,185,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,522696|1R01HS021477-01A1,Apr-14,31-Dec-17,May-19,12-Mar-14,null,21-Jan-19,"UC Davis Primary Care Network, Auburn, California, United States|UC Davis Primary Care Network Midtown, Sacramento, California, United States|Communicare Health Centers Salud Clinic, West Sacramento, California, United States",,https://ClinicalTrials.gov/show/NCT02084979
NCT02083432,Cognitive Behavioural Treatment of Intra-oral Injection-phobia in 10-16 Year Old Children and Adolescents,,Completed,No Results Available,Dental Anxiety,Behavioral: 5 session of CBT performed by specially trained dentists,"Intra-oral injection-phobia in children and adolescents. Prevalence, subgroups and the effect of cognitive behavioral treatment (CBT)",University of Bergen,All,10 Years to 16 Years   (Child),Not Applicable,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,2010/63,Dec-13,30-Jun-16,30-Jun-16,11-Mar-14,null,16-Aug-18,"University of Bergen, Bergen, Norway",,https://ClinicalTrials.gov/show/NCT02083432
NCT02083926,Ketamine Infusion for Social Anxiety Disorder,,Unknown status,No Results Available,Social Anxiety Disorder,Drug: Ketamine|Drug: Saline,"Visual Analog Scale (VAS) of Anxiety States|Anxiety Severity|Depression Severity|Clinical Global Impressions|Brief Psychiatric Rating Scale, Positive Symptom Subscale (BPRS-PS)|Clinician-Administered Dissociative States Scale|Self-Statement During Public Speaking Scale (SPSS)|Impromptu Speech Behavioral Assessment Test|Attention Bias|SAD Severity|Positive and Negative Affect Symptoms|State-Trait Anxiety Inventory",Yale University|Patterson Trust Awards Program in Clinical Research,All,"18 Years to 65 Years   (Adult, Older Adult)",Early Phase 1,18,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",1310012947,Mar-14,Mar-18,Mar-18,11-Mar-14,null,12-Jul-16,"Connecticut Mental Health Center, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT02083926
NCT02082561,False Safety Behavior Elimination Therapy: A Randomized Study of a Brief Individual Transdiagnostic Treatment for Anxiety Disorders,,Completed,No Results Available,Panic Disorder|Generalized Anxiety Disorder|Social Anxiety Disorder,Behavioral: Transdiagnostic Treatment (F-SET),The Structured Clinical Interview for the DSM-IV|Clinician Global Impressions Scale (CGI) - Severity of Illness Subscale|Work and Social Adjustment Scale (WSAS),Florida State University,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,28,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Florida State University,Jul-10,Sep-12,Sep-12,10-Mar-14,null,10-Mar-14,"Florida State University, Tallahassee, Florida, United States",,https://ClinicalTrials.gov/show/NCT02082561
NCT02082951,Family Empathic Behaviour Versus Nurse Empathic Behaviour,,Completed,No Results Available,Cardiovascular Disease,Behavioral: Empathic behaviour by nurses.|Behavioral: Empathic behaviour by family.,The primary outcome was Anxiety.,Juliana de Lima Lopes|Federal University of São Paulo,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,66,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor),UNIFESP23,May-11,Nov-12,Dec-12,10-Mar-14,null,10-Mar-14,"Federal University of São Paulo, São Paulo, SP, Brazil",,https://ClinicalTrials.gov/show/NCT02082951
NCT02081365,Clinical Management of Anxiety and Access to Health Care,,Completed,Has Results,Dental Anxiety,Behavioral: Computerized Dental Anxiety Treatment,Change in Modified Dental Anxiety Scale|Change in Clinical Severity Rating for Specific Phobia Module of Anxiety Disorders Interview Schedule for DSM-IV|Change in Fear Rating for Specific Phobia Module of Anxiety Disorders Interview Schedule for DSM-IV|Change in Avoidance Rating for Specific Phobia Module of Anxiety Disorders Interview Schedule for DSM-IV,Temple University|Pennsylvania Department of Health,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,151,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,4100054871,Jul-13,Dec-14,Dec-14,7-Mar-14,27-Jan-17,27-Jan-17,"Temple University Kornberg School of Dentistry, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT02081365
NCT02079012,Effects of a Walking Program in People With Mental Disorders,,Completed,No Results Available,Mental Disorders,Behavioral: 10-week walking program,Change in physical fitness pre - post|Change in physical fitness pre - follow-up|Change in physical activity pre - post|Change in physical activity pre - follow-up|Change in well-being pre - post|Change in well-being pre - follow-up|Change in psychosocial parameters pre - post|Change in psychosocial parameters pre - follow-up,Universitaire Ziekenhuizen Leuven|Vlaamse Federatie voor Sport en Recreatie in de Geestelijke Gezondheidszorg,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,135,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ML10148,Feb-14,Jun-16,Jun-16,5-Mar-14,null,28-Jun-16,"KU Leuven, Leuven, Vlaams-Brabant, Belgium",,https://ClinicalTrials.gov/show/NCT02079012
NCT02079311,Evaluation of Core Body Temperature When Using Forced Air Warming or an Active Blanket to Prevent Perioperative Hypothermia,,Completed,Has Results,Inadvertent Perioperative Hypothermia|Preoperative Anxiety Experienced by the Patient,Device: Active self warming blanket|Device: Forced air warming device,The Difference in Core Body Temperature in the Two Treatment Groups.,Molnlycke Health Care AB,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,55,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,MD13-001,Jan-14,Apr-14,Apr-14,5-Mar-14,13-Nov-15,13-Nov-15,"Universitätsklinikum Gießen und Marburg GmbH, Marburg, Germany|Ullevål - Oslo Universitetssykehus, Oslo, Norway|Royal Hallamshire Hospital, Sheffield, United Kingdom",,https://ClinicalTrials.gov/show/NCT02079311
NCT02077205,Manualised Cognitive Behavioral Therapy of Anxiety Disorders in Children and Adolescents in Routine Care Setting,,Unknown status,No Results Available,Anxiety Disorders,Behavioral: Manualised Cognitive Behavioral Therapy,"Severity rating of diagnosis (according to the Kinder-DIPS)|Spence Children's Anxiety Scale (SCAS)|Clinical Global Improvement Impression (CGI-I)|Interference rating as assessed by the ""Beurteilung der Beeinträchtigung/ Einschränkung des Patienten"" (BEE)|Depression as measured by the Short Moods and Feelings Questionnaire (SMFQ)|Strengths and Difficulties Questionnaire (SDQ)",Ruhr University of Bochum,All,"4 Years to 18 Years   (Child, Adult)",Not Applicable,200,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,no funding,Jan-12,Jun-14,Dec-15,4-Mar-14,null,4-Mar-14,"Ruhr-University of Bochum, Department of Psychology, AE Klinische Kinder- und Jugendpsychologie, Bochum, Nordrhein-Westfalen, Germany",,https://ClinicalTrials.gov/show/NCT02077205
NCT02077985,Sensory Adapted Dental Environment to Enhance Oral Care for Children With ASD,SADE,Completed,No Results Available,Autism,Behavioral: Sensory Adapted Dental Environment,Electrodermal activity (EDA)|Children's Dental Behavioral Rating Scale (CDBRS)|Number of hands used to restrain child|Frankl Scale|The Anxiety and Cooperation Scale (A & C Scale)|Time,University of Southern California|Children's Hospital Los Angeles,All,6 Years to 12 Years   (Child),Not Applicable,45,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,5R34DE022263-02,Oct-12,Jun-13,Jun-13,4-Mar-14,null,4-Mar-14,,,https://ClinicalTrials.gov/show/NCT02077985
NCT02072252,Mobile Phone App for Depression and Anxiety in Young Men Who Are Attracted to Men,TODAY!,Withdrawn,No Results Available,Depressive Symptoms|Anxiety Generalized,Behavioral: Mobile Phone Application,Patient Health Questionnaire-9 (PHQ-9)|GAD-7,Northwestern University|National Institute of Mental Health (NIMH),Male,"17 Years to 20 Years   (Child, Adult)",Phase 1|Phase 2,0,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,STU00061284|K08MH094441,14-Aug-17,14-Aug-17,14-Aug-17,26-Feb-14,null,17-Aug-17,"Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT02072252
NCT02068261,Working Memory Training in Adults With Substance Abuse and Executive Function Deficits.,,Unknown status,No Results Available,Substance Abuse|Executive Dysfunction|Anxiety|Depression|Antisocial Personality|Reading Disabilities,Behavioral: Computerized Cogmed working memory training|Behavioral: Treatment as usual,Change from baseline in substance abuse measured with Substance abuse scales in Adult Self Report (ASR; ASEBA).|Change from baseline in Adult Self Report (ASR; ASEBA) Attention problems scale.|Change from baseline in Adult Self Report (ASR; ASEBA) Internalizing index.|Change from baseline in Adult Self Report (ASR; ASEBA) Externalizing index.|Change from baseline in Adult Self Report (ASR; ASEBA) Adaptive functioning scales.|Change from baseline in Executive functioning measured with Behavior Rating Inventory of Executive Function-Adult (BRIEF-A).|Change from baseline in verbal working memory measured with performance on Digit span.|Change from baseline in visual working memory measured with performance on Span board.|Change from baseline in focused attention measured with performance on Conners Continuous Performance Test-II (CCPT-II).|Change from baseline in vigilance measured with performance on Conners Continuous Performance Test-II (CCPT-II).|Change from baseline in reading speed measured with performance on Reading speed in Diagnostic Reading and Writing Test (DLS; Swedish version).,Örebro Läns Landsting,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,RA02,Jan-14,Dec-16,Dec-16,21-Feb-14,null,23-Oct-15,"Psychiatric Research Centre, Örebro, Sweden",,https://ClinicalTrials.gov/show/NCT02068261
NCT02066792,Dose Timing of D-Cycloserine to Augment CBT for Social Anxiety Disorder,,Completed,No Results Available,Social Anxiety Disorder,Drug: D-Cycloserine|Drug: Placebo|Behavioral: Cognitive Behavioral Therapy,Short- and Long-Term Improvements in Social Anxiety Severity,University of Texas at Austin|Rush University Medical Center|Boston University|Southern Methodist University,All,"18 Years to 70 Years   (Adult, Older Adult)",Early Phase 1,173,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",R34MH099318,Apr-14,1-Jul-18,1-Jul-18,20-Feb-14,null,11-Oct-18,"Rush University Medical Center, Chicago, Illinois, United States|Boston University, Boston, Massachusetts, United States|University of Texas at Austin, Austin, Texas, United States",,https://ClinicalTrials.gov/show/NCT02066792
NCT02067559,Preventing Post-traumatic Stress in ICU Survivors: A Pilot Randomized Controlled Trial of ICU Diaries,,Completed,No Results Available,"Stress Disorders, Post Traumatic|Anxiety|Depression|Quality of Life",Behavioral: ICU Diary|Behavioral: Psychoeducation,Feasibility - enrollment of 1-2 participants per month|Efficacy at 90 days as determined by Impact of Event Scores (IES-R)|Change in IES-R 30 days post ICU discharge and access to follow up care at 90 days post ICU discharge|IES-R score of family member at 30 days post patient ICU discharge,University of Manitoba|Manitoba Medical Service Foundation,All,"17 Years and older   (Child, Adult, Older Adult)",Not Applicable,59,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,H2013:460|8-2014-07,Mar-14,Nov-16,Nov-16,20-Feb-14,null,25-Oct-18,"St. Boniface Hospital, Winnipeg, Manitoba, Canada",,https://ClinicalTrials.gov/show/NCT02067559
NCT02065843,Three Anxiolytic Drugs Used in Third Molar Surgery,,Completed,No Results Available,Dental Anxiety|Impacted Third Molar Tooth,Drug: Mulungu|Drug: Placebo|Drug: Passiflora incarnata|Drug: midazolam,Changes in anxiety report|Changes in blood pressure|Changes in heart rate|Changes in oxygen saturation,"Universidade Federal de Sergipe|University of Campinas, Brazil",All,18 Years to 35 Years   (Adult),Phase 2|Phase 3,30,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ANSI-388.427,Mar-14,Apr-14,Sep-14,19-Feb-14,null,28-Oct-16,"Federal University of Sergipe, Aracaju, Sergipe, Brazil",,https://ClinicalTrials.gov/show/NCT02065843
NCT02062658,Extending Ketamine's Effects in OCD With Exposure and Response Prevention (EX/RP),,Completed,Has Results,Obsessive-Compulsive Disorder,Drug: Ketamine|Behavioral: Exposure and Response Prevention,Number of Patients Who Met and Exceeded Response Criteria of Yale-Brown Obsessive-Compulsive Scale,New York State Psychiatric Institute|National Institute of Mental Health (NIMH),All,18 Years to 55 Years   (Adult),Phase 2,10,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,#6811|K23MH092434,Dec-13,Dec-15,Dec-15,14-Feb-14,27-Oct-16,29-Dec-16,"New York State Psychiatric Insitute, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT02062658
NCT02063828,Reducing Lung Cancer-Related Anxiety (RELAX),RELAX,Recruiting,No Results Available,Lung Cancer,Device: Group A - Device guided breathing low dose|Device: Group B - Device guided breathing high dose|Device: Group C - Usual Breathing Control Group,Participation Rate|Accrual Rate- number of patients accrued to the study|Adherence- amount of time the device is used|Retention- number of participants who complete the final assessment|DNA methylation levels|Gene Expression Levels|Salivary Cortisol Levels,Wake Forest University Health Sciences|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,75,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,IRB00038743|U10CA081851|WF-01213|1UG1CA189824|2R25CA122061-07|R21CA182111-01,30-Jul-15,1-May-19,1-May-19,14-Feb-14,null,3-Dec-18,"Beebe Health Campus, Rehoboth Beach, Delaware, United States|Cancer Center of Kansas, PA - Wichita, Wichita, Kansas, United States|Via Christi Hospitals, Wichita, Wichita, Kansas, United States|St Johns Hospital-Healtheast, Maplewood, Minnesota, United States|Margaret R Pardee Memorial Hospital, Hendersonville, North Carolina, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Greenville Health System NCORP, Greenville, South Carolina, United States|Greenville Memorial Hospital, Greenville, South Carolina, United States|Spartanburg Medical Center, Spartanburg, South Carolina, United States|RB Upstate Carolinas CCOP, Spartanburg, South Carolina, United States|Aurora NCORP, Milwaukee, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT02063828
NCT02061553,SMS Messaging to Reduce Depression and Anxiety Following TBI,,Recruiting,No Results Available,Traumatic Brain Injury,Behavioral: Motivation|Behavioral: Intention|Behavioral: BA-Tech,Change from baseline on Brief Symptom Inventory-18 (BSI-18) Global Severity Index,"Albert Einstein Healthcare Network|National Institute on Disability, Independent Living, and Rehabilitation Research",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,119,Other|U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,TBIMS HN4473|H133A120037,22-Oct-13,16-May-22,16-Sep-22,13-Feb-14,null,14-Dec-18,"Moss Rehabilitation Research Institue, Elkins Park, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT02061553
NCT02060448,Treatment Study for Non-Suicidal Self-Injury,NSSI,Completed,No Results Available,Self Injurious Behavior Without Suicidal Intent,Behavioral: Emotion awareness training|Behavioral: Cognitive reappraisal,Frequency of non-suicidal self-injurious thoughts and behaviors|Overall Anxiety Severity and Impairment Scale (OASIS)|Overall Depression Severity and Impairment Scale (ODSIS)|Beck Anxiety Inventory (BAI)|Beck Depression Inventory (BDI-II)|Deficits in Emotion Regulation Scale (DERS): Emotion Awareness and Nonacceptance of Negative Emotional Responses subscales|Southampton Mindfulness Questionnaire (SMQ)|Multi-dimensional Experiential Avoidance Questionnaire (MEAQ): Distraction/Suppression subscale|Emotion Regulation Questionnaire (ERQ)|Insomnia Severity Index (ISI)|Subjective Symptoms Scale (SSS),Boston University Charles River Campus|National Institute of Mental Health (NIMH),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,13,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,F31MH100761,Nov-13,Dec-15,Dec-15,12-Feb-14,null,21-Mar-17,"Center for Anxiety and Related Disorders, Boston University, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT02060448
NCT02059226,Evaluating an Internet-based Program for Anxious Youth: a Pilot RCT,,Completed,No Results Available,Anxiety,Behavioral: cognitive behavioural therapy|Other: Internet-based resource page,Change from baseline in anxiety at 8 weeks|Recruitment rate|Retention rate|Minimal Clinically Important Difference (MCID)|Intervention acceptability|Co-intervention use|Resource use/costs|Intervention adherence,Mandi Newton|IWK Health Centre|University of Alberta,All,13 Years to 17 Years   (Child),Not Applicable,94,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,Pro00036087|CIHR (MOP119531),Apr-14,Oct-16,Nov-16,11-Feb-14,null,28-Apr-17,"University of Alberta; Alberta Health Services, Edmonton, Alberta, Canada|IWK Health Centre, Halifax, Nova Scotia, Canada|Children's Hospital of Eastern Ontario (CHEO), Ottawa, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT02059226
NCT02059980,Developing Effective Response Inhibition Training for Symptom Relief in OCD and Trichotillomania,,Completed,Has Results,Obsessive Compulsive Disorder|Trichotillomania,Behavioral: Response inhibition training|Behavioral: Placebo Control Training,Composite Score of Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) and National Institute of Mental Health (NIMH)|Stop Signal Reaction Time|Clinical Global Impression Severity and Improvement|Commission Errors on the Go/No-go Task.,"University of Wisconsin, Milwaukee|National Institute of Mental Health (NIMH)",All,18 Years to 60 Years   (Adult),Not Applicable,45,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",R21-RIT_OC-LEE|R21MH094537,Aug-14,Aug-17,Aug-17,11-Feb-14,26-Sep-18,26-Sep-18,"Psychology Clinic, University of Wisconsin-Milwaukee, Milwaukee, Wisconsin, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/80/NCT02059980/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02059980
NCT02057991,Mindfulness-Based Exercise Video in Educating Hispanic/Latino Patients With Colorectal Cancer and Their Caregivers,,Terminated,No Results Available,Anxiety Disorder|Colon Cancer|Depression|Fatigue|Rectal Cancer,Other: educational intervention|Procedure: CAM exercise therapy|Other: caregiver-related intervention or procedure|Other: questionnaire administration|Other: laboratory biomarker analysis,Change in self-reported stress levels assessed using pre- and post-test assessments|Change in colorectal cancer knowledge assessed using pre- and post-test assessments|Changes in salivary cortisol levels using chemiluminescence immunoassay,University of Southern California|National Cancer Institute (NCI),All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,94,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,3C-13-6|NCI-2014-00164|R01CA155101|P30CA014089,7-Jan-14,9-Nov-16,9-Nov-17,7-Feb-14,null,29-Nov-17,"USC Norris Comprehensive Cancer Center, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT02057991
NCT02056483,REBECCA - Research in Rehabilitation After Breast Cancer,REBECCA,Completed,No Results Available,Anxiety|Depression|Adverse Effects|Health Behavior,Other: Screening-based nurse navigation,Psychological distress|Health related quality of life|Anxiety and depression|Smoking|Alcohol consumption|Body mass index|Physical activity|Use of rehabilitation services,"Danish Cancer Society|TRYG Foundation|Rigshospitalet, Denmark|Center for Kræft og Sundhed",Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,50,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,REBECCA,Jul-13,Jul-15,Jul-15,6-Feb-14,null,7-Aug-15,"Rigshospitalet, Copenhagen, Denmark",,https://ClinicalTrials.gov/show/NCT02056483
NCT02054845,BEWARE: Body Awareness Training in the trEatment of Wearing-off Related Anxiety in Patients With paRkinson's Disease,BEWARE,Unknown status,No Results Available,"Parkinsonism, Experimental|Parkinsonism, Treatment as Usual",Behavioral: Body awareness therapy|Other: Physical therapy,Self-efficacy|Anxiety|Depression|Balance performance|comfortable walking speed|Quality of life|Wearing-off symptoms|Activities of Daily Living independence|Freezing of Gait|Comfortable walking speed|Quality of Life|Freezing of gait,VU University Medical Center|Parkinsonvereniging,All,"Child, Adult, Older Adult",Not Applicable,36,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,CWO/13-05E,Jan-14,Dec-14,Dec-14,4-Feb-14,null,4-Feb-14,"VU Medical Center, Amsterdam, Noord-Holland, Netherlands",,https://ClinicalTrials.gov/show/NCT02054845
NCT02051192,Brief Behavioral Treatment for Anxiety in Young Children,PLET,Completed,No Results Available,"Obsessive-compulsive Disorder|Social Phobia|Generalized Anxiety Disorder|Specific Phobia|Separation Anxiety Disorder|Selective Mutism|Anxiety Disorder, Not Otherwise Specified",Behavioral: Parent-Led Exposure Therapy|Other: Treatment As Usual,Pediatric Anxiety Rating Scale|Clinical Global Impression - Severity|Clinical Global Improvement,University of South Florida,All,3 Years to 7 Years   (Child),Phase 1|Phase 2,58,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,PLET-13-0634,Jan-14,Aug-16,Aug-16,31-Jan-14,null,6-Oct-16,"Rothman Center for Pediatric Neuropsychiatry - University of South Florida, St. Petersburg, Florida, United States",,https://ClinicalTrials.gov/show/NCT02051192
NCT02044913,Randomized-controlled Trial of Aftercare-Coordination by Phone for Depression and Anxiety,,Completed,No Results Available,"Depression, Anxiety",Behavioral: Phone-based Aftercare-Coordination,"Measure of the symptom severity - Beck Depression Inventory (BDI)|Measure of health related quality of life - Short Form 8 Health Survey (SF-8), Measure of health related quality of life (EQ-5D)|Proportion of patients who get routine outpatient aftercare treatment at follow up (6 months after the intervention)|Patient-rated acceptance and satisfaction with the intervention",Universitätsklinikum Hamburg-Eppendorf,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,218,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,0421-FSCP-Z202,Mar-12,Jun-15,Jun-15,24-Jan-14,null,15-Jul-15,"University Medical Center Hamburg-Eppendorf, Centre of Psychosocial Medicine, Department of Medical Psychology, Hamburg, Germany",,https://ClinicalTrials.gov/show/NCT02044913
NCT02045225,HIV Prevention for HIV-Negative Men Via Reduction of Social Anxiety,,Completed,No Results Available,Social Anxiety|Substance Use,Behavioral: Reduction of social anxiety & substance use in gay/bi men,Instances of unprotected anal intercourse with sexual partners who are HIV-positive or of unknown HIV status|Severity of social anxiety and instances substance use in sexual situations,Ryerson University,Male,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,20,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,201203HHP-279414-PB1ABAF146056|201203HHP-279414,Feb-13,Jun-17,Jun-17,24-Jan-14,null,20-Jul-18,"Ryerson University, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT02045225
NCT02042976,Mindfulness-based Cognitive Therapy for Chronic Obstructive Pulmonary Disease,,Completed,No Results Available,Chronic Obstructive Pulmonary Disease (COPD)|Chronic Obstructive Lung Disease|Chronic Obstructive Airway Disease|Chronic Bronchitis|Emphysema,Behavioral: Mindfulness-based cognitive therapy|Behavioral: Pulmonary rehabilitation,Change from baseline in physical health status impairment on the COPD Assessment Test (CAT) six months after termination of the 8-week treatment program|Change from baseline in anxiety and depression on the Hospital Anxiety and Depression Scale (HADS) six months after termination of the 8-week treatment program|Change from baseline in physical activity at week 8|Change from baseline in inflammation at week 8,University of Aarhus|Aarhus University Hospital,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,84,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care",MBCT-KOL-2014,Feb-14,Sep-16,null,23-Jan-14,null,23-Feb-17,"Aarhus University Hospital, Aarhus, Aarhus C, Denmark",,https://ClinicalTrials.gov/show/NCT02042976
NCT02042001,Switching From Efavirenz/Atripla to Rilpivirine Among Patients With Neurocognitive or Neuropsychological Side Effects,SWEAR,Completed,No Results Available,Impaired Cognition|Depression/Anxiety|Poor Quality Sleep|Quality of Life|HIV-1 Infection,Drug: Immediate switch to TDF/FTC/RPV|Drug: Switch to TDF/FTC/RPV after 24 weeks,Neuropsychiatric side effects|Neurocognitive side effects|Composite neuropsychiatric/neurocognitive|Symptoms|Quality of Life|Cognitive failure|Viral suppression|Viral failure|Virological efficacy|Safety & Tolerability,Azienda Ospedaliera San Gerardo di Monza|Gilead Sciences,All,"18 Years and older   (Adult, Older Adult)",Phase 4,74,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IN-IT-264-1331,1-Jul-15,3-Jul-17,15-Jan-18,22-Jan-14,null,4-Jul-18,"Clinic of Infectious Diseases, AO San Gerardo, Monza, MB, Italy|Spedali Civili - University of Brescia, Brescia, Italy|Clinica di Malattie Infettive, Ospedale San Martino, Genova, Italy|AO San Paolo - University of Milan, Milan, Italy|Ospedale Amedeo di Savoia - University of Turin, Torino, Italy",,https://ClinicalTrials.gov/show/NCT02042001
NCT02040389,Visual Guidelines and Tutoring in Pediatric Urological Surgery,,Completed,No Results Available,Hypospadias|Undescended Testis|Hydrocele|Ureteropelvic Junction Stenosis|Anxiety,Behavioral: Picture book|Behavioral: Standard preoperative education,Level of parents anxiety|Numbers of parents non-planed calls/visits,Shaare Zedek Medical Center,All,"2 Months to 18 Years   (Child, Adult)",Not Applicable,120,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,92/13,Mar-14,Feb-15,Jun-16,20-Jan-14,null,27-Oct-16,"The Department of Pediatric Urology, Shaare Zedek Medical Center, Faculty of Medicine, Hebrew University, Jerusalem,, Israel",,https://ClinicalTrials.gov/show/NCT02040389
NCT02040649,Non-sedation Versus Sedation With a Daily Wake-up Trial in Critically Ill Patients Receiving Mechanical Ventilation - Effects on PTSD,,Completed,No Results Available,"Stress Disorders, Post-Traumatic|Depression|Anxiety","Other: Non-sedation|Other: Control, sedation (propofol, midazolam)",PTSD|Patient-reported quality of life|Depression|Anxiety,Palle Toft|Kolding Sygehus|The Danish Council for Strategic Research|University of Southern Denmark|Odense University Hospital,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,205,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,S-20130025b,Jan-14,Jun-17,Mar-19,20-Jan-14,null,15-Mar-19,"Lillebaelt Hospital, Kolding, Intensive Care Unit, Kolding, Denmark",,https://ClinicalTrials.gov/show/NCT02040649
NCT02040805,Comparison of Treatment for Hoarding Disorder,,Unknown status,No Results Available,Hoarding Disorder,Behavioral: Group Cognitive Behavioral Therapy|Behavioral: Peer Facilitated Manualized Support Group,Saving Inventory-Revised (SI-R)|Neuropsychological Test Battery,"University of California, San Francisco|Patient-Centered Outcomes Research Institute",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,323,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CE-1304-6000,Feb-14,Jan-17,Jan-17,20-Jan-14,null,25-Aug-16,"Mental Health Association San Francisco, San Francisco, California, United States",,https://ClinicalTrials.gov/show/NCT02040805
NCT02039193,Microtuning a Bonafide Treatment for GAD Patients - A Randomized Controlled Trial.,,Completed,No Results Available,Dyadic Peer-tutoring|Adherence Priming|Resource Priming,Behavioral: Cognitive behavioral therapy,Change of Beck Anxiety Inventory (BAI)|Change of Penn State Worry Questionnaire (PSWQ)|Change of State -Trait Anxiety (STAI)|Change of Beck Depression Inventory (BDI)|Change of Brief Symptom Inventory (BSI)|Change of BIS/BAS scale|Change of Inventory of Interpersonal Problems (IIP-64)|Change of Inventory of Interpersonal Strengths (IIS-64)|Change of Resource potential questionnaire (RES),University of Zurich|Swiss National Science Foundation,All,"18 Years and older   (Adult, Older Adult)",Phase 4,57,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,PZ00P1_136973 / 1|2011- 0475,Aug-12,May-15,Aug-15,17-Jan-14,null,3-Dec-15,"University of Zürich, Department of Psychology, Zürich, ZH, Switzerland",,https://ClinicalTrials.gov/show/NCT02039193
NCT02037568,Improved Outcome in Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Patients by Reducing Caregiver Distress,,Completed,Has Results,Hematopoietic/Lymphoid Cancer,Behavioral: fPER,Functional Assessment of Cancer Treatment - Blood/Marrow Transplant|Caregiver Distress - Principal Component Analysis|Perceived Stress Scale|Center for Epidemiological Studies Depression Scale|Spielberger State-Trait Anxiety Inventory|Change in Adrenal Activity Over Time|Change in Caregiver Telomere Length Over Time|Change in Caregiver Telomerase Activity Over Time|Caregiver Reaction Assessment,"University of Colorado, Denver|Patient-Centered Outcomes Research Institute",All,"18 Years to 85 Years   (Adult, Older Adult)",Not Applicable,159,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,13-2639,Jan-14,Apr-17,Sep-17,16-Jan-14,6-Dec-17,6-Dec-17,"University of Colorado Hospital, Aurora, Colorado, United States|Presbyterian/St. Luke's Medical Center (PSLMC), Denver, Colorado, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/68/NCT02037568/ICF_000.pdf|""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/68/NCT02037568/Prot_SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02037568
NCT02036658,Emotion Regulation During RCT of CBT vs. MBSR for Social Anxiety Disorder,,Completed,No Results Available,Social Anxiety Disorder,Behavioral: Cognitive Behavioral Group Therapy|Behavioral: Mindfulness-Based Stress Reduction,Changes in Liebowitz Social Anxiety Scale (LSAS),Stanford University|National Institute of Mental Health (NIMH),All,21 Years to 55 Years   (Adult),Not Applicable,108,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CBT-MBSR 10521038|R01MH076074,Mar-11,1-Sep-15,1-Sep-15,15-Jan-14,null,18-Jan-18,"Stanford University, Stanford, California, United States",,https://ClinicalTrials.gov/show/NCT02036658
NCT02035722,Intravitreal Injections-related Anxiety,,Completed,No Results Available,Age-related Macular Degeneration,Behavioral: Printed materials|Behavioral: Video,Anxiety|Knowledge of AMD,"University Health Network, Toronto",All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,73,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,UHN-110463AE,Sep-11,Apr-14,Jun-14,14-Jan-14,null,24-Feb-15,"Toronto Western Hospital, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT02035722
NCT02035878,Probiotics and the Microbiome: Clinical Intervention Trial for Anxiety and Depression,,Unknown status,No Results Available,Anxiety|Depression,Other: Probiotics|Drug: Placebo,Depression Anxiety and Stress Scale (DASS) - Time 1 (we are assessing change over time)|Depression Anxiety and Stress Scale (DASS) - Time 2 (we are assessing change over time)|Depression Anxiety and Stress Scale (DASS) - Time 3 (we are assessing change over time)|Anxiety Sensitivity Index (ASI) - Time 1 (we are assessing change over time)|Anxiety Sensitivity Index (ASI) - Time 2 (we are assessing change over time)|Anxiety Sensitivity Index (ASI) - Time 3 (we are assessing change over time),Acadia University,All,"18 Years and older   (Adult, Older Adult)",Phase 2,75,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",POTTERHUNTER_PROBIOTICS_2013,Aug-12,Oct-13,Apr-14,14-Jan-14,null,14-Jan-14,"Acadia University, Wolfville, Nova Scotia, Canada",,https://ClinicalTrials.gov/show/NCT02035878
NCT02033759,Patient Anxiety Associated With Lymphedema Surveillance Method,,"Active, not recruiting",No Results Available,Anxiety,Device: Bio-Impedance Testing|Other: Anxiety Questionnaire|Other: Traditional Circumferential Measurements,Anxiety|Upper Extremity Limb Volume,Mercy Integrative Medicine,Female,"18 Years to 85 Years   (Adult, Older Adult)",Not Applicable,45,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening,Anxiety & Lymphedema,Jun-14,Sep-16,Mar-19,13-Jan-14,null,29-Mar-18,"Mercy Clarkson/Clayton, Creve Coeur, Missouri, United States",,https://ClinicalTrials.gov/show/NCT02033759
NCT02028247,Psychotherapy for Anxiety in Children With Autism Spectrum Disorder,TAASD,Completed,No Results Available,Autism Spectrum Disorders|Autism|Asperger's Syndrome|Pervasive Developmental Disability - Not Otherwise Specified|Obsessive-compulsive Disorder|Social Phobia|Generalized Anxiety Disorder|Specific Phobia|Separation Anxiety Disorder,Behavioral: Personalized Cognitive-behavioral therapy|Behavioral: Standard Practice Cognitive-behavioral therapy,Change from Baseline in anxiety severity on the Pediatric Anxiety Rating Scale after 16 weeks of treatment.|Change from Baseline in anxiety severity on the Clinical Global Impressions Scale after 16 weeks of treatment.|Change from Baseline in anxiety severity on the Child and Adolescent Symptom Inventory after 16 weeks of treatment.|Change from Baseline in anxiety related impairment as measured by the Childhood Anxiety Impact Scale after 16 weeks of treatment.,"University of South Florida|Temple University|University of California, Los Angeles",All,8 Years to 13 Years   (Child),Phase 3,201,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,NICHD CBT for ASD,Jul-14,Oct-18,Oct-18,7-Jan-14,null,19-Mar-19,"Rothman Center for Neuropsychiatry, University of South Florida, Saint Petersburg, Florida, United States",,https://ClinicalTrials.gov/show/NCT02028247
NCT02028832,Pediatric Integrative Medicine Trial Pilot,PIM,Completed,No Results Available,Pain|Nausea|Vomiting|Anxiety,Procedure: PIM consult and service provision|Procedure: Usual care,Enrollment|Change in pain|Change in nausea/vomiting|Change in anxiety|Incidence of adverse events|Parent satisfaction with patient care|Length of hospital stay,University of Alberta|Lotte & John Hecht Memorial Foundation,All,up to 16 Years   (Child),Phase 3,872,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,PIM1,Feb-13,Feb-16,Sep-16,7-Jan-14,null,8-May-17,"Stollery Childrens' Hospital, Edmonton, Alberta, Canada",,https://ClinicalTrials.gov/show/NCT02028832
NCT02027844,Cartoon Distraction and Parental Presence on Anxiety in Pediatric Anesthesia,,Completed,Has Results,"Anxiety, Separation|Psychomotor Agitation",Behavioral: Cartoon|Behavioral: parental presence,"Modified Yale Preoperative Anxiety Scale Scores at Baseline, Arrival in Operating Room, and Inhalation Induction|Change From Baseline Parental Anxiety at Postinduction of Anesthesia",Yeungnam University College of Medicine,All,1 Year to 7 Years   (Child),Not Applicable,117,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,JUNG999ANXIETY,Dec-13,Jun-15,Jun-15,6-Jan-14,2-Nov-15,2-Nov-15,"Yeungnam University Hospital, Daegu, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02027844
NCT02028026,The Effects of Vilazodone on Glutamate in the Anterior Cingulate Cortex in Anxious Unipolar Depressives,,Withdrawn,No Results Available,Major Depressive Disorder|Anxiety|Comorbidity,Drug: Vilazodone|Drug: Citalopram,Glutamate Levels|Functional Connectivity,Massachusetts General Hospital,Female,18 Years to 50 Years   (Adult),Phase 4,0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",VII-IT-10|2013P000335,Apr-13,Feb-15,Apr-15,6-Jan-14,null,8-Nov-16,"Massachusetts General Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT02028026
NCT02024204,Uncontrolled Lower Respiratory Symptoms in the WTC Survivor Program,,"Active, not recruiting",No Results Available,Lung Diseases|Medication Compliance,Drug: Fluticasone propionate 230mcg for 3 Months|Drug: Current Treatment or no treatment|Drug: Salmeterol 21mcg for 3 Months,"Change in measures of airflow and lung volumes by spirometry and small airway dysfunction by impulse oscillometry and association with uncontrolled lower respiratory symptoms|Change in lower respiratory symptom control status|Bronchial Hyperresponsiveness|Inflammatory Markers Associated with Airway Disease (CRP, RAST, Eos and Periostin)|Gastroesophageal reflux symptoms|Chronic rhinosinusitis symptoms|Paradoxical vocal cord motion (PVCM)|Changes in levels of fractional exhaled nitric oxide (FeNO)|Dyspnea and Functional status",New York University School of Medicine|National Institute for Occupational Safety and Health (NIOSH/CDC),All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,94,Other|U.S. Fed,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,13-00448|1U01OH010404-01A1,4-Mar-14,Aug-19,Aug-19,31-Dec-13,null,29-Jan-19,"New York University School of Medicine, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT02024204
NCT02024594,Comparison of Effect of Nitrous Oxide-Oxygen Conscious Sedation and Cognitive-behavioral Therapy on Children's Anxiety in Dentistry,,Completed,No Results Available,Clinical Anxiety|Clinical Cooperation,Drug: Nitrous Oxide-Oxygen conscious sedation|Behavioral: cognitive-behavioral therapy,change from baseline in Clinical Anxiety and Cooperation scales.,Mashhad University of Medical Sciences,All,36 Months to 78 Months   (Child),Not Applicable,45,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),88311,Oct-09,Jul-10,null,31-Dec-13,null,31-Dec-13,,,https://ClinicalTrials.gov/show/NCT02024594
NCT02022709,Efficacy of Exposure and Response Prevention(ERP) and SSRIs in Chinese OCD Patients,,Unknown status,No Results Available,Obsessive-Compulsive Disorder|Anxiety Disorders|Mental Disorders,Drug: Fluoxetine|Drug: Sertraline|Drug: Paroxetine|Drug: Citalopram|Drug: Fluvoxamine|Behavioral: Exposure and Response Prevention,The change of Yale-Brown Obsessive-Compulsive Scale score|The change of Beck Depression Inventory(BDI-II) score|The change of Beck Anxiety Inventory(BAI) score|The change of Stress Perceived Questionnaire (PSS-10) score|The change of Behavioral Inhibition/Behavioral Activation System Scales score|The change of Barratt Impulsiveness Scale 11 (BIS-11) score|The change of Obsessive Beliefs Questionnaire-44(OBQ-44) score|The NEO-Five Factor Inventory-Revised (NEO-FFI-R)|The Early Trauma Inventory Self Report-Short Form(ETISR-SF),Shanghai Mental Health Center|Shanghai Municipal Science and Technology Commission|Shanghai Jiao Tong University School of Medicine,All,"16 Years to 65 Years   (Child, Adult, Older Adult)",Phase 4,60,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,124119a8601|YG2013MS65,Jan-14,Oct-17,Dec-17,30-Dec-13,null,27-Apr-17,"Shanghai Mental Health Center, Shanghai, Shanghai, China",,https://ClinicalTrials.gov/show/NCT02022709
NCT02023008,Interactive Gentle Yoga in Improving Quality of Life in Patients With Stage I-III Breast Cancer Undergoing Radiation Therapy,,Terminated,No Results Available,Anxiety Disorder|Depression|Ductal Breast Carcinoma in Situ|Fatigue|Stage IA Breast Cancer|Stage IB Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer,Procedure: yoga therapy|Other: internet-based intervention|Other: questionnaire administration,"Recruitment rates, calculated as the number of women enrolled divided by the number of women who screened eligible for the study|Retention rates, calculated as the proportion of enrolled women who complete all study measures at each time point|Adherence, measured by the total number of yoga classes attended by each participant|Participants' acceptability of the intervention, including ratings of ease/difficulty of use of the videoconferencing and participating in group classes from home using the device|Feedback regarding the participants' experience in the study|Change in depression as measured by HADS|Change in anxiety as measured by HADS|Change in fatigue as measured by visual analogue scale and Functional Assessment of Cancer Therapy-Fatigue|Change in sleep quality as measured by Pittsburgh Sleep Quality Inventory",Wake Forest University Health Sciences|National Cancer Institute (NCI),Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,6,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,IRB00026310|NCI-2013-02387|CCCWFU 01513|P30CA012197,May-14,Feb-15,Feb-15,30-Dec-13,null,2-Jul-18,"Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT02023008
NCT02021214,Effects of Methylphenidate (Ritalin®) on the Neural Basis of Anxiety,,Completed,No Results Available,PTSD,Drug: Methylphenidate|Drug: Placebo,Changes in blood oxygenation level-dependent BOLD signal responses|Changes in BOLD signal responses|Changes in skin conductance response|Latency and accuracy during a interoceptive stimulus task,"University of California, San Diego",Male,18 Years to 40 Years   (Adult),Early Phase 1,24,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",131297,Mar-14,Oct-14,Oct-14,27-Dec-13,null,3-Dec-14,"UCSD Psychiatry Clinical Research, San Diego, California, United States",,https://ClinicalTrials.gov/show/NCT02021214
NCT02021344,Mental Health First Aid for College Students,,Completed,No Results Available,Depression|Anxiety|Suicidal Ideation|Eating Disorders,Behavioral: Mental Health First Aid,Changes in mental health service utilization,University of Michigan|National Institute of Mental Health (NIMH),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,2543,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,NIMH 1RC1MH089757-01|1RC1MH089757-01,Sep-09,May-11,May-11,27-Dec-13,null,27-Dec-13,"University of Michigan, Ann Arbor, Michigan, United States",,https://ClinicalTrials.gov/show/NCT02021344
NCT02020824,Virtual Reality and Concept of Control in the Treatment of Acrophobia,CTRLSTRESS,Unknown status,No Results Available,Phobic Disorders,Behavioral: Exposure to anxiogenous environments|Other: Imagery with functional MRI initial|Other: Imagery with PET-scanner initial|Other: Imagery with functional MRI final|Other: Imagery with PET-scanner final,Behavioural Avoidance Test (BAT)|Brain activity (functional MRI)|Synaptic activity (PET-scan)|Cognitive measurements|Quality of life|Ergonomy|Psychophysiological|Adverse events,"Qualissima|Centre National de la Recherche Scientifique, France",All,18 Years to 60 Years   (Adult),Not Applicable,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CTRLSTRESS|2013-A01280-45 ID-RCB,Apr-14,Jun-17,Jul-17,25-Dec-13,null,30-Oct-15,"Service hospitalo-universitaire de psychologie médicale de psychiatrie d'adultes du Pr Lançon - CHU Marseille, Marseille, France",,https://ClinicalTrials.gov/show/NCT02020824
NCT02018185,Study of Magnetic Brain Stimulation in Treatment of Obsessive Compulsive Disorder,rTMS,Recruiting,No Results Available,Obsessive Compulsive Disorder,Device: Transcranial Magnetic Stimulation|Device: Sham Transcranial Magnetic Stimulation,Change in obsessive and compulsive symptom severity (Yale-Brown Obsessive Compulsive Scale),University of Manitoba|Manitoba Medical Service Foundation,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,30,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",B2013:144,Jan-14,Jul-19,Oct-19,23-Dec-13,null,4-Dec-18,"St. Boniface Hospital, Winnipeg, Manitoba, Canada",,https://ClinicalTrials.gov/show/NCT02018185
NCT02018471,Psychological Counselling in Diagnostic Screening,,Completed,No Results Available,Cancer,Behavioral: Psychoeducative training,Proportion of patients considered drop-outs|median BAI score after intervention|median COPE score - Social support score after intervention|median COPE score - Avoidance strategies score after intervention|median COPE score - Positive attitude score after intervention|median COPE score - Problem acceptance score after intervention|recruitment time (process)|mean number of recruited patients per week (process)|refusal rate among eligible patients (process)|rate of patients who obviously meet and do not meet the eligibility requirements (process)|number of questionnaires correctly filled out (process)|phone lines overloaded or waiting room overcrowded by study participants (management),Istituto Oncologico Veneto IRCCS,All,"25 Years to 65 Years   (Adult, Older Adult)",Not Applicable,43,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,IOV-2012 ANXIETY,Apr-12,Feb-13,May-13,23-Dec-13,null,23-Dec-13,,,https://ClinicalTrials.gov/show/NCT02018471
NCT02018848,Internet-delivered Attention Training for Obsessive-Compulsive Disorder,,Completed,No Results Available,Obsessive-Compulsive Disorder,Behavioral: Attention Training Program,Yale-Brown Obsessive-Compulsive Scale Self-Report Scale (Y-BOCS-SRS) T1|Yale-Brown Obsessive-Compulsive Scale Self-Report Scale (Y-BOCS-SRS) T2|Yale-Brown Obsessive-Compulsive Scale Self-Report Scale (Y-BOCS-SRS) T3|Obsessive-Compulsive Inventory-Revised (OCI-R) T1|Obsessive-Compulsive Inventory-Revised (OCI-R) T2|Obsessive-Compulsive Inventory-Revised (OCI-R) T3,Humboldt-Universität zu Berlin,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,108,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",HU-ATP-OCD-2013,Oct-13,Jul-14,Jul-14,23-Dec-13,null,13-Nov-14,"Humboldt-Universität zu Berlin, Berlin, Germany",,https://ClinicalTrials.gov/show/NCT02018848
NCT02014194,Attentional Bias Modification Treatment in OCD,,Completed,No Results Available,Obsessive-compulsive Disorder,Behavioral: attentional bias modification treatment,Percentage of reduction of attentional bias|Reduction of anxiety symptoms,Roseli Shavitt|University of Sao Paulo,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,30,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",13674113.2.0000.0068,Nov-13,Dec-16,Dec-16,18-Dec-13,null,25-Jan-18,"University of Sao Paulo Medical School, Sao Paulo, Brazil",,https://ClinicalTrials.gov/show/NCT02014194
NCT02013531,Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Adults With Major Depressive Disorder and Anxiety Symptoms,,Completed,Has Results,Major Depressive Disorder|Anxiety,Drug: Brexpiprazole,Mean Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score|Mean Change in Clinical Global Impression-Severity (CGI-S) Total Score|Mean Clinical Global Impression-Improvement (CGI-I) Score at Week 6.|Percentage of Participants With CGI-I Response Rate|Percentage of Participants With a MADRS Response|Percentage of Participants With a MADRS Remission|Mean Change From Baseline in Hamilton Depression Rating Scale (HAM-D17) Total Score|Mean Change From Baseline in Hamilton Anxiety Rating Scale (HAM-A) Total Score|Mean Change From Baseline in Sheehan Disability Scale (SDS) Mean Score|Mean Change From Baseline in Massachusetts General Hospital-Cognitive and Physical Functioning Questionnaire (MGH-CPFQ) Total Score|Mean Change From Baseline in Kellner Symptom Questionnaire (KSQ)|Mean Change From Baseline in Go/No-Go Task for P-inhibition Failures|Mean Change From Baseline in Go/No-Go Task for Mean Reaction Time|Mean Change From Baseline in Delay Discounting Task - Monetary Choice Questionnaire (MCQ) Score|Mean Change From Baseline in Delay and Probability Discounting Task (DPDT) Scores|Mean Change From Baseline to Week 6 in the Number of Impulsive Choices in the Delayed Reward Task (DRT)|Mean Change From Baseline in Food Delay Discounting Task|Mean Change From Baseline in Money Delay Discounting Task|Mean Change From Baseline in Barratt Impulsiveness Scale 11-item (BIS-11) Total Score,"Otsuka Pharmaceutical Development & Commercialization, Inc.|Otsuka Pharmaceutical Co., Ltd.",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,37,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,331-13-002,Nov-13,May-14,Jun-14,17-Dec-13,29-Mar-16,29-Mar-16,"Tuscon, Arizona, United States|Garden Grove, California, United States|Oceanside, California, United States|Temecula, California, United States|Gainesville, Florida, United States|Jacksonville, Florida, United States|Miami, Florida, United States|Atlanta, Georgia, United States|Lafayette, Indiana, United States|Baltimore, Maryland, United States|Boston, Massachusetts, United States|Haverhill, Massachusetts, United States|Rochester Hills, Michigan, United States|New York, New York, United States|Staten Island, New York, United States|Salem, Oregon, United States|Allentown, Pennsylvania, United States|Arlington, Texas, United States|Austin, Texas, United States|Woodstock, Vermont, United States|Richmond, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02013531
NCT02013609,"Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment",,Completed,Has Results,MDD,Drug: Brexpiprazole,Mean Change From Baseline to Week 12 in the Montgomery Asberg Depression Rating Scale (MADRS) Total Score|Mean Change From Baseline to Week 12 in Clinical Global Impression-Severity (CGI-S) Total Score|Mean Clinical Global Impression-Improvement (CGI-I) Score at Week 12|Number of Participants With CGI-I Response|Percentage of Participants With MADRS Response|Percentage of Participants With MADRS Remission|Mean Change From Baseline to Week 12 in Hamilton Depression Rating Scale (HAM-D17) Total Score|Mean Change From Baseline to Week 12 in Sheehan Disability Scale (SDS) 3-item Total/Summed Score|Mean Change From Baseline to Week 12 in Sheehan Disability Scale (SDS) Single Item Sub-scores|Mean Change From Baseline to Week 12 in Social Adaptation Self-evaluation Scale (SASS) Total Score|Mean Change From Baseline to Week 12 in Massachusetts General Hospital-Cognitive and Physical Functioning Questionnaire (MGH-CPFQ) Total Score|Mean Change From Baseline to Week 12 in Kellner Symptom Questionnaire (KSQ) Total Score|Mean Change From Baseline to Week 12 in Go/No-Go Task (P-inhibition Failure)|Mean Change From Baseline to Week 12 in Go/No-Go Task (Mean Reaction Time)|Mean Change From Baseline in Delay Discounting Task - Monetary Choice Questionnaire (MCQ) k Value|Mean Change From Baseline to Week 12 in the Number of Impulsive Choices in the Delayed Reward Task (DRT)|Mean Change From Baseline to Week 12 in Delay and Probability Discounting Task (DPDT)|Mean Change From Baseline in Food Delay Discounting Task (DDT)|Mean Change From Baseline in Money Delay Discounting Task|Mean Change From Baseline to Week 12 in Barratt Impulsiveness Scale 11-Item (BIS-11) Total Score,"Otsuka Pharmaceutical Development & Commercialization, Inc.|Otsuka Pharmaceutical Co., Ltd.",All,18 Years to 35 Years   (Adult),Phase 3,48,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,331-13-003,Nov-13,Sep-14,Oct-14,17-Dec-13,29-Mar-16,29-Mar-16,"Cerritos, California, United States|Costa Mesa, California, United States|Garden Grove, California, United States|Glendale, California, United States|Orange, California, United States|Riverside, California, United States|San Diego, California, United States|Norwich, Connecticut, United States|Fort Myers, Florida, United States|Hialeah, Florida, United States|Melbourne, Florida, United States|Orlando, Florida, United States|Atlanta, Georgia, United States|Prairie Village, Kansas, United States|Weymouth, Massachusetts, United States|Las Vegas, Nevada, United States|Brooklyn, New York, United States|Jamaica, New York, United States|Staten Island, New York, United States|Portland, Oregon, United States|Austin, Texas, United States|Houston, Texas, United States|San Antonio, Texas, United States|Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT02013609
NCT02011438,Coping With Adolescent Peer Victimization and Reducing Anxious/Depressed Symptoms,,Completed,No Results Available,Depression|Social Anxiety,Behavioral: UTalk,Anxiety Disorder Interview Schedule- Children (ADIS-C)|Clinicians Global Impression Scale (Severity and Improvement)|Revised Peer Experiences Questionnaire (subscales for Relational and Reputational PV)|Social Anxiety Scale for Adolescents|Centers for Epidemiological Studies Depression Scale|Perceived Support Scale- Friends and Family|Cyber Peer Experiences Questionnaire|Revised Peer Experiences Questionnaire|Health Behaviors,University of Miami|Columbia University,All,"13 Years to 18 Years   (Child, Adult)",Phase 2,49,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,1R34MH095959-01A1,Jun-12,May-15,Jun-15,13-Dec-13,null,17-Dec-15,"University of Miami, Coral Gables, Florida, United States",,https://ClinicalTrials.gov/show/NCT02011438
NCT02009358,Mental Health Promotion Interventions Among Migrant Workers in China,,Completed,No Results Available,Depression|Anxiety,Other: mental health promotion,Reducing rate of self-reported depression in BDI|Reducing rate of early detection of depression,Peking University,All,18 Years to 60 Years   (Adult),Not Applicable,913,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,GCY2009,Mar-10,Oct-12,Nov-12,12-Dec-13,null,25-Feb-14,,,https://ClinicalTrials.gov/show/NCT02009358
NCT02009839,Web-Based CBT Protocol for Treatment of Selective Mutism,,Completed,No Results Available,Selective Mutism,Behavioral: Meeky Mouse program|Other: Computer Games,Selective Mutism Questionnaire|Asian Children's Anxiety Scale-Caretaker Version (ACAS)|Asian Children's Anxiety Scale-Child (ACAS-C)|Clinical Global Impression (CGI),"National Healthcare Group, Singapore",All,6 Years to 12 Years   (Child),Not Applicable,38,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",NHG-SIG/05016,Jul-05,Sep-07,Sep-07,12-Dec-13,null,20-May-14,"Child Guidance Clinic, Singapore, Singapore",,https://ClinicalTrials.gov/show/NCT02009839
NCT02007694,Noradrenergic Manipulation and Virtual Reality Exposure Therapy in Phobic Participants,,Completed,No Results Available,Phobic Disorders,Behavioral: Virtual Reality Exposure Therapy (VRET),FAS (Flight Anxiety Situations Questionnaire)|AQ (Acrophobia Questionnaire)|WAQ (Weekly Anxiety Questionnaire)|FAM (Flight Anxiety Modalities Questionnaire)|ATHQ (Attitude towards heights questionnaire)|DASS (Depression Anxiety Stress Scale)|PIT (Prospective Imagery Task)|ASI (Anxiety Sensitivity Inventory)|SUDs (Subjective Units of Discomfort),VU University of Amsterdam,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2|Phase 3,56,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",2012-KP-2464,Mar-13,Dec-14,Dec-14,11-Dec-13,null,8-Jul-15,"University of Amsterdam, Amsterdam, Nord Holland, Netherlands",,https://ClinicalTrials.gov/show/NCT02007694
NCT02008396,MDMA-assisted Therapy for Social Anxiety in Autistic Adults,,Completed,No Results Available,Social Anxiety in Autistic Adults,Drug: Placebo|Drug: MDMA,Change in Lieberman Social Anxiety Scale score|Beck Depression Inventory (BDI)|State Trait Anxiety Inventory (STAI)|Perceived Stress Scale (PSS)|Interpersonal Reactivity Index (IRI)|Rosenberg Self-Esteem Scale (RSES)|Columbia Suicide Severity Rating Scale (C-SSRS)|The Awareness of Social Inference Test|Quality of Life Questionnaire|Emotion Regulation Questionnaire|Toronto Alexithymia Scale (TAS-20)|Peak systolic blood pressure|Peak diastolic blood pressure (DBP)|Peak heart rate (HR)|Peak body temperature (BT)|Average systolic blood pressure|Average diastolic blood pressure (DBP)|Average heart rate (HR)|Average body temperature (BT),Multidisciplinary Association for Psychedelic Studies|Los Angeles Biomedical Research Institute,All,"21 Years and older   (Adult, Older Adult)",Phase 2,12,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MAA-1,Feb-14,Aug-17,Aug-17,11-Dec-13,null,26-Sep-18,"Los Angeles Biomedical Research Institute, Torrance, California, United States",,https://ClinicalTrials.gov/show/NCT02008396
NCT02006199,Effect of Mindfulness Based Treatment for Obsessive-compulsive Disorder,,Withdrawn,No Results Available,Obsessive-compulsive Disorder,Behavioral: mindfulness meditation,Yale-Brown Obsessive compulsive scores|Neurocognitive profile (emotion-memory task),Seoul National University Hospital,All,"17 Years to 55 Years   (Child, Adult)",Not Applicable,0,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,1306-076-498,Oct-13,Jul-14,Jul-14,10-Dec-13,null,14-Oct-16,"Seoul National University Hospital, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02006199
NCT02002858,Smoking Cessation for Depression and Anxiety Treatment,SDAT,Completed,No Results Available,Smoking|Anxiety Disorders|Depression Disorders,Drug: Nicotine Patch|Behavioral: Depression and Anxiety Smoking Cessation Treatment|Behavioral: Educational-Support Psychotherapy,Smoking Status using the Timeline Follow-Back Assessment,University of Houston|National Institute on Drug Abuse (NIDA),All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,12,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,1R34DA03474101|R34DA034741,Oct-14,Nov-16,May-17,6-Dec-13,null,7-Jul-17,"Anxiety and Health Research Laboratory and Substance Use Treatment Clinic, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT02002858
NCT02003261,Japan Unified Protocol Clinical Trial for Depressive and Anxiety Disorders (JUNP Study),,"Active, not recruiting",No Results Available,Anxiety Disorders|Depressive Disorders,Behavioral: Unified Protocol with Treatment As Usual|Other: Treatment As Usual,GRID-Hamilton Depression Rating Scale-17 (GRID-HAMD)|Hamilton Anxiety Rating Scale 14 item(HAM-A)|Clinical Global Impression- Severity(CGI-S)|Clinical Global Impression-Improvement(CGI-I)|Responder Status assessed by GRID-HAMD|Remission of symptoms assessed by GRID-HAMD|Psychiatric diagnosis assessed by Structured Clinical Interview for the DSM(SCID),"National Center of Neurology and Psychiatry, Japan",All,"20 Years to 65 Years   (Adult, Older Adult)",Phase 3,104,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,KAKENHI 25705018,Nov-13,Oct-18,Mar-19,6-Dec-13,null,13-Jun-18,"National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan",,https://ClinicalTrials.gov/show/NCT02003261
NCT02002143,GMVs in Primary Care: An RCT of Group-Based Versus Individual Appointments to Reduce HbA1c in Older People,GAP,Recruiting,No Results Available,Type 2 Diabetes Mellitus (T2DM),Behavioral: Group Appointments|Behavioral: Individual Appointments (IAs),"Patients' control (decreased levels) of HemoglobinA1C (clinical)|Resting systolic blood pressure (mmHg)) (clinical)|Resting diastolic blood pressure (mmHg)) (clinical)|Electrical activity of the heart (ECG) (clinical)|C-reactive protein (mg/L) (clinical)|plasma glucose (mmol/L) (clinical)|High-density lipoprotein - cholesterol (HDL-C; mmol/L) (clinical)|Fasting low-density lipoprotein (LDL; mmol/L) (clinical)|Triglycerides (mmol/L) (clinical)|Height (cm), weight (kg), waist & hip circumference (cm), fat and muscle mass (g) (clinical)|Quality of life (as measured by the health state utility values of EQ-5D3L questionnaire (patient-reported quality of life/economic))|Health Care Utilization|Anxiety|Depression|Satisfaction With Life Scale|Physical Activity (PASE)|Physical Activity (SenseWear)|Goal Setting and Action Planning|Food Diary|Patient Self-Management","University of British Columbia|Ministry of Health, British Columbia",All,65 Years and older   (Older Adult),Not Applicable,128,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,H13-02812,Jan-14,Feb-19,Feb-20,5-Dec-13,null,22-Nov-17,"Gateway Clinic / Kent Place Clinic, Abbotsford, British Columbia, Canada|Centre for Hip Health and Mobility (Vancouver Coastal Health Research Institute/University of British Columbia), Vancouver, British Columbia, Canada",,https://ClinicalTrials.gov/show/NCT02002143
NCT02000245,Effects of Sympathy and Touch on Anxiety of Patients Undergoing Fiberoptic Bronchoscopy,,Completed,No Results Available,Anxiety,Behavioral: verbal expression for compassion|Behavioral: touch,change of visual analogue scale (VAS) for anxiety|Satisfaction of patients after fiberoptic bronchoscopy,Seoul National University Hospital,All,"19 Years and older   (Adult, Older Adult)",Not Applicable,267,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,STAF|1307-042-504,Oct-13,Dec-14,Dec-14,4-Dec-13,null,20-Apr-16,"Seoul National University Hospital, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02000245
NCT01998945,Back on My Feet: Emotional Recovery From Fall Injury,,Completed,No Results Available,Posttraumatic Stress Disorder|Subsyndromal Posttraumatic Stress Disorder|Fear of Falling,Behavioral: Exposure-based Cognitive Behavioral Therapy|Behavioral: Relaxation Training,Change from baseline clinician-rated PTSD at 6 weeks|Change from baseline fear of falling at 6 weeks|Change from baseline depression at 6 weeks|Change from baseline anxiety at 6 weeks|Change from baseline self-reported PTSD at 6 weeks,Weill Medical College of Cornell University|National Institute of Mental Health (NIMH),All,"60 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,22,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,1306014003|K23MH090244,Dec-13,Mar-15,Sep-15,3-Dec-13,null,16-Aug-16,"Weill Cornell Medical College, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT01998945
NCT01999920,Vilazodone for Separation Anxiety Disorder,,Completed,Has Results,Separation Anxiety Disorder,Drug: Vilazodone|Drug: Placebo,Clinical Global Impression-Improvement Scale|Change From Baseline Hamilton Rating Scale for Depression 17-item Total Score|Change From Baseline in Attachment Style Questionnaire Score|Change From Baseline in Quality of Life Enjoyment & Satisfaction Questionnaire|Change From Baseline on Structured Clinical Interview for Separation Anxiety Disorder|Change From Baseline on Adult Separation Anxiety - 27 Scale,New York State Psychiatric Institute|Forest Laboratories,All,18 Years to 60 Years   (Adult),Phase 4,24,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",#6856,Dec-13,Mar-17,30-Dec-17,3-Dec-13,31-Oct-17,7-Mar-18,"New York State Psychiatric Institute, New York, New York, United States","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/20/NCT01999920/SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/20/NCT01999920/ICF_001.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/20/NCT01999920/Prot_002.pdf",https://ClinicalTrials.gov/show/NCT01999920
NCT01998100,Maximizing Treatment Outcome in Post-Traumatic Stress Disorder (PTSD),,Completed,No Results Available,Post-Traumatic Stress Disorder,Behavioral: Prolonged Exposure|Behavioral: Exercise,PTSD Symptoms|BDNF (by blood sample)|General Mood and Anxiety Symptoms,University of Texas at Austin,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,28,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,KS10-106,Sep-10,Jul-13,Jul-13,28-Nov-13,null,29-Dec-15,"The University of Texas at Austin, Austin, Texas, United States|Southern Methodist University, Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT01998100
NCT01996644,A Double Blind Clinical Trial of DCS for Food Anxiety,,Completed,Has Results,Anorexia and Bulimia Nervosa,Drug: Placebo vs Setraline|Drug: Setraline,Anxiety as Measured by the Subjective Units of Distress (Ranging From 1 to 100).|Body Mass Index,Washington University School of Medicine|National Institute of Mental Health (NIMH),All,"14 Years to 65 Years   (Child, Adult, Older Adult)",Not Applicable,47,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",201212062|F31MH096433-01,Feb-13,Feb-14,Feb-14,27-Nov-13,27-Mar-18,27-Mar-18,"Washington University, Saint Louis, Missouri, United States",,https://ClinicalTrials.gov/show/NCT01996644
NCT01995422,Effect of Physical Activity on Depressive Symptoms With a 5 Month Follow-up,2DPAP,Completed,No Results Available,Major Depressive Disorder,Other: Physical activity program,"Effect of physical activity on depression|Distraction, self-efficacy and social support scores on 7-point Likert scales and balance on force platform","Laboratory Motricité, Interactions, Performance|Nantes University Hospital",All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,16,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,2011-A00934-37,Dec-11,May-14,Jun-14,26-Nov-13,null,1-Apr-15,"University of Nantes, Nantes, Pays de la Loire, France",,https://ClinicalTrials.gov/show/NCT01995422
NCT01993277,Evaluating Neuromodulation Technologies in Early Recovery,,Unknown status,No Results Available,Depression|Anxiety|Insomnia,Device: Nexalin Brain Stimulator|Device: Fischer Wallace Stimulator|Device: David Delight Stimulator|Behavioral: Relaxation Therapy,The Quick Inventory of Depressive Symptoms—Self-Report (QIDS-SR)|State-Trait Anxiety Inventory (STAI)|Pittsburgh Sleep Scale (PSS)|16-item Quality of Life Enjoyment and Satisfaction Questionnaire (QLES)|Brief Substance Craving Scale (BSCS),Behavioral Health of the Palm Beaches,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,200,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1,Dec-13,Jun-15,Oct-15,25-Nov-13,null,17-Dec-14,"Behavioral Health of the Palm Beaches, North Palm Beach, Florida, United States",,https://ClinicalTrials.gov/show/NCT01993277
NCT01993459,The Effects of Midazolam on the Quality of Postoperative Recovery,WOLII,Completed,No Results Available,Postoperative Period|Anxiety|Fatigue|Depression|Aggression,"Drug: Midazolam|Drug: NaCl (sodium chloride) 0,9%","Change in Quality of Recovery (QoR-40 Scale)|Change in anxiety measured with a Dutch translated State-Trait Anxiety Inventory (STAI)|Change in depressive moods and anxiety measured by a Dutch translation of the Hospital Anxiety and Depression Scale (HADS)|Change in fatigue measured by a validated Dutch questionnaire Multidimensional Fatigue Index : ""Multidimensionele Vermoeidheids Index"" (MVI-20)|Change in self-efficacy measured by a Dutch translation of General Self-Efficacy- Schwarzer (GSES).|Change in Systolic bloodpressure|Change in self-esteem measured by a Dutch translation of the and Rosenberg self-esteem scale (RSES)|Change in Diastolic Blood pressure|Temperature after surgery measured with an ear thermometer|Change in Heart Rate",Erasmus Medical Center,All,"18 Years and older   (Adult, Older Adult)",Phase 4,192,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",14091991,Feb-14,Oct-15,Oct-15,25-Nov-13,null,26-Jan-16,"Erasmus Medical Centre, Rotterdam, Zuid-Holland, Netherlands",,https://ClinicalTrials.gov/show/NCT01993459
NCT01993849,Use of N-Acetylcysteine (NAC) in Fingernail Biting,,Completed,Has Results,Onychophagia,Drug: N-Acetylcysteine (NAC)|Other: Placebo,Number of Participants Enrolled Within One Year,"Kevin Gray, MD|Medical University of South Carolina",All,18 Years to 30 Years   (Adult),Phase 3,23,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",Pro00028506,Oct-13,Jun-15,Jun-15,25-Nov-13,3-Oct-18,3-Oct-18,"Medical University of South Carolina, Charleston, South Carolina, United States",,https://ClinicalTrials.gov/show/NCT01993849
NCT01993901,The Influence of CSRT-led Telephone Follow-up on ESAS Scores in Patients Who Have Been Treated With Lung SBRT,,Withdrawn,No Results Available,"Lung Cancer, Anxiety Post SBRT",Other: CSRT led telephone follow up,Change in ESAS scores|Efficacy of CSRT led follow up,Sunnybrook Health Sciences Centre,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care,PBR041575,Sep-14,Aug-15,Nov-15,25-Nov-13,null,18-Apr-18,"Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT01993901
NCT01989728,Prevalence and Effect of Detecting Common Mental Disorders in Long-term Sickness Absence,PRW,Completed,No Results Available,Psychiatric Disorders|Common Mental Disorders|Depression|Anxiety|Somatoform Disorder,Procedure: psychiatric examination and feedback,duration until return to work|Psychological distress by subscales of Hopkins Symptom Checklist Revised (SCL-90-R),Region MidtJylland Denmark,Male,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,1121,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,sickness absence 1|RA,Nov-04,Oct-05,Dec-10,21-Nov-13,null,21-Nov-13,"Psychiatric Research Unit west, regional Psychiatric Services West, Herning, Denmark",,https://ClinicalTrials.gov/show/NCT01989728
NCT01990131,Computerized Anxiety Treatment for Suicide,CATS,Completed,No Results Available,Anxiety|Suicide,Other: Cognitive Anxiety Sensitivity Treatment|Other: Physical Health Education Training,Anxiety Sensitivity Index-3 (ASI-3)|Beck Suicide Scale (BSS),Florida State University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,74,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",RF02397,Oct-13,Jun-16,Jul-16,21-Nov-13,null,9-Aug-16,"Anxiety and Behavioral Health Clinic, Tallahassee, Florida, United States",,https://ClinicalTrials.gov/show/NCT01990131
NCT01988194,Pragmatic Research eXamining Inpatient Symptoms,PRAXIS,Completed,No Results Available,Postoperative Pain|Nausea|Vomiting|Anxiety|Depression,Device: Acupuncture,Self-reported pain|Self-reported nausea and vomiting|Self-reported anxiety and depression|Functionality and quality of life|Patient satisfaction|Self-reported global well-being|Self-reported global rating of change,"University of California, San Francisco",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,238,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,13-11353,Nov-13,Dec-14,Dec-15,20-Nov-13,null,1-Jun-17,"UCSF Medical Center at Mount Zion, San Francisco, California, United States",,https://ClinicalTrials.gov/show/NCT01988194
NCT01989247,How to Cope With Anxiety and Depression. A Randomized Controlled Trial.,,Completed,No Results Available,Depression|Anxiety|Self Efficacy,Behavioral: Self-management programme,"Depressive Symptoms (Beck's Depression Inventory (BDI-II))|State Anxiety (Spielbergers State-Trait Anxiety Inventory (STAI))|Self-efficacy (Chronic Disease Self-efficacy Scales - SECD-32 (Stanford Patient Education Research Center))|Self-efficacy (""Personal control"" from ""The Revised Illness Perception Questionnaire"" (IPQ-R))|Sleep Quality (The Pittsburgh Sleep Quality Index)|Exercise Behaviors (Stanford Patient Education Research Center)|Health related symptoms|Social/Role Activities Limitations Scale (Stanford Patient Education Research Center)|Self-efficacy (""Control/Manage Depression Scale from: ""Chronic Disease Self-efficacy Scales - SECD-32 (Stanford Patient Education Research Center))","University of Aarhus|National Board of Health, Denmark|Danish Committee for Health Education",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,853,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1-1010-46/1,Jun-13,Sep-14,Jan-16,20-Nov-13,null,8-Mar-16,"Aalborg Municipality, Aalborg, Denmark|Nordfyn Municipality, Bogense, Denmark|Ikast-Brande Municipality, Brande, Denmark|Gentofte Municipality, Charlottenlund, Denmark|Dragør Municipality, Dragør, Denmark|Esbjerg Municipality, Esbjerg, Denmark|Vesthimmerlands Municipality, Farsø, Denmark|Fredericia Municipality, Fredericia, Denmark|Frederikssund Municipality, Frederikssund, Denmark|Norddjurs Municipality, Grenå, Denmark|Haderslev Municipality, Haderslev, Denmark|Faxe Municipality, Haslev, Denmark|Helsingør Municipality, Helsingør, Denmark|Herning Municipality, Herning, Denmark|Holbæk Municipality, Holbæk, Denmark|Tårnby Municipality, Kastrup, Denmark|Fredensborg Municipality, Kokkedal, Denmark|Lyngby-Taarbæk Municipality, Kongens Lyngby, Denmark|Køge Municipality, Køge, Denmark|Hedensted Municipality, Løsning, Denmark|Næstved Municipality, Næstved, Denmark|Odense Municipality, Odense, Denmark|Roskilde Municipality, Roskilde, Denmark|Aabenraa Municipality, Rødekro, Denmark|Syddjurs Municipality, Rønde, Denmark|Silkeborg Municipality, Silkeborg, Denmark|Skanderborg Municipality, Skanderborg, Denmark|Slagelse Municipality, Slagelse, Denmark|Solrød Municipality, Solrød Strand, Denmark|Sorø Municipality, Sorø, Denmark|Rebild Municipality, Støvring, Denmark|Gladsaxe Municipality, Søborg, Denmark|Sønderborg Municipality, Sønderborg, Denmark|Varde Municipality, Varde, Denmark|Vejen Municipality, Vejen, Denmark|Vejle Municipality, Vejle, Denmark|Viborg Municipality, Viborg, Denmark",,https://ClinicalTrials.gov/show/NCT01989247
NCT01986296,ExAblate Transcranial MR Guided Focused Ultrasound in the Treatment of Medication Refractory Obsessive Compulsive Disorder,,"Active, not recruiting",No Results Available,Medication-refractory Obsessive Compulsive Disorder (OCD),Device: ExAblate Transcranial MRgFUS System,Effectiveness of the ExAblate Transcranial MRgFUS treatment of medication-refractory OCD|Device or procedure related Adverse Events reported,InSightec,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,25,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,OCD001,Jan-13,Dec-19,Dec-20,18-Nov-13,null,14-Jun-18,"Yonsei University Medical Center, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01986296
NCT01985347,"The SAD Study - SLEEP, ANXIETY & DEPRESSION Study A Prospective Cohort Study",SAD,Unknown status,No Results Available,"Patients With Anxiety and Depression, Who Have|Obstructive Sleep Apnoea|COPD",Device: CPAP,To establish the prevalence of anxiety and depression in patients with sleep disorders and compare how this prevalence differs from its prevalence in COPD and in the general population.|To evaluate whether treatment with CPAP improves anxiety and depression symptoms (HAD scale) at 3 and 12 months in OSA patients with anxiety and depression.,The Queen Elizabeth Hospital|Lyell McEwin Hospital,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,500,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,HREC/13/TQEHLMH/14,Nov-13,Dec-14,Mar-15,15-Nov-13,null,15-Nov-13,"The Queen Elizabeth Hospital, Adelaide, South Australia, Australia",,https://ClinicalTrials.gov/show/NCT01985347
NCT01985815,"Refining the Target for Deep Brain Stimulation (DBS) in Severe, Treatment Refractory Obsessive Compulsive Disorder (OCD)",,Completed,No Results Available,Obsessive-Compulsive Disorder,Device: VC/VS stimulation,Yale Brown Obsessive Compulsive Scale (Y-BOCS)|Clinical Global Impression (CGI)|Global assessment of functioning (GAF)|Hamilton scale for anxiety|Beck depression inventory|Inventory of Depressive Symptoms (IDS)|Patient Global Impression (PGI).|Symptom Checklist (SCL-90)|Quality of Life and Satisfaction Questionnaire (Q-Les-Q),Universitaire Ziekenhuizen Leuven,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,6,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",s50927,Mar-08,Feb-10,null,15-Nov-13,null,15-Nov-13,"UZ Leuven, Leuven, Vlaams-Brabant, Belgium",,https://ClinicalTrials.gov/show/NCT01985815
NCT01984593,"Impact of Yoga on Blood Pressure, Quality of Life and Stress in Patients With Hypertension",YHIP2,Completed,No Results Available,Hypertension,Other: Yoga,Hypertension|Quality of life,Region Skane|The Swedish Research Council,All,"30 Years to 80 Years   (Adult, Older Adult)",Not Applicable,190,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Region Skane,Nov-13,Mar-14,Mar-14,14-Nov-13,null,5-Nov-14,"Center for Primary Health Care Research, Lunds University, Malmö, Sweden",,https://ClinicalTrials.gov/show/NCT01984593
NCT01982422,Developmental Origins of Attention Deficit Hyperactivity Disorder,,Unknown status,No Results Available,Inattention|Impulsivity|Anxiety,"Behavioral: Whole Food, Nutrient-Dense Dietary Intervention",Functional neuroconnectivity of neonate assessed by MRI|Blood nutrient concentrations,Oregon Health and Science University,Female,18 Years to 50 Years   (Adult),Not Applicable,40,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,6749,Aug-12,May-14,Aug-14,13-Nov-13,null,13-Nov-13,"Oregon Health & Science University, Portland, Oregon, United States",,https://ClinicalTrials.gov/show/NCT01982422
NCT01982656,"Massage Technique for Pain, Anxiety and Delirium in SAH Patients",,Completed,No Results Available,Subarachnoid Hemorrhage|Anxiety|Pain|Delirium|Sleep,Other: Massage,Change in Pain Score|Sleep quantity,"Sara E. Hocker, M.D|Mayo Clinic",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,50,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,13-003346,Dec-13,31-Dec-17,22-Feb-18,13-Nov-13,null,23-Feb-18,"Mayo Clinic in Rochester, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT01982656
NCT01983033,Training Protocol 'Drop it'. The Impact of a Training Protocol Focused on Coping With Negative Repetitive Thinking on Cognitive and Behavioural Functioning of People Suffering From GAD or Minor or Moderate Depressive Disorder or Depressive Disorder in Remission,Drop It,Completed,No Results Available,Repetitive Negative Thinking|General Anxiety Disorder|Depressive Disorder|Depression|Anxiety Disorders|Worrying|Rumination,Behavioral: Drop It training session|Behavioral: treatment as usual,change in repetitive negative thinking|change in resting state fMRI|change in Quality of Life|change in self-esteem|change in depression and anxiety|change in personality features,"University Hospital, Ghent|University Ghent",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,80,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2013/708|B670201318392,Oct-13,Dec-16,Dec-16,13-Nov-13,null,25-May-17,"Ghent University Hospital, Ghent, Belgium",,https://ClinicalTrials.gov/show/NCT01983033
NCT01983254,Improving Psychological Distress Among Critical Illness Survivors and Their Caregivers,,Completed,Has Results,Intensive Care Unit Survivors|Informal Caregivers (Family and Friends),Behavioral: coping skills training|Other: education program,Hospital Anxiety and Depression Scale Score|Impact of Events Scale-revised (IES-R) Score,"Duke University|University of North Carolina, Chapel Hill|University of Pittsburgh|University of Washington|Patient-Centered Outcomes Research Institute",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,417,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Pro00043171|PCORI PFA 195,Oct-13,Feb-16,Apr-16,13-Nov-13,4-Apr-17,22-May-17,"University of North Carolina, Chapel Hill, North Carolina, United States|Duke University, Durham, North Carolina, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|University of Washington, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT01983254
NCT01980381,Treatment of Depression and/or Anxiety - the Tree Theme Method® (TTM) as an Intervention,,"Active, not recruiting",No Results Available,Depression|Anxiety,Other: Tree Theme Method ® (TTM),Psychological symptoms|Everyday occupations,Kronoberg County Council,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,121,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,LTK/120995,Jan-13,Dec-18,Dec-18,11-Nov-13,null,20-Mar-18,"Kronoberg County Council, Växjö, Kronoberg, Sweden",,https://ClinicalTrials.gov/show/NCT01980381
NCT01981018,MAPP: Imagery-focused Therapy for Bipolar Disorder,MAPP,Completed,No Results Available,Bipolar Disorder,Other: Imagery-focused Cognitive Therapy (ImCT - psychotherapy based on CBT principles),Anxiety and depression scores change|Changes in Imagery Characteristics|Anxiety and depression change maintenance at follow up|Mood instability|Depression and mania relapse rate and duration|Anxiety comorbidity|Medication compliance|General functioning and coping|Suicidality,Medical Research Council Cognition and Brain Sciences Unit|Cambridge and Peterborough NHS Foundation Trust|Oxford Health NHS Foundation Trust|University of Cambridge|University of Oxford,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,15,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MAPP_0174,Nov-13,Jul-15,Jul-15,11-Nov-13,null,30-Sep-15,"MRC Cognition and Brain Sciences Unit, Cambridge, United Kingdom|Cambridge and Peterborough NHS Foundation Trust, Cambridge, United Kingdom|University of Oxford, Department of Psychiatry, Oxford, United Kingdom|Oxford Health NHS Foundation Trust, Oxford, United Kingdom",,https://ClinicalTrials.gov/show/NCT01981018
NCT01981317,Stepped Care Cognitive Behavioral Therapy for Pediatric Obsessive Compulsive Disorder,SC-CBT,Completed,No Results Available,Obsessive Compulsive Disorder|Stepped Care Cognitive Behavioral Therapy,Behavioral: Stepped Care Cognitive Behavioral Therapy|Behavioral: Cognitive Behavioral Therapy,Children's Yale-Brown Obsessive-Compulsive Scale|Clinical Global Impression Improvement Scale|Clinical Global Impression Severity Scale,University of South Florida|Obsessive Compulsive Foundation,All,8 Years to 17 Years   (Child),Not Applicable,30,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,IOCDF2013,Oct-13,Mar-17,Oct-18,11-Nov-13,null,20-Mar-19,"The Rothman Center for Pediatric Neuropsychiatry, Saint Petersburg, Florida, United States",,https://ClinicalTrials.gov/show/NCT01981317
NCT01979263,Attention Bias Modification Treatment for Anxious Youth,ABMT,Terminated,No Results Available,Generalized Anxiety Disorder|Separation Anxiety Disorder|Social Phobia|Specific Phobia|Obsessive-Compulsive Disorder,Other: Attention Bias Modification Computer Task|Other: Placebo Computer Task,Change in clinical severity ratings on Anxiety Disorder Interview Schedule-Child and Parent Version|Variation in genes associated with treatment response,Weill Medical College of Cornell University,All,7 Years to 17 Years   (Child),Not Applicable,5,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",1207012686R001-IRB,Oct-13,17-Jan-17,17-Jan-17,8-Nov-13,null,7-Feb-19,"Payne Whitney Manhattan Child Division, New York, New York, United States|New York Presbyterian Hospital--Westchester Division, White Plains, New York, United States",,https://ClinicalTrials.gov/show/NCT01979263
NCT01980147,Skills for Wellness,SWELL,Recruiting,No Results Available,Schizophrenia|Bipolar Disorder|Major Depression,Behavioral: maCBT,Early antecedents to severe mental illness|Severe mental illness (long-term outcome)|Distress associated with unusual experiences|Functioning|psychotic-like experiences|basic symptoms|Anxiety|Affective lability - continuous|Affective lability|Anxiety - continuous,Nova Scotia Health Authority|Nova Scotia Health Research Foundation|Canadian Institutes of Health Research (CIHR),All,"9 Years to 21 Years   (Child, Adult)",Not Applicable,360,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,SFW-2013,22-Mar-14,Jan-21,Jan-22,8-Nov-13,null,17-Jul-18,"Capital District Health Authority, Halifax, Nova Scotia, Canada|Nova Scotia Health Authority, Halifax, Nova Scotia, Canada",,https://ClinicalTrials.gov/show/NCT01980147
NCT01977729,Sequencing CBT for Child Anxiety: CBT Plus Sertraline Versus Switch to Sertraline,,Terminated,Has Results,Anxiety Disorder of Adolescence,Drug: Sertraline|Behavioral: Cognitive Behavioral Therapy,Clinical Global Impression Severity & Improvement Scales|Multidimensional Anxiety Scale for Children,Yale University,All,8 Years to 16 Years   (Child),Phase 2,1,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1308012517,Oct-13,Sep-14,Sep-14,7-Nov-13,13-Apr-16,16-May-16,"Yale Child Study Center, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT01977729
NCT01976832,Music-with-Movement Intervention for People With Early Dementia and Their Families,,Completed,No Results Available,Dementia|Anxiety|Sleep|Depression|Quality of Life,Behavioral: Music with movement|Behavioral: Social interaction,Change of Rating anxiety in Dementia (RAID)|Change of Geriatric Depression Scale (GDS)|Change of Neuropsychiatric Inventory Questionnaire(NPI-Q)|Change of Pittsburgh Sleep Quality Index (PQSI)|Change of Quality of Life - Alzheimer's Disease (QOL-AD)|Change of Patient Health Questionnaire 9 (PHQ-9)|Change of Zarit Burden Scale (ZBS)|Change of World Health Organization Quality of Life-BREF (WHOQOL-BREF)|Change of Generalized Anxiety Disorder 7|Change of Mini-Mental State Examination (MMSE)|Change of Revised Life Event Scale (RLES)|Change of Lawton's Instrumental Activity of Daily Living (IADL)|Change of Modified Barthel Index (MBI),The Hong Kong Polytechnic University,All,65 Years and older   (Older Adult),Not Applicable,95,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,5-ZH96,Jul-14,May-16,Aug-16,6-Nov-13,null,5-Sep-16,"The Hong Kong Polytechnic University, Hong Kong, Hong Kong",,https://ClinicalTrials.gov/show/NCT01976832
NCT01975480,Efficacy of SNRI Treatment on Prefrontality in Patients With GAD and Other Comorbities,,Recruiting,No Results Available,Generalized Anxiety Disorder,Drug: Desvenlafaxine,Mean changes in the Hamilton Anxiety Rating Scale from baseline visit to week 16.|Mean change from baseline to week 16 on the measures of prefrontality including: Frontal System Behavioural Scale and Behaviour Rating Inventory of Executive Function-Adult,START Clinic for Mood and Anxiety Disorders,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,37,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,WS2382578,Jan-13,Jun-19,1-Jul-19,4-Nov-13,null,14-May-19,"START Clinic for Mood and Anxiety Disorders, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT01975480
NCT01971203,Efficacy of Extended-release Quetiapine (Seroquel XR) as Adjunctive Therapy to Cognitive Behavioral Therapy in the Treat,,Completed,Has Results,Major Depressive Disorder|Generalized Anxiety Disorder,Drug: seroquel xr|Behavioral: CBT,MADRS|HAM-A|Clinical Global Impression Scales for Severity and Improvement|Changes in Sexual Functioning Questionnaire (CSFQ),Icahn School of Medicine at Mount Sinai|AstraZeneca,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,62,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",GCO 09-0807,Sep-09,Jun-13,Jun-13,29-Oct-13,15-Feb-18,15-Feb-18,"Icahn School of Medicine at Mount Sinai, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT01971203
NCT01971216,Mother-infant Signalling During Breastfeeding,MOMS,Completed,No Results Available,Breastfeeding Women,Behavioral: Relaxation,"Maternal stress and anxiety|Breast milk volume at 12 weeks assessed non-invasively using stable isotope techniques|Breast milk cortisol concentrations at 12 weeks|Infant behaviour measured using a 3-day diary at 12 weeks|Infant weight and body composition measured using stable isotopes at 12 weeks|Physiological changes (maternal saliva cortisol, breast milk cortisol and milk volume) before and after physiological-mini test in intervention group at 2,6 and 12 weeks.|Non-nutrient factors in breast milk - leptin and ghrelin|Macronutrient composition of breast milk (fat and protein)","University College, London",Female,18 Years to 40 Years   (Adult),Not Applicable,64,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Other,13NT05,Dec-13,Mar-15,Jan-17,29-Oct-13,null,12-Jul-18,"Faculty of Medicine and Health Science, Universiti Putra Malaysia (UPM)., Kuala Lumpur, Malaysia",,https://ClinicalTrials.gov/show/NCT01971216
NCT01966705,Cognitive Behavior Therapy for Health Anxiety: A Comparison of Three Forms of Self-help,,Completed,No Results Available,Severe Health Anxiety|Somatic Symptom Disorder|Illness Anxiety Disorder,"Behavioral: Cognitive Behavior Therapy, exposure and response prevention (Internet, guided)|Behavioral: Cognitive Behavior Therapy, exposure and response prevention (Internet, unguided)|Behavioral: Cognitive Behavior Therapy, exposure and response prevention (Book, unguided)",Health Anxiety Inventory (HAI)|Illness Attitude Scale (IAS)|Whiteley Index (WI)|Montgomery-Åsberg Depression Rating Scale - Self report (MADRS-S)|Beck Anxiety Inventory (BAI)|Anxiety Sensitivity Index (ASI)|Sheehan Disability Scale (SDS)|Trimbos and institute of medical technology assessment cost questionnaire (TIC-P)|Euroqol-5D (EQ-5D)|Obsessive Compulsive Inventory Revised (OCI-R)|Yale-Brown Obsessive Compulsive Scale (Y-BOCS)|Alcohol Use Disorders Identification Test (AUDIT)|Insomnia Severity Index (ISI)|Self-rated health 5 (SRH-5)|The Swedish Scales of Personalities|Quality of Life Inventory (QOLI),Karolinska Institutet,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,132,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,InterBib,Oct-13,Nov-15,Nov-15,22-Oct-13,null,5-Nov-15,"Karolinska Institutet, Stockholm, Sweden",,https://ClinicalTrials.gov/show/NCT01966705
NCT01964092,Effect Evaluation of Individual Placement and Support (IPS),,Unknown status,No Results Available,Psychosis|Substance Abuse|Depression|Anxiety,Behavioral: Individual Placement and Support|Behavioral: Ordinary employment schemes,"Labor market participation in ordinary paid employment, or education.",NORCE Norwegian Research Centre AS|Norwegian Labour and Welfare Administration,All,"18 Years to 67 Years   (Adult, Older Adult)",Not Applicable,800,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,IPS-NAV,May-13,Dec-17,Dec-18,17-Oct-13,null,15-May-17,"Uni Research, Bergen, Norway",,https://ClinicalTrials.gov/show/NCT01964092
NCT01963689,Aromatherapy for Anxiety and Self-esteem: Clinical Trial,,Completed,No Results Available,Anxiety|Self Esteem,Other: Intervention Group 2|Other: Intervention Group 1|Other: Intervention Group 3,State-Trait Anxiety Inventory|Self-Esteem Scale,University of Sao Paulo,All,34 Years to 53 Years   (Adult),Not Applicable,34,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,469376,Jun-12,Sep-13,Sep-13,16-Oct-13,null,16-Oct-13,,,https://ClinicalTrials.gov/show/NCT01963689
NCT01963806,ACT-smart: Smartphone-supplemented iCBT for Social Phobia and/or Panic Disorder,,Completed,No Results Available,Panic Disorder|Phobic Disorders,Behavioral: Smartphone-supplemented iCBT|Behavioral: Therapist support|Other: Active waiting list,The Generalised Anxiety Disorder 7-item (GAD-7)|Self-rated Liebowitz Social Anxiety Scale (LSAS-SR)|Self-rated Panic Disorder Severity Scale (PDSS-SR)|9-item Patient Health Questionnaire (PHQ-9)|Quality of Life Inventory (QOLI),Stockholm University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,150,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ACT-smart,Sep-13,Nov-15,Nov-15,16-Oct-13,null,7-Mar-19,"Stockholm University, Stockholm, Sweden",,https://ClinicalTrials.gov/show/NCT01963806
NCT01959750,Psychological Intervention on Burnout in ICU Caregivers,,Completed,No Results Available,Burnout|Anxiety|Depression,Behavioral: problem-based sessions,"Measurement of the changes in the levels of anxiety, depression, and burnout in nurses and nursing auxiliaries.|Composite measurement of the changes of ICU activity and absenteeism before, during, just after and six months after the intervention.","University Hospital, Geneva",All,"Child, Adult, Older Adult",Not Applicable,166,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care",CER 08-220 (NAC08-069),Apr-09,Dec-09,Sep-13,10-Oct-13,null,10-Oct-13,"University Hopitals of Geneva, Geneva, Switzerland",,https://ClinicalTrials.gov/show/NCT01959750
NCT01958788,Testing Beliefs About Uncertainty in the Treatment of Generalized Anxiety Disorder,,Completed,Has Results,Generalized Anxiety Disorder,Behavioral: Cognitive-Behavioural Treatment,"Clinician's Severity Rating (CSR) Scale of Anxiety Disorders Interview Schedule for DSM-IV (ADIS-IV)|Worry and Anxiety Questionnaire (WAQ)|Intolerance of Uncertainty Scale (IUS)|Penn State Worry Questionnaire (PSWQ)|GAD Safety Behaviours Questionnaire (GAD-SBQ)|Beck Anxiety Inventory (BAI)|Beck Depression Inventory, 2nd Edition (BDI-II)","Concordia University, Montreal|Canadian Institutes of Health Research (CIHR)|Hopital du Sacre-Coeur de Montreal",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,7,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MOP-69066-620,Sep-13,Dec-14,Dec-14,9-Oct-13,23-Feb-16,23-Feb-16,"Concordia University, Montreal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT01958788
NCT01955954,Using the Canary Breathing System for Panic Disorder Patients,,Completed,Has Results,Panic Disorder,Device: Canary Breathing System,Percent of Subjects Achieving a 40% Decrease in Overall PDSS Score (Clinically Significant Response)|Percent of Subjects Achieving Zero Panic Attacks Reported in Previous Week,"Palo Alto Health Sciences, Inc.",All,18 Years to 60 Years   (Adult),Not Applicable,69,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PAHS 1-001-13,Sep-13,May-16,May-16,8-Oct-13,6-Feb-18,6-Feb-18,"San Francisco Bay Area Center for Cognitive Therapy, Oakland, California, United States|Institute of Living, Hartford, Connecticut, United States|Alexian Brothers Center for Anxiety and OCD, Hoffman Estates, Illinois, United States|Kansas City Center for Anxiety Treatment, P.A., Overland Park, Kansas, United States",,https://ClinicalTrials.gov/show/NCT01955954
NCT01956344,Neural Mechanisms of CBT Response in Hoarding Disorder,,"Active, not recruiting",No Results Available,Obsessive Compulsive Disorder,Behavioral: Cognitive Behavioral Therapy,Saving Inventory-Revised (SI-R)|Clinician Global Impression (CGI) Severity (Self Report and Clinician Administered),Hartford Hospital|National Institute of Mental Health (NIMH),All,20 Years to 60 Years   (Adult),Not Applicable,128,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment",1R01MH101163-01,Jul-13,Jun-18,Jun-19,8-Oct-13,null,2-Aug-18,"Anxiety Disorders Center, Institute of Living, Hartford, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT01956344
NCT01953042,Benefits of a Psychoeducation Program for Those Awaiting Treatment for OCD and OCD Spectrum Disorders,,Withdrawn,No Results Available,Obsessive-Compulsive Disorder|Anxiety Disorders,Behavioral: Psychoeducation,Change in Symptom Severity from Baseline in OCD and Spectrum Measures|Change in Quality of Life from Baseline,Sunnybrook Health Sciences Centre,All,"Child, Adult, Older Adult",Not Applicable,0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,279-2013,Sep-13,Mar-14,Mar-14,30-Sep-13,null,6-Sep-18,"Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT01953042
NCT01948895,Desvenlafaxine Monotherapy in Dysthymia,,Completed,No Results Available,Dysthymic Disorder,Drug: Desvenlafaxine,Montgomery-Åsberg Depression Rating Scale|Clinical Global Impression Scale|Health and Work Performance Questionnaire|Perceived Stress Scale|Quality of Life Enjoyment and Satisfaction Scale Quality of Life Enjoyment and Satisfaction Scale Quality of Life Enjoyment and Satisfaction Questionnaire|Quick Inventory of Depressive Symptomatology|Survey of Coping Profiles Endorsed|Sheehan Disability Scale|Work Productivity and Activity Impairment Questionnaire,Centre for Addiction and Mental Health,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,30,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,124/2012,Aug-12,Jun-14,Jun-14,24-Sep-13,null,7-Nov-14,"Medical Research Associates, Mississauga, Ontario, Canada|Centre for Addiction and Mental Health, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT01948895
NCT01949038,Alprazolam as Conscious Sedation for Upper Gastrointestinal Endoscopy,,Completed,No Results Available,Diagnostic Esophagogastroduodenoscopy,Drug: Oral alprazolam|Drug: Sublingual alprazolam|Drug: Oral placebo|Drug: Sublingual placebo,Procedure related pain/discomfort|Pre-procedure anxiety|Patients' satisfaction|Compliance|Duration of the procedure|Side effects,Isfahan University of Medical Sciences,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2|Phase 3,220,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Prevention",391009,Sep-11,Oct-12,Jan-13,24-Sep-13,null,18-Oct-13,"Private Outpatient Clinic of Gastroenterology, Isfahan, Iran, Islamic Republic of",,https://ClinicalTrials.gov/show/NCT01949038
NCT01949753,Influence of Pregnenolone on Exposure Therapy in Obsessive-compulsive Disorder,P-EX,Recruiting,No Results Available,Obsessive-compulsive Disorder (OCD),Behavioral: Exposure therapy with pharmacological facilitation|Behavioral: Exposure therapy,Subjective units of distress (SUD)|Low/high frequency index of heart rate variability (L/HFI),Universitätsklinikum Hamburg-Eppendorf,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,60,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",PV4398,Sep-13,Dec-17,Dec-18,24-Sep-13,null,3-Aug-17,"University Hospital Hamburg-Eppendorf, Hamburg, Germany",,https://ClinicalTrials.gov/show/NCT01949753
NCT01948622,Anxiety Control by Erythrina Mulungu,,Completed,No Results Available,Dental Anxiety|Impacted Third Molar Tooth,Drug: Mulungu|Drug: Placebo,Changes in anxiety report|Changes in blood pressure|Changes in heart rate|Changes in oxygen saturation,"Liane Maciel de Almeida Souza|University of Campinas, Brazil|Universidade Federal de Sergipe",All,18 Years to 35 Years   (Adult),Phase 1|Phase 2,30,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Mulungu-401-2011,Jan-12,Jun-12,Nov-12,23-Sep-13,null,23-Sep-13,"Federal University of Sergipe, Aracaju, Sergipe, Brazil",,https://ClinicalTrials.gov/show/NCT01948622
NCT01947179,Cognitive Anxiety Sensitivity Treatment for Suicide,CAST,Completed,No Results Available,Anxiety,Behavioral: Anxiety Risk Reduction,Anxiety Sensitivity Index (ASI)|Beck Suicide Scale (BSS),Florida State University|United States Department of Defense,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,108,Other|U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,3969,Sep-11,Jan-13,Feb-13,20-Sep-13,null,26-Sep-13,"Florida State University, Tallahassee, Florida, United States",,https://ClinicalTrials.gov/show/NCT01947179
NCT01947647,Transdiagnostic Psychotherapy for Veterans With Mood and Anxiety Disorders,TBT-RCT,Completed,No Results Available,Major Depressive Disorder|Persistent Depressive Disorder|Posttraumatic Stress Disorder|Panic Disorder|Social Phobia|Specific Phobia|Generalized Anxiety Disorder|Obsessive Compulsive Disorder,Behavioral: Transdiagnostic Behavior Therapy|Behavioral: Behavioral Activation Therapy,Change in Albany Panic and Phobia Questionnaire|Anxiety Disorder Interview Schedule-5|Depression Anxiety Stress Scales 21-Item Version|Illness Intrusiveness Ratings Scale|Satisfaction with Therapy and Therapist Scale - Revised|State-Trait Inventory for Cognitive and Somatic Anxiety - Trait Version,VA Office of Research and Development,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,105,U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,MHBA-018-13S|CX000845,17-Nov-14,1-Jun-18,31-Dec-18,20-Sep-13,null,11-Jan-19,"Ralph H. Johnson VA Medical Center, Charleston, SC, Charleston, South Carolina, United States",,https://ClinicalTrials.gov/show/NCT01947647
NCT01944423,Enhancing Panic and Smoking Reduction Treatment With D-Cycloserine,DCS/PSRT,Completed,No Results Available,Nicotine Addiction|Panic Attack,Drug: d-cycloserine|Drug: Pill Placebo|Drug: Nicotine replacement therapy|Behavioral: Panic and Smoking Reduction Treatment,Smoking Status,University of Texas at Austin,All,"18 Years to 65 Years   (Adult, Older Adult)",Early Phase 1,80,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",R34DA034658,Oct-13,Oct-18,Oct-18,17-Sep-13,null,15-Feb-19,"University of Texas at Austin, Austin, Texas, United States",,https://ClinicalTrials.gov/show/NCT01944423
NCT01941693,A Randomized Controlled Trial of Structured Stepped-care Intervention for Psychiatric Comorbidity,,Completed,No Results Available,Alcohol Dependence|Anxiety|Depression,Behavioral: Integrated care|Behavioral: Usual care,Alcohol consumption|Time to lapse|amount of alcohol consumption|Improvement in depressive or anxiety symptoms|Diagnosis severity,South West Sydney Local Health District|University of Sydney,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,86,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,X05-0279,Mar-07,Dec-10,Mar-13,13-Sep-13,null,13-Sep-13,"Drug Health Services, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia",,https://ClinicalTrials.gov/show/NCT01941693
NCT01941862,Depression and Anxiety Reduction Treatment for Suicide,DARTS,Completed,No Results Available,Anxiety|Depression|Suicide,Behavioral: Psychoeducation and Cognitive Bias Modification,Interpersonal Needs Questionnaire (INQ)|Anxiety Sensitivity Index-3 (ASI-3),Florida State University|United States Department of Defense,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,300,Other|U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,W81XWH-10-2-0181,Nov-13,Sep-17,Sep-17,13-Sep-13,null,19-Jun-18,"Florida State University, Tallahassee, Florida, United States",,https://ClinicalTrials.gov/show/NCT01941862
NCT01939210,Meditation-Based Breathing Training in Improving Target Motion Management and Reducing Distress in Patients With Abdominal or Lung Cancer Undergoing Radiation Therapy,,Terminated,No Results Available,Anxiety|Depression|Digestive System Neoplasm|Lung Neoplasm|Pain|Post-Traumatic Stress Disorder|Psychological Impact of Cancer,Other: Educational Intervention|Other: Meditation Therapy|Other: Questionnaire Administration,"Change in duty cycle, defined as the fraction of the time of the breathing cycle that the beam is on, before and after breath coaching|Changes in gate width|Changes in the length of the end expiration or end inspiration defined as when the breathing trace or internal motion change direction|Change in patients' self-reported levels of psychological distress, physical pain and discomfort, and post-traumatic stress associated with cancer diagnosis and radiation treatment",Albert Einstein College of Medicine|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,17,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,09-12-392|NCI-2013-01127|09-068|P30CA013330,Feb-10,Jun-15,2-Dec-15,11-Sep-13,null,18-May-18,"Albert Einstein College of Medicine, Bronx, New York, United States",,https://ClinicalTrials.gov/show/NCT01939210
NCT01938937,The Effect of Acute Transcranial Bright Light on Anxiety Symptoms,,Completed,No Results Available,Anxiety,Device: Transcranial bright light device|Device: Transcranial sham device,Change in total score of STAI-Y1,University of Oulu|Valkee Oy,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,60,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ANX-a,Mar-12,Feb-14,Feb-14,10-Sep-13,null,26-Feb-14,"Oulu University, Oulu, Finland",,https://ClinicalTrials.gov/show/NCT01938937
NCT01933191,Exercise Treatment of Dental Anxiety,,Completed,No Results Available,Dental Anxiety,Behavioral: Aerobic treadmill exercise|Behavioral: placebo exercise,Change from Baseline in VAS - visual analog scale|Change from Baseline in cortisol level|Change from Baseline in alpha-Amylase,"Charite University, Berlin, Germany",All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,30,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",221014,Aug-11,Sep-13,Oct-13,2-Sep-13,null,9-Feb-15,"Department of Psychiatry and Psychotherapy Campus Charité Mitte, Berlin, Germany",,https://ClinicalTrials.gov/show/NCT01933191
NCT01933243,Treatment of Anxiety and Anorexia Nervosa in Adolescents,TAANA,Completed,Has Results,Anxiety|Anorexia Nervosa,Drug: Fish oil|Drug: Placebo pill,Medication Side Effects Score|Beck Anxiety Inventory—Trait (BAIT),Andrea Bonny|Nationwide Children's Hospital,All,"12 Years to 21 Years   (Child, Adult)",Phase 2,24,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",TAANA-287112,Aug-13,Dec-16,Dec-16,2-Sep-13,23-Apr-18,23-Apr-18,"Nationwide Children's Hospital, Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT01933243
NCT01933789,Improving Communication About Serious Illness,ICSI,Completed,Has Results,"Critical Illness|Chronic Disease|Terminal Care|Palliative Care|Communication|Advance Care Planning|Neoplasm Metastasis|Lung Neoplasms|Pulmonary Disease, Chronic Obstructive|Heart Failure|End Stage Liver Disease|Kidney Failure, Chronic",Behavioral: Communication Feedback Form for Patients with Serious Illness,"Occurrence of Discussion About Goals of Care at Target Visit|Occurrence of Discussion About Goals of Care at Target Visit Among Patients Who Did Not Object to Future Discussion at Baseline|Goal-Concordant Care|Goal-Concordant Care Among Patients With Stable Treatment Preference|Quality of Communication (QOC): Four-Indicator Latent Construct|Quality of Communication (QOC): Individual QOC Items|Patient Health Questionnaire (PHQ-8): Two-Indicator Latent Construct|Patient Health Questionnaire (PHQ-8): Eight-Item Scale|Generalized Anxiety Disorder (GAD-7): Two-Indicator Latent Construct|Generalized Anxiety Disorder (GAD-7): Seven-Item Scale|Avoidance of Life-Sustaining Therapies, All Patients|Avoidance of Life-Sustaining Therapies, Patients With Comfort Care Preference|Palliative Care Consultation, Inpatient Stay - All Patients|Palliative Care Consultation, Inpatient Stay - Patients Most Likely to Benefit|Palliative Care Referral, Outpatient Visit - All Patients|Palliative Care Referral, Outpatient Visit - Patients Most Likely to Benefit|Palliative Care Consultation and/or Referral - All Patients|Palliative Care Consultation and/or Referral - Patients Most Likely to Benefit",University of Washington|Patient-Centered Outcomes Research Institute,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,817,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,44023,Sep-13,Dec-16,Dec-16,2-Sep-13,11-Feb-19,20-Mar-19,"Valley Medical Center, Renton, Washington, United States|Harborview Medical Center, Seattle, Washington, United States|Swedish Medical Center, Seattle, Washington, United States|Northwest Hospital and Medical Center, Seattle, Washington, United States|University of Washington Medical Center, Seattle, Washington, United States|UW Neighborhood Clinics, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT01933789
NCT01933919,A Phase 3 Study of Fluvoxamine (SME3110) in Pediatric/Adolescent Patients With Obsessive Compulsive Disorder,,Completed,Has Results,Obsessive Compulsive Disorder,Drug: Fluvoxamine maleate|Drug: Placebo,Mean Change From Baseline in the Japanese Children's Yale-Brown Obsessive Compulsive Scale 10-item Total Score at the End of Treatment in the First Phase|Mean Change From Baseline in the JCY-BOCS 10-item Total Score at the End of Treatment in the First Phase Stratified by Age|Mean Change From Baseline in the JCY-BOCS 10-item Total Score at the End of Treatment in the First Phase Stratified by Gender|Mean Change From Baseline in the JCY-BOCS 10-item Total Score at Each Visit During the First Phase|JCY-BOCS 10-item Total Score at Each Visit During the First Phase|Percentage of Participants Much Improved in Clinical Global Impression Improvement Assessment During the First Phase|Percentage of Participants With a ≥ 25% Decrease From Baseline in JCY-BOCS (10-item) Total Score at the End of Treatment in the First Phase|Percentage of Participants With a ≥ 35% Decrease From Baseline in JCY-BOCS (10-item) Total Score at the End of Treatment in the First Phase|Mean Change From Baseline in the JCY-BOCS 10-item Total Score at Each Visit During the Second Phase|Percentage of Participants Much Improved in Clinical Global Impression Improvement Assessment During the Second Phase|Number of Participants With Adverse Events During the First Phase|Number of Participants With Adverse Events During the Second Phase,"AbbVie|Meiji Seika Pharma Co., Ltd.",All,"6 Years to 18 Years   (Child, Adult)",Phase 3,38,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",M13-970,14-Aug-13,18-Jun-15,1-Jul-16,2-Sep-13,4-Dec-17,4-Dec-17,,,https://ClinicalTrials.gov/show/NCT01933919
NCT01929720,"Cognitive-Behavioral Intervention for Worry, Uncertainty, and Insomnia for Cancer Survivors",FOCUS,Completed,No Results Available,"Anxiety Disorder|Worry|Uncertainty|Sleep Disorders|Insomnia|Fatigue|Pain|Depression|Cognitive-behavioral Therapy|Psychological Intervention|Esophageal Cancer|Pancreatic Cancer|Leukemia|Lung Cancer|Multiple Myeloma|Ovarian Neoplasm|Stage III or IV Cervical or Uterine Cancer|Stage IIIB, IIIC, or IV Breast Cancer|Glioblastoma Multiforme|Relapsed Lymphoma|Stage III or IV Colorectal Cancer|Stage IIIC or IV Melanoma","Behavioral: Cognitive-behavioral therapy for worry, uncertainty & insomnia",Changes in worry on the Penn State Worry Questionnaire|Changes in sleep efficiency on the Insomnia Severity Index|Changes in intolerance of uncertainty on the Intolerance of Uncertainty Scale|Levels of cortisol|Levels of pro and anti-inflammatory cytokines|Levels of myeloid-derived suppressor cells (MDSC),"Ohio State University Comprehensive Cancer Center|American Cancer Society, Inc.|Lance Armstrong Foundation",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,33,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,OSU-09096|NCI-2012-02879,Aug-11,Sep-14,Sep-14,28-Aug-13,null,5-Apr-17,"Wexner Medical Center at The Ohio State University Department of Psychiatry, Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT01929720
NCT01928758,Reduced Nicotine Cigarettes in Smokers With Mood and Anxiety Disorders,,Completed,Has Results,Tobacco Dependence,Drug: Reduced Nicotine Content Cigarettes|Drug: Usual Nicotine Content Cigarettes,Plasma Cotinine Concentration|Quick Inventory of Depressive Symptomatology|Perceived Stress Scale|Minnesota Nicotine Withdrawal Scale,Milton S. Hershey Medical Center|National Institute on Drug Abuse (NIDA),All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,245,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Health Services Research",STUDY911|P50DA036107,Sep-15,11-Jan-18,23-Mar-18,27-Aug-13,8-Feb-19,2-Apr-19,"Massachusetts General Hospital, Boston, Massachusetts, United States|Penn State College of Medicine, Hershey, Pennsylvania, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/58/NCT01928758/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT01928758
NCT01928810,Physical Activity and Cognitive Behavioural Therapy in Panic Disorder and Agoraphobia,,Completed,No Results Available,Panic Disorder|Agoraphobia,Behavioral: Cognitive Behavioural Therapy,Hamilton Rating Scale for Anxiety (CIPS 1995)|Mobility Inventory (Chambless 1984)|Clinical Global Index (CIPS 1995)|Beck Depression Inventory (CIPS 1995)|Anxiety Sensitivity Index (Taylor 1998)|Body Sensations Questionnaire (Chambless 1984)|Agoraphobic Cognitions Questionaire (Chambless 1984)|Panic and Agoraphobia Scale,"Charite University, Berlin, Germany|German Federal Ministry of Education and Research",All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,78,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment",201015,Mar-11,Feb-14,Feb-14,27-Aug-13,null,9-Feb-15,,,https://ClinicalTrials.gov/show/NCT01928810
NCT01928823,Augmentation of Psychotherapy With D-Cycloserine in Agoraphobia,Exposure-DCS,Completed,No Results Available,Agoraphobia,Behavioral: CBT|Drug: D-Cycloserine,"Panic- and Agoraphobia Rating Scale (PAS)|Beck Anxiety Inventory (BAI)|Clinical Global Index (CGI)|Agoraphobic Cognitions, Body Sensations Questionnaire and Mobility Inventory (AKV)|Anxiety Sensitivity Index (ASI)|Beck Depression Inventory first revised(BDI II)|Brief Symptom Inventory (BSI)","Charite University, Berlin, Germany|German Federal Ministry of Education and Research",All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,73,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",221013,Nov-11,May-14,May-14,27-Aug-13,null,19-May-14,"Department of Psychiatry and Psychotherapy, Charité Campus Mitte - Universitätsmedizin Berlin, Berlin, Germany",,https://ClinicalTrials.gov/show/NCT01928823
NCT01928264,Physical Activity in Insurance Medicine: Effects on Patients With Psychiatric Disorders,PhysActIV,Terminated,No Results Available,Depressive Disorder|Somatoform Disorder|Anxiety Disorder|Personality Disorder,Behavioral: Physical activity,Change in the ability to work (h/d / %)|Change in participation skills (sum score)|Change in psychological functioning (sum scores)|Change in subjective sleep quality (sum score)|Change in subjectively perceived stress (sum score)|Change in Clinical Global Impression (sum score)|Change in Leisure-time physical activity (sum score)|Change in self-efficacy (sum score),"University Hospital, Basel, Switzerland|Psychiatric Hospital of the University of Basel|Institute for Exercise and Health Sciences, University of Basle, Switzerland",All,18 Years to 55 Years   (Adult),Not Applicable,13,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,114/13,Aug-13,Apr-14,Apr-14,23-Aug-13,null,16-Oct-15,"Psychiatric Hospital of the University of Basel, Basel, Switzerland",,https://ClinicalTrials.gov/show/NCT01928264
NCT01926613,Thinking Skills for Work in Severe Mental Illness,TSW,Completed,No Results Available,Schizophrenia|Schizoaffective Disorder|Major Depression|Bipolar Disorder|Anxiety Disorder,Behavioral: Thinking Skills for Work Program|Behavioral: Supported Employment,AMOUNT OF EMPLOYMENT|EXECUTIVE FUNCTIONING AND MEMORY,Dartmouth-Hitchcock Medical Center|National Institute of Mental Health (NIMH),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,110,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,MH077210|1R01MH077210-01,Apr-06,Oct-09,Oct-11,21-Aug-13,null,21-Aug-13,"Thresholds, Inc., Chicago, Illinois, United States|Mental Health Center of Greater Manchester, Manchester, New Hampshire, United States",,https://ClinicalTrials.gov/show/NCT01926613
NCT01920685,Computerised Interventions for Thinking and Anxiety in Delusions (CITADEL) Trial,CITADEL,Completed,No Results Available,Paranoia in People With Schizophrenia-spectrum Diagnosis,Other: Anxiety intervention,Green Paranoid Thoughts Scale,King's College London,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,25,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,13/LO/0690,Jan-14,Oct-16,Oct-16,12-Aug-13,null,20-Mar-17,"Oxleas NHS Foundation Trust, Dartford, Kent, United Kingdom|South London & Maudsley NHS Foundation Trust, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01920685
NCT01919970,Exposure-Focused Family-Based CBT for Youth With ASD and Comorbid Anxiety,,Completed,No Results Available,Autism|Asperger's Syndrome|Pervasive Developmental Disorder Not Otherwise Specified|Generalized Anxiety Disorder|Social Phobia|Separation Anxiety Disorder|Obsessive-compulsive Disorder|Specific Phobia,Other: Cognitive Behavioral Therapy|Other: Treatment as usual,Pediatric Anxiety Rating Scale|Clinical Global Impression - Severity Scale,University of South Florida,All,6 Years to 12 Years   (Child),Not Applicable,50,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,ASD-FET 2013,Aug-13,Aug-16,Aug-17,9-Aug-13,null,26-Oct-17,"Rothman Center for Neuropsychiatry, Saint Petersburg, Florida, United States",,https://ClinicalTrials.gov/show/NCT01919970
NCT01914874,Efficacy of a Mindfulness Meditation Program for Social Anxiety Disorder,,Completed,No Results Available,Social Anxiety Disorder,Behavioral: Mindfulness Meditation,Clinician-rated Liebowitz Social Phobia Scale|Social Phobia Inventory|Beck Depression Inventory|Social Adjustment Scale-Self-Report|CGI-Severity of Illness|Self-Compassion Scale|Five Facet Mindfulness Questionnaire,Hopital Montfort,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,39,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,DK-05-02-13,Jul-13,Jan-15,Jan-15,2-Aug-13,null,1-Jul-15,"Montfort Hospital, Ottawa, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT01914874
NCT01912287,GATE: Generalized Anxiety - A Treatment Evaluation,,Recruiting,No Results Available,Generalized Anxiety Disorder,Behavioral: Cognitive Behavioral Therapy|Behavioral: Stress Education|Behavioral: Yoga,Treatment Response as Assessed by the Clinical Global Impression-Improvement (CGI-I of 1 or 2) scale|Structured Interview Guide for the Hamilton Anxiety Rating Scale (SIGH-A),New York University School of Medicine|National Center for Complementary and Integrative Health (NCCIH),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,230,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,s17-00526|1R01AT007258-01A1,Dec-13,31-Mar-19,31-Mar-19,31-Jul-13,null,15-Feb-19,"Massachusetts General Hospital, Boston, Massachusetts, United States|Boston University, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT01912287
NCT01912391,Clinical Research Study to Evaluate Selegiline in the Treatment of Borderline Personality Disorder,,Completed,No Results Available,Borderline Personality Disorder,Drug: Selegiline|Drug: Placebo (for Selegiline),Primary Efficacy Measurement: Changes in the Hopkins Symptom Checklist 90-Revised (SCL 90-R) scale|Secondary Efficacy Measurement: Change in Hamilton Depression Inventory 17 Questions (HAM-D)|Clinical Global Impression of Change- Clinician (CGIc)|Clinical Global Impression Change- Patient (CGIp)|Sheehan Disability Scale (SDS),"Mood and Anxiety Research, Inc",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,30,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",PJM-01|WV26504-4245,Oct-12,Mar-15,Mar-15,31-Jul-13,null,8-Oct-15,"Mood and Anxiety Research, Inc, Fresno, California, United States",,https://ClinicalTrials.gov/show/NCT01912391
NCT01911351,Nitrous Oxide Use in Minor Procedures,,Completed,Has Results,Laceration|Abscess,Drug: Nitrous Oxide,FLACC Pain Scale|M-YPAS Anxiety Scale,New York City Health and Hospitals Corporation,All,3 Years to 12 Years   (Child),Not Applicable,82,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2013-296,Jul-13,Jun-14,Jun-14,30-Jul-13,11-Apr-16,11-Apr-16,"Jacobi Medical Center, Bronx, New York, United States",,https://ClinicalTrials.gov/show/NCT01911351
NCT01909167,Keeping Well:Online Cognitive Behavioral Therapy (CBT) for Pregnant Women With Depressive Symptoms,OnCBTDep,Unknown status,No Results Available,Anxiety|Mental Disorders|Postpartum Depression|Depressive Symptoms,Behavioral: Online Cognitive Behavioral Therapy (CBT)|Other: Treatment as usual,Changes in the Edinburgh Postnatal Depression Scale (EPDS)scores from 20 weeks antenatal to 10 weeks postnatal|Compliance and dropout rates from 20 weeks antenatal to 4 weeks postnatal|Changes in anxiety scores from 20 weeks antenatal to 10 weeks postnatal|Changes in bonding scores at 10 weeks postnatal,Imperial College London,Female,18 Years to 40 Years   (Adult),Not Applicable,120,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,13IC0475,Dec-14,Dec-15,Jan-16,26-Jul-13,null,6-Mar-14,"Queen Charlotte's and Chelsea Hospital, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01909167
NCT01909193,CBT vs. ABM vs. for Social Anxiety,,Completed,No Results Available,Social Phobia,Behavioral: Attention Bias Modification (ABM)|Behavioral: Cognitive Behavior Therapy,Liebovitz Social Anxiety Scale (LSAS) - diagnostic interview|Social Phobia Inventory (SPIN) - self-report questionnaire,Hebrew University of Jerusalem|Israel Science Foundation,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,69,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,1624,Jan-11,Jul-14,Nov-14,26-Jul-13,null,23-Feb-16,"The Hebrew University of Jerusalem, Jerusalem, Israel",,https://ClinicalTrials.gov/show/NCT01909193
NCT01908127,Efficacy of Film Modelling in Paediatric Dentistry,,Completed,Has Results,Cooperative Behaviour|Dental Anxiety,Behavioral: tell- show- do|Behavioral: film modelling|Drug: injection of local anesthesia solution|Procedure: occlusal cavity preparation,Behaviors of Children|Index of Heart Rate,Zahedan University of Medical Sciences,All,4 Years to 6 Years   (Child),Not Applicable,50,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)",1382,Sep-10,Feb-11,Apr-11,25-Jul-13,20-Jan-14,20-Jan-14,"Zahedan Dental School, Zahedan, Iran, Islamic Republic of",,https://ClinicalTrials.gov/show/NCT01908127
NCT01908205,Intranasal Oxytocin for the Treatment of Children and Adolescents With Autism Spectrum Disorders (ASD),OXY-R,Completed,No Results Available,Autism Spectrum Disorder,Drug: Intranasal Oxytocin|Drug: Placebo,Efficacy of intranasal oxytocin vs. placebo on measures of social function|Efficacy of intranasal oxytocin vs. placebo on measures of social cognition|Efficacy of intranasal oxytocin vs. placebo on measures of repetitive behaviors|Efficacy of intranasal oxytocin vs. placebo on measures of anxiety|Efficacy of intranasal oxytocin vs. placebo on measures of quality of life|Safety and tolerability of intranasal oxytocin in children and adolescents with ASD,"Evdokia Anagnostou|United States Department of Defense|Anagnostou, Evdokia, M.D.",All,10 Years to 17 Years   (Child),Phase 2,60,Other|U.S. Fed,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",OXY-R07-2013,Sep-13,Sep-15,Mar-16,25-Jul-13,null,20-Mar-17,"University of Minnesota, Minneapolis, Minnesota, United States|Holland Bloorview Kids Rehabilitation Hospital, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT01908205
NCT01906268,Attention Retraining for Anxiety Disorder Patients Resistent to Antidepressants,,Unknown status,No Results Available,Generalized Anxiety Disorder|Social Anxiety Disorder|Panic Disorder,Other: Attentional Bias Modification Treatment (ABMT) - Active|Other: Attentional Bias Modification Treatment - Placebo,"Overall Anxiety Severity and Impairment Scale (OASIS)|Panic Disorder Severity Scale (PDSS), Generalized Anxiety Disorder 7-item Scale (GAD-7) or Liebowitz Social Anxiety Scale (LSAS)|Beck Depression Inventory (BDI)|Beck Anxiety Inventory (BAI)|DSM-5 Cross-Disorder Dimensional Scale [Brazilian version]|Profile of Mood States (POMS)|Clinical Global Impression(CGI)",Hospital de Clinicas de Porto Alegre,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",13-0338,Jul-13,Dec-14,null,24-Jul-13,null,21-Jul-14,"Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil|Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil",,https://ClinicalTrials.gov/show/NCT01906268
NCT01907035,Anxiety-depressive Disorder in Primary Care and Cognitive-behavioral Treatment,PSICCAPAD,Unknown status,No Results Available,Anxiety-depressive Patients Mild to Moderate,Behavioral: A cognitive-behavioral intervention|Other: Usual care,Life Quality|Use of pharmacotherapy and sanitary services,Basque Health Service,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,246,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PSICCAPAD 2012|2011111064,Aug-12,Sep-13,Dec-15,24-Jul-13,null,24-Jul-13,"Comarca Ezkerraldea, Barakaldo, Bizkaia, Spain|Comarca Bilbao, Bilbao, Bizkaia, Spain|Comarca Uribe, Leioa, Bizkaia, Spain",,https://ClinicalTrials.gov/show/NCT01907035
NCT01903096,Treating Emotional Disorders in Primary Care With Psychological Techniques,PsychPC,Recruiting,No Results Available,Anxiety Disorders|Mood Disorders|Somatization Disorder|Pain Disorder,Behavioral: Cognitive Behavioral Treatment|Drug: Primary Care Treatment As Usual,Anxiety symptoms after psychological treatment versus Primary Care usual treatment.|Depressive symptoms after psychological treatment versus Primary Care usual treatment.|Somatic symptoms after psychological treatment versus Primary Care usual treatment.|Cognitive factors after psychological treatment versus Primary Care usual treatment.|Level of impairment after psychological treatment versus Primary Care usual treatment.|Quality of life after psychological treatment versus Primary Care usual treatment.|Frequency of primary care visits after psychological treatment versus Primary Care usual treatment.,"Psicofundación: Fundación Española para Promoción, Desarrollo Científico y Profesional de la Psicolo|Ministry of Health, Spain",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,1126,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",AP105162012|2013-001955-11,Mar-14,Dec-18,Dec-19,19-Jul-13,null,5-Apr-17,"Complutense University of Madrid, Madrid, Spain",,https://ClinicalTrials.gov/show/NCT01903096
NCT01903447,Negative Valence Brain Targets and Predictors of Anxiety and Depression Treatment,,Completed,No Results Available,Internalizing Psychopathologies (IPs) Depression and Anxiety,Drug: SSRI|Behavioral: CBT,Brain NVS Construct Measure (Composite),University of Illinois at Chicago|National Institutes of Health (NIH)|National Institute of Mental Health (NIMH),All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,271,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,2013-0325|R01MH101497,13-Dec-13,21-Feb-18,21-Feb-18,19-Jul-13,null,11-Oct-18,"University of Illinois at Chicago, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT01903447
NCT01902966,Feasibility - Beta Adrenergic Blockade (BB) in Cervical Cancer (CX),,"Active, not recruiting",No Results Available,Cervical Cancer,Drug: Propranolol|Behavioral: Diary|Behavioral: Relaxation Audio Recording|Behavioral: Questionnaires,Proportion of Patients Completing Symptom Inventories,M.D. Anderson Cancer Center,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,20,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,2013-0113|NCI-2013-02078|G-12-300,Sep-13,Sep-19,Sep-20,18-Jul-13,null,20-May-19,"Lyndon B. Johnson General Hospital (LBJ), Houston, Texas, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT01902966
NCT01901003,Sedative Premedication: Efficacy On Patient Experience,PremedX,Completed,No Results Available,Perioperative Anxiety,Drug: Lorazepam|Other: no premedication|Drug: Placebo (microcrystalline celluloses),the EVAN score|the perioperative level of anxiety,Assistance Publique Hopitaux De Marseille,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,1200,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",2011-005171-16|2011-32,Nov-12,Jun-14,Jun-14,17-Jul-13,null,21-Apr-15,"Assistance Publique Hopitaux de Marseille, Marseille, France",,https://ClinicalTrials.gov/show/NCT01901003
NCT01901796,Integrated Maternal Psychosocial Assessment to Care Trial (IMPACT) Full Trial,,Recruiting,No Results Available,Anxiety|Depression,Behavioral: Cognitive Behavioral Therapy,"The primary outcome of this study is the feasibility/acceptability of integrated psychosocial care and its components.|Maternal depression, anxiety, stress|Maternal coping|Relationship Adjustment|Parenting Stress|Parenting competence|Maternal-infant attachment|Trait anxiety","University of Calgary|Norlien Foundation|Women and Children's Health Research Institute, Canada",Female,"16 Years and older   (Child, Adult, Older Adult)",Not Applicable,54,Other,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment",36912,Jan-14,Dec-20,Dec-20,17-Jul-13,null,17-Jul-18,"Westview Health Centre, Stony Plain, Alberta, Canada",,https://ClinicalTrials.gov/show/NCT01901796
NCT01900301,Generalization of Extinction Learning,,Recruiting,No Results Available,Social Anxiety Disorder,Drug: Scopolamine|Drug: intranasal placebo,Eye blink startle reflex|Skin conductance responses and heart rate|Subjective Units of Distress|Self Statements During Public Speaking Scale|Personal Report of Confidence as a Speaker Scale|Subjective units of distress during in vivo speech,"University of California, Los Angeles",All,18 Years to 55 Years   (Adult),Phase 1,100,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MH101359-01,Aug-13,Jun-19,Jun-19,16-Jul-13,null,20-Aug-18,"University of California, Los Angeles, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT01900301
NCT01899001,Mood and Nutrition Interventions in Polycystic Ovary Syndrome,MANI-PCOS,Completed,No Results Available,Polycystic Ovary Syndrome (PCOS),Behavioral: Cognitive Behavioral Therapy|Behavioral: Nutrition Counseling,Assess change in mood symptoms after Cognitive Behavioral Therapy (CBT) and nutritional/exercise counseling compared to nutritional/exercise counseling alone.|Assess change in cardio metabolic risk factors after Cognitive Behavioral Therapy (CBT) and nutritional/exercise counseling compared to nutritional/exercise counseling alone.|Assess change in perceived stress and stress response after Cognitive Behavioral Therapy (CBT) and nutritional/exercise counseling compared to nutritional/exercise counseling alone.,University of Pennsylvania,Female,18 Years to 45 Years   (Adult),Not Applicable,40,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,818103,Jul-13,Aug-16,null,15-Jul-13,null,23-Nov-16,"Penn PCOS Center, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT01899001
NCT01899534,Mental Health E-screening in Pregnant and Postpartum Women,,Completed,No Results Available,Depression|Anxiety,Other: E-screening,The primary outcome is feasibility/acceptability of the process of e-screening (vs 'usual' screening).|Proportion of pregnant and postpartum women with clinical depression and anxiety.|Depression and anxiety|Cost-effectiveness of e-screening,University of Calgary|Canadian Institutes of Health Research (CIHR),Female,"16 Years and older   (Child, Adult, Older Adult)",Not Applicable,566,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Screening,39130,Jul-13,Dec-14,Dec-14,15-Jul-13,null,26-Oct-16,"Dickensfield Primary Care Maternity Clinic, Edmonton, Alberta, Canada|Royal Alexandra Hospital: Lois Hole Hospital for Women, Edmonton, Alberta, Canada|Sturgeon Primary Care Maternity Clinic, St. Albert, Alberta, Canada",,https://ClinicalTrials.gov/show/NCT01899534
NCT01892306,Pilot Study of Cognitive Behavioral Therapy for Anxiety and Bipolar I Disorder,,Completed,Has Results,Bipolar Disorder|Anxiety Disorders,Behavioral: UP CBT|Drug: Treatment as usual,Reductions Over Time in Anxiety Symptoms as Measured by Hamilton Anxiety Rating Scale|Reductions Over Time in Depression Symptoms as Measured by Hamilton Depression Rating Scale (HAM-D)|Treatment Acceptability as Measured by Client Satisfaction Questionnaire (CSQ)|Association Between Anxiety Symptom Change (HAM-A) and Difficulties in Emotion Regulation Scale (DERS)|Association Between Anxiety Symptom Change (HAM-A) and Reaction to Emotions (Affective Control Scale-ACS)|Association Between Anxiety Symptom Change (HAM-A) and Anxiety Sensitivity (Anxiety Sensitivity Index-ASI)|Association Between Anxiety Symptom Change (HAM-A) and Neuroticism (NEO Five-Factor Inventory- NEO-FFI-N),Massachusetts General Hospital,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,34,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,1F32MH098490-01,Jun-13,Dec-14,Dec-14,4-Jul-13,12-May-17,12-May-17,"Massachusetts General Hospital Bipolar Clinic and Research Program, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT01892306
NCT01891734,Enhancing Delivery of Problem Solving Therapy Using SmartPhone Technology,,Completed,Has Results,Depression|Anxiety,Other: Problem Solving Therapy plus Moving Forward|Other: Problem Solving Therapy,Depression Anxiety and Stress Scale (DASS)|Short Form Health Survey-12-Veterans (SF-12 V) Mental Composite Score|Client Satisfaction Questionnaire (CSQ-8),VA Office of Research and Development,All,18 Years to 64 Years   (Adult),Phase 1|Phase 2,33,U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,PPO 13-122,Apr-14,Mar-15,Mar-15,3-Jul-13,16-Sep-16,28-Nov-16,"Central Arkansas Veterans Healthcare System Eugene J. Towbin Healthcare Center, Little Rock, AR, No. Little Rock, Arkansas, United States",,https://ClinicalTrials.gov/show/NCT01891734
NCT01889342,Metacognitive Therapy Versus Cognitive Behavioral Therapy for Mixed Anxiety Disorders: A Randomized Controlled Trial.,,Completed,No Results Available,Mixed Anxiety Disorders,Behavioral: Metacognitive therapy|Behavioral: Cognitive behavioral therapy,"Anxiety Disorders Interview Schedule for DSM-IV-Lifetime Version|Beck Anxiety Inventory (BAI)|The Symptom Checklist 90(SCL90; Derogatis et al., 1996)|The Patient Health Questionnaire depression module (PHQ 9; Spitzer et al., 1999)|Metacognitions Questionnaire- 30 (MCQ-30; Wells & Cartwright-Hatton, 2003)|Working Alliance Inventory (WAI; Horwath & Greenberg, 1989)|Cognitive attentional syndrome 1 (CAS1; Wells, 2009)|The Repetitive Thinking Questionnaire(RTQ; McEvoy et al., 2010)|PTSD Symptom scale Self Report (PSSR; Foa et al., 1993)|Social Phobia Inventory (SPIN; Connor et al., 2000)|Mobility inventory (MI; Chambless, 1985)|SF 36|The Penn State Worry Questionnaire (PSWQ; Meyer, Miller, Metzger & Borkovec, 1990)|Youngs Schema Questionnaire YSQ -75 (Young, 1998)|The Inventory of Interpersonal Problems (IIP 64 C; Horowitz et al., 1988)|Dysfunctional emotion regulations scale (DERS; Graz & Roemer, 2004)",Modum Bad,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,90,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,SveJoh 1,Aug-13,Dec-15,Dec-15,28-Jun-13,null,8-Mar-16,"Modum Bad, Vikersund, Buskerud, Norway",,https://ClinicalTrials.gov/show/NCT01889342
NCT01886716,Retraining Attention to Treat Alcohol Dependence and Social Anxiety,AMP,Completed,Has Results,Alcohol Drinking|Anxiety Disorders,Behavioral: Anxiety Attention Training|Behavioral: Alcohol Attention Training|Behavioral: Control Training,Liebowitz Social Anxiety Scale|The Daily Drinking Questionnaire,University of Cincinnati|Miami University|Brown University|National Institute on Alcohol Abuse and Alcoholism (NIAAA),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,115,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",1R21AA021151,Jul-13,Dec-14,Dec-14,26-Jun-13,28-Dec-16,28-Dec-16,"University of Cincinnati Department of Family and Community Medicine, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT01886716
NCT01883739,Randomised Controlled Trial to Investigate the Effect of Parental Presence at Intensive Care Unit to Ward Transfer Bedside Rounds on Parental Anxiety and Children's Safety,,Completed,No Results Available,Parental Anxiety|Children's Safety,Other: Parental Presence at Handover Rounds,Change from baseline in parental STAI score|Rate of unplanned changes in medication and nutrition management,University of Alberta|Canadian Medical Protective Association,All,"Child, Adult, Older Adult",Not Applicable,200,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care,Pro 00037475,Jun-13,Jul-14,null,21-Jun-13,null,19-Dec-14,"Pediatric Cardiac ICU, Stollery Children's Hospital, Edmonton, Alberta, Canada",,https://ClinicalTrials.gov/show/NCT01883739
NCT01879826,Pediatric Laser Acupuncture and Renal Biopsy,,Unknown status,No Results Available,Pain|Anxiety,Device: Aculaser applied to kidney points|Device: Aculaser applied to sham points,patient pain/anxiety|Medication amount,"University of California, San Francisco",All,"7 Years to 25 Years   (Child, Adult)",Not Applicable,120,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care",Laser,Jul-13,Apr-15,Jun-16,18-Jun-13,null,2-Dec-15,"University of California San Francisco Hospital, San Francisco, California, United States|University of California, San Francisco, San Francisco, California, United States",,https://ClinicalTrials.gov/show/NCT01879826
NCT01875796,Integrated CBT for Cannabis Dependence With Co-occurring Anxiety Disorders,,Completed,No Results Available,Cannabis Dependence|Anxiety Disorders|Cannabis Use Disorder|Cannabis Abuse,Behavioral: Cognitive-Behavioral Therapy|Behavioral: Motivation Enhancement Therapy|Behavioral: Integrated Cannabis and Anxiety Reduction Treatment|Behavioral: False Safety Behavior Elimination Therapy,cannabis use|cannabis-related problems|anxiety,Louisiana State University and A&M College|National Institute on Drug Abuse (NIDA),All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,68,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,RDA031937A|1R34DA031937-01,Jun-13,Jul-16,null,12-Jun-13,null,25-Aug-16,"Louisiana State University Anxiety & Addictive Behaviors Clinic, Baton Rouge, Louisiana, United States",,https://ClinicalTrials.gov/show/NCT01875796
NCT01876225,Evaluating Pain and Discomfort Associated With Cervical Punch Biopsy,,Unknown status,No Results Available,Pain|Anxiety,Behavioral: Forced coughing during cervical punch biopsy,The pain associated with cervical biopsy|Length of cervical punch biopsy with and without cough intervention,Carmel Medical Center|THERE ARE NO FUNDING SOURCES TO THE STUDY.,Female,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,90,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,CMC-13-0033-CTIL,Jun-13,Jun-15,Jun-16,12-Jun-13,null,20-May-14,"Carmel Medical Center, Haifa, Israel|Lin Medical Center, Haifa, Israel",,https://ClinicalTrials.gov/show/NCT01876225
NCT01874379,"'M'-Technique, Guided Imagery, or Standard of Care on Anxiety and Pain Pre- & Post-operatively in Elective Joint Replacement Patients",M•TIJRP,Unknown status,No Results Available,Hip or Knee Replacement,Other: 'M'-Technique®|Other: Guided Imagery|Other: Standard of Care,Symptomatic pain relief expressed in Visual Analogue Scales from no pain 0-10 worst possible pain|Symptomatic anxiety relief expressed in Visual Analogue Scales from no anxiety 0-10 worst possible anxiety|Change from Baseline in Hamilton Anxiety Scale at Post Op Day 2|Patient Satisfaction Measure,Saint Clare's Health System|Saint Clare's Foundation,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,225,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,M•TIJRP|WIRB #: 20121832,Dec-12,Jun-14,null,11-Jun-13,null,11-Jun-13,"Saint Clare's Health System, Denville, New Jersey, United States",,https://ClinicalTrials.gov/show/NCT01874379
NCT01874717,Midazolam Sedation in Dentally Anxious Patients,,Completed,No Results Available,Dental Anxiety,Other: Conscious sedation for dental care|Drug: midazolam,Patient level of cooperation which is assessed using the French modified version of Venham scale|The level of patient stress which is assessed using the French modified version of Venham scale|Satisfaction level of the patient which is assessed using the French modified version of Venham scale|Satisfaction level of the accompanying person which is assessed using the French modified version of Venham scale|Satisfaction level of the operator which is assessed using the French modified version of Venham scale,"University Hospital, Clermont-Ferrand",All,"8 Years to 60 Years   (Child, Adult)",Phase 3,131,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CHU-0155,Jun-05,Aug-07,Aug-07,11-Jun-13,null,11-Jun-13,"CHU Clermont-Ferrand, Clermont-Ferrand, France",,https://ClinicalTrials.gov/show/NCT01874717
NCT01873482,Traditional African Healing Ceremony in a U.S. Population,,Completed,No Results Available,Chronic Fatigue Syndrome|Anxiety|Depression|Cancer,Behavioral: Movement to rhythm,"Report from each participant as to whether they found the experience positive, neutral or negative.|written narrative of experience",Duke University,All,"25 Years to 65 Years   (Adult, Older Adult)",Not Applicable,17,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,Pro00042492,May-14,May-14,null,10-Jun-13,null,3-Nov-14,"Duke University, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT01873482
NCT01870843,A Study to Evaluate the Impact of Escitalopram on Quality of Life and Social Functionality in Patients With Major Depressive Disorder With Anxiety Symptom,,Completed,Has Results,"Depressive Disorder, Major",Drug: Escitalopram,"Change in Quality of Life Enjoyment and Satisfaction Questionnaire, Short Form (Q-LES-Q-SF) From Baseline up to Day 56|Change in Sheehan Disability Scale (SDS) From Baseline up to Day 56|Remission Rate Based on Montgomery-Asberg Depression Rating Scale (MADRS) up to Day 56|Treatment Improvement Rate at the End of Week 1 and Week 2|Change in Montgomery-Asberg Depression Rating Scale (MADRS) Scores From Baseline up to Day 56|Change in Hamilton Anxiety Scale (HAM-A) Total Scores From Baseline up to Day 56|Change in Inventory of Depressive Symptomatology, Self-Report (QIDS-SR) Total Scores From Baseline up to Day 56|Depression Response Rate Based on Montgomery-Asberg Depression Rating Scale (MADRS) up to Day 56|Remission Rate Based on Hamilton Anxiety Scale (HAM-A) up to Day 56|Remission Rate Based on Inventory of Depressive Symptomatology, Self-Report (QIDS-SR) up to Day 56",Xian-Janssen Pharmaceutical Ltd.,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,261,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CR100826|ESCITALDEP4005|ESC-C-11-CN-002-V04,Mar-14,May-15,May-15,6-Jun-13,11-Jul-16,11-Jul-16,"Beijing, China|Guangzhou, China|Hangzhou, China|Hohhot, China|Jinan, China|Kunming, China|Nanjing, China|Shijiazhuang, China|Urumqi, China|Xiamen, China",,https://ClinicalTrials.gov/show/NCT01870843
NCT01870076,The Effect of Healing Touch on Sleep,Sleep7,Completed,Has Results,Elective Reconstructive Surgery Population,"Behavioral: Healing Touch|Behavioral: Healing Touch, Sham|Behavioral: Control, Presence",Healing Touch Will Improve Total Sleep Time|Preoperative Cortisol Level,"Shriners Hospitals for Children|Children's Hospital Medical Center, Cincinnati",All,"5 Years to 25 Years   (Child, Adult)",Not Applicable,41,Other,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2015-1253,12-Dec-15,15-May-17,3-Jul-17,5-Jun-13,20-Nov-17,20-Nov-17,"Shriners Hospitals for Children, Cincinnati, Ohio, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/76/NCT01870076/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT01870076
NCT01866605,A Study of Methods to Reduce Anxiety in Preoperative Elective Surgical Patients,,Completed,No Results Available,Anxiety,Drug: Midazolam|Drug: Normal Saline|Device: Bair Hugger,Visual analog scale score for anxiety|Thermal comfort|Recovery from anaesthesia|Satisfaction with care,Melbourne Health,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 4,120,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",HREC 2008.074,Jul-08,May-09,May-09,31-May-13,null,31-May-13,"Royal Melbourne Hospital, Parkville, Victoria, Australia",,https://ClinicalTrials.gov/show/NCT01866605
NCT01863459,Lisdexamfetamine Dimesylate in the Treatment of Adult ADHD With Anxiety Disorder Comorbidity,,Completed,No Results Available,Adult Attention Deficit Hyperactivity Disorder (ADHD) With Co-occuring Anxiety and Depressive Disorders,Drug: Lisdexamfetamine Dimesylate|Drug: placebo,ADHD Rating Scale|Clinical Global Impression - Improvement Scale (CGI-I)|Yale Global Tic Severity Scale (YGTSS)|the Overall Anxiety Severity and Impairment Scale (OASIS)|The Weiss Functional Impairment Rating Scale-Self Report (WFIRS-S)|Barkley Adult ADHD Rating Scale--IV(BAARS-IV)|Revised Padua Inventory|The Panic and Agoraphobia Scale (PAS)|Quick Inventory of Depressive Symptoms (QID-SR-16)|The Sheehan Disability Scale (SDS)|GAD-7|Social Phobia Inventory (SPIN)|The Life Events Questionnaire (LEQ)|The Pittsburgh Sleep Quality Index (PSQI)|Clinical Global Impression - Severity (CGI-S),"Centre for Anxiety, Attention Deficit and Trauma, Ontario, Canada|Shire",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,42,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",LDX-COMORB-1,Apr-13,Mar-17,Mar-17,29-May-13,null,2-Aug-17,"Centre for Anxiety, Attention Deficit and Trauma, Hamilton, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT01863459
NCT01858142,Helping Parents to Decide Whether They Want to be With Their Child During Anesthesia Induction,PPDT,Completed,No Results Available,Pre-operative Anxiety,Behavioral: Parental presence decision tool|Behavioral: Standard preparation,Modified Yale Pre-Operative Anxiety Scale,IWK Health Centre,All,2 Years to 10 Years   (Child),Not Applicable,104,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,1012940,Jun-13,Aug-13,null,21-May-13,null,21-Mar-16,"IWK Health Centre, Halifax, Nova Scotia, Canada",,https://ClinicalTrials.gov/show/NCT01858142
NCT01858298,Conservative Versus Non-conservative Treatment for Severe Dental Caries,,Completed,No Results Available,Dental Caries,Other: Conservative treatment: pulpectomy and composite resin crown|Other: Non-conservative treatment: Tooth extraction,oral health-related quality of life|anthropometric measures|loss of space|dental anxiety|Dental pain,"University of Sao Paulo|University College, London|Federal University of Minas Gerais",All,3 Years to 5 Years   (Child),Not Applicable,100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,usp|2013/10330-8,Dec-13,Mar-14,Mar-15,21-May-13,null,27-May-15,,,https://ClinicalTrials.gov/show/NCT01858298
NCT01858324,Evaluation of Educational Tools for Pregnant Women,,Completed,No Results Available,Preeclampsia,Other: Educational tools,Knowledge about preeclampsia|Anxiety|Satisfaction,Université de Sherbrooke,Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,247,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,13-025,Mar-14,Sep-14,Sep-14,21-May-13,null,4-Dec-14,"Centre Hopitalier Universiatire de Sherbrooke, Sherbrooke, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT01858324
NCT01856530,Effect of Oxytocin Nasal Sprays on Social Behavior in Social Anxiety Disorder,,Completed,Has Results,Social Anxiety Disorder,Drug: Oxytocin|Drug: Placebo,Social Cooperation|Disengagement From Social Threat Cues|Perceived Trust Scores on a 1-7 Likert Scale|Perceived Empathy Scores on a 1-7 Likert Scale|Perceived Preference Scores on a 1-7 Likert Scale|Perceived Rejection Scores on a 1-7 Likert Scale,Stefan G. Hofmann|Boston University Charles River Campus,Male,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,60,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",H-31668,Jul-12,Aug-13,Aug-13,17-May-13,15-Aug-14,13-Feb-18,"Center for Anxiety and Related Disorders at Boston University, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT01856530
NCT01856673,Evaluation of Two Community-based Mental Health Interventions for Violence-Displaced Afro-Descendants in Colombia.,ACOPLE,Completed,Has Results,Post-Traumatic Stress Disorder|Depression|Anxiety|Violence,Behavioral: Common Elements Treatment Approach|Behavioral: Narrative Community Group Therapy|Other: Standby group,"Score Difference in Symptoms of Anxiety, Depression and Post-traumatic Stress Disorders.|Score Difference in Total Mental Health Symptoms (TMHS) and Dysfunction","Universidad del Valle, Colombia|Heartland Alliance|United States Agency for International Development (USAID)|Johns Hopkins Bloomberg School of Public Health|Afrocolombian Displaced Association - AFRODES",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,521,Other|U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,HA-UV-JHU-2013-001|U1111-1138-4894,Jun-12,Sep-13,Jun-14,17-May-13,28-Sep-15,18-Feb-16,"Centro ACOPLE de Quibdó, Quibdó, Chocó, Colombia|Centro ACOPLE de Buenaventura, Buenaventura, Valle del Cauca, Colombia",,https://ClinicalTrials.gov/show/NCT01856673
NCT01853956,Bioequivalence Trial of Alprazolam 0.25 mg Tablets,,Completed,No Results Available,Anxiety Disorders,Drug: Alprazolam 0.25 mg,Peak Plasma Concentration (CMAX) of alprazolam|Area under the plasma concentration versus time curve (AUC) of alprazolam,GlaxoSmithKline,All,18 Years to 50 Years   (Adult),Phase 1,28,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other,116937,2-Dec-10,10-Dec-10,10-Dec-10,15-May-13,null,14-Jun-17,,,https://ClinicalTrials.gov/show/NCT01853956
NCT01854346,"Social Skills Group Training (""KONTAKT"") for Children and Adolescent With High-functioning Autism Spectrum Disorders",KONTAKT-RCT,Completed,No Results Available,Autism Spectrum Disorder (ASD)|Attention Deficit Hyperactivity Disorder (ADHD)|Anxiety|Depression,"Behavioral: Social skills group training, KONTAKT",Social Responsiveness Scale (SRS)|Adaptive Behavior Assessment System II (ABAS II)|Developmental Disabilities Modification of the Children's Global Assessment Scale (DD-CGAS)|Clinical Global Impression-Improvement/Severity (CGI)|Samples With DNA,"Karolinska Institutet|Child and Adolescent Psychiatry, Stockholm|Stockholm County Council, Sweden|Stiftelsen Sunnerdahls Handikappfond|The Swedish Research Council|The Pediatric Research Foundation at Astrid Lindgren Children's Hospital|Majblomman",All,8 Years to 17 Years   (Child),Not Applicable,296,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,KONTAKT,Aug-12,Mar-16,Mar-16,15-May-13,null,22-Aug-17,"Child & Adolescent Psychiatry Research Center, KIND, Stockholm, Sweden",,https://ClinicalTrials.gov/show/NCT01854346
NCT01850355,An Open-Label Trial of Buspirone for the Treatment of Anxiety in Youth With Autism Spectrum Disorders,,Recruiting,No Results Available,Autism Spectrum Disorders|Anxiety,Drug: Buspirone,Reduction in Pediatric Anxiety Rating Scale (PARS) score|Clinical Global Impression-Anxiety (CGI-Anxiety) Improvement Score,Massachusetts General Hospital,All,6 Years to 17 Years   (Child),Not Applicable,40,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2013-P-000661,Jul-13,Apr-19,Apr-19,9-May-13,null,6-Jun-18,"Massachusetts General Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT01850355
NCT01844115,"Safety, Efficacy and Tolerability of Vilazodone in (GAD) Generalized Anxiety Disorder",,Completed,No Results Available,Generalized Anxiety Disorder,Drug: Placebo|Drug: Vilazodone,Hamilton Rating Scale for Anxiety (HAM-A) total score|Sheehan Disability Scale (SDS) total score,Forest Laboratories,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,415,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",VLZ-MD-07,Apr-13,Mar-14,May-14,1-May-13,null,18-Mar-15,"Forest Investigative Site 023, Birmingham, Alabama, United States|Forest Investigative Site 013, Scottsdale, Arizona, United States|Forest Investigative Site 036, Beverly Hills, California, United States|Forest Investigative Site 001, Costa Mesa, California, United States|Forest Investigative Site 009, Oceanside, California, United States|Forest Investigative Site 026, Rancho Mirage, California, United States|Forest Investigative Site 017, Sherman Oaks, California, United States|Forest Investigative Site 034, Sherman Oaks, California, United States|Forest Investigative Site 030, Bradenton, Florida, United States|Forest Investigative Site 029, Gainesville, Florida, United States|Forest Investigative Site 035, Jacksonville, Florida, United States|Forest Investigative Site 032, Orlando, Florida, United States|Forest Investigative Site 021, West Palm Beach, Florida, United States|Forest Investigative Site 025, Atlanta, Georgia, United States|Forest Investigative Site 018, Decatur, Georgia, United States|Forest Investigative Site 022, Hoffman Estates, Illinois, United States|Forest Investigative Site 014, Berlin, New Jersey, United States|Forest Investigative Site 005, Cherry Hill, New Jersey, United States|Forest Investigative Site 015, Albuquerque, New Mexico, United States|Forest Investigative Site 027, Bronx, New York, United States|Forest Investigative Site 028, Brooklyn, New York, United States|Forest Investigative Site 010, Brooklyn, New York, United States|Forest Investigative Site 002, Cedarhurst, New York, United States|Forest Investigative Site 004, Mount Kisco, New York, United States|Forest Investigative Site 003, New York, New York, United States|Forest Investigative Site 007, New York, New York, United States|Forest Investigative Site 020, New York, New York, United States|Forest Investigative Site 019, Dayton, Ohio, United States|Forest Investigative Site 008, Portland, Oregon, United States|Forest Investigative Site 037, Allentown, Pennsylvania, United States|Forest Investigative Site 011, Media, Pennsylvania, United States|Forest Investigative Site 033, Memphis, Tennessee, United States|Forest Investigative Site 031, Dallas, Texas, United States|Forest Investigative Site 012, Herndon, Virginia, United States|Forest Investigative Site 016, Bellevue, Washington, United States|Forest Investigative Site 024, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT01844115
NCT01844492,Improving Patient and Family Centered Care in Advanced Critical Illness,PARTNER,Completed,No Results Available,Anxiety|Depression,Behavioral: The PARTNER Intervention|Other: ICU Usual Care Control,Hospital Anxiety and Depression Scale|Quality of Communication (QOC) scale|Patient-and Family Centeredness of Care Scale|Intensive Care Unit Length of Stay|Total Hospitalization costs|Impact of Events Scale of Care Scale,University of Pittsburgh,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,1420,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care,PRO13020304,23-Jul-12,18-Feb-16,18-Feb-16,1-May-13,null,20-Mar-18,"University of Pittsburgh Medical Centers, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT01844492
NCT01842217,Validation of [18F]FES for Imaging of Brain Estrogen Receptors,,Unknown status,No Results Available,Psychiatric/Mood Disorder   Patient|Estrogen Receptor Levels|Premenopausal|Postmenopausal,Procedure: FES-PET,Quantification of estrogen receptors in the human brain|Evalution of the levels of circulating estradiol in two patient cohorts and to evaluate the imaging technique,A.W.J.M.Glaudemans|University Medical Center Groningen,Female,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,12,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,NL41 608.042.12,Nov-13,Nov-14,Dec-14,29-Apr-13,null,13-Nov-13,"University Medical Centre Groningen, Groningen, Netherlands",,https://ClinicalTrials.gov/show/NCT01842217
NCT01837966,"Randomized, Placebo-Controlled Study: Effects of Lavender Aromatherapy on Preoperative Anxiety in Breast Patients",,Completed,Has Results,Anxiety; Generalized|Breast Diseases|Surgery,Other: Lavender oil|Other: Placebo,Anxiety Reduction,New York University School of Medicine,Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,93,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,12-03152,Jan-13,Sep-13,Jan-14,23-Apr-13,12-May-15,3-Mar-17,"NYU Langone Medical Center, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT01837966
NCT01834027,The Effect of Jazz on Postoperative Pain and Stress in Patients Undergoing Elective Hysterectomy,,Completed,Has Results,Pain|Anxiety,Behavioral: Jazz music|Behavioral: No music,Change in Heart Rate From Baseline on Arrival in PACU|Difference in Patient's Perception of Anxiety From Baseline Score Upon Arrival in the PACU|Mean Difference in Patient's Perception of Pain From Baseline|Mean Blood Pressure,Milton S. Hershey Medical Center,Female,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,56,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,IRB 40925,Mar-13,Jan-14,Jan-14,17-Apr-13,22-Aug-14,15-Apr-16,"Penn State Hershey Medical Center, Hershey, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT01834027
NCT01830881,Evaluation of Oral Midazolam in First-trimester Surgical Abortions,,Completed,Has Results,Pain|Anxiety|Nausea,Drug: Midazolam|Drug: Ibuprofen|Other: Placebo-Cherry syrup|Drug: Lidocaine,Subject Perception of Pain and Anxiety During Uterine Aspiration|Subject Anticipated Perception of Pain and Anxiety During Uterine Aspiration at Baseline|Subject Perception of Pain and Anxiety Upon Entering Procedure Room|Subject Perception of Pain and Anxiety Post Procedure|Subject Perception of Anxiety With Patient Positioning Procedure|Subject Perception of Pain During Cervical Dilation|State-Trait Anxiety Inventory for Anxiety at Baseline|Patient Satisfaction With Pain and Anxiety 30 Minutes Postoperatively|Subject Satisfaction With Pain and Anxiety 1-3 Days Post Procedure|Subject Extent of Amnesia Using Amnesia Score|Subject Extent of Amnesia|Subject Extent of Sedation|Subject Vital Signs (Heart Rate)|Subject Vital Signs (Heart Rate) 30 Minutes Postprocedure|Subject Nausea 30 Minutes Postprocedure|Subject's Correct Identification of Receiving Midazolam or Placebo|Subject Vital Signs (Oxygenation Saturation)|Subject Vital Signs (Oxygenation Saturation) 30 Minutes Postprocedure|Subject Sleepiness 30 Minutes Postprocedure|Number of Participants With Need for Additional Postoperative Pain Medication,Oregon Health and Science University,Female,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,124,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",OHSU IRB 9064,Apr-13,Dec-13,Jan-14,12-Apr-13,14-Jun-17,25-Jun-18,"Planned Parenthood Columbia Willamette, Portland, Oregon, United States",,https://ClinicalTrials.gov/show/NCT01830881
NCT01829100,Transdiagnostic Behavioral Activation Therapy for Youth Anxiety and Depression,,Completed,No Results Available,Depressive Disorder|Anxiety Disorders,Behavioral: Group Behavioral Activation Therapy (GBAT),Change in Diagnosis via the Anxiety Disorders Interview Schedule-IV-TR (ADIS-IV-TR)|Change in Children's Depression Rating Scale-Revised (CDRS-R),Rutgers University|The Klingenstein Third Generation Foundation,All,11 Years to 15 Years   (Child),Not Applicable,895,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,ChuDep2009,Sep-09,Dec-11,Jun-12,11-Apr-13,null,17-Oct-17,"Rutgers University, Piscataway, New Jersey, United States",,https://ClinicalTrials.gov/show/NCT01829100
NCT01826786,The Effects of JNJ-42165279 on the Neural Basis of Anxiety Disorders in Healthy Male Volunteers,,Completed,No Results Available,Healthy,Drug: JNJ-42165279 (100 mg)|Drug: Placebo,Brain activity patterns in the amygdala (almond-shaped part of the brain associated with motivation and emotional behavior)|Brain activity patterns in multiple areas of the emotional brain neurocircuitry|Startle response|The number of volunteers who experience adverse events as a measure of safety and tolerability.,"Janssen Research & Development, LLC",Male,18 Years to 45 Years   (Adult),Phase 1,43,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",CR100975|42165279ANX1001,Aug-13,Aug-14,Aug-14,9-Apr-13,null,15-Oct-14,"La Jolla, California, United States",,https://ClinicalTrials.gov/show/NCT01826786
NCT01825746,Goal Setting for Health Behavior and Psychosocial Issues in Primary Care,MOHR,Completed,No Results Available,Health Behaviors|Obesity|Substance Abuse|Anxiety|Depression,Other: Implementation of the MOHR assessment in primary care workflow,Reach|Effectiveness - Ask|Effectiveness - Goal Setting|Effectiveness - Assistance|Effectiveness - Referred|Cost|Health behavior and psychosocial changes,"Virginia Commonwealth University|National Cancer Institute (NCI)|Agency for Healthcare Research and Quality (AHRQ)|Office of Behavioral and Social Sciences Research (OBSSR)|University of California, Los Angeles",All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,3591,Other|NIH|U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,VCUFM0001|U58DP002759-01|R01CA140959,Mar-13,Feb-14,Feb-14,8-Apr-13,null,13-May-15,"UCLA Fielding School of Public Health, Los Angeles, California, United States|University of North Carolina, Chapel Hill, North Carolina, United States|OCHIN, Portland, Oregon, United States|Department of Health Promotion and Community Health Sciences, Texas A&M Health Sciences Center School of Rural Public Health, College Station, Texas, United States|University of Texas School of Public Health, Houston, Texas, United States|Vermont College of Medicine, Burlington, Vermont, United States|Virginia Ambulatory Care Outcomes Research Network, Richmond, Virginia, United States|Carilion Health System, Roanoke, Virginia, United States",,https://ClinicalTrials.gov/show/NCT01825746
NCT01819311,Attention Bias Modification Training for Child Anxiety CBT Nonresponders,,Completed,Has Results,Anxiety Disorders,Behavioral: Attention Bias Modification|Behavioral: Placebo Attention Task,Clinician Rating on the Pediatric Anxiety Rating Scale|Screen for Child Anxiety Related Emotional Disorders - Parent Version|Screen for Child Anxiety Related Emotional Disorders - Child Version,Florida International University|National Institute of Mental Health (NIMH),All,8 Years to 16 Years   (Child),Not Applicable,64,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MH097931,1-Apr-13,23-Jun-17,23-Jun-17,27-Mar-13,14-Aug-17,18-Oct-17,"Florida International University Center for Children and Families, Miami, Florida, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT01819311/Prot_SAP_001.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT01819311/ICF_002.pdf",https://ClinicalTrials.gov/show/NCT01819311
NCT01816204,Therapist Assisted Online Treatment for Anxiety,TAO-anxiety,Completed,No Results Available,Anxiety Disorders,Behavioral: Therapist assisted online treatment|Behavioral: face-to-face individual therapy,Behavioral Health Measure-20 (BHM-20),University of Florida,All,18 Years to 35 Years   (Adult),Not Applicable,300,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,539-2012,Jul-13,Sep-14,Sep-14,22-Mar-13,null,31-Aug-16,"Counseling and Wellness Center, University of Florida, Gainesville, Florida, United States",,https://ClinicalTrials.gov/show/NCT01816204
NCT01815398,Cognitive Skills Training for Homeless Youth,,Completed,No Results Available,Affective Disorders|Anxiety Disorders|Attention Deficit Disorder|Substance Abuse,Behavioral: Cognitive Remediation|Behavioral: Computer Skills Training,Global Cognition Score|Vocational outcome,New York State Psychiatric Institute|National Institute of Mental Health (NIMH),All,18 Years to 22 Years   (Adult),Not Applicable,188,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,#6586|1R21MH092569-01A1,Jul-12,Dec-15,Jan-17,21-Mar-13,null,28-Mar-17,"Covenant House New York, New York City, New York, United States",,https://ClinicalTrials.gov/show/NCT01815398
NCT01815099,Transcranial Magnetic Stimulation Treatment for Generalized Anxiety Disorder,,Terminated,Has Results,Generalized Anxiety Disorder,Device: rTMS Treatment,Change in The Structured Interview Guide for the Hamilton Anxiety Rating Scale (SIGH-A) Before and After TMS Treatment.,Hartford Hospital|Neuronetics,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,4,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DIEF003523.3,May-14,Aug-15,Aug-15,20-Mar-13,10-Apr-17,10-Apr-17,"Hartford Hospital, Hartford, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT01815099
NCT01813669,Integrative Coping Group for Children,ToPSY,Completed,No Results Available,Childhood Depression|Childhood Anxiety|Pediatric Pain|Migraines|ADHD|Pediatric Stomach Pain|Musculoskeletal Pain,Behavioral: Integrative Coping Group,The percentage of children who complete 80% of the intervention sessions|Change in Psychological and Somatic Symptoms,Duke University,All,10 Years to 12 Years   (Child),Not Applicable,28,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Pro00039087,Oct-12,Jun-14,Jun-14,19-Mar-13,null,20-Aug-14,"Duke Child and Family Study Center, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT01813669
NCT01814098,An Efficacy and Safety Study of Escitalopram Long-Term Treatment in Major Depressive Disorder With Associated Anxiety Symptoms,Lexapro,Completed,No Results Available,"Depressive Disorder, Major",Drug: Escitalopram,Percentage of Participants With Remission According to Montgomery-Asbery Depression Rating Scale (MADRS) and Hamilton Anxiety Scale (HAM-A)|Percentage of Participants Showing Response|Change From Baseline in MADRS Total Score at Week 24|Change From Baseline of Single Rating Item in MADRS Total Score at Week 24|Change From Baseline in Hamilton Depression Rating Scale (HAMD)-17 Score at Week 24|Change From Baseline in Hamilton Anxiety Scale (HAM-A) Score at Week 24|Change From Baseline of Single Rating Item in HAM-A at Week 24|Change From Baseline in Clinical Global Impression Score (CGI-S) at Week 24|Change From Baseline in Short Form-12 (SF-12) Score at Week 24,Xian-Janssen Pharmaceutical Ltd.,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,318,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CR016381|ESCITALDEP4002,7-Jul-09,31-May-11,30-Nov-11,19-Mar-13,null,2-Oct-17,"Beijng, China|Changsha, China|Hangzhou, China|Nanjing, China|Shanghai, China|Shenyang, China|Shijiazhuang, China|Tianjin, China|Wenzhou, China|Wuhan, China",,https://ClinicalTrials.gov/show/NCT01814098
NCT01812655,Comparison of Virtual Reality and Passive Distraction on Burn Wound Care Pain in Adolescents,,Terminated,Has Results,Burns|Wound Care|Pain,Device: Virtual Reality|Other: Passive Distraction,Self-reported Wound Care Procedure Pain Score|Desire for Distraction|Engagement With Distraction and Belief in Distraction's Efficacy,University of Arkansas|Arkansas Children's Hospital Research Institute|Arkansas Biosciences Institute|Arkansas Children's Hospital Burn Center,All,10 Years to 17 Years   (Child),Not Applicable,30,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care",109422,Jun-10,Apr-12,Apr-12,18-Mar-13,6-Aug-13,6-Aug-13,"Arkansas Children's Hospital, Little Rock, Arkansas, United States",,https://ClinicalTrials.gov/show/NCT01812655
NCT01813019,Study to Evaluate the Effect of AFQ056 in Obsessive Compulsive Disorder (OCD) Patients Resistant to Selective Serotonin Reuptake Inhibitor (SSRI) Therapy,,Terminated,Has Results,Patient Diagnosed With OCD and Resistant to SSRI Treatment|Failed SSRI Over 12 Weeks at Appropriate Doses,Drug: AFQ056|Drug: Placebo,Yale - Brown Obsessive Compulsive Scale (Y-BOCS) Absolute Change From Baseline at Week 17 (End of 16-week Dosing).|Y-BOCS Reduction in Total Score From Baseline,Novartis Pharmaceuticals|Novartis,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,50,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",CAFQ056A2225,Nov-13,Nov-14,Nov-14,18-Mar-13,21-Jul-16,2-Jan-17,"Novartis Investigative Site, San Diego, California, United States|Novartis Investigative Site, Watertown, Massachusetts, United States|Novartis Investigative Site, Brooklyn, New York, United States|Novartis Investigative Site, Burgas, Bulgaria|Novartis Investigative Site, Pazardzhik, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Varna, Bulgaria|Novartis Investigative Site, Strakonice, Czech Republic|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Freiburg, Germany|Novartis Investigative Site, Muenchen, Germany|Novartis Investigative Site, Nürnberg, Germany|Novartis Investigative Site, Ulm, Germany|Novartis Investigative Site, Bern, Switzerland",,https://ClinicalTrials.gov/show/NCT01813019
NCT01811043,Improving Biopsy Experiences Study for Women,IBEST,Completed,No Results Available,Imaging Guided Breast Biopsy,Behavioral: Guided Meditation|Behavioral: Music|Behavioral: Supportive Dialogue,Change in Anxiety|Rates of adherence to recommended follow-up care,Duke University,Female,"21 Years and older   (Adult, Older Adult)",Not Applicable,243,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care,Pro00038873,Aug-12,Feb-17,Feb-17,14-Mar-13,null,5-Dec-17,"Duke Cancer Institute, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT01811043
NCT01809990,Internet-delivered CBT for Adolescents With Obsessive-Compulsive Disorder - a Pilot Study,,Completed,No Results Available,Obsessive-Compulsive Disorder,Behavioral: Internet-delivered Cognitive Behavior Therapy,"Children's Yale Brown Obsessive Compulsive Scale, CY-BOCS|Spence Child Anxiety Scale - Child and Parent version|Child Depression Inventory|Strengths Difficulties Questionnaire|Children's Obsessional Compulsive Inventory Revised|Child Obsessive-Compulsive Impact Scale - Revised","Eva Serlachius|Stockholm County Council, Sweden|Karolinska Institutet",All,12 Years to 17 Years   (Child),Not Applicable,21,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BIPOCD1,Jan-13,Jan-14,Jan-14,13-Mar-13,null,30-Jun-14,"Karolinska insititute, Stockholm, Sweden",,https://ClinicalTrials.gov/show/NCT01809990
NCT01809067,The Effects of Lavender Aromatherapy on Reducing Stress and Anxiety During MRI Procedures.,,Completed,No Results Available,Anxiety,Other: Lavender aromatherapy inhalers,Comparison between patients using aromatherapy and those without aromatherapy|The number of MRI cancellations related to patient stress and anxiety will be compared between the aromatherapy group and those without aromatherapy.,Allina Health System,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,3887-2,Mar-13,Jun-13,Jun-13,12-Mar-13,null,8-Sep-16,"Abbott Northwestern Hospital, Minneapolis, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT01809067
NCT01807403,Comparison of DBS Targets in Obsessive-compulsive Disorder,PRESTOC2,Completed,No Results Available,Obsessive-Compulsive Disorder,Procedure: Deep brain stimulation,Severity of symptoms after each phase,Assistance Publique - Hôpitaux de Paris,All,18 Years to 60 Years   (Adult),Phase 3,8,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",P081203,Oct-10,Feb-16,Feb-16,8-Mar-13,null,18-May-16,"Centre d'investigation Clinique Pitié Salpêtrière, Paris, France",,https://ClinicalTrials.gov/show/NCT01807403
NCT01805583,Return to Work: Promoting Health and Productivity in Workers With Common Mental Disorders,SAFARI,Completed,No Results Available,Adjustment Disorders|Anxiety Disorders|Depression,Other: Acceptance and Commitment Therapy (ACT)|Other: workplace intervention (WPI),Return to work|Changes in symptom severity of depression|Changes in symptom severity of anxiety|Changes in score of burnout symptoms|Changes in scores of General function|Changes in scores of general satisfaction with life,"Karolinska Institutet|Stockholm County Council, Sweden",All,18 Years to 60 Years   (Adult),Not Applicable,352,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2012/2109-31/5,Mar-13,Oct-15,Oct-15,6-Mar-13,null,21-Mar-16,"FORUM-Centrum för psykiatrforskning, Danderyds sjukhus, Stockholm, Sweden",,https://ClinicalTrials.gov/show/NCT01805583
NCT01803204,Patient Education Before Orthognathic Surgery,,Completed,Has Results,Malocclusion|Anxiety|Micrognathism|Prognathism,Other: Booklet - Preoperative Educational,Number of Patients With Clinical Changes During the Postoperative Recovery|Average Test Arrangements on Surgery,University of Sao Paulo,All,18 Years to 60 Years   (Adult),Not Applicable,48,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Health Services Research",193.454,Feb-13,Dec-14,Sep-15,4-Mar-13,31-Jan-19,31-Jan-19,"Cristina Silva Sousa, Sao Paulo, Brazil",,https://ClinicalTrials.gov/show/NCT01803204
NCT01802424,FRIENDS as an Indicative Prevention Program in Norway,,Completed,No Results Available,Anxiety,Behavioral: The Friends program,"Change in anxiety symptoms from baseline to 12 months after completing the FRIENDS program, measured by the Spence Children Anxiety Scale (SCAS)|Changes in life-quality (measured by KINDL)from baseline to 12 months after completing the FRIENDS program|Changes in depressive symptoms (measured by the Short Mood and Feeling questionnaire)from baseline to 12 months after completing the FRIENDS program|Changes in psychosocial functioning (measured by the Strengths and difficulties questionnaire)from baseline until 12 months after having completed the FRIENDS program",NORCE Norwegian Research Centre AS,All,8 Years to 15 Years   (Child),Not Applicable,80,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,71 FRIENDS,Feb-12,Dec-13,Dec-14,1-Mar-13,null,7-Dec-15,"Fjell municipality, Bergen, Norway",,https://ClinicalTrials.gov/show/NCT01802424
NCT01798355,Children and Adolescents With Dental Anxiety - Randomized Controlled Study of Cognitive Behavioral Therapy,,Completed,No Results Available,Dental Anxiety,Behavioral: Cognitive Behavioral Therapy|Behavioral: Treatment As Usual,Changes in dental anxiety|Changes in Behavioral Avoidance,"Karolinska Institutet|Public Dental Health Services, Eastmaninstitutet, Pediatric Dentistry, Sweden",All,"7 Years to 19 Years   (Child, Adult)",Not Applicable,30,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,KIPED20130218,Jan-13,Sep-15,Sep-15,25-Feb-13,null,14-Sep-18,"Pediatric Dentistry, Department of Dental Medicine, Karolinska Institutet, Stockholm, Huddinge, Sweden",,https://ClinicalTrials.gov/show/NCT01798355
NCT01798459,The Effect of Methylphenidate Versus Placebo on State Anxiety in Children With Attention Deficit Hyperactivity Disorder.,,Unknown status,No Results Available,Attention Deficit Hyperactivity Disorder,Drug: Methylphenidate,State anxiety|Cognitive function|Patient's perspective,Shalvata Mental Health Center,All,"8 Years to 18 Years   (Child, Adult)",Not Applicable,30,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic",0009-12-SHA,Feb-13,Oct-15,May-16,25-Feb-13,null,23-Mar-15,"Shalvata, Hod-hasharon, Israel",,https://ClinicalTrials.gov/show/NCT01798459
NCT01796054,"Stress Free Now, a Mind-body Reduction Program for Nurses",SFN-Nurses,Completed,No Results Available,Psychological Stress|Anxiety|Depression,Behavioral: Stress Free Now online program|Behavioral: Group support session,Burnout|Perceived stress|Self-reported BMI|Emotional well-being|Insomnia|Psychosomatic symptoms|Mindfulness|Intent to leave nursing,The Cleveland Clinic,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,360,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),12-1398,Feb-13,Aug-14,Aug-14,21-Feb-13,null,10-Jan-17,"Cleveland Clinic, Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT01796054
NCT01796509,Study in Intensive Care Follow-up Programme in Improving Long-term Outcomes of ICU Survivors,SUIVI-REA,"Active, not recruiting",No Results Available,Quality of Life|Post ICU Discharge,"Other: Medical, psychological, social",Death or severe alteration of quality of life assessed after ICU discharge|Assessment of life quality in Medical domain|Assessment in psychological domain|Assessment in social domain|Assessment in economical cost,Assistance Publique - Hôpitaux de Paris,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,600,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,P100147,Dec-12,Sep-18,Apr-19,21-Feb-13,null,13-Mar-19,"Hôpital Raymond Poincaré, Garches, Ile De France, France",,https://ClinicalTrials.gov/show/NCT01796509
NCT01794156,Evaluation of a Cognitive Therapy (Inference-based-therapy) for the Treatment of Obsessional Compulsive Disorder,,"Active, not recruiting",No Results Available,Obsessive Compulsive Disorder,Behavioral: Cognitive behavior therapy|Behavioral: Mindfulness-based stress reduction|Behavioral: Inference-based therapy,"Yale-Brown Obsessive-Compulsive Scale (Y-BOCS)|Vancouver Obsessional Compulsive Inventory (VOCI)|Obsessive Beliefs Questionnaire (OBQ-44)|Beck Depression Inventory (BDI)|Beck Anxiety Inventory (BAI)|Over-Values Ideas Scale (OVIS)|Inferential Confusion Questionnaire (ICQ)|Semi-structured interview to assess primary inference process|Mindful Attention Awareness Scale (MAAS)|Global Assessment of Functioning (GAF) scale (DSM-IV, Axis V)|Systematic Quality of Life Inventory|Life Experience Survey|Social Support Questionnaire|Social Self-esteem Inventory",Centre de Recherche de l'Institut Universitaire en santé Mentale de Montréal|Canadian Institutes of Health Research (CIHR),All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,240,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,119587,Sep-12,Apr-17,30-Jun-18,18-Feb-13,null,24-Apr-18,"Centre de recherche de l'Institut universitaire en santé mentale de Montréal, Montréal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT01794156
NCT01789697,Text Message Study,,Terminated,No Results Available,Anxiety|Pain|Surgical Site Infection,Other: cellular device/computers,Change in Anxiety|Change in Pain|Change in Surgical Site,Duke University,All,"18 Years to 100 Years   (Adult, Older Adult)",Not Applicable,18,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Supportive Care",Pro00034182,Sep-12,Mar-14,Mar-14,12-Feb-13,null,9-Apr-18,"Duke University Medical Center, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT01789697
NCT01788800,Physical Activity and Cognitive Behavioural Therapy in Panic Disorder,,Completed,No Results Available,Panic Disorder,Behavioral: Cognitive Behavioural Therapy (CBT),Hamilton Rating Scale for Anxiety (CIPS 1995)|Panic and Agoraphobia Scale (Bandelow et al. 1995)|Beck Anxiety Inventory (CIPS 1995)|Clinical Global Index (CIPS 1995)|Beck Depression Inventory (CIPS 1995),"Charite University, Berlin, Germany|German Federal Ministry of Education and Research",All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,46,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",221012,Jan-09,Jan-13,May-13,11-Feb-13,null,16-May-13,,,https://ClinicalTrials.gov/show/NCT01788800
NCT01789125,Smoking Termination / Anxiety Reduction Treatment (ST/ART),START,Completed,No Results Available,Smoking|Anxiety Disorders,Drug: Nicotine Patch|Behavioral: Smoking Termination and Anxiety Reduction Treatment|Behavioral: Education-Supportive Psychotherapy,Short- and long-term point prevalence abstinence|Time to first smoking lapse and relapse,University of Houston|National Institute on Drug Abuse (NIDA),All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,74,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,1R34DA03131301A1|R34DA031313,Mar-12,Dec-15,Jun-16,11-Feb-13,null,23-Apr-19,"Anxiety and Health Research Laboratory and Substance Use Treatment Clinic, University of Houston, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT01789125
NCT01786083,Caring for Family Caregivers:a Research-action Study,,Completed,No Results Available,Depressive Symptoms|Anxiety|Emotions,Behavioral: Application of Problem Solving Technique,Anxiety|Depression|perceived wellbeing levels,Jordi Gol i Gurina Foundation|Preventive Services and Health Promotion Research Network,Female,"Child, Adult, Older Adult",Not Applicable,122,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Treatment,70489,Sep-07,Sep-09,Jul-11,7-Feb-13,null,8-Feb-13,"Primary Health Centers, Tarragona Province, Tarragona, Spain",,https://ClinicalTrials.gov/show/NCT01786083
NCT01784250,Efficacy of Clonidine and Propranolol in Dentistry (AAA),,Unknown status,No Results Available,Anxiety,Drug: Clonidine|Drug: Propranolol|Drug: Placebo,"Change from baseline in modified dental anxiety scale(MDAS)and vital signs (blood pressure, heart rate, respiratory rate, oxygen saturation) until four hours post treatment|Changes in Verbal Numerical Rating Scale (VNRS) at three, six, and twenty-four hours post treatment",CES University,All,"14 Years to 40 Years   (Child, Adult)",Phase 2,60,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CLON000,Aug-12,Apr-13,Apr-13,5-Feb-13,null,5-Feb-13,"Cooperative University, Envigado, Antioquia, Colombia",,https://ClinicalTrials.gov/show/NCT01784250
NCT01775605,Study of Use of Synera for Pain During Local Skin Infiltration With Lidocaine Before Epidural Placement,,Withdrawn,No Results Available,Pain|Anxiety,Drug: Synera,Rating of pain intensity upon lidocaine infiltration|Subject anxiety,Northwell Health,Female,"18 Years and older   (Adult, Older Adult)",Phase 4,0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant),11-376,Nov-13,Nov-14,Nov-14,25-Jan-13,null,14-May-15,"North Shore Unniversity Hospital, Manhasset, New York, United States",,https://ClinicalTrials.gov/show/NCT01775605
NCT01772498,HRV Biofeedback for Brain Tumour Survivors,,Suspended,No Results Available,Depression|Anxiety|Sleep Impairment,Behavioral: heart rate variability biofeedback,"Change from baseline in score on Beck Depression Inventory II at 8 weeks|Change from baseline scores on trait form of the State Trait Anxiety Inventory (Spielberger et al., 1983)at 8 weeks|Change from baseline in resting HRV High Frequency Power|Resting Low Frequency HRV power (0.04-0.15 Hz)|Change in the standard deviation of all NN intervals from baseline in resting heart beat|Subjective Acceptability ratings|Change from baseline score on the Short Form McGill Pain Questionnaire (SFMPQ)(Melzack, 1987)|Change from baseline in scores on the Pittsburgh Sleep Quality Index (Buysse et al., 1989)",British Columbia Cancer Agency|University of British Columbia,All,"19 Years and older   (Adult, Older Adult)",Not Applicable,15,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HRVB-123,Jan-13,Aug-15,Jun-16,21-Jan-13,null,6-May-15,"BC Cancer Agency, Vancouver, British Columbia, Canada",,https://ClinicalTrials.gov/show/NCT01772498
NCT01766401,"Safety, Efficacy and Tolerability of Vilazodone in Patients With Generalized Anxiety Disorder",VLZ-MD-06,Completed,No Results Available,Generalized Anxiety Disorder,Drug: Placebo|Drug: Vilazadone,Hamilton Rating Scale for Anxiety (HAM-A) total score|Sheehan Disability Scale (SDS) total score,Forest Laboratories,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,402,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",VLZ-MD-06,Jan-13,Jan-14,Apr-14,11-Jan-13,null,18-Mar-15,"Forest Investigative Site 022, Arcadia, California, United States|Forest Investigative Site 023, Beverly Hills, California, United States|Forest Investigative Site 010, Encino, California, United States|Forest Investigative Site 025, Newport Beach, California, United States|Forest Investigative Site 004, Redlands, California, United States|Forest Investigative Site 007, Sherman Oaks, California, United States|Forest Investigative Site 016, Temecula, California, United States|Forest Investigative Site 012, Upland, California, United States|Forest Investigative Site 017, Coral Springs, Florida, United States|Forest Investigative Site 028, Fort Myers, Florida, United States|Forest Investigative Site 002, Jacksonville, Florida, United States|Forest Investigative Site 020, Leesburg, Florida, United States|Forest Investigative Site 024, Miami, Florida, United States|Forest Investigative Site 001, Orlando, Florida, United States|Forest Investigative Site 026, Indianapolis, Indiana, United States|Forest Investigative Site 029, Shreveport, Louisiana, United States|Forest Investigative Site 019, Las Vegas, Nevada, United States|Forest Investigative Site 003, Canton, Ohio, United States|Forest Investigative Site 031, Columbus, Ohio, United States|Forest Investigative Site 021, Mason, Ohio, United States|Forest Investigative Site 030, Oklahoma City, Oklahoma, United States|Forest Investigative Site 005, Salem, Oregon, United States|Forest Investigative Site 014, Allentown, Pennsylvania, United States|Forest Investigative Site 015, Philadelphia, Pennsylvania, United States|Forest Investigative Site 027, Lincoln, Rhode Island, United States|Forest Investigative Site 006, Memphis, Tennessee, United States|Forest Investigative Site 008, Houston, Texas, United States|Forest Investigative Site 018, Houston, Texas, United States|Forest Investigative Site 011, Salt Lake City, Utah, United States|Forest Investigative Site 013, Woodstock, Vermont, United States",,https://ClinicalTrials.gov/show/NCT01766401
NCT01764789,Stress Reduction in Improving Quality of Life in Patients With Recurrent Gynecologic or Breast Cancer,,Completed,No Results Available,Anxiety Disorder|Depression|Fatigue|Leydig Cell Tumor|Ovarian Sarcoma|Ovarian Stromal Cancer|Pain|Peritoneal Carcinomatosis|Pseudomyxoma Peritonei|Recurrent Breast Cancer|Recurrent Cervical Cancer|Recurrent Endometrial Carcinoma|Recurrent Fallopian Tube Cancer|Recurrent Gestational Trophoblastic Tumor|Recurrent Ovarian Epithelial Cancer|Recurrent Ovarian Germ Cell Tumor|Recurrent Primary Peritoneal Cavity Cancer|Recurrent Uterine Sarcoma|Recurrent Vaginal Cancer|Recurrent Vulvar Cancer,Other: questionnaire administration|Procedure: quality-of-life assessment|Procedure: psychosocial assessment and care|Behavioral: behavioral intervention|Other: cognitive intervention|Other: educational intervention,"Quality of life(QoL)|Mood as assessed by the Profile of Mood States (POMS)|Depressive symptoms as assessed by the Center for Epidemiological Studies, Depression scale (CES-D)|Stress as assessed by the Impact of Event Scale (IES)|Pain as assessed by the Brief Pain Inventory (BPI)|Fatigue as assessed by the Fatigue Severity Index (FSI)|Diurnal cortisol slope|Inflammation",Ohio State University Comprehensive Cancer Center|National Cancer Institute (NCI),Female,"21 Years to 85 Years   (Adult, Older Adult)",Not Applicable,39,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,OSU-10026|NCI-2012-01177|R21CA135005,Oct-10,Jan-12,Jan-12,10-Jan-13,null,9-Oct-15,"Ohio State University Medical Center, Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT01764789
NCT01763736,Medical Use of Song In Critical Care (MUSIC),MUSIC,Terminated,No Results Available,Stress|Anxiety|Sleep,Behavioral: Music,Response on ICU Stressful Experiences Questionnaire|Change in vital signs|Change in Vital Signs,Brigham and Women's Hospital,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,52,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,2012-P-002287,Dec-12,Dec-14,Dec-14,9-Jan-13,null,21-Oct-15,"Brigham and Women's Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT01763736
NCT01764698,Delivery of Anxiety Disorder Treatment in Addictions Centers,,Completed,No Results Available,Anxiety Disorders|Substance Use Disorders,Behavioral: CALM-SUD|Behavioral: Treatment as usual,Brief Symptom Inventory|Timeline Follow Back|Overall Anxiety Severity and Impairment Scale|urine toxicology screen|Patient Health Questionnaire-8|Anxiety Sensitivity Index|Panic Disorder Severity Scale|Social Phobia Inventory|Penn State Worry Questionnaire|Posttraumatic Stress Disorder Checklist,"University of California, Los Angeles",All,18 Years to 60 Years   (Adult),Not Applicable,98,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,7K23DA031677,15-Nov-13,15-Nov-16,15-Nov-16,9-Jan-13,null,26-Oct-17,"Matrix Institute on Addictions, Los Angeles, California, United States|University of California-Los Angeles, Department of Psychiatry and Biobehavioral Sciences, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT01764698
NCT01763216,Improving Mood in Assisted Living Settings,,"Active, not recruiting",No Results Available,Depressive Symptoms|Clinical Depression,Other: Road Tour|Other: Boatload of Crosswords,Changes in the Patient Health Questionnaire (PHQ-9)|Changes in the Centers for Epidemiological Studies Depression (CESD) 12-item scale|Changes in the Useful Field of View (UFOV)|Changes in the Short Form 36 Item Health-Related Quality of Life (SF-36) Scale|Changes in the Short Form 12 Item Health-Related Quality of Life (SF-12)|Changes in the Brief Pain Invention (BPI)|Changes in the Generalized Anxiety Disorder (GAD-7) Questionnaire,Marianne Smith|University of Iowa,All,"55 Years and older   (Adult, Older Adult)",Not Applicable,300,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention",201208786,Feb-13,Nov-16,Jun-19,8-Jan-13,null,14-Jan-19,"Lakeview Village Retirement, Amana, Iowa, United States|The Fountains Senior Community Living, Bettendorf, Iowa, United States|Carlise Center for Assisted Living, Carlisle, Iowa, United States|Western Home Communities, Cedar Falls, Iowa, United States|Irving Point Affordable Assistant Living, Cedar Rapids, Iowa, United States|Keystone Cedars, Cedar Rapids, Iowa, United States|Meth-Wick Community, Cedar Rapids, Iowa, United States|Prairie Hills at Cedar Rapids, Cedar Rapids, Iowa, United States|Bickford of Clinton, Clinton, Iowa, United States|Woodlands Creek Active Retirement Community, Clive, Iowa, United States|Petersen Commons Assisted Living Community of Marycrest, Davenport, Iowa, United States|Ridgecrest Village, Davenport, Iowa, United States|Silvercrest Garner Active Retirement Community, Davenport, Iowa, United States|Senior Star at Elmore Place, Davenport, Iowa, United States|Wesley Acres, Des Moines, Iowa, United States|Valley View Village, Des Moines, Iowa, United States|The Kensington Assisted Living Community, Fort Madison, Iowa, United States|Legacy Senior Living Community, Iowa City, Iowa, United States|University of Iowa Colleges of Nursing and Public Health, Iowa City, Iowa, United States|Emerson Point, Iowa City, Iowa, United States|Melrose Meadows, Iowa City, Iowa, United States|Oaknoll Retirement Residence, Iowa City, Iowa, United States|Bishop Drumm--Martina Place, Johnston, Iowa, United States|Summit Pointe, Marion, Iowa, United States|The Villages at Marion, Marion, Iowa, United States|Iowa Veteran's Home, Marshalltown, Iowa, United States|Lutheran Living Senior Campus, Muscatine, Iowa, United States|Manor Health Care Center, Sigourney, Iowa, United States|Prairie Hills Assisted Living, Tipton, Iowa, United States|Friendship Village Retirement Community, Waterloo, Iowa, United States|Simpson Memorial Home, Inc., West Liberty, Iowa, United States|Highland Ridge Senior Living Community, Williamsburg, Iowa, United States",,https://ClinicalTrials.gov/show/NCT01763216
NCT01761396,School-based Treatment of Anxiety Research Study (STARS),STARS,Completed,No Results Available,Anxiety Disorders,Behavioral: CBT|Behavioral: UC,Clinical Global Impressions Improvement Scale|School Records|Teacher Report Form,UConn Health|U.S. Department of Education|Johns Hopkins University,All,"6 Years to 18 Years   (Child, Adult)",Not Applicable,216,Other|U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,NA00075767|R324A120405,Jul-12,1-May-18,30-Jun-18,4-Jan-13,null,8-Jan-19,"University of Connecticut Health Center, Farmington, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT01761396
NCT01757301,Comprehensive vs. Assisted Management of Mood and Pain Symptoms,CAMMPS,Completed,Has Results,Pain|Depression|Anxiety|Musculoskeletal|Fibromyalgia,Other: Assisted Symptom Management (ASM)|Other: Comprehensive Symptom Management (CSM),Composite Z-score of Pain-anxiety-depression Severity|Pain Average/Enjoyment of Life/General Activities Pain Scale (PEG)|Patient Health Questionnaire 9-item Depression Scale (PHQ-9)|Generalized Anxiety Disorder 7-Item Anxiety Scale (GAD-7)|Brief Pain Inventory (BPI),VA Office of Research and Development,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,296,U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,IIR 12-095,2-Jan-14,31-Jul-17,30-Nov-17,28-Dec-12,13-Mar-19,13-Mar-19,"Richard L. Roudebush VA Medical Center, Indianapolis, IN, Indianapolis, Indiana, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/01/NCT01757301/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT01757301
NCT01753141,Smoking Treatment and Anxiety Management Program,STAMP,Completed,No Results Available,Nicotine Dependence,Behavioral: Cognitive Behavioral Therapy for smoking cessation|Behavioral: Cognitive Behavioral Therapy for smoking cessation and anxiety sensitivity reduction.,Anxiety Sensitivity Index|Smoking Status,Florida State University,All,18 Years to 45 Years   (Adult),Not Applicable,378,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,R01MH076629-01A1,Jan-08,Aug-13,Aug-13,20-Dec-12,null,26-Sep-13,"Anxiety and Behavioral Health Clinic, Tallahassee, Florida, United States",,https://ClinicalTrials.gov/show/NCT01753141
NCT01751386,Baclofen for Treating Anxiety and Alcoholism,,Completed,Has Results,Alcoholism|Alcohol Dependence|Alcohol Drinking Related Problems|Alcohol Drinking|Anxiety Disorder,Drug: Baclofen|Other: Placebo,Total Amount of Alcohol Consumed During the Alcohol Self Administration (ASA) Session,National Institute on Alcohol Abuse and Alcoholism (NIAAA)|National Institutes of Health Clinical Center (CC),All,"21 Years to 65 Years   (Adult, Older Adult)",Phase 2,39,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other",130040|13-AA-0040,3-Dec-12,17-Aug-16,17-Aug-16,18-Dec-12,16-Aug-17,18-Sep-17,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT01751386
NCT01746667,Virtual Reality Exposure Therapy Versus Exposure in Vivo for Social Phobia,,Completed,No Results Available,Social Anxiety Disorder|Social Phobia,Behavioral: Exposure in vivo|Behavioral: Virtual Reality Exposure Therapy,"Change from baseline: Liebowitz Social Anxiety Scale-Self report|Change from baseline: Fear of Negative Evaluation Scale|Change from baseline: Behavioral Assessment Task (BAT), Public Speaking Performance Scale|Change from baseline: Structured Clinical Interview for DSM-IV (Social Phobia Module)|Change from baseline: Depression Anxiety Stress Scale|Change from baseline: Personality Disorder Belief Questionnaire|Change from baseline: Eurohis Quality of Life Scale",VU University of Amsterdam,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,70,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,5510207,Feb-12,Aug-15,Aug-15,11-Dec-12,null,1-Mar-17,"University of Amsterdam, Department of Clinical Psychology, Amsterdam, Netherlands",,https://ClinicalTrials.gov/show/NCT01746667
NCT01745562,Bioequivalence Trial of Alprazolam 0.5 mg Tablets,,Completed,No Results Available,Anxiety Disorders,Drug: Alprazolam 0.5 mg,Peak Plasma Concentration (CMAX) of alprazolam|Area under the plasma concentration versus time curve (AUC) of Alprazolam,GlaxoSmithKline,All,18 Years to 50 Years   (Adult),Phase 1,28,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other,116977,7-Dec-10,17-Dec-10,17-Dec-10,10-Dec-12,null,14-Jun-17,,,https://ClinicalTrials.gov/show/NCT01745562
NCT01745575,Bioequivalence Trial of Alprazolam 2 mg Tablets,,Completed,No Results Available,Anxiety Disorders,Drug: Alprazolam 2mg tablets|Drug: Alprazolam 2 mg tablets,Peak Plasma Concentration (CMAX) of alprazolam|Area under the plasma concentration versus time curve (AUC) of alprazolam,GlaxoSmithKline,All,18 Years to 40 Years   (Adult),Phase 1,26,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other,116981,28-Mar-10,5-Apr-10,5-Apr-10,10-Dec-12,null,20-Jun-17,,,https://ClinicalTrials.gov/show/NCT01745575
NCT01745601,Bioequivalence Study of Escitalopram Tablets 10 mg,,Completed,No Results Available,Anxiety Disorders,Drug: escitalopram 10 mg,Peak Plasma Concentration (CMAX) of escitalopram|Area under the plasma concentration versus time curve (AUC) of escitalopram,GlaxoSmithKline,Male,18 Years to 50 Years   (Adult),Phase 1,26,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other,117003,4-May-10,19-May-10,19-May-10,10-Dec-12,null,16-Jun-17,,,https://ClinicalTrials.gov/show/NCT01745601
NCT01743664,The Efficacy of EMDR in Patients With PTSD in Multiple Sclerosis,,Unknown status,No Results Available,Posttraumatic Stress Disorders|Multiple Sclerosis,Behavioral: EMDR|Behavioral: Relaxation,Proportion of participants no longer meeting the DSM IV-TR diagnostic criteria for PTSD among patients of the experimental group in comparison with those of the control group after the treatment.|Reduction in the IES scores after the treatment.|Proportion of participants no longer meeting the DSM IV-TR diagnostic criteria for PTSD among patients of the experimental group in comparison with those of the control group at the follow up.|Reduction in the IES scores at the follow-up.,San Luigi Gonzaga Hospital|Fondazione Italiana Sclerosi Multipla,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,60,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2009/R/11,May-10,Mar-13,Feb-14,6-Dec-12,null,7-Dec-12,"San Luigi Gonzaga University Hospital, Orbassano, Torino, Italy",,https://ClinicalTrials.gov/show/NCT01743664
NCT01744548,A Pilot Trial Of Transdiagnostic Cognitive Behavioural Therapy (tCBT) For Depression And Anxiety In Older People,,Unknown status,No Results Available,Depression|Anxiety,Behavioral: tCBT treatment,Hospital Anxiety and Depression Scale (HADS). This will assess symptom change over time in order to evaluate the efficacy of the tCBT intervention.|Hamilton Anxiety Rating Scale (HARS). This will assess symptom change over time in order to evaluate the efficacy of the tCBT intervention.|Hamilton Depression Rating Scale (HDRS). This will assess symptom change over time in order to evaluate the efficacy of the tCBT intervention.|Clinical Outcomes of Routine Evaluation - 10 (CORE-10). This will assess symptom change over time in order to evaluate the efficacy of the tCBT intervention.|Discharge Satisfaction Questionnaire (DSQ),King's College London,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,22,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,12/LO/1462,Dec-12,Dec-13,May-14,6-Dec-12,null,23-Jan-13,"South London and Maudsley NHS Trust, South London, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01744548
NCT01738711,Does CBT Improve the Perception/Impact of Cough and Breathlessness in IPF Patients,,Unknown status,No Results Available,Idiopathic Pulmonary Fibrosis|Cough|Breathlessness,Behavioral: Cognitive behavioural therapy,"validity of tools used|estimation of recruitment rate|number of patients needed|change in Hospital Anxiety and Depression Scale-Anxiety subset|change in Hospital Anxiety and Depression Scale-Depression subset|change in cough frequency|change in Medical Research Council (MRC) dyspnoea scale|change in pulmonary function tests (FVC, TLCO)|change in leicester cough questionnaire|change in MRC dyspnoea scale|change in 6 minute walk distance|change in six minute walk distance|change in King's brief interstitial lung disease questionnaire|change in generalised anxiety disorder questionnaire|change in EuroQol5 Dimension questionnaire",Royal Victoria Infirmary|Manchester University NHS Foundation Trust,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,30,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,IPF Protocol 12/NE/0309,Dec-12,Feb-14,Feb-14,30-Nov-12,null,12-Dec-12,"Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom|Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom",,https://ClinicalTrials.gov/show/NCT01738711
NCT01736631,Cognitive Behavioural Therapy for Social Phobia in People With Bipolar Disorder,,Recruiting,No Results Available,Social Phobia|Bipolar Disorder,Behavioral: Cognitive behavioural therapy (CBT),Acceptability of cognitive behavioural therapy for comorbid social phobia in bipolar disorder|Change on the Social Phobia Inventory (SPIN)|Change on the Liebowitz Social Anxiety Scale Scale Self-Report; Social Phobia Scale & Social Interaction Anxiety Scale; Social Phobia and Anxiety Inventory|Presence/absence of the social phobia diagnosis|Depression symptom change|Mania symptom change,Nova Scotia Health Authority,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,20,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CBTSPBD-001,Mar-13,Jan-19,Jan-19,29-Nov-12,null,21-Jun-17,"Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada",,https://ClinicalTrials.gov/show/NCT01736631
NCT01730625,Augmenting Effects of ABMT on CBT in Anxious Children: A Randomized Clinical Trial,,Completed,No Results Available,Anxiety Disorder,Behavioral: Cognitive behavioral therapy for anxiety|Behavioral: Attention Bias Modification Treatment,Change in frequency of anxiety symptoms (based on ADIS)|Change in severity of anxiety symptoms (based on ADIS)|SCARED parent/child,Tel Aviv University,All,"6 Years to 18 Years   (Child, Adult)",Not Applicable,119,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",ABMT-RCT,Oct-10,Jul-12,Jul-12,21-Nov-12,null,21-Nov-12,,,https://ClinicalTrials.gov/show/NCT01730625
NCT01729689,Cognitive Behavioral Therapy in Treating Anxiety in Patients With Stage IV Non-Small Cell Lung Cancer and Their Caregivers,,Completed,No Results Available,Anxiety Disorder|Recurrent Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer,Other: counseling intervention|Other: questionnaire administration|Procedure: quality-of-life assessment,"Feasibility, defined as 75% of participants complete at least 5 sessions, 75% of participants complete pre- and post-intervention assessment battery|Acceptability, based on qualitative analysis of exit interviews",Stanford University|National Cancer Institute (NCI),All,"Child, Adult, Older Adult",Not Applicable,13,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,LUN0053|NCI-2012-02096|25339,Nov-12,Nov-13,Nov-13,20-Nov-12,null,22-Aug-14,"Stanford University, Stanford, California, United States",,https://ClinicalTrials.gov/show/NCT01729689
NCT01727466,Treatment for Children With Autism and Anxiety,,Completed,No Results Available,Autism,Behavioral: Facing Your Fears,Change in Clinical Global Impression Scale - Improvement and Severity (CGIS-S; CGIS-I)|Anxiety Disorders Interview Survey for Children-Parent Version (ADIS-P),"University of Colorado, Denver|Autism Speaks",All,8 Years to 14 Years   (Child),Not Applicable,50,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,03-0245,Aug-06,Sep-09,Dec-09,16-Nov-12,null,16-Nov-12,,,https://ClinicalTrials.gov/show/NCT01727466
NCT01725750,Treatment of Post-Traumatic Brain Injury (Post-TBI) Fatigue With Light Therapy,,Completed,Has Results,Traumatic Brain Injury|Fatigue,Device: Bright White Light (BWL)|Device: Dim Red Light (DRL),Multidimensional Assessment of Fatigue (MAF)|TBI-QOL Fatigue|Neuro-QOL Depression and Sleep|Epworth Sleepiness Scale (ESS)|CNS Vital Signs TBI Rehab Toolbox|Cognitive Failures Questionnaire|Neuro-QOL Anxiety|Actiwatch Spectrum|Satisfaction With Life Scale|Treatment Satisfaction Questionnaire for Medication|Credibility/Expectancy Questionnaire,Icahn School of Medicine at Mount Sinai,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,88,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,GCO 12-1256|HSM 12-00759|H133A120084,Nov-12,Jun-17,Jun-17,14-Nov-12,11-Sep-18,21-Nov-18,"The Brain Injury Research Center at Icahn School of Medicine at Mount Sinai, New York, New York, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/50/NCT01725750/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT01725750
NCT01726179,Efficacy of Proximal Caries Infiltration,,"Active, not recruiting",No Results Available,Dental Health|Caries,Device: Icon infiltration|Device: control,caries progression after infiltration|stress reaction during treatment,DMG Dental Material Gesellschaft mbH|Universidade Federal do Rio de Janeiro|Brazilian agency (FAPERJ); grant: FAPERJ-APQ1 E-26/110.273/2012,All,5 Years to 7 Years   (Child),Not Applicable,66,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,ECIPRJ13,Dec-12,Dec-16,Aug-19,14-Nov-12,null,29-Sep-16,"Universidade do Estado do Rio de Janeiro, Faculdade de Odontologia., Rio de Janeiro, Brazil",,https://ClinicalTrials.gov/show/NCT01726179
NCT01726387,"Self-Management for Anxiety, Depression and Somatoform Disorders",SMADS,Completed,No Results Available,"Anxiety Depression (Mild or Not Persistent)|Major Depressive Disorder, Single Episode, Unspecified|Neurotic, Stress-related and Somatoform Disorders",Behavioral: Psychosocial Counseling|Behavioral: Usual Care,General Self-Efficacy Scale (GSE)|Change in Symptom Score Patient's Health Questionnaire (German Version)|Health Related Quality of Life,Universitätsklinikum Hamburg-Eppendorf|German Federal Ministry of Education and Research,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,364,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SMADS,Mar-13,Sep-15,Sep-15,14-Nov-12,null,6-Feb-18,"Primary Care Practices, Hamburg, Germany",,https://ClinicalTrials.gov/show/NCT01726387
NCT01724762,Efficacy of Nursing Orientation to Reduce the Anxiety of Patients Undergoing Bed Bath,,Completed,No Results Available,Acute Coronary Syndrome,Other: Nursing Orientation,STAI-state,Federal University of São Paulo|Conselho Nacional de Desenvolvimento Científico e Tecnológico,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,120,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label),UNIFESP0447,Apr-10,Oct-11,Oct-11,12-Nov-12,null,12-Nov-12,"Federal University of São Paulo, São Paulo, Brazil",,https://ClinicalTrials.gov/show/NCT01724762
NCT01725152,Ganaxolone Treatment in Children With Fragile X Syndrome,,Completed,No Results Available,Fragile x Syndrome,Drug: Ganaxolone|Drug: Placebo,"Clinician's Global Impression-Improvement (CGI-I)|Pediatric Anxiety Rating Scale (PARS)|Visual Analog Scale|Anxiety, Depression, and Mood Scale (ADAMS)|Aberrant Behavior Checklist|Swanson, Nolan, and Pelham-IV Questionnaire (SNAP-IV)","Marinus Pharmaceuticals|University of California, Davis|U.S. Army Medical Research and Materiel Command",All,6 Years to 17 Years   (Child),Phase 2,59,Industry|Other|U.S. Fed,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",1042-0800,Nov-12,16-Oct-15,1-Nov-16,12-Nov-12,null,19-Jun-18,"M.I.N.D. Institute at University of California at Davis Medical Center, Sacramento, California, United States|Antwerp University Hospital, Edegem, Belgium",,https://ClinicalTrials.gov/show/NCT01725152
NCT01723943,Educational Counseling in Improving Communication and Quality of Life in Spouses and Breast Cancer Patients,,Completed,No Results Available,Anxiety Disorder|Depression|Ductal Breast Carcinoma in Situ|Lobular Breast Carcinoma in Situ|Psychosocial Effects of Cancer and Its Treatment|Stage IA Breast Cancer|Stage IB Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer,Other: educational intervention|Other: counseling intervention|Other: psychosocial support for caregiver,Change in State-Trait Anxiety Inventory (STAI) spouse scores|Change in Center for Epidemiologic Studies Depression Scale (CES-D) spouse scores|Change in STAI patient scores|Change in CES-D patient scores|Change in spouse/partner Skills Checklist scores|Change in spouse/partner CASE scores|Change in spouse/partner Mutuality and Interpersonal Sensitivity Scale (MIS) scores|Change in patient MIS scores,University of Washington|National Cancer Institute (NCI),All,"Child, Adult, Older Adult",Not Applicable,108,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Supportive Care,8061|NCI-2013-01838|34500|P30CA015704|R01CA114561,Mar-09,Dec-14,Dec-14,8-Nov-12,null,8-Feb-18,"Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT01723943
NCT01723215,Prevention of Combat-related PTSD Using Attention Bias Modification (ABM): A Randomized Controlled Trial,,Completed,No Results Available,PTSD,Behavioral: Active ABMT8|Behavioral: Active ABMT4|Behavioral: Placebo,Changes in PTSD symptoms(PCL)|Probable PTSD diagnosis(CAPS)|Changes in Depression(PHQ-9)) and Anxiety(STAI),"Tel Aviv University|Medical Corps, Israel Defense Force|Walter Reed Army Institute of Research (WRAIR)",Male,18 Years to 28 Years   (Adult),Not Applicable,862,Other|U.S. Fed,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",TelAvivU,Dec-12,Feb-15,Feb-15,7-Nov-12,null,19-Mar-15,"IDF Military camps, Beer sheva, Israel",,https://ClinicalTrials.gov/show/NCT01723215
NCT01721824,The Effect of IPS-MA- A Modified Early Supported Employment Intervention for Individuals With Mood or Anxiety Disorders,,Completed,No Results Available,Affective Disorder|Major Depressive Disorder|Bipolar Disorder|Anxiety Disorder,Behavioral: The IPS-MA method,Competitive employment or education|Number of days of competitive employment or studying|Hamilton Rating Scale for Depression - 6 items|Hamilton Rating Scale for anxiety -6 item scale|Global Assessment of Function (GAF-F)|WHO-5 well-being index,Mental Health Centre Copenhagen,All,18 Years to 60 Years   (Adult),Not Applicable,326,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor),H-2-2011-FSP20,Oct-11,Mar-16,Jul-16,6-Nov-12,null,7-Jul-16,"Mental Health Center Ballerup, Mental Health Center Frederiksberg, Mental Health Center Copenhagen, and Mental Health Center of Northern Seeland, Ballerup, Denmark",,https://ClinicalTrials.gov/show/NCT01721824
NCT01716351,The Efficacy of Adapted Yoga in Managing Psychosocial Risk in Implantable Cardioverter Defibrillator (ICD) Patients,,Completed,No Results Available,Cardiac Arrhythmias,Behavioral: Adapted Yoga Intervention for Implantable Cardioverter Defibrillator (ICD) Recipients,Florida Shock Anxiety Scale (FSAS)|Self-Compassion Scale|The number of device-initiated ventricular defibrillations as recorded by their ICD device|The number of anti-tachycardia pacing events among participants as recorded by their ICD device|Expression Manipulation Test|Pennebaker Inventory|State-Trait Anxiety Inventory (STAI)|Positive Health Expectation Scale|Florida Patient Acceptance Survey (FPAS)|Center for Epidemiologic Study Depression Scale (CES-D)|Interpersonal Support Evaluation|Hospitalizations|Implantation Status|Medications|Co-morbidities|Ejection Fraction|Atrial Fibrillation,Yale University|National Center for Complementary and Integrative Health (NCCIH),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,55,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,#SR-1569|F31AT003757,Aug-07,Nov-10,Feb-11,29-Oct-12,null,29-Oct-12,,,https://ClinicalTrials.gov/show/NCT01716351
NCT01714986,Psychological Variables and Hyperglycemia in Diabetes Mellitus,ALEXIDIAB,Withdrawn,No Results Available,Diabetes Mellitus|Depression|Alexithymia|Anxiety,Behavioral: Affect School|Behavioral: Body Awareness Therapy,"Intervention with Affect School with Script Analysis and Basic Basal Awareness Therapy in patients with diabetes, psychological symptoms and high HbA1c|Level of HbA1c|Alexithymia|Anxiety|Self-image","Lund University|FoU Kronoberg, Landstinget Kronoberg",All,18 Years to 59 Years   (Adult),Not Applicable,0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,FoU-Kronoberg 4522,Mar-09,Dec-23,Dec-24,26-Oct-12,null,21-Dec-18,,,https://ClinicalTrials.gov/show/NCT01714986
NCT01712321,Study of Vilazodone to Treat Social Anxiety Disorder,,Unknown status,No Results Available,Social Anxiety Disorder,Drug: Vilazodone|Drug: Placebo,"Change in Liebowitz Social Anxiety Scale (LSAS) - total score|Responder rate, as defined by Clinical Global Impression of Improvement score of 1 or 2|Change in the Clinical Global Impression of Severity of Illness score|Change on the LSAS anxiety and avoidance subscales|Change in Hamilton Depression scale total|Change in Hamilton Anxiety scale total|Subject-assessed responder rate",The Medical Research Network|Forest Laboratories,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,30,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",VII-IT-07,Oct-12,Mar-14,Apr-14,23-Oct-12,null,20-Jan-14,"The Medical Research Network, LLC, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT01712321
NCT01707420,Preoperative Gabapentin for Post-tonsillectomy Pain in Children,,Completed,No Results Available,Post Operative Pain Management in Children With Tonsillectomy/Adenoidectomy,Drug: Gabapentin|Drug: liquid placebo,Total oral analgesia consumption|Self-report pain score,"University of Colorado, Denver",All,5 Years to 16 Years   (Child),Not Applicable,36,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",11-1687,Aug-12,Dec-15,Dec-15,16-Oct-12,null,23-May-16,"Children's Hospital Colorado, Aurora, Colorado, United States",,https://ClinicalTrials.gov/show/NCT01707420
NCT01708070,Trial of Asthma Self-Management Education in Patients With Depressive Symptoms,,Completed,No Results Available,Asthma|Depression|Anxiety,Behavioral: Asthma self-management,Change in asthma-related quality of life|Number of urgent resource utilization visits for asthma,"Hospital for Special Surgery, New York",All,"18 Years to 85 Years   (Adult, Older Adult)",Not Applicable,66,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Health Services Research,HL 098240,Oct-12,May-16,May-16,16-Oct-12,null,12-Sep-16,"Weill Cornell Internal Medicine Associates/Hospital for Special Surgery, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT01708070
NCT01708226,Attention Training for Childhood Obsessive Compulsive Disorder: An Open Case Series,AMPOCD,Completed,No Results Available,Obsessive Compulsive Disorder,Behavioral: Attention Modification Program,Children's Yale-Brown Obsessive Compulsive Scale Change From Pre-Treatment to Post-Treatment|Clinical Global Impression-Severity (CGI-S) and Improvement (CGI-I) Scales Change From Pre-Treatment to Post-Treatment|Attention Bias Assessment Change from Pre-Treatment to Post-Treatment,"University of California, Los Angeles|National Institute of Mental Health (NIMH)",All,8 Years to 17 Years   (Child),Phase 1,6,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IRB12-001459|1R34MH095885-01A1,Nov-12,Nov-13,Aug-16,16-Oct-12,null,16-Jan-17,"University of California Los Angeles, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT01708226
NCT01704768,COPE/Healthy Lifestyles for Teens: A School-Based RCT,,Unknown status,No Results Available,Healthy Lifestyle Behaviors|Depressive/Anxiety Symptoms,Behavioral: COPE/Healthy Lifestyles TEEN Program.|Behavioral: Healthy Teens Attention Control Program,Change in Body Mass Index Percentage (BMI%)|Change in Healthy Lifestyle Behaviors|Change in Depression and Anxiety Symptoms|Social Skills|Academic Performance|Change in Body Mass Index Percentile (%)|Change in Healthy Lifestyles Beliefs|Change in Perceived Difficulty of Leading a Healthy Lifestyle|Change in Triglycerides (Lipid Panels)|Change in Total Cholesterol (Lipid Panels)|Change in High-Density Lipoprotein (HDL)(Lipid Panels)|Change in Low-Density Lipoprotein (LDL) (Lipid Panels)|Change in High-Density Lipoprotein (HDL) (Lipid Panels),Arizona State University|National Institute of Nursing Research (NINR),All,14 Years to 16 Years   (Child),Not Applicable,1219,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",5R01NR012171|1R01NR012171-01A2,Jan-10,Dec-12,Jun-13,11-Oct-12,null,11-Oct-12,"Arizona State University, Phoenix, Arizona, United States",,https://ClinicalTrials.gov/show/NCT01704768
NCT01702220,Calmer Life: Testing the Effectiveness of a Treatment for Anxiety,,Completed,No Results Available,Generalized Anxiety Disorder|Anxiety Disorder NOS,Behavioral: CBT|Other: ECC,Geriatric Anxiety Inventory|Penn State Worry Questionnaire (PSWQ-A)|Generalized Anxiety Disorder-7|Patient Health Questionnaire-9|Insomnia Severity Index|Late-Life Functional Disability Index|SF-12 Health Survey|Client Satisfaction Questionnaire|Brief RCOPE|Health services use|Use of psychotropic medication|Brief Multidimensional Measure of Religiousness and Spirituality|Satisfaction with Life Scale|Geriatric Depression Scale,Baylor College of Medicine|Retirement Research Foundation|Archstone Foundation,All,"50 Years and older   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,H30928,Oct-12,Feb-15,Aug-15,8-Oct-12,null,12-Jan-16,"Houston Center for Quality of Care and Utilization Studies, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT01702220
NCT01701284,Repetitive Transcranial Magnetic Stimulation in Cancer Patients With Depression and Anxiety,rTMSinCP,Unknown status,No Results Available,Cancer in Remission (Any Type or Stage)|Depression|Anxiety,Device: Repetitive Transcranial Magnetic Stimulation (rTMS),Overall change in depression severity|Relative change in depression severity|Presence and changes in severity of side effects|Overall change in anxiety severity|Relative change in anxiety severity|Correlation of anxiety with change in depression severity|Correlation of anxiety with harm avoidance personality trait,Northwestern University|Neuronetics,Female,"22 Years to 70 Years   (Adult, Older Adult)",Not Applicable,30,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NU 12CC12|NCI-2012-01691,Dec-12,Aug-17,Aug-18,5-Oct-12,null,4-Oct-16,"Northwestern University, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT01701284
NCT01701011,Coping Intervention After Embryo Transfer,,Completed,Has Results,Anxiety|Depression,Behavioral: Coping intervention,Anxiety|Depression,Bart CJM Fauser|UMC Utrecht,Female,"Child, Adult, Older Adult",Not Applicable,377,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)",PRCI study,Oct-10,Feb-13,Feb-13,4-Oct-12,22-Dec-14,10-Aug-16,"University Medical Center Utrecht, Utrecht, Netherlands",,https://ClinicalTrials.gov/show/NCT01701011
NCT01696578,Effectiveness of Combined Intervention Approaches in the Treatment of Affective Disorders and Chronic Pain in War Victims,,Completed,No Results Available,PTSD|Depression|Anxiety|Chronic Pain|Anger,Behavioral: BF-CBT and group physiotherapy,Change of depression symptom from baseline at 3 and 6 months|Change of anxiety symptom from baseline at 3 and 6 months|Change of chronic pain symptom from baseline at 3 and 6 months|Change of anger from baseline at 3 and 6 months|Change of PTSD symptom from baseline at 3 and 6 months|Change of disability scale from baseline at 3 and 6 months|Change of hand-grip strength from baseline at 3 and 6 months|Change of standing balance from baseline at 3 and 6 months|Change of BMI from baseline at 3 and 6 months|Change of heart rate variability from baseline at 3 and 6 months,Rehabilitation and Research Centre for Torture Victims|Kosova Rehabilitation Centre for Torture Victims,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,31,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,RCTF5S2P4D1,Jan-12,Dec-12,Apr-14,1-Oct-12,null,24-Apr-14,"Kosova Rehabilitation Centre for Torture Victims, Pristina, Kosovo",,https://ClinicalTrials.gov/show/NCT01696578
NCT01694316,Use of a Novel Neuroplasticity-based Neurobehavioral Intervention for PTSD,,Completed,No Results Available,Anxiety|Depression,Behavioral: Computerized Neurobehavioral Intervention,WebNeuro Computerized Cognitive and Affective Assessment Battery|Clinician-assessed PTSD symptoms,Stanford University,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,54,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science,IRB-24890,Sep-12,Jan-17,Jan-17,27-Sep-12,null,16-Aug-18,"Stanford University, Department of Psychiatry and Behavioral Sciences, Stanford, California, United States",,https://ClinicalTrials.gov/show/NCT01694316
NCT01695291,Novel Medication Strategies Targeting Brain Mechanisms in Pediatric OCD,,Completed,Has Results,Obsessive Compulsive Disorder,Drug: Minocycline|Other: Placebo,"Yale-Brown Obsessive Compulsive Scale, Child Version (CYBOCS)|Striatal Glutamate Level Measured by Magnetic Resonance Spectroscopy (MRS).",New York State Psychiatric Institute|National Institute of Mental Health (NIMH)|Weill Medical College of Cornell University,All,"8 Years to 20 Years   (Child, Adult)",Phase 2,31,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",6574|R34MH095502-03,May-12,Feb-17,Jan-18,27-Sep-12,13-Mar-19,13-Mar-19,"Weill Cornell Medical Center, New York, New York, United States|New York State Psychiatric Institute, New York, New York, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/91/NCT01695291/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/91/NCT01695291/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT01695291
NCT01693874,Mindfulness-based Stress Reduction and Cognitive Function in Stress and Aging,,Completed,No Results Available,Anxiety Disorders|Depression,Behavioral: MBSR|Behavioral: control (health education),cognitive functioning|mind-wandering|mindfulness|anxiety and depressive symptoms,"Washington University School of Medicine|National Center for Complementary and Integrative Health (NCCIH)|University of California, San Diego",All,65 Years and older   (Older Adult),Phase 1|Phase 2,103,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,AT007064,Oct-11,Jun-14,Jun-14,26-Sep-12,null,23-Jul-14,"University of California San Diego, San Diego, California, United States|Washington University School of Medicine, St Louis, Missouri, United States",,https://ClinicalTrials.gov/show/NCT01693874
NCT01687764,Combination of Active or Placebo Attentional Bias Modification Treatment (ABMT) to Either Cognitive Behavioral Group Therapy (CBGT) or Psychoeducational Control Intervention (PCI) for Anxiety Disorders in Children,,Unknown status,No Results Available,Generalized Anxiety Disorder|Separation Anxiety Disorder|Social Anxiety Disorder,Other: Attentional Bias Modification Treatment (ABMT) - Active|Other: Attentional Bias Modification Treatment - Placebo|Behavioral: Cognitive Behavioral Group Therapy|Behavioral: Psychoeducational Control Intervention,"Pediatric Anxiety Rating Scale (PARS) / continuous|Clinical Global Impression - Improvement Scale (CGI-I) / dichotomous|Screen for Children and Anxiety Related Emotional Disorders (SCARED)|Childhood Depression Inventory (CDI)|Swanson, Nolan, and Pelham scale - Version IV (SNAP-IV)|Spence Children's Anxiety Scale (SCAS)|Neuropsychological measures|Biological measures",Hospital de Clinicas de Porto Alegre,All,7 Years to 11 Years   (Child),Not Applicable,90,Other,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",HCPA11-0249,Aug-11,Jan-13,Jan-13,19-Sep-12,null,19-Sep-12,"National Institute of Mental Health (NIMH), Bethesda, Maryland, United States|University of Queensland, Brisbane St Lucia, Queensland, Australia|Federal University of Rio Grande do Sul / Hospital de Clínicas de Porto Alegre (HCPA), Porto Alegre, Rio Grande do Sul, Brazil|Tel-Aviv University, Tel-Aviv, Israel",,https://ClinicalTrials.gov/show/NCT01687764
NCT01687933,The Effect of Virtual Reality Glasses on Labor Pain,,Completed,No Results Available,Labor Pain|Anxiety,"Device: three-dimensional glasses(manufactor Vuzix,wrap 920)|Other: usual care",pain and anxiety,Mashhad University of Medical Sciences,Female,18 Years to 29 Years   (Adult),Phase 2|Phase 3,30,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Virtual Reality System,Feb-11,Jul-12,Aug-12,19-Sep-12,null,19-Sep-12,,,https://ClinicalTrials.gov/show/NCT01687933
NCT01688115,Reduction of Preoperative Anxiety in Children: Clickamico Project 2nd Phase,,Completed,No Results Available,Preoperative Anxiety,Procedure: Video|Other: Standard care,Preoperative anxiety,University of Florence,All,6 Years to 11 Years   (Child),Not Applicable,40,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care,IPAD2012,Sep-12,Sep-14,Sep-14,19-Sep-12,null,29-Oct-15,,,https://ClinicalTrials.gov/show/NCT01688115
NCT01687140,The Use of D-Cycloserine to Augment CBT for Pediatric OCD,DCS,Unknown status,No Results Available,Obsessive-Compulsive Disorder,Drug: D-Cycloserine|Drug: Placebo,OCD symptom severity on the Children's Yale Brown Obsessive Compulsive Scale (CYBOCS),"University of California, Los Angeles",All,7 Years to 17 Years   (Child),Phase 2,26,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,Jul-12,Jul-14,Jul-14,18-Sep-12,null,18-Sep-12,"University of California, Los Angeles, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT01687140
NCT01686087,Attaining and Maintaining Wellness in Obsessive-compulsive Disorder,,Completed,No Results Available,Obsessive Compulsive Disorder,Behavioral: Monthly Booster Sessions of EX/RP|Procedure: Visits with MD and independent evaluators,Obsessive Compulsive Symptom Severity (Y-BOCS)|Depressive severity (HAMD17)|Quality of Life (QLESQ-S),New York State Psychiatric Institute|National Institute of Mental Health (NIMH),All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,137,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",6628|2R01MH045436-18,Oct-12,Jun-18,Jul-18,17-Sep-12,null,13-Mar-19,"New York State Psychiatric Institute, New York, New York, United States|University of Pennsylvania Center for the Treatment and Study of Anxiety, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT01686087
NCT01685528,VA Home-Based Emotional Learning With Practical Skills,VA-HELPS,Completed,No Results Available,Anxiety|Depression,Behavioral: CBT,Geriatric Anxiety Inventory|Penn State Worry Questionnaire (PSWQ-A)|Generalized Anxiety Disorder-7|SF-12 Health Survey|Brief RCOPE|Client Satisfaction Questionnaire|Patient Health Questionnaire-9|Geriatric Depression Scale|Working Alliance Inventory|Brief Multidimensional Measure of Religiousness and Spirituality|Insomnia Severity Index,"Baylor College of Medicine|South Central VA Mental Illness Research, Education & Clinical Center",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,18,Other|U.S. Fed,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,H-30655,Dec-12,May-14,Dec-15,14-Sep-12,null,7-Apr-16,"Houston Center for Quality of Care and Utilization Studies, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT01685528
NCT01684488,Trial of the Youth Readiness Intervention,YRI,Completed,No Results Available,"Anxiety Disorder/Anxiety State|Depressive Disorder/Psychology|Social Problems/Psychology|Stress, Psychological|Violence, Non-accidental",Behavioral: YRI|Other: EducAid educational programming,"Change in scores on the Oxford Measure of Psychosocial Adjustment & World Health Organization Disability Assessment Schedule, 2.0 (WHODAS 2.0)|Change in scores on the Youth Assessment Battery",Boston College|Caritas Freetown|International Rescue Committee|Harvard Medical School|Yale University|The City College of New York,All,"15 Years to 24 Years   (Child, Adult)",Not Applicable,443,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,RPCGA-YRI-21003|USIP-008-10F,Apr-12,Dec-14,Dec-14,13-Sep-12,null,31-May-18,"CARITAS Freetown, Freetown, Sierra Leone",,https://ClinicalTrials.gov/show/NCT01684488
NCT01682447,"Pulmonary Rehabilitation: Effects on Cognitive Functioning, Mood, Anxiety, and Quality of Life in Patients With COPD",,Completed,No Results Available,Chronic Obstructive Pulmonary Disease COPD,Other: Extensive Pulmonary Rehabilitation Program,Change in Objective Cognitive functioning|Change in Mood and Anxiety|Change in Quality of Life|Change in 6 Minute Walking distance Test(6-MWT)|Change in Subjective Cognitive Functioning|Adherence to pulmonary rehabilitation|Change in Fatigue|Dropout from pulmonary rehabilitation,University of Tilburg|Revant Schoondonck Center for Pulmonary Rehabilitation Breda|Revant Innovation foundation|Fonds NutsOhra,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,261,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other,NL33713.008.10,Jan-11,Dec-13,Jun-14,11-Sep-12,null,31-Oct-17,"Revant Schoondonck Center for Pulmonary Rehabilitation, Breda, Netherlands",,https://ClinicalTrials.gov/show/NCT01682447
NCT01680172,Oral Ketamine in the Treatment of Depression and Anxiety in Patients With Cancer,,Terminated,Has Results,Cancer|Depression|Anxiety,Drug: Ketamine|Drug: Placebo,Hospital Anxiety and Depression Scale - Anxiety Score (HADS-A)|Hospital Anxiety Depression Scale- Depression Score (HADS-D),Mayo Clinic,All,"18 Years and older   (Adult, Older Adult)",Phase 2,5,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care",12-001156,Aug-12,Feb-15,Feb-15,7-Sep-12,29-Feb-16,29-Feb-16,"Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Yuma Regional Medical Center, Yuma, Arizona, United States",,https://ClinicalTrials.gov/show/NCT01680172
NCT01680237,Cognitive Behavior Therapy vs Exposure in Vivo in the Treatment of Panic Disorder With Agoraphobia,,Recruiting,No Results Available,Panic Disorder With Agoraphobia,Behavioral: Cognitive behavior therapy|Behavioral: Exposure in-vivo,Change (from baseline) in the Mobility Inventory|Change (from baseline) in a Behavioral Approach Test,Ruhr University of Bochum,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,250,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BoSPmA,Oct-11,Dec-20,Dec-20,7-Sep-12,null,3-Sep-18,"Zentrum für Psychotherapie, Bochum, NRW, Germany",,https://ClinicalTrials.gov/show/NCT01680237
NCT01681329,Cognitive-Behavioral Treatment and Interpretation Modification Training for Adults With Generalized Anxiety Disorder,CBT+IMT-GAD,Completed,No Results Available,Generalized Anxiety Disorder,Behavioral: Cognitive-behavioral therapy|Other: Interpretation training,Change from baseline in severity of GAD symptoms assessed by structured interview|Change from baseline in severity of GAD symptoms|Change from baseline in severity of worry|Change from baseline in somatic anxiety|Change from baseline in depressive symptoms|Change from baseline in hostile attitudes|Change from baseline in intolerance of uncertainty|Change from baseline in beliefs about worry|Change from baseline in problem orientation|Change from baseline in cognitive avoidance,"Concordia University, Montreal|Hopital du Sacre-Coeur de Montreal|Université du Québec à Trois-Rivières|Université de Sherbrooke|Ryerson University|Brown University",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,79,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MOP-82771-12-04,Sep-12,Jun-18,Jun-18,7-Sep-12,null,20-Jul-18,"Hôpital du Sacré-Coeur de Montréal, Clinique des troubles anxieux, Montréal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT01681329
NCT01679457,Assessing Models of Exposure Therapy,,"Active, not recruiting",No Results Available,Obsessive-compulsive Disorders and Symptoms,Behavioral: ACT-Focused ERP|Behavioral: TAU-ERP,Client Post-ERP Session Questions (Day 1).|Client Post-ERP Session Questions (Day 2).,Mclean Hospital|Utah State University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,30,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2012-P-001010/1; McLean,Sep-12,Aug-19,Aug-19,6-Sep-12,null,12-Mar-19,"Obsessive Compulsive Disorder Institute at McLean Hospital, Belmont, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT01679457
NCT01680107,D-cycloserine Augmented CBT for Panic Disorder,,Terminated,No Results Available,Panic Disorder,Drug: d-cycloserine|Drug: placebo|Behavioral: cognitive-behaviour therapy,self-reported and clinician-rated anxiety and depression measures|emotional information processing,University of Oxford|Medical Research Council,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,33,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",MRC-01|2012-003191-39,Oct-12,31-Oct-17,30-Apr-18,6-Sep-12,null,3-May-18,"Department of Psychiatry, University of Oxford, Oxford, United Kingdom",,https://ClinicalTrials.gov/show/NCT01680107
NCT01678846,Good Schools Study,GSS,Completed,Has Results,Physical Violence|Educational Achievement|Mental Health|Sexual Violence|Violence Against Children,Behavioral: Good School Toolkit,Physical Violence From School Staff|Child Mental Health|Educational Achievement: Word Recognition in English|Safety and Well-being at School,"London School of Hygiene and Tropical Medicine|Raising Voices|Institute of Education, UK|Makerere University",All,"Child, Adult, Older Adult",Not Applicable,3820,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,LSHTM_6183,Jun-12,Jul-14,Jul-14,5-Sep-12,26-Jan-16,26-Jan-16,"District-wide, Multiple, Luwero District, Uganda",,https://ClinicalTrials.gov/show/NCT01678846
NCT01677429,The Assessment and Treatment of Balance Impairment Using Virtual Reality (VR) in Panic Disorder Patients,,Unknown status,No Results Available,Panic Disorder|Proprioceptive Disorders,Device: VR movie + balance challenge|Device: still pictures from VR|Behavioral: Cognitive Behavioral Therapy,Change in Panic or anxiety levels|Change in Balance impairment,Sheba Medical Center,All,18 Years to 45 Years   (Adult),Not Applicable,80,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",SHEBA-12-9520-AC-CTIL,Jun-15,Jun-16,Sep-16,3-Sep-12,null,24-Jun-15,"Sheba Medical Center, Sheba Rehabilitation Center for Advanced Technologies, Ramat Gan, Israel",,https://ClinicalTrials.gov/show/NCT01677429
NCT01674361,A Study of Bitopertin (RO4917838) in Combination With Selective Serotonin Reuptake Inhibitors (SSRIs) in Participants With Obsessive-Compulsive Disorder (OCD),,Completed,No Results Available,Obsessive-Compulsive Disorder,Drug: Bitopertin|Drug: Placebo|Drug: SSRI,Change From Baseline in Total Score on Yale-Brown Obsessive Compulsive Scale (Y-BOCS) After 12 Weeks of Treatment|Change From Baseline in Clinical Global Impression of Severity (CGI-S) Score After 12 Weeks of Treatment|Percentage of Participants with Response as per Pre-defined Criteria Based on the Y-BOCS and CGI|Change From Baseline in Global Social Functioning Using Sheehan Disability Scale (SDS) Total Score After 12 Weeks of Treatment|Change From Baseline in Global Social Functioning Using SDS Domain Scores After 12 Weeks of Treatment|Change From Baseline in Obsessive Compulsive Inventory-Revised (OCI-R) Score After 12 Weeks of Treatment|Change From Baseline in Columbia Suicide Severity Rating Scale After 12 Weeks of Treatment|Change From Baseline in 36-Item Short-Form Health Survey (SF-36) - Mental Component Summary After 12 Weeks of Treatment|Change From Baseline in SF-36 - Physical Component Summary After 12 Weeks of Treatment|Change From Baseline in SF-36 - Domain Scores After 12 Weeks of Treatment|Area Under The Concentration-Time Curve of Bitopertin,Hoffmann-La Roche,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,99,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WN28137,31-Dec-12,30-Apr-15,30-Apr-15,28-Aug-12,null,2-Aug-17,"Excell Research, Oceanside, California, United States|Stanford University School of Medicine, Stanford, California, United States|Yale University School of Medicine; Neuroscience Research Training Program, New Haven, Connecticut, United States|Compass Research North, LLC, Leesburg, Florida, United States|Medical Research Group of Central Florida, Orange City, Florida, United States|University of South Florida, Saint Petersburg, Florida, United States|University of South Florida, Tampa, Florida, United States|iResearch Atlanta, Decatur, Georgia, United States|Carman Research, Smyrna, Georgia, United States|Uni of Chicago; Centre For Advanced Medicine, Chicago, Illinois, United States|Louisiana Research Associates, New Orleans, Louisiana, United States|Massachusetts General Hospital - East, Boston, Massachusetts, United States|Boston Clinical Trials, Boston, Massachusetts, United States|Ambulatory Research Center (ARC), Department of Psychiatry, Minneapolis, Minnesota, United States|Precise Research Centers, Flowood, Mississippi, United States|St Louis Clinical Trials, Saint Louis, Missouri, United States|Mount Sinai School of Medicine; Department of Psychiatry, New York, New York, United States|Medical Research Network - New York, New York, New York, United States|Finger Lakes Clinical Research, Rochester, New York, United States|North Star Research, Middleburg Heights, Ohio, United States|Ips Research Company, Oklahoma City, Oklahoma, United States|Keystone Clinical Studies, LLC, Norristown, Pennsylvania, United States|Butler Hospital - Department of Psychiatry and Human Behavior, Providence, Rhode Island, United States|Clinical Neuroscience Solutions,Inc, Memphis, Tennessee, United States|FutureSearch Trials, LP, Austin, Texas, United States|Eastside Therapeutic Resource, Kirkland, Washington, United States|Dean Foundation, Middleton, Wisconsin, United States|Chokka Center for Integrative Health, Edmonton, Alberta, Canada|Okanagan Clinical Trials, Kelowna, British Columbia, Canada|True North Clinical Research-Halifax, Halifax, Nova Scotia, Canada|True North Clinical Research Kentville, Kentville, Nova Scotia, Canada|McMaster University - MacAnxiety Research Centre, Hamilton, Ontario, Canada|Sunny Johnson Medical Research Associates Inc.; Medical Research Associates, Mississauga, Ontario, Canada|START Clinic for Mood & Anxiety Disorders, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT01674361
NCT01672554,Clinical Benefits of Seroquel XR in Anxiety Disorder,,Unknown status,No Results Available,Schizophrenia|Anxiety,Drug: Quetiapine XR,Anxiety disorder|Tolerability and safety,Corporation de Recherche en Neuropsycho Pharmacologie de Quebec,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,40,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,D1443C00030,Dec-08,Apr-12,Oct-13,27-Aug-12,null,27-Aug-12,"CRNPQ, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT01672554
NCT01673035,Internet Treatment for Health Anxiety,HA-X,Completed,No Results Available,Hypochondriasis,"Behavioral: CBT, exposure and response prevention|Behavioral: BSM, stress management and applied relaxation",Health Anxiety Inventory (HAI)|Illness attitude scale (IAS)|Whiteley Index (WI)|Montgomery Åsberg depression rating scale-self report (MADRS-S)|Beck Anxiety Inventory (BAI)|Anxiety Sensitivity Index (ASI)|Insomnia severity index (ISI)|Sheehan disability scale (SDS)|Trimbos and institute of medical technology assessment cost questionnaire (TIC-P)|Euroqol-5D (EQ-5D)|Obsessive compulsive inventory revised (OCI-R)|Yale-brown obsessive compulsive scale (YBOCS)|AUDIT (alcohol use),Karolinska Institutet,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,178,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,HA-X,Sep-12,Dec-13,Dec-15,27-Aug-12,null,3-Mar-16,"Karolinska Institutet, Stockholm,, Stockholm, Sweden",,https://ClinicalTrials.gov/show/NCT01673035
NCT01671033,Treatment of Panic Disorder Via Internet With a Wireless Temperature Biofeedback Ring,,Terminated,No Results Available,Panic Disorder,Behavioral: Biofeedback|Behavioral: Muscle Relaxation,Score Change of The Panic Disorder Severity Scale(PDSS)|Score Change of relaxation-rating,Chimei Medical Center|National Cheng Kung University,All,20 Years to 60 Years   (Adult),Not Applicable,9,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IRB 09902-006,Feb-10,Dec-10,Jan-11,23-Aug-12,null,23-Aug-12,"Chimei Medical Center, Tainan, Taiwan",,https://ClinicalTrials.gov/show/NCT01671033
NCT01667328,Preoperative Massage in Breast Surgery Patients,,Completed,No Results Available,Anxiety|Presurgical Anxiety|Breast Cancer,Procedure: Massage therapy|Procedure: Standard of care,Anxiety level,Vassar Brothers Medical Center|Health Quest Systems|Dyson Center for Cancer Care,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,299,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,2012-2,Jun-12,Mar-18,19-Mar-18,17-Aug-12,null,3-May-18,"Vassar Brothers Medical Center, Poughkeepsie, New York, United States",,https://ClinicalTrials.gov/show/NCT01667328
NCT01667809,CBT vs RTW Intervention for Patients With Common Subclinical Mental Illness in Primary Care,,Completed,No Results Available,Anxiety Disorders|Major Depression|Stress Disorders|Primary Insomnia,Behavioral: Cognitive behavior therapy|Behavioral: Return to work,Sick leave|Clinician Severity Rating (CSR)|Montgomery-Åsberg Depression Rating Scale-Self-report (MADRS-S)|Insomnia Severity Index (ISI)|Health Anxiety Inventory (HAI)|Perceived Stress Scale (PSS)|Trimbos and Institute of Technology Cost Questionnaire for Psychiatry (TIC-P)|Quality of Life Inventory (QOLI)|EuroQol-5 dimension (EQ5D)|Sheehan Disability Scales (SDS)|Self-rated health 5 (SRH-5)|Obsessive Compulsive Inventory-Revised (OCI-R)|Liebowitz Social Anxiety Scale Self-report (LSAS-SR)|Panic Disorder Severity Scale Self-rated (PDSS-SR)|Penn-State Worry Questionnaire (PSWQ)|Post Traumatic Stress Disorder Symptom Scale-Self report (PTSDSS),"Karolinska Institutet|Stockholm County Council, Sweden",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,5,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,GVC CBT vs RTW II,Aug-12,Dec-15,Dec-15,17-Aug-12,null,3-Mar-16,"Karolinska Institutet and Gustavsberg primary care center, Stockholm,, Stockholm, Sweden",,https://ClinicalTrials.gov/show/NCT01667809
NCT01667822,"Cognitive Behavioral Therapy, Guided Self Help Versus Individual Therapy",,Completed,No Results Available,Anxiety Disorders|Major Depression|Stress Disorders|Primary Insomnia,Behavioral: Continued self help CBT|Behavioral: Individual CBT,Absolute improvement in disorder specific symptoms defined as closer to healthy than to clinical population or 2 standard deviations from clinical population|Montgomery-Åsberg Depression Rating Scale-Self-report (MADRS-S)|Work ability index (WAI)|Insomnia Severity Index (ISI)|Health Anxiety Inventory (HAI)|Perceived Stress Scale (PSS)|Trimbos and Institute of Technology Cost Questionnaire for Psychiatry (TIC-P)|Quality of Life Inventory (QOLI)|EuroQol-5 dimension (EQ5D)|Sheehan Disability Scales (SDS)|Self-rated health 5 (SRH-5)|Obsessive Compulsive Inventory-Revised (OCI-R)|Liebowitz Social Anxiety Scale Self-report (LSAS-SR)|Panic Disorder Severity Scale Self-rated (PDSS-SR)|Penn-State Worry Questionnaire (PSWQ),"Karolinska Institutet|Stockholm County Council, Sweden",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,396,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,Self help CBT,Aug-12,Dec-15,Dec-15,17-Aug-12,null,18-Oct-16,"Karolinska Institutet and Gustavsberg primary care center, Stockholm,, Stockholm, Sweden",,https://ClinicalTrials.gov/show/NCT01667822
NCT01663025,The Effects of Intra Operative Hand Reflexology for Patients Receiving Out Patient Vein Surgery,,Completed,No Results Available,Pain|Anxiety,Behavioral: Hand Reflexology,Pain|Anxiety|Satisfaction with treatment,The Whiteley Clinic,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,WC1HM,Jan-13,Jan-14,Feb-14,13-Aug-12,null,19-May-14,"The Whiteley Clinic at the Wimpole Clinic, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01663025
NCT01663909,Pain Management Using Guided Imagery for Adolescents Post-spinal Fusion,,Completed,No Results Available,Pain|Scoliosis,Behavioral: Guided imagery intervention,Level of pain intensity|Level of anxiety|Level of coping,St. Justine's Hospital,All,"11 Years to 20 Years   (Child, Adult)",Not Applicable,40,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,Scoliosis,May-10,Sep-11,Dec-11,13-Aug-12,null,13-Aug-12,"CHU Ste-Justine Hospital, Montreal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT01663909
NCT01659736,Transcranial Magnetic Stimulation Treatment for Generalized Anxiety Disorder,,Completed,Has Results,Generalized Anxiety Disorder,Device: TMS,Change in the Structured Interview Guide for the Hamilton Anxiety Rating Scale (SIGH-A) at Post-treatment and 3-month Follow-up.|Responder Status|Remission Status,Hartford Hospital|Neuronetics,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,26,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",DIEF003523.1,May-12,Dec-14,Dec-14,8-Aug-12,7-Jan-16,27-Apr-16,"Hartford Hospital, Hartford, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT01659736
NCT01659879,Multimedia Based Information to Parents in a Pediatric Acute Ward: A Randomized Controlled Trial,,Completed,No Results Available,Health Communication,Behavioral: Multimedia information|Behavioral: verbal information,parental anxiety|parental satisfaction with nursing care|Parental satisfaction with the health information given in the acute ward.,Norwegian University of Science and Technology|St. Olavs Hospital,All,"Child, Adult, Older Adult",Not Applicable,101,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,LBK-2010/12-1,Jan-11,Mar-11,Aug-11,8-Aug-12,null,14-Feb-17,"Department of Pediatrics, St. Olav's University Hospital, Trondheim, Norway",,https://ClinicalTrials.gov/show/NCT01659879
NCT01659125,Effectiveness and Neuropsychological Predictors of Guided Self-Help for Obsessive-Compulsive Disorder (OCD),,Completed,Has Results,Obsessive-Compulsive Disorder,"Behavioral: ""OCFighter""",Change in Yale-Brown Obsessive-Compulsive Scale (Y-BOCS)|Responder Status,Hartford Hospital,All,"18 Years to 69 Years   (Adult, Older Adult)",Not Applicable,26,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DIEF003581HI,Aug-12,Jun-14,Jun-14,7-Aug-12,7-Jan-16,7-Jan-16,"Hartford Hospital, Hartford, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT01659125
NCT01659359,The Effect of Virtual Reality Glasses on Pain and Anxiety,,Completed,No Results Available,Pain and Anxiety,Device: Virtual reality glasses and Lidocaine|Drug: Lidocaine,Virtual reality glasses decreased pain and anxiety during episiotomy,Mashhad University of Medical Sciences,Female,18 Years to 34 Years   (Adult),Phase 2|Phase 3,30,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,virtual reality glasses,Jan-11,Jul-12,Aug-12,7-Aug-12,null,8-Aug-12,,,https://ClinicalTrials.gov/show/NCT01659359
NCT01658059,Reducing Children's Anxiety Using Homeopathic Remedy Before Dental Treatment,,Completed,Has Results,Children's Dental Anxiety,Other: Homeopathic remedy|Other: Placebo,Reducing Children's Anxiety,Hadassah Medical Organization,All,5 Years to 12 Years   (Child),Not Applicable,22,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Other",rcauhr-HMO-CTIL,Sep-12,Dec-14,Dec-15,6-Aug-12,11-Mar-19,20-Mar-19,"Hadassah Medical Organization, Jerusalem, Israel",,https://ClinicalTrials.gov/show/NCT01658059
NCT01655485,Effect of a Social Script iPAD Application for Children With Autism Spectrum Disorder,,Completed,No Results Available,Anxiety,Other: Patient teaching,Child behaviors|Parent anxiety,Medical College of Wisconsin|Marquette University,All,4 Years to 16 Years   (Child),Not Applicable,32,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,255769-1,Oct-11,Jul-13,Jul-13,2-Aug-12,null,7-Aug-13,"Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT01655485
NCT01653548,Evaluating a Novel Method of Generalizing Emotion Regulation,EMOGEN,Completed,No Results Available,Problems With Emotion Regulation|Psychological Distress|Difficulties Coping With Negative Emotions|Anxiety|Depression|Borderline Personality Disorder,Behavioral: Habituation Reminder Training|Behavioral: Habituation Reminder|Behavioral: Habituation,Reduction in emotional arousal or speed to recovery from emotional arousal following a stressor.|Phone use feasibility,Duke University|National Institute of Mental Health (NIMH),All,18 Years to 55 Years   (Adult),Not Applicable,372,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science,Pro00035922|1R01MH095806-01A1,Aug-12,May-16,May-16,31-Jul-12,null,23-Jun-16,"Duke University Medical Center-Civitan Bldg, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT01653548
NCT01654510,A Systems Level Intervention for Unemployed Persons With Social Anxiety Disorder,,Completed,No Results Available,Social Anxiety Disorder,Behavioral: Cognitive Behavioral Therapy Group|Other: Vocational Services as Usual,Liebowitz Social Anxiety Scale|Employment Status,University of Michigan,All,18 Years to 60 Years   (Adult),Phase 2|Phase 3,165,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,HUM00017734,Apr-08,Mar-12,Mar-12,31-Jul-12,null,31-Jul-12,,,https://ClinicalTrials.gov/show/NCT01654510
NCT01652768,PRESENCE Project: An Early Palliative Care Intervention in Brain Tumors,,Terminated,No Results Available,Malignant Brain Tumors,Other: Research Questionnaires|Other: Palliative Care Team|Other: Educational Information Session for Patients and Caregivers|Other: Contact every 2 weeks|Other: Follow-up Surgical Visit Session|Other: Medical and/or Radiation Oncology Appointment Session,Feasibility of the intervention will be measured by participant surveys.|Change in distress level|Change in Anxiety level|Change in Depression level|Caregiver Response to the Caregiving Experience|Caregiver Mastery,Case Comprehensive Cancer Center,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,1,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,CASE1310,Dec-11,Aug-13,Aug-13,30-Jul-12,null,29-Aug-13,"Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT01652768
NCT01652807,Yoga for Stress and Mental Health,,Completed,No Results Available,Physiological Stress|Psychological Distress|Depression|Anxiety,Behavioral: Hatha Yoga,Perceived Stress Questionnaire|Feasibility|Distress Tolerance,Southern Methodist University,Female,25 Years to 45 Years   (Adult),Not Applicable,52,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,2012-028-DEBL,Feb-12,Sep-13,Sep-13,30-Jul-12,null,14-Jan-15,"Southern Methodist University, Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT01652807
NCT01649895,D-Cycloserine as an Adjunct to Internet-CBT for OCD,,Completed,No Results Available,Obsessive-compulsive Disorder,Drug: D-Cycloserine|Drug: Placebo,Yale Brown Obsessive Compulsive Scale (Y‐BOCS) (clinician rated)|Obsessive Compulsive Scale - Revised (OCI-R)|Yale Brown Obsessive Compulsive Scale (Y‐BOCS)(self-rated)|Montgomery Asberg Depression Rating Scale Self-rating (MADRS-S)|Euroqol|Trimbos and institute of medical technology assessment cost questionnaire for psychiatry (TIC-P)|Global assessment of functioning (GAF)|Clinical global impression (CGI)|Adverse events,"Christian Rück|The Swedish Research Council|Königska|Stockholm County Council, Sweden|Karolinska Institutet",All,"18 Years to 100 Years   (Adult, Older Adult)",Phase 4,128,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2011‐002819‐28,Aug-12,Jun-16,Jun-16,25-Jul-12,null,12-Dec-16,"M46 Huddinge sjukhus, Internetpsykiatrienheten/mottagningen för tvångssyndrom, Stockholm, Sweden",,https://ClinicalTrials.gov/show/NCT01649895
NCT01644812,Lifestyle Interventions for Generalized Anxiety Disorder,,Terminated,No Results Available,Aerobic Exercise|Stretching,Behavioral: Aerobic exercise|Behavioral: Stretching,Penn State worry Questionnaire|GAD-7|Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q)|Clinical Global Impressions Improvement/Severity (CGI)|Beck Anxiety Inventory (BAI)|Beck Depression Inventory (BDI)|Anxiety Sensitivity|Social Physique Anxiety,Southern Methodist University|Boston University,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,10,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2012-001-SMIJ-N,Mar-12,Jul-13,null,19-Jul-12,null,20-Aug-13,"BU Center for Anxiety and Related Disorders, Boston University, Boston, Massachusetts, United States|Anxiety Research and Treatment Program, SMU Department of Psychology, Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT01644812
NCT01644851,"Cognitive Training for Post Traumatic Stress Disorder: Effects on Cognitive, Emotional, and Brain Function",,Unknown status,No Results Available,Posttraumatic Stress Disorders,Behavioral: Executive function training,Neural activity in prefrontal regions during cognitive and emotional processing measured by functional magnetic resonance imaging.|Cognitive functioning as measured by neuropsychological assessment.,"University of Missouri, Kansas City|University of Kansas",Male,18 Years to 45 Years   (Adult),Not Applicable,40,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,UMKC SS11-212e,Jul-12,Jul-15,Jul-15,19-Jul-12,null,8-Dec-14,"Univesity of Missouri - Kansas City, Kansas City, Missouri, United States",,https://ClinicalTrials.gov/show/NCT01644851
NCT01644916,"""Consultation Liaison and Integrated Care for COPD Patients With Psychiatric Co-Morbidity""",COPD_HSRG,Completed,No Results Available,Chronic Obstructive Pulmonary Disease|Anxiety|Depression,Procedure: Integrated care|Procedure: Usual control,HADS score|Resource use and direct costs of care,"National University, Singapore|National University Hospital, Singapore|Singapore General Hospital|Alexandra Hospital, Singapore|St Luke's Hospital, Singapore|Changi General Hospital",All,"55 Years to 90 Years   (Adult, Older Adult)",Not Applicable,295,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research,COPD_HSRG_2010,Aug-12,Dec-17,Dec-17,19-Jul-12,null,7-Sep-18,"National University Hospital System, Singapore, Singapore",,https://ClinicalTrials.gov/show/NCT01644916
NCT01643642,Cost- Effectiveness Study of Brief Interventions for Mood and Anxiety Disorders,K&K,Completed,No Results Available,Depressive Disorder|Anxiety Disorder,Other: Cognitive behavioral treatment/farmacotherapy intervention|Other: Treatment As Usual,Effectiveness of the intervention|Cost-effectiveness intervention,"Leiden University Medical Center|Rivierduinen, Centre for Personality disorders Jelgersma",All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,182,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,P09.146/NL29380.058.09,Mar-10,Dec-12,Dec-12,18-Jul-12,null,11-Jun-13,"Rivierduinen, South Holland, Netherlands",,https://ClinicalTrials.gov/show/NCT01643642
NCT01642628,The Effect of Mirror Education for Women Undergoing Mastectomy,,Completed,No Results Available,Emotional Distress|Anxiety|Depression,Other: Mirror Education,Emotional well-being|Body image|Anxiety|Depression|Use of mirrors,Texas Woman's University|Memorial Hermann Health System|M.D. Anderson Cancer Center,Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,19,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,17006,Aug-12,Dec-13,Dec-13,17-Jul-12,null,1-Apr-14,"Memorial Hermann Healthcare System, Houston, Texas, United States|Texas Woman's University, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT01642628
NCT01636791,CBT Versus a Return to Work Intervention for Patients With Common Mental Illness in Primary Care,CBT vs RTW I,Completed,No Results Available,Anxiety Disorders|Major Depression|Stress Disorders|Primary Insomnia,Behavioral: Cognitive behavior therapy|Behavioral: Return to work,Sick leave|Clinician Severity Rating (CSR)|Montgomery-Åsberg Depression Rating Scale-Self-report (MADRS-S)|Work ability index (WAI)|Insomnia Severity Index (ISI)|Health Anxiety Inventory (HAI)|Perceived Stress Scale (PSS)|Trimbos and Institute of Technology Cost Questionnaire for Psychiatry (TIC-P)|Quality of Life Inventory (QOLI)|EuroQol-5 dimension (EQ5D)|Sheehan Disability Scales (SDS)|Self-rated health 5 (SRH-5)|Obsessive Compulsive Inventory-Revised (OCI-R)|Liebowitz Social Anxiety Scale Self-report (LSAS-SR)|Panic Disorder Severity Scale Self-rated (PDSS-SR)|Penn-State Worry Questionnaire (PSWQ)|Post Traumatic Stress Disorder Symptom Scale-Self report (PTSDSS),"Karolinska Institutet|Stockholm County Council, Sweden",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,211,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,GVC CBT vs RTW,Sep-12,Dec-15,Dec-15,10-Jul-12,null,3-Mar-16,"Karolinska Institutet and Gustavsberg primary care center, Stockholm, Sweden",,https://ClinicalTrials.gov/show/NCT01636791
NCT01637103,Treatment of Depressive Symptoms in Breast Cancer Patients: Comparison of Cognitive Therapy and Bright Light Therapy,,Completed,No Results Available,Treatment of Depressive Symptoms in Cancer Patients,Behavioral: Cognitive therapy of depression|Behavioral: Bright light therapy,Changes in depressive symptoms|Changes in subjective and objective parameters of sleep|Changes in fatigue|Changes in anxiety|Changes in quality of life,CHU de Quebec-Universite Laval|Canadian Institutes of Health Research (CIHR),All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,62,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,H10-12-123,Sep-11,Feb-15,Feb-15,10-Jul-12,null,10-May-16,"L'Hôtel-Dieu de Québec, Québec, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT01637103
NCT01635569,Clinical Outcomes in Pediatric Obsessive-Compulsive Disorder,,Recruiting,No Results Available,Obsessive-compulsive Disorder,Behavioral: Group-based family cognitive-behavioural therapy|Other: Waitlist,Children's Yale Brown Obsessive-Compulsive Scale (CY-BOCS),University of British Columbia|Michael Smith Foundation for Health Research,All,"5 Years to 18 Years   (Child, Adult)",Not Applicable,180,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,H12-01656,Oct-12,Jun-19,Jun-19,9-Jul-12,null,13-Sep-18,"BC Children's Hospital Research Institute, Vancouver, British Columbia, Canada",,https://ClinicalTrials.gov/show/NCT01635569
NCT01633008,Acceptance and Commitment Therapy for Adolescents and Young Adults With Neurofibromatosis and Chronic Pain,,Completed,No Results Available,Neurofibromatosis,Behavioral: ACT Workshop,"Pain improvement|Value of the ACT for future Ph2 trial.|Psychological well-being &amp; stress changes in parents|Explore improvements of pain interference, abilities, coping, anxiety,depression, etc|Relationship between pain and treatment adherence",National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),All,"12 Years to 99 Years   (Child, Adult, Older Adult)",Early Phase 1,28,NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,120155|12-C-0155,15-Jun-12,1-May-14,10-Jan-17,4-Jul-12,null,27-Sep-18,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT01633008
NCT01633125,Group Music Therapy for Chinese Prisoners,,Unknown status,No Results Available,Anxiety|Depression|Self-esteem,Other: Group music therapy,Change from baseline in State Trait Anxiety Inventory at 10 weeks|Change from baseline in State Trait Anxiety Inventory at 20 weeks|Change from baseline in Beck Depression Inventory at 10 weeks|Change from baseline in Beck Depression Inventory at 20 weeks|Change from baseline in Rosenberg Self-esteem Inventory at 10 weeks|Change from baseline in Rosenberg Self-esteem Inventory at 20 weeks|Change from baseline in Texas Social Behavior Inventory at 10 weeks|Change from baseline in Texas Social Behavior Inventory at 20 weeks,Aalborg University,All,18 Years to 60 Years   (Adult),Not Applicable,192,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Aau-1,Apr-12,Apr-13,Apr-14,4-Jul-12,null,4-Jul-12,"Xin An Prison, Beijing, Beijing, China",,https://ClinicalTrials.gov/show/NCT01633125
NCT01631500,Effects of an Integrative Treatment Model to Reduce Anxiety and Depression in Minor Mental Health Problems and Medically Unexplained Symptoms,,Completed,No Results Available,Depression|Anxiety|Irritable Bowel Syndrome|Fibromyalgia,Behavioral: Conventional treatment|Other: Integrative treatment|Other: Therapeutic acupuncture,Pre-post treatment change in anxiety as assessed with the Hospital Anxiety and Depression scale (HAD)|Pre-post treatment change in health-related quality of life (assessed with the SF-36 Mental Component Summary score(MCS))|Pre-post treatment change in sense of coherence (SOC)|Pre-post treatment change in depression as assessed with the Hospital Anxiety and Depression scale (HAD),Göteborg University|Ekhagastiftelsen|Fyrbodal Research and Development Council|Vastra Gotaland Region,All,20 Years to 55 Years   (Adult),Not Applicable,120,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,University of Gothenburg|VGFOUREG-82511,Jan-10,Jan-11,Jan-11,29-Jun-12,null,30-Aug-12,"Fyrbodal Research and Development Council, Vänersborg, Sweden",,https://ClinicalTrials.gov/show/NCT01631500
NCT01631682,Pilot Study of Pharmaceutical and Behavioral Interventions to Treat Anxiety Disorders,,Completed,Has Results,Posttraumatic Stress Disorder|Anxiety Disorder,Drug: Propranolol|Behavioral: Reactivation|Drug: Mifepristone|Drug: Intranasal oxytocin,Change From Baseline Skin Conductance Response,Massachusetts General Hospital,All,18 Years to 35 Years   (Adult),Phase 4,186,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),W81XWH-11-2-0092,Nov-10,Jan-15,Jan-15,29-Jun-12,23-Feb-17,23-Feb-17,"Massachusetts General Hospital, Charlestown, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT01631682
NCT01629966,"Safety, Efficacy and Tolerability of Vilazodone in Generalized Anxiety Disorder",VLZ-MD-05,Completed,No Results Available,Generalized Anxiety Disorder,Drug: Placebo|Drug: Vilazodone,Hamilton Rating Scale for Anxiety (HAM-A) total score|Sheehan Disability Scale (SDS) total score,Forest Laboratories,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,680,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",VLZ-MD-05,Jun-12,Feb-14,Mar-14,28-Jun-12,null,18-Mar-15,"Forest Investigative Site 001, Birmingham, Alabama, United States|Forest Investigative Site 021, Beverly Hills, California, United States|Forest Investigative Site 023, Glendale, California, United States|Forest Investigative Site 011, Paramount, California, United States|Forest Investigative Site 026, Norwich, Connecticut, United States|Forest Investigative Site 027, Waterbury, Connecticut, United States|Forest Investigative Site 005, Delray Beach, Florida, United States|Forest Investigative Site 014, Oakland Park, Florida, United States|Forest Investigative Site 019, South Miami, Florida, United States|Forest Investigative Site 038, Atlanta, Georgia, United States|Forest Investigative Site 035, Decatur, Georgia, United States|Forest Investigative Site 028, Chicago, Illinois, United States|Forest Investigative Site 030, Schaumburg, Illinois, United States|Forest Investigative Site 029, Topeka, Kansas, United States|Forest Investigative Site 033, Wichita, Kansas, United States|Forest Investigative Site 010, Lake Charles, Louisiana, United States|Forest Investigative Site 031, Baltimore, Maryland, United States|Forest Investigative Site 025, Boston, Massachusetts, United States|Forest Investigative Site 037, St. Louis, Missouri, United States|Forest Investigative Site 015, Las Vegas, Nevada, United States|Forest Investigative Site 016, Berlin, New Jersey, United States|Forest Investigative Site 007, Brooklyn, New York, United States|Forest Investigative Site 024, New York, New York, United States|Forest Investigative Site 032, New York, New York, United States|Forest Investigative Site 012, New York, New York, United States|Forest Investigative Site 020, Bismarck, North Dakota, United States|Forest Investigative Site 008, Cincinnati, Ohio, United States|Forest Investigative Site 041, Dayton, Ohio, United States|Forest Investigative Site 004, Oklahoma City, Oklahoma, United States|Forest Investigative Site 034, Oklahoma City, Oklahoma, United States|Forest Investigative Site 013, Portland, Oregon, United States|Forest Investigative Site 006, Memphis, Tennessee, United States|Forest Investigative Site 017, Wichita Falls, Texas, United States|Forest Investigative Site 003, Salt lake City, Utah, United States|Forest Investigative Site 018, Charlottesville, Virginia, United States|Forest Investigative Site 040, Bellevue, Washington, United States|Forest Investigative Site 039, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT01629966
NCT01630681,Internet Based Screening and Stepped Care for Cancer Patients With Anxiety and Depression Symptoms,AdultCan,Completed,No Results Available,Cancer|Anxiety|Depression,Behavioral: Internet-based stepped care,Change in depression|Change in anxiety|Change in health related quality of life|Change in Cancer related fatigue (CRF)|Change in insomnia|Change in posttraumatic stress,Uppsala University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,229,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,U-CARE AdultCan,Apr-13,Dec-16,Dec-16,28-Jun-12,null,16-Feb-17,"The hospital i Gävle, Gävle, Gävleborg, Sweden|Uppsala university hospital, Uppsala, Uppland, Sweden|Västmanlands hospital Västerås, Västerås, Västmanland, Sweden",,https://ClinicalTrials.gov/show/NCT01630681
NCT01627444,Acupuncture in Mothers of Very Low Birth Weight Infants,,Unknown status,No Results Available,Anxiety,Procedure: Ear acupuncture,Reduced anxiety,University of Sao Paulo,Female,18 Years to 45 Years   (Adult),Phase 2,20,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Supportive Care",Acupuncture_doctorate,Aug-11,Aug-12,Aug-12,25-Jun-12,null,25-Jun-12,"Hospital Universitário de Londrina, Londrina, Paraná, Brazil",,https://ClinicalTrials.gov/show/NCT01627444
NCT01623583,Effect of Including Synera® in Discussions on Dialysis Access Conversion in Patients With Needle Phobias,,Terminated,No Results Available,Needle Phobia|Phobic Disorders,Other: Enhanced Needle Phobia Intervention|Other: Standard Needle Phobia Intervention,Proportion of patients achieving a score of 3 or 4 on the stages of change questionnaire|Proportion of patients for whom the intervention was successful,Davita Clinical Research|Nuvo Research Inc.,All,"18 Years and older   (Adult, Older Adult)",Phase 4,10,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,2012-02-02-NVO-MI,Apr-14,Mar-15,Mar-15,20-Jun-12,null,16-Aug-16,"Sunset Dialysis Center, Rancho Cordova, California, United States|Natomas Dialysis, Sacramento, California, United States|Asheville Kidney Center, Asheville, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT01623583
NCT01624168,Effects of Tai Chi Chuan on Psychobiological Indicators of Anxiety and Sleep Quality in Young Adults,,Completed,Has Results,Anxiety,Behavioral: Anxiety Management Education|Behavioral: 10 week tai chi intervention|Behavioral: Enhanced tai chi instruction,Retention of Randomized Subjects During Intervention|Retention of Randomized Subjects for Follow-up|Adherence to Out-of-class Practice|Adherence to Practice After the Intervention|Change From Baseline in State Anxiety Scores|Change From Baseline in Pittsburgh Sleep Quality Index Scores,Appalachian State University,All,18 Years to 40 Years   (Adult),Not Applicable,75,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EBT Feasibility,Jan-13,Jun-14,Aug-14,20-Jun-12,29-Sep-15,8-Jan-16,"Appalachian State University, Boone, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT01624168
NCT01624584,A Study Comparing Two Treatments for Child With Anxiety,,Completed,No Results Available,Anxiety,Behavioral: Experimental treatment|Behavioral: Traditional Treatment,Pediatric Anxiety Rating Scale|Pediatric Anxiety Rating Scales,Mayo Clinic,All,7 Years to 17 Years   (Child),Phase 3,15,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,11-008970,Jun-12,Aug-14,Aug-14,20-Jun-12,null,10-Apr-15,"Mayo Clinic in Rochester, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT01624584
NCT01622374,"Effects of ""Music for the Mind"" on Pre-operative Anxiety in Dentistry",,Completed,No Results Available,Dental Anxiety,Behavioral: Music,STAI Inventory|Heart rate|Systolic blood pressure|Diastolic blood pressure,Azad University of Medical Sciences,All,"17 Years to 70 Years   (Child, Adult, Older Adult)",Phase 2|Phase 3,120,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention",Aminpasha_CT0001,Jan-11,Mar-11,Apr-11,19-Jun-12,null,19-Jun-12,,,https://ClinicalTrials.gov/show/NCT01622374
NCT01621815,Variance of Video Games Playing Patterns Among Adolescents With Psychiatric Disorders,,Completed,No Results Available,ADHD|Conduct|Depression|Anxiety|PDD,Behavioral: Video Game,,Shalvata Mental Health Center,Male,"13 Years to 18 Years   (Child, Adult)",Not Applicable,46,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,SH-12-13,Jul-12,Jan-15,Jan-15,18-Jun-12,null,20-May-15,"Shalvata MHC, Hod HaSharon, Israel",,https://ClinicalTrials.gov/show/NCT01621815
NCT01621828,Multimedia Information and Pre-operative Anxiety,MIPA,Terminated,No Results Available,Anxiety,Other: video|Other: leaflet,pre-operative anxiety,Imperial College London,All,"18 Years to 90 Years   (Adult, Older Adult)",Not Applicable,50,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care,CRO1879,Jul-12,Aug-12,Aug-12,18-Jun-12,null,9-May-19,"Imperial College Healthcare NHS Trust Charing Cross Hospital, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01621828
NCT01616797,A Novel Neurobehavioral Intervention for Emotion Regulation in Anxiety and Depression Across the Lifespan,,Completed,No Results Available,"Depression, Anxiety|Cognitive Training|Emotion Training|Emotion Regulation",Behavioral: Computerized neurobehavioral intervention,Completion|Proximal outcomes|Distal outcomes,Stanford University,All,18 Years to 60 Years   (Adult),Not Applicable,68,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,IRB-24813,Feb-14,Aug-18,Aug-18,12-Jun-12,null,7-Sep-18,"VA Palo Alto Health Care System (VAPAHCS), Palo Alto, California, United States|Stanford University Department of Pscyhiatry and Behavioral Sciences, Stanford, California, United States",,https://ClinicalTrials.gov/show/NCT01616797
NCT01617083,Antibiotic Treatment Trial for the PANDAS/PANS Phenotype,AZT,Completed,Has Results,PANS|PANDAS|Obsessive Compulsive Disorder (OCD),Drug: Azithromycin|Drug: Placebo,Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS)|Clinical Global Impressions-Severity OCD|Screen for Childhood Anxiety-Related Emotional Disorders (SCARED),University of South Florida|Massachusetts General Hospital,All,4 Years to 14 Years   (Child),Phase 2,47,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",6119-128500|270332,May-12,Dec-14,Dec-14,12-Jun-12,10-Apr-18,10-Apr-18,"Rothman Center for Neuropsychiatry, Saint Petersburg, Florida, United States",,https://ClinicalTrials.gov/show/NCT01617083
NCT01614041,Tandospirone Citrate in the Treatment of Patients With Generalized Anxiety Disorder,TACGAD,Recruiting,No Results Available,Generalized Anxiety Disorder,Drug: Usual dose treatment of Tandospirone|Drug: Comparative high dose of tandospirone treatment,Hamilton Anxiety Scale (HAMA) score changes from baseline to 6 weeks treatment|HAMA factor score changes after treatment,"Sumitomo Pharmaceutical (Suzhou) Co., Ltd.",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,300,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DSPC-SED-1101,Oct-11,Jul-19,Jul-19,7-Jun-12,null,17-Apr-19,"Shanghai Tongji Hospital, Shanghai, China",,https://ClinicalTrials.gov/show/NCT01614041
NCT01612104,Psychological First Aid With Children in a High Risk Group - a Repeated Single Case Design,,Completed,No Results Available,Post Traumatic Stress Disorder|Adjustment Disorder,Behavioral: Psychological First Aid,Children's Revised Impact of Event Scale (CRIES)|Child Post-Traumatic Cognition Inventory (CPTCI),NORCE Norwegian Research Centre AS,All,11 Years to 16 Years   (Child),Phase 1,11,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RKBU62,Mar-12,Jul-13,Aug-15,5-Jun-12,null,7-Dec-15,"The Children's House in Oslo, Oslo, Norway",,https://ClinicalTrials.gov/show/NCT01612104
NCT01612130,Valerian for Conscious Sedation in Patients Submitted to Impacted Lower Third Molars Surgery,,Completed,No Results Available,Dental Anxiety|Blood Pressure|Heart Rate,Drug: 100 mg of Valeriana officinalis L|Drug: Placebo 100mg,Signs and symptoms of anxiety|assessment of the blood pressure|Assesment of heart rate|Oxygen saturation|Side effects of drugs,"Federal University of the Valleys of Jequitinhonha and Mucuri|University of Campinas, Brazil",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,20,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",098/2002,Mar-03,Aug-03,Aug-03,5-Jun-12,null,6-Jun-12,"Oral-Maxillofacial Surgery Sector of the Piracicaba Dental School, Universidade Estadual de Campinas (Brazil), Piracicaba, São Paulo, Brazil",,https://ClinicalTrials.gov/show/NCT01612130
NCT01608295,Vilazodone for Treatment of Geriatric Depression,,Completed,Has Results,Major Depressive Disorder,Drug: Vilazodone; Viibryd|Drug: Paroxetine; Paxil,Hamilton Depression Rating Scale (HDRS)|UKU Side-effect Profile|Neurocognitive Measure: The Rey-Osterrieth Complex Figure Test|Changes in Proinflammatory Gene Expression From Baseline to Final Visit (up to 12 Weeks),"University of California, Los Angeles|Forest Laboratories",All,"60 Years and older   (Adult, Older Adult)",Phase 4,65,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",VII-IT-02,Jul-12,Sep-15,Sep-15,31-May-12,9-May-17,10-May-18,"UCLA Semel Institute, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT01608295
NCT01606852,Testing the Feasibility of Patient Controlled Sedation for Ventilated ICU Patients,PCS,Completed,Has Results,Acute Respiratory Failure|Anxiety,Drug: Dexmedetomidine,Aggregate Sedative Exposure During PCS Use (up to 5 Days).|Number of Participants With Adverse Events,"University of Minnesota - Clinical and Translational Science Institute|National Institute of Nursing Research (NINR)|Hospira, now a wholly owned subsidiary of Pfizer",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,15,Other|NIH|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IND 111693|R21NR012795,Mar-13,Jul-14,Jul-15,28-May-12,13-Mar-18,13-Mar-18,"University of Minnesota Medical Center, Minneapolis, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT01606852
NCT01606592,Psychotherapy Outcome and Self-selection Effects in Panic Disorder,,"Active, not recruiting",No Results Available,Panic Disorder (With or Without Agoraphobia),Behavioral: Panic Control Treatment (PCT)|Behavioral: Panic-Focused Psychodynamic Psychotherapy (PFPP)|Other: Waiting-list,"Change on Panic Disorder Severity Scale (PDSS; Shear et al., 1997)|Change in occupational status|Change in absence from work due to sickness|Change on Mobility Inventory for Agoraphobia (MI, Chambless et al, 1985)|Change in health care utilization (number of medical contacts, and emergency visits, medication)|Change on Clinical Outcomes in Routine Evaluation Scale(CORE; Evans et al., 2000)|Change on Montgomery Asberg Depression Rating Scale (MADRS-S; Montgomery & Asberg, 1979)",Region Skane,All,18 Years to 60 Years   (Adult),Not Applicable,216,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,POSE,Jan-10,Jun-19,Jun-19,25-May-12,null,9-Jan-19,"Lund University, Lund, Sweden",,https://ClinicalTrials.gov/show/NCT01606592
NCT01604707,Medical Yoga for Patients With Stress-related Symptoms and Diagnoses,,Completed,No Results Available,Stress|Anxiety|Depression,Other: Medical Yoga,Perceived stress scale|Shirom-Melamed Burnout Questionnaire,Region Örebro County,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,44,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,MEDYOG 1,Mar-11,May-12,May-12,24-May-12,null,4-Oct-16,,,https://ClinicalTrials.gov/show/NCT01604707
NCT01605253,Eszopiclone for the Treatment of Posttraumatic Stress Disorder,,Completed,No Results Available,Posttraumatic Stress Disorders,Drug: Eszopiclone|Drug: Placebo,Symptoms of Posttraumatic Stress Disorder|Sleep disturbance|Memory recall bias|Inflammatory markers (cytokines),Rush University Medical Center|National Institute of Mental Health (NIMH),All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,81,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",1R34MH091338-01A1,Mar-12,Dec-15,Dec-15,24-May-12,null,15-Apr-16,"Center for Anxiety and Traumatic Stress Disorders at Rush, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT01605253
NCT01599481,"Career Management to Improve Education, Employment and Retention for People With Anxiety and Depression",CAREER,Completed,No Results Available,Anxiety|Depression,Behavioral: Individual Career Management (ICM)|Behavioral: Standard Care,Length of Competitive Employment|Working Hours|Time to Employment|Salary|Number of Jobs|Job Terminations|Other occupational activity|Anxiety|Depression|Social Functioning|Health-related quality of Life|Work-related quality of Life|Self Esteem|Career Search Efficacy|Return to Work Efficacy|Productivity,South London and Maudsley NHS Foundation Trust,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,261,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Health Services Research,SLAM-ICM-1011,Oct-11,Apr-14,Apr-14,16-May-12,null,20-Aug-15,"Southwark Psychological Therapies Service, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01599481
NCT01599598,Coherence Training for Military Personnel,,Completed,No Results Available,Stress,Behavioral: Progressive Muscle Relaxation|Behavioral: Coherence Advantage,Stress symptomatology|School performance|Attrition,"United States Naval Medical Center, San Diego",All,"Child, Adult, Older Adult",Not Applicable,192,U.S. Fed,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NMCSD.2011.0130,Apr-12,Sep-14,Sep-14,16-May-12,null,19-Aug-16,"Surface Warfare Medicine Institute, San Diego, California, United States",,https://ClinicalTrials.gov/show/NCT01599598
NCT01599624,Stress Resilience Training System,SRTS,Completed,No Results Available,Stress|Anxiety|Depression|PTSD,Behavioral: Stress Resilience Training System (SRTS)|Behavioral: Progressive Muscle Relaxation (PMR),Perceived Stress Scale-10|Pittsburgh Sleep Quality Index (PSQI)|Generalized Anxiety Disorder Measure (GAD-7)|PTSD Checklist -Civilian Version (PCL-C)|Patient Health Questionnaire (PHQ-9)|Response to Stressful Experiences Scale (RSES)|Brief COPE|Unit Support|Quality of Life Scale (QOLS)|Performance Indicator|Attrition Rate,"United States Naval Medical Center, San Diego|Office of Naval Research (ONR)|Perceptronics Solutions",All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,68,U.S. Fed|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,NMCSD.2012.0032,Oct-12,May-15,May-15,16-May-12,null,19-Aug-16,,,https://ClinicalTrials.gov/show/NCT01599624
NCT01599143,Identifying Therapeutic Factors in an 8-Week (30 Hour) Mindfulness-Based Stress Reduction (MBSR) Program,mbsr,Completed,No Results Available,Cancer|Diabetes|Hypertension,Behavioral: Teaching Mindfulness-based Stress Reduction strategies,PSS-10|Toronto Mindfulness Scale (TMS),North York General Hospital,All,"18 Years and older   (Adult, Older Adult)",Phase 1,135,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,NYGH REB # 09-0041,Jan-09,Mar-12,Apr-12,15-May-12,null,15-May-12,,,https://ClinicalTrials.gov/show/NCT01599143
NCT01596608,"Magnetic Seizure Therapy (MST) for Treatment Resistant Depression, Schizophrenia, and Obsessive Compulsive Disorder",,Recruiting,No Results Available,Depressive Disorder|Schizophrenia|Schizoaffective Disorder|Obsessive-Compulsive Disorder,Device: Magnetic Seizure Therapy (MagPro MST),"Score on rating scale that corresponds to diagnosis: i) Hamilton Rating Scale for Depression, 24-item (HRSD-24); or ii) Yale-Brown Obsessive Compulsive Scale (Y-BOCS); or iii) Brief Psychiatric Rating Scale (BPRS)|Score on rating scale that corresponds to diagnosis: i) HRSD-24; or ii) Y-BOCS; or iii) BPRS|Cognitive Functioning|Neuroimaging (brain structure and activity)","Centre for Addiction and Mental Health|University Health Network, Toronto",All,"18 Years to 85 Years   (Adult, Older Adult)",Not Applicable,250,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,145-2010,Feb-12,Nov-19,Aug-20,11-May-12,null,9-Jan-19,"Centre for Addiction and Mental Health, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT01596608
NCT01595568,Prevention and Reduction of Alcohol and Drug Problems in a Clinical Psychiatric Youth Population,,Unknown status,No Results Available,Alcohol Abuse|Drug Abuse|Mood Disorder|Anxiety Disorder|Conduct Disorder,Behavioral: Personality-targeted interventions,Change in Binge drinking frequency|Change in Drinking frequency|Change in Drinking quantity|Change in Drinking problems|Change in Emotional and behavioural problems,St. Justine's Hospital,All,14 Years to 17 Years   (Child),Not Applicable,60,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,CER CHU Ste-Justine 3435,Feb-12,Jul-12,null,10-May-12,null,19-Jul-12,"CHU Ste-Justine, Montréal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT01595568
NCT01594606,Randomized Control Trial of an Animal-Assisted Intervention With Adjudicated Youth,,Completed,No Results Available,Conduct Disorder|Depression|Anxiety,Behavioral: Animal-assisted intervention,Change in Internalizing and Externalizing Symptoms as measured by the Achenbach Child Behavior Checklist-Teacher Report and Youth Self Report forms|Change in empathy toward other people,Wayne State University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),All,14 Years to 17 Years   (Child),Phase 3,150,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,R03HD070621,May-12,Aug-14,Jun-15,9-May-12,null,9-Dec-15,"Macomb County Juvenile Justice Center, Mt. Clemens, Michigan, United States",,https://ClinicalTrials.gov/show/NCT01594606
NCT01591408,EEG Biofeedback Therapy as an Adjunct Treatment for PTSD,,Completed,Has Results,PTSD|Anxiety|Trauma|Sleep Disorders,Device: EEG biofeedback,Improved Symptom Ratings,"United States Naval Medical Center, San Diego|Naval Health Research Center",Male,18 Years to 40 Years   (Adult),Not Applicable,68,U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,NMCSD.2012.0042,May-12,Oct-13,Oct-13,4-May-12,20-Dec-16,20-Dec-16,"OASIS PTSD program, San Diego, California, United States",,https://ClinicalTrials.gov/show/NCT01591408
NCT01591720,Tailored Internet-delivered Cognitive Behaviour Therapy in Primary Care,TAYLOR2,Completed,No Results Available,Depression|Anxiety Disorders,Behavioral: Tailored Internet-based CBT for depression and anxiety,Patient Health Questionnaire 9 (PHQ-9)|Generalised Anxiety Disorder Assessment 7 (GAD-7),Linkoeping University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,64,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GA-VR-DEP-2,Sep-10,Aug-11,Aug-11,4-May-12,null,4-May-12,"Linköping University, Department of Behavioral Sciences and Learning, Linköping, Sweden",,https://ClinicalTrials.gov/show/NCT01591720
NCT01590524,Feasibility Study on the Effect of Complementary Methods as Supportive Interventions for Parents of Children With Cancer,,Completed,No Results Available,Anxiety|Stress|Mood|Coping,Behavioral: Guided Imagery and Progressive Muscle Relaxation,Changes in the number of Participants with anxiety|Changes in the number of Participants with mood changes|stress level with Biodots,Cyprus University of Technology,All,"Child, Adult, Older Adult",Not Applicable,52,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,AC-GIPMRL-87,Apr-12,Sep-14,Oct-14,3-May-12,null,8-Oct-14,"Archbishob Makarios Hospital, Nicosia, Cyprus",,https://ClinicalTrials.gov/show/NCT01590524
NCT01589913,REmote Web Assisted Care for Heart Failure Patients With Implantable Cardioverter Defibrillators,REACH-ICD,Completed,No Results Available,Anxiety|Depression|Quality of Life,Behavioral: ICD-Forum,"change of psychosocial well-being (combined score for measures of anxiety, depression, and quality of life) from week 1 (T1) to one week after (T2) the 6-weeks prevention program|1. Health status 2. ICD-related trauma 3. Life-style factors 4. ICD-Related concerns 5. Psychological well-being 6. Type-D personality 7. Social support 8. Economic efficiency|psychophysiological parameters: heart rate variability|biometric markers: 1. proinflammatory cytokines 2. coagulation parameters",Wuerzburg University Hospital|University of Wuerzburg|Campus Bad Neustadt|Hospital Rothenburg ob der Tauber|University Hospital Brandenburg|Klinikum Aschaffenburg-Alzenau|Klinikum Bad Woerishofen|University of Leipzig,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,118,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,UKW-CHFC-G2,May-12,Jul-15,Aug-16,2-May-12,null,1-May-19,"Klinik Bad Wörishofen, Bad Wörishofen, Bavaria, Germany|Department of Cardiology, Center of Cardiovascular Medicine, Bad Neustadt An Der Saale, BY, Germany|Department of Internal Medicine, Krankenhaus Rothenburg ob der Tauber, Rothenburg ob der Tauber, BY, Germany|University of Wuerzburg, Wuerzburg, BY, Germany|Wuerzburg University Hospital, Department of Medicine I (Cardiology), Wuerzburg, BY, Germany|Klinikum Aschaffenburg-Alzenau, Aschaffenburg, Hessen, Germany|Klinik für Kardiologie und Pulmologie, Medizinische Hochschule Brandenburg, Brandenburg, Germany",,https://ClinicalTrials.gov/show/NCT01589913
NCT01585896,Self-Help Group for the Treatment of Hoarding Disorder,,Recruiting,No Results Available,Hoarding Disorder,Other: Self-Help Group,Hoarding Rating Scale,University of Miami,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20111146,Apr-12,Apr-21,Jun-21,26-Apr-12,null,5-Mar-19,"University of Miami, Coral Gables, Florida, United States",,https://ClinicalTrials.gov/show/NCT01585896
NCT01583296,LUCHAR - Latinos Using Counseling for Help With Asthma and Anxiety Reduction,LUCHAR,Completed,No Results Available,Asthma|Panic Disorder,Behavioral: Music Relaxation Therapy (MRT)|Behavioral: CBT and HRVB,Change in severity of panic disorder as measured by the Panic Disorder Severity Scale|Frequency of asthma medication use|Asthma control as measured by the Asthma Control Questionnaire|Treatment responder as measured by Clinical Global Impression Scale|Adherence to controller medications for asthma as measured by the Medication Adherence Report Scale,Albert Einstein College of Medicine|National Institute of Mental Health (NIMH),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,53,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2009-223|R34MH087679,Jul-10,Dec-13,Dec-13,24-Apr-12,null,24-Jul-18,"Jacobi Medical Center/North Central Bronx Hospital (NBHN), Bronx, New York, United States|Montefiore Medical Center: Moses Division/Weiler Division, Bronx, New York, United States",,https://ClinicalTrials.gov/show/NCT01583296
NCT01582815,A Study of JNJ-40411813 as Supplementary Treatment to an Antidepressant in Adults With Depression and Anxiety Symptoms,,Completed,No Results Available,Major Depressive Disorder,Drug: JNJ-40411813|Drug: Placebo,"The change from baseline to endpoint on the Hamilton Anxiety Rating scale (HAM-A6) score|The change from baseline to endpoint on the Hamilton Depression Rating Scale (HDRS17) total score|The change from baseline to endpoint on the SIGH-A (Structured Interview Guide of the Hamilton Anxiety Scale 14-item HAM-A) total score|The change from baseline to endpoint in the Clinical Global Impression - Improvement (CGI-I) scale|The change from baseline to endpoint in the Hamilton Depression Rating Scale (HDRS17) anxiety/somatization factor total score|The change from baseline to endpoint in the HAM-D6 score|The change from baseline to endpoint in the Inventory of Depressive Symptomatolgy -Clinician rated (IDS-C30) total score|The change from baseline to endpoint in the Inventory of Depressive Symptomatology - Clinician-Rated (IDS-C30) anxiety subscale|The change from baseline to Week 4 in the Work Limitations Questionnaire (WLQ)|The change from baseline to endpoint on the Perceived Stress Scale (PSS)|The change from baseline to endpoint in the Profile of Moods Scale-Brief Form (POMS-BF)|The change from baseline to endpoint on the Medical Outcomes Study- 12-item Sleep Scale Acute - Revised (MOS Sleep-R)|The number of patients with a Hamilton Depression Rating Scale (HDRS17) anxiety/somatization factor score ≥7 at Week 4|The number and percentage of patients with either ≥50% or ≥30% improvement on the HDRS17 total score at Week 4, and number and percentage of patients with HDRS 17 total score ≤ 7 at week 4|The number of patients at Week 4 with ≥ 50% improvement on the SIGH-A (Structured Interview Guide of the Hamilton Anxiety Scale 14-item HAM-A) total score","Janssen Research & Development, LLC",All,18 Years to 64 Years   (Adult),Phase 2,121,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",CR100851|40411813DAX2001|2011-006121-26,Sep-12,Nov-13,Nov-13,23-Apr-12,null,16-Jun-15,"Bourgas, Bulgaria|Kazanlak, Bulgaria|Rousse, Bulgaria|Sofia, Bulgaria|Varna, Bulgaria|Baja, Hungary|Budapest, Hungary|Gyõr, Hungary|Kalocsa, Hungary|Chisinau, Moldova, Republic of|Arad, Romania|Iasi, Romania|Nizny Novgorod, Russian Federation|Saratov, Russian Federation|St Petersburg, Russian Federation|St-Peterburg, Russian Federation|St-Petersburg, Russian Federation|Tomsk, Russian Federation|Donetsk, Ukraine|Glevakha, Ukraine|Kharkiv, Ukraine|Kiev, Ukraine|Lviv, Ukraine|Odessa, Ukraine|Smela, Ukraine|Uzhgorod, Ukraine|Village Stepanovka Kherson, Ukraine",,https://ClinicalTrials.gov/show/NCT01582815
NCT01577290,"An Internet-administered, Mindfulness Training Program for the Treatment of Anxiety",,Completed,No Results Available,Anxiety|Depression|Insomnia,Behavioral: Internet-administered Mindfulness Training Program|Behavioral: Discussion group,Change from baseline in Beck Anxiety Inventory (BAI)|Change from baseline in Beck Depression Inventory (BDI)|Change from baseline in Quality Of Life Inventory (QOLI)|Change from baseline in Insomnia Severity Index (ISI),Umeå University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,91,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IMA,Mar-12,Jun-13,Mar-14,13-Apr-12,null,1-Nov-16,"Department of Psychology, Umeå University, Umeå, Västerbotten, Sweden",,https://ClinicalTrials.gov/show/NCT01577290
NCT01577303,Treatment of Social Phobia With Cognitive Bias Modification,,Completed,No Results Available,Social Phobia,Behavioral: Cognitive bias modification training program variant 1|Behavioral: Cognitive bias modification training program variant 2|Behavioral: CBM training program variant 3|Behavioral: CBM training program variant 4|Behavioral: Control training variant 1|Behavioral: Control training variant 2,Change from baseline in Liebowitz Social Anxiety Scale Self-Rated (LSAS-SR)|Change from baseline in Quality Of Life Inventory (QOLI)|Change from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS)|Change from baseline in Social Phobia Scale + Social Interaction Anxiety Scale,Umeå University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,129,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",Attention training,Apr-12,Sep-13,Oct-13,13-Apr-12,null,1-Nov-16,"Department of Psychology, Umeå University, Umeå, Västerbotten, Sweden",,https://ClinicalTrials.gov/show/NCT01577303
NCT01577329,Mindfulness Mediation Intervention in Chronic Obstructive Pulmonary Disease (COPD),,Completed,Has Results,Chronic Obstructive Pulmonary Disease,Behavioral: Mindfulness meditation,Changes in Respiratory Rate,University of Michigan,All,"40 Years to 99 Years   (Adult, Older Adult)",Not Applicable,41,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,um-nursing-meditation,Oct-11,May-13,Jul-15,13-Apr-12,2-Aug-17,2-Aug-17,"University of Michigan, Ann Arbor, Michigan, United States",,https://ClinicalTrials.gov/show/NCT01577329
NCT01574014,Glucocorticoid Treatment for Social Phobia,,Terminated,No Results Available,Phobic Disorders|Phobias,Behavioral: CBGT|Drug: Hydrocortisone|Drug: Placebo,Change from baseline in spider phobia symptoms / social phobia symptoms|Change from baseline in state and trait anxiety|Change from baseline in personality traits|Change from baseline in amygdala activation,"University Hospital Inselspital, Berne|University of Basel",All,20 Years to 55 Years   (Adult),Phase 2,66,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",161/07|32003B_124947|2008DR2002,Jul-09,Mar-12,Apr-12,10-Apr-12,null,5-Dec-12,"Dep. of Psychiatric Neurophysiology, University Hospital of Psychiatry, University of Bern, Bern, Switzerland",,https://ClinicalTrials.gov/show/NCT01574014
NCT01570374,Internet-based Treatment of Generalized Anxiety Disorder,,Completed,No Results Available,Generalized Anxiety Disorder,Behavioral: Internet-based cognitive behavioral therapy (iCBT),Change from baseline in Penn State Worry Questionnaire (PSWQ)|Change from baseline in Beck Anxiety Inventory (BAI)|Change from baseline in Quality Of Life Inventory (QOLI)|Change from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS)|Change from baseline in Patient Health Questionnaire (PHQ-9)|Change from baseline in Generalized Anxiety Disorder-7 (GAD-7),Umeå University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,103,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Oroshjalpen,Jan-12,Jan-16,Feb-16,4-Apr-12,null,1-Nov-16,"Department of Psychology, Umeå University, Umeå, Västerbotten, Sweden",,https://ClinicalTrials.gov/show/NCT01570374
NCT01570400,Treatment of Social Phobia With Combined Cognitive Bias Modification and iCBT,SOFIE13a,Completed,No Results Available,Social Phobia,Behavioral: Internet-administered cognitive behavioral therapy (iCBT)|Behavioral: Cognitive bias modification training program variant 1|Behavioral: Cognitive bias modification training program variant 2,Change from baseline in Liebowitz Social Anxiety Scale Self-Rated (LSAS-SR)|Change from baseline in Quality Of Life Inventory (QOLI)|Change from baseline in Social Phobia Scale + Social Interaction Anxiety Scale|Change from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS)|Change from baseline in mini-SPIN,Umeå University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,133,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,SOFIE13a,Sep-12,Sep-14,Dec-14,4-Apr-12,null,1-Nov-16,"Department of Psychology, Umeå University, Umeå, Västerbotten, Sweden",,https://ClinicalTrials.gov/show/NCT01570400
NCT01570725,Virtual Reality to Reduce Anxiety in Ambulatory Surgical Operations,VRSurg,Withdrawn,No Results Available,Anxiety,Behavioral: Virtual reality exposure|Behavioral: Music only,Psychological measure of anxiety (VAS-A)|Physiological parameter (heart rate),Istituto Auxologico Italiano,All,"18 Years to 90 Years   (Adult, Older Adult)",Not Applicable,0,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,VR01,Oct-08,Feb-11,Feb-11,4-Apr-12,null,4-Apr-12,"Regional Hospital No. 25 of the IMSS, Mexico City, Mexico",,https://ClinicalTrials.gov/show/NCT01570725
NCT01571089,Anxiety Treatment Inspired by Dialectical Behavior Therapy (DBT),,Completed,No Results Available,Treatment Resistant Anxiety Disorders,Behavioral: DBT-inspired anxiety treatment,"Change in anxiety (Clark, D. M., Ehlers, A., McManus, F., Hackmann, A., Fennell, M., Campbell, H., Flower, T., Davenport, C., Louis, B., 2003).|Positive Negative Affect Scale (PANAS), (Watson, Clark & Tellegan, 1988).|Overall Anxiety Severity and Impairment Scale (OASIS), (Barlow, 2011).|Overall Depression Severity and Impairment Scale (ODSIS), (Barlow, 2011).|Difficulties in Emotion Regulation Scale (DERS), (Gratz & Roemer, 2004).|Five Fazet Mindfulness Questionnaire (Baer, Smith, Hopkins, Krietemeyer, & Toney, 2006).|WHOQOL-BREF (Skevington, Lofty, O´Connel & WHOQOL Group, 2004).|Structured Clinical Interview for DSM-IV-I (SCID-I), (First, Spitzer, Gibbon, & Williams, 2001).",Örebro County Council,All,18 Years to 64 Years   (Adult),Not Applicable,5,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,OLL-189011,Mar-12,Oct-14,Oct-14,4-Apr-12,null,20-May-15,"Psychiatric Clinic, Hallsberg, Örebro County, Sweden",,https://ClinicalTrials.gov/show/NCT01571089
NCT01566058,"Impact of the BB Box System on Postpartum Maternal Anxiety, Post Traumatic Stress and Mother-child Relationships",BBBox,Completed,No Results Available,"Stress Disorders, Post-Traumatic|Anxiety",Device: BB Box available|Other: No BB Box,Questionnaire HADS|Questionnaire PPQ (post traumatic stress disorder)|Massie Campbell scale for mother-child relationships|Number of infant cardiovascular events,Centre Hospitalier Universitaire de Nīmes,Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,59,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,LOCAL/2011/FBC-01|2012-A00327-36,Jan-13,Jan-14,Apr-15,29-Mar-12,null,30-Apr-15,"CHU de Nîmes - Hôpital Universitaire Carémeau, Nîmes Cedex 09, France",,https://ClinicalTrials.gov/show/NCT01566058
NCT01566318,Depression Agency-Based Collaboration,,Completed,No Results Available,Major Depression|Anxiety Disorder,Behavioral: Problem-Solving Therapy,Major depressive disorder|Generalized anxiety disorder,University of Pittsburgh|National Institute of Mental Health (NIMH),All,"60 Years and older   (Adult, Older Adult)",Not Applicable,104,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,P30MH090333-PRC1|P30MH090333,Mar-12,Feb-16,Jun-16,29-Mar-12,null,13-Dec-16,"University of Pittsburgh, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT01566318
NCT01565213,Transdiagnostic Group Treatments for Patients With Common Mental Disorders in Primary Health Care,,Completed,No Results Available,Anxiety Disorders|Depressive Disorders|Stress Disorders,Behavioral: CBT|Behavioral: MMI|Behavioral: CAU,Change in Quality of life as measured by the SF-36 (Mental Component Score)|Change in Psychopathology as measured by the Comprehensive Psychopathological Rating Scale Self-asssessmen (CPRS-S-A),Karolinska Institutet,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,245,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,LS 0506-1010,Jan-06,Sep-08,Sep-10,28-Mar-12,null,28-Mar-12,"Center for Family and Community Medicine, Karolinska Institutet,, Huddinge, Sweden",,https://ClinicalTrials.gov/show/NCT01565213
NCT01565629,Computer- Assisted Cognitive-Behavioral Treatment for Anxiety Disorders in Children With Autism Spectrum Disorders,CCAL,Completed,No Results Available,Autism|Asperger's Syndrome|Generalized Anxiety Disorder|Social Phobia|Separation Anxiety Disorder|Obsessive-compulsive Disorder,Behavioral: Computer assisted cognitive behavioral therapy.,Pediatric Anxiety Rating Scale|Anxiety Disorders Interview Schedule: Parent and Child Versions|Clinical Global Impression - Severity Scale,University of South Florida,All,7 Years to 12 Years   (Child),Not Applicable,40,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,CCAL-2012,Feb-12,Oct-16,Oct-16,28-Mar-12,null,26-Oct-17,"University of South Florida, Saint Petersburg, Florida, United States",,https://ClinicalTrials.gov/show/NCT01565629
NCT01563003,Cognitive Behavioral Therapy for Anxiety Disorders in Adolescents With Autism,,Completed,Has Results,Autism|Asperger's Syndrome|Pervasive Developmental Disorder Not Otherwise Specified|Generalized Anxiety Disorder|Social Phobia|Separation Anxiety Disorder|Obsessive-compulsive Disorder,Other: Cognitive Behavioral Therapy|Other: Treatment as usual,Pediatric Anxiety Rating Scale|Anxiety Disorders Interview Schedule Clinical Severity Rating|Clinical Global Impression - Severity Scale,University of South Florida,All,11 Years to 16 Years   (Child),Not Applicable,31,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,AASD-2012,Jun-11,Apr-15,Apr-15,26-Mar-12,17-Apr-15,17-Apr-15,"Rothman Center for Neuropsychiatry, St. Petersburg, Florida, United States",,https://ClinicalTrials.gov/show/NCT01563003
NCT01563198,Reduction of Claustrophobia and Patient Motion After Training of MRI Personnel in Comfort TalkTM,,Completed,Has Results,Claustrophobia|Complication of Diagnostic Procedure,Behavioral: Comfort Talk®,Change in Non-completion Rate of MRI Scans From the Average of the Baseline Year to the Average of One Year Post Training (All Scheduled Patients)|Change in Non-completion Rate of MRI Scans From the Average of the Baseline Year to the Average of One Year Post Training (Showing-Up Patients Only)|Change in No-Show Rates of Patients From the Average of the Baseline Year to the Average of One Year Post Training,"Hypnalgesics, LLC|Tufts Medical Center|Boston Medical Center|Ohio State University",All,"Child, Adult, Older Adult",Not Applicable,97712,Industry|Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,1R43AT0062696,Aug-11,Jul-15,17-Feb-16,26-Mar-12,14-Apr-17,14-Apr-17,"Tufts Medical Center, Boston, Massachusetts, United States|Boston Medical Center, Boston, Massachusetts, United States|Hypnalgesics, LLC, Brookline, Massachusetts, United States|Ohio State University Medical Center, Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT01563198
NCT01560728,Bringing What Works to Youth in Corrections: A Trauma Intervention,,Completed,No Results Available,Post-Traumatic Stress Disorder,Behavioral: Trauma-Focused Cognitive Behavioral Therapy,Rate of change in UCLA PTSD Reaction Index (UCLA PTSD RI) Trauma Symptom Severity|Rate of change in Child Behavioral Checklist Youth Self-Report Total Score,University of Texas at Austin|National Institute of Mental Health (NIMH),All,"13 Years to 18 Years   (Child, Adult)",Phase 1|Phase 2,57,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1R34MH095210-01,Nov-12,Jul-15,Jul-15,22-Mar-12,null,17-Mar-16,"Ron Jackson State Juvenile Correctional Facility, Brownwood, Texas, United States|Giddings State School, Giddings, Texas, United States|McClennan County State Juvenile Correctional Facility, Mart, Texas, United States",,https://ClinicalTrials.gov/show/NCT01560728
NCT01557894,Internet Treatment for Social Phobia in Romania,iSOFIE-Ro,Completed,Has Results,"Phobia, Social",Other: iSOFIE,Leibowitz Social Anxiety Scale - Self Report (LSAS-SR)|Social Phobia Inventory (SPIN)|Beck Depression Inventory-II (BDI-II)|Attitude and Belief Scale-II (ABS-II)|Anxiety Sensitivity Index (ASI),Babes-Bolyai University|Linkoeping University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,76,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TTudor,Apr-12,Mar-13,Mar-13,20-Mar-12,12-Aug-14,17-Sep-14,"Babes-Bolyai University, Cluj - Napoca, Cluj, Romania",,https://ClinicalTrials.gov/show/NCT01557894
NCT01555970,Efficacy Study of add-on Therapy With N-Acetylcysteine in Resistant Obsessive-compulsive Disorder,NACTOC,Completed,No Results Available,Obsessive-Compulsive Disorder,Drug: N-Acetylcysteine (NAC)|Drug: Placebo,Yale-Brown Obsessive-Compulsive Scale total score|Dimensional Yale-Brown Obsessive-Compulsive Scale score|Clinical Global Impression Scale|Beck Depression Inventory|Beck Anxiety Inventory,University of Sao Paulo|Fundação de Amparo à Pesquisa do Estado de São Paulo,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,40,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",NACTOC,Mar-12,Oct-14,Oct-14,16-Mar-12,null,24-Oct-14,"Instituto de Psiquiatria do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil",,https://ClinicalTrials.gov/show/NCT01555970
NCT01553578,"Healing Touch or Guided Imagery In Treating Pain, Fatigue, Nausea, and Anxiety in Patients Undergoing Chemotherapy",,Completed,No Results Available,Anxiety Disorder|Fatigue|Malignant Neoplasm|Nausea and Vomiting|Pain,Other: questionnaire administration|Procedure: therapeutic touch|Behavioral: management of therapy complications|Procedure: standard follow-up care,Change scores for each patient on pain scale|Change scores for each patient on fatigue scale|Change scores for each patient on nausea scale|Change scores for each patient on anxiety scale,Wake Forest University Health Sciences|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,244,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,IRB00018805|NCI-2012-00164|CCCWFU 97511,Feb-12,Feb-13,Feb-13,14-Mar-12,null,4-Jul-18,"Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT01553578
NCT01554150,Randomised Controlled Trial of Method of Levels Cognitive Therapy,,Completed,No Results Available,Mental Health Wellness 1|Depression|Anxiety,Behavioral: Method of Levels Cognitive Therapy,Patient Health Questionnaire mood subscale (PHQ-9)|Generalised Anxiety Disorder Assessment (GAD-7),University of Manchester,All,"16 Years and older   (Child, Adult, Older Adult)",Not Applicable,55,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,11/NW/0736,Feb-12,Jun-13,Jun-13,14-Mar-12,null,21-Jul-14,"Trafford Primary Care IAPT Services, Manchester, United Kingdom",,https://ClinicalTrials.gov/show/NCT01554150
NCT01551199,Exposure Therapy for Veterans With PTSD and Panic Attacks (Phase 1),,Completed,Has Results,PTSD|Panic Attacks,Behavioral: Multiple Channel Exposure Therapy- Veterans,Clinician Administered PTSD Scale (CAPS)|Anxiety Disorders Interview Schedule- DSM-IV (ADIS-IV),VA Office of Research and Development,All,18 Years to 64 Years   (Adult),Phase 1,7,U.S. Fed,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CDA2-012-09F-1,Mar-12,Feb-13,Jun-13,12-Mar-12,13-Jan-15,23-Feb-17,"Michael E. DeBakey VA Medical Center, Houston, TX, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT01551199
NCT01551225,Escitalopram Trial for Irritable Bowel Syndrome (IBS) Patients With Panic Disorder,,Completed,No Results Available,Irritable Bowel Syndrome|Panic Disorder,Drug: Escitalopram,Gastrointestinal Symptom Rating Scale (GSRS).|State Trait Anxiety Inventory (STAI).,Maastricht University Medical Center,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 4,32,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",102051,Jan-12,Sep-16,Sep-16,12-Mar-12,null,12-Jan-17,"Maastricht University Medical Center, Maastricht, Netherlands",,https://ClinicalTrials.gov/show/NCT01551225
NCT01551303,Effect of Intranasal Neuropeptide on Emotion Perception in Trait Anxiety,,Completed,Has Results,Social Intelligence,Drug: Oxytocin|Drug: Placebo,Affective Ratings in Affective Learning Task,Massachusetts General Hospital,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,47,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",2009P-000387,Feb-09,Dec-12,Dec-12,12-Mar-12,30-Jun-14,30-Jun-14,"Center for Anxiety and Traumatic Stress Disorders (CATSD), Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT01551303
NCT01549691,Reassessment of Premedication in Surgery,PREMED,Completed,No Results Available,Anxiety,Drug: Zopiclone|Drug: Alprazolam|Drug: placebo,anxiety scales|markers of stress,"University Hospital, Angers",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,455,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",PHRC 2011-20|2011-002553-65,Mar-12,Apr-13,Apr-13,9-Mar-12,null,25-Sep-13,"Clinique Sévigné, Cesson, Bretagne, France|Dept of Anesthesia, Hôpital Maison Blanche, Reims, Champagne, France|Dept of Anesthesia, Hôpital Tenon, Paris, Ile de France, France|Dept of Anesthesia, Hôpital Foch,, Suresnes, Ile de France, France|Centre Paul Papin, Angers, Maine et Loire, France|University Hospital, Angers, Maine et Loire, France|Clinique St Leonard, Trélazé, Maine et Loire, France|Dept of Anesthesia, Le Mans, Maine, France",,https://ClinicalTrials.gov/show/NCT01549691
NCT01546896,Effects of Buspar on Depressive Symptom Improvement and Neuroprotection in Patients With Anxiety Disorder,,Withdrawn,No Results Available,Anxiety Disorder,Drug: buspirone+alprazolam|Drug: alprazolam,"change from baseline in depressive symptom scores at 8 weeks|change from baseline in depressive symptom scores at 4 weeks|change from baseline in depressive symptom scores at 1 week|change from baseline in anxiety symptom scores at 8 weeks|change from baseline in anxiety symptom scores at 4 weeks|change from baseline in anxiety symptom scores at 1 week|changes from baseline in brain structure, function, and biochemical metabolism, analyzed using the computational approach|number of participants with adverse events",Seoul National University Hospital,All,"20 Years to 65 Years   (Adult, Older Adult)",Phase 4,0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,bsp2010,Mar-12,Feb-14,Feb-14,7-Mar-12,null,20-May-15,"Seoul National University Hospital, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01546896
NCT01545414,Internet-CBT (Cognitive Behavioral Therapy) for Depression and Anxiety in Parkinsons Disease,,Completed,No Results Available,Parkinson's Disease|Depression|Anxiety|Insomnia,Behavioral: ICBT|Behavioral: ICONTROL,Change (from baseline) in HADS|Change (from baseline) in MADRS-S|Change (from baseline) in ISI|Change (from baseline) in PDQ-8|Change (from baseline) in EQ-5D|Change (from baseline) in SDS|Change (from baseline) in NMSQuest,"Karolinska Institutet|Stockholm County Council, Sweden",All,"Child, Adult, Older Adult",Phase 3,150,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ICBT Parkinson,Feb-12,Aug-13,Aug-13,6-Mar-12,null,13-Feb-15,"Internetpsykiatrienehten (Internet Psychiatry Unit), Psykiatri Sydväst, SLSO, Stockholm, Sweden",,https://ClinicalTrials.gov/show/NCT01545414
NCT01543815,Well-Being Therapy by Personalized Mobile Technology Program for Psychological Distress and Promote Healthy Behaviors,WELL-ME,Completed,No Results Available,Psychological Distress,Behavioral: Well-Being Therapy based on Web Mobile Technology|Behavioral: Cognitive Behavior Therapy|Other: Standardized Care Management,Psychological distress|Quality of Life|Medical Adherence|Promotion of Healthy Lifestyle,University of Bergamo,All,"Child, Adult, Older Adult",Not Applicable,400,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,29399,Jan-06,Feb-09,Dec-10,5-Mar-12,null,6-Mar-12,,,https://ClinicalTrials.gov/show/NCT01543815
NCT01540305,Efficacy Study of Transcranial Magnetic Stimulation for Treatment of Obsessive-Compulsive Disorder,,Completed,No Results Available,Obsessive Compulsive Disorder,Device: Repetitive Transcranial Magnetic Stimulation (rTMS)|Device: Sham repetitive transcranial magnetic stimulation,Changes in Y-BOCS scale scores relative to baseline,University of Brasilia,All,18 Years to 60 Years   (Adult),Phase 2,22,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",49/09,May-11,Sep-11,Sep-11,28-Feb-12,null,28-Feb-12,"Laboratory of Neurosciences and Behavior, Biology Institute, University of Brasília, Brasília, DF, Brazil",,https://ClinicalTrials.gov/show/NCT01540305
NCT01537679,Meditation to Reduce Caregiver Stress,Meditation,Completed,No Results Available,Depression NOS|Major Depressive Disorder|Anxiety NOS,Behavioral: Kirtan Kriya meditation|Behavioral: Relaxation,Hamilton Depression Rating Scale (HDRS)|Caregiver Burden Scale|Connor-Davidson Resilience scale (CD-RISC),"University of California, Los Angeles",All,"45 Years and older   (Adult, Older Adult)",Not Applicable,40,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,10-000270; 09-03-086-01D,Mar-10,Aug-10,Jan-12,23-Feb-12,null,28-Nov-16,"UCLA Semel Institute, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT01537679
NCT01533402,Internet-delivered Cognitive Behavior Therapy (CBT) for Children Age 8-12 Years With Anxiety Disorders,,Completed,No Results Available,Anxiety Disorders,Behavioral: therapist support|Behavioral: Internet-delivered CBT,Anxiety symptoms|Quality of Life|comorbidity|Depressive symptoms|Funtional impairment|Client Satisfaction Scale|Parental psychopathology,"Karolinska Institutet|Stockholm County Council, Sweden|Barn-och ungdomspsykiatrin (BUP), Stockholm",All,8 Years to 12 Years   (Child),Not Applicable,128,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2011/2027-31/5,Feb-12,Dec-13,Apr-14,15-Feb-12,null,9-Sep-14,"Barn-och ungdomspsykiatrin, Stockholm, Stockholm, Sweden",,https://ClinicalTrials.gov/show/NCT01533402
NCT01533415,Use of Alpha-Stim Cranial-electrotherapy Stimulation (CES) in the Treatment of Anxiety,,Completed,No Results Available,Anxiety,Device: CES treatment using Alpha-Stim technology|Device: Shame CES Treatment,Anxiety symptoms as reported on the Hamilton Anxiety Rating Scale|Depression symptoms as reported on the Hamilton Depression Rating Scale 17,Wyndhurst Counseling Center|Liberty University,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,115,Other,Interventional,"Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",1241.020712,Feb-12,Dec-12,Dec-12,15-Feb-12,null,9-Apr-13,"Liberty Univeristy Student Care and Grad.Assist Office, Lynchburg, Virginia, United States|Wyndhurst Counseling Center, Lynchburg, Virginia, United States",,https://ClinicalTrials.gov/show/NCT01533415
NCT01533610,The Efficacy of Stellate Ganglion Block as Post-traumatic Stress Disorder (PTSD) Therapy: A Pilot Study,,Unknown status,No Results Available,"Stress Disorders, Post-Traumatic",Procedure: Stellate ganglion block,Difference in CAPS score activity|Depression scale|Anxiety scale|Quality of life scale|Biophysical responses,Southern California Institute for Research and Education,All,"18 Years to 90 Years   (Adult, Older Adult)",Phase 2,12,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,#1125,Feb-12,Feb-13,Feb-13,15-Feb-12,null,15-Feb-12,"VA Long Beach Healthcare system, Long Beach, California, United States",,https://ClinicalTrials.gov/show/NCT01533610
NCT01532219,Internet-delivered Psychodynamic Therapy for Depression and Anxiety Disorders,ATLAS,Completed,No Results Available,Depression|Anxiety,Behavioral: Internet-delivered Psychodynamic Treatment|Behavioral: Internet-delivered structured support,9-item Patient Health Questionnaire Depression Scale (PHQ-9)|7-item Patient Health Questionnaire Generalized Anxiety Disorder Scale (GAD-7)|Emotional Processing Scale (EPS-25)|Five Facets of Mindfulness Questionnaire (FFMQ),Linkoeping University,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GA-DEPANX2012-APT,Feb-12,Dec-12,Dec-12,14-Feb-12,null,24-Apr-13,"Linköping University, Department of Behavioral Sciences and Learning, Linköping, Sweden",,https://ClinicalTrials.gov/show/NCT01532219
NCT01531400,Investigation of Pain and Anxiety During Electrodiagnostic Examination Using Self-selected Music,,Completed,No Results Available,Pain|Anxiety,Other: self-selected music,"Pain (Visual Analogue Scale)|Anxiety, assessed by Linear Analogue Anxiety Scale (LAAS)",Chang Gung Memorial Hospital,All,"15 Years and older   (Child, Adult, Older Adult)",Not Applicable,61,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,cgmhpmr001,Dec-02,Nov-05,Nov-05,13-Feb-12,null,20-Mar-12,"Chang Gung Memorial Hospital, Taoyuan County, Taiwan",,https://ClinicalTrials.gov/show/NCT01531400
NCT01528371,Effect of Midazolam on White-coat Hypertensive Dental Patients,,Completed,No Results Available,Transient Hypertension,Drug: Midazolam|Drug: Normal Saline Solution (NSS),Blood pressure|Heart rate|Oxygen saturation|Visual analog scale about anxiety to dental treatment|Sedation level|Japanese version of STAI,Okayama University,All,20 Years to 64 Years   (Adult),Not Applicable,40,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care",yoshi0112,Oct-10,Jul-12,Jul-12,8-Feb-12,null,3-Oct-12,"Department of Dental Anesthesiology and Special Care Dentistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan",,https://ClinicalTrials.gov/show/NCT01528371
NCT01527955,"Kelee® Meditation: A Distinctive and Effective Therapeutic Intervention for Stress, Anxiety, and Depression",,Completed,No Results Available,Stress|Anxiety|Depression,Other: Kelee Meditation,"Change in Total Score of Depression, Anxiety, and Stress Scales-42 (DASS-42)|Change in Depression Subscale Score of DASS-42|Change in Anxiety Subscale Score of DASS-42|Change in Stress Subscale Score of DASS-42|Change in Total Score of Beck Depression Inventory-II (BDI-II)|Change in Total Score of Beck Anxiety Inventory (BAI)|Change in Total Score of Perceived Stress Scale-10 (PSS-10)|Change in Global Severity Index (GSI) of the Symptom Checklist-90-Revised (SCL-90-R)|Change in Mental Component Summary (MCS) of the Short Form-36 Health Survey (SF-36)","University of California, San Diego",All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,47,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IRB Project#081197,Sep-08,Sep-10,Jun-11,7-Feb-12,null,7-Feb-12,"Being Alive San Diego, San Diego, California, United States|University of California, San Diego Medical Center, San Diego, California, United States",,https://ClinicalTrials.gov/show/NCT01527955
NCT01526525,Perioperative Electroacupuncture on Postoperative Analgesia in Prostatectomy,,Completed,No Results Available,"Pain, Postoperative",Drug: Tramadol|Drug: Ketamine|Drug: Morphine|Procedure: sedation|Procedure: rescue analgesia|Drug: Parecoxib|Drug: paracetamol,"PAIN SCALES|PATIENTS PAIN THRESHOLD WITH ELECTRONIC PRESSURE ALGOMETER|NUMBER OF PARTICIPANTS WITH ADVERSE EVENTS|PATIENTS RESCUE ANALGESIA|CORTIZOL|PATIENTS WELLBEING,|SATISFACTION|SLEEP DISORDERS",G.Gennimatas General Hospital|Aristotle University Of Thessaloniki,Male,"50 Years to 75 Years   (Adult, Older Adult)",Phase 4,70,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,6151/ 22-7-2009,Jul-09,Sep-11,Feb-12,6-Feb-12,null,21-Feb-14,"G.Gennimatas GENERAL HOSPITAL OF THESSALONIKI, Thessaloniki, Greece",,https://ClinicalTrials.gov/show/NCT01526525
NCT01525576,Booster as an Adjunct to Internet-based Cognitive Behavior Therapy (CBT),,Completed,No Results Available,Obsessive-compulsive Disorder,Behavioral: Booster,"Change from Baseline of obsessions and compulsions after 3, 8 and 20 months after baseline.|Change from Baseline of obsessions and compulsions after 8 and 20 months.",Karolinska Institutet,All,"18 Years and older   (Adult, Older Adult)",Phase 2,98,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,OCD_B,Feb-12,Jul-12,Jul-12,3-Feb-12,null,31-Jul-12,"Psykiatri sydväst, Stockholm, Sweden",,https://ClinicalTrials.gov/show/NCT01525576
NCT01524185,FamilyLive Feasibility and Effectiveness Study,,Withdrawn,No Results Available,Mood Lability|PTSD|Anxiety,Behavioral: FamilyLive|Behavioral: Standard Mental Health Treatment,"To examine the feasibility of recruiting and conducting the proposed intervention and evaluation procedures on a cohort of children exposed to neglect and their caregivers using a randomized design.|Examine the effects of FL on heart rate variability, behavior, post traumatic stress disorder symptoms, and functioning","Hugo W. Moser Research Institute at Kennedy Krieger, Inc.|Substance Abuse and Mental Health Services Administration (SAMHSA)",All,"5 Years to 80 Years   (Child, Adult, Older Adult)",Early Phase 1,0,Other|U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NA_00022038,Feb-09,8-Jan-16,8-Jan-16,1-Feb-12,null,9-Apr-18,"Kennedy Krieger Institute, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT01524185
NCT01522287,Computer Assisted Cognitive Behavior Therapy for Obsessive Compulsive Disorder: A Comprehensive Stepped-Care Approach,,Completed,No Results Available,Obsessive Compulsive Disorder,Behavioral: Computer-Assisted Cognitive Behavior Therapy (BT STEPS),Yale Brown Obsessive Compulsive Scale (YBOCS)|PHQ-9|Work and Social Adjustment Scale (WSA),Center for Psychological Consultation,All,"18 Years and older   (Adult, Older Adult)",Phase 1,88,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,R43MH090612,Jan-12,Dec-13,Dec-13,31-Jan-12,null,14-Mar-14,"Center for Psychological Consultation, Madison, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT01522287
NCT01519895,Effectiveness of Telephone Intervention for Colorectal Cancer Caregivers,,Completed,No Results Available,Psychological Stress,Behavioral: Telephone intervention,Distress level|Burden of care|Quality of life,"Hospital Authority, Hong Kong",All,"18 Years to 90 Years   (Adult, Older Adult)",Phase 2,140,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,HKCTR-1336,Jun-11,Aug-12,Dec-12,27-Jan-12,null,15-Apr-15,"Queen Mary Hospital, Hong Kong, China",,https://ClinicalTrials.gov/show/NCT01519895
NCT01520376,Anxiety and Depression in Patients Hospitalizes for an Acute Exacerbation of COPD,ADPHA-EPOC,Completed,No Results Available,Chronic Obstructive Pulmonary Disease|Anxiety|Depression,Behavioral: Counselling,Efficacy of the intervention|Impact of diagnosis,"Nestor Soler Porcar, MD, PhD|Fundacion Clinic per a la Recerca Biomédica",All,"40 Years to 90 Years   (Adult, Older Adult)",Not Applicable,169,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care,ADPHA-EPOC,Oct-11,Oct-13,Apr-14,27-Jan-12,null,6-Jul-18,"Fundacio Clinic Per la Recerca Biomèdica - Hospital Clinic de Barcelona, Barcelona, Catalonia, Spain",,https://ClinicalTrials.gov/show/NCT01520376
NCT01513915,A Parent-only Group Cognitive Behavioral Intervention for Children With Anxiety Disorders: a Control Group Study,,Completed,No Results Available,Anxiety Disorders,Other: Group cognitive behavioral intervention,Revised Children's Manifest Anxiety (RCMA)|Children's Depression Inventory (CDI)|Depression-Anxiety-Stress Scale (DASS)|Children Global Assessment Scale (CGAS)|Assessment of Consumer Satisfaction|Strengths and Difficulties Questionnaire (SDQ) Home Version|Global Relational Assessment of Functioning (GRAF),Tehran University of Medical Sciences,All,"6 Years to 18 Years   (Child, Adult)",Not Applicable,40,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Parent CBT for Anxiety,Jul-08,May-09,Jul-09,20-Jan-12,null,26-Apr-16,"Rouzbeh Hospital, Tehran, Iran, Islamic Republic of",,https://ClinicalTrials.gov/show/NCT01513915
NCT01510834,Computerized Tailored Intervention for Behavioral Sequelae of PTSD in Veterans,CTI-PTSD,Completed,Has Results,Post Traumatic Stress Disorder|Smoking|Anxiety|Depression,"Behavioral: Multibehavioral, Computerized Tailored Intervention STR2IVE","Change in PCL-M Score (PTSD Symptom Checklist-Military [PCL-M], Weathers et al., 1993)|Change in QOLS Score T1 to T3 (Quality of Life Scale [QOLS], Flanagan, 1978, 1982)|Change in PSS From T1 to T3 (The Perceived Stress Scale [PSS] Cohen, Kamarck, & Mermelstein, 1983)|Change in PHQ-8 From T1-T3 (Patient Health Questionnaire [PHQ-8], Kroenke & Spitzer, 2002; Spitzer, Kroenke, & Williams, 1999)",VA Pacific Islands Health Care System|U.S. Army Medical Research and Materiel Command|Pro-Change Behavior Systems|University of Hawaii,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,90,U.S. Fed|Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,2009-04/JLS 0002|W81XWH-09-2-0106,Jul-11,Mar-12,Oct-12,18-Jan-12,4-Jul-13,7-Dec-17,"VA Pacific Island Health Care System, Honolulu, Hawaii, United States|Dept of Public Health, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, Hawaii, United States|Pro-Change Behavioral Systems, Inc., Kingston, Rhode Island, United States",,https://ClinicalTrials.gov/show/NCT01510834
NCT01510236,Self-help Program Via Internet for Adolescents With Cancer,U-CARE:TeenCan,Withdrawn,No Results Available,Cancer|Depression|Anxiety,Behavioral: Self-help program,Hospital Anxiety and Depression Scale (HADS)|Posttraumatic Stress Disorder Checklist ‐ Civilian Version (PCL-C)|UCLA Loneliness Scale|Rosenberg Self-Esteem Scale (RSE)|Satisfaction With Life Scale (SWLS)|Mental Health Continuum - Short form (MHC-SF)|EQ-5D|Posttraumatic Growth Inventory - Short form (PTGI-SF)|Health-related costs questionnaire|Time spent on self-help program,Uppsala University,All,"13 Years to 19 Years   (Child, Adult)",Phase 2,0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,U-CARE: TeenCan,Jan-13,Jul-15,May-18,16-Jan-12,null,28-May-15,"Drottning Silvias Barn- och Ungdomssjukhus, Göteborg, Sweden|Universitetssjukhuset, Linköping, Sweden|Barn- och Ungdomssjukhuset, Lund, Sweden|Astrid Lindgrens Barnsjukhus, Stockholm, Sweden|Norrlands Universitetssjukhus, Umeå, Sweden|Akademiska Barnsjukhuset, Uppsala, Sweden",,https://ClinicalTrials.gov/show/NCT01510236
NCT01509573,Pilot Feasibility Trial of the Family Strengthening Intervention in Rwanda (FSI-R),,Completed,No Results Available,Depressive Symptoms|Anxiety|Parenting,Behavioral: Family Strengthening Intervention in Rwanda (FSI-R),Change from Baseline in Mental Health of Children and Caregivers,Harvard School of Public Health|Partners in Health|Harvard University|Boston Children’s Hospital,All,"5 Years and older   (Child, Adult, Older Adult)",Not Applicable,82,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,RPCGA-FSI-15440,Jul-11,Jun-14,Jun-14,13-Jan-12,null,27-Aug-14,"Partners In Health/Inshuti Mu Buzima (PIH/IMB), Rwinkwavu, Rwanda",,https://ClinicalTrials.gov/show/NCT01509573
NCT01509872,Psychological and Psychosocial Intervention With War-Affected Children,,Completed,Has Results,"Stress Disorders, Post-Traumatic|Depression|Anxiety|Conduct|Pro-social Behavior",Behavioral: Trauma Focused Cognitive Behavioral Therapy|Behavioral: Child Friendly Space,Change in Post-traumatic Stress Symptoms as Measured by the University of California Los Angelus Post Traumatic Stress Disorder -Reaction Index|Change in Internalizing Symptoms as Measured by the African Youth Psychosocial Assessment Instrument|Change in Externalizing Symptoms as Measured by the African Youth Psychosocial Assessment Instrument|Change in Pro-Social Behaviors as Measured by the African Youth Psychosocial Assessment Instrument,"Queen's University, Belfast|Transcultural Psychosocial Organisation|UNICEF",All,"7 Years to 18 Years   (Child, Adult)",Not Applicable,50,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",PREC73-2011,Oct-11,Dec-11,Apr-12,13-Jan-12,9-Apr-19,9-Apr-19,"Child Friendly Space, Mwenga, South Kivu, Congo",,https://ClinicalTrials.gov/show/NCT01509872
NCT01508624,"Evaluation of Interventions to Improve Pain Relief, Perceived Anxiety and Recovery in Participants Receiving Office Based Surgery",,Completed,No Results Available,Varicose Veins|Pain,Other: Interaction|Other: Music|Behavioral: Touch - stress balls|Behavioral: DVD,Level of pain experienced at the time of surgery|Change in pain experienced from time of surgery to 8 weeks after surgery|Recovery|Anxiety,University of Surrey,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,404,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,6045559US,Apr-12,Oct-13,Nov-13,12-Jan-12,null,21-May-14,"The Whiteley Clinic, Guildford, United Kingdom|The University of Surrey, Guildford, United Kingdom",,https://ClinicalTrials.gov/show/NCT01508624
NCT01507571,Implementation and Evaluation of Dignity Therapy in Denmark,DignityDK,Completed,No Results Available,Cancer,Other: Dignity Therapy,Sense of dignity|Hopelessness|Anxiety|Depression|Not able to perform tasks of daily living|Suffering|performance status|Communication|Social Contact|Not able to attend to bodily functions|Physically distressing symptoms|Feeling how I look has changed|Feeling depressed|Feeling anxious|Feeling uncertain|Worried about future|Not able to think clearly|Not able to continue usual routines|Feeling no longer who I was|Not feeling worthwhile or valued|Not able to carry out important roles|Feeling life no longer has meaning or purpose|Feeling of not having made a meaningful contribution|Feeling of unfinished business|Concerns regarding spiritual life|Feeling like a burden to others|Feeling of not having control|Feeling of reduced privacy|Not feeling supported by friends or family|Not feeling supported by health care providers|Not feeling able to mentally fight illness|Not being able to accept things as they are|Not being treated with respect|Physical function|Emotional function|Overall quality of life|Fatigue|Nausea / Vomiting|Pain|Dyspnoea|Insomnia|Appetite loss|Constipation,Bispebjerg Hospital,All,"18 Years and older   (Adult, Older Adult)",Phase 2,80,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,DignityTherapyDK 01|PP04011,Sep-05,Sep-07,Sep-07,11-Jan-12,null,11-Jan-12,"Department of Palliative Medicine, Copenhagen, Denmark|Sankt Lukas Hospice, Hellerup, Denmark",,https://ClinicalTrials.gov/show/NCT01507571
NCT01507948,Brain Imaging of Psychotherapy for Posttraumatic Stress Disorder (PTSD),,Completed,No Results Available,Posttraumatic Stress Disorder (PTSD),Behavioral: Prolonged exposure,Clinician Administered PTSD scale (CAPS)|Mood and Anxiety Symptom Questionnaire (MASQ)|fMRI-assessed resting connectivity|Implicit emotion regulation,Stanford University|National Institutes of Health (NIH)|VA Office of Research and Development,All,18 Years to 60 Years   (Adult),Not Applicable,94,Other|NIH|U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,SU-10252011-8566,Sep-10,Jan-16,Jan-16,11-Jan-12,null,23-Jan-17,"VA Palo Alto Healthcare System, Palo Alto, California, United States|Stanford University, Department of Psychiatry, Stanford, California, United States",,https://ClinicalTrials.gov/show/NCT01507948
NCT01507155,An Open Label Study of Clinical Utility and Patient Outcomes of the Genecept Assay,COM-1,Completed,Has Results,Treatment Resistant Depression|Generalized Anxiety Disorder,Device: Genecept Assay,"Change From Baseline in Clinical Global Impressions Improvement (CGI-I) Scale at 3 Months|Efficacy Measured by QIDS-SR16, Q-LES-Q-SF, UKU Side Effects; and SAS at 3 Months","Genomind, LLC",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,685,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,COM-1,Apr-13,May-14,May-14,10-Jan-12,2-May-16,8-Jun-16,"Genomind, LLC, Chalfont, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT01507155
NCT01504191,Internet-based Cognitive Behavior Therapy After Myocardial Infarction,U-CARE: Heart,Unknown status,No Results Available,Depression|Anxiety|Myocardial Infarction,Behavioral: Internet‐based CBT,Change in Depression (difference between the intervention and the control group)|Change in Anxiety (difference between the intervention and the control group)|Change in Quality of Life (difference between the intervention and the control group)|Change in Perceived Social Support (difference between the intervention and the control group)|Change in Stress behaviors (difference between the intervention and the control group)|Change in Fatigue (difference between the intervention and the control group)|Change in Cardiac Anxiety (difference between the intervention and the control group)|Change in Sleeping Problems (difference between the intervention and the control group)|Change in Posttraumatic Stress (difference between the intervention and the control group)|Change in Posttraumatic Growth (difference between the intervention and the control group)|Quality of the Intervention|Change to Follow-up in Anxiety (difference between the intervention and the control group)|Change to Follow-up in Depression (difference between the intervention and the control group),Uppsala University,All,"up to 75 Years   (Child, Adult, Older Adult)",Phase 3,239,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,U-CARE: Heart,Sep-13,Dec-17,Dec-17,5-Jan-12,null,3-Mar-17,"Enköpings lassarett, Enköping, Sweden|Falu Lasarett, Falun, Sweden|Gävle sjukhus, Gävle, Sweden|Sahlgrenska sjukhuset, Göteborg, Sweden|Hässleholms sjukhus, Hässleholm, Sweden|Blekinge sjukhus, Karlskrona, Sweden|Karlstad sjukhus, Karlstad, Sweden|Kungälvs sjukhus, Kungälv, Sweden|Skaraborgs sjukhus, Lidköping, Sweden|Ljungby lasarett, Ljungby, Sweden|Skånes universitetssjukhus, Malmö, Sweden|Mora lassarett, Mora, Sweden|Nyköpings sjukhus, Nyköping, Sweden|Oskarshamns sjukhus, Oskarshamn, Sweden|Piteå älvdals sjukhus, Piteå, Sweden|Danderyds sjukhus, Stockholm, Sweden|Karolinska sjukhuset i Huddinge, Stockholm, Sweden|Karolinska sjukhuset i Solna, Stockholm, Sweden|Södersjukhuset, Stockholm, Sweden|Länssjukhuset Sundsvall-Härnösand, Sundsvall, Sweden|Uppsala Akademiska sjukhus, Uppsala, Sweden|Varberg sjukhus, Varberg, Sweden|Växjö centrallasarett, Växjö, Sweden|Ängelholms sjukhus, Ängelholm, Sweden|Universitetssjukhuset Örebro, Örebro, Sweden",,https://ClinicalTrials.gov/show/NCT01504191
NCT01504763,Measuring the Effect of Chair Massage on Stress Related Symptoms for Nurses,,Completed,No Results Available,Stress|Fatigue|Anxiety|Tension,Procedure: Chair massage,"Change in stress, anxiety and quality of life after 10 weeks of chair massage therapy in nursing staff using four self reported instruments.|Change from baseline of stress related symptoms in nursing staff at 5 weeks.|Change from baseline of stress related symptoms in nursing staff at 10 weeks.",Mayo Clinic,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,40,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,08-004874,Oct-10,Dec-10,Dec-10,5-Jan-12,null,8-Feb-12,"Mayo Clinic, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT01504763
NCT01502644,Opioid Treatment for Chronic Low Back Pain and the Impact of Mood Symptoms,,Completed,Has Results,Chronic Low Back Pain|Degenerative Disc Disease|Depression|Anxiety,Drug: Oxycodone|Drug: Morphine|Drug: Placebo,Percent Change in Average Daily Pain Score,Brigham and Women's Hospital|Arthritis Foundation|National Institute on Drug Abuse (NIDA),All,"21 Years to 75 Years   (Adult, Older Adult)",Phase 4,81,Other|NIH,Interventional,"Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",2007P-001047|5K23DA020681-05,Feb-09,Jan-13,Jan-13,2-Jan-12,8-Jun-17,11-Jul-17,"Brigham and Women's Hospital, Chestnut Hill, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT01502644
NCT01503151,Cognitive Biases Modification Treatment for Social Anxiety,CBMSP,Completed,No Results Available,Social Phobia,Behavioral: Attention Bias Modification Treatment (ABMT)|Behavioral: Interpretation Bias Modification (IBM)|Behavioral: Control Condition|Behavioral: Attention and Interpretive biases modification (CBM),Social Anxiety Scale (LSAS) - diagnostic interview|The Mini International Neuropsychiatric Interview (MINI).,Tel Aviv University,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,95,Other,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",CBM_SP_2012,Jan-12,Mar-14,Mar-14,2-Jan-12,null,2-Dec-14,"Tel-Aviv University, Tel-Aviv, Israel",,https://ClinicalTrials.gov/show/NCT01503151
NCT01498614,Psychological Impact in Diabetes: Intervention With Affect School and Basal Body Awareness,,Terminated,No Results Available,Diabetes Mellitus|Depression|Alexithymia|Anxiety,Behavioral: Affect School and Basal body awareness,Prevalence of depression|Level of A1C,"Lund University|Landstinget Kronoberg, Sweden",All,18 Years to 59 Years   (Adult),Not Applicable,321,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,FoU-Kronoberg Sweden 4522,Mar-09,28-Nov-18,28-Nov-18,23-Dec-11,null,30-Nov-18,"Landstinget Kronoberg, Vaxjo, Kronoberg, Sweden",,https://ClinicalTrials.gov/show/NCT01498614
NCT01496612,Buspirone Therapy for Localized Epilepsy,,Terminated,No Results Available,Anxiety Disorder|Seizures|Epilepsy|Partial Epilepsy|Depression,Drug: Buspirone,Difference in seizure rate between the baseline and buspirone periods.|Neuropsychological and mood indices before and three months after starting buspirone,National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC),All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,9,NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",120033|12-N-0033,22-Nov-11,19-Apr-16,19-Apr-16,21-Dec-11,null,20-May-19,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT01496612
NCT01496690,Pregablin for Anxiety-comorbidity in Patients With Schizophrenia,PACS,Completed,No Results Available,Schizophrenia|Anxiety-comorbidity to Schizophrenia,Drug: Pregabalin|Drug: Pregabalin Placebo Capsules,Hamilton Anxiety Scale|UKU-Overall adverse effect scale,"University of Aarhus|Albert Einstein College of Medicine|GCP-unit at Aarhus University Hospital, Aarhus, Denmark|The Hospital Pharmcacy North Denmark Region, Denmark|Pfizer",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,54,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Eudra CT nr 2010-024488-42|N-20100097,Jan-12,Dec-16,Dec-16,21-Dec-11,null,9-Jan-17,"Aalborg University Hospital, Psychiatry, Aalborg, Denmark",,https://ClinicalTrials.gov/show/NCT01496690
NCT01492452,The Anxiety of Parents of Children Undergoing Cardiac Surgery,,Completed,No Results Available,Anxiety,Other: standardized guidelines for nursing,anxiety inventory,Instituto de Cardiologia do Rio Grande do Sul,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,44,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Single (Participant),UP4555/10,Dec-10,May-11,May-11,15-Dec-11,null,15-Dec-11,,,https://ClinicalTrials.gov/show/NCT01492452
NCT01492738,The Effect of Acupuncture on Anxiety and Working Memory,,Completed,No Results Available,Memory Impairment|Anxiety,Procedure: Acupuncture,Change in anxiety level|Memory task,National University of Health Sciences,All,18 Years to 30 Years   (Adult),Not Applicable,90,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NUHS H1011,Feb-11,Dec-11,Dec-11,15-Dec-11,null,15-Apr-15,"Tiffani Kim Institute, Chicago, Illinois, United States|A Center for Oriental Medicine, Wilmette, Illinois, United States",,https://ClinicalTrials.gov/show/NCT01492738
NCT01491880,Treatment Study for Rural Latino Youth With Anxiety,,Unknown status,No Results Available,Anxiety Disorders|Separation Anxiety Disorder|Social Anxiety Disorder|Specific Phobia|Generalized Anxiety Disorder,Behavioral: Therapist-Assisted by Telephone|Behavioral: Self-Help,Consumer Satisfaction Questionnaire|Barriers to Treatment Participation Scale,"University of California, San Diego|National Institute of Mental Health (NIMH)",All,8 Years to 13 Years   (Child),Phase 1|Phase 2,40,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,MH090149|R34MH090149,Nov-11,Dec-12,Dec-12,14-Dec-11,null,18-Jan-12,"University of California, San Diego, San Diego, California, United States",,https://ClinicalTrials.gov/show/NCT01491880
NCT01491035,Pharmacokinetics and Tolerability of Vortioxetine (Lu AA21004) in Child and Adolescent Patients With Depressive or Anxiety Disorder,,Completed,Has Results,Depressive Disorder|Anxiety Disorder,Drug: Vortioxetine,Cmax of Vortioxetine|AUC(0-24h) of Vortioxetine|t½ of Vortioxetine|Cmax of Lu AA34443|AUC(0-24h) of Lu AA34443|t½ of Lu AA34443|Oral Clearance (CL/F) of Vortioxetine,H. Lundbeck A/S,All,7 Years to 17 Years   (Child),Phase 2,48,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,12708A|2010-020170-42,Apr-12,Dec-14,Jun-15,13-Dec-11,15-Jan-16,16-Mar-17,"US003, Washington, District of Columbia, United States|US004, Wichita, Kansas, United States|US002, Cincinnatti, Ohio, United States|US001, Cleveland, Ohio, United States|DE002, Berlin, Germany|DE001, Mainz, Germany|DE003, Ulm, Germany",,https://ClinicalTrials.gov/show/NCT01491035
NCT01490307,A Family Intervention for Adolescent Problem Behavior (AKA Project Alliance 2),PAL-2,Completed,No Results Available,Substance Use|Conduct Disorder|Depression|Anxiety,Behavioral: Family Check-Up,growth in substance use|growth in antisocial behavior|growth in deviant peer involvement|growth in family management skills|positive change in family relationship quality,University of Oregon|National Institute on Drug Abuse (NIDA),All,"Child, Adult, Older Adult",Not Applicable,593,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,R01DA018374,Feb-06,Jan-10,Mar-11,12-Dec-11,null,12-Dec-11,"University of Oregon-Child and Family Center, Portland, Oregon, United States",,https://ClinicalTrials.gov/show/NCT01490307
NCT01488799,Motivational Interviewing and Cognitive Behavioural Therapy for Generalized Anxiety Disorder,,Completed,No Results Available,Anxiety Disorders|Generalized Anxiety Disorder,Behavioral: Motivational Interviewing and Cognitive Behavioural Therapy,Penn State Worry Questionnaire (PSWQ)|Satisfaction with Life Scale (SWLS)|Inventory of Interpersonal Problems (IIP)|Depression Anxiety Stress Scale (DASS),"York University|Ryerson University|University of Massachusetts, Amherst",All,"16 Years to 65 Years   (Child, Adult, Older Adult)",Not Applicable,85,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",MOP114909,Jan-12,Dec-15,Dec-15,8-Dec-11,null,29-Dec-15,"York University, Toronto, Ontario, Canada|Ryerson University, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT01488799
NCT01487473,The Effects of Mindfulness-Based Stress Reduction on Attention and Pain-related Symptoms in Chronic Pain Patients,,Completed,No Results Available,Pain,Behavioral: Mindfulness-Based Stress Reduction,Pain disability and Attention|Depression|Anxiety|Stress|Mindfulness|Acceptance|Pain Intensity,"York University|Mount Sinai Hospital, Canada|Wasser Pain Management Centre|Rasch Foundation",All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,49,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,FWA00003852,Dec-11,Nov-13,Nov-13,7-Dec-11,null,13-Feb-14,"Mount Sinai Hospital, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT01487473
NCT01486121,Sedation Optimisation Strategy (S.O.S.) Ventilation,,Completed,No Results Available,Surgery|Critical Illness|Mechanical Ventilation Complication|Organ Dysfunction Syndrome|Intensive Care Unit Syndrome,Other: Therapy strategy,"Time to successful intubation|Dose and duration of sedation|Type and duration of mechanical ventilation|Complications acquired in ICU|Length of stay in ICU and hospital|Mortality|Quality of life, anxiety, depression, post-traumatic stress disorder 3 and 12 months after ICU discharge|Incidence and duration of organ dysfunctions","University Hospital, Montpellier",All,"18 Years and older   (Adult, Older Adult)",Phase 3,140,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,8667,Dec-11,Apr-15,Apr-15,6-Dec-11,null,2-Dec-15,"Department of Anesthesiology & Critical Care, Estaing University Hospital, Clermont-Ferrand, France|Department of Anesthesiology & Critical Care, St Eloi University Hospital, Montpellier, France|Department of Anesthesiology & Critical Care, Caremeau University Hospita, Nimes, France",,https://ClinicalTrials.gov/show/NCT01486121
NCT01486615,Premedication With Melatonin and Alprazolam Combination Versus Alprazolam or Melatonin Alone,,Completed,Has Results,Anxiety,Drug: meloset (melatonin)|Drug: stresnil ( melatonin and alprazolam)|Drug: (alprax) alprazolam|Drug: placebo,Change in VAS Anxiety Score Relative to Baseline After Premedication|Change in VAS Anxiety Score Relative to Baseline at 30 Minutes After Premedication|Change in VAS Anxiety Score Relative to Baseline at One Hour After Premedication|Sedation Score at One Hour After Premedication|Orientation Score|Number of Patients With Intact Memory|Amount of Propofol Consumption|Number of Patients With Loss of Memory for Being Transferred to Operating Room.,B.P. Koirala Institute of Health Sciences,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,80,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",2/18 (Acd. 796/067/068),Oct-11,Jan-12,Jan-12,6-Dec-11,5-Oct-12,5-Oct-12,"B. P. Koirala Institute of Health Sciences, Dharan, Koshi, Nepal|Dr Krishna Pokharel, Dharan, Koshi, Nepal",,https://ClinicalTrials.gov/show/NCT01486615
NCT01482806,Online Treatments for Mood and Anxiety Disorders in Primary Care,,Completed,No Results Available,Depression|Generalized Anxiety Disorder|Panic Disorder,Behavioral: CCBT+ISG/Collaborative Care|Behavioral: CCBT/Collaborative Care,SF-12 MCS|Hamilton Rating Scale for Depression|Hamilton Rating Scale for Anxiety|WHO Health and Work Performance Questionnaire|Health Services Utilization and Costs|Attitudes to Computerized CBT|Computerized CBT and Internet Support Group Usage,University of Pittsburgh|National Institute of Mental Health (NIMH),All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2|Phase 3,700,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,R01MH093501,Feb-12,Dec-15,30-May-17,1-Dec-11,null,24-Jul-17,"University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT01482806
NCT01483339,Metacognitive Therapy for Patients With Obsessive-Compulsive Disorder,,Completed,No Results Available,Obsessive-Compulsive Disorder,Behavioral: Metacognitive Therapy|Behavioral: Exposure and Response Prevention,"Change in Symptom Severity (Yale Brown Obsessive-Compulsive Scale; YBOCS) from Pretest to Posttest to Follow-up|Change in Symptom Severity (Padua Inventory; PI) from Pretest to two in-between timepoints to Posttest to Follow-up|Change in Metacognitions from Pretest to two in-between timepoints to Posttest to Follow-up|Change in Obsessive Beliefs (Obsessive-Beliefs Questionnaire, OBQ) from Pretest to two in-between timepoints to Posttest to Follow-up|Change in Behavioral Avoidance (Behavioral Avoidance Test, BAT) from Pretest to two in-between timepoints to Posttest to Follow-up|Change in Depression (Beck Depression Inventory, BDI) from Pretest to Posttest to Follow-up|Change in Anxiety (Beck Anxiety Inventory, BAI) from Pretest to Posttest to Follow-up|Change in Patient-Therapist-Alliance from Pretest to two in-between timepoints to Posttest to Follow-up|Change in Symptom Severity (Clinical Global Impressions; CGI) from Pretest to two in-between timepoints to Posttest to Follow-up|Treatment expectancy (Treatment Expectancy Questionnaire) after the first treatment session|Satisfaction with the treatment at Posttest|Change in Symptom Severity (Obsessive-Compulsive Disorder Scale; OCD-S) measured before every treatment session",Philipps University Marburg Medical Center|Psychotherapie-Ambulanz Marburg e.V.,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,37,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MCT_OCD_2011,Nov-11,Jul-17,Aug-17,1-Dec-11,null,6-Oct-17,"Philipps Univerity Marburg, Department of Clinical Psychology and Psychotherapy, Marburg, Hessen, Germany",,https://ClinicalTrials.gov/show/NCT01483339
NCT01476371,Study of Mindfulness-based Group Treatment in Patients With Depression and Anxiety,,Completed,No Results Available,Mental Disorders,Behavioral: Mindfulness-based group treatment,Depression symptoms|Anxiety and depression symptoms|Self-rated health|Systemic inflammation,Lund University,All,20 Years to 64 Years   (Adult),Not Applicable,215,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CPF-0001,Jan-12,Jun-12,Apr-14,22-Nov-11,null,26-Sep-14,,,https://ClinicalTrials.gov/show/NCT01476371
NCT01477203,Multimodal Assessment of Neurobiological Markers for Psychiatric Disorders,MAN-BIOPSY,Completed,No Results Available,Major Depressive Disorder (MDD)|Anxiety Disorder,Drug: Escitalopram,SSRI induced changes in BOLD (blood oxygen level dependent) response over time|SSRI induced changes in ERPs (event-related potentials) over time|biochemical data,Medical University of Vienna,All,18 Years to 50 Years   (Adult),Phase 4,289,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,FA103FC001|2011-004860-31,Nov-11,Sep-16,Sep-16,22-Nov-11,null,14-Sep-16,"Medical University of Vienna, Department for Psychiatrie and Psychotherapie, Vienna, Austria",,https://ClinicalTrials.gov/show/NCT01477203
NCT01473017,Improving Mental Health in Diabetes: A Guided Self-Help Study,,Unknown status,No Results Available,Type 2 Diabetes|Anxiety|Depression,Behavioral: CBT-based Guided Self-Help,Anxiety and/or depression in Type 2 Diabetes|Quality of life,University of Edinburgh,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,120,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,11/NHS/0055,Nov-11,Sep-13,Sep-13,17-Nov-11,null,17-Nov-11,"Raigmore Hospital, Inverness, Highlands, United Kingdom",,https://ClinicalTrials.gov/show/NCT01473017
NCT01470469,"SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)",,Completed,Has Results,"Generalized Anxiety Disorder (GAD)|Anxiety, Separation|Phobia, Social",Drug: SPD503 (extended-release Guanfacine hydrochloride)|Drug: Placebo,Change From Baseline in Systolic Blood Pressure at Up to 12 Weeks|Change From Baseline in Diastolic Blood Pressure at Up to 12 Weeks|Change From Baseline in Pulse Rate at Up to 12 Weeks|Change From Baseline in Height at up to 12 Weeks|Change From Baseline in Weight at up to 12 Weeks|Change From Baseline in Electrocardiogram (ECG) QRS Interval at up to 12 Weeks|Change From Baseline in ECG QTcF Interval at up to 12 Weeks,Shire,All,6 Years to 17 Years   (Child),Phase 2,83,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SPD503-210,Jan-12,Jul-13,Jul-13,11-Nov-11,23-May-14,23-May-14,"Birmingham Research Group, Inc, Birmingham, Alabama, United States|Dr. Joseph H. Rodd, Carson, California, United States|Sun Valley Research, Imperial, California, United States|Irvine Center for Clinical Research, Irvine, California, United States|Sharp Mesa Vista Hospital, Clinical Research Department, San Diego, California, United States|Elite Clinical Trials, Inc, Wildomar, California, United States|Florida Clinical Research Center, Bradenton, Florida, United States|Sarkis Clinical Trials, Gainsville, Florida, United States|Kolin Research Group, Winter Park, Florida, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|Institute of Behavioral Medicine, LLC, Smyrna, Georgia, United States|Lake Charles Clinical Trials, Lake Charles, Louisiana, United States|Rochester Center for Behavioral Medicine, Rochester Hills, Michigan, United States|Midwest Research Group, St Charles, Missouri, United States|Premier Psychiatric Group, LLC, Lincoln, Nebraska, United States|Center for Psychiatry and Behavioral Medicine, Inc, Las Vegas, Nevada, United States|Center for Emotional Fitness, Cherry Hill, New Jersey, United States|Columbia University, NY State Psychiatric Institute, New York, New York, United States|Weill Cornell Medical Center, New York, New York, United States|Finger Lakes Clinical Research, Rochester, New York, United States|Richmond Behavioral Associates, Staten Island, New York, United States|Duke University Medical Center, Duke Child and Family Study Center, Durham, North Carolina, United States|University of Cincinnati, Department of Psychiatry and Behavioral Neuroscience, Cincinnati, Ohio, United States|University Hospitals of Cleveland Medical Center, Cleveland, Ohio, United States|Professional Psychiatric Services, Mason, Ohio, United States|North Star Research, Middleburg Heights, Ohio, United States|IPS Research Company, Oklahoma City, Oklahoma, United States|Coastal Carolina Research Center, Mount Pleasant, South Carolina, United States|Research Strategies of Memphis, LLC, Memphis, Tennessee, United States|FutureSearch Clinical Trials, LP, Austin, Texas, United States|Houston Clinical Trials LLC, Houston, Texas, United States|Ericksen Research and Development, Clinton, Utah, United States|NeuroScience, Inc., Herndon, Virginia, United States",,https://ClinicalTrials.gov/show/NCT01470469
NCT01466751,Neurobehavioral Intervention as a Novel Treatment Approach for Emotion-Regulatory Deficits,,Completed,No Results Available,Anxiety|Depression,Behavioral: Computerized Neurobehavioral Intervention,Emotional conflict adaptation - fMRI imaging and behavioral|Anxiety - self-report symptoms,Stanford University,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,58,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science,IRB-19338,Jan-11,Jan-13,Dec-13,8-Nov-11,null,18-Nov-14,"Stanford University, Department of Psychiatry and Behavioral Sciences, Stanford, California, United States",,https://ClinicalTrials.gov/show/NCT01466751
NCT01466270,Study of Donepezil in Female Breast Cancer Survivors With Cognitive Dysfunction,,Completed,Has Results,Anxiety Disorder|Breast Cancer|Cognition Disorders|Depression|Fatigue|Sleep Disorders,Drug: donepezil hydrochloride|Drug: Placebo,Retention|Compliance|HVLT-IR|Fatigue,Wake Forest University Health Sciences|National Cancer Institute (NCI),Female,"18 Years and older   (Adult, Older Adult)",Phase 2,62,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",IRB00019792-1|U10CA081851|REBACCCWFU 97211,Apr-12,Oct-13,Oct-13,7-Nov-11,9-Jan-15,9-Aug-18,,,https://ClinicalTrials.gov/show/NCT01466270
NCT01464697,Oral Micronized Progesterone for Perimenopausal Vasomotor Symptoms,,Unknown status,No Results Available,Hot Flushes|Night Sweats,Drug: Oral micronized progesterone|Drug: placebo,Vasomotor Symptoms (VMS)/ VMS Score|Frequency of VMS|Severity of VMS|Sleep problems and anxiety,University of British Columbia,Female,35 Years to 58 Years   (Adult),Phase 3,249,Other,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",H10-02975,Oct-11,Jun-17,Jun-17,3-Nov-11,null,9-May-17,"Participation from home or in-person at University of British Columbia/Centre for Menstrual Cycle and Ovulation Research (CeMCOR)/Vancouver Coastal Health Research Institute, Vancouver, British Columbia, Canada",,https://ClinicalTrials.gov/show/NCT01464697
NCT01463137,Attention Bias Modification Training in Social Phobia/Social Anxiety Disorder,SOFIE-11,Completed,No Results Available,Social Phobia,Behavioral: Attention bias modification,Change from baseline in Liebowitz Social Anxiety Scale self rated version|Change from baseline in Social Phobia Screening Questionnaire|Change from baseline in Social Interaction Anxiety Scale (SIAS)|Change from baseline in Social Phobia Scale (SPS)|Change from baseline in Montgomery Åsberg Depression Rating Scale (MADRS-S)|Change from baseline in Quality of Life Inventory (QOLI),Umeå University,All,"18 Years to 100 Years   (Adult, Older Adult)",Not Applicable,129,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SOFIE-11,Oct-11,Jan-13,Jan-13,1-Nov-11,null,1-Nov-16,"Department of Psychology, Umeå University, Umeå, Västerbotten, Sweden",,https://ClinicalTrials.gov/show/NCT01463137
NCT01463241,Behavioral and Affective Skills in Coping (BASIC) Open Trial,BASIC,Completed,No Results Available,Anxiety Disorders|Depressive Disorders|Disruptive Behavior Disorders,Behavioral: Behavioral and Affective Skills in Coping (BASIC),"Change from baseline in diagnostic status at post-treatment: Schedule for Affective Disorders and Schizophrenia for School-Age Children- Present and Lifetime Version (K-SADS-PL)|Change from baseline in child/adolescent problem areas at post-treatment: Child Behavior Checklist -- Problem Portion (CBCL)|Change from baseline in child/adolescent problem areas at post-treatment: Youth Self-Report Form -- Problem Portion (YSR)|Change from baseline in child/adolescent problem areas during treatment and at post-treatment: Brief Problem Checklist (BPC; Chorpita, Reise, Weisz, et al. 2010)|Change from baseline in target problem during treatment and at post-treatment: Weekly Target Problem Report (TPR; STEPs Team, 2008)|Change from baseline in clinical global impression during treatment course: Clinical Global Impression-Improvement (CGI-I) Scale (Guy, 1970).|Services for Children & Adolescents - Parent Interview (SCAPI; Jensen et al., 2004)|Service Assessment for Children and Adolescents-Treatment and Auxiliary Service Use Scales (SACA; Horwitz et al., 2001)|Therapeutic Alliance Scale for Children (TASC; Shirk & Saiz, 1992)|Therapy Process Observational Coding System-Alliance Scale (TPOCS-A; McLeod & Weisz, 2005)|Parent Child Satisfaction Scales (PCSS; Hawley, Weersing, & Weisz, 1998)|Therapist Satisfaction Inventory (TSI; Addis & Krasnow's, 2000)",Judge Baker Children's Center,All,8 Years to 15 Years   (Child),Not Applicable,24,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,R34MH085963-03,Nov-11,Oct-13,Oct-13,1-Nov-11,null,16-Apr-15,"Judge Baker Children's Center, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT01463241
NCT01459068,Mental Health Assessment Project on the Thailand-Burma Border,MHAP,Completed,Has Results,Depression|Anxiety|Posttraumatic Stress,Behavioral: Common Elements Treatment Approach,Depression|Posttraumatic Stress Symptoms|Functional Impairment|Anxiety Symptoms|Aggression Behaviors|Alcohol Use,Johns Hopkins Bloomberg School of Public Health|Burma Border Projects,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,347,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,IRB00003601|DFD-A-00-08-00308-0,Aug-11,Nov-12,Nov-12,25-Oct-11,6-Jun-14,6-Jun-14,"Assistance Association for Political Prisoners; Mae Tao Clinic; Social Action for Women, Mae Sot, Tak Province, Thailand",,https://ClinicalTrials.gov/show/NCT01459068
NCT01453439,Cognitive-Behavioral Therapy and Supportive Psychotherapy for Body Dysmorphic Disorder,,Unknown status,No Results Available,Body Dysmorphic Disorder|Obsessive-Compulsive Spectrum Disorder|Anxiety Disorders|Somatoform Disorders,Behavioral: Cognitive Behavioral Therapy|Behavioral: Supportive Psychotherapy,Body Dysmorphic Disorder Symptoms (as measured by the BDD-YBOCS)|Insight regarding BDD Symptoms (as measured by the BABS)|Depressive symptoms (as measured by the BDI-II)|Functioning and life satisfaction (as measured by the SDS and Q-LESQ-SF)|Treatment credibility and satisfaction with treatment (as measured by the Credibility/Expectancy Rating and CSQ-8)|Beliefs about appearance (as measured by the ASI-R)|Neuropsychological functioning (as measured by the ROCF)|Information processing (as measured by the ERT),Massachusetts General Hospital|National Institute of Mental Health (NIMH),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,120,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,R01MH091078|2010-P-001021/2,Aug-11,Apr-16,Apr-16,17-Oct-11,null,16-Mar-16,"Massachusetts General Hospital, Boston, Massachusetts, United States|Rhode Island Hospital, Providence, Rhode Island, United States",,https://ClinicalTrials.gov/show/NCT01453439
NCT01453452,"S1008: Exercise, Diet, & Counseling in Improving Weight Loss in Overweight Female Breast or Colorectal Cancer Survivors",,Completed,No Results Available,Anxiety Disorder|Breast Cancer|Cognitive/Functional Effects|Colorectal Cancer|Depression|Fatigue|Pain|Psychosocial Effects of Cancer and Its Treatment|Weight Changes,Behavioral: behavioral dietary intervention|Behavioral: exercise intervention|Other: counseling intervention|Procedure: quality-of-life assessment,"Attendance of ≥ 2 Curves sessions/week for a minimum of 36 of the 52 weeks of intervention|Increase in fruit and vegetable consumption by 1 full serving per day (not including iceberg lettuce, potatoes, or fruit juices) OR reduce caloric intake by 100 kcal/day|Changes in anthropometric measures (weight, BMI, waist circumference, hip circumference)|Changes in body composition (% body fat as assessed by DXA scan at 12 months only)|Changes in minutes spent per week in moderate-to-vigorous intensity aerobic activity using Curves attendance records and a 7-day physical activity recall assessment|Changes in dietary intake patterns based on three separate 24-hour diet recalls|Changes in metabolic and hormonal biomarkers associated with breast and colorectal cancer-recurrence risk (fasting insulin, fasting glucose, hemoglobin A1C, bioavailable estradiol, free testosterone, and adiponectin)|Changes in anxiety, depression, fatigue, sleep, satisfaction with social roles, pain, and physical function as measured by the PROMIS-43|DNA methylation patterns",Southwest Oncology Group|National Cancer Institute (NCI),Female,"up to 120 Years   (Child, Adult, Older Adult)",Phase 2,50,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,S1008|U10CA037429|NCI-2011-03539,Mar-12,Aug-15,Jul-17,17-Oct-11,null,8-Dec-17,"Arizona Cancer Center at University Medical Center North, Tucson, Arizona, United States|University of Arizona Health Sciences Center, Tucson, Arizona, United States|Kaiser Permanente-Deer Valley Medical Center, Antioch, California, United States|Kaiser Permanente, Fremont, Fremont, California, United States|Kaiser Permanente, Fresno, California, United States|Kaiser Permanente, Hayward, Hayward, California, United States|Kaiser Permanente-Modesto, Modesto, California, United States|Kaiser Permanente-Oakland, Oakland, California, United States|Kaiser Permanente-Redwood City, Redwood City, California, United States|Kaiser Permanente-Richmond, Richmond, California, United States|Kaiser Permanente-Roseville, Roseville, California, United States|Kaiser Permanente-South Sacramento, Sacramento, California, United States|Kaiser Permanente - Sacramento, Sacramento, California, United States|Kaiser Permanente-San Francisco, San Francisco, California, United States|Kaiser Permanente-Santa Teresa-San Jose, San Jose, California, United States|Kaiser Permanente-San Rafael, San Rafael, California, United States|Kaiser Permanente Medical Center - Santa Clara, Santa Clara, California, United States|Kaiser Permanente-Santa Rosa, Santa Rosa, California, United States|Kaiser Permanente-South San Francisco, South San Francisco, California, United States|Kaiser Permanente-Stockton, Stockton, California, United States|Kaiser Permanente Medical Center-Vacaville, Vacaville, California, United States|Kaiser Permanente-Vallejo, Vallejo, California, United States|Kaiser Permanente-Walnut Creek, Walnut Creek, California, United States|Kaiser Permanente Moanalua Medical Center, Honolulu, Hawaii, United States|Loyola University Medical Center, Maywood, Illinois, United States|Cancer Center of Kansas - Chanute, Chanute, Kansas, United States|Cancer Center of Kansas - Dodge City, Dodge City, Kansas, United States|Cancer Center of Kansas - Fort Scott, Fort Scott, Kansas, United States|Cancer Center of Kansas-Independence, Independence, Kansas, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Cancer Center of Kansas-Kingman, Kingman, Kansas, United States|Lawrence Memorial Hospital, Lawrence, Kansas, United States|Cancer Center of Kansas-Liberal, Liberal, Kansas, United States|Cancer Center of Kansas - Newton, Newton, Kansas, United States|Cancer Center of Kansas - Parsons, Parsons, Kansas, United States|Cancer Center of Kansas - Pratt, Pratt, Kansas, United States|Cancer Center of Kansas - Salina, Salina, Kansas, United States|Cancer Center of Kansas - Wellington, Wellington, Kansas, United States|Associates In Womens Health, Wichita, Kansas, United States|Cancer Center of Kansas-Wichita Medical Arts Tower, Wichita, Kansas, United States|Cancer Center of Kansas - Main Office, Wichita, Kansas, United States|Via Christi Regional Medical Center, Wichita, Kansas, United States|Wichita CCOP, Wichita, Kansas, United States|Cancer Center of Kansas - Winfield, Winfield, Kansas, United States|William Beaumont Hospital, Royal Oak, Michigan, United States|William Beaumont Hospital - Troy, Troy, Michigan, United States|Columbia University Medical Center, New York, New York, United States|Cancer Centers of the Carolinas - Faris, Greenville, South Carolina, United States|Cancer Centers of the Carolinas - Grove Commons, Greenville, South Carolina, United States|Greenville Memorial Hospital, Greenville, South Carolina, United States|Greenville CCOP, Greenville, South Carolina, United States|Cancer Centers of the Carolinas-Greer Medical Oncology, Greer, South Carolina, United States|Cancer Centers of the Carolinas - Seneca, Seneca, South Carolina, United States|Cancer Centers of the Carolinas - Spartanburg, Spartanburg, South Carolina, United States|Southwest Oncology Group, San Antonio, Texas, United States|Swedish Medical Center-Edmonds, Edmonds, Washington, United States|Swedish Medical Center-First Hill, Seattle, Washington, United States|University of Washington Medical Center, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT01453452
NCT01451697,Cognitive Remediation for Neuropsychological Impairment in Compulsive Hoarding,,Completed,No Results Available,Hoarding Disorder|Attentional Impairment,Behavioral: Cognitive Remediation|Behavioral: Control (Placebo),Continuous Performance Task (computerized version): change from Baseline in Attentional Functioning at 8 Weeks,Hartford Hospital,All,"18 Years and older   (Adult, Older Adult)",Early Phase 1,20,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DIMA003472HI,Jul-11,Jul-12,Oct-12,14-Oct-11,null,20-May-19,"Anxiety Disorders Center, Institute of Living/Hartford, Hartford, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT01451697
NCT01447966,Family Based Cognitive-Behavioral Treatment for Preschoolers With Obsessive Compulsive Disorder,,Completed,No Results Available,Obsessive Compulsive Disorder (OCD),Behavioral: Cognitive Behavioral Therapy,Clinician Global Impression - Improvement Scale (Measure of patient improvement at relevent timepoints)|CYBOCS - Childrens Yale Brown Obsessive Compulsive Scale,University of South Florida,All,3 Years to 8 Years   (Child),Not Applicable,31,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,YC-OCD,May-11,Jun-13,Mar-14,6-Oct-11,null,26-Mar-14,"University of South Florida - Rothman Center for Neuropsychiatry, St. Petersburg, Florida, United States",,https://ClinicalTrials.gov/show/NCT01447966
NCT01446588,Ocular Hypertension And Yoga Study,OHAYS,Withdrawn,No Results Available,Ocular Hypertension|Sleep Disturbance|Stress|Anxiety|Depression,Behavioral: Yoga Intervention,Intraocular Pressure (IOP)|Body Mass Index (BMI) (i.e. weight and height)|Blood pressure|Respiratory Rate (RR)|Pittsburgh Sleep Quality Index (PSQI)|Perceived Stress Scale (PSS)|Beck Anxiety Index (BAI)|Beck Depression Index (BDI)|Positive and Negative Affect Schedule (PANAS)|Vision Test/Ocular Disease Catastrophizing Scale|Philadelphia Mindfulness Scale (PHLMS)|Exit Survey|Practice Log,Johns Hopkins University,All,"18 Years to 90 Years   (Adult, Older Adult)",Not Applicable,0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NA_00041019,Jun-12,Dec-12,Dec-12,5-Oct-11,null,26-May-14,"Lions Vision and Research Rehabilitation, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT01446588
NCT01442805,Use of Virtual Reality in the Treatment of Flying Phobia,,Completed,No Results Available,Flying Phobia,Behavioral: Virtual Reality Exposure Therapy|Behavioral: Exposure Therapy through Imagination,Flight taken|Physiological Measures|Specific Questionnaires,Luxembourg Institute of Health|Centre Hospitalier du Luxembourg,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,36,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20080102,Oct-08,Sep-11,Mar-12,29-Sep-11,null,15-Mar-17,"Centre de Recherche Public de la Santé, Strassen, Luxembourg",,https://ClinicalTrials.gov/show/NCT01442805
NCT01441843,Resistance Under the Microscope,,Completed,Has Results,Anxiety,Drug: Lorazepam|Drug: NaCl 0.9% (Sodium Chloride),Quality of Recovery Score|Anxiety|Fatigue|Aggression Regulation|Depressive Mood|Somatic Symptoms and Complaints,Erasmus Medical Center,All,"18 Years and older   (Adult, Older Adult)",Phase 4,400,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NL3253507810,Oct-10,Sep-11,Sep-11,28-Sep-11,10-Mar-14,1-Mar-18,"Erasmus University Medical Center, Rotterdam, Netherlands",,https://ClinicalTrials.gov/show/NCT01441843
NCT01437046,Doxazosin an a1 Antagonist for Alcohol Dependence,,Completed,No Results Available,Alcohol Dependence|Anxiety,Drug: Doxazosin|Drug: Placebo,drinking days per week (DDW)|drinks per week (DPW)|alcohol craving|anxiety|Adverse Events,Brown University|National Institute on Alcohol Abuse and Alcoholism (NIAAA),All,"18 Years and older   (Adult, Older Adult)",Phase 2,48,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",1101000328|1R21AA019994-01A1,Nov-11,Aug-13,Mar-15,20-Sep-11,null,22-Jul-15,"Brown University Center for Alcohol and Addiction Studies, Providence, Rhode Island, United States",,https://ClinicalTrials.gov/show/NCT01437046
NCT01427894,Maternal Singing During Kangaroo Care in Preterm Infants,,Completed,No Results Available,Prematurity|Maternal Anxiety,Other: Maternal singing with Kangaroo Care,Reduced Heart Rate|Reduced respiratory rate|Als' Behavioral Score,Meir Medical Center,All,up to 6 Months   (Child),Not Applicable,30,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Investigator)|Primary Purpose: Supportive Care,Mc(0023)(2011)ctil,Nov-11,Nov-14,Nov-14,2-Sep-11,null,16-Mar-16,"NICU, Kfar-Saba, Israel",,https://ClinicalTrials.gov/show/NCT01427894
NCT01425619,The Effect of Medical Clowns and Topical Anesthetic Cream on Pain and Anxiety in Children Undergoing Allergy Skin Tests,,Completed,No Results Available,Anxiety Disorder|Allergic Skin Reaction,Biological: Cream of Macrogol cetostearyl ethers|Drug: Cream of Lidocaine 2.5 %.and Prilocaine 2.5 %|Behavioral: Care and treatment from a medical clown,The level of anxiety experienced by children undergoing allergy skin tests and receiving application of local anesthetic cream and/or care and treatment from medical clowns|Severity of pain experienced by these children,Meir Medical Center,All,"1 Year to 18 Years   (Child, Adult)",Not Applicable,160,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,CLOWN 1,Oct-11,Apr-14,Apr-14,30-Aug-11,null,8-Oct-15,"Arnon Goldberg, Allergy and Clinical Immunology Unit, Meir Medical Center, Kfar-Saba, Israel",,https://ClinicalTrials.gov/show/NCT01425619
NCT01424384,Emotional Processing in Healthy Volunteers in the Presence of an Investigational Anxiolytic,,Completed,No Results Available,Depressive Disorder and Anxiety Disorders,Drug: Citalopram|Drug: GSK424887|Drug: Plactebo To Match,"Multiple emotional and psychometric battery of tests|Adverse Events, laboratory values, vital signs, ECGs",GlaxoSmithKline,Male,18 Years to 45 Years   (Adult),Phase 1,54,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",105012,19-Sep-08,30-Apr-09,30-Apr-09,29-Aug-11,null,7-Jul-17,"GSK Investigational Site, Oxford, United Kingdom",,https://ClinicalTrials.gov/show/NCT01424384
NCT01422447,Research of Prevention and Intervention of Mental Health Problems,RPIMHP,Completed,No Results Available,Anxiety|Depression|Alcohol-abuse,Other: regular intervention|Other: community intervention,"evaluate the changes of mental health state of community residents before and after intervention|prevalence of depression,anxiety and alcohol abuse|public awareness and attitude towards mental health knowledge|service needs and utilization|the reliability and validity of PHQ-9, HPQ-7 and AUDIT|assessment of the situation of community mental health service resources|assessment the changes of early stage of mental disorders in population before and after intervention",Shanghai Mental Health Center,All,"13 Years to 65 Years   (Child, Adult, Older Adult)",Not Applicable,42016,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention,MZhao-001,Oct-10,Dec-12,Dec-12,24-Aug-11,null,25-Nov-15,"Capital Normal University, Beijing, Beijing, China|Shenzhen mental health center, Shenzhen, Guangdong, China|Mental Health Center in Hunan Province, Hunan, Hunan, China|Harbin medical university, Harbin, Jilin, China|中国, Shanghai, Shanghai, China|Mental Health of Sichuan Province, Sichuan, Sichuan, China|Mental Health of Xinjiang Province, Xinjiang, Xinjiang, China",,https://ClinicalTrials.gov/show/NCT01422447
NCT01420848,Auriculotherapy Effectiveness on Stress and Anxiety in Nursing Student,,Completed,Has Results,Stress|Anxiety,Other: Auriculotherapy|Other: Placebo Group,Students Stress Levels|Students Anxiety Levels,University of Sao Paulo,All,19 Years to 55 Years   (Adult),Phase 2,71,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,SISNEP CAAE 0107.0.360.000-11,Jan-11,Aug-11,Aug-11,22-Aug-11,15-Jul-13,15-Jul-13,"Real e Benemérita Associação Portuguesa de Beneficência, São Paulo, Brazil",,https://ClinicalTrials.gov/show/NCT01420848
NCT01420055,Fingolimod -Response According to Coping - Evaluation,GRACE,Completed,No Results Available,"Multiple Sclerosis, Relapsing-Remitting",Drug: fingolimod,"To assess the mean change in Hospital Anxiety Depression Scale (HADS) anxiety sub-score between baseline and Month 4 in RRMS fingolimod treated patient total population, and according to coping profile (task, emotion or avoidance oriented).|To assess patient Clinical Global Impression (CGI) and clinician CGI at M4 in total population, and according to coping profile.|To evaluate the safety and tolerability of fingolimod 0.5 mg/day (especially initial cardiac effects, liver function and macular edema onset)|To explore treatment satisfaction with fingolimod in patients with RRMS either naive (rapidly evolving severe RRMS) or who transitioned from previous treatment with Disease Modifying Therapy using the TSQM 9 and according to coping profile",Novartis Pharmaceuticals|Novartis,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,189,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CFTY720DFR03|2011-001280-49,Aug-11,Jun-13,Jun-13,19-Aug-11,null,18-Nov-16,"Novartis Investigative Site, Agen Cedex 9, France|Novartis Investigative Site, Amiens Cedex 1, France|Novartis Investigative Site, Angers Cedex 1, France|Novartis Investigative Site, Auxerre, France|Novartis Investigative Site, Avignon, France|Novartis Investigative Site, Bayonne, France|Novartis Investigative Site, Beziers, France|Novartis Investigative Site, Bobigny Cedex, France|Novartis Investigative Site, Brest, France|Novartis Investigative Site, Calais, France|Novartis Investigative Site, Castelnau-le-Lez, France|Novartis Investigative Site, Chambray les Tours, France|Novartis Investigative Site, Cherbourg, France|Novartis Investigative Site, Clermont-Ferrand Cedex 1, France|Novartis Investigative Site, Créteil, France|Novartis Investigative Site, Dijon, France|Novartis Investigative Site, Epinal, France|Novartis Investigative Site, Grenoble Cedex 9, France|Novartis Investigative Site, Hagueneau, France|Novartis Investigative Site, La Rochelle cedex 1, France|Novartis Investigative Site, La Seyne sur mer, France|Novartis Investigative Site, Le Kremlin Bicetre, France|Novartis Investigative Site, Le Mans Cedex 09, France|Novartis Investigative Site, Limoges, France|Novartis Investigative Site, Lyon, France|Novartis Investigative Site, Marseille, France|Novartis Investigative Site, Marseille, France|Novartis Investigative Site, Metz, France|Novartis Investigative Site, Montpellier, France|Novartis Investigative Site, Montpellier, France|Novartis Investigative Site, Nimes, France|Novartis Investigative Site, Orsay, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Poitiers, France|Novartis Investigative Site, Pontoise, France|Novartis Investigative Site, Reims, France|Novartis Investigative Site, Rennes Cedex, France|Novartis Investigative Site, Roanne, France|Novartis Investigative Site, Saint Aubin sur Scie, France|Novartis Investigative Site, Saint Jean, France|Novartis Investigative Site, Sainte Foy les Lyon, France|Novartis Investigative Site, Saumur, France|Novartis Investigative Site, Strasbourg Cedex, France|Novartis Investigative Site, Talant, France|Novartis Investigative Site, Toulouse, France|Novartis Investigative Site, Tourcoing, France|Novartis Investigative Site, Tours Cedex, France",,https://ClinicalTrials.gov/show/NCT01420055
NCT01416805,Computerized Cognitive Behavioral Therapy for Childhood Anxiety in Community Health Centers,,Completed,No Results Available,Generalized Anxiety Disorder|Social Phobia|Separation Anxiety Disorder,Behavioral: Computerized Cognitive Behavioral Therapy|Behavioral: Treatment as usual,PARS|ADIS-C/P,University of South Florida|Access Behavioral Health|Henderson Behavioral Health|Directions for Mental Health,All,7 Years to 13 Years   (Child),Phase 3,188,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,1R18HS018665,Aug-11,Dec-15,Dec-15,15-Aug-11,null,26-Oct-17,"Directions for Mental Health, Clearwater, Florida, United States|Henderson Behavioral Health, Fort Lauderdale, Florida, United States|Access Behavioral Health, Pensacola, Florida, United States|University of South Florida, Saint Petersburg, Florida, United States",,https://ClinicalTrials.gov/show/NCT01416805
NCT01414023,Assessing the Effects of a Neurobehavioral Intervention on Symptoms of Obsessive Compulsive Disorder,CCT-OC,Completed,No Results Available,Obsessive Compulsive Disorder,Behavioral: Cognitive Control Training|Behavioral: Peripheral Vision Task,OCI-R scores|BDNF serum levels,Boston University,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,48,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,BU-2487,Jul-11,Jul-12,null,11-Aug-11,null,21-Jul-15,"Boston University, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT01414023
NCT01411709,A Study On The Effect Of Vitano® On Physiological And Psychological Responses To Psychological Stress,,Completed,No Results Available,Mild Stress/Anxiety,Drug: Vitano,Blood pressure measurements|Measures of cognitive function,University of Surrey|Dr. Willmar Schwabe GmbH & Co. KG,All,18 Years to 35 Years   (Adult),Phase 4,80,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CRC287,Jan-11,Jul-11,Jul-11,8-Aug-11,null,30-Mar-15,"University of Surrey, Guildford, Surrey, United Kingdom",,https://ClinicalTrials.gov/show/NCT01411709
NCT01411774,D-cycloserine Augmentation of Cognitive Behavioral Therapy (CBT) for Pediatric Obsessive-compulsive Disorder (OCD),,Completed,Has Results,Obsessive-compulsive Disorder,Behavioral: Cognitive-behavioral therapy|Drug: d-cycloserine|Drug: Pill placebo,Children's Yale-Brown Obsessive-Compulsive Scale.|Clinical Global Impression-Severity,University of South Florida|Massachusetts General Hospital,All,7 Years to 17 Years   (Child),Phase 3,142,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",1R01MH093381,Jun-11,Jun-16,Jun-17,8-Aug-11,23-Jan-18,23-Jan-18,"University of South Florida, Saint Petersburg, Florida, United States|Massachusetts General Hospital, Cambridge, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT01411774
NCT01409642,Family Focused Treatment of Pediatric Obsessive Compulsive Disorder,PFIT,Unknown status,No Results Available,Obsessive-Compulsive Disorder,Behavioral: Individual Child CBT|Behavioral: Positive Family Interaction Therapy,OCD symptom severity on the Children's Yale Brown Obsessive Compulsive Scale (CYBOCS),"University of California, Los Angeles",All,8 Years to 17 Years   (Child),Not Applicable,40,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,K23MH085058,Jan-08,Dec-16,Dec-16,4-Aug-11,null,13-May-16,"University of California, Los Angeles, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT01409642
NCT01409044,Effect of Music on Pain and Anxiety After Surgery,,Terminated,No Results Available,Postop Adult ICU Patients,Other: Music,"Opiate use|Pain, anxiety and distress outcome measures",National Institutes of Health Clinical Center (CC),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,62,NIH,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,110201|11-CC-0201,17-Jun-11,9-May-13,8-Aug-17,3-Aug-11,null,10-Aug-17,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT01409044
NCT01404871,Predicting Medication Response in Obsessive Compulsive Disorder,,Completed,No Results Available,Obsessive Compulsive Disorder,Drug: clomipramine|Drug: escitalopram|Drug: duloxetine,"YBOCS Obsessive-Compulsive Severity Score|Clinical Global Improvement - Improvement Scale|Change in cortical Inhibition (CI) as measured with Transcranial Magnetic Stimulation.|Genotype marker data for SLC1A1, GRIN2B, 5HT1B, 5HT2A and P450 enzymes CYP2D6 and CYP2C19.|Tolerability/side effects measure with Udvalg for Liniske Undersogelser Side Effect Rating Scale (UKU).|Clinical Global Impression - Severity Scale.|Depression symptoms will be rated with the Beck Depression Inventory (BDI).|DYBOCS (Dimensional Yale-Brown Obsessive-Compulsive Scale)",Sunnybrook Health Sciences Centre|Obsessive Compulsive Foundation|Centre for Addiction and Mental Health,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,26,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor),OCF-Richter,Apr-09,Oct-11,Dec-11,28-Jul-11,null,31-Jan-13,"Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|The Centre for Addiction and Mental Health, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT01404871
NCT01404208,2/2 D-Cycloserine Augmentation of CBT for Pediatric OCD,,Completed,Has Results,Obsessive-Compulsive Disorder,Drug: D-Cycloserine|Drug: Placebo,Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS)|Clinical Global Impression-Severity (CGI-Severity),Massachusetts General Hospital|National Institute of Mental Health (NIMH)|University of South Florida,All,7 Years to 17 Years   (Child),Not Applicable,206,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2011P000875|1R01MH093402-01A1,Jul-11,Sep-15,Dec-16,27-Jul-11,27-Feb-17,28-Mar-17,"Massachusetts General Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT01404208
NCT01402258,Internet-administrated Treatment of Anxiety Symptoms for Young Adults,NOVA-IV,Unknown status,No Results Available,Anxiety Disorders|Depression,Behavioral: Tailored Internet-administrated CBT-Treatment,Beck Anxiety Inventory (BAI)- Change from baseline|Quality of Life Inventory (QOLI)- Change from baseline|Montgomery Åsberg Depression Rating Scale-Self Rated (MADRS-S)- Change from baseline|Clinical Outcome in Routine Evaluation - Outcome Measure (CORE-OM)- Change from baseline,Linkoeping University,All,"16 Years to 25 Years   (Child, Adult)",Not Applicable,30,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GA-FORSS-2011-150291,Apr-11,Dec-14,Jun-15,26-Jul-11,null,29-Apr-13,"Department of Behavioral Sciences and Learning, Linköping University, Linköping, Östergötland, Sweden",,https://ClinicalTrials.gov/show/NCT01402258
NCT01398007,Use of the Camouflage Syringe to Reduce Dental Anxiety and Fear in Children,,Completed,No Results Available,Anxiety|Fear,Procedure: Camouflage syringe,Venham's clinical rating scale|Venham's Picture Test|Parental Emotional Stress Questionnaire|Recall questionnaire,"Government Dental College and Hospital, India|Lata Medical Research Foundation, Nagpur",All,2 Years to 14 Years   (Child),Phase 2,100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SUT2503,Oct-05,Apr-06,Apr-06,20-Jul-11,null,11-Mar-15,"Government Dental College and Hospital, Nagpur, Maharashtra, India",,https://ClinicalTrials.gov/show/NCT01398007
NCT01398514,Influence of Escitalopram on Fear Conditioning,,Completed,Has Results,Fear Conditioning,Drug: Escitalopram,Physiological Reactivity as Measured by Square-root Transformed Skin Conductance Conditioned Response in Early Extinction Trials 1 to 4|Physiological Reactivity as Measured by Square-root Transformed Skin Conductance Conditioned Response in Acquisition Trials 1 to 5,Massachusetts General Hospital|Forest Laboratories,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 4,65,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",2008-P-001314,Oct-08,Jun-11,Jun-11,20-Jul-11,27-Sep-13,11-Jun-14,,,https://ClinicalTrials.gov/show/NCT01398514
NCT01396876,The Effects of Medical Clowns in Children Undergoing Blood Tests,,Completed,No Results Available,Pain|Anxiety,Behavioral: clown,Pain score|Parental anxiety level|Procedure's success rate|Overall report of procedure's comfort,Tel-Aviv Sourasky Medical Center,All,3 Years to 10 Years   (Child),Not Applicable,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TASMC-11-SR-525-CTIL,Jul-11,Dec-12,Dec-12,19-Jul-11,null,19-Jun-14,"Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel",,https://ClinicalTrials.gov/show/NCT01396876
NCT01397032,Attention Bias Modification Treatment for Children With Social Anxiety,,Completed,No Results Available,Social Phobia,Behavioral: Attention Bias Modification Treatment (ABMT)|Behavioral: Attention Control Condition,Anxiety Disorders Interview Schedule for DSM-IV (ADIS)|Social Phobia and Anxiety Inventory for Children (SPAI-C) and for Parents (SPAI-c-p),Tel Aviv University,All,"7 Years to 18 Years   (Child, Adult)",Phase 2,67,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",2009340,Apr-11,Aug-14,Aug-14,19-Jul-11,null,27-May-15,"Tel-Aviv University, Tel-Aviv, Israel",,https://ClinicalTrials.gov/show/NCT01397032
NCT01395953,Double-blind Trial of Buspirone for the Treatment of Anxiety in Youth With Autism Spectrum Disorders,,Withdrawn,No Results Available,Autism Spectrum Disorder (ASD),Drug: Buspirone|Drug: Placebo,Reduction in Pediatric Anxiety Rating Scale (PARS) Score|Clinical Global Impression-Anxiety (CGI-Anxiety) Improvement Score,Massachusetts General Hospital,All,6 Years to 17 Years   (Child),Phase 2,0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",2011-P-000703,Nov-11,Jul-13,Jul-13,18-Jul-11,null,7-Apr-15,"Massachusetts General Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT01395953
NCT01394250,"Vibrating, Cold Device for Pediatric Intravenous (IV) Cannulation Pain Relief",,Completed,Has Results,Pain|Anxiety,Device: Buzzy|Drug: Topical Lidocaine 4% Cream,"Change From Baseline in Faces Pain Scale Revised (FPS-R) at 30 Minutes After IV Cannulation|Comparison of the Face, Legs, Activity, Cry, Consolability Scale (FLACC) Score Immediately After IV Cannulation Between Groups",Children's Hospital of Philadelphia,All,"4 Years to 18 Years   (Child, Adult)",Phase 2,240,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,11-007970,Jun-11,Sep-13,Sep-13,14-Jul-11,15-May-15,16-Sep-16,"Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT01394250
NCT01393301,Integrated Treatment for Smoking Cessation & Anxiety in People With HIV,Project Quit,Completed,Has Results,Nicotine Dependence|Symptoms of Anxiety|HIV,Behavioral: Integrated cognitive-behavioral therapy for smoking cessation and anxiety|Behavioral: Control,Treatment Acceptability|Long-term Point Prevalence Abstinence (PPA; Pilot RCT Phase)|Short-term Point Prevalence Abstinence (PPA; Pilot RCT Phase)|Treatment Related Changes in Psychological Distress.,Massachusetts General Hospital|Southern Methodist University|University of Houston|National Institute on Drug Abuse (NIDA),All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,72,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,R34DA031038-01A1|1R34DA031038-01A1,Oct-11,May-15,May-15,13-Jul-11,20-Mar-19,20-Mar-19,"Massachusetts General Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT01393301
NCT01393691,A Clinical Research Studying Interventions for Nighttime Fears in Preschool Children,,Completed,No Results Available,Nighttime Fears,Behavioral: CBT with parent involved play|Behavioral: Triadic expressive play therapy,nighttime fear and sleep logs|Nighttime fears interview (child) and nighttime fears questionnaire (parents)|Activity-based sleep monitoring (Actigraphy),alan apter|Rabin Medical Center,All,4 Years to 6 Years   (Child),Not Applicable,90,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",6191,Jun-11,Apr-14,Apr-14,13-Jul-11,null,9-Jul-15,"Rabin Medical Center, Petach Tikva, Israel",,https://ClinicalTrials.gov/show/NCT01393691
NCT01392690,Evaluation of a Primary Prevention Program for Anxiety Disorders Using Story Books,TrucsDeDom,Completed,No Results Available,Anxiety,Behavioral: Dominique's Handy Tricks,Change from pre-program on the Coping scale for children and youth|Change from pre-program on the Childhood anxiety sensitivity index,Universite du Quebec en Outaouais,All,9 Years to 12 Years   (Child),Not Applicable,73,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,RegieRegionale-07-2000-05|Les Trucs de Dominique,Mar-00,Aug-02,Aug-02,12-Jul-11,null,28-Jul-11,"Universite du Quebec en Outaouais, Gatineau, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT01392690
NCT01390168,Internet-administrated Treatment of Anxiety Disorders,NOVA II,Completed,No Results Available,Anxiety Disorders|Depression,Behavioral: Tailored Internet-administrated CBT-Treatment|Behavioral: Waitlist,Change from baseline in Clinical Outcome in Routine Evaluation - Outcome Measure (CORE-OM)|Change from baseline in Beck Anxiety Inventory (BAI)|Change from baseline in Montgomery Åsberg Depression Rating Scale-Self Rated (MADRS-S)|Change from baseline in Quality of Life Inventory (QOLI),Umeå University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PC-FAS-2008-1145,Jan-10,Dec-12,Dec-12,8-Jul-11,null,5-Mar-13,"Department of Behavioural Sciences and Learning, Linköping University, Linköping, Östergötland, Sweden",,https://ClinicalTrials.gov/show/NCT01390168
NCT01388231,Transfer of Manualized Cognitive-Behavioral Therapy (CBT) for Social Phobia Into Clinical Practice,,Unknown status,No Results Available,Social Phobia,Behavioral: CBT-Manualized Intervention|Behavioral: CBT-Treatment as Usual,Severity of Social Phobia Symptoms|Diagnostic Status of Social Phobia|Assessment of Symptoms of Social Anxiety (Performance Anxiety)|Assessment of Symptoms of Social Anxiety (Social Phobic Cognitions)|Assessment of a Change in Safety Behaviors in Social Anxiety|Assessment of Other Social Anxiety Symptoms|Assessment of Symptoms of Depression|Assessment of Emotion Regulation|Assessment of the Quality of Life|Assessment of the Times Missing from Work|Assessment of the General Level of Severity of Social Anxiety Symptoms,Technische Universität Dresden|Goethe University|University of Göttingen,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2|Phase 3,116,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",01GV1001,Sep-10,Jun-13,Jun-13,6-Jul-11,null,8-Jul-11,"Outpatient clinical services and day clinic center Technical University Dresden (IAP-TUD), Dresden, Saxony, Germany",,https://ClinicalTrials.gov/show/NCT01388231
NCT01385163,Intervention Effectiveness in Improving Psychosocial and Economic Well-being of Sexual Violence Survivors in DRC,,Unknown status,No Results Available,Depression|Anxiety|PTSD,Behavioral: Treatment as usual|Behavioral: Voluntary Savings/Loans Assoc|Behavioral: Cognitive Processing Therapy,Severity of mental health symptoms|Economic development,Johns Hopkins Bloomberg School of Public Health,Female,"18 Years to 90 Years   (Adult, Older Adult)",Not Applicable,1000,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,JHU-AMHR-IRC-2010,Oct-10,Aug-12,Jul-13,29-Jun-11,null,18-Jul-11,"Village based, Bakavu, South Kivu Province, Congo",,https://ClinicalTrials.gov/show/NCT01385163
NCT01380379,Self-Defense Training in Women With Trauma,,Completed,Has Results,"Depression|Anxiety|Stress Disorders, Post-Traumatic",Behavioral: Life skills and self-defense training,Change in Self-efficacy From Baseline to Post-treatment|Change in Assertiveness Between Baseline and Post-intervention,Stanford University,Female,"21 Years to 65 Years   (Adult, Older Adult)",Not Applicable,9,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SU-04152011-7701|20776,Apr-11,Aug-13,Nov-15,27-Jun-11,1-Feb-17,1-Feb-17,"Stanford University School of Medicine, Stanford, California, United States",,https://ClinicalTrials.gov/show/NCT01380379
NCT01378923,Evaluation of Re-Entry Values and Mindfulness Program (REVAMP) With Jail Inmates,REVAMP,Unknown status,No Results Available,Impulsive Behavior|Substance Abuse|HIV Risk Behavior|Anxiety|Depression|Criminogenic Thinking,Behavioral: REVAMP|Behavioral: TAU,Recidivism - Self Report of undetected crimes|Recidivism - Self Report of Arrests|Recidivism - Official Records of arrests|Substance Dependence symptoms - Texas Christian University (TCU) measure|HIV Risk Behavior - Sex and Intravenous Drug Use (IDU) - TCU|Acceptability - number of participants who report finding the treatment helpful and number who would recommend the treatment to a friend|Mindfulness - Self report using Mindfulness Inventory: Nine Dimensions (MI:ND)|Self Control - Self report using Brief Self control Scale (BSC)|Self-Compassion - Self report using Neff's scale|Distress-Driven Impulsivity - Behavioral measure using Balloon Analog Reaction Test (BART) preceded by mirror tracing task|Psychological Symptoms - Self report using Personality Assessment Inventory,George Mason University,Male,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,40,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CCT-01,Apr-11,Jun-13,Jun-13,23-Jun-11,null,7-May-13,"Fairfax County Adult Detention Center, Fairfax, Virginia, United States",,https://ClinicalTrials.gov/show/NCT01378923
NCT01379885,Reducing Immunization Distress (RID),RID,Terminated,No Results Available,Pain,Behavioral: Standard technique|Behavioral: Parent participation technique,Child pain intensity|Time for completion of immunization|Child and parent satisfaction with procedure,"University of California, San Francisco|Pediatric Medical Group",All,4 Years to 6 Years   (Child),Not Applicable,77,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,UCaliforniaSF,Jun-11,Jan-13,Jan-13,23-Jun-11,null,1-Feb-13,"Pediatric Medical Group, Berkeley, California, United States",,https://ClinicalTrials.gov/show/NCT01379885
NCT01377883,Clown Care for Botulinum Toxin (BTX),,Completed,No Results Available,Cerebral Palsy|Pain,Other: standard|Behavioral: clown care,Visual Analogue Scale,Shaare Zedek Medical Center,All,"2 Years to 18 Years   (Child, Adult)",Not Applicable,25,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CL_BTX2011,Jan-10,May-11,Jun-11,22-Jun-11,null,31-Dec-18,,,https://ClinicalTrials.gov/show/NCT01377883
NCT01376349,Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms,,Completed,Has Results,Breast Cancer|Gynecologic Cancer,Drug: prasterone|Other: placebo,Alleviation of the Most Bothersome Vaginal Symptom (Vaginal Dryness or Dyspareunia) Over 12 Weeks,Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)|Mayo Clinic,Female,"18 Years and older   (Adult, Older Adult)",Phase 3,464,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care",NCCTG-N10C1|CDR0000702003|NCI-2011-02677,Jul-11,Aug-13,Nov-17,20-Jun-11,25-Aug-17,7-Feb-19,"Mayo Clinic Scottsdale, Scottsdale, Arizona, United States|Aurora Presbyterian Hospital, Aurora, Colorado, United States|Boulder Community Hospital, Boulder, Colorado, United States|Penrose Cancer Center at Penrose Hospital, Colorado Springs, Colorado, United States|St. Anthony Central Hospital, Denver, Colorado, United States|Porter Adventist Hospital, Denver, Colorado, United States|Presbyterian - St. Luke's Medical Center, Denver, Colorado, United States|St. Joseph Hospital, Denver, Colorado, United States|Rose Medical Center, Denver, Colorado, United States|CCOP - Colorado Cancer Research Program, Denver, Colorado, United States|Swedish Medical Center, Englewood, Colorado, United States|Poudre Valley Hospital, Fort Collins, Colorado, United States|Front Range Cancer Specialists, Fort Collins, Colorado, United States|North Colorado Medical Center, Greeley, Colorado, United States|Littleton Adventist Hospital, Littleton, Colorado, United States|Sky Ridge Medical Center, Lone Tree, Colorado, United States|Hope Cancer Care Center at Longmont United Hospital, Longmont, Colorado, United States|McKee Medical Center, Loveland, Colorado, United States|Parker Adventist Hospital, Parker, Colorado, United States|St. Mary - Corwin Regional Medical Center, Pueblo, Colorado, United States|North Suburban Medical Center, Thornton, Colorado, United States|Exempla Lutheran Medical Center, Wheat Ridge, Colorado, United States|Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center, Hartford, Connecticut, United States|Herbert D. Kerman Regional Oncology Center - Daytona Beach, Daytona Beach, Florida, United States|University of Florida Shands Cancer Center, Gainesville, Florida, United States|Mayo Clinic - Jacksonville, Jacksonville, Florida, United States|Kapiolani Medical Center at Pali Momi, 'Aiea, Hawaii, United States|Cancer Research Center of Hawaii, Honolulu, Hawaii, United States|OnCare Hawaii, Incorporated - Lusitana, Honolulu, Hawaii, United States|Queen's Cancer Institute at Queen's Medical Center, Honolulu, Hawaii, United States|Straub Clinic and Hospital, Incorporated, Honolulu, Hawaii, United States|Hawaii Medical Center - East, Honolulu, Hawaii, United States|OnCare Hawaii, Incorporated - Kuakini, Honolulu, Hawaii, United States|Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, United States|Castle Medical Center, Kailua, Hawaii, United States|Kauai Medical Clinic, Lihue, Hawaii, United States|Maui Memorial Medical Center, Wailuku, Hawaii, United States|Pacific Cancer Institute - Maui, Wailuku, Hawaii, United States|Saint Alphonsus Cancer Care Center at Saint Alphonsus Regional Medical Center, Boise, Idaho, United States|Idaho Urologic Institute, PA, Meridian, Idaho, United States|Illinois CancerCare - Bloomington, Bloomington, Illinois, United States|St. Joseph Medical Center, Bloomington, Illinois, United States|Illinois CancerCare - Canton, Canton, Illinois, United States|Illinois CancerCare - Carthage, Carthage, Illinois, United States|Eureka Community Hospital, Eureka, Illinois, United States|Illinois CancerCare - Eureka, Eureka, Illinois, United States|Galesburg Clinic, PC, Galesburg, Illinois, United States|Illinois CancerCare - Havana, Havana, Illinois, United States|Illinois CancerCare - Kewanee Clinic, Kewanee, Illinois, United States|Illinois CancerCare - Macomb, Macomb, Illinois, United States|Trinity Cancer Center at Trinity Medical Center - 7th Street Campus, Moline, Illinois, United States|Moline, Illinois, United States|Illinois CancerCare - Monmouth, Monmouth, Illinois, United States|OSF Holy Family Medical Center, Monmouth, Illinois, United States|BroMenn Regional Medical Center, Normal, Illinois, United States|Community Cancer Center, Normal, Illinois, United States|Illinois CancerCare - Community Cancer Center, Normal, Illinois, United States|Community Hospital of Ottawa, Ottawa, Illinois, United States|Oncology Hematology Associates of Central Illinois, PC - Ottawa, Ottawa, Illinois, United States|Cancer Treatment Center at Pekin Hospital, Pekin, Illinois, United States|Illinois CancerCare - Pekin, Pekin, Illinois, United States|Proctor Hospital, Peoria, Illinois, United States|CCOP - Illinois Oncology Research Association, Peoria, Illinois, United States|Oncology Hematology Associates of Central Illinois, PC - Peoria, Peoria, Illinois, United States|Methodist Medical Center of Illinois, Peoria, Illinois, United States|OSF St. Francis Medical Center, Peoria, Illinois, United States|Illinois CancerCare - Peru, Peru, Illinois, United States|Illinois Valley Community Hospital, Peru, Illinois, United States|Illinois CancerCare - Princeton, Princeton, Illinois, United States|Illinois CancerCare - Spring Valley, Spring Valley, Illinois, United States|CCOP - Carle Cancer Center, Urbana, Illinois, United States|Elkhart Clinic, LLC, Elkhart, Indiana, United States|Michiana Hematology-Oncology, PC - Elkhart, Elkhart, Indiana, United States|Elkhart General Hospital, Elkhart, Indiana, United States|St. Francis Hospital Cancer Care Services, Indianapolis, Indiana, United States|Howard Community Hospital, Kokomo, Indiana, United States|Center for Cancer Therapy at LaPorte Hospital and Health Services, La Porte, Indiana, United States|Saint Anthony Memorial Health Centers, Michigan City, Indiana, United States|Michiana Hematology-Oncology, PC - South Bend, Mishawaka, Indiana, United States|Saint Joseph Regional Medical Center, Mishawaka, Indiana, United States|Michiana Hematology Oncology PC - Plymouth, Plymouth, Indiana, United States|Reid Hospital & Health Care Services, Richmond, Indiana, United States|CCOP - Northern Indiana CR Consortium, South Bend, Indiana, United States|Memorial Hospital of South Bend, South Bend, Indiana, United States|Michiana Hematology Oncology PC - La Porte, Westville, Indiana, United States|Bettendorf, Iowa, United States|Cedar Rapids Oncology Associates, Cedar Rapids, Iowa, United States|Mercy Regional Cancer Center at Mercy Medical Center, Cedar Rapids, Iowa, United States|Medical Oncology and Hematology Associates - West Des Moines, Clive, Iowa, United States|Mercy Cancer Center - West Lakes, Clive, Iowa, United States|CCOP - Iowa Oncology Research Association, Des Moines, Iowa, United States|John Stoddard Cancer Center at Iowa Methodist Medical Center, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates at John Stoddard Cancer Center, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates at Mercy Cancer Center, Des Moines, Iowa, United States|Mercy Cancer Center at Mercy Medical Center - Des Moines, Des Moines, Iowa, United States|John Stoddard Cancer Center at Iowa Lutheran Hospital, Des Moines, Iowa, United States|Siouxland Hematology-Oncology Associates, LLP, Sioux City, Iowa, United States|Mercy Medical Center - Sioux City, Sioux City, Iowa, United States|St. Luke's Regional Medical Center, Sioux City, Iowa, United States|Methodist West Hospital, West Des Moines, Iowa, United States|Cancer Center of Kansas, PA - Chanute, Chanute, Kansas, United States|Cancer Center of Kansas, PA - Dodge City, Dodge City, Kansas, United States|Cancer Center of Kansas, PA - El Dorado, El Dorado, Kansas, United States|Cancer Center of Kansas - Fort Scott, Fort Scott, Kansas, United States|Cancer Center of Kansas-Independence, Independence, Kansas, United States|Cancer Center of Kansas, PA - Kingman, Kingman, Kansas, United States|Lawrence Memorial Hospital, Lawrence, Kansas, United States|Cancer Center of Kansas, PA - Liberal, Liberal, Kansas, United States|Cancer Center of Kansas, PA - McPherson, McPherson, Kansas, United States|Cancer Center of Kansas, PA - Newton, Newton, Kansas, United States|Cancer Center of Kansas, PA - Parsons, Parsons, Kansas, United States|Cancer Center of Kansas, PA - Pratt, Pratt, Kansas, United States|Cancer Center of Kansas, PA - Salina, Salina, Kansas, United States|Cancer Center of Kansas, PA - Wellington, Wellington, Kansas, United States|Associates in Womens Health, PA - North Review, Wichita, Kansas, United States|Cancer Center of Kansas, PA - Medical Arts Tower, Wichita, Kansas, United States|Cancer Center of Kansas, PA - Wichita, Wichita, Kansas, United States|CCOP - Wichita, Wichita, Kansas, United States|Via Christi Cancer Center at Via Christi Regional Medical Center, Wichita, Kansas, United States|Cancer Center of Kansas, PA - Winfield, Winfield, Kansas, United States|Hickman Cancer Center at Bixby Medical Center, Adrian, Michigan, United States|Saint Joseph Mercy Cancer Center, Ann Arbor, Michigan, United States|CCOP - Michigan Cancer Research Consortium, Ann Arbor, Michigan, United States|Oakwood Cancer Center at Oakwood Hospital and Medical Center, Dearborn, Michigan, United States|Green Bay Oncology, Limited - Escanaba, Escanaba, Michigan, United States|Genesys Hurley Cancer Institute, Flint, Michigan, United States|Hurley Medical Center, Flint, Michigan, United States|Genesys Regional Medical Center, Grand Blanc, Michigan, United States|Van Elslander Cancer Center at St. John Hospital and Medical Center, Grosse Pointe Woods, Michigan, United States|Dickinson County Healthcare System, Iron Mountain, Michigan, United States|Foote Memorial Hospital, Jackson, Michigan, United States|Sparrow Regional Cancer Center, Lansing, Michigan, United States|St. Mary Mercy Hospital, Livonia, Michigan, United States|Community Cancer Center of Monroe, Monroe, Michigan, United States|Mercy Memorial Hospital - Monroe, Monroe, Michigan, United States|St. Joseph Mercy Oakland, Pontiac, Michigan, United States|Mercy Regional Cancer Center at Mercy Hospital, Port Huron, Michigan, United States|Seton Cancer Institute at Saint Mary's - Saginaw, Saginaw, Michigan, United States|Lakeland Regional Cancer Care Center - St. Joseph, Saint Joseph, Michigan, United States|Lakeside Cancer Specialists, PLLC, Saint Joseph, Michigan, United States|St. John Macomb Hospital, Warren, Michigan, United States|MeritCare Bemidji, Bemidji, Minnesota, United States|St. Joseph's Medical Center, Brainerd, Minnesota, United States|Fairview Ridges Hospital, Burnsville, Minnesota, United States|Mercy and Unity Cancer Center at Mercy Hospital, Coon Rapids, Minnesota, United States|Essentia Health - Duluth Clinic, Duluth, Minnesota, United States|CCOP - Duluth, Duluth, Minnesota, United States|Miller - Dwan Medical Center, Duluth, Minnesota, United States|Fairview Southdale Hospital, Edina, Minnesota, United States|Mercy and Unity Cancer Center at Unity Hospital, Fridley, Minnesota, United States|Hutchinson Area Health Care, Hutchinson, Minnesota, United States|Immanuel St. Joseph's, Mankato, Minnesota, United States|HealthEast Cancer Care at St. John's Hospital, Maplewood, Minnesota, United States|Minnesota Oncology - Maplewood, Maplewood, Minnesota, United States|Virginia Piper Cancer Institute at Abbott - Northwestern Hospital, Minneapolis, Minnesota, United States|Hennepin County Medical Center - Minneapolis, Minneapolis, Minnesota, United States|New Ulm Medical Center, New Ulm, Minnesota, United States|Humphrey Cancer Center at North Memorial Outpatient Center, Robbinsdale, Minnesota, United States|Mayo Clinic Cancer Center, Rochester, Minnesota, United States|CentraCare Clinic - River Campus, Saint Cloud, Minnesota, United States|Coborn Cancer Center, Saint Cloud, Minnesota, United States|CCOP - Metro-Minnesota, Saint Louis Park, Minnesota, United States|Park Nicollet Cancer Center, Saint Louis Park, Minnesota, United States|Regions Hospital Cancer Care Center, Saint Paul, Minnesota, United States|United Hospital, Saint Paul, Minnesota, United States|St. Francis Cancer Center at St. Francis Medical Center, Shakopee, Minnesota, United States|Lakeview Hospital, Stillwater, Minnesota, United States|Ridgeview Medical Center, Waconia, Minnesota, United States|Willmar Cancer Center at Rice Memorial Hospital, Willmar, Minnesota, United States|Minnesota Oncology - Woodbury, Woodbury, Minnesota, United States|Mercy Clinic Cancer and Hematology - Rolla, Rolla, Missouri, United States|CCOP - Cancer Research for the Ozarks, Springfield, Missouri, United States|St. John's Regional Health Center, Springfield, Missouri, United States|Hulston Cancer Center at Cox Medical Center South, Springfield, Missouri, United States|CCOP - Montana Cancer Consortium, Billings, Montana, United States|St. Vincent Healthcare Cancer Care Services, Billings, Montana, United States|Hematology-Oncology Centers of the Northern Rockies - Billings, Billings, Montana, United States|Billings Clinic - Downtown, Billings, Montana, United States|Bozeman Deaconess Cancer Center, Bozeman, Montana, United States|St. James Healthcare Cancer Care, Butte, Montana, United States|Benefis Sletten Cancer Institute, Great Falls, Montana, United States|St. Peter's Hospital, Helena, Montana, United States|Kalispell Regional Medical Center, Kalispell, Montana, United States|Montana Cancer Specialists at Montana Cancer Center, Missoula, Montana, United States|Montana Cancer Center at St. Patrick Hospital and Health Sciences Center, Missoula, Montana, United States|Cancer Resource Center - Lincoln, Lincoln, Nebraska, United States|CCOP - Missouri Valley Cancer Consortium, Omaha, Nebraska, United States|Immanuel Medical Center, Omaha, Nebraska, United States|Alegant Health Cancer Center at Bergan Mercy Medical Center, Omaha, Nebraska, United States|Lakeside Hospital, Omaha, Nebraska, United States|Creighton University Medical Center, Omaha, Nebraska, United States|Lovelace Medical Center - Downtown, Albuquerque, New Mexico, United States|Presbyterian Cancer Treatment Center at Presbyterian Kaseman Hospital, Albuquerque, New Mexico, United States|University of New Mexico Cancer Center, Albuquerque, New Mexico, United States|University of New Mexico Cancer Center - South, Las Cruces, New Mexico, United States|Rutherford Hospital, Rutherfordton, North Carolina, United States|MeritCare Broadway, Fargo, North Dakota, United States|Dakota Cancer Institute at Dakota Clinic - South University, Fargo, North Dakota, United States|CCOP - MeritCare Hospital, Fargo, North Dakota, United States|Altru Cancer Center at Altru Hospital, Grand Forks, North Dakota, United States|Wood County Oncology Center, Bowling Green, Ohio, United States|Adena Regional Medical Center, Chillicothe, Ohio, United States|Riverside Methodist Hospital Cancer Care, Columbus, Ohio, United States|CCOP - Columbus, Columbus, Ohio, United States|Grant Medical Center Cancer Care, Columbus, Ohio, United States|Zangmeister Center, Columbus, Ohio, United States|Mount Carmel Health - West Hospital, Columbus, Ohio, United States|Doctors Hospital at Ohio Health, Columbus, Ohio, United States|Grandview Hospital, Dayton, Ohio, United States|Good Samaritan Hospital, Dayton, Ohio, United States|David L. Rike Cancer Center at Miami Valley Hospital, Dayton, Ohio, United States|Samaritan North Cancer Care Center, Dayton, Ohio, United States|CCOP - Dayton, Dayton, Ohio, United States|Grady Memorial Hospital, Delaware, Ohio, United States|Community Cancer Center, Elyria, Ohio, United States|Hematology Oncology Center, Elyria, Ohio, United States|Blanchard Valley Medical Associates, Findlay, Ohio, United States|Middletown Regional Hospital, Franklin, Ohio, United States|Wayne Hospital, Greenville, Ohio, United States|Charles F. Kettering Memorial Hospital, Kettering, Ohio, United States|Fairfield Medical Center, Lancaster, Ohio, United States|Lima Memorial Hospital, Lima, Ohio, United States|Strecker Cancer Center at Marietta Memorial Hospital, Marietta, Ohio, United States|Northwest Ohio Oncology Center, Maumee, Ohio, United States|Knox Community Hospital, Mount Vernon, Ohio, United States|Licking Memorial Cancer Care Program at Licking Memorial Hospital, Newark, Ohio, United States|St. Charles Mercy Hospital, Oregon, Ohio, United States|Toledo Clinic - Oregon, Oregon, Ohio, United States|Southern Ohio Medical Center Cancer Center, Portsmouth, Ohio, United States|Community Hospital of Springfield and Clark County, Springfield, Ohio, United States|Flower Hospital Cancer Center, Sylvania, Ohio, United States|Mercy Hospital of Tiffin, Tiffin, Ohio, United States|Toledo Hospital, Toledo, Ohio, United States|St. Vincent Mercy Medical Center, Toledo, Ohio, United States|Medical University of Ohio Cancer Center, Toledo, Ohio, United States|CCOP - Toledo Community Hospital, Toledo, Ohio, United States|St. Anne Mercy Hospital, Toledo, Ohio, United States|Toledo Clinic, Incorporated - Main Clinic, Toledo, Ohio, United States|UVMC Cancer Care Center at Upper Valley Medical Center, Troy, Ohio, United States|Fulton County Health Center, Wauseon, Ohio, United States|Mount Carmel St. Ann's Cancer Center, Westerville, Ohio, United States|United States Air Force Medical Center - Wright-Patterson, Wright-Patterson Air Force Base, Ohio, United States|Ruth G. McMillan Cancer Center at Greene Memorial Hospital, Xenia, Ohio, United States|Genesis - Good Samaritan Hospital, Zanesville, Ohio, United States|Clackamas Radiation Oncology Center, Clackamas, Oregon, United States|Providence Milwaukie Hospital, Milwaukie, Oregon, United States|Providence Newberg Medical Center, Newberg, Oregon, United States|Willamette Falls Hospital, Oregon City, Oregon, United States|Providence Cancer Center at Providence Portland Medical Center, Portland, Oregon, United States|CCOP - Columbia River Oncology Program, Portland, Oregon, United States|Providence St. Vincent Medical Center, Portland, Oregon, United States|Morgan Cancer Center at Lehigh Valley Hospital - Cedar Crest, Allentown, Pennsylvania, United States|Lehigh Valley Hospital - Muhlenberg, Bethlehem, Pennsylvania, United States|Geisinger Cancer Institute at Geisinger Health, Danville, Pennsylvania, United States|Geisinger Hazleton Cancer Center, Hazleton, Pennsylvania, United States|Geisinger Medical Group - Scenery Park, State College, Pennsylvania, United States|Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center, Wilkes-Barre, Pennsylvania, United States|AnMed Cancer Center, Anderson, South Carolina, United States|Bon Secours St. Francis Health System, Greenville, South Carolina, United States|Carolina Blood and Cancer Care Associates, PA, Lancaster, South Carolina, United States|Carolina Blood and Cancer Care, Rock Hill, South Carolina, United States|CCOP - Upstate Carolina, Spartanburg, South Carolina, United States|Gibbs Regional Cancer Center at Spartanburg Regional Medical Center, Spartanburg, South Carolina, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States|Sanford Cancer Center at Sanford USD Medical Center, Sioux Falls, South Dakota, United States|Fredericksburg Oncology, Incorporated, Fredericksburg, Virginia, United States|Southwest Washington Medical Center Cancer Center, Vancouver, Washington, United States|Northwest Cancer Specialists at Vancouver Cancer Center, Vancouver, Washington, United States|Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center, Green Bay, Wisconsin, United States|Green Bay Oncology, Limited at St. Mary's Hospital, Green Bay, Wisconsin, United States|St. Mary's Hospital Medical Center - Green Bay, Green Bay, Wisconsin, United States|St. Vincent Hospital Regional Cancer Center, Green Bay, Wisconsin, United States|Franciscan Skemp Healthcare - La Crosse Campus, La Crosse, Wisconsin, United States|Holy Family Memorial Medical Center Cancer Care Center, Manitowoc, Wisconsin, United States|Bay Area Cancer Care Center at Bay Area Medical Center, Marinette, Wisconsin, United States|Green Bay Oncology, Limited - Oconto Falls, Oconto Falls, Wisconsin, United States|St. Nicholas Hospital, Sheboygan, Wisconsin, United States|Green Bay Oncology, Limited - Sturgeon Bay, Sturgeon Bay, Wisconsin, United States|Rocky Mountain Oncology, Casper, Wyoming, United States|Welch Cancer Center at Sheridan Memorial Hospital, Sheridan, Wyoming, United States",,https://ClinicalTrials.gov/show/NCT01376349
NCT01376596,Group Cognitive-behavioral Intervention for Social Anxiety in Schizophrenia,,Completed,No Results Available,Social Anxiety|Schizophrenia,Behavioral: Cognitive-Behavioral Therapy based intervention immediately|Behavioral: Wait list,Social anxiety symptom reduction|Positive and negative symptoms of schizophrenia reduction,McGill University|Canadian Institutes of Health Research (CIHR),All,18 Years to 50 Years   (Adult),Phase 1|Phase 2,49,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,10-273-PSY,Aug-11,Jan-13,Jan-13,20-Jun-11,null,10-Apr-14,"RUIS McGill CBT Teaching & Research Program, Montreal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT01376596
NCT01375114,The Effects of Ginseng on Cancer-Related Fatigue,,"Active, not recruiting",No Results Available,Advanced Cancers|Solid Tumors,Drug: Panax Ginseng|Dietary Supplement: Placebo|Behavioral: Questionnaires,Efficacy of Panax Ginseng in Reducing Cancer Related Fatigue,M.D. Anderson Cancer Center|Indena S.p.A,All,"18 Years and older   (Adult, Older Adult)",Phase 2,158,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",2009-0854|NCI-2011-01127,Oct-11,Oct-19,Oct-19,17-Jun-11,null,8-Nov-18,"University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT01375114
NCT01374100,Effect of Qigong Therapy in Patients With Advanced Lung and Gastrointestinal Cancer Undergoing Chemotherapy,,Terminated,No Results Available,"Carcinoma, Non-Small-Cell Lung|Cancer of the Gastrointestinal Tract",Behavioral: Standard Exercise|Behavioral: Qigong Exercise,Change in Depression and Anxiety|Change in Quality of Life (QoL)|Change in functional capacity|Change in cancer Symptoms|Program Satisfaction,McGill University|Jewish General Hospital,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,52,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care,08-068,Feb-09,May-11,May-11,15-Jun-11,null,16-May-18,"Jewish General Hospital, Montreal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT01374100
NCT01372670,Does Hydroxyzine Decrease Anxiety in Underweight Patients Diagnosed With an Eating Disorder,,Withdrawn,No Results Available,"Anxiety in Those Patients With Anorexia Nervosa|Eating Disorder Not Otherwise Specified, BMI (<=18)",Drug: Hydroxyzine|Drug: hydroxyzine HCL|Other: Placebo,Self-reported anxiety,HealthPartners Institute|Park Nicollet Eating Disorder Institute,All,"8 Years to 25 Years   (Child, Adult)",Phase 4,0,Other,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",04091-11,Jan-12,Apr-13,Apr-13,14-Jun-11,null,15-Nov-16,"Melrose Institute, Minneapolis, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT01372670
NCT01371110,Intravenous Ketamine in the Treatment of Obsessive-Compulsive Disorder,IVKetamine,Terminated,Has Results,Obsessive Compulsive Disorder,Drug: Ketamine|Drug: Midazolam,Change in Yale-Brown Obsessive Compulsive Scale (Y-BOCCS) Rating OCD Symptom Severity From Baseline to 24-hours After Ketamine Administration|Percentage of Patients Who Meet Response and Remission,Wayne Goodman MD|Icahn School of Medicine at Mount Sinai|Baylor College of Medicine,All,"21 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,3,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",GCO 11-1113|HSM#11-01536,Jun-12,Jun-15,Jun-15,10-Jun-11,2-Oct-17,18-Jan-18,"Clinical Research Centers at Icahn School of Medicine at Mount Sinai, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT01371110
NCT01368510,Intensive Cognitive-Behavioral Therapy For Obsessive-Compulsive Disorder,,Unknown status,No Results Available,Obsessive-Compulsive Disorder (OCD),Behavioral: Intensive Cognitive Behavioral Therapy (CBT)|Behavioral: Waitlist,MRSI glutamate|Y-BOCS,"University of California, Los Angeles|National Institute of Mental Health (NIMH)",All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,75,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment",R01MH085900,Jul-11,Jun-15,Jun-15,8-Jun-11,null,18-Dec-14,"UCLA Obsessive-Compulsive Disorder Intensive Treatment Program, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT01368510
NCT01368302,Attention Bias Modification Treatment (ABMT) for Patients With Post Traumatic Stress Disorder (PTSD),,Completed,No Results Available,Attention Bias Modification Treatment (ABMT),Behavioral: Attention Bias Modification Treatment (ABMT),Clinician-Administered PTSD Scale (CAPS)|PTSD Check List (PCL),Tel Aviv University,Male,"Child, Adult, Older Adult",Phase 2,52,Other,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",949-2010,Jul-11,Mar-13,Mar-13,7-Jun-11,null,2-Dec-14,"Tel Aviv University, Tel Aviv, Israel",,https://ClinicalTrials.gov/show/NCT01368302
NCT01366677,Yoga for Persons With Severe Visual Impairment,RPY,Completed,No Results Available,Sleep Disturbance|Stress|Anxiety|Depression|Balance Impairment,Behavioral: Yoga Intervention,Static Balance|Perceived Stress Scale|Profile of Mood States - Short Form|Exit Survey|Fear of Falling Questionnaire,Johns Hopkins University,All,"18 Years to 85 Years   (Adult, Older Adult)",Not Applicable,21,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,NA_00039032,Aug-10,Dec-13,Dec-13,6-Jun-11,null,26-May-14,"Lions Vision and Research Rehabilitation, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT01366677
NCT01365377,Impact of Information Strategy Based on Booklet on Anxiety in Family in ICU,FAMILLE,Unknown status,No Results Available,Anxiety|Depression|Post-traumatic Stress Disorders,Other: booklet deliverance and use in the process of daily information,"Decreased of the Anxiety Score of 20% in the ""brochure arm"" from admission to discharge of ICU.|Decreased of Depression Scoring on the HADS|Diagnostic and following of Post-traumatic stress disorder|Assessment of quality of life in patients and relatives",Groupe Hospitalier Pitie-Salpetriere,All,"16 Years and older   (Child, Adult, Older Adult)",Not Applicable,180,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,FAMILLE-JJR-2,Apr-11,Apr-12,Apr-13,3-Jun-11,null,3-Jun-11,"Intensive Care Unit, Groupe Hospitalier Pitie-Salpetriere, Paris, France",,https://ClinicalTrials.gov/show/NCT01365377
NCT01365676,GAMALINE®+HIPERICIN® for PMS Treatment and Vasomotor Symptoms,657/10UFCSPA,Unknown status,No Results Available,"Premenstrual Syndrome|Uterus; Hemorrhage, Preclimacteric or Premenopausal",Drug: GAMALINE® + HIPERICIN®|Drug: GAMALINE®,PMS calendar|LAB Tests|WHOQOL,Phytopharm Consulting Brazil|Herbarium Laboratório Botânico Ltda|Federal University of Health Science of Porto Alegre,Female,25 Years to 55 Years   (Adult),Phase 3,240,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",GAM+HIP,Mar-12,Oct-12,Dec-12,3-Jun-11,null,6-Dec-11,"Ambulatório de Ginecologia e Obstetrícia ISCMPA, Porto Alegre, RS, Brazil",,https://ClinicalTrials.gov/show/NCT01365676
NCT01362114,The Effect of Sihogayonggolmoryeo-tang on the Anxiety of Hwa-byung,,Unknown status,No Results Available,Hwa-byung,Drug: SIHOGAYONGGOLMORYU TANG EXTRACT GRAN|Other: Placebo,Hamilton Anxiety Scale(HAM-A)|State-Trait Anxiety Inventory(STAI)|Beck Depression Inventory(BDI)|WHO Quality of Life Abbreviated(WHOQOL-BREF)|Heart Rate Variability(HRV)|likert scale|Hwa-byung scale|State-Trait Anger Expression Inventory (STAXI)|Insomnia Severity Index (ISI)|Instrument of Oriental Medical Evaluation for Hwa-Byung,Korea Health Industry Development Institute,All,"20 Years to 65 Years   (Adult, Older Adult)",Phase 4,160,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",B080009,Jul-10,May-12,Jun-12,27-May-11,null,18-Apr-12,"Oriental Hospital of Daejon University, Daejon, Choong-Chung-Do, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01362114
NCT01361074,In Vivo Versus Augmented Reality Exposure for Small Animal Phobia,VARESAP,Completed,No Results Available,Phobic Disorders,Behavioral: In Vivo Exposure for Animal Phobia following Öst´s guidelines|Behavioral: Augmented Reality Exposure for Animal Phobia following Öst´s guidelines,"Change in Behavioral Avoidance Test (BAT, Öst, Salkovskis, and Hellström's, 1991) at pre, post intervention and 3 and 12-month follow-up periods|Change in Spider Phobia Beliefs Questionnaire (SPBQ; adapted from Arntz, Lavy, Van der Berg, & Van Rijsoort, 1993) at pre, post intervention and 3 and 12-month follow-up periods",Universitat Jaume I|University of Valencia,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,UJaumeI01,Jan-11,May-11,Jan-13,26-May-11,null,4-Dec-15,"University Jaume I, Castellon, Spain|University Jaume I, Castellón, Spain",,https://ClinicalTrials.gov/show/NCT01361074
NCT01357694,BRIA - Bridging Intervention in Anesthesiology,BRIA,Completed,No Results Available,Psychiatric or Mood Diseases or Conditions,Behavioral: psychotherapeutic contacts,participation in psychosocial therapy|psychiatric distress,"Charite University, Berlin, Germany",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,220,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,BRIA,May-11,Feb-13,Sep-14,23-May-11,null,26-Jan-15,"Department of Anesthesiology and Intensive Care Medicine, Charité - Universitätsmedizin Berlin, Germany, Berlin, Germany",,https://ClinicalTrials.gov/show/NCT01357694
NCT01355523,"The Effect of Melatonin on Depression, Anxiety, Cognitive Function and Sleep Disturbances in Breast Cancer Patients",MELODY,Terminated,Has Results,Breast Cancer|Depression,Drug: Melatonin (N-acetyl-5-methoxytryptamine)|Drug: Placebo,Major Depression Inventory (MDI)- Depression at One Point in the Study|Per Protocol - Depression at One Point in the Study Period|Intention to Treat (Underestimate) - Depression at One Point in the Study Period|Intention to Treat (Overestimate) - Depression at One Point in the Study Period|Area Under the Curve (AUC) for VAS Data on Anxiety - Immediate Postoperative Period|Area Under the Curve (AUC) for VAS Data on Anxiety - Long-term Postoperative Period|Area Under the Curve (AUC) for Data on Sleepiness (KSS) - Immediate Postoperative Period|Area Under the Curve (AUC) for Data on Sleepiness (KSS) - Long-term Postoperative Period|Area Under the Curve (AUC) for VAS Data on Fatigue - Immediate Postoperative Period|Area Under the Curve (AUC) for VAS Data on Fatigue - Long-term Postoperative Period|Area Under the Curve (AUC) for Data on General Well-being - Immediate Postoperative Period|Area Under the Curve (AUC) for VAS Data on General Well-being - Long-term Postoperative Period|Area Under the Curve (AUC) for VAS Data on Pain - Immediate Postoperative Period|Area Under the Curve (AUC) for VAS Data on Pain - Long-term Postoperative Period|Area Under the Curve (AUC) for VAS Data on Sleep Quality - Immediate Postoperative Period|Area Under the Curve (AUC) for VAS Data on Sleep Quality - Long-term Postoperative Period|Sleep Architecture|HPER3 Genotype|Incidence of Postoperative Cognitive Dysfunction (POCD) App. 2 Weeks Postoperatively.|Incidence of Postoperative Cognitive Dysfunction (POCD) App. 10 Weeks Postoperatively,"Melissa Voigt Hansen|University of Copenhagen|Rigshospitalet, Denmark|Pharma Nord|Herlev Hospital",Female,"30 Years to 75 Years   (Adult, Older Adult)",Phase 2|Phase 3,54,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MVH-03|2010-022460-12|2007-58-0015/HEH.750.89-12|H-4-2011-007,Jul-11,Jan-13,Jan-13,18-May-11,6-May-14,6-May-14,"Herlev Hospital, Copenhagen, Denmark",,https://ClinicalTrials.gov/show/NCT01355523
NCT01354691,Safety and Efficacy Study of Ladostigil in Mild to Moderate Probable Alzheimer's Disease,,Completed,No Results Available,Alzheimer's Disease|Dementia|Memory Loss|Cognitive Impairment,Drug: ladostigil hemitartrate,ADAS-Cog: Alzheimer's Disease Assessment Scale-Cognitive Subscale|Safety Evaluation|Neuropsychiatric Inventory (NPI)|Cornell Scale for Depression in Dementia (CSDD)|Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL)|Mini-Mental State Examination (MMSE)|ADAS-Cog: Alzheimer's Disease Assessment Scale - Cognitive Subscale,Avraham Pharmaceuticals Ltd,All,"60 Years to 85 Years   (Adult, Older Adult)",Phase 2,201,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CR100101/CO15570,Feb-11,Sep-12,Mar-13,17-May-11,null,23-Jul-13,"Medizinische Univeritat Graz, Universitatsklinik fur Neurologie, Auenbruggerplatz 22, Graz, Austria|Privatordination Horn, HamerlingstraBe 15, Horn, Austria|Allgemeines Krankenhaus der Stadt Linz, KrankenhausstraBe 9, Linz, Austria|Privatordination, Lainzerstrasse 20, Wein, Austria|General Hospital Pula, Negrijeva 6, Pula, Croatia|General Hospital Zabok, Bracak 8, Zabok, Croatia|Clinical Hospital Center Zagreb, Kispaticeva 12, Zagreb, Croatia|Clinical Hospital Dubrava, Avenija Gojka Suska 6, Zagreb, Croatia|Polyclinic Neuron, Salata 12, Zagreb, Croatia|Psychiatric Hospital Vrapce, Bolnicka cesta 32, Zagreb, Croatia|Klinische Forschung Hamburg GmbH, Hoheluftaussee 18, Hanburg, Germany|Klinische Forschung Schwerin GmbH, FriedrichstraBe 1, Schwerin, Germany|Studienzentrum Nordwest, Lange StraBe 23-25, Westerstede, Germany|Clinical Centre of Serbia, Dr. Subotica 6, Beograd, Serbia|Military Medical Academy, Crnotravska 17, Beograd, Serbia|CAE Oroitu Centro Atencion Especializada C/Jata, 9, Algorta (Vizcaya), Spain|Centro Geroinnova Barcelona, Calle Mandoni n 17, Barcelona, Spain|Fundacio ACE, Institut Catala de Neurosciencies Aplicadas, C/Margues de Sentmenat 35-37, Barcelona, Spain|Institud d' Assistencia Sanitaria de Girona, Edifici La Republica - C/Dr. Castany, s/n, SALT (Girona), Spain",,https://ClinicalTrials.gov/show/NCT01354691
NCT01348997,E-health Intervention for Cancer Survivors 2.0,,Withdrawn,No Results Available,Cancer,Behavioral: Project Onward website + 16 person social network|Behavioral: Project Onward website + 8 person social network,"Depression, as measured by the Hospital Anxiety and Depression Scale (HADS)|Anxiety, as measured by the Hospital Anxiety and Depression Scale (HADS)|Website utilization (e.g., number of logins, average visit length, total time spent on the site, number of exercises completed)",Northwestern University,All,"19 Years and older   (Adult, Older Adult)",Phase 1,0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NU Lurie 10CC01,May-11,Oct-13,Nov-13,6-May-11,null,7-Oct-14,"Northwestern University, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT01348997
NCT01349231,Ketamine Infusion for Obsessive-Compulsive Disorder,,Completed,Has Results,Obsessive-compulsive Disorder,Drug: ketamine,OCD Severity|Depression Symptoms,Yale University|National Alliance for Research on Schizophrenia and Depression,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,10,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,901004660,Feb-09,Dec-11,Dec-11,6-May-11,9-Jun-14,9-Jun-14,"Connecticut Mental Health Center/ YNHH, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT01349231
NCT01348529,Internet Cognitive Behavior Therapy (CBT) for Obsessive Compulsive Disorder (OCD),,Completed,No Results Available,Obsessive Compulsive Disorder,Behavioral: Internet CBT,Change from Baseline of obsessions and compulsions after 15 weeks and 6 months after treatment.|Change from Baseline of cost data after 15 weeks and 6 months after treatment.|Change from Baseline of depressive symptoms after 15 weeks and 6 months after treatment.|Change from Baseline of quality of life after 15 weeks and 6 months after treatment,Karolinska Institutet,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,23,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,OCDP1,Sep-10,Mar-11,Mar-11,5-May-11,null,21-Mar-18,"Internetpsykatrienheten, M46, Psykiatri sydväst, Stockholm, Sweden",,https://ClinicalTrials.gov/show/NCT01348529
NCT01347099,Internet-based Cognitive Behavior Therapy (CBT) for Obsessive Compulsive Disorder (OCD),,Completed,No Results Available,Obsessive Compulsive Disorder,Behavioral: Internet-based cognitive behavior therapy|Behavioral: Support therapy on Internet,Change from Baseline of obsessions and compulsions after 10 weeks and at 3- and 12 months after treatment.|Change from Baseline of depressive symptoms after 10 weeks and at 3- and 12 months after treatment.|Change from Baseline of meta cognitions after 10 weeks and at 3- and 12 months after treatment.|Change from Baseline of quality of life after 10 weeks and at 3- and 12 months after treatment.,Karolinska Institutet,All,"18 Years and older   (Adult, Older Adult)",Phase 2,101,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,OCD-S,Feb-11,Jun-11,Jun-11,4-May-11,null,21-Mar-18,"Psykiatri Sydväst, Stockholm, Sweden",,https://ClinicalTrials.gov/show/NCT01347099
NCT01346228,Using Smart Phone Technology To Rural Veterans,,Unknown status,No Results Available,Panic Disorders|Anxiety Disorders,Behavioral: Panic Control Treatment (PCT),Panic Control Treatment (PCT),"Michael Debakey Veterans Affairs Medical Center|South Central VA Mental Illness Research, Education & Clinical Center",All,18 Years to 64 Years   (Adult),Not Applicable,15,U.S. Fed,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,H-28199,Apr-11,May-13,Aug-13,2-May-11,null,2-May-11,"Michael E. DeBakey VA Medical Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT01346228
NCT01346241,Improving Access To Services to Community Based Outpatient Clinics (CBOC's),,Unknown status,No Results Available,Panic Disorder,Behavioral: Intensive Panic Control Treatment (IPCT),Intensive Panic Control Treatment (IPCT),Michael Debakey Veterans Affairs Medical Center,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,50,U.S. Fed,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,H-28272,Apr-11,Apr-13,Apr-13,2-May-11,null,2-May-11,"Michael E. DeBakey VA Medical Center and CBOC's (Lufkin, Texas City, and Conroe), Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT01346241
NCT01343732,"Tolerability, Safety and Efficacy of the HAC-Coil Deep Transcranial Magnetic Stimulation in Medication Resistance Obsessive Compulsive Disorder (OCD) Subjects",,Recruiting,No Results Available,Obsessive Compulsive Disorder,Device: Deep TMS,Y-BOCS Scale (Yale-Brown Obsessive Compulsive Disorder),Brainsway,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,40,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other,OCD-DTMS-1,Jun-11,Nov-18,Nov-18,28-Apr-11,null,25-Jan-18,"Sheba Medical Center, Ramat Gan, Israel",,https://ClinicalTrials.gov/show/NCT01343732
NCT01342549,Treatment Strategy for Alcohol Use Disorders in Veterans With TBI,AUD,Completed,Has Results,Alcohol Dependence,Drug: Valproate|Drug: Naltrexone,Time to Relapse to Heavy Drinking as Defined by Having 5 or More Drinks in a Sitting for Men and Will be Assessed Using the Time Line Follow Back for Recent Drinking Method. A Structured Questionnaire Will Review Alcohol Consumed on the Previous Week.,VA Office of Research and Development,Male,18 Years to 60 Years   (Adult),Phase 3,62,U.S. Fed,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",D7201-I,Sep-11,Jun-15,Jun-15,27-Apr-11,9-Jun-16,9-Jun-16,"Iowa City VA Health Care System, Iowa City, IA, Iowa City, Iowa, United States|Michael E. DeBakey VA Medical Center, Houston, TX, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT01342549
NCT01341873,Nursing Intervention in Supporting Family Caregivers of Patients Undergoing Stem Cell Transplant,,Withdrawn,No Results Available,Anxiety Disorder|Depression|Fatigue,Other: educational intervention|Other: psychosocial support for caregiver|Procedure: quality-of-life assessment|Other: questionnaire administration,"Test the effects of an advanced practice nursing (APN) intervention for family caregivers (FCs) in the experimental group using questionnaires measuring quality of life and psychological distress as compared to the FCs in the control group.|Test the effects of an advanced practice nursing (APN) intervention for family caregivers (FCs) in the experimental group using questionnaires measuring caregiver burden and skills preparedness as compared to the FCs in the control group.|Through the use of questionnaires, comparison of self-care behaviors for FCs of Hematopoietic Cell Transplant (HCT) patients between the experimental and control groups|Through the use of questionnaires, comparison of resource use between the experimental and control groups|Through the use of questionnaires, identification of subgroups of FCs who benefit most from the Family Care Intervention (FCI) in relation to sociodemographic characteristics, caregiver health status, and patient characteristics|Through the use of questionnaires, measure FCs satisfaction with the FCI",City of Hope Medical Center|National Cancer Institute (NCI),All,"21 Years and older   (Adult, Older Adult)",Not Applicable,0,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Supportive Care,10235|NCI-2011-00574,May-12,Oct-16,null,26-Apr-11,null,23-Apr-12,,,https://ClinicalTrials.gov/show/NCT01341873
NCT01337713,Efficacy of Massage Therapy in the Treatment of Generalized Anxiety Disorder (GAD),GAD,Completed,No Results Available,Generalized Anxiety Disorder,Other: Swedish Massage|Other: Light Touch,Hamilton Anxiety Scale,Emory University|National Center for Complementary and Integrative Health (NCCIH),All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,40,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment",IRB00052054|7R21AT004208-02,Sep-10,Jan-14,Jul-14,19-Apr-11,null,27-Jul-17,"Emory University, Department of Psychiatry, Atlanta, Georgia, United States",,https://ClinicalTrials.gov/show/NCT01337713
NCT01335152,Online Stress Management and Coping Skills Training for Women With Breast Cancer,,Completed,No Results Available,Breast Cancer,Behavioral: Coping with Breast Cancer web-based workbook,PHQ GAD-7 - Anxiety|CES-D 10|FACT-B: Functional Assessment of Cancer Therapy - Breast|Revised Impact of Event Scale|Benefit Finding Scale for breast cancer|CANCER BEHAVIOR INVENTORY (CBI-B),"Talaria, Inc|National Cancer Institute (NCI)",Female,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,100,Industry|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CA106154|5R44CA106154-03,Apr-10,Apr-11,Aug-11,14-Apr-11,null,7-May-14,"Talaria, Inc, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT01335152
NCT01333098,Antiglucocorticoid Therapy for Cognitive Impairment in Late-life Anxiety Disorders,Mifepristone,Completed,Has Results,Anxiety Disorders,Drug: Mifepristone,"Drug Acceptability, as Measured by Number of Participants With Dose-limiting Side Effects|Number of Participants With Self-reported Side Effects|Cognitive Changes Over Time, as Measured by Between Group and Within-subjects Comparison of Neuropsychological Measures.|Anxiety Symptoms",Washington University School of Medicine,All,"60 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,15,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,201011836,Sep-12,Apr-13,Apr-13,11-Apr-11,18-Mar-19,18-Mar-19,"Washington University School of Medicine, Saint Louis, Missouri, United States",,https://ClinicalTrials.gov/show/NCT01333098
NCT01331876,Modification of Cerebral Activity of Obsessive Compulsive Disorder (OCD) Patients During Cognitive and Behavioral Therapy,TOC TOC,Completed,No Results Available,Obsessive Compulsive Disorder,Behavioral: Cognitive and behavioral Therapy,Changes in brain activity associated with different types of Cognitive Behavioral Therapy Obsessive Compulsive Disorder,"Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,35,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,C09-02|2009-A00652-55,Oct-09,Apr-12,Jul-12,8-Apr-11,null,2-Oct-12,"Pitié-Salpêtrière hospital, Paris, France",,https://ClinicalTrials.gov/show/NCT01331876
NCT01329770,Safety and Efficacy Study of Antioxidants for the Treatment of the Fragile X Syndrome,SXF-TRA152,Completed,No Results Available,Fragile X Syndrome,Dietary Supplement: Ascorbic Acid (Vitamin C) and Alpha-tocopherol (Vitamin E)|Dietary Supplement: Placebo,Changes in the baseline Conner's Parent and Teacher Scales at 12 and 24 weeks|Change in the baseline measure of the Inventory of behaviour development (DBC-P24) at 12 and 24 weeks|Wechsler Intelligence Scale for children|Composite measure of blood and urine.,Yolanda de Diego Otero|The Mediterranean Institute for the Advance of Biotechnology and Health Research,Male,"6 Years to 18 Years   (Child, Adult)",Phase 2,30,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2009-017837-23,Dec-10,Apr-15,Apr-15,6-Apr-11,null,14-Apr-15,"Psychiatric Service. Hospital Carlos Haya, Malaga, Spain",,https://ClinicalTrials.gov/show/NCT01329770
NCT01329835,Effect of Psycho-education on Gestational Weight Gain and Anxiety/Depression in Obese Pregnant Women,,Unknown status,No Results Available,Obese Pregnant Women,Behavioral: Lifestyle counseling|Other: brochure,Gestational weight gain|Evolutions in anxiety and depression during pregnancy,Limburg Catholic University College|PHL University College,Female,18 Years to 50 Years   (Adult),Not Applicable,180,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,GWG32011,Mar-08,Apr-11,Dec-13,6-Apr-11,null,6-Dec-11,"St-Jans Hospital ZOL, Genk, Limburg, Belgium|Jessa Hospital, Hasselt, Limburg, Belgium|SFZ, Heusden, Limburg, Belgium",,https://ClinicalTrials.gov/show/NCT01329835
NCT01329133,Deep Brain Stimulation and Obsessive-compulsive Disorder,STOC2,"Active, not recruiting",No Results Available,Obsessive-Compulsive Disorder,Procedure: Deep Brain Stimulation (DBS),"Combination of three criteria (composite criterion), as follows: a. Y-BOCS score ≤ 16 / and b. Technical feasibility (each leads in the target) / and c. Safety, as assessed by any serial adverse event|Remission as defined by a Y-BOCS score ≤ 16 at M13|Number of electrode contacts correctly located within the chosen brain target (0, 1 or 2)|Monitoring of psychological and somatic complaints made spontaneously by the patient over the course of the present trial, in combination to the semi-structured interview for collecting side effects|Scores on neuropsychological tests exploring all executive functions|Percentage change in the total Y-BOCS score from M1 to M13|Therapeutic response, as indicated by a 35% decrease or more in the Y-BOCS score and a score of 1 or 2 (very much or much improved) on the CGI improvement scale from M1 to M13|Percentage change in the Y-BOCS obsessive and compulsive subscores from M1 to M13|Percentage change in the overall Padua Inventory score, MADRS score, BAS score from M1 to M13|Percentage change in the total and depression and anxiety subscale scores on the HAD scale from M1 and M13|Ratings of functional disability and quality of life|Correlations between efficacy and anatomical positioning of both stimulation electrodes within the chosen brain target|cost comparison of therapeutic strategies|Cost / effectiveness ration|Cost-utility rati","University Hospital, Bordeaux",All,18 Years to 60 Years   (Adult),Phase 3,31,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,CHUBX 2010/43,4-Apr-11,Mar-20,Mar-20,5-Apr-11,null,3-Jan-19,"Bordeaux University Hospital, Bordeaux, France|Clermont-Ferrand University Hospital, Clermont-Ferrand, France|Henri Mondor Hospital, Créteil, France|Grenoble University Hospital, Grenoble, France|Lille University Hospital, Lille, France|Lyon University Hospital, Lyon, France|Marseille University Hospital, Marseille, France|Nice University Hospital, Nice, France|Pitié-Salpêtrière Hospital, Paris, France|Sainte-Anne Hospital, Paris, France|Poitiers University Hospital, Poitiers, France|Rennes University Hospital, Rennes, France|Strasbourg University Hospital, Strasbourg, France|Toulouse University Hospital, Toulouse, France",,https://ClinicalTrials.gov/show/NCT01329133
NCT01323699,Behavioral Treatments for Anxiety and Depression in Veterans With Parkinson's Disease,BehTA-D,Completed,No Results Available,Parkinson Disease|Anxiety|Depression,Behavioral: Cognitive Behavioral Therapy,Hospital Anxiety and Depression Scale and Hamilton Anxiety Scale|Hamilton Depression Scale and Geriatric Depression Scale - 15|Parkinson's Disease Questionnaire -8|Client Satisfaction Questionnaire,"Michael Debakey Veterans Affairs Medical Center|South Central VA Mental Illness Research, Education & Clinical Center",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,20,U.S. Fed,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,H-28002,Nov-11,Feb-13,Feb-13,28-Mar-11,null,1-May-13,"Michael E. DeBakey Veteran Affairs Medical Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT01323699
NCT01323556,Mechanisms of Panic Disorders Treatment,,Unknown status,No Results Available,Panic Disorder|Agoraphobia|Panic Attacks,Behavioral: Cognitive Behavioural Therapy (CBT),Hamilton Anxiety Rating Scale (HARS)|Clinician Global Impression Scale (CGI)|Panic and Agoraphobia Scale (PAS)|Mobility Inventory|Number of panic attacks,University Medicine Greifswald|German Federal Ministry of Education and Research,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2|Phase 3,180,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AH 11.2009,Mar-10,Oct-11,May-12,25-Mar-11,null,11-Apr-11,"Prof. Dr. Alfons Hamm, Greifswald, Germany",,https://ClinicalTrials.gov/show/NCT01323556
NCT01322243,Effect of Metabolic State on Anxiety in Human Subjects,,Terminated,No Results Available,Healthy Volunteers,Other: Dietary manipulation,Functional magnetic resonance imaging (fMRI) blood oxygenation level dependent (BOLD) signals as indications of neural activity during exposure to an anxiety-inducing stress.|Physiological and behavioral parameters of emotional and metabolic state.|Response inhibition (impulse control) is also a secondary outcome for this study,Rockefeller University,All,20 Years to 40 Years   (Adult),Not Applicable,10,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,EKE-0724,Mar-11,Feb-13,Feb-13,24-Mar-11,null,20-May-13,"The Rockefeller University, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT01322243
NCT01320956,"Study of the Effects of Hypnosis Before Undergoing Surgery, on Anxiety in Children Aged 10 to 18 Years",HYPOPANX,Completed,No Results Available,Osteotomy and Spinal Column Surgery,Behavioral: Pre operative nurse consultation and Hypnosis|Other: Pre operative nurse consultation,Level of anxiety at day 1 (24 hours after surgery)|Anxiety level|Pain after surgery,Assistance Publique - Hôpitaux de Paris,All,10 Years to 215 Months   (Child),Not Applicable,120,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care,P100112|2010-A01165-34,Mar-11,Mar-13,Mar-13,23-Mar-11,null,4-Nov-15,"Hôpital Robert Debré, Paris, France",,https://ClinicalTrials.gov/show/NCT01320956
NCT01320800,CBT for Social Anxiety Disorder Delivered by School Counselors,,Completed,No Results Available,Social Anxiety Disorder,Behavioral: Skills for Academic and Social Success|Behavioral: Skills for Life,"Change in Diagnostic severity of social anxiety disorder (ADIS CSR score)|Change in Treatment response/non-response (a CGI-I of Improved or better, ratings of 1-3, 3 = Improved)|Change in Diagnostic status: presence or absence of social anxiety disorder|Change in Overall and school functioning: spare-time, peer relations, home life, school attendance, grades, and LSAS-CA school items total score|Change in Adolescent and parent ratings of social anxiety scale scores (self and parent SPAI-C), and adolescent ratings of depression (BDI-II)",New York University School of Medicine|National Institute of Mental Health (NIMH),All,14 Years to 17 Years   (Child),Phase 2,126,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",MH81881|R01MH081881,Oct-10,Feb-15,Feb-15,22-Mar-11,null,29-Jan-16,"New York University School of Medicine, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT01320800
NCT01316302,12-Week Study of Pristiq (Desvenlafaxine) Social Anxiety Disorder,,Completed,Has Results,Social Anxiety Disorder,Drug: Pristiq|Drug: Placebo,Change in the Liebowitz Social Anxiety Scale (LSAS) Total Score|Clinical Global Impression of Improvement Scale (CGI-I)|Patient Global Impression of Change,The Medical Research Network|Pfizer,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 4,63,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",PF2010SAD|WS1228302,Apr-11,Nov-12,Dec-12,16-Mar-11,8-Oct-14,17-Oct-16,"The Medical Research Network, LLC, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT01316302
NCT01316744,Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain,,Unknown status,No Results Available,Cancer,Drug: ketamine hydrochloride|Other: pharmacogenomic studies|Other: questionnaire administration|Procedure: assessment of therapy complications|Procedure: quality-of-life assessment,"Time to treatment failure|Initial treatment benefit (at day 4 of assessment period of 16 days) using the sensory component of the McGill Short-Form Questionnaire|Difference in overall pain between the study arms based on the visual-analogue score|Difference in neuropathic pain between the study arms based on the Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) pain scale|Worst pain score (index neuropathic site) in the previous 24 hours (between the two arms) at study baseline and then during study assessment period|Patient distress between the two arms based on NCCN Distress Thermometer|Side effects and tolerability of trial drug|Effect of the intervention on quality-of-life scores (based on Euroqol thermometer), anxiety and depression (based on HAD scale), and opioid requirements",University of Glasgow|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 3,214,Other,Interventional,Allocation: Randomized|Masking: Double|Primary Purpose: Supportive Care,CDR0000696704|CRUK-KPS-2008-01|EU-21012|EUDRACT-2007-002080-27|ISRCTN-49116945,Apr-09,Oct-11,null,16-Mar-11,null,13-May-11,"Royal Brompton Hospital, London, England, United Kingdom|Edinburgh Cancer Centre at Western General Hospital, Edinburgh, Scotland, United Kingdom|Beatson West of Scotland Cancer Centre, Glasgow, Scotland, United Kingdom",,https://ClinicalTrials.gov/show/NCT01316744
NCT01313403,Imaging Serotonin 5HT1A Receptors in Patients With Major Depressive Disorder,,Withdrawn,No Results Available,Major Depression|Unipolar Depression|Depression|Anxiety Disorder,Other: Antidepressant (SSRI),,National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC),All,18 Years to 55 Years   (Adult),Not Applicable,0,NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,110097|11-M-0097,10-Feb-11,25-Apr-12,25-Apr-12,11-Mar-11,null,2-Jul-17,,,https://ClinicalTrials.gov/show/NCT01313403
NCT01312116,Psychodynamic Internet Treatment Versus Cognitive Behavioral Therapy (CBT) for Generalized Anxiety Disorder,,Completed,No Results Available,Generalized Anxiety Disorder,Behavioral: iCBT|Behavioral: iPDT,Penn State Worry Questionnaire (PSWQ)|Montgomery Åsberg Depression Rating Scale-Self Rated (MADRS-S)|Quality of Life Inventory (QOLI)|Beck Depression Inventory (BDI)|Beck Anxiety Inventory (BAI)|Trimbos and iMTA questionnaire on Costs associated with Psychiatric illness (TIC-P)|State Trait Anxiety Inventory (STAI)|Generalized Anxiety Disorder Questionnaire IV (GAD-Q IV),Linkoeping University|Stockholm University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,81,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Dnr 2007-0756,Jan-09,Oct-09,Dec-10,10-Mar-11,null,10-Mar-11,"Linköping University, Linköping, Östergötland, Sweden",,https://ClinicalTrials.gov/show/NCT01312116
NCT01312571,Treatment of Social Phobia Over the Internet,SOFIE-8,Completed,No Results Available,Social Phobia,Behavioral: Internet-based cognitive behavioural therapy (iCBT)|Behavioral: Internet-based computerized attention training,Differences in recruited brain regions measured using regional cerebral blood flow|Social Phobia Screening Questionnaire (SPSQ)|Liebowitz Social Anxiety Scale self rated version (LSAS-SR)|Social Interaction Anxiety Scale (SIAS)|Social Phobia Scale (SPS)|Variation in genes that have been associated with emotional processing|Montgomery Åsberg Depression Rating Scale (MADRS-S)|Beck Anxiety Inventory (BAI)|Quality of Life Inventory (QOLI),Umeå University|Uppsala University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,26,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,2010-185-31 M,Aug-10,Feb-16,Feb-16,10-Mar-11,null,1-Nov-16,"Department of Psychology, Umeå University, Umeå, Västerbotten, Sweden",,https://ClinicalTrials.gov/show/NCT01312571
NCT01311180,A Clinical Trial to Study the Effects of Sensoril® for Patients With Generalized Anxiety Disorder,,Completed,No Results Available,Generalized Anxiety Disorder,Drug: Sensoril®|Drug: Placebo,Change in the Hamilton Anxiety Rating Scale (HAM-A) total score|Change in the Montgomery Asberg Depression Rating Scale (MADRS) total score|Change in the Clinical Global Impression Scales (CGI) for Severity scores.,"Natreon, Inc.",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,120,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",Natreon-GAD-02-001,Mar-11,Nov-12,Nov-12,9-Mar-11,null,21-Apr-15,"Asha Hospital, Hyderabad, Andhra Pradesh, India|Sheth V S General Hospital, Ahmedabad, Gujurat, India|Spandana Nursing Home, Bangalore, Karnataka, India|JSS Medical College Hospital, Mysore, Karnataka, India|Sridhar Neuro Psychiatric Center, Shimoga, Karnataka, India|Poona Hospital & Research Centre, Pune, Maharashtra, India|Manobal Medical Research Centre, Lucknow, Uttar Pradesh, India",,https://ClinicalTrials.gov/show/NCT01311180
NCT01310634,Epidemiology and Prevention of Anxiety and Depression in Parents of Hospitalized Neonates,,Completed,No Results Available,Depression,Behavioral: Comprehensive intervention,Parental anxiety symptoms,Nanjing Medical University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,600,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NMU-FY2011-236,Jan-11,Sep-11,Dec-11,8-Mar-11,null,28-Oct-14,"Nanjing Maternal and Child Care Hospital, Nanjing, Jiangsu, China",,https://ClinicalTrials.gov/show/NCT01310634
NCT01309074,Does Pregabalin Improve Symptoms of Anxiety in Patients With Epilepsy? A Comparison With Sertraline,,Terminated,No Results Available,Epilepsy|Anxiety,Drug: Pregabalin-Lyrica|Drug: Sertraline,Improvement of anxiety symptoms measured with the changes of the total scores of GAD-7 & HAM-A.|Change in Quality of life measures assessed with the QOLIE-89.,Rush University Medical Center,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 4,2,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",GA0082BY,Nov-09,Dec-12,Dec-12,4-Mar-11,null,7-Dec-12,"Rush University Medical Center, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT01309074
NCT01304862,Electronic Self-management Resource Training for Mental Health,eSMART-MH,Unknown status,No Results Available,Depression|Generalized Anxiety Disorder,Behavioral: eSMART-MH intervention|Behavioral: Educational videos about healthy living,Engagement in Mental Health Treatment: Medical Adherence Medication Module (MAMMM)|Mental Illness Stigma: Alienation Subscale|Mental Health Literacy: In Our Own Voice Knowledge Measure (IOOVKM)|Patient Activation: Patient Activation Measure (PAM)|Effective Communication: Patients' Self-Competence Subscale (PSC)|Symptom Severity: Hospital Anxiety and Depression Scale (HADS)|Feasibility and Acceptability of Intervention,Case Western Reserve University,All,18 Years to 25 Years   (Adult),Phase 1,100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,KL2RR024990,Feb-11,Dec-11,Dec-11,28-Feb-11,null,28-Feb-11,"Frances Payne Bolton School of Nursing, Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT01304862
NCT01302964,Mirtazapine Treatment of Anxiety in Children and Adolescents With Pervasive Developmental Disorders,,Completed,Has Results,Autism Spectrum Disorders,Drug: Placebo|Drug: Mirtazapine,"Mean 10-Week Change in Pediatric Anxiety Rating Scale 5-Item Total Score, Double-blind Phase|Proportion of Participants Who Responded to Treatment at 10 Weeks According to the Improvement Item of the Clinical Global Impression-Scale (Response Defined as CGI-I=1 or CGI-I=2)",Massachusetts General Hospital|Autism Speaks,All,5 Years to 17 Years   (Child),Phase 3,30,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2012P001009,Aug-10,10-Oct-17,10-Oct-17,24-Feb-11,7-Nov-18,7-Nov-18,"Riley Child and Adolescent Psychiatry Clinic Riley Hospital, Indianapolis, Indiana, United States|Lurie Center -MassGeneral Hospital, Lexington, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/64/NCT01302964/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT01302964
NCT01303536,Ondansetron Augmentation in Treatment-resistant OCD,,Completed,No Results Available,Obsessive Compulsive Disorder,Drug: Ondansetron,Yale Brown Obsessive Compulsive Scale|The Drug Effect scale,"Institute of Neuroscience, Florence, Italy",All,18 Years to 60 Years   (Adult),Phase 4,21,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,OND2,Dec-09,Mar-10,Mar-10,24-Feb-11,null,24-Feb-11,"Institute of Neuroscience, Florence, Italy",,https://ClinicalTrials.gov/show/NCT01303536
NCT01296321,Tailored Internet-administrated Treatment of Panic Symptoms - A Randomised Controlled Trial,NOVA III,Unknown status,No Results Available,Anxiety Disorders|Depression,Behavioral: Tailored Internet-administrated CBT-Treatment|Behavioral: Waitlist,Panic Disorder Severity Scale (PDSS)|Clinical Outcome in Routine Evaluation - Outcome Measure (CORE-OM)|Beck Anxiety Inventory (BAI)|Montgomery Åsberg Depression Rating Scale-Self Rated (MADRS-S)|Quality of Life Inventory (QOLI),Linkoeping University,All,18 Years to 45 Years   (Adult),Not Applicable,57,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GA-FAS-2008-1145,Feb-10,Apr-11,Apr-11,15-Feb-11,null,16-Feb-11,,,https://ClinicalTrials.gov/show/NCT01296321
NCT01293838,Cipralex® for Anxiety Disorders in Adolescents,CAP-E,Unknown status,No Results Available,Anxiety Disorder,Drug: Cipralex®,Treatment Efficacy|Physiological response to stress|Suicide risk,University of Ottawa|H. Lundbeck A/S,All,"13 Years to 18 Years   (Child, Adult)",Phase 1,30,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IMHR REB#2007036|123485,Mar-08,Jan-12,Jan-12,11-Feb-11,null,11-Feb-11,"The University of Ottawa Institute of Mental Health Research, Ottawa, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT01293838
NCT01291043,Efficacy of Shiatsu in Individuals With Fibromyalgia: a Randomized Clinical Trial,,Completed,No Results Available,Fibromyalgia,Other: Shiatsu,Change from baseline in VAS at 8 weeks|Change from baseline in FIQ at 4 weeks|Change from baseline in PSQI at 4 weeks|Change from baseline in STAI at 4 weeks|Change from baseline in VSRT at 4 weeks|Change from baseline in FIQ at 8 weeks|Change from baseline in PSQI at 8 weeks|Change from baseline in STAI at 8 weeks|Change from baseline in VSRT at 8 weeks|Change from baseline in VAS at 4 weeks|Change from baseline in ABC scale at 4 weeks|Change from baseline in ABC scale at 8 weeks|Change from baseline in PT mean at 4 weeks|Change from baseline in PT mean at 8 weeks,University of Sao Paulo General Hospital,All,30 Years to 60 Years   (Adult),Not Applicable,34,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1297/09,Jul-10,Nov-11,Nov-11,7-Feb-11,null,15-Nov-12,"University of Sao Paulo General Hospital, Sao Paulo, Brazil",,https://ClinicalTrials.gov/show/NCT01291043
NCT01289197,"Health Promotion in Early Adolescence: Sleep, Activity, and Emotion Regulation",,Completed,No Results Available,Sleep Disorders|Physical Activity|Depression|Anxiety,Behavioral: Family Check Up,Home visit assessment,University of Pittsburgh,All,10 Years to 13 Years   (Child),Not Applicable,324,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,5R01HD057893-02,Apr-09,Mar-13,Mar-13,3-Feb-11,null,11-Jan-16,"University of Pittsburgh, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT01289197
NCT01285115,The Comparative Clinical Study of Gamisoyosan on Anxiety of Generalized Anxiety Disorder According to Dosage Form,,Completed,No Results Available,Generalized Anxiety Disorder,Drug: Placebo|Drug: KyungBangn-Gamisoyosan-x-gwarip|Drug: KyungBangn Gamisoyosan,Hamilton Anxiety Scale(HAM-A)|State-Trait Anxiety Inventory(STAI)|Beck Depression Inventory(BDI)|Symptom Checklist-90-Revised(SCL-90R)|WHO Quality of Life Abbreviated(WHOQOL-BREF)|Heart Rate Variability(HRV)|PSWQ|GSES|RSE,Korea Health Industry Development Institute,All,"20 Years to 65 Years   (Adult, Older Adult)",Phase 3,147,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",B082005,Dec-08,Jun-10,Jul-10,27-Jan-11,null,27-Jan-11,"Oriental Hospital of Daejon University, Daejon, Choong-Chung-Do, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01285115
NCT01285284,Effect of Music Over the Tolerance to Colonoscopy.,EMOC,Unknown status,No Results Available,Pain|Anxiety,Other: Music|Other: No music,The administered dose of midazolam|Level of anxiety|Evolution of vital signs|Colonoscopy time|Patient's global evaluation of the procedure|Time since the beginning of the procedure until the discharge|How difficult the colonoscopy was?|Adverse effects|The level of pain|Willing of repeating the procedure.,Pontificia Universidad Catolica de Chile|Clínica UC San Carlos de Apoquindo.|Hospital Provicial Dr. Rafael Avaria Valenzuela,All,"18 Years and older   (Adult, Older Adult)",Phase 4,300,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Treatment,10-237,Mar-11,Sep-11,Oct-11,27-Jan-11,null,9-Aug-11,"Hospital Provicial Dr. Rafael Avaria Valenzuela, Curanilahue, Octava Región, Chile|Clínica UC San Carlos de Apoquindo, Santiago, Región Metropolitana, Chile|Centro Médico UC San Joaquín, Santiago, RM, Chile|Hospital Clínico. Pontificia Universidad Católica de Chile, Santiago, RM, Chile",,https://ClinicalTrials.gov/show/NCT01285284
NCT01283607,E-health Cognitive Behavioral Therapy in Women Treated by in Vitro Fertilization (IVF),,Completed,No Results Available,Depression|Anxiety|Infertility,Behavioral: Digicoach,scores on anxiety and depression|(para)medical consumption|process evaluation of the webbased cognitive behavioral therapy (CBT)|productivity loss|health related quality of life|IVF outcome|economical evaluation,University Medical Center Nijmegen|Stichting Nuts Ohra,Female,18 Years to 42 Years   (Adult),Not Applicable,120,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention,Digicoach,Feb-11,Jul-13,Jul-13,26-Jan-11,null,18-Nov-13,"Radboud University Nijmegen Medical Centre, department of obstetrics and gynecology, Nijmegen, Netherlands",,https://ClinicalTrials.gov/show/NCT01283607
NCT01281969,Intravenous Immunoglobulin for PANDAS (Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections),,Unknown status,No Results Available,Obsessive-Complusive Disorder|Children|Anxiety Disorder|Autoimmune Disease|PANDAS,Drug: Gamunex Intravenous Immunoglobulin|Drug: Placebo,"Active IVIG will be significantly superior to sham IVIG in reducing OC symptoms and providing global relief of neuropsychiatric symptomatology.|The degree of treatment response is expected to correlate with the percentage reduction in Abs titers following IVIG administration.|The degree of treatment response is also expected to correlate with decreased inflammation in specific regions of the brain, as demonstrated by changes on MRI",National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC),All,4 Years to 13 Years   (Child),Phase 3,48,NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,110058|11-M-0058,Jan-11,Dec-15,Dec-16,24-Jan-11,null,1-Sep-16,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT01281969
NCT01277354,Effectiveness of Cognitive Processing Therapy in Pregnant Women With a History of Pregnancy Loss/Complication,,Terminated,Has Results,Post-traumatic Stress Disorder|Stress Disorders|Anxiety|Depression,Behavioral: Cognitive Processing Therapy|Behavioral: Waitlist Placebo,CPT Effectiveness as Determined by the Number of Participants With CAPS Score Decrease of 50% From Baseline to Week 6,University of Pennsylvania|March of Dimes,Female,18 Years to 49 Years   (Adult),Not Applicable,2,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,810277|March of Dimes Foundation,Apr-10,Jun-11,Jun-11,14-Jan-11,8-Aug-16,17-Apr-17,"Penn Center for Women's Behavioral Wellness, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT01277354
NCT01275872,Effect of Guided Imagery and Progressive Muscle Relaxation as a Means to Improve the Psychological Well-being and the Quality of Life for Patients With Breast and Prostate Cancer,,Completed,No Results Available,Breast Cancer|Prostate Cancer,Other: Guided Imagery and Progressive Muscle Relaxation,Stress|Quality of Life|Fatigue|Anxiety|Depression|Nausea-vomit|Pain,Cyprus University of Technology,All,"18 Years to 72 Years   (Adult, Older Adult)",Not Applicable,200,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,AC-GIPMR-85,Apr-10,Jul-11,Oct-11,13-Jan-11,null,1-Nov-11,"Bank of Cyprus Oncology Centre, Nicosia, Cyprus",,https://ClinicalTrials.gov/show/NCT01275872
NCT01275989,Ear Acupuncture Effectiveness In Reducing The Signs And Symptoms Of Stress And Anxiety,EAEIRTSOSAA,Terminated,No Results Available,"Inclusion Criteria:|Voluntary Participation in the Study With Available Time for Submission to the Sessions, Which Occur Over Two Months.|Have a Score of Stress Medium, High or Very High in the LSS Questionnaire, Completion of the STAI and General Form.|Exclusion Criteria:|Pregnant Students.",Other: Ear acupuncture,,University of Sao Paulo|Santander,All,"Child, Adult, Older Adult",Not Applicable,56,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,848/2009,Mar-10,Sep-10,Nov-10,13-Jan-11,null,13-Jan-11,,,https://ClinicalTrials.gov/show/NCT01275989
NCT01275248,Efficacy and Safety Study of Low-Dose Ondansetron For Adjunctive Therapy In Adult Patients With Obsessive-Compulsive Disorder,,Terminated,No Results Available,Obsessive-compulsive Disorder,Drug: Ondansetron|Drug: Placebo,Core Period: Change from baseline in the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) total at Month 3 score|Extension Period: Participants with Safety Adverse Experiences|Core Period: Participants Considered Responders as Measured by the Clinical Global Impression-Improvement (CGI-I) Score|Core Period: Change from Baseline in the Clinical Global Impression-Severity (CGI-S) Score at Month 3|Core Period: Change from Baseline in the Sheehan Disability Scale (SDS) Score at Month 3,Transcept Pharmaceuticals,All,"18 Years and older   (Adult, Older Adult)",Phase 2,130,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",OND-003,Jan-11,Sep-15,Sep-15,12-Jan-11,null,18-Jan-13,"Southwestern Research, Inc., Beverly Hills, California, United States|Sun Valley Research Center, Imperial, California, United States|Pacific Institute for Medical Research, Los Angeles, California, United States|Compass Research, LLC, Orlando, Florida, United States|University of South Florida, St. Petersburg, Florida, United States|Emory University, Atlanta, Georgia, United States|Carman Research, Smyrna, Georgia, United States|McLean Hospital, Belmont, Massachusetts, United States|Beacon Clinical Research, LLC, New Bedford, Massachusetts, United States|Ambulatory Research Center, Dept of Psychiatry, Minneapolis, Minnesota, United States|Comprehensive Clinical Research, Berlin, New Jersey, United States|Montefiore Medical Center, Child Psychiatry Annex, Bronx, New York, United States|Biobehavioral Institute, Hofstra, Great Neck, New York, United States|Eastside Comprehensive Medical Center, LLC, New York, New York, United States|Columbia University Medical Center NYS Psychiatric Institute, New York, New York, United States|Richard H. Weisler, MD, PA, and Associates, Raleigh, North Carolina, United States|Quest Therapeutics of Avon Lake, Avon Lake, Ohio, United States|Lindner Center of HOPE University of Cincinnati, Mason, Ohio, United States|The Body Dysmorphic Disorder (BDD) Program, Providence, Rhode Island, United States|Clinical Trials of Texas, Inc, San Antonio, Texas, United States|Dean Foundation, Middleton, Wisconsin, United States|The Rogers Center for Research and Training, Milwaukee, Wisconsin, United States|Grupo de Estudios Medicos y Familiares, Mexico City, Federal District, Mexico|Instituto Mexicano de Investigacion Clinica S.A. de C.V. (IMIC), Mexico City, Federal District, Mexico|Hospital Aranda de la Parra S.A. de C.V., Leon, Guanajuato, Mexico|Estudios Integrales en Salud Mental, S.C., Guadalajara, Jalisco, Mexico|CIT Neuropsique, Monterrey, Nuevo Leon, Mexico|Centro par alas Adicciones y Salud Mental S.A., Monterrey, Nuevo Leon, Mexico|Instituto de Informacion e Investigacion en Salud Mental, A.C. (INFOSAME), Monterrey, Nuevo Leon, Mexico|Instituto para el Fortalecimiento de Capacidades en Salud, Tlalnepantla, State of Mexico, Mexico|Instituto para el Fortalecimiento de Capacidades en Salud: Focus Salud Mexico S.C., Merida, Yucatan, Mexico|Hospital Lomas de San Luis Internacional, San Luis Potosi, Mexico",,https://ClinicalTrials.gov/show/NCT01275248
NCT01268657,Intervention for Anxiety After Falls,,Completed,No Results Available,Posttraumatic Stress Disorder (PTSD)|Specific Phobia|Anxiety,Behavioral: Education|Behavioral: Relaxation Training|Behavioral: Cognitive Restructuring|Behavioral: Behavioral Activation|Behavioral: Exposure,"The Clinician Administered PTSD Scale (CAPS) and Survey of Activities and Fear of Falling in the Elderly (SAFE) will be primary outcomes.|Beck Anxiety Inventory, Beck Depression Inventory, Reintegration to Normal Living, Health Related Quality of Life, and other measures will be included.",Weill Medical College of Cornell University,All,65 Years to 105 Years   (Older Adult),Phase 1,23,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,K23 MH 09244,Jan-11,Nov-13,Feb-14,31-Dec-10,null,16-Aug-16,"Weill Cornell Medical College, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT01268657
NCT01259596,Telephone Psychotherapy for Late-Life Generalized Anxiety Disorder (GAD),,Completed,Has Results,Generalized Anxiety Disorder,Behavioral: cognitive behavioral therapy|Behavioral: nondirective supportive therapy,Changes From Baseline in Penn State Worry Questionnaire (PSWQ-A) at Week 13|Changes From Baseline in Hamilton Anxiety Rating Scale (HAM-A) at Week 13|Changes From Baseline in Beck Depression Inventory (BDI) at 13 Weeks|Pepper Center Tool for Disability (PCT-D)|Short Form (36) Health Survey (SF-36) to Week 13|Insomnia Severity Index (ISI)|Changes From Baseline in Generalized Anxiety Disorder-7 (GAD-7) to Week 13,Wake Forest University Health Sciences|National Institute of Mental Health (NIMH),All,"60 Years and older   (Adult, Older Adult)",Not Applicable,141,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IRB00010377|R01MH083664,Jan-11,Feb-15,Feb-15,14-Dec-10,3-Oct-17,29-Aug-18,"Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT01259596
NCT01256008,Intervention Study of Depression in Breast Cancer Patients,,Completed,Has Results,Breast Cancer|Depression|Anxiety,Behavioral: CBT|Behavioral: Clinical Management,Hamilton Depression Rating Scale (HAMD-17)|Hamilton Anxiety Scale (HAMA-14)|Visual Analogue Scale (VAS)|Athens Insomnia Scale(AIS)|Functional Assessment of Cancer Treatment (FACT-B),"Wenzhou Medical University|Anhui Medical University|Central South University|Harbin Medical University|Second Affiliated Hospital, School of Medicine, Zhejiang University|Wuhan University",Female,"20 Years to 65 Years   (Adult, Older Adult)",Not Applicable,392,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,2009BAI77B06-3,Dec-10,Dec-12,Feb-13,8-Dec-10,10-Apr-15,1-May-15,"Wenzhou Medical University, Wenzhou, Zhejiang, China",,https://ClinicalTrials.gov/show/NCT01256008
NCT01256151,Pharmacokinetics Of Alprazolam Sublingual Tablet Versus Conventional Tablet,,Completed,No Results Available,Anxiety Disorder,Drug: Alprazolam tablet|Drug: Alprazolam sublingual,Area under the curve (AUC) from time zero to last measurable time of alprazolam|Peak concentration of alprazolam|Area under the curve from time zero to infinity|AUC% extrapolated|Time of Cmax|half-life of alprazolam|Clinically significant safety laboratory tests|Clincally significant vital signs|Clinically significant adverse events,Pfizer,All,18 Years to 55 Years   (Adult),Phase 1,28,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,A6131024,Jan-11,May-11,May-11,8-Dec-10,null,26-May-11,"Pfizer Investigational Site, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT01256151
NCT01253044,Acceptance and Commitment Therapy (ACT) for OEF/OIF Veterans,,Completed,Has Results,Distress|Anxiety|Depression|Postconcussive Symptoms,Behavioral: Acceptance and Commitment Therapy|Behavioral: Present Centered Therapy,Brief Symptom Inventory 18 (BSI-18)|Sheehan Disability Inventory,Veterans Medical Research Foundation,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,160,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,W81XWH-08-2-0159,Nov-10,Aug-13,Aug-13,3-Dec-10,19-Oct-15,19-Oct-15,"VA San Diego Healthcare System, La Jolla, California, United States|Walter Reed National Military Medical Center, Washington, District of Columbia, United States|Togus VA Medical Center, Augusta, Maine, United States|Durham VA Medical Center, Durham, North Carolina, United States|Cincinnati VA Medical Center, Cincinnati, Ohio, United States|VA Puget Sound Health System, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT01253044
NCT01244711,Open-Label Pilot Study to Examine the Value of Substituting Quetiapine for Benzodiazepines,,Terminated,Has Results,Major Depression|Generalized Anxiety Disorder,Drug: quetiapine,Montgomery Asberg Depression Rating Scale (MADRS),Weill Medical College of Cornell University|AstraZeneca,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,1,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IRUSQUET0483,Sep-08,Sep-11,Sep-11,19-Nov-10,6-Mar-15,3-Apr-15,"Weill Cornell Medical College, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT01244711
NCT01243606,Efficacy Evaluation of a Unified Transdiagnostic Treatment for Anxiety Disorders,,Completed,No Results Available,Anxiety Disorders|Mood Disorders,Behavioral: Single Diagnosis Treatment Protocol|Behavioral: Unified Protocol (UP),Anxiety Disorders Interview Schedule (ADIS): change over time|Clinical Global Impression Severity (CGI-S) and Improvement Scales (CGI-I): change over time|Structured Interview Guide for the Hamilton Anxiety and Depression Rating Scale (SIGH-A and SIGH-D): change over time|Yale-Brown Obsessive Compulsive Scale Interview-II (Y-BOCS-II): change over time|Panic Disorder Severity Scale (PDSS): change over time|Liebowitz Social Anxiety Scale (LSAS): change over time|Generalized Anxiety Disorder Severity Scale (GADSS): change over time|Overall Anxiety Sensitivity and Impairment Scale (OASIS)/ Overall Depression Sensitivity and Impairment Scale (ODSIS): change over time|Work and Social Adjustment Scale (WSAS):change over time,Boston University Charles River Campus|National Institute of Mental Health (NIMH),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,250,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1R01MH090053-01,Dec-10,May-17,May-17,18-Nov-10,null,9-Oct-17,"Center for Anxiety and Related Disorders at Boston University, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT01243606
NCT01242735,Exercise and Health Intervention for Patients With Obsessive Compulsive Disorder (OCD),,Completed,No Results Available,Obsessive Compulsive Disorder,Behavioral: Aerobic exercise|Behavioral: Health and Wellness,Yale-Brown Obsessive Compulsive Scale (Y-BOCS; OCD symptomatology),Butler Hospital|National Institute of Mental Health (NIMH),All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,56,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1006-001|1R01MH086513-01A1,Nov-10,Mar-15,Mar-15,17-Nov-10,null,22-Jul-15,"Butler Hospital, Providence, Rhode Island, United States",,https://ClinicalTrials.gov/show/NCT01242735
NCT01242865,Self Help Intervention to Decrease Stress,,Completed,No Results Available,"Stress, Psychological",Behavioral: Attention and Interpretation Therapy,To assess the feasibility of testing a self help stress management program for improving stress in a pilot clinical trial.|To assess the efficacy of the self help stress management program on resilience.|To assess the efficacy of the self help stress management program on stress.|To assess the efficacy of the self help stress management program on anxiety.|To assess the efficacy of the self help stress management program on mindfulness.|To assess the efficacy of the self help stress management program on overall quality of life.,Mayo Clinic,All,"18 Years to 90 Years   (Adult, Older Adult)",Not Applicable,33,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,10-006367,Dec-10,Jan-12,Jan-12,17-Nov-10,null,26-Apr-13,"Mayo Clinic, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT01242865
NCT01229709,Mindfulness Based Tinnitus Reduction (MBTR): A Symptom Perception Shift Program,MBTR,Completed,No Results Available,Tinnitus|Anxiety|Depression,Behavioral: Mindfulness Based Tinnitus Reduction,Change in Tinnitus Handicap Inventory (THI)|Change in Symptom Checklist-90- Revised|Change in Five-Factor Mindfulness Questionnaire (FFMQ)|Change in Hamilton Anxiety & Depression Scale (HADS)|Change in Tinnitus Visual Analogue Scale (VAS),"University of California, San Francisco",All,"18 Years and older   (Adult, Older Adult)",Phase 2,10,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,H8935-35834-01,Jan-11,Jun-11,Jun-11,28-Oct-10,null,28-Oct-14,"UCSF Audiology Clinic, San Francisco, California, United States|UCSF, San Francisco, California, United States",,https://ClinicalTrials.gov/show/NCT01229709
NCT01230047,Mindfulness and Lifestyle Interventions for Depression and Anxiety: A Pilot Study,,Unknown status,No Results Available,Depression|Anxiety|Major Depression,Behavioral: Psychoeducational course,Beck Depression Inventory (BDI)|Beck Anxiety Inventory (BAI)|Client Medication Use|Client Currently Seeing Therapist,Arizona State University,All,"18 Years to 90 Years   (Adult, Older Adult)",Not Applicable,30,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1018,Oct-10,Jan-11,Oct-11,28-Oct-10,null,28-Oct-10,"Utah Youth Village, Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT01230047
NCT01228890,Primary Care Internet-Based Depression Prevention for Adolescents (CATCH-IT),CATCH-IT,Withdrawn,No Results Available,Depression|Anxiety|Externalizing Symptoms|Substance Abuse,Behavioral: CATCH-IT|Behavioral: AMPE,"To determine whether the CATCH-IT 2-R depression prevention intervention prevents or delays major depressive episodes, as well as non-affective disorder episodes, compared to AMPE.|To determine if participants in the CATCH-IT 2-R group exhibit more rapid favorable changes of depressive symptoms/and or vulnerability/protective factors compared with the AMPE group.|To determine if participants in the CATCH-IT 2-R program report lower perceived educational impairment, greater quality of life, greater health-related quality of life, and lower incidence of other mental disorders (anxiety, substance/alcohol use).|To determine for whom (moderators) and how (mediators) the CATCH-IT 2-R program works in this population.",University of Chicago|Harvard Vanguard Medical Associates,All,13 Years to 17 Years   (Child),Phase 3,0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",10-464-A,Sep-10,Apr-11,Apr-11,27-Oct-10,null,17-Dec-12,"University of Chicago, Chicago, Illinois, United States|Access Community Health Network, Chicago, Illinois, United States|Northshore University Health Systems, Evanston, Illinois, United States|Harvard Vanguard Medical Associates, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT01228890
NCT01227980,Corticotropin-Releasing Hormone Receptor 1 (CRH1) Antagonism in Anxious Alcoholics^,,Completed,Has Results,Alcohol-Related Disorders|Alcohol Dependence|Alcoholism|Anxiety Disorder,Drug: Pexacerfont|Drug: Placebo,Alcohol Craving in Response to the Alcohol Cue Script|Alcohol Craving in Response to the Stress Script,National Institute on Alcohol Abuse and Alcoholism (NIAAA)|National Institutes of Health Clinical Center (CC),All,"21 Years to 65 Years   (Adult, Older Adult)",Phase 2,70,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",110010|11-AA-0010,Oct-10,Jul-14,Jul-14,25-Oct-10,10-Dec-15,2-Feb-16,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT01227980
NCT01226511,A Study in Pediatric Participants With Generalized Anxiety Disorder,,Completed,Has Results,"Anxiety Neuroses|Anxiety States, Neurotic|Neuroses, Anxiety",Drug: Duloxetine|Drug: Placebo,Change From Baseline to 10-Week Endpoint in the Pediatric Anxiety Rating Scale (PARS) Severity Score Evaluated for Symptoms Identified on the Generalized Anxiety Subsection of the PARS Symptom Checklist|Response Rate at Endpoint for Generalized Anxiety Disorder (GAD) Using Pediatric Anxiety Rating Scale (PARS) Severity Score for GAD|Change From Baseline to 10-Week Endpoint on the Pediatric Anxiety Rating Scale (PARS) Severity Total Score Evaluated for All Symptoms Identified on the PARS Symptom Checklist Symptoms|Change From Baseline to 10-Week Endpoint on the Clinical Global Impression of Severity (CGI-S) Scale|Remission Rate at Endpoint for Generalized Anxiety Disorder (GAD) Using Clinical Global Impressions of Severity (CGI-S) Scale|Change From Baseline to 10-Week Endpoint in the Children's Global Assessment Scale (CGAS)|Percentage of Participants During the 10-Week Period With Treatment-Emergent (New or Worsening) Suicidal Ideation as Assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)|Percentage of Participants During the 10-Week Period With Treatment-Emergent (New or Worsening) Suicidal Behavior as Assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)|Change From 10-Week to 28-Week Endpoint in the Pediatric Anxiety Rating Scale (PARS) Severity Score Evaluated for Symptoms Identified on the Generalized Anxiety Subsection of the PARS Symptom Checklist|Change From 10-Week to 28-Week Endpoint on the Pediatric Anxiety Rating Scale (PARS) Severity Total Score Evaluated for All Symptoms Identified on the PARS Symptom Checklist Symptoms|Change From 10-Week to 28-Week Endpoint on the Clinical Global Impression of Severity (CGI-S) Scale|Change From 10-Week to 28-Week Endpoint in the Children's Global Assessment Scale (CGAS)|Percentage of Participants During the 18-Week Extension Period With Treatment-Emergent (New or Worsening) Suicidal Ideation as Assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)|Percentage of Participants During the 18-Week Extension Period With Treatment-Emergent (New or Worsening) Suicidal Behavior as Assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS),Eli Lilly and Company,All,7 Years to 17 Years   (Child),Phase 3,281,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",12929|F1J-MC-HMGI,Jun-11,Feb-13,Jun-13,22-Oct-10,5-Mar-14,5-Mar-14,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hialeah, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Smyrna, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Libertyville, Illinois, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lexington, Kentucky, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Troy, Michigan, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gladstone, Missouri, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Omaha, Nebraska, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cherry Hill, New Jersey, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New York, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rochester, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cincinnati, Ohio, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cleveland, Ohio, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oklahoma City, Oklahoma, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Richmond, Virginia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bellevue, Washington, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Spokane, Washington, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Insurgentes Cuicuilco, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mexico City, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Monterrey, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Luis Potosi, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Zona Centro, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bloemfontein, South Africa|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cape Town, South Africa|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pretoria, South Africa",,https://ClinicalTrials.gov/show/NCT01226511
NCT01223677,Rumination-focused CBT Training for the Prevention of Depression and Anxiety,,Completed,No Results Available,Depression|Anxiety Disorders,Behavioral: Rumination Focused CBT,Beck Depression Inventory II (BDI-II)|Mood and Anxiety Symptom Questionnaire (MASQ-30),VU University of Amsterdam|ZonMw: The Netherlands Organisation for Health Research and Development,All,"15 Years to 22 Years   (Child, Adult)",Phase 1,251,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,50-50105-96-635,Oct-10,Sep-14,Sep-14,19-Oct-10,null,3-Dec-14,"University of Amsterdam, Amsterdam, Noord-Holland, Netherlands",,https://ClinicalTrials.gov/show/NCT01223677
NCT01224067,Adjunctive Quetiapine in the Treatment of Refractory Social Anxiety Disorder in Adults,,Completed,No Results Available,Social Anxiety Disorder,Drug: Quetiapine,Liebowitz Social Anxiety Scale (LSAS)|Clinical Global Impression of Improvement (CGI-I) scores,Cambridge Health Alliance|AstraZeneca,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,40,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CHA-IRB-0094/11/04,Mar-06,Jul-08,Oct-08,19-Oct-10,null,18-Apr-17,"Cambridge Health Alliance, Cambridge, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT01224067
NCT01221792,Carvedilol Versus Placebo for Treatment in Post Traumatic Stress Disorder (PTSD),,Unknown status,No Results Available,Post-Traumatic Stress Disorder,Drug: Carvedilol|Drug: Placebo,Davidson Trauma Scale (DTS)|Clinician Administered PTSD Scale (CAPS)|Insomnia Severity Index (ISI),Columbia Northwest Pharmaceuticals,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,80,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CVD-PT-10203,Oct-10,Jun-11,Aug-11,15-Oct-10,null,8-Jun-11,"Artemis Institute for Clinical Research, San Diego, California, United States|Lake Charles Clinical Trials, Lake Charles, Louisiana, United States|Northwest Clinical Research Center, Bellevue, Washington, United States",,https://ClinicalTrials.gov/show/NCT01221792
NCT01217788,Intranasal PH94B for Management of the Symptoms of Generalized Social Phobia,PH94B-SAD,Completed,No Results Available,Social Phobia|Social Anxiety Disorder,Drug: PH94B intranasal spray,Subjective Unit of Discomfort Scale|Number of patients with adverse events as a measure of safety and tolerability on the psychometric scale,"Pherin Pharmaceuticals, Inc.",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,90,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",PH94B CL022,Feb-08,Feb-11,Mar-11,8-Oct-10,null,10-May-11,"Medical Research Network, New York City, New York, United States",,https://ClinicalTrials.gov/show/NCT01217788
NCT01214304,Aromatherapy to Reduce Pain and Anxiety During Cervical Colposcopy,Lavender Colpo,Completed,No Results Available,Colposcopy,Other: Essential Lavender Oil|Other: Lavender Scent,Pain Level|Anxiety Level,Mike O'Callaghan Military Hospital|American Academy of Family Physicians,Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,262,U.S. Fed|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",FWH20100154H,Feb-11,Nov-13,Nov-13,5-Oct-10,null,25-Nov-13,"Mike O'Callaghan Federal Medical Center, Las Vegas, Nevada, United States",,https://ClinicalTrials.gov/show/NCT01214304
NCT01207960,Efficacy of Eye Movement Desensitization and Reprocessing (EMDR) in Dental Phobia,EMDR-DP,Completed,No Results Available,Dental Phobia,Behavioral: Eye Movement Desensitization and Reprocessing (EMDR),Dental anxiety|General psychopathology|Anxiety and depression|Behavioral test|Dental treatment,University Hospital Muenster,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,24,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2007-137-f-S,Jan-10,Sep-11,Sep-11,23-Sep-10,null,4-May-12,"Psychosomatics in Dentistry, Dept. of Prosthodontics & Material Science, University Hospital Muenster, Muenster, Germany",,https://ClinicalTrials.gov/show/NCT01207960
NCT01205191,Cell Phone-supported Cognitive Behavioural Therapy,LINNEA,Unknown status,No Results Available,Anxiety,Behavioral: Cell-phone supported CBT|Behavioral: CBT with digital audio player support|Behavioral: CBT,Anxiety|Adherence,Linkoeping University,All,18 Years to 25 Years   (Adult),Phase 2|Phase 3,400,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,LFP5/08,Apr-11,Jun-12,Jun-12,20-Sep-10,null,15-Jun-11,"""Unga Vuxna"" Clinic, Linkoping, Ostergotland, Sweden",,https://ClinicalTrials.gov/show/NCT01205191
NCT01204229,Motivational and Cognitive Intervention for College Drinkers,MCID,Unknown status,No Results Available,Alcohol Consumption|Anxiety|Depression,Behavioral: Motivational and Cognitive Intervention for Drinkers (MCID)|Behavioral: Brief Motivational Intervention (BMI),Alcohol Consumption and Drinking-Related Negative Consequences|Anxiety|Depression|Cost efficacy data,University of Cincinnati|National Institute on Alcohol Abuse and Alcoholism (NIAAA),All,18 Years to 25 Years   (Adult),Phase 1,100,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,R21AA1AA017291A1,May-10,May-12,null,17-Sep-10,null,22-Apr-11,"Psychology Department, University of Cincinnati, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT01204229
NCT01203293,Cognitive Behavioral Therapy (CBT) for Latinos With Generalized Anxiety Disorder in the General Medical Sector,,Completed,No Results Available,Generalized Anxiety Disorder,Behavioral: Cognitive behavior based therapy|Behavioral: Treatment as usual,Penn State Worry Questionnaire|SF-36 Social Functioning Scale|Quality of Life Inventory,University of Puerto Rico|National Institute of Mental Health (NIMH),All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,90,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,5SC1MH90599-2,Sep-09,Feb-13,Feb-13,16-Sep-10,null,28-Aug-14,"University of Puerto Rico, Medical Sciences Campus, San Juan, Puerto Rico",,https://ClinicalTrials.gov/show/NCT01203293
NCT01201967,A Collaborative Care Program to Improve Treatment of Depression and Anxiety Disorders in Cardiac Patients,MOSAIC,Completed,Has Results,Depression|Generalized Anxiety Disorder|Panic Disorder,Other: Collaborative care|Other: Usual care,Change in Mental Health-related Quality of Life From Baseline to 24 Weeks|Change in Depression Symptoms From Baseline to 24 Weeks|Change in Anxiety Symptoms From Baseline to 24 Weeks|Rate of Adequate Treatment of Depression and/or Anxiety Symptoms 5 Days After Enrollment|Change in Adherence to Health Behaviors From Baseline to 24 Weeks|Number of Rehospitalizations From Baseline to 24 Weeks|Change in Health Status From Baseline to 24 Weeks|Change in Physical Function From Baseline to 24 Weeks|Change in Physical Health-related Quality of Life From Baseline to 24 Weeks,Massachusetts General Hospital|American Heart Association,All,"18 Years and older   (Adult, Older Adult)",Phase 4,183,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,2010P-001414,Sep-10,Jun-13,Jun-13,15-Sep-10,25-Sep-14,25-Sep-14,"Massachusetts General Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT01201967
NCT01201304,Comparison of Methods for the Delivery of Interoceptive Exposure,,Unknown status,No Results Available,Anxiety Sensitivity,Behavioral: Standard exposure|Behavioral: Enhanced exposure|Behavioral: Intensive exposure|Behavioral: Expressive writing,Fear of Anxiety-Related Body Sensations|Hypervigilance to anxiety-related body sensations|Beck Anxiety Inventory|Peak Anxiety During a Symptom Induction Task,University of Wyoming,All,"18 Years and older   (Adult, Older Adult)",Phase 2,120,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IEstudyUW,Jan-10,Apr-12,Apr-12,14-Sep-10,null,31-Jan-12,"University of Wyoming, Laramie, Wyoming, United States",,https://ClinicalTrials.gov/show/NCT01201304
NCT01200641,Evaluation of Anxiolysis and Pain Associated With Retrobulbar Eye Block for Cataract Surgery : Melatonin Versus Gabapentin,,Completed,No Results Available,Anxiety|Pain,Drug: Melatonin|Drug: Gabapentin|Drug: placebo,"pain will be assessed by verbal pain score (VPS) of 10 (0 = no pain and 10 = worst pain imaginable)|anxiety will be assessed by verbal anxiety score (VAS) of 10 (0 = completely calm and 10 = the worst possible anxiety)|mean arterial blood pressure will be assessed by noninvasive automatic blood pressure measurement|heart rate will be assessed by echocardiogram monitoring|satisfaction of surgeon according to three degree scale as very bad, moderate, good will be assessed",Qazvin University Of Medical Sciences,All,"35 Years to 85 Years   (Adult, Older Adult)",Phase 1|Phase 2,90,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",ACTRN12610000727044,Sep-10,Dec-10,Jan-11,13-Sep-10,null,11-Oct-12,"Qazvin university of medical science, Qazvin, Iran, Islamic Republic of",,https://ClinicalTrials.gov/show/NCT01200641
NCT01199107,Maximizing Treatment Outcome and Examining Sleep in Post-traumatic Stress Disorder (PTSD),,Completed,No Results Available,Post-Traumatic Stress Disorder,Behavioral: Prolonged Exposure|Behavioral: Exercise|Behavioral: Wellness Intervention,PTSD Symptoms|Sleep Quality|BDNF (by blood sample)|General Mood and Anxiety Symptoms,Southern Methodist University,All,18 Years to 54 Years   (Adult),Phase 3,9,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,KS10-106,Sep-10,Aug-13,Aug-13,10-Sep-10,null,10-Dec-14,"Southern Methodist University, Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT01199107
NCT01197313,Depression and Quality of Life in Chronic Heart Failure Patients and the Caregivers,,Completed,No Results Available,Chronic Heart Failure (CHF)|Anxiety and Depression|Quality of Life (QOL)|Exercise,Other: Home-based exercise,Psychologic aspect|Functional capacity|Disability level|Quality of life,National Taiwan University Hospital,All,"20 Years to 80 Years   (Adult, Older Adult)",Not Applicable,51,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,9561709097,Dec-06,Dec-07,Dec-07,9-Sep-10,null,9-Sep-10,"National Taiwan University Hospital, Taipei, Taiwan",,https://ClinicalTrials.gov/show/NCT01197313
NCT01198197,PET Brain and Whole Body Distribution Studies for Nociceptin/Orphanin FQ Peptide (NOP) Receptor Using [11C]NOP-1A,,Completed,No Results Available,Pain|Anxiety|Depression,Drug: NOP-1A,"For the PET scans, we will measure the regional densities of NOP receptors as distribution volume (VT). Distribution volume is the ratio at equilibrium of brain uptake to the concentration of parent radioligand in plasma.",National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC),All,18 Years to 50 Years   (Adult),Early Phase 1,41,NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,100204|10-M-0204,3-Sep-10,null,28-Feb-14,9-Sep-10,null,17-Dec-18,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT01198197
NCT01196312,Anxiety Sensitivity Treatment for Heroin Users,ASTH-HR,Unknown status,No Results Available,Anxiety,Behavioral: Anxiety sensitivity therapy,Anxiety Sensitivity Index-3|Timeline Follow Back 90 days,University of Maryland,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DA023384,Oct-09,Mar-11,Sep-11,8-Sep-10,null,8-Sep-10,"Salvation Army Harbor Light Treatment Facilitiy, Washington, District of Columbia, United States",,https://ClinicalTrials.gov/show/NCT01196312
NCT01194765,Distance-Based Cognitive-Behavioural Therapy for High Anxiety Sensitivity: A Randomized Controlled Trial,,Completed,No Results Available,Anxiety Sensitivity,Other: Distance-based Cognitive Behavioural Therapy,Change from Pre-Treatment in Anxiety Sensitivity Level at Post-Treatment|Change from Pre-Treatment in Severity of Panic Symptoms at 8 Weeks|Change from Pre-Treatment in Participants' Daily Functioning at 8 Weeks|Participant Satisfaction with Treatment at Post-Treatment|Change from Pre-Treatment in in General Anxiety Symptoms at 8 Weeks|Change from Pre-Treatment in Frequency of Pain-Related Anxiety Symptoms at 8 Weeks|Change from Pre-Treatment in Social Anxiety Symptoms at 8 Weeks|Change from Pre-Treatment in Frequency and Severity of Posttraumatic Stress Symptoms at 8 weeks|Change from Pre-Treatment in Drinking Motives at 8 weeks|Change from Pre-Treatment in Frequency of Binge Drinking at 8 weeks|Change from Pre-Treatment in Quantity and Frequency of Alcohol-Related Negative Consequences Experienced at 8 Weeks|Change from Pre-Treatment in Alcohol Expectancies at 8 Weeks|Change from Pre-Treatment in Anxiety Sensitivity Level at 8 weeks|Change from Pre-Treatment in Anxiety Sensitivity Level at Follow-up|Change from Pre-Treatment in Severity of Panic Symptoms at Post-Treatment|Change from Pre-Treatment in Frequency and Intensity of Physical Exercise at Follow-up|Change from Pre-Treatment in in General Anxiety Symptoms at Post-Treatment|Change from Pre-Treatment in in General Anxiety Symptoms at Follow-up|Change from Pre-Treatment in Frequency of Pain-Related Anxiety Symptoms at Post-Treatment|Change from Pre-Treatment in Frequency of Pain-Related Anxiety Symptoms at Follow-up|Change from Pre-Treatment in Frequency of Depressive Symptoms at 8 Weeks|Change from Pre-Treatment in Frequency of Depressive Symptoms at Post-Treatment|Change from Pre-Treatment in Frequency of Depressive Symptoms at Follow-up|Change from Pre-Treatment in Social Anxiety Symptoms at Post-Treatment|Change from Pre-Treatment in Social Anxiety Symptoms at Follow-up|Change from Pre-Treatment in Frequency and Severity of Posttraumatic Stress Symptoms at Post-Treatment|Change from Pre-Treatment in Frequency and Severity of Posttraumatic Stress Symptoms at Follow-up|Change from Pre-Treatment in Drinking Motives at Post-Treatment|Change from Pre-Treatment in Drinking Motives at Follow-up|Change from Pre-Treatment in Frequency of Binge Drinking at Post-Treatment|Change from Pre-Treatment in Frequency of Binge Drinking at Follow-up|Change from Pre-Treatment in Quantity and Frequency of Alcohol-Related Negative Consequences Experienced at Post-Treatment|Change from Pre-Treatment in Quantity and Frequency of Alcohol-Related Negative Consequences Experienced at Follow-up|Change from Pre-Treatment in Alcohol Expectancies at Post-Treatment|Change from Pre-Treatment in Alcohol Expectancies at Follow-up|Change from Pre-Treatment in Participants' Daily Functioning at Post-Treatment|Change from Pre-Treatment in Participants' Daily Functioning at Follow-up|Change from Pre-Treatment in Neuroticism at Post-Treatment|Changes from Pre-Treatment in Neuroticism at 8 weeks|Change from Pre-Treatment in Neuroticism at Follow-up,Dalhousie University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,180,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,DAL10-01,Jan-11,Aug-12,Dec-12,3-Sep-10,null,22-Jan-14,"Dalhousie University, Halifax, Nova Scotia, Canada",,https://ClinicalTrials.gov/show/NCT01194765
NCT01193530,The Use of Light Therapy for Managing Sleep Disturbances in Patients With Advanced Cancer,,Terminated,Has Results,Advanced Cancers,Other: Bright Light Therapy|Other: Dim Red Light Therapy|Behavioral: Questionnaires|Behavioral: Study Diaries|Device: Red Light Litebook|Device: Bright Light Litebook,Effect of Bright Light Therapy on Sleep Disturbances Compared to Dim Red Light in Patients With Advanced Cancer Followed at a Palliative Care Outpatient Clinic at a Comprehensive Cancer Center,M.D. Anderson Cancer Center,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,12,Other,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",2009-0738|NCI-2012-01793,Jun-11,Mar-16,Mar-16,2-Sep-10,26-Mar-19,26-Mar-19,"University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT01193530
NCT01194076,Wait-list Study of One-Week Intensive Cognitive-Behavioral Therapy for Pediatric Obsessive-Compulsive Disorder (OCD),5dayOCD,Completed,No Results Available,Obsessive Compulsive Disorder,Behavioral: 5-day intensive treatment,Children's Yale Brown Obsessive Compulsive Scale (CYBOCS)|Spence children's anxiety scale,Mayo Clinic|University of South Florida|Fordham University,All,7 Years to 17 Years   (Child),Not Applicable,28,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,09-0082590,May-10,May-12,May-12,2-Sep-10,null,30-May-12,"University of South Florida, Tampa, Florida, United States|Mayo Clinic, Rochester, Minnesota, United States|Fordham University, Bronx, New York, United States",,https://ClinicalTrials.gov/show/NCT01194076
NCT01190774,Anxiety Assessment Intervention in Dental Patients,ANXDEN,Completed,No Results Available,Anxiety State,Behavioral: Information to health provider without patient knowledge|Behavioral: dentist behaviour and patient expectancy,State Anxiety|Discussion of dental anxiety with dentist,University of St Andrews|University of Manchester,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,182,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Health Services Research",Denanx0103,Sep-03,Apr-04,Sep-04,30-Aug-10,null,30-Aug-10,"University of Manchester, Manchester, United Kingdom",,https://ClinicalTrials.gov/show/NCT01190774
NCT01187511,CRF1 Antagonist GSK561679 in Alcoholism,,Completed,Has Results,Alcohol Dependence,Drug: GSK561679|Drug: Placebo,Alcohol Craving in Response to the Alcohol Cue Script|Alcohol Craving in Response to the Stress Script|Alcohol Craving in Response to the Trier/Cue-reactivity Procedure|Anxiety Symptom Ratings Measured Bi-weekly During the Treatment Period|Depression Symptom Ratings Measured Bi-weekly During the Treatment Period|Spontaneous Alcohol Craving Measured Bi-weekly During the Treatment Period,National Institute on Alcohol Abuse and Alcoholism (NIAAA)|National Institutes of Health Clinical Center (CC),Female,"21 Years to 65 Years   (Adult, Older Adult)",Phase 2,44,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",100046|10-AA-0046,Jan-10,Sep-15,Sep-15,24-Aug-10,7-Nov-16,7-Nov-16,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT01187511
NCT01187784,Cognitive-Behavioral Therapy for Children With High-Functioning Autism Spectrum Disorder and Anxiety,,Completed,No Results Available,Autism Spectrum Disorder|Autism|Asperger Syndrome|PDD-NOS,Behavioral: Coping Cat cognitive-behavioral therapy for anxious youth,Anxiety Disorders Interview Schedule - Child/Parent Version|Multidimensional Anxiety Scale for Children|Spence Children's Anxiety Scale (Child and Parent Versions),Alliant International University|National Foundation for Autism Research|Autism Society of America - San Diego Chapter,All,7 Years to 14 Years   (Child),Phase 1,22,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,McNallyKeehn,May-09,Aug-10,Aug-10,24-Aug-10,null,24-Aug-10,"Alliant International University, San Diego, California, United States",,https://ClinicalTrials.gov/show/NCT01187784
NCT01187797,Effects of Emotional Stimulation on the Stress Levels of Healthy Persons,,Completed,No Results Available,Depression|Somatization Disorder|Anger|Anxiety,Other: Emotional stimulation,Depression|Somatization,"Charite University, Berlin, Germany",All,18 Years to 45 Years   (Adult),Phase 1|Phase 2,21,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,EA408109,Aug-10,Sep-10,Sep-10,24-Aug-10,null,25-Oct-10,"Charité Universitätsmedizin Berlin, Berlin, Germany",,https://ClinicalTrials.gov/show/NCT01187797
NCT01185561,A Pychoeducational Intervention for Women With Diabetes,SWEEP,Completed,Has Results,Depression|Anxiety|Anger,Behavioral: Psychoeducational intervention,Center for Epidemiologic Studies Depression (CES-D) Score|State-Trait Anxiety Inventory (STAI Form Y-1) State Anxiety Sub-test Score|State-Trait Anxiety Inventory (STAI Form Y-1) Trait Anxiety Sub-test Score|State-Trait Anger Expression Inventory (STAXI) Anger Expression Sub-test Score,Loyola University,Female,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,74,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,108324,Mar-07,Nov-09,Nov-09,20-Aug-10,14-Dec-16,14-Dec-16,"Loyola University Medical Center, Maywood, Illinois, United States",,https://ClinicalTrials.gov/show/NCT01185561
NCT01182051,A Study of Family-based Cognitive-behavioral Therapy for Chronic Pediatric Headache and Anxiety,,Completed,No Results Available,Pediatric|Headache|Anxiety,Behavioral: CBT or relaxation training,Daily Headache and Anxiety Diary|Pediatric Anxiety Rating Scale (PARS)|Pediatric Migraine Disability Assessment (PedMIDAS),Johns Hopkins University|Migraine Research Foundation,All,7 Years to 17 Years   (Child),Not Applicable,15,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,NA-00019444,Mar-10,Jun-12,Jun-12,16-Aug-10,null,24-May-13,"Johns Hopkins, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT01182051
NCT01180842,Treatment of Anxiety/Depression and Pain Through Relaxation Yoga for Patient With Cystic Fibrosis (CF),,Completed,No Results Available,Cystic Fibrosis,Other: Yoga treatment program,Improve Quality of Life measured through self report questionnaires|Reduce symptoms of pain measured through self report questionnaires|Reduce symptoms of anxiety measured through self report questionnaires and cortisol testing|Reduce symptoms of sleep disturbance measured through self report questionnaires|Reduce symptoms of depression measured through self report questionnaires and cortisol testing,Children's Hospitals and Clinics of Minnesota,All,"9 Years to 18 Years   (Child, Adult)",Phase 2,20,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0911-104,Mar-10,Dec-13,Dec-13,12-Aug-10,null,14-Feb-14,"Children's Hospitals and Clinics of Minnesota, Minneapolis, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT01180842
NCT01178385,Cognitive-Behavioral Treatment for Anxiety Disorders in Children With Autism Spectrum Disorders,,Completed,Has Results,Autism|Asperger's Syndrome|Generalized Anxiety Disorder|Social Phobia|Separation Anxiety Disorder|Obsessive-compulsive Disorder,Behavioral: Cognitive-behavioral therapy|Behavioral: Treatment as Usual,Pediatric Anxiety Rating Scale (Measures the Severity of Anxiety Symptoms)|Anxiety Disorders Interview Schedule Highest Anxiety Clincian Severity Rating (Measures the Severity of the Child's Anxiety Symptoms)|Clinical Global Impression - Severity Scale (This Scale Measures the Severity of the Child's Anxiety Symptoms).,University of South Florida,All,7 Years to 11 Years   (Child),Phase 2|Phase 3,45,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,ACH-2010,Apr-10,Dec-12,Dec-12,10-Aug-10,2-Apr-13,2-Apr-13,"Rothman Center for Neuropsychiatry, University of South Florida, St. Petersburg, Florida, United States",,https://ClinicalTrials.gov/show/NCT01178385
NCT01178554,The Clinic Treatment Project,CTP,Completed,No Results Available,Anxiety|Depression|Problem Behavior,Behavioral: psychotherapy|Behavioral: evidence-based treatment|Behavioral: modular evidence-based treatment,"Brief Problem Checklist (BPC, parent and child forms)|The Children's Interview for Psychiatric Syndromes-Child and Parent Forms (ChIPS/P-ChIPS)|Top Problems Assessment|Youth Self-Report Form (YSR)|Child Behavior Checklist (CBCL)|Therapeutic Alliance Scale for Children|Service Assessment for Children and Adolescents: Treatment and Auxiliary Service Use Scales|Revised Children's Anxiety and Depression Scale|Brief Symptom Inventory|Brief Impairment Scale|Services for Children & Adolescents - Parent Interview (SCAPI)",Judge Baker Children's Center|MacArthur Foundation|University of Hawaii|University of Illinois at Chicago,All,7 Years to 13 Years   (Child),Not Applicable,203,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",83423-0,Jun-05,May-09,Jun-10,10-Aug-10,null,16-Mar-11,"The University of Hawaii at Manoa, Honolulu, Hawaii, United States|Judge Baker Children's Center, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT01178554
NCT01178632,Therapeutic Effect of an Herbal Medicine on Anxiety,,Unknown status,No Results Available,Anxiety Disorders,Drug: Passiflora|Drug: Valeriana officinalis,Hamilton anxiety scale score|Insomnia gravity index|Clinical global impression rate scale and Patient global evaluation rate scale,Millet Roux,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,136,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MR4009,Oct-10,Dec-11,Jul-12,10-Aug-10,null,10-Aug-10,"Clinical Pharmacology Unit - Unifac, Fortaleza, Ceara, Brazil",,https://ClinicalTrials.gov/show/NCT01178632
NCT01178671,Combined Mirtazapine and SSRI Treatment of PTSD: A Placebo-Controlled Trial,,Completed,Has Results,Posttraumatic Stress Disorder,Drug: Mirtazapine|Drug: Sertraline|Other: Sugar pill,PTSD Severity|Time to Discontinuation of Study Treatment|Alternative Measure of PTSD Severity|PTSD Self-rated Severity|Depression Severity|Response Status|Remission Status|Adverse Effects|Sleep Quality|Sexual Functioning,"Research Foundation for Mental Hygiene, Inc.|National Institute of Mental Health (NIMH)",All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 4,38,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",R34MH091336,Jul-10,May-14,Jun-14,10-Aug-10,29-Feb-16,8-Apr-16,"Anxiety Disorders Clinic, New York State Psychiatric Institute, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT01178671
NCT01177969,Cognitive Behavioral Therapy (CBT) for Anxiety Disorders in Autism: Adapting Treatment for Adolescents,,Completed,Has Results,"Anxiety Disorders in Youth With Autism, Asperger's Syndrome, and Pervasive Developmental Disorder Not Otherwise Specified",Behavioral: Cognitive-Behavioral Therapy|Behavioral: Wait-list,Pediatric Anxiety Rating Scale.|Anxiety Disorders Interview Schedule: Child and Parent Versions,"University of South Florida|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|University of California, Los Angeles|University of Miami",All,11 Years to 14 Years   (Child),Phase 1|Phase 2,33,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,1R34HD065274-01,Nov-09,Apr-14,Apr-14,9-Aug-10,1-Jul-14,1-Jul-14,"Univeristy of California at Los Angeles, Los Angeles, California, United States|University of South Florida, St. Petersburg, Florida, United States",,https://ClinicalTrials.gov/show/NCT01177969
NCT01177072,Study of Effectiveness of Mental Health Interventions Among Torture Survivors in Southern Iraq,,Completed,No Results Available,Depression|Anxiety|Post-Traumatic Stress Disorder,Other: Cognitive Processing Therapy|Other: Components-Based Intervention,Severity of Trauma. This will be the difference in group mean score of severity of depression based on a sum of ratings of various standard depression symptoms from the Hopkins Symptom Checklist and locally defined symptoms.|Ability to Function. This is the difference in group mean of ability to function based on the sum of ratings of functional ability among various tasks identified by the local population as important functions (men and women have separate tasks).,"Johns Hopkins Bloomberg School of Public Health|Heartland Alliance|Ministry of Health, Iraq|United States Agency for International Development (USAID)",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,342,Other|U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,JHSPH-3034,Mar-11,Jul-12,Jul-12,6-Aug-10,null,3-May-13,"Ministry of Health Iraq, Several cities in Iraq (Karbala, Basra, Najaf, etc.), Iraq",,https://ClinicalTrials.gov/show/NCT01177072
NCT01172652,Ziprasidone in Bipolar Disorder With Comorbid Lifetime Panic or Generalized Anxiety Disorder(GAD),Pfizer Anxiety,Completed,No Results Available,Bipolar Disorder|Panic Disorder|Generalized Anxiety Disorder,Drug: Ziprasidone|Drug: Placebo,"CGI-21|Sheehan Panic Disorder Scale (SPS), (HAM-A), Young Mania Rating Scale (YMRS), Sheehan Irritability Scale (SIS), Rapid Ideas Scale RISC, MADRS, PGI-21 symptoms, CGI-BP, Family Impact Scale (FIS), Sheehan Disability Scale (SDS).",VA Palo Alto Health Care System|Pfizer|University of South Florida|Lindner Center of HOPE,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,49,U.S. Fed|Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SUP0005-17504,Apr-10,Oct-11,Oct-11,30-Jul-10,null,19-Mar-12,"VA Palo Alto Health Care System & Stanford School of Medicine, Palo Alto, California, United States|University of South Florida Institute for Research in Psychiatry, Tampa, Florida, United States|Lindner Center of Hope University of Cincinnati Medical Center, Mason, Ohio, United States",,https://ClinicalTrials.gov/show/NCT01172652
NCT01172873,D-Cycloserine Augmentation to CBT With Exposure and Response Prevention in Adults and Adolescents With OCD,,Completed,Has Results,Obsessive Compulsive Disorder,Drug: D-cycloserine|Behavioral: Exposure and Response Prevention (EX/RP),Child Yale-Brown Obsessive Compulsive Scale (CY-BOCS) for Adolescents|Multidimensional Anxiety Scale for Children (MASC)|Beck Depression Inventory (BDI),New York State Psychiatric Institute|Emory University,All,12 Years to 17 Years   (Child),Not Applicable,16,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,#5828,Sep-08,Sep-10,Dec-10,30-Jul-10,23-Dec-13,19-Aug-14,"New York State Psychiatric Institute/Columbia University, New York City, New York, United States",,https://ClinicalTrials.gov/show/NCT01172873
NCT01172275,N-acetylcysteine (NAC) for Pediatric Obsessive-Compulsive Disorder,,Unknown status,No Results Available,Obsessive-Compulsive Disorder,Drug: N-Acetylcysteine|Drug: Placebo,Improvement in OCD Severity|Improvement in OCD Symptom Dimensions|Overall Improvement|Adverse Effects,Yale University,All,8 Years to 17 Years   (Child),Phase 2,11,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",YCSC1004006623,Jul-12,Dec-17,Dec-17,29-Jul-10,null,13-Jan-17,"Yale Child Study Center, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT01172275
NCT01169480,The Impact of Giving a Massage,,Completed,No Results Available,"Mental State, Reported as Depression, Anxiety or Stress",Behavioral: Give a massage,"Perceived, self-reported stress, anxiety and depression|Perceived, self-reported state and trait anxiety",Parker Research Institute,All,"18 Years to 65 Years   (Adult, Older Adult)",Early Phase 1,20,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other",Massage Study - I,Jun-10,Sep-10,Sep-10,26-Jul-10,null,20-Jun-17,"Parker College School of Massage, Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT01169480
NCT01168661,"Yoga, Mindfulness and Cognitive Psychotherapy as Treatment for Stress and Burnout",,Completed,No Results Available,"Stress, Psychological|Burnout, Professional|Anxiety|Depression",Behavioral: Yoga|Behavioral: Mindfulness based cog psychotherapy|Behavioral: Cognitive psychotherapy,Reduced stress measured by qualitative questionnaires|Reduced cortisol secretion,"Karolinska Institutet|Stockholm County Council, Sweden",All,"16 Years to 65 Years   (Child, Adult, Older Adult)",Not Applicable,90,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Pickup 2003,Aug-07,Apr-10,Apr-10,23-Jul-10,null,23-Jul-10,"Karolinska Institutet, Stockholm, Huddinge, Sweden",,https://ClinicalTrials.gov/show/NCT01168661
NCT01162811,Visualization and Structured Attention Behaviour for Pain and Anxiety Reduction During Ablation of Atrial Fibrillation,,Completed,No Results Available,Atrial Fibrillation,Behavioral: visualization together with structured behavioural attention.,Pain and anxiety is determined from self-reporting by the patient on a validated NRS scale.|Amount of Medication used /kg (Fentanyl and Midazolam) during the ablation procedure)|Number of adverse events during the ablation procedure,"Rigshospitalet, Denmark",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,140,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,J. nr. 2007-58-0015.).,Nov-09,Jul-11,Jul-11,15-Jul-10,null,21-Jul-11,"Coepenhagen University Hospital, Rigshospitalet, Copenhagen, Copenhagen Ø, Denmark",,https://ClinicalTrials.gov/show/NCT01162811
NCT01158001,Telemedicine for Improved Delivery of Psychosocial Treatments for Post Traumatic Stress Disorder,,Completed,No Results Available,Posttraumatic Stress Disorders|Depression|Anxiety,Behavioral: Prolonged exposure therapy,Clinician-administered PTSD Scale (CAPS) diagnostic interview|PHQ-9 (self-reported depression)|PTSD Checklist (PCL; self-reported PTSD symptoms)|Neuropsychological testing battery to assess cognitive functioning,Veterans Medical Research Foundation|United States Department of Defense|University of Pennsylvania,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,211,Other|U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,080513|PT074431,May-09,Jun-12,Sep-12,8-Jul-10,null,24-Jun-15,"VA San Diego Healthcare System, San Diego, California, United States",,https://ClinicalTrials.gov/show/NCT01158001
NCT01158430,Acceptance and Commitment Group Therapy (ACT) for Patients With Health Anxiety,ACT,Completed,No Results Available,Hypochondriasis|Somatization Disorder,Behavioral: ACT group therapy,"Health anxiety measured by the Whiteley-7 index|Social level of functioning measured with Short Form health status questionnaire from the medical outcome status (SF-36)|Social level of functioning, emotional disorders measured with relevant sub-scales from Symptom Check List, 90 items (SCL 90)|Social level of functioning measured with an alcohol dependency questionnaire (CAGE)|Illness perception measured with Illness Perception Questionnaire (IPQ)|Physical symptoms measured with somatisation subscales from Symptom Check List, 90 items (SCL 90)|Health care use (National Patient Register & National Health Service Register (general practitioner (GP) contacts/consultations, specialists, physiotherapists, dentists, GPs' emergency service), The Danish Medicine Agency (medicine consumption)).|Sick days (the DREAM database - the register-based evaluation of the extent of marginalization)|ACT process measures measured with Five Facet Mindfulness Questionnaire (FFMQ)|ACT process measures measured with Acceptance and Action Questionnaire - II (AAQ II)",University of Aarhus,All,20 Years to 60 Years   (Adult),Not Applicable,126,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2001001,Mar-10,Apr-13,Apr-13,8-Jul-10,null,15-Apr-13,"The Research Clinic for Functional Disorders, Aarhus University Hospital, Aarhus C, Denmark",,https://ClinicalTrials.gov/show/NCT01158430
NCT01155804,Assessment of the Effectiveness of a Program of Preparation to Pregnancy and Delivery,,Unknown status,No Results Available,Lumbago|Anxiety,Behavioral: preparation of the delivery,To assess the well being of the women trought the proportion of women with back pain and stress urinary incontinence,Center for Research on Reproductive Health of Campinas|Fundação de Amparo à Pesquisa do Estado de São Paulo,Female,"16 Years to 40 Years   (Child, Adult)",Phase 4,192,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,FAPESP2010,Jun-09,Sep-11,Oct-11,2-Jul-10,null,1-Jul-11,"Centro de Atençao Integral a Saude da Mulher CAISM, Campinas, SP, Brazil",,https://ClinicalTrials.gov/show/NCT01155804
NCT01152580,Melatonin Osteoporosis Prevention Study,MOPS,Completed,Has Results,Osteoporosis|Osteopenia,Dietary Supplement: melatonin|Dietary Supplement: sugar pill,"The Effect of Melatonin (3 mg) or Placebo on the Mean Change in Serum Osteocalcin (OC) Levels in Women After 6 Months, as Compared to Baseline|The Effect of Melatonin (3 mg) or Placebo on the Mean Change in Serum Type-1 Collagen Cross-linked N-telopeptide (NTX) Levels in Women After 6 Months, as Compared to Baseline.|The Effect of Melatonin (3 mg) or Placebo on the Mean Change in Bone Density in Women After 6 Months, as Compared to Baseline.|The Effect of Melatonin (3 mg) or Placebo on the Mean Change in Menopause-Specific Quality of Life (MENQOL) Physical Domain Scores in Women After 6 Months, as Compared to Baseline.|The Effect of Melatonin (3 mg) or Placebo on the Mean Change in Menopause-Specific Quality of Life (MENQOL) Vasomotor Domain Scores in Women After 6 Months, as Compared to Baseline.|The Effect of Melatonin (3 mg) or Placebo on the Mean Change in Menopause-Specific Quality of Life (MENQOL) Psychosocial Domain Scores in Women After 6 Months, as Compared to Baseline.|The Effect of Melatonin (3 mg) or Placebo on the Mean Change in Menopause-Specific Quality of Life (MENQOL) Sexual Domain Scores in Women After 6 Months, as Compared to Baseline.|The Effect of Melatonin (3 mg) or Placebo on the Mean Change in the Pittsburgh Sleep Quality Index (PSQI) in Women After 6 Months, as Compared to Baseline.",Duquesne University,Female,45 Years to 54 Years   (Adult),Phase 1,19,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",Jul-88,Sep-08,Jul-10,Jul-10,29-Jun-10,12-Mar-12,13-Mar-12,"Duquesne University School of Pharmacy Center for Pharmacy Care, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT01152580
NCT01151696,Pain and Anxiety Management of Traumatic Emergency in a Pre-hospital Setting,,Completed,No Results Available,Pain,Drug: Atarax (Hydroxyzine)|Drug: Placebo,"Percentage of patients with pain relief (with a NRS score of 3/10 or lower)|pain score comparisons|pain and anxiety comparisons|comparison of adverse events|patient and investigator satisfaction with analgesia|assessment of post traumatic anxiety, stress and other related disorders","University Hospital, Toulouse",All,"18 Years and older   (Adult, Older Adult)",Phase 4,140,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",0918703|2009-015529-35,May-10,Sep-13,Jan-14,28-Jun-10,null,23-Jul-14,"Universty Hospital Toulouse SAMU 31, Toulouse, France",,https://ClinicalTrials.gov/show/NCT01151696
NCT01149265,Online Support Groups for Depression and Anxiety,,Unknown status,No Results Available,Depression|Anxiety,Behavioral: Online support group|Behavioral: Expressive writing,The Center for Epidemiological Studies Depression Scale|Satisfaction with Life Scale|The Medical Outcomes Study Social Support Survey|Generalised Anxiety Disorder Assessment|The Illness perception questionnaire,"University College, London",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,1000,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,UCL1376/001,May-10,Feb-11,Feb-11,23-Jun-10,null,21-Jul-10,"University College London, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01149265
NCT01149772,"Adjusting to Chronic Conditions Using Education, Support, and Skills",ACCESS,Completed,Has Results,Chronic Obstructive Pulmonary Disease|Heart Failure|Anxiety|Depression,Behavioral: ACCESS,Patient Health Questionnaire -9 (PHQ-9)|Beck Anxiety Inventory (BAI)|Chronic Respiratory Questionnaire_Fatigue|Chronic Respiratory Questionnaire_Mastery|Chronic Respiratory Questionnaire_Dyspnea|Kansas City Cardiomyopathy Questionnaire (KCCQ),VA Office of Research and Development,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,302,U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,IIR 09-088|2619,Feb-11,Oct-14,Oct-14,23-Jun-10,18-Jan-16,24-Feb-16,"VA Medical Center, Oklahoma City, Oklahoma City, Oklahoma, United States|Michael E. DeBakey VA Medical Center, Houston, TX, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT01149772
NCT01147614,Brief Cognitive Behavioral Therapy (CBT) for Pediatric Anxiety and Depression in Primary Care,BCBT-PC,Completed,No Results Available,Anxiety|Depression,Behavioral: Brief Cognitive Behavioral Therapy (BCBT)|Behavioral: Specialty mental health care referral (SMHC),Clinical Global Impression|Pediatric Anxiety Rating Scale|Children's Depression Rating Scale - Revised|Health Utilities Index,San Diego State University|University of Pittsburgh|Kaiser Permanente|National Institute of Mental Health (NIMH),All,8 Years to 16 Years   (Child),Not Applicable,185,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,7887933|5R01MH084935,Sep-10,Apr-16,Apr-16,22-Jun-10,null,14-Apr-16,"San Diego State University, San Diego, California, United States|Western Psychiatric Institute and Clinics, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT01147614
NCT01147913,Computerized Information-Processing Bias Retraining in Depressed Adolescents,,Completed,No Results Available,Major Depression,Behavioral: Computerized Information-Processing Bias Retraining|Behavioral: Attention Control Training,"Test of Interpretation Bias (TIB)|Test of Interpretation Bias|Kiddie-Schedule of Affective Disorders and Schizophrenia-Epidemiologic Version (K-SADS-E; Orvaschek & Puig-Antich, 1987)|Beck Depression Inventory, 2nd Version|State-Trait Anxiety Scale (STAI)|Structured Clinical Interview for DSM-IV (SCID-IV; First et al, 1997), Mood Disorder Modules only|Dysfunctional Attitudes Scale (DAS)|CANTAB Affective Go-No Go Task (AGN)",Massachusetts General Hospital,All,"14 Years to 21 Years   (Child, Adult)",Phase 2,48,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",F32MH088065-01,Mar-10,Apr-12,Apr-12,22-Jun-10,null,3-May-12,"Clinical and Research Program in Pediatric Psychopharmacology at Massachusetts General Hospital, Cambridge, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT01147913
NCT01147952,The Effect of Exercise on Peripheral Blood Gene Expression in Angina,,Completed,No Results Available,Angina Pectoris,Behavioral: Structured exercise training,Peripheral blood gene expression|peripheral blood gene expression|Angina status|Angina Status|Anxiety Score|Depression Score,Sheffield Teaching Hospitals NHS Foundation Trust,All,"30 Years to 80 Years   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,STH15565,Nov-10,May-14,May-14,22-Jun-10,null,14-Apr-16,"NIHR Cardiovascular Biomedical Research Unit, Sheffield, South Yorkshire, United Kingdom",,https://ClinicalTrials.gov/show/NCT01147952
NCT01147978,Proactive Communication Strategy in Intensive Care Unit and Post Traumatic Stress Symptoms,FAMIREAXV,Completed,No Results Available,Critically Ill Patients,Behavioral: End of ICU stay conference,"Symptoms of PTSD in ICU patients|Symptoms of PTSD, anxiety, and depression in ICU patients|Symptoms of PTSD, anxiety, and depression in families","Assistance Publique - Hôpitaux de Paris|University Paris 7 - Denis Diderot|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,303,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,K070101|ID RCB / 2007-A01044-49,Apr-09,Aug-12,Nov-12,22-Jun-10,null,23-Apr-14,"Medical ICU, Paris, France",,https://ClinicalTrials.gov/show/NCT01147978
NCT01148186,An Intervention Study to Reduce the Use and Impact of Potentially Inappropriate Medications Among Older Adults,,Terminated,No Results Available,Polypharmacy|Incontinence|Insomnia|Anxiety,Behavioral: knowledge transfer tool,"Complete discontinuation of the targeted potentially inappropriate medication (e.g. benzodiazepines, oxybutynin)|Cognitive function|Sleep efficiency|incontinence-related self-efficacy|frequency of urinary incontinence episodes",Centre de Recherche de l'Institut Universitaire de Geriatrie de Montreal|Canadian Institutes of Health Research (CIHR),All,65 Years and older   (Older Adult),Phase 4,300,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,CIHR-2009MOP-201314-KTE,Jun-10,May-13,May-13,22-Jun-10,null,15-May-13,"Le Groupe Jean Coutu Inc., Longueuil, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT01148186
NCT01148316,Developing Adaptive Treatment Strategies for Children and Adolescents With Obsessive-compulsive Disorder.,SMART,Completed,No Results Available,Obsessive-Compulsive Disorder,Drug: fluoxetine|Behavioral: Group cognitive-behavioral therapy,Treatment response status at week 28|Treatment response status at week 14|Predictors of treatment response at week 28,Roseli Shavitt|University of Pernambuco|University of Sao Paulo,All,7 Years to 17 Years   (Child),Not Applicable,144,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IPq-HCFMUSP - 259,Aug-10,Jun-13,Dec-13,22-Jun-10,null,24-Oct-14,"Institue of Psychiatry - Hospital of Clinics - University of São Paulo, São Paulo, Brazil",,https://ClinicalTrials.gov/show/NCT01148316
NCT01146730,At Work and Coping - Effect Study of Workcoping for Patients With Anxiety and Depression,AWaC,Completed,No Results Available,Anxiety|Depression,Behavioral: Workcoping and IPS|Behavioral: Ordinary care by GP or NAV,Sick leave data|Psychopathology,NORCE Norwegian Research Centre AS|Norwegian Labour and Welfare Administration,All,18 Years to 60 Years   (Adult),Not Applicable,1202,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,Workcoping2010,Jun-10,Mar-16,May-18,17-Jun-10,null,11-Jul-18,"Uni Reserach, Bergen, Norway",,https://ClinicalTrials.gov/show/NCT01146730
NCT01141010,Effect of Psychological Interventions on Maternal Outcomes Undergoing Cesarean,PIMAC,Completed,No Results Available,Perioperative Psychology,Other: Language,Self anxiety assessment scale (SAS)|Self depression assessment scale (SDS)|Visual analog scale of pain (VAS pain)|Saliva cortisol level|Vital signs|SAS scorings|SDS scoring|VAS pain scoring,Nanjing Medical University|Confidential Enquiry into Maternal and Child Health,Female,19 Years to 50 Years   (Adult),Not Applicable,365,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Supportive Care",NJFY1021005|10NJMS067,May-10,Aug-10,Aug-10,10-Jun-10,null,25-Aug-10,"Nanjing Maternity and Child Health Care Hospital, Nanjing, Jiangsu, China",,https://ClinicalTrials.gov/show/NCT01141010
NCT01135745,Deep Brain Stimulation for Obsessive Compulsive Disorder (OCD PMCF),,Completed,No Results Available,Obsessive Compulsive Disorder,Device: Reclaim® Deep Brain Stimulation,"Characterization of Adverse Events related to implant procedures, device or stimulation|To characterize improvement from baseline in OCD symptoms assessed by YBOCS.",MedtronicNeuro,All,"18 Years and older   (Adult, Older Adult)",Phase 4,32,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,OCD PMCF Study 1.02.7003,Apr-10,May-15,May-15,3-Jun-10,null,23-Jan-18,"Universitaire Ziekenhuis Leuven, Leuven, Belgium|Universitätsklinikum Schleswig-Holstein Campus Lübeck, Lübeck, Germany|Hadassah-Hebrew University Medical Center, Jerusalem, Israel|A.O. San Paolo Polo Universitario, Milan, Italy|Hospital Ciutat Sanitaria I Universitaria de Bellvitge, Barcelona, Spain|Hospital Virgen de las Nieves, Granada, Spain|Karolinska University Hospita, Stockholm, Sweden|Inselspital Bern, Bern, Switzerland",,https://ClinicalTrials.gov/show/NCT01135745
NCT01130103,Combination Treatment for Posttraumatic Stress Disorder (PTSD) After the World Trade Center (WTC) Attack,,Completed,Has Results,Posttraumatic Stress Disorder,Drug: Paroxetine|Behavioral: Prolonged Exposure Therapy,"Clinician Administered PTSD Scale (CAPS)|Number of Participants Who Met Remission Criterion|Treatment Response at Weeks 5 and 10|Hamilton Depression Scale 0 = no Depression Symptoms 40 = Extreme Depression Symptoms|Quality of Life Enjoyment and Satisfaction Scale Total Score at Week 0,5,10","Research Foundation for Mental Hygiene, Inc.|National Institute of Mental Health (NIMH)",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 4,37,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",R01MH068173,Mar-04,Feb-10,Feb-10,25-May-10,14-Aug-12,4-Dec-12,"New York State Psychiatric Institute, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT01130103
NCT01128712,Effect on Anxiety in Partial Epilepsy Patients Treated With Pregabalin,,Terminated,No Results Available,"Epilepsy, Complex Partial",Drug: Pregabalin,"Change in Beck Anxiety Score|Change in BDI , NHS3 , STAI , NDDI-E and seizure frequency",Northeast Regional Epilepsy Group|Pfizer,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 4,4,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NEREG-001,Apr-10,Jul-14,Jul-14,24-May-10,null,14-Sep-17,"Northeast Regional Epilepsy Group, Hackensack, New Jersey, United States",,https://ClinicalTrials.gov/show/NCT01128712
NCT01128777,Teens Coping With Parental Military Deployment,Helping Hand,Terminated,No Results Available,Emotional Distress|Behavior Problems,Behavioral: Cognitive Behavioral Group Therapy|Behavioral: Nondirective supportive group therapy,Depressed mood|Behavior problems,Brown University|National Institute of Mental Health (NIMH),All,13 Years to 17 Years   (Child),Phase 1,6,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,R34MH082164,Jan-11,Apr-12,Apr-12,24-May-10,null,4-Jul-13,"Brown Univerity, Providence, Rhode Island, United States",,https://ClinicalTrials.gov/show/NCT01128777
NCT01128309,Stress Reduction and Anxiety: Effects on the Function and Structure of the Brain,,Completed,No Results Available,Generalized Anxiety Disorder,Behavioral: Stress Reduction Intervention|Behavioral: Active Control intervention,brain activation and structure as assessed by MRI,Massachusetts General Hospital|European Commission,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,29,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,2010P000947|236975,May-10,Apr-11,Apr-11,21-May-10,null,7-May-12,"Massachusetts General Hospital, Charlestown, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT01128309
NCT01126294,Perioperative Melatonin in Lumbar Laminectomy,,Unknown status,No Results Available,Pain and Anxiety in Patients Undergoing Surgery for Lumbar Laminectomy.,Dietary Supplement: 5 mg melatonin|Dietary Supplement: 10 mg melatonin|Dietary Supplement: Placebo,Pain|Anxiety,"University Health Network, Toronto",All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,84,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",09-0172-B,Apr-10,Jul-11,Sep-11,19-May-10,null,19-May-10,"Toronto Western Hospital, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT01126294
NCT01121211,Hormonal Factors in the Treatment of Anorexia Nervosa,,Completed,Has Results,Anorexia Nervosa|Eating Disorder|Anxiety|Depression,Drug: Testosterone|Drug: Placebo,Change From Baseline in Weight|Change From Baseline in Depression Symptom Severity,Massachusetts General Hospital|National Institute of Mental Health (NIMH),Female,18 Years to 45 Years   (Adult),Phase 2,90,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2009P-001845/1|5R01MH083657-05A2,Apr-10,Feb-16,Feb-16,12-May-10,26-Apr-17,10-Aug-17,"Massachusetts General Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT01121211
NCT01118780,A Study of Duloxetine in Elderly Generalized Anxiety Disorder,,Completed,Has Results,Generalized Anxiety Disorder,Drug: Duloxetine|Drug: Placebo,"Change From Baseline to Week 10 in Hamilton Anxiety Rating Scale (HAMA) Total Score|Change From Baseline to Week 10 in Sheehan Disability Scale (SDS) Global Functional Impairment Score|Change From Baseline to Week 10 in Hamilton Anxiety Rating Scale (HAMA) (Psychic Anxiety Factor Score, Somatic Anxiety Factor Score, and Individual Item Scores: Anxious Mood Item and Tension Item)|Change From Baseline to Week 10 Endpoint in Hospital Anxiety Depression Scale (HADS) Subscale Scores|Clinical Global Impressions of Improvement Scale (CGI-Improvement) at Week 10|Patient's Global Impressions of Improvement Scale (PGI-Improvement) at Week 10|Change From Baseline to Week 10 in Brief Pain Inventory-Modified Short Form (BPI-SF) Pain Severity and Interference Subscales|Change From Baseline to Week 10 in Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF) Total Score|Number of Participants With Treatment-Emergent Suicide-Related Ideation and Behavior Based on the Columbia Suicide Severity Rating Scale (C-SSRS)|Change From Baseline to Week 10 in Sheehan Disability Scale (SDS) Work/School, Social Life, and Family/Home Management Individual Impairment Scores|Percentage of Participants With Response or Remission at Week 10 (Response and Remission Rates)|Percentage of Participants With Functional Remission at Week 10 (Functional Remission Rate)|Percentage of Participants With Sustained Improvement (Sustained Improvement Rate)|Adverse Events (AEs) Leading to Discontinuation From Study|Percentage of Participants Reporting Falling Down|Time to First Response|Time to First Remission|Time to Sustained Improvement Overall|Time to First Functional Remission|Time to First Improvement",Eli Lilly and Company,All,65 Years and older   (Older Adult),Phase 4,291,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",12866|F1J-MC-HMGF,Oct-10,Jul-12,Jul-12,7-May-10,2-Sep-13,2-Sep-13,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Orlando, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Prairie Village, Kansas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Baltimore, Maryland, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nashua, New Hampshire, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toms River, New Jersey, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Staten Island, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cincinnati, Ohio, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Philadelphia, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Clinton, Utah, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bellevue, Washington, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Buenos Aires, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rosario, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Santiago Del Estero, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vienna, Austria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sydney, Nova Scotia, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chatham, Ontario, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Berlin, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hattingen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Aguascalientes, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Monterrey, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chelmno, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tuszyn, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bayamon, Puerto Rico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ponce, Puerto Rico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chesterfield, United Kingdom",,https://ClinicalTrials.gov/show/NCT01118780
NCT01119469,Comparing Cognitive Therapy and Exposure Therapy in Individuals With Hypochondriasis,,Completed,No Results Available,Hypochondriasis|Somatoform Disorders,Behavioral: Psychotherapy (CT or ET),Hypochondriasis Yale-Brown Obsessive-Compulsive Scale (H-YBOCS)|Illness Attitude Scales (IAS)|Beck-Depression Inventory II (BDI-II)|Beck Anxiety Inventory (BAI)|Brief Symptom Inventory (BSI)|Scale for the Assessment of Illness Behavior (SAIB)|Health-related quality of life (SF-12)|Cognitions About Body and Health Questionnaire (CABAH),Goethe University|German Research Foundation,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,84,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"WE 4654/2-1, WE 4654/2-3",Jun-10,Aug-14,Aug-14,7-May-10,null,6-Aug-14,"Department of Clinical Psychology and Psychotherapy of the Wolfgang Goethe University, Frankfurt, Hessen, Germany",,https://ClinicalTrials.gov/show/NCT01119469
NCT01117467,Factors Affecting Medical Student Learning in Simulation Scenarios,,Completed,No Results Available,Learning,Other: Simulation scenario,Learning during simulation scenario as measured qualitatively,University of Oxford,All,18 Years to 60 Years   (Adult),Not Applicable,76,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),10/H0501/7,May-10,Dec-10,Dec-10,5-May-10,null,19-Jun-12,"University of Oxford, Oxford, Oxfordshire, United Kingdom",,https://ClinicalTrials.gov/show/NCT01117467
NCT01117545,Psychological Symptom Change in Veterans After Six Sessions of EFT (Emotional Freedom Techniques),,Completed,No Results Available,"Stress Disorders, Post-Traumatic",Behavioral: EFT (Emotional Freedom Techniques),PTSD Scores on the PCL-M Assessment,Soul Medicine Institute,All,"18 Years to 90 Years   (Adult, Older Adult)",Not Applicable,59,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,SMI-PTSD-5410,May-10,Jul-17,Dec-17,5-May-10,null,25-Apr-18,"Soul Medicine Institute, Santa Rosa, California, United States",,https://ClinicalTrials.gov/show/NCT01117545
NCT01117753,Research on Outpatient Adolescent Treatment for Comorbid Substance Use and Internalizing Disorders,,Completed,No Results Available,Substance-Related Disorders|Depressive Disorder|Anxiety Disorder,Behavioral: OutPatient Treatment for Adolescents (OPT-A)|Behavioral: Treatment As Usual,Substance use|Mental Health,Medical University of South Carolina|National Institute on Drug Abuse (NIDA),All,10 Years to 17 Years   (Child),Phase 2,140,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,MUSC19301|1R01DA025616-01A1,Jul-09,Jun-14,Jun-14,5-May-10,null,13-Apr-15,"Medical University of South Carolina, Department of Psychiatry & Behavioral Sciences, Family Services Research Center, Charleston, South Carolina, United States",,https://ClinicalTrials.gov/show/NCT01117753
NCT01114802,E-health Intervention for Cancer Survivors,Onward,Completed,No Results Available,Cancer,Behavioral: Project Onward website + social network|Behavioral: Project Onward website,"Depression, as measured by the Hospital Anxiety and Depression Scale (HADS)|Website utilization (e.g., number of logins, average visit length, total time spent on the site, number of exercises completed)",Northwestern University,All,"19 Years and older   (Adult, Older Adult)",Phase 1,31,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,STU00026896,Apr-10,Apr-11,Jun-11,3-May-10,null,19-Mar-14,"Northwestern University, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT01114802
NCT01114100,The Effects of Treatment With Sertraline for Noncardiac Chest Pain,,Completed,No Results Available,Panic Attacks|Chest Pain|Depression,Drug: sertraline|Drug: placebo,panic attacks|17 items Hamilton depression (HAMD) rating scale score|Hospital Anxiety and Depression Scale (HADS)reduction score|Clinical Global Impression (CGI) improvement|EuroQol (EQ-5D)score|Medical Outcomes Study 36-Item Short Form Health Survey (SF-36) score|health care costs,Maastricht University Medical Center|Pfizer,All,"18 Years and older   (Adult, Older Adult)",Phase 4,210,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MEC99-128,Jan-00,Dec-02,Dec-02,30-Apr-10,null,18-May-10,"Maastricht University Medical Centre, Maastricht, Netherlands",,https://ClinicalTrials.gov/show/NCT01114100
NCT01110343,Conventional vs Mindfulness Intervention in Parents of Children With Disabilities,PSIP,Completed,No Results Available,Psychological Stress|Depression|Anxiety,Behavioral: mindfulness intervention|Behavioral: Conventional parent Support Group,"Parenting Stress Index Scores|Beck Depression Inventory, Parenting Stress Index, Epworth Sleep Scale, Positive Affect Index, Life Satisfaction Scale, Mindfulness Questionnaire, Ryff's Well being Scale, Health Questionnaire, Achenbach Child Behavior Checklist|Beck Anxiety Inventory|Salivary Cortisol measures|Ryff's scale of Well-being",Vanderbilt University|National Institutes of Health (NIH)|National Center for Complementary and Integrative Health (NCCIH),All,"17 Years to 85 Years   (Child, Adult, Older Adult)",Not Applicable,243,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,090965|1RC1AT005612-01,Feb-10,Jan-13,Jan-13,26-Apr-10,null,4-Jun-15,"Vanderbilt University, Nashville, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT01110343
NCT01108393,Efficacy of Agomelatine in Patients With Obsessive-Compulsive Disorder,,Completed,No Results Available,Obsessive Compulsive Disorder,Drug: Agomelatine A|Drug: Placebo,Y-BOCS total score|NIMH-OC score|MADRS total score,Servier,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,74,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",CL2-20098-072|2009-016713-20,May-10,Aug-12,Apr-13,22-Apr-10,null,11-Apr-18,"Department of Psychiatry Chaim Sheba Medical Center, Tel Hashomer, Israel",,https://ClinicalTrials.gov/show/NCT01108393
NCT01107704,Family Support Intervention in Intensive Care Units (The Four Supports Study),,Completed,No Results Available,Physician-Family Communication in Intensive Care Units|Surrogate Decision-making for Critically Ill Patients,Behavioral: Family Support Intervention,Family Outcome: Family members' depressive symptoms|Patient Outcome: Patient centeredness of care,University of Pittsburgh|National Institute on Aging (NIA),All,"50 Years and older   (Adult, Older Adult)",Not Applicable,159,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,K23AG032875,Apr-10,Aug-13,Aug-13,21-Apr-10,null,27-Jan-14,"University of Pittsburgh Medical Center (UPMC), Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT01107704
NCT01102764,Prolonged Exposure (PE) for Post Traumatic Stress Disorder (PTSD): Telemedicine Versus In Person,,Completed,Has Results,PTSD,Behavioral: Telemedicine|Behavioral: In Person,Treatment Completion|PTSD Checklist-Military (PCL-M)|Beck Depression Inventory-II (BDI-II)|Clinician Administered PTSD Scale for DSM-IV (CAPS IV)|Deployment Risk and Resiliency Inventory (DRRI)|Health Related Functioning: Medical Outcome Study (MOS) Short Study Forms-36 Health Survey (SF 36)|Charleston Psychiatric Outpatient Satisfaction Scale (CPOSS-VA)|Treatment Credibility|Service Delivery Perceptions Questionnaire|Structured Clinical Interview for DSM-IV (SCID-I)|Prior Experience With Computer and Audiovisual Technology,VA Office of Research and Development|University of Pennsylvania|University of Hawaii,All,"21 Years to 99 Years   (Adult, Older Adult)",Not Applicable,150,U.S. Fed|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Health Services Research",IAC 09-040|19695,Oct-10,Jun-15,Sep-15,13-Apr-10,1-Sep-16,4-Mar-19,"Ralph H. Johnson VA Medical Center, Charleston, SC, Charleston, South Carolina, United States",,https://ClinicalTrials.gov/show/NCT01102764
NCT01102803,D-Cycloserine to Enhance Cognitive Behavioral Therapy (CBT) for Acrophobia,,Completed,Has Results,Phobic Disorders,Behavioral: Individual Cognitive Behavioral Therapy (CBT)|Drug: D-Cycloserine|Drug: Placebo,Acrophobia Questionnaire With Avoidance (AAVQ)|Attitudes Towards Heights Questionnaire (ATHQ)|Clinical Global Improvement Scale (CGI)|Behavioral Avoidance Test (BAT),Southern Methodist University,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,40,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",KS09-81,Apr-10,Jul-11,Jul-11,13-Apr-10,21-Feb-13,21-Feb-13,"Southern Methodist University, Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT01102803
NCT01100255,Pilot Study of Ketamine in Adults With Obsessive-Compulsive Disorder (OCD),,Completed,Has Results,Obsessive-Compulsive Disorder,Drug: Ketamine infusion|Other: Saline,Number of Patients Who Met and Exceeded Response Criteria of Yale-Brown Obsessive-Compulsive Scale.,New York State Psychiatric Institute,All,18 Years to 55 Years   (Adult),Phase 2,15,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)",6906R/5883,Apr-10,Dec-15,Dec-15,8-Apr-10,27-Oct-16,20-Feb-17,"New York State Psychiatric Institute, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT01100255
NCT01100268,Enhancing Attention in Adults With Compulsive Hoarding,,Completed,Has Results,Hoarding Disorder,Drug: Methylphenidate ER,Number of Patients Who Met and Exceeded Response Criteria of Attention Deficit Hyperactivity Disorder Symptom Scale|Number of Patients Who Met Response Criteria for the Saving Inventory-Revised.,New York State Psychiatric Institute|Hartford Hospital,All,18 Years to 50 Years   (Adult),Phase 2,4,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,6133,Apr-10,Apr-11,Apr-11,8-Apr-10,15-Aug-13,18-Sep-14,"Institute of Living, Hartford, Connecticut, United States|New York State Psychiatric Insitute, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT01100268
NCT01098695,Early Family-Centered Prevention of Drug Use Risk (Aka Early Steps),Early Steps,Completed,No Results Available,Substance Use|Conduct Disorder|Depression|Anxiety,Other: Ecological Family Intervention and Treatment (EcoFIT),Home visit assessment,University of Oregon|University of Pittsburgh|University of Virginia,All,2 Years to 3 Years   (Child),Not Applicable,731,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,3R01DA016110,Mar-03,Nov-15,Nov-15,5-Apr-10,null,21-Jan-19,"University of Oregon-Child and Family Center, Eugene, Oregon, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|University of Virginia, Charlottesville, Virginia, United States",,https://ClinicalTrials.gov/show/NCT01098695
NCT01093976,Marinol in Trichotillomania or Obsessive Compulsive Disorder,,Completed,Has Results,Trichotillomania|Obsessive Compulsive Disorder,Drug: Dronabinol,Massachusetts General Hospital Hairpulling Scale (MGH-HPS) Total Score,University of Chicago,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,14,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0909M72088,Apr-10,Jan-11,Feb-11,26-Mar-10,27-Sep-13,27-Sep-13,"Ambulatory Research Center, Minneapolis, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT01093976
NCT01093053,Mind-Body Skills Groups for the Treatment of War Zone Stress in Military and Veteran Populations,,Completed,No Results Available,"Stress Disorders, Post Traumatic|Brain Injuries|Depressive Disorder|Anxiety Disorders|Anger",Behavioral: Mind-Body Skills Groups|Other: Standard Treatment,PTSD checklist - military version|State-Trait Anger Expression Inventory-2|The Pittsburgh Sleep Quality Index|The Patient Health Questionnaire-9|State-Trait Anxiety Inventory|The Posttraumatic Growth Inventory|The Medical Outcomes Study Short Form SF-36|The Inventory of Functional Impairment,The Center for Mind-Body Medicine|U.S. Army Medical Research and Materiel Command|Southeast Louisiana Veterans Health Care System,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,108,Other|U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,8144040,Sep-10,Sep-13,Sep-13,25-Mar-10,null,29-Jan-14,"Southeast Louisiana Veterans Healthcare System, New Orleans, Louisiana, United States",,https://ClinicalTrials.gov/show/NCT01093053
NCT01093313,Attention Training and Cognitive Therapy,,Completed,No Results Available,Social Phobia,Behavioral: Cognitive therapy|Behavioral: attention training,,University of Sydney,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,46,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,USydney9274,Aug-06,Apr-07,Mar-08,25-Mar-10,null,25-Mar-10,"The University of Sydney, Sydney, New South Wales, Australia",,https://ClinicalTrials.gov/show/NCT01093313
NCT01089764,Couplelinks.ca - An Online Intervention for Couples Affected by Breast Cancer,couplelinks,Unknown status,No Results Available,Distress|Breast Cancer|Depression|Anxiety,Behavioral: Couplelinks.ca website,Revised Dyadic Adjustment Survey RDAS|Dyadic Coping,Canadian Breast Cancer Research Alliance|York University|Sunnybrook Health Sciences Centre|British Columbia Cancer Agency|CancerCare Manitoba|Queen Elizabeth II Health Sciences Centre,All,18 Years to 53 Years   (Adult),Phase 3,260,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,H10-00300,Nov-10,May-15,Jun-15,19-Mar-10,null,14-Aug-13,"British Columbia Cancer Agency Research Centre, Vancouver, British Columbia, Canada|CancerCare Manitoba, Winnipeg, Manitoba, Canada|Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada|York University, Toronto, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT01089764
NCT01088542,The Community Youth Development Study: A Test of Communities That Care,CYDS III,Completed,No Results Available,Substance Abuse|Juvenile Delinquency|Sexual Behavior|Criminal Behavior|Violence|Depression|Anxiety|Suicide|Sexually Transmitted Infection|Educational Attainment,Behavioral: Communities That Care,"Targeted risk and protective factors, substance use, delinquency, violence|CTC coalition functioning, prevention system transformation, evidence-based program (EBP) implementation|Substance use disorder, depression and generalized anxiety disorder, sexual risk behavior",University of Washington|National Institute on Drug Abuse (NIDA),All,"10 Years and older   (Child, Adult, Older Adult)",Not Applicable,52323,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,STUDY00000692|R01DA015183,Oct-03,Dec-16,Dec-16,17-Mar-10,null,18-May-17,"University of Washington, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT01088542
NCT01081249,Effects of Oxytocin on Behavior and Physiology in a Psychotherapy Setting,OT-PT,Completed,Has Results,Behavior|Anxiety,Drug: Placebo then intranasal oxytocin|Drug: Intranasal oxytocin then placebo,Verbal and Nonverbal Behavior in Therapy Session: Effects of Drug|Salivary Cortisol|Heart Rate Variability (HRV)|Subjective Ratings of Anxiety and Trust of the Therapist,"MacDonald, Kai, M.D.",Male,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,18,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",UCSD IRB 080953,Dec-08,Jul-12,Jul-12,5-Mar-10,16-Oct-14,16-Oct-14,"Kai MacDonald, MD 3368 2nd Ave Ste B, San Diego, California, United States",,https://ClinicalTrials.gov/show/NCT01081249
NCT01076777,Physical Exercise Versus Cognitive-behavioral Therapy (CBT) for Panic Disorders: A Randomised Controlled Trial,,Completed,No Results Available,Panic Disorder,Behavioral: Physical exercise|Behavioral: Cognitive-behavioral therapy,Mobility Inventory (MI) - Alone & Accompanied|Agoraphobic Cognitions Questionnaire (ACQ)|Body Sensations Questionnaire|Panic frequency - Self-report & Clinician-rating|Panic distress/disability - Self-report & Clinician-rating|Beck Anxiety Inventory (BAI)|State-Trait Anxiety Inventory - State & Trait (STAI S/T)|Beck Depression Inventory II (BDI-II)|Quality of Life Inventory (QoLI),University of Bergen|Norwegian Department of Health and Social Affairs,All,18 Years to 50 Years   (Adult),Phase 2,36,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,3.2007.499 (REK),May-07,Dec-09,Dec-09,26-Feb-10,null,26-Feb-10,"Solli Hospital, Bergen, Nesttun, Norway",,https://ClinicalTrials.gov/show/NCT01076777
NCT01075672,Outcomes of Cognitive Behavioral Therapy (CBT) Interventions Provided by Unlicensed Professionals,,"Active, not recruiting",No Results Available,Obsessive Compulsive Disorder|Body Dysmorphic Disorder|Tourette Syndrome|Trichotillomania|Panic Disorder|Social Phobia|Generalized Anxiety Disorder|Depression|Post-Traumatic Stress Disorder|Attention Deficit Hyperactivity Disorder|Eating Disorder|Specific Phobia|General Medical Condition,Behavioral: Cognitive behavioral therapy (CBT),The Schwartz Outcome Scale (SOS-10),Massachusetts General Hospital,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,250,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2009P002479,Jan-10,Jan-20,Jan-20,25-Feb-10,null,7-May-18,"Cognitive-Behavioral Therapy and Behavioral Medicine Programs, Massachusetts General Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT01075672
NCT01072344,Long Term Chamomile Therapy for Anxiety,,Completed,Has Results,Generalized Anxiety Disorder,Drug: Chamomile (Matricaria recutita),"Time to Relapse in Each Treatment Condition.|The Proportion of Subjects in Each Treatment Condition Who Relapse.|Frequency, Severity, and Duration of Treatment-emergent Adverse Events.|Frequency of Discontinuation Symptoms at the Start of Double-blind Therapy in Each Treatment Condition.|Frequency of Early Study Discontinuation in Each Treatment Condition.",University of Pennsylvania,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,180,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AT005074,Feb-10,Jun-15,Jun-15,22-Feb-10,6-Jul-17,6-Jul-17,"Depression Research Unit, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT01072344
NCT01066143,Generalized Anxiety and Seroquel,GAD,Terminated,Has Results,Generalized Anxiety Disorder|Seroquel XR,Drug: Seroquel XR,Change From Baseline in GAD Symptomatology at the Week 12 Timepoint.,Mclean Hospital,All,18 Years to 55 Years   (Adult),Not Applicable,8,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2009-P-001662,Feb-10,Feb-13,Feb-13,10-Feb-10,17-May-17,17-May-17,"McLean Hospital, Belmont, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT01066143
NCT01066299,Influence of Oxytocin on the Startle Reflex and on Its Modulation,,Unknown status,No Results Available,Psychiatric Disorders,Drug: Syntocinon®|Drug: inactive nasal spray,Eye blink response to the tones measured as the peak activity of the left musculus orbicularis oculi that will be compared between the active drug and the placebo conditions.|Anxiety ratings assessed with the State-Trait-Inventory that will used as a covariate in the ANOVAs.,University of Zurich|University of Basel|University of Freiburg,Male,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,50,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",OXT_PSY1,May-10,Sep-12,Dec-12,10-Feb-10,null,29-Nov-11,"University Hospital Zurich, Division of Psychiatry and Psychotherapy, Zurich, Switzerland",,https://ClinicalTrials.gov/show/NCT01066299
NCT01064700,Bright Light: A Novel Treatment for Anxiety,,Completed,No Results Available,Anxiety|Depression|Sleep,Device: Litebook Bright Light Box|Device: Litebook inactivated negation ion generator (the placebo),Spielberger State Anxiety Inventory|Hamilton Anxiety|Beck Depression Inventory|Pittsburgh Sleep Quality Inventory,University of South Carolina|Liteboook Company,All,18 Years to 35 Years   (Adult),Phase 1,33,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",HSA-3469,Oct-06,Dec-07,Dec-07,8-Feb-10,null,8-Feb-10,"Chronobiology Lab, University of South Carolina, Columbia, South Carolina, United States",,https://ClinicalTrials.gov/show/NCT01064700
NCT01061983,Electrical Stimulation of the Internal Capsule for Intractable Obsessive-compulsive Disorder (OCD),,Completed,No Results Available,Obsessive-Compulsive Disorder,Device: Medtronic Activa Deep Brain Stimulation,"Obsessive-compulsive disorder (OCD) severity (Yale-Brown Obsessive-Compulsive Scale)|Depression severity (Hamilton Depression Scale), Anxiety (Hamilton Anxiety Scale), and neuropsychological battery.",Butler Hospital|Medtronic,All,18 Years to 55 Years   (Adult),Phase 2,5,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,204,Jan-01,Apr-04,Oct-12,4-Feb-10,null,25-Feb-13,"Butler Hospital, Providence, Rhode Island, United States",,https://ClinicalTrials.gov/show/NCT01061983
NCT01062646,Multimodal Music Therapy for Children With Anxiety Disorders,,Completed,No Results Available,Anxiety,Behavioral: Multimodal music therapy|Behavioral: Community treatment as usual,Diagnosis of an anxiety disorder (DSM IV),University of Ulm,All,8 Years to 12 Years   (Child),Phase 3,36,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MUSICANXCHILD,May-06,Dec-08,Sep-09,4-Feb-10,null,4-Feb-10,,,https://ClinicalTrials.gov/show/NCT01062646
NCT01059578,First Study in Humans With GSK206136,NSB101909,Completed,No Results Available,Depressive Disorder and Anxiety Disorders,Drug: GSK206136|Drug: PLACEBO|Radiation: PET,"Adverse event monitoring, vital signs (blood pressure, heart rate, ECGs, clinical laboratory assessments (standard laboratory parameters); pharmacokinetics parameters: AUC, Cmax, t1/2|Brain receptor occupancy",GlaxoSmithKline,Male,18 Years to 45 Years   (Adult),Phase 1,33,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",101909,23-May-06,18-Dec-06,18-Dec-06,1-Feb-10,null,10-Aug-17,"GSK Investigational Site, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01059578
NCT01059591,First Study in Humans With GSK424887,,Completed,No Results Available,Depressive Disorder and Anxiety Disorders,Drug: GSK424887|Drug: Placebo|Radiation: PET,"Adverse event monitoring, vital signs (blood pressure, heart rate, ECGs, clinical laboratory assessments (standard laboratory parameters); Area under the concentration-time curve (AUC), Maximum observed concentration (Cmax) , tmax|Brain receptor occupancy",GlaxoSmithKline,Male,18 Years to 45 Years   (Adult),Phase 1,26,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",105011,25-May-06,25-Jan-07,25-Jan-07,1-Feb-10,null,11-Aug-17,"GSK Investigational Site, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01059591
NCT01056458,Auricular Acupressure for Perimenopausal Women With Anxiety,AAA,Unknown status,No Results Available,Auricular Acupressure|Anxiety|Menopause|Insomnia,Other: auricular acupressure|Other: sham acupressure,"Hamilton Anxiety Rating Scale|Menopause Rating Scale,Short Form Health Survey(SF-36),CGI",Chang-Hua Hospital|China Medical University Hospital,Female,40 Years to 60 Years   (Adult),Not Applicable,90,Other,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",98DMR291,Jan-10,Jan-11,Jan-11,26-Jan-10,null,31-May-10,"Chang-Hua Hospital, Changhua, Taiwan",,https://ClinicalTrials.gov/show/NCT01056458
NCT01053637,Pain and Anxiety Management With Oral Narcotic for Pediatric Suture Repair,,Completed,No Results Available,Children|Lacerations|Procedures|Child|Pain,Drug: hydrocodone/acetaminophen|Drug: Sugar water,Statistical difference in pain scores in children during laceration repair between study and placebo group|Statistical difference in State-Trait Anxiety Inventory for Children (STAIC) scores for children age 8-17 years during laceration repair,Texas Children's Hospital,All,2 Years to 17 Years   (Child),Not Applicable,85,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",H-22684,Feb-09,Jan-12,May-15,21-Jan-10,null,13-May-15,"Baylor College of Medicine, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT01053637
NCT01050465,MedlinePlus Health Prescriptions: Developing a Pragmatic Approach for Clinic Use,,Completed,No Results Available,Acne Vulgaris|Allergic Rhinitis|Anxiety|Asthma|Back Pain|Prostatic Hyperplasia|Bursitis|Chronic Obstructive Pulmonary Disease|Cough|Coronary Artery Disease|Depression|Diabetes Mellitus|Diarrhea|Gastroesophageal Reflux|Fibromyalgia|Headache|HIV Infections|Hypothyroidism|Hyperlipidemia|Hypertension|Influenza|Sleep Initiation and Maintenance Disorders|Irritable Bowel Syndrome|Migraine Disorders|Obesity|Obstructive Sleep Apnea|Osteoarthritis|Senile Osteoporosis|Shoulder Pain|Sinusitis|Smoking Cessation|Tobacco Use Cessation|Menopause|Urinary Incontinence|Urinary Tract Infection|Vaginitis|Vertigo,Other: health information prescription,seeking information using MedlinePlus,University of Missouri-Columbia|National Library of Medicine (NLM),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,907,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),HHSN276200800445P,May-09,Oct-10,Dec-10,15-Jan-10,null,30-Sep-16,,,https://ClinicalTrials.gov/show/NCT01050465
NCT01049477,The Effects of Music Therapy on Women's Anxiety Before and During Cesarean Delivery,,Completed,No Results Available,Pregnancy|Cesarean Section,Other: Music group|Other: Non music group,The intervention of patient-selected music before and after Cesarean delivery will decrease anxiety levels in a patient population undergoing Cesarean delivery.,Wake Forest University|Wake Forest University Health Sciences,Female,18 Years to 50 Years   (Adult),Not Applicable,50,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Supportive Care,FMC 2007-0906,Sep-08,Dec-14,Dec-14,14-Jan-10,null,8-Nov-17,"Forsyth Medical Center, Winston-Salem, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT01049477
NCT01048164,Measuring the Effect of Therapeutic Massage on Pain and Discomfort in Cardiac Cath Lab Staff,,Completed,No Results Available,Stress|Fatigue|Anxiety,Procedure: Massage,"Compare and contrast the level of pain and discomfort in staff that wear lead aprons at baseline, end of first 5-weeks of massage therapy, end of the second 5-weeks of massage therapy and to those that do not get massage during that same period.|Compare the level of stress, anxiety, and relaxation in staff that wear lead aprons, at baseline, end of first 5-weeks of massage therapy, end of the second 5-weeks of massage therapy and to those that do not get massage during that same period.",Mayo Clinic,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,08-000190,Apr-08,Jul-08,Jul-08,13-Jan-10,null,5-Jan-12,"Mayo Clinic, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT01048164
NCT01043900,Efficacy of Repetitive Transcranial Magnetic Stimulation (rTMS) as an add-on Treatment for Resistant OCD,,Completed,No Results Available,Obsessive-Compulsive Disorder,Procedure: repetitive transcranial magnetic stimulation (rTMS),"A reduction of at least 30 % in the Yale-Brown Obsessive Compulsive Scale (YBOCS) scores and an ""improved"" or ""much improved"" score on the Clinical Global Impression (CGI) improvement scale by the end of follow-up",University of Sao Paulo General Hospital,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,30,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",cgmansur01,Aug-03,Aug-09,Aug-09,7-Jan-10,null,7-Jan-10,,,https://ClinicalTrials.gov/show/NCT01043900
NCT01040611,Effectiveness of Music Therapy,TMT,Unknown status,No Results Available,Tuberculosis,Behavioral: Music therapy,"Effectiveness of music therapy on anxiety, depression and physiological responses",Taipei Medical University WanFang Hospital,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,66,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care,EVA98-13,Oct-09,Sep-10,Sep-10,29-Dec-09,null,19-Nov-10,"Taipei Medical University -WanFang Hospital, Taipei, Taiwan",,https://ClinicalTrials.gov/show/NCT01040611
NCT01038570,Comparative Study Between Prader-Willi Patients Who Take Oxytocin Versus Placebo,,Completed,No Results Available,Prader Willi Syndrome,Drug: Syntocinon®/- Spray|Drug: Physiological serum (Sodium chloride),"Result scores at Psychological tests : ""Reading the mind in the eyes"" (RMET), Tests for evaluation of the ""theory of mind"" : Sally and Ann, Cartoons,""L'esprit des autres"", ""Social Attribution Task"" (SAT).|Result scores at daily stress, anxiety and eating behavior tests","University Hospital, Toulouse",All,"18 Years and older   (Adult, Older Adult)",Phase 2,24,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",09 071 03,Jun-09,Sep-09,Sep-09,24-Dec-09,null,12-May-17,"Hôpital marin d'Hendaye, Hendaye, Pyrénées-Atlantiques, France",,https://ClinicalTrials.gov/show/NCT01038570
NCT01038882,Randomized Study With Midazolam for Sedation in Flexible Bronchoscopy,,Completed,No Results Available,Sedation|Tolerance|Anxiety|Satisfaction,Drug: Midazolam|Other: Physiological serum,To analyse if the use of a local anaesthetic with midazolam whilst performing an flexible bronchoscopy improves the quality of examination in terms of tolerance for the patient|To know if there is an improvement in the acceptance of a second or further flexible bronchoscopy and if this improves the satisfaction of the bronchoscopist as far as the examination performed is concerned,Hospital Universitario La Fe,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,238,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)",HLaFe 324/08,Oct-08,Jan-09,Jan-09,24-Dec-09,null,24-Dec-09,"Hospital Universaitario La Fe, Valencia, Spain",,https://ClinicalTrials.gov/show/NCT01038882
NCT01038960,"Exercise Training in ICD Recipients; Effect on Therapy Delivered, Depression and Anxiety",ETHIC,Completed,No Results Available,Ventricular Tachycardia,Behavioral: Exercise training,"Therapy delivered from ICD, Anxiety score, functional status|HRV, Endothelial function",Helse Stavanger HF|Stavanger Health Research,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,40,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ETHIC-SUS-AIL-09|068.08,Apr-08,Dec-12,Dec-12,24-Dec-09,null,25-Aug-16,"Stavanger Health Research, Stavanger, Norway",,https://ClinicalTrials.gov/show/NCT01038960
NCT01037101,D-Cycloserine-Enhancer of One-Session Treatment for Phobia of Heights,,Unknown status,No Results Available,Height Phobia,Behavioral: In Vivo Exposure Therapy|Behavioral: Virtual Reality Exposure Therapy|Drug: D-Cycloserine|Drug: Placebo,"Specific Phobia (acrophobia) diagnosis based on Anxiety Disorders Interview Schedule-IV (ADIS-IV)|Physiological responses to phobia-related stimuli, percentage of steps completed and Subjective Units of Distress during a Behavioral Avoidance Test (BAT)",CAMC Health System|West Virginia University|University of Charleston,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,80,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",07-01-1896,Jul-09,Dec-14,Dec-14,21-Dec-09,null,14-Oct-13,"West Virginia University School of Medicine Charleston Division, Charleston, West Virginia, United States",,https://ClinicalTrials.gov/show/NCT01037101
NCT01035242,"""Association Splitting"" in Obsessive-Compulsive Disorder (OCD)",,Completed,No Results Available,Obsessive-Compulsive Disorder,"Behavioral: ""association splitting""|Behavioral: cognitive remediation",Total score of the Yale-Brown Obsessive Compulsive Scale (Y-BOCS)|Obsession subscore of the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) and the total score of the Obsessive-Compulsive Inventory (OCI-R),Universitätsklinikum Hamburg-Eppendorf|German Research Foundation,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,156,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,JE 540/3-1,Mar-09,Jul-12,Jul-12,18-Dec-09,null,25-Mar-15,"University Medical Center Hamburg Eppendorf, Hamburg, Germany",,https://ClinicalTrials.gov/show/NCT01035242
NCT01035294,A Mindfulness-based Intervention for Treatment of Anxiety in ICD (Implantable Cardioverter Defibrillator) Patients,,Completed,No Results Available,Anxiety Disorder in Conditions Classified Elsewhere,Behavioral: mindfulness based intervention (MBI)|Behavioral: usual care,Study feasibility|Hospital Anxiety and Depression (HAD) anxiety scores|Five Factors of Mindfulness scores (FFM),"University of Massachusetts, Worcester|National Center for Complementary and Integrative Health (NCCIH)",All,"21 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,46,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,H-13078|1F32AT005048-01A1,Jul-09,Dec-11,Dec-11,18-Dec-09,null,30-Jan-12,"UMass Memorial Medical Center, Worcester, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT01035294
NCT01033851,Stress Reduction Techniques and Anxiety: Therapeutic and Neuroendocrine Effects,,Completed,Has Results,Generalized Anxiety Disorder,Behavioral: Mindfulness Based Stress Reduction|Behavioral: Stress Management Education,Active Symptoms of Generalized Anxiety Disorder|Clinical Global Impression of Severity (CGIS) of Anxiety Symptoms.,Massachusetts General Hospital|National Center for Complementary and Integrative Health (NCCIH),All,"18 Years and older   (Adult, Older Adult)",Phase 4,89,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",2008-P-000275|5K23AT004432,Mar-08,Jan-12,Feb-13,17-Dec-09,11-Jun-13,4-Jun-14,"Massachusetts General Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT01033851
NCT01033136,Exposure Therapy For Veterans With PTSD And Panic Attacks,,Completed,Has Results,PTSD|Panic Attacks,Behavioral: Multiple Channel Exposure Therapy - Veterans|Behavioral: Cognitive Processing Therapy,Change in PTSD Symptoms (CAPS) Between MCET-V and CPT Groups|Change in PDSS Scores Over Time for MCET-V and CPT Groups,VA Office of Research and Development,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,93,U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,CDA2-012-09F,1-Jan-13,30-Sep-16,1-Jan-17,16-Dec-09,20-Jul-18,17-Sep-18,"Michael E. DeBakey VA Medical Center, Houston, TX, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT01033136
NCT01031927,N-methyl Glycine (Sarcosine) for the Treatment of Obsessive Compulsive Disorder (OCD),,Completed,No Results Available,Obsessive Compulsive Disorder,Drug: N-methyl glycine,Yale-Brown Obsessive Compulsive Scale|Hamilton Anxiety Rating scale,China Medical University Hospital|Taipei City Hospital,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,30,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DMR96-IRB-75,Jun-07,Feb-09,null,15-Dec-09,null,29-Dec-09,"China Medical University Hospital, Taichung, Taiwan",,https://ClinicalTrials.gov/show/NCT01031927
NCT01031186,First Time in Human Study,FTIM,Completed,No Results Available,Depressive Disorder and Anxiety Disorders,Drug: GSK356278|Drug: PLACEBO,To assess safety and tolerability of single escalating oral doses of GSK356278 in healthy male volunteers|To investigate the pharmacokinetics of single escalating doses of GSK356278 in healthy male volunteers,GlaxoSmithKline,Male,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,20,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,113324,23-Nov-09,7-Apr-10,7-Apr-10,14-Dec-09,null,27-Jul-17,"GSK Investigational Site, Randwick, New South Wales, Australia",,https://ClinicalTrials.gov/show/NCT01031186
NCT01031511,Effect of Cognitive Behavioural Therapy (CBT) for Children With Autistic Spectrum Disorders,,Unknown status,No Results Available,Autism Spectrum Disorder|Anxiety,Behavioral: Cognitive Behavioural Therapy|Other: Social Recreational,Anxiety level of child|Parent Stress Level,"National Healthcare Group, Singapore|Nanyang Technological University|Autism Resource Centre, Singapore",All,9 Years to 16 Years   (Child),Early Phase 1,73,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,DSRB Ref Code: A/05/091|NMRC/1002/2005|130/2005,Jun-05,Jan-10,Feb-11,14-Dec-09,null,14-Dec-09,"Institute of Mental Health, Singapore, Singapore, Singapore",,https://ClinicalTrials.gov/show/NCT01031511
NCT01025908,Cognitive Behavior Psychotherapy in Panic Disorder,,Completed,No Results Available,Panic Disorder|Agoraphobia,Behavioral: Psychotherapy|Behavioral: Supportative psychotherapy,Number of panic attacks|Decrease agoraphobic symptoms,Universidade Federal do Rio de Janeiro,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,50,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,LABPR,May-06,Aug-06,Apr-07,4-Dec-09,null,1-Feb-10,"Institute of Psychiatry - UFRJ, Rio de Janeiro, RJ, Brazil",,https://ClinicalTrials.gov/show/NCT01025908
NCT01018992,Evaluation of GSK561679 in Women With Post-Traumatic Stress Disorder,,Completed,Has Results,"Stress Disorders, Post-Traumatic",Drug: GSK561679|Drug: Placebo,"Efficacy, Measured by Change in the Clinician-Administered PTSD Scale (CAPS) Score|Efficacy, Measured by Response Rate of at Least 50% Improvement in CAPS Score at the End of 6 Weeks as Compared to Baseline|Efficacy, Measured by Change in the Montgomery-Asberg Depression Rating Scale (MADRS) Score|Safety, Measured by the Number of Subjects That Experienced an Adverse Event",Emory University|Icahn School of Medicine at Mount Sinai,Female,"21 Years to 65 Years   (Adult, Older Adult)",Phase 2,267,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Diagnostic",IRB00022717|MH069056,Dec-09,Aug-14,Aug-14,25-Nov-09,30-Jul-15,7-Mar-17,"Stress and Health Research Program, San Francisco VA Medical Center, University of California San Francisco, San Francisco, California, United States|Emory University, Atlanta, Georgia, United States|Mount Sinai School of Medicine, New York, New York, United States|Baylor College of Medicine, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT01018992
NCT01020032,Effect of Music Therapy on Pain,,Completed,No Results Available,Chronic Pain,"Other: Individual receptive music therapy by ""U sequence"" method",Score on a Visual Analogical Scale (VAS) for actual pain|Score on the Hospital Anxiety and Depression (HAD) Scale|Medicinal consumption,Association de Musicothérapie Applications et Recherches Cliniques|Centre d'Evaluation et du Traitement de la Douleur CHU Saint-Eloi|Unité de Recherche Clinique et Epidémiologie (DIM) CHU Arnaud de Villeneuve|Centre Mémoire de Ressource et de Recherche équipe INSERM U888 CHU Montpellier,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,87,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,AMARC 200801,Sep-06,Nov-08,Dec-08,25-Nov-09,null,25-Nov-09,"CHRU Saint Eloi, Centre d'Evaluation et du Traitement de la Douleur, Montpellier, France",,https://ClinicalTrials.gov/show/NCT01020032
NCT01015586,Treatment of Alcohol Dependence and Comorbid Bipolar Disorder,,Completed,Has Results,Alcohol Dependence|Bipolar Disorder|Depression|Mania|Psychosis,Drug: Lamotrigine|Drug: Placebo,Percent Days Abstinent From Alcohol|Percent Heavy Drinking Days|Biomarkers of Alcohol Use: Carbohydrate-deficient Transferrin (CDT)|Biomarkers of Alcohol Use: Gamma-glutamyltransferase (GGT)|Montgomery-Asberg Depression Rating Scale (MADRS) Score|Young Mania Rating Scale (YMRS) Scores|Neurocognitive Performance (California Verbal Learning Test),Medical University of South Carolina|National Institute on Alcohol Abuse and Alcoholism (NIAAA),All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,43,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",HR#19550|K23AA017666,Feb-10,May-14,Sep-14,18-Nov-09,9-Jan-19,9-Jan-19,"Clinical Neuroscience Division, Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, South Carolina, United States",,https://ClinicalTrials.gov/show/NCT01015586
NCT01013363,The Use of Music for Pain and Anxiety Control During Abortion,,Completed,No Results Available,Pain|Anxiety,Other: iPod Nano digital music player,Pain and anxiety experienced during first trimester abortion.|Heart rate and blood pressure changes.|Overall patient satisfaction.|Provider assessment of patient's pain.,Columbia University|Family Planning Fellowship,Female,"Child, Adult, Older Adult",Not Applicable,106,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AAAE0439,Sep-09,Dec-09,Dec-09,13-Nov-09,null,19-Nov-12,"Columbia University, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT01013363
NCT01006187,Comparison of Different Methods for Reducing Pain From Influenza Vaccine Injections,,Completed,No Results Available,Pain|Anxiety,Drug: Liposomal lidocaine|Drug: Vapocoolant spray|Other: Rubbing adjacent to the injection site|Other: Distraction,Pain from adult intramuscular influenza virus injection|Adverse Events|Anxiety,The Hospital for Sick Children,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,352,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,1000014280,Oct-09,Nov-09,Nov-09,2-Nov-09,null,19-Jul-11,"The Hospital for Sick Children, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT01006187
NCT01004302,Radiosurgical Treatment for Obsessive-compulsive Disorder,,Terminated,No Results Available,Obsessive-compulsive Disorder,Procedure: ventral capsular/ventral striatal gamma capsulotomy,"A reduction of at least 35 % in the Yale-Brown Obsessive Compulsive Scale (YBOCS) scores and an ""improved"" or ""much improved"" score on the Clinical Global Impression (CGI) scale",University of Sao Paulo General Hospital|Brown University,All,18 Years to 60 Years   (Adult),Phase 2,16,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CAPPesq 521/02|CAPPesq 0968/05|CONEP 4891,Jul-03,Jan-13,Jan-15,29-Oct-09,null,12-Oct-12,"Department and Institute of Psychiatry, General Hospital, University of São Paulo Medical School, São Paulo, SP, Brazil",,https://ClinicalTrials.gov/show/NCT01004302
NCT00997490,Study of the Antidepressant Efficacy of a Combination Herbal Drug Preparation (NEURAPAS Balance),,Terminated,No Results Available,Depressive Disorder,"Drug: Neurapas® balance (Herbal combination out of hypericum, valerian, passionflower)|Drug: film-coated sugar-pill",HAM-D 21|Self-Rating Depression Scale (SDS)|HAMILTON Anxiety Scale (HAM-A)|Clinical Global Impressions (CGI)|BULLINGER Quality of Life questionnaire (SF-36)|Sleep questionnaire (SQ),Pascoe Pharmazeutische Praeparate GmbH,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,67,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",PSC 120/99,Jan-01,Jul-02,Feb-03,19-Oct-09,null,17-May-10,"Dr. Urlea-Schoen, Siegen, NRW, Germany",,https://ClinicalTrials.gov/show/NCT00997490
NCT00997893,Research Investigation of Soy and Estrogen,RISE,Completed,No Results Available,Menopause|Hot Flashes,Dietary Supplement: Phytoestrogen|Drug: Estradiol|Drug: medroxyprogesterone acetate|Other: Placebo,quality of life,University of Illinois at Chicago|National Institute of Mental Health (NIMH),Female,"40 Years to 65 Years   (Adult, Older Adult)",Phase 2,96,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2009-0052|5R01MH083782-05,Dec-09,May-15,May-15,19-Oct-09,null,27-Jul-15,"University of Illinois at Chicago, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT00997893
NCT00997087,"A Randomized, Double-Blind, Placebo-Controlled Trial of Flumazenil for the Treatment of Obsessive Compulsive Disorder",OCD,Terminated,No Results Available,Obsessive Compulsive Disorder,Drug: Flumazenil,"Yale Brown Obsessive Compulsive Score|Safety will be assessed by Adverse Events, Changes in physical exam, laboratory values.",Parkway Medical Center,All,19 Years to 60 Years   (Adult),Phase 2,11,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",JGS-001,Oct-09,Dec-12,Dec-12,16-Oct-09,null,22-Apr-14,"James G. Sullivan, MD, Birmingham, Alabama, United States",,https://ClinicalTrials.gov/show/NCT00997087
NCT00994786,A Study of Pregabalin (Lyrica) Augmentation in Serotonin Reuptake Inhibitor-Refractory Obsessive Compulsive Disorder,,Unknown status,No Results Available,Obsessive-Compulsive Disorder,Drug: pregabalin|Drug: Placebo,Yale-Brown-Obsessive-Compulsive-Scale|Clinical Global Impression - Improvement|Montgomery Asberg Depression Rating Scale|Sheehan Disability Scale|Beck Depression Inventory|Clinical Global Impression - Severity|Saving Inventory - Revised|Dimensional Yale-Brown-Obsessive Compulsive Scale (D-Y-BOCS)|Padua Inventory,McMaster University|Pfizer|Hamilton Health Sciences Corporation,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,66,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",06-273,Jan-09,Jan-19,Mar-19,14-Oct-09,null,10-Apr-18,"MacAnxiety Research Centre, Hamilton, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT00994786
NCT00992953,Virtual Reality (VR) Therapy for Post-Traumatic Stress Disorder (PTSD),,Completed,No Results Available,Post-Traumatic Stress Disorder,Behavioral: Treatment as Usual|Behavioral: Virtual Reality Exposure with Stimulus Control,,"Office of Naval Research (ONR)|Naval Hospital Camp Pendleton|Virtual Reality Medical Center|United States Naval Medical Center, San Diego",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,136,U.S. Fed|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,S-05-005,Jan-05,Oct-09,Oct-09,9-Oct-09,null,9-Oct-09,"Naval Hosptial Camp Pendleton, Camp Pendlton, California, United States|Naval Medical Center San Diego (NMCSD), San Diego, California, United States",,https://ClinicalTrials.gov/show/NCT00992953
NCT00992979,Therapeutic Massage to Manage Withdrawal Related Anxiety,,Completed,No Results Available,Substance Withdrawal Syndrome|Drug Withdrawal Symptoms|Anxiety,Procedure: Therapeutic Massage|Procedure: Relaxation Control,State and Trait Anxiety (Spielberger State Trait Anxiety Inventory of Adults (Y1 and Y2))|Heart Rate and Blood Pressure|Sleep Quality,Dalhousie University|Holistic Health Research Foundation of Canada,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,80,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment",DAL09-01|HHRFC #2007-06,Jun-08,Jan-09,Jan-09,9-Oct-09,null,9-Oct-09,"Addiction Prevention and Treatment Services; Capital District, Halifax, Nova Scotia, Canada",,https://ClinicalTrials.gov/show/NCT00992979
NCT00991770,Massage Therapy and Port-a-Catheter Insertion,,Completed,No Results Available,Cancer|Anxiety|Pain|Surgery,Other: Massage Therapy|Other: Attention Control,Efficacy of massage therapy for reducing pre-operative anxiety among predominantly low income minority cancer patients undergoing surgical placement of an implanted port.|Efficacy of massage therapy for reducing post-operative pain among predominantly low income minority cancer patients undergoing surgical placement of an implanted port.|Feasibility of using massage therapy to reduce pre-operative anxiety and post-operative pain among predominantly low income minority cancer patients undergoing surgical placement of an implanted port.|Effects of massage on the duration of the surgical procedure|Effect of massage on the amount of anesthesia used during the surgical procedure|Related costs of providing massage therapy to patients undergoing port-a-cath implantation,Boston Medical Center|Massage Therapy Foundation,All,"18 Years and older   (Adult, Older Adult)",Phase 1,60,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment",H27681,Feb-09,Oct-11,Oct-11,8-Oct-09,null,7-Dec-11,"Boston Medical Center - Ambulatory Surgery, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT00991770
NCT00990977,Mindfulness and Cancer Mamma - Clinical Trial MBSR Among Women Operated for Breast Cancer,MICA,Completed,No Results Available,Breast Cancer,Behavioral: mindfulness based stress reduction (MBSR),"SCL-90r Depression and anxiety subscales|clinical databases, containing information on BC (stage, treatment protocol) and comorbidity (other acute or chronic physical or psychiatric diseases)|standardized validated psychometric scales",Danish Cancer Society|University of Copenhagen|Herlev Hospital,Female,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2|Phase 3,336,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,DanishCS|2007-41-1654,Mar-08,Dec-10,Nov-11,7-Oct-09,null,30-Jun-15,"Danish Cancer Sociaty Research Center, Suvivorship, Copenhagen, Denmark",,https://ClinicalTrials.gov/show/NCT00990977
NCT00989937,Oxytocin Add-on Study for Stable Anxiety Patients,,Suspended,No Results Available,Anxiety Disorders,Drug: Oxytocin|Drug: Placebo,Total Score on the Hamilton Anxiety Scale (HAM-A)|Clinical Global Impression - Severity of Illness (CGI-S|Clinical Global Impression - Global Improvement (CGI-I|Social Phobia Inventory (SPIN)|The State-Trait Anxiety Inventory (STAI)|The Profile of Mood States (POMS)|Sheehan Disability Scale (SDS)|Arizona Sexual Experience Scale (ASEX)|Hamilton-Depression Scale (HAM-D)|Reading Trust in the Mind in the Eyes Test (RTET)|Childhood Trauma Questionnaire [CTQ]|Global Assessment of Functioning (GAF),"University of California, San Diego",All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,40,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",Oxytocin Anxiety,Feb-09,Apr-11,null,6-Oct-09,null,22-Dec-16,"UCSD Medical Center, San Diego, California, United States",,https://ClinicalTrials.gov/show/NCT00989937
NCT00990340,Comparison of a Needle-free Injection Method With a Needle-syringe Injection Method,T-jet®,Completed,Has Results,Growth Hormone Deficiency,Device: T-jet® containing TevTropin®|Procedure: TevTropin® needle-syringe injection method,Subject-reported Injection Anxiety Immediately Before Administration|Subject-reported Injection Pain Immediately Following Administration.|Subject or Caregiver Reported Perception of Ease of Preparation as Recorded Weekly on a 5-point Scale.|Subject or Caregiver Reported Perception of Ease of Administration as Recorded Weekly on a 5-point Scale.|Subject-reported Overall Satisfaction Following the End of Each Period of the Study.,Teva Pharmaceutical Industries,Male,7 Years to 17 Years   (Child),Phase 4,52,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PM201,Sep-09,Jun-10,Aug-10,6-Oct-09,25-Jul-11,25-Jul-11,,,https://ClinicalTrials.gov/show/NCT00990340
NCT00989365,Effect of Aerobic Training on Asthmatic Patients,,Completed,No Results Available,Anxiety|Depression|Airway Inflammation,Other: Aerobic training,"psychosocial morbidity and airway inflammation|autonomic modulation, aerobic capacity, pulmonary function",University of Sao Paulo General Hospital|Fundação de Amparo à Pesquisa do Estado de São Paulo|Conselho Nacional de Desenvolvimento Científico e Tecnológico|Laboratório de Investigação Médica,All,20 Years to 50 Years   (Adult),Not Applicable,100,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Asthmatraining,Jan-07,Sep-09,Sep-09,5-Oct-09,null,5-Oct-09,"Clinical Hospital, School of Medicine, University of São Paulo, São Paulo, Brazil",,https://ClinicalTrials.gov/show/NCT00989365
NCT00989053,The Effect of Selective Serotonin Reuptake Inhibitor (SSRI) Treatment on Affective Symptoms and Fertility Treatment Outcome in Women Undergoing in Vitro Fertilization (IVF),,Unknown status,No Results Available,Depression|Anxiety|In Vitro Fertilization,Drug: escitalopram|Drug: placebo,positive blood βHCG|psychiatric evaluation questionnaires,Tel-Aviv Sourasky Medical Center,Female,18 Years to 45 Years   (Adult),Not Applicable,120,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",TASMC-09-GAR-078-CTIL,Jan-10,Jan-12,Jan-12,2-Oct-09,null,2-Oct-09,"Tel Aviv Sourasky Medical Center, Tel Aviv, Israel",,https://ClinicalTrials.gov/show/NCT00989053
NCT00984321,A Pilot Study of Geriatric Specific Interventions for Quality of Life in Elderly Patients With Cancer,,Recruiting,No Results Available,Breast Cancer|Prostate Cancer|Lung Cancer|Lymphoma Cancer|Gynecological Cancers,Behavioral: group intervention and questionnaires|Behavioral: individual phone intervention and questionnaires|Behavioral: expressive writing (arm will not be include in the randomization),"To test the feasibility, tolerability and acceptability of a Geriatric Specific Psychoeducational Intervention (GSPI) by examining the rates of eligibility, acceptance, and adherence.|To examine the impact of these GSPI in both formats on depressive symptoms, anxiety, demoralization, coping, loneliness and isolation, and spirituality compared to the control group.",Memorial Sloan Kettering Cancer Center|Joan Karnell Cancer Center at Pennsylvania,All,70 Years and older   (Older Adult),Not Applicable,126,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,09-116,Sep-09,Sep-19,Sep-19,25-Sep-09,null,11-Dec-18,"Memorial Sloan Kettering Cancer Center, New York, New York, United States|Joan Karnell Cancer Center at Pennsylvania, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00984321
NCT00982345,Brain Imaging of Quetiapine Response in Anxious Depression,,Completed,Has Results,Major Depression,Drug: quetiapine (Seroquel XR),17-item Hamilton Depression Rating Scale (HDRS),Indiana University School of Medicine|AstraZeneca|Indiana University,All,18 Years to 60 Years   (Adult),Phase 4,20,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0901-13,Mar-09,Mar-12,Mar-12,23-Sep-09,30-Sep-16,30-Sep-16,"Indiana University Adult Psychiatry Clinic, Indianapolis, Indiana, United States",,https://ClinicalTrials.gov/show/NCT00982345
NCT00982748,Yoga Breathing for Fatigue in Patients Undergoing Chemotherapy,,Completed,No Results Available,Breast Cancer,Behavioral: Pranayama (Yoga Breathing) Techniques,Feasibility|Cancer associated symptoms and quality of life,"University of California, San Francisco",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,25,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,08803|Mt.Zion Healthfund 20070658,Oct-08,Dec-09,Dec-09,23-Sep-09,null,25-Aug-11,"Osher Center for Integrative Medicine, UCSF, San Francisco, California, United States",,https://ClinicalTrials.gov/show/NCT00982748
NCT00982800,"Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?",,Completed,No Results Available,Prostate Cancer,Drug: Gabapentin|Drug: Placebo Sugar Pill,Will Gabapentin 200mg TID have pain and opioid sparing effects?|Does postoperative Gabapentin have perioperative anxiety sparing effects and do these effects last beyond hospital discharge?|3. Will improved analgesia with Gabapentin facilitate recovery and demonstrate effects on health related quality of life?,Sunnybrook Health Sciences Centre,Male,"18 Years to 75 Years   (Adult, Older Adult)",Phase 4,60,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",075-2005,Jun-07,Jan-10,Jan-10,23-Sep-09,null,6-Aug-10,"Sunnybrook Health Sciences Center, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT00982800
NCT00979693,Psilocybin-Assisted Psychotherapy for Anxiety in People With Stage IV Melanoma,,Withdrawn,No Results Available,Anxiety|Stage IV Melanoma,Drug: psilocybin,Hospital Anxiety and Depression Scale|Spielberger-State-Trait Inventory (STAI)|Hamilton Anxiety Rating Scale|Natural killer (NK) cell count|European Organization For Research and Treatment of Cancer; Quality of Life Questionnaire-C15|Hamilton Depression Rating Scale|Functional Assessment of Chronic Illness Therapy-spirituality,Multidisciplinary Association for Psychedelic Studies,All,"18 Years and older   (Adult, Older Adult)",Phase 2,0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",PCA1,Jan-12,Apr-13,Jun-13,18-Sep-09,null,17-Sep-14,"Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States",,https://ClinicalTrials.gov/show/NCT00979693
NCT00979888,Study of How Caregivers Help Patients Cope With Respiratory and Other Symptoms Caused by Lung Cancer,,Unknown status,No Results Available,Anxiety Disorder|Depression|Dyspnea|Fatigue|Lung Cancer,Other: educational intervention|Other: informational intervention|Other: psychosocial support for caregiver|Other: questionnaire administration|Procedure: dyspnea management|Procedure: management of therapy complications,"Consolidation of knowledge of existing interventions and their characteristics|Patients', caregivers', and healthcare professionals' views on existing interventions|Utilization of any additional interventions not currently described in the literature|Exploration of patients' perspectives on interrelationships among symptoms, in terms of clusters or causal relationships|Patients', caregivers', and healthcare professionals' views of the desirable components/characteristics of a novel intervention using the Discrete Choice Experiment 'Best-Worst' scale|Exploration of what is 'usual care' in the context of the study",University of Manchester|National Cancer Institute (NCI),All,"Child, Adult, Older Adult",Not Applicable,80,Other,Interventional,Masking: None (Open Label)|Primary Purpose: Supportive Care,CDR0000649867|UM-LC-Symptom-Clusters|EU-20972,Jul-09,Jul-10,null,18-Sep-09,null,26-Aug-13,"University of Manchester, Manchester, England, United Kingdom",,https://ClinicalTrials.gov/show/NCT00979888
NCT00978484,A Head-to-head Comparison of Virtual Reality Treatment for Post Traumatic Stress Disorder,,Unknown status,No Results Available,Post Traumatic Stress Disorder,Behavioral: Virtual Reality Exposure Therapy - Dynamic|Behavioral: Augmented Exposure Therapy,"Clinician Administered PSTD Scale (CAPS)|PTSD Checklist, Military Version (PCL-M):|The Patient Health Questionnaire 9 (PHQ-9):|Beck Anxiety Inventory (BAI):|Behavioral Reactivity Test (BRT)|Automated Neuropsychological Assessment Metric (ANAM)|Mini International Neuropsychiatric Interview (MINI)|Shehan Disability Scale (SDS)","United States Naval Medical Center, San Diego|Defense Centers of Excellence for Psychological Health and Traumatic Brain Injury|The Geneva Foundation|Marine Corps Base Camp Pendlton|Naval Hospital Camp Pendlton",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,150,U.S. Fed|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,W81XWH-08-1-0755,Sep-09,Sep-14,Oct-14,17-Sep-09,null,30-Jun-14,"Camp Pendlton, Camp Pendlton, California, United States|Naval Medical Center San Diego (NMCSD), San Diego, California, United States",,https://ClinicalTrials.gov/show/NCT00978484
NCT00978185,Acupressure Wristbands or Standard Care in Controlling Nausea Caused by Chemotherapy,,Completed,No Results Available,"Anxiety Disorder|Nausea and Vomiting|Unspecified Adult Solid Tumor, Protocol Specific",Other: medical chart review|Other: questionnaire administration|Procedure: acupressure therapy|Procedure: quality-of-life assessment|Procedure: sham intervention|Procedure: standard follow-up care,Incidence and severity of nausea as assessed by the Rhodes Index of Nausea & Vomiting before and after chemotherapy|Incidence and extent of acute and delayed nausea and vomiting by the MASCC Antiemesis Tool at day 10 of each course|Quality of life as assessed by FACT-G at baseline and at day 10 of each course|Anxiety as assessed by the Hospital Anxiety & Depression Scale at baseline|Expectation for nausea and vomiting as assessed by the Patient Expectations of Nausea/Vomiting after each chemotherapy course|Measure of blindness (to intervention vs sham) assessed after chemotherapy|Sociodemographic and treatment characteristics assessed at baseline,University of Manchester|National Cancer Institute (NCI),All,"16 Years and older   (Child, Adult, Older Adult)",Phase 3,699,Other,Interventional,Allocation: Randomized|Primary Purpose: Supportive Care,CDR0000649812|UM-ACMCN|EU-20971,Nov-08,Oct-10,Oct-10,16-Sep-09,null,26-Aug-13,"University of Manchester, Manchester, England, United Kingdom",,https://ClinicalTrials.gov/show/NCT00978185
NCT00974402,Psychotherapy Treatment of Deployment-Related PTSD in Primary Care Settings,,Completed,No Results Available,Post-Traumatic Stress Disorders|Stress Disorders|Combat Disorders,Behavioral: Cognitive Behavioral Therapy,PTSD symptomatology,The University of Texas Health Science Center at San Antonio|Brooke Army Medical Center|Wilford Hall Medical Center|South Texas Veterans Health Care System,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,35,Other|U.S. Fed,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HSC20090194H|BAMC C.2009.022|W81XWH-08-2-0109,Mar-08,Jun-12,Jun-12,10-Sep-09,null,18-Sep-14,"South Texas Veterans Health Care System (STVHCS), San Antonio, Texas, United States|Brooke Army Medical Center (BAMC), San Antonio, Texas, United States|Wilford Hall Medical Center, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT00974402
NCT00971815,Effects of 3 Months of Selective Serotonin Reuptake Inhibitor (SSRI)-Treatment on Metabolism and Hypothalamic-pituitary-adrenal (HPA)-Axis in Young Men Born With Low Birth Weight,LBW-SSRI,Completed,No Results Available,Insulin Resistance|Low Birth Weight|Type 2 Diabetes|Cardiovascular Disease|Melancholic Depression|Anxiety Disorders,Drug: Escitalopram|Drug: placebo,"Changes in rate of glucose dissappearance|Changes in the 24-hour AUC of free plasma cortisol|24 hour basal plasma cortisol/ACTH profile as measured every 3rd hour.|hippocampic volume and structure as assessed by MRI|24 hour bloodpressure profile|MRI spectroscopy of fat in skeletal muscle tissue|MRI spectroscopy of fat in liver|Abdominal fat as assessed by MRI|MDI questionnaire scores|SCL-92 questionnaire scores|Fasting blood lipid profile|Ratio between insulin and glucose concentrations in blood during an oral glucose tolerance test (OGTT)|Whole body fat content as assessed by a dexa scanning|Hepatic insulin sensitivity as assessed suppression of endogenous glucose production (calculated by infusion of 3H-labelled glucose)|10 pm to midnight basal plasma ACTH/cortisol concentration ratio as measured by blood sampling every 10th minute.|increase in blood pressure and heart rate during Stroops Stress test|Increase in plasma ACTH, cortisol and epinephrine concentrations during Stroops Stress Test|SRPAS questionnaire scores|Actigraph GT3X activity monitoring|Whole body bone mass density and T-/Z-scores as assessed by a dexa scanning|Plasma-Inflammation markers",University of Aarhus,Male,20 Years to 35 Years   (Adult),Not Applicable,60,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",M-20080132,May-09,Sep-11,Apr-14,4-Sep-09,null,5-Jun-17,"Medical Dep M, Diabetes and Endocrinology Aarhus University Hospital, Aarhus Sygehus, Aarhus, Denmark",,https://ClinicalTrials.gov/show/NCT00971815
NCT00969020,"A Telemedicine Solution for Remote Support of Rehabilitation, for Patients Undergoing, Total Hip Arthroplasty Surgery",RRS,Completed,No Results Available,Quality of Life|Anxiety,Procedure: remote rehabilitation support,EQ5D|LOS|SCL-90-r|TUG|anxiety,Regionshospitalet Silkeborg|Caretech Innovation|Lundbeck Foundation,All,"Child, Adult, Older Adult",Not Applicable,72,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care,2009-RSI-RRS,Sep-09,Mar-12,Aug-12,31-Aug-09,null,24-Oct-12,"Regionshospitalet SIlkeborg, Silkeborg, Denmark",,https://ClinicalTrials.gov/show/NCT00969020
NCT00964717,Chiropractic for Back and Neck Pain in an Emergency Department Setting,CBNP,Completed,No Results Available,Back Pain|Neck Pain|Anxiety,Procedure: real chiropractic|Procedure: Sham Chiropractic,A comparable difference in pain levels between a combined medication and chiropractic treatment to medication treatment alone as measured by the Numeric Rating Scale (NRS)|A comparable difference in range of motion between a combined medication and chiropractic treatment to medication treatment alone as measured by Spine Scan Device and physical exam using goniometer|A comparable difference in patient self reported anxiety assessed by Hebrew version of the anxiety and somatization sections of the Symptom Check List-90 questioner (SCL-90)|A comparable difference in the amount of analgesic pain medication consumed by the patients during the day of treatment and after 24 hours|A comparable difference in safety and patient satisfactory as measured by overall satisfactory and safety questionnaires,Assaf-Harofeh Medical Center,All,18 Years to 60 Years   (Adult),Phase 1|Phase 2,52,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",126/08,May-09,Sep-11,Sep-11,25-Aug-09,null,31-Jan-12,"Asaf Harofeh Medical Center, Beer Yaakov, Zerifin, Israel",,https://ClinicalTrials.gov/show/NCT00964717
NCT00965211,Evaluation of the HBDL Coil Transcranial Magnetic Stimulation (TMS) Device - Safety and Feasibility Study for the Treatment of Tourette Syndrome,,Unknown status,No Results Available,Tourette's Syndrome|Obsessive Compulsive Disorder,Device: HBDL-coil Repetitive Deep Transcranial magnetic stimulation (rdTMS),The Yale Global Tic Severity rating Scale (YGTSS)|Yale-Brown Obsessive Compulsive Disorder Scale (YBOCS),Shalvata Mental Health Center,All,18 Years to 55 Years   (Adult),Not Applicable,20,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TMS HBDL,Sep-09,Jan-13,Jan-13,25-Aug-09,null,5-Jan-12,"Shalvata Mental Health Center, Hod Hasharon, Israel|Shalvata Mental Health Center, Hod Hasharon, Israel",,https://ClinicalTrials.gov/show/NCT00965211
NCT00962403,Evaluation of a Yoga Intervention for Post-Traumatic Stress Disorder,EYIPTSD,Completed,No Results Available,Post-Traumatic Stress Disorder,Behavioral: Yoga treatment,Clinician Administered PTSD Scale (CAPS)|PTSD Checklist Military Version (PCL-M)|Impact of Events Scale - Revised (IES-R)|25-item Resilience Scale (RS)|Twenty-four-hour urinary samples|10-minute segment of a seated 30-minute electrocardiogram recording session|Beck Depression Inventory (BDI)|Spielberger State Trait Anxiety Inventory (STAI)|Daily Sleep Wake Diaries|Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q)|Credibility Expectancy Questionnaire (CEQ)|Body-Oriented State Questionnaire (BOSC)|5-Facet Mindfulness Questionnaire (FFMQ)|Perceived Stress Scale (PSS)|Yoga Follow-up Questionnaire|PTSD Checklist Civilian Version (PCL-C),Brigham and Women's Hospital|United States Department of Defense,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,108,Other|U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2009-P-000717|08144033,Aug-09,May-12,May-12,20-Aug-09,null,20-Mar-13,"Brigham and Women's Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT00962403
NCT00961454,Photobiomodulation to Alter Cerebral Blood Flow and to Affect the Emotional Status of Patients With Major Depression,,Completed,No Results Available,Major Depression|Anxiety Disorder|Post-Traumatic Stress Disorder|Substance Abuse Disorder,Device: Photobiomodulation with a super-luminous light emitting diode,Hamilton Depression Rating Scale|Hamilton Anxiety Rating Scale,Massachusetts General Hospital,All,18 Years to 60 Years   (Adult),Phase 1,10,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2008P-000937,Jan-09,Jun-09,Jun-09,19-Aug-09,null,19-Aug-09,"Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT00961454
NCT00961493,RCT of an Acceptance-based Behavior Therapy for GAD,,Completed,No Results Available,Generalized Anxiety Disorder,Behavioral: Acceptance based behavioral therapy|Behavioral: Applied relaxation,"Anxiety Disorders Interview Schedule for DSM-IV, Clinician Severity Rating of GAD|Hamilton Anxiety Rating Scale|Penn State Worry Questionnaire|Beck Depression Inventory - II|Quality of Life Inventory","University of Massachusetts, Boston|National Institute of Mental Health (NIMH)",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,81,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,R01MH074589|NIH MH074589|DSIR 83-ATAS2,Mar-07,Feb-13,Feb-13,19-Aug-09,null,19-Jun-13,"Center for Anxiety and Related Disorders at Boston University, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT00961493
NCT00962039,Anxiety and Recurrent Abdominal Pain in Children,,Unknown status,No Results Available,Abdominal Pain|Anxiety,Drug: Citalopram,"Clinical Global Impression Scale - Improvement (CGI-I) will be used to assess overall global illness improvement. CGI-I scores of 1 (""very much improved"") or 2 (""much improved"") indicate an acceptable treatment response.|Abdominal Pain Index (API) is a well-validated and reliable measure of abdominal pain assessing the frequency, duration, and intensity of abdominal pain over the prior 2 weeks. The API will be a continuous primary outcome measure.",National Institute of Mental Health (NIMH),All,"7 Years to 18 Years   (Child, Adult)",Phase 2|Phase 3,100,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",R01MH069715|DAHBR B4-TBI,Jul-04,Apr-10,Apr-10,19-Aug-09,null,19-Aug-09,"The Research Institute at Nationwide Children's Hospital, Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT00962039
NCT00960830,Mirtazapine Reduces ICD Shocks in ICD Patients With Depression and Anxiety,,Completed,No Results Available,Depression|Anxiety,Drug: mirtazapine,number of implantable cardioverter defibrillator shocks|improvement of depression,Universidad Nacional de Rosario,All,65 Years to 87 Years   (Older Adult),Not Applicable,40,Other,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",PS990,Apr-07,Apr-08,Nov-08,18-Aug-09,null,18-Aug-09,"Cl Sn Nicol, San Nicolas, Bs As, Argentina",,https://ClinicalTrials.gov/show/NCT00960830
NCT00961298,An Open Label Trial of Duloxetine in the Treatment of Irritable Bowel Syndrome and Comorbid Generalized Anxiety Disorder,,Completed,Has Results,Irritable Bowel Syndrome|Generalized Anxiety Disorder,Drug: Duloxetine,Clinical Global Impression Scale|Hamilton Anxiety Rating Scale|Irritable Bowel Syndrome-Quality of Life Scale|Irritable Bowel Syndrome Severity Scoring System,West Penn Allegheny Health System,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,17,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,RC-4656,Sep-09,Dec-11,Dec-11,18-Aug-09,9-Jul-14,9-Jul-14,,,https://ClinicalTrials.gov/show/NCT00961298
NCT00958880,Yohimbine to Enhance Cognitive Behavioral Therapy (CBT) for Social Anxiety,,Completed,Has Results,Social Anxiety Disorder,Behavioral: Group Cognitive Behavioral Therapy|Drug: Yohimbine Hydrochloride|Drug: Sugar Pill,The Liebowitz Social Anxiety Scale (LSAS)|Social Phobic Disorders Severity and Change Form,Southern Methodist University,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,40,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",KS09-088,Mar-09,Jan-13,Jan-13,13-Aug-09,11-Nov-13,11-Nov-13,"Boston University, Boston, Massachusetts, United States|Southern Methodist University, Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT00958880
NCT00957112,"Acupuncture or Self-Acupuncture in Managing Cancer-Related Fatigue in Women Who Have Received Chemotherapy for Stage I, Stage II, or Stage IIIA Breast Cancer",,Completed,No Results Available,Anxiety Disorder|Breast Cancer|Depression|Fatigue,Procedure: acupuncture therapy|Procedure: standard follow-up care,General fatigue as measured by the Multidimensional Fatigue Inventory|Mental fatigue as measured by the Multidimensional Fatigue Inventory|Anxiety as measured by the Hospital Anxiety and Depression Scale|Depression as measured by the Hospital Anxiety and Depression Scale|Quality of life as measured by the FACT-G and Breast Cancer module,University of Manchester|National Cancer Institute (NCI),Female,"Child, Adult, Older Adult",Phase 3,320,Other,Interventional,Allocation: Randomized|Masking: None (Open Label)|Primary Purpose: Supportive Care,CDR0000649750|UM-ASA|EU-20970,Oct-07,Oct-10,Feb-13,12-Aug-09,null,26-Aug-13,"University of Manchester, Manchester, England, United Kingdom",,https://ClinicalTrials.gov/show/NCT00957112
NCT00957359,Psilocybin Cancer Anxiety Study,,"Active, not recruiting",No Results Available,Cancer,Drug: Psilocybin|Drug: Niacin,anxiety|depression|pain|Quality of Life|Attitude toward disease progression,New York University School of Medicine,All,"18 Years to 76 Years   (Adult, Older Adult)",Phase 1|Phase 2,32,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",06-954,Feb-09,Dec-19,Dec-19,12-Aug-09,null,31-Jan-19,"NYU College of Dentistry Bluestone Center for Clinical Research, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00957359
NCT00956085,Memantine Augmentation in Treatment-Resistant Adults With Obsessive-Compulsive Disorder,,Completed,Has Results,Obsessive-Compulsive Disorder,Drug: Memantine,Number of Patients Who Met and Exceeded Response Criteria of Yale-Brown Obsessive-Compulsive Scale.,New York State Psychiatric Institute,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,12,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,6924R/5972,Aug-09,Dec-15,Dec-15,11-Aug-09,10-May-17,21-Jun-17,"New York State Psychiatric Institute, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00956085
NCT00953654,Exercise Training for the Treatment of Generalized Anxiety Disorder,,Completed,Has Results,Generalized Anxiety Disorder,Other: Strength Training|Other: Endurance Training,Generalized Anxiety Disorder (GAD) Remission as Measured by Anxiety Disorders Interview Schedule-Adult Version (ADIS-IV) Severity Ratings|Worry Symptoms,University of Georgia,Female,18 Years to 39 Years   (Adult),Not Applicable,30,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,UGA-2009-01913-1,Aug-09,May-10,May-10,6-Aug-09,29-Sep-10,9-Sep-16,"The University of Georgia, Athens, Georgia, United States",,https://ClinicalTrials.gov/show/NCT00953654
NCT00951483,Cardiovascular Biomarkers and Quetiapine in Depression and Anxiety Patients,,Completed,Has Results,Depression|Anxiety,Drug: Quetiapine-XR,C-Reactive Protein at 12 Weeks|Change in Hamilton Rating Scale for Depression With Seven Items (HAM-D-7)|Change in Hamilton Rating Scale for Depression With 17 Items (HAM-D-17)|Change in Hamilton Rating Scale for Depression With 21 Items (HAMD-21)|Change in Hamilton Rating Scale for Anxiety (HAM-A)|Change in Beck Depression Inventory (BDI)|Change in 14-item Perceived Stress Scale (PSS-14),Loyola University,All,"20 Years to 65 Years   (Adult, Older Adult)",Phase 4,91,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,201880,Jul-09,Oct-11,Oct-11,4-Aug-09,24-Oct-16,24-Oct-16,"Loyola University Health System, Maywood, Illinois, United States",,https://ClinicalTrials.gov/show/NCT00951483
NCT00948974,Variations of Cognitive Behavior Therapy for Social Anxiety Disorder,,Completed,Has Results,Social Anxiety Disorder,Behavioral: Cognitive Therapy|Behavioral: Acceptance and Commitment Therapy,Social Phobia and Anxiety Inventory (SPAI) - Social Phobia Subscale|Outcomes Questionnaire|Behavioral Assessment Test,Drexel University,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,88,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,18345,Jan-10,Jan-15,Dec-15,30-Jul-09,5-Oct-18,5-Oct-18,"Drexel University, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00948974
NCT00947570,Neural Functioning Underlying Anxiety and Its Treatment (The INSULA Study),,Completed,No Results Available,Generalized Anxiety Disorder|Panic Disorder|Anxiety Disorders,Behavioral: Cognitive behavioral therapy for anxiety,"Blood oxygen level dependent (BOLD) response in amygdala, insula, and medial prefrontal cortex, as measured with functional magnetic resonance imaging (fMRI)","University of California, San Diego|National Institute of Mental Health (NIMH)",All,18 Years to 55 Years   (Adult),Not Applicable,60,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,R01MH065413|DATR A2-AIA,Oct-07,Aug-12,Aug-12,28-Jul-09,null,31-Dec-12,,,https://ClinicalTrials.gov/show/NCT00947570
NCT00944268,Efficacy and Tolerability Study to Treat Mild and Moderate Anxiety,E01ATCAL0308,Unknown status,No Results Available,Anxiety|Efficacy|Tolerability,"Drug: Passiflora, Crataegus e Salix",Hamilton Scales|Safety evaluation by adverse events relate.,Ativus Farmaceutica Ltda,All,"18 Years and older   (Adult, Older Adult)",Phase 3,124,Industry,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,E01-AT-CAL-03-08,Sep-09,Dec-09,Jan-10,23-Jul-09,null,24-Jul-09,"Faculdade de Medicina do ABC, Santo André, São Paulo, Brazil",,https://ClinicalTrials.gov/show/NCT00944268
NCT00944957,"Patient Preference, Sleep Quality, and Anxiety/Depression: A Comparison of Raltegravir and Efavirenz",Switch-ER,Unknown status,No Results Available,Sleep Disorders|HIV Infections,Drug: Raltegravir for the first 2 weeks|Drug: Efavirenz for the last 2 weeks|Drug: Efavirenz for the first 2 weeks|Drug: Raltegravir for the last 2 weeks,"Symptoms and neurological side effects of study drugs|Levels of daytime sleepiness|Sleep Quality|Patient preference|Symptoms of depression, anxiety and stress will be assessed","University Hospital, Geneva|University of Bern|University of Lausanne Hospitals|Hospital Lugano|University Hospital, Basel, Switzerland|Hospital of Neuchâtel|University Hospital, Zürich",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",IEC 09-087,Nov-09,Dec-09,Apr-10,23-Jul-09,null,12-Jan-10,"University Hopistal of Geneva, Geneva, Switzerland",,https://ClinicalTrials.gov/show/NCT00944957
NCT00942539,Midazolam Sedation for Neonatal Lumbar Puncture,,Terminated,No Results Available,Pain|Anxiety,Drug: Midazolam,"The Simplified Neonatal Facial Coding System will be used for assessment of pain. Scoring will be composed from four specific facial actions (brow bulge, nasolabial furrow, eye squeeze, and open mouth) and the presence or absence of crying|Physician's level of satisfaction from the procedural conditions|LP Success rate|Adverse sedation reactions",Rambam Health Care Campus,All,up to 30 Days   (Child),Phase 2,12,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,2958CTIL,Jul-09,Jul-11,Jul-11,21-Jul-09,null,6-May-14,"Rambam Health Care Campus, Haifa, Israel",,https://ClinicalTrials.gov/show/NCT00942539
NCT00938093,Treatment of Late-life Anxiety in Primary Care Settings,,Completed,No Results Available,Generalized Anxiety Disorder|Panic Disorder|Anxiety Disorder Not Otherwise Specified,Behavioral: Cognitive behavioral therapy|Behavioral: Enhanced usual care,PSWQ-A|HAM-A,Wake Forest University Health Sciences|National Institute of Mental Health (NIMH),All,"60 Years and older   (Adult, Older Adult)",Not Applicable,60,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,MH65281,Mar-06,Feb-09,Feb-09,13-Jul-09,null,13-Aug-18,,,https://ClinicalTrials.gov/show/NCT00938093
NCT00937235,Treatment of Smoking Among Individuals With PTSD,,Completed,Has Results,Cigarette Smoking|Nicotine Dependence|Post-traumatic Stress Disorder|Tobacco Use Disorder,Drug: Varenicline|Behavioral: Medication Management Counseling|Behavioral: Prolonged Exposure,Number of Participants With 7-day Point Prevalence Smoking Abstinence|Blood Serum Cotinine|Posttraumatic Symptom Scale Interview (PSS-I) at Post-Treatment|Posttraumatic Symptom Scale Interview (PSS-I) Total Score at 3-Month Follow-Up|Hamilton Depression Scale (HAM-D) Total Score at Post-Treatment|Hamilton Depression Scale (HAM-D) Total Score at 3-Month Follow-Up|TLFB - Total Cigarettes Smoked Week Before Appointment (at Post-Treatment)|TLFB - Cigarettes Smoked Week Before 3-Month Follow-up,University of Pennsylvania|National Institute on Drug Abuse (NIDA),All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,142,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,R01DA023507,Jan-09,Dec-15,Dec-15,10-Jul-09,7-Sep-17,14-Nov-17,"University of Pennsylvania School of Medicine, Dept of Psychiatry, Center for Treatment and Study of Anxiety, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00937235
NCT00932919,Thought Field Therapy and Cognitive Therapy for Agoraphobia,,Completed,No Results Available,Agoraphobia,Behavioral: Thought field therapy|Behavioral: Cognitive therapy|Behavioral: Wait list,Change in agoraphobic situation scores in ADIS.|Interference score in ADIS|Mobility Inventory|Agoraphobic Cognitions Questionnaire|Body Sensations Questionnaire|BDI|BAI|WHOQOL-BREF|SF-36|Safety Seeking Behaviours Questionnaire.|Panic scale,Sorlandet Hospital HF,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,72,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,SSHF-70343-AUIR-2,Oct-06,Nov-10,Nov-10,7-Jul-09,null,23-Apr-14,"Sorlandet Hospital, Arendal, Norway",,https://ClinicalTrials.gov/show/NCT00932919
NCT00932178,Calmer Life: A Worry Reduction Program for Older Adults,,Completed,No Results Available,Anxiety,Behavioral: Calmer Life,"Geriatric Depression Scale (GDS), Geriatric Anxiety Inventory (GAI), Penn State Worry Questionnaire (PSWQ-A), State-Trait Anxiety Inventory (STAI)",Baylor College of Medicine,All,"50 Years and older   (Adult, Older Adult)",Not Applicable,32,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MIRECC006|VA ID Number: 09E02.H,Apr-09,Feb-16,Feb-16,3-Jul-09,null,23-Jan-18,"Michael E DeBakey VA Medical Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00932178
NCT00932204,Study of Sequentially Applied Repetitive Transcranial Magnetic Stimulation in Obsessive- Compulsive Disorders,,Completed,No Results Available,Obsessive-compulsive Disorder,Device: repetitive transcranial magnetic stimulation (Magstim rapid magnetic stimulator),"The primary outcome measure for the study was score on the Y-BOCS. The responder on Y-BOCS is defined as a Y-BOCS decrease at least 25% from the baseline at post-treatment (at 4 weeks)|The secondary outcome measures were the scores of MADRS and HARS, to examine the effects on cognitive functions of rTMS, a computerized Stroop task was conducted and side effect checklist.",Severance Hospital,All,19 Years to 60 Years   (Adult),Not Applicable,21,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",4-2006-0318,Feb-07,Jan-08,Jan-08,3-Jul-09,null,7-Sep-18,"Yonsei Univ. Health System Severance Hospital, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT00932204
NCT00932685,Does Distraction With a Hand Held Video Game Reduce Preoperative and Emergence Anxiety in Children?,,Completed,No Results Available,Pediatric Emergence Agitation and Pain,Drug: Midazolam|Device: Game Boy,postoperative pain|emergence agitation,"University of Medicine and Dentistry of New Jersey|Nintendo of North America|Rutgers, The State University of New Jersey",All,4 Years to 12 Years   (Child),Not Applicable,119,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,0120030315A,Dec-05,Jun-07,Jul-07,3-Jul-09,null,3-Jul-09,"University Hospital, Newark, New Jersey, United States",,https://ClinicalTrials.gov/show/NCT00932685
NCT00930293,Efficacy and Feasibility of a Personalized Treatment for Depression With Co-Occurring Anxiety,,Completed,Has Results,Depression|Anxiety,Behavioral: Interpersonal Psychotherapy for Depression with Panic and Anxiety Symptoms (IPT-PS)|Behavioral: Brief Supportive Psychotherapy (BSP)|Drug: Citalopram hydrobromide,Number of Participants Meeting Depression Remission Criteria|Weeks to Depression Remission,University of Pittsburgh|National Institute of Mental Health (NIMH),All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,50,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,R01MH085874|MH085874-01|PRO08070009|PCC: DSIR 84-CT,Jul-09,Jun-12,Jun-12,30-Jun-09,9-Feb-16,9-Feb-16,"Western Psychiatric Institute and Clinic, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00930293
NCT00928772,Cranial Electro Therapy Stimulation in Reducing Perioperative Anxiety,,Terminated,Has Results,Anxiety,Device: CRANIAL ELECTROTHERAPY (Alpha Stim) + SHAM MIDAZOLAM|Drug: MIDAZOLAM + SHAM ELECTRODES SIMULATING CRANIAL ELECTROTHERAPY|Other: NO SEDATION WITH SHAM CRANIAL ELECTROSTIMULATION AND PLACEBO VERSED,Anxiety During Cataract Surgery Under Topical Anesthesia|Eye Discomfort Perception During Cataract Surgery Under Topical Anesthesia|Mean Arterial Pressure During the Cataract Surgery Under Topical Anesthesia|Heart Rate During Cataract Surgery Under Topical Anesthesia,University of Oklahoma,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 4,115,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",14694,Jul-09,Feb-12,Feb-12,26-Jun-09,20-Apr-17,20-Apr-17,"Oklahoma City VA Medical Center, Oklahoma City, Oklahoma, United States",,https://ClinicalTrials.gov/show/NCT00928772
NCT00926471,Social Skills and Anxiety Reduction Treatment for Children and Adolescents With Autism Spectrum Disorders,,Completed,No Results Available,"Autistic Disorder|Child Development Disorders, Pervasive",Behavioral: Cognitive Behavioral Therapy (CBT) Program,Child and Adolescent Symptom Inventory 20-Item Anxiety Subscale (CASI-20),Virginia Polytechnic Institute and State University|National Institute of Mental Health (NIMH),All,12 Years to 17 Years   (Child),Phase 1,30,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,K01MH079945|DDTR B2-MBA,Sep-08,May-11,Jan-13,23-Jun-09,null,7-Nov-13,"Virginia Polytechnic Institute and State University, Blacksburg, Virginia, United States",,https://ClinicalTrials.gov/show/NCT00926471
NCT00921063,A 5-Week Trial Of PD 0332334 And Alprazolam Extended Release Compared To Placebo In Patients With Generalized Anxiety Disorder,,Completed,No Results Available,Generalized Anxiety Disorder,Drug: PD 0332334|Drug: placebo|Drug: Alprazolam extended release,"HAM-A Total Score|HAM-A total score at week 1, 2 and 4|HAM-A somatic and psychic subscales|HAM-A responders|HAM-A sustained responders|DAS-A (daily assessment of symptoms of anxiety) and GA-VAS (VAS scale for global anxiety)|CGI-I (Clinical Global Impression of Improvement) and PGI-I (Patient Global Impression of Change)|HAM-D total score|Sheehan Disability Score (SDS)|Treatment Satisfaction Questionaire for Medication",Pfizer,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,222,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",A5361007,Nov-05,Jul-06,Jul-06,16-Jun-09,null,19-Feb-10,,,https://ClinicalTrials.gov/show/NCT00921063
NCT00920387,Lysergic Acid Diethylamide (LSD)-Assisted Psychotherapy in People With Illness-related Anxiety,,Completed,No Results Available,Anxiety,Drug: Experimental 200 mcg Lysergic acid diethylamide|Drug: Active Comparator 20 mcg lysergic acid diethylamide|Behavioral: Psychotherapy,Spielberger State-Trait Inventory (STAI)|Hospital Anxiety and Depression Scale (HADS)|Daily visual analog pain scale (VAPS)|Daily Anxiety/Pain Medication Diary|Symptom Checklist 90|European Organization for Research and Treatment of Cancer - Quality of Life Questionnaire,Multidisciplinary Association for Psychedelic Studies,All,"18 Years and older   (Adult, Older Adult)",Phase 2,12,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",LDA1,Feb-08,Jul-12,Sep-12,15-Jun-09,null,7-May-14,"Private Practices of Peter Gasser MD, Solothurn, Switzerland",,https://ClinicalTrials.gov/show/NCT00920387
NCT00914329,Gelsemium Sempervirens in Anticipatory Anxiety,ANXIHOMEV,Completed,No Results Available,Anxiety,Drug: Gelsemium Sempervirens|Drug: Placebo,"Anxiety level evaluated by the STAI-E, in absolute value and et difference with basal state, according to the treatment received by the volunteers (Gelsemium sempervirens 5CH, 15CH or placebo)|anxiety level measured by the visual analogic scale of anxiety, in absolute value and difference with the basal state, according to the treatment received by the volunteers (Gelsemium sempervirens 5CH, 15CH or placebo)|anxiety level measured by the scale of anxiety state in competition (EEAC), in absolute value and difference with the basal state, according to the treatment received by the volunteers (Gelsemium sempervirens 5CH, 15CH or placebo)|Continue measure of arterial pressure, heart rate, respiratory rate, according to the treatment received by the volunteers (Gelsemium sempervirens 5CH, 15CH or placebo)|anxiety measured by STAI-T|score of stress-test","University Hospital, Grenoble|BOIRON",All,18 Years to 40 Years   (Adult),Phase 3,180,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",DCIC 08 20,Jun-09,Apr-10,May-10,5-Jun-09,null,3-Jun-10,"Clinical Research Center, Grenoble, France",,https://ClinicalTrials.gov/show/NCT00914329
NCT00912535,Quetiapine Augmentation for Primary Anxiety Disorder or Mood Disorders With Co-morbid Anxiety Symptoms,,Completed,No Results Available,Primary Anxiety Disorders|Mood Disorders With Comorbid Anxiety Symptoms,Drug: Quetiapine extended release tablet|Drug: Placebo,Hamilton Anxiety Scale(HAMA-A) total score|Item scores for Abnormal Involuntary Movement Scale(AIMS)|Item scores of Barnes-Akathisia Rating Scale (BARS)|Item scores of Simpson-Angus Scale(SAS)|Body Weight|Vital signs|Adverse event/Serious adverse event,Chang Gung Memorial Hospital|AstraZeneca,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,39,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",D1443C00026,May-09,Jul-10,Jul-10,3-Jun-09,null,5-Jan-12,"Chang Gung Memorial Hospital - Keelung, Keelung, Taiwan",,https://ClinicalTrials.gov/show/NCT00912535
NCT00911794,Written Disclosure Therapy for Anxiety and Stress in Patients With Chronic Lung Disease,,Completed,No Results Available,Chronic Lung Diseases|COPD|Pulmonary Fibrosis,Other: Disclosure Writing (Written Disclosure Therapy)|Other: Neutral (Sham) Writing,Dyspnea and quality of life|Six-minute walk distance|Spirometry values (FEV1 and FVC),"Winthrop University Hospital|Stony Wold-Herbert Fund, Inc.",All,"18 Years to 90 Years   (Adult, Older Adult)",Not Applicable,66,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,7300,Jan-07,Jan-08,Mar-09,2-Jun-09,null,2-Jun-09,,,https://ClinicalTrials.gov/show/NCT00911794
NCT00903474,Mindful Movement Program in Improving Quality of Life in Older Female Breast Cancer Survivors,,Completed,No Results Available,Anxiety Disorder|Breast Cancer|Cancer Survivor|Cognitive/Functional Effects|Depression|Psychosocial Effects of Cancer and Its Treatment,Other: questionnaire administration|Other: study of socioeconomic and demographic variables|Procedure: CAM exercise therapy|Procedure: psychosocial assessment and care|Procedure: quality-of-life assessment|Procedure: stress management therapy,"Effects of the Mindful Movement Program on psychological well-being, distress, fear of recurrence, physical well-being, upper-body symptom bother, social well-being, body image, and spiritual well-being at baseline and weeks 12 and 18|Effects of this program on attention and attitude|Differences of attention and attitude between the experimental group and the control group|Perceptions of the program as described by the experimental group",City of Hope Medical Center|National Cancer Institute (NCI),Female,"50 Years and older   (Adult, Older Adult)",Not Applicable,49,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,08061|CHNMC-08061,Aug-08,Apr-10,Apr-10,18-May-09,null,8-Jun-15,"City of Hope Comprehensive Cancer Center, Duarte, California, United States",,https://ClinicalTrials.gov/show/NCT00903474
NCT00902226,Escitalopram in Patients With Social Anxiety Disorder,,Completed,Has Results,Social Anxiety Disorder,Drug: Escitalopram,Effect of Escitalopram After 12 Weeks Using the Clinical Global Impression (CGI-I)|Effect of Escitalopram After 12 Weeks Using the Clinical Global Impression (CGI-S)|Percentage of Patients Who Responded to Escitalopram After 12 Weeks of Treatment Using CGI-I <= 2|Percentage of Patients Who Achieved Remission After 12 Weeks of Treatment Using CGI-S <= 2|Effect of Escitalopram After 12 Weeks Using Sheehan Disability Scale (SDS) Work|Effect of Escitalopram After 12 Weeks Using Sheehan Disability Scale (SDS) Family|Effect of Escitalopram After 12 Weeks Using Sheehan Disability Scale (SDS) Social,H. Lundbeck A/S,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,30,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,12133A,Mar-09,Dec-09,Mar-10,15-May-09,10-Jun-11,10-Jun-11,"RU001, Moscow, Russian Federation",,https://ClinicalTrials.gov/show/NCT00902226
NCT00902330,Cranial Stimulation for Chemotherapy Symptoms in Breast Cancer,,Completed,Has Results,Anxiety Disorder|Breast Cancer|Depression|Fatigue|Pain|Sleep Disorders,Procedure: energy-based therapy|Procedure: sham intervention,"Effects of CES as Compared to Sham CES on Symptoms of Depression, Anxiety, Fatigue, Pain and Sleep Disturbances in Women Receiving Adjuvant Chemotherapy for Early-stage Breast Cancer|To Examine Whether the Symptoms of Depression, Anxiety, Fatigue, Sleep Disturbances and Pain Form a Cluster.|Means and Standard Deviations of Biomarkers Log(CRP pg/ml), Log(IL-1b pg/ml), Log(IL-6 pg/ml) and Log(TNF-a pg/ml).|Relationships Among Biomarkers Log(CRP pg/ml), Log(IL-1b pg/ml), Log(IL-6 pg/ml) and Log(TNF-a pg/ml).|Relationships Among Anxiety, Depression, Fatigue, Pain and Sleep Scores - Means at Baseline|Relationships Among Symptom Scores - Correlations at Baseline Chemotherapy|Relationships Among Quality of Life Scores - Means at Baseline|Relationships Among Quality of Life Scores - Correlations at Baseline|Mean and Standard Deviation of Biomarkers Log(CRP pg/ml), Log(IL-1b pg/ml), Log(IL-6 pg/ml) and Log(TNF-a pg/ml).|Relationships Among Biomarkers Log (CRP), Log (IL-1B), Log (IL6), and Log (TNF-a) - Correlations at Midpoint Chemotherapy|Relationships Among Anxiety, Depression, Fatigue, Pain and Sleep Scores - Means at Midpoint Chemotherapy|Relationships Among Symptom Scores - Correlations at Midpoint Chemotherapy|Relationships Among Quality of Life Scores - Means at Midpoint Chemotherapy|Relationships Among Quality of Life Scores - Correlations at Midpoint Chemotherapy|Relationships Among Biomarkers Log (CRP), Log (IL-1B), Log (IL6), and Log (TNF-a) - Correlations at End of Treatment|Relationships Among Anxiety, Depression, Fatigue, Pain and Sleep Scores - Means at End of Chemotherapy|Relationships Among Symptom Scores - Correlations at End of Chemotherapy|Effects of Treatment on Quality of Life - Means at End of Treatment|Relationships Among Quality of Life Scores - Correlations at End of Chemotherapy",Virginia Commonwealth University|National Cancer Institute (NCI),Female,"18 Years and older   (Adult, Older Adult)",Phase 3,161,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Supportive Care",MCC-11995|HM11995|CDR0000641994|NCI-2011-00234,Apr-09,May-13,May-14,15-May-09,2-Apr-15,23-Nov-15,,,https://ClinicalTrials.gov/show/NCT00902330
NCT00902564,Escitalopram in Patients With Generalized Anxiety Disorder,,Completed,Has Results,Generalized Anxiety Disorder,Drug: Escitalopram,Effect of Escitalopram After 8 Weeks of Treatment in Patients With GAD Using the Hamilton Anxiety Scale (HAMA)|Effect of Escitalopram After 8 Weeks Using the Clinical Global Impression (CGI-I)|Effect of Escitalopram After 8 Weeks Using the Clinical Global Impression (CGI-S)|Percentage of Patients Who Responded to Escitalopram After 8 Weeks of Treatment Using CGI-I <= 2|Percentage of Patients Who Achieved Remission After 8 Weeks of Treatment Using CGI-S <= 2|Effect of Escitalopram After 8 Weeks Using Sheehan Disability Scale (SDS) Work|Effect of Escitalopram After 8 Weeks Using Sheehan Disability Scale (SDS) Family|Effect of Escitalopram After 8 Weeks Using Sheehan Disability Scale (SDS) Social|Percentage of Patients Who Responded According to >= 50% Improvement From Baseline to Week 8 in HAMA Total Score,H. Lundbeck A/S,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,30,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,12132A,Mar-09,Dec-09,Mar-10,15-May-09,10-Jun-11,10-Jun-11,"RU001, Moscow, Russian Federation",,https://ClinicalTrials.gov/show/NCT00902564
NCT00901082,The Effectiveness of Information and Relaxation on Pre-procedural Block Anxiety and Procedural Discomfort During Medial Branch Block,TIRAP,Completed,No Results Available,Chronic Pain,Behavioral: Relaxation and information session,Change in the anxiety level prior to the nerve block as per the state trait anxiety questionnaire|Perceived pain as measured by NRS (numerical rating scale)|Unchanged catastrophization level|Satisfaction level of the overall experience|Ease of performing the nerve block,Louise Lamb|McGill University Health Center,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Supportive Care,GEN08-051,Apr-09,Apr-11,Feb-12,13-May-09,null,6-Oct-15,"MUHC, Montreal General Hospital, Montreal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT00901082
NCT00899392,Improving Informed Consent in Pediatric Endoscopy,,Completed,Has Results,Informed Consent|Procedural State Anxiety|Subject's Satisfaction,Other: Emmi Pediatric Upper Endoscopy Patient Education Module,Attainment of Informed Consent as Measured by Consent Instrument (Consent-20)|Subject (Parental) Satisfaction as Measured by Modified Group Health Association of America-9 Survey (mGHAA-9)|Subject (Parental) State Anxiety as Measured by the Spielberger-State Trait Anxiety Inventory (s-STAI) (State Section)|Questions Asked by Subjects (Parents)|GI Suite Flow Efficiency Measured in 15 Minute Increments,Children's Hospital of Philadelphia|Midwestern University,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,148,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",2008-6-6053,Sep-08,Mar-09,Mar-09,12-May-09,30-Jul-13,30-Jul-13,"Chidren's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00899392
NCT00895700,Internet-based Intervention in Cardioverter-defibrillator Patients to Enhance Quality of Life,WEBCARE,Unknown status,No Results Available,Heart Diseases|Implantable Cardioverter-Defibrillators,Behavioral: web-based multifactorial intervention,Anxiety|Anxiet|Cortisol awakening response,University of Tilburg|Erasmus Medical Center|Amphia Hospital|Catharina Ziekenhuis Eindhoven|Canisius-Wilhelmina Hospital|Onze Lieve Vrouwe Gasthuis|Vlietland Ziekenhuis,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,350,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),UVT-MP-001,Mar-10,Feb-13,Feb-14,8-May-09,null,19-Jun-12,"Canisius-Wilhelmina Hospital, Nijmegen, Gelderland, Netherlands|Amphia Hospital, Breda, Noord Brabant, Netherlands|Catharina Hospital, Eindhoven, Noord Brabant, Netherlands|Onze Lieve Vrouwe Gasthuis (OLVG), Amsterdam, Noord-Holland, Netherlands|Erasmus Medical Center, Rotterdam, Zuid Holland, Netherlands|Vlietland Ziekenhuis, Schiedam, Netherlands",,https://ClinicalTrials.gov/show/NCT00895700
NCT00894465,Midazolam Effect in Children Undergoing Voiding Cystourethrogram (VCUG),,Terminated,Has Results,Vesicoureteral Reflux,Drug: midazolam|Drug: placebo,Anxiety Score From the Modified Yale Preoperative Anxiety Scale|Anxiety Score From the State-Trait Anxiety Inventory,Washington University School of Medicine|Society of Pediatric Urology,All,2 Years to 6 Years   (Child),Not Applicable,44,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)",HRPO # 06-0665,Aug-06,Jun-09,Aug-09,7-May-09,9-Dec-16,9-Dec-16,"Washington University, ST Louis, Missouri, United States",,https://ClinicalTrials.gov/show/NCT00894465
NCT00894699,"A Study to Evaluate the Clinical Efficacy, Safety and Tolerability of ARX-F03 Sublingual Sufentanil/Triazolam NanoTab™ in Patients Undergoing an Elective Abdominal Liposuction Procedure",,Completed,Has Results,Sedation|Anxiety|Pain,Drug: Sublingual Sufentanil/Triazolam NanoTab™ (ARX-F03)|Drug: Placebo NanoTab™,Summed Richmond Agitation Sedation Score (RASS) Over the 4-hour Study Period (SRS-4),"AcelRx Pharmaceuticals, Inc.",All,18 Years to 60 Years   (Adult),Phase 2,40,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ARX-C-007,Jun-09,Sep-09,Sep-09,7-May-09,25-Jun-14,25-Jun-14,"Lotus Clinical Research, Inc., Pasadena, California, United States",,https://ClinicalTrials.gov/show/NCT00894699
NCT00892463,Identifying Very Early Response to Seroquel Extended Release (XR) Augmentation for Major Depressive Disorder,,Completed,No Results Available,"Depressive Disorder, Major",Drug: Quetiapine (Seroquel) XR,The QIDS-SR16 (Quick Inventory of Depressive Symptomatology - Self-report)|HADS (Hamilton Anxiety Depression Scale) VADIS,Sunnybrook Health Sciences Centre|AstraZeneca,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,26,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,D1443L00072,May-09,Dec-10,Dec-10,4-May-09,null,28-Jul-11,"Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT00892463
NCT00889005,Prevention of Post-traumatic Stress Disorder by Telephone Based Cognitive Behavioral Therapy,,Completed,Has Results,Stress Disorder - Post-traumatic (Acute),Other: Telephone Based Cognitive Behavioral Therapy,Severity of PTSD Symptoms,Hadassah Medical Organization,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,139,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,Shalev_Phone_2009,May-09,Sep-12,Dec-12,28-Apr-09,1-Nov-18,1-Nov-18,"Hadassah University Hospital, Jerusalem, Israel",,https://ClinicalTrials.gov/show/NCT00889005
NCT00887679,Treatment Effects of Escitalopram (Lexapro®) on Generalized Anxiety Disorder in Patients With HIV and AIDS,,Completed,Has Results,Anxiety Disorders|HIV Infections,Drug: Escitalopram,Change From Randomization to End of Treatment in Scores on the Hamilton Anxiety Rating Scale (HAM-A)|Changes From Randomization to End of Treatment in Scores on the Beck Depression Inventory|Change From Randomization to End of Treatment in Scores for the Clinical Global Impression(CGI-S and CGI-I)|Change From Randomization to End of Treatment for Trail Making Tet (TMT)|Changes From Randomization to End of Treatment in Scores on the Mini Mental State Examination (MMSE)|Changes From Randomization to End of Treatment in Scores on the Sheehan Disability Scores (SDS),Duke University|Forest Laboratories,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,30,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Pro00011288|LXP-MD-0148,May-09,Sep-09,Sep-10,24-Apr-09,10-Mar-14,31-Oct-14,"Duke University Medical Center, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT00887679
NCT00886314,Clown Doctors and a Sedative Premedicant for Children Undergoing Surgery,,Unknown status,No Results Available,Insomnia,Drug: midazolam|Other: clown doctor,Preoperative anxiety,Shaare Zedek Medical Center,All,2 Years to 12 Years   (Child),Not Applicable,80,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,12345,Jun-09,Sep-09,null,22-Apr-09,null,20-Oct-09,"Shaare Zedek Medical Center, Jerusalem, Israel",,https://ClinicalTrials.gov/show/NCT00886314
NCT00884897,Oxytocin and Social Cognition in Schizophrenia,,Completed,Has Results,Social Cognition|Social Anxiety|Emotional Intelligence,Drug: Oxytocin|Drug: Placebo,To Determine Whether Exogenous OT Enhances Emotional Intelligence and Improves Performance on Measures of Social Cognition for Schizophrenia or Schizoaffective Patients|To Determine Whether OT Improves Measures of Social Anxiety.,University of Maryland|National Institute on Drug Abuse (NIDA),All,18 Years to 55 Years   (Adult),Phase 2,28,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",HP-00041024|P50MH082999,Jan-10,Jan-12,Jan-12,21-Apr-09,1-Jun-17,1-Jun-17,"Maryland Psychiatric Research Center (MPRC) Outpatient Research Program (ORP); the MPRC Treatment Research Program (TRP), Catonsville, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00884897
NCT00881465,Videophone Administered Cognitive-Behavioral Therapy for Pediatric Obsessive-Compulsive Disorder,,Completed,Has Results,Obsessive Compulsive Disorder,Behavioral: Cognitive-behavioral therapy|Behavioral: Wait-list control,"Children's Yale-Brown Obsessive-Compulsive Scale (CY-BOCS; Scahill et al., 1997). The CY-BOCS is a 10-item Semi-structured Measure of Obsession and Compulsion Severity Over the Previous Week. This Measure Will Serve as the Primary Outcome Index.|Clinical Global Impression - Severity (CGI-S; National Institute of Mental Health, 1985). The CGI-S is a 7-point Clinician Rating of Severity of Psychopathology.|Clinical Global Improvement (CGI; Guy, 1976). The CGI is a 7-point Rating of Treatment Response Anchored by 1 (""Very Much Improved) and 7 (""Very Much Worse"").",University of South Florida,All,7 Years to 17 Years   (Child),Phase 2,31,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,USF-09-0155,Mar-09,Jun-10,Jun-10,15-Apr-09,15-May-15,11-Jun-15,"University of South Florida, St. Petersburg, Florida, United States",,https://ClinicalTrials.gov/show/NCT00881465
NCT00878735,The Effects of a Meditation Retreat on Healthy Volunteers and Cancer Patients: an fMRI Study,Sesshin,Completed,No Results Available,Healthy|Cancer,Behavioral: Zen meditation,"To evaluate the neural correlates of performance modulation on an attention paradigm (the Stroop word-color task; SWCT) and on an emotional paradigm (the frustration paradigm) before and after a Zen meditation retreat.|Anxiety, stress and depression symptoms, self-compassion feelings and mindfulness state will also be evaluated in healthy volunteers and cancer patients.",Hospital Israelita Albert Einstein|Federal University of São Paulo,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,96,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Supportive Care,Sesshin|Elisa,Jan-08,Jan-09,null,9-Apr-09,null,9-Jun-14,"Instituto Israelita de Ensino e Pesquisa Albert Einstein, São Paulo, Brazil",,https://ClinicalTrials.gov/show/NCT00878735
NCT00872118,Brief Intervention for Socially Anxious College Drinkers,BISAD,Completed,No Results Available,Alcohol Consumption|Alcohol Negative Consequences|Social Anxiety,Behavioral: Brief Intervention for Socially Anxious Drinkers (BISAD)|Behavioral: Enhanced Alcohol Skills Building and Education Program,heavy drinking days|total alcohol consumption|drinking-related negative consequences|social (interactional) anxiety|alcohol expectancies of social evaluative situations|drink refusal self-efficacy in social situations,University of Cincinnati|National Institute on Alcohol Abuse and Alcoholism (NIAAA),All,18 Years to 26 Years   (Adult),Phase 1,53,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,NIAAA-Tran-AA014014|R21AA017291|NIH Grant R21AA014014,Apr-04,Apr-07,Mar-08,31-Mar-09,null,16-Sep-10,"Psychology Department, University of Cincinnati, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT00872118
NCT00872716,Quetiapine in Specific Phobia,QUISS,Completed,No Results Available,Specific Phobia,Drug: Quetiapine XR|Other: Placebo,VAS-Anxiety|State-Trait-Anxiety-Inventory (STAI)|Beck Anxiety Inventory (BAI)|Phobia specific questionnaire|Acute Panic Inventory (API)|Profile of Mood States (POMS)|VAS-Avoidance|VAS-Tension|VAS-Sedation|amygdala reactivity,University Hospital Muenster|AstraZeneca,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,60,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",D1443L00051|EudraCT-Nr: 2008-001371-30,Apr-09,Mar-11,Mar-11,31-Mar-09,null,31-Mar-11,"University Hospital Muenster, Department of Psychiatry, Muenster, Germany",,https://ClinicalTrials.gov/show/NCT00872716
NCT00872820,Examining Long-Term Effects and Neural Mediators of Behavioral Treatments for Social Anxiety Disorder,,Completed,No Results Available,Social Anxiety Disorder,Behavioral: Acceptance- and commitment-based behavioral therapy|Behavioral: Cognitive behavioral therapy,"Brain activity, assessed using functional magnetic resonance imaging (fMRI)|Social anxiety symptoms","University of California, Los Angeles|National Institute of Mental Health (NIMH)",All,18 Years to 45 Years   (Adult),Not Applicable,50,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,R21MH081299|DATR A3-NSS,Oct-08,Sep-13,Sep-13,31-Mar-09,null,11-Dec-14,"UCLA Psychology Department - Franz Hall, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT00872820
NCT00871143,Cognitive Behaviour Therapy (CBT) for Body Dysmorphic Disorder (BDD),,Completed,Has Results,Body Dysmorphic Disorder,Behavioral: CBT specific for BDD|Behavioral: Non specific CBT,"Yale Brown Obsessive Compulsive Scale (Modified for BDD) (BDD -YBOCS) (Phillips et al., 1997)|Brown Assessment of Beliefs to Measure the Strength of Conviction in Beliefs About Being Ugly (Eisen et al., 1998)|Montgomery Asberg Depression Rating Scale (Montgomery and Asberg, 1979).|Appearance Anxiety Inventory (AAI)|Patient Health Questionnaire (PHQ)-9|Generalised Anxiety Disorder (GAD)-7|Body Image Quality of Life Inventory (BIQLI)","Institute of Psychiatry, London",All,"17 Years to 65 Years   (Child, Adult, Older Adult)",Not Applicable,46,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,PAXKAYR|0,Apr-09,May-11,Sep-12,30-Mar-09,6-Oct-15,6-Oct-15,"South London and Maudsley NHS Trust, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT00871143
NCT00871884,Evaluation of Two Treatments for Chronic Post Concussion Syndrome,,Terminated,No Results Available,Post Concussion Syndrome|Head Injury,Behavioral: Psychoeducation|Behavioral: Relaxation Training|Behavioral: Interoceptive Exposure,Post Concussion Symptom Checklist|Anxiety Sensitivity Index|State Trait Anxiety Inventory|Zung Self Rated Depression Scale,Simon Fraser University,All,"19 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,10,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,1234567,Apr-08,Jan-14,Jan-14,30-Mar-09,null,22-Jan-14,"Clinical Psychology Centre, Simon Fraser University, Burnaby, British Columbia, Canada",,https://ClinicalTrials.gov/show/NCT00871884
NCT00870753,Yoga in Treatment of Eating Disorders,,Unknown status,No Results Available,Eating Disorders,Behavioral: Yoga,reduction in eating disorders symptoms assessed by Eating Disorders Examination clinical interview|increased body awareness,Norwegian School of Sport Sciences|University of Oslo,All,"18 Years and older   (Adult, Older Adult)",Phase 1,50,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,2.2006.1243,Mar-09,Dec-10,Dec-11,27-Mar-09,null,27-Mar-09,"Norwegian School of Sport Sciences, Oslo, Norway",,https://ClinicalTrials.gov/show/NCT00870753
NCT00868374,Quetiapine Extended Release (XR) Treatment of Major Depressive Disorder With Comorbid Generalized Anxiety Disorder,MDD/GAD,Terminated,Has Results,Major Depressive Disorder|Generalized Anxiety Disorder,Drug: Quetiapine XR|Drug: Placebo,Change in 17 Item Hamilton Rating Scale for Depression (HAM-D-17),Keming Gao|AstraZeneca|University Hospitals Cleveland Medical Center,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,23,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",12/7/2029,Jun-08,Oct-11,Oct-11,25-Mar-09,11-Feb-14,29-Dec-16,"University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT00868374
NCT00866411,Cranial Electrotherapy Stimulation (CES) for Soldiers With Combat-Related Symptoms,CES,Unknown status,No Results Available,Combat Related Symptoms|Irritability|Anger,Procedure: cranial electrotherapy stimulation (CES) with Alpha-Stim|Procedure: placebo,Irritability Visual Analog Scale|State Anxiety Scale|Pittsburgh Sleep Quality Index|Epworth Sleepiness Scale|General Sleep Disturbance Scale|Sleep Self Care Questionnaire|Combat Exposure Scale|Trauma Imagery Scale|State - Anxiety Scale|Profile of Mood States|Visual Analog|Center for Epidemiological Center for Epidemiological Studies - Depression Scale|Depression Visual Analog|PTSD CheckList - Military Version|Veteran's Outcomes Survey Short Form - 36|Medication Use Questionnaire|Spielberger State-Trait Anger Expression Inventory-2(STAXI-2),Brooke Army Medical Center,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100,U.S. Fed,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",C.2007.147,May-07,May-09,Jan-10,20-Mar-09,null,20-Mar-09,"Carl R. Darnall Army Medical Center, Fort Hood, Texas, United States|Brooke Army Medical Center, Fort Sam Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00866411
NCT00866632,Improving Psychological Wellness After Acquired Brain Injury,,Unknown status,No Results Available,Depression|Anxiety|Brain Injury,Behavioral: Cognitive Behavioural Therapy,"Greater reduction in distress as determined by improved scores on the Global Severity Index of the Symptom Checklist 90-R.|Reduction in psychological distress and improvement in coping as determined by improved scores on the Depression Anxiety Stress Scale, Community Integration Scale, and the Satisfaction with Life questionnaire.",Toronto Rehabilitation Institute|Ontario Neurotrauma Foundation|Peel Halton Acquired Brain Injury Services,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,75,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,2007-ABI-COP-538,Jun-08,Dec-10,null,20-Mar-09,null,10-Sep-10,"Peel Halton Acquired Brain Injury Service, Mississauga, Ontario, Canada|Toronto Rehabilitation Institute, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT00866632
NCT00864123,D-Cycloserine Augmentation of Therapy for Pediatric Obsessive-Compulsive Disorder,,Completed,Has Results,Obsessive-compulsive Disorder,Behavioral: Cognitive-behavioral therapy|Drug: D-cycloserine|Drug: Placebo pill,"Children's Yale-Brown Obsessive-Compulsive Scale (CY-BOCS; Scahill et al., 1997).|Clinical Global Impression - Severity (CGI-S; National Institute of Mental Health, 1985). The CGI-S is a 7-point Clinician Rating of Severity of Psychopathology.|Adverse Symptom Checklist (ASC; Goodman, 2005).",University of South Florida,All,8 Years to 17 Years   (Child),Phase 2,30,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MH076775,Jan-08,Nov-09,Nov-09,18-Mar-09,17-Oct-12,17-Oct-12,"University of South Florida, St. Petersburg, Florida, United States",,https://ClinicalTrials.gov/show/NCT00864123
NCT00862212,Phased Treatment for Social Anxiety Disorder and Coping Behaviors in a Medical Setting,,Completed,No Results Available,Social Anxiety Disorder|Alcohol Use Disorders,Behavioral: Brief Alcohol Intervention,"alcohol use, as indexed by (1) Drinks per Week and (2) Drinks per Drinking Day|alcohol intervention effect on hazardous drinker status",Medical University of South Carolina|National Institutes of Health (NIH)|National Institute on Alcohol Abuse and Alcoholism (NIAAA),All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,83,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",R01AA013379-05A1,Jan-09,Jul-12,Jul-12,16-Mar-09,null,23-Apr-13,"University of Minnesota, Minneapolis, Minnesota, United States|Medical University of South Carolina, Charleston, South Carolina, United States",,https://ClinicalTrials.gov/show/NCT00862212
NCT00861666,Forgiveness-Based Writing to Prevent Post-Traumatic Stress Disorder (PTSD) in Operation Enduring Freedom/Operation Iraqi Freedom (OEF/OIF) Veterans,,Unknown status,No Results Available,"Stress Disorders, Traumatic|Anxiety Disorders|PTSD",Behavioral: Forgiveness-Based Writing,TEI-SF (Treatment Evaluation Inventory-Short Form)|CSQ-8 (Client Satisfaction Questionnaire)|SCID-PTSD Module|DASS-21 (Depression Anxiety and Stress Scales)|PCL-C (PTSD Checklist- Civilian Version)|PTCI (Posttraumatic Cognitions Inventory),"South Central VA Mental Illness Research, Education & Clinical Center",All,18 Years to 64 Years   (Adult),Not Applicable,20,U.S. Fed,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,H-23892,Oct-08,Jul-09,Jul-09,13-Mar-09,null,3-Jun-09,"Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00861666
NCT00859365,Acupuncture for Back and Neck Pain in an Emergency Room Setting,ABNP,Completed,No Results Available,Back Pain|Neck Pain|Anxiety|Range of Motion,Procedure: Real Acupuncture|Procedure: Placebo Acupuncture|Procedure: No intervention,A comparable difference in pain levels between a combined medication and acupuncture treatment to medication treatment alone as measured by the Numeric Rating Scale (NRS)|4.2.1 A comparable difference in range of motion between a combined medication and acupuncture treatment to medication treatment alone as measured by Spine Scan Device and physical exam using gonoimeter|4.2.2 A comparable difference in patient self reported anxiety assessed by Hebrew version of the anxiety and somatization sections of the Symptom Check List-90 questioner (SCL-90)|4.2.3 A comparable difference in the amount of analgesic pain medication consumed by the patients during the week following the treatment|4.2.4 A comparable difference in safety and patient satisfactory as measured by overall satisfactory and safety questionnaires,Assaf-Harofeh Medical Center,All,18 Years to 60 Years   (Adult),Phase 1|Phase 2,65,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",127/08,Jan-09,Sep-11,Sep-11,11-Mar-09,null,31-Jan-12,"Asaf Harofeh Medical Center, Beer-Yaacob, Zerifin, Israel",,https://ClinicalTrials.gov/show/NCT00859365
NCT00855192,Antenatal Relaxation Group for Anxiety and Depression Management,ARG,Unknown status,No Results Available,Anxiety|Depression,Behavioral: mindful meditation|Behavioral: interpersonal therapy,Depression as measured by Edinburgh Postnatal Depression Scale and anxiety as measured by the State-Trait Anxiety Inventory and the Cambridge Worry Scale,"University of Saskatchewan|Royal University Hospital Foundation, Saskatoon, SK, Canada",Female,"16 Years to 60 Years   (Child, Adult)",Not Applicable,20,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Beh #07-10,Oct-08,Dec-09,Dec-09,4-Mar-09,null,18-Mar-10,"Saskatoon Community Village, Saskatoon, Saskatchewan, Canada|University of Saskatchewan Department of Psychiatry, Saskatoon, Saskatchewan, Canada",,https://ClinicalTrials.gov/show/NCT00855192
NCT00854919,Effectiveness and Safety of Atypical Antipsychotic Agents in Augmenting SSRI-Refractory Obsessive-Compulsive Disorder,OCDDRUG,Completed,No Results Available,SSRI-Refractory Obsessive-Compulsive Disorder,Drug: atypical antipsychotic drug|Behavioral: exposure response prevention,"Yale-Brown Obsessive-Compulsive Scale|yale-Brown Obsessive-Compulsive Scale|BMI, TG, T-CHO, FBS",Osaka City University,All,20 Years to 50 Years   (Adult),Phase 4,null,Other,Interventional,,18591305,Jan-06,Dec-07,Dec-07,3-Mar-09,null,3-Mar-09,"Dept of Neuropsychiatry, Osaka City University, graduate School of Medicine, Osaka, Japan",,https://ClinicalTrials.gov/show/NCT00854919
NCT00851071,Interventional Study of Anxiety Symptoms in the Implantable Cardioverter Defibrillator (ICD) Patient,,Completed,No Results Available,Anxiety,Behavioral: Cognitive Behavioral Therapy,Patients in the CBT intervention arm will have a higher reduction in anxiety and experience better quality of life compared to usual care at 3 months.|Patients in the CBT intervention arm will have a lower rate of firings (shocks).,The Cleveland Clinic,All,"Child, Adult, Older Adult",Not Applicable,28,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IRB# 08-913,Feb-09,Dec-11,20-Dec-17,25-Feb-09,null,22-Dec-17,"Cleveland Clinic, Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT00851071
NCT00850226,Comparing Acceptance and Commitment Therapy (ACT) and Cognitive Therapy (CT) for Test Anxiety,,Completed,No Results Available,Anxiety,Behavioral: CT|Behavioral: ACT,grades on final exams,Drexel University,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,50,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,17111,Feb-09,Feb-10,Feb-10,24-Feb-09,null,2-Jun-10,"Drexel University, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00850226
NCT00848367,Binge Eating Disorder Treatment Study,,Completed,Has Results,Binge Eating Disorder,Behavioral: Group Psychodynamic Interpersonal Psychotherapy,Frequency of Binge Eating in the Past 28 Days|Depression Symptoms,Ottawa Hospital Research Institute|Canadian Institutes of Health Research (CIHR),Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,102,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,2007254-01H,Apr-07,Sep-10,Dec-11,20-Feb-09,11-Dec-13,7-Feb-14,"Regional Centre for the Treatment of Eating Disorders, Ottawa, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT00848367
NCT00847561,Effectiveness of a Family-Based Treatment for Preventing Anxiety Disorders in At-Risk Children,,Completed,Has Results,Anxiety Disorders,Behavioral: Family-based CBT|Behavioral: Information Monitoring,"Anxiety Disorders Interview Schedule for Diagnostic and Statistical Manual for Psychological Disorders-IV, Child and Parent Versions (C/P-ADIS)",Johns Hopkins University|National Institute of Mental Health (NIMH),All,6 Years to 13 Years   (Child),Not Applicable,136,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,R01MH077312|R01MH077312-01|DDTR B4-TBI,Aug-08,May-14,May-14,19-Feb-09,3-Jun-14,24-Mar-17,"The Johns Hopkins University School of Medicine, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00847561
NCT00845234,Establishing a Standard for Peri-operative Implantable Cardioverter Defibrillator (ICD) Patient Education,,Completed,No Results Available,Arrhythmia,Behavioral: Intervention,Score on measure assessing construct of quality of life|Score on measure assessing depression|score on measure assessing construct of patient acceptance of device|score on measure assessing anxiety,East Carolina University|Aurora Denver Cardiology Associates|Medtronic,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,62,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,00293-2008-0356-1,Jul-08,Jan-11,Jan-11,18-Feb-09,null,26-Feb-13,"Aurora Denver Cardiology Associates, Aurora, Colorado, United States|Aurora Denver Cardiology Associates, Lone Tree, Colorado, United States|East Carolina Heart Institute, Greenville, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT00845234
NCT00845260,Internet-Versus Group-Administered Cognitive Behavior Therapy for Panic Disorder,IP2,Completed,No Results Available,Panic Disorder,Behavioral: Internet-based cognitive behavior therapy (CBT).|Behavioral: Group CBT,Panic Disorder Severity Scale (PDSS)|Montgomery-Åsberg Depression Rating Scale (MADRS) Anxiety Sensitivity Index (ASI) Sheehan Disability Scale (SDS),"Karolinska Institutet|Stockholm County Council, Sweden",All,"18 Years and older   (Adult, Older Adult)",Phase 3,113,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,IP2|Dnr 04-034/4,Dec-04,Dec-07,Dec-07,18-Feb-09,null,18-Feb-09,"Karolinska Institutet, Department of Clinical Neuroscience, Section of psychiatry, Karolinska Hospital Solna R5, Stockholm, Sweden",,https://ClinicalTrials.gov/show/NCT00845260
NCT00842946,Exposure With Acceptance-Based Versus Habituation-Based Rationale for Public Speaking Anxiety,,Completed,Has Results,Public Speaking|Social Fear,Behavioral: Exposure w/ Acceptance-Based Rationale|Behavioral: Exposure w/ Habituation-Based Rationale,Number of Participants in Remission (Per Structured Clinical Interview for DSM-IV Axis I Disorders (SCID)),Drexel University,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,45,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,DRX-17819,Feb-09,Nov-09,Nov-09,12-Feb-09,2-Jun-14,2-Jun-14,"Drexel University, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00842946
NCT00841022,Information and Anaesthesia in Paediatrics,,Completed,No Results Available,Anxiety,Other: Information with comics,"Level of anxiety scale (STAIC-S)|Level of verbal comprehension : WISC 4 (similitude, vocabulary and comprehension)|Level of anxiety scale (STAIC-T)",Hospices Civils de Lyon,All,6 Years to 16 Years   (Child),Not Applicable,115,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,2008.518,Feb-09,Apr-13,Apr-13,11-Feb-09,null,23-Oct-13,"Hospices Civils de Lyon, Lyon, France",,https://ClinicalTrials.gov/show/NCT00841022
NCT00836069,Fixed Dose Study of PD 0332334 and Paroxetine for the Treatment of Generalized Anxiety Disorder,,Terminated,No Results Available,Anxiety Disorders,Drug: PD 0332334|Drug: Paroxetine|Drug: Placebo,Hamilton Anxiety Scale,Cedars-Sinai Medical Center|Pfizer,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,5,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",15002,Oct-08,Feb-09,Apr-10,4-Feb-09,null,10-May-19,"Cedars-Sinai Medical Center Department of Psychiatry and Behavioral Neurosciences, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT00836069
NCT00833469,Escitalopram (Lexapro) for the Treatment of Postpartum Depression,LexaproPPD,Completed,Has Results,Postpartum Depression,Drug: Escitalopram,Change in Clinician-rated Montgomery-Asberg Depression Rating Scale (MADRS)|Change in Edinburgh Postnatal Depression Scale (EPDS)|Change in Beck Anxiety Inventory (BAI),Massachusetts General Hospital|Forest Laboratories,Female,18 Years to 45 Years   (Adult),Phase 4,7,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2008-P-001509,Jan-09,Apr-11,Apr-11,2-Feb-09,6-Aug-14,6-Aug-14,"Massachusetts General Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT00833469
NCT00833898,Stress Management Intervention for Caregivers of Patients Undergoing Bone Marrow Transplant (BMT),,Completed,Has Results,Hematopoietic/Lymphoid Cancer,Device: Paced respiration as part of PEPRR|Behavioral: PEPRR,Behavioral - Stress Level as Measured by the Perceived Stress Scale (PSS)|Physiological - Cortisol Awakening Response (CAR)|Depression Measured by the Center for Epidemiological Studies Depression Scale (CESD)|State Anxiety as Measured by the Spielberger State-Trait Anxiety Inventory (STAI)|Total Mood Disturbance (TMD) Score Using the Profile of Mood States (POMS)|Stress as Measured by Caregiver Burden Using the Caregiver Reaction Assessment (CRA)|Sleep as Assessed by the Pittsburgh Sleep Quality Inventory (PSQI) Total Score|Mental Component Summary Via the Short-Form 36-Item Health Survey Version 2.0 (SF-36M)|Physical Component Summary Via the Short-Form 36-Item Health Survey Version 2.0 (SF-36P)|Stress as Measured by the Impact of Events Scale (IES)|The Slope of the Diurnal Decline in Salivary Cortisol (SlopeC)|The Slope of the Diurnal Decline (SlopeD) in Salivary Dehydroepiandrosterone (DHEA)|Area Under the Curve for Salivary Cortisol (AUCc)|Area Under the Curve for Salivary DHEA (AUCd)|Host Defense Assessed by Natural Killer (NK) Cell Cytotoxicity|Plasma C-reactive Protein (CRP)|Plasma Inflammatory Marker Interleukin 1 Beta (IL-1 Beta)|Plasma Inflammatory Marker Interleukin 6 (IL-6)|Plasma Inflammatory Marker Interleukin 4 (IL-4)|Plasma Inflammatory Marker Interleukin 10 (IL-10)|Plasma Inflammatory Marker Tumor Necrosis Factor (TNF),"University of Colorado, Denver|National Cancer Institute (NCI)",All,"18 Years and older   (Adult, Older Adult)",Phase 3,298,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,08-0303|1R01CA126971-01A1,Nov-08,Jun-13,Jun-13,2-Feb-09,10-Sep-15,9-Dec-15,"University of Colorado Cancer Center at UC Health Sciences Center, Aurora, Colorado, United States|Presbyterian/St. Luke's Medical Center (PSLMC) - Denver Midtown, Denver, Colorado, United States",,https://ClinicalTrials.gov/show/NCT00833898
NCT00832468,The Complementary Effect of Ear Acupressure on Older Patients With Chronic Insomnia,,Completed,No Results Available,Insomnia,Other: ear acupressure|Other: sham ear acupressure,"polysomnography|Pittsburgh sleep quality index, Heart rate variability, SF-36",National Yang Ming University,All,"55 Years to 75 Years   (Adult, Older Adult)",Phase 2,72,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",97032R,Dec-08,Nov-09,Dec-09,30-Jan-09,null,8-Dec-09,"Taipei Veterans General Hospital, Taipei, Taiwan",,https://ClinicalTrials.gov/show/NCT00832468
NCT00828152,Internet-delivered Cognitive Behavioral Therapy (CBT) for Health Anxiety,Ha1b,Completed,No Results Available,Hypochondriasis,Behavioral: Internet-delivered CBT.|Behavioral: On line discussion group,Health Anxiety Inventory|IAS|BAI|MADRS-S|QOLI|WI,Karolinska Institutet,All,"18 Years and older   (Adult, Older Adult)",Phase 2,80,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Ha1b,Jan-09,Jun-10,Jul-10,23-Jan-09,null,6-May-15,"Psykiatri Sydväst, Stockholm, Sweden",,https://ClinicalTrials.gov/show/NCT00828152
NCT00825539,Pharmacodynamic/Pharmacokinetic Study of AQW051 in Schizophrenia,,Completed,No Results Available,Schizophrenia,Drug: AQW051|Drug: Placebo,Part 1: Assess BOLD response in key brain areas in schizophrenia patients during the performance of tasks as measured by (fMRI) in people with schizophrenia.|Part 2: Assess safety and tolerability of multiple doses of AQW051 schizophrenia patients.|Measure: To assess the effects of a single dose of AQW051 on performance of working and episodic memory tasks in people with schizophrenia. (Part 1)|Measure: To determine the relationship of exposure to brain activation after a single dose of AQW051 in people with schizophrenia. (Part 1)|Measure: To determine the dose-exposure response relationship of multiple doses of AQW051 in people with schizophrenia. (Part 2)|Measure: To explore effects of multiple doses of AQW051 on measures of cognition in people with schizophrenia. (Part 2),Novartis Pharmaceuticals|Novartis,All,18 Years to 60 Years   (Adult),Phase 1|Phase 2,68,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",CAQW051A2202,Jan-09,Nov-11,Nov-11,21-Jan-09,null,28-Feb-13,"West LA VA Healthcare Center (UCLA), Los Angeles, California, United States|Department of Psychiatry & Behavioural Sciences, Feinberg School of Medicine (Northwestern University), Chicago, Illinois, United States|Maryland Psychiatric Research Centre, Spring Grove Hospital Grounds, Baltimore, Maryland, United States|Massachusetts General Hospital (Freedom Trail Clinic), Boston, Massachusetts, United States|Washington University, St Louis, Missouri, United States|Columbia University, New York, New York, United States|JUH Clinical Research (Duke University),, Butner, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT00825539
NCT00826111,The Effects of Eszopiclone and Lexapro on Prefrontal Glutamate and GABA in Depression With Anxiety and Insomnia,,Completed,Has Results,Depression|Anxiety|Insomnia,Drug: Eszopiclone|Drug: Placebo,Change in Anterior Cingulate Cortex Glutamine From Baseline to Week 1.|Change in Thalamic Glutamine From Baseline to Week 1|Change in Anterior Cingulate Cortex Glutamate From Baseline to Week 1|Change in Thalamic Glutamate From Baseline to Week 1|Change in Anterior Cingulate Cortex GABA From Baseline to Week 1|Change in Thalamic GABA From Baseline to Week 1|Change in Hamilton Depression Rating Scale Score From Baseline to Week 10|Change in Hamilton Anxiety Rating Scale Score From Baseline to Week 10|Change in Insomnia Severity Index Score From Baseline to Week 10,"Steward St. Elizabeth's Medical Center of Boston, Inc.|Sunovion",Female,18 Years to 55 Years   (Adult),Phase 4,19,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",427,Aug-07,Jan-11,Jul-11,21-Jan-09,29-Jun-12,29-Jun-12,"Steward St. Elizabeth's Medical Center of Boston, Inc., Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT00826111
NCT00824681,Effect of Music Therapy on Families of Burn Patients,MTS3,Terminated,No Results Available,Burns,Behavioral: Sound Of Family Together (S.O.F.T.) Music Program|Other: Non-Therapy Related Activities (NTRA),Anxiety level,MetroHealth Medical Center|The Cleveland Music School Settlement|Kulas Foundation,All,6 Years to 14 Years   (Child),Phase 1,30,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,06-00891,Sep-07,Jul-10,Jul-10,19-Jan-09,null,23-Jul-10,"MetroHealth Medical Center, Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT00824681
NCT00825136,Treatment of Panic Disorder Via Internet With a Wireless Temperature Biofeedback Ring,,Terminated,No Results Available,Panic Disorder,Behavioral: relaxation|Behavioral: biofeedback (finger temperature biofeedback),score change of The Panic Disorder Severity Scale(PDSS)|score change of MOS 36-Item Short-Form Health Survey (SF-36),Chimei Medical Center,All,18 Years to 60 Years   (Adult),Not Applicable,10,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IRB 09707-001,Jul-08,Feb-09,May-09,19-Jan-09,null,21-Aug-12,"Psychiatry Department, Chimei Medical Center, Tainan, Taiwan",,https://ClinicalTrials.gov/show/NCT00825136
NCT00823017,Effect of Music on Patients in Intensive Care Units,MTS2,Withdrawn,No Results Available,Intensive Care Unit,Other: Patient-preferred music|Other: Relaxation Music|Other: Standard Care Environment,Pain level|Anxiety level|Comfort level|Heart rate|Respiration rate|Blood pressure|Saliva/Serum Cortisol level|Saliva/Serum Immunoglobulin A Concentration|Psychophysical properties of relaxation music,MetroHealth Medical Center|The Cleveland Music School Settlement|Kulas Foundation|Arthur Flagler Fultz Research Award (American Music Therapy Association),All,"18 Years and older   (Adult, Older Adult)",Phase 1,0,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,IRB06-00070,Jul-06,Jul-10,2-Mar-11,15-Jan-09,null,18-May-18,"MetroHealth Medical Center, Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT00823017
NCT00822497,Efficacy of Music Therapy Protocols for Burn Debridement,MTS1,Completed,No Results Available,Pain Management,Behavioral: Music-Based Imagery (MBI)|Behavioral: Music Alternate Engagement (MAE),"Pain, Anxiety, Muscle Tension levels|Narcotics & Anxiolytics (dosage)",MetroHealth Medical Center|The Cleveland Music School Settlement|Kulas Foundation,All,"7 Years and older   (Child, Adult, Older Adult)",Phase 1,50,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,99-00147,Oct-04,Jul-10,Jul-10,14-Jan-09,null,23-Jul-10,"MetroHealth Medical Center, Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT00822497
NCT00822601,Study of Repetitive Transcranial Magnetic Stimulation Efficacy on Obsessive Compulsive Disorder (OCD),TMS-TOC,Completed,No Results Available,Obsessive-Compulsive Disorder,Device: rTMS|Device: Sham Comparator,Yale-Brown Obsessive Compulsive Scale (YBOCS)|Clinical Global Impression - Severity (CGI-S)|- Clinical Global Impression - Improvement (CGI-I)|Global Assessment of Functioning (GAF)|- Montgomery Asberg Depression Rating Scale (MADRS)|Brief Anxiety Scale (BAS|Sheehan Disability Scale (SDS)|Hospital Anxiety and Depression (HAD) scale|Maudsley Obsessional Inventory (MOCI)|LPO scale,Assistance Publique - Hôpitaux de Paris,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,40,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",AOR07067,Nov-08,Apr-12,Apr-12,14-Jan-09,null,31-Jul-12,"Pitie Salpetriere Hospital, Paris, France",,https://ClinicalTrials.gov/show/NCT00822601
NCT00821288,Post-treatment Care of Breast Cancer Survivors,,Completed,No Results Available,Breast Neoplasm,Behavioral: Survivorship Intervention|Behavioral: Facing Forward,Change in FACIT-TS questionnaire score,Columbia University|Susan G. Komen Breast Cancer Foundation,Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,140,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care,AAAC5741|DISP0706868,Jul-07,Oct-11,May-13,13-Jan-09,null,19-Jun-17,"Columbia Unviersity Medical Center, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00821288
NCT00820794,A Phase 1 Study To Estimate The Effects Of PD 0332334 On Lithium Pharmacokinetics In Healthy Subjects,,Withdrawn,No Results Available,Generalized Anxiety Disease,Drug: Lithium|Drug: PD 0332334,"Lithium pharmacokinetic endpoints: area under curve from 0 to infinity (AUCinf), area under curve from 0 to last quantifiable concentration (AUClast), half-life (T1/2), and maximum serum concentration (Cmax).|The nature, incidence, duration, and severity of adverse events; discontinuation due to adverse events; clinical safety lab; 12-lead ECG; and vital signs will be monitored in this study.|No Secondary Outcomes",Pfizer,All,21 Years to 55 Years   (Adult),Phase 1,0,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label),A5361034,May-09,Jun-09,Jun-09,12-Jan-09,null,5-Mar-15,,,https://ClinicalTrials.gov/show/NCT00820794
NCT00819208,Health Education Materials With or Without a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer,,Recruiting,No Results Available,Anxiety Disorder|Cognitive/Functional Effects|Colorectal Cancer|Depression|Fatigue|Psychosocial Effects of Cancer and Its Treatment|Sleep Disorders|Excercise,Behavioral: exercise intervention|Other: counseling intervention|Other: educational intervention|Other: laboratory biomarker analysis|Other: questionnaire administration|Other: study of socioeconomic and demographic variables|Procedure: fatigue assessment and management|Procedure: quality-of-life assessment|Other: Educational Intervention|Other: Fitness testing,"Disease-free survival|Overall survival|Patient-reported outcomes, including quality of life, using SF-36, FACIT-F, PSQI, and HADS questionnaires|Objective markers of physical fitness (i.e., body mass index, hip and waist circumference, cardiovascular fitness, and physical function)|Physical activity behavior as assessed by TPAQ|Safety profile according to NCI CTCAE version 3.0|Correlative biological markers including biochemical and molecular markers associated with insulin-related growth factor and cytokines associated with the mechanisms of fatigue|Economic evaluations including cost-effective analysis and cost utility analysis|Predictors of physical activity adherence as assessed by Social Cognitive Determinants of Exercise questionnaire","Canadian Cancer Trials Group|Survivorship Research Group|Queen's University, Belfast",All,"18 Years and older   (Adult, Older Adult)",Phase 3,962,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,CO21|CAN-NCIC-CO21|CDR0000629834,3-Dec-08,Dec-29,Dec-30,8-Jan-09,null,10-Apr-19,"Henry Ford Hospital, Detroit, Michigan, United States|Dartmouth-Hitchcock, Lebanon, New Hampshire, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Armidale Hospital, Armidale, New South Wales, Australia|Bankstown-Lidcombe Hospital, Bankstown, New South Wales, Australia|Southern Highlands Cancer Centre, Bowral, New South Wales, Australia|Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia|North Coast Cancer Institute Coffs Harbour, Coffs Harbour, New South Wales, Australia|Concord Repatriation General Hospital, Concord, New South Wales, Australia|Liverpool Hospital, Liverpool, New South Wales, Australia|Newcastle Private Hospital, Newcastle, New South Wales, Australia|North Coast Cancer Institute - Port Macquarie, Port Macquarie, New South Wales, Australia|Prince of Wales Hospital, Randwick, New South Wales, Australia|Royal North Shore Hospital, St Leonards, New South Wales, Australia|Tamworth Hospital, Tamworth, New South Wales, Australia|Riverina Cancer Care Centre, Wagga Wagga, New South Wales, Australia|Sydney Adventist Hospital, Wahroonga, New South Wales, Australia|Royal Brisbane and Women's Hospital, Herston, Queensland, Australia|Princess Alexandra, Woolloongabba, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Flinders Medical Centre, Bedford Park, South Australia, Australia|The Queen Elizabeth Hospital, Woodville, South Australia, Australia|Ballarat Health Services, Ballarat, Victoria, Australia|St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia|Royal Perth Hospital, Perth, Western Australia, Australia|Macarthur Cancer Therapy Centre - Campbelltown Hospital, Campbelltown, Australia|Tom Baker Cancer Centre, Calgary, Alberta, Canada|Cross Cancer Institute, Edmonton, Alberta, Canada|BCCA - Vancouver Cancer Centre, Vancouver, British Columbia, Canada|CancerCare Manitoba, Winnipeg, Manitoba, Canada|Horizon Health Network, Fredericton, New Brunswick, Canada|The Moncton Hospital, Moncton, New Brunswick, Canada|Regional Health Authority B, Zone 2, Saint John, New Brunswick, Canada|Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada|Kingston Health Sciences Centre, Kingston, Ontario, Canada|Grand River Regional Cancer Centre, Kitchener, Ontario, Canada|London Regional Cancer Program, London, Ontario, Canada|Trillium Health Partners - Credit Valley Hospital, Mississauga, Ontario, Canada|Stronach Regional Health Centre at Southlake, Newmarket, Ontario, Canada|Ottawa Hospital Research Institute, Ottawa, Ontario, Canada|Niagara Health System, St. Catharines, Ontario, Canada|Toronto Rehab, Toronto, Ontario, Canada|Odette Cancer Centre, Toronto, Ontario, Canada|Mount Sinai Hospital, Toronto, Ontario, Canada|University Health Network, Toronto, Ontario, Canada|L'Hotel-Dieu de Levis, Levis, Quebec, Canada|Allan Blair Cancer Centre, Regina, Saskatchewan, Canada|Saskatoon Cancer Centre, Saskatoon, Saskatchewan, Canada|Montpellier 34298, France|Exercise Medicine Center for Diabetes and Cancer, Seoul, Korea, Republic of|Belfast City Hospital, Belfast, Co. Antrim, United Kingdom",,https://ClinicalTrials.gov/show/NCT00819208
NCT00816699,Effects of Providing Preprint Preoperative Anesthetic Risk Information,,Completed,No Results Available,Preoperative Anxiety,Other: preprint preoperative anesthetic risk information,"Spielberger State Trait Anxiety Inventory Scale|Knowledge, proportion of patients who cancel surgery, proportion who refuse regional anesthesia",Mahidol University,All,"16 Years to 80 Years   (Child, Adult, Older Adult)",Phase 1|Phase 2,103,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Si325/2008,Dec-08,Aug-10,Sep-10,5-Jan-09,null,11-Mar-11,"Faculty of Medicine, Siriraj Hospital, Mahidol Unversity, Bangkok, Thailand",,https://ClinicalTrials.gov/show/NCT00816699
NCT00814931,Examining the Effects of CXB722 in Neuroendocrine Stress Response in Healthy Males,CXB722-100,Completed,No Results Available,Stress|Anxiety,Drug: CXB722|Drug: Placebo,"Plasma cortisol and salivary cortisol levels|Plasma ACTH|Plasma epinephrine and norepinephrine|Profile of Mood States (POMS) Tension-Anxiety|Fatigue-Inertia, and Vigor-Activity factor scores|""State"" score on the Spielberger State-Trait Anxiety Scale (SSTAS)|Seven Visual Analog Scales (VAS)|HR, and systolic and diastolic BP",CeNeRx BioPharma Inc.|National Institute on Aging (NIA),Male,18 Years to 34 Years   (Adult),Phase 1,23,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AG0114,Dec-08,Dec-08,Dec-08,25-Dec-08,null,13-Jan-09,"University of South Florida, Tampa, Florida, United States",,https://ClinicalTrials.gov/show/NCT00814931
NCT00809380,Parental Presence During Fracture Reduction in Children at the Emergency Department; A Randomized Controlled Trial,PP,Terminated,No Results Available,Conscious Sedation|Anxiety,Behavioral: Parental presence|Behavioral: Control,The children's anxiety will be measured using the State-Trait Anxiety Inventory (STAI) score (in children older than 12) or State-Trait Anxiety Inventory for children (STAIC) scores (in children from 8 to 12 years old)|The parents' anxiety will be measured using the STAI scores.|Procedure time|Doses and types of medications used|Fracture reduction success and failure rates|Attempt of reduction by the residents|STAI and STAIC scores in children at induction of conscious sedation will be compared between both groups|Children's anxiety levels will also be assessed with the modified Yale Preoperative Anxiety Scale,St. Justine's Hospital|Association des Médecins d'Urgence du Quebec,All,"8 Years to 18 Years   (Child, Adult)",Not Applicable,12,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,PP,Jun-09,Oct-11,Oct-11,17-Dec-08,null,19-Mar-13,"CHU Sainte-Justine, Montreal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT00809380
NCT00809536,Investigation Of How PD 0332334 And Metformin Are Eliminated From The Body When They Are Administered At The Same Time,,Terminated,No Results Available,Generalized Anxiety Disorder,Drug: Metformin|Drug: PD 0332334,"Metformin and PD 0332334 area under the curve (AUC) from time 0 to infinity (AUCinf)|Metformin and PD 0332334 AUC from 0 to last quantifiable concentration (AUClast)|Metformin and PD 0332334 half-life (t1/2)|Metformin and PD 0332334 maximum plasma concentration|Clinical safety laboratories|Incidence, duration and severity of adverse events when study medications administered alone and concurrently|Discontinuation due to adverse events when study medications administered alone and concurrently|12-lead ECGs|Vital signs",Pfizer,All,21 Years to 55 Years   (Adult),Phase 1,24,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label),A5361031,Jan-09,Feb-09,Feb-09,17-Dec-08,null,17-Feb-10,"Pfizer Investigational Site, Singapore, Singapore",,https://ClinicalTrials.gov/show/NCT00809536
NCT00807937,Proof of Concept in Patients With Generalized Anxiety Disorder (GAD)AZD7325,,Completed,Has Results,Anxiety Disorders,Drug: AZD7325|Drug: Lorazepam|Drug: Placebo,Change in the Hamilton Rating Scale for Anxiety (HAM-A) Total Score|Change in Hospital Anxiety and Depression Scale for Anxiety (HADS-A) Total Score|Change in Psychic Anxiety Factor as Measured by HAM-A Psychic Cluster Score|Change in Somatic Symptoms as Measured by HAM-A Somatic Cluster Score|Change in Quality of Life Enjoyment and Satisfaction Questionnaire Short Form (Q-LES-Q-SF) Percent Maximum Total Score,AstraZeneca,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,369,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",D1140C00014,Dec-08,May-09,May-09,15-Dec-08,8-Oct-10,8-Oct-10,"Research Site, Mesa, Arizona, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Carson, California, United States|Research Site, Escondido, California, United States|Research Site, Glendale, California, United States|Research Site, Irvine, California, United States|Research Site, Redlands, California, United States|Research Site, Riverside, California, United States|Research Site, Sherman Oaks, California, United States|Research Site, Fort Lauderdale, Florida, United States|Research Site, Fort Myers, Florida, United States|Research Site, Gainsville, Florida, United States|Research Site, Hallandale Beach, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Maitland, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, St. Petersburg, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, West Palm Beach, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Hoffman Estates, Illinois, United States|Research Site, Oak Brook, Illinois, United States|Research Site, Schaumburg, Illinois, United States|Research Site, Lafayette, Indiana, United States|Research Site, Terre Haute, Indiana, United States|Research Site, Shreveport, Louisiana, United States|Research Site, Glen Burnie, Maryland, United States|Research Site, Westminster, Maryland, United States|Research Site, Braintree, Massachusetts, United States|Research Site, Piscataway, New Jersey, United States|Research Site, Cedarhurst, New York, United States|Research Site, New York, New York, United States|Research Site, Staten Island, New York, United States|Research Site, Raleigh, North Carolina, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Dayton, Ohio, United States|Research Site, Willoughby, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Eugene, Oregon, United States|Research Site, Salem, Oregon, United States|Research Site, Allentown, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Charleston, South Carolina, United States|Research Site, Bartlett, Tennessee, United States|Research Site, Austin, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Wichita Falls, Texas, United States|Research Site, Richmond, Virginia, United States|Research Site, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00807937
NCT00808249,AZD7325 Proof of Concept in Patients With Generalized Anxiety Disorder (GAD),,Completed,Has Results,Anxiety Disorders,Drug: AZD7325|Drug: Placebo,Change From Baseline in the Hamilton Rating Scale for Anxiety (HAM-A) Total Score|Change in Hospital Anxiety and Depression Scale for Anxiety (HADS-A) Total Score|Change in Psychic Anxiety Symptoms as Measured by HAM-A Psychic Anxiety Factor Score|Change in Somatic Symptoms as Measured by HAM-A Somatic Factor Score|Change in Sheehan Disability Scale (SDS) Global Total Score,AstraZeneca,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,725,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",D1140C00006,Dec-08,May-09,May-09,15-Dec-08,19-May-11,20-Jun-11,"Research Site, Birmingham, Alabama, United States|Research Site, Tucson, Arizona, United States|Research Site, Arcadia, California, United States|Research Site, Beverly Hills, California, United States|Research Site, Cerritos, California, United States|Research Site, Chino, California, United States|Research Site, Encino, California, United States|Research Site, Los Alamitos, California, United States|Research Site, Novato, California, United States|Research Site, Oceanside, California, United States|Research Site, San Diego, California, United States|Research Site, Norwich, Connecticut, United States|Research Site, Ft Myers, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Pembroke Pines, Florida, United States|Research Site, St Petersberg, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Winter Park, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Marietta, Georgia, United States|Research Site, Smyrna, Georgia, United States|Research Site, Libertyville, Illinois, United States|Research Site, Park Ridge, Illinois, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Overland Park, Kansas, United States|Research Site, Baltimore, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Cambridge, Massachusetts, United States|Research Site, St. Louis, Missouri, United States|Research Site, Clementon, New Jersey, United States|Research Site, Fresh Meadows, New York, United States|Research Site, Mount Kisco, New York, United States|Research Site, New York, New York, United States|Research Site, Rochester, New York, United States|Research Site, Raleigh, North Carolina, United States|Research Site, Winston-salem, North Carolina, United States|Research Site, Bismarck, North Dakota, United States|Research Site, Beechwood, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Middleburg Heights, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Portland, Oregon, United States|Research Site, Jenkintown, Pennsylvania, United States|Research Site, Norristown, Pennsylvania, United States|Research Site, Memphis, Tennessee, United States|Research Site, Friendswood, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Woodstock, Vermont, United States|Research Site, Herndon, Virginia, United States|Research Site, Spokane, Washington, United States|Research Site, Middleton, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT00808249
NCT00807157,Evaluation of a Probiotic On Anxiety and Stress in Healthy Adults Sensible to Daily Stress,BIOSTRESS,Completed,No Results Available,Anxiety|Stress,Dietary Supplement: PROBIOSTICK® during 30 days|Dietary Supplement: Placebo during 30 days,"SCL 90 questionnaire|Stress perçu, coping de vitaliano, hospital anxiety and depression questionnaires and urinary cortisol measurement",Institut Rosell Lallemand,All,30 Years to 60 Years   (Adult),Not Applicable,66,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",BIOSTRESS 11008,Dec-08,Apr-09,Apr-09,11-Dec-08,null,24-Apr-09,"Biofortis, Nantes, France",,https://ClinicalTrials.gov/show/NCT00807157
NCT00805493,Double-Blind Placebo-Controlled Trial of Riluzole in Pediatric Bipolar Disorder,,Terminated,Has Results,Bipolar Disorder|Anxiety Disorders|Bipolar Affective Disorder|Bipolar Depression,Drug: Riluzole,Clinical Global Impression--Improvement|Pediatric Anxiety Scale,National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC),All,9 Years to 17 Years   (Child),Phase 2,6,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",090042|09-M-0042,Nov-08,Jun-12,Jun-12,9-Dec-08,23-Aug-13,15-Sep-17,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00805493
NCT00804180,Group Therapy Intervention for Children and Adolescents With Injection-Related Anxiety and Their Caregivers,,Withdrawn,No Results Available,Anxiety,Behavioral: Self-Injection Anxiety Counseling,"State Trait Anxiety Inventory: (Spielberger, 1983)|Pediatric Quality of Life Inventory - Generic Core Scales (PedsQL) - Short Form: (Varni, Seid, & Kurtin, 2001)|Subjective Units of Distress Scale|Parental Report of Child's Injection Adherence Percentage (over period of 10 physician-prescribed injection time points)","Medical College of Wisconsin|Children's Hospital and Health System Foundation, Wisconsin",All,8 Years to 17 Years   (Child),Not Applicable,0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"CHW 08/137, GC 742",Oct-08,Aug-09,Aug-09,8-Dec-08,null,23-Jun-15,"Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT00804180
NCT00803361,Duloxetine for the Treatment of Generalized Anxiety Disorder,,Completed,Has Results,Generalized Anxiety Disorder,Drug: Duloxetine|Drug: Placebo,"Change From Baseline in the Hospital Anxiety and Depression Scale (HADS) Anxiety Subscale Score at Endpoint|Change From Baseline in the Hamilton Anxiety (HAMA) Rating Scale Total Score at Endpoint|Mean Clinical Global Impressions (CGI) Improvement Score at Endpoint|Change From Baseline in Brief Pain Inventory (BPI) - Short Form Severity (BPI-S) and Interference (BPI-I) Scores at Endpoint|Change From Baseline in Sheehan Disability Scale (SDS) at Endpoint, Global Functioning Scores|Change From Baseline in Visual Analogue Scale (VAS) for Pain at Endpoint|Change From Baseline in the Hospital Anxiety and Depression Scale (HADS) Depression Subscale Score at Endpoint",Eli Lilly and Company|Boehringer Ingelheim,All,"18 Years and older   (Adult, Older Adult)",Phase 3,210,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",11517|F1J-MC-HMFJ,Dec-08,Jan-10,Jan-10,5-Dec-08,17-Dec-10,17-Dec-10,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Beijing, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Guang Zhou, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hangzhou, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kunming, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nanjing, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Shanghai, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Xi'An, China",,https://ClinicalTrials.gov/show/NCT00803361
NCT00803400,Efficacy of Aerobic Exercise Added to Alprazolam in Panic Disorder Treatment,AEIPDT,Completed,Has Results,Panic Disorder,Drug: Alprazolam|Drug: Alprazolam + Aerobic exercise,Participants´Endpoint Change From Baseline in Hamilton Anxiety Rating Scale|Participants´Endpoint Change From Baseline in Clinical Global Impression Severity Scale (CGI-S)|Participants´Endpoint Change From Baseline in Clinical Global Impression Improvement Scale (CGI-I),University of Buenos Aires,All,20 Years to 60 Years   (Adult),Phase 4,150,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,UDHFMEDUBA0709,Jul-05,Jul-08,Oct-08,5-Dec-08,5-Dec-08,7-May-09,"Psychiatry Academic Unit at J.A.Fernandez Hospital, University of Buenos Aires Medicine School Department of Mental Health, Buenos Aires, Capital Federal, Argentina",,https://ClinicalTrials.gov/show/NCT00803400
NCT00801970,"Fear of Childbirth (Tokophobia) - Etiology, Essence and Clinical Implications",,Unknown status,No Results Available,Phobias,Behavioral: Psychological Treatment|Behavioral: Group Therapy,"Tokophobia existing and new measures (e.g. Pregnancy anxiety scale, Levin, 1991; Tokophobia subjective scale)|For pregnant subjects - labor preference, duration and pain medication assessment.",Tel-Aviv Sourasky Medical Center,Female,"Child, Adult, Older Adult",Not Applicable,150,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TASMC-08-MB-0064-CTIL,Jan-08,Jun-10,Jan-11,4-Dec-08,null,4-Dec-08,"Psychiatry Outpatient Clinic - Sourasky Medical Center, Tel Aviv, Israel",,https://ClinicalTrials.gov/show/NCT00801970
NCT00800280,Evaluating The Effects Of Cimetidine On The Elimination Of PD 0332334 From The Body,,Terminated,No Results Available,Generalized Anxiety Disorder,Drug: PD 0332334|Drug: cimetidine,"PD 0332334 area under the curve (AUC) from 0 to infinity (AUCinf)|PD 0332334 AUC from 0 to last quantifiable concentration (AUClast)|Half-life (t1/2) of PD 0332334|Maximum plasma concentration (Cmax) of PD 0332334|Evaluate the incidence, duration and severity of adverse events|Evaluate the discontinuation due to adverse events|Clinical safety labs|ECG|Vital signs",Pfizer,All,18 Years to 55 Years   (Adult),Phase 1,12,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label),A5361030,Jan-09,Feb-09,Feb-09,2-Dec-08,null,17-Feb-10,"Pfizer Investigational Site, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT00800280
NCT00798941,ICU Patient and Family Comfort Study,,Completed,No Results Available,Pain|Thirst|Anxiety|Satisfaction,Behavioral: mouth care|Behavioral: pain intervention,patient-reported pain|patient-reported thirst|Family-reported anxiety|Family-reported satisfaction,"University of California, San Francisco|Icahn School of Medicine at Mount Sinai",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,120,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,8033609,Feb-09,Jan-10,Jan-10,27-Nov-08,null,8-Jul-10,"U.C. San Francisco, San Francisco, California, United States",,https://ClinicalTrials.gov/show/NCT00798941
NCT00796497,Ondansetron in Treatment Resistant Obsessive Compulsive Disorder (OCD),,Completed,No Results Available,Obsessive Compulsive Disorder,Drug: ondansetron,Yale-Brown Obsessive Compulsive Scale (Y-BOCS)|clinical global impression (CGI),"Institute of Neuroscience, Florence, Italy",All,18 Years to 55 Years   (Adult),Phase 4,14,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,ONDAN-1,Mar-08,Nov-08,Dec-08,24-Nov-08,null,24-Feb-11,"Institute of Neuroscience, Florence, Italy",,https://ClinicalTrials.gov/show/NCT00796497
NCT00795379,Testing the Use of Interoceptive Exposure to Reduce Barriers to Psychotherapy,,Unknown status,No Results Available,Anxiety,Behavioral: Interoceptive Exposure,Anxiety Sensitivity Index-3,G.V. (Sonny) Montgomery VA Medical Center,Male,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,40,U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MIRECC 5-1006,Nov-08,Nov-09,null,21-Nov-08,null,21-Nov-08,"G.V. (Sonny) Montgomery VAMC, Jackson, Mississippi, United States",,https://ClinicalTrials.gov/show/NCT00795379
NCT00794456,Association of Passiflora Incarnata L; Crataegus Oxyacantha L and Salix Alba L. on Mild and Moderate Anxiety,,Completed,No Results Available,Anxiety Disorder,Drug: Passiflora ; Crataegus and Salix|Drug: Valeriana,Hamilton anxiety scale|Insomnia gravity index; global clinical impression; patients global evaluation,Marjan Industria e Comercio ltda,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,150,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",MJ 3002-08,Sep-09,Oct-13,Oct-13,20-Nov-08,null,8-Jul-14,"Unidade de Farmacologia Clínica - UNIFAC, Fortaleza, Ceará, Brazil|SPDM - Associação Paulista para o Desenvolvimento da Medicina - Hospital São Paulo, Sao Paulo, Brazil",,https://ClinicalTrials.gov/show/NCT00794456
NCT00792584,"Patient Preference, Sleep Quality, and Anxiety/Depression: A Randomized Comparison of Etravirine and Efavirenz",SWITCH-EE,Completed,No Results Available,Sleep Disorders,Drug: etravirine|Drug: efavirenz,"Symptoms and neurological side effects of study drugs|Levels of daytime sleepiness|Sleep Quality|Patient preference|Symptoms of depression, anxiety and stress will be assessed","University Hospital, Geneva|University of Bern|University of Lausanne Hospitals|Hospital Lugano|University Hospital, Basel, Switzerland|Hospital of Neuchâtel",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,50,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",08-136,Nov-08,Nov-08,Jun-09,18-Nov-08,null,12-Sep-11,"Geneva Hospital, Geneva, Switzerland",,https://ClinicalTrials.gov/show/NCT00792584
NCT00792181,To Relieve Pain and Anxiety - an Intervention Study in Ambulance Services,,Completed,No Results Available,Acute Myocardial Infarction|Pain,Drug: Midazolam|Other: Course intervention - a professional development course for caregivers.,,"Sahlgrenska University Hospital, Sweden",null,"Child, Adult, Older Adult",Phase 1,2800,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MPA Dnr 151:2008/4564,Jun-08,Nov-08,null,17-Nov-08,null,17-Nov-08,,,https://ClinicalTrials.gov/show/NCT00792181
NCT00790868,"Exposure, D-Cycloserine Enhancement, and Genetic Modulators in Panic Disorder",DCSPanic,Completed,Has Results,Panic Disorder,Drug: d-cycloserine|Drug: placebo,Panic Disorder Severity Scale (PDSS)|Remission Status|Depression Severity|Quality of Life Ratings|Role Functioning,Boston University Charles River Campus|National Institute on Drug Abuse (NIDA)|National Institute of Mental Health (NIMH),All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,180,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",R01MH081116,Apr-08,Aug-14,Aug-14,14-Nov-08,7-Mar-18,7-Mar-18,"Institute of Living, Hartford, Connecticut, United States|Rush University Medical Center, Chicago, Illinois, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Boston University, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT00790868
NCT00788034,Relapse-prevention Study With Lu AA21004 (Vortioxetine) in Patients With Generalized Anxiety Disorder,,Completed,No Results Available,Generalized Anxiety Disorder,Drug: Lu AA21004|Drug: Placebo,"Time to relapse|Relapse rates, Hamilton Anxiety Rating Scale (HAM-A), Clinical Global Impression Scale (CGI), MOS SF-36, Sheehan Disability Scale (SDS), Adverse events, Clinical laboratory tests, Vital signs, ECG",H. Lundbeck A/S,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,459,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",12473A|2008-001673-15,Oct-08,Jun-10,Jul-10,10-Nov-08,null,23-Jun-15,"AR010, Buenos Aires, Argentina|AR012, Buenos Aires, Argentina|AR002, Buenos Aires, Argentina|AR008, Buenos Aires, Argentina|AR003, Buenos Aires, Argentina|AR013, Buenos Aires, Argentina|AR004, Cordoba, Argentina|AR015, La Plata, Argentina|AR006, Mendoza, Argentina|AR009, Mendoza, Argentina|AR001, Santa Fé, Argentina|CL004, Antofagasta, Chile|CL001, Coquimbo, Chile|CL002, Santiago, Chile|CL003, Santiago, Chile|CL005, Santiago, Chile|CL007, Santiago, Chile|CL008, Santiago, Chile|CL006, Vina del Mar, Chile|CO003, Barranquilla, Colombia|CO001, Bogotá, Colombia|CO005, Bogotá, Colombia|CO006, Envigado, Colombia|CO002, Medellin, Colombia|CO007, Medellin, Colombia|CO004, Pareira, Colombia|CR002, Escazu, Costa Rica|CR004, Guadalupe, Costa Rica|CR001, San José, Costa Rica|CR003, San Pedro, Costa Rica|EE001, Tallinn, Estonia|EE004, Tallinn, Estonia|EE002, Tartu, Estonia|FI006, Espoo, Finland|FI008, Helsinki, Finland|FI001, Helsinki, Finland|FI004, Helsinki, Finland|FI011, Helsinki, Finland|FI010, Helsinki, Finland|FI005, Juväskylä, Finland|FI012, Kuopio, Finland|FI002, Oulu, Finland|FI009, Rauma, Finland|FI003, Turku, Finland|FI007, Turku, Finland|FR011, Arcachon, France|FR010, Caen, France|FR016, Douai, France|FR012, Nantes, France|FR004, Nîmes, France|FR013, Palaiseau, France|FR007, Rennes, France|FR001, Saint-André-de-Cubzac, France|FR002, Strasbourg, France|FR015, Toulouse, France|FR005, Toulouse, France|HU005, Budapest, Hungary|HU004, Budapest, Hungary|HU002, Budapest, Hungary|HU001, Gyula, Hungary|HU006, Nagykallo, Hungary|HU008, Sopron, Hungary|PE003, Lima, Peru|PE002, Lima, Peru|RU004, Chita, Russian Federation|RU006, St. Petersburg, Russian Federation|RU002, St. Petersburg, Russian Federation|RU003, St. Petersburg, Russian Federation|RU001, Tomsk, Russian Federation|ZA006, Bloemfontein, South Africa|ZA004, Cape Town, South Africa|ZA011, Cape Town, South Africa|ZA012, Cape Town, South Africa|ZA003, Cape Town, South Africa|ZA010, Cape Town, South Africa|ZA007, Gauteng, South Africa|ZA001, Gauteng, South Africa|ZA009, Gauteng, South Africa|ZA002, Kempton Park, South Africa|ZA008, KwaZulu Natal, South Africa|ZA005, Welkom, South Africa",,https://ClinicalTrials.gov/show/NCT00788034
NCT00787397,"Sleep, Mood, and Behavior Study",,Completed,No Results Available,Sleep Difficulties in Pediatric Anxiety Disorder|Generalized Anxiety Disorder|Separation Anxiety Disorder|Social Phobia,Behavioral: Cognitive Behavioral Therapy-Sleep,"Evidence of sleep therapy effects on anxiety symptoms are established by assessments of clinical status, symptoms, affective style, sleep,parent-child interactions using rating scales, self-report measures, and behavioral observations.",University of Pittsburgh|National Institute of Mental Health (NIMH),All,9 Years to 14 Years   (Child),Not Applicable,51,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PRO08010426|P50MH080215-01A1,Feb-09,Dec-13,Dec-13,7-Nov-08,null,8-Jan-16,"University of Pittsburgh, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00787397
NCT00785135,"Effects of Prismatic Spectacle Lenses on Symptoms of Dizziness, Headache and Anxiety as Caused by Vertical Heterophoria",,Completed,No Results Available,"Binocular Dysfunction|Vertical Heterophoria|Vision, Binocular|Vision Disparity",Device: Lenses containing prismatic correction|Device: Lenses not containing prismatic correction,"Evidence of change / improvement of symptoms of headache, dizziness and anxiety as demonstrated by validated, self-administered survey tools for these symptoms|Evidence that a new survey tool developed by the authors to assess changes / improvement in dizziness, headache and anxiety associated with Vertical Heterophoria correlates to validated, self-administered survey tools for these same symptoms",Vision Specialists of Birmingham|Essilor International,All,"14 Years and older   (Child, Adult, Older Adult)",Phase 3,13,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",VSofB 20081276,Nov-08,Nov-15,Nov-15,5-Nov-08,null,9-Dec-15,"Vision Specialists of Birmingham, Birmingham, Michigan, United States",,https://ClinicalTrials.gov/show/NCT00785135
NCT00776685,Adventure: Teacher Delivered Personality-targeted Interventions for Substance Misuse,Adventure,Completed,No Results Available,Alcohol Abuse|Drug Abuse|Depression|Panic Disorder|Conduct Disorder,Behavioral: Personality-targeted interventions,"Binge drinking frequency|Drinking frequency|drinking quantity|Drinking problems|illicit drug use events|Emotional and behavioural problems, targeted and school-wide effects",King's College London|Action on Addiction,All,13 Years to 16 Years   (Child),Phase 2|Phase 3,3190,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,Adventure,May-07,Mar-10,May-10,21-Oct-08,null,27-Jun-11,"Institute of Psychiatry, King's College London, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT00776685
NCT00774150,Transdisciplinary Studies of CBT for Anxiety in Youth: Child Anxiety Treatment Study,CATS,Completed,No Results Available,Generalized Anxiety Disorder|Separation Anxiety Disorder|Social Phobia,Behavioral: Cognitive Behavioral Therapy|Behavioral: Client Centered Therapy,"Evidence of therapy effects on anxiety symptoms are established by assessments of clinical status, symptoms, affective style, sleep,parent-child interactions using rating scales, self-report measures, and behavioral observations.|Cognitive and affective information processing will be measured using fMRI, pupil dilation/eye tracking, and event-related potential (ERP) assessment.",University of Pittsburgh|National Institute of Mental Health (NIMH),All,9 Years to 14 Years   (Child),Not Applicable,194,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,PRO07110273|P50MH080215-01A1,Oct-08,Jul-14,Jul-14,17-Oct-08,null,18-Jul-14,"University of Pittsburgh, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00774150
NCT00774813,Nexalin Therapy for the Treatment of Depressive Symptoms,,Completed,No Results Available,Depression,Device: Nexalin 1.3mA Device|Device: Nexalin 15mA device|Drug: placebo device and Citalopram,Hamilton Depression Rating Scale (HAM-D21)|Clinical Global Impression (CGI)|Montgomery-Asberg Depression Rating Scale (MADRS)|Beck's Depression Inventory|Hamilton Anxiety Rating Scale (HAM-A)|Hospital Anxiety and Depression Scale (HADS)|Medication Usage Log|Adverse Event Log,"Kalaco Scientific, Inc.",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,120,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CPMS-7003,Oct-07,May-08,May-08,17-Oct-08,null,17-Oct-08,"Leningrad Regional Center of Addiction, Leningrad, Vsevolozhsky District, Russian Federation|St. Petersburg City Center of Neuroses, St. Petersburg, Russian Federation",,https://ClinicalTrials.gov/show/NCT00774813
NCT00773162,Flushing in Social Anxiety Disorder on Seroquel,,Completed,No Results Available,Social Anxiety Disorder,Drug: Seroquel|Drug: Sugar Pill,"Changes in intensity of the vasodilatory response to 10 mM topical m-N over 16 weeks.|Mean change from baseline on the HAM-A, CGI, SF-36, LSAS, SPIN, SIAS, SPS, ASI, BAI, BDI, SHEEHAN, EUROQUEL, BIS/BAS, PSWQ, IUS",START Clinic for Mood and Anxiety Disorders|AstraZeneca,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,21,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",AzSeroSP,Oct-08,Aug-13,Aug-13,16-Oct-08,null,25-Feb-14,"START Clinic for the Mood and Anxiety Disorders, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT00773162
NCT00769925,Assessing Different Methods of Anxiety Care in Pediatric Settings,,Unknown status,No Results Available,Anxiety Disorders,Behavioral: Cognitive Behavior Therapy-Primary Care|Behavioral: Therapist-Assisted Bibliotherapy-Primary Care,Clinical Severity Rating on Anxiety Diagnostic Interview Schedule for Children for primary anxiety disorder|Clinical Global Impression scale-Improvement Change|Screening for Anxiety Related Emotional Disorders (SCARED) parent and child self-report scales,"University of California, San Diego|National Institute of Mental Health (NIMH)",All,8 Years to 13 Years   (Child),Not Applicable,52,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,K01MH072952|DSIR 84-CTS,Nov-08,Jan-12,Feb-12,9-Oct-08,null,10-Jan-12,"University of California San Diego, San Diego, California, United States",,https://ClinicalTrials.gov/show/NCT00769925
NCT00767754,Changes of Cerebral Glucose Metabolism After 12 Weeks of Paroxetine Treatment in Panic Disorder,,Completed,No Results Available,Panic Disorder,Drug: Paxil CR,"18FDG PET, PDSS & HAM-A",Samsung Medical Center,All,20 Years to 60 Years   (Adult),Phase 4,37,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SMC IRB 2006-07-091,Jan-07,Jun-07,Dec-08,7-Oct-08,null,25-Jul-11,"Samsung Medical Center, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT00767754
NCT00767871,Changes of Cerebral Glucose Metabolism and After 12 Weeks of Escitalpram Treatment in Panic Disorder,,Completed,No Results Available,Panic Disorder,Drug: Lexapro,"18FDG-PET, PDSS & HAM-A",Samsung Medical Center|H. Lundbeck A/S,All,20 Years to 60 Years   (Adult),Phase 4,46,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,SMCIRB2007-01-024,Mar-07,Aug-07,Dec-08,7-Oct-08,null,25-Jul-11,"Samsung Medical Center, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT00767871
NCT00764933,Structured Information During the Intensive Care Unit Stay,,Completed,No Results Available,Anxiety,Behavioral: Structured information|Other: Unspecific conversation,Patient self-reported anxiety|Confusion Assessment Method for the ICU (CAM-ICU)|Patient self reported health-related quality of life,Martin-Luther-Universität Halle-Wittenberg|German Federal Ministry of Education and Research,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,211,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,PfVMS-T4,Jan-08,Dec-09,Mar-10,2-Oct-08,null,3-Jun-10,"Sana Herzchirurgische Klinik Stuttgart GmbH, Stuttgart, BW, Germany|Universitätsklinikum Gießen und Marburg, Kooperationsstudien Pflegedienst/Ärztlicher Dienst, Klinik für Visceral-, Thorax- und Gefäßchirurgie, Klinik für Herz- und thorakale Gefäßchirurgie, Standort Marburg, Marburg, HES, Germany|Institut für Gesundheits- und Pflegewissenschaft, Universitätsklinik für Anästhesiologie und operative Intensivmedizin, Medizinische Fakultät, Martin-Luther-Universität Halle-Wittenberg, Halle, SAN, Germany",,https://ClinicalTrials.gov/show/NCT00764933
NCT00765219,Cognitive Behavior Treatment of Older Adults With Generalized Anxiety Disorder in Primary Care,,Completed,No Results Available,Generalized Anxiety Disorder,Behavioral: CBT|Other: Usual Care,Anxiety|Depression|Sleep quality|Use of alcohol|Functional and health status|Quality of life|Pain|Satisfaction with CBT and general health care|Service utilization|Use of psychotropic medications,Baylor College of Medicine|National Institute of Mental Health (NIMH),All,"60 Years and older   (Adult, Older Adult)",Not Applicable,222,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,H23798|R01MH053932-10A1,May-08,Dec-13,Apr-15,2-Oct-08,null,23-Jul-15,"Houston Center for Quality of Care and Utilization Studies, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00765219
NCT00762099,"Perioperative Pregabalin Use, Rehabilitation, Pain Outcomes and Anxiety Following Hip Surgery",RCT,Unknown status,No Results Available,Anxiety,Drug: Pregabalin|Drug: Placebo,Physical function 6 weeks and 3-months post-total hip arthroplasty,Sunnybrook Health Sciences Centre|Pfizer,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 4,184,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2008-PFE-01,May-09,Dec-11,Dec-11,30-Sep-08,null,8-Apr-11,"Holland Orthopaedic and Arthritic Centre, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT00762099
NCT00761033,Music to Reduce Pain and Anxiety in the Pediatric Emergency Department,,Completed,No Results Available,Pain|Distress,Behavioral: music,Observation Scale of Behavioral Distress-Revised (OSBD-R)|Pain,University of Alberta|Stollery Children's Hospital Foundation,All,3 Years to 6 Years   (Child),Not Applicable,42,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,B-010908,Oct-08,null,null,26-Sep-08,null,8-Dec-16,"Stollery Children's Hospital, Edmonton, Alberta, Canada",,https://ClinicalTrials.gov/show/NCT00761033
NCT00758966,Naltrexone SR and Fluoxetine Combination Therapy in Subjects With Obsessive-Compulsive Disorder,,Terminated,No Results Available,Obsessive-Compulsive Disorder,Drug: Fluoxetine 60 mg|Drug: Naltrexone 32 mg and fluoxetine 60 mg|Drug: Naltrexone SR 32 mg,Evaluate the mean change from baseline to Week 10 in total Yale-Brown Obsessive Compulsive Scale (Y-BOCS) score between the combination treatment group versus fluoxetine alone and naltrexone SR alone,"Orexigen Therapeutics, Inc",All,18 Years to 60 Years   (Adult),Phase 2,8,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",NF-101,Sep-08,Dec-08,Dec-08,25-Sep-08,null,29-Nov-12,"Synergy Clinical Research, National City, California, United States|California Clinical Trials, San Diego, California, United States|University of Florida, Department of Psychiatry, Gainesville, Florida, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|Indiana University School of Medicine, Indianapolis, Indiana, United States|Global Medical Institute, LLC, Princeton, New Jersey, United States|Brooklyn Medical Institute, Brooklyn, New York, United States|Community Research, Cincinnati, Ohio, United States|Summit Research Network, Inc., Portland, Oregon, United States|Carolina Clinical Research Services, Columbia, South Carolina, United States|Northbrooke Research Center, Brown Deer, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT00758966
NCT00759395,"Study of Antidepressant Efficacy of a Selective, High Affinity Enkephalinergic Agonist in Anxious Major Depressive Disorder (AMDD)",,Completed,Has Results,Anxious Major Depressive Disorder,Drug: AZD2327|Drug: Placebo,Hamilton Rating Scale for Depression (HAM-D) Total Score.|Hamilton Rating Scale for Anxiety (HAM-A) Total Score.|Psychic Anxiety Item of the Hamilton Rating Scale for Depression (HAM-D).|The Number of Participants With at Least 50% Reduction of Hamilton Rating Scale for Depression (HAM-D)Total Score.|The Number of Participants With at Least 50% Reduction of Hamilton Rating Scale for Anxiety (HAM-A)Total Score.,AstraZeneca,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,22,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",D0880C00021,Jan-09,Oct-11,Oct-11,25-Sep-08,8-Nov-12,8-Nov-12,"Research Site, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00759395
NCT00751465,Dysfunctional Attention Processes in Fear of Blushing: Specificity and Changeability,,Completed,No Results Available,"Phobia, Social",Behavioral: Task Concentration Training|Behavioral: Standard CBT,Brief Social Phobia Scale|Social Phobia Composite|Changes in objective attention test data,Technische Universität Dresden|German Research Foundation,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,82,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EK198082007|DFG HO1900/5-1,Nov-08,Dec-10,Dec-10,12-Sep-08,null,11-Sep-15,"TU Dresden, Dresden, Germany",,https://ClinicalTrials.gov/show/NCT00751465
NCT00749944,"Assessing Neuropsychiatric Symptoms Including Depression, Anxiety, Irritability, and Suicidal Thoughts or Behavior in Subjects Quitting Smoking on Varenicline Tartrate or Placebo",,Completed,Has Results,Smoking Cessation,Drug: varenicline|Drug: placebo,Change From Baseline in the Profile of Mood States (POMS): Total Mood Disturbance (TMD)|Change From Baseline in the Profile of Mood States (POMS): Tension-Anxiety Subscale|Change From Baseline in the Profile of Mood States (POMS): Depression-Dejection Subscale|Change From Baseline in the Profile of Mood States (POMS): Anger-Hostility Subscale|Change From Baseline in the Profile of Mood States (POMS): Vigor Subscale|Change From Baseline in the Profile of Mood States (POMS): Fatigue Subscale|Change From Baseline in the Profile of Mood States (POMS): Confusion Subscale|Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS): Total Score|Change From Baseline in the Hamilton Anxiety Scale (HAM-A): Total Score|Change From Baseline in the Overt Aggression Scale (Modified) (OAS-m): Aggression Total Score|Change From Baseline in the Overt Aggression Scale (Modified) (OAS-m): Irritability Total Score|Change From Baseline in the Overt Aggression Scale (Modified) (OAS-m): Suicidality Total Score|Change From Baseline in the Social Dysfunction and Aggression Scale (SDAS): Total Score|Change From Baseline in the Barratt Impulsiveness Scale - Version 11 (BIS-11): Total Score|Change From Baseline in the Minnesota Nicotine Withdrawal Scale (MNWS): Total Score|Change From Baseline in the Minnesota Nicotine Withdrawal Scale (MNWS): Negative Affect Domain Subscale|Change From Baseline in the Minnesota Nicotine Withdrawal Scale (MNWS): Insomnia Domain Subscale|Change From Baseline in the Minnesota Nicotine Withdrawal Scale (MNWS): Urge to Smoke Subscale|Change From Baseline in the Minnesota Nicotine Withdrawal Scale (MNWS): Restlessness Subscale|Change From Baseline in the Minnesota Nicotine Withdrawal Scale (MNWS): Increased Appetite Subscale|Number of Participants Exceeding Thresholds for the Profile of Mood States (POMS): Total Score|Number of Participants Exceeding Thresholds for the Montgomery-Asberg Depression Rating Scale (MADRS): Total Score|Number of Participants Exceeding Thresholds for the Hamilton Anxiety Scale (HAM-A): Total Score|Number of Participants Exceeding Thresholds for the Overt Aggression Scale (Modified) (OAS-m): Agression Total Score|Number of Participants Exceeding Thresholds for the Overt Aggression Scale (Modified) (OAS-m): Irritability Total Score|Number of Participants Exceeding Thresholds for the Overt Aggression Scale (Modified) (OAS-m): Suicidality Total Score|Number of Participants Exceeding Thresholds for the Barratt Impulsiveness Scale - Version 11 (BIS-11): Total Score|Number of Participants Exceeding Thresholds for the Social Dysfunction and Aggression Scale (SDAS): Total Score|Number of Participants With Carbon Monoxide Confirmed Daily Smoking Cessation|Number of Participants With 7-day Point Prevalence of Abstinence (Smoking Cessation)|Change From Baseline in the Number of Cigarettes Smoked Per Day,Pfizer,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 4,110,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",A3051115,Sep-08,Jul-09,Aug-09,10-Sep-08,9-Aug-10,31-Aug-10,"Pfizer Investigational Site, Austin, Texas, United States|Pfizer Investigational Site, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT00749944
NCT00748761,Cognitive Behavioral Therapy for Pediatric Obsessive-Compulsive Disorder,,Unknown status,No Results Available,Obsessive-Compulsive Disorder,Behavioral: Cognitive Behavioral Therapy (CBT)|Behavioral: Waitlist,"Regional concentration of glutamate and glutamine in brain, as measured by Magnetic Resonance Spectroscopic Imaging (MRSI)|Overall score on child Yale-Brown Obsessive-Compulsive Scale","University of California, Los Angeles|National Institute of Mental Health (NIMH)",All,"6 Years to 18 Years   (Child, Adult)",Not Applicable,108,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,R01MH081864|DDTR B2-NDO,Jun-08,Apr-15,Apr-15,9-Sep-08,null,18-Dec-14,"UCLA Child Psychiatry, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT00748761
NCT00748956,Intranasal Administration of Neuropeptide Y in Healthy Male Volunteers,NPY,Completed,Has Results,Mood Disorder|Anxiety Disorders,Drug: Low dose NPY|Drug: High dose NPY|Drug: Placebo,Levels of NPY in CSF|Systematic Assessment of Treatment-Emergent Effects (SAFTEE)|Appetite Scale|Post-sleep Questionnaire|Quick Inventory of Depressive Symptoms (QIDS)|Profile of Mood States (POMS),Dennis Charney|Icahn School of Medicine at Mount Sinai,Male,25 Years to 45 Years   (Adult),Phase 2,10,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",GCO 05-0986|PT050986,Jan-10,Dec-10,Jan-12,9-Sep-08,17-May-17,1-Aug-17,"Mount Sinai School of Medicine, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00748956
NCT00749177,Blending Two Worlds: Traditional Aboriginal Healing Strategies for Depression and Anxiety,B2W,Terminated,No Results Available,Anxiety|Depression,Other: Traditional Healing options,"Provide Aboriginal and First Nation youth and their families with treatment options consistent with cultural beliefs. Improving outcomes in the management of anxiety and depression.|1. Encourage Aboriginal and First Nation clients to seek treatment earlier from a culturally supportive system. 2. Validate the benefit of traditional diet and healing methods in the treatment of stress, anxiety and depression","Fraser Health|Ministry of Children and Family Development, British Columbia",All,"up to 18 Years   (Child, Adult)",Not Applicable,4,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening,FHA-MHA-B2W,Nov-08,Aug-11,Aug-11,9-Sep-08,null,6-Mar-15,"Child and Youth Mental Health, Surrey North, Surrey, British Columbia, Canada",,https://ClinicalTrials.gov/show/NCT00749177
NCT00749203,Ketamine as a Rapid Treatment for Post-traumatic Stress Disorder (PTSD),KetPTSD,Completed,Has Results,"Stress Disorders, Post-Traumatic|PTSD|Depression|Anxiety Disorder",Drug: Midazolam|Drug: Ketamine,Impact of Event Scale - Revised (IES-R)|Clinician-Administered PTSD Scale (CAPS)|Quick Inventory of Depressive Symptomatology - Self Report (QIDS-SR)|Montgomery-Asberg Depression Rating Scale (MADRS)|Hopkins Verbal Learning Test (HVLT),Dennis Charney|United States Department of Defense|Icahn School of Medicine at Mount Sinai,All,21 Years to 55 Years   (Adult),Phase 2,41,Other|U.S. Fed,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",GCO 07-1199|PT074949|IF1554104|A-15236,Jan-09,Sep-13,Sep-13,9-Sep-08,14-Feb-18,14-Feb-18,"Icahn School of Medicine at Mount Sinai, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00749203
NCT00748267,Hypnosis in Reducing Pain and Other Side Effects in Women Undergoing Surgery for Breast Cancer,,Completed,No Results Available,Anxiety Disorder|Breast Cancer|Nausea and Vomiting|Pain,Other: questionnaire administration|Procedure: hypnotherapy|Procedure: therapeutic conventional surgery,Pain as measured by the Condensed Memorial Symptom Assessment Scale (CMSAS)-Modified at baseline (pre-intervention) and prior to discharge from the Post Anesthesia Care Unit|Nausea as measured by the CMSAS-Modified at baseline and prior to discharge from the Post Anesthesia Care Unit|Vomiting as measured by the CMSAS-Modified at baseline and prior to discharge from the Post Anesthesia Care Unit|Generalized distress as measured by the CMSAS-Modified at baseline and prior to discharge from the Post Anesthesia Care Unit|Anxiety as measured by the CMSAS-Modified at baseline and prior to discharge from the Post Anesthesia Care Unit|Surgical and anesthesia time|Recovery time|Medications|Levels of consciousness|Standard clinical measures of levels of anesthesia|Significant surgical events|Patient satisfaction,City of Hope Medical Center|National Cancer Institute (NCI),Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,20,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,08029|P30CA033572|CHNMC-08029|CDR0000612523,Aug-08,Feb-10,Dec-10,8-Sep-08,null,7-Mar-11,"City of Hope Comprehensive Cancer Center, Duarte, California, United States",,https://ClinicalTrials.gov/show/NCT00748267
NCT00746239,Ramelteon for Sleep Initiation Insomnia in Individuals With Panic Disorder Who Are Also on Escitalopram for Anxiety,,Terminated,Has Results,Panic Disorder|Insomnia,Drug: Placebo and Escitalopram|Drug: Ramelteon and Escitalopram,Evaluate the Effects of Ramelteon on Sleep Quality in Panic Disorder Patients Who Are Also Treated With Escitalopram.|Evaluate the Association of Improving Sleep Quality (With Ramelteon) on Improvement in Severity of Panic Disorder/Anxiety.,"Milton S. Hershey Medical Center|Takeda Pharmaceuticals North America, Inc.",All,18 Years to 50 Years   (Adult),Not Applicable,11,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",07-013R,Aug-08,Jul-10,Jul-10,3-Sep-08,15-Oct-15,30-May-18,"Penn State Hershey Medical Center, Hershey, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00746239
NCT00744627,Efficacy and Safety of Vortioxetine (Lu AA21004) for Treatment of Generalized Anxiety Disorder in Adults.,,Completed,Has Results,Generalized Anxiety Disorder,Drug: Vortioxetine|Drug: Placebo,Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score at Week 8|Change From Baseline in the Hospital Anxiety and Depression (HAD) Anxiety Subscale at Week 8|Clinical Global Impression Scale-Global Improvement at Week 8|Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Week 8|Percentage of Responders in HAM-A Total Score at Week 8|Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score at Week 8 in Participants With Baseline HAM-A ≥25|Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Social Functioning Subscore at Week 8|Change From Baseline in Hamilton Anxiety Scale (HAM-A) Total Score at Other Weeks Assessed|Change From Baseline in the Hospital Anxiety and Depression (HAD) Anxiety Subscale at Other Weeks Assessed|Clinical Global Impression Scale-Global Improvement at Other Weeks Assessed|Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Other Weeks Assessed|Percentage of Responders in HAM-A Total Score at Other Weeks Assessed|Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score at Other Weeks Assessed in Participants With Baseline HAM-A ≥25|Percentage of Participants in HAM-A Remission at Each Week Assessed|Change From Baseline in Clinical Global Impression Scale-Severity of Illness at Each Week Assessed|Change From Baseline in the Hospital Anxiety and Depression (HAD) Depression Subscale at Each Week Assessed|Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Social Functioning Subscore at Other Weeks Assessed|Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Physical Functioning Subscore at Each Week Assessed|Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Role-Physical Subscore at Each Week Assessed|Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Bodily Pain Subscore at Each Week Assessed|Change From Baseline in 36-Item Short-Form Health Survey (SF-36) General Health Subscore at Each Week Assessed|Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Vitality Subscore at Each Week Assessed|Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Role-Emotional Subscore at Each Week Assessed|Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Mental Health Subscore at Each Week Assessed|Health Care Resource Utilization as Assessed by the Health Economic Assessment Questionnaire,Takeda|H. Lundbeck A/S,All,"18 Years and older   (Adult, Older Adult)",Phase 3,301,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",LuAA21004_311|2008-001766-90|U1111-1112-3487,Sep-08,Jul-09,Jul-09,1-Sep-08,3-Mar-14,3-Mar-14,"Tallinn, Estonia|Viljandi, Estonia|Bad Saarow, Germany|Berlin, Germany|Bochum, Germany|Huettenberg, Germany|Rodgau, Germany|Schwerin, Germany|Wiesbaden, Germany|Liepaja, Latvia|Riga, Latvia|Sigulda, Latvia|Kaunas, Lithuania|Palanga, Lithuania|Vilnius, Lithuania|Białystok, Poland|Gdynia, Poland|Gorlice, Poland|Leszno, Poland|Skórzewo, Poland|Toruń, Poland|Tuszyn, Poland|Bucharest, Romania|Oradea, Romania|Ekaterinburg, Russian Federation|Kazan, Russian Federation|Lipetsk, Russian Federation|Moscow, Russian Federation|Rostov-on-Don, Russian Federation|Samara, Russian Federation|Smolensk, Russian Federation|St. Petersburg, Russian Federation|Stavropol, Russian Federation|Dnepropetrovsk, Ukraine|Kharkiv, Ukraine|Liev, Ukraine|Lugansk, Ukraine|Simferopol, Ukraine",,https://ClinicalTrials.gov/show/NCT00744627
NCT00743834,Cost-Effectiveness of Adding Web-Based Cognitive-Behavioral Therapy (CBT) to Luvox CR for Obsessive Compulsive Disorder (OCD),,Unknown status,No Results Available,Obsessive Compulsive Disorder,Drug: Luvox CR|Behavioral: Behavioral Therapy,The primary outcome measure (Y-BOCS score) will be obtained by clinician rating,"Rogers Center for Research & Training, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 4,50,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,JIIT-07-LCR001a,Sep-08,Aug-09,Dec-09,29-Aug-08,null,4-Sep-08,"The Rogers Center for Research & Training, Inc., Milwaukee, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT00743834
NCT00742664,Behavioral Treatment of Obsessive-Compulsive Symptoms in Youth With Prader-Willi Syndrome: A Pilot Project,,Completed,No Results Available,Prader Willi Syndrome|Obsessive-compulsive Disorder,Behavioral: Cognitive-behavioral therapy|Behavioral: Wait-list control,"Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS; Scahill et al., 1997).|Clinical Global Improvement (CGI; Guy, 1976).",University of South Florida|Johns Hopkins All Children's Hospital,All,6 Years to 17 Years   (Child),Phase 1|Phase 2,24,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,FPWR-CBT-001,Sep-08,Jul-11,Jul-11,28-Aug-08,null,8-Aug-11,"All Children's Hospital, St. Petersburg, Florida, United States",,https://ClinicalTrials.gov/show/NCT00742664
NCT00743041,The Effect of EFT on Psychological States in a Veterans Population,,Completed,No Results Available,"Stress Disorders, Post-Traumatic",Behavioral: Emotional Freedom Techniques (EFT),Scores on the PCL-M (PTSD Symptom Checklist-Military),Soul Medicine Institute,All,"18 Years to 75 Years   (Adult, Older Adult)",Early Phase 1,100,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Supportive Care",SMI-PTSD-82508,Dec-08,Dec-09,May-10,28-Aug-08,null,25-Apr-18,"Soul Medicine Institute, Santa Rosa, California, United States",,https://ClinicalTrials.gov/show/NCT00743041
NCT00739765,Effectiveness of Three Different Psychotherapies for Chronic Post-Traumatic Stress Disorder,,Completed,Has Results,Post-Traumatic Stress Disorder,Behavioral: Interpersonal Psychotherapy|Behavioral: Prolonged Exposure Therapy|Behavioral: Relaxation Therapy,Clinician-Administered PTSD Scale (CAPS)|Hamilton Depression Rating Scale,New York State Psychiatric Institute|National Institute of Mental Health (NIMH),All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,110,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"#5660, R01 MH079078|R01MH079078",Apr-08,Mar-13,Mar-14,22-Aug-08,16-Nov-15,5-Mar-19,"New York State Psychiatric Institute, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00739765
NCT00738738,6-Month Open-Label Safety Study Of PD 0332334 In Elderly Patients With Generalized Anxiety Disorder (GAD),,Withdrawn,No Results Available,Generalized Anxiety Disorder,Drug: PD-0332334,"Discontinuations due to adverse events or adverse events occurring during and after the discontinuation of trial medication|The nature, incidence, duration, and severity of adverse events.|Suicide related adverse events will be further assessed using the Columbia Suicide Severity Rating Scale as needed|The primary outcome is safety which will be assessed throughout the 6-months by physical exams, monitoring of vital signs, body weight changes, and clinical safety laboratory|Electrocardiograms will be performed to assess any changes in cardiac functioning related to the compound|Symptom severity of generalized Anxiety Disorder (GAD) will be measured by the Hamilton Rating Scale for Anxiety (HAM-A).|Overall Health Care utilization will be assessed with the Health Care Utilization (HCU) questionnaire.|Also, the Daily Diary (including the Daily assessment of Symptoms DAS-A and Global Anxiety - Visual Analog Scale (GA-VAS) and the Clinical Global Impression of Severity (CGI-S) will be used to assess symptoms of GAD.|Plasma concentrations will be collected to evaluate the population pharmacokinetics and the dose/exposure relationships for safety and efficacy .",Pfizer,All,65 Years and older   (Older Adult),Phase 3,0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,A5361036,Jan-09,Feb-09,Feb-09,20-Aug-08,null,3-Dec-12,"Pfizer Investigational Site, Orlando, Florida, United States|Pfizer Investigational Site, Prairie Village, Kansas, United States",,https://ClinicalTrials.gov/show/NCT00738738
NCT00737399,Anxiety and Depression Levels in Cancer Patients After Self-Application of EFT (Emotional Freedom Techniques),,Recruiting,No Results Available,Depression,Behavioral: Lifestyle Counseling with Emotional Freedom Techniques (EFT),depression|anxiety|pain|insomnia,Soul Medicine Institute,All,"18 Years to 89 Years   (Adult, Older Adult)",Early Phase 1,14,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,SMI-CHOL-82008,Sep-08,Apr-21,Dec-21,19-Aug-08,null,25-Apr-18,"Soul Medicine Institute, Santa Rosa, California, United States",,https://ClinicalTrials.gov/show/NCT00737399
NCT00735618,Relaxation and Heart Rate Variability,,Completed,Has Results,Cancer,Other: Guided Relaxation,Differences Between Pre/Post ESAS Score,M.D. Anderson Cancer Center,All,"Child, Adult, Older Adult",Not Applicable,20,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2008-0028,Jun-08,Sep-08,Sep-08,15-Aug-08,19-Dec-11,19-Dec-11,"UT MD Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00735618
NCT00735995,Effectiveness of Cognitive Behavioral Therapy (CBT) for Child Anxiety Disorders in Community Clinics in Norway,,Completed,No Results Available,Separation Anxiety Disorder|Social Phobia|Generalized Anxiety Disorder,Behavioral: Cognitive behavioral therapy (individual)|Behavioral: Cognitive behavioral therapy (group),Status of primary anxiety disorder at inclusion based on the ADIS interview schedule with parents and youth|Symptom score on the MASC|CGAS,Regionsenter for barn og unges psykiske helse|The Research Council of Norway,All,7 Years to 12 Years   (Child),Phase 2,165,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,186036/V50|186036,Aug-08,Oct-13,Dec-13,15-Aug-08,null,26-Sep-18,"Akershus Universitetssykehus HF, Lorenskog, Norway|Sykehuset Asker og Baerum, Baerum BUP, Rud, Norway|Sykehus Telemark Helseforetak, Skien og Porsgrunn BUP, Skien, Norway",,https://ClinicalTrials.gov/show/NCT00735995
NCT00736021,Treatment of Post-traumatic Stress Disorder With High Doses of Escitalopram,,Completed,No Results Available,"Stress Disorders, Post Traumatic",Drug: Escitalopram,Post-traumatic Stress Disorder (PTSD) and PTSD symptoms as recorded by the Clinicians Administered PTSD Scale (CAPS)|Proportion of Participants completing the study,Hadassah Medical Organization,All,"21 Years to 65 Years   (Adult, Older Adult)",Not Applicable,38,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HMO_SHALEV_02,Sep-08,Mar-10,Mar-10,15-Aug-08,null,23-Mar-10,"Hadassah University Hospital, Jerusalem, Israel",,https://ClinicalTrials.gov/show/NCT00736021
NCT00736346,Treatment of Panic Disorder Among Individuals Consulting Emergency Departments for Non Cardiac Chest Pain,MADONA,Unknown status,No Results Available,Panic Disorder|Anxiety Disorder|Mental Disorder,Behavioral: Brief cognitive-behavioral treatment for Panic Disorder|Behavioral: Cognitive-Behavior Therapy for Panic Disorder|Drug: paroxetine,"Panic Disorder diagnosis|Panic symptomatology, psychological distress, quality of life, and use of health services",Universite du Quebec a Montreal|Canadian Institutes of Health Research (CIHR),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,204,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MOP 81128 (CIHR),Oct-05,Dec-09,Jun-10,15-Aug-08,null,15-Aug-08,"Hôtel-Dieu de Lévis, Lévis, Quebec, Canada|Institut de Cardiologie de Montréal (Montreal Heart Institute), Montréal, Quebec, Canada|Hôpital du Sacré-Coeur de Montréal, Montréal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT00736346
NCT00734370,Virtual Reality Exposure Therapy in Agoraphobic Participants,,Completed,No Results Available,Panic Disorder|Agoraphobia,Behavioral: Virtual Reality Exposure Therapy for agoraphobic participants|Behavioral: Standard exposure in vivo for agoraphobic participants,Panic Disorder Severity Scale (PDSS); Mobility Inventory for Agoraphobia (MI); Behavioural Avoidance Test (BAT)|Beck Anxiety Inventory (BAI); Anxiety Sensitivity Inventory (ASI); Beck Depression Inventory (BDI); Panic Disorder Severity Scale (PDSS); Agoraphobic Cognitions Questionnaire (ACQ); Bodily Sensations Questionnaire (BSQ); Panic Appraisal Inventory (PAI),VU University of Amsterdam,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,55,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,KP-2008-518,Oct-08,Jun-11,Jan-12,14-Aug-08,null,13-Sep-18,"University of Amsterdam, Amsterdam, Netherlands",,https://ClinicalTrials.gov/show/NCT00734370
NCT00734422,Facilitation of Fear Extinction With Yohimbine Hydrochloride in Phobic Participants,,Completed,No Results Available,Phobic Disorders,Behavioral: Virtual Reality Exposure Therapy,Flight Anxiety Situations Questionnaire (self-report); Flight Anxiety Modality Questionnaire (self-report)|Severity of Anxiety Symptoms (Beck Anxiety Inventory) Anxiety Sensitivity (Anxiety Sensitivity Inventory),VU University of Amsterdam,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2|Phase 3,67,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",KP-2007-226,Jul-08,Jun-09,Jul-10,14-Aug-08,null,13-Sep-18,"University of Amsterdam, Amsterdam, Netherlands",,https://ClinicalTrials.gov/show/NCT00734422
NCT00735267,A 52-Week Open-Label Safety Study of PD 0332334 in Subjects With Generalized Anxiety Disorder (GAD),,Terminated,No Results Available,Generalized Anxiety Disorder,Drug: PD 0332334,"The nature, incidence, and duration of adverse events monitored throughout the study by physical exam|Electrocardiogram will be performed at screening and during follow up visits to assess the safety and tolerability of the compound in terms of clinically significant cardiovascular changes|The Columbia Suicide Severity Rating scale will be used to assess any suicide related adverse events|The nature, incidence, and duration of adverse events monitored throughout the study by vital signs evaluation at each visit, weight measurements and clinical laboratory monitoring periodically|All discontinuations due to adverse events will be reviewed throughout the trial to assess the safety and tolerability of the compound|The Hamilton Rating Scale for Anxiety (HAM-A) will be used to assess symptoms of Generalized Anxiety Disorder (GAD) over a one year time period.|The Clinical Global Impression of Severity (CGI-S), and the Daily Diary (DD) will also be used to assess symptoms of GAD over a one year time period.|The Health Care Utilization Questionnaire will be utilized to assess overall Health Care over a one year time period.",Pfizer,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,468,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,A5361022,Oct-08,Apr-09,Apr-09,14-Aug-08,null,16-Nov-12,"Pfizer Investigational Site, Birmingham, Alabama, United States|Pfizer Investigational Site, Litchfield Park, Arizona, United States|Pfizer Investigational Site, Arcadia, California, United States|Pfizer Investigational Site, Beverly Hills, California, United States|Pfizer Investigational Site, Costa Mesa, California, United States|Pfizer Investigational Site, Costa Mesa, California, United States|Pfizer Investigational Site, Encino, California, United States|Pfizer Investigational Site, Escondido, California, United States|Pfizer Investigational Site, Murrieta, California, United States|Pfizer Investigational Site, National City, California, United States|Pfizer Investigational Site, Newport Beach, California, United States|Pfizer Investigational Site, Orange, California, United States|Pfizer Investigational Site, Pasadena, California, United States|Pfizer Investigational Site, Redlands, California, United States|Pfizer Investigational Site, San Diego, California, United States|Pfizer Investigational Site, San Diego, California, United States|Pfizer Investigational Site, Sherman Oaks, California, United States|Pfizer Investigational Site, Temecula, California, United States|Pfizer Investigational Site, Upland, California, United States|Pfizer Investigational Site, Wildomar, California, United States|Pfizer Investigational Site, Denver, Colorado, United States|Pfizer Investigational Site, Hamden, Connecticut, United States|Pfizer Investigational Site, Norwich, Connecticut, United States|Pfizer Investigational Site, Altamonte Springs, Florida, United States|Pfizer Investigational Site, Ft. Myers, Florida, United States|Pfizer Investigational Site, Jacksonville, Florida, United States|Pfizer Investigational Site, Maitland, Florida, United States|Pfizer Investigational Site, Miami, Florida, United States|Pfizer Investigational Site, Miami, Florida, United States|Pfizer Investigational Site, Orange City, Florida, United States|Pfizer Investigational Site, Orlando, Florida, United States|Pfizer Investigational Site, South Miami, Florida, United States|Pfizer Investigational Site, West Palm Beach, Florida, United States|Pfizer Investigational Site, Atlanta, Georgia, United States|Pfizer Investigational Site, Atlanta, Georgia, United States|Pfizer Investigational Site, Marietta, Georgia, United States|Pfizer Investigational Site, Libertyville, Illinois, United States|Pfizer Investigational Site, Naperville, Illinois, United States|Pfizer Investigational Site, Park Ridge, Illinois, United States|Pfizer Investigational Site, Greenwood, Indiana, United States|Pfizer Investigational Site, Terre Haute, Indiana, United States|Pfizer Investigational Site, Overland Park, Kansas, United States|Pfizer Investigational Site, Prairie Village, Kansas, United States|Pfizer Investigational Site, Wichita, Kansas, United States|Pfizer Investigational Site, Owensboro, Kentucky, United States|Pfizer Investigational Site, Lake Charles, Louisiana, United States|Pfizer Investigational Site, Baltimore, Maryland, United States|Pfizer Investigational Site, Belmont, Massachusetts, United States|Pfizer Investigational Site, Boston, Massachusetts, United States|Pfizer Investigational Site, Fall River, Massachusetts, United States|Pfizer Investigational Site, Haverhill, Massachusetts, United States|Pfizer Investigational Site, Pittsfield, Massachusetts, United States|Pfizer Investigational Site, Omaha, Nebraska, United States|Pfizer Investigational Site, Las Vegas, Nevada, United States|Pfizer Investigational Site, Nashua, New Hampshire, United States|Pfizer Investigational Site, Albuquerque, New Mexico, United States|Pfizer Investigational Site, Bronx, New York, United States|Pfizer Investigational Site, Brooklyn, New York, United States|Pfizer Investigational Site, New York, New York, United States|Pfizer Investigational Site, New York, New York, United States|Pfizer Investigational Site, New York, New York, United States|Pfizer Investigational Site, Rochester, New York, United States|Pfizer Investigational Site, Raleigh, North Carolina, United States|Pfizer Investigational Site, Columbus, Ohio, United States|Pfizer Investigational Site, Dayton, Ohio, United States|Pfizer Investigational Site, Toledo, Ohio, United States|Pfizer Investigational Site, Toledo, Ohio, United States|Pfizer Investigational Site, Bethany, Oklahoma, United States|Pfizer Investigational Site, Oklahoma City, Oklahoma, United States|Pfizer Investigational Site, Oklahoma City, Oklahoma, United States|Pfizer Investigational Site, Portland, Oregon, United States|Pfizer Investigational Site, Salem, Oregon, United States|Pfizer Investigational Site, Allentown, Pennsylvania, United States|Pfizer Investigational Site, Media, Pennsylvania, United States|Pfizer Investigational Site, Norristown, Pennsylvania, United States|Pfizer Investigational Site, Philadelphia, Pennsylvania, United States|Pfizer Investigational Site, Lincoln, Rhode Island, United States|Pfizer Investigational Site, Columbia, South Carolina, United States|Pfizer Investigational Site, Memphis, Tennessee, United States|Pfizer Investigational Site, Memphis, Tennessee, United States|Pfizer Investigational Site, Austin, Texas, United States|Pfizer Investigational Site, Dallas, Texas, United States|Pfizer Investigational Site, Dallas, Texas, United States|Pfizer Investigational Site, DeSoto, Texas, United States|Pfizer Investigational Site, Houston, Texas, United States|Pfizer Investigational Site, Houston, Texas, United States|Pfizer Investigational Site, Lake Jackson, Texas, United States|Pfizer Investigational Site, San Antonio, Texas, United States|Pfizer Investigational Site, Woodstock, Vermont, United States|Pfizer Investigational Site, Charlottesville, Virginia, United States|Pfizer Investigational Site, Seattle, Washington, United States|Pfizer Investigational Site, Middleton, Wisconsin, United States|Pfizer Investigational Site, Waukesha, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT00735267
NCT00734071,An Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder,,Completed,Has Results,Generalized Anxiety Disorder,Drug: Vortioxetine|Drug: Placebo,Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score at Week 8|Change From Baseline in the Hospital Anxiety and Depression (HAD) Anxiety Subscale at Week 8|Clinical Global Impression Scale-Global Improvement at Week 8|Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Week 8|Percentage of Responders in HAM-A Total Score at Week 8|Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score at Week 8 in Participants With Baseline HAM-A ≥25|Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Social Functioning Subscore at Week 8|Change From Baseline in Hamilton Anxiety Scale (HAM-A) Total Score at Other Weeks Assessed|Change From Baseline in the Hospital Anxiety and Depression (HAD) Anxiety Subscale at Other Weeks Assessed|Clinical Global Impression Scale-Global Improvement at Other Weeks Assessed|Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Other Weeks Assessed|Percentage of Responders in HAM-A Total Score at Other Weeks Assessed|Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score at Other Weeks Assessed in Participants With Baseline HAM-A ≥25|Percentage of Participants in HAM-A Remission at Each Week Assessed|Change From Baseline in Clinical Global Impression Scale-Severity of Illness at Each Week Assessed|Change From Baseline in the Hospital Anxiety and Depression (HAD) Depression Subscale at Each Week Assessed|Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Social Functioning Subscore at Other Weeks Assessed|Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Physical Functioning Subscore at Each Week Assessed|Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Role-Physical Subscore at Each Week Assessed|Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Bodily Pain Subscore at Each Week Assessed|Change From Baseline in 36-Item Short-Form Health Survey (SF-36) General Health Subscore at Each Week Assessed|Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Vitality Subscore at Each Week Assessed|Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Role-Emotional Subscore at Each Week Assessed|Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Mental Health Subscore at Each Week Assessed|Health Care Resource Utilization as Assessed by the Health Economic Assessment Questionnaire,Takeda|H. Lundbeck A/S,All,"18 Years and older   (Adult, Older Adult)",Phase 3,304,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",LuAA21004_310|U1111-1114-4876,Jun-08,Jan-09,Mar-09,13-Aug-08,18-Dec-13,18-Dec-13,"Anaheim, California, United States|Arcadia, California, United States|Irvine, California, United States|National City, California, United States|Sherman Oaks, California, United States|Upland, California, United States|Washington, District of Columbia, United States|Bradenton, Florida, United States|Coral Gables, Florida, United States|North Miami, Florida, United States|St Petersburg, Florida, United States|Tampa, Florida, United States|Oak Brook, Illinois, United States|Park Ridge, Illinois, United States|Lafayette, Indiana, United States|Wichita, Kansas, United States|Baltimore, Maryland, United States|Fall River, Massachusetts, United States|Worcester, Massachusetts, United States|Flowood, Mississippi, United States|Bronx, New York, United States|Brooklyn, New York, United States|New York, New York, United States|Morganton, North Carolina, United States|Cincinnati, Ohio, United States|Toledo, Ohio, United States|Oklahoma City, Oklahoma, United States|Portland, Oregon, United States|Lincoln, Rhode Island, United States|Memphis, Tennessee, United States|Austin, Texas, United States|San Antonio, Texas, United States|Charleston, West Virginia, United States",,https://ClinicalTrials.gov/show/NCT00734071
NCT00730691,Efficacy of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder,,Completed,Has Results,Generalized Anxiety Disorder,Drug: Placebo|Drug: Vortioxetine|Drug: Duloxetine,Change From Baseline in the Hamilton Anxiety (HAM-A) Scale Total Score at Week 8|Change From Baseline in Hospital Anxiety and Depression (HAD) - Anxiety Subscale at Week 8|Mean Clinical Global Impression Scale-Global Improvement (CGI-I) at Week 8|Change From Baseline in Sheehan Disability Scale (SDS) at Week 8|Percentage of Responders in HAM-A Total Score at Week 8|Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score at Week 8 in Participants With Baseline HAM-A ≥25|Change From Baseline in Hamilton Anxiety Scale (HAM-A) Total Score at Other Weeks Assessed|Change From Baseline in Hospital Anxiety and Depression (HAD) - Anxiety Subscale at Other Weeks Assessed|Mean Clinical Global Impression Scale-Global Improvement (CGI-I) at Other Weeks Assessed|Change From Baseline in Sheehan Disability Scale (SDS) at Other Weeks Assessed|Percentage of Responders in HAM-A Total Score at Other Weeks Assessed|Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score at Other Weeks Assessed in Participants With Baseline HAM-A ≥25|Percentage of Participants in HAM-A Remission at Each Week Assessed|Change From Baseline in Clinical Global Impression Scale-Severity of Illness (CGI-S)|Change From Baseline in Hospital Anxiety and Depression (HAD) - Depression Subscale at All Weeks Assessed|Health Care Resource Utilization Assessed by the Health Economic Assessment Questionnaire,Takeda|H. Lundbeck A/S,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,781,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",LuAA21004_308|U1111-1114-3966,Jun-08,Feb-09,Feb-09,8-Aug-08,18-Dec-13,18-Dec-13,"Anaheim, California, United States|Beverly Hills, California, United States|Fresno, California, United States|Los Angeles, California, United States|Oceanside, California, United States|San Diego, California, United States|Sherman Oaks, California, United States|Widomar, California, United States|Denver, Colorado, United States|Farmington, Connecticut, United States|Norwalk, Connecticut, United States|Coral Gables, Florida, United States|Jacksonville, Florida, United States|Maitland, Florida, United States|Miami, Florida, United States|Orlando, Florida, United States|Tampa, Florida, United States|West Palm Beach, Florida, United States|Winter Park, Florida, United States|Atlanta, Georgia, United States|Roswell, Georgia, United States|Smyrna, Georgia, United States|Honolulu, Hawaii, United States|Oakbrook Ter, Illinois, United States|Terre Haute, Indiana, United States|Owensboro, Kentucky, United States|Shreveport, Louisiana, United States|Rockville, Maryland, United States|Chesterfield, Missouri, United States|St Louis, Missouri, United States|Nashua, New Hampshire, United States|Clementon, New Jersey, United States|Princeton, New Jersey, United States|Albuquerque, New Mexico, United States|Brooklyn, New York, United States|Cedarhurst, New York, United States|New York, New York, United States|Rochester, New York, United States|Staten Island, New York, United States|Charlotte, North Carolina, United States|Raleigh, North Carolina, United States|Beachwood, Ohio, United States|Cleveland, Ohio, United States|Dayton, Ohio, United States|Toledo, Ohio, United States|Eugene, Oregon, United States|Portland, Oregon, United States|Salem, Oregon, United States|Allentown, Pennsylvania, United States|Media, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Columbia, South Carolina, United States|Memphis, Tennessee, United States|Nashville, Tennessee, United States|Dallas, Texas, United States|DeSoto, Texas, United States|Houston, Texas, United States|Lake Jackson, Texas, United States|Wichita Falls, Texas, United States|Midvale, Utah, United States|Woodstock, Vermont, United States|Richmond, Virginia, United States|Seattle, Washington, United States|Brown Deer, Wisconsin, United States|Middleton, Wisconsin, United States|Milwaukee, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT00730691
NCT00731120,Study of Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder,,Completed,Has Results,Generalized Anxiety Disorder,Drug: Vortioxetine|Drug: Placebo,Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score|Change From Baseline in Hamilton Anxiety Scale (HAM-A) Total Score at Other Weeks Assessed|Percentage of Responders in HAM-A Total Score at Week 8|Percentage of Participants in HAM-A Remission at Week 8|Clinical Global Impression Scale-Global Improvement (CGI-I) at Each Week Assessed|Change From Baseline in Clinical Global Impression Scale-Severity of Illness (CGI-S)|Change From Baseline in Hospital Anxiety and Depression (HAD) Scales|Change From Baseline in Sheehan Disability Scale (SDS) at Week 8|Change From Baseline in 36-item Short-form Health Survey (SF-36)|Health Care Resource Utilization Assessed by the Health Economic Assessment Questionnaire,Takeda|H. Lundbeck A/S,All,"18 Years and older   (Adult, Older Adult)",Phase 3,457,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",LuAA21004_309|U1111-1114-2380,Jun-08,Jan-09,Feb-09,8-Aug-08,18-Dec-13,18-Dec-13,"Birmingham, Alabama, United States|Anaheim, California, United States|Cerritos, California, United States|Costa Mesa, California, United States|Orange, California, United States|Redlands, California, United States|Cromwell, Connecticut, United States|Norwich, Connecticut, United States|Hockessin, Delaware, United States|Fort Myers, Florida, United States|Jacksonville, Florida, United States|Lady Lake, Florida, United States|Miami, Florida, United States|Atlanta, Georgia, United States|Chicago, Illinois, United States|Libertyville, Illinois, United States|Valparaiso, Indiana, United States|Overland Park, Kansas, United States|Prairie Village, Kansas, United States|Boston, Massachusetts, United States|Braintree, Massachusetts, United States|Pittsfield, Massachusetts, United States|St Louis, Missouri, United States|Cherry Hill, New Jersey, United States|Fresh Meadows, New York, United States|New York, New York, United States|Olean, New York, United States|Cincinnati, Ohio, United States|Columbus, Ohio, United States|Middleburg Heights, Ohio, United States|Oklahoma City, Oklahoma, United States|Emmaus, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Reading, Pennsylvania, United States|North Charleston, South Carolina, United States|Nashville, Tennessee, United States|Houston, Texas, United States|San Antonio, Texas, United States|Midlothian, Virginia, United States|Waukesha, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT00731120
NCT00728923,Pilot Study of Minocycline (NPL-2003) in Adults With Obsessive-Compulsive Disorder (OCD),,Completed,Has Results,Obsessive Compulsive Disorder,Drug: NPL-2003,Number of Patients Who Met and Exceeded Response Criteria of Yale-Brown Obsessive-Compulsive Scale|Number of Patients That Met Response Criteria for the Hamilton Depression Rating Scale.,New York State Psychiatric Institute,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,9,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,5707,Aug-08,Jul-10,Jul-11,6-Aug-08,2-Apr-12,2-Apr-12,"New York State Psychiatric Institute, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00728923
NCT00727155,Adjusting to Chronic Conditions Using Education Support and Skills,ACCESS,Completed,No Results Available,Anxiety|Depression,Behavioral: Adjusting to Chronic Conditions Using Education Support and Skills,"Beck Depression Inventory, State Trait Anxiety Inventory, SF-36 Health Survey",US Department of Veterans Affairs|VA Office of Research and Development,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,3,U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,H23264,Sep-08,Mar-09,Mar-09,1-Aug-08,null,10-Jul-09,"Houston VA Medical Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00727155
NCT00725725,Org 25935 Versus Placebo as Augmentation to Cognitive-behavioral Therapy to Treat Panic Disorder (P05705),,Terminated,Has Results,Panic Disorder,Behavioral: Cognitive-behavioral therapy|Drug: Org 25935|Drug: Placebo,"Change in Panic Disorder Severity Scale (PDSS) Score From Baseline to End-of-Treatment (EOT)|Change in PDSS Score From Baseline to Visit 4|Change in PDSS Score From Baseline to Follow-Up|Structured Clinical Interview for DSM-IV-TR Axis 1 Disorders, Patient Edition With Psychotic Screen (SCID-I/P With Psy Screen) Score at Screening|SCID-I/P With Psy Screen Score at EOT|Change in Clinical Global Impression-Severity (CGI-S) Score|Change in Structured Interview Guide for the Hamilton Anxiety Scale (SIGH-A) Score|Change in Anxiety Sensitivity Index (ASI) Score|Change in Montgomery-Asberg Rating Scale for Depression (MADRS) Score|Change in Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) Score|Number of Participants Experiencing an Adverse Event (AE)|Number of Participants Discontinuing Study Therapy Due to AEs",Merck Sharp & Dohme Corp.,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,46,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",P05705|MK-8435-002|Org 172012,23-Jul-08,23-Apr-10,23-Apr-10,30-Jul-08,30-Dec-16,16-Oct-18,,,https://ClinicalTrials.gov/show/NCT00725725
NCT00724490,Unilateral Deep Brain Stimulation (DBS) of the Nucleus (Nucl.) Accumbens (Acc.) in Patients With Treatment Resistant Obsessive Compulsive Disorder (OCD),,Completed,No Results Available,Obsessive Compulsive Disorder,Procedure: Deep Brain Stimulation,Yale-Brown Obsessive Compulsive Scale|Beck Depression Inventory,University of Cologne,All,"21 Years to 65 Years   (Adult, Older Adult)",Not Applicable,16,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Ocdbs-Psy-120304,Feb-04,Sep-07,Feb-08,29-Jul-08,null,29-Jul-08,"Department of Psychiatry, University of Cologne, Cologne, NRW, Germany",,https://ClinicalTrials.gov/show/NCT00724490
NCT00723008,Cranial Electrotherapy Stimulation in Burned Patients,CES,Completed,Has Results,Post Traumatic Stress Disorders|Burns,Device: Alpha Stim 100 (Cranial Electrotherapy Stimulation),Mean Post-Traumatic Stress Questionnaire-Military (PCL-M) Score|Mean Center for Epidemiological Studies-Depression Scale (CES-D) Score|Mean Brief Profile of Mood States (BPOMS) Score|Mean Visual Analogue Scale of Pain (VAS-P) Before and After Cranial Electrotherapy Stimulation (CES).|Mean Visual Analogue Scale of Anxiety (VAS-A) Before and After Cranial Electrotherapy Stimulation (CES).|Mean General Sleep Disturbance Scale (GSDS) Score,United States Army Institute of Surgical Research,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,20,U.S. Fed,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",H-07-024,May-07,Jun-10,Dec-10,28-Jul-08,22-Mar-13,22-Mar-13,"USAISR, Fort Sam Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00723008
NCT00723060,Comparison of Effects Between Conventional Dose and High Dose Escitalopram on Clinical Improvement in Patients With Obsessive-compulsive Disorder,,Completed,No Results Available,Obsessive Compulsive Disorder,Drug: escitalopram,"The difference of Y-BOCS score average from baseline to 16-week|1) CGI-S, CGI-I 2) GAF 3) HAM-D, HAM-A",Seoul National University Hospital,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,176,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",11769A,Sep-08,Jan-11,Jan-11,28-Jul-08,null,8-Aug-11,"Seoul National University Hospital, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT00723060
NCT00721526,Disulfiram Combined With Lorazepam for Alcohol Dependence and Anxiety Disorder,,Completed,No Results Available,Alcohol Dependence|Anxiety Disorder,Drug: disulfiram plus lorazepam,Percent days abstinent from alcohol|retention in treatment|drinking consequences|drinks per drinking day|remission status|time to first heavy drinking day|Hamilton anxiety scale score|adverse events,University of New Mexico|National Institute on Alcohol Abuse and Alcoholism (NIAAA),All,"18 Years and older   (Adult, Older Adult)",Phase 4,45,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NIAAA-BOG_AA016555|K24AA016555|NIH Grant K24AA016555,Aug-09,Aug-12,Aug-12,24-Jul-08,null,30-Jan-13,"University of New Mexico Addiction and Substance Abuse Programs, Albuquerque, New Mexico, United States",,https://ClinicalTrials.gov/show/NCT00721526
NCT00720200,ICU Family Communication Study,,Completed,No Results Available,"Depression|Depressive Symptoms|Anxiety|Stress Disorders, Post-Traumatic|ICU Hospitalization|Care and Treatment in ICU",Behavioral: Facilitator-Based intervention|Behavioral: Usual Care,Patient Health Questionaire (PHQ-9)|Post-Traumatic Stress Disorder Checklist (PCL)|Generalized Anxiety Disorder (GAD-7) Survey|Quality of Dying and Death Questionaire|Evaluate length of stay in ICU/hospital|Costs during ICU stay including estimated costs of intervention|Families' ratings of the quality of communication generally and specifically in the family conference|Clinicians' ratings of the quality of clinician-family in the family conference|Clinicians' ratings of nurse-physician collaboration,University of Washington|National Institute of Nursing Research (NINR),All,"18 Years and older   (Adult, Older Adult)",Phase 3,593,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,33584-C|2R01NR005226,Jun-08,Mar-14,May-14,22-Jul-08,null,16-Sep-14,"Valley Medical Center, Renton, Washington, United States|Harborview Medical Center, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00720200
NCT00715039,Clinical Study Assessing a New Scale to Measure Onset of Action in Generalized Anxiety Disorder,,Completed,No Results Available,Anxiety Disorders,Drug: lorazepam|Drug: placebo|Drug: paroxetine,"Average change from baseline over the first 6 days of treatment assessment (Study Days 2 through 7) on the Daily Assessment of Symptoms - Anxiety (DAS-A) questionnaire.|CGIC at endpoint (LOCF)|PGIC at endpoint (LOCF)|Q-LES-Q change from baseline to endpoint (LOCF)|SF-36v2 Mental Health change from baseline to endpoint (LOCF)|HADS-A change from baseline to endpoint (LOCF)|HADS-D change from baseline to endpoint (LOCF)|Change from baseline to endpoint (Weeks 1, 2, 4, and 5) in the HAM-A total score.|Change from baseline to daily time point (Study Days 2 through 7) on the DAS-A.|DAS-A change from baseline to endpoint (LOCF)|DAS-A 30% and 50% improvement at endpoint;|DAS-A 30% sustained improvement beginning at week 1|HAM-A 30% sustained improvement beginning at week 1|HAM-A 30% and 50% improvement at endpoint|GA-VAS average change from baseline over the first 6 days|Change from baseline to daily time point on the GA-VAS(study days 2 through 7)|GA-VAS change from baseline to endpoint|GA-VAS sustained 30% improvement beginning at week 1|GA-VAS 30% and 50% improvement at endpoint",Pfizer,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,169,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science",A9001141,Oct-03,null,May-04,15-Jul-08,null,3-Oct-08,"Pfizer Investigational Site, Glendale, California, United States|Pfizer Investigational Site, Northridge, California, United States|Pfizer Investigational Site, Orange, California, United States|Pfizer Investigational Site, San Diego, California, United States|Pfizer Investigational Site, Sherman Oaks, California, United States|Pfizer Investigational Site, Van Nuys, California, United States|Pfizer Investigational Site, Casselberry, Florida, United States|Pfizer Investigational Site, Orlando, Florida, United States|Pfizer Investigational Site, Atlanta, Georgia, United States|Pfizer Investigational Site, Marietta, Georgia, United States|Pfizer Investigational Site, Overland Park, Kansas, United States|Pfizer Investigational Site, Overland Park, Kansas, United States|Pfizer Investigational Site, Albuquerque, New Mexico, United States|Pfizer Investigational Site, Albuquerque, New Mexico, United States|Pfizer Investigational Site, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT00715039
NCT00715806,Claustrophobia and Magnetic Resonance Imaging,CLAUSTRO,Completed,No Results Available,Claustrophobia,Device: Open MRI scanner.|Device: Closed MRI scanner.,The ability of an open MRI scanner to reduce claustrophobic reactions that prevent MR examinations.|Impact of MR imaging results on subsequent measurement.,"Charite University, Berlin, Germany",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,174,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic,EA1/020/08,Jun-08,Aug-09,Aug-09,15-Jul-08,null,23-Jun-11,"Charité, Berlin, Germany",,https://ClinicalTrials.gov/show/NCT00715806
NCT00708240,Treatment Youth With Obsessive-Compulsive Disorder,,Unknown status,No Results Available,Obsessive Compulsive Disorder,Drug: Escitalopram,Children's Yale-Brown Obsessive Compulsive Scale score.|Clinical Global Impression for Severity of Illness and Improvement,University of Ottawa|H. Lundbeck A/S,All,"13 Years to 19 Years   (Child, Adult)",Phase 4,40,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IMHR-REB-2006-14,Jan-07,Aug-10,Dec-10,2-Jul-08,null,2-Jul-08,"University of Ottawa Institute of Mental Health Research, Ottawa, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT00708240
NCT00708396,Tolerability And Efficacy Of High Dose Escitalopram In The Treatment Of Patients Suffering From Schizophrenia And Obsessive-Compulsive Disorder (OCD) - An Open Label Study,,Unknown status,No Results Available,OCD|Schizophrenia,Drug: Escitalopram,1. Yale-Brown Obsessive Compulsive Scale (Y-BOCS) Symptom Checklist|2. Positive and negative symptoms scale ( PANSS)|3. The Clinical Global Impression scales (CGI) consist of two sub-scales: The Severity of illness (CGI-S) and the Global improvement (CGI-I).|4. Blood lipids and blood glucose prior to escitalopram up-titration over 20mg/d and at last visit|5. EKG and physical examination will be performed at baseline 6. AE checklist at every visit 7. Recent and concomitant medications at every visit,BeerYaakov Mental Health Center,All,"18 Years and older   (Adult, Older Adult)",Phase 4,20,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Escitalopram -199CTIL,Jul-08,Jul-10,Jul-10,2-Jul-08,null,27-Jan-09,"Beer-Yaacov MHC, Beer-Yaacov, Israel",,https://ClinicalTrials.gov/show/NCT00708396
NCT00706836,PharmacofMRI of Anxiolytic Medications (Pregabalin),,Completed,Has Results,Anxiety Disorders,Drug: Pregabalin 50mg|Drug: Pregabalin 200 MG|Drug: placebo,Effect of Pregabalin (Two Doses) Versus Placebo,"University of California, San Diego|National Institute of Mental Health (NIMH)",All,18 Years to 30 Years   (Adult),Phase 4,16,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Diagnostic,UCSD IRB 060407 - B|R01MH075792,Jun-08,Dec-08,Dec-08,30-Jun-08,22-Dec-14,9-Apr-19,"University of California, San Diego, La Jolla, California, United States",,https://ClinicalTrials.gov/show/NCT00706836
NCT00706290,Brief CBT for Anxiety and Advanced Cancer,,Completed,No Results Available,"Anxiety|Depression|Unspecified Adult Solid Tumor, Protocol Specific|Cancer|Cognitive Behavioral Therapy",Behavioral: Brief Cognitive Behavioral Therapy,Anxiety symptoms as measured by the Hamilton Anxiety Rating Scale|Depression as measured by the Montgomery Asberg Depression Rating Scale|Quality of life as measured by the Functional Assessment of Scale Cancer Therapy (FACT-G),Massachusetts General Hospital|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 2,49,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,CDR0000597438|1R03CA128478-01|2007P000368,Apr-07,Aug-10,Aug-10,27-Jun-08,null,6-Jun-14,"Massachusetts General Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT00706290
NCT00703833,A Study of MK0777 Gel Extrusion Module (GEM) in the Treatment of Outpatients With Generalized Anxiety Disorder (0777-019),,Completed,No Results Available,Generalized Anxiety Disorder,Drug: MK0777|Drug: Placebo (unspecified),Measure the reduction of anxiety|Safety and efficacy,Merck Sharp & Dohme Corp.,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,51,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",0777-019|MK0777-019|2007_630,Sep-02,Feb-03,Feb-03,24-Jun-08,null,2-Nov-15,,,https://ClinicalTrials.gov/show/NCT00703833
NCT00703885,PharmacofMRI (Functional Magnetic Resonance Imaging) of Anxiolytic Medications (Alprazolam),,Completed,Has Results,Anxiety Disorders,Drug: 0.25 mg alprazolam|Drug: 1.0 mg alprazolam|Drug: placebo,Effect of Alprazolam Versus Placebo on BOLD fMRI During Emotion Processing|Voxelwise Brain Imaging Data,"University of California, San Diego|National Institute of Mental Health (NIMH)",All,18 Years to 30 Years   (Adult),Phase 4,16,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Diagnostic,UCSD IRB 060407 - A|R01MH075792,Jan-08,Aug-08,Aug-08,24-Jun-08,22-Dec-14,22-Dec-14,"University of California, San Diego, La Jolla, California, United States",,https://ClinicalTrials.gov/show/NCT00703885
NCT00704379,Treatment Strategy to Prevent Mood Disorders Following Traumatic Brain Injury,,Completed,Has Results,Traumatic Brain Injury,Drug: Placebo|Drug: Sertraline,"Time to Onset of Diagnostic and Statistical Manual (DSM) IV Defined Mood and Anxiety Disorders Associated With Traumatic Brain Injury (TBI)|Total Community Integration Questionnaire Scores|Iowa Gambling Task Score|Memory Function Composite|Social Functioning Examination Total Score|Neuroimaging Variables (i.e., Fractional Anisotropy [FA] of Frontal White Matter Such as the Cingulate Gyrus)",Baylor College of Medicine|National Institute of Neurological Disorders and Stroke (NINDS),All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2|Phase 3,94,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Prevention",R01NS055827|1R01NS055827-01A2,Jun-08,Apr-14,Apr-14,24-Jun-08,12-May-15,25-Aug-15,"Baylor College of Medicine, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00704379
NCT00703547,A First Time in Human Study of GSK586529 in Healthy Volunteers,,Completed,No Results Available,Depressive Disorder and Anxiety Disorders,Drug: GSK586529 capsules|Drug: GSK586529 tablets|Drug: Placebo,Pharmacokinetics|Blood levels of GSK586529 to determine pharmacokinetic parameters|Urinary recovery of GSK586529,GlaxoSmithKline,Male,18 Years to 45 Years   (Adult),Phase 1,21,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Primary Purpose: Prevention,CRZ107432,28-Jan-08,11-Apr-08,11-Apr-08,23-Jun-08,null,22-Aug-17,"GSK Investigational Site, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT00703547
NCT00701064,Bright Light: An Adjunct Treatment for Combat Posttraumatic Stress Disorder (PTSD),,"Active, not recruiting",Has Results,Posttraumatic Stress Disorder,Other: Bright Light Exposure|Other: Negative Ion Generator,Clinical Assessed PTSD Scale (CAPS-2)|Clinical Global Impressions Scale (CGI)|Posttraumatic Stress Disorder Checklist (PCL-M),VA Office of Research and Development|Arizona State University,All,18 Years to 60 Years   (Adult),Not Applicable,71,U.S. Fed|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,MHBA-008-08S,1-Jan-09,21-Nov-12,30-Sep-19,19-Jun-08,29-Apr-15,15-May-19,"Wm. Jennings Bryan Dorn VA Medical Center, Columbia, SC, Columbia, Arizona, United States",,https://ClinicalTrials.gov/show/NCT00701064
NCT00701675,Pharmacological Treatment of Generalized Anxiety Disorder in the Elderly,Sert-GAD,Completed,Has Results,Generalized Anxiety Disorder,Drug: sertraline 50 mg daily|Drug: sertraline 100 mg daily|Drug: Placebo 50 or 100 mg,"Comparisons of End of Study HAM-A Score Means for Sertraline 50 mg vs Placebo, Sertraline 100 mg vs Placebo, and Sertraline 50 mg vs. Sertraline 100 mg",VA Office of Research and Development,All,"60 Years and older   (Adult, Older Adult)",Phase 4,42,U.S. Fed,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CLIN-005-04F,Oct-05,Jul-09,Sep-09,19-Jun-08,29-Dec-16,29-Dec-16,"VA Medical Center, Tuscaloosa, Tuscaloosa, Alabama, United States|Miami VA Healthcare System, Miami, FL, Miami, Florida, United States|Ralph H Johnson VA Medical Center, Charleston, Charleston, South Carolina, United States",,https://ClinicalTrials.gov/show/NCT00701675
NCT00699127,Organizing the Information Given to Parents of NICU Infants in Order to Reduce Their Anxiety,,Withdrawn,No Results Available,Anxiety,Behavioral: Lecture,Difference between questionnaires at the first week and the last week to hospitalization.,Hillel Yaffe Medical Center,All,up to 4 Months   (Child),Not Applicable,0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,HY-19-2008-CTIL,Jul-08,Jul-08,Jul-08,17-Jun-08,null,4-Jul-08,"Hillel Yaffe medical center, Hadera, Israel",,https://ClinicalTrials.gov/show/NCT00699127
NCT00698113,Parent-Delivered Massage in Paediatric Cancer,,Unknown status,No Results Available,Anxiety|Depression|Stress|Pediatric Cancers,Procedure: Massage|Other: Journaling,"To test the feasibility of the educational intervention in parent-delivered massage for children undergoing treatment for cancer at a paediatric oncology centre, to guide sample size estimation for a future randomized trial.|My Story|Memorial Symptom Assessment Scale|Pediatric Inventory for Parents|Stait-Trait Anxiety Inventory for Adults|The Center for Epidemiologic Studies Depression (CES-D) Scale|State-Trait Anxiety Inventory for Children|Parent Journals|Child Journals",Centennial College|SickKids Foundation|Stollery Children's Hospital|Canadian Institute of Natural and Integrative Medicine,All,"6 Years to 18 Years   (Child, Adult)",Not Applicable,24,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,CENT-SK-CAM07-323R|CAM 07-323R,Apr-07,Apr-09,Jun-09,16-Jun-08,null,19-Jun-09,"Stollery Children's Hospital, Edmonton, Alberta, Canada|Centennial College, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT00698113
NCT00696852,"Mindfulness, Yoga, and Cardiovascular Disease",,Completed,No Results Available,Cardiovascular Disease|Stress|Anxiety|Depression,"Behavioral: Mindfulness Meditation|Behavioral: Yoga|Behavioral: Exercise, Relaxation, and Health Education","change in inflammatory markers|change in psychological and physiological markers of anxiety, depression, and cardiovascular disease",The Cleveland Clinic,All,"40 Years to 75 Years   (Adult, Older Adult)",Not Applicable,64,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,BHBI-1201,Jun-08,May-09,May-09,13-Jun-08,null,24-Sep-12,"The Cleveland Clinic, Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT00696852
NCT00695630,Flumazenil Reversal of Oral Triazolam,,Completed,No Results Available,Dental Anxiety,Drug: Flumazenil|Drug: Placebo,Observer Assessment of Alertness/Sedation|BIS,University of Washington|National Institutes of Health (NIH),All,18 Years to 40 Years   (Adult),Phase 1|Phase 2,14,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",30779|U54DE014254|T32007132,Sep-06,Dec-07,Dec-07,12-Jun-08,null,12-Jun-08,"Dental Fears Research Clinic, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00695630
NCT00690729,Cognitive-Behavioral Bibliotherapy for the Treatment of Obsessive Compulsive Disorder in Children and Adolescents,,Completed,No Results Available,Obsessive-Compulsive Disorder,Behavioral: Cognitive Behavioral Bibliotherapy|Behavioral: Cognitive Behavioral Therapy,Child Yale-Brown Obsessive Compulsive Scale|NIMH Clinician's Global Impression|Children's Obsessional Compulsive Inventory|Child OCD Impact Scale|March Anxiety Scale for Children|Children's Depression Inventory|Child Behavior Checklist|Family Assessment Measure III,UConn Health,All,"8 Years to 18 Years   (Child, Adult)",Not Applicable,22,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,H06-170,Jul-05,Mar-10,Aug-10,5-Jun-08,null,30-Aug-10,"Institute of Living, Hartford, Connecticut, United States|University of Connecticut, Storrs, Connecticut, United States|University of Connecticut, Waterbury, Connecticut, United States|University of Connecticut, West Hartford, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT00690729
NCT00688818,Quetiapine in Co-Morbid Depressive and Anxiety Disorders,,Completed,No Results Available,Major Depressive Disorder|Dysthymic Disorder|Anxiety Disorders|Generalized Anxiety Disorder|Social Anxiety Disorder|Panic Disorder|Post-traumatic Stress Disorder,Drug: Quetiapine|Drug: Placebo,Hamilton Depression Rating Scale (HAMD-17)|Hamilton Anxiety Scale|Quality of Life Enjoyment and Satisfaction Scale|Penn State Worry Questionnaire|Panic Disorder Severity Scale|Leibowitz Social Anxiety Scale|Post-traumatic Diagnostic Scale|Clinical Global Impression Scale,Centre for Addiction and Mental Health,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,108,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",183/2007,Jun-08,Jun-13,Jun-13,3-Jun-08,null,21-Aug-14,"Chatham-Kent Health Alliance, Chatham, Ontario, Canada|Centre for Neuropsychiatric Study, Markham, Ontario, Canada|Credit Valley Medical Arts Centre, Mississauga, Ontario, Canada|Centre for Addiction and Mental Health, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT00688818
NCT00684320,Attention Disengagement Training for Social Phobia,SPAttn,Completed,Has Results,Social Anxiety Disorder,Behavioral: Attention Disengagement Training (ADT)|Behavioral: Placebo Condition,Liebowitz Social Anxiety Scale (LSAS)|Social Phobia and Anxiety Inventory,San Diego State University|National Institute of Mental Health (NIMH),All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,48,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",R34MH073004-03,Sep-06,Aug-11,Aug-11,26-May-08,1-May-14,1-May-14,"San Diego State University, San Diego, California, United States",,https://ClinicalTrials.gov/show/NCT00684320
NCT00684541,Interpretation Modification Program for Social Phobia,SP Interp,Completed,Has Results,Social Anxiety Disorder|Social Phobia,Behavioral: Interpretation Modification Program|Behavioral: Interpretation Control Condition,Liebowitz Social Anxiety Scale (LSAS)|Social Phobia and Agoraphobia Inventory,San Diego State University|National Institute of Mental Health (NIMH),All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,49,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",1-Amir|5R34MH073004-03,Sep-07,Aug-11,Aug-11,26-May-08,1-May-14,1-May-14,"San Diego State University, San Diego, California, United States",,https://ClinicalTrials.gov/show/NCT00684541
NCT00681720,Positron Emission Tomography (PET) Study With (11C)Flumazenil to Determine Central GABAA Receptor Occupancy of AZD7325,PET,Completed,No Results Available,Anxiety,Drug: AZD7325|Drug: Radioligand (11C) flumazenil,"Positron emission tomography using the radioligand (11C)flumazenil|To assess safety of AZD7325 by assessment of adverse events, vital signs, ECGs, physical examination, psychometric tests and laboratory variables.|Investigate the pharmacokinetics of AZD7325 following single doses of AZD7325 by assessment of drug concentration in plasma",AstraZeneca,Male,20 Years to 45 Years   (Adult),Phase 1,4,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,D1140C00007|EudractCT 2007-005436-86,Feb-08,Jul-08,Jul-08,21-May-08,null,21-Aug-08,"Research Site, Stockholm, Sweden",,https://ClinicalTrials.gov/show/NCT00681720
NCT00681746,Positron Emission Tomography (PET) Study With (11C) Flumazenil to Determine Central GABAA Receptor Occupancy of AZD6280,PET,Completed,No Results Available,Anxiety,Drug: AZD6280|Drug: (11C) flumazenil,"Positron emission tomography using the radioligand (11C) flumazenil|To assess safety of AZD7325 by assessment of adverse events, vital signs, ECGs, psychometric tests and laboratory variables.|Investigate the pharmacokinetics of AZD6280 following single doses of AZD6280 by assessment of drug concentration in plasma.",AstraZeneca,Male,20 Years to 45 Years   (Adult),Phase 1,8,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,D0850C00011|EudractCT 2007-006683-29,Feb-08,Sep-08,Sep-08,21-May-08,null,10-Dec-10,"Research Site, Stockholm, Sweden",,https://ClinicalTrials.gov/show/NCT00681746
NCT00680602,Group Cognitive Behavioral Therapy Versus Fluoxetine for Obsessive-Compulsive Disorder: a Practical Trial,GCBTVF,Completed,No Results Available,Obsessive Compulsive Disorder,"Behavioral: Group Cognitive Behavior Therapy|Drug: SSRI (fluoxetine, sertraline, paroxetine, citalopram)","Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) (Goodman et al., 1989) and Clinical Global Impressions (CGI) (Guy, 1976) will be implemented at pre and post treatment by a blind evaluator to the treatment received.|Quality of life measured by SF 36 and social adjustment measured by EAS.",University of Sao Paulo|Fundação de Amparo à Pesquisa do Estado de São Paulo,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,158,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research,06/50829-8,Jan-06,Sep-08,Sep-08,20-May-08,null,16-Feb-09,"Institute of Psychiatry, Clinics Hospital, University of São Paulo Medical School, São Paulo, SP, Brazil",,https://ClinicalTrials.gov/show/NCT00680602
NCT00678444,Patient Satisfaction Study: Clean Intermittent Self-Catheterization Teaching,,Completed,Has Results,Anxiety,Other: Educational video,State-Trait Anxiety Inventory-State Scores|Patient Satisfaction Scores - Visual Analogue Scores (VAS).,University of Pittsburgh,Female,"18 Years to 100 Years   (Adult, Older Adult)",Not Applicable,199,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,PRO07070018,Apr-08,Apr-11,Jan-12,15-May-08,3-Aug-18,3-Aug-18,"University of Pittsburgh Medical Center - Center for Female Bladder and Pelvic Health, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00678444
NCT00677352,A Study Of Sertraline Compared With Paroxetine In The Treatment Of Panic Disorder,,Completed,Has Results,Panic Disorder,Drug: sertraline|Drug: Paroxetine,Mean Change From Baseline in Panic and Agoraphobia Scale (PAS) Total Score at the End of Treatment Phase|Percentage of Participants of Responder in Clinical Global Impression (CGI) - Improvement|Mean Change From Baseline in Panic Attack at the End of Treatment Phase|Mean Change From Baseline in Hamilton Anxiety Rating Scale Total Score at the End of Treatment Phase|Number of Participants With Summary of Adverse Events in Treatment Phase|Summary of Adverse Events in Tapering Phase|Percentage of Participants With Deterioration in Antidepressant Discontinuation Scale During Tapering Phase,Pfizer,All,20 Years to 64 Years   (Adult),Phase 4,321,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",A0501088,May-08,Jan-10,Feb-10,14-May-08,6-May-11,20-May-11,"Pfizer Investigational Site, Nagoya, Aichi, Japan|Pfizer Investigational Site, Fukuoka-shi, Fukuoka, Japan|Pfizer Investigational Site, Kitakyushu-shi, Fukuoka, Japan|Pfizer Investigational Site, Kitakyusyu-shi, Fukuoka, Japan|Pfizer Investigational Site, Sapporo-Shi, Hokkaido, Japan|Pfizer Investigational Site, Sapporo, Hokkaido, Japan|Pfizer Investigational Site, Higashiibaraki-gun, Ibaraki, Japan|Pfizer Investigational Site, Fujisawa-city, Kanagawa, Japan|Pfizer Investigational Site, Sagamihara-Shi, Kanagawa, Japan|Pfizer Investigational Site, Yokohama-Shi, Kanagawa, Japan|Pfizer Investigational Site, Yokohama, Kanagawa, Japan|Pfizer Investigational Site, Kawaguchi-shi, Saitama, Japan|Pfizer Investigational Site, Saitama city, Saitama, Japan|Pfizer Investigational Site, Chiyoda-ku, Tokyo, Japan|Pfizer Investigational Site, Kita-ku, Tokyo, Japan|Pfizer Investigational Site, Minato-ku, Tokyo, Japan|Pfizer Investigational Site, Musashino, Tokyo, Japan|Pfizer Investigational Site, Nakano-Ku, Tokyo, Japan|Pfizer Investigational Site, Nakanoku, Tokyo, Japan|Pfizer Investigational Site, Setagaya-ku, Tokyo, Japan|Pfizer Investigational Site, Shinjuku-ku, Tokyo, Japan|Pfizer Investigational Site, Toshima-ku, Tokyo, Japan|Pfizer Investigational Site, Nakano-ku, Yokohama, Japan|Pfizer Investigational Site, Minato-ku, Japan",,https://ClinicalTrials.gov/show/NCT00677352
NCT00676364,Randomized Control Trial of a Topical Anesthetic to Evaluate Pain and Anxiety During Venipuncture,,Completed,Has Results,Pain|Anxiety,Drug: 4% lidocaine topical anesthetic cream|Drug: Placebo cream,Pain From Venipuncture|Anxiety of Venipuncture,"Jenny Boucher, PharmD|Lehigh Valley Hospital",All,"5 Years to 18 Years   (Child, Adult)",Phase 4,114,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",1-20030313,Mar-03,Feb-08,Feb-08,13-May-08,25-Sep-12,25-Sep-12,"Lehigh Valley Hospital, Allentown, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00676364
NCT00675909,Improving Sedation of Children Undergoing Procedures in the Emergency Department,,Completed,Has Results,Anxiety,Drug: Aerosolized Intranasal midazolam|Drug: Aerosolized Buccal Midazolam|Drug: Oral midazolam,"Change in CHEOPS Score Measured Level of Sedation From Baseline (Presentation in ED, Before Sedation) to Start of Procedure (Laceration Repair).|Time From Study Drug Administration to Start of Procedure|Duration of Procedure|Physician Rating of Sedation|Nurse Rating of Sedation",Seattle Children's Hospital,All,6 Months to 7 Years   (Child),Not Applicable,180,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care",2005-0260A,Nov-06,Dec-09,Jan-10,12-May-08,7-Jun-12,9-Nov-18,,,https://ClinicalTrials.gov/show/NCT00675909
NCT00674219,Memantine Treatment for Obsessive-compulsive Disorder and Generalized Anxiety Disorder,,Completed,Has Results,Obsessive-Compulsive Disorder|Generalized Anxiety Disorder,Drug: Memantine,Psychometric Scores,"University of California, Los Angeles|Saban Family Foundation",All,18 Years to 64 Years   (Adult),Phase 3,17,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,04-08-063-03,May-05,Jan-08,Jan-08,7-May-08,10-May-19,10-May-19,"UCLA, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT00674219
NCT00671853,Quetiapine Extended Release (XR) in Bipolar Patients With Comorbid Generalized Anxiety Disorder (GAD),,Completed,Has Results,Bipolar Disorder|Anxiety|Anxiety Disorders|Substance Use Disorders,Drug: Quetiapine XR|Drug: Placebo for quetiapine XR,Change in the 17 Item Hamilton Rating Scale for Depression (HAM-D-17) Score|Response Rate (≥ 50% Improvement) on Hamilton Rating Scale for Depression (HAM-D-17)|Remission Rate (≤ 7) on Hamilton Rating Scale for Depression (HAM-D-17)|Change in Clinical Global Impressions of Improvement or Severity (CGI-I or S) Score|Change in the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) Score|Change in Hamilton Rating Scale for Anxiety (HAM-A),University Hospitals Cleveland Medical Center|National Alliance for Research on Schizophrenia and Depression|AstraZeneca,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,120,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",10/6/2019,Apr-08,Mar-11,Mar-11,5-May-08,11-Oct-13,29-Dec-16,"University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT00671853
NCT00669526,Clinical and Cost Effectiveness of Brief Cognitive-Behavioral Therapy (CBT) for Pediatric Internalizing Disorders,,Completed,No Results Available,Depression|Anxiety,Behavioral: BCBT|Behavioral: SMHC referral,Clinician Global Impressions - Improvement (CGI-I),Robert Wood Johnson Foundation|National Institute of Mental Health (NIMH)|William T. Grant Foundation,All,7 Years to 17 Years   (Child),Phase 2,60,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,51653,Oct-04,Mar-07,Apr-07,30-Apr-08,null,30-Apr-08,"University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00669526
NCT00668265,Anxiety in Recovering Opiate Dependence,,Terminated,Has Results,Generalized Anxiety Disorder|Comorbid Opiate Dependence in Remission|Status Post Methadone-Maintenance Treatment,Drug: Quetiapine,Hamilton Anxiety Scale at 16 Weeks|Beck Depression Inventory at 16 Weeks,Beth Israel Medical Center|AstraZeneca,All,"21 Years to 65 Years   (Adult, Older Adult)",Phase 4,14,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",IRB # (112-07)|IRUSQUET0443,Jan-08,Aug-11,Aug-11,29-Apr-08,18-Feb-13,18-Feb-13,"Su Casa Methadone-to-Abstinence Rehabilitation, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00668265
NCT00663078,Group Cognitive Behavioral Therapy (CBT) Intervention for Women With Mild to Moderate Depression,BackonTrack,Completed,No Results Available,Depression|Anxiety,Behavioral: Brief CBT Group therapy,PHQ-9 Score,University of Bristol,Female,30 Years to 54 Years   (Adult),Early Phase 1,75,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,07/H0107/60,Aug-07,Mar-09,Mar-09,22-Apr-08,null,14-Jan-10,"Merrywood GP Practice Knowle West,, Bristol, United Kingdom|Wellspring Healthy Living Centre, Bristol, United Kingdom",,https://ClinicalTrials.gov/show/NCT00663078
NCT00662259,Drug Treatment Validation of Functional Magnetic Resonance Imaging in Generalized Anxiety Disorder,GAD,Completed,No Results Available,Generalized Anxiety Disorder,Drug: Alprazolam (Xanax)|Drug: Placebo,Percent signal change in brain activity in the amygdala when viewing emotional faces|Percent signal change in brain activity in the insula when anticipating viewing emotional pictures.|Score on the Hamilton Anxiety Scale|Score on the Penn State Worry Scale,"University of California, San Diego|Hoffmann-La Roche",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,32,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",WP21030,Apr-08,Sep-09,Sep-09,21-Apr-08,null,20-May-19,"University of California, San Diego, San Diego, California, United States",,https://ClinicalTrials.gov/show/NCT00662259
NCT00662584,Repetitive Magnetic Transcranial Stimulation (rTMS) in the Treatment of Generalized Anxiety Disorder (GAD),,Completed,No Results Available,Generalized Anxiety Disorder,Procedure: Repetitive transcranial magnetic stimulation (rTMS),Structured Interview for the Hamilton Anxiety Rating Scale (SIGH-A)|The Clinical Global Impression (CGI) Scale of Severity/Improvement|Structured Interview for the Hamilton Depression Rating Scale (SIGH-D)|The Side-Effects Questionnaire,"University of California, Los Angeles|Phillis and Brian Harvey Foundation|Saban Family Foundation",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,10,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,05-05-045-01,Aug-06,Mar-07,Apr-07,21-Apr-08,null,19-Aug-16,"UCLA, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT00662584
NCT00663013,Virtual Reality for Burn Wound Care Pain Control,,Unknown status,No Results Available,Pain|Anxiety,Other: Virtual Reality,"pain perception|anticipatory anxiety|current psychiatric diagnosis, is related to pain|""pain catastrophizing"" is related to higher pain perception and greater benefits from the VR",Weill Medical College of Cornell University,All,"12 Years and older   (Child, Adult, Older Adult)",Not Applicable,12,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,701008961,Oct-07,May-10,May-10,21-Apr-08,null,4-Jan-11,"New York Presbyterian Hospital, WRH Burn Center, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00663013
NCT00659932,Dealing With Anxiety: A Cognitive Behavioural Program for Diabetes,,Completed,No Results Available,Diabetes Mellitus Type 2,Behavioral: Immediate Cognitive behavioural therapy (CBT)|Behavioral: Delayed CBT,Hemoglobin A1C (HbA1C)|Depression Anxiety Stress Scale (DASS)|Diabetes Quality of Life (ADDQoL),Hunter and New England Health,All,"Child, Adult, Older Adult",Not Applicable,64,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment,02/03/13/3.18,May-02,Mar-05,Mar-05,17-Apr-08,null,17-Apr-08,"Royal Newcastle Hospital, Newcastle, New South Wales, Australia",,https://ClinicalTrials.gov/show/NCT00659932
NCT00658372,A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (2),,Terminated,No Results Available,Generalized Anxiety Disorder,Drug: PD 0332334|Drug: Paroxetine|Drug: Placebo,"The efficacy of PD 0332334 in the treatment of GAD will be measured by the change in the Hamilton Anxiety Rating Scale (HAM-A) total scores from baseline observed following 8 weeks of double-blind treatment.|The safety and tolerability of PD 0332334 in subjects with GAD will be monitored in this study|Average (across the week 1, 2, 4, 6 and 8 visits) HAM-A change from baseline score|Change from baseline in the HAM-A total score at weeks 1, 2, 4, and 6|Change from Baseline to Week 8 on the Medical Outcomes Study Sleep Scale subscales|Response rate on the patient-rated PGI-C at week 8|The ""Week 1 Sustained Responder"" rate based on the HAM A (where ""Week 1 Sustained Responders"" are defined as subjects with a 50% or greater improvement from baseline on the HAM A total score at Week 1 that is sustained until the Week 8 visit)|Change from Baseline to Days 2- 8 and Weeks 2, 4, 6, 8 on the DAS A (total score)|Change from Baseline to Week 8 on the Medical Outcomes Study Sleep Scale (MOS SS) Sleep Disturbance Score|Response rate on the HAM-A at week 1 and week 8|Change from Baseline to Week 1 on the Medical Outcomes Study Sleep Scale (MOS SS) Sleep Disturbance Score|Change from baseline in the 17-item HAM-D total score at weeks 1, 2, 4, and 8|Change from Baseline in the psychic subscale score of the HAM A (Items 1- 6 and 14) at Week 8|Change from baseline in the somatic subscale score of the HAM-A (items 7 - 13)|Change from baseline to week 8 in the QLesQ General Activity Score|Worsening and improvement from baseline to week 8 on the changes in the Sexual Functioning Questionnaire (CSFQ)|Remission rate based on the HAM A at Week 8|Response rate on the clinician-rated CGI-I ate week 1 and week 8|Change from baseline in CGI-S at week 8|Change from baseline to Days 2-8 and weeks 2, 4, 6 and 8 on the GA-VAS (diary)|Change from baseline to week 8 on the Sheehan Disability Scale (SDS) total score",Pfizer,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,360,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",A5361018,May-08,Mar-09,Mar-09,15-Apr-08,null,16-Nov-12,"Pfizer Investigational Site, Arcadia, California, United States|Pfizer Investigational Site, Costa Mesa, California, United States|Pfizer Investigational Site, Escondido, California, United States|Pfizer Investigational Site, Los Angeles, California, United States|Pfizer Investigational Site, San Diego, California, United States|Pfizer Investigational Site, Hamden, Connecticut, United States|Pfizer Investigational Site, Boca Raton, Florida, United States|Pfizer Investigational Site, Honolulu, Hawaii, United States|Pfizer Investigational Site, Naperville, Illinois, United States|Pfizer Investigational Site, Park Ridge, Illinois, United States|Pfizer Investigational Site, Prairie Village, Kansas, United States|Pfizer Investigational Site, New Orleans, Louisiana, United States|Pfizer Investigational Site, Haverhill, Massachusetts, United States|Pfizer Investigational Site, Pittsfield, Massachusetts, United States|Pfizer Investigational Site, Flint, Michigan, United States|Pfizer Investigational Site, Flint, Michigan, United States|Pfizer Investigational Site, Minneapolis, Minnesota, United States|Pfizer Investigational Site, St. Paul, Minnesota, United States|Pfizer Investigational Site, New York, New York, United States|Pfizer Investigational Site, Olean, New York, United States|Pfizer Investigational Site, Rochester, New York, United States|Pfizer Investigational Site, Dayton, Ohio, United States|Pfizer Investigational Site, Allentown, Pennsylvania, United States|Pfizer Investigational Site, Bartlett, Tennessee, United States|Pfizer Investigational Site, Memphis, Tennessee, United States|Pfizer Investigational Site, Dallas, Texas, United States|Pfizer Investigational Site, DeSoto, Texas, United States|Pfizer Investigational Site, Houston, Texas, United States|Pfizer Investigational Site, Salt Lake City, Utah, United States|Pfizer Investigational Site, Budapest, Hungary|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, St. Petersburg, Russian Federation|Pfizer Investigational Site, Tainan, Taiwan",,https://ClinicalTrials.gov/show/NCT00658372
NCT00658762,A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder (3),,Terminated,No Results Available,Generalized Anxiety Disorder,Drug: PD 0332334|Drug: paroxetine|Drug: Placebo,"Change from Baseline in HAM-A total score at Week 8|To assess the safety and tolerability of PD 0332334 in subjects with GAD|Response rate on the HAM-A at Week 1 and Week 8|Remission rate based on the HAM-A at Week 8|Change from Baseline in the somatic subscale score of the HAM-A (item 7-13) at Week 8|Change from Baseline to Week 8 on the Medical Outcomes Study - Sleep Scale subscales|Worsening and improvement (from Baseline to Week 8) on the Changes in Sexual Functioning Questionnaire (CSFQ).|Change from Baseline to Week 8 on the Sheehan Disability Scale (SDS) total score|Change from Baseline in the HAM-A total score at Weeks 1, 2, 4 and 6)|Response rate on the PGI-C at Week 8|Response rate on the CGI-I at Week 1 and Week 8|Change from Baseline to Week 8 on the Medical Outcomes Study Sleep Scale (MOS-SS) Sleep Disturbance Score|Average (across the Week 1, 2, 4, 6 and 8 visits) HAM-A Change from Baseline score|Change from Baseline to Days 2-8 and Weeks 2, 4, 6 and 8 on the GA-VAS (diary)|The ""Week 1 Sustained Responser"" rate based on the HAM-A|Change from Baseline in the psychic subscale score of the HAM-A (Items 1-6 and 14) at Week 8.|Change from Baseline to Days 2-8 and Weeks 2, 4, 6, 8 on the DAS-A (total score)|Change from Baseline to Week 8 in the Q-Les-Q General Activities Score|Change from Baseline to Week 1 on the Medical Outcomes Study Sleep Scale (MOS-SS) Sleep Disturbance Score|Change from Baseline in the 17-item HAM-D total score at Weeks 1, 2, 4, and 8|Change from Baseline in CGI-S at Week 8",Pfizer,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,286,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",A5361020,May-08,Apr-09,Apr-09,15-Apr-08,null,16-Nov-12,"Pfizer Investigational Site, Birmingham, Alabama, United States|Pfizer Investigational Site, Glendale, California, United States|Pfizer Investigational Site, Orange, California, United States|Pfizer Investigational Site, Temecula, California, United States|Pfizer Investigational Site, Upland, California, United States|Pfizer Investigational Site, Wildomar, California, United States|Pfizer Investigational Site, Ft. Myers, Florida, United States|Pfizer Investigational Site, Orange City, Florida, United States|Pfizer Investigational Site, Atlanta, Georgia, United States|Pfizer Investigational Site, Marietta, Georgia, United States|Pfizer Investigational Site, Greenwood, Indiana, United States|Pfizer Investigational Site, Wichita, Kansas, United States|Pfizer Investigational Site, Omaha, Nebraska, United States|Pfizer Investigational Site, New York, New York, United States|Pfizer Investigational Site, Syracuse, New York, United States|Pfizer Investigational Site, Beachwood, Ohio, United States|Pfizer Investigational Site, Cincinnati, Ohio, United States|Pfizer Investigational Site, Cleveland, Ohio, United States|Pfizer Investigational Site, Oklahoma City, Oklahoma, United States|Pfizer Investigational Site, Oklahoma City, Oklahoma, United States|Pfizer Investigational Site, Salem, Oregon, United States|Pfizer Investigational Site, Media, Pennsylvania, United States|Pfizer Investigational Site, Norristown, Pennsylvania, United States|Pfizer Investigational Site, Dallas, Texas, United States|Pfizer Investigational Site, Houston, Texas, United States|Pfizer Investigational Site, Houston, Texas, United States|Pfizer Investigational Site, Woodstock, Vermont, United States|Pfizer Investigational Site, Budapest, Hungary",,https://ClinicalTrials.gov/show/NCT00658762
NCT00658008,A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (1),,Terminated,No Results Available,Generalized Anxiety Disorder,Drug: PD 0332334|Drug: Paroxetine|Drug: Placebo,"The efficacy of PD 0332334 in the treatment of GAD will be measured by the change in the Hamilton Anxiety Rating Scale (HAM-A) total scores from baseline observed following 8 weeks of double-blind treatment.|The safety and tolerability of PD 0332334 in subjects with GAD will be monitored in this study|Worsening and improvement from baseline to week 8 on the changes in the Sexual Functioning Questionnaire (CSFQ)|Response rate on the patient-rated PGI-C at week 8|Change from baseline to week 8 on the Sheehan Disability Scale subscales|Change from baseline in the somatic subscale score of the HAM-A (items 7 - 13)|Response rate on the HAM-A at week 1 and week 8|Response rate on the clinician-rated CGI-I ate week 1 and week 8|Change from Baseline in the psychic subscale score of the HAM A (Items 1- 6 and 14) at Week 8|Change from Baseline to Week 1 on the Medical Outcomes Study Sleep Scale (MOS SS) Sleep Problems Index II|Change from Baseline to Week 8 on the Medical Outcomes Study Sleep Scale (MOS SS) Sleep Problems Index II|Change from baseline in the HAM-A total score at weeks 1, 2, 4, and 6|Change from baseline in the 17-item HAM-D total score at weeks 1, 2, 4, and 8|Change from Baseline to Week 8 on the Medical Outcomes Study Sleep Scale subscales|Remission rate based on the HAM A at Week 8|Change from baseline in CGI-S at week 8|Change from baseline to week 8 in the QLesQ General Activity Score|The ""Week 1 Sustained Responder"" rate based on the HAM A (where ""Week 1 Sustained Responders"" are defined as subjects with a 50% or greater improvement from baseline on the HAM A total score at Week 1 that is sustained until the Week 8 visit)|Change from Baseline to Days 2 8 and Weeks 2, 4, 6, 8 on the DAS A (total score)|Change from baseline to week 8 on the Sheehan Disability Scale (SDS) total score|Change from baseline to Days 2-8 and weeks 2, 4, 6 and 8 on the GA-VAS (diary)|Average (across the week 1, 2, 4, 6 and 8 visits) HAM-A change from baseline score",Pfizer,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,501,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",A5361019,Apr-08,Mar-09,Mar-09,14-Apr-08,null,16-Nov-12,"Pfizer Investigational Site, Litchfield Park, Arizona, United States|Pfizer Investigational Site, Costa Mesa, California, United States|Pfizer Investigational Site, Pasadena, California, United States|Pfizer Investigational Site, Redlands, California, United States|Pfizer Investigational Site, Denver, Colorado, United States|Pfizer Investigational Site, Norwich, Connecticut, United States|Pfizer Investigational Site, Altamonte Springs, Florida, United States|Pfizer Investigational Site, Maitland, Florida, United States|Pfizer Investigational Site, Miami, Florida, United States|Pfizer Investigational Site, Miami, Florida, United States|Pfizer Investigational Site, South Miami, Florida, United States|Pfizer Investigational Site, Terre Haute, Indiana, United States|Pfizer Investigational Site, Overland Park, Kansas, United States|Pfizer Investigational Site, Topeka, Kansas, United States|Pfizer Investigational Site, Shreveport, Louisiana, United States|Pfizer Investigational Site, Baltimore, Maryland, United States|Pfizer Investigational Site, Boston, Massachusetts, United States|Pfizer Investigational Site, St. Charles, Missouri, United States|Pfizer Investigational Site, Las Vegas, Nevada, United States|Pfizer Investigational Site, Clementon, New Jersey, United States|Pfizer Investigational Site, Willingboro, New Jersey, United States|Pfizer Investigational Site, Albuquerque, New Mexico, United States|Pfizer Investigational Site, Bronx, New York, United States|Pfizer Investigational Site, Bronx, New York, United States|Pfizer Investigational Site, Brooklyn, New York, United States|Pfizer Investigational Site, New York, New York, United States|Pfizer Investigational Site, Raleigh, North Carolina, United States|Pfizer Investigational Site, Toledo, Ohio, United States|Pfizer Investigational Site, Toledo, Ohio, United States|Pfizer Investigational Site, Bethany, Oklahoma, United States|Pfizer Investigational Site, Bala Cynwyd, Pennsylvania, United States|Pfizer Investigational Site, Media, Pennsylvania, United States|Pfizer Investigational Site, Norristown, Pennsylvania, United States|Pfizer Investigational Site, Philadelphia, Pennsylvania, United States|Pfizer Investigational Site, Philadelphia, Pennsylvania, United States|Pfizer Investigational Site, Columbia, South Carolina, United States|Pfizer Investigational Site, Memphis, Tennessee, United States|Pfizer Investigational Site, Austin, Texas, United States|Pfizer Investigational Site, Dallas, Texas, United States|Pfizer Investigational Site, Lake Jackson, Texas, United States|Pfizer Investigational Site, San Antonio, Texas, United States|Pfizer Investigational Site, Burlington, Vermont, United States|Pfizer Investigational Site, Charlottesville, Virginia, United States|Pfizer Investigational Site, Charlottesville, Virginia, United States|Pfizer Investigational Site, Waukesha, Wisconsin, United States|Pfizer Investigational Site, Budapest, Hungary|Pfizer Investigational Site, Budapest, Hungary|Pfizer Investigational Site, Catania, Italy|Pfizer Investigational Site, Torino, Italy|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Khotkovo, Moscow region, Russian Federation",,https://ClinicalTrials.gov/show/NCT00658008
NCT00645983,Chamomile Therapy for Generalized Anxiety,,Completed,No Results Available,Generalized Anxiety Disorder,Dietary Supplement: Chamomile Extract|Other: Placebo,Score on Hamilton Anxiety Rating Scale|Beck Anxiety Index Rating,University of Pennsylvania|National Center for Complementary and Integrative Health (NCCIH)|Office of Dietary Supplements (ODS),All,"18 Years and older   (Adult, Older Adult)",Phase 4,61,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",R21AT001916,Oct-05,Jan-08,Jan-08,28-Mar-08,null,2-Dec-09,"Depression Research Unit, Universityof Pennsylvania School of Medicine, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00645983
NCT00643435,Self-Efficacy Enhancing Interviewing Techniques Study,SEE-IT,Completed,No Results Available,Diabetes|Depression|Anxiety|Asthma|Post-Traumatic Stress Disorder,Behavioral: Self-efficacy enhancing interviewing techniques training|Behavioral: Control intervention,"Resident physician use of self-efficacy enhancing patient interviewing techniques, assessment via coding of audio recordings from standardized patient encounters","University of California, Davis|National Institute of Mental Health (NIMH)",All,"Child, Adult, Older Adult",Not Applicable,64,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research,200715598-1,Feb-06,Jun-07,Mar-08,26-Mar-08,null,26-Mar-08,,,https://ClinicalTrials.gov/show/NCT00643435
NCT00643032,Preoperative Anxiety and Postoperative Pain in Children,,Unknown status,No Results Available,Post-Operative Pain|Pre-Operative Anxiety,Procedure: Transcutaneous iliohypogastric|Procedure: Perioperative administration near the nerve,,Hillel Yaffe Medical Center,All,3 Months to 12 Years   (Child),Phase 4,250,Other,Interventional,Allocation: Randomized|Primary Purpose: Treatment,50/2007,Mar-08,Jan-10,null,25-Mar-08,null,25-Mar-08,"Hillel Yaffe Medical Center, Hadera, Israel",,https://ClinicalTrials.gov/show/NCT00643032
NCT00641303,"Acupuncture in Reducing Muscle and Bone Symptoms in Women Receiving Letrozole, Exemestane, or Anastrozole for Stage 0, Stage I, Stage II, or Stage III Breast Cancer",,Completed,No Results Available,Anxiety Disorder|Breast Cancer|Depression|Fatigue|Hot Flashes|Pain|Sleep Disorders,Procedure: acupuncture therapy|Procedure: sham intervention,"Health Assessment Questionnaire Disability Index (HAQ-DI) score|Pain scores on visual analog scale (VAS)|Change in amount and/or frequency of oral analgesic use|Number of patients who discontinue or change AI therapy|Change in menopausal symptoms (NSABP-revised), hot flash frequency (HFRDIS), sleep quality (PSQI), depression score (CESD), and overall quality of life (EuroQOL) in patients at weeks 4, 8, and 24 vs week 0 of acupuncture treatment|Change in plasma estrogen concentrations, beta endorphin concentration, and cytokine profile from week 0 to week 8",University of Maryland|National Cancer Institute (NCI)|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,Female,"18 Years and older   (Adult, Older Adult)",Phase 2,51,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care",HP-00043225|P30CA006973|JHOC-J07110|SKCCC J07110|JHOC-NA_00013024|GCC 0930,May-08,Oct-11,Nov-11,24-Mar-08,null,31-Jan-12,"University of Maryland Marlene and Stewart Greenebaum Cancer Center, Baltimore, Maryland, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00641303
NCT00641368,R4Power: An Online Resilience Program for Adolescents,R4Power,Unknown status,No Results Available,Depression|Anxiety,Behavioral: R4Power Program|Other: Waitlist Control,Adolescents' coping strategies by self-report|Adolescents' depressive symptoms by self-report|Adolescents' symptoms of anxiety by self-report,Swarthmore College,All,11 Years to 15 Years   (Child),Phase 1,200,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,07-08-003,Oct-07,Oct-09,Oct-09,24-Mar-08,null,24-Mar-08,"Swarthmore College, Swarthmore, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00641368
NCT00641394,The Effect of Psychotherapy on Stress Biochemistry: An RCT of Psychotherapy and Emotional Freedom Techniques (EFT),,Completed,No Results Available,Stress|Depression|Anxiety,Behavioral: Psychotherapy: Emotional Freedom Techniques (EFT)|Behavioral: Cognitive Behavioral Therapy (CBT),"spot cortisol level|SA-45 symptom assessment questionnaire, with subscales for depression, anxiety, hostility, interpersonal sensitivity, phobias, and other psychological traits",Soul Medicine Institute,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,83,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",SMI-CORT-32008,Apr-08,Aug-10,Sep-10,24-Mar-08,null,25-Apr-18,"Soul Medicine Institute, Santa Rosa, California, United States",,https://ClinicalTrials.gov/show/NCT00641394
NCT00641940,Girls in Transition Study: Helping Girls Enter the Teenage Years,GT,Unknown status,No Results Available,Depression|Anxiety,Behavioral: Girls in Transition (GT) program|Behavioral: Waitlist Control,Adolescents' coping strategies by self-report|Adolescents' depressive symptoms by self-report|Adolescents' symptoms of anxiety by self-report|Adolescents' feelings of hopelessness by self-report|Adolescents' perceptions of their physical appearance by self-report,Swarthmore College|University of Pennsylvania,Female,"Child, Adult, Older Adult",Phase 1,32,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,803680,Oct-05,Jun-08,Jun-08,24-Mar-08,null,24-Mar-08,"Swarthmore College, Swarthmore, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00641940
NCT00640133,Effectiveness of Deep Brain Stimulation for Treating People With Treatment Resistant Obsessive-Compulsive Disorder,,"Active, not recruiting",No Results Available,Obsessive-Compulsive Disorder,Device: Active DBS|Device: Sham DBS,"Obsessive-compulsive disorder (OCD) severity (Yale-Brown Obsessive-Compulsive Scale)|Global social and occupational functioning (Global Assessment of Functioning and Social and Occupational Function Assessment Scale)|Quality of life (Quality of Life Enjoyment and Satisfaction Questionnaire, and the Range of Impaired Functioning Tool)|Depression severity (Montgomery-Asberg Depression Rating Scale, and Hamilton Depression Rating Scale)|Anxiety (Hamilton Anxiety Rating Scale)|Illness severity (Patient Global Impression, Clinical Global Impression, and Clinical Global Impression - Exposure Therapy)|Behavioral activation and avoidance (Behavioral Activation for Depression Scale, and the Cognitive-Behavioral Avoidance Scale)",Butler Hospital|National Institute of Mental Health (NIMH),All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,27,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",U01MH076179|DSIR 83-ATSO,Mar-08,Feb-17,Feb-18,21-Mar-08,null,4-Aug-17,"Kaiser Permanente Redwood City Hospital, Redwood City, California, United States|George Washington University Hospital, Washington, D.C., District of Columbia, United States|University of Florida, Gainesville, Florida, United States|University of Chicago, Chicago, Illinois, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States|The Cleveland Clinic, Cleveland, Ohio, United States|Butler Hospital, Providence, Rhode Island, United States",,https://ClinicalTrials.gov/show/NCT00640133
NCT00638729,Clonidine Versus Midazolam for Premedication,,Completed,No Results Available,Anxiety|Pain,Drug: midazolam|Drug: clonidine|Drug: placebo,Effect of premedication on bispectral index|Effect of premedication on postoperative recovery,University of Schleswig-Holstein,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Supportive Care",A 157/01,Aug-05,Mar-07,Mar-07,19-Mar-08,null,19-Mar-08,"Department of Anaesthesiology and Intensive Care Medicine, University of Schleswig-Holstein Campus Kiel, Kiel, Germany",,https://ClinicalTrials.gov/show/NCT00638729
NCT00635635,Guided Imagery for Military Sexual Trauma-Related Posttraumatic Stress Disorder (PTSD),,Completed,No Results Available,"Stress Disorder, Post Traumatic|Military Sexual Trauma",Behavioral: Guided Imagery Audio|Behavioral: Music Audio,PTSD Severity - Clinician Administered PTSD Scale (CAPS)|Neuroactive Steroid assay,Duke University|National Institutes of Health (NIH)|Durham VA Medical Center,Female,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,40,Other|NIH|U.S. Fed,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Health Services Research",Pro00001282,Oct-07,Mar-10,May-10,14-Mar-08,null,26-May-10,"Durham VA Medical Center, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT00635635
NCT00634608,Integrating Targeted MedlinePlus Health Prescriptions Into Clinic Practice Workflow,,Completed,No Results Available,Allergic Rhinitis|Asthma|Back Pain|Benign Prostatic Hypertrophy|Bursitis|Depression|Anxiety|Diabetes Mellitus|Esophageal Reflux|HIV Infections|Hyperlipidemia|Hypertension|Insomnia|Irritable Bowel Syndrome|Obesity|Osteoporosis (Senile)|Shoulder Pain|Sinusitis|Symptomatic Menopause|Urinary Incontinence|Urinary Tract Infection|Vaginitis,Other: Health Information Prescription,health information experiences of the patient|clinician feedback on the health information prescription process,University of Missouri-Columbia|National Library of Medicine (NLM),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,224,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),HHSN276200700263P,Feb-08,Mar-09,Sep-09,13-Mar-08,null,30-Sep-16,"University of Missouri, Department of Internal Medicine, Columbia, Missouri, United States",,https://ClinicalTrials.gov/show/NCT00634608
NCT00634790,A Study To Assess the Safety of Extended Release Alprazolam for the Treatment of Adolescents With Panic Disorder or Anxiety With Panic Attacks,,Terminated,No Results Available,Panic Disorder,Drug: alprazolam XR,"Endpoint change from baseline to Week 24 in Digit Symbol-Coding Test, immediate recall, and delayed recall|Baseline-to-peak Physician's Withdrawal Checklist change score during 6-week taper off alprazolam|The incidence of treatment-emergent adverse event during treatment with alprazolam XR|Descriptive estimates of the persistence of safety events and adverse events at study endpoint|Endpoint change from baseline to Week 24 in the Panic Disorder Severity Scale-Adolescent version total and item scores|Endpoint (Week 24) Clinical Global Impression (CGI)-Improvement score|Endpoint change from baseline to Week 24 in CGI-Severity score|Endpoint (Week 24) Pediatric Quality of Life, Enjoyment, and Satisfaction Questionnaire improvement score",Pfizer,All,13 Years to 17 Years   (Child),Phase 4,49,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,A6131004,May-04,null,Oct-04,13-Mar-08,null,10-Apr-08,"Pfizer Investigational Site, Little Rock, Alaska, United States|Pfizer Investigational Site, Phoenix, Arizona, United States|Pfizer Investigational Site, Scottsdale, Arizona, United States|Pfizer Investigational Site, Burbank, California, United States|Pfizer Investigational Site, Elcentro, California, United States|Pfizer Investigational Site, La Mesa, California, United States|Pfizer Investigational Site, Los Angeles, California, United States|Pfizer Investigational Site, Oceanside, California, United States|Pfizer Investigational Site, San Diego, California, United States|Pfizer Investigational Site, San Marcos, California, United States|Pfizer Investigational Site, Gainesville, Florida, United States|Pfizer Investigational Site, Hialeah, Florida, United States|Pfizer Investigational Site, Jacksonville, Florida, United States|Pfizer Investigational Site, North Miami, Florida, United States|Pfizer Investigational Site, St. Petersburg, Florida, United States|Pfizer Investigational Site, West Palm Beach, Florida, United States|Pfizer Investigational Site, Decatur, Georgia, United States|Pfizer Investigational Site, Boise, Idaho, United States|Pfizer Investigational Site, Schaumburg, Illinois, United States|Pfizer Investigational Site, Terre Haute, Indiana, United States|Pfizer Investigational Site, Overland Park, Kansas, United States|Pfizer Investigational Site, Lexington, Kentucky, United States|Pfizer Investigational Site, Owensboro, Kentucky, United States|Pfizer Investigational Site, New Orleans, Louisiana, United States|Pfizer Investigational Site, New Orleans, Louisiana, United States|Pfizer Investigational Site, Baltimore, Maryland, United States|Pfizer Investigational Site, Clinton Township, Michigan, United States|Pfizer Investigational Site, Saint Paul, Minnesota, United States|Pfizer Investigational Site, Omaha, Nebraska, United States|Pfizer Investigational Site, Las Vegas, Nevada, United States|Pfizer Investigational Site, Clementon, New Jersey, United States|Pfizer Investigational Site, Kenilworth, New Jersey, United States|Pfizer Investigational Site, Morristown, New Jersey, United States|Pfizer Investigational Site, Bismarck, North Dakota, United States|Pfizer Investigational Site, Cleveland, Ohio, United States|Pfizer Investigational Site, Lyndhurst, Ohio, United States|Pfizer Investigational Site, Eugene, Oregon, United States|Pfizer Investigational Site, Bala Cynwyd, Pennsylvania, United States|Pfizer Investigational Site, Hershey, Pennsylvania, United States|Pfizer Investigational Site, Media, Pennsylvania, United States|Pfizer Investigational Site, Columbia, South Carolina, United States|Pfizer Investigational Site, Selmer, Tennessee, United States|Pfizer Investigational Site, San Antonio, Texas, United States|Pfizer Investigational Site, Salt Lake City, Utah, United States|Pfizer Investigational Site, Midlothian, Virginia, United States|Pfizer Investigational Site, Richmond, Virginia, United States|Pfizer Investigational Site, Middleton, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT00634790
NCT00635076,A Study to Assess the Long-Term Use of Alprazolam Extended Release (XL) in the Treatment of Adolescents With Panic Disorder,,Terminated,No Results Available,Panic Disorder,Other: placebo|Drug: alprazolam XR,"Baseline-to-peak Physician Withdrawal Checklist change score during taper off Alprazolam|The incidence of treatment-emergent adverse events during 6 months of treatment with alprazolam XR|Endpoint change from baseline in Digit Symbol-Coding Test, immediate recall, and delayed recall|Endpoint change from baseline in Hamilton Anxiety Rating scale|Endpoint change compared with baseline in the Panic Disorder Severity Scale - Adolescent Version total and item scores|Endpoint compared with baseline for Clinical Global Impression (CGI)-Improvement scale|Endpoint change compared with baseline in CGI-Severity score|Endpoint compared with baseline in Pediatric Quality of Life, Enjoyment, and Satisfaction Questionnaire improvement score|Descriptive estimates of the persistence of safety events and adverse events",Pfizer,All,13 Years to 17 Years   (Child),Phase 4,3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",A6131007,Jul-04,null,Sep-04,13-Mar-08,null,10-Apr-08,"Pfizer Investigational Site, Eugene, Oregon, United States|Pfizer Investigational Site, San Antonio, Texas, United States|Pfizer Investigational Site, Middleton, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT00635076
NCT00635531,A Study to Evaluate the Use of Extended Release Alprazolam in the Treatment of Adolescents With Panic Disorder,,Terminated,No Results Available,Panic Disorder,Other: placebo|Drug: alprazolam XR,"Endpoint change from baseline in the Panic Disorder Severity Scale for Adolescents (PDSS-A) total score|Endpoint change from baseline in the weekly frequency of 4-symptom panic attacks|Weekly change in the PDSS-A total score|Weekly change and endpoint change from baseline in Clinical Global Impression (CGI)-Severity scale|Weekly change and endpoint change from baseline in CGI-lmprovement scale|Weekly change and and endpoint change from baseline in PDSS-A item scores|Endpoint change from baseline in the Hamilton anxiety rating scale total score|Endpoint change from baseline in the Children's Depression Rating Scale (CDRS-R) total score|Endpoint change from baseline in Pediatric Quality of Life, Enjoyment, Satisfaction Questionnaire|Safety assessments will include physical examination, electrocardiogram and laboratory assessments obtained at initial screening, and at the end-of-study visit|Cognitive and memory effects (free verbal recall test and Digit- Symbol Coding Test)|Population pharmacokinetic analysis|Vital signs",Pfizer,All,13 Years to 17 Years   (Child),Phase 4,16,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",A6131002,Apr-04,null,Sep-04,13-Mar-08,null,10-Apr-08,"Pfizer Investigational Site, Hialeah, Florida, United States|Pfizer Investigational Site, Jacksonville, Florida, United States|Pfizer Investigational Site, North Miami, Florida, United States|Pfizer Investigational Site, Boise, Idaho, United States|Pfizer Investigational Site, Terre Haute, Indiana, United States|Pfizer Investigational Site, New Orleans, Louisiana, United States|Pfizer Investigational Site, Baltimore, Maryland, United States|Pfizer Investigational Site, Saint Paul, Minnesota, United States|Pfizer Investigational Site, Omaha, Nebraska, United States|Pfizer Investigational Site, Lyndhurst, Ohio, United States|Pfizer Investigational Site, Eugene, Oregon, United States|Pfizer Investigational Site, Media, Pennsylvania, United States|Pfizer Investigational Site, Columbia, South Carolina, United States|Pfizer Investigational Site, Lake Jackson, Texas, United States|Pfizer Investigational Site, San Antonio, Texas, United States|Pfizer Investigational Site, Wichita Falls, Texas, United States|Pfizer Investigational Site, Bellevue, Washington, United States|Pfizer Investigational Site, Middleton, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT00635531
NCT00633984,D-Cycloserine Enhancement of Exposure in Social Phobia,,Completed,Has Results,Social Anxiety Disorder,Behavioral: Cognitive Behavioral Group Therapy (CBGT)|Drug: D-Cycloserine|Drug: Placebo,Liebowitz Social Anxiety Scale (LSAS)|CGI - Clinical Global Impression of Improvement,Massachusetts General Hospital|Boston University|Southern Methodist University|National Institutes of Health (NIH)|National Institute of Mental Health (NIMH),All,"18 Years and older   (Adult, Older Adult)",Phase 4,169,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2007-P-000386|R01MH075889,Mar-07,Mar-12,Sep-12,12-Mar-08,14-May-14,14-May-14,"Center for Anxiety and Traumatic Stress Disorders, Massachusetts General Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT00633984
NCT00632229,"Double Blinded, Placebo-Controlled Trial of Paliperidone Addition in SRI-Resistant Obsessive-Compulsive Disorder",,Completed,Has Results,Obsessive-Compulsive Disorder,Drug: Paliperidone|Drug: Placebo,Yale Brown Obsessive Compulsive Scale|Clinical Global Impressions - Severity of Obsessive-Compulsive Symptoms,"University of South Florida|Indiana University|Ortho-McNeil Janssen Scientific Affairs, LLC",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,34,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",USF 08-0100,Oct-07,Sep-13,Sep-13,10-Mar-08,6-Feb-14,6-Feb-14,"University of South Florida, St. Petersburg, Florida, United States|University Hospital Outpatient Center, Psychiatry, Indianapolis, Indiana, United States",,https://ClinicalTrials.gov/show/NCT00632229
NCT00628888,A Waitlist-Controlled Trial of the Unified Protocol for the Treatment of Emotional Disorders in Adolescents,,Completed,No Results Available,Anxiety Disorders|Depression,Behavioral: Unified Protocol for Adolescents (UP-A),"Clinical Severity Rating (CSR) on the Anxiety Disorders Interview Schedule for DSM-IV, child and parent versions (ADIS-IV-C/P)|Treatment gains and overall patient functioning measured by: Clinical Global Impression Scale(CGI)|Emotion Regulation indices|Changes in Anxiety and Depressive symptomology assessed by the CBCL and RCADS (parent and child version)",University of Miami|National Institute of Mental Health (NIMH),All,"12 Years to 18 Years   (Child, Adult)",Not Applicable,51,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,K23MH073946|DDTR BK-TKPD,Jul-06,Sep-12,Sep-12,5-Mar-08,null,19-Dec-14,"Child and Adolescent Mood and Anxiety Treatment (CAMAT) Program, Miami, Florida, United States",,https://ClinicalTrials.gov/show/NCT00628888
NCT00628979,Addressing Help-Seeking Barriers in Developing an Intensive Treatment for Veterans With Panic Disorder,,Completed,No Results Available,Panic Disorder,Behavioral: CBT,Qualitative data regarding treatment seeking barriers|Panic attack frequency and severity; treatment acceptability,US Department of Veterans Affairs|VA Office of Research and Development,All,"18 Years to 74 Years   (Adult, Older Adult)",Not Applicable,23,U.S. Fed,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MIRECC004,Mar-08,Mar-08,Jul-09,5-Mar-08,null,3-Jul-09,"Michael E. DeBakey VA Medical Center (152), Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00628979
NCT00624780,Safety and Efficacy Evaluation Of Pregabalin (Lyrica) With Patients With Generalized Anxiety Disorder,,Completed,Has Results,Generalized Anxiety Disorder,Drug: Pregabalin|Drug: Lorazepam|Drug: Placebo,Change From Baseline in Hamilton Anxiety Scale (HAM-A) for Cohort 1 (Less Than 3-Month Last Visit) at Discontinuation Week 1|Change From Baseline in Hamilton Anxiety Scale (HAM-A) for Cohort 1 (Less Than 3-Month Last Visit) at Discontinuation Week 2|Change From Baseline in Hamilton Anxiety Scale (HAM-A) for Cohort 2 (3-Month Last Visit) at Discontinuation Week 1|Change From Baseline in Hamilton Anxiety Scale (HAM-A) for Cohort 2 (3-Month Last Visit) at Discontinuation Week 2|Change From Baseline in Hamilton Anxiety Scale (HAM-A) for Cohort 3 (6-Month Last Visit) at Discontinuation Week 1|Change From Baseline in Hamilton Anxiety Scale (HAM-A) for Cohort 3 (6-Month Last Visit) at Discontinuation Week 2|Change From Last Visit on Treatment in Physician's Withdrawal Checklist (PWC) Score for Cohort 1 (Less Than 3-Month Last Visit) at Discontinuation Week 1|Change From Last Visit on Treatment in Physician's Withdrawal Checklist (PWC) Score for Cohort 1 (Less Than 3-Month Last Visit) at Discontinuation Week 2|Change From Last Visit on Treatment in Physician's Withdrawal Checklist (PWC) Score for Cohort 2 (3-Month Last Visit) at Discontinuation Week 1|Change From Last Visit on Treatment in Physician's Withdrawal Checklist (PWC) Score for Cohort 2 (3-Month Last Visit) at Discontinuation Week 2|Change From Last Visit on Treatment in Physician's Withdrawal Checklist (PWC) Score for Cohort 3 (6-Month Last Visit) at Discontinuation Week 1|Change From Last Visit on Treatment in Physician's Withdrawal Checklist (PWC) Score for Cohort 3 (6-Month Last Visit) at Discontinuation Week 2|Number of Participants With Rebound Anxiety for Cohort 1 (Less Than 3-Month Last Visit)|Number of Participants With Rebound Anxiety for Cohort 2 (3-Month Last Visit)|Number of Participants With Rebound Anxiety for Cohort 3 (6-Month Last Visit)|Number of Participants With Discontinuation-Emergent Signs and Symptoms (DESS) for Cohort 1 (Less Than 3-Month Last Visit)|Number of Participants With Discontinuation-Emergent Signs and Symptoms (DESS) for Cohort 2 (3-Month Last Visit)|Number of Participants With Discontinuation-Emergent Signs and Symptoms (DESS) for Cohort 3 (6-Month Last Visit)|Change From Baseline in Physician's Withdrawal Checklist (PWC) Score for Cohort 1 (Less Than 3-Month Last Visit) at Discontinuation Week 1 and 2|Change From Baseline in Physician's Withdrawal Checklist (PWC) Score for Cohort 2 (3-Month Last Visit) at Discontinuation Week 1 and 2|Change From Baseline in Physician's Withdrawal Checklist (PWC) Score for Cohort 3 (6-Month Last Visit) at Discontinuation Week 1 and 2|Physician's Withdrawal Checklist (PWC) Score for Cohort 1 (Less Than 3-Month Last Visit)|Physician's Withdrawal Checklist (PWC) Score for Cohort 2 (3-Month Last Visit)|Physician's Withdrawal Checklist (PWC) Score for Cohort 3 (6-Month Last Visit)|Change From Last Visit of Treatment in Hamilton Anxiety Scale (HAM-A) for Cohort 1 (Less Than 3-Month Last Visit) at Discontinuation Week 1 and 2|Change From Last Visit of Treatment in Hamilton Anxiety Scale (HAM-A) for Cohort 2 (3-Month Last Visit) at Discontinuation Week 1 and 2|Change From Last Visit of Treatment in Hamilton Anxiety Scale (HAM-A) for Cohort 3 (6-Month Last Visit) at Discontinuation Week 1 and 2|Hamilton Anxiety Scale (HAM-A) for Cohort 1 (Less Than 3-Month Last Visit)|Hamilton Anxiety Scale (HAM-A) for Cohort 2 (3-Month Last Visit)|Hamilton Anxiety Scale (HAM-A) Score for Cohort 3 (6-Month Last Visit)|Hamilton Anxiety Scale (HAM-A) Score for Period 1|Hamilton Anxiety Scale (HAM-A) Score for Period 2|Change From Baseline in Hamilton Anxiety Scale (HAM-A) Score at Week 12|Change From Baseline in Hamilton Anxiety Scale (HAM-A) Score at Week 24|Clinical Global Impression - Severity (CGI-S) Score for Period 1|Clinical Global Impression - Severity (CGI-S) Score for Period 2|Change From Baseline in Clinical Global Impression - Severity (CGI-S) Score at Week 12|Change From Baseline in Clinical Global Impression - Severity (CGI-S) Score at Week 24|Clinical Global Impression - Improvement (CGI-I) Score at the End of Period 1|Clinical Global Impression - Improvement (CGI-I) Score at the End of Period 2,Pfizer,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,615,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",A0081147,May-09,Apr-12,Apr-12,27-Feb-08,19-Apr-13,19-Apr-13,"Pfizer Investigational Site, La Plata, Buenos Aires, Argentina|Pfizer Investigational Site, Lanus, Prov. de Buenos Aires, Argentina|Pfizer Investigational Site, Buenos Aires, Argentina|Pfizer Investigational Site, Buenos Aires, Argentina|Pfizer Investigational Site, Buenos Aires, Argentina|Pfizer Investigational Site, Wien, Austria|Pfizer Investigational Site, Wien, Austria|Pfizer Investigational Site, San Jose, Costa Rica|Pfizer Investigational Site, San Jose, Costa Rica|Pfizer Investigational Site, Rijeka, Croatia|Pfizer Investigational Site, Split, Croatia|Pfizer Investigational Site, Zagreb, Croatia|Pfizer Investigational Site, Brno, Czech Republic|Pfizer Investigational Site, Ceske Budejovice, Czech Republic|Pfizer Investigational Site, Litomerice, Czech Republic|Pfizer Investigational Site, Lnare, Czech Republic|Pfizer Investigational Site, Melnik, Czech Republic|Pfizer Investigational Site, Praha 10- Strasnice, Czech Republic|Pfizer Investigational Site, Praha 2, Czech Republic|Pfizer Investigational Site, Praha 6, Czech Republic|Pfizer Investigational Site, Strakonice, Czech Republic|Pfizer Investigational Site, Espoo, Finland|Pfizer Investigational Site, HUS, Finland|Pfizer Investigational Site, Joensuu, Finland|Pfizer Investigational Site, Kuopio, Finland|Pfizer Investigational Site, Seinajoki, Finland|Pfizer Investigational Site, Turku, Finland|Pfizer Investigational Site, Athens, Greece|Pfizer Investigational Site, Ellisbridge, Ahmedabad, India|Pfizer Investigational Site, Tirupati, Andhra Pradesh, India|Pfizer Investigational Site, Mangalore, Karnataka, India|Pfizer Investigational Site, Pune, Maharashtra, India|Pfizer Investigational Site, Chennai, Tamil Nadu, India|Pfizer Investigational Site, Denpasar, Bali, Indonesia|Pfizer Investigational Site, Jakarta, Jakarta Selatan, Indonesia|Pfizer Investigational Site, Jakarta Selatan, Jakarta, Indonesia|Pfizer Investigational Site, Surabaya, Indonesia|Pfizer Investigational Site, Kaunas, Lithuania|Pfizer Investigational Site, Kaunas, Lithuania|Pfizer Investigational Site, Klaipeda, Lithuania|Pfizer Investigational Site, Vilnius, Lithuania|Pfizer Investigational Site, Acapulco, Guerrero, Mexico|Pfizer Investigational Site, Zapopan, Jalisco, Mexico|Pfizer Investigational Site, Mexico D.F., Mexico|Pfizer Investigational Site, Khotkovo, Moscow region, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, St. Petersburg, Russian Federation|Pfizer Investigational Site, Belgrade, Serbia|Pfizer Investigational Site, Kragujevac, Serbia|Pfizer Investigational Site, Ljubljana, Slovenia|Pfizer Investigational Site, Langreo, Asturias, Spain|Pfizer Investigational Site, Zamora, Spain|Pfizer Investigational Site, Istanbul, Turkey|Pfizer Investigational Site, Kocaeli, Turkey",,https://ClinicalTrials.gov/show/NCT00624780
NCT00623454,Non Cardiac Chest Pain and Benign Palpitations,,Completed,No Results Available,Anxiety/Depression in Cardiological Unit,Behavioral: Cognitive behaviour therapy,Body sensation questionnaire (BSQ)|Beck Depression Inventory (BDI),Norwegian University of Science and Technology,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,40,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,4.2006.1110 (REK),Mar-07,Apr-09,Apr-09,26-Feb-08,null,29-Aug-11,"Cardiological Out-patient Clinic, Molde, Norway",,https://ClinicalTrials.gov/show/NCT00623454
NCT00620958,Cognitive Behavioral Therapy With Parental Involvement for Treating Children With Anxiety Disorders,,Completed,No Results Available,Anxiety Disorders,Behavioral: Individual cognitive behavioral therapy (ICBT)|Behavioral: Parent relationship training (PRT2) With Individual Cognitive Behavioral Therapy (ICBT)|Behavioral: Parent reinforcement training (PRT1) With Individual Cognitive Behavioral Therapy (ICBT),"Clinician Severity Rating on the Anxiety Disorders Interview Schedule for Children (ADIS C/P)|Child Manifest Anxiety Scale for Children, Revised",Florida International University|National Institute of Mental Health (NIMH),All,8 Years to 11 Years   (Child),Not Applicable,341,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,R01MH079943|DSIR 84-CTS|1R01MH079943-01A1,Aug-08,Dec-16,Dec-16,22-Feb-08,null,2-Aug-17,"Florida International University, Miami, Florida, United States",,https://ClinicalTrials.gov/show/NCT00620958
NCT00621270,Safety and Effectiveness Study of BCI-540 Versus Placebo in the Treatment of Major Depressive Disorder With Concomitant Anxiety,,Completed,No Results Available,Major Depressive Disorder|Anxiety,Drug: BCI-540,"Co-primary outcome measures will be the change from Baseline to Week 6 on the total score of the Inventory of Depressive Symptomatology-Clinician Version (IDS-C30) and the Hamilton Rating Scale for Anxiety (HAM-A).|The safety, tolerability and side effect profile of BCI-540 will also be measured by adverse events, clinical laboratory values, electrocardiograms, vital signs, and the Physician Withdrawal Checklist (PWC).",BrainCells Inc.,All,21 Years to 60 Years   (Adult),Phase 2,115,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",BCI-540-CL-001,Jan-08,Oct-09,Oct-09,22-Feb-08,null,24-Oct-11,"Grey Nuns Hospital, Clinical Research, Edmonton, Alberta, Canada|Okanagan Clinical Trials, Kelowna, British Columbia, Canada|Dr. Alexander McIntyre, Inc, Penticton, British Columbia, Canada|University of British Columbia Mood Disorders Centre, Vancouver, British Columbia, Canada|Dr. D. McIntosh & Dr. K. Kjernisted Clinical Research Inc., Vancouver, British Columbia, Canada|Eden Mental Health Centre, Winkler, Manitoba, Canada|Sanjay Siddhartha, MD, Miramichi, New Brunswick, Canada|Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada|Autar K. Munshi, MD, Sydney, Nova Scotia, Canada|Robert Fairbairn, MD, Chatham, Ontario, Canada|Providence Care Mental Health Services, Kingston, Ontario, Canada|Robert G. Luton, MD, London, Ontario, Canada|Anxiety and Mood Disorder Center, Mississauga, Ontario, Canada|Ottawa Psychopharmacology Clinic, Ottawa, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|University Health Network, Dept. of Psychiatry, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT00621270
NCT00619892,"A Study of Quetiapine SR (Seroquel SR) to Treat SSRI-Resistant, Comorbid Panic Disorder Patients",,Completed,Has Results,Panic Disorder,Drug: quetiapine XR|Drug: placebo,"Change in Mean Total Panic Disorder Severity Scale (PDSS) Scores|Change in Scores in Measurements of Depressive Symptoms (Hamilton Depression Rating Scale, HAM-D), Generalized Anxiety Symptoms (Hamilton Anxiety Rating Scale, HAM-A) and the Sleep Quality Item of the Pittsburgh Sleep Quality Index (PSQI).",Indiana University|AstraZeneca,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,26,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",0703-22|IRUSQUET0445,Feb-08,Dec-11,Dec-11,21-Feb-08,21-Jan-16,21-Jan-16,"University Hospital Outpatient Center, Psychiatry, Indianapolis, Indiana, United States",,https://ClinicalTrials.gov/show/NCT00619892
NCT00620776,Combined Treatment for Generalized Anxiety Disorder (GAD),,Completed,Has Results,Generalized Anxiety Disorder,Behavioral: Cognitive Behavioral Therapy|Drug: Venlafaxine XR,Hamilton Anxiety Rating Scale (HAM-A)|Hospital Anxiety Depression Scale (HAD)-Anxiety Score|Hospital Anxiety Depression Scale (HAD)-Depression Score|Hamilton Rating Scale for Depression (HAM-D)-17-item Score|Clinical Global Impression (CGI)-Severity Score|Clinical Global Impression (CGI)-Improvement Score|Quality of Life Subscale of the General Health Questionnaire (GHQ)|Penn State Worry Questionnaire (PSWQ)|Physical Component Score of the 12-Item Short Form Survey (SF-12)|Mental Component Score of the 12-item Short Form Survey (SF-12)|Clinical Response Rate|50 Percent or Greater Reduction in PSWQ Score,University of Pennsylvania|National Institute of Mental Health (NIMH),All,"18 Years and older   (Adult, Older Adult)",Phase 2,69,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,802307|5R34MH072678-02,Oct-06,Mar-08,Mar-08,21-Feb-08,16-Feb-17,16-Feb-17,"University of Pennsylvania, 3535 Market Street, Suite 650, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00620776
NCT00619138,Treatment of Social Phobia and Panic Disorder in Adults,TSPPA,Completed,No Results Available,Social Phobia|Panic Disorder,Behavioral: individual cognitive-behavioural therapy|Behavioral: stepped care model,Clinical Severity Ratings|Questionnaires: The Panic Attack Scale The Body Sensations Questionnaire The Agoraphobic Cognitions Questionnaire The Mobility Inventory for Agoraphobia Social Phobia Scale The Social Interaction Anxiety Scale,Haukeland University Hospital,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,174,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,17650,Mar-08,May-12,Dec-15,20-Feb-08,null,26-Jan-16,"haukelandUH, Bergen, Norway",,https://ClinicalTrials.gov/show/NCT00619138
NCT00616447,rTMS Treatment in Patients With General Anxiety Disorder,,Completed,No Results Available,Generalized Anxiety Disorder,Device: Repetitive transcranial magnetic stimulation|Device: placebo sham,Hamilton Anxiety Rating Scale (ham-a)|Clinical Global Impression|Hamilton Depression Rating Scale-21|Pittsburgh Sleep Quality Index|SF-36 QOL version (1)|Visual Analogue Scales,Queen's University|Military Medical Academy,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,30,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",PSIY-270-07,Jan-08,Nov-12,Nov-12,15-Feb-08,null,16-Dec-15,"Military Medical Academy, Sofia, Bulgaria|Providence Care Mental Health Services, Kingston, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT00616447
NCT00616486,rTMS in Treatment of Obsessive Compulsive Disorder (OCD),,Completed,No Results Available,Obsessive Compulsive Disorder,Device: repetitive transcranial magnetic stimulation|Device: sham (placebo),Yale-Brown Obsessive Compulsive Scale (YBOCS)|Clinical Global Impression|Hamilton Depression Rating Scale-21(HDRS)|Pittsburgh Sleep Quality Index (PSQI)|Hamilton Anxiety Rating Scale (HARS)|SF-36 QOLS version (1)|Visual Analogue Scale,Queen's University|Military Medical Academy|Dokuz Eylul University,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,24,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",psiy-266-07,Jan-08,May-10,Nov-12,15-Feb-08,null,16-Dec-15,"Military Medical Academy, Sofia, Bulgaria|Providence Care, Mental Health Services, Kingston, Ontario, Canada|Dokuz Eylul University, Izmir, Turkey",,https://ClinicalTrials.gov/show/NCT00616486
NCT00616655,Generalized Anxiety Disorder Proof of Concept Efficacy and Safety Study of SEP-225441 (Eszopiclone) In GAD Subjects,,Completed,Has Results,Generalized Anxiety Disorder,Drug: eszopiclone|Drug: Placebo,"Change From Baseline to Week 8 in the Total Score on the Hamilton Anxiety Scale (HAM-A), as Assessed by the Site-trained Rater|Change From Baseline Hamilton Anxiety Scale (HAM-A) Total Score (Except for Week 8)|Change in Individual Item Scores on HAM-A|Change From Baseline in Clinician Global Impression of Severity (CGI-S)|Clinical Global Impression- Improvement (CGI-I)|Hamilton Anxiety Scale (HAM-A) 50% Anxiolytic Response|Hamilton Anxiety Scale (HAM-A) Remission|Change From Baseline on Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) Short Form|Change From Baseline Insomnia Severity Index (ISI) Total Score|Change From Baseline Sheehan Disability Scale (SDS)|Change From Baseline Epworth Sleepiness Scale (ESS)",Sunovion,All,18 Years to 50 Years   (Adult),Phase 2,456,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",194-027,Jan-08,Dec-08,Dec-08,15-Feb-08,21-Aug-15,8-Apr-16,"Birmingham Psychiatry Pharaceutical Studies, Inc., Birmingham, Alabama, United States|Arcadia, California, United States|Southwestern Research, Inc., Beverly Hills, California, United States|Southwestern Research, Inc., Burbank, California, United States|California Clinical Trials Medical Group, Glendale, California, United States|California clinical Trials Medical Group, Glendale, California, United States|Newport Beach, California, United States|Excell Research, Oceanside, California, United States|California Clinical Trials Medical Group, Paramount, California, United States|Southwestern Research, Inc., Pasadena, California, United States|California clinical Trials Medical Group, San Diego, California, United States|Stanford Universtiy Medical center, Stanford, California, United States|University of CT Health Center, Farmington, Connecticut, United States|Comprehensive Psychiatric Care, PC, Norwich, Connecticut, United States|Florida Clinical Research Center LLC, Bradenton, Florida, United States|Sarkis Clinical Trials, Gainsville, Florida, United States|Clinical Neuroscience Solutions, Inc., Jacksonville, Florida, United States|Clinical Neuroscience Solutions, Inc., Orlando, Florida, United States|Comprehensive NeuroScience, Inc., St. Petersburg, Florida, United States|Stedman Clinical Trials, LLC, Tampa, Florida, United States|Janus Center for Psychiatric Research, West Palm Beach, Florida, United States|Comprehensive NeuroScience, Inc., Atlanta, Georgia, United States|Carmen Research, Smyrna, Georgia, United States|Alexian Brothers Center for Psychiatric Research, Hoffman Estates, Illinois, United States|Comprehensive NeuroScience, Inc., Park Ridge, Illinois, United States|Vince and Associats Clinical Research, Overland Park, Kansas, United States|Clinical Trials Technology, Inc., Prairie Village, Kansas, United States|Pedia Research, LLC, Owensboro, Kentucky, United States|Pharasite Research, Inc., Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Coastal Research Associates, Inc., Braintree, Massachusetts, United States|Center for Emotional Fitness, Cherry Hill, New Jersey, United States|CRI Worldwide, LLC, Clementon, New Jersey, United States|Social Psychiatry Research Institute, Brooklyn, New York, United States|Neurobehavioral Research, Inc., Cedarhurst, New York, United States|Comprehensive NeuroScience, Inc., Fresh Meadows, New York, United States|Fieve Clinica Services, Inc., New York, New York, United States|Medical & Behavioral Health Research, PC, New York, New York, United States|Medical & Behavioral Health Research, P.C., New York, New York, United States|Richmond Behavioral Associates, Staten Island, New York, United States|Glenwood Psychiatric Associates, P.L.L.C., Raleigh, North Carolina, United States|Horizon Medical Services, Bismarck, North Dakota, United States|North Coast Clinical Trials, Beachwood, Ohio, United States|Patient Priority Clinical Sties, LLC, Cincinnati, Ohio, United States|Midwest Clinical Research Center, Dayton, Ohio, United States|North Star Mdical Research, LLC, Middleburg Heights, Ohio, United States|IPS Research Company, Oklahoma City, Oklahoma, United States|Oregon Center for Clinical Investigations, Inc., Eugene, Oregon, United States|Oregon Center for Clinical Investigations, Inc., Salem, Oregon, United States|CRI Worldwide, LLC, Philadelphia, Pennsylvania, United States|rhode Island Mood & Memory Research Institute, East Providence, Rhode Island, United States|Clinical Neuroscience Solutions, Inc., Memphis, Tennessee, United States|Future Search Trials, Austin, Texas, United States|Carolos Guerra, Jr., M.D., Houston, Texas, United States|San Antonio Psychiatric Research Center, San Antonio, Texas, United States|Grayline Clinical Drug Trials, Wichita Falls, Texas, United States|University of Virginia, Center for Psychiatric Clinical Research, Charlottesville, Virginia, United States",,https://ClinicalTrials.gov/show/NCT00616655
NCT00612859,Study to Assess the Efficacy and Safety of Levetiracetam for the Treatment of Social Anxiety Disorder (Generalized Type),,Completed,No Results Available,Anxiety Disorders,Drug: levetiracetam,"change in Liebowitz Social Anxiety Scale (LSAS) score from Visit 2 to the last Evaluation period visit attended using last observation carried forward (LOCF) methods|Safety: monitoring of AEs, clinical laboratory tests, physical examination and vital signs.",UCB Pharma,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,217,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,N01086,Sep-03,Jun-04,Jun-04,12-Feb-08,null,26-Nov-13,,,https://ClinicalTrials.gov/show/NCT00612859
NCT00613067,ERP N1 as a Treatment Predictor of Generalized Anxiety Disorder,N1,Completed,No Results Available,Generalized Anxiety Disorder,Drug: escitalopram,Event related potential (ERP) N100|- HAMA - HAMD - CGI - Beck Anxiety Inventory(self rating),Inje University,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,35,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IB-0709-053,Dec-07,Apr-10,May-10,12-Feb-08,null,30-Jun-10,"Psychiatry department, Inje Univ. Ilsanpaik Hospital, Goyang, Kyunggi, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT00613067
NCT00609648,Computer Assisted Relaxation Learning for Dental Offices,CARL,Completed,No Results Available,Dental Anxiety,Behavioral: Computer Assisted Relaxation Learning|Behavioral: Pamphlet,Modified Interval Scale of Anxiety Response at dental injection appointment|Completion of the behavioral avoidance test|Needle Survey|Modified Dental Anxiety Scale|Dental Fear Survey,University of Washington|National Institute of Dental and Craniofacial Research (NIDCR),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,84,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,30641-B|U54DE014254|U01DE016750|U01DE016752,Jan-08,Jul-10,Jul-10,7-Feb-08,null,20-Feb-13,"Dr. Gary Templeman, DDS, Corvallis, Oregon, United States|Michael C Hazel, DMD, PC, West Linn, Oregon, United States|Northwest Dental Fears Research, Bremerton, Washington, United States|Valley View Health Center, Chehalis, Washington, United States|Dental Fears Research Clinic, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00609648
NCT00609960,Clowns as Treatment for Preoperative Anxiety in Children: A Randomized Controlled Trial,,Completed,No Results Available,Pre Operative Anxiety,Behavioral: clowns present|Drug: midazolam,anxiety level,Sheba Medical Center,All,2 Years to 8 Years   (Child),Not Applicable,65,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Supportive Care,SHEBA-05-3739-IK-CTIL,Jan-06,Jan-07,Jan-07,7-Feb-08,null,7-Feb-08,"Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel",,https://ClinicalTrials.gov/show/NCT00609960
NCT00606541,"An Open Label, Double-blind Discontinuation Study of Quetiapine Extended Release(XR)",,Terminated,No Results Available,Social Anxiety Disorder,Drug: Quetiapine XR|Drug: Placebo,"Kaplan Meier survival of Clinical Global Impression of Improvement (CGI-I)|Percentage of CGI-I, BSPS, SPIN",Duke University,All,"18 Years to 65 Years   (Adult, Older Adult)",Early Phase 1,55,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",Pro00002146|eIRB2146|IRUSQUET0452,Jan-08,Dec-11,Nov-12,4-Feb-08,null,1-Aug-14,"Duke University Medical Center, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT00606541
NCT00601965,Antidepressant Treatment Plus Cognitive Behavioral Therapy for Generalized Anxiety Disorder in Older Adults,,Completed,Has Results,Generalized Anxiety Disorder,Drug: Escitalopram|Drug: Placebo|Behavioral: Cognitive behavioral therapy (CBT),Hamilton Anxiety Rating Scale|Penn State Worry Questionnaire,Veterans Medical Research Foundation|National Institute of Mental Health (NIMH),All,"60 Years and older   (Adult, Older Adult)",Not Applicable,73,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",R34MH080151,Oct-07,Sep-11,Sep-11,28-Jan-08,25-Aug-16,25-Aug-16,"UCSD Outpatient Psychiatric Services, San Diego, California, United States|Washington University, St. Louis, Missouri, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00601965
NCT00602212,Virtual Reality as Anxiety Management Tool for Generalized Anxiety Disorder,INTREPID,Completed,No Results Available,Generalized Anxiety Disorder,Behavioral: relaxation with virtual reality (VR)|Behavioral: relaxation and biofeedback virtual reality,"level of anxiety measured by: psychometric questionnaires (PSWQ, BAI, Anti, CID, STAI) and psychophysiological measures ((skin conductance response (SCR), muscle tension, heart and respiratory rates)|subjective measures (diary)",Istituto Auxologico Italiano,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,24,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,03E701|IST-2002-507464,Feb-08,Dec-10,Jun-11,28-Jan-08,null,9-Sep-11,"Istituto Auxologico Italiano, Milano, Italy",,https://ClinicalTrials.gov/show/NCT00602212
NCT00602563,Attention Training for Generalized Anxiety Disorder,,Completed,No Results Available,Generalized Anxiety Disorder,Behavioral: AMP|Behavioral: Applied Relaxation (AR)|Behavioral: Clinical Monitoring (CM)|Behavioral: Combining the AMP and AR,Hamilton Anxiety Rating Scale|Worry Domains Questionnaire,San Diego State University|National Institute of Mental Health (NIMH),All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,193,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",5R01MH087623-04|R01MH087623,Dec-07,Jun-16,Jun-16,28-Jan-08,null,7-Dec-16,"San Diego State University, San Diego, California, United States",,https://ClinicalTrials.gov/show/NCT00602563
NCT00599742,Comorbidity Between Balance and Childhood Anxiety,,Unknown status,No Results Available,Anxiety,Behavioral: Balance training|Behavioral: Motor training,Balance improvement and anxiety reduction,Lev-Hasharon Mental Healtlh Center|Tel Aviv University|Institute of Physical Education and Sports Sciences|University of Haifa,All,8 Years to 14 Years   (Child),Not Applicable,64,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,LH22/2007.CTIL|920070174,Dec-07,Dec-10,Dec-10,24-Jan-08,null,24-Jan-08,"Child and Adolescent Mental Health Clinic, Lev Hasharon MHC, Netanya, Israel|Wingate Institute for Physical Education, Netanya, Israel",,https://ClinicalTrials.gov/show/NCT00599742
NCT00596414,Sedation and Analgesia for Transjugular Liver Biopsy: A Randomized Double Blind Placebo Controlled Trial,,Completed,No Results Available,Cirrhosis|Chronic Hepatitis|Anxiety,Procedure: transjugular liver biopsy|Drug: placebo|Drug: midazolam|Drug: midazolam + pethidine,Patient tolerance to the procedure,Erasme University Hospital,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 4,180,Other,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BHTJ-1,May-03,Oct-05,Oct-05,17-Jan-08,null,17-Jan-08,"Hopital Erasme - Dpt of Gastroenterology, Brussels, Belgium",,https://ClinicalTrials.gov/show/NCT00596414
NCT00595231,Exploratory Study to Evaluate the Effect of SYN111 (Rufinamide) in Patients With Generalized Anxiety Disorder (GAD),,Completed,Has Results,Generalized Anxiety Disorder,Drug: SYN111|Drug: Placebo,Change From Baseline in Hamilton Anxiety Scale (HAMA) - Total Score: Summary Statistics - Observed|Change From Baseline in Hospital Anxiety and Depression Scale (HADS). Summary Statistics|Change From Baseline in Montgomery-Asberg Depression Scale (MADRS) Summary Statistics.|Change From Baseline in Clinical Global Impression Scale for Severity of Illness: (CGI-S)|Change From Baseline Raskin Depression Scale.|Change From Baseline in Covi Anxiety Scale (CAS) - Index Total Score: Summary Statistics Observed,Biotie Therapies Inc.|Syneos Health,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,239,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SYN111-CL03,Mar-08,Oct-08,Oct-08,16-Jan-08,23-Jan-19,27-Feb-19,"Carmen Research, Atlanta, Georgia, United States|Midwest Clinical Research Center, Dayton, Ohio, United States",,https://ClinicalTrials.gov/show/NCT00595231
NCT00596284,Cognitive Behavior Therapy for Treating Anxiety in People With Dementia,,Completed,No Results Available,Anxiety Disorders|Dementia,Behavioral: Cognitive Behavioral Therapy of Anxiety in Dementia (CBT-AD)|Behavioral: Enhanced Usual Care (EUC),Rating Anxiety in Dementia (RAID) and Neuropsychiatric Inventory (NPI)- Anxiety subscales|Quality of Life in Alzheimer's Disease (QOL-AD)|Geriatric Depression Scale (GDS)|Penn State Worry Questionnaire (PSWQ)|Geriatric Anxiety Inventory (GAI),Baylor College of Medicine|National Institute of Mental Health (NIMH),All,"50 Years and older   (Adult, Older Adult)",Phase 1,34,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,R34MH078925|DATR A4-GPS,Jan-08,Jun-10,Jun-10,16-Jan-08,null,13-Aug-15,"Baylor College of Medicine, Houston, Texas, United States|Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00596284
NCT00593515,Effects of Parental Behavior on Child Anxiety Regulation,,Completed,No Results Available,Separation Anxiety Disorder|Social Phobia|Generalized Anxiety Disorder,Behavioral: Family cognitive behavioral therapy|Behavioral: Child-focused cognitive behavioral therapy,Anxiety Disorders Interview Schedule--Child and Parent Versions|Multidimension Anxiety Scale for Children,"University of California, Los Angeles|National Institute of Mental Health (NIMH)",All,6 Years to 13 Years   (Child),Phase 2,40,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,1F31MH064999,Mar-00,Apr-04,Apr-04,15-Jan-08,null,15-Jan-08,"UCLA, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT00593515
NCT00592384,Project to Improve Symptoms and Mood in People With Spinal Cord Injury,PRISMS,Completed,Has Results,Major Depressive Disorder|Dysthymia|Spinal Cord Injuries,Drug: venlafaxine XR|Drug: placebo,Hamilton Depression Rating Scale-17|Hamilton Depression Rating Scale-Maier Subscale|Symptom Checklist-20 Depression Subscale|Modified Brief Pain Inventory|Modified Ashworth Spasticity Scale|Structured Clinical Interview for DSM IV Depression Module|SF-12|Side Effects Checklist|Craig Handicap and Reporting Technique|Satisfaction With Life|Sheehan Disability Scale|Clinical Global Impression|Patient Global Impression|Hamilton Rating Scale for Anxiety,University of Washington|University of Michigan|Shirley Ryan AbilityLab|University of Alabama at Birmingham|Baylor Health Care System|University of Miami|New York University,All,18 Years to 64 Years   (Adult),Phase 4,133,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",31665-D|H133A060107;,Jul-07,Sep-12,Sep-12,14-Jan-08,1-Jan-15,1-Jan-15,"University of Alabama, Birmingham, Alabama, United States|University of Miami, Miami, Florida, United States|Rehabilitation Institute of Chicago, Chicago, Illinois, United States|University of Michigan, Ann Arbor, Michigan, United States|Baylor Institute for Rehabilitation, Dallas, Texas, United States|University of Washington/Harborview Medical Center, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00592384
NCT00592852,Fluoxetine for Obsessive-Compulsive Disorder in Children and Adolescents With Bipolar Disorder,,Terminated,Has Results,Pediatric Bipolar Disorder|Pediatric OCD,Drug: fluoxetine,Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS)|Young Mania Rating Scale (YMRS),Massachusetts General Hospital,All,6 Years to 17 Years   (Child),Phase 4,13,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2005-P-001840,Dec-05,Sep-10,Sep-10,14-Jan-08,6-Mar-12,20-Nov-12,"Massachusetts General Hospital, Cambridge, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT00592852
NCT00591565,An 8 Week Open-Label Study to Evaluate the Efficacy and Safety of Acamprosate Calcium (Campral) as Augmentation Therapy in Patients With Anxiety Symptoms Who Are Only Partial Responders to SSRI or SNRI Antidepressants,,Completed,Has Results,Anxiety,Drug: Acamprosate,Change From Baseline at 8 Weeks in the HAM-A Scale,State University of New York - Upstate Medical University|Forest Laboratories,All,18 Years to 64 Years   (Adult),Not Applicable,13,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CMP-MD-15,Jun-06,Dec-09,Dec-09,11-Jan-08,18-Dec-14,18-Dec-14,"SUNY Upstate Medical University Psychiatry Dept., Syracuse, New York, United States",,https://ClinicalTrials.gov/show/NCT00591565
NCT00591825,fMRI Study Examining Effects of D-cycloserine in Specific Phobia,,Completed,Has Results,Phobias,Drug: D-cycloserine|Drug: Placebo,fMRI Brain Activations During Symptom Provocation|Cognitive Functioning Measured Using the Wechsler Memory Scale III (Logical Memory and Faces Subtests)|Cognitive Functioning Measured Using the Rey-Osterrieth Complex Figure Test (RCFT)|Cognitive Functioning Measured Using the Iowa Gambling Test|Cognitive Functioning Measured Using the Wisconsin Card Sorting Task,University of Kansas Medical Center|American Psychological Foundation|Nepalese Psychological Association,All,18 Years to 55 Years   (Adult),Phase 2,54,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",10362|GCRC 0046|HSCL 15970,Mar-06,Dec-12,Dec-12,11-Jan-08,5-Jun-17,5-Jun-17,"University of Kansas Medical Center, Hoglund Brain Imaging Center, Kansas City, Kansas, United States",,https://ClinicalTrials.gov/show/NCT00591825
NCT00586001,A Unified Treatment for Anxiety Disorders,,Completed,Has Results,Emotional Disorders|Anxiety Disorders,Behavioral: Unified Protocol for Transdiagnostic Treatment of Emotional Disorders,"Anxiety Disorders Interview Schedule for DSM-IV|Structured Interview Guide for the Hamilton Anxiety Rating Scale|Structured Interview Guide for the Hamilton Depression Rating Scale|Positive and Negative Affect Scale|Beck Depression Inventory - II|Beck Anxiety Inventory|Work and Social Adjustment Scale|Panic Disorder Severity Scale - Self Report Version|Penn State Worry Questionnaire|Social Interaction Anxiety Scale|Quality of Life Inventory|Yale-Brown Obsessive Compulsive Scale|Emotion Regulation Questionnaire - 2|BIS/BAS Scales (Carver & White, 1994)|Affective Control Scale|Anxiety Sensitivity Index|The Thought-Action Fusion Scale (Shafran et al., 1996)|Intolerance of Uncertainty Scale (IUS)|The Trait Meta-Mood Scale (TMMS; Salovey et al., 1995)",Boston University Charles River Campus,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,37,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,5R34MH070693-02,Sep-05,Nov-08,Nov-10,4-Jan-08,11-Dec-18,11-Dec-18,,,https://ClinicalTrials.gov/show/NCT00586001
NCT00586586,Effectiveness Study of CBT for Anxiety in Children,ATACA,Completed,No Results Available,Separation Anxiety Disorder|Social Anxiety Disorder|Generalized Anxiety Disorder,Behavioral: Cognitive behavioural therapy,Anxiety disorders according to the ADIS-IV C/P interview|Anxiety symptom score according to the Spence Children Anxiety Scale|Depressive symptoms according to the Mood and Feelings Questionnaire,Haukeland University Hospital|University of Bergen,All,8 Years to 15 Years   (Child),Phase 2,222,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,17563,2-Jan-08,1-Jun-12,21-Mar-14,4-Jan-08,null,8-Aug-17,"Haukeland University Hospital, Bergen, Norway",,https://ClinicalTrials.gov/show/NCT00586586
NCT00583739,Yoga to Reduce Cancer Fatigue,,Completed,No Results Available,Breast Neoplasm,Behavioral: Yoga,Determine if an 8 week yoga program designed for breast cancer patients improves subjective reports of overall well being and fatigue|Analyze symptoms of depression and anxiety,University of Iowa,All,"18 Years and older   (Adult, Older Adult)",Phase 2,66,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,200707733,Aug-07,Oct-08,Oct-08,31-Dec-07,null,4-Dec-08,"The University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States",,https://ClinicalTrials.gov/show/NCT00583739
NCT00579280,Quetiapine SR and Divalproex Sodium ER in the Treatment of Anxiety in Bipolar Disorder With Panic Disorder and/or GAD,,Unknown status,No Results Available,Bipolar Disorder|Panic Disorder|Generalized Anxiety Disorder,Drug: quetiapine SR|Drug: divalproex sodium ER|Drug: placebo,"The primary outcome measure is the Clinician Global Improvement Scale for Anxiety Symptoms (CGI-21).|Sheehan Panic Disorder Scale (SPS), (HAM-A), Young Mania Rating Scale (YMRS), Sheehan Irritability Scale (SIS), Rapid Ideas Scale RISC, MADRS, PGI-21 for anxiety symptoms, CGI-BP, Family Impact Scale (FIS), Sheehan Disability Scale (SDS).",University of South Florida|AstraZeneca,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,90,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",AZ 1107,Jul-07,May-10,May-10,24-Dec-07,null,17-Jan-11,"VA Palo Alto HCS & Stanford School of Medicine, Palo Alto, California, United States|University of South Florida College of Medicine, Tampa, Florida, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT00579280
NCT00580151,The Use of Clonidine in Pain and Anxiety Associated With Acute Burn Injury in Children,clonidine,Terminated,Has Results,Pain|Anxiety,Drug: clonidine|Drug: placebo,Pain Reduction|Anxiety Reduction,"The University of Texas Medical Branch, Galveston",All,"4 Years to 20 Years   (Child, Adult)",Not Applicable,9,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",04-101|IFFA,Jun-04,Jun-14,Jun-14,24-Dec-07,23-Feb-15,23-Feb-15,"Shriners Hospital for Children; Shriners Burns Hospital, Galveston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00580151
NCT00578214,Safety and Efficacy of Oral Midazolam for Perioperative Anxiety Relief of Patients Undergoing Mohs Micrographic Surgery,,Completed,Has Results,Basal Cell Carcinoma|Squamous Cell Carcinoma|Skin Cancer|Anxiety,Drug: Randomized Midazolam|Other: Placebo|Drug: Local Anesthesia|Drug: Prospective Midazolam,Patient Anxiety at Baseline|Patient Anxiety at 60 and 120 Minutes|Patient Alertness at Baseline|Patient Alertness at 60 and 120 Minutes|Patient Cognitive Function at Baseline and 60 Minutes|Patient Cognitive Function at 120 Minutes|Blood Pressure at 30 Minutes|Heart Rate at 30 Minutes|Respiratory Rate at 30 Minutes|Pulse Oximetry at 30 Minutes|Blood Pressure at 60 Minutes|Heart Rate at 60 Minutes|Respiratory Rate at 60 Minutes|Pulse Oximetry at 60 Minutes,Mayo Clinic,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,75,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",07-000848,Mar-07,Apr-08,Jun-08,21-Dec-07,9-Feb-12,9-Feb-12,"Mayo Clinic, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT00578214
NCT00576719,Effectiveness of Intensive Cognitive Behavioral Therapy in Treating Adolescent Panic Disorder and Agoraphobia,,Completed,No Results Available,Panic Disorder|Agoraphobia,Behavioral: Intensive panic control treatment without parent involvement|Behavioral: Intensive panic control treatment with parent involvement|Other: Waitlist control,"Anxiety Disorders Interview Schedule-Child and Parent Versions: Clinical Severity Rating, Agoraphobia Ratings, Panic Attack Frequency Scores, and Internal Sensation Anxiety Ratings|Panic Disorder Severity Scale-Child Version|Multidimensional Anxiety Scale for Children|Childhood Anxiety Sensitivity Index|Fear and Avoidance Hierarchy|Children's Depression Inventory|The Panic Attack Record|Subjective Symptoms Scale|Panic and Phobia Questionnaire|Participant Global Impression of Improvement (PGI)|Perceptions of Treatment Questionnaire: Adolescent and Parent Versions|Children's Perception Scale (Locus of Control Scale)|Child Behavior Checklist (CBCL)|Stress Index for Parents of Adolescents|Parenting Locus of Control Scale|Therapy Attitude Inventory|Family Assessment Measure (FAM)|Depression Anxiety and Stress Scale (DASS)",Boston University|National Institute of Mental Health (NIMH),All,12 Years to 17 Years   (Child),Phase 2,63,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,R01MH068277|DSIR 84-CTS,Mar-05,Mar-11,Mar-11,19-Dec-07,null,20-Feb-14,"Boston University, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT00576719
NCT00569608,Early Hospital Discharge Program in Neonatology,EDNEO,Completed,No Results Available,Prematurity,Other: Early Discharge,Reduction in the length of hospitalization.|Parental stress|Use of Health Resources of the Community|Reduction in cost of hospitalization,Fundacion Para La Investigacion Hospital La Fe,All,36 Weeks to 42 Weeks   (Child),Not Applicable,140,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care,FIHLaFe|AP015/06,Jan-05,null,Oct-06,7-Dec-07,null,7-Dec-07,"Hospital Universitario La Fe, Valencia, Spain",,https://ClinicalTrials.gov/show/NCT00569608
NCT00569647,Preoperative Anxiety in Pediatric Reconstructive Burn Patients: The Role of Virtual Reality Hypnosis,,Completed,No Results Available,Anxiety,Device: Virtual Reality Hypnosis|Device: Placebo,anxiety reduction,Shriners Hospitals for Children,All,"14 Years to 21 Years   (Child, Adult)",Not Applicable,25,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,277444040,Nov-05,null,May-06,7-Dec-07,null,7-Dec-07,,,https://ClinicalTrials.gov/show/NCT00569647
NCT00569829,Modular Cognitive Behavioral Therapy for the Treatment of Child Anxiety Disorders in Elementary School Settings,KATES,Completed,No Results Available,Separation Anxiety Disorder|Generalized Anxiety Disorder|Social Phobia,Behavioral: cognitive behavioral therapy,Clinician's Global Impressions-Improvement (CGI) scale|Anxiety Disorders Interview Schedule IV: Child and Parent Version,"University of California, Los Angeles",All,5 Years to 12 Years   (Child),Phase 2,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,G04-06-117-04,Jan-04,Jun-08,Jun-09,7-Dec-07,null,30-Mar-12,,,https://ClinicalTrials.gov/show/NCT00569829
NCT00564967,A Comparison Between Internet Therapy and Group Therapy for Social Phobia - A Trial Using Cognitive Behavioural Therapy,IS1,Completed,No Results Available,Social Phobia,Behavioral: CBT via the Internet|Behavioral: CBT group therapy,"Liebowitz Social Anxiety Scale (LSAS)|SIAS, SPS,QOLI,MADRS-S, BAI,ASI,CGI, WQ, GAF, TIC-P, SSP",Karolinska Institutet,All,"16 Years and older   (Child, Adult, Older Adult)",Phase 3,128,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,IS1|Dnr 2005/178-31,Nov-07,Aug-10,Aug-10,29-Nov-07,null,26-Oct-10,"Psykiatri Sydväst, Stockholm County Council, Stockholm, Sweden",,https://ClinicalTrials.gov/show/NCT00564967
NCT00564564,Quetiapine Augmentation Versus Clomipramine Augmentation of SSRI for Obsessive-compulsive Disorder Patients,QCAT,Completed,No Results Available,Obsessive Compulsive Disorder,Drug: Quetiapine|Drug: Clomipramine,YBOCS|CGI|Tolerability|Cardiotoxicity,University of Sao Paulo|Conselho Nacional de Desenvolvimento Científico e Tecnológico,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,21,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,968/05|2005/55628-08,Jan-06,Dec-07,Dec-07,28-Nov-07,null,27-Oct-17,"Institute of Psychiatry, Clinics Hospital, University of São Paulo Medical School, São Paulo, SP, Brazil",,https://ClinicalTrials.gov/show/NCT00564564
NCT00564239,Psychological Prevention of Internalizing Disorders,,Completed,No Results Available,Anxiety Symptoms|Depressive Symptoms|Somatoform Symptoms,Behavioral: Cognitive Behavioral Group Therapy,"Child Behavior Checklist (german version)|Inventar zur Erfassung der Lebensqualität bei Kindern und Jugendlichen (ILK)- Assessment of life quality, parent and child versions|Spence Children's Anxiety Scale (SCAS)|Depressionsinventar für Kinder- und Jugendliche (DIKJ), german depression inventory based on CDI|Giessener Beschwerdebogen für Kinder- und Jugendliche (GBB-KJ), report of somatic symptoms, parent and child versions|Culture Fair Intelligence Test (CFT 20-R)|Symptom-Checklist (SCL-90-R), german version","Philipps University Marburg Medical Center|Institute of Behavioral-Therapy and -Medicine at the Philipps University Marburg|Dept. of Child and Adolescent Psychiatry, Philipps University Marburg",All,8 Years to 12 Years   (Child),Not Applicable,77,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,IVV-001-2007,Nov-07,May-09,May-09,27-Nov-07,null,30-Apr-18,"Institut für Verhaltenstherapie und -medizin (IVV), Marburg, Hessen, Germany",,https://ClinicalTrials.gov/show/NCT00564239
NCT00559559,PAtient NOtifier Feature for Reduction of Anxiety,Panoramic,Completed,No Results Available,"Tachycardia, Ventricular",Device: ICD implant + Patient Notifier turned OFF|Procedure: ICD Implant + Patient Notifier turned ON,"Reduction in device related anxiety, related to battery depletion, as assessed by the Duru Questionnaire (question 9) Reduction in device related anxiety, related to device malfunction, as assessed by the Duru Questionnaire (question 10)|Reduction in general anxiety Evolution over time in anxiety for the different personality types Cross-overs Sensitivity and Specificity of the Patient Notifier™ Number of appropriate/inappropriate ICD therapies Hospitalizations Mortality",Abbott Medical Devices,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,362,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,CR06002HV,Dec-07,Dec-10,Dec-10,16-Nov-07,null,4-Feb-19,"UniversitätsSpital Zürich, Zürich, Switzerland",,https://ClinicalTrials.gov/show/NCT00559559
NCT00557648,Evaluating the Effectiveness of Early Cognitive Behavioral Therapy With or Without Parental Involvement in Treating Anxious Children,,Completed,No Results Available,Anxiety Disorders,Behavioral: Group CBT for children|Behavioral: Group CBT for children plus parent training,"Composite Clinician Severity Rating (CSR) on the Anxiety Disorders Interview Schedule (ADIS) for DSM-IV for primary anxiety diagnosis|Multidimensional Anxiety Scale for Children, Scale for Child Anxiety Related Emotional Disorders, Clinical Global Impressions-Improvement Scale, Family Adaptability and Cohesion Evaluation Scale II, and Behavior Assessment System for Children",University of Minnesota - Clinical and Translational Science Institute|National Institute of Mental Health (NIMH),All,7 Years to 11 Years   (Child),Not Applicable,61,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,R21MH065369,Oct-02,Jul-07,Jul-07,14-Nov-07,null,26-May-14,"Divisions of Child and Adolescent Psychiatry, University of Minnesota Medical School, Minneapolis, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT00557648
NCT00555139,A Study To Compare The Putative Anxiolytic Effect Of 2 New Drugs In Subjects With Social Anxiety Disorder,,Completed,No Results Available,Social Phobia,Drug: GSK561679 tablet|Drug: GW876008 tablet|Drug: alprazolam|Drug: Placebo,"Changes of fMRI activation in amygdala of subjects with SAD during an emotional task after having received different compounds. Change in the VAS score in response to Public Speaking stress after having received different compounds.|Changes of fMRI activation patterns in all brain areas in subjects with SAD during an emotional task or resting state. Changes of cortisol levels and other stress indicators in response to Public Speaking stress.|Pk samples:|Cortisol, ACTH:|Indicators of physiological state during the fMRI session:|Heart rate (HR), Respiratory rate (RR), ventilation (pneumatic pletismography), and carbon dioxide percutaneous measurements monitored during the whole procedure (control and exploratory profile tests).|Visual Analog Scale (VAS) measurements of distress|Maddox wing test.|questionnaire for sédation.|plasma levels of the various compounds to derive pharmacokinetic parameters|Safety and tolerability will be evaluated by adverse event monitoring, physical examination, ECG, vital signs and laboratory parameters",GlaxoSmithKline,All,18 Years to 64 Years   (Adult),Phase 1,35,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Primary Purpose: Treatment,CRH108571,27-Mar-07,10-Jan-08,10-Jan-08,7-Nov-07,null,4-Aug-17,"GSK Investigational Site, Barcellona, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Hospitalet de Llobregat, Spain|GSK Investigational Site, Mataro (Barcelona), Spain|GSK Investigational Site, Sabadell (Barcelona), Spain|GSK Investigational Site, Terrassa - Barcelona, Spain",,https://ClinicalTrials.gov/show/NCT00555139
NCT00546624,GEM 1.5 mg b.i.d. to 4.5 mg b.i.d. Versus Lorazepam in GAD (0777-026),,Completed,No Results Available,Anxiety Disorder,Drug: MK0777,,Merck Sharp & Dohme Corp.,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,38,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,0777-026|2007_632,Nov-02,Feb-03,Feb-03,19-Oct-07,null,2-Nov-15,,,https://ClinicalTrials.gov/show/NCT00546624
NCT00546923,Study Evaluating Venlafaxine Extended-Release in Depressed and Anxious Patients,,Completed,No Results Available,Anxiety Disorders|Depression,Drug: Venlafaxine XR,"The primary endpoint is the change from baseline to Week 12 in the PHQ-15 total score.|Efficacy will be evaluated by changes in the total scores of the HAM-D17, HAM-A, CGI, MQOL-PS, VAS and SF-36. Safety will be monitored by collecting spontaneously reported adverse events; vital signs and laboratory measures according to the Schedule.",Wyeth is now a wholly owned subsidiary of Pfizer,All,"18 Years and older   (Adult, Older Adult)",Phase 4,210,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,0600B-101568,Aug-04,null,Jun-06,19-Oct-07,null,19-Oct-07,,,https://ClinicalTrials.gov/show/NCT00546923
NCT00545922,Cognitive Behavioral Therapy for Anxiety and Depression in COPD,,Completed,No Results Available,Anxiety|Depression|Chronic Obstructive Pulmonary Disease,Behavioral: Cognitive behavioral therapy|Behavioral: Minimal Telephone Contact,Beck Anxiety Inventory|Beck Depression Inventory-II|St. George's Respiratory Questionnaire|Pittsburgh Sleep Quality Inventory|Actigraphy (Sleep effectiveness),University of Bergen,All,"40 Years and older   (Adult, Older Adult)",Phase 2,51,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,REK 3.2007.1668,Apr-05,null,Nov-07,17-Oct-07,null,16-Nov-07,"Outpatient pulmonary clinic, Haukeland University Hospital, Bergen, Norway",,https://ClinicalTrials.gov/show/NCT00545922
NCT00544492,"Study of Pain, Anxiety and Complications Related to Cannulation of Arteriovenous (AV) Fistula in Chronic Hemodialysis Patients",,Completed,No Results Available,Dialysis|Fistula,Device: catheter for AV fistula cannulation,"A. Buttonhole vs. rope ladder AV fistula cannulation, comparison of pain, anxiety, bleeding time and fistula related complications B. Rope ladder AV fistula cannulation using catheters with cylindrical vs. bevel point, comparison of pain",Universitaire Ziekenhuizen Leuven,All,"18 Years and older   (Adult, Older Adult)",Phase 4,40,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,S50619,Oct-07,Mar-10,Mar-10,16-Oct-07,null,20-Dec-11,"University Hospital Gasthuisberg, Leuven, Belgium",,https://ClinicalTrials.gov/show/NCT00544492
NCT00543920,A Study of MK0777 in the Treatment of Outpatients With Generalized Anxiety Disorder (0777-020),,Completed,No Results Available,Anxiety Disorders,Drug: MK0777,,Merck Sharp & Dohme Corp.,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,60,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,0777-020|2007_633,Aug-02,Feb-03,Feb-03,15-Oct-07,null,26-Nov-15,,,https://ClinicalTrials.gov/show/NCT00543920
NCT00542685,A 10-Week Study Evaluating the Efficacy And Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder,,Completed,No Results Available,Generalized Anxiety Disorder,Drug: PD 0332334|Drug: Placebo,"The efficacy of PD 0332334 in the treatment of GAD will be measured by the change in the Hamilton Anxiety Rating Scale (HAM-A) total scores from baseline observed following 8 weeks of double-blind treatment.|The safety and tolerability of PD 0332334 in subjects with GAD will be monitored in this study.|Response rate on the clinician-rated CGI-I at Week 1 and Week 8.|Change from Baseline to Week 8 on the Medical Outcomes Study-Sleep Scale (MOSS-SS) subscales.|Change from Baseline to Week 8 on the Sheehan Disability Scale (SDS) total score.|Change from Baseline to Days 2-8 and Weeks 2, 4, 6, 8 on the DAS-A (total score).|Response rate on the HAM-A at Week 1 and Week 8.|Change from Baseline in the somatic subscale score of the HAM-A (Items 7-13) at Week 8.|Remission rate based on the HAM-A at Week 1 and Week 8.|Response rate on the patient-rated PGI-C at Week 8.|The ""Week 1 Sustained Responder"" rate based on the HAM-A (where ""Week 1 Sustained Responders"" are defined as subjects with a 50% or greater improvement from baseline on the HAM-A total score at Week 1 that is sustained until the Week 8 visit).|Change from Baseline in HAM-A total score at Weeks 1, 2, 4, and 6.|Change from Baseline in the 17-item HAM-D total score at Weeks 1, 2, 4, and 8.|Change from Baseline to Week 8 on the Sheehan Disability Scale subscales.|Change from Baseline in CGI-S at Week 8.|Change from Baseline in the psychic subscale score of the HAM-A (Items 1-6 and 14) at Week 8.|Change from Baseline to Week 8 on the Medical Outcomes Study Sleep Scale (MOS-SS) total score.|Change from Baseline to Week 8 in the Q-Les-Q General Activities Score.|Change from Baseline to Week 1 on the Medical Outcomes Study Sleep Scale (MOS-SS) total score.|Change from Baseline to Days 2-8 and Weeks 2, 4, 6, 8 on the GA-VAS (diary).",Pfizer,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,551,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",A5361017,Oct-07,Dec-08,Dec-08,11-Oct-07,null,16-Nov-12,"Pfizer Investigational Site, Beverly Hills, California, United States|Pfizer Investigational Site, Encino, California, United States|Pfizer Investigational Site, National City, California, United States|Pfizer Investigational Site, Newport Beach, California, United States|Pfizer Investigational Site, San Diego, California, United States|Pfizer Investigational Site, Sherman Oaks, California, United States|Pfizer Investigational Site, Farmington, Connecticut, United States|Pfizer Investigational Site, Jacksonville, Florida, United States|Pfizer Investigational Site, Jacksonville, Florida, United States|Pfizer Investigational Site, Orlando, Florida, United States|Pfizer Investigational Site, Tampa, Florida, United States|Pfizer Investigational Site, West Palm Beach, Florida, United States|Pfizer Investigational Site, Atlanta, Georgia, United States|Pfizer Investigational Site, Atlanta, Georgia, United States|Pfizer Investigational Site, Marietta, Georgia, United States|Pfizer Investigational Site, Libertyville, Illinois, United States|Pfizer Investigational Site, Schaumburg, Illinois, United States|Pfizer Investigational Site, Lafayette, Indiana, United States|Pfizer Investigational Site, Owensboro, Kentucky, United States|Pfizer Investigational Site, Lake Charles, Louisiana, United States|Pfizer Investigational Site, Glen Burnie, Maryland, United States|Pfizer Investigational Site, Rockville, Maryland, United States|Pfizer Investigational Site, Belmont, Massachusetts, United States|Pfizer Investigational Site, Fall River, Massachusetts, United States|Pfizer Investigational Site, Farmington Hills, Michigan, United States|Pfizer Investigational Site, Nashua, New Hampshire, United States|Pfizer Investigational Site, Cherry Hill, New Jersey, United States|Pfizer Investigational Site, Piscataway, New Jersey, United States|Pfizer Investigational Site, Brooklyn, New York, United States|Pfizer Investigational Site, New York, New York, United States|Pfizer Investigational Site, Staten Island, New York, United States|Pfizer Investigational Site, Chapel Hill, North Carolina, United States|Pfizer Investigational Site, Durham, North Carolina, United States|Pfizer Investigational Site, Columbus, Ohio, United States|Pfizer Investigational Site, Portland, Oregon, United States|Pfizer Investigational Site, Philadelphia, Pennsylvania, United States|Pfizer Investigational Site, Philadelphia, Pennsylvania, United States|Pfizer Investigational Site, Lincoln, Rhode Island, United States|Pfizer Investigational Site, Charleston, South Carolina, United States|Pfizer Investigational Site, Houston, Texas, United States|Pfizer Investigational Site, Richmond, Virginia, United States|Pfizer Investigational Site, Seattle, Washington, United States|Pfizer Investigational Site, Middleton, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT00542685
NCT00540098,Paroxetine vs Placebo Combined With Aerobic Exercise or Relaxation in Panic Disorder,Exparox,Completed,No Results Available,Panic Disorder,Drug: paroxetine + aerobic exercise|Drug: Paroxetine + relaxation|Drug: Placebo + aerobic exercise|Drug: Placebo + relaxation,Severity of Panic disorder due to Scores on the Panic and Agoraphobia Scale (P&A)|Severity of panic disorder due to scores on the Clinical Global Impression scale (CGI)|Symptom severity due to Hamilton Anxiety Scale (HAMA)|Symptom severity due to the Montgomery and Asberg depression rating scale (MADRS)|Response and remission analysis between groups,University of Göttingen|GlaxoSmithKline,All,18 Years to 60 Years   (Adult),Phase 4,75,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",290060/552,Sep-01,null,Jun-05,5-Oct-07,null,5-Oct-07,"University of Göttingen, Dept of Psychiatry and Psychotherapy, Göttingen, Germany",,https://ClinicalTrials.gov/show/NCT00540098
NCT00539357,A Pilot Study of Cranial Electrotherapy Stimulation[CES] for Generalized Anxiety Disorder,,Completed,No Results Available,Generalized Anxiety Disorder,Device: Cranial electrotherapy stimulation (CES),"The Hamilton Anxiety Rating Scale (HAM-A)|the Clinical Global Impression Improvement CGI-I scale (beginning at week 2), the 17-item Hamilton Rating Scale for Depression, Patients Global Impressions-Improvement ande the Four-Dimensional Anxiety and Depression Scale","University of California, Los Angeles",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,12,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,04-08-121-02,Aug-05,null,Mar-06,4-Oct-07,null,8-Aug-16,,,https://ClinicalTrials.gov/show/NCT00539357
NCT00539513,N-Acetylcysteine Augmentation in Treatment-Refractory Obsessive-Compulsive Disorder,,Terminated,Has Results,Obsessive-Compulsive Disorder,Drug: N-Acetylcysteine|Drug: placebo,Yale-Brown Obsessive-Compulsive Scale (Y-BOCS)at Baseline|Yale-Brown Obsessive-Compulsive Scale (Y-BOCS)at 12 Weeks|The Hamilton Depression Inventory (HAM-D)at Baseline|The Hamilton Depression Inventory (HAM-D)at 12 Weeks,Yale University,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,10,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",YOCD-2,Jun-06,Apr-11,Apr-11,4-Oct-07,8-Mar-13,1-Apr-13,,,https://ClinicalTrials.gov/show/NCT00539513
NCT00539578,Treatment of Patients With Anxiety Disorder (0777-022),,Completed,No Results Available,Generalized Anxiety Disorder,Drug: MK0777|Drug: Comparator: placebo (unspecified),,Merck Sharp & Dohme Corp.,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,270,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",0777-022|MK0777-022|2007_622,Sep-02,Feb-03,Feb-03,4-Oct-07,null,2-Nov-15,,,https://ClinicalTrials.gov/show/NCT00539578
NCT00537615,"An Open-label Study to Investigate the Absorption, Metabolism and Excretion of Radiolabeled PD 0332334 in Six Healthy Male Volunteers",,Completed,No Results Available,Generalized Anxiety Disorder,Drug: PD 0332334,"Radioactivity parameters in plasma and whole blood - Cmax , Tmax , AUCinf, AUClast, t1/2, CL/F and V/F.|Total 14C data in blood, urine and feces|Ratio of radioactivity in red blood cells to plasma (RBC/plasma)|Cumulative recovery of radioactivity in urine and feces|Identification of metabolites in feces, plasma and urine if possible|Plasma, urine and fecal PD 0332334 pharmacokinetic parameters - Cmax, Tmax, AUClast, AUCinf, t1/2, CL/F, V/F, CLR, Ae24 and Ae24(%)|Pharmacokinetic analysis of metabolites if detectable",Pfizer,Male,18 Years to 55 Years   (Adult),Phase 1,6,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,A5361010,Sep-07,null,Oct-07,1-Oct-07,null,17-Feb-10,"Pfizer Investigational Site, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT00537615
NCT00536679,Relative Bioavailability and Food Effect Study for GSK163090 in Healthy Male and Female Volunteers,,Completed,No Results Available,Depressive Disorder and Anxiety Disorders,"Drug: GSK163090 capsule, fasted|Drug: GSK163090 Tablet, fasted|Drug: GSK163090 Tablet, fed","Pharmacokinetic parameters for GSK163090. Pharmacokinetic blood samples will be collected up to 72 hours post-dose following each dosing session.|Additional pharmacokinetic parameters, safety, and tolerability.",GlaxoSmithKline,All,18 Years to 55 Years   (Adult),Phase 1,16,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,103268,20-Sep-07,5-Nov-07,5-Nov-07,28-Sep-07,null,3-Aug-17,"GSK Investigational Site, Neuss, Nordrhein-Westfalen, Germany",,https://ClinicalTrials.gov/show/NCT00536679
NCT00536094,School-based Treatment for Anxious Children,,Completed,No Results Available,Anxiety Disorders,Behavioral: Cognitive behavioral therapy (CBT)|Behavioral: Treatment as usual (TAU),Anxiety Disorders Interview Schedule for DSM-IV: Child Version|Screen for Child Anxiety Related Disorders (SCARED) - Child Version,Johns Hopkins University|National Institute of Mental Health (NIMH),All,7 Years to 17 Years   (Child),Phase 3,40,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",R34MH074552|DSIR 84-CTS,Oct-06,Dec-09,Dec-09,27-Sep-07,null,24-Sep-13,"Johns Hopkins School of Medicine, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00536094
NCT00534599,Generalized Anxiety Disorder Adjunct Study,,Completed,Has Results,Anxiety|Anxiety Disorders|Anxiety Neuroses|Anxiety States,Drug: Placebo|Drug: quetiapine fumarate XR,"Least Square Mean Change From Randomization to Week 8 in Hamilton Rating Scale for Anxiety (HAM-A) Total Score|Least Square Mean Change From Randomization to Week 8 in Clinical Global Impression-Severity of Illness (CGI-S) Score|Number of Patients With Clinical Global Impression-Global Improvement (CGI-I) Score of ""Much/Very Much Improved"" at Week 8|Least Square Mean Change From Randomization to Week 8 in HAM-A Psychic Anxiety Subscale Score|Least Square Mean Change From Randomization to Week 8 in HAM-A Somatic Anxiety Subscale Score|Number of Patients With HAM-A Response (≥50% Score Reduction From Randomization) at Week 8|Number of Patients With HAM-A Remission (Total Score ≤7) at Week 8|Least Square Mean Change From Randomization to Week 8 in Quality of Life Enjoyment and Satisfaction Questionaire (Q-LES-Q) Percent Maximum Total Score|Mean Change From Randomization to Week 8 in Q-LES-Q Item 15 (Satisfaction With Medication) Score|Mean Change From Randomization to Week 8 in Q-LES-Q Item 16 (Overall Quality of Life) Score|Least Square Mean Change From Randomization to Week 1 in HAM-A Total Score|Least Square Mean Change From Randomization to Week 1 in HAM-A Psychic Anxiety Subscale Score|Least Square Mean Change From Randomization to Week 1 in HAM-A Somatic Anxiety Subscale Score|Least Square Mean Change From Randomization to Week 1 in CGI-S Score|Number of Patients With HAM-A Response (≥50% Score Reduction From Randomization) at Week 1",AstraZeneca,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,409,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",D1441L00016,Aug-07,Sep-08,Sep-08,26-Sep-07,5-Apr-11,14-Apr-11,"Research Site, Birmingham, Alabama, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Beverly Hills, California, United States|Research Site, Encino, California, United States|Research Site, Fresno, California, United States|Research Site, La Mesa, California, United States|Research Site, Oceanside, California, United States|Research Site, Redlands, California, United States|Research Site, San Diego, California, United States|Research Site, San Francisco, California, United States|Research Site, Sherman Oaks, California, United States|Research Site, Bradenton, Florida, United States|Research Site, Dayton, Florida, United States|Research Site, Hialeah, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Maitland, Florida, United States|Research Site, Miami, Florida, United States|Research Site, North Miami, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, West Palm Beach, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Columbus, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Lafayette, Indiana, United States|Research Site, Merrillville, Indiana, United States|Research Site, Terre Haute, Indiana, United States|Research Site, Prairie Village, Kansas, United States|Research Site, Owenboro, Kentucky, United States|Research Site, New Orleans, Louisiana, United States|Research Site, Rockville, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Cherry Hill, New Jersey, United States|Research Site, Clementon, New Jersey, United States|Research Site, Brooklyn, New York, United States|Research Site, Cedarhurst, New York, United States|Research Site, Fresh Meadows, New York, United States|Research Site, New York, New York, United States|Research Site, Rochester, New York, United States|Research Site, Staten Island, New York, United States|Research Site, Toledo, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Portland, Oregon, United States|Research Site, Salem, Oregon, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Memphis, Tennessee, United States|Research Site, Houston, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Witchita Falls, Texas, United States|Research Site, Richmond, Virginia, United States|Research Site, Bellevue, Washington, United States|Research Site, Seattle, Washington, United States|Research Site, Spokane, Washington, United States",,https://ClinicalTrials.gov/show/NCT00534599
NCT00535340,An Eight-Week Study to Evaluate the Efficacy and Safety of SR58611A in Elderly Patients With Generalized Anxiety Disorder,GEMINI,Terminated,No Results Available,Anxiety Disorders,Drug: SR58611A,Change from baseline to visit 7 (Day 56) in the 14-item Hamilton Anxiety Rating Scale (HAM-A) total score|Clinical Global Impression (CGI) Severity of Illness Score|Adverse events,Sanofi,All,"60 Years and older   (Adult, Older Adult)",Phase 3,55,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",EFC5895|EudraCT 2006-004147-33,Mar-07,Aug-07,Aug-07,26-Sep-07,null,12-Mar-09,"Sanofi-Aventis Administrative Office, Vienna, Austria|Sanofi-Aventis Administrative Office, Zagreb, Croatia|Sanofi-Aventis Administrative Office, Helsinki, Finland|Sanofi-Aventis Administrative Office, Bucuresti, Romania|Sanofi-Aventis Administrative Office, Bratislava, Slovakia",,https://ClinicalTrials.gov/show/NCT00535340
NCT00533806,Comparing the Effectiveness of Two Family-based Therapies in Treating Young Children With Obsessive-Compulsive Disorder,,Completed,No Results Available,Obsessive Compulsive Disorder,Behavioral: Cognitive Behavior Therapy|Behavioral: Relaxation Therapy,Children's Yale-Brown Obsessive Compulsive Scale|Clinical Global Improvement,Rhode Island Hospital|National Institute of Mental Health (NIMH),All,5 Years to 8 Years   (Child),Phase 3,127,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,R01MH079217|DSIR 84-CTS,Oct-07,Oct-12,Jan-13,21-Sep-07,null,11-Mar-13,"Duke Child and Family Study Center, Durham, North Carolina, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Brown Medical School/ Rhode Island Hospital/ Pediatric Anxiety Research Clinic, Providence, Rhode Island, United States",,https://ClinicalTrials.gov/show/NCT00533806
NCT00526266,Evaluating Physiological Markers of Emotional Trauma: A Randomized Controlled Comparison of Mind-Body Therapies,,Completed,No Results Available,"Hypermobility, Joint|Depression|Anxiety",Behavioral: Emotional Freedom Techniques (EFT)|Behavioral: Diaphragmatic Breathing (DB),Mental Health Symptoms|Range of Motion (ROM) of joints of the upper body,Soul Medicine Institute,All,"18 Years to 85 Years   (Adult, Older Adult)",Not Applicable,37,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ROM-ACEP-SMI-IMCSR-1,Sep-07,Jan-18,Jan-18,10-Sep-07,null,25-Apr-18,"Integrative Medical Clinic of Santa Rosa (IMCSR), Santa Rosa, California, United States",,https://ClinicalTrials.gov/show/NCT00526266
NCT00523718,Riluzole Augmentation in Treatment-refractory Obsessive-compulsive Disorder,,Completed,Has Results,Obsessive-compulsive Disorder|Ocd,Drug: riluzole|Drug: placebo,Partial Responders by Yale-Brown Obsessive-Compulsive Scale (Y-BOCS)|Average Hamilton Depression Inventory (HAM-D)|Average Hamilton Anxiety Inventory (HAM-A)|Clinical Global Impression (CGI) - Severity of Illness Item,Yale University,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,40,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",YOCD-1,Sep-06,Aug-15,Aug-15,31-Aug-07,23-Mar-16,4-Jul-16,"Yale OCD Research Clinic, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT00523718
NCT00521352,Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Panic Disorder With Comorbid Major Depression,rTMS,Completed,Has Results,Panic Disorder|Major Depressive Disorder,Device: Active Repetitive Transcranial Magnetic Stimulation (rTMS)|Device: Sham Repetitive Transcranial Magnetic Stimulation (rTMS),"Panic Disorder Severity Scale (PDSS)|Hamilton Depression Rating Scale (HDRS), 28 Item Version|Clinical Improvement (CGI-S)",New York State Psychiatric Institute,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,25,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",5517,Oct-07,Jun-11,Jun-11,27-Aug-07,22-Sep-14,22-Sep-14,"New York State Psychiatric Institute, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00521352
NCT00521417,Short- and Long-term Group Psychotherapy,KOLG-P,"Active, not recruiting",No Results Available,Mood Disorders|Anxiety Disorders|Personality Disorders,Behavioral: short-term dynamic therapy|Behavioral: long-term dynamic therapy,"scl-90-R, IIP-C, GAF",University of Oslo|Brigham Young University,All,"20 Years to 70 Years   (Adult, Older Adult)",Phase 2,140,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,aker2004-77,Aug-05,Aug-18,Aug-20,27-Aug-07,null,2-May-16,"Distriktpsykiatrisk senter Helse sunnmøre, Ålesund, Norway",,https://ClinicalTrials.gov/show/NCT00521417
NCT00520429,Transforming Psychotherapy for Chronically Ill Patients,,Completed,No Results Available,"Heart Failure, Congestive|Pulmonary Disease, Chronic Obstructive|Depression|Anxiety",Behavioral: ACCES - Adjusting to Chronic Conditions with Education and Support,"State-trait Anxiety Inventory (STAI), a 40-item self-report measure of anxiety symptoms.Beck Depression Inventory-II (BDI-II), assessing 21 depression symptoms. Client Satisfaction Questionnaire (CSQ), an 8-item, empirical, self-report measure.|Kansas City Cardiomyopathy Questionnaire (KCCQ), a 23-item self-report measure of constructs. Chronic Respiratory Questionnaire (CRQ), measuring QoL change over time in COPD patients. Short Form 36 (SF-36), a generic measure of health-related QoL.",US Department of Veterans Affairs|VA Office of Research and Development,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,23,U.S. Fed,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MIRECC001,Aug-07,Jul-08,Sep-08,24-Aug-07,null,7-Jan-09,"Houston VA Medical Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00520429
NCT00517387,"The Effects of Quetiapine XR on Cognition, Mood and Anxiety Symptoms in SSRI-Resistant Unipolar Depression",,Completed,No Results Available,Unipolar Depression,Drug: Quetiapine XR,"Primary outcome will be measurements of cognitive function, determined both prior to treatment and after 8 weeks of treatment.|To evaluate Quetiapine XR compared to placebo, in SSRI-nonresponsive unipolar patients, in treatment of anxiety and depressive symptoms and biomarkers, improving patient's overall quality of life, and to evaluate its safety and tolerability.",University of British Columbia|AstraZeneca,All,"19 Years to 65 Years   (Adult, Older Adult)",Phase 3,64,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",H07-00629,Sep-07,Sep-10,Sep-10,16-Aug-07,null,16-Nov-10,"University of British Columbia Hospital, Vancouver, British Columbia, Canada",,https://ClinicalTrials.gov/show/NCT00517387
NCT00515879,Effect of D-cycloserine Plus Cognitive Behavioral Therapy on People With Social Phobia,,Completed,Has Results,Social Anxiety Disorder,Drug: D-cycloserine|Behavioral: Cognitive behavioral therapy (CBT)|Drug: Placebo,Social Phobic Disorders Severity and Change Form|Liebowitz Social Anxiety Scale (LSAS)|Social Phobia and Anxiety Inventory|Quality of Life Enjoyment and Satisfaction Questionnaire|Liebowitz Self-Rated Disability Scale|Range of Impaired Functioning Tool,Boston University Charles River Campus|National Institute of Mental Health (NIMH),All,"18 Years and older   (Adult, Older Adult)",Phase 3,169,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",R01MH078308|R01MH075889,Dec-07,Dec-11,Dec-11,14-Aug-07,23-Jul-15,26-Feb-19,"Boston University, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT00515879
NCT00515242,Therapeutic Massage for Generalized Anxiety Disorder,CALM,Completed,No Results Available,Generalized Anxiety Disorder,Behavioral: massage|Behavioral: thermotherapy|Behavioral: relaxing environment,"anxiety|worry, depression, disability",Kaiser Permanente|National Center for Complementary and Integrative Health (NCCIH),All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1|Phase 2,68,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,R21AT002560,Sep-07,Oct-08,Aug-09,13-Aug-07,null,13-Oct-17,"Group Health Research Institute, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00515242
NCT00515255,Study of NPL-2003 in Adolescents With Obsessive Compulsive Disorder (OCD),,Terminated,No Results Available,Obsessive Compulsive Disorder,Drug: Minocycline,The change in OCD symptoms using CY-BOCS|The Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS)|NIMH Global OC Scale|Clinical Global Impressions of Improvement (CGI-I)|The Children's Depression Rating Scale (CDRS-R)|Columbia Suicide-Severity Rating Scale (SSRS)|Multidimensional Anxiety Scale for Children (MASC)|Global Assessment Scale for Children (CGAS),Neuropharm,All,12 Years to 17 Years   (Child),Phase 2,6,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NPL-2003-1-POCD-001,Jul-07,Apr-08,Apr-08,13-Aug-07,null,27-Apr-12,"New York State Psychiatric Institute, Columbia University, New York, New York, United States|University Hospitals Case Medical Center, Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT00515255
NCT00513565,A Study To Investigate Effects Of GSK561679 On Brain Activation During Emotional Processing In Healthy Volunteers,,Completed,No Results Available,Depressive Disorder and Anxiety Disorders,Drug: single dose,Differences in fMRI brain activation (BOLD) response in specific brain regions|Physiologic changes|Visual Analogue Scale measurement of physical reactions|Blood level of GSK561679|Vital signs & ECG recording|Lab tests for blood & urine,GlaxoSmithKline,Female,18 Years to 50 Years   (Adult),Phase 1,22,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Diagnostic",CRS105510,13-Sep-07,14-May-09,14-May-09,8-Aug-07,null,21-Jul-17,"GSK Investigational Site, La Jolla, California, United States",,https://ClinicalTrials.gov/show/NCT00513565
NCT00509951,Parent-Augmented Cognitive Behavioral Therapy to Treat Children With Specific Phobias,,Completed,No Results Available,Anxiety Disorders|Specific Phobia,Behavioral: One-session exposure treatment|Behavioral: Augmented one-session exposure treatment,Anxiety Disorders Interview Schedule for DSM-IV: Presence of Specific Phobia|Clinical Global Impression: Severity of Specific Phobia,Virginia Polytechnic Institute and State University|National Institute of Mental Health (NIMH),All,7 Years to 14 Years   (Child),Not Applicable,154,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,R01MH074777|DSIR 84-CTS,Jul-07,May-12,May-12,1-Aug-07,null,7-Jun-13,"Child Study Center, Blacksburg, Virginia, United States",,https://ClinicalTrials.gov/show/NCT00509951
NCT00508911,A Study To Evaluate The Effect Of GW876008 On The Pharmacokinetics Of Oral Contraceptive Pills,,Terminated,No Results Available,Social Phobia,Drug: GW876008|Drug: COC,"Blood level of oral contraceptive pills|1)PK parameters of oral contraceptives|2)PK parameters of GW876008|3)Blood level of sex hormones 4) Frequency of breakthrough bleeding 5) adverse event,12-lead ECG and vital signs and laboratory tests|Ethinylestradiol and levonorgestrel blood levels to determine pharmacokinetic parameter|Serum concentrations of LH, FSH.|Serum concentration of progesterone and estradiol",GlaxoSmithKline,Female,18 Years to 45 Years   (Adult),Phase 1,4,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,CRH103002,8-Jun-07,22-Oct-07,22-Oct-07,30-Jul-07,null,4-Aug-17,"GSK Investigational Site, Harrow, Middlesex, United Kingdom",,https://ClinicalTrials.gov/show/NCT00508911
NCT00491348,Effects of Duloxetine on Pathological Worry in Patients With Generalized Anxiety Disorder: A fMRI Study,,Terminated,No Results Available,Worry|Anxiety,Drug: duloxetine hydrochloride,difference of brain activation on worry,National Taiwan University Hospital,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,23,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,950508,Apr-07,Nov-08,Nov-08,26-Jun-07,null,23-Dec-08,"National Taiwan University Hospital, Taipei, Taiwan",,https://ClinicalTrials.gov/show/NCT00491348
NCT00485615,An Open Label Trial of Omega 3(o3mega+Joy)in the Treatment of Social Phobia,OMEGA3SP,Completed,No Results Available,Social Anxiety Disorder,Drug: Omega 3 Joy enteric coated concentrated fish oil,"Changes in intensity of the vasodilatory response to 10 mM topical m-N over 16 weeks.|SPIN, SIAS,SPS, ASI, BDI, BAI, SDS, Euroquol, SF 36, BI/BAS, BTSQ, BPS, Niacin Flushing Challenge",START Clinic for Mood and Anxiety Disorders|Genuine Health,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,8,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GHOMEGA3SP,Oct-08,Aug-13,Aug-13,13-Jun-07,null,30-Oct-13,"START Clinic for Mood and Anxiety Disorders 900-790 Bay St., Toronto,, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT00485615
NCT00485888,Flushing in Social Anxiety Disorder on Cipralex,,Completed,No Results Available,Social Anxiety Disorder,Drug: Cipralex|Drug: Placebo,"Changes in intensity of the vasodilatory response to 10 mM topical m-N over 16 weeks.|Mean change from baseline on the LSAS, HAM-A, SPIN,BAI, SPS, SIAS, BTS-Q, BPS,Sheehan Disability Scale, Euroquol SF-36, PSWQ",START Clinic for Mood and Anxiety Disorders|H. Lundbeck A/S,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,71,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",LuCipMNSP,Oct-08,Aug-13,Aug-13,13-Jun-07,null,30-Oct-13,"START Clinic for the Mood and Anxiety Disorders, Toronto,, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT00485888
NCT00482820,A Clinical Research Studying a Method of Intervention for Children Diagnosed With Anxiety Disorder: Attentional Bias Intervention,,Completed,No Results Available,Anxiety,Behavioral: attention-bias training,anxiety questionnaire - that are specified in the protocol. mood scale- as described in the protocol attention bias scores- as described in the protocol,Rabin Medical Center,All,7 Years to 12 Years   (Child),Not Applicable,80,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Basic Science",4373,Jul-07,Sep-12,Sep-12,5-Jun-07,null,7-Feb-13,,,https://ClinicalTrials.gov/show/NCT00482820
NCT00481325,Study of Pexacerfont (BMS-562086) in the Treatment of Outpatients With Generalized Anxiety Disorder,,Completed,No Results Available,Generalized Anxiety Disorder,Drug: pexacerfont|Drug: escitalopram|Drug: placebo,Mean change from baseline to Week 8 on the Site-Rated Hamilton Anxiety Rating Scale (total score)|Mean change from baseline to Week 8 on the Sheehan Disability Scale (SDS) Total Score|Mean change from baseline to Week 8 on the Gastrointestinal Symptom Index Total Score,Bristol-Myers Squibb,Female,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2|Phase 3,260,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",CN148-015,Jul-07,Mar-08,Mar-08,1-Jun-07,null,12-Oct-15,"Pivotal Research Centers, Mesa, Arizona, United States|Pacific Clinical Research Medical Group, Burbank, California, United States|Us Clinical Research Centers, Llc, Costa Mesa, California, United States|Pacific Institute For Medical Research, Inc., Los Angeles, California, United States|Affiliated Research Institute, San Diego, California, United States|Pacific Clinical Research Medical Group, Upland, California, United States|Radiant Research, Inc., Denver, Colorado, United States|University Of Connecticut Health Center, Farmington, Connecticut, United States|Comprehensive Psychiatric Care, Pc, Norwich, Connecticut, United States|Meridien Research, Brooksville, Florida, United States|Clinical Neuroscience Solutions, Jacksonville, Florida, United States|Comprehensive Neuroscience, Inc., St Petersburg, Florida, United States|Stedman Clinical Trials, Tampa, Florida, United States|Janus Center For Psychiatric Research, West Palm Beach, Florida, United States|Carman Research, Smyrna, Georgia, United States|Indiana University School Of Medicine, Indianapolis, Indiana, United States|Alpine Clinic, Lafayette, Indiana, United States|Cientifica, Inc. At Prairie View Inc., Newton, Kansas, United States|Ctt, Inc., Prairie Village, Kansas, United States|J. Gary Booker, Md, Apmc, Shreveport, Louisiana, United States|Pharmasite Research, Inc., Baltimore, Maryland, United States|Capital Clinical Research Associates, Rockville, Maryland, United States|Boston Clinical Trials, Inc., Boston, Massachusetts, United States|Regions Hospital, St. Paul, Minnesota, United States|Neurobehavioral Research, Inc., Cedarhurst, New York, United States|Bioscience Research, Llc, New York, New York, United States|Fieve Clinical Services, Inc., New York, New York, United States|Social Psychiatry Research Institute, New York, New York, United States|Behavioral Medical Research Of Staten Island, Staten Island, New York, United States|Richmond Behavioral Associates, Staten Island, New York, United States|North Carolina Neuropsychiatry, Pa, Charlotte, North Carolina, United States|Medark Clinical Research, Morganton, North Carolina, United States|Psychiatry And Clinical Research, Raleigh, North Carolina, United States|Community Research, Cincinnati, Ohio, United States|Midwest Clinical Research Center, Dayton, Ohio, United States|Ips Research Company, Oklahoma City, Oklahoma, United States|University Of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Oregon Center For Clinical Investigations, Inc. (Occi, Inc), Salem, Oregon, United States|Lehigh Valley Hospital, Allentown, Pennsylvania, United States|Rhode Island Mood & Memory Research Institute, East Providence, Rhode Island, United States|Medical University Of South Carolina, Charleston, South Carolina, United States|Carolina Clinical Research Services, Llc, Columbia, South Carolina, United States|Avera Research Institute, Sioux Falls, South Dakota, United States|Clinical Neuroscience Solutions, Inc., Memphis, Tennessee, United States|Futuresearch Trials, Austin, Texas, United States|Futuresearch Trials Of Dallas, Dallas, Texas, United States|Claghorn-Lesem Research Clinic, Houston, Texas, United States|Medlabs Research Of Houston, Inc., Houston, Texas, United States|Red Oak Psychiatry Associates, Pa, Houston, Texas, United States|Dominion Clinical Research, Midlothian, Virginia, United States|Dean Foundation For Health Research & Education, Middleton, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT00481325
NCT00477451,Staccato Alprazolam in Panic Attack,,Completed,Has Results,Treatment of Induced Panic Attack,Drug: Inhaled placebo|Drug: Inhaled alprazolam 1 mg|Drug: Inhaled alprazolam 2 mg|Drug: IV doxapram,Number of Participants With Doxapram-induced Panic Attack|Duration of the Doxapram-induced Panic Attack|Borg Max Change From Baseline,"Alexza Pharmaceuticals, Inc.",All,18 Years to 55 Years   (Adult),Phase 2,49,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AMDC-002-201,May-07,Apr-08,Apr-08,23-May-07,16-Jun-17,16-Jun-17,"SUNY Downstate Medical Center, Brooklyn, New York, United States|New York State Psychiatric Institute, New York, New York, United States|Mt. Sinai School Of Medicine, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00477451
NCT00475969,Duloxetine vs Placebo in the Treatment of General Anxiety,,Completed,No Results Available,Anxiety,Drug: duloxetine|Drug: placebo,Hamilton Anxiety Rating Scale (HAMA) total score (Hamilton 1959)|Sheehan Disability Scale (SDS) Global Functional Impairment score (Sheehan 1983)|Hospital Anxiety Depression Scale (HADS; Zigmond and Snaith 1983)|Clinical Global Impressions of Improvement scale (CGI-Improvement; Guy 1976)|Patient's Global Impressions of Improvement scale (PGI-Improvement; Guy 1976)|Symptom Questionnaire-Somatic Subscale (SQ-SS),Eli Lilly and Company|Boehringer Ingelheim,All,"18 Years and older   (Adult, Older Adult)",Phase 3,327,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,6089|F1J-MC-HMDT,Aug-04,null,Jun-05,21-May-07,null,21-May-07,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Indianapolis, Indiana, United States",,https://ClinicalTrials.gov/show/NCT00475969
NCT00471588,Characterize The Modulatory Effects Of Dopamine D2/D3 Receptor Agonist And Antagonist Drugs On Compulsive Behaviors,,Completed,No Results Available,Obsessive-Compulsive Disorder,"Drug: Pramipexole, Amisulpride","Investigate that drug addicts or OCD patients will show similar abnormalities of compulsive behaviour and functional activation of ventral fronto-striatal systems. MRI scans will occur on Wk 1, 2 and 3. Neuropsychological testing Wk 1, 2 and 3.|Test the prediction that a dopamine D2/D3 agonist drug (pramipexole)by PK levels. PK sample taken on Week 1 only.|Measure of brain functional activation at rest.|Measure of behavioural performance|Measure of peripheral blood for gene expression and proteomic changes.|Genetic variation in selected genes|Clinical measures (SSRS, SSR, BL-VAS, BDI-II)",GlaxoSmithKline,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,52,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",TMT106512,Aug-06,Dec-07,Dec-07,10-May-07,null,15-Sep-14,"GSK Investigational Site, Cambridge, Cambridgeshire, United Kingdom",,https://ClinicalTrials.gov/show/NCT00471588
NCT00470483,A Study To Compare Emotional Changes In Subjects With Social Anxiety Disorder,,Completed,No Results Available,Social Phobia,Drug: Placebo treatment during 8 weeks|Drug: Paroxetine treatment during 8 weeks,fMRI BOLD response in the amygdala and insula elicited by the Matching Emotional Face paradigm at baseline and after 8 weeks of treatment. State-anxiety inventory (STAI-S) after the Public Speaking challenge (only patients).|fMRI BOLD response in selected neuroanatomical ROI elicited by the by Resting State and by other exploratory paradigms at baseline (all subjects) and after 8 weeks of treatment with paroxetine compared to placebo (only patients).,GlaxoSmithKline,All,18 Years to 60 Years   (Adult),Phase 1,56,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",TMT106386,22-Jan-07,7-Jan-09,7-Jan-09,7-May-07,null,18-Jul-17,"GSK Investigational Site, Barcelona, Spain",,https://ClinicalTrials.gov/show/NCT00470483
NCT00466609,Using Drug Augmentation to Treat Obsessive Compulsive Disorder Patients Who Did Not Respond to Previous Treatment,EPMTOC,Completed,No Results Available,Obsessive Compulsive Disorder,Drug: Clomipramine (fluoxetine plus clomipramine)|Drug: Quetiapine (fluoxetine plus quetiapine)|Drug: Placebo (fluoxetine plus placebo),YBOCS|QoL|Social Adaptation|Tolerability|BDI|BAI|CGI|Cardiotoxicity|Plasma levels,University of Sao Paulo|Fundação de Amparo à Pesquisa do Estado de São Paulo|Conselho Nacional de Desenvolvimento Científico e Tecnológico|Novartis,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,54,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",05/55628-8|2005/55628-08,May-07,Mar-10,Apr-10,27-Apr-07,null,30-Oct-17,"Institute of Psychiatry, Sao Paulo, SP, Brazil",,https://ClinicalTrials.gov/show/NCT00466609
NCT00465595,Psychopharmacology of Psilocybin in Cancer Patients,,Completed,Has Results,Depressive Symptoms|Anxiety|Cancer,Drug: psilocybin,GRID-HAM-D-17 -- Structured Interview Guide for the Hamilton Depression Scale.|HAM-A Assessed With the SIGH-A -- a Structured Interview Guide for the Hamilton Anxiety Rating Scale (SIGH-A).,Johns Hopkins University|Heffter Research Institute,All,"21 Years to 80 Years   (Adult, Older Adult)",Phase 2,56,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care",NA_00001390|Johns Hopkins IRB5 NA_00001390,Apr-07,Dec-14,Dec-16,25-Apr-07,19-Jul-18,19-Jul-18,"Behavioral Pharmacology Research Unit, Johns Hopkins Bayview Campus, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00465595
NCT00464698,Duloxetine for the Treatment of Obsessive Compulsive Disorder (OCD),FIJ-MC-1003,Completed,Has Results,Obsessive Compulsive Disorder,Drug: Duloxetine,"Y-BOCS Scores at 1st and Last Visit|BDI (Beck Depression Inventory) - First and Last Visit (Week 0 and Week 17).|BAI (Beck Anxiety Inventory) - First and Last Visit (Week 0 and Week 17)|QLESQ (Quality of Life, Enjoyment, and Satisfaction Questionnaire) - First and Last Visit (Week 0 and Week 17)|Clinical Global Impressions Scale at Week 3 and Week 17",Massachusetts General Hospital|Eli Lilly and Company,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,20,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2005-P-002159|FIJ-MC-1003,Dec-05,Dec-13,Dec-13,24-Apr-07,7-Mar-17,19-Mar-19,"Massachusetts General Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT00464698
NCT00458094,Peer Support for Increasing Physical Activity in People With Serious Mental Illnesses,,Completed,No Results Available,Schizophrenia|Depression|Bipolar Disorder|Anxiety Disorders|Cognitive Disorders|Personality Disorders,Behavioral: Physical activity intervention with peer support (PA+PS)|Behavioral: Physical activity intervention without peer support (PA),Cardiorespiratory fitness|Weight|Waist circumference|Physical activity|Health status|Center for Epidemiology Depression Scale|Exercise-related self-efficacy|General perceived efficacy|Participation,Johns Hopkins University|National Institute of Mental Health (NIMH),All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,100,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,R34MH078613|DAHBR 96-BHB,Mar-07,Dec-09,Dec-09,9-Apr-07,null,6-Dec-17,"Johns Hopkins University, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00458094
NCT00456937,Escitalopram in Schizophrenia in OCD- Open Label Study,,Completed,No Results Available,Schizophrenia,Drug: Escitalopram,,BeerYaakov Mental Health Center|Lundbeck Israel,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,15,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label),Escitalopram-173CTIL,Jul-06,Sep-08,Sep-08,5-Apr-07,null,27-Jan-09,"Beer Yaakov MHC, Beer Yaakov, Israel",,https://ClinicalTrials.gov/show/NCT00456937
NCT00457106,A Single-Blind Trial of Risperidone vs. Paroxetine for Treatment of Panic Attacks,,Completed,No Results Available,Major Depression With Panic Attacks|Panic Disorder,Drug: Paroxetine|Drug: Risperidone,Hamilton Anxiety Rating Scale|Hamilton Depression Rating Scale|Panic Disorder Severity Scale|Sheehan Panic and Anxiety Scale - Patient rated|Clinical Global Impressions Scale,Beth Israel Medical Center,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,90,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Treatment,IRB#: 082-02,Jun-02,Jun-03,Jun-03,5-Apr-07,null,1-Dec-10,"Beth Israel Medical Center, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00457106
NCT00452738,The Effect of Pre Surgery Dog Visits on Post Surgery Consumption of Pain Medication,Dog,Withdrawn,No Results Available,Post Tonsillectomy Pain,Behavioral: Therapy dog|Behavioral: Costumed character|Behavioral: Parents-only,"Bieri Faces Scale upon arrival, after intervention, and at discharge|Modified Yale Preoperative Anxiety Scale upon arrival, after intervention, and in surgical preparation room",Oklahoma State University Center for Health Sciences,All,4 Years to 7 Years   (Child),Not Applicable,0,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single|Primary Purpose: Treatment,2006036,Apr-07,null,Feb-08,27-Mar-07,null,21-Apr-15,"Oklahoma State University Surgi-Center, Tulsa, Oklahoma, United States",,https://ClinicalTrials.gov/show/NCT00452738
NCT00451516,St. John's Wort And Kava In The Treatment Of Major Depressive Disorder With Comorbid Anxiety,,Completed,No Results Available,"Depressive Disorder, Major|Anxiety Disorders",Drug: Herbal medicine (St. John's wort and Kava),BDI II|BAI|DASS|WHOQOL|Daily Mood Monitoring Form,The University of Queensland,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,50,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment,2006000925,Mar-07,Oct-07,Oct-07,23-Mar-07,null,19-May-08,"RBWH, Brisbane, Queensland, Australia",,https://ClinicalTrials.gov/show/NCT00451516
NCT00451750,Cortisol in the Treatment of Phobias,,Completed,No Results Available,Phobia,Drug: Cortisol,visual analog scales for fear and acrophobia questionnaires,"University of Zurich|University Hospital, Basel, Switzerland",All,18 Years to 55 Years   (Adult),Not Applicable,40,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2007DR3069,May-07,Sep-09,Sep-09,23-Mar-07,null,12-Jan-10,"University of Basel, Basel, Switzerland",,https://ClinicalTrials.gov/show/NCT00451750
NCT00449241,Acupuncture Treatment in Adults Undergoing Diagnostic OGD : A Double-Blind Placebo Controlled Randomized Trial,,Unknown status,No Results Available,Anxiety,Device: Acupuncture,"Anxiety elicited during EGD|Overall tolerance, overall satisfaction, patient’s willingness to repeat procedure and recovery time",Chinese University of Hong Kong,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,210,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,CRE-2006.227-T,Nov-06,null,Jul-07,20-Mar-07,null,20-Mar-07,"Combined Endoscopy Centre, Alices Ho Miu Ling Netherole Hospital, Hong Kong, China",,https://ClinicalTrials.gov/show/NCT00449241
NCT00447733,Integrated Treatment to Persons With Mental Disorders and Co-occurring Substance Use Disorders,ROP,Completed,No Results Available,Anxiety Disorders|Mood Disorders|Substance Use Disorders,Behavioral: Integrated mental health and substance use treatment|Behavioral: Treatment as usual,"The Symptom Check List 90 (SCL90-r), The Alcohol Use Disorder Identification Test (AUDIT), The Drug Use Disorder Identification Test (DUDIT).|The Addiction Severity Index (Europ ASI)",University of Oslo|SINTEF Health Research,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,76,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,78i068|NFR175394/V50,Mar-07,Dec-10,Dec-10,15-Mar-07,null,26-Mar-12,,,https://ClinicalTrials.gov/show/NCT00447733
NCT00446719,Safety and Antidepressant Effects of Rellidep in Major Depressive Disorder,,Completed,No Results Available,Depression,Drug: Rellidep,50% improvement on Hamilton Depression Rating Scale-17 at 8 weeks|Clinical Global Impression-Severity and Improvement|Montgomery Asberg Depression Rating Scale (MADRS) at 8 weeks|Medical Outcomes Study Short-Form 36 (SF-36)at 8 weeks|Beck Depression Inventory Scale (BDI) a t 8 weeks|Hamilton rating scale for Anxiety (HAM-A)at 8 weeks|UKU,"Mount Sinai Hospital, Canada",All,18 Years to 64 Years   (Adult),Phase 2|Phase 3,23,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MSH 06-0307-A,Aug-07,Dec-08,Dec-08,13-Mar-07,null,5-Jan-11,"Mount Sinai Hospital, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT00446719
NCT00446407,Evaluating the Benefits and Affordability of a Program to Improve the Care of Common Mental Disorders in Primary Care,MANAS,Completed,No Results Available,Depressive Disorders|Anxiety Disorders|Depression,Other: Collaborative Stepped Care Intervention|Other: Enhanced Usual Care,"Recovery from Common Mental Disorder (defined by ICD10)|Case of CMD among all screen-positive participants at 2, 6 and 12 months|Case of CMD among all sub-threshold cases|Recovery from CMD (defined by ICD10) among the subgroup with ICD-10 Depression at baseline|Psychological morbidity (mean scores)|Disability levels|Costs of illness","London School of Hygiene and Tropical Medicine|Wellcome Trust|Sangath|Voluntary Health Association of Goa, India|Government of Goa, India",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,2796,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,MANAS,Apr-07,Feb-10,Feb-10,12-Mar-07,null,1-Apr-15,"Sangath, Porvorim, Goa, India",,https://ClinicalTrials.gov/show/NCT00446407
NCT00442923,"""The Evaluation of Stimulant Withdrawal""",MARC,Withdrawn,No Results Available,Anxiety|Relapse|Substance Addiction,Drug: Coreg,,Aaron J. Janowsky|National Institute on Drug Abuse (NIDA)|Oregon Health and Science University,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,0,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Basic Science,1P50DA018165,1-Jul-07,30-Jun-10,30-Jun-11,5-Mar-07,null,31-Jan-19,"US Veterans Hospital, Portland, Oregon, United States",,https://ClinicalTrials.gov/show/NCT00442923
NCT00441636,"Treatment Resistant Depression and Obstructive Sleep Apnea, Effect of Continuous Positive Airway Pressure (CPAP)",,Recruiting,No Results Available,"Depression|Sleep Apnea, Obstructive",Device: continuous positive airway pressure (CPAP),Montgomery Asberg Depression Rating Scale (MADRS)|Symbol digit modalities|Stroop Test|Trail-Making test|Pittsburgh Sleep Quality Index (PSQI)|Epworth Sleepiness Score (ESS)|Beck Anxiety Inventory (BAI)|SF-36 questionnaire|Profile of mood state (POMS)|HAM-D21,Queen's University,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,120,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,PSIY-247-06,Mar-07,Dec-19,Dec-19,1-Mar-07,null,30-Apr-18,"Providence Continuing Care Centre, Mental Health Services, Kingston, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT00441636
NCT00440700,Anxiety Self-Management for ICU Patients Receiving Mechanical Ventilation,,Completed,Has Results,Anxiety,"Behavioral: Anxiety Self-Management, Patient preferred relaxing music|Behavioral: Control 1: Noise-cancelling headphones|Behavioral: Control 2: Standard of Care",Sedative Exposure|State Anxiety|Length of ICU Stay|Length of Mechanical Ventilatory Support|Urinary Cortisol,University of Minnesota - Clinical and Translational Science Institute,All,"18 Years and older   (Adult, Older Adult)",Phase 2,364,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0601M79066,Jul-06,Jun-11,Jun-11,27-Feb-07,26-Apr-13,26-Apr-13,"University of Minnesota Medical Center, Minneapolis, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT00440700
NCT00440713,Aripiprazole in the Treatment of Post-Traumatic Stress Disorder Symptoms,AripipPTSD,Completed,No Results Available,Posttraumatic Stress Disorder,Drug: Aripiprazole|Behavioral: Interpersonal Therapy,"CAPS (Clinician Administered Posttraumatic Scale) score (PTSD symptoms)|Beck Depression Inventory|Beck Anxiety Inventory|Social Adjustment Scale|Global Assessment Functioning|MOS SF-36, quality of life|Dropout|complete the trial",Federal University of São Paulo,All,18 Years to 60 Years   (Adult),Phase 3,40,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single|Primary Purpose: Treatment,1,Jan-04,null,Mar-06,27-Feb-07,null,27-Feb-07,,,https://ClinicalTrials.gov/show/NCT00440713
NCT00438386,Aripiprazole for the Treatment of Refractory Anxiety,,Completed,No Results Available,Generalized Anxiety Disorder|Panic Disorder,Drug: Aripiprazole,Hamilton Anxiety Rating Scale|Clinician Global Impression-Severity|Connor Davidson Resilience Scale|Panic Disorder Severity Scale,Massachusetts General Hospital|Bristol-Myers Squibb,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 4,null,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2004-P-000935,Apr-05,null,Jun-07,22-Feb-07,null,10-Aug-09,"Center for Anxiety and Traumatic Stress Disorders at Massachusetts General Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT00438386
NCT00438685,Outpatient Adolescent Treatment for Comorbid Substance Use and Internalizing Disorders,,Completed,No Results Available,Substance-Related Disorders|Depressive Disorder|Anxiety Disorder,Behavioral: Outpatient MST/OPTION-A|Behavioral: Usual Services,"Urine Drug Screen at 4 weeks, 8 weeks, 12 weeks, 24 weeks|Score on Depression/Anxiety Scale (RCADS) at 4 weeks, 8 weeks, 12 weeks, 24 weeks|Measured at Intake, 3 Months, and 6 Months|Global assessment of symptoms|Parenting|School|Behavioral|Family relationship/communication/problem solving|Consumer satisfaction|Daily Drug/Alcohol use",Medical University of South Carolina|National Institute on Drug Abuse (NIDA),All,12 Years to 17 Years   (Child),Phase 1,40,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,1R21DA017118-01|R21DA017118,Oct-04,Aug-07,Sep-10,22-Feb-07,null,14-Jun-18,"Medical University of South Carolina, Department of Psychiatry & Behavioral Sciences, Family Services Research Center, Charleston, South Carolina, United States",,https://ClinicalTrials.gov/show/NCT00438685
NCT00438971,The Efficacy and Tolerability of Duloxetine for the Treatment of Panic Disorder,,Completed,Has Results,Panic Disorder,Drug: Duloxetine,Panic Disorder Severity Scale (PDSS)|Clinical Global Impression of Severity Scale (CGI-S)|Panic Attack Scale (PAS),Massachusetts General Hospital|Eli Lilly and Company,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 4,15,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2006-P-000263,Aug-06,Jan-09,Jan-09,22-Feb-07,19-Dec-13,27-Apr-16,"The Center for Anxiety and Traumatic Stress Disorders at Massachusetts General Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT00438971
NCT00435695,"Study Of Safety, Blood Levels, And Brain Receptor Occupancy Of GSK163090 Using PET Imaging In Healthy Males",,Completed,No Results Available,Healthy Subjects|Depressive Disorder and Anxiety Disorders,Drug: GSK163090,Brain receptor occupancy of GSK163090 Plasma concentrations of GSK163090|Vitals signs ECGs Clinical Laboratory test results,GlaxoSmithKline,Male,18 Years to 45 Years   (Adult),Phase 1,13,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HTP103265,Nov-06,Dec-07,Dec-07,15-Feb-07,null,4-Jun-12,"GSK Investigational Site, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT00435695
NCT00434759,Social Phobia Intervention Study of Mannheim,,Completed,Has Results,Social Phobia,Behavioral: cognitive therapy|Behavioral: stepped care program based on cognitive therapy,Change From Baseline in Social Interaction Anxiety Scale (SIAS)|Change From Baseline in Social Phobia Scale (SPS)|Change From Baseline in Liebowitz Social Anxiety Scale (LSAS)|Change From Baseline in Brief Symptom Inventory (BSI)|Change on Baseline in Center for Epidemiologic Studies Depression Scale (CES-D),"Central Institute of Mental Health, Mannheim|German Research Foundation",All,18 Years to 60 Years   (Adult),Not Applicable,89,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,SP-32000,Sep-06,May-09,Dec-11,13-Feb-07,28-Nov-12,28-Nov-12,"Central Institute of Mental Health, Mannheim, Baden-Württemberg, Germany",,https://ClinicalTrials.gov/show/NCT00434759
NCT00426608,To Investigate Effects GSK561679 on Part of the Body's System That Controls the Balance of Many of the Hormones.,,Completed,No Results Available,Depressive Disorder and Anxiety Disorders,Drug: metyrapone|Drug: alprazolam|Drug: placebo|Drug: GSK561679,"Blood levels of ACTH: over 24 hours|Blood levels of GSK561679, metyrapone, alprazolam, cortisol: over 24 hours Questionnaires: each visit Safety (ECG/vital signs/Adverse Events/ laboratory): over 24 hours",GlaxoSmithKline,Male,18 Years to 45 Years   (Adult),Phase 1,20,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Primary Purpose: Diagnostic,CRS105511,6-Oct-06,8-Jan-07,8-Jan-07,25-Jan-07,null,11-Sep-17,"GSK Investigational Site, Cambridge, Cambridgeshire, United Kingdom",,https://ClinicalTrials.gov/show/NCT00426608
NCT00426426,Comparing Cognitive Behaviour Therapy (CBT) With Metacognitive Therapy (MCT) in the Treatment of GAD,,Completed,No Results Available,Generalized Anxiety Disorder,Behavioral: Cognitive-Behavioural Therapy|Behavioral: Meta-Cognitive Therapy|Behavioral: Waiting list,PSWQ by post treatment and by two year follow up.|STAI-T,Norwegian University of Science and Technology|Penn State University|University of Manchester,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,68,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,4.2006.2369|NSD: sak 15436,Jan-07,Dec-14,Dec-15,24-Jan-07,null,11-Oct-18,"Department of Psychology, Norwegian University of Science and Technology, Trondheim, Norway",,https://ClinicalTrials.gov/show/NCT00426426
NCT00417118,An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Generalized Anxiety Disorder,,Completed,No Results Available,Generalized Anxiety,Drug: Saredutant|Drug: Escitalopram|Drug: Placebo,Change from baseline to Day 56 of treatment in the Hamilton Anxiety Rating Scale (HAM-A) total score.|Change from baseline in the Clinical Global Impression Severity of Illness score.,Sanofi,All,"18 Years and older   (Adult, Older Adult)",Phase 3,365,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",EFC5583,Dec-06,Apr-08,Apr-08,29-Dec-06,null,24-May-16,"Sanofi-Aventis Administrative Office, Brussels, Belgium|Sanofi-Aventis Administrative Office, Laval, Canada|Sanofi-Aventis Administrative Office, Helsinki, Finland|Sanofi-Aventis Administrative Office, Paris, France|Sanofi-Aventis Administrative Office, Milano, Italy|Sanofi-Aventis Administrative Office, Stockholm, Sweden|Sanofi-Aventis Administrative Office, Istanbul, Turkey",,https://ClinicalTrials.gov/show/NCT00417118
NCT00413010,Pregabalin in the Treatment of Patients With Generalized Anxiety Disorder (GAD).,,Completed,Has Results,Generalized Anxiety Disorder,Drug: pregabalin|Drug: placebo,Change in Hamilton Anxiety Rating Scale (HAM-A) Total Scores|Change in HAM-A Total Score at Weekly Visits|Number of Responders Using Hamilton Anxiety Rating Scale (HAM-A)|Subjects in Remission Using Hamilton Anxiety Rating Scale (HAM-A) Total Score|Time to Onset of Sustained Hamilton Anxiety Rating Scale (HAM-A) Improvement|Number of Responders Using Clinical Global Impression of Improvement (CGI-I) Score|Clinical Global Impression of Severity (CGI-S) Score|Change in Hamilton Depression Rating Scale (HAM-D) Total Score,Pfizer,All,"18 Years and older   (Adult, Older Adult)",Phase 3,356,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",A0081103,Dec-06,Feb-08,Mar-08,19-Dec-06,2-Dec-09,9-Dec-09,"Pfizer Investigational Site, Arcadia, California, United States|Pfizer Investigational Site, Burbank, California, United States|Pfizer Investigational Site, Redlands, California, United States|Pfizer Investigational Site, Sherman Oaks, California, United States|Pfizer Investigational Site, Norwich, Connecticut, United States|Pfizer Investigational Site, Destin, Florida, United States|Pfizer Investigational Site, Fort Walton Beach, Florida, United States|Pfizer Investigational Site, Miami, Florida, United States|Pfizer Investigational Site, South Miami, Florida, United States|Pfizer Investigational Site, Overland Park, Kansas, United States|Pfizer Investigational Site, Wichita, Kansas, United States|Pfizer Investigational Site, Shreveport, Louisiana, United States|Pfizer Investigational Site, Shreveport, Louisiana, United States|Pfizer Investigational Site, Baltimore, Maryland, United States|Pfizer Investigational Site, Boston, Massachusetts, United States|Pfizer Investigational Site, Olive Branch, Mississippi, United States|Pfizer Investigational Site, St. Charles, Missouri, United States|Pfizer Investigational Site, Omaha, Nebraska, United States|Pfizer Investigational Site, Clementon, New Jersey, United States|Pfizer Investigational Site, Albuquerque, New Mexico, United States|Pfizer Investigational Site, New York, New York, United States|Pfizer Investigational Site, Beachwood, Ohio, United States|Pfizer Investigational Site, Cincinnati, Ohio, United States|Pfizer Investigational Site, Cleveland, Ohio, United States|Pfizer Investigational Site, Bala Cynwyd, Pennsylvania, United States|Pfizer Investigational Site, Media, Pennsylvania, United States|Pfizer Investigational Site, Philadelphia, Pennsylvania, United States|Pfizer Investigational Site, Philadelphia, Pennsylvania, United States|Pfizer Investigational Site, Columbia, South Carolina, United States|Pfizer Investigational Site, Memphis, Tennessee, United States|Pfizer Investigational Site, Memphis, Tennessee, United States|Pfizer Investigational Site, Houston, Texas, United States|Pfizer Investigational Site, Houston, Texas, United States|Pfizer Investigational Site, Lake Jackson, Texas, United States|Pfizer Investigational Site, Waukesha, Wisconsin, United States|Pfizer Investigational Site, Brno, Czech Republic|Pfizer Investigational Site, Litomerice, Czech Republic|Pfizer Investigational Site, Praha 2, Czech Republic|Pfizer Investigational Site, Praha 5, Czech Republic|Pfizer Investigational Site, Praha 6, Czech Republic|Pfizer Investigational Site, Praha 8 - Bohnice, Czech Republic|Pfizer Investigational Site, Viljandi, Viljandi mk., Estonia|Pfizer Investigational Site, Tallinn, Estonia|Pfizer Investigational Site, Tartu, Estonia|Pfizer Investigational Site, Helsinki, Finland|Pfizer Investigational Site, Joensuu, Finland|Pfizer Investigational Site, Kuopio, Finland|Pfizer Investigational Site, Budapest, Hungary|Pfizer Investigational Site, Budapest, Hungary|Pfizer Investigational Site, Pecs, Hungary|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Smolensk, Russian Federation|Pfizer Investigational Site, Smolensk, Russian Federation|Pfizer Investigational Site, St Petersburg, Russian Federation|Pfizer Investigational Site, St. Petersburg, Russian Federation|Pfizer Investigational Site, St. Petersburg, Russian Federation|Pfizer Investigational Site, Belgrade, Serbia|Pfizer Investigational Site, Belgrade, Serbia|Pfizer Investigational Site, Belgrade, Serbia|Pfizer Investigational Site, Kragujevac, Serbia|Pfizer Investigational Site, Dnipropetrovsk, Ukraine|Pfizer Investigational Site, Dnipropetrovsk, Ukraine|Pfizer Investigational Site, Donetsk, Ukraine|Pfizer Investigational Site, Kyiv, Ukraine|Pfizer Investigational Site, Lugansk, Ukraine|Pfizer Investigational Site, Lviv, Ukraine",,https://ClinicalTrials.gov/show/NCT00413010
NCT00413296,Levetiracetam in Post-Traumatic Stress Disorder,PTSD,Completed,No Results Available,Post-Traumatic Stress Disorder,Drug: levetiracetam|Drug: Placebo|Drug: Levetriracetam,Clinical Global Impressions - Improvement (CGI-I)|Davidson Trauma Scale (DTS)|Hospital Anxiety and Depression Scale (HADS)|Connor-Davidson Resilience Scale (CD-RISC)|36-item Short Form Health Survey (SF-36)|Pittsburgh Sleep Quality Index|Work Productivity and Activity Improvement Questionnaire (WPAI)|Sheehan Disability Inventory (SDI),Duke University|UCB Pharma,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2|Phase 3,16,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",Pro00007843|7031-05-4R0,Nov-05,Sep-07,Mar-08,19-Dec-06,null,21-Jul-14,"Duke University Medical Center, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT00413296
NCT00411398,A 10 Week Open-Label Pilot Study to Evaluate the Effectiveness and Safety of Memantine(Namenda) as Augmentation Therapy in Patients With Generalized Anxiety Disorder,,Completed,Has Results,"General Anxiety Disorder, Social Anxiety Disorder",Drug: Namenda/Memantine,Hamilton Anxiety Scale,State University of New York - Upstate Medical University,All,18 Years to 64 Years   (Adult),Phase 3,15,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NAM-MD-46|IRB # 5343,Dec-06,May-10,May-10,14-Dec-06,10-Dec-14,10-Dec-14,"SUNY Upstate Medical University Psychiatry Dept., Syracuse, New York, United States",,https://ClinicalTrials.gov/show/NCT00411398
NCT00407199,The Use of Quetiapine (Seroquel) in the Treatment of Social Phobia: Public Speaking Environment,,Completed,No Results Available,Social Phobia,Drug: quetiapine,Personal Report of Confidence as a Speaker (PRCS)|Liebowitz Social Anxiety Scale (LSAS)|Brief Social Phobia Scale|Social Phobia Inventory|Fear of Negative Evaluation Scale|In session-Subjective Units of Distress|Blood Pressure and heart rate monitored within session,University of Minnesota - Clinical and Translational Science Institute|AstraZeneca,All,18 Years to 25 Years   (Adult),Phase 4,20,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment,0608M91257|M91527,Dec-06,Sep-07,Sep-07,4-Dec-06,null,27-Oct-11,"University of Minnesota, Minneapolis, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT00407199
NCT00405535,Adjunctive Glycine for Obsessive Compulsive Disorder,,Completed,No Results Available,Obsessive Compulsive Disorder,Drug: glycine|Other: placebo,Y-BOCS (Yale-Brown Obsessive Compulsive Scale)|NIMC-OC scale|CGI-Improvement|QLS(Quality of Life Scale)|Sheehan Disability Scale,Nathan Kline Institute for Psychiatric Research|Obsessive Compulsive Foundation,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,24,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",04I/C06,Jun-04,null,Dec-06,30-Nov-06,null,16-Dec-16,"The Nathan Kline Institute for Psychiatric Research, Orangeburg, New York, United States",,https://ClinicalTrials.gov/show/NCT00405535
NCT00403962,A Combination Therapy In Patients With Social Anxiety Disorder,,Completed,No Results Available,Social Phobia,Drug: vestipitant/paroxetine,"Change in score on a Social Anxiety Disorder rating scale following 12 weeks of treatment.|Change in score on a number of rating scales following 12 weeks of treatment assessing symptomatic, behavioural and functional parameters which together provide a more complete description of the disorder.",GlaxoSmithKline,All,18 Years to 64 Years   (Adult),Phase 2,204,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,NKP103401,Nov-04,null,Aug-05,27-Nov-06,null,15-Sep-16,"GSK Investigational Site, Hilleroed, Denmark|GSK Investigational Site, Hvidovre, Denmark|GSK Investigational Site, Koebenhavn K, Denmark|GSK Investigational Site, Koebenhavn OE, Denmark|GSK Investigational Site, Risskov, Denmark|GSK Investigational Site, Skanderborg, Denmark|GSK Investigational Site, Soroe, Denmark|GSK Investigational Site, Huettenberg, Hessen, Germany|GSK Investigational Site, Achim, Niedersachsen, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Bergen, Norway|GSK Investigational Site, Hamar, Norway|GSK Investigational Site, Oslo, Norway|GSK Investigational Site, Sandvika, Norway|GSK Investigational Site, Bloemfontein, South Africa|GSK Investigational Site, Tygerberg, South Africa",,https://ClinicalTrials.gov/show/NCT00403962
NCT00401726,"Open-Label, Randomized Study Evaluating Treatment With Venlafaxine Extended-Release Plus Dialogues Time to Talk Program",,Completed,Has Results,"Depressive Disorder, Major",Drug: Venlafaxine ER|Behavioral: Dialogues Time to Talk Program,"Number of Patients Responding ""Very Satisfied"" on Satisfaction With Depression Care Scale (SDCS)|Change in 17-item Hamilton Depression Scale Score From Baseline to 16 Weeks|Patient Global Impression of Improvement (PGI-I) Score|Change in WHO 5-item Well Being Index Score From Baseline to 16 Weeks|Number of Patients Compliant With Therapy|Change in Inventory of Depressive Symptomatology - Self-Report (IDS-SR) Score From Baseline to 16 Weeks|Change in Sheehan Disability Scale Score From Baseline to 16 Weeks|Number of Patients by Clinical Global Improvement - Global Improvement Score at 16 Weeks",Wyeth is now a wholly owned subsidiary of Pfizer,All,"18 Years and older   (Adult, Older Adult)",Phase 4,537,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0600B1-416,Jun-06,null,Oct-07,20-Nov-06,29-Jun-10,23-Apr-12,"Birmingham, Alabama, United States|Birmingham, Alabama, United States|Mesa, Arizona, United States|Little Rock, Arkansas, United States|San Jose, California, United States|Avon, Connecticut, United States|Cromwell, Connecticut, United States|Wilmington, Delaware, United States|Ocala, Florida, United States|Pinellas Park, Florida, United States|Stuart, Florida, United States|Atlanta, Georgia, United States|Cartersville, Georgia, United States|Rome, Georgia, United States|Idaho Falls, Idaho, United States|Newburgh, Indiana, United States|Waterloo, Iowa, United States|Metairie, Louisiana, United States|Benzonia, Michigan, United States|Interlochen, Michigan, United States|Kalamazoo, Michigan, United States|Chesterfield, Missouri, United States|Omaha, Nebraska, United States|Las Vegas, Nevada, United States|Charlotte, North Carolina, United States|Charlotte, North Carolina, United States|Cincinnati, Ohio, United States|Columbus, Ohio, United States|Kettering, Ohio, United States|Mason, Ohio, United States|Mogadore, Ohio, United States|Allentown, Pennsylvania, United States|Newtown, Pennsylvania, United States|Reading, Pennsylvania, United States|Warwick, Rhode Island, United States|Anderson, South Carolina, United States|Greer, South Carolina, United States|Bristol, Tennessee, United States|Dallas, Texas, United States|Fort Worth, Texas, United States|Plano, Texas, United States|San Antonio, Texas, United States|Salt Lake City, Utah, United States|Charleston, West Virginia, United States",,https://ClinicalTrials.gov/show/NCT00401726
NCT00397722,Treatment Of Patients With Social Anxiety Disorder,,Completed,No Results Available,Social Phobia,Drug: GW876008|Drug: paroxetine,Change from randomization in the clinician-administered LSAS total score at the end of the treatment phase (Week 12)|Change from randomization on the LSAS Fear subscale score at Week 12|Change from randomization on the LSAS Avoidance subscale score at Week 12|Change from randomization on the Social Avoidance and Distress Scale (SADS) total score at Week 12|Number of participants with abnormal electrocardiogram (ECG) findings any time post randomization|Change from Randomization in Vital Signs: systolic and diastolic blood pressure (SBP and DBP)|Change from Randomization in vital signs : heart rate|Number of participants with chemistry data outside the normal range (Any time post-Randomization)|Number of participants with hematology data outside the normal range (Any time post-Randomization)|Number of participants with All adverse events (AE) and serious adverse events SAE)|Trough Concentration (Ctrough)|Exposure at steady state (AUC (0-τ)),GlaxoSmithKline,All,18 Years to 64 Years   (Adult),Phase 2,299,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment,CRH103390,9-Nov-06,5-Sep-07,5-Sep-07,9-Nov-06,null,11-Jul-17,"GSK Investigational Site, Beverly Hills, California, United States|GSK Investigational Site, Burbank, California, United States|GSK Investigational Site, Temecula, California, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Orlando, Florida, United States|GSK Investigational Site, Smyrna, Georgia, United States|GSK Investigational Site, Oakbrook Terrace, Illinois, United States|GSK Investigational Site, Rockville, Maryland, United States|GSK Investigational Site, Farmington Hills, Michigan, United States|GSK Investigational Site, Nutley, New Jersey, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, Media, Pennsylvania, United States|GSK Investigational Site, Edmonton, Alberta, Canada|GSK Investigational Site, Kelowna, British Columbia, Canada|GSK Investigational Site, Miramichi, New Brunswick, Canada|GSK Investigational Site, Mississauga, Ontario, Canada|GSK Investigational Site, Kuopio, Finland|GSK Investigational Site, Rauma, Finland|GSK Investigational Site, Turku, Finland|GSK Investigational Site, Huettenberg, Hessen, Germany|GSK Investigational Site, Achim, Niedersachsen, Germany|GSK Investigational Site, Goettingen, Niedersachsen, Germany|GSK Investigational Site, Westerstede, Niedersachsen, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Hamar, Norway|GSK Investigational Site, Oslo, Norway|GSK Investigational Site, Sandvika, Norway|GSK Investigational Site, Tygerberg, Eastern Cape, South Africa|GSK Investigational Site, Durban, South Africa|GSK Investigational Site, Observatory ,Cape Town, South Africa|GSK Investigational Site, Göteborg, Sweden|GSK Investigational Site, Malmö, Sweden|GSK Investigational Site, Uppsala, Sweden",,https://ClinicalTrials.gov/show/NCT00397722
NCT00397098,Prevention of Relapse Study of SR58611A in Improved Patients With Generalized Anxiety Disorder,VEGA,Terminated,No Results Available,Anxiety Disorders,Drug: SR58611A,"The primary criterion is the time to relapse of anxious symptoms (in days) from randomization date defined by either:|HAM-A total score ≥ 15 confirmed at a subsequent visit 2 weeks later unless the patient drops out,or|Any drop-out for lack of efficacy (according to investigator's decision),or|Prescription/use of alternative or additional treatments for relief of psychiatric symptoms.|Change from baseline (V7) in:-Clinical Global Impression (CGI) Severity of Illness Score|Hamilton Anxiety Rating Scale (HAM-A)",Sanofi,All,"18 Years and older   (Adult, Older Adult)",Phase 3,257,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",LTE5894|EudraCT 2006-002253-71,Nov-06,Sep-07,Sep-07,8-Nov-06,null,12-Mar-09,"Sanofi-Aventis Administrative Office, Macquarie Park, Australia|Sanofi-Aventis Administrative Office, Santiago, Chile|Sanofi-Aventis Administrative Office, Paris, France|Sanofi-Aventis Administrative Office, Berlin, Germany|Sanofi-Aventis Administrative Office, Budapest, Hungary|Sanofi-Aventis Administrative Office, Milan, Italy|Sanofi-Aventis Administrative Office, Mexico, Mexico|Sanofi-Aventis Administrative Office, Moscow, Russian Federation|Sanofi-Aventis Administrative Office, Barcelona, Spain",,https://ClinicalTrials.gov/show/NCT00397098
NCT00396552,Treating Refractory Obsessive Compulsive Disorder With rTMS,,Completed,No Results Available,Obsessive Compulsive Disorder,Device: refractory transcranial magnetic stimulation (rTMS)|Device: Sham condition,Degree of change on the Yale-Brown Obsessive Compulsive Disorder Scale,Centre for Addiction and Mental Health,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,19,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",100/2006,Jun-06,Dec-11,Dec-11,7-Nov-06,null,15-Feb-13,"Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|Centre for Addiction and Mental Health, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT00396552
NCT00393874,Efficacy of Sleep Interventions for Posttraumatic Stress Disorder (PTSD),EASI-P,Completed,Has Results,Anxiety Disorders|Mood Disorders|Insomnia|Nightmares,Behavioral: Behavioral Sleep Intervention|Drug: Prazosin|Drug: Placebo,Insomnia Severity Index|Sleep Diary Measures|PSG Composite Measure|PSQI,University of Pittsburgh|U.S. Army Medical Research and Materiel Command,All,18 Years to 55 Years   (Adult),Not Applicable,50,Other|U.S. Fed,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",PR054093|W81XWH-06-1-0257,Oct-06,Jun-10,Jun-11,30-Oct-06,24-Oct-16,24-Oct-16,"Western Phychiatric Institute and Clinic, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00393874
NCT00392522,50% Nitrous Oxide and 50% Oxygen (MEOPA) Conscious Sedation Versus Placebo in Fiberoptic Bronchoscopy,,Unknown status,No Results Available,Fiberoptic Bronchoscopy,Drug: 50% Nitrous Oxide and 50% Oxygen (MEOPA),Efficacy in term of pain control Visual Analogic Scale|anxiety control (COVI Scale)|cough|number of general anaesthesias,Hospices Civils de Lyon,All,"18 Years to 90 Years   (Adult, Older Adult)",Phase 3,64,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,2004.417,Nov-06,null,null,26-Oct-06,null,5-Oct-07,"Corinne Depagne, Lyon, France",,https://ClinicalTrials.gov/show/NCT00392522
NCT00391456,Animal-Assisted Therapy for Hospitalized Heart Failure Patients,,Completed,No Results Available,Heart Failure,Behavioral: Animal-assisted Therapy,Blood pressure|heart rate|pulmonary artery pressure|pulmonary capillary wedge pressure|right atrial pressure|cardiac index|systemic vascular resistance|plasma levels of epinephrine|plasma levels of norepinephrine|state anxiety,"University of California, Los Angeles|Pet Care Trust",All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,76,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,#01061809|ISRCTN26749623,Nov-01,null,Jul-04,24-Oct-06,null,3-Jun-16,"UCLA Medical Center, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT00391456
NCT00390533,An Eight-week Study to Evaluate the Efficacy and Safety of 2 Doses of Saredutant in Patients With Generalized Anxiety Disorder,,Completed,No Results Available,Generalized Anxiety,Drug: Saredutant|Drug: Placebo,Change from baseline to Day 56 of treatment in the Hamilton Anxiety Rating Scale (HAM-A) total score.|Change from baseline to Day 56 of treatment in the Clinical Global Impression Severity of Illness score.,Sanofi,All,"18 Years and older   (Adult, Older Adult)",Phase 3,428,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",EFC5582|SR48968,Sep-06,Feb-08,Feb-08,20-Oct-06,null,24-May-16,"Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States|Sanofi-Aventis Administrative Office, Macquarie Park, Australia",,https://ClinicalTrials.gov/show/NCT00390533
NCT00390650,A North-American Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Generalized Anxiety Disorder,,Completed,No Results Available,Anxiety,Drug: Saredutant,The primary outcome of the study is the change from baseline to Day 56 of treatment in the Hamilton Anxiety Rating Scale (HAM-A) total score.|The key secondary efficacy outcome is change from baseline in the Clinical Global Impression Severity of Illness score.,Sanofi,All,"18 Years and older   (Adult, Older Adult)",Phase 3,366,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,EFC5581|SR48968,Oct-06,Nov-07,Nov-07,20-Oct-06,null,6-Apr-11,"Sanofi-Aventis, Bridgewater, New Jersey, United States|Sanofi-Aventis, Laval, Canada",,https://ClinicalTrials.gov/show/NCT00390650
NCT00389064,Efficacy and Safety Study of Seroquel SR in the Treatment of Generalised Anxiety Disorder,,Completed,Has Results,Anxiety Disorders,Drug: Quetiapine XR|Drug: Placebo,Change in the Hamilton Rating Scale for Anxiety (HAM-A) Total Score|Change in Health-related Quality of Life as Measured by Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) Percent Maximum Total Score|Change in the Clinical Global Impression - Severity of Illness (CGI-S) Score|Change in Psychic Anxiety Factor as Measured by HAM-A Psychic Cluster Score|Change in Somatic Symptoms as Measured by HAM-A Somatic Cluster Score|Hamilton Rating Scale for Anxiety (HAM-A) Response.|Number of Patients Reaching Hamilton Rating Scale for Anxiety (HAM-A) Remission|Change in Montgomery-Asberg Depression Rating Scale (MADRS)|Change in the Visual Analogue Scale (VAS) Measuring Pain|Safety and Well Tolerated as Measured in Adverse Event|Safety and Well Tolerated as Measured by Extra Pyramidal Symptoms (EPS),AstraZeneca,All,66 Years and older   (Older Adult),Phase 3,450,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",D1448C00015|EUDRACT No: 2006-001195-21,Sep-06,Apr-08,Apr-08,18-Oct-06,23-Jun-09,4-Apr-12,"Research Site, Ft Myers, Florida, United States|Research Site, Gainsville, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Sarasota, Florida, United States|Research Site, Roswell, Georgia, United States|Research Site, Boston, Massachusetts, United States|Research Site, Bronx, New York, United States|Research Site, Brooklyn, New York, United States|Research Site, Avon Lake, Ohio, United States|Research Site, Eugene, Oregon, United States|Research Site, Jenkintown, Pennsylvania, United States|Research Site, Austin, Texas, United States|Research Site, Houston, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Tallinn, Estonia|Research Site, Tartu, Estonia|Research Site, Viljandi, Estonia|Research Site, Bialystok, Poland|Research Site, Gorlice, Poland|Research Site, Katowice, Poland|Research Site, Krakow, Poland|Research Site, Leszno, Poland|Research Site, Skorzewo, Poland|Research Site, Torun, Poland|Research Site, Wroclaw, Poland|Research Site, Arkhangelsk, Russian Federation|Research Site, Izhevsk, Russian Federation|Research Site, Lipetsk, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Nizhny Novgorod, Russian Federation|Research Site, Perm, Russian Federation|Research Site, Saratov, Russian Federation|Research Site, St-petersburg, Russian Federation|Research Site, Stavropol, Russian Federation|Research Site, Voronezh, Russian Federation|Research Site, Glevakha, Kiev Region, Ukraine|Research Site, Dnepropetrovsk, Ukraine|Research Site, Dnipropetrovsk, Ukraine|Research Site, Donetsk, Ukraine|Research Site, Kiev, Ukraine|Research Site, Lugansk, Ukraine|Research Site, Odessa, Ukraine|Research Site, Vinnitsa, Ukraine",,https://ClinicalTrials.gov/show/NCT00389064
NCT00389493,Risperidone or Cognitive-Behavioral Therapy for Improving Medication Treatment for Obsessive-compulsive Disorder,,Completed,Has Results,Obsessive-Compulsive Disorder,Drug: Risperidone|Behavioral: Exposure/ritual prevention therapy (EX/RP)|Drug: Placebo,Score on the Yale-Brown Obsessive Compulsive Scale (Y-BOCS)|Social Adjustment Scale-SR|Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form|Hamilton Depression Rating Scale (Ham-D)|Brown Assessment of Beliefs (BABS),New York State Psychiatric Institute|National Institute of Mental Health (NIMH),All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,100,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",#5188/#6258R|R01MH045436-02|DSIR 83-ATAS|R01MH045436|R01MH045404,Oct-06,Jun-12,Dec-12,18-Oct-06,25-Apr-14,25-Apr-14,"New York State Psychiatric Institute, New York, New York, United States|University of Pennsylvania Center for the Treatment and Study of Anxiety, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00389493
NCT00387010,Open-Label Study to Evaluate the Effect of Treatment With Fentanyl Buccal Tablets on Pain Anxiety Symptoms When Used for the Management of Breakthrough Pain,,Terminated,Has Results,Pain|Chronic Pain|Breakthrough Pain,Drug: Fentanyl Buccal Tablets,Change From Baseline in the Pain Anxiety Symptoms Scale (PASS) Total Score at Approximately Week 5|Change From Baseline in the Pain Anxiety Symptoms Scale (PASS) Subscale Scores at Approximately Week 5|Change From Baseline in the Beck Depression Inventory at Approximately Week 5|Change From Baseline in the West Haven-Yale Multidimensional Pain Inventory Subscales at Approximately Week 5|Medication Preference From the Pain Flare Treatment Satisfaction Questionnaire at Approximately Week 5|Patient Assessment of Ability to Go to Work at Approximately Week 5|Patient Assessment of Ability to Perform at Work at Approximately Week 5|Patient Assessment of Ability to Walk at Approximately Week 5|Patient Assessment of Ability to Exercise at Approximately Week 5|Patient Assessment of Ability to Participate in Social Events at Approximately Week 5|Patient Assessment of Ability to Have Sex at Approximately Week 5|Patient Assessment of Ability to Enjoy Life at Approximately Week 5|Clinical Assessment of Patient Function - General Activities - at Approximately Week 5|Clinical Assessment of Patient Function - Patient's Walking Ability - at Approximately Week 5|Clinical Assessment of Patient Function - Patient's Ability to Work/Perform Activities of Daily Living - at Approximately Week 5|Clinical Assessment of Patient Function - Patient's Relationship With Others - at Approximately Week 5|Clinical Assessment of Patient Function - Patient's Enjoyment of Life - at Approximately Week 5|Summary of Participants' Successful Dosing Levels of Fentanyl Buccal Tablets to Control Episodes of Breakthrough Pain (BTP),Cephalon|Teva Pharmaceutical Industries,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,218,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C25608/3054/BP/US,Dec-06,Oct-07,Oct-07,12-Oct-06,22-Oct-12,22-Oct-12,"Birmingham Pain Center, Birmingham, Alabama, United States|Arizona Research Center, Phoenix, Arizona, United States|Orange County Clinical Trials, Anaheim, California, United States|Vertex Clinical Research, Bakersfield, California, United States|Lovelace Scientific Resources, Inc., Beverly Hills, California, United States|Synergy Clinical Research Center, National City, California, United States|Pain Institute of Santa Monica, Santa Monica, California, United States|Integrative Pain Manage Centers, Westminster, Colorado, United States|Advanced Diagnostic Pain Treatment Center, New Haven, Connecticut, United States|Alliance Medical Research Group, Clearwater, Florida, United States|Innovative Research of West Florida, Largo, Florida, United States|Lovelace Scientific Resources, Inc., Sarasota, Florida, United States|Stedman Clinical Trials, Tampa, Florida, United States|Dawsonville Family Medicine, Dawsonville, Georgia, United States|Millennium Pain Center, Bloomington, Illinois, United States|Pain and Rehabilitation Clinic of Chicago, Chicago, Illinois, United States|Elkhart Clinic, LLC, Elkhart, Indiana, United States|Rehabilitation Associates of Indiana, Indianapolis, Indiana, United States|Northwest Indiana Center for Clinical Research, PC, Valparaiso, Indiana, United States|ICRI, Inc., Overland Park, Kansas, United States|Willis-Knighton Pain Management Center, Shreveport, Louisiana, United States|Montana Cancer Specialists, Missoula, Montana, United States|Lovelace Scientific Resources Center, Henderson, Nevada, United States|Clinical Research Center of Nevada, Las Vegas, Nevada, United States|SUNY - Stonybrook, Stony Brook, New York, United States|Pain Consultants of Oregon, Eugene, Oregon, United States|Allegheny Pain Management, PC, Altoona, Pennsylvania, United States|Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States|DeGarmo Institute of Medical Research, Greer, South Carolina, United States|Comprehensive Pain Specialists, PLLC, Hendersonville, Tennessee, United States|KRK Medical Research, Richardson, Texas, United States|BeXar Clinical Trials, LLC, Richardson, Texas, United States|Lifetree Clinical Research, Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT00387010
NCT00387049,Anxiety Sensitivity Program for Smoking Cessation,,Completed,No Results Available,Smoking Cessation,Behavioral: Anxiety Sensitivity Program for Smoking Cessation,"Smoking status|Where applicable, length of time from Quit Day to relapse.",University of Vermont|National Institute on Drug Abuse (NIDA),All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,80,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,R01DA018734,Jan-05,Aug-09,Apr-10,12-Oct-06,null,22-Oct-10,"University of Vermont, Burlington, Vermont, United States",,https://ClinicalTrials.gov/show/NCT00387049
NCT00382291,Effectiveness of Sertraline and Cognitive Behavioral Therapy in Treating Pediatric Obsessive-Compulsive Disorder,,Completed,Has Results,Obsessive-Compulsive Disorder,Drug: Regular Titration|Drug: Placebo|Drug: Slow Titration,Clinical Global Impression - Severity of Activation (CGI-SA)|Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS) Total Score,University of Florida|National Institute of Mental Health (NIMH),All,7 Years to 17 Years   (Child),Phase 4,56,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic",R01MH078594|DSIR 84-CTM,Feb-09,Feb-11,Feb-11,29-Sep-06,12-Mar-13,12-Mar-13,"University of Florida, Gainesville, Florida, United States|University of South Florida, Tampa, Florida, United States",,https://ClinicalTrials.gov/show/NCT00382291
NCT00381979,Supportive Expressive Therapy for Depressed and Anxious Adolescents,,Completed,No Results Available,Depression|Anxiety,Other: Supportive Expressive Therapy,"BDI|MASC|Measures collected at pre, post, and follow-up|YSR|CBCL|FAM|CRI|SSRS",Centre for Addiction and Mental Health,All,"15 Years to 24 Years   (Child, Adult)",Not Applicable,20,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,169/2003,Jan-04,Oct-07,Oct-07,28-Sep-06,null,22-Oct-15,"Centre for Addiction and Mental Health, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT00381979
NCT00380419,Effects of Interpersonal Psychotherapy on Depression During and After Pregnancy,,Completed,No Results Available,Depression|Anxiety Disorders,Behavioral: Interpersonal Psychotherapy (IPT),"Mothers' depression symptom severity, as determined by the 17-item Hamilton Rating Scale for Depression (HAM-D 17)|Infant birth outcomes|Biologic measures related to depression in both mothers and infants",University of Michigan|National Institute of Mental Health (NIMH),Female,21 Years to 45 Years   (Adult),Not Applicable,120,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HUM00007344|R21MH072673|DSIR 83-ATAS,Oct-06,Aug-09,Aug-09,26-Sep-06,null,30-May-13,"University of Michigan, Ann Arbor, Michigan, United States",,https://ClinicalTrials.gov/show/NCT00380419
NCT00380731,Effect of Behavior Therapy on Responses to Social Stimuli in People With Social Phobia,,Completed,No Results Available,Social Phobia,Behavioral: Individual Cognitive Behavioral Therapy,Liebowitz Social Anxiety Scale|fMRI BOLD response|Behavioral assessment|Clinical Global Impression Improvement Scale|Social Interaction Anxiety Scale|Sheehan Disability Scale|Quality of Life Inventory,Stanford University|National Institute of Mental Health (NIMH),All,21 Years to 55 Years   (Adult),Not Applicable,124,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,R01MH076074|DATR A3-NSS,Sep-06,Aug-11,Aug-11,26-Sep-06,null,30-Nov-11,"Stanford University, Stanford, California, United States",,https://ClinicalTrials.gov/show/NCT00380731
NCT00376922,Music in Reducing Anxiety and Pain in Adult Patients Undergoing Bone Marrow Biopsy for Hematologic Cancers or Other Diseases,,Completed,No Results Available,Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Lymphoproliferative Disorder|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms|Pain|Precancerous Condition|Psychosocial Effects of Cancer and Its Treatment,Procedure: music therapy,State anxiety as measured by the State-Trait Anxiety Inventory (STAI) questionnaire|Perceived pain level as measured by the Visual Analogue Scale|Patient satisfaction as measured by a post-procedure questionnaire,Wake Forest University Health Sciences|National Cancer Institute (NCI),All,"18 Years to 120 Years   (Adult, Older Adult)",Not Applicable,65,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,CDR0000495315|CCCWFU-98306|CCCWFU-IRB00000468,Jun-06,May-07,May-10,15-Sep-06,null,30-May-17,"Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT00376922
NCT00374192,The Treatment of Insomnia in Symptomatic Peri- and Postmenopausal Women,,Completed,No Results Available,Menopause|Insomnia,Drug: Eszopiclone|Drug: Placebo,To examine the effect of treatment with eszopiclone on sleep-onset and sleep-maintenance insomnia in peri- and postmenopausal women.|To examine the effect of eszopiclone on mood and quality of life in peri- and postmenopausal women with insomnia who have comorbid depressive and/or anxiety symptoms.,Massachusetts General Hospital|Sunovion,Female,"40 Years and older   (Adult, Older Adult)",Not Applicable,67,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2006-P000194,Feb-06,Jul-07,Jul-07,11-Sep-06,null,10-Aug-09,"Massachusetts General Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT00374192
NCT00374348,Aripiprazole in the Treatment of Patients With Schizophrenia and Symptoms of Obsessive Compulsive Disorder (OCD),,Completed,No Results Available,Schizophrenia OCD|Obsessive Compulsive Disorder,Drug: Aripiprazole,"The overall effectiveness of Aripiprazole will be evaluated by use of the BPRS, Yale-Brown OCD scale and Clinical Global Impression-Improvement (CGI-I) scale, including efficacy in reduction of psychosis and obsessions.Improvements in YBOCS and BPRS scor|Physical Examination, Psychiatric evaluation with YBOCS, BPRS and CGI scales, EPS scale, routine hematology and chemistry tests, urinalysis,urine drug screening,urine pregnancy test, ECG recording","Jamaica Hospital Medical Center|Bristol-Myers Squibb|Department of Psychiatry, Jamaica Hospital Medical Center|Research Division",All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,10,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,JH-PSY-Aripiprazole/Schiz/OCD,Mar-05,May-08,May-08,11-Sep-06,null,16-Sep-11,"Jamaica Hospital Medical Center Department of Psychiatry, Jamaica, New York, United States",,https://ClinicalTrials.gov/show/NCT00374348
NCT00374543,Ziprasidone for the Treatment of Generalized Anxiety in Patients With Bipolar Disorder,,Terminated,Has Results,Generalized Anxiety Disorder|Bipolar Disorder,Drug: Ziprasidone|Drug: Placebo,Hamilton Anxiety Rating Scale (HAM-A)|Clinical Global Impression of Improvement (CGI-I),Massachusetts General Hospital|Pfizer,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 4,3,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2006-P-000142,Feb-06,Oct-07,Nov-08,11-Sep-06,16-Apr-14,16-Apr-14,"Center for Anxiety and Traumatic Stress Disorders at Massachusetts General Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT00374543
NCT00374166,An Eight-week Study Evaluating the Efficacy and Tolerability of Two Doses of SSR149415 in Outpatients With Generalized Anxiety Disorder,,Completed,No Results Available,Anxiety Disorders,Drug: SSR149415|Drug: Placebo|Drug: Paroxetine,Change from baseline to Day 56 in the 14-item Hamilton Anxiety Rating Scale (HAM-A) total score.|Change from baseline to Day 56 in the Clinical Global Impression (CGI) Severity of Illness score.,Sanofi,All,18 Years to 64 Years   (Adult),Phase 2,325,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",DFI5880,Aug-06,Feb-08,Feb-08,8-Sep-06,null,25-May-16,"Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States",,https://ClinicalTrials.gov/show/NCT00374166
NCT00373022,Moderate Physical Activity in Helping Patients Recover Physically and Emotionally From Stage II Or Stage III Colorectal Cancer,,Completed,No Results Available,Anxiety Disorder|Colorectal Cancer|Depression|Psychosocial Effects of Cancer and Its Treatment,Behavioral: exercise intervention|Other: flow cytometry|Other: laboratory biomarker analysis|Procedure: management of therapy complications|Procedure: psychosocial assessment and care|Procedure: quality-of-life assessment,"Effect of moderate physical activity on quality of life as measured by the Functional Assessment of Cancer Therapy-Colon questionnaire|Effect of moderate physical activity on depression and anxiety as measured by the Beck Depression Inventory and the Spielberger State-Trait Anxiety Inventory|Effect of moderate physical activity on attitudes related to physical activity as measured by the American Council on Exercise History questionnaire|Serum levels and patterns of immune function as measured by cytokine, neutrophil, T cell, B cell, natural killer (NK) cell, and immunoglobulin levels|Correlation of serum levels and patterns of immune function (cytokine, neutrophil, T cell, B cell, NK cell, and immunoglobulin levels) with physical activity levels",University of Arizona|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,45,Other|NIH,Interventional,Allocation: Randomized|Primary Purpose: Supportive Care,CDR0000491199|P30CA023074|UARIZ-A04.04,Jan-04,Dec-06,Dec-06,7-Sep-06,null,27-May-10,"Arizona Cancer Center at University of Arizona Health Sciences Center, Tucson, Arizona, United States",,https://ClinicalTrials.gov/show/NCT00373022
NCT00371644,Treatment for Veterans With Military Sexual Trauma,,Completed,Has Results,"Stress Disorders, Post-Traumatic|Depressive Symptoms|Anxiety Symptoms|Quality of Life",Behavioral: Cognitive Processing Therapy|Behavioral: Present-Centered Therapy,PTSD Checklist (PCL),US Department of Veterans Affairs|VA Office of Research and Development,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,129,U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,D4445-R|IRB 06-036,Feb-07,Jun-10,Jun-11,4-Sep-06,16-Dec-14,15-Jan-15,"VA North Texas Health Care System, Dallas, Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT00371644
NCT00369642,A Controlled Trial of Daily Cognitive-Behavioral Therapy for Pediatric Obsessive-Compulsive Disorder,,Completed,No Results Available,Obsessive-Compulsive Disorder,Behavioral: Cognitive-behavioral therapy,"Children's Yale-Brown Obsessive-Compulsive Scale (CY-BOCS; Scahill et al., 1997)|Clinical Global Impression - Severity (CGI-S; National Institute of Mental Health, 1985)|Clinical Global Improvement (CGI; Guy, 1976)|Multidemisional Anxiety Scale for Children|Children's Depression Inventory|Family Accommodation Scale",University of South Florida,All,7 Years to 17 Years   (Child),Phase 3,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,UF212-2004,Oct-04,null,Dec-06,29-Aug-06,null,9-Aug-10,"University of Florida, Gainesville, Florida, United States",,https://ClinicalTrials.gov/show/NCT00369642
NCT00368745,"Efficacy and Safety of Pregabalin vs Placebo for Generalized Anxiety Disorder (GAD) Symptoms in Subjects Discontinuing Benzodiazepine Treatment and Remaining 6 Weeks on Study Medication, Free From Benzodiazepine Use.",GAD,Completed,Has Results,Generalized Anxiety Disorder,Drug: Pregabalin|Drug: Placebo,Number of Subjects at Endpoint (Post Alprazolam Free Week 6 or Last Observation Carried Forward [LOCF] Post Alprazolam Free Week 1) Who Are Benzodiazepine Free|Mean Change From Baseline in Hamilton Anxiety Scale (HAM-A) Scores|Number of Subjects With > = 6 Point Increase in Physician's Withdrawal Checklist (PWC) Scores|Number of Subjects With > = 5 New PWC Symptoms|Mean Change From Baseline in Physician's Withdrawal Checklist (PWC) Scores|Mean Change From Baseline in Clinical Global Impression Severity (CGI-S) Scale Scores.|Mean Scores for Clinical Global Impression-Improvement (CGI-I) Scale|Mean Scores for Patient Global Impression-Improvement (PGI-I)|Mean Change From Baseline in Digit Symbol Substitution Test (DSST) Scores|Time to Discontinuation|Time to First Use of Rescue Medication|Number of Subjects in Relapse Free State at 6-week Benzodiazepine-free Endpoint (Alprazolam Free Week 6),Pfizer,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,108,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",A0081092,Sep-06,Aug-08,Aug-08,25-Aug-06,9-Nov-09,11-Nov-09,"Pfizer Investigational Site, San Pedro de Montes de Oca, San José, Costa Rica|Pfizer Investigational Site, Plzen, Czech Republic|Pfizer Investigational Site, Praha 10, Czech Republic|Pfizer Investigational Site, Praha 6, Czech Republic|Pfizer Investigational Site, Praha 7, Czech Republic|Pfizer Investigational Site, Praha-Bubenec, Czech Republic|Pfizer Investigational Site, Paris, Cedex 12, France|Pfizer Investigational Site, Arcachon, France|Pfizer Investigational Site, Caen, France|Pfizer Investigational Site, Elancourt, France|Pfizer Investigational Site, Nantes-Orvault, France|Pfizer Investigational Site, Guatemala, Guatemala|Pfizer Investigational Site, L'Aquila, Italy|Pfizer Investigational Site, Milan, Italy|Pfizer Investigational Site, Tepic, Nayarit, Mexico|Pfizer Investigational Site, Mexico D.f., Mexico|Pfizer Investigational Site, San Luis Potosi, Mexico|Pfizer Investigational Site, Langreo, Asturias, Spain|Pfizer Investigational Site, Barcelona, Spain|Pfizer Investigational Site, Barcelona, Spain|Pfizer Investigational Site, Zamora, Spain",,https://ClinicalTrials.gov/show/NCT00368745
NCT00363298,Dextro-Amphetamine Versus Caffeine in Treatment-resistant OCD,,Completed,Has Results,Obsessive-Compulsive Disorder,Drug: dextro-amphetamine|Drug: Sham Comparison,Number of Subjects With Clinical Global Impressions Scale - Improvement (CGI-I) Score of 1 or 2|Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) Score,Stanford University|Obsessive Compulsive Foundation,All,18 Years to 55 Years   (Adult),Not Applicable,24,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",97134,Aug-06,Mar-08,Mar-08,15-Aug-06,28-Mar-17,28-Mar-17,"Stanford University School of Medicine, Stanford, California, United States",,https://ClinicalTrials.gov/show/NCT00363298
NCT00360802,Effectiveness of Cognitive Behavioral Treatment and Mindfulness Based Stress Reduction (MBSR) for Chronic Low Back Pain,,Completed,No Results Available,Chronic Low Back Pain,Behavioral: Cognitive Behavioral Treatment|Behavioral: Mindfulness Based Stress Reduction,"Degree of improvement in: anxiety, quality of life|Degree of improvement in: pain, disability, catastrophizing, depression, anger, analgesic medication, satisfaction with treatment received",Kovacs Foundation|Spanish Back Pain Research Network (REIDE)|Fondo de Investigacion Sanitaria|Universitat Autonoma de Barcelona,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,330,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)",FK-FIS-22,May-06,Mar-09,May-09,7-Aug-06,null,28-May-09,"Universidad Autónoma de Barcelona, Dept. Psicología Básica, Evolutiva y de la Educación, Bellaterra, Barcelona, Cataluña, Spain",,https://ClinicalTrials.gov/show/NCT00360802
NCT00360451,Effectiveness of School-Based Cognitive Behavioral Therapy in Preventing Depression in Young Adolescents,,Completed,No Results Available,Depression|Anxiety,Behavioral: Adolescent only Penn Resiliency Program (Adolescent PRP)|Behavioral: Parent Penn Resiliency Program (Parent PRP),"Adolescents' depressive symptoms by self-report|Adolescents' symptoms of anxiety by self-report|Adolescents' symptoms of depression and anxiety, including clinical levels of symptoms, as assessed by diagnostic interview|Adolescents' externalizing symptoms by teacher report|Adolescents' attributional style by self-report|Parental depression by self-report|Parental anxiety by self-report|Parental attributional style by self-report",University of Pennsylvania|National Institute of Mental Health (NIMH),All,"Child, Adult, Older Adult",Phase 3,400,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,R01 MH0522070|5R01MH052270|DSIR CT-P,Sep-02,Mar-08,Mar-08,4-Aug-06,null,10-Sep-15,"University of Pennsylvania, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00360451
NCT00358995,A Cognitive Behavioral Therapy of Primary Obsessions in Obsessive Compulsive Disorder,,Completed,No Results Available,Obsessive Compulsive Disorder,Behavioral: Cognitive Behavioral Therapy|Behavioral: Stress Management Therapy (SMT),"The primary outcome of the study is to determine if CBT is more effective than SMT in reducing distorted beliefs and OCD symptoms in study participants post treatment, as well as six and twelve months post treatment.|The secondary outcome of the study is to determine if change in appraisals of intrusive thoughts will mediate symptom change during and after treatment (i.e. follow-up).",University of British Columbia,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,84,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,H02-80132,Jul-02,Sep-07,Sep-07,1-Aug-06,null,19-Feb-14,"UBC Hospital, The Anxiety Disorders Clinic, Vancouver, British Columbia, Canada",,https://ClinicalTrials.gov/show/NCT00358995
NCT00355693,"Effect Site Controlled, Reaction Time Safeguarded, Patient Maintained Sedation With Propofol in Anxious Patients",,Unknown status,No Results Available,"Oral Surgical Procedures|Surgery, Oral|Dental Anxiety|Surgery|Colonoscopy",Device: Pump for propofol delivery,"Minimal Sedation Level obtained (modified Objective Observers's Assessment of Sedation)|(Scores 5, fully awake to 1, unresponsive)|Maximal change in oxygen saturation (SpO2)|Effect site concentrations of propofol|Anxiety Levels|Requirement for supplementary oxygen (if SpO2 < 90%)|Requirement for airway support|Maximal change in heart rate (HR) and blood pressure (BP)|Operator assessment (ease of procedure, cooperation)|Patient Satisfaction and recollection",University of Glasgow|Equity Partners (University Challenge Fund),All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,60,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,9812/A,Oct-06,null,Feb-07,24-Jul-06,null,24-Aug-06,"Duncan Street Dental Centre, Edinburgh, United Kingdom|Glasgow Dental Hospital and School, Glasgow, United Kingdom",,https://ClinicalTrials.gov/show/NCT00355693
NCT00353470,Comparison of Psychotherapy Programs to Treat Panic Disorder,,Completed,No Results Available,Anxiety Disorders|Panic Disorder|Agoraphobia,Behavioral: Cognitive behavioral therapy|Behavioral: Applied relaxation training (ART)|Behavioral: Panic focused psychodynamic psychotherapy (PFPP),Panic Disorder Severity Scale|Sheehan Disability Scale|Clinical Global Impressions Scale|Hamilton Depression Rating Scale|Hamilton Anxiety Rating Scale|Anxiety Disorder Sensitivity Index|Brief Body Sensitivity Interpretation Questionnaire|Panic-Specific Reflective Function,Weill Medical College of Cornell University|National Institute of Mental Health (NIMH),All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,201,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,R01MH070918|R01MH070664,Sep-06,Mar-12,Sep-12,18-Jul-06,null,3-May-18,"Weill Medical College of Cornell University, New York, New York, United States|University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00353470
NCT00352768,Fluvoxamine Maleate in the Treatment of Obsessive-Compulsive Disorder: A Post-marketing Clinical Study in Children and Adolescents,,Terminated,No Results Available,Obsessive Compulsive Disorder,Drug: Fluvoxamine maleate|Drug: Placebo,the time of onset of 25% decrease from baseline in the Japanese Version of the Children's Yale-Brown Obsessive Compulsive Scale (JCY-BOCS) 10-item total score|The Clinical Global Impression(CGI) improvement at Week 10,Solvay Pharmaceuticals,All,"8 Years to 18 Years   (Child, Adult)",Phase 4,20,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",S114.3.118,Aug-06,Apr-09,Apr-09,17-Jul-06,null,4-Mar-10,"S114.3.118 Kohnodai Hospital, National Center of N, Chiba prefecture, Japan|S114.3.118 Kyushu University Hospital, Fukuoka prefecture, Japan|S114.3.118 Hiroshima-city Funairi Hospital, Hiroshima prefecture, Japan|S114.3.118 Goryokai Hospital, Hokkaido prefecture, Japan|S114.3.118 Hyogo Children's Hospital, Hyogo prefecture, Japan|S114.3.118 Kobe University Hospital, Hyogo prefecture, Japan|S114.3.118 National Hospital Organization Kagawa C, Kagawa prefecture, Japan|S114.3.118 National Hospital Organization Kikuti N, Kumamoto prefecture, Japan|S114.3.118 National Hospital Organization Sakakiba, Mie prefecuture, Japan|S114.3.118 Nara Medical University Hospital, Nara prefecture, Japan|S114.3.118 Tokushima University Hospital, Tokushima prefecture, Japan",,https://ClinicalTrials.gov/show/NCT00352768
NCT00352469,Trial of Seroquel SR for Alcohol Dependence and Comorbid Anxiety,,Completed,No Results Available,Alcoholism|Anxiety Disorders|Generalized Anxiety Disorder|Post-Traumatic Stress Disorder|Panic Disorder|Obsessive-Compulsive Disorder,Drug: Seroquel XR,"Aim 1: To determine whether Seroquel SR reduces alcohol use and prolongs sobriety as measured by the Time Line Follow Back Method and breathalyzer test in individuals with alcohol dependence and co-morbid anxiety.|Aim 2: To determine whether Seroquel SR decreases craving as measured by the Pennsylvania Craving Scale, in individuals with alcohol dependence and co-morbid anxiety.|Aim 3: To determine whether Seroquel SR reduces anxiety symptoms as measured by the Hamilton Rating Scale for Anxiety (HAM-A), in individuals with alcohol dependence and co-morbid anxiety.",Creighton University|AstraZeneca,All,"19 Years to 65 Years   (Adult, Older Adult)",Phase 4,20,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",IRUSQUET408,Feb-06,Nov-08,Nov-08,14-Jul-06,null,8-Dec-08,"Creighton University Department of Psychiatry, Omaha, Nebraska, United States",,https://ClinicalTrials.gov/show/NCT00352469
NCT00347269,Primary Care Intervention Strategy for Anxiety Disorders,,Completed,Has Results,Post-traumatic Stress Disorder|Generalized Anxiety Disorder|Panic Disorder|Social Anxiety Disorder,Behavioral: Cognitive-behavioral therapy|Drug: Psychotropic medication optimization|Behavioral: Treatment as Usual,"BSI-12 (Anxiety and Somatization Subscales)|Functioning Outcomes as Measured by 3-item Sheehan Disability Scales and SF-12 and Disorder-specific Severity Scales as Measured by the ASI, PDSS-SR, GADS (Modified), SPIN, PCL-C, and the PHQ-9",University of Washington|National Institute of Mental Health (NIMH),All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 4,1004,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,28630|U01MH057858-05|DSIR 83-ATAS,Jun-06,Oct-09,Oct-09,4-Jul-06,19-May-17,19-May-17,"University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|University of California, La Jolla, California, United States|University of California, Los Angeles, California, United States|University of Washington, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00347269
NCT00346112,"Rehabilitation, Quality of Life, and Exercise Tolerance in Patients With an ICD",,Terminated,No Results Available,Heart Patients After ICD Implantation,Procedure: psycho-educational,Anxiety and Depression,"University Hospital Inselspital, Berne",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,null,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),P-KARE-01,Jun-06,null,Dec-09,29-Jun-06,null,9-Nov-10,"University Hospital (Inselspital) Berne, Bern, Switzerland",,https://ClinicalTrials.gov/show/NCT00346112
NCT00344474,Personality-targeted Interventions for Adolescent Alcohol Misuse,Preventure,Completed,No Results Available,Alcohol Abuse|Drug Abuse|Depression|Panic Disorder|Conduct Disorder,Behavioral: PRE-Venture: Personality Risk Education,"Time to onset and severity of drug use|Frequency and Quantity of Drinking|Problem drinking symptoms|Psychiatric symptoms (depression, panic anxiety, antisocial behaviours), coping skills, motives for drinking",King's College London|Action on Addiction,All,13 Years to 16 Years   (Child),Phase 2|Phase 3,710,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,PAJTXVA|229/03,Nov-03,May-06,Jul-08,26-Jun-06,null,27-Jun-11,"Institute of Psychiatry, King's College London, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT00344474
NCT00343707,PET (Positron Emission Tomography)/Public Speaking Study With A Combination Of 2 Medications In Social Anxiety Patients,,Completed,No Results Available,Depressive Disorder and Anxiety Disorders,Drug: vestipitant|Drug: paroxetine,"To assess, by mean of Positron Emission Tomography, the degree of regional Cerebral Blood Flow in different brain regions involved in the emotional brain circuit during public speaking task before treatment and after eight weeks of treatment.|To assess symptomatic and physiological measures of anxiety induced by the public speaking task and social anxiety symptoms during eight weeks of treatment. To evaluate safety, tolerability and the effect on sexual function of treatment.",GlaxoSmithKline,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,72,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",NKP102280,Nov-04,Nov-05,Nov-05,23-Jun-06,null,15-Sep-16,"GSK Investigational Site, Uppsala, Sweden",,https://ClinicalTrials.gov/show/NCT00343707
NCT00337870,Painful Procedures in the Emergency Department: A Distraction Intervention (3-5 Year Olds),ERPain,Completed,No Results Available,Anxiety|Pain,Behavioral: PAT,CAMPIS coding of visual pain response video-recorded during the procedure|Parental reports of: Child pain ratings (Faces Pain Scale Revised)|Child anxiety ratings|CHEOPS analysis,IWK Health Centre|Mayday Fund,All,3 Years to 5 Years   (Child),Phase 2,131,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,3416|Mayday grant,Mar-06,Aug-09,Aug-09,20-Jun-06,null,12-Sep-13,"IWK Health Centre, Halifax, Nova Scotia, Canada",,https://ClinicalTrials.gov/show/NCT00337870
NCT00338325,Reading Preoperatively to Reduce Anxiety in Day Surgery,,Completed,No Results Available,Pre-operative Pediatric Anxiety,Behavioral: Reading program,Kuttner's face scale of anxiety for children|Speilberger's State-Trait Anxiety Inventory (STAI) for the adults.|Conners' Parent Rating Scale - Revised - Hyperactive and Anxiety scores|Data from Semi-Structured Qualitative Parental Interviews,IWK Health Centre,All,2 Years to 8 Years   (Child),Phase 2,200,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,3317|IWK studentship award,Jun-05,Jun-05,Apr-06,20-Jun-06,null,16-Jun-15,,,https://ClinicalTrials.gov/show/NCT00338325
NCT00338364,Painful Procedures in the Emergency Department: A Distraction Intervention,ERPain,Completed,No Results Available,Pediatric Pain and Anxiety,Behavioral: PAT,CAMPIS coding of visual pain response video-recorded during the procedure|Child pain ratings (Faces Pain Scale Revised)|Child anxiety ratings|CHEOPS analysis,IWK Health Centre|Mayday Fund,All,6 Years to 12 Years   (Child),Phase 2,189,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,3202|Mayday grant,Jan-06,Aug-09,Aug-09,20-Jun-06,null,12-Sep-13,"IWK Health Centre, Halifax, Nova Scotia, Canada",,https://ClinicalTrials.gov/show/NCT00338364
NCT00335946,A Pilot Investigational Study: Treatment of Anxiety With Non-Needle Electro-Acupuncture,,Completed,No Results Available,"Anxiety, Mild to Moderate",Device: HANS non-needle acupuncture|Procedure: Stimulation of two acupuncture points bi-lateral,Spielberger STAI test,Logan College of Chiropractic,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,40,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RD0602060019,Jun-06,Dec-06,Dec-06,12-Jun-06,null,17-Oct-08,"Logan College of Chirpractic, Chesterfield, Missouri, United States",,https://ClinicalTrials.gov/show/NCT00335946
NCT00332891,An Eight-Week Study to Evaluate the Efficacy and Safety of SR58611A in Patients With Generalized Anxiety Disorder,ELECTRA,Completed,No Results Available,Anxiety Disorders,Drug: SR58611A,"The primary outcome of the study is the change from baseline to Day 56 of treatment in the Hamilton Anxiety Rating Scale (HAM-A) total score.|The main secondary outcomes are the changes from baseline to Day 56 of treatment in the CGI Severity of Illness Score, percentage of patients with HAM-A treatment response and change from baseline in the HAM-A somatic and psychic anxiety factor scores.",Sanofi,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,508,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",EFC5891,Mar-06,Apr-07,Apr-07,2-Jun-06,null,9-Mar-09,"Sanofi-Aventis Administrative Office, Sofia, Bulgaria|Sanofi-Aventis Administrative Office, Zagreb, Croatia|Sanofi-Aventis Administrative Office, Praha, Czech Republic|Sanofi-Aventis Administrative Office, Warszawa, Poland|Sanofi-Aventis Administrative Office, Belgrade, Serbia",,https://ClinicalTrials.gov/show/NCT00332891
NCT00332046,fMRI Study Comparing BOLD Activation Patterns Using GW679769 In Subjects With Social Anxiety Disorder,,Completed,No Results Available,Social Anxiety Disorder,Drug: GW679769,"Change in images of the brain, when stimulated, after once daily dosing for 12 weeks with GW679769, comparator or placebo in subjects with SAD.|Blood levels of GW679769 and comparator at the Week 1 and Week 12 Change in clinical rating scales from baseline to Week 12 Safety & tolerability",GlaxoSmithKline,All,18 Years to 50 Years   (Adult),Phase 1,57,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Diagnostic,NKF10015,Jan-06,null,null,1-Jun-06,null,16-Oct-08,"GSK Investigational Site, La Jolla, California, United States",,https://ClinicalTrials.gov/show/NCT00332046
NCT00330720,Impact of An Emergency Response System on Anxiety and Health-Care Use,,Completed,No Results Available,Anxiety|Falls|Fear of Falling,Device: Emergency Response System (Device),"Anxiety measured with the Hospital Anxiety and Depression Scale, at 1 month|Fear of Falling, using Falls Efficacy Scale at 1 month|Proportion who Returned to the Emergency Department by 2 months|Proportion who are Hospitalized by 2 months|Length of Stay by 2 months, in Days.",Sunnybrook Health Sciences Centre|The Physicians' Services Incorporated Foundation|Lifeline,All,70 Years and older   (Older Adult),Not Applicable,80,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single|Primary Purpose: Treatment,205-2002|PSIF Grant #02-13,Nov-02,null,Jun-04,29-May-06,null,29-May-06,"Sunnybrook Health Sciences Center, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT00330720
NCT00330174,Acamprosate in Alcoholics With Comorbid Anxiety or Depression,,Completed,Has Results,Alcohol Dependence|Major Depression|Social Anxiety Disorder|Generalized Anxiety Disorder,Drug: Acamprosate,Percent Days Drinking|Montgomery-Asberg Depression Rating Scale (MADRS)|Liebowitz Social Anxiety Scale|Hospital Anxiety and Depression Scale,Medical University of South Carolina|Mclean Hospital|Columbia University,All,18 Years to 60 Years   (Adult),Phase 4,90,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",CMP-MD-04,Apr-06,Sep-10,Sep-10,26-May-06,13-Apr-15,13-Apr-15,"McLean Hospital, Belmont, Massachusetts, United States|Columbia University College of Physicians & Surgeons, New York, New York, United States|Behavioral Health Services of Pickens County, Pickens, South Carolina, United States",,https://ClinicalTrials.gov/show/NCT00330174
NCT00330291,Xyrem for Treatment Refractory Insomnia Due to PTSD,,Withdrawn,No Results Available,"PTSD|Anxiety, Post Traumatic",Drug: Xyrem,,State University of New York - Upstate Medical University,All,18 Years to 64 Years   (Adult),Phase 2,0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,4975,Aug-05,Aug-06,Aug-06,26-May-06,null,7-Sep-12,"SUNY Upstate Medical University, Syracuse, New York, United States",,https://ClinicalTrials.gov/show/NCT00330291
NCT00329264,Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo in Generalized Anxiety Disorder,TITANIUM,Completed,No Results Available,Generalized Anxiety Disorder,Drug: Quetiapine fumarate,Change from randomization in the HAM-A total score at Day 57|Change from randomization in CGI-S score at Day 57,AstraZeneca,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,876,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,D1448C00009|Titanium,Apr-06,null,Aug-07,24-May-06,null,25-Mar-09,"Research Site, Springdale, Arizona, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Encino, California, United States|Research Site, Newport Beach, California, United States|Research Site, Oceanside, California, United States|Research Site, Redlands, California, United States|Research Site, Santa Ana, California, United States|Research Site, Denver, Colorado, United States|Research Site, Norwich, Connecticut, United States|Research Site, Washington, District of Columbia, United States|Research Site, Ft Walton Beach, Florida, United States|Research Site, Gainsville, Florida, United States|Research Site, Hialeah, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Winter Park, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Smyrna, Georgia, United States|Research Site, Eagle, Idaho, United States|Research Site, Chicago, Illinois, United States|Research Site, Oak Brook, Illinois, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Topeka, Kansas, United States|Research Site, New Orleans, Louisiana, United States|Research SIte, Fall River, Massachusetts, United States|Research Site, Farmington Hills, Michigan, United States|Research Site, Ridgeland, Mississippi, United States|Research Site, St. Louis, Missouri, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Cherry Hill, New Jersey, United States|Research Site, Clementon, New Jersey, United States|Research Site, Brooklyn, New York, United States|Research Site, New York City, New York, United States|Research Site, Rochester, New York, United States|Research Site, Staten Island, New York, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Durham, North Carolina, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Toledo, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Tulsa, Oklahoma, United States|Research Site, Portland, Oregon, United States|Research Site, Allentown, Pennsylvania, United States|Research Site, Norristown, Pennsylvania, United States|Research Site, Lincoln, Rhode Island, United States|Research Site, Memphis, Tennessee, United States|Research Site, Austin, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Friendswood, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Woodstock, Vermont, United States|Research Site, Herndon, Virginia, United States|Research Site, Midlothian, Virginia, United States|Research Site, Bellevue, Washington, United States|Research Site, Seattle, Washington, United States|Research Site, Charleston, West Virginia, United States",,https://ClinicalTrials.gov/show/NCT00329264
NCT00329446,Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo & Active Control in Generalized Anxiety Disorder,GOLD,Completed,No Results Available,Generalized Anxiety Disorder,Drug: Quetiapine Fumarate|Drug: Escitalopram oxylate,Change from randomization in the HAM-A total score at Day 57|Change from randomization in CGI-S score at Day 57,AstraZeneca,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,800,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,D1448C00010|GOLD,Apr-06,null,Sep-07,24-May-06,null,25-Mar-09,"Research Site, Birmingham, Alabama, United States|Research Site, Scottsdale, Arizona, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Beverly Hills, California, United States|Research Site, Burbank, California, United States|Research Site, La Mesa, California, United States|Research Site, Orange, California, United States|Research Site, Pasadena, California, United States|Research Site, San Diego, California, United States|Research Site, Sherman Oaks, California, United States|Research Site, Upland, California, United States|Research Site, Wildomar, California, United States|Research Site, New Britain, Connecticut, United States|Research Site, Washington, District of Columbia, United States|Research Site, Boca Raton, Florida, United States|Research Site, Bradenton, Florida, United States|Research Site, Deland, Florida, United States|Research Site, Fort Lauderdale, Florida, United States|Research Site, Ft Myers, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Maitland, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, West Palm Beach, Florida, United States|Research Site, Edwardsville, Illinois, United States|Research Site, Merrillville, Indiana, United States|Research Site, Terre Haute, Indiana, United States|Research Site, Newton, Kansas, United States|Research Site, Prairie Village, Kansas, United States|Research Site, Owensboro, Kentucky, United States|Research Site, Lake Charles, Louisiana, United States|Research Site, Baltimore, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Haverhill, Massachusetts, United States|Research Site, Okemos, Michigan, United States|Research Site, St. Paul, Minnesota, United States|Research Site, St. Louis, Missouri, United States|Research Site, Kenilworth, New Jersey, United States|Research Site, Princeton, New Jersey, United States|Research Site, Toms River, New Jersey, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, New York City, New York, United States|Research Site, Chapel Hill, North Carolina, United States|Research Site, Cleveland, Ohio, United States|Research Site, Dayton, Ohio, United States|Research Site, Toledo, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Eugene, Oregon, United States|Research Site, Salem, Oregon, United States|Research Site, Allentown, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Columbia, South Carolina, United States|Research Site, Memphis, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Dallas, Texas, United States|Research Site, Houston, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Richmond, Virginia, United States|Research Site, Kirkland, Washington, United States|Research Site, Spokane, Washington, United States|Research Site, Morgantown, West Virginia, United States",,https://ClinicalTrials.gov/show/NCT00329446
NCT00326430,Residential Cognitive and Interpersonal Therapy for Social Phobia,,Completed,No Results Available,Social Phobia,"Behavioral: Cognitive Therapy, Interpersonal Therapy",Social Avoidance|Social Anxiety|General Anxiety|Depression|Interpersonal Problems|Personality Disorders,Modum Bad,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2|Phase 3,80,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Treatment,1,Oct-01,null,Jun-04,16-May-06,null,16-May-06,"Modum Bad, Vikersund, Buskerud, Norway",,https://ClinicalTrials.gov/show/NCT00326430
NCT00325221,Psychosomatic Effects of Implantable Cardioverter Defibrillator With Home Monitoring Function (QUANTUM),,Completed,No Results Available,Arrhythmia|Quality of Life,Device: HM on|Device: HM Off,Hospital Anxiety and Depression Scale (HADS) anxiety score|HADS depression score|Quality of life (SF-12)|Prevalence of Type D personality among ICD patients|Frequency of contacts between patient and physician|Patient's perception of ICD therapy|Patient mobility,Biotronik SE & Co. KG,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,148,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HS033,Aug-06,Jan-12,Oct-12,12-May-06,null,31-Jan-13,"Krankenhaus der Barmherzigen Schwestern Ried, Ried, Austria|Hanusch-Krankenhaus, Wien, Austria|Herzzentrum Coswig, Coswig, Germany|Universitätsklinikum Erlangen, Erlangen, Germany|Krankenhaus Martha-Maria Nürnberg, Nuernberg, Germany|Universitätsklinikum Würzburg, Würzburg, Germany|Universitätsklinikum, Zürich, Switzerland",,https://ClinicalTrials.gov/show/NCT00325221
NCT00322504,Acupuncture for Anxiety in Women With Breast Cancer: A Feasibility Study,,Completed,No Results Available,Breast Cancer,Procedure: Accupuncture,,University of New Mexico,Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,10,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,INST 0520C,Jan-06,null,Sep-06,8-May-06,null,7-Jan-10,"University of New Mexico, Albuquerque, New Mexico, United States",,https://ClinicalTrials.gov/show/NCT00322504
NCT00322595,Efficacy and Safety Study of Seroquel SR in the Treatment of Generalized Anxiety Disorder,SILVER,Completed,No Results Available,Generalized Anxiety Disorder,Drug: Quetiapine fumarate|Drug: Paroxetine,To evaluate the efficacy compared to placebo in the treatment of anxiety symptoms in patients with generalized anxiety disorder (GAD) at Day 57 (= end of treatment).|To evaluate efficacy by evaluating response rate.,AstraZeneca,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,800,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,D1448C00011|2005-005054-46|Silver,May-06,null,May-07,8-May-06,null,22-Dec-08,"Research Site, City Bell, Buenos Aires, Argentina|Research Site, Godoy Cruz, Mendoza, Argentina|Research Site, Rosario, Santa Fe, Argentina|Research Site, Buenos Aires, Argentina|Research Site, Cordoba, Argentina|Research Site, La Plata, Argentina|Research Site, Mendoza, Argentina|Research Site, Kardjali, Bulgaria|Research Site, Ruse, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Veliko Tarnovo, Bulgaria|Research Site, Vratza, Bulgaria|Research Site, Kelowna, British Columbia, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, Miramichi, New Brunswick, Canada|Research Site, Corner Brook, Newfoundland and Labrador, Canada|Research Site, Sydney, Nova Scotia, Canada|Research Site, Brantford, Ontario, Canada|Research Site, Chatham, Ontario, Canada|Research Site, Markham, Ontario, Canada|Research Site, Mississauga, Ontario, Canada|Research Site, Orleans, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Gatineau, Quebec, Canada|Research Site, Sherbrooke, Quebec, Canada|Research Site, Saskatoon, Saskatchewan, Canada|Research Site, Brno, Czech Republic|Research Site, Litomerice, Czech Republic|Research Site, Olomouc, Czech Republic|Research Site, Plzen, Czech Republic|Research Site, Praha 10, Czech Republic|Research Site, Praha 2, Czech Republic|Research Site, Praha 5, Czech Republic|Research Site, Praha 6, Czech Republic|Research Site, Prerova, Czech Republic|Research Site, Prostojov, Czech Republic|Research Site, Arhus, Denmark|Research Site, Frederiksberg, Denmark|Research Site, Kobenhavn, Denmark|Research Site, Helsinki, Finland|Research Site, Jarvenpaa, Finland|Research Site, Salo, Finland|Research Site, Turku, Finland|Research Site, Angouleme, France|Research Site, Arcachon, France|Research Site, Cherbourg, France|Research Site, Elancourt, France|Research Site, La Valette Du Var, France|Research Site, Le Pecq, France|Research Site, NIMES Cedex 4, France|Research Site, Rennes, France|Research Site, Toulouse, France|Research Site, Bad Saarow, Germany|Research Site, Berlin, Germany|Research Site, Bochum, Germany|Research Site, Göttingen, Germany|Research Site, Hamburg, Germany|Research Site, München, Germany|Research Site, Siegen, Germany|Research Site, Distrito Federal, Mexico|Research Site, Guadalajara, Mexico|Research Site, Mexico, Mexico|Research Site, Brattvag, Norway|Research Site, Oslo, Norway|Research Site, Paradis, Norway|Research Site, Bucharest, Romania|Research Site, Pitesti, Romania|Research Site, Sibiu, Romania|Research Site, Bojnice, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Brezno, Slovakia|Research Site, Kosice, Slovakia|Research Site, Liptovsky Mikulas, Slovakia|Research Site, Zilina-Bytcica, Slovakia|Research Site, Bloemfontein, South Africa|Research Site, Cape Town, South Africa|Research Site, Durban, South Africa|Research Site, Pretoria, South Africa|Research Site, Barcelona, Spain|Research Site, Madrid, Spain|Research Site, Oviedo, Spain|Research Site, Salamanca, Spain|Research Site, Linkoping, Sweden|Research Site, Lund, Sweden|Research Site, Malmo, Sweden|Research Site, Sundsvall, Sweden|Research Site, Uppsala, Sweden",,https://ClinicalTrials.gov/show/NCT00322595
NCT00322803,"ELB139 Given Orally to Patients With Concurrent Panic Disorder, Challenged by CO2 Inhalation After a Single Dose and One Week of Treatment",,Terminated,No Results Available,Panic Disorder,Drug: ELB139,degree of subjective anxiety as measured on a Visual Analogue Scale for Anxiety(VAS-A) assessed immediately after the CO2-challenge (VAS-A-post)|difference of the degree of anxiety measured as the difference between the pre- and post challenge scores on the Visual Analogue Scale for Anxiety (VAS-A-delta)|Total Symptom Score assessed immediately after CO2 challenge (TSS-post)|Difference of the Total Symptoms Score (TSS) measured as the difference between the pre- and post challenge scores (TSS-delta),elbion AG,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,24,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment,ELB139202-05|EudraCT Number:2005-005708-17,May-06,null,Oct-06,8-May-06,null,29-Sep-06,"Charité – University Clinics Berlin, Berlin, Germany|Emovis, The institute of emotional health, Berlin, Germany|Academic Anxiety Center and Department of Psychiatry & Neuropsychology; Maastricht University, Maastricht, Netherlands",,https://ClinicalTrials.gov/show/NCT00322803
NCT00321971,Prevention of Depression in Spouses of People With Cognitive Impairment,,Completed,Has Results,Depression,Behavioral: PST-MCI/AD Caregiving|Behavioral: NT-MCI/AD Caregiving,Depressive Symptoms,University of Pittsburgh|National Institute of Mental Health (NIMH),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,73,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,K23MH070719,Feb-07,Dec-11,Dec-11,4-May-06,7-Mar-18,3-Apr-18,"University of Pittsburgh Alzheimer's Disease Research Center (ADRC), Pittsburgh, Pennsylvania, United States|Duquesne Univeristy, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00321971
NCT00318539,Addition of Quetiapine in Obsessive Compulsive Disorder - Westenberg Study,,Completed,No Results Available,Obsessive Compulsive Disorder,Drug: Quetiapine,"The change in Yale Brown obsessive compulsive scale (Y-BOCS) from baseline to week 10 and the number of responders are the primary efficacy parameters.|Criteria for response will be a 25% or greater change from baseline on the Y-BOCS and a final CGI rating of ""much improved or ""very much improved"".|The onset of response to treatment, using the time to a sustained response as criterion|Side effect profiles, Quality of life, Cognitive functioning",AstraZeneca,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,90,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,D1441C09907,Dec-03,null,Aug-06,27-Apr-06,null,21-Jan-11,"Research Site, Utrecht, Netherlands",,https://ClinicalTrials.gov/show/NCT00318539
NCT00318669,Social Anxiety Disorder Study Of Paroxetine,,Completed,No Results Available,Social Phobia,Drug: Paroxetine hydrochloride hydrate,Change from baseline in the LSAS total score at week 12 (Score at week 12 - Score at week 0)|Proportion of patients responding with a CGI Global Improvement Item score. Change from baseline in the CGI Severity of Illness score. Change from baseline in the HAM-D total score. Proportion of patients continuing treatment.,GlaxoSmithKline,All,18 Years to 64 Years   (Adult),Phase 3,390,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",PIR104776,Dec-05,Nov-06,Nov-06,27-Apr-06,null,15-Apr-13,"GSK Investigational Site, Fukuoka, Japan|GSK Investigational Site, Fukuoka, Japan|GSK Investigational Site, Fukuoka, Japan|GSK Investigational Site, Saitama, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site",,https://ClinicalTrials.gov/show/NCT00318669
NCT00316316,Cognitive Behavioral Therapy Plus Motivational Interviewing for Treatment of Obsessive-Compulsive Disorder,,Completed,No Results Available,Obsessive-Compulsive Disorder,Behavioral: Motivational interviewing plus exposure and response prevention (MI plus EX/RP)|Behavioral: Exposure and response prevention (EX/RP),"Obsessive-compulsive symptoms|Adherence, depression, insight, and quality of life",New York State Psychiatric Institute|National Institute of Mental Health (NIMH),All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,30,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,#5124|R34MH071570|DAHBR 96-BHA,Mar-06,Mar-10,Mar-10,20-Apr-06,null,16-Mar-12,"New York State Psychiatric Institute, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00316316
NCT00316355,Stepped Care for Treating Obsessive-Compulsive Disorder,,Completed,Has Results,Obsessive-compulsive Disorder,Behavioral: Traditional CBT|Behavioral: Stepped-Care CBT,Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) Total Score|Treatment-related Total Cost Estimates,Hartford Hospital|National Institute of Mental Health (NIMH),All,"18 Years to 69 Years   (Adult, Older Adult)",Not Applicable,34,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,R34MH071464,Jun-06,Jan-10,Jan-10,20-Apr-06,6-Jun-16,21-Feb-18,"Institute of Living/Hartford Hospital, Hartford, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT00316355
NCT00314210,Safety and Efficacy Maintenance Study of Quetiapine SR to Treat GAD Patients.,PLATINUM,Completed,No Results Available,Anxiety Disorders,Drug: Quetiapine SR,Time from randomisation to occurrence of an anxiety event|Occurrence of an anxiety event|Change from randomisation in HAM-A/CGI-S scores|In HAM-A psychic/somatic anxiety factor scores|In MADRS total score and in MADRS item 10 score (suicidal thought)|Change in Patient Reported Outcomes (PRO): QLESQ/PSQ/SDS,AstraZeneca,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,575,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,D1448C00012|EUDRACT Number: 2005-005055-18,Mar-06,null,Aug-07,13-Apr-06,null,25-Mar-09,"Research Site, Mesa, Arizona, United States|Research Site, Peoria, Arizona, United States|Research Site, Phoenix, Arizona, United States|Research Site, Fresno, California, United States|Research Site, La Mesa, California, United States|Research Site, Oceanside, California, United States|Research Site, Redlands, California, United States|Research Site, Coral Springs, Florida, United States|Research Site, Deland, Florida, United States|Research Site, Ft Myers, Florida, United States|Research Site, Gainsville, Florida, United States|Research Site, Hialeah, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, North Miami, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, St Petersberg, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Columbus, Georgia, United States|Research Site, Marietta, Georgia, United States|Research Site, Roswell, Georgia, United States|Research Site, Coeur D'alene, Idaho, United States|Research Site, Hoffman Estates, Illinois, United States|Research Site, Libertyville, Illinois, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Lafayette, Indiana, United States|Research Site, Valparaiso, Indiana, United States|Research Site, Prairie Village, Kansas, United States|Research Site, Owensboro, Kentucky, United States|Research Site, Paducah, Kentucky, United States|Research Site, Shreveport, Louisiana, United States|Research Site, Glen Burnie, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Cambridge, Massachusetts, United States|Research Site, Pittsfield, Massachusetts, United States|Research Site, St Charles, Missouri, United States|Research Site, Piscataway, New Jersey, United States|Research Site, Bronx, New York, United States|Research Site, Cedarhurst, New York, United States|Research Site, New York, New York, United States|Research Site, Rochester, New York, United States|Research Site, Avon Lake, Ohio, United States|Research Site, Beechwood, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research SIte, Middleburg Heights, Ohio, United States|Research Site, Toledo, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Allentown, Pennsylvania, United States|Research Site, Havertown, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, N. Charleston, South Carolina, United States|Research Site, Memphis, Tennessee, United States|Research Site, Desoto, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Wichita Falls, Texas, United States|Research Site, Midvale, Utah, United States|Research Site, Richmond, Virginia, United States|Research Site, Brisbane, Queensland, Australia|Research Site, Everton Park, Queensland, Australia|Research Site, West Burleigh, Queensland, Australia|Research Site, Malvern, Victoria, Australia|Research Site, Prahran, Victoria, Australia|Research Site, Edmonton, Alberta, Canada|Research Site, Bathurst, New Brunswick, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, Kingston, Ontario, Canada|Research Site, Orleans, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Waterloo, Ontario, Canada|Research Site, Gatineau, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Helsinki, Finland|Research Site, Joensuu, Finland|Research Site, Kuopio, Finland|Research Site, Oulu, Finland|Research Site, Pori, Finland|Research Site, Seinajoki, Finland|Research Site, Turku, Finland|Research Site, Berlin, Germany|Research Site, Gottingen, Germany|Research Site, Jena, Germany|Research Site, Leipzig, Germany|Research Site, München, Germany|Research Site, Naumburg, Germany|Research Site, Nurnberg, Germany|Research Site, Schwerin, Germany|Research Site, Siegen, Germany|Research Site, Balassagyarmat, Hungary|Research Site, Budapest, Hungary|Research Site, Gyor, Hungary|Research Site, Gyula, Hungary|Research Site, Kecskemét, Hungary|Research Site, Nyíregyháza, Hungary|Research Site, Bandung, West Java, Indonesia|Research Site, Jakarta, Indonesia|Research Site, Seoul, Korea, Republic of|Research Site, Cebu City, Philippines|Research Site, Davao City, Philippines|Research Site, Mandaluyong City, Philippines|Research Site, Manila, Philippines|Research Site, Quezon City, Philippines|Research Site, Moscow, Russian Federation|Research Site, Saratov, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, Reading, Berkshire, United Kingdom|Research Site, Crawley, West Sussex, United Kingdom|Research Site, Blackpool, United Kingdom|Research Site, Bolton, United Kingdom|Research Site, Cardiff, United Kingdom|Research Site, Chorley, United Kingdom|Research Site, Coventry, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Hamilton, United Kingdom|Research Site, Liverpool, United Kingdom|Research Site, Manchester, United Kingdom",,https://ClinicalTrials.gov/show/NCT00314210
NCT00310427,Effect of LY686017 on Alcohol Craving,,Completed,Has Results,Alcohol Dependence|Alcoholism,Drug: LY686017|Drug: Placebo,"Craving for Alcohol (Spontaneous)|Change From Baseline in Spontaneous Alcohol Craving at Week 1, During the First of Two Weekly Ratings.|Change From Baseline in Spontaneous Alcohol Craving at Week 1, During the Second of Two Weekly Ratings.|Change From Baseline in Spontaneous Alcohol Craving at Week 2, During the First of Two Weekly Ratings.|Change From Baseline in Spontaneous Alcohol Craving at Week 2, During the Second of Two Weekly Ratings.|Change From Baseline in Spontaneous Alcohol Craving at Week 3, During the First of Two Weekly Ratings.|Change From Baseline in Spontaneous Alcohol Craving at Week 3, During the Second of Two Weekly Ratings.|Craving for Alcohol Evoked by Alcohol-cue Challenge",National Institute on Alcohol Abuse and Alcoholism (NIAAA)|Eli Lilly and Company|National Institutes of Health Clinical Center (CC),All,"21 Years to 65 Years   (Adult, Older Adult)",Phase 2,66,NIH|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",060129|06-AA-0129,Mar-06,Mar-08,Mar-08,3-Apr-06,9-Apr-10,20-Apr-10,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00310427
NCT00308724,Treating Late-Life Generalized Anxiety Disorder (GAD) in Primary Care,,Completed,No Results Available,Generalized Anxiety Disorder,Behavioral: Cognitive Behavior Therapy|Behavioral: Telephone check-in,Anxiety|Functional and health status|Quality of life|Satisfaction with CBT and general health care|Service utilization|Depression|Sleep quality|Use of alcohol and other substances,"Baylor College of Medicine|National Institute of Mental Health (NIMH)|National Institutes of Health (NIH)|The University of Texas Health Science Center, Houston|Kelsey Research Foundation|Kelsey-Seybold Clinic|VA Medical Center, Houston",All,"60 Years and older   (Adult, Older Adult)",Phase 3,148,Other|NIH|U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,H15958|R01MH053932,Mar-04,Jan-08,Apr-15,30-Mar-06,null,23-Jul-15,"Houston Center for Quality of Care and Utilization Studies, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00308724
NCT00307697,A Letter Intervention in Primary Care Patients to Improve Depression and Anxiety Disorders,,Completed,No Results Available,Depression|Anxiety,Procedure: receipt of copy of psychiatic assessment letter,score on a depression/anxiety rating scale at 1 month and 3 months|score on a quality of life scale at 1 month and 3 months,Bayside Health|Beyondblue (The National Depression Initiative),All,"18 Years and older   (Adult, Older Adult)",Phase 1,200,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PMHT-01/06,Jun-06,Sep-07,Sep-07,28-Mar-06,null,28-Nov-13,"Primary Mental Health and Early Intervention Team, Melbourne, Victoria, Australia",,https://ClinicalTrials.gov/show/NCT00307697
NCT00307320,Study Examining Stress During Pregnancy,,Unknown status,No Results Available,Stress,Behavioral: Relaxation Training,,University of Virginia|University of Arizona,Female,18 Years to 40 Years   (Adult),Not Applicable,40,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HIC 12234,Mar-06,Dec-09,Dec-09,27-Mar-06,null,30-Dec-09,"University of Virginia, Department of Psychology, Charlottesville, Virginia, United States",,https://ClinicalTrials.gov/show/NCT00307320
NCT00305500,Tolerability and Efficacy of High Dose Escitalopram for the Treatment of Obsessive-Compulsive Disorder (OCD),,Completed,No Results Available,Obsessive-Compulsive Disorder,Drug: escitalopram,Safety as recorded by adverse-events and side-effects reports.|Reduction in YBOCS scores at week 18,Abarbanel Mental Health Center,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,100,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EscitaHD001,Mar-06,null,Dec-06,22-Mar-06,null,26-Jul-06,"Abarbanel MHC, Bat-Yam, Israel",,https://ClinicalTrials.gov/show/NCT00305500
NCT00302770,Efficacy of Quetiapine in Generalised Social Anxiety Disorder,,Terminated,No Results Available,Social Anxiety Disorder,Drug: quetiapine,"Change on Lebowitz Social Anxiety Scale (LSAS) from baseline to endpoint|Number of responders, time to onset of response of sustained response to treatment",AstraZeneca,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,50,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,D1449C00008,Jun-06,Dec-06,Dec-06,15-Mar-06,null,27-Jan-11,"Research Site, Utrecht, Netherlands",,https://ClinicalTrials.gov/show/NCT00302770
NCT00302978,Changes in Brain Activity (Functional MRI Study) Before and After Behavioral Therapy of Height Phobia,,Completed,No Results Available,Height Phobia|Fear of Heights,Behavioral: Behavior therapy,CGI|acrophobia questionnaire,New York State Psychiatric Institute,All,18 Years to 40 Years   (Adult),Not Applicable,40,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,5215,Mar-06,null,Jun-06,15-Mar-06,null,15-Dec-11,,,https://ClinicalTrials.gov/show/NCT00302978
NCT00303147,Cognitive and Health Benefits of Expressive Writing for Family Caregivers Under Stress,,Unknown status,No Results Available,"Stress, Psychological|Anxiety",Behavioral: Expressive Writing,General Health Questionnaire|Impact of Events Scale|Zarit Burden Interview (short form)|California Verbal Learning Test|Ruff 2 & 7 Selective Attention Test|Wechsler Adult Intelligence Scale (WAIS),University of Toronto|Baycrest Centre for Geriatric Care,All,"18 Years and older   (Adult, Older Adult)",Phase 1,120,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,11438,May-03,null,Jul-05,15-Mar-06,null,15-Mar-06,"University of Toronto, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT00303147
NCT00302744,Effects of Psilocybin in Advanced-Stage Cancer Patients With Anxiety,,Completed,No Results Available,Anxiety,Drug: Psilocybin (drug),Anxiety,Los Angeles Biomedical Research Institute|Heffter Research Institute,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,12,Other,Interventional,"Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",HEFFTER11287-01,Apr-04,Dec-08,Dec-08,14-Mar-06,null,29-Jan-13,"Harbor-UCLA Medical Center, Torrance, California, United States",,https://ClinicalTrials.gov/show/NCT00302744
NCT00302107,A Placebo-Controlled Study of Mirtazapine for PTSD,,Completed,Has Results,Anxiety|PTSD,Drug: Mirtazapine|Drug: Placebo,Structured Interview of Posttraumatic Stress Disorder (SIP),US Department of Veterans Affairs|VA Office of Research and Development,All,"19 Years to 65 Years   (Adult, Older Adult)",Phase 4,78,U.S. Fed,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MHBA-019-05F,Apr-06,May-11,Jun-12,13-Mar-06,26-Nov-14,26-Nov-14,"Tuscaloosa VAMC, Tuscaloosa, Alabama, United States",,https://ClinicalTrials.gov/show/NCT00302107
NCT00299611,Augmentation Study of Levetiracetam in Obsessive Compulsive Disorder,,Terminated,No Results Available,Obsessive-Compulsive Disorder,Drug: Sertraline|Drug: Levetiracetam|Drug: Placebo,Clinical Global Impression-improvement (CGI-I)|Yale-Brown Obsessive-Compulsive Scale (YBOCS)|Hospital Anxiety and Depression Scale|Sheehan Disability Scale (SDS),Duke University|UCB Pharma,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2|Phase 3,12,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Pro00008596,Nov-05,Dec-07,Apr-08,7-Mar-06,null,11-Apr-13,"Duke University Medical Center, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT00299611
NCT00296790,Ambien CR vs. Placebo For Treatment Of Insomnia Associated With Anxiety When Used Concomitantly With Escitalopram (Lexapro),,Completed,No Results Available,Insomnia,Drug: zolpidem tartrate,Evaluate safety and hypnotic efficacy of zolpidem tartrate extended release vs. placebo in treatment of insomnia associated with Generalized Anxiety Disorder when used concomitantly with escitalopram|To show that treating insomnia from beginning of SSRI (Selective Serotonin Reuptake Inhibitor) treatment for anxiety results in improvement in quality of life and possibly greater response to anti-anxiety therapy,Sanofi,All,21 Years to 64 Years   (Adult),Phase 4,372,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,PM_L_0167,Feb-06,null,Feb-07,27-Feb-06,null,12-Oct-07,"Sanofi-Aventis, Bridgewater, New Jersey, United States",,https://ClinicalTrials.gov/show/NCT00296790
NCT00294346,Safety and Efficacy Study of AV608 in Subjects With Social Anxiety Disorder,,Completed,No Results Available,Social Phobia,Drug: AV608,Liebowitz Social Anxiety Scale (LSAS),Avera Pharmaceuticals,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,180,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,AV608-105,Feb-06,Dec-06,Dec-06,22-Feb-06,null,25-Feb-08,"Birmingham Research Group, Inc., Birmingham, Alabama, United States|Pivotal Research Centers, Mesa, Arizona, United States|Southwestern Research, Inc., Beverly Hills, California, United States|Affiliated Research Institute, San Diego, California, United States|CNS Healthcare, Jacksonville, Florida, United States|Comprehensive Neuroscience, Inc., Saint Petersburg, Florida, United States|University of South Florida, Tampa, Florida, United States|DuPont Clinical Research, Inc., Rockville, Maryland, United States|Capital Clinical Research Associates, Rockville, Maryland, United States|Medical Research Network, LLC, New York, New York, United States|Hartford Research, Cincinnatti, Ohio, United States|IPS Research Company, Oklahoma City, Oklahoma, United States|Summit Research Network, Portland, Oregon, United States|Claghorn-Lesem Research Clinic, LLP, Bellaire, Texas, United States|Croft Group Research Center, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT00294346
NCT00291031,Study of the Effect of Imagery Rehearsal Therapy (IRT) of Nightmares,,Completed,No Results Available,Nightmares|Anxiety Disorders|Mood Disorders|Personality Disorders,Behavioral: Imagery Rehearsal Therapy (IRT),Frequency of nightmares scored in prospective daily nightmare logs|Frequency of nightmares scored on the Nightmare Frequency Questionnaire|Intensity of nightmares scored in prospective daily nightmare logs|Effects of nightmares scored on the Nightmare Effects Survey|Nightmare distress scored on the Nightmare Distress Questionnaire|Sleep problems scored on the SLEEP-50|Psychiatric symptoms scored on the Symptom Check List (SCL-90)|Symptoms of post-traumatic stress disorder scored on the Zelf Inventarisatie Lijst PTSS ZIL (= PTSD Inventory)|Quality of life scored on the abbreviated World Health Organization Quality of Life scale (WHOQoL-Bref)|Nightmare efficacy and content measured by Nightmare Efficacy & Content Questionnaire,GGZ Centraal|Utrecht University,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,112,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,WO-SG-114NM,Feb-06,Jan-11,Aug-11,13-Feb-06,null,17-Oct-13,"GGZ Centraal, De Meregaard, Almere, Netherlands|GGZ Centraal, Zon & Schild, Amersfoort, Netherlands|GGZ Centraal, De Rembrandthof, Hilversum, Netherlands",,https://ClinicalTrials.gov/show/NCT00291031
NCT00291070,Effects of L-Theanine in Boys With ADHD,,Completed,No Results Available,Attention Deficit Hyperactivity Disorder,Drug: L-theanine,"Cognitive performance|Sleep quality, hyperactive behaviors, anxiety",University of British Columbia,Male,8 Years to 12 Years   (Child),Phase 2,100,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",C04-0605,Oct-05,Jul-06,Jul-06,13-Feb-06,null,6-May-08,"Canadian Center for Functional Medicine, Coquitlam, British Columbia, Canada",,https://ClinicalTrials.gov/show/NCT00291070
NCT00289432,Hospital Based Group Intervention for Breast Cancer Patients.,,Completed,No Results Available,Breast Cancer|Anxiety|Depression|Quality of Life|Coping,Behavioral: Psychoeducative|Other: Support group,Scores on Health-related quality of life,Ullevaal University Hospital|The Royal Norwegian Ministry of Health|Oslo University Hospital,Female,"18 Years to 74 Years   (Adult, Older Adult)",Not Applicable,450,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor),INCAM,Apr-06,Feb-09,Dec-14,9-Feb-06,null,30-Apr-15,"Ullevaal University Hospital, Oslo, Norway",,https://ClinicalTrials.gov/show/NCT00289432
NCT00288899,Benefits of 'Repeat Back' Protocols Within A Computer-Based Informed Consent Program,,Completed,No Results Available,"Surgery|Cholecystectomy, Laparoscopic|Prostatectomy|Arthroplasty, Replacement, Hip|Endarterectomy, Carotid","Other: Enhanced surgical iMedConsent process (with ""repeat back"")|Other: standard surgical iMedConsent process",Patient comprehension; Patient satisfaction; Patient anxiety; Patient compliance; Provider acceptance|Risk-adjusted surgical outcomes,VA Office of Research and Development,All,"18 Years and older   (Adult, Older Adult)",Phase 1,575,U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Health Services Research,IAF 05-308,7-Aug-06,31-Mar-09,31-Mar-09,8-Feb-06,null,6-Jun-17,"VA Eastern Colorado Health Care System, Denver, CO, Denver, Colorado, United States|James A. Haley Veterans' Hospital, Tampa, FL, Tampa, Florida, United States|Atlanta VA Medical and Rehab Center, Decatur, GA, Decatur, Georgia, United States|VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA, Boston, Massachusetts, United States|VA Portland Health Care System, Portland, OR, Portland, Oregon, United States|VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA, Pittsburgh, Pennsylvania, United States|Michael E. DeBakey VA Medical Center, Houston, TX, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00288899
NCT00283660,"Zinc, Mental Health, and School Performance in Guatemalan Schoolchildren",,Completed,No Results Available,Depression|Anxiety,Dietary Supplement: 10 mg zinc oxide|Other: Placebo,Symptoms of depression|Symptoms of anxiety|attention problems and school performance|activity levels|zinc levels,Emory University|National Institute of Mental Health (NIMH)|Institute of Nutrition of Central America and Panama (INCAP)|Mexican National Institute of Public Health,All,7 Years to 11 Years   (Child),Not Applicable,750,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",IRB00045755|R01MH067981|DSIR 84-CTM,Jan-06,Oct-06,Oct-06,30-Jan-06,null,17-Nov-15,"Instituto de Nutrición de Centro América y Panamá - INCAP, Guatemala City, Guatemala",,https://ClinicalTrials.gov/show/NCT00283660
NCT00282828,Improving Treatment Outcomes in Pharmacotherapy of Generalized Social Anxiety Disorder,,Completed,Has Results,Social Phobia,Drug: Sertraline|Drug: Venlafaxine|Drug: Placebo|Drug: Clonazepam,"Rates of Remission (LSAS≤30) After 12 Weeks of Randomized Treatment During Phase II, Among Phase I Non-responders|Post-treatment Social Phobia Severity as Defined by Endpoint LSAS Scores",Massachusetts General Hospital|National Institute of Mental Health (NIMH),All,"18 Years and older   (Adult, Older Adult)",Phase 4,397,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",R01MH070919|PA-01-123|DSIR 83-ATAS,Mar-06,Dec-11,Dec-11,27-Jan-06,14-Oct-13,14-Oct-13,"University of California San Diego, La Jolla, California, United States|Center for Anxiety and Traumatic Stress Disorders, Boston, Massachusetts, United States|McMaster University Medical Centre Anxiety Disorders Clinic, Hamilton, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT00282828
NCT00280670,"CBT for Comorbid Anxiety Disorders in Children With Autism, Asperger Syndrome, or PDD-NOS",BIACA,Completed,No Results Available,Autistic Disorder|Asperger Syndrome|Anxiety Disorders,Behavioral: Cognitive-behavioral therapy,Score on anxiety diagnostic interview after treatment or waitlist|Score on anxiety rating scale after treatment or waitlist|Score on daily living skills rating scale after treatment or waitlist|Score on children's social functioning and service use after treatment or waitlist,"University of California, Los Angeles",All,7 Years to 11 Years   (Child),Phase 2,20,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,R03MH075806-01,Jan-05,Aug-08,Aug-09,23-Jan-06,null,2-Apr-12,"University of California, Los Angeles, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT00280670
NCT00279617,Levetiracetam Treatment of Panic Disorder and Lactate-Induced Panic Attacks,,Completed,No Results Available,Panic Disorder,Drug: levetiracetam,Hamilton Anxiety scale (HAM-A),Lindner Center of HOPE|UCB Pharma|University of Cincinnati,All,"18 Years and older   (Adult, Older Adult)",Phase 3,15,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2-Miefert,Jan-06,Feb-09,Mar-09,19-Jan-06,null,13-Dec-11,"University of Cincinnati Medical Center, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT00279617
NCT00277654,Study of Risperidone Monotherapy in Ambulatory Bipolar Disorder With Concurrent Moderately Severe Anxiety and Lifetime Panic or Generalized Anxiety Disorder,,Completed,No Results Available,Bipolar Disorder|Anxiety Disorder,Drug: Risperidone,Clinical Global Improvement-21 Anxiety scale (CGI-21 Anxiety)|Hamilton Anxiety scale (HAM-A),Lindner Center of HOPE|Janssen Pharmaceuticals|University of Cincinnati,All,"18 Years and older   (Adult, Older Adult)",Phase 3,111,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",RIS-PAD-402,Feb-04,Mar-09,Mar-09,16-Jan-06,null,13-Dec-11,"University of Cincinnati Medical Center, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT00277654
NCT00273039,A Study Of A New Medicine (GW679769) For The Treatment Of Social Anxiety Disorder,,Completed,No Results Available,Social Anxiety Disorder|Anxiety Disorders,Drug: paroxetine,"The primary outcome measure will be the change from baseline in the Liebowitz Social Anxiety Scale (LSAS)|Secondary outcome measures include the change from baseline in the following scales: the Clinical Global Impression-Global Improvement, the Clinical Global Impression -Severity of Illness, and the Sheehan Disability Scale.",GlaxoSmithKline,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,242,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,NKF100110,Aug-05,Sep-06,Sep-06,9-Jan-06,null,26-Oct-16,"GSK Investigational Site, Beverly Hills, California, United States|GSK Investigational Site, Burbank, California, United States|GSK Investigational Site, Jacksonville, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, North Miami, Florida, United States|GSK Investigational Site, Orlando, Florida, United States|GSK Investigational Site, Smyrna, Georgia, United States|GSK Investigational Site, Oakbrook Terrace, Illinois, United States|GSK Investigational Site, Rockville, Maryland, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, Oklahoma City, Oklahoma, United States|GSK Investigational Site, Philadelphia, Pennsylvania, United States|GSK Investigational Site, Lake Jackson, Texas, United States|GSK Investigational Site, La Plata/Buenos Aires, Buenos Aires, Argentina|GSK Investigational Site, Cordoba, Córdova, Argentina|GSK Investigational Site, Buenos Aires, Argentina|GSK Investigational Site, Ciudad Autonoma de Buenos Aires, Argentina|GSK Investigational Site, Edmonton, Alberta, Canada|GSK Investigational Site, Kelowna, British Columbia, Canada|GSK Investigational Site, Miramichi, New Brunswick, Canada|GSK Investigational Site, Providencia / Santiago, Región Metro De Santiago, Chile|GSK Investigational Site, Santiago, Región Metro De Santiago, Chile|GSK Investigational Site, San José, Costa Rica|GSK Investigational Site, Monterrey, Nuevo León, Mexico|GSK Investigational Site, Mexico, D.F., Mexico",,https://ClinicalTrials.gov/show/NCT00273039
NCT00269594,An Open-Label Study Of Lamictal In Neurotic Excoriation,,Completed,No Results Available,Neurotic Disorders|Obsessive-Compulsive Disorder,Drug: Lamictal (lamotrigine),Yale-Brown Obsessive Compulsive Scale Modified for Neurotic Excoriation|Skin Picking Symptom Assessment Scale (SP-SAS) and the Clinical Global Impression scale,University of Minnesota - Clinical and Translational Science Institute,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,25,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0510M77009,Jan-06,null,Sep-06,23-Dec-05,null,30-Apr-07,"University of Minnesota, Minneapolis, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT00269594
NCT00267566,Strongest Families (Formerly Family Help Program): Pediatric Anxiety,FHP-ANX,Completed,No Results Available,Anxiety Disorder,Behavioral: Strongest Families (formerly Family Help Program): Anxiety Program,Diagnosis using KSADS|Symptomology frequency as evidenced by diary data;|Anxiety specific measure (MASC- self-report);|Disability Measure;|Child Health Questionnaire|Economic Outcome assessment,IWK Health Centre|Canadian Institutes of Health Research (CIHR),All,6 Years to 12 Years   (Child),Phase 2,91,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,2234a|CIHR CAHR-43273,Aug-03,Sep-07,Apr-08,21-Dec-05,null,12-Sep-13,"IWK Health Centre, Halifax, Nova Scotia, Canada",,https://ClinicalTrials.gov/show/NCT00267566
NCT00266747,An Eight-Week Study to Evaluate the Efficacy and Safety of SR58611A in Patients With Generalized Anxiety Disorder,AQUARIUS,Completed,No Results Available,Anxiety Disorders,Drug: SR58611A,"The primary outcome of the study is the change from baseline to Day 56 of treatment in the Hamilton Anxiety Rating Scale (HAM-A) total score.|The main secondary outcomes are the changes from baseline to Day 56 of treatment in the CGI Severity of Illness Score, percentage of patients with HAM-A treatment response and change from baseline in the HAM-A somatic and psychic anxiety factor scores.",Sanofi,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,366,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",EFC5893,Dec-05,Jan-07,Jan-07,19-Dec-05,null,12-Mar-09,"Sanofi-Aventis Administrative Office, Buenos Aires, Argentina|Sanofi-Aventis Administrative Office, Vienna, Austria|Sanofi-Aventis Administrative Office, Tallinn, Estonia|Sanofi-Aventis Administrative Office, Paris, France|Sanofi-Aventis Administrative Office, Moscow, Russian Federation|Sanofi-Aventis Administrative Office, Midrand, South Africa|Sanofi-Aventis Administrative Office, Bromma, Sweden",,https://ClinicalTrials.gov/show/NCT00266747
NCT00266409,Trial to Compare Time to Response in the Symptoms of Anxiety to Concomitant Treatment With Niravam™ and an SSRI or SNRI to Treatment With an SSRI or SNRI Alone in Subjects With Generalized Anxiety Disorder or Panic Disorder,,Completed,Has Results,Generalized Anxiety Disorder|Panic Disorder,Drug: Niravam|Drug: SSRI/SNRI,Cumulative Percent of Participants Showing a Response in the Symptoms of Anxiety (Decrease in Total Hamilton Anxiety (HAM-A) -Score of >=50%) in the Intent-to-treat Population (Kaplan-Meier-estimates)|Cumulative Percent of Participants Showing a Response in the Symptoms of Anxiety (Decrease in Total Hamilton Anxiety (HAM-A) -Score of >=50%) in the Per Protocol Population (Kaplan-Meier-estimates)|Change From Baseline in the Total HAM-A Score After 1 Week|Change From Baseline in the Total HAM-A Score After 2 Weeks|Change From Baseline in the Total HAM-A Score After 3 Weeks|Change From Baseline in the Total HAM-A Score After 4 Weeks|Change From Baseline in the Total HAM-A Score After 5 Weeks|Change From Baseline in the Total HAM-A Score After 6 Weeks|Change From Baseline in the Total HAM-A Score After 7 Weeks|Change From Baseline in the Total HAM-A Score After 8 Weeks|Change From Baseline in the Total HAM-A Score at Endpoint During the 8 Week Treatment Period|Clinical Response (Decrease From Baseline in Total HAM-A-score >=50%) After 1 Week|Clinical Response (Decrease From Baseline in Total HAM-A-score >=50%) After 2 Weeks|Clinical Response (Decrease From Baseline in Total HAM-A-score >=50%) After 3 Weeks|Clinical Response (Decrease From Baseline in Total HAM-A-score >=50%) After 4 Weeks|Clinical Response (Decrease From Baseline in Total HAM-A-score >=50%) After 5 Weeks|Clinical Response (Decrease From Baseline in Total HAM-A-score >=50%) After 6 Weeks|Clinical Response (Decrease From Baseline in Total HAM-A-score >=50%) After 7 Weeks|Clinical Response (Decrease From Baseline in Total HAM-A-score >=50%) After 8 Weeks|Clinical Response (Decrease From Baseline in Total HAM-A-score >=50%) at Endpoint During the 8 Week Treatment Period|Change in Severity of Illness From Baseline Using the Clinical Global Impression Improvement (CGI-I) Score After 2 Weeks|Change in Severity of Illness From Baseline Using the Clinical Global Impression - Improvement (CGI-I) Score After 4 Weeks|Change in Severity of Illness From Baseline Using the Clinical Global Impression - Improvement (CGI-I) Score After 8 Weeks|Change in Severity of Illness From Baseline Using the Clinical Global Impression - Improvement (CGI-I) Score at Endpoint During the 8 Week Treatment Period|Subject's Assessment of Treatment Effect as Measured by the Patient Global Impression (PGI) Score After 1 Week|Subject's Assessment of Treatment Effect as Measured by the Patient Global Impression (PGI) Score After 2 Weeks|Subject's Assessment of Treatment Effect as Measured by the Patient Global Impression (PGI) Score After 3 Weeks|Subject's Assessment of Treatment Effect as Measured by the Patient Global Impression (PGI) Score After 4 Weeks|Subject's Assessment of Treatment Effect as Measured by the Patient Global Impression (PGI) Score After 5 Weeks|Subject's Assessment of Treatment Effect as Measured by the Patient Global Impression (PGI) Score After 6 Weeks|Subject's Assessment of Treatment Effect as Measured by the Patient Global Impression (PGI) Score After 7 Weeks|Subject's Assessment of Treatment Effect as Measured by the Patient Global Impression (PGI) Score After 8 Weeks|Subject's Assessment of Treatment Effect as Measured by the Patient Global Impression (PGI) Score at Endpoint During the 8 Week Treatment Period|Change From Baseline in HAM-A-insomnia Subscore After 1 Week|Change From Baseline in HAM-A-insomnia Subscore After 2 Weeks|Change From Baseline in HAM-A-insomnia Subscore After 3 Weeks|Change From Baseline in HAM-A-insomnia Subscore After 4 Weeks|Change From Baseline in HAM-A-insomnia Subscore After 5 Weeks|Change From Baseline in HAM-A-insomnia Subscore After 6 Weeks|Change From Baseline in HAM-A-insomnia Subscore After 7 Weeks|Change From Baseline in HAM-A-insomnia Subscore After 8 Weeks|Change From Baseline in HAM-A-insomnia Subscore at Endpoint During the 8 Week Treatment Period|Change From Baseline in HAM-A-psychic Factors Subscore After 1 Week|Change From Baseline in HAM-A-psychic Factors Subscore After 2 Weeks|Change From Baseline in HAM-A-psychic Factors Subscore After 3 Weeks|Change From Baseline in HAM-A-psychic Factors Subscore After 4 Weeks|Change From Baseline in HAM-A-psychic Factors Subscore After 5 Weeks|Change From Baseline in HAM-A-psychic Factors Subscore After 6 Weeks|Change From Baseline in HAM-A-psychic Factors Subscore After 7 Weeks|Change From Baseline in HAM-A-psychic Factors Subscore After 8 Weeks|Change From Baseline in HAM-A-psychic Factors Subscore at Endpoint During the 8 Week Treatment Period|Change From Baseline in HAM-A-somatic Subscore After 1 Week|Change From Baseline in HAM-A-somatic Subscore After 2 Weeks|Change From Baseline in HAM-A-somatic Subscore After 3 Weeks|Change From Baseline in HAM-A-somatic Subscore After 4 Weeks|Change From Baseline in HAM-A-somatic Subscore After 5 Weeks|Change From Baseline in HAM-A-somatic Subscore After 6 Weeks|Change From Baseline in HAM-A-somatic Subscore After 7 Weeks|Change From Baseline in HAM-A-somatic Subscore After 8 Weeks|Change From Baseline in HAM-A-somatic Subscore at Endpoint During the 8 Week Treatment Period|Presence of Any Panic Attack(s) (for Subjects With Panic Disorder Only) After 1 Week|Presence of Any Panic Attack(s) (for Subjects With Panic Disorder Only) After 2 Weeks|Presence of Any Panic Attack(s) (for Subjects With Panic Disorder Only) After 3 Weeks|Presence of Any Panic Attack(s) (for Subjects With Panic Disorder Only) After 4 Weeks|Presence of Any Panic Attack(s) (for Subjects With Panic Disorder Only) After 5 Weeks|Presence of Any Panic Attack(s) (for Subjects With Panic Disorder Only) After 6 Weeks|Presence of Any Panic Attack(s) (for Subjects With Panic Disorder Only) After 7 Weeks|Presence of Any Panic Attack(s) (for Subjects With Panic Disorder Only) After 8 Weeks|Presence of Any Panic Attack(s) (for Subjects With Panic Disorder Only) at Endpoint During the 8 Week Treatment Period,UCB Pharma,All,"18 Years and older   (Adult, Older Adult)",Phase 4,418,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SP0851,Oct-05,Jun-06,Jun-06,16-Dec-05,2-Oct-09,27-Oct-14,"Schwarz, Milwaukee, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT00266409
NCT00264654,Long-term Study Of Paroxetine in Women and Men,SAD,Completed,No Results Available,Social Phobia,Drug: BRL29060A|Drug: paroxetine hydrochloride hydrate,Change from baseline in the LSAS total score at week 52 (Score at week 52- Score at week 0)|Proportion of patients responding with a CGI Global Improvement Item. Change from baseline in the CGI Severity of Illness score. Change from baseline in the HAM-D total score. Proportion of patients continuing treatment.,GlaxoSmithKline,All,18 Years to 64 Years   (Adult),Phase 3,50,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PIR104777,Oct-05,Nov-05,Nov-05,13-Dec-05,null,15-Apr-13,"GSK Investigational Site, Saitama, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site",,https://ClinicalTrials.gov/show/NCT00264654
NCT00264238,Memantine Augmentation in Obsessive-Compulsive Disorder,,Completed,Has Results,Obsessive-Compulsive Disorder,Drug: Memantine,Mean Change in Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) From Baseline to End of Treatment (12 Weeks)|Mean Change in Montgomery-Asberg Depression Rating Scale (MADRS) From Baseline to End of Treatment (12 Weeks),Stanford University,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,15,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SUSPO34313,Jan-06,Jun-08,Jun-08,12-Dec-05,7-Mar-17,30-May-17,"Stanford University School of Medicine, Stanford, California, United States",,https://ClinicalTrials.gov/show/NCT00264238
NCT00261261,Family-Centered Behavioral Preparation for Surgery,,Completed,No Results Available,Anxiety,Behavioral: ADVANCE|Drug: Midazolam|Procedure: Parental presence,Anxiety in children: modified Yale Preoperative anxiety scale|Anxiety in parents: STAI|Emergence delirium|Analgesic consumption|Time to discharge from recovery room,Yale University|National Center for Research Resources (NCRR),All,2 Years to 10 Years   (Child),Not Applicable,400,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Treatment,ADVANCE,Jan-01,null,Dec-04,2-Dec-05,null,2-Dec-05,"Yale University, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT00261261
NCT00260533,Efficacy and Tolerability of Atomoxetine (Strattera) in Adult Patients With Generalized Social Anxiety Disorder,,Completed,Has Results,Generalized Social Phobia,Drug: atomoxetine|Drug: placebo,"Clinical Global Impression (Change Version, Also Known as Improvement Version)","University of California, San Diego|Eli Lilly and Company",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2|Phase 3,27,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",40100,Nov-05,Jul-08,Jul-08,1-Dec-05,11-Mar-14,24-Jun-16,,,https://ClinicalTrials.gov/show/NCT00260533
NCT00257361,D-Cycloserine Augmentation of Exposure and Response Prevention Treatment for Obsessive-Compulsive Disorder,,Withdrawn,No Results Available,Obsessive Compulsive Disorder,Drug: D-Cycloserine,YBOCS|Response rate,University of Florida|Obsessive Compulsive Foundation,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,0,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label),IRB Protocol #639-2004|00053428,Jul-05,null,null,22-Nov-05,null,30-Sep-13,,,https://ClinicalTrials.gov/show/NCT00257361
NCT00254735,Quetiapine Augmentation in Severe Obsessive Compulsive Disorder,,Completed,No Results Available,Obsessive Compulsive Disorder,Drug: quetiapine fumarate|Drug: SSRI/Clomipramine,Absolute change of OCD symptoms from baseline to endpoint on the total Y-BOCS score.|Change of comorbid psychiatric symptoms and measures of quality of life from baseline to endpoint documented by different scales.|Evaluation of the safety and tolerability profile of quetiapine compared to placebo added to a baseline medication of SSRI/clomipramine.,AstraZeneca,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,44,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,5077/9059|D1441C09059,Apr-02,null,Mar-06,17-Nov-05,null,18-Dec-07,"Research Site, Freiburg, Germany|Research Site, Lübeck, Germany",,https://ClinicalTrials.gov/show/NCT00254735
NCT00255112,TAFF-Psychological Treatment of Separation Anxiety Disorder,,Completed,No Results Available,Separation Anxiety Disorder,Behavioral: family based cognitive behavior therapy,DSM-IV criteria for Separation Anxiety Disorder|Global Success Rating (GSR)|Separation Anxiety Inventory for Children (SAI)|Revised Children's Manifest Anxiety Scale (RCMAS)|Sheehan Disability Scale (SDS)|Inventory for the Assessment of Quality of Life in Children and Adolescents (IQL),"University Hospital, Basel, Switzerland|Swiss National Science Foundation",All,5 Years to 13 Years   (Child),Not Applicable,64,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PP001--68701|Trennungsangstprojekt NZX 1303,Jun-04,Dec-09,null,17-Nov-05,null,11-Jun-15,"Institute of Psychology, Basel, Basel-Stadt, Switzerland",,https://ClinicalTrials.gov/show/NCT00255112
NCT00252174,MDMA-assisted Therapy in People With Anxiety Related to Advanced Stage Cancer,,Terminated,Has Results,Anxiety Disorder|Cancer,Drug: Stage 1 Active Methylenedioxymethamphetamine|Drug: Stage 1 Low dose Methylenedioxymethamphetamine|Behavioral: Psychotherapy|Drug: Stage 2 Active Methylenedioxymethamphetamine,"Spielberger State-Trait Anxiety Inventory (STAI)|Quality of Life - European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)|Anxiety - Hamilton Anxiety Rating Scale (HAM-A)|Quality of Life - Functional Assessment of Chronic Illness Therapy- Spiritual Well-being Scale (FACIT-Sp),Karnofsky Performance Rating Scale (KPRS), Memorial Symptom Assessment Scale (MSAS), Mini-Mental Status Exam (MMSE), Self-Expansiveness Level Form|Hamilton Depression Rating Scale (HAM-D)|Depression, Thoughts of Death - Schedule of Attitudes Toward Hastened Death (SAHD)|Daily Use of Anxiolytics - Daily Diary|Daily Experience of Pain - Visual Analog Pain Scale (VAPS)|The Hospital Anxiety and Depression Scale (HADS)|Daily Assessment of Anxiety - the Visual Analog Anxiety Scale (VAAS)|Beck Hopelessness Scale (BHI)",Brigham and Women's Hospital|Mclean Hospital,All,"18 Years and older   (Adult, Older Adult)",Phase 2,2,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","76,770",Feb-07,Dec-10,Mar-11,11-Nov-05,5-May-17,14-Nov-17,"McLean Hospital, Belmont, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT00252174
NCT00252343,Efficacy and Safety of SR58611A in Patients With a Generalized Anxiety Disorder,LIBRA,Completed,No Results Available,Anxiety Disorder,Drug: SR58611A,14-item Hamilton Anxiety Rating Scale (HAM-A) total score|Change from baseline in Clinical Global Impression (CGI)|Severity of Illness score|Safety assessments,Sanofi,All,"18 Years and older   (Adult, Older Adult)",Phase 3,360,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",EFC5892,Sep-05,Feb-07,Feb-07,11-Nov-05,null,12-Mar-09,"Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States",,https://ClinicalTrials.gov/show/NCT00252343
NCT00251420,Writing About Disease: Effect on Rehabilitation?,,Completed,No Results Available,COPD|Asthma,Procedure: writing about disease,Quality of life|Perceived health status|Trait anxiety|Forced expiratory volume in 1 second (FEV1)|6-minute walking distance,LHL Helse|The norwegian association for heart and lung patients,All,"20 Years to 70 Years   (Adult, Older Adult)",Not Applicable,180,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),G22-1,Dec-05,null,Dec-07,10-Nov-05,null,7-May-09,"Glittreklinikken, Hakadal, Akershus, Norway",,https://ClinicalTrials.gov/show/NCT00251420
NCT00251303,Riluzole to Treat Child and Adolescent Obsessive-Compulsive Disorder With or Without Autism Spectrum Disorders,,Completed,Has Results,Obsessive-Compulsive Disorder|Autism Spectrum Disorder|Autism|Asperger Disorder|Developmental Disorder,Drug: Riluzole|Drug: Placebo,Much/Very Much Improved on Clinical Global Impressions - Improvement Score (CGI-I)|Children's Yale-Brown Obsessive-Compulsive Scale Scores (CY-BOCS),National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC),All,7 Years to 17 Years   (Child),Phase 2,78,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",050225|05-M-0225,Aug-05,Feb-12,Feb-12,9-Nov-05,15-Jul-14,15-Jul-14,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00251303
NCT00248612,Psychosocial and Medication Treatment for Anxiety in Alcoholism,,Completed,Has Results,Alcohol-Related Disorders|Anxiety Disorders,Drug: Venlafaxine|Behavioral: CBT|Other: Progressive muscle relaxation therapy (PMR)|Other: Placebo medication,Clinical Global Impression Scale-I (CGI-I)|Clinical Global Impression Scale-S (CGI-S)|Craving Desire Scale (CDS)|Number of Participants Abstinent|Treatment Completion|Medication Compliance Rates|DASS Stress Subscale Score|HAM-A Scale|HAM-D Scale,Boston Medical Center|National Institute on Alcohol Abuse and Alcoholism (NIAAA),All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2|Phase 3,162,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",H-22529|R01AA013727-01A1,Sep-03,Mar-09,Mar-09,4-Nov-05,17-Aug-17,24-Jan-18,"Boston Medical Center, Boston, Massachusetts, United States|Center for Anxiety and Related Disorders, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT00248612
NCT00248183,A Study To Evaluate PRX-00023 In Patients With Generalized Anxiety Disorder (GAD),,Completed,No Results Available,Anxiety Disorders,Drug: PRX-00023,,"Epix Pharmaceuticals, Inc.",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,310,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,PRX-CP-007,Aug-05,null,Jun-06,3-Nov-05,null,3-Apr-08,"Vista Medical Research, Mesa, Arizona, United States|Pivotal Research Center, Mesa, Arizona, United States|Anaheim Research Center, Anaheim, California, United States|Pacific Clinical Research Group, Upland, California, United States|Connecticut Clinical Research, Cromwell, Connecticut, United States|The George Washington University, Washington, District of Columbia, United States|Gulf Coast Clinical Research Center, Fort Myers, Florida, United States|Atlanta Institute of Research and Medicine, Atlanta, Georgia, United States|Northwest Behavioral Research, Marietta, Georgia, United States|Louisiana Research Associates, New Orleans, Louisiana, United States|Pivotal Research Center, Royal Oak, Michigan, United States|Comprehensive Neurosciences, Kenilworth, New Jersey, United States|Mount Sinai School of Medicine, New York, New York, United States|Oregon Center for Clinical Investigations, Portland, Oregon, United States|Oregon Center for Clinical Investigations, Salem, Oregon, United States|Unversity of Pennsylvania, Philadelphia, Pennsylvania, United States|Future Search Trials, Austin, Texas, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Comprehensive Neurosciences, Falls Church, Virginia, United States|Sidney Lerfald, MD, Charleston, West Virginia, United States",,https://ClinicalTrials.gov/show/NCT00248183
NCT00247754,VP3: Vancouver Primary Prevention Program (Anxiety Disorders Prevention in School Children),,Completed,No Results Available,Anxiety,Behavioral: Cognitive Behaviour Treatment,Anxiety symptoms,University of British Columbia|Canadian Institutes of Health Research (CIHR),All,7 Years to 13 Years   (Child),Not Applicable,281,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Prevention,B01-0072,Nov-02,null,Jun-05,2-Nov-05,null,2-Nov-05,"University of British Columbia, Faculty of Education, Vancouver, British Columbia, Canada",,https://ClinicalTrials.gov/show/NCT00247754
NCT00247832,Readiness for Discharge Following Lobectomy,,Unknown status,No Results Available,Pain|Anxiety,Behavioral: Self-directed motivation|Behavioral: Personal motivational interviewing,"Perceived readiness for discharge VAS score (at discharge)|Length of stay, physician's and nurses perceived readiness for discharge, visitation rates, anxiety score, pain score (at discharge), primary and secondary outcomes (at post-op days 3, 5 and follow-up)",University of British Columbia|Canadian Institutes of Health Research (CIHR),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,99,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,C05 - 0500,Oct-05,Dec-11,Dec-11,2-Nov-05,null,16-Nov-11,"Vancouver General Hospital Chest Centre, Vancouver, British Columbia, Canada",,https://ClinicalTrials.gov/show/NCT00247832
NCT00246441,Paroxetine for Comorbid Social Anxiety Disorder and Alcoholism,,Completed,Has Results,Social Anxiety Disorder|Social Phobia|Alcohol Use Disorder|Alcohol Abuse|Alcohol Dependence,Drug: Paroxetine|Drug: Placebo,"Social Anxiety Severity|Alcohol Use, Quantity and Frequency|Drinking to Cope",Medical University of South Carolina|National Institute on Alcohol Abuse and Alcoholism (NIAAA),All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,42,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",NIAAARAN013379|R01AA013379,Mar-02,Feb-08,Feb-08,31-Oct-05,27-Sep-18,27-Sep-18,"Medical University of South Carolina, Institute of Psychiatry, Charleston, South Carolina, United States",,https://ClinicalTrials.gov/show/NCT00246441
NCT00245609,"Trial of Pregabalin, Alprazolam, and Placebo in Subjects With Anxiety Prior to Dental Procedure",,Completed,No Results Available,Dental Anxiety,Drug: Pregabalin|Drug: Alprazolam|Drug: Placebo,"Change from baseline to endpoint on the Visual Analogue Scale for Anxiety.|The changes from baseline to endpoint, and changes from baseline to each rating timepoint differ among the three treatment groups for the VAS-Anxiety, VAS-Sedation, Time to Onset of Activity Scales scores, and, Dental Anxiety scales.",Pfizer,All,"18 Years and older   (Adult, Older Adult)",Phase 2,90,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,A0081072,Jan-06,null,Oct-06,28-Oct-05,null,21-Mar-08,"Pfizer Investigational Site, Berlin, Germany|Pfizer Investigational Site, Goettingen, Germany|Pfizer Investigational Site, Heidelberg, Germany|Pfizer Investigational Site, Koeln, Germany|Pfizer Investigational Site, Muenchen, Germany|Pfizer Investigational Site, Tuebingen, Germany|Pfizer Investigational Site, Manchester, Greater Manchester, United Kingdom|Pfizer Investigational Site, Leeds, West Yorkshire, United Kingdom|Pfizer Investigational Site, Sheffield, United Kingdom",,https://ClinicalTrials.gov/show/NCT00245609
NCT00245817,HINCAB-study. Home Based Intervention in Nursing for Coronary Artery Bypass Patients,,Completed,No Results Available,Anxiety|Depression,Behavioral: HINCAB,Anxiety and depression symptoms|Health related quality of life,Ullevaal University Hospital|Oslo University Hospital,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,203,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),HINCAB,Aug-03,Jan-05,Jul-05,28-Oct-05,null,11-Mar-11,"Ullevål University Hospital, Oslo, Norway",,https://ClinicalTrials.gov/show/NCT00245817
NCT00236015,A 10-Week Efficacy and Safety Study of Gabitril in the Treatment of Adults With Generalized Anxiety Disorder,,Completed,No Results Available,Anxiety Disorder,Drug: Gabitril,"Reduction of symptomatology associated with Generalized Anxiety Disorder as assessed by the change from baseline to end point in the total score of the HAM-A scale.|Assessment of proportion of responders and patients in remission according to HAM-A scores and CGI ratings by visit, assessment of the safety and tolerability in patients with GAD",Cephalon|Teva Pharmaceutical Industries,All,18 Years to 64 Years   (Adult),Phase 3,880,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double,C6671/3030/AX/US,Nov-04,null,Mar-06,12-Oct-05,null,9-May-14,"Pivotol Research Centers, Mesa, Arizona, United States|Pivotal Research Center, Peoria, Arizona, United States|Valley Clinical Research, El Centro, California, United States|Radiant Research Irvine, Irvine, California, United States|Pharmacology Research Institute, Los Alamitos, California, United States|Pharmacology Research Institute, Riverside, California, United States|Clinical Innovations, Inc., Santa Ana, California, United States|Radiant Research, Denver, Colorado, United States|University of Connecticut Health Center, Farmington, Connecticut, United States|Miami Research Associates, Miami, Florida, United States|Medical Research Group of Central Florida, Orange City, Florida, United States|Clinical Neuroscience Solutions, Inc., Orlando, Florida, United States|Roskamp Institute, Clinical Trials Division, Sarasota, Florida, United States|Stedman Clinical Trials, Tampa, Florida, United States|Emory University, Atlanta, Georgia, United States|American Medical Research, Aurora, Illinois, United States|Henry Lahmeyer MD & Associates, Northfield, Illinois, United States|Midwest Center for Neurobehavioral Medicine, Oakbrook Terrace, Illinois, United States|Indiana University Hospital AOC, Indianapolis, Indiana, United States|Vince & Associates Clinical Research, Overland Park, Kansas, United States|Pedia Research, LLC, Owensboro, Kentucky, United States|Four Rivers Clinical Research, Paducah, Kentucky, United States|LSU Health Science Center, Shreveport, Louisiana, United States|Capital Clinical Research Associates, Rockville, Maryland, United States|Dupont Clinical Research, Rockville, Maryland, United States|Center for Psychopharmacologic Research and Treatment, Worcester, Massachusetts, United States|Wayne State University, Detroit, Michigan, United States|Regions Hospital - Department of Behavioral Health, St. Paul, Minnesota, United States|Radiant Research, Las Vegas, Nevada, United States|Center for Emotional Fitness, Moorestown, New Jersey, United States|Fieve Clinical Services, Inc., New York, New York, United States|Behavioral Medical Research of Staten Island, Staten Island, New York, United States|Medark Clinical Trials and Research, Morganton, North Carolina, United States|Richard Weisler, MD and Associates, Raleigh, North Carolina, United States|Wake Research Associates, LLC, Raleigh, North Carolina, United States|Midwest Clinical Research Center, Dayton, Ohio, United States|Pahl Pharmaceutical Research, LLC, Oklahoma City, Oklahoma, United States|Oregon Center for Clinical Investigations, Inc., Eugene, Oregon, United States|Keystone Clinical Studies, LLC, Norristown, Pennsylvania, United States|CNS Research Institute, Philadelphia, Pennsylvania, United States|Clinical Neuroscience Solutions, Inc., Memphis, Tennessee, United States|Future Search Trials, Austin, Texas, United States|Claghorn-Lesem Research Clinic, Inc., Bellaire, Texas, United States|Mood Disorders Research Clinic; UT Southwestern Medical Center at Dallas, Dallas, Texas, United States|R/D Clinical Research, Inc., Lake Jackson, Texas, United States|Croft Group Research Center, San Antonio, Texas, United States|University of Utah Mood Disorders Clinic, Salt Lake City, Utah, United States|Dean Foundation, Middleton, Wisconsin, United States|University of Alberta, Edmonton, Alberta, Canada|University of British Columbia, Vancouver, Vancouver, British Columbia, Canada|St. Boniface General Hospital, Winnipeg, Manitoba, Canada|Mood Disorders Clinic, Hamilton, Ontario, Canada|Center for Addiction and Mental Health, Mood and Anxiety Program, Toronto, Ontario, Canada|Clinique Marie-Fitzbach,, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT00236015
NCT00236054,A 10-Week Efficacy and Safety Study for of Gabitril in the Treatment of Adults With Generalized Anxiety Disorder,,Completed,No Results Available,Generalized Anxiety Disorder,Drug: Gabitril,"Reduction of symptomatology associated with Generalized Anxiety Disorder as assessed by the change from baseline to endpoint in the total score of the HAM-A scale.|Assessment of proportion of responders and|patients in remission according to HAM-A scores and CGI ratings by|visit, assessment of the safety and tolerability in patients with GAD",Cephalon|Teva Pharmaceutical Industries,All,18 Years to 64 Years   (Adult),Phase 3,440,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,C6671/3032/AX/US,Oct-04,null,Dec-05,12-Oct-05,null,9-May-14,"Pacific Institute for Medical Research, Inc., Los Angeles, California, United States|Pharmacology Research Institute, Newport Beach, California, United States|Affiliated Research Institute, San Diego, California, United States|Health Quest Clinical Trials, San Diego, California, United States|Pacific Clinical Research Medical Group, Upland, California, United States|UF Behavioral Health Clinic, Jacksonville, Florida, United States|Janus Center for Psychiatric Research, West Palm Beach, Florida, United States|Atlanta Institute of Medicine & Research - Atlanta Clinic, Atlanta, Georgia, United States|Cunningham Clinical Research, LLC, Edwardsville, Illinois, United States|LSUHSC Anxiety and Mood Disorders Clinic, New Orleans, Louisiana, United States|Summit Research Network, Farmington Hills, Michigan, United States|Social Psychiatry Research Inst., Brooklyn, New York, United States|Eastside Comprehensive Medical Center, New York, New York, United States|Medical and Behavioral Health Research, PC, New York, New York, United States|Hartford Research Group Ltd., Cincinnati, Ohio, United States|Oregon Center for Clinical Investigations, Inc., Salem, Oregon, United States|South East Health Consultants, LLC, Charleston, South Carolina, United States|Northwest Clinical Research Center, Bellevue, Washington, United States|Northbrooke Research, Brown Deer, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT00236054
NCT00236067,A 10-Week Study for Efficacy and Safety Study of Gabitril in the Treatment of Adults With Generalized Anxiety Disorder,,Completed,No Results Available,Generalized Anxiety Disorder,Drug: Gabitril,"Reduction of symptomatology associated with Generalized Anxiety Disorder as assessed by the change from baseline to endpoint in the total score of the HAM-A scale.|Assessment of proportion of responders and patients in remission according to HAM-A scores and CGI ratings by visit, assessment of the safety and tolerability in patients with GAD",Cephalon|Teva Pharmaceutical Industries,All,18 Years to 64 Years   (Adult),Phase 3,440,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,C6671/3031/AX/US,Oct-04,null,Mar-06,12-Oct-05,null,9-May-14,"Birmingham Research Group, Birmingham, Alabama, United States|Southwestern Research Institute, Beverly Hills, California, United States|Pharmacology Research Institute, Northridge, California, United States|Pacific Clinical Research, Orange, California, United States|Carman Research, Smyrna, Georgia, United States|Hawaii Clinical Research Center, Honolulu, Hawaii, United States|Hartford Research Group, Florence, Kentucky, United States|Summit Research Network, Okemos, Michigan, United States|CNS Research Institute, Clementon, New Jersey, United States|Social Psychiatry Research Inst., Brooklyn, New York, United States|Neurobehavioral Research, Inc., Lawrence, New York, United States|Social Psychiatry Research Inst., New York, New York, United States|The Medical Research Network, New York, New York, United States|Northcoast Clinical Trials, Beachwood, Ohio, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Summit Research Network, Portland, Oregon, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Carolina Clinical Research Services, Columbia, South Carolina, United States|Radiant Research, Salt Lake City, Salt Lake City, Utah, United States|Comprehensive Neuroscience of Northern Virginia, Arlington, Virginia, United States|Summit Research Network, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00236067
NCT00235508,Safety and Efficacy of Eszopiclone in Patients With Generalized Anxiety Disorder,,Completed,No Results Available,Insomnia|Generalized Anxiety Disorder,Drug: Eszopiclone (Lunesta),The change from baseline in subjective sleep latency averaged over the double-blind treatment period.|Change from baseline in subjective total sleep time averaged over the double blind treatment period.,Sunovion,All,18 Years to 64 Years   (Adult),Phase 4,420,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",190-902,Jun-05,Apr-06,Apr-06,10-Oct-05,null,22-Feb-12,"Birmingham, Alabama, United States|Mesa, Arizona, United States|Scottsdale, Arizona, United States|Irvine, California, United States|La Mesa, California, United States|National City, California, United States|Oceanside, California, United States|Orange, California, United States|Pasadena, California, United States|Redlands, California, United States|Riverside, California, United States|San Diego, California, United States|Farmington, Connecticut, United States|Washington, District of Columbia, United States|Coral Springs, Florida, United States|Fort Lauderdale, Florida, United States|Gainesville, Florida, United States|Jacksonville, Florida, United States|Orlando, Florida, United States|Pembroke Pines, Florida, United States|St. Petersburg, Florida, United States|Atlanta, Georgia, United States|Augusta, Georgia, United States|Smyrna, Georgia, United States|Northfield, Illinois, United States|Indianapolis, Indiana, United States|Owensboro, Kentucky, United States|Baltimore, Maryland, United States|Rockville, Maryland, United States|Braintree, Massachusetts, United States|Brighton, Massachusetts, United States|Brockton, Massachusetts, United States|Cambridge, Massachusetts, United States|Watertown, Massachusetts, United States|St. Louis, Missouri, United States|Kenilworth, New Jersey, United States|Piscataway, New Jersey, United States|Brooklyn, New York, United States|Lawrence, New York, United States|New York, New York, United States|Durham, North Carolina, United States|Raleigh, North Carolina, United States|Winston-Salem, North Carolina, United States|Bismarck, North Dakota, United States|Beachwood, Ohio, United States|Cincinnati, Ohio, United States|Dayton, Ohio, United States|Middleburg Heights, Ohio, United States|Eugene, Oregon, United States|Portland, Oregon, United States|Salem, Oregon, United States|Moon Township, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Scotland, Pennsylvania, United States|Columbia, South Carolina, United States|Memphis, Tennessee, United States|Austin, Texas, United States|Houston, Texas, United States|Richardson, Texas, United States|San Antonio, Texas, United States|Wichita Falls, Texas, United States|Falls Church, Virginia, United States|Richmond, Virginia, United States|Middleton, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT00235508
NCT00234689,Efficacy of Naltrexone Treatment as Augmentation to SSRI in OCD Patients,,Completed,No Results Available,Obsessive Compulsive Disorder,Drug: Naltrexone,,Sheba Medical Center,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,null,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double,SHEBA-99-1897-JZ-CTIL,Jan-02,Dec-04,Dec-04,7-Oct-05,null,30-Jan-08,"Chaim Sheba Medical Center, Ramat-Gan, Israel",,https://ClinicalTrials.gov/show/NCT00234689
NCT00234793,Maternal Problem-Solving in Childhood Cancer,,Completed,No Results Available,Stress|Cancer,Behavioral: Problem-Solving Skills Training,"The primary aim of the study is to evaluate the effectiveness of problem-solving training provided to mothers of children with newly diagnosed cancer in decreasing negative affectivity|e.g. depression, anxiety, and increasing satisfaction with resource utilization|Standardized measures at three time points: pre-intervention, post-intervention, 3 months post the second time point",University of Rochester|National Institutes of Health (NIH),Female,"Child, Adult, Older Adult",Phase 3,433,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),RO1 CA098964-02|RSRB 09840,May-03,null,Apr-10,7-Oct-05,null,15-Jun-15,"Children's Hospital Los Angeles, Los Angeles, California, United States|Oregon Health Sciences University, Portland, Oregon, United States|Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States|UT/MD Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00234793
NCT00233675,Evaluate the Safety of GABITRIL in Adults With Generalized Anxiety Disorder,,Completed,No Results Available,General Anxiety Disorder,Drug: GABITRIL (tiagabine hydrochloride; CEP-6671),,Cephalon|Teva Pharmaceutical Industries,null,"Child, Adult, Older Adult",Phase 3,null,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C6671A/301/AX/US,Aug-03,Feb-05,null,6-Oct-05,null,9-May-14,"Pivotal Research Center, Mesa, Arizona, United States|Southwestern Research, Beverly Hills, California, United States|Pharmacology Research Institut, Newport Beach, California, United States|Pharmacology Research Institut, Northridge, California, United States|Pacific Clinical Research Medi, Orange, California, United States|Radiant Research San Diego, San Diego, California, United States|Affiliated Research Institute, San Diego, California, United States|Radiant Research Denver, Denver, Colorado, United States|University of Connecticut, Farmington, Connecticut, United States|Clinical Neuroscience Solution, Jacksonville, Florida, United States|Clinical Neuroscience Solution, West Palm Beach, Florida, United States|Carman Research, Smyrna, Georgia, United States|Cunningham Clinical Research, Edwardsville, Illinois, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Summit Research Network Farmin, Farmington Hills, Michigan, United States|CNS Research Institute, Clementon, New Jersey, United States|Social Psychiatry Research Ins, Brooklyn, New York, United States|Fieve Clinical Services, Inc., New York, New York, United States|Medical and Behavioral, New York, New York, United States|Medical Research Network, New York, New York, United States|Richard Weisler, MD and Assoc, Raleigh, North Carolina, United States|Summit Research Network Inc., Portland, Oregon, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|South East Health Consultants, Charleston, South Carolina, United States|Claghorn-Lesem Research, Bellaire, Texas, United States|Radiant Research Salt Lake, Salt Lake City, Utah, United States|Comprehensive Neuroscience Of, Falls Church, Virginia, United States|Summit Seattle Boren, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00233675
NCT00231335,Efficacy and Safety Study of Escitalopram Augmentation in Treatment Resistant Schizophrenia,,Completed,No Results Available,Schizophrenia|Schizoaffective Disorder,Drug: escitalopram,Reduction of severity of symptoms defined as decrease of >20% from baseline to final evaluation on the PANSS total score.|Changes on depression/anxiety dimensions of PANSS subscales defined as decrease of >20% from baseline to final evaluation.,Emory University|Forest Laboratories,All,18 Years to 55 Years   (Adult),Phase 4,30,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,408-2005,Mar-06,null,Jul-07,4-Oct-05,null,7-Dec-10,,,https://ClinicalTrials.gov/show/NCT00231335
NCT00229645,"A Double Blind, Randomized Placebo Controlled Study of the Efficacy, Safety and of Quetiapine Fumarate (Seroquel®) as Potentiation SSRI's, and SNRI's Treatment in Major Depression With Anxiety",,Completed,No Results Available,Major Depression With Comorbid Anxiety Symptoms,Drug: Quetiapine Fumarate (Seroquel®),"To compare the efficacy of quetiapine versus placebo over 8 weeks as an adjunctive agent for unipolar non-psychotic adult outpatients on SSRI or SNRI therapy with residual symptoms of depression and comorbid anxiety symptoms. This will be measured by the|1. Hamilton Depression Scale (HAM-D) total score,|2. Hamilton Anxiety Scale (HAM-A) total score",Dr Alexander McIntyre Inc.,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,D1441C00017,Nov-03,null,Apr-05,30-Sep-05,null,13-Jul-16,"Dr. A. McIntyre, Penticton, British Columbia, Canada",,https://ClinicalTrials.gov/show/NCT00229645
NCT00229281,Short Term Group Therapy for Anxiety Disorder,,Completed,No Results Available,Anxiety Disorder,Behavioral: Group therapy,,Sheba Medical Center,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,30,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SHEBA-05-3680-JZ-CTIL,Feb-04,null,null,29-Sep-05,null,27-Dec-07,"Chaim Sheba Medical Center, Ramat-Gan, Israel",,https://ClinicalTrials.gov/show/NCT00229281
NCT00229320,Short Term Group Therapy for OCD,,Completed,No Results Available,Obsessive Compulsive Disorder,Behavioral: Group therapy,,Sheba Medical Center,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,null,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),SHEBA-05-3679-JZ-CTIL,Feb-05,null,Nov-05,29-Sep-05,null,30-Jan-08,"Chaim Sheba Medical Center, Ramat-Gan, Israel",,https://ClinicalTrials.gov/show/NCT00229320
NCT00229385,Treatment With Ziprasidone for Schizophrenia Patients With Obsessive Compulsive Disorder (OCD),,Completed,No Results Available,Schizophrenia|Obsessive Compulsive Disorder,Drug: Ziprasidone,YBOCS,Sheba Medical Center,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,45,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic,SHEBA-03-3061-JS-CTIL,Jan-06,Apr-08,Apr-10,29-Sep-05,null,31-Dec-13,"Chaim Sheba Medical Center, Ramat-Gan, Israel",,https://ClinicalTrials.gov/show/NCT00229385
NCT00226343,Depakote-ER for Depressive and Bipolar Depression,,Completed,No Results Available,Bipolar Disorder,Drug: Depakote-ER,Anxiety and Depressive Symptom severity,Cambridge Health Alliance|Northwestern University,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,25,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,CHA-IRB-0007/07/03,Aug-03,Jan-06,Aug-06,27-Sep-05,null,18-Apr-17,,,https://ClinicalTrials.gov/show/NCT00226343
NCT00214994,Study to Evaluate the Safety and Efficacy of GABITRIL Treatment in Adults With Generalized Anxiety Disorder.,,Completed,No Results Available,Anxiety Disorders,Drug: Gabitril,,Cephalon|Teva Pharmaceutical Industries,All,18 Years to 64 Years   (Adult),Phase 3,null,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C6671/3033/AX/US,Jan-05,null,Dec-06,22-Sep-05,null,9-May-14,"Birmingham Research Group, Birmingham, Alabama, United States|Pivotal Research Center, Mesa, Arizona, United States|Pivotal Research, Peoria, Arizona, United States|Southwestern Research, Beverly Hills, California, United States|Valley Clinical Research, El Centro, California, United States|Irvine Center for Clinical Res, Irvine, California, United States|Pharmacology Research Institute, Los Alamitos, California, United States|Pacific Institue for Medical, Los Angeles, California, United States|Pharmacology Research Institute, Newport Beach, California, United States|Pacific Clinical Research Medi, Orange, California, United States|Pharmacology Research Institute, Riverside, California, United States|Affiliated Research Institute, San Diego, California, United States|HealthQuest Clinical Trials, San Diego, California, United States|Clinical Innovations Inc., Santa Ana, California, United States|Radiant Research Denver, Denver, Colorado, United States|University of Connecticut, Farmington, Connecticut, United States|University of Florida, Jacksonville, Florida, United States|Miami Research Associates, Miami, Florida, United States|Medicial Research Group of Central Florida, Orange City, Florida, United States|Clinical Neuroscience Solution, Orlando, Florida, United States|Roskamp Institute, Sarasota, Florida, United States|Stedman Clinical Trials, Tampa, Florida, United States|Clinical Neuroscience Solution, West Palm Beach, Florida, United States|Atlanta Institue of Medicaine, Atlanta, Georgia, United States|Emory University, Atlanta, Georgia, United States|Carman Research, Smyrna, Georgia, United States|Hawaii Clinical Research, Honolulu, Hawaii, United States|American Medical Research, Aurora, Illinois, United States|Cunningham Clinical Research, Edwardsville, Illinois, United States|Henry Lahmeyer, MD, Northfield, Illinois, United States|Midwest Center for Neurobehavi, Oakbrook Terrace, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|Vince and Associates Clinical, Overland Park, Kansas, United States|Hartford Research Ltd, Florence, Kentucky, United States|Pedia Research, LLC, Owensboro, Kentucky, United States|Four Rivers Clinical Research, Paducah, Kentucky, United States|LSUHSC New Orleans, New Orleans, Louisiana, United States|LSUHSC in Shreveport, Shreveport, Louisiana, United States|Capital Clinical Research Asso, Rockville, Maryland, United States|Dupont Clinical Research, Rockville, Maryland, United States|University of Massachusetts, Worcester, Massachusetts, United States|Wayne State University, Detroit, Michigan, United States|Summit Research Network Farmin, Farmington Hills, Michigan, United States|Summit Research Network Michig, Okemos, Michigan, United States|Regions Hospital, St. Paul, Minnesota, United States|Radiant Research Las Vegas, Las Vegas, Nevada, United States|CNS Research Institute, Clementon, New Jersey, United States|Center for Emotional Fitness, Moorestown, New Jersey, United States|University of New Mexico, Albuquerque, New Mexico, United States|Social Psychiatry Research Ins, Brooklyn, New York, United States|Neurobehavioral Research, Inc., Lawrence, New York, United States|Eastside Comprehensive Medical, New York, New York, United States|Fieve Clinical Services, Inc., New York, New York, United States|Medical and Behavioral, New York, New York, United States|Medical Research Network, New York, New York, United States|Behavioral Medical Research, Staten Island, New York, United States|Medark Clinical Trials and Research, Morganton, North Carolina, United States|Richard Weisler, MD and Assoc, Raleigh, North Carolina, United States|Wake Research Associates, Raleigh, North Carolina, United States|North Coast Clinical Trials, Beechwood, Ohio, United States|Hartford Research Group, Cincinnati, Ohio, United States|Midwest Clinical Research Ctr, Dayton, Ohio, United States|University of Oklahoma, Oklahoma City, Oklahoma, United States|Pahl Pharmaceutical Research, Oklahoma City, Oklahoma, United States|OCCI Eugene, Eugene, Oregon, United States|Summit Research Network Inc., Portland, Oregon, United States|OCCI, Inc., Salem, Oregon, United States|Keystone Clinical Studies LLC, Norristown, Pennsylvania, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|CNS Research Institute PC, Philadelphia, Pennsylvania, United States|South East Health Consultants, Charleston, South Carolina, United States|Carolina Clinical Research Ser, Columbia, South Carolina, United States|Clinical Neuroscience Solution, Memphis, Tennessee, United States|FutureSearch Trials, Austin, Texas, United States|Claghorn-Lesem Research, Bellaire, Texas, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Fabre Research Clinics, Inc., Houston, Texas, United States|R D Clinical Research, Lake Jackson, Texas, United States|Croft Group Research Center, San Antonio, Texas, United States|Radiant Research Salt Lake, Salt Lake City, Utah, United States|University of Utah, Salt Lake City, Utah, United States|Comprehensive Neuroscience Of, Arlington, Virginia, United States|Northwest Clinical Research, Bellevue, Washington, United States|Summit Seattle Boren, Seattle, Washington, United States|Northbrook Research Center, Brown Deer, Wisconsin, United States|Dean Foundation, Middleton, Wisconsin, United States|University of Alberta, Edmonton, Alberta, Canada|University of British Columbia, Vancouver, British Columbia, Canada|St. Boniface General Hospital, Winnipeg, Manitoba, Canada|McMaster University Medical Ce, Hamilton, Ontario, Canada|Center for Addiction and Mental Health, Mood and Anxiety Program, Toronto, Ontario, Canada|Mood & Anxiety Disorders Ctr, Toronto, Ontario, Canada|Clinique Marie-Fitzbach, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT00214994
NCT00215137,Pilot Study to Evaluate Escitalopram in Obsessive-compulsive Disorder,,Completed,Has Results,OCD,Drug: escitalopram|Drug: Placebo ( sugar pill),Yale Brown Obsessive Compulsive Scale,Duke University|Forest Laboratories,All,"18 Years and older   (Adult, Older Adult)",Phase 2,14,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Pro00013150|5731-04-4R0,Oct-04,Jan-09,Mar-09,22-Sep-05,29-Oct-13,23-Jul-14,"Duke University Medical Center, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT00215137
NCT00215150,Geodon for the Treatment of Refractory Social Anxiety Disorder,SAD,Completed,Has Results,Social Anxiety Disorder,Drug: Ziprasidone|Drug: Sertraline,Brief Social Phobia Scale(BSPS),Duke University|Pfizer,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,51,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Pro00012882|6479,Nov-04,Dec-08,Jul-09,22-Sep-05,24-May-13,31-Oct-14,"Duke University Medical Center, Durham, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT00215150
NCT00215163,Paroxetine-CR to Treat Post-Traumatic Stress Disorder (PTSD) Symptomatic After Initial Exposure Therapy,,Completed,No Results Available,"Stress Disorders, Post-Traumatic",Drug: Cognitive-behavioral therapy and paroxetine-CR,Short PTSD Rating Interview (SPRINT)|Davidson Trauma Scale (DTS)|Clinical Global Impressions Severity Scale (CGI-S)|Clinical Global Impressions Improvement Scale (CGI-I)|Posttraumatic Diagnostic Scale (PDS)|Beck Depression Inventory (BDI)|Quality of Life Enjoyment and Satisfaction Questionnaire/General Activities Subscale (Q-LES-Q/GA)|Sheehan Disability Scale (SDS)|Connor-Davidson Resilience Scale (CD-RISC)|Post-Traumatic Cognitions Inventory (PTCI)|Severity of Symptoms Scale (SOSS)|Pittsburgh Sleep Quality Index (PSQI)|World Assumptions Scale (WAS)|Mood-SR Lifetime,Duke University|GlaxoSmithKline|Massachusetts General Hospital,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2|Phase 3,17,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,4304|4304-02-12,Dec-02,null,Jun-06,22-Sep-05,null,30-May-13,"University of California at San Diego, San Diego, California, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Duke University Medical Center, Durham, North Carolina, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00215163
NCT00215241,Risperidone Augmentation for PTSD,,Completed,No Results Available,Post-Traumatic Stress Disorder,Drug: sertraline and risperidone,Clinician Administered PTSD Scale (CAPS)|Davidson Trauma Scale (DTS)|Beck Depression Inventory|Quality of Life/Q-LES-Q|Connor-Davidson Resilience Scale|Clinical Global Improvement Scale (CGI-I)|Positive and Negative Symptoms Scale (PANSS),Duke University|Janssen Pharmaceuticals,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2|Phase 3,80,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,5816|5816-05-4R1,Apr-04,null,Jul-06,22-Sep-05,null,22-Sep-14,"Emory University Medical Center, Atlanta, Georgia, United States|Medical University of South Carolina, Charleston, South Carolina, United States",,https://ClinicalTrials.gov/show/NCT00215241
NCT00215254,Quetiapine in Social Anxiety Disorder,,Completed,No Results Available,Social Anxiety Disorder,Drug: quetiapine,Brief Social Phobia Scale (BSPS)|Clinical Global Impressions of Severity (CGI-S)|Clinical Global Impressions of Improvement (CGI-I)|Social Phobia Inventory (SPIN)|Hospital Anxiety and Depression Scale (HADS)|Connor Davidson Resilience Scale (CD-RISC)|Sheehan Disability Inventory (SDI)|Barnes Akathisis Scale (BAS)|Simpson-Angus Scale (SAS),Duke University|AstraZeneca,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2|Phase 3,15,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,5639-04-3R0,Mar-04,null,Feb-06,22-Sep-05,null,19-Dec-06,"Duke University Medical Center, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT00215254
NCT00216294,Safety Study of the Drug RG1068 in Patients With Obsessive Compulsive Disorder,,Completed,No Results Available,Obsessive Compulsive Disorder (OCD),Drug: RG1068 (Synthetic Human Secretin),"Change in Yale-Brown Obsessive Compulsive Scale and|Clinical Global Impression of Change Scale|Change in Hamilton Anxiety Scale,|Montgomery-Asberg Depressing Rating Scale, and|the Sickness Impact Profile","Indiana University School of Medicine|Shekhar, Anantha M.D., Ph.D.|Repligen Corporation|Indiana University",All,18 Years to 40 Years   (Adult),Phase 2,16,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Educational/Counseling/Training,0407-32|4587029,Feb-05,null,Apr-06,22-Sep-05,null,17-Jul-06,"LaRue Carter Hospital, Indianapolis,, Indiana, United States",,https://ClinicalTrials.gov/show/NCT00216294
NCT00219349,Cognitive-Behavioral Therapy and Escitalopram for Generalized Anxiety Disorder(GAD),,Completed,Has Results,Generalized Anxiety Disorder,Behavioral: Cognitive Behavioral Therapy|Drug: escitalopram,"Change in Hamilton Anxiety Rating Scale Score|Change in Clinical Global Impressions-Severity Index|Change in Generalized Anxiety Disorder Severity Scale|Change in Penn State Worry Questionnaire|Change in State-Trait Anxiety Inventory, State Subscale|Clinical Global Impressions-Improvement Index|Change in Hamilton Rating Scale for Depression|Change in Beck Depression Inventory-II",New York State Psychiatric Institute|Forest Laboratories,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,25,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,#4941,Jan-05,Jul-08,Jul-08,22-Sep-05,9-May-12,19-Dec-17,"Anxiety Disorders Clinic, New York State Psychiatric Institute, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00219349
NCT00206765,Risperidone vs. Paroxetine for Panic Attacks,,Terminated,No Results Available,Major Depressive Disorder With Panic Attacks|Panic Disorder,Drug: Risperidone|Drug: Paroxetine,,Beth Israel Medical Center,All,21 Years to 55 Years   (Adult),Phase 2,90,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Treatment,082-02,Jan-03,Jul-05,Jul-05,21-Sep-05,null,22-Oct-12,"Beth Israel Medical Center, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00206765
NCT00208169,Abilify Therapy for Reducing Comorbid Substance Abuse,,Completed,No Results Available,Schizophrenia|Schizoaffective Disorder|Bipolar Disorder|Major Depressive Disorder|Anxiety Disorders|Substance Abuse,Drug: Aripiprazole,"The primary outcome measure will be days of abstinence during the 12-week follow-up, as measured by the Time Line Follow Back Scale (TLFBS) and the Addiction Severity Index (ASI).|Secondary outcome measures will assess severity of symptoms as measured by the Hamilton Depression Rating Scale (HAM-D), Hamilton Anxiety Scale (HAM-A), Young Mania Rating Scale (YMRS), and the Brief Psychiatric Rating Scale (BPRS)|The Penn Alcohol Craving Scale will also be used.",Creighton University|Bristol-Myers Squibb,All,"19 Years to 65 Years   (Adult, Older Adult)",Phase 4,30,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,05-13685,Mar-05,null,Jun-07,21-Sep-05,null,24-Aug-07,"Creighton University Psychiatry and Research Center, Omaha, Nebraska, United States",,https://ClinicalTrials.gov/show/NCT00208169
NCT00208572,Treatment of Citalopram for Anxiety Disorders Following a Traumatic Brain Injury,,Unknown status,No Results Available,Traumatic Brain Injury,Drug: Citalopram,DSM-IV diagnostic criteria for Anxiety Disorder Due to General Medical Condition|Spielberger State Anxiety Inventory|Other psychiatric and psychosocial scales|Neuropsychological test scores|Work Status and Military Duty Status,"Walter Reed Army Medical Center|The Defense and Veterans Brain Injury Center|VA Palo Alto Health Care System|Hunter Holmes McGuire VA Medical Center|United States Naval Medical Center, San Diego|Wilford Hall Medical Center|James A. Haley Veterans Administration Hospital",All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,104,U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,03-71013|WU#03-71013,Nov-03,null,Feb-08,21-Sep-05,null,5-Oct-07,"Walter Reed Army Medical Center, Washington, District of Columbia, United States",,https://ClinicalTrials.gov/show/NCT00208572
NCT00208741,Study To Evaluate The Effects Of Gabitril™ In Patients With Social Anxiety Disorder,,Completed,No Results Available,Social Anxiety Disorder,Drug: Gabitril,Liebowitz Social Anxiety Scale (LSAS)|Clinical Global Impression-Change (CGI-C)|Hamilton Anxiety Scale (HAM-A)|Social Phobia Inventory (SPIN)|Pittsburgh Sleep Quality Index (PSQI)|36-Item Short-Form Health Survey (SF-36)|Clinical Global Impression-S (CGI-S).,Emory University|Cephalon,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,50,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Treatment,0337-2002,Jun-02,null,Nov-03,21-Sep-05,null,11-Nov-13,"Emory University School of Medicine, Atlanta, Georgia, United States|Hillside Hospital of the North Shore-Long Island Jewish Health System, Long Island, New York, United States|Columbia/New York State Psychiatric Institute, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00208741
NCT00208910,Muscle Relaxation Therapy With Odorant Cue,,Completed,No Results Available,Generalized Anxiety Disorder|Anxiety,Behavioral: Odorant Cue,PSWQ|HAM-A,Emory University,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,15,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single|Primary Purpose: Treatment,0860-2003,Nov-03,null,May-05,21-Sep-05,null,11-Nov-13,"Emory University School of Medicine, Atlanta, Georgia, United States",,https://ClinicalTrials.gov/show/NCT00208910
NCT00211744,Topiramate Augmentation in the Treatment of Obsessive-Compulsive Disorder,,Completed,No Results Available,Obsessive-compulsive Disorder,Drug: topiramate,To evaluate the safety and efficacy of adjunctive topiramate vs. placebo in the treatment of OCD,Montefiore Medical Center|Ortho-McNeil Pharmaceutical,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,24,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,04-0379,Aug-04,null,Aug-06,21-Sep-05,null,30-May-18,"Mount Sinai School of Medicine, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00211744
NCT00197951,Clinical Trial With Ziprasidone for the Treatment of Psychiatric Pathology Associated to Alcoholism,,Completed,No Results Available,Depression|Anger|Anxiety|Alcoholism,Drug: Treatment of psychiatric symptoms associated to alcoholism,Score opf SCL-90-R psychiatric symptoms scale.|Alcohol consumption (amount and frequency)|Alcohol craving|Other substances consumption,Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|Pfizer,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,60,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,2004-001056-36,Oct-04,null,Apr-07,20-Sep-05,null,23-Apr-07,"Unidad de Conductas Adictivas//Servicio de Psiquiatría//Hospital de la Santa Creu i Sant Pau, Barcelona, Spain",,https://ClinicalTrials.gov/show/NCT00197951
NCT00198094,A Study of Sertraline and Early Alprazolam XR Administration Versus Sertraline Only in Panic Disorder Patients,,Completed,No Results Available,Panic Disorder,Drug: Sertraline and Alprazolam XR,Panic symptoms scale score|CGI-I|CGI-S|Sheehan Disability Scale,Indiana University School of Medicine|Pfizer|University of Pennsylvania|University of South Florida|Indiana University,All,"18 Years and older   (Adult, Older Adult)",Phase 4,150,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,0311-34|IU 1003,Dec-03,null,Sep-07,20-Sep-05,null,22-Oct-07,"University of South Florida, Department of Psychiatry and Behavioral Medicine, Tampa, Florida, United States|University Hospital Outpatient Center, Psychiatry, Indianapolis, Indiana, United States|University of Pennsylvania, Mood and Anxiety Disorders Section, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00198094
NCT00198692,Self-Management Program for Persons With Limb Loss,,Completed,No Results Available,Amputation|Depression|Pain|Anxiety,Behavioral: self-management,"The primary outcome measures are pain, anxiety, depression, and positive mood.|Secondary outcome measures are restrictions in activities and participation and health related quality of life",Johns Hopkins Bloomberg School of Public Health|University of Washington|Amputee Coalition of America,All,"18 Years to 85 Years   (Adult, Older Adult)",Not Applicable,500,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label),R04/CCU322981-02,Aug-03,null,Mar-06,20-Sep-05,null,28-Oct-08,"Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00198692
NCT00202514,Placebo Controlled Trial of Depakote ER in Alcohol Dependent Patients With Mood and/or Anxiety Symptoms,,Completed,No Results Available,Alcoholism|Alcohol Related Disorders|Mood Disorders,Drug: divalproex sodium extended release,"mood and anxiety symptoms over time [SCL-90-R (Symptom Check List)].|scores on additional measures of depression (Ham-D),|scores on additional measures of anxiety (Ham-A),|scores on additional measures of irritability (AIAQ),|Alcohol and other drug consumption (timeline followback),|urine toxicology,|Alcohol craving (Obsessive-Compulsive Drinking Scale),|medication side effects,|sleep diary,|concomitant medication use,",Seattle Institute for Biomedical and Clinical Research|Abbott,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2|Phase 3,40,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,R&D protocol #: RDIS 0009,Sep-04,Jul-06,Jul-06,20-Sep-05,null,8-Oct-09,"VA Puget Sound Health Care System, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00202514
NCT00202709,Can Thought Field Therapy (TFT) be Helpful for Patients With an Anxiety Disorder?,,Completed,No Results Available,Agoraphobia|Social Phobia|PTSD,Behavioral: Thought Field Therapy (TFT),Global symptom index (gsi) on the Symptom checklist 90 revised (SCL-90-R)|Davidson Trauma Scale|Liebowitz Social Anxiety Scale|Hospital Anxiety and Depression Scale (HADS)|Fear Questionnaire (FQ)|Sheehan Disability Scale,Sorlandet Hospital HF,All,"Child, Adult, Older Adult",Not Applicable,52,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SSHF-AUIR-1,May-02,Aug-03,Aug-03,20-Sep-05,null,28-Jul-11,"Sorlandet Hospital, Arendal, Norway",,https://ClinicalTrials.gov/show/NCT00202709
NCT00205244,Preoperative Preparation for Children,,Completed,No Results Available,Elective Surgery|Anxiety,"Behavioral: Healing images, relaxation and distraction materials","do children who receive the intervention have less anxiety, easier induction and emergence from anesthesia|do children who receive the intervention have fewer changes in post-hospital behaviors","University of Wisconsin, Madison",All,4 Years to 12 Years   (Child),Not Applicable,null,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,M-2003-0495,17-Feb-04,16-Aug-07,16-Aug-07,20-Sep-05,null,12-Mar-19,"University of Wisconsin, Madison, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT00205244
NCT00190879,Placebo-Controlled Study of Atomoxetine Hydrochloride in the Treatment of Adults With ADHD and Comorbid Social Anxiety Disorder,,Completed,No Results Available,Attention Deficit Hyperactivity Disorder|Comorbid Social Anxiety Disorder,Drug: Atomoxetine hydrochloride|Drug: placebo,Reduction in signs and symptoms of ADHD as measured by the mean changes from baseline to endpoint in Conner's adult ADHD rating scale|Reduction in signs and symptoms of social anxiety as measured by the mean changes from baseline to endpoint in Liebowitz social anxiety scale,Eli Lilly and Company,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,440,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,9855|B4Z-US-LYDQ,Jun-05,null,May-07,19-Sep-05,null,8-Jun-07,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wildomar, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bradenton, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gainesville, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lexington, Kentucky, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Belmont, Massachusetts, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Okemos, Michigan, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rochester Hills, Michigan, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., St. Charles, Missouri, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nashua, New Hampshire, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cherry Hill, New Jersey, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cedarhurst, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New York, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Charlotte, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Charleston, South Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Houston, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lake Jackson, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Antonio, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Burlington, Vermont, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Midlothian, Virginia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Middleton, Wisconsin, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rio Piedras, Puerto Rico",,https://ClinicalTrials.gov/show/NCT00190879
NCT00191022,Comparison of LY686017 With a Marketed Drug in the Treatment of Social Anxiety Disorder,,Completed,No Results Available,Social Phobia,Drug: LY686017|Drug: paroxetine|Drug: placebo,Superiority is defined as a statistically greater reduction of the mean change from baseline to endpoint (after 12 weeks of treatment) in the Liebowitz Social Anxiety Scale (LSAS) total score.|To compare the safety and tolerability of LY686017 with placebo during 12-week treatment.|To evaluate efficacy of LY686017 compared with placebo in treatment of social anxiety disorder during 12-week therapy based on mean improvement in the following measures:|The Liebowitz Social Anxiety subscale scores|The Clinical Global Impression-Improvement scale|The Hamilton Anxiety Scale total score and|The Clinical Global Impression-Severity scale|To assess the efficacy of LY686017 compared with placebo on health outcomes as measured by the Sheehan Disability scale.|To investigate the population pharmacokinetics of LY686017 following multiple administrations of LY686017.|To ascertain whether another approved marketed drug for|social anxiety disorder is statistically significantly more efficacious than placebo in this study.,Eli Lilly and Company,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,185,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,7958|H8R-MC-HJAG,Dec-04,null,Jan-07,19-Sep-05,null,13-Feb-07,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Burbank, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Newport Beach, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Denver, Colorado, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, New Britain, Connecticut, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Gainesville, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Indianapolis, Indiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Baltimore, Maryland, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Belmont, Massachusetts, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, New York, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Portland, Oregon, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Media, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Houston, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Herndon, Virginia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Richmond, Virginia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, West Allis, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT00191022
NCT00195598,Study Comparing Venlafaxine vs. Paroxetine in Panic Disorder,,Completed,No Results Available,Panic Disorders,Drug: VENLAFAXINE|Drug: Paroxetine,To evaluate the improvement of social function following therapy with Venlafaxine extended release (XR)in the Treatment of Panic Disorder in comparison to Paroxetine.|Obtain the tolerability of using Venlafaxine extended release (XR) in the treatment of Panic Disorder in comparison to Paroxetine.,Wyeth is now a wholly owned subsidiary of Pfizer,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,70,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0600B-101359,Jan-05,Apr-06,Apr-06,19-Sep-05,null,2-Apr-10,"Jundiai, Sao Paulo, Brazil|Santo Andre, Sao Paulo, Brazil|Sao Paulo, Brazil|Sao Paulo, Brazil",,https://ClinicalTrials.gov/show/NCT00195598
NCT00179348,Yoga-Based Rehabilitation Program in Reducing Physical and Emotional Side Effects in Patients With Cancer,,Completed,No Results Available,Alopecia|Anxiety|Breast Carcinoma|Cognitive Side Effects of Cancer Therapy|Colorectal Carcinoma|Depression|Fatigue|Lung Carcinoma|Nausea and Vomiting|Pain|Psychological Impact of Cancer|Sleep Disorder|Weight Change,Procedure: Quality-of-Life Assessment|Procedure: Yoga,"Change in Functional Assessment of Cancer Therapy summary score (physical, emotional, spiritual, and social QOL)|Program compliance as measured by Yoga - Daily Practice Calendar and Yoga Class Attendance Record and Yoga Evaluation Form|Program satisfaction measured by Yoga - Daily Practice Calendar and Yoga Class Attendance Record and Yoga Evaluation Form|Pain|Mood|spiritual well-being",Albert Einstein College of Medicine|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,399,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,CCI# 00-7|NCI-2014-01579|2000-007|NCI R03 CA88598-01A1|01-02-038|P30CA013330|R03CA088598,8-Feb-01,20-Jul-16,20-Jul-16,16-Sep-05,null,24-Jan-17,"Albert Einstein College of Medicine, Bronx, New York, United States",,https://ClinicalTrials.gov/show/NCT00179348
NCT00182000,Effectiveness of D-Cycloserine as an Aid to Enhance Learning for Individuals With OCD Receiving Behavior Therapy,,Completed,Has Results,Obsessive-Compulsive Disorder,Drug: seromycin|Behavioral: Behavior Therapy,Yale-Brown Obsessive Compulsive Scale (YBOCS)|Clinical Global Impressions Scale (CGI)|Beck Depression Inventory (BDI)|Beck Anxiety Inventory (BAI)|Obsessional Beliefs Questionnaire (OBQ)|Short-Form Health Survey (SF-36)|Disability Inventory,Massachusetts General Hospital|Hartford Hospital,All,"18 Years and older   (Adult, Older Adult)",Phase 3,33,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2003-P-001325,Nov-03,Jan-08,null,16-Sep-05,6-Jul-12,16-Jul-12,,,https://ClinicalTrials.gov/show/NCT00182000
NCT00182455,Efficacy of Adding Topiramate to Current Treatment in Treatment-Resistant Generalized Social Phobia (GSP),,Recruiting,No Results Available,Social Phobia,Drug: Topiramate|Drug: Placebo,Clinical Global Impression - Improvement (CGI-I) ≤ 2|Mean change in Liebowitz Social Anxiety Scale (LSAS)|Social Phobia Scale|Social Phobia Inventory|Clinical Global Impression -Severity|Quality of life and Employment Satisfaction Questionnaire Sheehan Disability Scale|Montgomery Asberg Depression Rating Scale|Beck Depression Inventory|Beck Anxiety Inventory,"McMaster University|Janssen-Ortho Inc., Canada|Hamilton Health Sciences Corporation",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,48,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",04-080,Mar-04,Dec-18,Mar-19,16-Sep-05,null,11-Apr-18,"MacAnxiety Research Centre, Hamilton, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT00182455
NCT00182520,Efficacy of Adding Topiramate to Current Treatment in Refractory Obsessive Compulsive Disorder (OCD),,Unknown status,No Results Available,Obsessive Compulsive Disorder,Drug: Topiramate|Drug: placebo,Yale-Brown Obsessive Compulsive Scale (Y-BOCS)|Clinical Global Impression - Improvement ≤ 2|Montgomery Asberg Depression Rating Scale|Sheehan Disability Scale|Beck Depression Inventory|PI-SWUR Hoarding Scale|Self Report Y-BOCS,"McMaster University|Janssen-Ortho Inc., Canada|Hamilton Health Sciences Corporation",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,48,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",01-133,Jan-02,Feb-19,Apr-19,16-Sep-05,null,10-Apr-18,"MacAnxiety Research Centre, Hamilton, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT00182520
NCT00182533,Sertraline in Generalized Social Phobia With Co-Occurring Anxiety and Mood Disorders,,Terminated,No Results Available,"Phobia, Social|Panic Disorder|Agoraphobia|Obsessive-Compulsive Disorder|Anxiety Disorders|Major Depressive Disorder",Drug: Sertraline|Drug: Placebo,Clinical Global Impression - Improvement ≤ 2|Liebowitz Social Anxiety Scale [LSAS] (mean change from baseline)|Mean change from baseline on the following scales: Quality of Life and Employment Satisfaction Questionnaire|Sheehan Disability Scale|Social Phobia Scale|Brief Social Phobia Scale|Penn State Worry Questionnaire|Panic and Agoraphobia Scale|Davidson Trauma Scale|Social Anxiety Spectrum Self-Report (SHY-SR)|Yale-Brown Obsessive Compulsive Scale|Montgomery-Asberg Depression Rating Scale (MADRS),Hamilton Health Sciences Corporation|Pfizer|McMaster University,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 4,170,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",02-195,Jul-02,Jan-18,Jan-18,16-Sep-05,null,22-Mar-18,"MacAnxiety Research Centre, Hamilton, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT00182533
NCT00183274,Effectiveness of Long-Term Versus Short-Term Treatment of Generalized Anxiety Disorder With Venlafaxine XR,,Completed,Has Results,Anxiety Disorders,Drug: Venlafaxine XR|Drug: Placebo,"Hamilton Rating Scale for Anxiety|Clinical Global Impressions, Severity of Illness",University of Pennsylvania|National Institute of Mental Health (NIMH),All,"18 Years and older   (Adult, Older Adult)",Phase 4,268,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MH65963|R01MH065963,Jan-04,Sep-09,Sep-09,16-Sep-05,30-Nov-16,16-Jan-17,"University of Pennsylvania, 3535 Market Street, Suite 670, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00183274
NCT00183326,Treating Post Traumatic Stress Disorder in Children Exposed to Domestic Violence,,Completed,No Results Available,"Stress Disorders, Post-Traumatic|Anxiety|Depression",Behavioral: Trauma-focused cognitive behavioral therapy (TF-CBT)|Behavioral: Child-centered supportive therapy (CCT),PTSD symptoms|Anxiety|Depression|Behavior|Contact with perpetrator,Allegheny Singer Research Institute|National Institute of Mental Health (NIMH),All,7 Years to 14 Years   (Child),Not Applicable,124,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,R01MH072590|DDTR B3-PDS,May-04,Jul-15,Jul-15,16-Sep-05,null,4-Jul-18,"Women's Center and Shelter of Greater Pittsburgh, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00183326
NCT00183521,Breathing Regulation Training for Individuals With Panic Disorder,,Completed,No Results Available,Panic Disorder,Behavioral: Raise-CO2 breathing regulation training|Behavioral: Lower-CO2 breathing regulation training|Behavioral: Control,Breathing regulation,Stanford University|National Institute of Mental Health (NIMH),All,18 Years to 60 Years   (Adult),Not Applicable,136,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,R01MH066953|DATR A2-AIR,Mar-05,Nov-08,Nov-08,16-Sep-05,null,2-Dec-11,"Stanford University & VA Health Care System, Palo Alto, California, United States",,https://ClinicalTrials.gov/show/NCT00183521
NCT00183690,Prolonged Exposure Therapy Versus Active Psychotherapy in Treating Post-Traumatic Stress Disorder in Adolescents,,Completed,No Results Available,Post-Traumatic Stress Disorder,Procedure: Prolonged Exposure Therapy|Procedure: Active Psychotherapy,Symptoms of post-traumatic stress disorder|Symptoms of depression|Clinical global assessment of overall functioning,National Institute of Mental Health (NIMH),All,"12 Years to 18 Years   (Child, Adult)",Phase 1,60,NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,R34MH071660|DATR AD-TS,Sep-04,Mar-08,Jun-08,16-Sep-05,null,12-Dec-08,"Schneider Children's Medical Center of Israel, Petach Tikvah, Israel",,https://ClinicalTrials.gov/show/NCT00183690
NCT00184106,"RCT of Cognitive Therapy, Paroxetine, Combined CT and Paroxetine and Placebo",,Completed,No Results Available,Phobic Disorders,"Drug: Seroxat, Cognitive therapy, Seroxat+ cognitive therapy",The proportion responders as measured by FAIR OF NEGATIVE EVALUATION and SPAI at 12 and 24 week.|A patient is classified as responder if the decrease on FNE is equivalent with or above 40%.|Relapse rate during 6 and 12 months of follow up.,Norwegian University of Science and Technology|St. Olavs Hospital,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,86,Other,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SP/NTNU-2005,Oct-04,Dec-09,Dec-10,16-Sep-05,null,27-Aug-18,"Dept. of Psychology, NTNU, Trondheim, Dragvoll, Norway",,https://ClinicalTrials.gov/show/NCT00184106
NCT00184145,EMDR in the Treatment of Specific Phobia.,,Withdrawn,No Results Available,Specific Phobia,Other: EMDR (Eye Movement Desensitization and Reprocessing)|Other: Exposure therapy,Behavioral Approach Test towards the feared animal.|Scores on self-report questionnaires on phobic symptoms|Neuropsychological function|Cognitive strategies,Norwegian University of Science and Technology|St. Olavs Hospital,All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Not Applicable,0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,EPLK-2004,Jun-04,Sep-04,Sep-04,16-Sep-05,null,28-Feb-17,,,https://ClinicalTrials.gov/show/NCT00184145
NCT00184262,Exposure and Response Prevention With Behavioral- Versus Cognitive Therapy Rationale in Obsessive Compulsive Disorder,,Completed,No Results Available,Obsessive-Compulsive Disorder,Behavioral: ERP cognitive therapy|Behavioral: ERP behavioral therapy,scores on Y-BOCS and SCID-I,Norwegian University of Science and Technology|Norwegian Foundation for Health and Rehabilitation,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,35,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,4941.1,Jan-03,null,Dec-06,16-Sep-05,null,21-Mar-12,"Norwegian University of Science and Technology, INM, Trondheim, Norway",,https://ClinicalTrials.gov/show/NCT00184262
NCT00187928,Study to Determine the Efficacy and Safety of Adjunctive Topiramate in the Treatment of Obsessive-Compulsive Disorder,,Completed,No Results Available,Obsessive-Compulsive Disorder,Drug: Topiramate,,University of Florida|Ortho-McNeil Pharmaceutical,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,96,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Treatment,CAPSS-217,Jan-03,Mar-06,Mar-06,16-Sep-05,null,5-Oct-11,"UF Health Science Center, Gainesville, Florida, United States",,https://ClinicalTrials.gov/show/NCT00187928
NCT00188227,Comparison of Three Different Pain and Anxiety Reducing Methods in Adult Patients Undergoing Bone Marrow Puncture,,Completed,No Results Available,Patients Undergoing Puncture of the Bone Marrow,Drug: Midazolam (sedative)|Drug: Piritramid (analgetic)|Behavioral: Cognitive exercises,"Reduction of pain and anxiety during and after the punction procedure|Comparison of the efficacy of the three investigated methods to the placebo group, as well as to the group not receiving any pretreatment at all.|Duration of the effective pain reduction in each of the investigated groups|Assessment of the quality of life in the period immediately after the bone marrow puncture",Technische Universität Dresden,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 4,748,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Prevention,CGC05MK1001,Sep-01,null,Nov-03,16-Sep-05,null,20-Apr-07,"Medizinische Klinik und Poliklinik I, University Clinic Carl Gustav Carus, Dresden, Sachsen, Germany",,https://ClinicalTrials.gov/show/NCT00188227
NCT00168506,Panic Disorder and Cardiac Risk,,Unknown status,No Results Available,Panic Disorder,Drug: SSRI|Drug: CBT|Drug: CBT/SSRI,,"Baker Heart Research Institute|National Health and Medical Research Council, Australia",All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,50,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NHMRC P - 01,Jun-02,null,Dec-08,15-Sep-05,null,5-Apr-07,"Baker Heart Research Institute, Melbourne, Victoria, Australia",,https://ClinicalTrials.gov/show/NCT00168506
NCT00169377,Subthalamic Nucleus (STN) Stimulation and Obsessive-Compulsive Disorder (OCD),,Completed,No Results Available,Obsessive Compulsive Disorder,Procedure: deep brain stimulation|Procedure: No stimulation,Yale-Brown-Obession and Compulsion Scale (YBOCS)|Global assessment of function (GAF)|Clinical Global Impression(CGI)|Montgomery and Asberg Depression Rating scale (MADRS)|Hospital Anxiety Depression scale (HAD-S)|Sheehan Disability Scale (SDS)|Brief Scale for Anxiety (BABS)|Social Adjustment scale self-report (SAS-SR)|neuropsychological tests|adverse event|Quality of life (SF-36)|Stimulation parameters,Marie-laure Welter|Assistance Publique - Hôpitaux de Paris|Groupe Hospitalier Pitie-Salpetriere,All,18 Years to 60 Years   (Adult),Phase 1|Phase 2,16,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",P030422,Oct-05,null,May-07,15-Sep-05,null,22-Mar-18,"Bordeaux, France|Clermont-Ferrand, France|Grenoble, France|Nantes, France|Nice, France|Centre d'Investigation Clinique-Hôpital Pitié-Salpêtrière, Paris, France|Saint-Anne, Paris, France|Poitiers, France|Rennes, France|Toulouse, France",,https://ClinicalTrials.gov/show/NCT00169377
NCT00170365,Restorative Yoga for Stress Management,,Completed,No Results Available,Stress|Anxiety,Behavioral: Restorative Yoga,The primary outcome measurement were the Spielberger State-Trait Anxiety Inventory scores.|Secondary measurements were :|-number of sessions attended|-results of restorative yoga questionnaire on patient care and stress levels|-results of Job Stress Survey,Hennepin Healthcare Research Institute.|Hennepin Faculty Associates,All,"21 Years to 70 Years   (Adult, Older Adult)",Not Applicable,30,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HSR-04-2412,Jul-04,null,Mar-05,15-Sep-05,null,14-Sep-16,"Hennepin Faculty Associates/ Hennepin County Medica Center, Minneapolis, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT00170365
NCT00174850,Switching From an SSRI to Tiagabine(GABITRIL) in Order to Alleviate SSRI Induced Sexual Dysfunction,,Completed,No Results Available,Anxiety|Sexual Dysfunction,Drug: Gaitril,"none as yet, date being analyzed|none as yet.",State University of New York - Upstate Medical University,All,18 Years to 64 Years   (Adult),Phase 4,30,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,4984|1042242-1|33625,Jul-04,null,May-05,15-Sep-05,null,18-Sep-08,"Psychiatry Dept. SUNY Upstate Medical University, Syracuse, New York, United States",,https://ClinicalTrials.gov/show/NCT00174850
NCT00176670,A GameBoy as a Distraction Before Surgery in Children,,Completed,No Results Available,Anxiety,Drug: midazolam or GameBoy or parental presence,Yale Preoperative Anxiety Scale|10-14 days post hospitalization behavioral questionnaire,"University of Medicine and Dentistry of New Jersey|Rutgers, The State University of New Jersey",All,4 Years to 16 Years   (Child),Phase 2,158,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,120030315,Jan-04,Apr-06,Apr-06,15-Sep-05,null,6-Oct-16,"New Jersey Medical School, Newark, New Jersey, United States",,https://ClinicalTrials.gov/show/NCT00176670
NCT00177008,Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social Anxiety,,Completed,No Results Available,Schizophrenia|Schizoaffective Disorder|Social Anxiety Disorder,Drug: Aripiprazole,Liebowitz Social Anxiety Scale- Change from Baseline to Final Visit|Sheehan Disability Scale- Change from Baseline to Final Visit|Lehman Quality of Life Interview- Change from Baseline to Final Visit|Instrumental Activities of Daily Living-Change from Baseline to Final Visit|Clinical Global Impression scales [CGI]and [CGI-C]- change from Baseline to Final Visit.|Ultimate game paradigm as a measure of social cohesion- Change from Baseline to Final Visit|Arizona sexual dysfunction scale- Change from Baseline to Final Visit|COSAPSQ -Change from Baseline to Final Visit|HAM-D-Change from Baseline to Final Visit|PANSS- Change from Baseline to Final Visit|CAGE -Change from Baseline to Final Visit,"University of Medicine and Dentistry of New Jersey|Bristol-Myers Squibb|Rutgers, The State University of New Jersey",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,18,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,4680,Mar-04,null,Jan-07,15-Sep-05,null,29-Jan-07,"Robert Wood Johnson Medical School - Psychiatry Dept., Piscataway, New Jersey, United States",,https://ClinicalTrials.gov/show/NCT00177008
NCT00177996,Pharmacotherapy in Depression With Panic Spectrum,,Completed,No Results Available,Major Depression,Drug: sertraline hydrochloride,Somatic Symptoms Scale (SSC)|Hamilton Rating Scale For Depression- 25 item (HRSD 25)|Global Assessment of Functioning (GAF),University of Pittsburgh,All,18 Years to 60 Years   (Adult),Phase 4,30,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",10403,Oct-01,Jan-07,Jan-07,15-Sep-05,null,15-Jan-16,"Western Psychiatric Insititue and Clinic, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00177996
NCT00178022,A Trial of Two On-Line Interventions for Child Brain Injury,,Completed,No Results Available,Traumatic Brain Injury|Depression|Anxiety Disorders,Behavioral: Case management and problem solving therapy,"Previous investigations using problem solving therapy have documented large effect sizes on measures of problem solving and depression.|Similarly, the single previous controlled intervention following pediatric traumatic brain injury (TBI) demonstrated a large effect on self-report measures of depression and anxiety.","University of Pittsburgh|Children's Hospital Medical Center, Cincinnati|Centers for Disease Control and Prevention",All,5 Years to 17 Years   (Child),Not Applicable,120,Other|U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double,410002,Feb-05,null,Sep-06,15-Sep-05,null,29-May-08,"University of Pittsburgh, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00178022
NCT00163917,A Study of the Effectiveness of Virtual Reality Relaxation Combined With Patient-Controlled Analgesia (PCA) Morphine for Those Undergoing Burn Dressing Changes,,Unknown status,No Results Available,Anxiety|Pain,Device: Virtual reality relaxation,Association between hypnotic susceptibility and pain scores|Association between hypnotic susceptibility and anxiety scores|Measurement of pain by visual analogue scale (VAS)|Measurement of anxiety by Burns Specific Anxiety Rating by VAS|Rating of hypnotic susceptibility and morphine use|Satisfaction rating|Morphine use|Incidence of side effects relating to morphine and VR,Bayside Health,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,90,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,107/ 04,Sep-04,null,null,14-Sep-05,null,15-Mar-07,"The Alfred Hospital, Melbourne, Victoria, Australia",,https://ClinicalTrials.gov/show/NCT00163917
NCT00164203,The Feelings Club: Evaluating a School-based Intervention for Children at Risk for Depression and Anxiety Disorders,,Completed,No Results Available,Anxiety|Depression,Behavioral: Cognitive Behavioral Therapy|Behavioral: School-based CBT|Behavioral: activity control condition,"Children's Depression Inventory, Multi Anxiety Scale for children, Harter Inventory and Social Skills Rating Scale",Centre for Addiction and Mental Health,All,7 Years to 13 Years   (Child),Not Applicable,150,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",CBT_FC,Apr-05,Dec-07,Aug-11,14-Sep-05,null,5-Aug-11,"Centre for Addiction and Mental Health, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT00164203
NCT00167479,A Study of Risperidone Monotherapy in Bipolar Anxiety,,Completed,No Results Available,Bipolar Disorder|Panic Disorder|Generalized Anxiety Disorder,Drug: risperidone (Risperdal),"Clinician Global Improvement Scale (CGI-21)|Sheehan Panic Disorder Scale (SPS)|The Psychic and Somatic factors of the HAM-A|Young Mania Rating Scale, Total Score|Inventory of Depressive Symptoms, Total Score|Patient Global Improvement Scale (PGI-21)|The Clinician Global Improvement-Bipolar (CGI-BP)|The Family Impact Scale (FIS)|The Sheehan Disability Scale - Total Disability Score, Work Disability Score, Social Disability Score, Family Disability Score","University of South Florida|Janssen, LP",All,"18 Years and older   (Adult, Older Adult)",Phase 4,60,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,101541d|RIS-BIP-408,Sep-03,null,Sep-06,14-Sep-05,null,11-Sep-06,"University of South Florida Psychiatry Center, Tampa, Florida, United States|University of Cincinatti, Cincinatti, Ohio, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT00167479
NCT00158327,Telephone-Based Care Management Program for Individuals With Anxiety Disorders,,Completed,No Results Available,Anxiety Disorders|Panic Disorder,Behavioral: Telephone-based collaborative care|Behavioral: Usual care,Health-related quality of life (SF-36 MCS)|Generalized anxiety symptoms|Panic disorder severity scale (PDSS)|PHQ-9|Alcohol use|Health services utilization|Health care costs,University of Pittsburgh|National Institute of Mental Health (NIMH),All,18 Years to 64 Years   (Adult),Phase 3,360,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,R01MH059395|RELAX|DSIR 82-SEPC,Mar-04,Jun-10,Feb-11,12-Sep-05,null,22-Jan-14,"University of Pittsburgh, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00158327
NCT00159965,Treatments for Psychogenic Nonepileptic Seizures (NES),NES,Completed,Has Results,"Convulsion, Non-Epileptic|Conversion Disorder|Depression|Stress Disorders, Post-Traumatic",Drug: sertraline|Drug: placebo,Number of Nonepileptic Seizures (NES)|Beck Depression Inventory-II (BDI-II)|Modified Hamilton Depression Scale (MHRS)|Global Assessment of Functioning (GAF)|Davidson Trauma Scale (DTS)|Barratt Impulsivity Scale (BIS)|Dissociative Experiences Scale (DES)|Symptom Checklist 90 (SCL-90)|Oxford Handicap Scale (OHS)|Clinical Global Impressions - Severity (CGI-S)|Clinical Global Impressions - Improvement (CGI-I)|Family Assessment Device (FAD)|Longitudinal Interval Follow-Up Evaluation Range of Impaired Functioning Tool (LIFE-RIFT)|Quality of Life in Epilepsy-31 (QOLIE-31),Rhode Island Hospital|National Institute of Neurological Disorders and Stroke (NINDS),All,"18 Years to 95 Years   (Adult, Older Adult)",Phase 4,38,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",5K23NS045902-05|5K23NS045902,Dec-03,Jun-08,Jun-09,12-Sep-05,25-Jan-11,20-Nov-14,"Rhode Island Hospital, Providence, Rhode Island, United States",,https://ClinicalTrials.gov/show/NCT00159965
NCT00161694,Use of Sucrose to Relieve Pain During Eye Exams in Infants,,Terminated,No Results Available,Apnea of Prematurity|Retinopathy of Prematurity|Pain,Dietary Supplement: sucrose solution,,Weill Medical College of Cornell University,All,"5 Weeks and older   (Child, Adult, Older Adult)",Not Applicable,300,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Prevention,412007634,Jul-05,null,null,12-Sep-05,null,4-Jun-08,"NYPH - Weill Cornell Medical Center, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00161694
NCT00151450,Comparison of Pregabalin Versus Venlafaxine XR and Placebo in the Treatment of Generalized Anxiety Disorder,,Completed,No Results Available,Anxiety,Drug: Pregabalin|Drug: Venlafaxine XR,Evaluation of the efficacy of pregabalin and Venlafaxine XR in the treatment of generalized anxiety disorder.,Pfizer,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,390,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,A0081012,Mar-05,null,Nov-06,9-Sep-05,null,21-Mar-08,"Pfizer Investigational Site, De Pinte, Belgium|Pfizer Investigational Site, Gent, Belgium|Pfizer Investigational Site, Ghent, Belgium|Pfizer Investigational Site, Waregem, Belgium|Pfizer Investigational Site, Kelowna, British Columbia, Canada|Pfizer Investigational Site, Hamilton, Ontario, Canada|Pfizer Investigational Site, Ottawa, Ontario, Canada|Pfizer Investigational Site, Gatineau, Quebec, Canada|Pfizer Investigational Site, Saint-Jean-Sur-Richelieu, Quebec, Canada|Pfizer Investigational Site, Angouleme, France|Pfizer Investigational Site, Arcachon, France|Pfizer Investigational Site, Bully Les Mines, France|Pfizer Investigational Site, Cherbourg, France|Pfizer Investigational Site, Elancourt, France|Pfizer Investigational Site, Orvault, France|Pfizer Investigational Site, Rennes, France|Pfizer Investigational Site, Saint-andre-de-cubzac, France|Pfizer Investigational Site, Savigny Sur Orge, France|Pfizer Investigational Site, Strasbourg, France|Pfizer Investigational Site, Versailles, France|Pfizer Investigational Site, Bray, County Wicklow, Ireland|Pfizer Investigational Site, Vicenza, Bassano Del Grappa, Italy|Pfizer Investigational Site, Citta' Di Castello, Perugia, Italy|Pfizer Investigational Site, Catania, Italy|Pfizer Investigational Site, Sassari, Italy|Pfizer Investigational Site, Wildervank, GR, Netherlands|Pfizer Investigational Site, Hoogvliet, Netherlands|Pfizer Investigational Site, Huizen, Netherlands|Pfizer Investigational Site, Losser, Netherlands|Pfizer Investigational Site, Musselkanaal, Netherlands|Pfizer Investigational Site, Oude Pekela, Netherlands|Pfizer Investigational Site, Langreo, Asturias, Spain|Pfizer Investigational Site, VIC, Barcelona, Spain|Pfizer Investigational Site, Alcala de Henares, Madrid, Spain|Pfizer Investigational Site, Gandia, Valencia, Spain|Pfizer Investigational Site, Barcelona, Spain|Pfizer Investigational Site, Madrid, Spain|Pfizer Investigational Site, Salamanca, Spain|Pfizer Investigational Site, Zamora, Spain|Pfizer Investigational Site, Göteborg, Sweden|Pfizer Investigational Site, Linkoping, Sweden|Pfizer Investigational Site, Lund, Sweden|Pfizer Investigational Site, Malmö, Sweden|Pfizer Investigational Site, Stockholm, Sweden|Pfizer Investigational Site, Sundsvall, Sweden|Pfizer Investigational Site, Trollhattan, Sweden",,https://ClinicalTrials.gov/show/NCT00151450
NCT00151554,Reducing Intensive Care Unit (ICU) Related Anxiety Through a Structured Information Program,,Completed,No Results Available,Heart Diseases,Behavioral: ICU-specific information program,Patient self-reported anxiety|ICU related discomfort|Objective health status parameters|Overall satisfaction with care|Quality of life,Philipps University Marburg Medical Center|Pflegeverbund Mitte-Süd|Stabstelle Pflegeforschung|Institut für Theoretische Chirurgie|Klinik für Herzchirurgie|Klinik für VTG-Chirurgie,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,140,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),PflegeverbundMarburg2|BMBF grant 01GT0303,Feb-05,Sep-06,Dec-06,9-Sep-05,null,29-Jul-10,"University Hospital Marburg, Marburg, Hessen, Germany",,https://ClinicalTrials.gov/show/NCT00151554
NCT00152763,Psychological Support for Patients With an Implantable Cardioverter Defibrillator,,Completed,Has Results,Anxiety|Depression,Behavioral: Cognitive Behaviour Therapy (CBT)|Other: Usual Cardiac Care (UCC),Hospital Anxiety and Depression Scale - Depression Scale at Baseline|Hospital Anxiety and Depression Scale - Depression Scale at 6-months Follow-up|Hospital Anxiety and Depression Scale - Depression Scale at 12-months Follow-up|Hospital Anxiety and Depression Scale - Anxiety Scale at Baseline|Hospital Anxiety and Depression Scale - Anxiety Scale at 6-months Follow-up|Hospital Anxiety and Depression Scale - Anxiety Scale at 12-months Follow-up|Impact of Events Scale-Revised - Total Score at Baseline|Impact of Events Scale-Revised - Total Score at 6-months Follow-up|Impact of Events Scale-Revised - Total Score at 12-months Follow-up|Impact of Events Scale-Revised - Intrusiveness Scale at Baseline|Impact of Events Scale-Revised - Intrusiveness Scale at 6-months Follow-up|Impact of Events Scale-Revised - Intrusiveness Scale at 12-months Follow-up|Impact of Events Scale-Revised - Avoidance Scale at Baseline|Impact of Events Scale-Revised - Avoidance Scale at 6-months Follow-up|Impact of Events Scale-Revised - Avoidance Scale at 12-months Follow-up|Impact of Event Scale-Revised Hyperarousal Scale at Baseline|Impact of Event Scale-Revised Hyperarousal Scale at 6-months Follow-up|Impact of Event Scale-Revised Hyperarousal Scale at 12-months Follow-up|Crown-Crisp Experiential Index - Phobic Anxiety Scale at Baseline|Crown-Crisp Experiential Index - Phobic Anxiety Scale at 6-months Follow-up|Crown-Crisp Experiential Index - Phobic Anxiety Scale at 12-months Follow-up|SF-36 Mental Component Summary Scale at Baseline|SF-36 Mental Component Summary Scale at 6-months Follow-up|SF-36 Mental Component Summary Scale at 12-months Follow-up|SF-36 Physical Component Summary Score at Baseline|SF-36 Physical Component Summary Score at 6-months Follow-up|SF-36 Physical Component Summary Score at 12-months Follow-up|Percentage of Participants Who Received ICD Therapies,"University Health Network, Toronto",All,"18 Years and older   (Adult, Older Adult)",Phase 3,193,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,NA 5170|Grant number NA 5170,Oct-03,Sep-07,Nov-07,9-Sep-05,28-Jan-11,28-Jan-11,"Toronto General Hospital, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT00152763
NCT00152776,Treating Climacteric Symptoms With a Complex Homeopathic Remedy,,Completed,No Results Available,Menopause|Anxiety Disorders|Depression,Drug: ovaria comp 10 globuli 3 times per day 24 weeks,"Climacteric symptoms|Climacteric symptoms (vegetative, psychological, urogenital subscales of the MRS II)|Follow-up for another 12 weeks of treatment or after cross-over to the placebo group|Follow-up for cross-over to placebo after 24 weeks of treatment|Diurnal profile of cortisol level before and after treatment phases|Anxiety and depression measured by Hospital Anxiety and Depression Scale (HADS-D) before and after treatment period",Heidelberg University|Wala GmbH,Female,"45 Years and older   (Adult, Older Adult)",Phase 4,102,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",HD04,Feb-05,Dec-06,Dec-06,9-Sep-05,null,14-Jun-18,"Department of Complementary and Integrative Medicine, Heidelberg, Baden-Württemberg, Germany",,https://ClinicalTrials.gov/show/NCT00152776
NCT00148434,Study on Impact of Patient-Held Guidelines on Blood Pressure,,Completed,No Results Available,Hypertension,Behavioral: Patient-held guideline for hypertension,Proportion of patients with systolic blood pressure <150 and diastolic blood pressure <90|Average systolic blood pressure|Average cholesterol|Proportion of patients with cholesterol < 5.0mmol/l|Hospital Anxiety and Depression Score|Proportion with appropriate use of aspirin and statins according to UK guideline|Satisfaction with care|Perception of involvement with decision making,Ashgrove Research Practice|University of Edinburgh,All,"Child, Adult, Older Adult",Phase 2,300,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Prevention,OOB/3/19/F25|OOB/3/19/F25 CSO,Jan-02,null,Mar-03,8-Sep-05,null,27-Sep-05,"Ashgrove Health Centre, Blackburn West Lothian, United Kingdom",,https://ClinicalTrials.gov/show/NCT00148434
NCT00149799,Effectiveness of Escitalopram in the Treatment of Body Dysmorphic Disorder,,Completed,Has Results,Anxiety Disorders|Somatoform Disorders,Drug: Escitalopram|Drug: Placebo,Phase II Relapse of Body Dysmorphic Disorder (BDD) Symptoms (as Measured by the BDD-YBOCS)|Phase I Response to Escitalopram (as Measured by the BDD-YBOCS)|Change in Depression Symptoms (HAM-D) During the Double-blind Relapse Prevention Phase of the Trial (Phase II)|Change in Functional Impairment Symptoms (LIFE-RIFT) Over Double-blind Relapse Prevention Phase of the Trial (Phase II)|Change in Quality of Life (Q-LES-Q-SF) Over Double-blind Relapse Prevention Phase of the Trial (Phase II),Massachusetts General Hospital|National Institute of Mental Health (NIMH)|Rhode Island Hospital,All,"18 Years and older   (Adult, Older Adult)",Phase 3,100,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",R01MH072854|2004-P-002305|DSIR 83-ATSO,May-05,Mar-13,Mar-13,8-Sep-05,21-Nov-14,5-Dec-17,"Massachusetts General Hospital, Boston, Massachusetts, United States|Rhode Island Hospital, Providence, Rhode Island, United States",,https://ClinicalTrials.gov/show/NCT00149799
NCT00150449,Determine Long-Term Safety and Tolerability of Pregabalin in Patients With Anxiety Disorders.,,Completed,No Results Available,Anxiety Neuroses,Drug: Pregabalin,Safety Tolerability,Pfizer,All,"18 Years and older   (Adult, Older Adult)",Phase 3,511,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1008-100,Jan-01,null,Mar-06,8-Sep-05,null,14-Jul-06,"Pfizer Investigational Site, A-1040 Wien, Austria|Pfizer Investigational Site, Wein, Austria|Pfizer Investigational Site, Wien, Austria|Pfizer Investigational Site, Brussels, Belgium|Pfizer Investigational Site, De Pinte, Belgium|Pfizer Investigational Site, Gent, Belgium|Pfizer Investigational Site, Kortrijk, Belgium|Pfizer Investigational Site, Lede, Belgium|Pfizer Investigational Site, Liege, Belgium|Pfizer Investigational Site, Sint-Denijs-Westrem, Belgium|Pfizer Investigational Site, Tielt, Belgium|Pfizer Investigational Site, Tournai, Belgium|Pfizer Investigational Site, Tallinn, Estonia|Pfizer Investigational Site, Tartu, Estonia|Pfizer Investigational Site, Reims, Cedex, France|Pfizer Investigational Site, Denguin, France|Pfizer Investigational Site, Elancourt, France|Pfizer Investigational Site, Metz, France|Pfizer Investigational Site, Montesson, France|Pfizer Investigational Site, Montigny les Metz, France|Pfizer Investigational Site, Saint Etienne du Gres, France|Pfizer Investigational Site, Wasquehal, France|Pfizer Investigational Site, Bad-Deurrheim, Germany|Pfizer Investigational Site, Bremerhaven, Germany|Pfizer Investigational Site, Gottingen, Germany|Pfizer Investigational Site, Gottingen, Germany|Pfizer Investigational Site, Hamburg, Germany|Pfizer Investigational Site, Kothen, Germany|Pfizer Investigational Site, Lauf, Germany|Pfizer Investigational Site, Oldenburg, Germany|Pfizer Investigational Site, Osnabrueck, Germany|Pfizer Investigational Site, Siegen, Germany|Pfizer Investigational Site, Spaichingen, Germany|Pfizer Investigational Site, Ness Ziona, Israel|Pfizer Investigational Site, Bassano del Grappa (Vicenza), Italy|Pfizer Investigational Site, Bologna, Italy|Pfizer Investigational Site, Milano, Italy|Pfizer Investigational Site, Roma, Italy|Pfizer Investigational Site, Riga, Latvia|Pfizer Investigational Site, Ambacht, Netherlands|Pfizer Investigational Site, BV Losser, Netherlands|Pfizer Investigational Site, GC Nijmegen, Netherlands|Pfizer Investigational Site, Hoogvliet, Netherlands|Pfizer Investigational Site, Huizen, Netherlands|Pfizer Investigational Site, Losser, Netherlands|Pfizer Investigational Site, RC Dordrecht, Netherlands|Pfizer Investigational Site, Zwigndrecht, Netherlands|Pfizer Investigational Site, Zwijndreacht, Netherlands|Pfizer Investigational Site, Zwijndrecht, Netherlands|Pfizer Investigational Site, Zwijndrecht, Netherlands|Pfizer Investigational Site, Zwijndrecht, Netherlands|Pfizer Investigational Site, Bialystok, Poland|Pfizer Investigational Site, Bydgoszcz, Poland|Pfizer Investigational Site, Katowice, Poland|Pfizer Investigational Site, Olsztyn, Poland|Pfizer Investigational Site, Torun, Poland|Pfizer Investigational Site, Tuszyn, Poland|Pfizer Investigational Site, Warszawa, Poland|Pfizer Investigational Site, Wroclaw, Poland|Pfizer Investigational Site, Zabrze, Poland|Pfizer Investigational Site, Goodwood, Cape Town, South Africa|Pfizer Investigational Site, Paarl, Cape Town, South Africa|Pfizer Investigational Site, Kempton Park, Johannesburg, South Africa|Pfizer Investigational Site, Rosebank, Johannesburg, South Africa|Pfizer Investigational Site, Hatfield, Pretoria, South Africa|Pfizer Investigational Site, Bellville, South Africa|Pfizer Investigational Site, Bloemfontein, South Africa|Pfizer Investigational Site, Bloemfontein, South Africa|Pfizer Investigational Site, East London, South Africa|Pfizer Investigational Site, George, South Africa|Pfizer Investigational Site, Hurlingham, Johannesburg, South Africa|Pfizer Investigational Site, Pietersburg, South Africa|Pfizer Investigational Site, Pinetown Natal, South Africa|Pfizer Investigational Site, Pretoria, South Africa|Pfizer Investigational Site, Pretoria, South Africa|Pfizer Investigational Site, Sandton, South Africa|Pfizer Investigational Site, Somerset West, South Africa|Pfizer Investigational Site, Westville, South Africa|Pfizer Investigational Site, Oviedo, Asturias, Spain|Pfizer Investigational Site, Granollers, Barcelona, Spain|Pfizer Investigational Site, Barcelona, Spain|Pfizer Investigational Site, Barcelona, Spain|Pfizer Investigational Site, Madrid, Spain|Pfizer Investigational Site, Madrid, Spain|Pfizer Investigational Site, Madrid, Spain|Pfizer Investigational Site, Madrid, Spain|Pfizer Investigational Site, Pamplona, Spain|Pfizer Investigational Site, Sevilla, Spain|Pfizer Investigational Site, Zaragoza, Spain|Pfizer Investigational Site, Kharkov, Ukraine|Pfizer Investigational Site, Lviv, Ukraine|Pfizer Investigational Site, Odessa, Ukraine|Pfizer Investigational Site, Maidenhead, Berkshire, United Kingdom|Pfizer Investigational Site, Slough, Berks, United Kingdom|Pfizer Investigational Site, Falmouth, Cornwall, United Kingdom|Pfizer Investigational Site, Fowey, Cornwall, United Kingdom|Pfizer Investigational Site, Penzance, Cornwall, United Kingdom|Pfizer Investigational Site, Saltash, Cornwall, United Kingdom|Pfizer Investigational Site, St. Austell, Cornwall, United Kingdom|Pfizer Investigational Site, Downpatrick, County Down, United Kingdom|Pfizer Investigational Site, Chesterfield, Derbyshire, United Kingdom|Pfizer Investigational Site, Plymouth, Devon, United Kingdom|Pfizer Investigational Site, Bexhill on Sea, East Sussex, United Kingdom|Pfizer Investigational Site, Bexhill-on-sea, East Sussex, United Kingdom|Pfizer Investigational Site, Leigh-On-Sea, Essex, United Kingdom|Pfizer Investigational Site, Leslie, Fife, United Kingdom|Pfizer Investigational Site, Limekilns, Fife, United Kingdom|Pfizer Investigational Site, Cathcart, Glasgow, United Kingdom|Pfizer Investigational Site, Clarckston, Glasgow, United Kingdom|Pfizer Investigational Site, Rutherglen, Glasgow, United Kingdom|Pfizer Investigational Site, Bolton, Lancashire, United Kingdom|Pfizer Investigational Site, Chelsea, London, United Kingdom|Pfizer Investigational Site, Bangor, Northern Ireland, United Kingdom|Pfizer Investigational Site, Greenisland, Carrickfergus, Northern Ireland, United Kingdom|Pfizer Investigational Site, Houston, Renfrewshire, United Kingdom|Pfizer Investigational Site, Epworth, Doncaster, South Yorkshire, United Kingdom|Pfizer Investigational Site, St. John's, Woking, Surrey, United Kingdom|Pfizer Investigational Site, Trowbridge, Wiltshire, United Kingdom|Pfizer Investigational Site, Inkberrow, Worcestershire, United Kingdom|Pfizer Investigational Site, Birmingham, United Kingdom|Pfizer Investigational Site, Bolton, United Kingdom|Pfizer Investigational Site, Bolton, United Kingdom|Pfizer Investigational Site, Chesterfield, United Kingdom|Pfizer Investigational Site, Cookstown, United Kingdom|Pfizer Investigational Site, Coventry, United Kingdom|Pfizer Investigational Site, Coventry, United Kingdom|Pfizer Investigational Site, Coventry, United Kingdom|Pfizer Investigational Site, Coventry, United Kingdom|Pfizer Investigational Site, Dundee, United Kingdom|Pfizer Investigational Site, Earlsdon, Coventry, United Kingdom|Pfizer Investigational Site, Glasgow, United Kingdom|Pfizer Investigational Site, Glasgow, United Kingdom|Pfizer Investigational Site, Glasgow, United Kingdom|Pfizer Investigational Site, Leeds, United Kingdom|Pfizer Investigational Site, London, United Kingdom|Pfizer Investigational Site, Port Glasgow, United Kingdom|Pfizer Investigational Site, Rugby, United Kingdom|Pfizer Investigational Site",,https://ClinicalTrials.gov/show/NCT00150449
NCT00141115,Levetiracetam for the Treatment of Alcohol Dependence and Anxiety,,Completed,Has Results,Alcoholism|Generalized Anxiety Disorder|Panic Disorder|Social Phobia|Anxiety Disorders,Drug: levetiracetam,Participants Who Reported Reductions in Alcohol Consumption|Percent of Drinking Days,New York State Psychiatric Institute|UCB Pharma,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,3,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,4773,Mar-04,Jan-08,Jan-08,1-Sep-05,15-Sep-17,24-Apr-19,"New York State Psychiatric Institute, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00141115
NCT00139854,"A Multicenter, Open-Label, Randomized Crossover Trial to Assess Subject Preference for Alprazolam Orally Disintegrating Tablets Compared to Conventional Alprazolam Tablets in Subjects With Anxiety",,Completed,No Results Available,ANXIETY,Drug: Alprazolam orally disintegrating tablets,,UCB Pharma,All,"18 Years and older   (Adult, Older Adult)",Phase 3,null,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label),SP829,Aug-04,Nov-04,Nov-04,31-Aug-05,null,30-Aug-13,"Schwarz, Milwaukee, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT00139854
NCT00135525,Study Of Generalized Anxiety Disorder,,Completed,No Results Available,Anxiety Disorder|Anxiety Disorders,Drug: Paroxetine|Drug: Placebo,"Mean change from baseline in the Hamilton Anxiety Scale (HAM-A) total score (at Week 8, last observation carried forward [LOCF])|Mean change from baseline in the HAM-A score (at Weeks 1, 2, 4 and 6); in the Severity of Illness (CGI SI) score; in the SDS and MADRS total scoreProportion of responders based on the Clinical Global Impression Global Improvement (CGI GI) score",GlaxoSmithKline,All,"18 Years and older   (Adult, Older Adult)",Phase 2,null,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",BRL29060A/856,May-03,Oct-05,May-06,26-Aug-05,null,31-Jan-11,,,https://ClinicalTrials.gov/show/NCT00135525
NCT00134615,Testing the Right Question Project (RQP) Health Education Strategy in a Mental Health Setting,RQP,Completed,No Results Available,"Diagnosis, Psychiatric",Behavioral: RQP patient health education module,"Patient activation|Patient empowerment at 4, 6 and 8 weeks|Retention in care at one year",Massachusetts General Hospital|National Institutes of Health (NIH)|National Institute on Minority Health and Health Disparities (NIMHD),All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,231,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research,CHA-IRB-0080/07/04|P20MD000537,Aug-04,Dec-05,Dec-05,25-Aug-05,null,3-Jun-16,"Windsor Street Health Center, Cambridge, Massachusetts, United States|MGH Chelsea Healthcare Center, Chelsea, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT00134615
NCT00131339,Augmenting Exposure Therapy With an N-Methyl-D-Aspartate (NMDA) Agonist for Panic Disorder,,Completed,No Results Available,Panic Disorder,Behavioral: Cognitive behavioral therapy|Drug: D-cycloserine,significant reduction in panic symptoms after completion of treatment,Hartford Hospital,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,40,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,TOLI001428HI,Nov-04,null,Mar-07,18-Aug-05,null,26-Aug-09,"Hartford Hospital, Hartford, Connecticut, United States|Center for Anxiety and Related Disorders at Boston University, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT00131339
NCT00129610,Study of Virtual Reality Therapy and Cognitive Behavior Therapy in Panic Disorder With Agoraphobia,,Unknown status,No Results Available,Panic Disorder|Agoraphobia,Behavioral: Virtual Reality Therapy|Behavioral: Cognitive Behavior Therapy,"The response criterion is a decrease of 50% of the agoraphobia subscore on the Fear Questionnaire|Pre-test, post-test, 6 months and one year|Panic Disorder Severity Scale|Agoraphobic cognitions|Panic, phobia, generalized anxiety|Trait State Anxiety Inventory (STAI)|Hamilton Anxiety Scale|Dissociative experiences|Beck Depression Inventory|Quality of Life, handicap|Spatial cognition: Rey’s Figure and Rod and Frame test|Therapeutic expectations (pre-test)|Therapeutic relationship (post-test)",Hospices Civils de Lyon,All,18 Years to 60 Years   (Adult),Not Applicable,90,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Educational/Counseling/Training,2002.307,Jan-04,null,null,12-Aug-05,null,27-Apr-07,"Hôpital Pierre Wertheimer, Bron, France",,https://ClinicalTrials.gov/show/NCT00129610
NCT00128388,Psychodynamic Therapy for Treating Panic Disorder,,Completed,No Results Available,Panic Disorder,Other: PFPP|Other: ART,PDSS (panic disorder severity scale)|SDS (Sheehan disability scale)|HARS (Hamilton anxiety rating scale)|HDRS (Hamilton depression rating scale),Weill Medical College of Cornell University|National Institute of Mental Health (NIMH),All,18 Years to 55 Years   (Adult),Phase 2|Phase 3,49,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,K23MH001849|DSIR AT-CD,Feb-00,Jan-05,Jul-05,9-Aug-05,null,27-Jun-13,"Weill Medical College, New York City, New York, United States",,https://ClinicalTrials.gov/show/NCT00128388
NCT00128401,Use of an Antibiotic as an Enhancer for the Treatment of Social Phobia,,Completed,Has Results,Phobic Disorders|Anxiety|Social Phobia,Drug: D-Cycloserine|Drug: Placebo,Clinical Global Improvement (CGI-S) Scale|Liebowitz Social Anxiety Scale (LSAS),National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC),All,"8 Years to 55 Years   (Child, Adult)",Phase 2,48,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",050198|05-M-0198,Aug-05,Jun-12,Aug-12,9-Aug-05,20-May-14,20-May-14,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00128401
NCT00127465,Investigating the Impact of Tailored Reports on Anxiety Amongst Cancer Patients and Their Confidants,,Completed,No Results Available,Breast Neoplasms|Prostatic Neoplasms|Laryngeal Neoplasms|Cervix Neoplasms,Procedure: Issue of information booklet,patients' views three months after intervention|use of booklet with others between intervention and three month follow up|change in reported social support between recruitment and three month follow up|change in anxiety and depression between recruitment and three month follow up|confidants' views three months after intervention|change in confidants' anxiety and depression between recruitment and three month follow up,University of Plymouth,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,400,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label),ESRC-L328253025,Nov-01,null,Jul-03,5-Aug-05,null,11-Dec-08,"Beatson Oncology Centre, Glasgow, United Kingdom",,https://ClinicalTrials.gov/show/NCT00127465
NCT00126282,A Medication Trial Combined With Behavior Therapy for Individuals With Obsessive-compulsive Disorder,,Completed,No Results Available,Obsessive-Compulsive Disorder,Behavioral: behavior therapy|Drug: D-Cycloserine,significant reduction of OCD symptoms after the completion of treatment|significant reduction of depressive symptoms after the completion of treatment,Massachusetts General Hospital,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,50,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2003-P-0001325,Dec-03,null,Dec-07,3-Aug-05,null,29-Jul-09,"Anxiety Disorders Center, The Institute of Living, Hartford, Connecticut, United States|Massachusetts General Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT00126282
NCT00122369,Self Hypnotic Relaxation As An Adjunct To Local Anesthesia During Large Core Breast Biopsy,,Completed,Has Results,Breast Cancer|Anxiety|Pain,Behavioral: Self-hypnotic Relaxation|Behavioral: Empathic Attention,Anxiety Ratings at Specified Time Point During the Procedure|Time Trends of Anxiety Experience|Pain Ratings at Specified Time Point During the Procedure|Time Trends of Pain Experience|Salivary Cortisol Secretion|Impact of Event Scale (IES-15),Beth Israel Deaconess Medical Center|United States Department of Defense,All,"18 Years and older   (Adult, Older Adult)",Phase 2,240,Other|U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),DAMD 17-01-1-0153|2001P-001681,Mar-02,Mar-04,Mar-04,22-Jul-05,7-Feb-13,28-Feb-13,"Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT00122369
NCT00122824,Duloxetine Compared With Placebo in Patients With Generalized Anxiety Disorder,,Completed,No Results Available,Anxiety Disorders,Drug: duloxetine hydrochloride|Drug: placebo,"To assess duloxetine 120 mg once daily is superior to placebo in the treatment of GAD, defined as statistically greater reduction on the mean change anxiety symptoms as measured by the HAMA total score.|Self-reported anxiety symptomatology;Pain;Quality of Life;Clinical Global Improvement;HAMA factor scores",Eli Lilly and Company|Boehringer Ingelheim,All,"18 Years and older   (Adult, Older Adult)",Phase 3,480,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,5075|F1J-MC-HMBR,Jun-04,null,Sep-05,22-Jul-05,null,6-Nov-07,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Cincinnati, Ohio, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Oulu, Finland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Bourg-en-Bresse, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Berlin, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Paarl, South Africa|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Barcelona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Uppsala, Sweden",,https://ClinicalTrials.gov/show/NCT00122824
NCT00122837,"A Comparison of Duloxetine Hydrochloride, Marketed Comparator, and Placebo in the Treatment of Generalized Anxiety Disorder",,Completed,No Results Available,Anxiety Disorder,Drug: Duloxetine|Drug: venlafaxine|Drug: placebo,"Assess whether duloxetine hydrochloride 60 to 120 mg QD is superior to placebo in the treatment of GAD, defined as statistically greater reduction in anxiety symptoms as measured by the HAMA|Self-reported anxiety symptomatology|Quality of Life|Clinical Global Improvement|HAMA factor scores",Eli Lilly and Company|Boehringer Ingelheim,All,"18 Years and older   (Adult, Older Adult)",Phase 3,560,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,7106|F1J-MC-HMDW,Apr-05,null,Jan-07,22-Jul-05,null,18-Oct-07,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Buenos Aires, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Cordoba, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Rosario, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Everton Park, Queensland, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Spring Hill, Queensland, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Toowoomba, Queensland, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Armadale, Victoria, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Liège, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Tielt, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Kelowna, British Columbia, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Vancouver, British Columbia, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Winnipeg, Manitoba, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Ottawa, Ontario, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Toronto, Ontario, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Mexico City, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, San Luis Potosi, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Moscow, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Changhua, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Taichung, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Taipei, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Tao-Yuan, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Glasgow, Scotland, United Kingdom",,https://ClinicalTrials.gov/show/NCT00122837
NCT00122850,"A Comparison of Duloxetine Hydrochloride, Marketed Comparator, and Placebo in the Treatment of Generalized Anxiety Disorder",,Completed,No Results Available,Anxiety Disorders,Drug: Duloxetine|Drug: venlafaxine|Drug: placebo,"To assess whether duloxetine hydrochloride 60 to 120 mg once daily is superior to placebo in the treatment of GAD during a 10-week, double-blind acute therapy phase, defined as statistically greater reduction in anxiety symptoms as measured by the HAMA.|Self-reported anxiety symptomatology;Quality of Life;Clinical Global Improvement;HAMA factor scores",Eli Lilly and Company|Boehringer Ingelheim,All,"18 Years and older   (Adult, Older Adult)",Phase 3,480,Industry,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Treatment,7107|F1J-MC-HMDU,Oct-04,null,Nov-05,22-Jul-05,null,6-Nov-07,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Birmingham, Alabama, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, La Mesa, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Denver, Colorado, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Washington, District of Columbia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Coral Springs, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Jacksonville, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Maitland, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Libertyville, Illinois, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Oakbrook Terrace, Illinois, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Florence, Kentucky, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Baltimore, Maryland, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Belmont, Massachusetts, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Cambridge, Massachusetts, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Clementon, New Jersey, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, New York, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Oklahoma City, Oklahoma, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Philadelphia, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Richmond, Virginia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00122850
NCT00122863,Duloxetine Compared With Placebo in the Prevention of Relapse in Generalized Anxiety Disorder,,Completed,No Results Available,Anxiety Disorders,Drug: Duloxetine Hydrochloride|Drug: placebo,Assess the long-term maintenance of efficacy of duloxetine 60 to 120 mg QD compared with placebo by a comparison of the time to relapse among patients with GAD who responded to duloxetine during the open-label acute therapy phase after 22 to 26 weeks.|Self-reported anxiety symptomatology|Pain|Quality of Life|Clinical Global Improvement and HAMA Factor scores|Maintenance of Effect,Eli Lilly and Company|Boehringer Ingelheim,All,"18 Years and older   (Adult, Older Adult)",Phase 3,380,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,7108|F1J-MC-HMDV,Jan-05,null,Mar-07,22-Jul-05,null,31-Aug-07,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559 or 317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sherman Oaks, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559 or 317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fort Myers, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559 or 317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Atlanta, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559 or 317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Libertyville, Illinois, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559 or 317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Prairie Village, Kansas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559 or 317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Belmont, Massachusetts, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559 or 317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., St. Charles, Missouri, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559 or 317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New York, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559 or 317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chapel Hill, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559 or 317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Allentown, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559 or 317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Media, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559 or 317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lincoln, Rhode Island, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559 or 317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Charleston, South Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559 or 317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lake Jackson, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559 or 317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wichita Falls, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559 or 317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Woodstock, Vermont, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559 or 317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bellevue, Washington, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559 or 317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seattle, Washington, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559 or 317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Milwaukee, Wisconsin, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559 or 317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wien, Austria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559 or 317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Aix En Provence, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559 or 317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Arcachon, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559 or 317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bordeaux, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559 or 317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bourg-des-Comptes, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559 or 317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Caen, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559 or 317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cherbourg, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559 or 317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Clermont- Ferrand, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559 or 317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Metz, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM - 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Montigny-Les-Metz, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559 or 317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mulhouse, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559 or 317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Orvault, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559 or 317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rennes, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559 or 317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Berlin, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559 or 317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dresden, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559 or 317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gottingen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM - 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hildesheim, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559 or 317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leipzig, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559 or 317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Munchen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559 or 317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Werneck, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559 or 317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Almere, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559 or 317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nijverdal, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559 or 317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rotterdam, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559 or 317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Coimbra, Portugal|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559 or 317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lisboa, Portugal|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559 or 317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Porto, Portugal|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559 or 317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hato Rey, Puerto Rico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559 or 317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ponce, Puerto Rico",,https://ClinicalTrials.gov/show/NCT00122863
NCT00121069,Study of Escitalopram in the Treatment of Specific Phobia,,Completed,No Results Available,Phobic Disorders,Drug: Escitalopram,Response based on a criterion of 50% or greater reduction in the Marks Main Phobia Questionnaire and Marks Fear Questionnaire from baseline|Response based on CGI-I category,"Connor, Kathryn M., M.D.|Forest Laboratories",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2|Phase 3,12,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,2/9/3990,Sep-02,null,Sep-04,21-Jul-05,null,21-Jul-05,"Dept of Psychiatry and Behvaioral Science, Duke Unviersity Medical Center, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT00121069
NCT00121888,Trial of Paroxetine-CR for the Treatment of Patients With Post Traumatic Stress Disorder Remaining Symptomatic After Initial Exposure Therapy,,Completed,No Results Available,"Stress Disorders, Post-Traumatic",Behavioral: Prolonged Exposure Therapy|Drug: Paroxetine-CR,Symptoms of post traumatic stress disorder|Clinical global improvement,Massachusetts General Hospital,All,"18 Years to 72 Years   (Adult, Older Adult)",Phase 1|Phase 2,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,2002-P-001879,Dec-02,null,Jun-07,21-Jul-05,null,6-Jun-14,"Massachusetts General Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT00121888
NCT00120458,Black Cohosh as Alternative Therapy for Treating Menopause-Related Anxiety,,Completed,No Results Available,Generalized Anxiety Disorder|Menopause,Dietary Supplement: Black cohosh,Score on Hamilton Anxiety Rating Scale|Quality of life and functional outcome ratings,University of Pennsylvania|National Center for Complementary and Integrative Health (NCCIH)|Office of Dietary Supplements (ODS),Female,"18 Years and older   (Adult, Older Adult)",Phase 4,50,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",R21AT002289-01A1,Jul-05,Dec-08,Dec-08,18-Jul-05,null,2-Mar-10,"Depression Research Unit, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00120458
NCT00118833,St. John's Wort for the Treatment of Generalized Social Anxiety Disorder (GSAD),,Completed,No Results Available,Anxiety Disorders|Mental Health,Drug: Hypericum perforatum (St. John's wort),"Clinical Global Impression (CGI), designed to assess global severity of illness and change in the clinical condition over time|Brief Social Phobia Scale (BSPS)|Liebowitz Social Anxiety Scale|Social Phobia Inventory (SPIN)|Self-Rating Depression Scale (SDS)|Hospital Anxiety and Depression Scale (HADS)",National Center for Complementary and Integrative Health (NCCIH),All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,56,NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,K23AT000583-01,Aug-02,null,Jun-06,12-Jul-05,null,26-Sep-07,"Duke University Medical Center, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT00118833
NCT00118001,Psychotherapy of Generalized Anxiety Disorder,,Completed,No Results Available,Anxiety Disorders,Behavioral: Worry exposure|Behavioral: Applied relaxation,"At post-treatment: anxiety (Hamilton Anxiety Rating Scale, HARS), depression (Hamilton Depression Scale, HAM-D), trait-anxiety (State-Trait-Anxiety Inventory, STAI-T)|At 6-month follow-up: M-CIDI (Composite International Diagnostic Interview, generalized anxiety disorder section)|At post-treatment, 6 and 12 month follow-ups:|worry (Penn State Worry Questionnaire, PSWQ)|general symptoms (Brief Symptom Inventory, BSI)|depression (Beck Depression Inventory, BDI)|interpersonal problems (Inventory of Interpersonal Problems - IIP)|meta-cognitions (Meta Cognitions Questionnaire)|thought suppression (White Bear Suppression Inventory) tolerance for uncertainty (Ungewissheitstoleranzskala, UGTS)|positive and negative affect (Positive and Negative Affect Schedule, PANAS)|At post-treatment: behavior assessment tests",German Research Foundation,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,70,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"HO 1900/3-1, HO 1900/3-2",Oct-01,null,Jul-06,11-Jul-05,null,1-Apr-15,"Technische Universität Dresden, Dresden, Germany",,https://ClinicalTrials.gov/show/NCT00118001
NCT00116532,Escitalopram for the Treatment of Obsessive Compulsive Disorder (OCD),,Completed,No Results Available,Obsessive Compulsive Disorder,Drug: Escitalopram,"Y-BOCs scores at 1st and last visit (16 weeks later)|Clinical Global impressions Scale at 2nd visit (2 weeks after 1st visit) and 6th visit (16 weeks post 1st visit)|HAMD - first and last visit (Given week 0, 2, 4, 8, 12, & 16. Comparisons from week 0 and 16)|BDI - first and last visit (Given week 0, 2, 4, 8, 12, & 16. Comparisons from week 0 and 16)|BAI - first and last visit Given week 0, 2, 4, 8, 12, & 16. Comparisons from week 0 and 16)|QLESQ - first and last visit (week 0 and 16)",Massachusetts General Hospital|Forest Laboratories,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,30,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2002-P-000895|LXP-MD-14|1200-211220,Oct-02,null,Feb-07,30-Jun-05,null,24-Apr-07,"Massachusetts General Hospital - OCD Clinic, Charlestown, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT00116532
NCT00114374,SSRI Administration to Reduce Acute Stress Disorder Symptoms and Prevent Depression and PTSD in Physical Trauma Victims,,Terminated,No Results Available,Anxiety Disorder,Drug: Escitalopram,Symptoms of Acute Stress Disorder|Symptoms of Posttraumatic Stress Disorder|Clinical Global Improvement,Massachusetts General Hospital,All,"18 Years and older   (Adult, Older Adult)",Phase 3,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Prevention,2004-P-001633,Jun-05,null,Jun-07,15-Jun-05,null,9-Jun-14,"Massachusetts General Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT00114374
NCT00114127,Duloxetine for Social Anxiety Disorder: Prediction of Long Term Outcome,,Completed,Has Results,Anxiety Disorder,Drug: Duloxetine|Drug: Placebo,Anxiety Symptoms as Assessed by Liebowitz Social Anxiety Scale|CGI-S,Massachusetts General Hospital,All,"18 Years and older   (Adult, Older Adult)",Phase 3,28,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",2004-P-001384,Jun-04,Nov-08,Jul-10,14-Jun-05,7-Jun-12,10-Jun-14,"Massachusetts General Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT00114127
NCT00113295,Combination of Paroxetine CR and Quetiapine for the Treatment of Refractory Generalized Anxiety Disorder,,Completed,Has Results,Anxiety Disorder,Drug: Continued Paroxetine CR|Drug: Quetiapine|Drug: Placebo,"Hamilton Anxiety Scale (HAM-A) Score at Study Endpoint.|Remission (HAM-A ≤ 7)|Response, Clinical Global Impression of Improvement (CGI-I)|Depressive Symptoms, Montgomery-Asberg Depression Rating Scale (MADRS)|The Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q).",Massachusetts General Hospital,All,"18 Years to 72 Years   (Adult, Older Adult)",Phase 4,50,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",2003-P001805,Feb-04,Feb-07,Nov-07,8-Jun-05,23-Apr-14,23-Apr-14,"Massachusetts General Hospital, Boston, Massachusetts, United States|Duke University Medical Center, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT00113295
NCT00108836,"Efficacy, Safety and Tolerability of XBD173 in Patients With Generalized Anxiety Disorder",,Completed,No Results Available,Anxiety Disorders,Drug: XBD173,"Mean reduction in anxiety from baseline to week 6|The difference on day 4 in effect between placebo and the individual doses of XBD173 on reduction in anxiety and depression|Pharmacokinetic assessments at baseline|Pharmacogenetic assessments at baseline|Pharmacogenomic and proteomic assessments at baseline|Metabonomic assessments at visits 4, 7 and 10",Novartis Pharmaceuticals|Novartis,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,400,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,CXBD173A2204,Mar-05,null,May-06,20-Apr-05,null,20-May-10,"Investigational Site, Anaheim, California, United States|Investigational Site, Los Angeles, California, United States|Investigational Site, Newport Beach, California, United States|Investigational Site, Redlands, California, United States|Investigational Site, San Diego, California, United States|Investigational Site, Ft. Meyers, Florida, United States|Investigational Site, St. Petersburg, Florida, United States|Investigational Site, West Palm Beach, Florida, United States|Investigational Site, Atlanta, Georgia, United States|Investigational Site, Hoffman Estates, Illinois, United States|Investigational Site, Oak Brook, Illinois, United States|Investigational Site, Overland Park, Kansas, United States|Investigational Site, Dayton, Ohio, United States|Investigational Site, Portland, Oregon, United States|Investigational Site, Madison, Tennessee, United States|Investigational Site, Memphis, Tennessee, United States|Investigational Site, Edmonton, Alberta, Canada|Investigational Site, Kelowna, British Columbia, Canada|Investigational Site, Hamilton, Ontario, Canada|Investigational Site, Ottawa, Ontario, Canada|Investigational Site, Toronto, Ontario, Canada|Investigational Site, Montreal, Quebec, Canada|Investigational Site, Sherbrooke, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT00108836
NCT00108576,Divalproex Sodium in the Treatment of PTSD (Post-Traumatic Stress Disorder),,Completed,No Results Available,PTSD,Drug: Divalproex|Other: placebo,Clinician Administered PTSD Scale (CAPS),VA Office of Research and Development,All,"19 Years to 65 Years   (Adult, Older Adult)",Phase 3,101,U.S. Fed,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MHBS-026-01,Oct-03,Aug-05,Sep-05,18-Apr-05,null,21-Oct-15,"Tuscaloosa VA Medical Center, Tuscaloosa, AL, Tuscaloosa, Alabama, United States",,https://ClinicalTrials.gov/show/NCT00108576
NCT00108277,Respiratory Dysregulation and Breathing Training in Anxious Outpatients,,Completed,Has Results,Anxiety,Behavioral: Breathing Training-Raise CO2|Behavioral: Breathing Training- Lower CO2,Episodic Anxiety Scale,US Department of Veterans Affairs|VA Office of Research and Development,All,"Child, Adult, Older Adult",Not Applicable,92,U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MHBA-028-04S,Apr-05,Dec-08,Sep-10,15-Apr-05,8-Jan-15,19-Jan-15,"VA Palo Alto Health Care System, Palo Alto, California, United States",,https://ClinicalTrials.gov/show/NCT00108277
NCT00106860,A Long-Term Study Continuing on From Study 04-001-01 of an Experimental Medication in Adults With Anxiety Disorder,,Completed,No Results Available,Anxiety Disorder,Drug: a benzodiazepine drug,"Assessment (over 37 additional weeks following the double-blind study) of the safety of the experimental drug in long-term use in subjects with Generalized Anxiety Disorder (GAD)|Evaluate the long-term efficacy of open-label study of the experimental drug in subjects with GAD|Assessment of the long-term effects on the quality of life, social and occupational functioning, sleep, and daytime sedation in subjects with GAD",Jazz Pharmaceuticals,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,158,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,04-003,Mar-05,null,Mar-06,1-Apr-05,null,9-Jan-08,"Florida Clinical Research Center, Bradenton, Florida, United States|Clinical Neuroscience Solutions, Inc., Jacksonville, Florida, United States|Meridien Research, St. Petersburg, Florida, United States|CNS Research Institute (CRI), Clementon, New Jersey, United States|Midwest Clinical Research Center, Dayton, Ohio, United States|Neurology and NeuroscienceCenter of Ohio, Toledo, Ohio, United States|IPS Research Company, Oklahoma City, Oklahoma, United States|Oregon Center for Clinical Research, Inc., Eugene, Oregon, United States|Suburban Research Associates, Media, Pennsylvania, United States|CNS Research Institute (CRI), Philadelphia, Pennsylvania, United States|Future Search Trials, Austin, Texas, United States|Comprehensive Neuroscience of Northern Virginia, Falls Church, Virginia, United States|Northwest Clinical Research Center, Bellevue, Washington, United States",,https://ClinicalTrials.gov/show/NCT00106860
NCT00106249,Transcranial Magnetic Stimulation (TMS) and Obsessive Compulsive Disorder (OCD),,Completed,Has Results,Obsessive-Compulsive Disorder,Device: Repetitive Transcranial Magnetic Stimulation (rTMS)|Device: Sham,Clinical Improvement (Yale-Brown Obsessive Compulsive Scale/Y-BOCS)|Motor Cortex Excitability (Motor Threshold)|Motor Cortex Excitability (Short Intracortical Inhibition),New York State Psychiatric Institute,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,27,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",5926R,Nov-04,Jan-14,Jan-14,22-Mar-05,27-Jan-17,27-Jan-17,"New York State Psychiatric Institute, Experimental Therapeutics, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00106249
NCT00105885,Telephone Care as a Substitute for Routine Psychiatric Medication,Telepsych,Completed,No Results Available,Major Depression|Posttraumatic Stress Disorders|Anxiety Disorders,Procedure: telephone care,"Healthcare utilization (VHA and non-VHA patient visits); patient time spent obtaining care (including travel time); time provider spends in direct patient care.|Patient satisfaction at baseline, midpoint, end of study; provider satisfaction at baseline, midpoint, end of study; patient medication compliance; SF12V and brief symptom checklist scores|SF12V and brief symptom checklist scores|patient medication compliance|provider satisfaction",US Department of Veterans Affairs|VA Office of Research and Development,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,324,U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TEL 01-146,Nov-03,Sep-08,Sep-08,18-Mar-05,null,10-Feb-14,"VA Medical & Regional Office Center, White River, White River Junction, Vermont, United States",,https://ClinicalTrials.gov/show/NCT00105885
NCT00105911,A Cognitive-Behavioral Intervention for Depression and Anxiety in COPD,,Completed,No Results Available,"Depressive Disorders|Anxiety Disorders|Pulmonary Disease, Chronic Obstructive",Behavioral: Cognitive Behavioral Therapy,,US Department of Veterans Affairs|VA Office of Research and Development,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,222,U.S. Fed,Interventional,Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Treatment,IIR 00-097,Jul-02,null,Jun-05,18-Mar-05,null,7-Apr-15,"Michael E. DeBakey VA Medical Center, Houston, TX, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00105911
NCT00105586,Drug Therapy for Generalized Anxiety Disorder Among the Elderly,,Completed,Has Results,Anxiety Disorders|Generalized Anxiety Disorder,Drug: Escitalopram,Response Using Clinical Global Impressions-Improvement Scale (CGI-I)|Quality of Life,University of Pittsburgh|National Institute of Mental Health (NIMH),All,"60 Years and older   (Adult, Older Adult)",Phase 4,177,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",R01MH070547,Dec-04,Jan-08,Apr-08,16-Mar-05,8-May-17,8-May-17,"University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00105586
NCT00102427,Improving Quality of Primary Care for Patients With Anxiety and/or Panic Disorders,,Completed,No Results Available,Panic Disorder|Anxiety Disorder,Behavioral: Telephone-based collaborative care management,Anxiety symptoms,University of Pittsburgh|National Institute of Mental Health (NIMH),All,18 Years to 64 Years   (Adult),Phase 2|Phase 3,null,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Treatment,R01MH059395,Jul-00,null,May-03,31-Jan-05,null,22-Jan-14,"University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00102427
NCT00100035,Polarity Therapy for American Indian Caregivers of Dementia Patients,,Completed,No Results Available,Stress|Depression|Anxiety,Procedure: Polarity therapy,Perceived stress,National Center for Complementary and Integrative Health (NCCIH),All,"35 Years to 65 Years   (Adult, Older Adult)",Phase 1,50,NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,R21AT001627-01A1,Aug-04,Apr-07,Apr-07,23-Dec-04,null,22-Apr-08,"Center for World Indigenous Studies, Olympia, Washington, United States",,https://ClinicalTrials.gov/show/NCT00100035
NCT00097708,Experimental Medication For the Treatment of Generalized Anxiety Disorder,,Completed,Has Results,Anxiety Disorder,Drug: experimental anti-anxiety drug,Change in HAM-A Total Score,Jazz Pharmaceuticals,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,511,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,JZP 04-001-01,Nov-04,null,Dec-05,30-Nov-04,3-Oct-14,3-Oct-14,"Birmingham Research Group, Inc., Birmingham, Alabama, United States|Crest Clinical Trials, Inc., Anaheim, California, United States|Southwesten Research, Inc., Beverly Hills, California, United States|Southwestern Research Institute, Burbank, California, United States|University of California - San Diego - Dept of Psychiatry, San Diego, California, United States|Clinical Innovations, Santa Ana, California, United States|Stanford University Medical Center, Stanford, California, United States|Diablo Clinical Research, Inc., Walnut Creek, California, United States|Alpine Clinical Research Center, Boulder, Colorado, United States|New Britain General Hospital, New Britain, Connecticut, United States|Florida Clinical Research Center, Bradenton, Florida, United States|ACT Clinical Research, DeLand, Florida, United States|University Clinical Research DeLand, Inc., DeLand, Florida, United States|Sarkis Clinical Trials, Gainsville, Florida, United States|Clinical Neuroscience Solutions, Inc., Jacksonville, Florida, United States|Clinical Neuroscience Solutions, Inc., Orlando, Florida, United States|Meridien Research, St. Petersburg, Florida, United States|Institute of Research in Psychiatry, Tampa, Florida, United States|Janus Center for Psychiatric Research, West Palm Beach, Florida, United States|Atlanta Institute of Medicine and Research, Marietta, Georgia, United States|Radiant Research, Boise, Idaho, United States|American Medical Research, Inc., Oak Brook, Illinois, United States|Peak Medical Research, LLC, Owensboro, Kentucky, United States|New Orlean Medical Institute, Metairie, Louisiana, United States|Brentwood Research Institute, Shreveport, Louisiana, United States|Pharmasite Research, Inc., Baltimore, Maryland, United States|McLean Hospital, Belmont, Massachusetts, United States|Pivotal Research Centers - Detroit, Royal Oak, Michigan, United States|MedClin Research, St. Louis, Missouri, United States|CNS Research Institute (CRI), Clementon, New Jersey, United States|ClinSearch, Inc., Kenilworth, New Jersey, United States|Princeton Medical Institute, Princeton, New Jersey, United States|Social Psychiatry Research Institute, Brooklyn, New York, United States|Midwest Clinical Research Center, Dayton, Ohio, United States|Neurology and Neuroscience Center of Ohio, Toledo, Ohio, United States|IPS Research Company, Oklahoma City, Oklahoma, United States|Laureate Psychiatric Clinic and Hospital, Tulsa, Oklahoma, United States|Oregon Center for Clinical Investigations, Inc., Eugene, Oregon, United States|Suburban Research Associates, Media, Pennsylvania, United States|CNS Research Institute, Philadelphia, Pennsylvania, United States|Southeast Health Consultants, LLC, Charleston, South Carolina, United States|CNS, Inc., Memphis, Tennessee, United States|Clinical Research Associates, Inc., Nashville, Tennessee, United States|FutureSearch Trials, Austin, Texas, United States|Research Across America, Dallas, Texas, United States|R/D Clinical Research, Inc., Lake Jackson, Texas, United States|Lifetree Clinical Research, Salt Lake City, Utah, United States|Comprehensive Neuroscience of Northern Virginia, Falls Church, Virginia, United States|Dominion Clinical Research, Inc., Midlothian,, Virginia, United States|Northwest Clinical Research Center, Bellevue, Washington, United States",,https://ClinicalTrials.gov/show/NCT00097708
NCT00097253,The Effects of Smell on Mood and Physical Responses,,Completed,Has Results,Stress|Anxiety|Depression,Behavioral: Exposure to relaxant and stimulant odors,Cortisol and Catecholamine Production|Immune Function|Skin Barrier Repair|Immune Function: Delayed Hypersensitivity to Candida(DTH),National Center for Complementary and Integrative Health (NCCIH),All,18 Years to 44 Years   (Adult),Phase 1,56,NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",R21AT002122-01,Aug-05,Mar-06,Mar-06,22-Nov-04,4-Feb-10,18-Feb-10,"Ohio State University Institute for Biobehavioral Medicine Research, Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT00097253
NCT00088738,Evaluation of Substance P Neurotransmission in Panic Disorder by PET Imaging of NK1 Receptors With [18F]SPA-RQ,,Completed,No Results Available,Panic Disorder|Healthy,Drug: [18F] SPA-RQ,,National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC),All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,84,NIH,Interventional,Primary Purpose: Treatment,040189|04-M-0189,27-Jul-04,null,10-Sep-08,2-Aug-04,null,2-Jul-17,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00088738
NCT00083980,Kava Kava for the Treatment of Generalized Anxiety Disorder (GAD),,Terminated,No Results Available,Anxiety Disorders,Drug: Venlafaxine ER|Drug: Sugar pill|Drug: Kava,Hamilton Anxiety Scale,National Center for Complementary and Integrative Health (NCCIH),All,"Child, Adult, Older Adult",Phase 2,16,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",R01AT000150-01A1,Jun-02,Jun-04,Aug-04,7-Jun-04,null,19-Oct-12,,,https://ClinicalTrials.gov/show/NCT00083980
NCT00082303,Music Imagery for Patients Receiving Chemotherapy for Leukemia or Non-Hodgkin’s Lymphoma,,Completed,No Results Available,"Leukemia|Lymphoma, Non-Hodgkin",Behavioral: Music Imagery,,National Center for Complementary and Integrative Health (NCCIH),All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1|Phase 2,60,NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,F32AT001144-01,Jul-02,null,null,6-May-04,null,18-Aug-06,"Indiana University Cancer Center/University Hospital, Indianapolis, Indiana, United States",,https://ClinicalTrials.gov/show/NCT00082303
NCT00081406,Individual and Family Therapy for Children With Anxiety Disorders,,Completed,No Results Available,Anxiety,Behavioral: Individual Child CBT|Behavioral: Family CBT|Behavioral: Education/Support/Attention,,Temple University|National Institute of Mental Health (NIMH),All,9 Years to 13 Years   (Child),Phase 2|Phase 3,150,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,R01MH059087|DSIR CT-S,Jul-00,null,null,12-Apr-04,null,6-Mar-14,"Temple University Child and Adolescent Anxiety Disorders Clinic, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00081406
NCT00078728,Family-Based Prevention Program for Childhood Anxiety,,Completed,Has Results,Anxiety Disorders,Behavioral: Family-Based Anxiety Prevention Program|Behavioral: Evaluation only,Number of Children With Child Anxiety Diagnosis|Child Anxiety Diagnoses,Johns Hopkins University|National Institute of Mental Health (NIMH),All,"7 Years and older   (Child, Adult, Older Adult)",Not Applicable,40,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,K23MH063427,Sep-03,Jul-07,Jul-07,8-Mar-04,16-Dec-13,7-Feb-18,"Johns Hopkins University School of Medicine, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00078728
NCT00078767,Pharmacologic Treatment of PTSD in Sexually Abused Children,,Completed,Has Results,"Stress Disorders, Post-Traumatic",Behavioral: Trauma-Focused Cognitive Behavioral Therapy|Drug: Sertraline Pill|Drug: Placebo Oral Tablet,Kiddie-Sads-Present and Lifetime (KSADS-PL) Scale for PTSD|Mood and Feelings Questionnaire (MFQ) for Depressive Symptoms|Anxiety Symptoms|Global Impairment|Incidence of Suicidality,Allegheny Singer Research Institute|National Institute of Mental Health (NIMH),All,10 Years to 17 Years   (Child),Phase 3,24,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",K02MH001938,Apr-01,Mar-06,Mar-06,8-Mar-04,28-Mar-17,5-Apr-17,"Allegheny General Hospital Center for Traumatic Stress in Children and Adolescents, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00078767
NCT00074802,Adding Cognitive Behavioral Therapy to Drug Treatment for Social Anxiety Disorder,,Completed,Has Results,Social Anxiety Disorder,Drug: Paroxetine|Behavioral: Cognitive behavioral therapy (CBT),Liebowitz Social Anxiety Scale (LSAS)|Clinical Global Impression Improvement Scale (CGI-I)|Social Interaction Anxiety Scale (SIAS)|Social Phobia Scale (SPS)|Brief Fear of Negative Evaluation Scale (BFNE)|Liebowitz Self-Report Disability Scale (LSRDS)|Quality of Life Inventory (QOLI),Temple University|National Institute of Mental Health (NIMH),All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,150,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,R01MH064481|DSIR 83-ATAS|R01MH064726|GSK ID: 101618,Dec-03,May-08,May-08,22-Dec-03,14-Jun-17,14-Jun-17,"New York State Psychiatric Institute Anxiety Disorders Clinic, New York, New York, United States|Adult Anxiety Clinic of Temple University, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00074802
NCT00074815,Treatment of Obsessive Compulsive Disorder in Children,,Completed,Has Results,Obsessive-Compulsive Disorder,Drug: Serotonin reuptake inhibitors management|Behavioral: Cognitive behavioral therapy by a psychologist|Behavioral: Instructional cognitive behavioral therapy by a psychiatrist,Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS)|Child Obsessive -Compulsive Impact Scale (COIS)|Child Depression Inventory|Pediatric Adverse Event Rating Scale (PAERS),Duke University|National Institute of Mental Health (NIMH),All,7 Years to 17 Years   (Child),Phase 3,124,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,Pro00008097|R01MH055121|DSIR 84-CTM,Sep-03,Nov-09,Nov-09,22-Dec-03,11-Feb-13,29-Jul-14,"Duke Child and Family Study Center, Durham, North Carolina, United States|University of Pennsylvania, The Center for the Treatment and Study of Anxiety, Philadelphia, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States",,https://ClinicalTrials.gov/show/NCT00074815
NCT00073619,Preventing Anxiety Disorders in Urban Youth,,Completed,No Results Available,Anxiety Disorders,Behavioral: Cognitive-behavioral group therapy,Revised Children's Manifest Anxiety Scale|Wechsler Individual Achievement Test-Screener|Multicultural Events Schedule for Adolescents|Children's Report of Exposure to Violence,Johns Hopkins Bloomberg School of Public Health|National Institute of Mental Health (NIMH),All,8 Years to 12 Years   (Child),Not Applicable,200,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,R21MH063143|DSIR CT-P,Dec-01,Jul-07,Jul-11,3-Dec-03,null,23-Jun-16,"Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00073619
NCT00073632,Acceptance-Based Treatment for Generalized Anxiety Disorder,,Completed,No Results Available,Anxiety Disorders|Generalized Anxiety Disorder,Behavioral: Acceptance Based Behavioral Therapy,"Clinician Severity Rating from ADIS for GAD|Penn State Worry Questionnaire|Depression Anxiety and Stress Scales, anxiety and stress subscales","University of Massachusetts, Boston|National Institute of Mental Health (NIMH)",All,"18 Years and older   (Adult, Older Adult)",Phase 1,50,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,R21MH063208|DSIR AT-AS,May-02,Jul-06,Aug-06,3-Dec-03,null,6-Nov-13,"Center for Anxiety and Related Disorders, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT00073632
NCT00073645,Family and Peer Involvement in the Treatment of Anxiety Disorders in Children,,Completed,No Results Available,Anxiety Disorders,Behavioral: Peer/Group CBT|Behavioral: Family/Parents CBT,"ADIS C/P Interference Rating Scales (Silverman & Albano, 1996)|Children's Manifest Anxiety Scale - Revised (RCMAS; Reynolds & Richmond, 1978) and Internalizing subscale of the Child Behavior Checklist (CBCL; Achenbach, 1991)",Florida International University|National Institute of Mental Health (NIMH),All,8 Years to 14 Years   (Child),Phase 1,241,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,R01MH063997|DSIR 84-CTS,Jul-02,Dec-07,Jul-08,3-Dec-03,null,20-Aug-13,"Florida International University, Miami, Florida, United States",,https://ClinicalTrials.gov/show/NCT00073645
NCT00073684,Optimal Treatment Strategies for Sexually Abused Children,,Completed,No Results Available,"Child Abuse, Sexual",Behavioral: Trauma focused cognitive behavioral therapy (TF-CBT)|Behavioral: Brief abuse-focused treatment|Behavioral: Brief coping skills treatment|Behavioral: Extended abuse-focused treatment|Behavioral: Extended coping skills treatment,K-SADS-PL PTSD|Child Depression Inventory (CDI),Rowan University|National Institute of Mental Health (NIMH),All,4 Years to 11 Years   (Child),Phase 3,210,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,R01MH064776|DSIR 84-CTS,Aug-03,Jul-09,Jul-09,3-Dec-03,null,8-May-14,"CARES Institute, Stratford, New Jersey, United States",,https://ClinicalTrials.gov/show/NCT00073684
NCT00073333,Assessment and Treatment of Social Skills Deficits in Individuals With Social Phobia,,Completed,Has Results,Social Phobia,Behavioral: Social Skills Training|Behavioral: Exposure Treatment|Behavioral: Placebo,Social Phobia Remission|Social Phobia Remission Rate at 6 Month Follow-up|Score on the SPAI,Milton S. Hershey Medical Center|National Institute of Mental Health (NIMH),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,379,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,R01MH062547,Dec-02,Mar-08,Mar-08,21-Nov-03,2-Jul-13,18-Jul-13,"Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00073333
NCT00073346,Treatment of Compulsive Hoarding,,Completed,No Results Available,Obsessive-Compulsive Disorder,Behavioral: Cognitive Behavioral Treatment,,Boston University|National Institute of Mental Health (NIMH),All,"18 Years and older   (Adult, Older Adult)",Phase 1,52,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,R21MH068539|DATR A2-AIA,Sep-03,null,Aug-06,21-Nov-03,null,20-Jun-13,"Hartford Hospital, Institute of Living, Hartford, Connecticut, United States|Boston University, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT00073346
NCT00071630,Therapeutic Processes and Treatment Outcome in Adolescents With Anxiety Disorders,,Completed,No Results Available,Anxiety Disorders,Behavioral: Cognitive Behavioral Therapy,,Temple University|National Institute of Mental Health (NIMH),All,8 Years to 13 Years   (Child),Phase 4,130,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,R01MH064484|DSIR CT-S,Sep-02,null,Aug-05,30-Oct-03,null,7-Nov-13,"Temple University, Philadelphia, Pennsylvania, United States|Macquarie University, Sydney, New South Wales, Australia",,https://ClinicalTrials.gov/show/NCT00071630
NCT00063375,Interactive Computer Treatment for Panic Disorder,,Completed,No Results Available,Panic Disorder,Behavioral: Computer Based Cognitive Behavioral Therapy,,Florida State University|National Institute of Mental Health (NIMH),All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,60,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,R21MH062056|DSIR AT-AS,Jan-02,Feb-07,null,27-Jun-03,null,25-Oct-13,"Florida State University, Tallahassee, Florida, United States",,https://ClinicalTrials.gov/show/NCT00063375
NCT00057733,Stress Management Training in Patients Undergoing Radiation Therapy for Cancer,,Completed,No Results Available,"Anxiety Disorder|Depression|Unspecified Adult Solid Tumor, Protocol Specific",Procedure: psychosocial assessment and care|Procedure: quality-of-life assessment,,University of South Florida|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,null,Other|NIH,Interventional,Allocation: Randomized,MCC-0108|CDR0000069466|NCI-5721|NCI-P02-0227|TAGH-20291,Feb-03,Apr-05,Jun-06,9-Apr-03,null,30-May-13,"CCOP - Western Regional, Arizona, Phoenix, Arizona, United States|CCOP - Bay Area Tumor Institute, Oakland, California, United States|Howard University Cancer Center at Howard University Hospital, Washington, District of Columbia, United States|MBCCOP - Howard University Cancer Center, Washington, District of Columbia, United States|Comprehensive Cancer Care Center at Bethesda Memorial Hospital, Boynton Beach, Florida, United States|H. Lee Moffitt Cancer Center and Research Institute at University of South Florida, Tampa, Florida, United States|Cancer Care and Research Pavilion at St. Joseph's/Candler, Savannah, Georgia, United States|CCOP - Cancer Research for the Ozarks, Springfield, Missouri, United States|MBCCOP-Our Lady of Mercy Cancer Center, Bronx, New York, United States|CCOP - Columbus, Columbus, Ohio, United States|CCOP - Scott and White Hospital, Temple, Texas, United States|CCOP - Northwest, Tacoma, Washington, United States",,https://ClinicalTrials.gov/show/NCT00057733
NCT00057603,Deep Brain Stimulation for Treatment-Resistant Obsessive Compulsive Disorder,,Completed,No Results Available,Obsessive-Compulsive Disorder,Procedure: Deep Brain Stimulation,"Obsessive-compulsive scales, depression scales, neuropsychological evaluations, and survey",University of Florida|National Institute of Mental Health (NIMH),All,"23 Years to 65 Years   (Adult, Older Adult)",Not Applicable,6,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,R21MH064161|DATR A5-ETMA,Jan-01,Jul-09,Jul-09,7-Apr-03,null,9-Nov-11,"University of Florida College of Medicine, Gainesville, Florida, United States",,https://ClinicalTrials.gov/show/NCT00057603
NCT00055068,Family Based Treatment of Early Childhood Obsessive Compulsive Disorder,,Completed,No Results Available,Obsessive-Compulsive Disorder,Behavioral: Cognitive Behavioral Therapy (CBT)|Behavioral: Relaxation Training,,Rhode Island Hospital|National Institute of Mental Health (NIMH),All,5 Years to 8 Years   (Child),Phase 3,38,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,R21MH060669|DSIR CT-S,Mar-02,null,Feb-06,20-Feb-03,null,7-May-14,"Rhode Island Hospital/Brown University, Providence, Rhode Island, United States",,https://ClinicalTrials.gov/show/NCT00055068
NCT00005850,Combination Chemotherapy Plus Fluoxetine in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer,,Completed,No Results Available,Anxiety Disorder|Depression|Fatigue|Lung Cancer,Drug: cisplatin|Drug: fluoxetine|Drug: gemcitabine hydrochloride,Change in the MHI-17 global psychological distress subscale|Overall survival|Failure-free survival,Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI),All,"Child, Adult, Older Adult",Phase 2,21,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CALGB-119802|U10CA031946|CLB-119802|CDR0000067871,Aug-01,Sep-03,Sep-03,27-Jan-03,null,4-Jul-16,"Northeast Alabama Regional Medical Center, Anniston, Alabama, United States|Veterans Affairs Medical Center - San Diego, San Diego, California, United States|Veterans Affairs Medical Center - Washington, DC, Washington, District of Columbia, United States|Broward General Medical Center, Fort Lauderdale, Florida, United States|Memorial Regional Hospital Comprehensive Cancer Center, Hollywood, Florida, United States|Florida Hospital Cancer Institute, Orlando, Florida, United States|Helen and Harry Gray Cancer Institute at Good Samaritan Medical Center, West Palm Beach, Florida, United States|University of Chicago Cancer Research Center, Chicago, Illinois, United States|Louis A. Weiss Memorial Hospital, Chicago, Illinois, United States|West Suburban Center for Cancer Care, River Forest, Illinois, United States|Saint Anthony Medical Center, Rockford, Illinois, United States|Fort Wayne Medical Oncology and Hematology, Incorporated, Fort Wayne, Indiana, United States|Baptist Hospital East - Louisville, Louisville, Kentucky, United States|Veterans Affairs Medical Center - Baltimore, Baltimore, Maryland, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Beth Israel Medical Center, Boston, Massachusetts, United States|Lakeland Medical Center - St. Joseph, Saint Joseph, Michigan, United States|Ellis Fischel Cancer Center - Columbia, Columbia, Missouri, United States|Barnes-Jewish Hospital, Saint Louis, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Veterans Affairs Medical Center - Las Vegas, Las Vegas, Nevada, United States|Cooper University Hospital, Camden, New Jersey, United States|Elmhurst Hospital Center, Elmhurst, New York, United States|Queens Cancer Center of Queens Hospital, Jamaica, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|State University of New York - Upstate Medical University, Syracuse, New York, United States|Veterans Affairs Medical Center - Syracuse, Syracuse, New York, United States|CCOP - Syracuse Hematology-Oncology Associates of Central New York, P.C., Syracuse, New York, United States|Veterans Affairs Medical Center - Asheville, Asheville, North Carolina, United States|NorthEast Oncology Associates, Concord, North Carolina, United States|Veterans Affairs Medical Center - Durham, Durham, North Carolina, United States|Cape Fear Valley Health System, Fayetteville, North Carolina, United States|Lenoir Memorial Hospital Cancer Center, Kinston, North Carolina, United States|FirstHealth Moore Regional Hospital, Pinehurst, North Carolina, United States|New Hanover Regional Medical Center, Wilmington, North Carolina, United States|Veterans Affairs Medical Center - Fargo, Fargo, North Dakota, United States|Veterans Affairs Medical Center - Dallas, Dallas, Texas, United States|Martha Jefferson Hospital, Charlottesville, Virginia, United States|Virginia Oncology Associates - Norfolk, Norfolk, Virginia, United States|Oncology and Hematology Associates of Southwest Virginia, Inc., Roanoke, Virginia, United States|St. Mary's Medical Center, Huntington, West Virginia, United States|Ministry Medical Group - Northern Region, Rhinelander, Wisconsin, United States|University of Puerto Rico School of Medicine Medical Sciences Campus, San Juan, Puerto Rico",,https://ClinicalTrials.gov/show/NCT00005850
NCT00014482,Music Therapy to Ease Pain and Emotional Distress in Patients With Hematologic Cancer Who Are Undergoing High-Dose Therapy and Stem Cell Transplantation,,Completed,No Results Available,Anxiety Disorder|Chronic Myeloproliferative Disorders|Depression|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Pain,Procedure: pain therapy|Procedure: psychosocial assessment and care,,Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,null,Other|NIH,Interventional,Allocation: Randomized,00-134|CDR0000068547|NCI-G01-1934,Dec-00,Mar-03,Mar-03,27-Jan-03,null,18-Jun-13,"Memorial Sloan-Kettering Cancer Center, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00014482
NCT00022074,Gabapentin For the Control of Hot Flashes in Women With Breast Cancer,,Completed,No Results Available,Anxiety Disorder|Breast Cancer|Depression|Hot Flashes,Drug: gabapentin|Procedure: quality-of-life assessment,,Gary Morrow|National Cancer Institute (NCI)|University of Rochester,Female,"up to 120 Years   (Child, Adult, Older Adult)",Not Applicable,null,Other|NIH,Interventional,Allocation: Randomized|Masking: None (Open Label)|Primary Purpose: Supportive Care,CDR0000068780|URCC-U2101|NCI-P01-0183,Jul-01,Jun-05,Jun-05,27-Jan-03,null,15-Oct-15,"MBCCOP - Gulf Coast, Mobile, Alabama, United States|CCOP - Greater Phoenix, Phoenix, Arizona, United States|CCOP - Scottsdale Oncology Program, Scottsdale, Arizona, United States|CCOP - Colorado Cancer Research Program, Incorporated, Denver, Colorado, United States|MBCCOP - Hawaii, Honolulu, Hawaii, United States|CCOP - Central Illinois, Decatur, Illinois, United States|CCOP - Wichita, Wichita, Kansas, United States|CCOP - Kalamazoo, Kalamazoo, Michigan, United States|CCOP - Metro-Minnesota, Saint Louis Park, Minnesota, United States|CCOP - Northern New Jersey, Hackensack, New Jersey, United States|CCOP - North Shore University Hospital, Manhasset, New York, United States|CCOP - Syracuse Hematology-Oncology Associates of Central New York, P.C., Syracuse, New York, United States|CCOP - Southeast Cancer Control Consortium, Winston-Salem, North Carolina, United States|CCOP - Columbus, Columbus, Ohio, United States|CCOP - Dayton, Dayton, Ohio, United States|CCOP - Virginia Mason Research Center, Seattle, Washington, United States|CCOP - Northwest, Tacoma, Washington, United States|CCOP - Marshfield Medical Research and Education Foundation, Marshfield, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT00022074
NCT00052078,Child and Adolescent Anxiety Disorders (CAMS),,Completed,Has Results,Anxiety Disorders|Social Phobia|Generalized Anxiety Disorder,Drug: Sertraline (SRT)|Behavioral: Cognitive Behavioral Therapy (CBT)|Drug: Placebo,Clinical Global Impression - Improvement Scale,Johns Hopkins University|National Institute of Mental Health (NIMH),All,7 Years to 17 Years   (Child),Phase 3,488,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",U01MH064089|DSIR 84-CTP,Jan-03,Oct-07,Mar-08,23-Jan-03,25-Apr-17,19-Sep-17,"UCLA, Los Angeles, California, United States|Johns Hopkins University, Baltimore, Maryland, United States|NYSPI/Columbia University, New York, New York, United States|Duke University, Durham, North Carolina, United States|Temple University, Philadelphia, Pennsylvania, United States|University of Pittsburgh/WPIC, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00052078
NCT00051207,Therapy for Depression With Co-occurring Panic or Anxiety Symptoms,,Completed,No Results Available,Depression|Anxiety Disorders|Panic Disorder,Behavioral: Interpersonal Psychotherapy (IPT)|Behavioral: IPT for Depression with Co-occurring Panic and Anxiety Symptoms (IPT-PS),,University of Pittsburgh,All,18 Years to 60 Years   (Adult),Phase 1|Phase 2,36,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,R21MH061948|DSIR AT-AS,Nov-02,null,Aug-05,8-Jan-03,null,25-Jun-13,"Western Psychiatric Institute and Clinic - Depression and Manic Depression Program, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00051207
NCT00051220,Treatment for Specific Phobias in Children,,Completed,No Results Available,Phobic Disorders|Anxiety Disorders,Behavioral: One-Session Treatment for Specific Phobias,,Virginia Polytechnic Institute and State University|National Institute of Mental Health (NIMH),All,7 Years to 16 Years   (Child),Phase 1|Phase 2,150,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment",R01MH059308|DSIR CT-S,Oct-01,Sep-06,Sep-06,8-Jan-03,null,7-Jun-13,"VA Polytech. Institute and State University, Blacksburg, Virginia, United States|University of Stockholm, Stockholm, Sweden",,https://ClinicalTrials.gov/show/NCT00051220
NCT00050804,Evaluation of Stress Disorders,,Completed,No Results Available,Acute Traumatic Stress Disorders|Post-Traumatic Stress Disorders,Drug: sertraline,,National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC),All,"Child, Adult, Older Adult",Phase 4,80,NIH,Interventional,Primary Purpose: Treatment,030036|03-M-0036,Dec-02,null,Feb-04,20-Dec-02,null,4-Mar-08,"National Institute of Mental Health (NIMH), Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00050804
NCT00001966,Mind-Body Therapy for Pain in Ehlers-Danlos Syndrome,,Completed,No Results Available,Ehlers-Danlos Syndrome|Pain,Drug: Mind-body therapy,,National Human Genome Research Institute (NHGRI)|National Institutes of Health Clinical Center (CC),All,"Child, Adult, Older Adult",Phase 2,40,NIH,Interventional,Primary Purpose: Treatment,000054|00-HG-0054,Jan-00,null,Jan-01,10-Dec-02,null,4-Mar-08,"National Human Genome Research Institute (NHGRI), Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00001966
NCT00045903,Cognitive Behavioral Therapy Plus Drug Treatment for Obsessive Compulsive Disorder,1-Aug,Completed,No Results Available,Obsessive-Compulsive Disorder,Behavioral: Exposure and Ritual Prevention (Cognitive Behavioral Therapy)|Behavioral: Stress Management Therapy (Cognitive Behavior Therapy),Obsessive-compulsive symptoms measured at Month 2|General functioning measured at Month 2,New York State Psychiatric Institute|National Institute of Mental Health (NIMH),All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,136,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,IRB #4734R|R01MH045436-01|DSIR AT-CT,Aug-00,Jan-07,Jan-07,17-Sep-02,null,23-Apr-14,"New York State Psychiactic Institute, Anxiety Disorders Clinic, New York, New York, United States|University of Pennsylvania Center for the Treatment and Study of Anxiety, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00045903
NCT00044772,Study Evaluating Venlafaxine ER in Patients With Panic Disorder,,Completed,No Results Available,Panic Disorder,Drug: Venlafaxine ER,,Wyeth is now a wholly owned subsidiary of Pfizer,All,"18 Years and older   (Adult, Older Adult)",Phase 3,653,Industry,Interventional,Primary Purpose: Treatment,0600B5-399,Nov-01,Apr-03,Apr-03,6-Sep-02,null,14-Aug-09,,,https://ClinicalTrials.gov/show/NCT00044772
NCT00044642,Lorazepam-Induced Toxicity in the Aged,,Completed,No Results Available,Anxiety Disorders|Generalized Anxiety Disorder,Drug: Lorazepam,,Nathan Kline Institute for Psychiatric Research|National Institute of Mental Health (NIMH),All,"60 Years and older   (Adult, Older Adult)",Phase 4,90,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Diagnostic,R01MH059142|DATR A4-GPX,Dec-00,null,Jul-07,5-Sep-02,null,6-Dec-13,"NYU/Bellevue General Clinical Research Center (8East), New York, New York, United States|Nathan S. Kline Institute, Orangeburg, New York, United States",,https://ClinicalTrials.gov/show/NCT00044642
NCT00043537,Treatment of Childhood Social Phobia,,Completed,No Results Available,Social Phobia,Behavioral: Social Effectiveness Therapy for Children (SET-C)|Drug: Fluoxetine|Drug: Pill Placebo,,University of Central Florida|National Institute of Mental Health (NIMH),All,8 Years to 16 Years   (Child),Phase 3,139,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",R01MH053703,Apr-01,Sep-06,Sep-06,12-Aug-02,null,1-Aug-13,"Maryland Center for Anxiety Disorders, University of Maryland, College Park, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00043537
NCT00042380,Examination of a Soy-Based Supplement for Major Depression,,Completed,No Results Available,Depression,Drug: Novasoy,,National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC),All,"Child, Adult, Older Adult",Phase 2,120,NIH,Interventional,Primary Purpose: Treatment,020254|02-M-0254,Jul-02,null,Apr-05,29-Jul-02,null,4-Mar-08,"National Institute of Mental Health (NIMH), Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00042380
NCT00038896,Study Evaluating Venlafaxine ER in Adults With Panic Disorder,,Completed,No Results Available,Panic Disorder,Drug: Venlafaxine ER,,Wyeth is now a wholly owned subsidiary of Pfizer,All,"18 Years and older   (Adult, Older Adult)",Phase 3,343,Industry,Interventional,Primary Purpose: Treatment,0600B5-353,Apr-01,Dec-02,Dec-02,7-Jun-02,null,14-Aug-09,,,https://ClinicalTrials.gov/show/NCT00038896
NCT00035412,St. John's Wort Versus Placebo in Social Phobia,,Completed,No Results Available,Phobic Disorders,Drug: St. John’s Wort,,National Center for Complementary and Integrative Health (NCCIH),All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,40,NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,R21AT000502-01A1,Dec-01,null,Aug-04,6-May-02,null,18-Aug-06,"The Dean Foundation for Health, Research, and Education, Madison, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT00035412
NCT00035438,St. John’s Wort Vs. Placebo in Obsessive-Compulsive Disorder.,,Completed,No Results Available,Obsessive Compulsive Disorder,Drug: St. John’s Wort,,National Center for Complementary and Integrative Health (NCCIH),All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,60,NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,R21AT000391-01,May-02,null,Sep-03,6-May-02,null,4-Aug-06,"University of Oklahoma Health Science Center, Oklahoma City, Oklahoma, United States|Dean Foundation, Madison, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT00035438
NCT00034034,Acupuncture to Reduce Symptoms of Advanced Colorectal Cancer,,Completed,No Results Available,Colorectal Neoplasms,Procedure: Acupuncture,,National Center for Complementary and Integrative Health (NCCIH),All,"18 Years and older   (Adult, Older Adult)",Phase 1,105,NIH,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single|Primary Purpose: Treatment,R01AT001028-01,Jun-02,null,Aug-06,22-Apr-02,null,5-Jan-07,"University of Pittsburgh Medical Center, Cancer Institute, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00034034
NCT00031317,Evaluation of Clonazepam and Paroxetine for Panic Disorder With Depression,,Completed,No Results Available,Panic Disorder,Drug: Paroxetine|Drug: Clozapine,,National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC),All,"Child, Adult, Older Adult",Phase 4,60,NIH,Interventional,Primary Purpose: Treatment,020136|02-M-0136,Feb-02,null,Jun-05,1-Mar-02,null,4-Mar-08,"National Institute of Mental Health (NIMH), Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00031317
NCT00012584,Treatment of Youth With ADHD and Anxiety,,Completed,No Results Available,"Attention Deficit Hyperactivity Disorder|Anxiety, Separation|Social Phobia|Generalized Anxiety Disorder",Drug: methylphenidate|Drug: fluvoxamine,,National Institute of Mental Health (NIMH),All,6 Years to 17 Years   (Child),Not Applicable,120,NIH,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,N01 MH12012|DSIR CT,Nov-00,May-02,May-02,16-Mar-01,null,24-Jun-09,"UCLA Neuropsychiatric Institute, Los Angeles, California, United States|Johns Hopkins School of Medicine, Baltimore, Maryland, United States|New York University Child Study Center, New York, New York, United States|New York State Psychiatric Institute, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT00012584
NCT00004367,Vestibular Dysfunction In Adult Patients With Panic Disorder With or Without Agoraphobia,,Completed,No Results Available,Anxiety Disorder|Panic Disorder,Procedure: Clinical vestibular tests,,National Center for Research Resources (NCRR)|University of Pittsburgh,All,18 Years to 55 Years   (Adult),Not Applicable,165,NIH|Other,Interventional,Primary Purpose: Diagnostic,199/11945|UPITTS-9504279605,May-00,null,null,19-Oct-99,null,24-Jun-05,"University of Pittsburgh, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00004367
